

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

10/006780

L6 FILE 'REGISTRY' ENTERED AT 14:27:22 ON 07 OCT 2003
1217 S ATPASE?/CN

- key terms

L6 FILE 'HCAPLUS' ENTERED AT 14:27:30 ON 07 OCT 2003
L6 1217 SEA FILE=REGISTRY ABB=ON PLU=ON ATPASE?/CN
L7 166 SEA FILE=HCAPLUS ABB=ON PLU=ON (PLASMODIUM OR FALCIPARU
M) AND (L6 OR ATPASE OR ADENOSINE(2W)(TRIPHOSPHATASE OR
TRI PHOSPHATASE))
L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (MICROTUB? OR
MICRO TUBUL?)

L6 1217 SEA FILE=REGISTRY ABB=ON PLU=ON ATPASE?/CN
L7 166 SEA FILE=HCAPLUS ABB=ON PLU=ON (PLASMODIUM OR FALCIPARU
M) AND (L6 OR ATPASE OR ADENOSINE(2W)(TRIPHOSPHATASE OR
TRI PHOSPHATASE))
L9 87 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (PROTEIN OR
PEPTIDE OR POLYPROTEIN OR POLYPEPTIDE)
L10 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND STIMUL?

L12 11 L8 OR L10

L12 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:454501 HCAPLUS

DOCUMENT NUMBER: 139:35072

TITLE: Vectors comprising nucleotide sequences for
target immunogen, PI31, CIIIA and antisense
HERNA mRNA, and their uses including use as
vaccines

INVENTOR(S): McCreavy, David Thomas; Fraser, William Duncan;
Gallagher, James Anthony

PATENT ASSIGNEE(S): University of Liverpool, UK

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048371	A2	20030612	WO 2002-GB5512	20021206
WO 2003048371	A3	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2001-29338 A 20011207

GB 2002-23829 A 20021012

AB The invention provides vectors (such as viral vectors, plasmid

THIS PAGE BLANK (USPTO)

vectors or phagemids) comprising: (a) a heterologous nucleotide sequence encoding an antigenic **polypeptide** from a pathogen (such as viral, bacterial, parasitic or fungal); (b) a nucleotide sequence encoding a protease inhibitor (such as human PI31); a nucleotide sequence for a constitutive, regulatable, and/or cell/tissue-specific promoter; and (d) a nucleotide sequence encoding an inhibitory RNA mols., specifically an antisense human HERNA oligonucleotides. The invention also provides vectors comprising a nucleotide sequence encoding CIITA, a **polypeptide** that **stimulates** the expression of MHC class II genes. The invention further provides the use of said vectors as vaccines in production of an immune response (humoral) to said antigens in an animal, such as human, wherein said vaccination may be against a viral, fungal, bacterial or parasitic disorder. Still further, the invention relates: (a) using said vectors in production of antibodies, wherein said antibodies may be of therapeutic and/or of diagnostic use; (b) that said vectors may be adapted for expression of humanized or chimeric antibodies; and (c) that said vectors may be used to used to immunize animals for production of hybridomas expressing a monoclonal antibody against antigen of interest. Finally, the invention provides the cDNA sequences of mouse CIITA, and human PI31; and partial cDNA sequence of human HERNA helicase. The invention related that the use of said vectors containing said sequences can be used to enhance secretion of translated immunogen, and enhance DNA vaccination bias away from an MHC class I event towards MHC class II event. In the examples, the invention presented the construction of two vectors, pcDNAFinal and pcDNA6TR-IRES-CIITA, wherein pcDNAFinal contains nucleotide sequences encoding immunogen parathyroid hormone-related **protein** (PTHrP), antisense HERNA mRNA, PI31 and CD4+ T-cell epitope from lymphocytic choriomeningitis virus and wherein pcDNA6TR-IRES-CIITA encodes CIITA. Specifically, the invention related that: (a) antisense HERNA RNA can increase the transcriptional efficiency of vectors resulting in greater levels of transgene expression; (b) PI31 can inhibit proteasome digestion of recombinant antigen making it more assessable to MHC class II antigens; (c) inclusion of CD4+ T-cell epitope ensured that degraded immunogen-MHC class II complex bound to CD4+ T cells; and (d) inclusion of CIITA **protein** allowed for over-expression of MHC class II antigens.

IT **9000-83-3, Atpase**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (promoter of; vectors comprising sequences for promoter, target immunogen, PI31, CIITA and antisense HERNA mRNA, and their uses, including as vaccines towards various disorders)

L12 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:454460 HCAPLUS

DOCUMENT NUMBER: 139:31820

TITLE: **Plasmodium falciparum**
kinesin motor **protein** KinI-1 with
microtubule-stimulated
ATPase activity and uses for diagnosis
and treatment of malaria

INVENTOR(S): Sakowicz, Roman; Beraud, Christophe; Guo, Jun;
Freedman, Richard

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 68 pp.

THIS PAGE BLANK (USPTO)

10/006780

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048320	A2	20030612	WO 2002-US38360	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003104496	A1	20030605	US 2001-6780	20011130
PRIORITY APPLN. INFO.:			US 2001-6780	A2 20011130
			US 2002-86935	A2 20020228

AB The present invention relates to **protein** and cDNA sequences of a new kinesin motor **protein**, P. **falciparum** KinI-1 (PfKinI-1), and the use of these comps. for the diagnosis, treatment, or prevention of malaria. The invention provides isolated nucleic acid and amino acid sequences of kinesin superfamily motor **protein** KinI-1, which has **microtubule stimulated ATPase** activity and/or depolymerizes **microtubules**. The invention further relates to antibodies to PfKinI-1, methods of screening for PfKinI-1 modulators using biol. active PfKinI-1, and kits for screening for PfKinI-1 modulators.

IT **9000-83-3, ATPase**
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**microtubule-stimulated; Plasmodium falciparum** kinesin motor **protein** KinI-1 with **microtubule-stimulated ATPase** activity and uses for diagnosis and treatment of malaria)

L12 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:435206 HCAPLUS

DOCUMENT NUMBER: 139:909

TITLE: (Sequences of **Plasmodium falciparum** kinesin KinI-1 and use for treating malaria)

INVENTOR(S): Sakowicz, Roman; Beraud, Christophe; Guo, Jun; Freedman, Richard

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searcher : Shears 308-4994

THIS PAGE BLANK (USPTO)

US 2003104496	A1	20030605	US 2001-6780	20011130
WO 2003048320	A2	20030612	WO 2002-US38360	20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-6780 A2 20011130
US 2002-86935 A2 20020228

AB The invention provides sequences of **Plasmodium falciparum** kinesin KinI-1. The invention also relates to the use of KinI-1 for the diagnosis, treatment, or prevention of malaria.

IT **9000-83-3, ATPase**
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**microtubule-stimulated**; sequences of **Plasmodium falciparum** kinesin KinI-1 and use for treating malaria)

L12 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:752115 HCAPLUS

DOCUMENT NUMBER: 137:289734

TITLE: Sequence of **Plasmodium falciparum** chromosomes 2, 10, 11 and 14

AUTHOR(S): Gardner, Malcolm J.; Shallom, Shamira J.; Carlton, Jane M.; Salzberg, Steven L.; Nene, Vishvanath; Shoaibi, Azadeh; Ciecko, Anne; Lynn, Jeffery; Rizzo, Michael; Weaver, Bruce; Jarrahi, Behnam; Brenner, Michael; Parvizi, Babak; Tallon, Luke; Moazzez, Azita; Granger, David; Fujii, Claire; Hansen, Cheryl; Pederson, James; Feldblyum, Tamara; Peterson, Jeremy; Suh, Bernard; Angiuoli, Sam; Perte, Mihaela; Allen, Jonathan; Selengut, Jeremy; White, Owen; Cummings, Leda M.; Smith, Hamilton O.; Adams, Mark D.; Venter, J. Craig; Carucci, Daniel J.; Hoffman, Stephen L.; Fraser, Claire M.

CORPORATE SOURCE: The Institute for Genomic Research, Rockville, MD, 20850, USA

SOURCE: Nature (London, United Kingdom) (2002), 419(6906), 531-534
CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The mosquito-borne malaria parasite **Plasmodium falciparum** kills an estimated 0.7-2.7 million people every year, primarily children in sub-Saharan Africa. Without effective interventions, a variety of factors-including the spread of parasites resistant to antimalarial drugs and the increasing insecticide resistance of mosquitoes-may cause the number of malaria

THIS PAGE BLANK (USPTO)

cases to double over the next two decades. To **stimulate** basic research and facilitate the development of new drugs and vaccines, the genome of **Plasmodium falciparum** clone 3D7 has been sequenced using a chromosome-by-chromosome shotgun strategy. This report describes nucleotide sequences of chromosomes 10, 11 and 14, and a re-anal. of the chromosome 2 sequence. These chromosomes represent about 35% of the 23-megabase **P. falciparum** genome. The sequences are deposited in GenBank/EMBL/DDBJ under accession nos. AE001362.2 (chromosome 2), AE014185 (chromosome 10), AE014186 (chromosome 11), and AE014187 (chromosome 14).

only NA
no other

IT 465605-54-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; complete sequence of **Plasmodium falciparum** chromosomes 2, 10, 11 and 14)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:485238 HCAPLUS

DOCUMENT NUMBER: 137:242895

TITLE: Comparative genomic analysis in the region of a major **Plasmodium**-refractoriness locus of **Anopheles gambiae**

AUTHOR(S): Thomasova, Dana; Ton, Lucas Q.; Copley, Richard R.; Zdobnov, Evgeny M.; Wang, Xuelan; Hong, Young S.; Sim, Cheolho; Bork, Peer; Kafatos, Fotis C.; Collins, Frank H.

CORPORATE SOURCE: European Molecular Biology Laboratory, Heidelberg, 69117, Germany

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(12), 8179-8184

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have sequenced six overlapping clones from a library of bacterial artificial chromosome (BAC) clones derived from a laboratory strain of the mosquito, **Anopheles gambiae**, the major vector of human malaria in Africa. The resulting uninterrupted 528-kb sequence is from the 8C region of the mosquito 2R chromosome, at or very near the major refractoriness locus associated with melanotic encapsulation of parasites. This sequence represents the first extensive view of the mosquito genome structure encompassing 48 genes. Genomic comparison reveals that the majority of the orthologues are found in six microsyntenic clusters in *Drosophila melanogaster*. A BAC clone that is wholly contained within this region demonstrates the existence of a remarkable degree of local polymorphism in this species, which may prove important for its population structure and vectorial capacity.

IT 9000-83-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(V-type, sequence homolog to; comparative genomic anal. in the region of a major **Plasmodium**-refractoriness locus of **Anopheles gambiae**)

THIS PAGE BLANK (USPTO)

10/006780

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L12 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:394971 HCAPLUS

DOCUMENT NUMBER: 135:118715

TITLE: Expression and functional characterization of a
Plasmodium falciparum Ca²⁺-
ATPase (PfATP4) belonging to a subclass
unique to apicomplexan organisms

AUTHOR(S): Krishna, Sanjeev; Woodrow, Charles; Webb,
Richard; Penny, Jeff; Takeyasu, Kunio; Kimura,
Masatsugu; East, J. Malcolm

CORPORATE SOURCE: Department of Infectious Diseases, St. George's
Hospital Medical School, London, SW17 ORE, UK

SOURCE: Journal of Biological Chemistry (2001), 276(14),
10782-10787

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have obtained a full-length P type **ATPase** sequence
(PfATP4) encoded by **Plasmodium falciparum** and
expressed PfATP4 in *Xenopus laevis* oocytes to study its function.
Comparison of the hitherto incomplete open reading frame with other
Ca²⁺-**ATPase** sequences reveals that PfATP4 differs
significantly from previously defined categories. The
Ca²⁺-dependent **ATPase** activity of PfATP4 is
stimulated by a much broader range of [Ca²⁺]_{free} (3.2-320
μM) than are an avian SERCA1 pump or rabbit SERCA 1a (maximal
activity < 10 μM). The activity of PfATP4 is resistant to
inhibition by ouabain (200 μM) or thapsigargin (0.8 μM) but is
inhibited by vanadate (1 mM) or cyclopiazonic acid (1 μM). We
used a quant. polymerase chain reaction to assay expression of mRNA
encoding PfATP4 relative to that for β-tubulin in synchronized
asexual stages and found variable expression throughout the life
cycle with a maximal 5-fold increase in meronts compared with ring
stages. This anal. suggests that PfATP4 defines a novel subclass of
Ca²⁺-**ATPases** unique to apicomplexan organisms and
therefore offers potential as a drug target.

IT 9000-83-3, **ATPase**

RL: BAC (Biological activity or effector, except adverse); BPR
(Biological process); BSU (Biological study, unclassified); PRP
(Properties); BIOL (Biological study); PROC (Process)
(calcium-activated, PfATP4; expression and functional
characterization of a **Plasmodium falciparum**
Ca²⁺-**ATPase** (PfATP4) belonging to a subclass unique to
apicomplexan organisms)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L12 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1994:694055 HCAPLUS

DOCUMENT NUMBER: 121:294055

TITLE: **Plasmodium falciparum**:

THIS PAGE BLANK (USPTO)

further characterization of putative cation
ATPases

AUTHOR(S): Krishna, Sanjeev; Cowan, Gill M.; Robson,
 Kathryn J.; Meade, John C.

CORPORATE SOURCE: Inst. Mol. Med., John Radcliffe Hosp., Oxford,
 OX3 9DU, UK

SOURCE: Experimental Parasitology (1994), 78(1), 113-17
 CODEN: EXPAAA; ISSN: 0014-4894

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The emergence of multi-drug resistant strains of **Plasmodium**
falciparum and the current lack of a vaccine have
stimulated research to identify new chemotherapeutic
 targets. The authors have focused on the isolation and
 characterization of nucleotide sequences encoding putative "P"-type
 cation **ATPases** from **P. falciparum**, because
 selective inhibitors of mammalian members of this transporter family
 are well studied, and some are already in clin. use. This report
 describes the isolation and sequence anal. of two addnl. members of
 this family, **ATPases** 2 and 3, and their differential
 expressivity during the erythrocytic stage of parasite development.
 Amino acid sequence anal. identified the 7 amino acid motifs present
 at the phosphorylation site (DKTGTLT) of other P-type cation
ATPases, in both clones. **ATPase** 2 was localized
 to chromosome 5 and **ATPase** 3 to chromosome 12 on a
 Southern blot of chromosomes resolved by pulsed-field gel
 electrophoresis. Northern blot anal. showed that both
ATPases 2 and 3 were expressed during the erythrocytic stage
 of the infection. **ATPase** 2 has a mRNA transcript size of
 5.5-6 kb and is expressed at the schizont stage of development.
ATPase 3 mRNA is approx. 5 kb in size and the strongest
 signal corresponds to mRNA from parasites at the ring stage of
 development (12-24 h postinvasion), although mRNA is also detected
 in all other erythrocytic stages examined

IT **9000-83-3, ATPase**
 RL: PRP (Properties)
 (2 and 3; sequence and chromosomal localization and developmental
 expression of genes encoding P-type cation **ATPases** 2
 and 3 of **Plasmodium falciparum**)

L12 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1994:407323 HCAPLUS

DOCUMENT NUMBER: 121:7323

TITLE: Immunomodulatory **peptides** binding to
 human major histocompatibility complex (MHC)
 class II allotype

INVENTOR(S): Urban, Robert Glen; Chicz, Roman M.; Vignali,
 Dario A. A.; Hedley, Mary Lynne; Stern, Lawrence
 J.; Strominger, Jack L.

PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA

SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searcher :	Shears	308-4994
------------	--------	----------

THIS PAGE BLANK (USPTO)

-----	-----	-----	-----	-----
WO 9404557	A1	19940303	WO 1992-US6692	19920811
W: JP				
JP 08502244	T2	19960312	JP 1992-506181	19920811
PRIORITY APPLN. INFO.:			WO 1992-US6692	19920811

AB A purified oligopeptide preparation comprising an amino acid sequence identical to that of a segment of a naturally-occurring human **protein** that binds to human major histocompatibility complex (MHC) class II allotype is provided. The human **protein** is an MHC class I or II mol., HLA-A2, invariant chain (Ii), etc.,. A method is described for inhibiting an immune response in a human patient by contacting an antigen-presenting cell (APC) of the patient with a therapeutic composition or an immune-**stimulating** complex (ISCOM) containing the oligopeptide, or by expression of the oligopeptide-coding sequence linked to a trafficking sequence in APCs. The oligopeptide also can be used for inducing an immune response against pathogens. The options of the oligopeptide delivery system is also described. Purification and characterization of 6 HLA-DR antigens (HLA-DR1.apprx.4; HLA-DR7.apprx.8) from Epstein-Barr virus-transformed human B lymphoblastoid cell lines were demonstrated.

IT **9000-83-3, ATPase**
 RL: BIOL (Biological study)
 (Na+/K+, **peptides** of, as immunomodulators)

L12 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1991:673744 HCAPLUS
 DOCUMENT NUMBER: 115:273744
 TITLE: **Stimulation** of the interaction between actin and myosin by Physarum caldesmon-like **protein** and smooth muscle caldesmon
 AUTHOR(S): Ishikawa, Ryoki; Okagaki, Tsuyoshi; Higashi-Fujime, Sugie; Kohama, Kazuhiro
 CORPORATE SOURCE: Sch. Med., Gunma Univ., Maebashi, 371, Japan
 SOURCE: Journal of Biological Chemistry (1991), 266(32), 21784-90
 CODEN: JBCHA3; ISSN: 0021-9258
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB An actin-binding **protein** was purified from the **plasmodia** of a lower eukaryote, *P. polycephalum*, with an apparent mol. weight of 210 kDa on SDS-PAGE. This **protein** bound to actin filaments with a stoichiometry of 1:7-8 in a Ca2+-calmodulin-dependent manner. Antibody raised against caldesmon from smooth muscle cross-reacted with the 210-kDa **protein**. In vitro motility assay revealed that the 210-kDa **protein** increased the sliding velocity of actin filaments on Physarum myosin. The 210-kDa **protein** more than doubled the actin-activated **ATPase** activity of Physarum myosin under comparative conditions of in vitro motility assay. Further increases in the concentration of the 210-kDa **protein** decreased its **stimulatory** effects. Ca2+-calmodulin prevented the **stimulatory** effects of the 210-kDa **protein**. Unexpectedly, smooth muscle caldesmon also increased the sliding velocity of actin filaments on smooth muscle myosin at lower concns. The well-known inhibitory effect of smooth muscle caldesmon on the actin-myosin interaction was observed with this motility assay when the concentration of the caldesmon was increased further. The

THIS PAGE BLANK (USPTO)

stimulatory and inhibitory effects were confirmed by measurements of actin-activated **ATPase** activity of smooth muscle myosin. From estns. of the intracellular concns. of the 210-kDa **protein** and smooth muscle caldesmon in vivo, it appears that effects of the former and the latter on actin-myosin interactions in vivo are **stimulatory** and inhibitory, resp.

IT 9000-83-3, **ATPase**

RL: BIOL (Biological study)
(of myosin, actin-binding **protein** of Physarum polycephalum and caldesmon of smooth muscle effect on)

L12 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1989:3408 HCAPLUS

DOCUMENT NUMBER: 110:3408

TITLE: Purification of **Plasmodium falciparum** digestive vacuoles and partial characterization of the vacuolar membrane **ATPase**

AUTHOR(S): Choi, Inpyo; Mego, John L.

CORPORATE SOURCE: Dep. Biol., Univ. Alabama, Tuscaloosa, AL, USA

SOURCE: Molecular and Biochemical Parasitology (1988), 31(1), 71-8

CODEN: MBIPDP; ISSN: 0166-6851

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **P. falciparum** digestive vacuoles containing Fe³⁺ oxide granules were purified from parasite homogenates by centrifugation on discontinuous sucrose gradients. Digestive vacuole membranes prepared by osmotic lysis and washed with KCl showed no detectable contamination by erythrocyte membrane **proteins** and only minimal contamination by nonvacuolar parasite **proteins**. Purified vacuolar membranes were 2.6-fold enriched in total parasite membrane **ATPase** activity. This **ATPase** was optimally active at pH 7 in the presence of >2 mM Mg²⁺. Ca²⁺ and Mn²⁺ were .apprx.80-90% as effective as Mg²⁺, and Zn²⁺, Co²⁺, and Fe²⁺ also exerted some **stimulatory** effect. The vacuolar membrane also hydrolyzed GTP, UTP, CTP, and ADP, but AMP and 3',5'-cAMP were hydrolyzed only one-tenth as effectively as ATP. The **ATPase** was unaffected by vanadate, ouabain, or oligomycin but was significantly inhibited by the proton pump inhibitors NEM and NBD-Cl. Of 6 antimalarial drugs tested, quinine and quinacrine were the most effective inhibitors and mefloquine was the least effective.

IT 9000-83-3P, **ATPase**

RL: PREP (Preparation)
(of digestive vacuoles of **Plasmodium falciparum**, purification and characterization of)

L12 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1982:434955 HCAPLUS

DOCUMENT NUMBER: 97:34955

TITLE: A novel 36,000-dalton actin-binding protein purified from microfilaments in Physarum **plasmodia** which aggregates actin filaments and blocks actin-myosin interaction

AUTHOR(S): Ogihara, Satoshi; Tonomura, Yuji

CORPORATE SOURCE: Fac. Sci., Osaka Univ., Osaka, 560, Japan

SOURCE: Journal of Cell Biology (1982), 93(3), 604-14

THIS PAGE BLANK (USPTO)

10/006780

CODEN: JCLBA3; ISSN: 0021-9525

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB The **plasmodia** of *P. polycephalum* contains large aggregates of entangled actin microfilaments. Treatment with Triton X-100 gave a demembraned cytoskeleton consisting of entangled actin filaments which showed almost no interaction with rabbit skeletal myosin. A novel actin-binding protein purified from the cytoskeleton stoichiometrically binds to actin and causes actin filaments to curl and aggregate. The protein inhibits **ATPase** activity as well as the superpptn. of reconstituted rabbit skeletal muscle actomyosin. This protein has a mol. weight of 36,000 and binds 7 mol of actin/mol 36,000 polypeptide.

IT 9000-83-3

RL: BIOL (Biological study)

(inhibition of, of actomyosin, actin-binding protein inhibition of)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 14:31:47 ON 07 OCT 2003)

L13 3 S L8

L14 21 S L10

L15 24 S L13 OR L14

L16 17 DUP REM L15 (7 DUPLICATES REMOVED)

L16 ANSWER 1 OF 17 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: 2003-505298 [47] WPIDS

DOC. NO. CPI: C2003-135135

TITLE: New vector, useful for preparing a composition for treating or preventing bacterial, viral, fungal or parasitic infection.

DERWENT CLASS: B04 C06 D16

INVENTOR(S): FRASER, W D; GALLAGHER, J A; MCCREAVY, D T

PATENT ASSIGNEE(S): (UYLI-N) UNIV LIVERPOOL

COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003048371	A2	20030612	(200347)*	EN	52
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003048371	A2	WO 2002-GB5512	20021206

PRIORITY APPLN. INFO: GB 2002-23829 20021012; GB 2001-29338 20011207

AN 2003-505298 [47] WPIDS

Searcher : Shears 308-4994

THIS PAGE BLANK (USPTO)

AB WO2003048371 A UPAB: 20030723

NOVELTY - An vector comprising a heterologous nucleic acid sequence encoding an antigenic **polypeptide** and a nucleic acid molecule comprising a 3188 base pair sequence, given in the specification, a nucleic acid molecule which hybridizes to it and which encodes a protease inhibitor **polypeptide**, or nucleic acid molecules which comprise degenerate nucleic acid sequences. The vector is adapted for the expression of each **polypeptide**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) inducing an immune response to an antigenic **polypeptide**;
- (2) an antibody;
- (3) a cell transformed with the novel vector;
- (4) producing humanized or chimeric antibody;
- (5) a hybridoma cell line which produces a monoclonal antibody;
- (6) a vaccine comprising the novel vector; and
- (7) vaccinating an animal, preferably a human, against at least one pathological condition.

ACTIVITY - Antibacterial; Virucide; Antiparasitic; Antifungal; Anti-HIV; Antiulcer.

No biological data is given.

MECHANISM OF ACTION - Gene therapy; Vaccine.

USE - The vector is useful for preparing a composition for preventing or treating AIDS, herpes, rubeola, rubella, varicella, influenza, common cold or viral meningitis; septicemia, tuberculosis, bacteria-associated food poisoning, blood infections, peritonitis, endocarditis, sepsis, bacterial meningitis, pneumonia, stomach ulcers, gonorrhea, strep throat, streptococcal-associated toxic shock, necrotizing fasciitis, impetigo, histoplasmosis, Lyme disease, gastro-enteritis, dysentery or shigellosis; Candidiasis; or trypanosomiasis, malaria, schistosomiasis or Chagas disease (claimed).

Dwg.0/9

L16 ANSWER 2 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003300235 EMBASE

TITLE: The pathophysiology of **falciparum** malaria.

AUTHOR: Clark I.A.; Cowden W.B.

CORPORATE SOURCE: I.A. Clark, Sch. of Biochem./Molecular Biology, Australian National University, Canberra, ACT 0200, Australia. ian.clark@anu.edu.au

SOURCE: Pharmacology and Therapeutics, (1 Aug 2003) 99/2 (221-260).

Refs: 466

ISSN: 0163-7258 CODEN: PTHDT

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 004 Microbiology

017 Public Health, Social Medicine and Epidemiology

026 Immunology, Serology and Transplantation

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB **Falciparum** malaria is a complex disease with no simple

THIS PAGE BLANK (USPTO)

explanation, affecting organs where the parasite is rare as well as those organs where it is more common. We continue to argue that it can best be understood in terms of excessive **stimulation** of normally useful pathways mediated by inflammatory cytokines, the prototype being tumor necrosis factor (TNF). These pathways involve downstream mediators, such as nitric oxide (NO) that the host normally uses to control parasites, but which, when uncontrolled, have bioenergetic failure of patient tissues as their predictable end point. **Falciparum** malaria is no different from many other infectious diseases that are clinically confused with it. The sequestration of parasitized red blood cells, prominent in some tissues but absent in others with equal functional loss, exacerbates, but does not change, these overriding principles. Recent opportunities to stain a wide range of tissues from African pediatric cases of **falciparum** malaria and sepsis for the inducible NO synthase (iNOS) and migration inhibitory factor (MIF) have strengthened these arguments considerably. The recent demonstration of bioenergetic failure in tissue removed from sepsis patients being able to predict a fatal outcome fulfils a prediction of these principles, and it is plausible that this will be demonstrable in severe **falciparum** malaria. Understanding the disease caused by **falciparum** malaria at a molecular level requires an appreciation of the universality of poly(ADP-ribose) polymerase-1 (PARP-1) and Na(+)/K(+)-**ATPase** and the protean effects of activation by inflammation of the former that include inactivation of the latter. .COPYRGT. 2003 Elsevier Inc. All rights reserved.

L16 ANSWER 3 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 1
 ACCESSION NUMBER: 2003191572 EMBASE
 TITLE: Replication fork-**stimulated** eIF-4A from **Plasmodium** cynomolgi unwinds DNA in the 3' to 5' direction and is inhibited by DNA-interacting compounds.
 AUTHOR: Tuteja R.; Tuteja N.; Malhotra P.; Chauhan V.S.
 CORPORATE SOURCE: R. Tuteja, Intl. Ctr. for Genetic Eng./Biotech., Aruna Asaf Ali Marg, New Delhi 110067, India. renu@icgeb.res.in
 SOURCE: Archives of Biochemistry and Biophysics, (1 Jun 2003) 414/1 (108-114).
 Refs: 47
 ISSN: 0003-9861 CODEN: ABBIA4
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB **Plasmodium** cynomolgi. DEAD-box DNA helicase 45 (PcDDH45) is an ATP-dependent DNA-unwinding enzyme with intrinsic DNA-dependent **ATPase** activity and is highly homologous to eIF-4A. In this study, we have further characterized and tested the effect of various DNA-interacting compounds on the DNA-unwinding activity of PcDDH45. The results show that PcDDH45 translocates in the 3' to 5' direction along the bound strand, a replication fork-like structure of the substrate **stimulates** its DNA-unwinding activity, and it failed to unwind blunt-ended duplex DNA. Of various compounds

THIS PAGE BLANK (USPTO)

tested, only cisplatin, 4',6'-diamidino-2-phenylindole, daunorubicin, and nogalamycin were inhibitory to the unwinding activity of PcDDH45 with apparent IC(50) values of 1.0, 4.0, 7.5, and 1.7 μ M, respectively. These results suggest that the interaction of these compounds with duplex DNA generate a complex that probably impedes the translocation of PcDDH45, resulting in inhibition of unwinding activity. This study is one of the first to demonstrate the effect of various DNA-binding compounds on a malaria parasite DNA helicase and should make an important contribution to our better understanding of the nucleic acid transactions in the parasite. .COPYRG. 2003 Elsevier Science (USA). All rights reserved.

L16 ANSWER 4 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 2002:547065 SCISEARCH
 THE GENUINE ARTICLE: 566XK
 TITLE: Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: A search for reversal agents
 AUTHOR: Perez-Victoria J M; Di Pietro A; Barron D; Ravelo A G; Castanys S; Gamarro F (Reprint)
 CORPORATE SOURCE: CSIC, Inst Parasitol & Biomed Lopez Neyra, C Ventanilla 11, Granada 18001, Spain (Reprint); CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain; CNRS, UMR 5086, Inst Biol & Chim Prot, Lyon, France; Univ Lyon 1, CNRS, Lab Prod Nat, F-69622 Villeurbanne, France; Univ La Laguna, Inst Bioorgan Antonio Gonzalez, Tenerife, Spain
 COUNTRY OF AUTHOR: Spain; France
 SOURCE: CURRENT DRUG TARGETS, (AUG 2002) Vol. 3, No. 4, pp. 311-333.
 Publisher: BENTHAM SCIENCE PUBL LTD, PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS.
 ISSN: 1389-4501.
 DOCUMENT TYPE: General Review; Journal
 LANGUAGE: English
 REFERENCE COUNT: 193

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Protozoan parasites are responsible for important diseases that threaten the lives of nearly one-quarter of the human population world-wide. Among them, leishmaniasis has become the second cause of death, mainly due to the emergence of parasite resistance to conventional drugs. P-glycoprotein (Pgp)-like transporters overexpression is a very efficient mechanism to reduce the intracellular accumulation of many drugs in cancer cells and parasitic protozoans including *Plasmodium* and *Leishmania*, thus conferring a multidrug resistance (MDR) phenotype. Therefore, there is a great clinical interest in developing inhibitors of these transporters to overcome such a resistance. Pgps are active pumps belonging to the ATP-binding cassette (ABC) superfamily of **proteins**, and consist of two homologous halves, each containing a transmembrane domain (TMD) involved in drug efflux, and a cytosolic nucleotide-binding domain (NBD) responsible for ATP binding and hydrolysis. Most conventional cancer MDR modulators interact with the drug-binding sites on the TMDs of Pgps, but they are also usually transported and the required concentrations for a permanent inhibition produce subsequent side-effects that hamper their clinical use. Besides, they only poorly modulate the

THIS PAGE BLANK (USPTO)

resistance in protozoan parasites. We review here a rational strategy developed to overcome the MDR phenotype in *Leishmania*, consisting in: i) the selection of an MDR *Leishmania tropica* line that overexpresses a Pgp-like transporter; ii) the use of their cytosolic NBDs as new pharmacological targets; iii) the search of new natural compounds that revert the MDR phenotype in *Leishmania* by binding to the TMDs; iv) the combination of subdoses of the above selected modulators directed to both targets in the transporter, NBDs and TMDs, to accumulate their reversal effects while diminishing their toxicity. In this way, we have reverted the MDR phenotype in *Leishmania*, including the resistance to the most promising new antileishmania agents, the alkyl-lysophospholipids. This approach might be extrapolated to be used in other eukaryotic cells.

L16 ANSWER 5 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2002097347 EMBASE
 TITLE: Cytoskeleton of apicomplexan parasites.
 AUTHOR: Morrisette N.S.; Sibley L.D.
 CORPORATE SOURCE: N.S. Morrisette, Department of Molecular Microbiology, Washington Univ. School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110, United States. naomi@borcim.wustl.edu
 SOURCE: Microbiology and Molecular Biology Reviews, (2002) 66/1 (21-38).
 Refs: 200
 ISSN: 1092-2172 CODEN: MMBRF7
 COUNTRY: United States
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 004 Microbiology
 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB The Apicomplexa are a phylum of diverse obligate intracellular parasites including *Plasmodium* spp., the cause of malaria; *Toxoplasma gondii* and *Cryptosporidium parvum*, opportunistic pathogens of immunocompromised individuals; and *Eimeria* spp. and *Theileria* spp., parasites of considerable agricultural importance. These protozoan parasites share distinctive morphological features, cytoskeletal organization, and modes of replication, motility, and invasion. This review summarizes our current understanding of the cytoskeletal elements, the properties of cytoskeletal proteins, and the role of the cytoskeleton in polarity, motility, invasion, and replication. We discuss the unusual properties of actin and myosin in the Apicomplexa, the highly stereotyped **microtubule** populations in apicomplexans, and a network of recently discovered novel intermediate filament-like elements in these parasites.

L16 ANSWER 6 OF 17 MEDLINE on STN DUPLICATE 2

ACCESSION NUMBER: 2001560947 MEDLINE
 DOCUMENT NUMBER: 21519010 PubMed ID: 11606229
 TITLE: **Microtubule** associated motor proteins of *Plasmodium falciparum* merozoites.
 AUTHOR: Fowler R E; Smith A M; Whitehorn J; Williams I T; Bannister L H; Mitchell G H
 CORPORATE SOURCE: Malaria Laboratory, Department of Immunobiology,

THIS PAGE BLANK (USPTO)

10/006780

Guy's, King's and St Thomas' School of Medicine, KCL,
Guy's Hospital, London Bridge, London, SE1 9RT, UK..
ruth.fowler@ed.ac.uk

SOURCE: MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (2001 Oct)
117 (2) 187-200.
Journal code: 8006324. ISSN: 0166-6851.

PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200201
ENTRY DATE: Entered STN: 20011022
Last Updated on STN: 20020201
Entered Medline: 20020131

AB We have studied the occurrence, stage specificity and cellular location of key molecules associated with **microtubules** in **Plasmodium falciparum** merozoites. Antibodies to gamma tubulin, conventional kinesin and cytoplasmic dynein were used to determine the polarity of merozoite **microtubules** (mt), the stage specificity of the motor proteins and their location during merozoite development. We conclude that the minus ends of the mts are located at their apical pole. Kinesin was present throughout the lifecycle, appearing as a distinct crescent at the apex of developing merozoites. The vast majority of cytoplasmic dynein reactivity occurred in late merogony, also appearing at the merozoite apex. Destruction of mt with dinitroanilines did not affect the cellular location of kinesin or dynein. In invasion assays, dynein inhibitors reduced the number of ring stage parasites. Our results show that both conventional kinesin and cytoplasmic dynein are abundant, located at the negative pole of the merozoite mt and, intriguingly, appear there only in very late merogony, prior to merozoite release and invasion.

L16 ANSWER 7 OF 17 MEDLINE on STN

ACCESSION NUMBER: 2001297917 MEDLINE
DOCUMENT NUMBER: 21273137 PubMed ID: 11378198
TITLE: Two classes of plant-like vacuolar-type H(+)-pyrophosphatases in malaria parasites.
AUTHOR: McIntosh M T; Drozdowicz Y M; Laroia K; Rea P A; Vaidya A B
CORPORATE SOURCE: Department of Microbiology and Immunology, MCP Hahnemann University, 2900 Queen Lane, Philadelphia, PA 19129, USA.. michael.t.mcintosh@drexel.edu
CONTRACT NUMBER: AF28398
SOURCE: MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (2001 May) 114 (2) 183-95.
Journal code: 8006324. ISSN: 0166-6851.

PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF115766; GENBANK-AF115767; GENBANK-AF283528
ENTRY MONTH: 200108
ENTRY DATE: Entered STN: 20010806
Last Updated on STN: 20010806
Entered Medline: 20010802

AB In plants, cytosolic inorganic pyrophosphate (PP(i)) is hydrolyzed by energy-conserving vacuolar-type H(+)-pyrophosphatases (V-PPases)

THIS PAGE BLANK (USPTO)

that harness the free energy of PP(i) hydrolysis to establish transmembrane H(+) gradients. Here we describe the identification and cloning of two genes, PfVPP1 and PfVPP2, from the malaria parasite *Plasmodium falciparum*. Inferred to encode type I (K(+)-dependent) and type II (K(+)-independent) V-PPases, respectively, PfVPP1 and PfVPP2 appeared more sequence divergent from each other than from their type I and type II counterparts in plants. The steady state levels of PfVPP1 mRNA were high in comparison to PfVPP2 mRNA throughout the erythrocytic phases of infection. Western analyses of trophozoite membranes using generic V-PPase antibodies (PAB(HK) and PAB(TK)) demonstrated appreciable amounts of a Mr 67000 **polypeptide** whose associated aminomethylenediphosphonate- (AMDP) inhibitable PPase activity was markedly **stimulated** by K(+). Immunofluorescence microscopy of infected erythrocytes revealed PfVPP antigen associated with both the parasite plasma membrane and punctate intracellular inclusions. Transient transfection of a PfVPP1-GFP fusion further supported the localization of PfVPP1 to the parasite plasma membrane. Based on these findings and the growth-retarding effects of AMDP, *P. falciparum* is concluded to possess both type I and type II V-PPases of which the former has the greatest potential for contributing to the establishment of H(+) gradients across the parasite plasma membrane under conditions of energy limitation.

L16 ANSWER 8 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 2001:373496 SCISEARCH
 THE GENUINE ARTICLE: 427QR
 TITLE: Detection and localization of a Ca²⁺-**ATPase** activity in *Toxoplasma gondii*
 AUTHOR: Bouchot A; Jaillet J D; Bonhomme A (Reprint); Pezzella-D'Alessandro N; Laquerriere P; Kilian L; Burlet H; Gomez-Marin J E; Pluot M; Bonhomme P; Pinon J M
 CORPORATE SOURCE: CHU Maison Blanche, IFR 53, UPRES EA 2070, 51 Rue Cognacq Jay, F-51095 Reims, France (Reprint); CHU Maison Blanche, IFR 53, UPRES EA 2070, F-51095 Reims, France; CHU Maison Blanche, IFR 53, Lab Parasitol Mycol, F-51095 Reims, France; Lab Microscopie Elect Analyt & Quantitat, IFR 53, Reims, France; Hop Robert Debre, Anat Pathol Lab, Reims, France; Univ Nacl Colombia, Hosp San Juan de Dios, Dept Med Interna, Grp Pathol Infecciosa, Santafe De Bogota, Colombia
 COUNTRY OF AUTHOR: France; Colombia
 SOURCE: CELL STRUCTURE AND FUNCTION, (FEB 2001) Vol. 26, No. 1, pp. 49-60.
 Publisher: JAPAN SOC CELL BIOLOGY, SHIMOTACHIURI OGAWA-HIGASHI, KAMIKYOKU KYOTO, 602, JAPAN.
 ISSN: 0386-7196.
 DOCUMENT TYPE: Article; Journal
 LANGUAGE: English
 REFERENCE COUNT: 59

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB *Toxoplasma gondii*, the agent causing toxoplasmosis, is an obligate intracellular protozoan parasite. A calcium signal appears to be essential for intracellular transduction during the active process of host cell invasion. We have looked for a Ca²⁺-transport **ATPase** in tachyzoites and found Ca²⁺-**ATPase**

THIS PAGE BLANK (USPTO)

activity (11-22 nmol Pi liberated/mg **protein**/min) in the tachyzoite membrane fraction, This ATP-dependent activity was **stimulated** by Ca²⁺ and Mg²⁺ ions and by calmodulin, and was inhibited by pump inhibitors (sodium orthovanadate or thapsigargin). We used cytochemistry and X-ray microanalysis of cerium phosphate precipitates and immunolabelling to find the Ca²⁺, Mg²⁺-**ATPase**. It was located mainly in the membrane complex, the conoid, nucleus, secretory organelles (rhoptries, dense granules) and in vesicles with a high calcium concentration, Thus, *Toxoplasma gondii* possesses Ca²⁺-pump **ATPase** (Ca²⁺, Mg²⁺-**ATPase**) as do eukaryotic cells.

L16 ANSWER 9 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 2000:622594 SCISEARCH
 THE GENUINE ARTICLE: 343QA
 TITLE: Vacuolar proton pyrophosphatase activity and pyrophosphate (PPi) in *Toxoplasma gondii* as possible chemotherapeutic targets
 AUTHOR: Rodrigues C O; Scott D A; Bailey B N; deSouza W; Benchimol M; Moreno B; Urbina J A; Oldfield E; Moreno S N J (Reprint)
 CORPORATE SOURCE: UNIV ILLINOIS, COLL VET MED, DEPT PATHOBIOL, MOL PARASITOL LAB, 2001 S LINCOLN AVE, URBANA, IL 61802 (Reprint); UNIV ILLINOIS, COLL VET MED, DEPT PATHOBIOL, MOL PARASITOL LAB, URBANA, IL 61802; UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801; UNIV ILLINOIS, DEPT BIOPHYS, URBANA, IL 61801; UNIV SANTA URSULA, RIO JANEIRO, BRAZIL; INST VENEZOLANO INVEST CIENT, CARACAS, VENEZUELA; UNIV FED RIO DE JANEIRO, INST BIOFIS CARLOS CHAGAS FILHO, BR-21941 RIO JANEIRO, BRAZIL
 COUNTRY OF AUTHOR: USA; BRAZIL; VENEZUELA
 SOURCE: BIOCHEMICAL JOURNAL, (1 AUG 2000) Vol. 349, Part 3, pp. 737-745.
 Publisher: PORTLAND PRESS, 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND.
 ISSN: 0264-6021.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: English
 REFERENCE COUNT: 50

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The addition of PPi promoted the acidification of a subcellular compartment in cell homogenates of *Toxoplasma gondii* tachyzoites, implying the presence of a proton-translocating pyrophosphatase. The proton gradient was collapsed by addition of the K⁺/H⁺ antiporter nigericin, and was also inhibited by addition of the PP, analogue aminomethylenediphosphonate (AMDP). Both proton transport and PPi hydrolysis were dependent upon K⁺, but Na⁺ caused partial inhibition of these activities. PPi hydrolysis was sensitive in a dose-dependent manner to AMDP, imidodiphosphate, NaF and to the thiol reagent N-ethylmaleimide. This activity was unaffected by common inhibitors of phosphohydrolases, except that NaO₃V (sodium orthovanadate) **stimulated** the activity by 87%. Immunofluorescence microscopy, using antisera raised against conserved **peptide** sequences of a plant vacuolar pyrophosphatase, suggested that the pyrophosphatase in *T. gondii* tachyzoites was located in the plasma membrane and intracellular

THIS PAGE BLANK (USPTO)

vacuoles of the parasite. High-field P-31-NMR spectroscopy showed that PPI was more abundant than ATP in tachyzoites. Bisphosphonates (PPI analogues), drugs that are used in the treatment of bone diseases, inhibited proton transport and PPI hydrolysis in tachyzoite homogenates, and also inhibited intracellular proliferation of tachyzoites in tissue culture cells.

L16 ANSWER 10 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 2000:385352 SCISEARCH
 THE GENUINE ARTICLE: 314FV
 TITLE: AVP2, a sequence-divergent, K⁺-insensitive H⁺-translocating inorganic pyrophosphatase from arabidopsis
 AUTHOR: Drozdowicz Y M; Kissinger J C; Rea P A (Reprint)
 CORPORATE SOURCE: UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 (Reprint); UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104
 COUNTRY OF AUTHOR: USA
 SOURCE: PLANT PHYSIOLOGY, (MAY 2000) Vol. 123, No. 1, pp. 353-362.
 Publisher: AMER SOC PLANT PHYSIOLOGISTS, 15501 MONONA DRIVE, ROCKVILLE, MD 20855.
 ISSN: 0032-0889.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE; AGRI
 LANGUAGE: English
 REFERENCE COUNT: 42

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Plant vacuolar H⁺-translocating inorganic pyrophosphatases (V-PPases; EC 3.6.1.1) have been considered to constitute a family of functionally and structurally monotonous intrinsic membrane **proteins**. Typified by AVP1 (V. Sarafian, Y. Kim, R.J. Poole, P.A. Rea [1992] Proc Natl Acad Sci USA 89: 1775-1779) from Arabidopsis, all characterized plant V-PPases share greater than 84% sequence identity and catalyze K⁺-**stimulated** H⁺ translocation. Here we describe the molecular and biochemical characterization of AVP2 (accession number AF182813), a sequence-divergent (36% identical) K⁺-insensitive, Ca²⁺-hypersensitive V-PPase active in both inorganic pyrophosphate hydrolysis and H⁺ translocation. The differences between AVP2 and AVP1 provide the first indication that plant V-PPases from the same organism fall into two distinct categories. Phylogenetic analyses of these and other V-PPase sequences extend this principle by showing that AVP2, rather than being an isoform of AVP1, is but one representative of a novel category of AVP2-like (type II) V-PPases that coexist with AVP1-like (type I) V-PPases not only in plants, but also in apicomplexan protists such as the malarial parasite **Plasmodium falciparum**.

L16 ANSWER 11 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 DUPLICATE 3
 ACCESSION NUMBER: 96:116360 SCISEARCH
 THE GENUINE ARTICLE: TT475
 TITLE: ISOLATION AND CHARACTERIZATION OF SEA SPONGE MYOSIN
 AUTHOR: KANZAWA N (Reprint); TAKANO OHMURO H; MARUYAMA K
 CORPORATE SOURCE: CHIBA UNIV, FAC SCI, DEPT BIOL, CHIBA 263, JAPAN (Reprint); UNIV TOKYO, FAC MED, DEPT PHARMACOL, TOKYO 113, JAPAN

THIS PAGE BLANK (USPTO)

COUNTRY OF AUTHOR: JAPAN
 SOURCE: ZOOLOGICAL SCIENCE, (DEC 1995) Vol. 12, No. 6, pp. 765-769.
 ISSN: 0289-0003.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE; AGRI
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 17

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Myosin was purified to a homogeneity from sea sponge, Halichondria okadai. The myosin consisted of 220 kDa heavy chain, 18 kDa calcium binding light chain and 21 kDa phosphorylatable light chain. Rotary shadowed images showed the two headed myosin (myosin II) with a 160 nm tail. The myosin was less soluble in a KCl solution as compared to rabbit skeletal myosin.

The K+-stimulated and Ca2+-stimulated ATPase activities of sea sponge myosin were 0.46 and 0.07 μ mol Pi min⁻¹ mg⁻¹, respectively. The Mg2+ activated myosin ATPase activity showed no significant enhancement by the addition of rabbit skeletal muscle actin despite that the light chain was phosphorylated by myosin light chain kinase from chicken gizzard. Sea sponge myosin 18 kDa light chain bound to Ca2+ ion but was not phosphorylated like Physarum plasmodia myosin light chains.

L16 ANSWER 12 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 95:282492 SCISEARCH
 THE GENUINE ARTICLE: QT916
 TITLE: DRUG-STIMULATED ATPASE ACTIVITY OF THE HUMAN P-GLYCOPROTEIN
 AUTHOR: SCARBOROUGH G A (Reprint)
 CORPORATE SOURCE: UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC, 27599 (Reprint)
 COUNTRY OF AUTHOR: USA
 SOURCE: JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, (FEB 1995)
 Vol. 27, No. 1, pp. 37-41.
 ISSN: 0145-479X.
 DOCUMENT TYPE: General Review; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 41

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The human multidrug resistance **protein**, or P-glycoprotein (Pgp), exhibits a high-capacity drug-dependent ATP hydrolytic activity that is a direct reflection of its drug transport capability. This activity is readily measured in membranes isolated from cultured insect cells infected with a baculovirus carrying the human mdrl cDNA. The drug-stimulated ATPase activity is a useful alternative to conventional screening systems for identifying high-affinity drug substrates of the Pgp with potential clinical value as chemosensitizers for tumor cells that have become drug resistant. Using this assay system, a variety of drugs have been directly shown to interact with the Pgp. Many of the drugs **stimulate** the Pgp ATPase activity, but certain drugs bind tightly to the drug-binding site of the Pgp without eliciting ATP hydrolysis. Either class of drugs may be useful as chemosensitizing agents. The baculovirus/insect cell Pgp ATPase assay system may also facilitate future studies

THIS PAGE BLANK (USPTO)

of the molecular structure and mechanism of the Pgp.

L16 ANSWER 13 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1993:346268 BIOSIS
DOCUMENT NUMBER: PREV199396043268
TITLE: Absence of transitory (Ca-2+)-i flux during early in vitro metacyclogenesis of Trypanosoma cruzi.
AUTHOR(S): Krassner, Stuart M. (1); Chang, Johnny; Pak, Sung; Luc, Kim-Oanh; Granger, Barbara
CORPORATE SOURCE: (1) Dep. Dev. Cell Biol., Univ. Calif., Irvine, CA 92717 USA
SOURCE: Journal of Eukaryotic Microbiology, (1993) Vol. 40, No. 2, pp. 224-230.
ISSN: 1066-5234.
DOCUMENT TYPE: Article
LANGUAGE: English

AB The phorbol ester TPA (phorbol 12-myristate 13-acetate) substitutes for CO-2 as an agonist for transforming Trypanosoma cruzi epimastigotes to the metacyclic trypomastigote stage in a starvation medium consisting of phosphate buffered saline + 10 mM proline, 10 mM sodium acetate and 0.035% NaHCO-3. Since TPA is thought to **stimulate protein kinase C** by mimicking the activity of the secondary messenger diacylglycerol, the above result suggested that T. cruzi metacyclogenesis could be activated by a Ca-2+-dependent **protein kinase C** signal induction pathway. Accordingly, cytosolic calcium Bux ((Ca-2+)-i) in epimastigotes, activated with 5% CO-2 or TPA (10⁻⁷ M), was measured with the Ca-2+ molecular probe, fluo-3AM. In addition, (Ca-2+)-i was measured in cells incubated with putative metacyclogenic agonists (e.g. proline, glutamate, bioamines, ionophores and catecholamines). None of the compounds studied, except for EGTA, affected cytosolic Ca-2+ levels. Control assays with 11 mu-M thapsigargin, which mobilizes noncytoplasmic Ca-2+ stores by inhibiting endoplasmic reticulum Ca-2+-ATPase, validated our fluorometric assay procedure. Although thapsigargin significantly increases cytoplasmic Ca-2+ fluorescence, it has no effect on transformation. The **protein kinase C** inhibitors staurosporine, H-7 and HA 1004 were tested for their effect on T. cruzi metacyclogenesis. Low concentrations of staurosporine and HA 1004 significantly elevated Peru strain transformation while H-7 had no effect on Peru strain metacyclogenesis. Inhibitor H-7 did significantly depress CL transformation. The results indicate that induction of T. cruzi metacyclic trypomastigote formation by CO-2 and TPA is not accompanied by changes in cytosolic Ca-2+ and do not provide supporting evidence for participation of a **protein kinase C**-mediated phosphoinositide cascade in metacyclogenesis.

L16 ANSWER 14 OF 17 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 92042085 MEDLINE
DOCUMENT NUMBER: 92042085 PubMed ID: 1834662
TITLE: **Stimulation** of the interaction between actin and myosin by Physarum caldesmon-like **protein** and smooth muscle caldesmon.
AUTHOR: Ishikawa R; Okagaki T; Higashi-Fujime S; Kohama K
CORPORATE SOURCE: Department of Pharmacology, Gunma University School of Medicine, Japan.
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1991 Nov 15) 266

THIS PAGE BLANK (USPTO)

10/006780

(32) 21784-90.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199112
ENTRY DATE: Entered STN: 19920124
Last Updated on STN: 19970203
Entered Medline: 19911223

AB We have purified an actin-binding **protein** from the **plasmodia** of a lower eukaryote, *Physarum polycephalum*, with an apparent molecular mass of 210,000 daltons on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This **protein** bound to actin filaments with a stoichiometry of 1:7-8 in a $\text{Ca}(2+)$ -calmodulin-dependent manner. Antibody raised against caldesmon from smooth muscle cross-reacted with the 210-kDa **protein**. In vitro motility assay revealed that the 210-kDa **protein** increased the sliding velocity of actin filaments on *Physarum* myosin. The 210-kDa **protein** more than doubled the actin-activated **ATPase** activity of *Physarum* myosin under comparative conditions of in vitro motility assay. Further increases in the concentration of the 210-kDa **protein** decreased its **stimulatory** effects. $\text{Ca}(2+)$ -calmodulin prevented the **stimulatory** effects of the 210-kDa **protein**. Unexpectedly, smooth muscle caldesmon also increased the sliding velocity of actin filaments on smooth muscle myosin at lower concentrations. The well-known inhibitory effect of smooth muscle caldesmon on the actin-myosin interaction was observed with this motility assay when the concentration of the caldesmon was increased further. The **stimulatory** and inhibitory effects were confirmed by measurements of actin-activated **ATPase** activity of smooth muscle myosin. From estimations of the intracellular concentrations of the 210-kDa **protein** and smooth muscle caldesmon in vivo, it appears that effects of the former and the latter on actin-myosin interactions in vivo are **stimulatory** and inhibitory, respectively.

L16 ANSWER 15 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
ACCESSION NUMBER: 91:631866 SCISEARCH
THE GENUINE ARTICLE: GP804
TITLE: **STIMULATION OF THE INTERACTION BETWEEN
ACTIN AND MYOSIN BY PHYSARUM CALDESMON-LIKE
PROTEIN AND SMOOTH-MUSCLE CALDESMON**
AUTHOR: ISHIKAWA R (Reprint); OKAGAKI T; HIGASHIFUJIME S;
KOHAMA K
CORPORATE SOURCE: GUNMA UNIV, SCH MED, DEPT PHARMACOL, MAEBASHI, GUNMA
371, JAPAN (Reprint); NIHON UNIV, PHYS SCI LABS,
FUNABASHI, CHIBA 274, JAPAN; NAGOYA UNIV, FAC SCI,
DEPT MOLEC BIOL, NAGOYA, AICHI 464, JAPAN
COUNTRY OF AUTHOR: JAPAN
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1991) Vol. 266,
No. 32, pp. 21784-21790.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 30

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

THIS PAGE BLANK (USPTO)

AB We have purified an actin-binding **protein** from the **plasmodia** of a lower eukaryote, *Physarum polycephalum*, with an apparent molecular mass of 210,000 daltons on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This **protein** bound to actin filaments with a stoichiometry of 1:7-8 in a Ca^{2+} -calmodulin-dependent manner. Antibody raised against caldesmon from smooth muscle cross-reacted with the 210-kDa **protein**. In vitro motility assay revealed that the 210-kDa **protein** increased the sliding velocity of actin filaments on *Physarum* myosin. The 210-kDa **protein** more than doubled the actin-activated **ATPase** activity of *Physarum* myosin under comparative conditions of in vitro motility assay. Further increases in the concentration of the 210-kDa **protein** decreased its **stimulatory** effects. Ca^{2+} -calmodulin prevented the **stimulatory** effects of the 210-kDa **protein**. Unexpectedly, smooth muscle caldesmon also increased the sliding velocity of actin filaments on smooth muscle myosin at lower concentrations. The well-known inhibitory effect of smooth muscle caldesmon on the actin-myosin interaction was observed with this motility assay when the concentration of the caldesmon was increased further. The **stimulatory** and inhibitory effects were confirmed by measurements of actin-activated **ATPase** activity of smooth muscle myosin. From estimations of the intracellular concentrations of the 210-kDa **protein** and smooth muscle caldesmon in vivo, it appears that effects of the former and the latter on actin-myosin interactions in vivo are **stimulatory** and inhibitory, respectively.

L16 ANSWER 16 OF 17 MEDLINE on STN DUPLICATE 5
 ACCESSION NUMBER: 89040035 MEDLINE
 DOCUMENT NUMBER: 89040035 PubMed ID: 2972931
 TITLE: Purification of **Plasmodium falciparum** digestive vacuoles and partial characterization of the vacuolar membrane **ATPase**.
 AUTHOR: Choi I; Mego J L
 CORPORATE SOURCE: Department of Biology, University of Alabama, Tuscaloosa 35487.
 SOURCE: MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1988 Oct) 31 (1) 71-8.
 Journal code: 8006324. ISSN: 0166-6851.
 PUB. COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198812
 ENTRY DATE: Entered STN: 19900308
 Last Updated on STN: 19900308
 Entered Medline: 19881220

AB **Plasmodium falciparum** digestive vacuoles containing ferric oxide granules were purified from parasite homogenates by centrifugation on discontinuous sucrose gradients. Digestive vacuole membranes prepared by osmotic lysis and washed with KCl showed no detectable contamination by erythrocyte membrane **proteins** and only minimal contamination by non-vacuolar parasite **proteins**. Purified vacuolar membranes were 2.6-fold enriched in total parasite membrane **ATPase** activity. This **ATPase** was optimally active at pH 7 in the

THIS PAGE BLANK (USPTO)

presence of at least 2 mM Mg²⁺. Ca²⁺ and Mn²⁺ were approximately 80-90% as effective as Mg²⁺, and Zn²⁺, Co²⁺ and Fe²⁺ also exerted some **stimulatory** effect. The vacuolar membrane also hydrolyzed GTP, UTP, CTP and ADP, but AMP and 3',5'-cyclic AMP were hydrolyzed only one-tenth as effectively as ATP. The **ATPase** was unaffected by vanadate, ouabain or oligomycin but was significantly inhibited by the proton pump inhibitors NEM and NBD-Cl. Of 6 antimalarial drugs tested, quinine and quinacrine were the most effective inhibitors and mefloquine was the least effective.

L16 ANSWER 17 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 74138989 EMBASE

DOCUMENT NUMBER: 1974138989

TITLE: The biosynthesis of plasmodial myosin during starvation of *Physarum polycephalum*.

AUTHOR: White F.H.; Lascelles J.

CORPORATE SOURCE: Dept. Bacteriol., Univ. California, Los Angeles, Calif. 90025, United States

SOURCE: Biochemical Journal, (1973) 135/4 (639-647).
CODEN: BIJOAK

DOCUMENT TYPE: Journal

FILE SEGMENT: 029 Clinical Biochemistry

LANGUAGE: English

AB The actomyosin **protein** complex of *Physarum polycephalum* was prepared from vegetative and starved **plasmodia**. The yield of actomyosin per unit wet wt was the same from both types of **plasmodia**. Myosin was resolved from the complex by gel filtration and purified by ion exchange chromatography. The Ca²⁺ **stimulated adenosine triphosphatase** activities of myosin preparations from vegetative and starved **plasmodia** were not appreciably different. Synthesis of myosin de novo was shown to occur during the starvation phase of the life cycle by the isolation of labelled myosin preparations from **plasmodia** starved in the presence of [2-¹⁴C]glycine. Fractionation of polyacrylamide gels after gel filtration of labelled myosin confirmed the presence of label in the **adenosine triphosphatase** active myosin band. It is concluded that during starvation myosin synthesis continues although there is a net loss of approx. 50% of the total **protein**. Sodium dodecyl sulphate polyacrylamide gel electrophoresis of *Physarum* myosin showed the presence of low molecular weight components of the molecule, similar to those of muscle myosins. The content and composition of the free amino acid pool to *Physarum* was measured at various time intervals during the vegetative and starvation phases of the life cycle.

(FILE 'MEDLINE' ENTERED AT 14:43:41 ON 07 OCT 2003)

L29 12195 SEA FILE=MEDLINE ABB=ON PLU=ON "PLASMODIUM FALCIPARUM"/CT

L30 28410 SEA FILE=MEDLINE ABB=ON PLU=ON ADENOSINETRIPHOSPHATASE/CT

L31 17 SEA FILE=MEDLINE ABB=ON PLU=ON L29 AND L30

L31 ANSWER 1 OF 17 MEDLINE on STN

AN 2002675294 MEDLINE

TI Transport processes in *Plasmodium falciparum*-infected erythrocytes:

THIS PAGE BLANK (USPTO)

- potential as new drug targets.
- AU Krishna Sanjeev; Eckstein-Ludwig Ursula; Joet Thierry; Uhlemann Anne-Catrin; Morin Christophe; Webb Richard; Woodrow Charles; Kun Jorgen F J; Kremsner Peter G
- SO INTERNATIONAL JOURNAL FOR PARASITOLOGY, (2002 Dec 4) 32 (13) 1567-73. Ref: 39
Journal code: 0314024. ISSN: 0020-7519.
- AB Plasmodium falciparum infection induces alterations in the transport properties of infected erythrocytes that have recently been defined using electrophysiological techniques. Mechanisms responsible for transport of substrates into intraerythrocytic parasites have also been clarified by studies of three substrate-specific (hexose, nucleoside and aquaglyceroporin) parasite plasma membrane transporters. These have been characterised functionally using the *Xenopus laevis* oocyte heterologous expression system. The same expression system is currently being used to define the function of parasite 'P' type ATPases responsible for intraparasitic [Ca(2+)] homeostasis. We review studies on these transport processes and examine their potential as novel drug targets.
- L31 ANSWER 2 OF 17 MEDLINE on STN
- AN 2001479314 MEDLINE
- TI Characterization of P-type ATPase 3 in *Plasmodium falciparum*.
- AU Rozmajzl P J; Kimura M; Woodrow C J; Krishna S; Meade J C
- SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (2001 Sep 3) 116 (2) 117-26. Journal code: 8006324. ISSN: 0166-6851.
- AB We report the nucleotide sequence, derived amino acid sequence and expression profile of P-type ATPase 3 (PfATPase3) from *Plasmodium falciparum*. An open reading frame of 7362 nucleotides, interrupted by a single intron of 168 nt, encoded a protein product of 2394 amino acids with a predicted MW of 282791 Da. Hydropathy analysis of PfATPase3 revealed six amino-terminal and six carboxyl-terminal membrane spanning regions (M1-12) flanking a large hydrophilic domain with a smaller hydrophilic loop between M4 and M5. Based on a phylogenetic comparison of conserved domains present in P-type ATPases from other organisms, PfATPase3 resembled a Type-V ATPase for which the transport affinity is unknown. The PfATPase3 topology was interrupted by four regions, termed 'inserts', unique to malarial P-type ATPases, which were high in asparagine residues and charged amino acids (inserts I1-I4). Inserts I1 and I3 also contained repeated amino acid motifs. The number and composition of repeated amino acid motifs in insert I3 were variable in seven *P. falciparum* strains tested. PfATPase3 was 80.2% similar to the non-insert portions of *P. yoelii* ATPase3, although their inserts differed in length and composition. PfATPase3 mRNA was most abundant relative to beta-tubulin during the latter half of the erythrocytic cycle and was also present in gametocytes. Using affinity-purified antibody to a 14 amino acid PfATPase3 epitope, a 260 kDa protein was detected by Western analysis. Based on immunofluorescence, the PfATPase3 protein was located intracellularly in gametocytes and, to a lesser extent, in late erythrocytic stages.
- L31 ANSWER 3 OF 17 MEDLINE on STN
- AN 2000386953 MEDLINE
- TI Molecular cloning of a gene encoding a 20S proteasome beta subunit from *Plasmodium falciparum*.
- AU Li G D; Li J L; Mugthin M; Ward S A

THIS PAGE BLANK (USPTO)

- SO INTERNATIONAL JOURNAL FOR PARASITOLOGY, (2000 May) 30 (6) 729-33.
Journal code: 0314024. ISSN: 0020-7519.
- AB A novel gene was cloned from *Plasmodium falciparum*. Database searches indicated this gene to be a member of the 20S proteasome beta-subunit family. Comparison of the gene's genomic DNA sequence with cDNA sequence revealed a 156-bp intron 85 bp downstream from the start codon. The nucleotide sequence of the gene contains one open reading frame encoding 265 amino acids with a predicted molecular mass of 30.9 kDa and a pI of 6.2. Northern blot analysis showed the transcript size to be approximately 1.6 kb indicating that some 800 bp of the transcript is non-coding.
- L31 ANSWER 4 OF 17 MEDLINE on STN
- AN 2000002518 MEDLINE
- TI Cloning and partial characterization of the proteasome S4 ATPase from *Plasmodium falciparum*.
- AU Certad G; Abraham A; Georges E
- SO EXPERIMENTAL PARASITOLOGY, (1999 Nov) 93 (3) 123-31.
Journal code: 0370713. ISSN: 0014-4894.
- AB Certad, G., Abraham, A., and Georges, E. 1999. Cloning and Partial characterization of the proteasome S4 ATPase from *Plasmodium falciparum*. *Experimental Parasitology* 93, 123-131. The ATP-ubiquitin-proteasome pathway mediates the nonlysosomal degradation of cytosolic proteins in eukaryotic cells. The activities of this pathway have been shown to regulate cell growth and differentiation through modulation of regulatory proteins. The proteasome is a large complex consisting of two multisubunit structures, the 20S and 19S(PA700) or P28 complexes, that combine to form the 26S particles. In this study, we describe the cloning of a cDNA encoding the proteasome subunit 4 ATPase homologue from *Plasmodium falciparum* (PFS4). Analysis of the PFS4 cDNA sequence shows an open reading frame encoding a deduced protein of 455 amino acids. Moreover, comparison of PFS4 cDNA sequence to that of genomic fragments encoding PFS4 showed identical sequences with no detectable introns. Database searches revealed a high sequence identity to those of rice, yeast, mouse, *Drosophila*, and human S4 ATPases. However, PFS4 contains two unique inserts of nine and seven amino acid residues in the N-terminal domain. Interestingly, only the rice S4 contains the latter (seven amino acids) insert with four identical amino acids. In vitro expression of the full-length cDNA encoding the PFS4, using a transcription-translation-coupled reticulocyte lysate, shows a 50-kDa [(35)S]methionine-labeled protein which was immunoprecipitated with PFS4 anti-peptide antiserum. Southern blot analysis of genomic DNA digests shows a single gene copy of PFS4 in *P. falciparum*. Of interest was the effect of the proteasome-specific natural product, lactacystin, on the growth of the parasite, with IC(50) values of 0.6-0.92 microM. The latter IC(50) values of lactacystin for different clones of *P. falciparum* are comparable to those obtained for mammalian cell lines (0.65 microM), suggesting the presence of a conserved proteasome complex. Moreover, lactacystin was equally toxic to drug-sensitive and resistant parasites.
Copyright 1999 Academic Press.
- L31 ANSWER 5 OF 17 MEDLINE on STN
- AN 97418800 MEDLINE
- TI A *Plasmodium falciparum* homologue of the ATPase subunit of a multi-protein complex involved in chromatin remodelling for

THIS PAGE BLANK (USPTO)

- transcription.
- AU Ji D D; Arnot D E
- SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1997 Sep) 88 (1-2) 151-62.
Journal code: 8006324. ISSN: 0166-6851.
- AB A Plasmodium falciparum homologue of one of the components of a chromatin-remodelling complex which controls binding of transcription factors to nucleosome core particles has been cloned and characterised. The gene encodes 1422 amino acids with an estimated molecular mass of 167 kDa. The protein, SNF2L, shares 60% amino acid identity in its conserved DNA-dependent ATPase domain with yeast transcription factors originally identified by characterising mating type switch mutants. It also contains sequences related to the so-called SWI3, ADA2, N-CoR and TFIIIB B" or SANT DNA binding domains which are characteristic of these transcriptional activation factors. The SNF2L gene has two short introns in the 3' region of the coding sequence of the gene and is transcribed into a single approximately 6.5 kb messenger RNA species which is present throughout the asexual stages of the cell cycle. Southern blotting and pulsed field gel electrophoresis experiments show that SNF2L is a single copy gene. located on P. falciparum chromosome 11.
- L31 ANSWER 6 OF 17 MEDLINE on STN
- AN 96408665 MEDLINE
- TI Analysis of a cation-transporting ATPase of Plasmodium falciparum.
- AU Dyer M; Jackson M; McWhinney C; Zhao G; Mikkelsen R
- SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1996 Jun) 78 (1-2) 1-12.
Journal code: 8006324. ISSN: 0166-6851.
- AB We have cloned and characterised one gene, PfATPase4 which encodes a P-type ATPase containing all the primary sequence motifs characteristic of this class of transmembrane ion transporters, and also a fragment of a second P. falciparum P-type ATPase pseudogene (PfATPase5). Analysis of conserved domains and motifs of specific ATPases reveals that PfATPase4 is most analogous to Ca²⁺ ATPases of the endoplasmic reticulum. The PfATPase4 gene gives rise to a transcript of 8 kb shortly after erythrocyte invasion. Although this mRNA is not detected in later stages, the protein detected immunologically at 190 kDa persists throughout and is detected in free merozoites. Immunofluorescence microscopy reveals that the PfATPase4 protein is concentrated in discrete compartments at the periphery of the parasite. Detailed sequence and structural analyses of these and the other P-type ATPases of P. falciparum described previously, reveals that they comprise an unusual family in several respects. Firstly, the large number of non-homologous genes so far characterised reflects the complexities of ionic regulation in the diverse environments encountered by the parasite. Secondly, the plasmodial P-type ATPase family may be classified both at primary sequence and structural levels into two distinct groups-those typical of P-type ATPases (including PfATPase4) and those which are much more divergent. A third complexity is illustrated by the fact that one of the other members [1] here termed PfATPase6, has an even greater similarity to the sarcoplasmic reticulum Ca²⁺ ATPases than does PfATPase4, which raises questions about the possible functional relationship between these two members.
- L31 ANSWER 7 OF 17 MEDLINE on STN
- AN 95309711 MEDLINE

THIS PAGE BLANK (USPTO)

- TI Cloning of a new cation ATPase from *Plasmodium falciparum*: conservation of critical amino acids involved in calcium binding in mammalian organellar Ca(2+)-ATPases.
- AU Trottein F; Thompson J; Cowman A F
- SO GENE, (1995 May 26) 158 (1) 133-7.
Journal code: 7706761. ISSN: 0378-1119.
- AB In order to study molecules that may be involved in pH gradient formation in *Plasmodium*, we have identified a novel cation-translocating ATPase (P-type ATPase) gene from *P. falciparum* (Pf). We report the full-length nucleotide and deduced amino acid (aa) sequences of this gene that we called PfATPase4. The PfATPase4 protein shares features with the different members of eukaryotic P-type ATPases, such as a similar transmembrane (TM) organization and aa identity in functionally important regions. Interestingly, the PfATPase4 protein possesses conserved aa involved in calcium binding in mammalian organellar Ca(2+)-ATPases.
- L31 ANSWER 8 OF 17 MEDLINE on STN
- AN 95154293 MEDLINE
- TI Molecular cloning and sequence of two novel P-type adenosinetriphosphatases from *Plasmodium falciparum*.
- AU Trottein F; Cowman A F
- SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (1995 Jan 15) 227 (1-2) 214-25.
Journal code: 0107600. ISSN: 0014-2956.
- AB We have identified two novel P-type ATPase genes from *Plasmodium falciparum* and report the full-length nucleotide and derived amino acid sequence of the ATPase2 gene from *P. falciparum* (PfATPase2). PfATPase2 is phylogenetically remote from the different members of prokaryotic and mammalian P-type ATPases but shares features with a putative membrane-spanning Ca2+ ATPase involved in ribosome function in yeast. PfATPase2 is expressed during the intraerythrocytic life cycle of the parasite and appears to be required in the late stages of its asexual development. We also present the partial sequence of another malarial gene displaying sequence similarity with the family of P-type transporting ATPases (PfATPase4). We have analysed the organisation of the genes encoding the P-type ATPases of *P. falciparum* and show that they are a highly dispersed gene family.
- L31 ANSWER 9 OF 17 MEDLINE on STN
- AN 95021518 MEDLINE
- TI Cloning and characterization of the vacuolar ATPase B subunit from *Plasmodium falciparum*.
- AU Karcz S R; Herrmann V R; Trottein F; Cowman A F
- SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1994 May) 65 (1) 123-33.
Journal code: 8006324. ISSN: 0166-6851.
- AB The transvacuolar pH gradient determines, to a significant extent, the distribution of the antimalarial drug chloroquine in *Plasmodium falciparum*. A proton pump, similar to the vacuolar ATPase found in many cell types, appears to regulate a pH gradient across the membranes of acidic compartments of the parasite. In order to understand and define the components involved in the maintenance of the vacuolar pH gradient, we have cloned and characterized a gene, designated VAP B, encoding a *P. falciparum* homologue of the B subunit of the vacuolar ATPase. The VAP B gene encodes a protein of 494 amino acids which has between 69% and 74% amino acid identity with the sequences of vacuolar ATPase B subunits of other organisms. The VAP B gene exists as a single copy gene on chromosome 4 that gives rise to a RNA transcript of 2.4 kb. Antibodies raised to the

THIS PAGE BLANK (USPTO)

VAP B protein react specifically with a protein of 56-kDa, consistent with the size predicted from the gene sequence and with the homologous protein from other organisms. The 56-kDa protein is expressed throughout the asexual life cycle and subcellular localization by indirect immunofluorescence shows that the protein has a heterogeneous distribution over most of the parasite. This suggests that the function of the vacuolar proton ATPase is not confined to the regulation of the pH of the digestive vacuole.

- L31 ANSWER 10 OF 17 MEDLINE on STN
 AN 94131050 MEDLINE
 TI Plasmodium falciparum: further characterization of putative cation ATPases.
 AU Krishna S; Cowan G M; Robson K J; Meade J C
 SO EXPERIMENTAL PARASITOLOGY, (1994 Feb) 78 (1) 113-7.
 Journal code: 0370713. ISSN: 0014-4894.
- L31 ANSWER 11 OF 17 MEDLINE on STN
 AN 93241225 MEDLINE
 TI Cloning and characterization of a vacuolar ATPase A subunit homologue from Plasmodium falciparum.
 AU Karcz S R; Herrmann V R; Cowman A F
 SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1993 Apr) 58 (2) 333-44.
 Journal code: 8006324. ISSN: 0166-6851.
- AB The distribution of the antimalarial drug chloroquine is determined to a significant extent by a transvacuolar pH gradient in Plasmodium falciparum. A proton pump similar to the vacuolar ATPase found in many cell types has been suggested to maintain a pH gradient across the membranes of acidic compartments in the parasite. In order to understand and define the components involved in the mechanism of acidification of parasite vesicles, we have cloned and characterized a gene, designated VAP-A, encoding a P. falciparum homologue of the catalytic A subunit of the vacuolar ATPase. The VAP-A gene encodes a polypeptide of 611 amino acids which shows between 56 to 61% amino acid identity over its entire length with the sequences of vacuolar ATPase A subunits from several species. The VAP-A gene exists as a single copy gene on P. falciparum chromosome 13 and gives rise to a transcript of 3.7 kb. Antibodies raised against a VAP-A gene segment expressed in Escherichia coli react specifically with a 67-kDa polypeptide, consistent with the size predicted from the sequence and with the size of the corresponding polypeptide in other organisms. The 67-kDa protein is present throughout the asexual erythrocytic cycle and is expressed at similar levels in 5 P. falciparum isolates of differing chloroquine sensitivity. Sequence analysis of the coding region of the VAP-A gene from 2 chloroquine-sensitive and 3 chloroquine-resistant isolates has shown no changes that are linked to chloroquine resistance. Therefore, a proposed chloroquine resistance-linked vacuolar acidification defect does not involve mutations in the VAP-A gene in the isolates we have studied.
- L31 ANSWER 12 OF 17 MEDLINE on STN
 AN 93132070 MEDLINE
 TI A family of cation ATPase-like molecules from Plasmodium falciparum.
 AU Krishna S; Cowan G; Meade J C; Wells R A; Stringer J R; Robson K J
 SO JOURNAL OF CELL BIOLOGY, (1993 Jan) 120 (2) 385-98.
 Journal code: 0375356. ISSN: 0021-9525.
- AB We report the nucleotide and derived amino acid sequence of the

THIS PAGE BLANK (USPTO)

ATPase 1 gene from *Plasmodium falciparum*. The amino acid sequence shares homology with the family of "P"-type cation translocating ATPases in conserved regions important for nucleotide binding, conformational change, or phosphorylation. The gene, which is present on chromosome 5, has a product longer than any other reported for a P-type ATPase. Interstrain analysis from 12 parasite isolates by the polymerase chain reaction reveals that a 330-bp nucleotide sequence encoding three cytoplasmic regions conserved in cation ATPases (regions a-c) is of constant length. By contrast, another 360-bp sequence which is one of four regions we refer to as "inserts" contains arrays of tandem repeats which show length variation between different parasite isolates. Polymorphism results from differences in the number and types of repeat motif contained in this insert. Inserts are divergent in sequence from other P-type ATPases and share features in common with many malarial antigens. Studies using RNA from the erythrocytic stages of the malarial life cycle suggest that ATPase 1 (including the sequence which encodes tandem repeats) is expressed at the large ring stage of development. Immunolocalization has identified ATPase 1 to be in the region of the parasite plasma membrane and pigment body. These findings suggest a possible model for the genesis of malarial antigens.

- L31 ANSWER 13 OF 17 MEDLINE on STN
 AN 92134363 MEDLINE
 TI Energy dependence of chloroquine accumulation and chloroquine efflux in *Plasmodium falciparum*.
 AU Krogstad D J; Gluzman I Y; Herwaldt B L; Schlesinger P H; Wellems T E
 SO BIOCHEMICAL PHARMACOLOGY, (1992 Jan 9) 43 (1) 57-62.
 Journal code: 0101032. ISSN: 0006-2952.
 AB Chloroquine inhibits the growth of susceptible malaria parasites at low (nanomolar) concentrations because of an energy-requiring drug-concentrating mechanism in the parasite secondary lysosome (food vacuole) which is dependent on the acidification of that vesicle. Chloroquine resistance results from another energy-requiring process: efflux of chloroquine from the resistant parasite with a half-time of 2 min. Chloroquine efflux is inhibited reversibly by the removal of metabolizable substrate (glucose); it is also reduced by the ATPase inhibitor vanadate. These results suggest that chloroquine efflux is an energy-requiring process dependent on the generation and hydrolysis of ATP. Chloroquine efflux cannot be explained by differences in drug accumulation between chloroquine-susceptible and -resistant parasites because the 40-50-fold difference in initial efflux rates between -susceptible and -resistant parasites is unchanged when both parasites contain the same amount of chloroquine. Although chloroquine efflux is phenotypically similar to the efflux of anticancer drugs from multidrug-resistant (mdr) mammalian cells, it is not linked to either of the mdr-like genes of the parasite.
- L31 ANSWER 14 OF 17 MEDLINE on STN
 AN 91101662 MEDLINE
 TI Accumulation of chloroquine by membrane preparations from *Plasmodium falciparum*.
 AU Herwaldt B L; Schlesinger P H; Krogstad D J
 SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1990 Sep-Oct) 42 (2) 257-67.
 Journal code: 8006324. ISSN: 0166-6851.

THIS PAGE BLANK (USPTO)

AB Chloroquine susceptibility and resistance have been associated respectively with the uptake and efflux of chloroquine by *Plasmodium falciparum*. We made membrane preparations from parasitized and unparasitized red cells in order to study chloroquine accumulation in a cell-free system. The accumulation of [³H]chloroquine by these preparations is inhibited by unlabeled chloroquine and thus is specific. Only membranes from parasitized red cells demonstrate time-dependent chloroquine accumulation; membranes from unparasitized red cells do not. Chloroquine accumulation is eliminated by detergent (0.05% Triton X-100) and reduced by a hypertonic medium, consistent with accumulation inside membrane vesicles rather than binding to membranes. Accumulation is energy dependent; it has a specific requirement for ATP, which cannot be replaced with GTP, CTP, UTP, TTP or ADP, an apparent K_m of 21 μM and an apparent V_{max} of 4.6 pmol (mg protein)⁻¹ h⁻¹. Vesicle acidification is MgATP dependent, and is reversed by NH₄Cl. Chloroquine accumulation is inhibited by reduced medium pH, N-ethylmaleimide or oligomycin, but not by vanadate or ouabain. These studies demonstrate that membrane vesicles prepared from parasitized red cells provide a model system for the study of chloroquine accumulation by *P. falciparum*.

L31 ANSWER 15 OF 17 MEDLINE on STN

AN 91077466 MEDLINE

TI Ion metabolism in malaria-infected erythrocytes.

AU Tanabe K

SO BLOOD CELLS, (1990) 16 (2-3) 437-49. Ref: 61
Journal code: 7513567. ISSN: 0340-4684.

AB Malaria parasites of the genus *Plasmodium* spend much of their asexual life cycle inside the erythrocytes of their vertebrate hosts. Parasites presumably have to exploit metabolic and transport mechanisms to adapt themselves to the host erythrocyte's physicochemical environment. This review surveys the metabolism and transport of Ca²⁺, alkali cations, and H⁺ in malaria-infected erythrocytes. The Ca²⁺ content of *Plasmodium*-infected erythrocytes increases as the parasite matures. An increase in the influx of extracellular Ca²⁺ into infected erythrocytes is evident at later stages of parasite development. In infected erythrocytes, Ca²⁺ is almost exclusively localized in the parasite compartment and changes but little in the cytosol of the host cell. The importance of Ca²⁺ in supporting the growth of intraerythrocytic parasites and the invasion of erythrocytes by the merozoite has been assessed by depletion of extracellular Ca²⁺ with chelators, or by disturbance of the metabolism and transport of Ca²⁺ with a variety of Ca²⁺ modulators. Membranes of malaria-infected erythrocytes change their permeability to alkali cations. Hence, levels of K⁺ decrease and levels of Na⁺ increase in the cytosol of infected erythrocytes. Intraerythrocytic parasites maintain a high K⁺, low Na⁺ state, suggesting a mechanism for transporting K⁺ inward and Na⁺ outward against concentration gradients of the alkali cations across the parasite plasma membrane and/or the parasitophorous vacuole membrane (PVM). Concomitantly, *P. falciparum* can grow in Na⁽⁺⁾-enriched human erythrocytes. Experimental evidence suggests that *Plasmodium* possesses in its plasma membrane a proton pump which is very sensitive to orthovanadate, carbonylcyanide m-chlorophenylhydrazone, a protonophore, and dicyclohexylcarbodiimide, an inhibitor of H⁽⁺⁾-ATPase, but is only slightly sensitive to inhibitors of bacterial and mitochondrial respiration, such as antimycin A, CN⁻,

THIS PAGE BLANK (USPTO)

or N3-, and ouabain, a Na⁺, K⁽⁺⁾-ATPase inhibitor. By operating this proton pump, parasites extrude H⁺ and thus generate an electrochemical gradient of protons (an internal negative membrane potential and a concentration gradient of protons) across the parasite plasma membrane. The electrochemical gradient apparently drives inward movement of Ca²⁺ and, possibly, glucose from the cytosol of infected erythrocytes. Little is known about the transport properties of the PVM. Recent sequence studies suggest that Plasmodium contains a cation-transporting ATPase which exhibits a high homology to the Ca²⁺(+)-ATPase of rabbit skeletal muscle sarcoplasmic reticulum. (ABSTRACT TRUNCATED AT 250 WORDS)

L31 ANSWER 16 OF 17 MEDLINE on STN
 AN 89040035 MEDLINE
 TI Purification of Plasmodium falciparum digestive vacuoles and partial characterization of the vacuolar membrane ATPase.
 AU Choi I; Mego J L
 SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1988 Oct) 31 (1) 71-8.
 Journal code: 8006324. ISSN: 0166-6851.
 AB Plasmodium falciparum digestive vacuoles containing ferric oxide granules were purified from parasite homogenates by centrifugation on discontinuous sucrose gradients. Digestive vacuole membranes prepared by osmotic lysis and washed with KCl showed no detectable contamination by erythrocyte membrane proteins and only minimal contamination by non-vacuolar parasite proteins. Purified vacuolar membranes were 2.6-fold enriched in total parasite membrane ATPase activity. This ATPase was optimally active at pH 7 in the presence of at least 2 mM Mg²⁺. Ca²⁺ and Mn²⁺ were approximately 80-90% as effective as Mg²⁺, and Zn²⁺, Co²⁺ and Fe²⁺ also exerted some stimulatory effect. The vacuolar membrane also hydrolyzed GTP, UTP, CTP and ADP, but AMP and 3',5'-cyclic AMP were hydrolyzed only one-tenth as effectively as ATP. The ATPase was unaffected by vanadate, ouabain or oligomycin but was significantly inhibited by the proton pump inhibitors NEM and NBD-Cl. Of 6 antimalarial drugs tested, quinine and quinacrine were the most effective inhibitors and mefloquine was the least effective.

L31 ANSWER 17 OF 17 MEDLINE on STN
 AN 74085067 MEDLINE
 TI Bongkrekic acid and the adenosinetriphosphate requirement of malaria parasites.
 AU Trager W
 SO EXPERIMENTAL PARASITOLOGY, (1973 Dec) 34 (3) 412-6.
 Journal code: 0370713. ISSN: 0014-4894.

FILE 'HCAPLUS' ENTERED AT 14:45:35 ON 07 OCT 2003
 L32 8 SEA FILE=HCAPLUS ABB=ON PLU=ON (PLASMODIUM OR FALCIPARU
 M) AND ADENOSINETRIPHOSPHATASE
 L33 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L32 AND (MICROTUB? OR
 MICRO TUBUL? OR ((PROTEIN OR PEPTIDE OR POLYPROTEIN OR
 POLYPEPTIDE) AND STIMUL?))
 (FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
 JICST-EPLUS, JAPIO' ENTERED AT 14:47:45 ON 07 OCT 2003)
 L34 1 S L33
 L35 0 S L34 NOT L15

FILE 'HOME' ENTERED AT 14:50:06 ON 07 OCT 2003

THIS PAGE BLANK (USPTO)

10/006780

(FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 14:40:14 ON 07 OCT 2003)

L17 131 S "SAKOWICZ R"?/AU
L18 561 S "BERAUD C"?/AU
L19 10837 S "GUO J"?/AU
L20 4357 S "FREEDMAN R"?/AU
L21 3 S L17 AND L18 AND L19 AND L20
L22 42 S L17 AND (L18 OR L19 OR L20)
L23 108 S L18 AND (L19 OR L20)
L24 6 S L19 AND L20
L25 15730 S L17 OR L18 OR L19 OR L20
L26 14 S (PLASMODIUM OR FALCIPARUM) AND (L22 OR L23 OR L25)
L27 18 S L21 OR L24 OR L26
L28 10 DUP REM L27 (8 DUPLICATES REMOVED)

Author(s)

L28 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:454460 HCAPLUS

DOCUMENT NUMBER: 139:31820

TITLE: **Plasmodium falciparum**
kinesin motor protein KinI-1 with
microtubule-stimulated ATPase activity and uses
for diagnosis and treatment of malaria

INVENTOR(S): **Sakowicz, Roman; Beraud,**
Christophe; Guo, Jun;
Freedman, Richard

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048320	A2	20030612	WO 2002-US38360	20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003104496	A1	20030605	US 2001-6780	20011130
PRIORITY APPLN. INFO.:			US 2001-6780	A2 20011130
			US 2002-86935	A2 20020228

AB. The present invention relates to protein and cDNA sequences of a new kinesin motor protein, **P. falciparum** KinI-1 (PfKinI-1), and the use of these compns. for the diagnosis, treatment, or prevention of malaria. The invention provides isolated nucleic acid and amino acid sequences of kinesin superfamily motor protein KinI-1, which has microtubule stimulated ATPase activity and/or depolymerizes microtubules. The invention further relates to antibodies to PfKinI-1, methods of screening for PfKinI-1 modulators

THIS PAGE BLANK (USPTO)

using biol. active PfKinI-1, and kits for screening for PfKinI-1 modulators.

L28 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:435206 HCAPLUS

DOCUMENT NUMBER: 139:909

TITLE: Sequences of **Plasmodium falciparum** kinesin KinI-1 and use for treating malaria

INVENTOR(S): **Sakowicz, Roman; Beraud, Christophe; Guo, Jun; Freedman, Richard**

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003104496	A1	20030605	US 2001-6780	20011130
WO 2003048320	A2	20030612	WO 2002-US38360	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-6780 A2 20011130
US 2002-86935 A2 20020228

AB The invention provides sequences of **Plasmodium falciparum** kinesin KinI-1. The invention also relates to the use of KinI-1 for the diagnosis, treatment, or prevention of malaria.

L28 ANSWER 3 OF 10 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: 2003-492112 [46] WPIDS

CROSS REFERENCE: 2002-352124 [38]; 2003-491700 [46]

DOC. NO. CPI: C2003-131606

TITLE: New human microtubule motor protein (kinesin motor protein KinI-3) and nucleic acid, useful for diagnosing, preventing or treating e.g. cancer, restenosis, inflammation, neurological disorders or disorders of vesicular transport.

DERWENT CLASS: B04 D16

INVENTOR(S): **BERAUD, C; DAVIES, K A; FREEDMAN, R; GUO, J; PATEL, U A**

PATENT ASSIGNEE(S): (CYTO-N) CYTOKINETICS

COUNTRY COUNT: 1

PATENT INFORMATION:

THIS PAGE BLANK (USPTO)

10/006780

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003036075	A1	20030220	(200346)*		31

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003036075	A1 CIP of	US 2000-675227	20000929
	Div ex	US 2001-967908	20010928
		US 2002-159151	20020531

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2003036075	A1 CIP of	US 6461855

PRIORITY APPLN. INFO: US 2001-967908 20010928; US 2000-675227
20000929; US 2002-159151 20020531

AN 2003-492112 [46] WPIDS
CR 2002-352124 [38]; 2003-491700 [46]
AB US2003036075 A UPAB: 20030719

NOVELTY - An isolated microtubule motor protein, which has greater than 70 % sequence identity to a 1368 amino acid sequence (P1), given in the specification as measured using a sequence comparison algorithm, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an isolated nucleic acid sequence:
 - (a) encoding the microtubule motor protein described above, where the motor the protein's activity includes microtubule depolymerization activity; or
 - (b) comprising a sequence which has greater than 60 % sequence identity with nucleotide comprising 6409 base pairs (N1), given in the specification;
- (2) an expression vector comprising the nucleic acid encoding the microtubule motor protein;
- (3) a host cell transfected with the vector of (2);
- (4) screening for modulators of KinI-3 comprising:
 - (a) providing the biologically active KinI-3;
 - (b) contacting the biologically active KinI-3 with a candidate agent in a test and control concentration; and
 - (c) assaying for the level of KinI-3 activity, where the KinI-3 activity consists of binding activity or ATPase activity, and where a change in activity between the test and control concentration indicates a modulator; and
- (5) a compound that modulates KinI-3, which is identified using the method of (4).

ACTIVITY - Cytostatic; Vasotropic; Immunomodulator; Antiinflammatory; Vulnerary; Antirheumatic; Antiarthritic; Antiarteriosclerotic; Antigout; Antipsoriatic; Antidiabetic; Ophthalmological; Immunosuppressive; Neuroprotective.

No biological data is given.

MECHANISM OF ACTION - ATPase Modulator; Microtubule Motor Protein Modulator.

USE - The KinI-3 protein, nucleic acid, or its modulator, is useful for diagnosing, preventing or treating cellular proliferation

THIS PAGE BLANK (USPTO)

(e.g. cancers (e.g. bronchogenic, carcinoma, Kaposi's sarcoma, lymphoma, leukemia, osteoid osteoma, glioblastoma, etc.), hyperplasia, restenosis, cardiac hypertrophy, immune disorders or inflammation), neurological disorders, or disorders of vesicular transport. These disorders also include atherosclerosis, hemangiomas, acoustic neuromas, vascular malfunctions, abnormal wound healing, rheumatoid arthritis, Bechet's disease, gout, psoriasis, diabetic retinopathy, corneal graft rejection, glaucoma, Osler Webber syndrome, etc.. The protein, nucleic acid or the KinI-3 modulator regulates cell cycle, as well as cellular proliferation. The KinI-3 protein or nucleic acid is also useful for screening therapeutic agents or KinI-3 modulators, which may be used for treating the above-mentioned diseases or disorders.
Dwg.0/9

L28 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2002:256423 HCAPLUS
 DOCUMENT NUMBER: 136:274347
 TITLE: Human kinesin motor protein KinI-3, protein and cDNA sequences and tissue expression
 INVENTOR(S): Beraud, Christophe; **Guo, Jun;**
Freedman, Richard; Patel, Umesh A.;
 Davies, Katherine A.
 PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026929	A2	20020404	WO 2001-US30750	20010928
WO 2002026929	A3	20020613		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6461855	B1	20021008	US 2000-675227	20000929
US 6432659	B1	20020813	US 2000-724510	20001127
US 6436686	B1	20020820	US 2000-723216	20001127
EP 1330535	A2	20030730	EP 2001-977340	20010928
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2000-675227 A 20000929
 WO 2001-US30750 W 20010928

AB The invention provides isolated nucleic acid and amino acid sequences for human kinesin KinI-3. The invention also relates to antibodies to KinI-3. The invention also relates to methods of screening for KinI-3 modulators using biol. active KinI-3, and kits

THIS PAGE BLANK (USPTO)

for screening for KinI-3 modulators. The invention shows that kinesin KinI-3 is unregulated in lung, colon and breast cancers.

L28 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2002:351338 HCAPLUS
 DOCUMENT NUMBER: 137:74991
 TITLE: A mechanism for microtubule depolymerization by KinI kinesins
 AUTHOR(S): Moores, Carolyn A.; Yu, Ming; Guo, Jun; Beraud, Christophe; Sakowicz, Roman; Milligan, Ronald A.
 CORPORATE SOURCE: Department of Cell Biology, CB227, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Molecular Cell (2002), 9(4), 903-909
 CODEN: MOCEFL; ISSN: 1097-2765
 PUBLISHER: Cell Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Whereas most kinesins motor along microtubules, KinI kinesins are microtubule depolymerizing machines. Surprisingly, we found that a KinI fragment consisting of only the motor core is capable of ATP-dependent depolymerization. The motor binds along microtubules in all nucleotide states, but in the presence of AMPPNP, microtubule depolymerization also occurs. Structural characterization of the products of AMPPNP-induced destabilization revealed a snapshot of the disassembly machine in action as it precisely deformed a tubulin dimer. While conventional kinesins use the energy of ATP binding to execute a "power-stroke," KinIs use it to bend the underlying protofilament. Thus, the relatively small class-specific differences within the KinI motor core modulate a fundamentally conserved mode of interaction with microtubules to produce a unique depolymerizing activity.
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 ACCESSION NUMBER: 2003:156397 BIOSIS
 DOCUMENT NUMBER: PREV200300156397
 TITLE: Interaction of a KinI motor core with microtubules.
 AUTHOR(S): Moores, C. A. (1); Hekmat-Nejad, M.; Yu, M.; Sakowicz, R.; Milligan, R. A. (1)
 CORPORATE SOURCE: (1) Dept. of Cell Biology, Scripps Research Institute, La Jolla, CA, USA USA
 SOURCE: Molecular Biology of the Cell, (Nov. 2002, 2002) Vol. 13, No. Supplement, pp. 280a. print.
 Meeting Info.: 42nd Annual Meeting of the American Society for Cell Biology San Francisco, CA, USA December 14-18, 2002 American Society for Cell Biology
 . ISSN: 1059-1524.
 DOCUMENT TYPE: Conference
 LANGUAGE: English

L28 ANSWER 7 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 ACCESSION NUMBER: 2002:563016 SCISEARCH
 THE GENUINE ARTICLE: 570RY

THIS PAGE BLANK (USPTO)

TITLE: Potential long-term toxicity of repeated orally administered doses of artemether in rats.

AUTHOR: Xiao S H; Yang Y Q; You Q Q; Utzinger J; Guo H F; Jiao P Y; Mei J Y; **Guo J**; Bergquist R; Tanner M (Reprint)

CORPORATE SOURCE: Swiss Trop Inst, POB, CH-4002 Basel, Switzerland (Reprint); Swiss Trop Inst, CH-4002 Basel, Switzerland; Chinese Acad Prevent Med, Inst Parasit Dis, Shanghai 200025, Peoples R China; Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA; WHO, WHO Special Programme Res & Training Trop Dis, World Bank, UNDP, CH-1211 Geneva 27, Switzerland

COUNTRY OF AUTHOR: Switzerland; Peoples R China; USA

SOURCE: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, (JAN 2002) Vol. 66, No. 1, pp. 30-34. Publisher: AMER SOC TROP MED & HYGIENE, 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA. ISSN: 0002-9637.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 29

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Artemether, an efficacious antimalarial drug, effectively prevents patent schistosome infections and morbidity, as established in laboratory models and in clinical trials. In view of concern about the potential long-term toxicity, rats were treated orally with 80 mg/kg artemether once every 2 weeks for 5 months. After the final treatment, routine blood test results were normal except for reversible reductions of reticulocyte counts and reversible increases in hemoglobin levels. Liver and kidney function and histopathological examination showed no differences between treated and untreated rats. Administration of 400 mg/kg artemether resulted in transient focal vesicle degeneration of the liver or slight damage to the proprius layer lamina of intestinal villi. No damage to the central nervous system tissues, including cerebrum, cerebellum, midbrain, thalamus, pons, medulla oblongata, and spinal cord, was seen at either concentration. There were no alterations in electrocardiograms during the 6-month treatment period. We conclude that 80 mg/kg artemether administered once every 2 weeks is safe, and doses of 400 mg/kg do not result in evidence of neurotoxicology.

L28 ANSWER 8 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

ACCESSION NUMBER: 2000:878709 SCISEARCH

THE GENUINE ARTICLE: 374GN

TITLE: A statistical-based approach to assessing the fidelity of combinatorial libraries encoded with electrophoric molecular tags. Development and application of tag decode-assisted single bead LC/MS analysis

AUTHOR: Dolle R E (Reprint); **Guo J**; OBrien L; Jin Y; Piznik M; Bowman K J; Li W N; Egan W J; Cavallaro C L; Roughton A L; Zhao Q; Reader J C; Orlowski M; JacobSamuel B; Carroll C D

CORPORATE SOURCE: PHARMACOEPIA INC, DEPT CHEM, POB 5350, PRINCETON, NJ 08543 (Reprint); PHARMACOEPIA INC, DEPT ANALYT CHEM, PRINCETON, NJ 08543; PHARMACOEPIA INC, DEPT BIOL, PRINCETON, NJ 08543; PHARMACOEPIA INC, CTR INFORMAT & DRUG DISCOVERY, PRINCETON, NJ 08543

THIS PAGE BLANK (USPTO)

COUNTRY OF AUTHOR: USA
SOURCE: JOURNAL OF COMBINATORIAL CHEMISTRY, (NOV-DEC 2000)
Vol. 2, No. 6, pp. 716-731.
Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW,
WASHINGTON, DC 20036.
ISSN: 1520-4766.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: PHYS; LIFE
LANGUAGE: English
REFERENCE COUNT: 78


ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB A statistical sampling protocol is described to assess the fidelity of libraries encoded with molecular tags. The methodology, termed library QA, is based on the combined application of tag decode analysis and single bead LC/MS. The physical existence of library compounds eluted from beads is established by comparing the molecular weight predicted by tag decode with empirical measurement. The goal of sampling is to provide information on overall library fidelity and an indication of the performance of individual library synthons. The minimal sampling size n for library QA is $10 \times$ the largest synthon set. Data are reported as proportion (p) \pm lower and upper boundary (lb-ub) computed at the 95% confidence level ($\alpha = 0.05$). As a practical demonstration, library QA was performed on a 25 200-member library of statine amides (size = $40 \times 63 \times 10$). Sampling was conducted three times at n similar to 630 beads per run for a total of 1902 beads. The overall proportions found for the three runs were consistent with one another: $p = 84.4\%$, lb-ub = 81.5-87.2%; $p = 83.1\%$, lb-ub = 80.2-85.95; and $p = 84.5\%$, lb-ub = 81.8-87.3%, suggesting the true value of p is close to 84% compound confirmation. The performance p_i of individual synthons was also computed. Corroboration of QA data with biological screening results obtained from assaying the library against cathepsin D and plasmeprin II is discussed.

L28 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 1998:630381 HCAPLUS
DOCUMENT NUMBER: 129:331033
TITLE: Identification of potent inhibitors of
Plasmodium falciparum
plasmeprin II from an encoded statine
combinatorial library
AUTHOR(S): Carroll, Carolyn DiIanni; Patel, Hitesh;
Johnson, Theodore O.; Guo, Tao; Orlowski, Marc;
He, Zhen-Min; Cavallaro, Cullen L.; **Guo,**
Joan; Oksman, Anna; Gluzman, Ilya Y.;
Connelly, James; Chelsky, Daniel; Goldberg,
Daniel E.; Dolle, Roland E.
CORPORATE SOURCE: Department Biology, Pharmacopeia, Inc.,
Princeton, NJ, 08540, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1998),
8(17), 2315-2320
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

THIS PAGE BLANK (USPTO)

10/006780



AB An encoded 13,020-member combinatorial library I [R1 = Me, Bu, MeO(CH2)3, Ph(CH2)4, PhCH2, 2-pyridylmethyl, 3-pyridylmethyl; R2 = CH2Ph, Me, CH2CHMe2; R3 = side chain from 31 natural and unnatural L- and D-amino acids; R4 = Ph, 2-naphthylmethyl, 2,4-(MeO)2C6H3, cyclopropyl, 2-carboxy-4-methylcyclohexyl, 4-(4-HOC6H4)C6H4, 5-phenyl-2-pyrrolylethyl, Me3C, 4-methylcyclohexyl, 2-naphthyloxymethyl, Et2NCH2CH2, 4-(Me2NCH2)C6H4, n-heptyl, 3-tetrahydrofuryl, 4-[(HO2C)2CHO]C6H4, HOCHMeCH2, 2,4-Cl2C6H4O(CH2)3, PhCH2] was synthesized containing a statine core. Evaluation of this library with plasmepsin II, an aspartyl protease required for Hb metabolism in the malaria parasite, led to the identification of potent and selective inhibitors as well as novel structure-activity relationships.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 10 OF 10 MEDLINE on STN
ACCESSION NUMBER: 93338845 MEDLINE
DOCUMENT NUMBER: 93338845 PubMed ID: 1307277
TITLE: Effect of sodium artesunate on **Plasmodium** yoelii analysed by flow cytometry.
AUTHOR: Han W S; Zhou W Q; Wang B X; Li Z M; Zuo L F; Guo J W
CORPORATE SOURCE: Department of Parasitology, Hebei Medical College, Shijiazhuang.
SOURCE: CHUNG-KUO CHI SHENG CHUNG HSUEH YU CHI SHENG CHUNG PING TSA CHIH CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, (1992) 10 (3) 204-7.
Journal code: 8709992. ISSN: 1000-7423.
PUB. COUNTRY: China
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Chinese
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199309
ENTRY DATE: Entered STN: 19930917
Last Updated on STN: 19930917
Entered Medline: 19930902

AB The effect of sodium artesunate on **Plasmodium** yoelii-infected mouse erythrocytes was analysed by flow cytometry. The results showed that malarial DNA content in experimental group was obviously decreased 2-5 hours after the drug was administered, fluorescence distribution of malarial DNA almost disappeared within 24 hours after the administration. Thus we deem that sodium artesunate can inhibit the DNA synthesis in P. yoelii.

FILE 'HOME' ENTERED AT 14:43:32 ON 07 OCT 2003

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:13:56 ; Search time 130 Seconds
(without alignments)
2556.706 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 6842
Sequence: 1 MNSKIVVVRKRLSELEKK.....KLVQDNKSNMDNNHHKK 1288

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_23:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phase:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriophage:*
17: sp_archaeoprotein:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	6842	100.0	1351	0814Y0	0814Y0 plasmodium
2	903.5	13.2	2577	0814M1	0814M1 plasmodium
3	876.5	12.8	3207	081H00	081H00 plasmodium
4	857	12.5	3248	081C09	081C09 plasmodium
5	854.5	12.5	2235	081B09	081B09 plasmodium
6	851	12.4	5561	081IC9	081IC9 plasmodium
7	850.5	12.4	1422	08MMY3	08MMY3 dictyostel
8	847.5	12.4	1681	081548	081548 plasmodium
9	839	12.3	3178	0812P8	0812P8 plasmodium
10	838	12.2	3256	08MMY3	08MMY3 dictyostel
11	838	12.2	3256	081DV7	081DV7 plasmodium
12	830.5	12.1	3069	081350	081350 plasmodium
13	830	12.1	2874	081C00	081C00 plasmodium
14	827.5	12.1	2432	081519	081519 plasmodium
15	826.5	12.1	1824	0815A3	0815A3 plasmodium
16	826.5	12.1	2672	081EB4	081EB4 plasmodium

17	824	12.0	901	5	081806	081806 dictyostel
18	819.5	12.0	1483	5	081I07	081I07 plasmodium
19	819.5	12.0	4466	5	081LS4	081LS4 plasmodium
20	817.5	11.9	2275	5	081HV8	081HV8 plasmodium
21	816	11.9	2041	5	081BK6	081BK6 plasmodium
22	815.5	11.9	1774	5	081A08	081A08 plasmodium
23	813	11.9	3848	5	081DR0	081DR0 plasmodium
24	810.5	11.8	2472	5	081ZM5	081ZM5 dictyostel
25	810	11.8	1200	5	097277	097277 plasmodium
26	808	11.8	2612	5	0815X5	0815X5 plasmodium
27	807	11.8	1918	5	08SSW3	08SSW3 dictyostel
28	804	11.8	2206	5	081B08	081B08 plasmodium
29	804	11.8	8591	5	081B94	081B94 plasmodium
30	803	11.7	1785	5	0815Z0	0815Z0 plasmodium
31	802	11.7	2763	5	081I48	081I48 plasmodium
32	801	11.7	1770	5	081I33	081I33 plasmodium
33	800	11.7	2940	5	081HP9	081HP9 plasmodium
34	799.5	11.7	3569	5	081BV8	081BV8 plasmodium
35	798	11.7	1605	5	0814X5	0814X5 plasmodium
36	797.5	11.7	1922	5	081L84	081L84 plasmodium
37	796	11.6	800	10	094GM1	094GM1 oryza sativ
38	795.5	11.6	706	10	091W81	091W81 arabidopsis
39	795.5	11.6	1182	5	081ET5	081ET5 plasmodium
40	795	11.6	1437	5	081C24	081C24 plasmodium
41	794	11.6	684	10	0940Y8	0940Y8 arabidopsis
42	793.5	11.6	2849	5	081HY4	081HY4 plasmodium
43	791	11.6	3334	5	081IS9	081IS9 plasmodium
44	790.5	11.6	703	10	09AVP4	09AVP4 nicotiana t
45	789.5	11.5	799	10	091US1	091US1 arabidopsis

ALIGNMENTS

RESULT 1

0814Y0 PRELIMINARY; PRT; 1351 AA.
ID 0814Y0;
AC 0814Y0;
DT 01-MAR-2003 (T-REMBLrel. 23, Created)
DT 01-MAR-2003 (T-REMBLrel. 23, Last sequence update)
DE Kinesin-like protein, putative.
DE PFL2165W.
GN Plasmodium falciparum (isolate 3D7).
OS Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
CX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Angiuoli S.,
RA Pertea M., Allen J., Selengut J., Haft D., Mather M.W., Valdeya A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrell B.;
RA "Genome sequence of the human malaria parasite Plasmodium
falciparum";
RL Nature 419:498-511(2002).
RL EMBL: A014851; AAN36517.1;
SQ SEQUENCE 1351 AA; 156007 MW; 8B69594BFD73C788 CRC64;

Query Match 100.0%; Score 6842; DB:5; Length 1351;
Best Local Similarity 100.0%; Pred. No. 7, 1e-268;
Matches 1288; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MNSKIVVVRKRLSELEKKKSDIITVKNCTIYIDPRYVDMTKIETREFTVDKY 60
DB 64 MNSKIVVVRKRLSELEKKKSDIITVKNCTIYIDPRYVDMTKIETREFTVDKY 123

[illegible]

Db	1204	EDIKMSLEEDIKTAQSIYERKRVLLTKLLLFKKAVDTQJNNFISDLRKOLVMCHICNN	1263
Qy	1201	NPDDQFHFYAVSRLEKDIINLIMRQIWCESENRLLYQPLVBYQNKANSVILLNYSN	1263
Db	1264	NPDDQFHFYAVSRLEKDIINLIMRQIWCESENRLLYQPLVBYQNKANSVILLNYSN	1323
Qy	1261	NGDIILINKKLVODNIKSMDDHNNIHHK	1288
Db	1324	NGDIILINKKLVODNIKSMDDHNNIHHK	1351

RESULT 2		
ID	OB1AM1	PRELIMINARY; PRT, 2577 AA.
AC	OB1AM1	
DT	01-MAR-2003 (TREMBLrel. 23, Created)	
DT	01-MAR-2003 (TREMBLrel. 23, Last sequence update)	
DT	01-MAR-2003 (TREMBLrel. 23, Last annotation update)	
DE	Hypothetical protein.	
GN	MAL8P1.153.	
OS	Plasmodium falciparum (isolate 3D7).	
OC	Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.	
OX	NCBI_TaxID=36329;	
RN	[1]	
RP	SEQUENCE FROM N. A.	
RA	Seeger K., Murphy L., Harris D., Berriman M., Pain A., Hall N.,	
RA	Quali M., Bartell B., to the EMBL/GenBank/DBJ databases.	
RL	Submitted (Sep-2002) to the EMBL/GenBank/DBJ databases.	
DR	EMBL, AL844507, CAD51342.1; --	
KW	Hypothetical protein.	
SO	SEQUENCE 2577 AA; 299292 MW; 025BEC240587F4D7 CRC64;	

Query Match	13.2%	Score 903.5;	DB 5,	Length 2577;
Best Local Similarity	23.1%;	Pred. No. 1.le-28;		
Matches 430; Conservative	228;	Mismatches 482;	Indels 721;	Gaps 89

```

QY 19 KKKKSDLIITYKXNNCTLIYIDBPXKVMPTKXIER---HEPFLVXKVPDFTY--DPFITY- 71
Db 111 KKKKKRYCYCDIND-----KLNFKVNEKRKCTNBSYNNRYNDYDKLNDNFSKYL 159
QY 72 --ENTIKELIIDLYENGCVCSCAFYQGTSGSKTYMTLGSOPYGSDTPGIFFOYAAGDIPT 129
Db 160 SSKNNKK-----NSNLKSSNSLFISEQPEQGEDEPLEFSQDITIK 200
QY 130 FLNITY-----DDNTKRGFISFYEIYCGELY--DLLQKRRKVAAL 167
Db 201 LIYFMENFIKKKKKENFQNNKGOLGDRTN-----EYDWTYKKSYSYDXKVRK----- 249
QY 168 ENGGKEVVVKKDLKILRVLT-----EELIKMID--GVILLR 201
Db 250 KEGKINIKVKVNIQNNVINKVAVELALIGRDSLSTLPEEVKGENQVITIKIDEKGRDD 309
QY 202 KIG--VNSQNDSSRSXALINIDKD-----INKTSJGKIAFIDLASERADPYVSOKQ 255
Db 310 KIGVLNDENVRKMLNGLLVCNEBNEEVIKVEYLLK-----ENNINDIMKDV 360
QY 256 TOTDQAN-----INRSLALKECIRAMDSDKNHIPIFR----- 287
Db 361 YKTMSNSNMLKMENTIENDINLTSICYKEKXSSPESDVTINIEYEGKGIPIINGDTIDEN 420
QY 288 --DSELTKVLRD---IFVGSKSIM--IANISPTIS-----CCEQT----- 321
Db 421 IIDEKENKIIKDEKEYMEIGANNDDIINDCKKNMKMEISMLKMGKCVESNNISSEAYKE 480
QY 322 -----LMTLYRSRVKQNFKNKSTCINEDBDTNTERTIISLDSK 358
Db 481 BEKLKIIDIDINYLOKNEMFPNMDIFPPITIKNF---NLCKNKKEKQKMKRNTITERRY 537
QY 359 -GSEMNASSIENWVYKXSHLLSNNN---NKINRGKINDK-----IERNN-----ILK 402
Db 538 LGNKNKNININYN---NNINMYNNNNNISLKKVQCNMSNGKGVATSESSNNNCPSEKXYIK 594

```

QY	403	NK-SFDKPRRG-----	FTSTFGKXSLNDID-----	X	428		
Db	595	NKIYTSKLRMGJLMLLKIEKKSRRGRPGGASIKYKKEJGEOKKKDDCMJLJFDSKRR		654			
QY	429	IKKKNKKGLI-----	NYKSTL-YNDNTINKGHNNNNNNNNNDNNNDNNNDNNNDNNND		478		
Db	655	VKSKSRKOKL.PDNRRNNNNNNNNKONLIDIMNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN		714			
QY	479				478		
Db	715	YVVVGATNIGNGKKEFANCL.PYDNPEYHNVINKDLIRNLIWVDTSNMKSYNS		774			
QY	479	-----SSMYNNMT-----	NHMTNN	519			
Db	775	HNGDNFNLKNIEPESFTNTNTNLKSKSHNN		834			
QY	520	P-----QPNYAFTDTSDFSSLDDMNC-----	HLNNDSIFLHKKULRDN-----	560			
Db	835	TFVENNEBN-----	DIGNF--YNPKSCVPYUOKTNNNINQVDDNVCQKXNYNVSFNNSQVH	888			
QY	561	-----KLKRRS--	CNINMKKKNNLIHLARHVSGLT.MF-----	593			
Db	889	PPYNNHEEYKONSSKYCWNVTYNNYMHNNINNVYA--	GSMMACJLSENSYKONDEDCKIYN	947			
QY	594	--SYDPOKDKONTFF-----	KSINIKMEDNTP-KDILVESRVSMMGNV-----	L	636		
Db	948	NNNNEENKNDINVIIRMYTKSKSHYQRM--	NVPTKDLKNE--VYKTHAVYTCVAVISKRT	10029			
QY	637	LGLNKATHTDSTKDEHNNDKINNGVINIINNSVNSINNSN-----	NMSINN-SMNSGN	691			
Db	1003	ISLN-NIWLDS.PNEQMTNGYENEDMNVNFKSDENYTNMTGYMDKINNMMNLVNT		10616			
QY	692	SIYSNYSNOSISDQIRY--	VNEWDTSNK-----	NNDNIFDAISCNNMYPNITN	742		
Db	1062	KPTRKNNKSNKAGKDKTKSRDGRKNNDSNSPQJ.FEDNHDEYKD-----	DDN--	NNNN	11144		
QY	743	NN		802			
Db	1115	NN		11698			
QY	803	NNODGNV--	YSMN-----	FCHN.LND-----	KNTL-----	IDLANKKOKDN--	838
Db	1170	NNQDNINYNYTKDHEGNNMTSFYNNNITNTYLDKENYLCHEQNNITYLQNEKGRNNDAF		12299			
QY	839	-----	IHCDDNIIQNRNDEKCKKTNFYNNNNIVYVN-----		NM	874	
Db	1230	LGPEONCIATJGSCNNNNNNNDTSSNNKOKKLIRNNNFQNVNVNNYNTIDNKKCLYNTVNI		12899			
QY	875	GNNNSPRMKYGLCSGHSIDNNKC-N	NEKKNEMKCN--	EMKDNH-----		915	
Db	1290	INNNEKR-----	GULCYIKVKKNNMLHNNNNIICNNTFEERFDDNTVHMSYDQLYNF	13433			
QY	916	-----	IKSNNNSSSSSSSNN--	NIVN--	NINDDTFQNDYCHND	952	
Db	1344	LNEEBEKKKKRRKKKKKSPITINNOGININNDGININNDGININNDGININNDGININNDGININNN		14031			
QY	953	TFTRRKNTTINSNIYQ-ND	DIYITISLN-----		DYMS-----	986	
Db	1404	G-NINNDNINNNNNIIIGETODPYLTHINNHHMKQNNNSQNIYHNKKYDYLWENDSN		1462			
QY	987	NTLHFKEKTYTFLSTNEDITN-K	MEGEGHRLDDOKYDN--	DNNVND-----		10355	
Db	1463	MNLDDEKIGYQKITSKKNEGIMGKKRKYORKDNKVADSVFTGNNSVFNLPSLY		15222			
QY	1036	-----	NNQNVNDNVNNNVNDNVNNNDKNNVNDNNVNDVDDDDVDFHIIKPNNNY	1087			
Db	1523	TKVENEIDVNNNNI-N	INNNNNI--	NNINNNININNNNNNN--		INNNNNNNSNT	1574
QY	1088	LSYFOKNDITLINCLNLSISSMYDT				KEILNITLS	1125
Db	1575	CTYNNYNTYEVYNDIHNDKXXXXKSDSKRDNSKKKIYNQKTIENNKKESPDNEMN		1634			
QY	1126	KYKAEKONVIRKYIN-----				EDIKMSLEBIDTKQAQSIYEKRR	1163

```

Db      1635 NYNHELEKRYTDSINNNGNTHKGYIKNNYNNNNYHLHDVNTSVSSLNKASSF-----N 1650
Qy      1364 VLTITKLLLEFKK-----NVDTOIN-----NET--SDLRKOLV--- 11933
Db      1691 TIFNNSRSTFKSLSPNSDVTNMADELINVLGANSISTGNSGTGCTECVCDGNKDLGLYI 1750
Qy      1194 -----MCHI CANNPPDQFHFAVYSLEKDIIVLIMLRQ 1226
Db      1751 QKVDEMDKAGHMNKVDFINSGNNDYKKNKLIINNKMVDFEFNNVTGTGYSNSI----- 18033
Qy      1227 IMCESENLRU---LYQFLVVEYQNKNSVLYVNSSN-----GDITILNK 1265
Db      1804 --GSDKRYRLNCLNCKNSMDLYK---STNNTIINNMMNNIFPNBCNNRYVCGSGDDNMFPLNK 1858
Qy      1270 K 1270
Db      1859 K 1859

RESULT 3
Q8IH00 PRELIMINARY; PRT; 3207 AA.
ID ID Q8IH00
AC Q8IH00:
DT 01-MAR-2003 (TREMblrel_23, Created)
DT 01-MAR-2003 (TREMblrel_23, Last sequence update)
DT 01-MAR-2003 (TREMblrel_23, Last annotation update)
Db Hypothetical protein.
GN PF11_0479.
OS Plasmodium falciparum (isolate 3D7).
CC Eukaryote, Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=22255705; PubMed=12356864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eichen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Angioli S.,
RA Perteira M., Allen J., Selengut J., Haft D., Mather M.W., Valdivia A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA Venter J.C., Cummings L.M., Subramanian G.M., Mungall C.,
RA Fraser C.M., Barrrell B.;
RA "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AE014843; AAN36059.1; -.
KW Hypothetical protein.
SQ SEQUENCE 3207 AA; 377920 MW; 71C32BF8B8BF06A59 CRC64;

Query Match 12.8%; Score 876.5; DB 5; Length 3207;
Best Local Similarity 23.3%; Pred. No. 1.7e-27;
Matches 388; Conservative 245; Mismatches 520; Indels 513; Gaps 76;

Qy 1 MNSKIKVAVKRPSELSEKKKKSDIITVK-----NNCTLYIDEPKYKVMYKYE 51
Db 5 IQETLQKKKKKKKKKKSDRKEDKNDIILNKNEBEDNINNNTILYSPDFDKINYSYKTK 64

Qy 52 RHEFIVDKVDFVDNFTYENTIKPLIIDLYNGCV-----CSCFAYGQTGSGK 101
Db 65 NHHLENDKIKEE--DDHEIKRKLKILNTVFYIDKCIHFKKFSKDELYKTFIYSNFLTKA 122

Qy 102 TYMTLSQRPYGOS-----DRPGFQVYAGGIPTF-----LNIYDK-----DNKGIIF 143
Db 123 LILYPSLMPVECTIEIKIKIKENETTFPAIEQFNFSLIHAVSSYQTGTQTENNHNPFY 162

Qy 144 ISFEYIC-----GKLYDLQKKKVALENGKEKVVAKDKILRLFKELILK 193
Db 183 TNYQSGITKNDNIPYINQNIIFP-----NNIKKKYMLDD-----K 217

Qy 194 MIDGVLLRKIGVNSQND-----SSSHAILNIDLKDINKNTSLGKIAPIDLA 241

```

Db 218 FGSTSLNNNNNNNNNNNNNNNDKYLNTYVASPRGQIYLN-FQDINNHHNNNI----- 270
Qy 242 GSEBQADTVSONKQOTDGANINRSLLALKECIRAMSDKXHIFFRSELTQVLADIJVG 301
Db 271 -----NSYSNNKFFNYMLNKN-----LEETRSYVNDYRNI-INPNLN----- 309
Qy 302 KSKSIMLANISPTISCEQTLNLTIRYSRVKQFKKSCICINEEDDTNERISILDSKSE 361
Db 310 NSNNVHNNIYPELN---NTYNNNNNTYHLNNVHSTSLQNNYNNPNNDH----- 356
Qy 362 MNASSIEVVIKSHLNNNNNNKINRGKINDIERNNI----- 400
Db 357 -SMKIKKIEYNNNNNNNNNNNNNNNNNNNNNNNNNNNNIYPELDTLHLYKATINEYDI 415
Qy 401 -----LNKRSF-----DKRREGFTSTF----- 417
Db 416 ELKICTTLNNKYICRYIGHSQMTLYNHRICICIGVCKEDTDYLVHFIILNNGIYGS 475
Qy 418 GKYSGLNDIKIKKKK-----KGLINYSKTYNDNTINKKNNNNNNNNNNNDNN 472
Db 476 GKCSVSIIIRKIQINTDRIITFKHIIKTPLYLYSKEDKXKNSNNNNNNNNNNNSN 535
Qy 473 NNNNDSSSVYNNMI--NMMINNNINNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNN 530
Db 536 NNNNSNSNSNNNTNSNSNSNSNSNNNTNSNSNSNSNNNNNNNNNN-----TTTNS 588
Qy 531 DESSLDNCHLNNDK-----SIFLKKNLBDNI----- 560
Db 589 SSSNNNNNNYNNNYKNEKELNNSGLESHSIIIMNNNDIHNINNNNNIITDLNNNV 648
Qy 561 ---KLKRSSCDNTNNKKNNLHLARHVSGLT-----MPSYDQK 599
Db 649 NQSNKNNNNIIDYNNNNNNNDYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 708
Qy 600 NND-----NTPFKS-----NINKEEDNTPEDILYESRANYSNNNGVYLGLNK---NTHDI 647
Db 709 NTNNNLANNNTSSTNFRINNNMDSN-----IYNTTCNNPKKAIINNININDSINKHNI 763
Qy 648 ---STYDENHNDK-----INNGVINIINSNVNSIN-----NSNMN 681
Db 764 FNNMHLHLNDHSYIQQNLKYNHNNVNTNLIYNNPIMNNIINDDINNLSIENKEDNN 823
Qy 662 SINNSNMN---SNSIY-----KSNYSNQSIS---DVOIRYNE 714
Db 824 EINHDSDDSDSSSHITLAKSDKXKXYPALNPKYQNHQNHNNINQNNLEQIKEND 883
Qy 715 MDTSN-----KN-----NDNIFDAISCD-----NNMY 737
Db 884 QONNHKELIKKELANDTISSTIEDTNDYSKYITSSDISQNNTLNSFOHKEISVNTMY 943
Qy 738 PNTNNNNNNNNNNNNNNNNNNNDIVE--NYNNDGTNNMGLVAYNSHNLFOPNKNTSNI 795
Db 944 NNIIDNNNNIIDDNNNNNNNYFCIPGYNTKE-----YKNIYNTYVNNAN-HIY 994
Qy 796 QNINNNKNNODGNVYSMFCHYNLNDKYYL-----DLNKEOK----- 835
Db 995 NMMNISYNNSAYNNYVYNNFNHNSYHNNYIILHNNFHNPNYNYDNIQNEQKLYNYON 1054
Qy 836 DNGHGCDDNI-----IONRDFEKKKTYNFYNNN---NIVYNNNMG-----NNNSPRM 882
Db 1055 DERQNNSPHINTDPRKAVNSNNF-LPINTPHYNNNLHNNIILTESNLNRKKNENDIPSS 1113
Qy 883 -----KYGLCG-----SHTSIDMKKNEMKNNEM-----KDNEMKDNHISKNNNN----- 922
Db 1114 YSQIHQHQICKVEEYYSI-NQNTNNNNNNVMMAMTSNNIPLDNNYNNKKNKIYK 1172
Qy 923 ---SSSSSSNNNI-YNNIND-DTFQN--DYCHADNTFTIRKKNNTINSNI-----YON 971
Db 1173 HINHHINQKNNVEYENLNSCNDQNKETCNOOLI-----SSNNNNNISSTYTFQN 1226
Qy 972 DDIIYT-----INSLDYSNTLHFKKETYPTLSTNEDIYNKMEG--KHIRLDDO 1023

Db 1227 NNDFTKKSQYNNHNDIYKINTT---SENVGSPTHNNKTSIYNHKKGGYEQHTQONNEQ 1283
Qy 1024 KYDDNNNNVNDNNKNNVNDNNVNDNN---NVDNNVNDNNKNNVNDNNVNDDDVDPHNIK 1080
Db 1284 NNEQNSEQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNIQNI 1343
Qy 1081 NFNNNEX-----LSYFOKAVDTIINNCLNSIDISSMYDPEKELIINNILLSKYKAEKDNV 1136
Db 1344 NSNNBSIKTYVTFTFKKNNQIYNS--NNV-ISKQOHDNTNILLNNININ-----IKENINR 1396
Qy 1137 KYINEDIKNNLSLEIDKTAQSIYEKKRVLTLLKLPKKNVDTQINNE---TSDLRKDLV 1193
Db 1397 HKINE-----FQWEXSKNIDIEKNNCLTTK---YDKNDENDNENDNTYNNKONDIY 1445
Qy 1194 MCHICNNPDDQHFYFAYSLEKDIINLMLRQWCESENLRLLYQFLVEX----- 1245
Db 1446 ICNNHNSHVOXNY---NNNESMINENNI---TIEGELNNSTE---EFTNELIKK 1496
Qy 1246 ---QNSANSVLNVSNNNGDIILNKLQVQDNKSMHNNIHK 1287
Db 1497 DSLEKKSQDTFKLKL---NNEIKKEEK--KONI-NIFINNIIYE 1536

RESULT 4

08ICP9 PRELIMINARY; PRT; 3248 AA.
AC 08ICP9;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Hypothetical protein.
GN Mal6pL307.
OS Plasmidium falciparum (isolate 3D7).
OC Eukaryote; Alveolata; Apicomplexa; Haemosporida; Plasmidium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Chervach I., Davis P., Goodhead I., Stevens K., Mungall K.,
RA Berriman M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrett B.,
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL844505; CAD50391.1; -
KM Hypothetical protein.
SQ SEQUENCE 3248 AA; 374892 MW; F72C129A97E38466 CRC64;

Query Match 12.5%; Score 857; DB 5; Length 3248;
Best Local Similarity 23.0%; Pred. No. 1e-26;
Matches 347; Conservative 220; Mismatches 413; Indels 530; Gaps 62;

Qy 202 KIGVNSQNDSE---SRSHAILN-----IDLKDNKNTSLGKIAFIPLAGSERG 246
Db 371 KVTIGSYNNEDKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNN 420
Qy 247 ADVSONKQOTDGANINRSLLALKECIRAMSDKXHIFFRSELTQVLADIJVGSKSI 306
Db 421 PLNQQN-----NI-----EINH-----MEDNFP--SNDI 443
Qy 307 MIANISPTISCEQTLNLTIRYSRVKQFKKS-----TCINEEDDTNERISILD 356
Db 444 M-----NTIPYSPTKKIKIEKRMKNNIMHPNVIKNNDENND-MQKMS 487
Qy 357 SKGSEMASSIEVY----- 417
Db 488 ANNIDMMASVNNIDNNKMCATVNDINKMSVNNIDINKMGANNIDINKMGANNIDMDHNM 547
Qy 379 SNNNN---NKN-----RGKINDIERNNILKXKSPDKP-----EGFTSTFGKYS--- 421
Db 548 SNNNDLIMNNKYNNHMMINNNKIPIKFPANENIRIGKTDHPKLGKQVAYTRSCYENNNI 607
Qy 422 ---SLANDIKIKK---KGLINYSKTYNDNTINKKNNNNNNNNNNNDNNNDNNNNNN 475
Db 608 EYNEENNDIKGNKRIIRKNNIMFNTNNNNNNNDNSNNNNNSNNNNNSNNNNNNNNNN 667

Oy		476	NNSSSSVANNIINHHINNINNNINNIIVNANNNNN-----NNNSHNHLPOGPNVA-----	525
Dd		668	NNSNSNNNNNNNNNNNNNNNNNNNNKKNKKNNNSNNNSNYNNNSNNNAOQTIGENITS	727
Oy		526	-----FTDTSDFSLDDMCHLANNNDKSIFLHKQULRDNIKLNKSSCDJINMK---	574
Dd		728	TSYQONNNFYEKRNNEVEIKRINIINENPCODEK-----NKELKKGMVPKQDITLNEYTNKLII	783
Oy		575	-----KKNNLHARHSVSGKLTWESYDPQOKNDTPEFSNINKMEDNTPKOILYESR	626
Dd		784	NKMAELTWQKULKKKMRANINACL5--GSNNNINNNNIIIFYEFIK--DDNYNNNICLANE	840
Oy		627	NV-SNMAGNVLLGLNKHNTH-----HDISF--KDEHNDKI--NGCVTIINNSVANSINN	677
Dd		.841	ELANNNNNNNLIIPDNCKNCYNKOLHLNSTINFNRUNNNNNIDNNNNININNININNNIK	900
Oy		678	SNNMSINNNSMN-----SNSIYK--	695
Dd		901	NNDYIKYKNNLNFEKEBEKEKEKEKEKKIKKDKNDKEKEKLPBNEBEOQRILIKG	960
Oy		696	--SNYSNQSI5DVOIRYVNEMDT5-----NKONDNI-----FDAISCNNN--	736
Dd		961	KTOXINSRKKIT-----KCINSNSSSYLMANDNNNNNYIKENTKALAFQONININLNTLS	1016
Oy		737	--YENINT-----NNNNNNNNNNNNNNIIDVERYN---NRGCTNNSMLY	776
Dd		1017	NMCPHVLSVLNFKNMENOMARRNSSFNNNIINNHLLNDMFNFQHLNLKHINPIML-	1075
Oy		777	AYNSHNLFPQPN-----NKNTSIOUINTKNOQCNVAYS	812
Dd		1076	--STHGSLQKNNVQMKRNTKKIPEPENIEMSFPAKINSNNINIEHMMN--NNIN--	1128
Oy		813	NMPCHYLNDKNYLIDLNNKEQOKNUIHCDDNIIIONBNDEPKKKKTFFYNNNNIIVIYNN	872
Dd		1130	--AYNNNNNNNM-I--NNGTNETPRKTRASLTMQININIQKNNFTLSKHODV----	1180
Oy		873	NMGNNNSPRMKCYGLCGSHTSIDMKNK-----NEKNNEMKD-----	908
Dd		1181	-MNNINSYHO-----HYNEDEMKNKAYPEPFINLEHQMTTTIDGNKRKVSHESD	1233
Oy		909	-NEKDNHIKS--NNNSSSSSSSNNINYNNI-----DDDTQONDV--	947
Dd		1234	LNRMLNNNLNLPNNINNTNNIINNINNNVVNLYGKTVQONSPLKMTGSLHANNTI	1293
Oy		948	-----CHNDFTLRKKNNT-----INSNTYQNDDIYT-----	977
Dd		1294	NKMVYVPEPONIITHGTNTTITTTTTNNNNNNNNNSGYNNNTYYPDKKYDNSNNPTINDF	1353
Oy		978	INSLNDYMSNTLHFKEKYTYPTLSTNEDIY-----NKEMEKGHIRLDOD	1023
Dd		1354	IINHLLNDTQNKRYTLASSHAAMONSCHUYINNISINNYYNNMKMMNNNNNNNISKNS	1413
Oy		1024	KYDDNDNNNVU-----NNKKNVNDNVDDNNVDN-----HYDN	1056
Dd		1414	LANNINVGNNVLGVKQVSN	1473
Oy		1057	NDKA-ANYDANNV-----DNDDDVDVFNIKPFNNNEXTLSFYQKVDTIIN-N	1101
Dd		1474	NNRIINNDDNNVILIAPYDIMSRENTQONNLMAAVQNVYSNNNTGGFLYVKQDIYVANK	1533
Oy		1102	CUNSLDIS-----MYDTEILNILLSKYKA-----EKDNVIKYYINEDIK	1144
Dd		1534	MINKENKYSLETTHPYNHIDKQMOTDFNNNNNNNSINNKKSGAMINVNNYNNQNIHRMN	1593
Oy		1145	NMSLEEDIKTAOSI-----YEKRKULLTLLLLLFKKNVU-----	1178
Dd		1594	NTNTTVQNNVSSLNKKNNSSNNNNLPPYDKENVYNIKYDDLNNCNAVANNIPIGTG	1653
Oy		1179	-----TOJNNE-----TSDLRKDLVWCHICNNNP-----DDOFHYVASRLKEDIIN	1220
Dd		1654	INLANSVLQZLNNNMKKNI5EDINKGDILSPFGNALPPIYDRNEYVASSISEKATNINE	1713
Oy		1221	LIMLRQIWCESENRLLYOPLVEYQKSAVSILLANSSNGDITLLNKKLVQ-----DNI	1276

[illegible]

[illegible]

RT	Sequence	Score	DB	Length
RT	"Genome sequence of the human malaria parasite Plasmodium falciparum".	12.4%	DB 5	Length 5561
RL	Nature 419:498-511(2002).	23.3%	Pred. No. 3e-26	
DR	EMBL; AE014821; AAN6928.1; "		Mismatches 484; Indels 568; Gaps 73;	
KW	Hypothetical protein.			
SQ	SEQUENCE 5561 AA; 658524 MW; 98BF06CAC3C2B52B CRC64;			
Query Match		12.4%	Score 851;	DB 5; Length 5561;
Best local similarity		23.3%	Pred. No. 3e-26;	
Matches 385;		Conservative 212;	Mismatches 484;	Indels 568; Gaps 73;
QY	19 KKKKSDIIYKNNCTLYIDEPKRVMTKTY---EHEFIVDKVPDFTVD-----	66		
DB	521 KKKNTVNTITSYCVSFNQLYTSKQICMTYKRNYSISLDHMSNINITYKTLIF	580		
QY	67 -----NETVYENIKPLIIDLYENGVCVCSGAFAGQTSKTYTMLSQPYGSDTDCIF	120		
DB	581 LLLLLLFSSYNNTNNTNTVQLDYO-----CYKNVHNN-----	613		
QY	121 QYAAADIFTEPLNTYDKNTKCIFISFE-----YCGKU--YDLQKRCVAA--	166		
DB	614 -----YLFYENTLIVANRRYTFVSYSVALMRTINLIMLNKLYIDIFIKNLVCGHG	668		
QY	167 -----LENGKEVYVKDKILKLVLFKEELILKMGIVLRLKIGVNSODES	212		
DB	669 FTLFHEKHEFNQYIVANNNTIV--VLVLIVGRNRRTIOIEPRRIYKLPVILNLS	726		
QY	213 SRSHALINIDLKINQTSLEKIAFIDLAGSERGADTVSONKQOTDGANINSLALKE	272		
DB	727 RKNKLYNTIYSCGHFNPKL--YCFEI-----FKQRNNEIYDGVNHEKS-----	769		
QY	273 CIRAMDSCKN---HLPF---RSELTKVLRDIFVGSKSISMTANISPTSSC-----E	319		
DB	770 -----KNYMDHVAFVAKKKSFLQTSYDLY--HFKNYDNKLFNNISLCYINLB	819		
QY	320 QTLNT-----LRYSSRYKFNPK	337		
DB	820 HRNNVQKYIHADMSHFPKKYKEDKGINQYITYYKANFYLRVNFLLNFIKRTKIVINI	879		
QY	338 STCIINEEDDTYTERISILDSKGSSEMASSLENNVI-----KSN	375		
DB	880 VLCL-----FKLLILT---KELIVYILNLFYYIMLKCYFVLYNIIEYETERDY	928		
QY	376 HLLSNNNNNKKIKRGKINDIKERRNILLKKSFDKREGEFTFGKYSLLNDIDKIKAKK	435		
DB	929 MLMGLYNSK--REFKNDKCD--LEFK-----NINEKERKAK	962		
QY	436 GLIYKSLTYNDNTINKNNNNNNNNNNNNNNNNNNNNNNNNNNSSSWNNNNININNI	495		
DB	963 FVSCATNNEYDN-----NNNNNNNNNNNNNNNNNNNNNNNNNNND-----NNNNND	1009		
QY	496 NNNIVANNNNNNNNNNNNNNNNNNHLLPQRYAFETDTSFSLDDMCHLNNDKSIFLHKX	555		
DB	1010 NNNNNYNNNNNNNNNNNNNNNNNNY--NNNNNGGDEND-----ENNDK-----KKE	1053		
QY	556 LKDNITKLKRNSSCDINMKKKKNNILHARVSGSKLTFESYDQKNDCTPFKSNINMKED	615		
DB	1054 DNDNDNINMLLEND--CKKRTBRKRTSDSKXTINKWTTRGRKSTSMALAHID--AN	1109		
QY	616 NTPKQIITYESR---VSMNGNGLVLGLNKATHHIDSTDEAHNNKINNGVINIINSNV	672		
DB	1110 MLKKNLVINNGNYYNNNNINNSILLNNMOENY--MNDKSSIMLNNNIPNKQNMKAN	1165		
QY	673 NSINSSNNNSIINSSNSIYKSYN-----SNQISIDVOIRYV--NEMDTSN	719		
DB	1166 GQINNEIMNDNTMYNNNNMGNHNNNNNGHNNNNMNGHNNNHSHNNHHISNM--NN	1222		
QY	720 KNNNDIFF-----DAISCDNNYF-----NITNNNNNNNNNNNNNNNNNDIVENY	763		
DB	1224 QLNNNIYNNRIVGIGYMSNVQGHHMSPHMNNITIVANNNNNNNNNSNNNNNNNNNNNN	1283		
QY	764 NNRDGT-----NNSMKLYAYSNHLFQDPNNKQTSNI-----QNTNTKKNQDGN	808		

Db	1284	NNNNSSGSNCVNTLRLNNLMK----	NNFNQNRNVNNNSINIHSSNNNNNN----	1334
Qy	809	VNYSNPFCHYALNDKGYLIDLANKQKX-	NIHGCDDNNI-----	IQNRN 851
Db	1335	-NYNIHLTHQKINSNNNNINNNNN	LMNNGKLYHQMSNRYHGTVPILPNNV	HNGGTSISNIN 1393
Qy	852	DPEKKKKTNFVNNNNIVIVNNMG----	NNNSPRKCYGLCGSHTSIDMKNN	EMKKNEMK 907
Db	1334	HMNNINNNNNNNINNMSSSNMGTSPI	NHPIPHKKGSTHMSNQITRYAMNM	SLNPINV 1453
Qy	908	DNEMK-----	DNHIKSNNSSSSSSSN--NNIYNN	INDDTEQO----- 944
Db	1454	DNKNVTLNRKNSCTYNFMNPNPMTYS	MMNNVYNNNSNNMNSLSLPNNICSG	GITIMPVMSKGX 1513
Qy	945	-NDYCHDNTFTIRKKNNTNINS-----	NIYONDIIYITNSLNDY 984	
Db	1514	IKDFTAINNSF-----	RNNNNINNNNNNSNMHNSSMHNS	SMHNNNNVHNNNNNNNVMS 1569
Qy	985	MSNTLT-----	LHFEKXT--YF-----	TLST 1003
Db	1570	MNNRSEONIIANNMIKTEMRNNLM	NKLVNRQHMNMKYSEKYPMTYMI	ONNNVYT 1629
Qy	1004	NEDI-----	YNKMEG-----	KAIRLDDOKY 1025
Db	1630	NRDMMIINNNGINGINNGFINYM	KNKNTLKNKNKITEYTYDHLHND	PLSPMDTY 1689
Qy	1026	D-DNDNNNVNKKNNVNNVNDNNV	NDNNKNNVNDNNVNDDDVDVFNH	KNFNN 1084
Db	1690	DIGHNNNNI--NNMNI--NNVNI	NNINI--NSINNINNN-----	SIHSV---N 1732
Qy	1085	NEYSYFQKAVDTIINNCLNSLDS-	-MYDTYELANNILSKYKAEKONV	KYKYNED 1142
Db	1733	TKFMLNKEDDKTLHPNLYNNQ	OVSNTRYQTEEBEINTVNNHSS	PTIMKKKHGX-S 1791
Qy	1143	IKNMSLEID-----	KTAOSIYERKVLTLTL-----	LLPFRKNV--DTQINNE-- 1184
Db	1792	LKNSKEDDLNNNNQILRSVKI	NMKNKYDNLFKPIPLERNYEG	FTLQKNIKODDTINDEKTF 1851
Qy	1185	-----TSDLRKOLVNC	HCICNNPNDDQFHFVARSRL	EKDIIINLIMRQI-----WCSE 1232
Db	1852	MLENNEDKEDDAIYCDLSNIN-	-----FKTFKQYNDLNTK	LANILKJLNDKTNFKONCYQ 1905
Qy	1233	MLRLLYQ--FLVFE-----	YONKSANSVLNVSSNG 1262	
Db	1906	-----LYEIEFLIEKFL	DISHLKYHNNFTHTFYN	NCKLYAYONKE--NTVLIHIKEENV 1960
Qy	1263	DIILLNKKL-----	VQDHIKSMOHN 1283	
Db	1961	D-----NKNIGHGLD	IHLTHENNETKEDHN 1985	

RESULT 7

Q8MMY3 PRELIMINARY; PRT; 1422 AA.

AC Q8MMY3; ID Q8MMY3; AC Q8MMY3; DT 01-OCT-2002 (TREMELREL. 22, Created)

DT 01-OCT-2002 (TREMELREL. 22, Last sequence update)

DT 01-MAR-2003 (TREMELREL. 23, Last annotation update)

DE CG5792 protein. 6/101.

OS Dictyostelium discoideum (Slime mold).

OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.

OX NCBI_Taxid=44689; RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=AX4;

RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,

RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,

RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.,

RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.",

RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.

DR EMBL, AC116965; AAM3216.1; -

DR InterPro, IPR002110; ANK.

DR SMART, SMO0248; ANK. 2.

[illegible]


```

Db 1110 -CINKNFINITVPSNVNINNEIEDONSANT-YDALSKINDMEL--KQMSDNNNN 1164
Qy 1279 SMDHNNI 1285
Db 1165 NNNNNNNI 1171

RESULT 9
0812P8 PRELIMINARY; FRT: 3178 AA.
ID 0812P8
AC 0812P8;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Protein kinase, putative.
GN PF1280C.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_TaxID=36329;
RN 11
RP SEQUENCE FROM N.A.
RX MEDLINE=22255708; Pubmed=12368867;
RA Hall N., Pain A., Berriman M., Churcher C., Harris B., Harris D.,
RA Mungall K., Bowman S., Atkin R., Baker S., Barron A., Brooks K.,
RA Buckee C.O., Burrows C., Cherevach I., Chillingworth C.,
RA Chillingworth T., Christodoulou Z., Clark L., Clark R., Cotton C.,
RA Cronin A., Davies R., Davis P., Dear P., Dearden F., Doggett J.,
RA Feltwell T., Goble A., Goodhead I., Gwilliam R., Hamlin N., Hance Z.,
RA Harper D., Hauser H., Hornsby T., Holroyd S., Horrocks P.,
RA Humphray S., Jagels K., James K.D., Johnson D., Kerhoulou A.,
RA Knights A., Konfortov B., Kyes S., Larke N., Lawson D., Lennard N.,
RA Line A., Maddison M., McLean J., Mooney P., Moule S., Murphy L.,
RA Oliver K., Omond D., Price C., Quail M.A., Rabbittowitch E.,
RA Rajandream M.A., Rutter S., Rutherford K.M., Sanders M., Simmonds M.,
RA Seeger K., Sharp S., Smith R., Squares R., Squares S., Stevens K.,
RA Taylor K., Tivey A., Unwin L., Whitehead S., Woodward J.,
RA Sulston J.E., Craig A., Newbold C., Barrell B.G;
RT "Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13.";
RL Nature 419:557-531(2002).
DR EMBL; AL929358; CAD51942.1; -.
KW Kinase.
SQ SEQUENCE 3178 AA; 366959 MW; 82PB35F0914C4DED CRC64;

Query Match 12.3%; Score 839; DB 5; Length 3178;
Best Local Similarity 23.6%; Pred. No. 5.4e-26;
Matches 332; Conservative 210; Mismatches 420; Indels 444; Gaps 55;

```

```

Db 529 YKKLTPKJKNDEDEDEIKLEGDPNDQVINDVNDYDDDNQTHRKSNNNDNN 588
Qy 500 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 556
Db 589 DNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 647
Qy 557 RDNIKLKNSSCDINAKKKNNLHLARHSVSKLTFSPQKKNKTFEFSKINKEDN 616
Db 648 YNNNDVINFPNDNIMEYKN-----ISSLSYKVCADSTYNNNDIN----- 650
Qy 617 TPQDIIYESRNVSNMNGVLLGLNKOTHHIDISTFDENNDNKINGVINIINNSVNSIN 676
Db 691 -----NNTNNNTSNNNTNNNTNNNTSNTSNTSNTSNTSNTSNTSNTSNTSNT 728
Qy 677 NSMNSINNSMNSNISYKSNVNSNSISDVQRYRYNEMDTS----- 719
Db 739 NNTYNNIRVSNNNHCDHHNSYDTENIINVEDLLYNNDLKKNSDHFIDVEEGIRRYNK 798
Qy 720 -----KANNDIFPAISCDNNMY-----PNTNNNNNNNN-----NNNN 753
Db 799 RLISYQKIQTNESEDIRKNDNYNN--NLANDMFSSNDENIKTNEPNNSSISFYKNTS 856
Qy 754 N--NNIDVENYNNRDTNNSMKTLYAYNSHLFQPDNNKNTSNIQNTNKNQDQNVN 810
Db 857 NFLINDICDDNKQDPSVEKURHISYNSYEKEEQNLKHSLSLENNYINVENARINNF 916
Qy 811 YSNRFGHYLNKQNYIDL-----NNKEQDKNIGCDNNIIQNRPDPEKKK 858
Db 917 FS--CNVYITDPTKTNNTNTTYTNGNNNNNNNNNIDDDKNDGDDKNNNIDLNRYKRRN 973
Qy 859 TNEYNNN--NIVYNNNMGNNSPRMKYGLCSHTSIDNM-----K 897
Db 974 SNSSNNIHYNDKMYMPSYKKNISTINMYEPYSHSGMNVYIDEHAFYGSFLNKEKA 1033
Qy 898 NNEMKNN-----EKNDEMKDNHISKNNSSSSSSSSNNNY-----N 935
Db 1034 NKKIKHKNNNMKSYIDIDHTDYNDFISDPFNNMGSDNYVNVYDDEDVNNNVGN 1093
Qy 936 NIN-----DDPTFQNDYCH-----NDPTFRKKNNTINS- 966
Db 1094 NIDGNDIDGNDIDGNDIDGNDIDGNDIDGNDIDGNDIDGNDIDGNDIDGNDIDGND 1153
Qy 967 NIYONDIIYITINSIANDY-----MSNTLHFKERYTPTSTNEDI---YN 1009
Db 1154 NMSSESVAIVSHDLKKNVYKNSINLEDQKCKMPSYHIDICANTYEKINHMDVAVHSN 1213
Qy 1010 KEMEGGRIID--DQKXDDNDN-----NNVDN-N 1036
Db 1214 NHHKTHTDMKQVFPDQHCYVSGNMEYIKDNNNTVNSINSNMSMNSLNDVNNVNNIN 1273
Qy 1037 NKNVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVNDVND 1094
Db 1274 NVNNM--NVNNM--NVNNM--NVNNM--NVNNM--NVNNM--NVNNM--NVNNM-- 1322
Qy 1095 VDTIINNCNSLDSISMYDTEKILNNIILSKYKAKDKVVIKYNEDIKKMSLEEDIKT 1154
Db 1323 ---VHNS-NSMKSGICEYMMNNYLNLRMS--KQDDNTNKKVDGNHYN----- 1366
Qy 1155 AOSIYERKRYLLTKLLLFKKNVDTQINN--ETSDLRKDLVYCHICNNPPDQFHYAY 1211
Db 1367 SQIIGMKKQDVLYSDMSNMYYEMNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1417
Qy 1212 SRLKCDIT--NLMLKQIWESENLRLLYQFLVVEYONKANSVLANVSSNGDI--- 1264
Db 1418 ---NDSLKFKKNFTMSNNL--CGSTNNM-----NNTILNNVNLKDINTM 1457
Qy 1265 ILLNKKLVQDNIKN--SMD-HNNTH 1286
Db 1458 DLLNSRKYNMKNVYSTVDILNNVH 1483

RESULT 10

```


[illegible]

QY	1272	VODNIKSM--	-DHNNI	1285
Db	3077	ISHMKIMTMYPIYNNI	3093	
RESULT 12				
ID	081350	PRELIMINARY;	PRT;	3069 AA.
AC	081350			
DT	01-MAR-2003	(TREMBlrel. 23, Created)		
DT	01-MAR-2003	(TREMBlrel. 23, Last sequence update)		
DT	01-MAR-2003	(TREMBlrel. 23, Last annotation update)		
DE		Hypothetical protein.		
GN	PFI0495W.			
OS	Plasmidium falciparum (isolate 3D7).			
OC	Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmidium.			
OX	NCBI_Taxid:36329;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE:22255708; PubMed:12368867;			
RA	Hall N., Pain A., Bertiman M., Churcher C., Harris B., Harris D.,			
RA	Mungall K., Bowman S., Atkin R., Baker S., Barron A., Brooks K.,			
RA	Buckee C.O., Burrows C., Cherevach I., Chillingworth C.,			
RA	Chillingworth T., Christodoulou Z., Clark L., Clark R., Corton C.,			
RA	Croin A., Davies R., Davis P., Dear P., Dearden F., Doggett J.,			
RA	Fellwell T., Goble A., Goodhead I., Gwilliam R., Hamlin N., Hance Z.,			
RA	Harper D., Hauser H., Hornsby T., Holroyd S., Horrocks P.,			
RA	Humphrey S., Jorgels K., James K.D., Johnson D., Kethnou A.,			
RA	Knights A., Kontofortis B., Kyes S., Laik N., Lawson D., Lennard N.,			
RA	Line A., Maddison M., Mclean J., Mooney P., Moule S., Murphy L.,			
RA	Oliver K., Ormond D., Price C., Quail M.A., Rabinowitsch E.,			
RA	Rajandream M.A., Rutter S., Rutherford K.M., Sanders S., Simmonds M.,			
RA	Seeger K., Sharp S., Smith R., Squares R., Squares S., Stevens K.,			
RA	Taylor K., Tivey A., Unwin L., Whitehead S., Woodward J.,			
RA	Sulston J.E., Craig A., Newbold C., Barrett B.G;			
RT	"Sequence of Plasmidium falciparum chromosomes 1, 3-9 and 13."			
RL	Nature 419:527-531 (2002).			
DR	EMBL; AL929356; CAD51785.1; -			
KW	Hypothetical protein.			
SO	SEQUENCE 3069 AA; 368341 MW; 731D5B1C386643B3 CR664;			
Query Match	12.1%;	Score 830.5;	DB 5;	Length 3069;
Best Local Similarity	21.6%;	Pred. No. 1.2e-25;		
Matches 374;	Conservative 230;	Mismatches 483;	Indels 643;	Gaps 72.
QY	21	KKSDIITVKNKCTLYIDEPYKYVMTKYIERHEFYDKFDDVDVNFVYENTYIKP--	77	
Db	614	EKDERKYNNYNNNTCSY-EONKTYMD-TNYLYNHE--DK-----NNYSTKNKDLNERNK	662	
QY	78	--LIIDYENGCVSCFAYGGTSGKTYTLMGSPY-QGSDTPGIPOYAADIF--TFL	131	
Db	663	RFSSKNLVNNSHSEC-----PYDQIISKFLFTIHANNNLKDEKTL	704	
QY	132	NIYD-----KDN-----TKGIFISFEYI	149	
Db	705	TTFDEKSDDDHHHHNNNNNNNNNNINDNNYLNHVSLSNNFVSHGKXNGFPKNNLNI	764	
QY	150	YCGKLYD---LLOKRMVAALENGKEVYVKDKILIRVLTKEELILMDIGVLLRKIGV	205	
Db	765	ECQKINQOSDQLFYDNKQIMCPYNNKKDIFNNVDYKLLNLKNDYL-----	809	
QY	206	NSQNDSSRSALINILDKDIN-----KNTSLGKIATF-----IDLAGEKGDATVS	251	
Db	810	NYSSYSNSIHRKYSDDINSLHAKKSICKKSSCNNIKKGKMKYNCYNHDMLYNEHEKSM	869	
QY	252	Q-----NKQOTDTGA---NINRSLALKECIRAMSDKN-----	282	
Db	870	EYERVAKAKMNCRLIQKDNVRSYVINKSIHRNERINNIYNNNNNCDDNNNRDYHCD	929	
QY	283	--HLPFSDSLTKVLRDIPFGKSKSIMIANISPIISCEQTL-----NLRKSSKRYN	333	
Db	930	TRAHKSSSNEYNK-----YNGNDIICNDHNLSHTLSTKYDFVSLDNNNDSSNNYSLEEN	984	


```

Oy 334 F-----KXSTCINEEDPTERTISILDSKSGSEMMASTIEN-- 369
Db 985 FNFNLIINKEKKRPKLSNNKNNENYKNCENTYENHNDYENYENYENHKNYENHK 1044
Oy 370 -----VWIKSNHL 378
Db 1045 NYENHKYENHKNCEAMAYNDLFQGEINQNGKYVADKECFKNDXEYIFKNSKLLKNNELL 1104
Oy 379 SNNNNNNKINRGKINDKIERNN---LKKKSPKPREGSTPTGKSSLANDIDKIKONKK 435
Db 1105 FKNNESLP--KNNENIFKNNENLIFKNNENIFKNNENIFKNNENIFKNNENIFKNNENIF 1161
Oy 436 GLIN-YKSTLYNDNT-----NKKHNNNNNNNNNNNNNNNNNNNNNNNNNNSSSMVNNIN 488
Db 1162 KFOYIFYANCPENYLNKCLIDNOCKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNND 1212
Oy 489 HMINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 548
Db 1213 ---NNNDKNNND--NNNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1244
Oy 549 IFLHKONLRDNYKLNKSSCDNNM---KKKNNILARHSVGS---KLTMFSYDPOKN 600
Db 1245 FPNHFKD-----DMVNI FSDRRNSNYHATKISYDMNKLKGTRELSTY--KE 1288
Oy 601 KONTEPKSNINKEEDNTEPDILYESRNVSNMNGVLLGLNKTKTHDSTKDEHNH--DNK 658
Db 1289 KHQITNEQKVM-----ICEKNNNTENN-----KNNNNNNNNNNNNNNNNNNNNNN 1333
Oy 659 INNGVINIINNSVNSINNSNNNSINNSNNNSIYKSNYNSNOSISDVQIRYNEWDT 718
Db 1334 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1385
Oy 719 NKNNDNIFPDASCNNMYPNTNNN--NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 777
Db 1386 NINN-----CNNNNKNNYDNNINNNCDKNNNNNNNNNNNNNNNNNNNNNNNNNN 1432
Oy 778 YNSHNLPOPDNNKNTSNION-----INTKNNODGAVNY--SMNFCYVNLNDKNYLI 827
Db 1433 YDNHINNCDNNKNTKNSLSLEYCYNKIHHKDBERNAGYLSLNOQKSVSKIEII 1492
Oy 828 DIANK-EQKDKNIHGCDDNIIIONRDF-EKKKKTFFYNNNNIYIVN--NNMGNNSSPMK 883
Db 1493 KNNENIYKRIIDNSRIIISNNYFPEFNKSLFYKNNMLYNISKNNLHGNN----- 1547
Oy 884 YGLCSHNSIDMKNNEM-----KNN-----KNN-----KNN-----KNN----- 909
Db 1548 ---KNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1602
Oy 910 ---EMKDNHISKNNNNSSSSSSNNNNIYN--NINDDPTFONDYCHNDPTF----- 954
Db 1603 IYNNKLOLINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1662
Oy 955 ---TIRKNNNTNINSNIYOND----- 973
Db 1663 QNNITMKKKNKSVLFPCYHNEDEBEKHYIKKAVIKNELDKNNENNTTEKIIDYIIDVDKI 1722
Oy 974 ---IITY-----INSLN-- 982
Db 1723 YDNKYIYDNNLLQORKKKKKVENYDFVLIDICEKTPRNKLLLEKLNIAIYINALEIS 1782
Oy 983 ---DY--MSNTLAFKEKYTYPTLSTNEIDYNKEMEGK-----HIRLDD 1021
Db 1783 SKYHNRSYDYVQKFLHLOKKNITRYNNKNDYIKYKIDOKKKKKKKRKSNIYIHD 1842
Oy 1022 QDK-----YDD--NDN-----NNVDNNKNNV-- 1041
Db 1843 QGQFMENNTDFIKNRTNSIHSYLDENKLIYDQNDNNTPYMLYNNLSRBRNSMYH 1902
Oy 1042 ---DNVDNNND-----NNVDNNKNNVNDNNNDND 1072
Db 1903 HDEENNEDEYLDIEDEDEHHQYVENYRYRHKNNNNNNNNNNNNNNNNNNNNNNNN 1961
Oy 1073 DVDFNHKNPNNEYLSTYFQK---NVDTIINNCLNSLDISSMYDOTEKILNILLSKYK 1128

```

```

Db 1962 -----NNNNNYFFCHNNKTEMEKITEIONMLSKKIRLGAVNDEYNTNOPIFNKFS 2013
Oy 1129 AEK---DNVAKYINIBIKMSLEIDKTOQSIYERKXVLLTLLLLFFKKNVTOQINNET 1185
Db 2014 FEFDLNFITNSDLDLNNK--ENIKNLEL-ERRKVAINCIMKELKD-----ONES 2064
Oy 1186 SDRKDLWMCICHNNNDPQFHFAYSRLEKDIINILMLRQIWCESENNRLYQFLVEY 1245
Db 2065 EYLSDDQHHVNLKKNMTHIYDLS--DKSTYNY-----NTGKCINYLLEK 2112
Oy 1246 QNSKANSVLIN--VSSNNGD-----ITLKKLVODNIKNSMDHNNIHK 1288
Db 2113 MHESENKEFIKNFEVNNADHINMEIFKKKKKKKYKHNNNSHKNKE 2162

RESULT 13
O8ICX0 PRELIMINARY; PRT; 2874 AA.
AC O8ICX0;
DT 01-MAR-2003 (TREMBlrel, 23, Created)
DT 01-MAR-2003 (TREMBlrel, 23, Last sequence update)
DT 01-MAR-2003 (TREMBlrel, 23, Last annotation update)
DE Hypothetical protein, expressed.
GN MAL6P1.48.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Cherevach I., Davis P., Goodhead I., Stevens K., Mungall K.,
RA Bertram M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrell B.;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL044505; CAD50319.1; -.
KW Hypothetical protein.
SQ SEQUENCE 2874 AA; 334409 MW; 65541406B59D8CB CRC64;

Query Match 12.1%; Score 830; DB 5; Length 2874;
Beet local similarity 23.6%; Pred. No. 1,1e-25;
Matches 323; Conservative 213; Mismatches 412; Indels 422; Gaps 56;

Oy 206 NSQNDSSRSHALINIDKINKNTSLGKIAFIDLAGSEGADTVSON-----KOTQT 258
Db 33 NSRNDPNPDROW-LNNNDNPNINDPNNN-----DNPNNNDPNNDNPNNDNPNNN 83
Oy 259 DGANINSL--ALKECIRAMSD-----KNHIFPRDSELYTKLRDIFVCKSKSIMIAN 310
Db 84 DNPINIQVYLNFLFKEGDNYIDEDLVYTKNEFLYAVKEL--ILDKKGLGEDEHPLCS 141
Oy 311 ISPTSCCEOTLNTLRSSRYKFNK-----KSTCINEEDPTERTISILDSKSGEMA 364
Db 142 -----NFKFPELEKNIARNFEDENDQYVNSFERDFPNRRLINDEHDFNNKRN 189
Oy 365 SSIENVIKSNHLSSNNNNNNKINRGKINDKIE--RNNILKNSFDPKREGISTFGKYS 421
Db 190 YKNNNEFFYNN--NNNNNNNNNNNNYNNRDERDFCRNNL--NDSFD----- 231
Oy 422 SLANDIDKIKKKKK--GLINYSKTLVNDNTINKHNNNNNNNNNNNNNNNNNNNNNNNN 479
Db 232 SLNNNDNNNNNNRRNFSGIRNNKFKFPHDNNNSLINNNNNNNNNNNNNNNNNNNNN 291
Oy 480 SSMVNNMIMHMINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 520
Db 292 NSYKKS--WYATDSNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 347
Oy 521 QPNYAFDTSDPSSLDPMNCHLN--NNDKSIFLHKKULRDNILKKNSSCDNNINAKKN 578
Db 348 -----NSGMNHNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 391
Oy 579 LHLARHSVGSKLTMFSYDPOKNKNTFFKSNINKEEDNTEPDILYESRNVSNMNGVLLG 638
Db 392 --DAKSNISIDM-----KNTSHEINVDNN--NNYMHLLYNNNDMTKNN----- 431

```


QY	639	LNKTHHDSIDSTDEN-----	-HNDKKNKNGVNIINISVNSIINNSNNSINSNN	668			
Db	432	-KKNY-----TDKRIIHKREDYTYINESHYDQ-----	LNTNTINHKNN--KNINNNNN	481			
QY	689	NSNSIYSKSNYSNQSISDVOIRYVNM-----	-DTSNKNNDNI--FF	727			
Db	482	NNNNKHNNFGNN-----	QLPYIQHNNNESGAGAGPNDIVADHSKKNVENFNSPSF	535			
QY	728	DAISCDNN-----	MY-----PNTTN-----	743			
Db	536	VSVNKNGNIQNNSNYYNKGVNNVTKSGEMVNTSYGSLPNINNNMDWKMKKYYKFSN		595			
QY	744	-----	NNNNNNNNNNNNNNI--DVENYTNRRDGTNNSMKLYVNSH---	781			
Db	596	NNMNSMNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNSMAHYNNHHHL		655			
QY	782	-----	NLFQPDNKK-----NTSNIQNIINTKKNQDQVNV	810			
Db	656	NNAGVYESYRLIEEKKKDSIQEYEPNNIYMNKNENMKKGPSINILRDNNNNNNNNFN		715			
QY	811	YSMNFCHVYLNKNTYLIDLNKKEQKQKNIHGCNNI-----	IQNNDEPKKKTTFYNN	864			
Db	716	YNNNF--NTYQHOYGQKGSITNVVNTVNNIINTHNNANNFNYMNVNTNNNDVEKKNKGYKOS		774			
QY	865	NNIIVVNNNNNNNNPMMKYGCGSHTSIDNMKNEMKNEMKD--NEMKDNHISNNNN		922			
Db	775	SNKNNNNNNNIGNNT-----	TYENMENNIAKSEKSNSTSHSFDAKQIOTTN	823			
QY	923	SSSSSSSSNNNT-----	YNNINDDTFQNDYCHNDFTTIRKKNNTINSNIYONDIIT--Y	976			
Db	824	FTGSHYYNNKILRTNEKNKSNKESKSVIEDDMS-----	LIRKK--SSITDNKKASDOLLWH	875			
QY	977	TINSLNDYMSNTLLHFEKQYTYPTLSTN-----	EDIYKMEGHIRLDDQDKY	102			
Db	876	KMSQFDRNNKSIILESEKKQDVTKNNKPKAKKNKSSKQKKEGCVNNKKDEKN		935			
QY	1026	DDNDNNNVNNNNKN-----	NVDNNVNDNNVNDNNVDNNDKN	106			
Db	936	NNNNNDPDDNNNNNNNSNTYGTPTPLNTAMTYGKGNITSNNNNNNNNNNNNNNNNNNNN		995			
QY	1062	VDNNNVN-----	DDDDVDPHN-----IKENNNEYLSYF-----	109			
Db	996	NNNNKSNRMVGMATISNIKEHPVDNRNNYNNKDKIMNNNNNSVILKKNKNE--	SVFTGSSN	105			
QY	1092	-----	QKRVDTII--NNCNSLD--	ISMYDTKEIILN	112		
Db	1054	INSVNNMEKENEMVEKKKKQKQVELNHEGKDNQDINSKDGNNSPKSLNSNOQNNNNNNN		111			
QY	1121	NILLSKYKA--EKDVVIKKYINE--DIKNSSLESIDPTAOSIYEKRYVLTLLKLLFKKRV		117			
Db	1114	NNKQKKKKKKKKKKKDLTKGNVEDNDVNNKLYALADMABELQKD-----	ILLNGNDE	116			
QY	1178	DTQINNETSDLRKDLVMCHI CNNDPDDQHFYAYSLEKDIINLMLKROIWCESENLRLL		123			
Db	1167	KTNNNNIHNNESHKSYV--HENYVFGDQDQINNYNNKQNNNITVEL-----	DHNNNDNL	121			
QY	1238	YQFLVVEYQNKSAHSVILNVSSNNQDIIILNKLYQDNIKNSMDHNNHHK		1287			
Db	1219	MOKNIMLMDNITPQDSLQKIKNNNNSVENLALNLTHTVKNKNNEMNNISK		1268			
RESULT 14							
ID	Q81519	PRELIMINARY; PRT: 2432 AA.					
AC	Q81519						
DT	01-MAR-2003	(TrEMBLrel. 23, Created)					
DT	01-MAR-2003	(TrEMBLrel. 23, Last sequence update)					
DT	01-MAR-2003	(TrEMBLrel. 23, Last annotation update)					
DE	Hypothetical protein.						
GN	Pfl085W.						
OS	Plasmodium falciparum (isolate 3D7).						
OC	Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.						

OX	NCBI_TaxId=36329;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RC-	STRAIN=3D7;	
RX	MEDLINE=22255705; PubMed=12368864;	
RA	Gardner M.J., Hall A., White O., Berriman M., Hyman R.W.,	
RA	Carden J.C., Pailin A., Nelson K.E., Bowman S., Paulsen I.T., James K.,	
RA	Eisen J.A., Rutherford C., Salzberg S.L., Craig A., Kyes S.,	
RA	Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Anguilo S.,	
RA	Pertea M., Allen U., Selengut U., Haft D., Mather M., Valiya A.B.,	
RA	Martin D.M.A., Pailamb A.H., Frumholz M.J., Roos D.S., Ralph S.A.,	
RA	McPhaden G.I., Cummings L.M., Subramanian G.M., Mungall C.,	
RA	Verter J.C., Cancuci D.J., Hoffmann S.L., Newbold C., Davis R.W.,	
RA	Fraser C.M., Barrrell B.;	
RT	"Genome sequence of the human malaria parasite Plasmodium	
RT	falciparum".	
RL	Nature 419:498-511(2002).	
DR	EMBL; AE014847; AAN36303.1; -.	
KW	Hypothetical protein.	
SQ	SEQUENCE 2432 AA; 284064 MW; EF0989EBB11BD3A33 CRC64;	

[illegible]

```
QY 655 -----NDNKT---NNGVINIINNSNVS---INNSNMSI-----NNSNMSNLSYKS 696
Db 1255 NIFSNVAVTNDTDLHACNNEORNNISNHNKKNVNLNVAHSINKELENYINSTODYT 1314
QY 697 NYSNOSISDVQIRVYEMDTSNKNDNIFFDAISCDN-NMYPIVITNNNNNNNNNNNN 755
Db 1315 NYDKNGCGLTLCIDIKKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNNNNNNNNN 1374
QY 756 NNIDVENYNRDGTN---NSMKLYAN-----SHNLFOPDNKN 791
Db 1375 KDIIILKNKNNINNNANIFNINSLEKELDLNDISKNEKKKKCVIRIKKRRKVPKRRNN 1434
QY 792 TSN-----IQNTTKKNNODG--- 807
Db 1435 INNRKNGSYKCDTFRVKNKJNNGPMKPKNNKTYTSSCJINMCAISDLSTIKKKNFVI 1494
QY 808 -----NVSVMNFCNYLN----- 821
Db 1495 GNYPTNGSVYITNGEANTTNNKKNDHRKKKKKYYNENNNNYCNNSNNSNNNNNNNS 1554
QY 822 ---DKNYLIDLNNKEQOK---NIHG----- 841
Db 1555 HFGKKNRRGDNDDEDEKNNKRNIGKNGDEDEEDYGEDDNNNEENHNNKKNIKRKN 1614
QY 842 -----CDNNIIIONRNDPEKKKXTNF-----YNNNNIVIVNNNNMGN 877
Db 1615 KKSNAKAYNNNDNENKJNNKOTFHLPKXNYEYTMNNNNYNNNNEYNKODEELKNNYEDNQ 1674
QY 878 NSPRKGYLCSHTSIDNMK-----NNEKNNEMKDNEMKNNHKSNNSSS 925
Db 1675 DNGDILKHSCTNGNDVGVKSKYKHNDHSDGNNNDIINNSSNNNNNNNNNNNNNNNN 1734
QY 926 SSSNNNNIYNNND-----DDTFO-----NDYCHNDFTTIRKANT 962
Db 1735 NNNNNNNNNNNNNNNCTNCAVTDLMNLSNLSKESYLTNYSNHN--NINFINN 1792
QY 963 NINSNIYONDIIYITNSLN--DYMSNTLHFEKEXYTPJSTNE-DIYNKEM----- 1012
Db 1793 NHKKNFLANNENVOFPNNNNYKDYVNN--KNTLEPNNTYINHNINELNFKKMLIANNLY 1850
QY 1013 -----EGHRIPLD-----DODKYDDNN 1031
Db 1851 INYVGINNDRYMNGIINNSQMSYNNHFRNDIISNVLKGVRLNKESHYKNNKNGNSNN 1910
QY 1032 NYDNNNNKNN---VDNVDNNNNVNDNNNDNDK--NNVDNNND----- 1068
Db 1911 NNNNNNNNNNDEDDNNNDNDGDNDNDNNNEBNNNIDRIIPFGHNNNNVSMKN 1970
QY 1069 NDDDDVDPHNTKPNNNNEYSYFOKQVDTIINNCLNSLDISSMYDTKEILLNNILSKYK 1128
Db 1971 NDGKNEDNNNNNNNNNN-----NNNNNNNNNNNSDNNNNRRGNNNIIIPFLYNNK 2022
QY 1129 AEKDNVYIKKYINEDIKNMSLEBIDTAOSIYEKRYVLTKLILLFKQVNDTOINNETSDL 1188
Db 2023 FCMNNNNANNPNNGNI-----INNFTNN-- 2044
QY 1189 RKDLYMCHICNNP-----DDQPH-FYAVSRLEKDIINIMRQIWCSEBNRLXYQ 1239
Db 2045 ---GMAH---NENPNNNINSFNNNNHLEPHKGYIOYKDLIPNMMEPTAY-----LNLGE 2093
QY 1240 FLAVEKONKSAN-----SVLLNYSNNNGDII-----LANKKLYODNIK 1277
Db 2094 RRSKSYENSSYKKCDLMKRRYELQKAILLNDENLKEVIDEIRNSTITLIPQKIRG--R 2151
QY 1278 NSMDHNN-IH 1286
Db 2152 NTLDCNHPH 2161
RESULT 15
ID 0815A3 PRELIMINARY; PRT; 1824 AA.
AC 0815A3;
```

```
DT 01-MAR-2003 (T-EMBLrel. 23, Created)
DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (T-EMBLrel. 23, Last annotation update)
DE Asparagine-rich protein, putative.
GN Pf1530W.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_Taxid=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyte S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Angiuoli S.,
RA Pertea M., Allen J., Selengut J., Haft D., Mather M.W., Valdiva A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McPadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrrell B.,
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AEO14849; AAN36392.1;
SQ SEQUENCE 1824 AA; 212658 MW; 6CECEDEA6960084E CRC64;

Query Match 12.1%; Score 826.5; DB 5; Length 1824;
Best local Similarity 23.2%; Pred. No. 1e-25;
Matches 376; Conservative 244; Mismatches 450; Indels 549; Gaps 76;

8 VVRKRPISLEKKKKKSDITVKNCTL-YI-----DEPRYKVM----- 46
Db 191 ILKNPLMBQDNKSN-----NCTLIYIKKTSLDNHSRIKNEKEHINQALV 243
QY 47 ---TKYIERHEFIVDKVPDVTNFTYENTIRPLIIDLYENGCVSCFAYGOTSGKTY 103
Db 244 RSKRPVASELEKLEKEQFEEIKQEDLYVDEIGRLILSPDNC----- 287
QY 104 TMLGSO---PYGSDTPGIFQYVAGDI-----FTFLNY--DKONTG----- 141
Db 288 TLVLDQIKDYKLSKD---TEMLRGEIEKIKONNNNLNRYLLIKMOKKMDLFPNNDM 344
QY 142 ---IFISFEYELGYCKLVLDQKRVAALENG--KKEV--VKDLK---ILRVLTKEEL 190
Db 345 LNDIKISFYDF-----EKM-----NGEYKEFEHIEDKRRKRIIYILCKQI 390
QY 191 ILKMDGVLLRKIGVNSQNDSSRSHAILNIDLKINKTSLGKIAFIDLAGEERGADTV 250
Db 391 IYILEE--LYKNVYKNIKKE-----KYINKLYNNKFMFYI----- 424
QY 251 SOKQOTDGCANIRSLALKECTIRANDSDKNHIFPDSLETIKVLRIPIFGKSKSIMIAN 310
Db 425 ---LNKANNNSFNNNTIV-----EKNKH-----IVNHEVILKRETEQVES 461
QY 311 ISPTISCEOTLNTLRSSRYKFNKSTCINEEDPTNTERIS--ILDSKSEMN--ASSI 367
Db 462 VLENV--LENVLDEBQSFKEKIKINIMBRNLEFDKYVEKIDIHSDIFENNHYLSND 519
QY 368 ENVVYKSNHLLSNNNNNKINRGKINDKIERNNILKNSPKPREGFTSTGKYSLLNDID 427
Db 520 TNVSLSEN---ASKTKQINKLANKQIS--NCFKONNNNNETQFSLTCLTESSFMD--K 574
QY 428 KIKKKKKGLINYSTLYNDNTINKKNNNNNNNNND----- 464
Db 575 KKEKNSRK-----ETNITNEQGEDYSNDILNNDNNNNVHVCNDSFEMKIHYNDQFNH 629
QY 465 -----NDNNNDNNNNN--NNDSSM-----VNNMIMHMINNNINNNNNNNNNNNNS 514
Db 630 YPIITNNNNNSNNNNNNNNNNNNIYHNISNNNNNIGNNNNNNNNNNNNNNNNNNNNNN 689
QY 515 HNNHLPQPNVAFPTDTSFSSLDNNKCHLN-----NNDKSIPLHKKNLNDNIKX 563
```

```

Db 690 QFNTHFNNNLINQNDQYNI-PLNNHNLNQLTTOGNCNNNELS-----KQLSNOFNNQ 743
Qy 564 NRSSCDNIMNKKKNNLHARSHVSGSLTMFSYDP-----OKNK----- 601
Db 744 VKSLPLNNIVGSANN---LVNEYFSDMYIISWVEKSAACQYPRELPSAERKLSEYIV 800
Qy 602 -----DNTEFP-----KSNINKMEDNTP---KDIILYE 624
Db 801 AKEQMLYLRYWGYDEIDNIYFHPKSGSHIKIKFKPSMCMNNFLKAYKNTDPMKEDMFR 860
Qy 625 SRNV-----SNANGVLLGLNKK-----THHDIST- 649
Db 861 FENLPLRSSISVDRLERAVPRSSAAEFKKMKLKNYODLFLPKCNFVCEEDMOTIE 920
Qy 650 ---KDEHNNDKINNGVYNIINNSGVNSINNSNNNSINNSMNSIYKSYNSQGISD 706
Db 921 NMEGLDHYDTYNKQVILQNKNDITANKLNEQSLSMKMANINIHDEYPPNN--- 976
Qy 707 VOIRYVEMDTSNKKNNDIFEDALSCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNN 766
Db 977 ---INNINNKKNNNIIILD-----EHHHHNNNNNNNNNNNNNNNAI----- 1014
Qy 767 DGTNSKLYAYNSHNLPODPNN-----KATSNIQNIINTKKNQOGVNYSNPFCHYN 819
Db 1015 --VNNSSISIPVAGINSYAPGVNHGFLGSNNNAVMMNTTITKTNNDLN-----NLGSSS 1067
Qy 820 LNDKNYLLDNNK-----EQOKNKHGC----- 842
Db 1068 TGAKNYKMDINNNLFVGTKIDNNTLNINTDHFNTDVMKNIHNTLTITTTTTTMAKNENDI 1127
Qy 843 --DNNTIIONRDFEKKKKTFNNNNNNIYI-----VNNNNGNNSPRMKYGLCSHTSIDN 895
Db 1128 MNVNNLHNNTMFASRTSSSKNNNNNNININSINIVNNNNNNNN-----VNNNNNN 1177
Qy 896 MKNNEMKQNE--MD-----NEKMDHAKISNNNSSSSSNNNIYNNIN- 938
Db 1178 INNNGSNNNYLLKOKSLNRENGSLSNLNFNTNNNNNNNNNNNNNNNNNNNNNNNNNNML 1237
Qy 939 --DDDTFONDYCHNDTFTIRKKNNTNINSNIYONDII-----YTINSLN-DYMSNT 988
Db 1238 SSASVNLNANLNINSNTI--NNNTMNSTNIMNNNILLSNNIISNNVNNNTKOPLAN 1295
Qy 989 LHFKEKTYPTLSTNED-----IYKMEKGHILDDQKYDDNDNNNVN- 1036
Db 1296 -FNLKNTHTYASLTSNGNNNNLNEQFISYNSNTE---NINNNSNNNSNNNSNNNN 1350
Qy 1037 ---MKKNVD-NVYDNNVNDVNDKKNVDNNNVN-----DDDDVDFFN 1078
Db 1351 SNTMNSNNNSNNNSNNNSNNNSNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1410
Qy 1079 IKPNNNNEYL-SYFOKRVDTIINNCLNSLDISSMYDTKEILNNIILSKYKAEDNVYIK 1137
Db 1411 INNHGHNMAHADKAV-AVYVPLANNIDINS---KKE--NNLLANLYK-----NS 1456
Qy 1138 YINEDIQMSLEEDKTAQSIYERK-----KYLTLKLLLPKKNVDTQINETS 1187
Db 1457 YLANN--TNSGNTFSGORNOQKCLNTYNNKLEBELBELNEK-----YNNNE--D 1507
Qy 1188 LRKDLVMDCHICNNPDQFHFYVSLKEDIINILMRQWCESE-----N 1233
Db 1508 LKQDL-----KQLINIDFINDIDMEYEEGHSYNNETFLTSTN 1544
Qy 1234 LRLLYGLAVE-YONKSANSVILNVS--SNNGDITLNNK-----KLVDONIKSMOHN 1283
Db 1545 SSLQRTTYPKNPSPMENTLLTVSSTSNNGNINIKREYQYDVKLPYNNVMNCDEQN 1603

```

```

RESULT 16
Q8IEE4 PRELIMINARY; PRT; 2672 AA.
AC Q8IEE4;
DT 01-MAR-2003 (Tremblrel. 23, Created)
01-MAR-2003 (Tremblrel. 23, Last sequence update)

```

```

DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Hypothetical protein.
GN PHA201.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Berris B., Lennard N., Clark L., Line A., Barron A., Corton C.,
RA Berriman M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Omond D., Sanders M., Hayes R., Hall S., Quail M., Batteil B.,
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL644509; CAD52316.1; -
KW Hypothetical protein.
SQ
SEQUENCE 2672 AA; 310742 MW; 8929A8A4AC08464 CRC64;

Query Match 12.1%; Score 826.5; DB 5; Length 2672;
Best Local Similarity 22.5%; Pred. No. 1.5e-25;
Matches 368; Conservative 215; Mismatches 410; Indels 641; Gaps 72;

Qy 158 LOKRQVVALENGKEKVVYKDLKILRVL-----TKRELKMDIGVLLR 201
Db 1 MKERKVSQVSKESKSLVENDNFCNNYRNPFYMENDKKNMKEKEE-----R 49
Qy 202 KIGVNSQDSSSRSHAILND---LKDINK--NTSLGIATFDLAGSER---GADTV 250
Db 50 KEIFTSRNDSS---LVVDYNNKMMNDINKYENTILN-----SNNSCNNFPNPDQI 97
Qy 251 SQNKQOTODGANINRSLALKECIRAMSDKNHIPPDSSELYVLADIYVGSKSIIMIAN 310
Db 98 IYNNVYLSNGP-VNNS-----VNSNNTNNNNM-----NNNNMNSN 131
Qy 311 ISPTISCEBQDTLNTLAFSSRVKPKKSTCINE-----EDQNTERTISLDS 357
Db 132 M-----VNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 177
Qy 358 KQSENNASSIENIVIKSHILSN--NNKINKGKINDKIERNNILKNSFDK----- 408
Db 178 MNDNNMNDMMNDMMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNN 237
Qy 409 PREGFTSTGKY---SSLND-----IDKIKKKKKGLIN-----YYS 442
Db 238 NKEPFIQOTQMYLKDANNMILNSCYVNTSMCDSCSNMNSNVSNMVDKITVDHSCMSNNS 297
Qy 443 TLVNDTP--INKKNNNNNNNNND-----NDNNNDNNNNNNNN----- 477
Db 298 NDHNNNSNCYVYNNNDYNDYNDYNDYNDYNDYNDYNDYNNYNNYNTKQEGCKOG 357
Qy 478 -----DSSMVMNNINH-----MINNNINNNINNVN 503
Db 358 KIGNGKLVMDNMNPNINEHNNIYRERIDSLNTYNNNTSNKYNNYVNIINDENNNNNNNN 417
Qy 504 NN-----NNNNNNNN 512
Db 418 NNANYKNMENPEPKYTNKKYAEENILKDSNDIHVAVDVSLEFHTCDIVSNPYNNNNNNN 477
Qy 513 NSNNHNLPOQNYAFDTQSPSSLD----- 536
Db 478 CGSSNNI IHSNPLVENTSFCSENNHTSIYPPKKNKNNNNNNNNNNNNNNNNNNNNNN 537
Qy 537 -----DMNGCHL--NNNDSIFLHKKNLRDNIKLNRSSCDN-----INMKKKCN--NLH 580
Db 538 FPEQCHINCDLSNNNNYAVLTNKNYNSNLNBSGYNVSTCCNNNDPFHANNNNNNNNYNIQIN 597
Qy 581 LARSHVSGSLTMFSYDPQOKNDTPFKSNINKKEDNTPPDILYESHVS-----NNN 632
Db 598 IKDINVINIKLENYFENVLANNNNNT--KEYIINTYNNKMHIDIDTOHNVHLLNNSIKSIND 655
Qy 633 GNV-----LLGKNTKTHDIDST--KDEHNNDKINNGV-----NLINNSNV--NS 674
Db 656 NNLEHINPMMETQPTPHI FNNIILNNSHNSNPFSDSVISNIKEITRNITDSSVIRNL 715
Qy 675 INNSNM-----NSINNSNNNSIYKSYNSQGISDV----- 707

```

Dd	716	LNMMQMDKLVANNNNNNNYINNDIKGMDGGGVALQNMPTKMSIVTAAYTMSVTSLSGN	775
Qy	708	-----QIRYVENMD-----TSKNKNDNIFFDAISCDNNMYPNITNNNNNN	749
Dd	776	LENIKRPSQYMNMSYLGAVNKIKYIKNDHLSF-----NKEDIIGNNNNNNNAENTK	828
Qy	750	-----ANNNNNNNIDVENYNRD-----GTRNSMKLYAYSNHLFPQD--NMQTSN-----I	795
Dd	829	NHNINSNNNDNNNDNNNDNNNDNNDSDGNN-----YNNHHKMGDKLNNFNSNWIKLT	882
Qy	736	QNIITNNKQNDG-----VYNSMNF-----HYNLDKMYLLIDLNKEQXDKNHGCD	843
Dd	883	KSFQASDVEDENELPIANANFYIYNFLNGHFNFKADNIRIDINSKMGSGNISLSD	941
Qy	844	NNIIGNRDFFEKKKKTTFYNNNNIYIYANNNGNNNSPFRKTYGLCGSHTSIDMKNEKN	903
Dd	942	NDM--NHNINS-----NNNINSNNNNNNND--NNNNNNNNNNNNNNNNNNNNI	990
Qy	904	NEMKNEMKDNHKKNNNNSSSSSSNNITYNIND-----DFFQV-----	945
Dd	991	NNNSGKNMPTMNSLML	1050
Qy	946	-----DYCHNDYT-----FTIR-----	958
Dd	1051	LPKIKGVFDSGRRVWASMGNGQKQYFVKFEGQAQALYATARTAVNCLQRP	1110
Qy	959	-----KNNITNSINY-----QNDIITYTINSINDY	984
Dd	1111	HKPRMSKRLSEKKLLLMKEGKELNGNECNNNNNNYISKNGEDDD-----NIEDSY	1165
Qy	985	MSNTLLHREKTYTTLSTNEDITYKMEGKHIRLDD-----KYD--1026	
Dd	1166	NDDEICEDEENY--DIDHND-----EYDIDDDGNGDNGSDNDDEHYDI	1215
Qy	1027	---DNDNNVDDNNKKNVDDNVD--NNVDDNVDDNDKKNVDDNVDNDDDDVDVFNH---	1079
Dd	1216	TNNDNDNNNDNNNDNNNDNNNDNNNDNNNDNNNDNNNDNNNDKIDMQSGDREYGIANN	1275
Qy	1080	-----KNFNNNEYLSTYFO-----KNVD-----TIINNCINSLDIS	1109
Dd	1276	ESKNGVGNIGQIGNIGVGNKGNVGNKGVKVEKIGPDIKDEYMSKITNDQTKQD	1335
Qy	1110	SNYDTEKELIANNILSKYAEKDNVYIKYINEDIOM--SLEEDTKAQSIYERKRYLL	1166
Dd	1336	IANETTKIITYPNNITDNNHIVADNVCLIMASNLENIPEDKKHGEQNVITHSIDEQXD--Q	1393
Qy	1167	TYLLLLFKKN-----VTOIINNETSDLRKOLVWCHICNNPPDQGFHYAVSRLK	1216
Dd	1394	SNKPFRRERKGNKANNYDNFYNSFRKKLSDINEBI-----NKSDE-----EK	1437
Qy	1217	DIINILMLRQICESENELRLQFLVVEYKONSASVLLNVSSNGDIITLLNKKLQV--D	1274
Dd	1438	EVSQINSLK--YKCEEN-----DQNYDKQEKIION--DTNECEIITCINLBESTKID	1466
Qy	1275	NIKNSMDHNNHKK 1288	
Dd	1487	NLKDL---SLHKE 1496	
RESULT 17			
Q8T806			
ID	PRELIMINARY;	PRT;	901 AA.
AC	Q8T806;		
DT	01-JUN-2002 (Tremblrel. 21, Created)		
DT	01-JUN-2002 (Tremblrel. 21, Last sequence update)		
DT	01-MAR-2003 (Tremblrel. 23, Last annotation update)		
DS	Hypothetical 102.9 kDa protein.		
OC	Dictyostelium discoideum (Slime mold).		
OC	Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.		
OX	NCBI_Taxid=44689;		
RN	(1)		
RP	SEQUENCE FROM N.A.		

[illegible]

```

Db      720 GSKKCDHLECESEILIKLEFTHIKLHHHKKEDIDIDCPCKLIKSIQKRIYVFSK--- 776
Qy      1172 LFKK-----NVDQIN-----NETSDLRKDLWMCH 1196
Db      777 --KKEQKDDNNNSKPVNSKVATLISHNPSNNIDKIDNNNNKNNKNTNNLEND----- 829
Qy      1197 ICNNPPDOHFHYAVSRLEKDIINLIMROIWCESENLRLLYOFVLEYONKANSVTLN 1256
Db      830 ---NNDSNNNNYLENEEPEIY-----FQDLKPPNNNNNN---N 863
Qy      1257 VSSNNGDIILNKKLVODN--IKNSMDHN 1284
Db      864 NNNNNND-----NNNDNNNDNNNDNNNDNN 889

RESULT 18
081107
ID      081107 PRELIMINARY; PRT; 1483 AA.
AC      081107;
DT      01-MAR-2003 (Tremblrel. 23, Created)
DT      01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT      01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE      Asparagine-rich antigen.
GN      Pf1_0111.
OS      Plasmodium falciparum (isolate 3D7).
OC      Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX      NCBI_TaxID=56329;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=3D7;
RA      MEDLINE=22255705; PubMed=12368864;
RA      Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA      Carlson J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA      Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA      Chan M.-S., Nene V., Shallow S.D., Suh B., Peterson J., Angiuoli S.,
RA      Pertea M., Allen J., Selengut J., Haft D., Macher M.W., Valdeya A.B.,
RA      Martin D.M.A., Fairhead A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA      McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA      Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA      Fraser C.M., Batteil B.;
RT      "genome sequence of the human malaria parasite Plasmodium
RT      falciparum";
RL      Nature 419:498-511 (2002).
DR      EMBL: AE014837; AAN35697.1;
SQ      SEQUENCE 1483 AA; 173923 MW; F93DB19A2A34D5F1 CRC64;

Query Match 12.0%; Score 819.5; DB 5; Length 1483;
Best Local Similarity 25.5%; Pred. No. 1.6e-25;
Matches 319; Conservative 160; Mismatches 333; Indels 439; Gaps 57;

Qy      189 ELIKMIDGYLKR-----IGVNSQ-----DESSRHAIITND 222
Db      11 ELPLKNDVDVDEKDVITNAGININSENSNGVEIKEGDEKDHIOENDDETIVNEVD 70
Qy      223 LKD-----INRNTSLGKIAFIDLAGERGADTVSQNKQTOTGAGINRSLALKECIRA 276
Db      71 LKDDDEVYENKKE-----EKSSNRWADWCECDAPLVDTYNNNDMDKG-----KV 117
Qy      277 MDSDKNIIPRDESLTKVLRFIVGSKSITMANISPTISCECETLTLTLYSSRVKFN 336
Db      118 VDN-----FNNSDMNNMKQNYMAPKN-----DMNNYATCYEYIYNLHIDI-----T 152
Qy      337 KSTCINEEDTTERISILDSK-----SEMANS-----SIE--- 368
Db      163 KEELIYLFDDYRKRIINILKRGKTAAYVEFDNIEIMNSLELNGMIYSGNNSFSGT 222
Qy      369 -NVVKSNNHLLSNNNKIRNGKINDIERNNILKNSKFPKPRGFTSTFGKYSLLNDID 427
Db      223 ISVILNDKKNKFNHVNQKN--KFKKGIINRN--NNFNSIRQG-----ANNNA 267
Qy      428 KIKKKKKGLINKSTLYNDNTINKGNNNNNNNNNDNNNDNNNNNNNDSSSMVNN-- 485

```

```

Db      268 NIMNN-----YNGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 315
Qy      486 -----MINHINNINNININIVNN-----NNNNNNNNNNNNNNNNNNNNNNNNNN 524
Db      316 FENDNNKMMMDMKVGVNTINNMMQNFYNNIKSYLYNNNQVGSIVHNNH--QQNN 373
Qy      525 APTDTSFSSLDMM--CHLNNDKSIPLHKKNLNDNIKLNRSSCDNIYN-----KKKN 578
Db      374 MLNDKNNNNNAFNFQNGNYLNN-----HNNKQSLADN--NNNNNNNNNNNNNNNTGQTEGRK 428
Qy      579 LHLARISVSKLTMFSYDPOKADNTFFKSNINIKMEDNTFKDILYES-----RVNS 629
Db      429 LILKKSVPLOKSYVNP-----NIFGEA--KPVIDPEKILNSTTEKMDNTSN 480
Qy      630 NNGNVYLLGLNKYTHDIDSTDENND-----NKINNGVININNSNV 672
Db      481 NNNNN-----NNNSDDDAEKKNENIDMEKKKQOQEGTDKYLKLSHNN--NTNNNNI 533
Qy      673 NSINNSNNNSINNSNNNSNS--IYKSNYSNQSISDVOIRYVENMDTSKNNNDIPEFA 729
Db      534 NEFNKN-----KNTNNSMKNVFNFKKNTNTNFN-----YNNFNANTKNNNN----- 579
Qy      730 ISCDNNMYPIYITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 789
Db      580 -----NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 612
Qy      790 KNTSNIQNTNTNKNQDGNVYVSMNFCYVNLNDKYLIDLNKKEQDKNIHGCDDNIION 849
Db      613 KNNNNLESNNMSGKQLANLHNS-----GNTVSNNNVNDNN----- 649
Qy      850 RNDPEKKKTTFYNNNNNIYVNNNNNNNSPRKKYGLCSHSITDMKNKNNEMKNNKON 909
Db      650 -----KKNNNVNNKNF--NKNDNNNITR-----DFSLLKNTPEPDNKNIN 689
Qy      910 -EMKNDHYSKNN-----NSSSSSSNNNIYNN--IND-----DTFONDYCHND 951
Db      690 VSVYIHHIYENNNKLYGNOEDETSNNNNNNNNYNNENGTSGNMKKGFNNFNTGMMND 749
Qy      952 NFTTIRKNTNTNS--NIYONDITITNSLNDYMSNTLHFKERKTYP-----TLST 1003
Db      750 KKNVDHNNNTPYQKELNLIKDD--KVNIIKIIKKN--IKREBNNTAPVNSGVNLSS 804
Qy      1004 NEDIYV-----KEMEGKH-----RLDDODKYD-----DND 1029
Db      805 SSNFRDSSNNRGGKMEKKVAVENLLNNDRLGLKNMDDEBYDINNNMSKNTERY 864
Qy      1030 NNNVDDNNKKNVNNVNDNNVNDNV----- 1055
Db      1056 --NNDKNNVDNNVDN-----DDDDVDFNH--IKNNNNNEYLSYFOK 1093
Qy      925 DENGDEENDDNNSNNIYNGETGENEKYKDKYHDKLDNTNESVKSNDNYESDVSD 984
Qy      1094 NVDTIINNCISLIDISMYDPTKEILNIIILSKYKAKONVIKRYINEDIKNMSLE----- 1149
Db      985 TNNITDNNNNNDITS-----TNLKSITLQITKRR--YKKTDTDETENNNAVNEEA 1035
Qy      1150 -----EID-----KTAQSIYERKVVLLTKLLLFKKAVDT 1179
Db      1036 NGDSNANASGSKIDILIKPILKKGNIWEAR-----THLLVEQGENAVT 1082

RESULT 19
081154
ID      081154 PRELIMINARY; PRT; 4466 AA.
AC      081154;
DT      01-MAR-2003 (Tremblrel. 23, Created)
DT      01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT      01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE      Hypothetical protein.
GN      Pf14_0170.
OS      Plasmodium falciparum (isolate 3D7).

```

OC Eukaryota: Alveolata, Apicomplexa, Haemosporidia, Plasmodium.
OX NCBI_TaxID=36529.
RN (1)
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Bertman M., Hyman R.W.,
RA Carlton J.M., Pahn A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan W.-S., Nene V., Shalimov S.J., Sun B., Peterson J., Anguoli S.,
RA Perlea M., Allen J., Selengut J., Hatt D., Mather M.W., Valiya A.B.,
RA Martin D.M.A., Fairclamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McPadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Frazer C.M., Barrell B.;
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511 (2002).
DR EMBL, AB014818; AAN36782.1; -.
KW Hypothetical protein.
SQ SEQUENCE 4466 AA; 519821 MW; ECFPA4865DCBFA76 CRC64;

Query Match 12.0%; Score 819.5; DB 5; Length 4466;
Best Local Similarity 21.9%; Pred. No. 4,5e-25;
Matches 399; Conservative 263; Mismatches 505; Indels 659; Gaps 82;

18 EKKKKDSDIIVYKNNKCTIYIDEPYKVMYTKIIEHFIYD-----KVFPDYV---DNF 68
1205 KSKKKGNKNNINKKSSSTFLDEKK-KSQTLEHNNMMSVDDNNNNNNGNINIKYGNNV 1263
69 TVYENTIK-PLIIDYENGCCSCFAYQQTSGKTYTLMGSGPYGQSDTPEGIFOYAAADI 127
1264 TLKKKKKGSVYDILKNN---VEIGRYGKIQENNETKTTDDQPIGEN---SLFNNFED- 1316
128 FPELNIYDKDNKGFIS-FYFIYGG-----KLVDLCKRKVAALENGKKEVYKD--- 178
1317 YYYTYDYDDPIMASDDISDDYE-DGEDEEESDSDRDNKITYINDRYEIKIEDVQ 1374
179 -----LK-ILRVLTKEELIKM-IDGVLLRKTIQVNSONDSSSRSHAIINTDKD 225
1375 IRDVEFFNNLKSIVAKKTSSEMDLIYNNFLNKIKKEIFDNIQLSCEIFLLLN--FIE 1432
226 INKNTSLGIAITIDLAGSRGDYVQSKQTOTDGANINRSL-----ALKECIR 275
1433 ITRKDSYRKLILKNI-GAWIGITIGRNKPLMSKYMNIKQLLYAVNGYLITFPALCK 1491
276 AMDSDKNHIFPDS-----ELTKVLRDIFVGKS-KSIMANISPTSCCEOTLWLRYS 329
1492 ILESIKNSKIFPPPMPTWYSILNLGELHQSILTIILEIIEIFNFK--INFDYNN 1549
330 RYKNEFNKSTCINIED---DTNERISILDSKSDMAASIE-----NV 370
1550 KNIITISRNLPVNSNDLPFRNSFNEHVSYNISINENNMSISVAIEITPTVYKSFNTNI 1609
371 VKSNHLLSNNNNNNKINRGKIN---DKIERNNILNKSPDKREGPTSPFGKSYSLND 427
1610 ITSEN--LININNDKIRRGGLGSLINKDYRFMLNNYN---TTQALATSEKTSNNNNIN 1666
428 KIKKKKKGLIYKSTLYNDNTINKKNNNNNNNNNDNNNDNNNNNNNNSSVWNNMI 487
1665 N-----NNSSSNNNNNNNNSSSSNNNNNNNNNNNNNNNNNNNSNDLSPFGANC 1714
488 NEMINN-----NINNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 539
1715 SLIINNRKEDGKNNNTFDLNNNNNNININNNNAHIMHLND-NNAHLSNGK-NIVNVL 1772
540 CH-----LNNNDSKIFLAKKQLR--DNIKLKN-----RSSCDNITANKKNNILARSHV 586
1773 CASSSDIMLNNNYRFTFEMNPLNNVNNKI-KKNDIVKSTYKTNL--TNDVHQSSSV 1830
587 GSKLTIMESYDPOKKNDFPFKSNINKMEDYTFDILYESRNVSNNGAVLLGAKYTHHD 646
1831 SKKLT-----NPNIMKCN-----HLNTISNYLSN-----DNNINHM 1861

```

QY 647 ISTDENHNDKINGVINIINNNSVNTSINMSNSIN----- 665
Db 1862 YTKGSVANNNNNNIINNNNNNIINNNNIINN-NNNNFTIINSMMDYQVDDNIYNNMYVKNM 1920
QY 686 --SNM--NSNSIYKSNYSNOSISDQIRY-----VNEMD----- 716
Db 1921 DISMMNNNEFTKNNNSNMEBCVADVKRSNNKKOXLNIDPKNNI PKSSNNYINJTKR 1980
QY 717 --TSNKN-----DNIFPDALS-----CDNNMY 737
Db 1981 FSVANNKIETSYKLDMEKNGKLVHNKEMIYYEYENYWKDSYASSSPSMMNNINVKGSYMSDLF 2040
QY 738 PNITNNNN-----NNNNNNNNNNNNIIDVENYNNROGCTNSMKL----- 775
Db 2041 KNMLNNNNLEKLNKEYNNNNNNNNNNIINNNSGSSNNNOYSKNMMMLPESVCSPIYVGN 2100
QY 776 --YASNHNLFQ-----PDNNKOTSINQINTNKNQODGVNYSNMFCHYN--LND----- 822
Db 2101 NEMSKKHMMYQEHANNPMMNNNNNNNN--NININNNNNNNIINNNSVVENEILNDELN 2159
QY 823 --KNYLDLN----- 830
Db 2160 ILKNLILISPIQILIKIHPFKALITYLAFDSIKEVITSIVDRFVLGCITTRBELYKDF 2219
QY 831 NKEOKDKNIH-----GC-----DNNITON----- 849
Db 2220 ANESKETIIMHKVSLMATSISSSLVLVSCCKPLKNMILQULRNIIEONPERRPNLLIIV 2279
QY 850 ----- 849
Db 2280 DFITLINDINILLYLIEQVAIEKSSIEIEIMKPIYASRYARILKNLINDNTTRY 2339
QY 850 ----- 849
Db 2340 NALPSFLKAHNTILKHIQVYKNFMWLKI FKKLOKILSNNNNMEQNGOEYENEAQNNYP 2399
QY 850 -----RNDPEKKKKTNFYNNNN-----IIV----- 870
Db 2400 NKRMNDNPNQPOOKYAGADPNDPNNNVKESQLEHNNNNNNIINNNGINDGLIKIKR 2459
QY 871 -----NNNNNNNSPMM-----KYLGCSSH-----TSIDNM 896
Db 2460 DDAPEKDDNNNNNNNEKTSKFPMDNKFYHDNNIMONNEDNNHNLVTSHHKNLSKINTV 2519
QY 897 KNNKKNKNEMKDNEMKN-----HKS-----NNNSSSSSSSNNNIYNNINDDQFQNDYCH 949
Db 2520 NNNGNLPIPKKNSIKENSNEFHIGNYVINSNNVILFPMNNNLVNSCN---FNWY-N 2574
QY 950 NDNFTFR-RKNNTNINSINITYONDDIYTTINSILDYNSNTLHFKEKYTYPTLSYED- 1006
Db 2575 NKNSNFPYKSDTNPFTNRYVNDVNTGNRMRYMVSNNMVDQVGNQVQNNNSS 2634
QY 1007 -----IYNKMEGKHIRLDDQKYDDNDDNNVNNKN--NVDN--NVDN--NVDN-- 1052
Db 2635 GNMDTGIYD-----HI-----HDKNGNSIENSNGKICNTKNISINNVSINNRQ 2681
QY 1053 -----NVDNNDKKNVDDNNVDDDDVDVPHNKNFNNEBYLSYFQKNDVTIINNCLS 1105
Db 2682 KKSEYEMNDGNNSNTQVGSNINHFEKTFRGLTENDDND--SGFKN-GLFNNVVCN 2738
QY 1106 LD--ISSM-YDDTKEIILN-----ILSKYKAEKN-VIKKYINEDIKMSLEEDK--- 1153
Db 2739 MNGYIPNNNYVHNHNDVLNQGNNMMNBNQYMMIINNITMKGI--IKNNLFNELNHYIG 2795
QY 1154 TAQSIYEKXKVLTKLLLFKKNVDQIINNETSRLKDYLVCH-ICNNNDDQCHFYAYS 1212
Db 2796 TNSNINMSND--LNKMAIYKMMI-SNNENILNNNIIEKLVDNNDMCGGFTTNSNNISNI 2853
QY 1213 RLEKXIIILMLRQIWCSENLRLLYQFLVVEYQKNSAVLNVSSNNGDIILNKKLIV 1272
Db 2854 NNNNNIINNANNNNIINNANNM-----NANNINNTCIKLMKNKONINOGLDSEIN 2901

```

QY 1273 QDNIN-----SMDHNN-IHK 1287
DB 2302 NKNINNDNINHLKAMDNNQKFIHK 2927

RESULT 20
Q8IHV8 PRELIMINARY; PRT; 2275 AA.
ID Q8IHV8
AC Q8IHV8
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Hypothetical protein.
GN Pf11.0418.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
NCBI_TaxID=36329;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Easen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Aingoli S.,
RA Perera M., Allen J., Selengut J., Haft D., Macher M.W., Valdivia A.B.,
RA Martin D.M.A., Fairhead A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Borel B.;
RT "Genome sequence of the human malaria parasite Plasmodium
falciparum."
RL Nature 419:498-511 (2002).
DR EMBL: A6014842; AAN36001.1; -
KM Hypothetical protein. 267960 MW; FC804F5EB2AED1B7 CRC64;
SQ SEQUENCE 2275 AA; 267960 MW; FC804F5EB2AED1B7 CRC64;

Query Match 11.9%; Score 817.5; DB 5; Length 2275;
Best Local Similarity 24.0%; Pred. No. 2.9e-25;
Matches 386; Conservative 229; Mismatches 449; Indels 546; Gaps 81;

QY 41 RYKVDNMTYIERHEFIYDKVFDVTNPNFYV-----ENTKPLIIDLYENGCVSC 91
DB 54 RYKLNCKRKKRNR-----DENLDDFEFYIKWKYDSDEMTWP-----FEN---LSP 97

QY 92 FAYGQT-----GSGKTYTMGSGQPTGSGDPTGFIQYACD 126
DB 98 NLKGQARKVALQLTETIDNCNKNKNEKNEGENIEETVGD-----NINRYIEGN 148

QY 127 IFFFLNLYDKDNKGFISFEYIYCGKLYD---LLQKRVVALEN---GKKEVVKD--- 178
DB 149 I---INNMMNSQGNV-----EQYNNKYVQOTRLVQTVLNPKNKMGIEIKRPDIDD 200

QY 179 -----LKILRVLYTEELLKMDIGVLLRKIGVNSQNDSSSRSHAILN-----IDLKD 225
DB 201 DDEEIIINIMRELEKEMN--KKEKNKLRNRNPSLFNMSNSRLSMEINSLYENGSHKMDVTY 259

QY 226 INKTSISGKTAFLDPLASERKADTVSONKOTQTDGANI----- 263
DB 260 IGKKTGKNISILSTNRIINDDNNNNNNNNNNIYNNKIYNNRYNNNNYCKYSTDLSDY 319

QY 264 -NRSILALKECIRAMDSKNIIPF-RDSELTLYLRDIFVGSKSIMLANSPTSCCEOT 321
DB 320 GNNNSVHLNDLHLHNDSEKNLFLYDSD-----DLI---KQDSRIAN-----DIH 362

QY 322 LNTLRYSRYVKNFKNK--STCINEEDPTTERISILDSKG--SEMASSIEENVVIXSN- 375
DB 363 YNNLFISKSIKJLRNKYLESLN-----NNINNKIIFDESILKKNKGLSGPSMLCINNNE 418

QY 376 -----HLN--NNNNKINCKINDKIERNNILKNSFPDRBEGFTSPCKYS---- 421
DB 419 KSKKCKPHTFVNTVNSKNKNENIIND-----FNKKESSQNDTSFL---YSTDR 468

QY 422 SLNDI-----DKIKKKKGLINX-----STLYNDNTINK 452
DB 469 STDYITRKEKIKPLQKESIINNEEDVQEHKKLLDKGNNNDDSDTDNNDDK 528

QY 453 KH-----NNNNNNNDNNNDNNNNNNNNSSSVNVMIMINNNIN 496
DB 529 NNNNDKNDNDKNDNDNDNNNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 588

QY 497 NNTLVNN-----NNNNNNNNNSH--NNHLF-----QPNVAF-----TDTS 530
DB 589 NGDNCNNNDNNNDNNNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 648

QY 531 DFESSLDMNCHLN-----NNDKSIFLHKRL--RDNIKLKRRSSCDNIMKKNNLHARS 585
DB 649 NSNSYNSNSNSMFEYNNININIDEGNKILAKNGDLKRIK--NVLNKK----- 697

QY 586 VSGKLTMSYDPOKNDKNTFFKSNINKMEDNTPKDIYLSR-----NVSMMNGVLLGLNK 641
DB 698 -GTRF-LPSY-----NTCFKKQICNLKKNKKKLIVNSMKNFNISQVNNAN-----NE 743

QY 642 NTH-----HDSIKDENHNDKINNQVITINNSNVN-----SINNSNKSIN 684
DB 744 NNEEFKQCLONGDQTKKRLQHEKKKSTNSKSIINNNNNNYDYNYHFNKKRSEDD 803

QY 685 NSNMNSNITSYKSNYSNOSISDVQIRYV-----NE-----MDTSKNNDNIFEDAI 732
DB 804 NSPEFDSYFTNSANTIDQVSLVQKYLALPENENIMATDYLNTTNNND----- 855

QY 733 DNNMYNITN--NNNNNNNNNNNNNNNNIDVENYNNRQGTNSMKLYAYNSHLPOPDNK 790
DB 856 -NKNDNNINNEEDNNKNDNINNDNNNNDDNNNDNNNN-----DDNNK 901

QY 791 NTSNININNTKNNDQGNV-----NYSNMFCYNNLNDKRY 825
DB 902 N-----NDNNKNDNDKNTCKKGRKTNIKKILVNDNNNIGLGNSSNE--YDTHDVA- 954

QY 826 LIDLNNKQKDKN-IHGCD--NNIQRNDPEKKKTFYNNNNNIYVNNNNGNNNSPRK 883
DB 955 -----NNSNNTINIMHNSLSDFIDEDKIFKQSGNIIYKN--LFCNKKSISNSAYVN 1007

QY 884 YGI-----CGSHTSIDMKKN-----EMKN--NEMKDNEMKN-----HI 916
DB 1008 RGISEYAEENIDKFNINNOCKNNYFLNLKELQNIYASEKYSKKGNLVSCKINDYI 1067

QY 917 KSNN--NNSSSSSSSNNIYNNIND-----DTFQDYCHN--DNFT 955
DB 1068 YNNNSGNNSSNNNSNNNNNNNNIRKSYINKLTESEYDSVEFLINRYCKNTNKS 1127

QY 956 IRKNNNTINSNIYONDIIYITINSINDYMSNTLHFEKETYPTLSTNEDIYNN--EM 1012
DB 1128 KXINDENGTNPEINDIKY-----INDNNNSSTNSRSLIHDLSND--FNKIGDEL 1181

QY 1013 EGGHRL--DDQKYDNDNNNVN--NKNVNVNVDNNVNDV-----NNDKNNV 1062
DB 1182 KRQSGITKENQYAHVDDIDDEEBEENTDKN--NNTIRSIQSDIIYKILNDEKSKS 1239

QY 1063 DNNNV-----DNDDDVDYF-----INIKFNNNEYS 1089
DB 1240 QONVHILKNDINSEFEKKDGENDEVFSSDNMKSNITYAAKNNSSSEFNKKHLMK 1299

QY 1090 YFO-----KNV-----TIINCLNSLD--ISSMVDOTEILN----- 1120
DB 1300 KTOHLNMDKIKKKKSKVSDSTNNNNHNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1359

QY 1121 -----NILLRYKAEKDNVKKYINEDIKNNLSLEIDKTAOSIYERKRVLLTKLLLFK 1174
DB 1360 KQDYINVLNENLALKEN--RTYNSKDL--NISKE--NENANGHIRSNSTYDTSILNR 1414

QY 1175 KAVDQINNETSDLKDLYVMCHI--CANNPDQGHFAVAYLEEDINILMLRQWESNL 1234
DB 1415 KIPEISGEKENYENLNLGRTFHDSIE-----YSTRPK----- 1449

QY 1235 RLLOYFLVVEYQNKANSVTLNVSSNGDIILNKKLVQDNINKSMHNN 1284

Db 1450 RVLPFEINKEDHONKK-----LKKNNLLDDKVGDDDDNN 1483

RESULT 21

081BK6 PRELIMINARY; PRT; 2041 AA.
 AC 081BK6:
 DT 01-MAR-2003 (Tremblrel. 23, Created)
 DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
 DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
 DE Hypothetical protein.
 GN MAL7P1.132.
 OS Plasmodium falciparum (isolate 3D7).
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 OK NCBI_TaxID=36329;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Seeger K., Murphy L., Harris D., Berriman M., Pain A., Hall N.,
 RA Quail M., Barrell B.;
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AL844506; CAD5094.1; -.
 KW Hypothetical protein.
 SQ SEQUENCE 2041 AA; 243553 MW; B5BDD4D494E9A4C6 CRC64;

Query Match 11.9%; Score 816; DB 5; Length 2041;
 Best Local Similarity 24.3%; Pred. No. 3e-25; Mismatches 438; Indels 398; Gaps 62;
 Matches 332; Conservative 201;

199 LTRKGVSONDESSRSHALINIDKIDINKTSLGKIFIDLAGSERGADTVSONKQOT 258
 380 ILNDILRRSNNNNNNNNNN--NINKLNNNNNNNNNNCKYKLLTYNTSS-----LARKKOD 431
 259 DGANINRSLALKECIRAMDSDKPHIPRDSLETYLVDIFPGKSKSTMIANISTPISCC 318
 432 BEKKEKELNLTNKIYIVNPNKKCNISFDDYDLSADPNFYVNTSIVDYVIGTIPN-- 489
 319 EQLTLTRYSRVKPKFK--STCINEEDT--NTERISLDSGSEKNAS----- 366
 490 DVEPK-----KTKNNHIDKQWMDHDKNNKTKKEHNITDKIITYEDNEKGYDKNM 542
 367 -----IENVVTKSHNLLSNNNNNNKINRGKINDIERNNILKNSFKDEGFTSTFGKY 420
 543 YNFLVDLNTIDKQMETPYINKHKFKYNNENYNE--EDNNMTIEKQYD--YFSYDTYKKM 599
 421 SGLNIDIKTKKKKKG-LIYKSTLYNDNTI-----NKKANN----- 457
 600 NNFNDIDFVKNEKKGKGNLNNINIMYDNVYIGLQGVDFRTPMRYNNVNNYEEDEFPY 659
 458 -NNNN-----NDNNNDNNNNNNNNSSGAVNNMTNMI----- 491
 660 KNNSNISVAKNEKQVQYNSFENSNNNNNNNNNNNCKKBAKHYDKHIDKYNENL 719
 492 -----NN 518
 720 GYKTDKGDHVDENLSKMSPFHKFENDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 779
 519 LPQNYAFDTSDFSLLDMNCHLNNNDKSIPLHK--NLNDNTKLKRSKSCDNIANKK 575
 780 ---NNNYN-----NNYINENNLKHEONKIGANGNSFLKNSNPLFDDMDKY 825
 576 KNNLHLARHSVSKLTMFSYDPOKNDTPFKSNI---NKMEDNPKDILY--ESRVSNM 631
 826 KNDQY-----DKINK--NHSVYERKSVLYKNNIPIINTLKKQNDNEILLYDNPETNI 877
 632 NGNVLTGLNKTTHDIDSTYDEN-----HNDKINGVNIINN--SVNSINNSN 679
 878 FRTDGDGNHFTDFTLKKHTNIIEMNKLINKNNDDKLT--LDVNDNIIFFNNKIKNTN 936
 680 KMSINNSNNSIYKSTNNSNOSIS-----DVQIRYVNMDSNKK--N 722
 937 NNN 966

Oy 723 DNIF-----FDALSCDN---NMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 769
 Db 997 DDMILNNNTSLNMEKNCVNNITIKYPIYINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1056

Oy 770 NNSKLYAYNSHNLFOPDNNKTSNTQNTNKNODGVN--YSNPFCHYNLNDK---N 824
 Db 1057 NNNWP-----YSDCKDKXIN---KIFQNYDENIDDKLSNICFNKKENDIYN 1103

Oy 825 YLIDLNNKQDKNHHOCNNIIONRDEKCKK-----TNFNNNNIYIVNN 872
 Db 1104 VIKYNSPMHISTVMNNAHTVLKKGFYLENNNNVPRDITVNNNNLYNN-----IHN 1158

Oy 873 NMGNNNSPRM-----KXGLGSHTSIDNMKNEN--KXNEKONEMKNHISK 919
 Db 1159 NNNNNKSETLNLGRTNNKSDILNNNTNNSYIYNNNLLYKGNNDDEYKETDIYKDN 1218

Oy 920 N-----NNSSSSSNNNNIYNNINDDTFQ-----DY 947
 Db 1219 NISQKYPNKNINIFHKDEYEKLDQNVTKLKKDYNN--NVHDEVYKNNNTKYNLHKON 1276

Oy 948 CHNDNTTIRKNNNT---NSNIYON-----DI-----LYTINSND-----YM 985
 Db 1277 IFNNNEVDLEKQNTNIFPNKCNIFNNFNKQENDIKKKNLYSHDINKKKEPEYIKYG 1336

Oy 986 SNTLLHFKEKYTYPTSTNEDIYNNKEGHRILDDQKYDND--NNNVNNNNKXND 1042
 Db 1337 HNHIGHQANKNPFLTHFNDDQKNY---NIFLNPFTKINIDIGYKHSNNVYHFK 1393

Oy 1043 N-----NVDNNNDNVNDNDKNNVNDNDND--DDVFNHAKFN--NNEYS-- 1089
 Db 1394 NVHKKGDTQNNHNNNNNNNNNNNNNNFTNNHQQNKALPPLPEKTNKKYNGSQNNSHLYK 1453

Oy 1090 YFOKNVDTIINNCNSLDI-----SSMYODTK---ELNNILSKYKAEKDNVYIKYI 1139
 Db 1454 FFEENDTKHKDLSIQETNQINGGANNIYNTNINSNIMLNM-----NENNSHLYI 1505

Oy 1140 NEDIKNSLBEIDTAOSIYERKVLTKLLLFKQKVDQIINNETSDLRKLYMCHICN 1199
 Db 1506 NE-IVNKKDEHN-----TNLLVNNHN-----NNNNNNNNNNNNNNNNNNNN 1546

Oy 1200 --NPPD---DQFFVYASLEKDIIVLMLRQWSESLR--LLYO-----FLVY 1243
 Db 1547 DTSNPDQKKNLNNPFP-----SHIRKNNILYNEKQELFLVE 1584

Oy 1244 EYKNSANSVLYNYSN-----NGDITLKKKLQVDNIKSMHD--NN 1284
 Db 1585 NKKGRDLENYFNETYNAKNTNNDNIFHNNKRGKDCIBSTLYLYNN 1633

RESULT 22

081AUB PRELIMINARY; PRT; 1774 AA.
 AC 081AUB:
 DT 01-MAR-2003 (Tremblrel. 23, Created)
 DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
 DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
 DE Hypothetical protein.
 GN MAL8P1.104.
 OS Plasmodium falciparum (isolate 3D7).
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 OK NCBI_TaxID=36329;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Seeger K., Murphy L., Harris D., Berriman M., Pain A., Hall N.,
 RA Quail M., Barrell B.;
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AL844507; CAD51262.1; -.
 KW Hypothetical protein.
 SQ SEQUENCE 1774 AA; 200169 MW; 182115F3C2F4BA4 CRC64;

Query Match 11.9%; Score 815.5; DB 5; Length 1774;
 Best Local Similarity 24.5%; Pred. No. 2.8e-25;
 Matches 318; Conservative 199; Mismatches 411; Indels 369; Gaps 55;


```

Qy 212 SSRSHALINDLKIDN---KNTSLGKIAFIDLAGSERGADTVSONKOTOTDGANINSL 268
Db 586 SNANGLLNTLNTLNNINNTINGSLGGMNNGHTNNNNNNNNNGAIAIMNNGM 645
Qy 269 ALKCC-----IRADSKNHI PPRDSELYLADI----- 298
Db 646 GINNSMNIISGLSTLNMNNLGRISLGSTSNINLNNISNMEILNKGSIISINSC 705
Qy 299 ---EVGSKSIMINISPTISCCBOTLNTLAFSSRVKFKKSCICINEEDTNERISIL 355
Db 706 DENMIGLKNITSTNGELIG--NMINNYYANAI--NYNNY--VNSINNTSSNNSFL 759
Qy 356 DSKSEMVASSIENVVYKSNHLSNNNNKINRGKINDKIERNNI--LKNSFPDPRGFG 413
Db 760 NS-----VNYNTAYAHGNNPISPGG--NNMSTNNYYSIQNK----- 795
Qy 414 TSTGKISS--LNDIDTKKN-----KKKGLINYKST---LYNDNTINKK 453
Db 796 YSNFGKYSNINLYNPLSQSINEVKSAGBEDYCDIDKSIDNLGSSKSPANNKLLGKI 855
Qy 454 HNNNNNN-----NNDNDNNNNNNNNNNSSSVNMMIMHNNNNNN 498
Db 856 NNNNNNNIISSSSTSHHINEFKTISNNNSNINNNNLINNTSTVHPNNEP--NMNDTNN 913
Qy 499 INVNNNNNN-----NNNNNSHNNHLPQPVYAFDTG-----DPSLDDMNCILNN 544
Db 914 LNIKRNKNBESFISDLSTNKGELNMGDHYGEMELNLYOMNMIKREKYEDEKINNNN 973
Qy 545 NDKSIFLHKKNLRDNILKRNSSCDNINRKK---KNLHLARHSVSGSLTMSYDPQKN 600
Db 974 MSKMMML--NLNNSSISNYYNLLNNMNSNNDLIKNNNTTYMKINMISININGVTNT 1030
Qy 601 KDNFFPK--SNINKMEDNTPKDIYESRNV---SNMGNVTLGLKNTHTHIDSKDNH- 654
Db 1031 VLNTDLKVSMLNONGINVTNSTYISANSIDNNNNNNNNLNGNINHDGNSGKGINHT 1090
Qy 655 ---NDNKKIN-----NGYININNSNVNS-----I 675
Db 1091 NPTIINDNKINVAHSHKGNISIDGMWINGPINTNSNKYSBEKGDANTEDKIGYKA 1150
Qy 676 NNSMNSINNSMNSISYKSNVNSOSISDVQIRYNEKDTSKN-NDNIFPDASCN 734
Db 1151 NDNNNNSNNRRNNGKVLNNKNSKNG-----NNKSKSKSKNNNDPNKASGDN 1201
Qy 735 NMYE-----NITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 789
Db 1202 LNEPDYKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1252
Qy 790 KATSNIONINTNKNNOGAVYKSNFCHYMLNDKQVYLDLNNKEOKDKNTHGCDNITION 849
Db 1253 SNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1303
Qy 850 RNDFEKKKTNFYNNNNNIVIVNNMGNNSFPMYKGLCGSHTSIDNKKNNEMKNNEMKN 909
Db 1304 SNNNNNNHSTLISNDVTIYSNNDNEDNS-----NHTTNNNEQDDKKNMKN-- 1351
Qy 910 EMKONHKK-----SNNNNSSSSSSNNNIN--NINDDDTFQK-----DYC----- 948
Db 1352 -TEGNHKKFSKQHGNNMTRKNDKKNFVNSNINVSNEVDVNNFNMI INQRMHCNRYI 1410
Qy 949 -----HNDTFIRKKNNT-----NINSINYONDI--TYTI 978
Db 1411 NFIKEDEQVDOKEHLASNISHTLNEDSNEIMDKTSYNNPYNNANAYKSDNIKLYR- 1469
Qy 979 NSLNDYNSNTLLHREKERYTPTLSTNEDIYKNEK-EGKHLRLDDQDYKDDNNNNVNNN 1037
Db 1470 -----GEEKSSHQILKKNFSSNNSNTEGEGIIHMDMKNKPNNAIDILGN 1517
Qy 1038 KN-----NVDN-----NDNNNVNDVNDNDKNAVND--NAVNDNDDVDVDFHAKIKFNNNEY 1087
Db 1518 ENLLGIGLNNLYNPNVHNTERNELNNTMTNKNKVNKCNNDMLHKKOINNFN----- 1573

```

```

Qy 1088 LSYFOKNVDTIINNCINLSDISSMYDTEILNINLLSKYKAKOVYKKYINEDIKMS 1147
Db 1574 -----IINKVYHNINNSL-----FSNN--MSNVVASENV-----NINNNS 1609
Qy 1148 LEEIDKTAQSIYKRR-----VLLTKLL-----LFKAVDVOQINNETSDLRK 1190
Db 1610 --NTNNTANNPNFKKSKSKANLNVFQOSLNNLNNLNNFYLNNENSFNKIMNYSINIS 1667
Qy 1191 DLVWCHICNNRPDQGFHYAVSRLEKDIINLIMLROICWSEENRLRLOFLVVEYQKSA 1250
Db 1668 TSYFTNDNNNNNTQHYTSSFIPEHPATDKVTKQ--SSEN----- 1707
Qy 1251 NSVILNVSSNNGDIILLNKKLYODNI-----KNSMDN 1283
Db 1708 -----NNNINNSSTWYKEX-EEPNLNPKEKNVVDKN 1738

RESULT 23
Q8IDRO
ID Q8IDRO PRELIMINARY; PRT; 3848 AA.
AC Q8IDRO;
DT 01-MAR-2003 (T-EMBLrel. 23, Created)
DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (T-EMBLrel. 23, Last annotation update)
DE Hypochemical protein.
GN pf13.0235.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxId=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Harris B., Lennard N., Clark L., Lane A., Barron A., Corton C.,
RA Barriman M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrell B.,
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL844509; CAD52559.1; -.
KW Hypochemical protein.
SQ
SEQUENCE 3848 AA; 454964 MW; 57D2700BEA3F5A9A CRC64;

Query Match 11.9%; Score 813; DB 5; Length 3848;
Best Local Similarity 24.0%; Pred. No. 7, 2e-25;
Matches 330; Conservative 241; Mismatches 435; Indels 368; Gaps 66;

Qy 126 DIFPLNIYDK-----DNFKGIFISFEIYEGKLYDLQKRMVALENGKEVYVVDL 179
Db 1288 DILNY--IYBENPFLIDNIK-----YELDOVYNQMMNKKTDNITLIND- 1330
Qy 180 KILRVLTKEELLKIMIDGVLKRTGVNSQNDSSRSHALINDLKIDINKTSLGKIAFID 239
Db 1331 KILHNLKLDNSTHGMQD---IPNISYDNKMKKSSNNH---NNDLNNNNNNY----- 1375
Qy 240 LAGSERGADTVSONKOTOTDGANINSLALKECIPTAMDSD-KNHI PPRDSEI--TKVL 295
Db 1376 -----YNNYYLNNNNFENKRVLELLSNNNCFNRINQFQCNKFNPEPMLMTNDIA 1428
Qy 296 RDIYFGKSKI--MIANISPTISCCBOTLNTLAFSSRV-KYFKKSTCICNEE 344
Db 1429 DDLSISNEDVNDIYNIRTDILKRLMYLSNNYNNNMIETDNYILHSHYQNDHILNEL 1488
Qy 345 DDTNERISILDSKSEMN-----ASSIENVVYKSNHLL-----SNNNNKKI----- 386
Db 1489 NNNTVYYNNIKKKKKFNQQLPRTGRNEDFIENNHHIYTPNNIYNNNNNNKKLADSEIM 1548
Qy 387 -----NKGKINDKI-----ERNNILKKSXDKPRREGTSTFGKYSISLNDID 427
Db 1549 ENVMQTONQNNYQFNTESNDMLKNIPQENNFLLPNSMEX-----FGEIINY-DKN 1599
Qy 428 KIKKNNKKGLINYKSTLYNDNTINKKNNNNNNNNNDNNNN-----NDNNNNNNNDSS 481
Db 1600 NIEEN-----IMFENMYNN--VNNNINGNANNGNINGNANILGNINGNANNNNNINSN 1652
Qy 482 MYNNMILNHNINNNIN--NNINVNNNNNNNNNNNNSHNNHLPQPNYAFDTSDPSLDMNC 540

```

```

Db      1653 NINS--NNNSNNNSNNNSNNNSNNNSNNNSNNNSNNI-----NSNNINS 1701
Qy      541 HLANNKSIPLHKKKRLRNITKLRSSCDNIMKKKKNNLHLARHSVSKLTMFSYDPOK 600
Db      1702 NIYNN-----WYNNMYKNNVJISSNNNYINNINNE-----QHSNPMNNTYGYDLSNN 1748
Qy      601 KDNFFKSN-----NKMEDNTPKDI---LYESRNVSNMGN-----634
Db      1749 VNHLEFYNNIMDGRNINNNNNIIONENIKGIPIHYKSNHNVVNTNFDIYDVPKXT 1808
Qy      635 -----VLLGLNKNTHHDS--TKDENH--NDNKINNGV--INIINNSVNSINNSMN 681
Db      1809 SMDNKFVGEYISDEERYTDIINLNDENINIKNIINNININDMNVYDNNISHSNNNNFD 1868
Qy      682 SINNSNNNSNISTYKSNVNSNOS-----ISDVQIRYVENDTSKKNNDNIFPDALSCDN 734
Db      1869 YIKNDNNNNNNINDRFDSRNSYESCFPLLTNGPYEENNTSSN-----ILCNO 1919
Qy      735 NMYPITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 794
Db      1920 DV--NLTNNNFINTESNISNNYNOQLISDNNNEGNINNNKRVFNNNVL-----1966
Qy      795 IONTNTKKNODGVNYSNPFCHYNLNDKNVLD--LNKKEQKKNIGCDNNIIONEND 852
Db      1967 INNCTINDNNVNDNMQIDSMIDGMIDSN--MIDSNMGNNNNNNNNN--ERNIENN 2023
Qy      853 FEKKKTFYNNNNNIVYNNMGNNSPRMKTGLCGSHTSIDMKMKNEMKMDNEMK 912
Db      2024 GNNIENNNGNN-----IENNNGN-----IENNNGNIIIDNNMIDNNI 2073
Qy      913 DNHKSN--NSSSSSSNNNINNNI-----DDDFOND-----YCHADNFT 955
Db      2074 DNLLDNLDNNMIDNNMMDNNMYDHIINFTINSPIADMSFEEDPKMYMIHINEDI 2133
Qy      956 IRKKNNTINS--NIYONDIIYITNSLNDVNSNTLHFEKXYTPISTN---EDIYN 1009
Db      2134 INLTMEDLIINSENYKKDN--TSYLLYONCKNFKLVNSVEIBOTNIMDSNNTYN 2190
Qy      1010 K-----ENEKKIRLDDQ--DKYD-----ND-----NNVVDNN 1037
Db      2191 KITEENETNSHILLEEKINKTNDCKNDEINDHSLAILKKNPSEKKIINNHNHNK 2250
Qy      1038 KNNVNNVNDNNVNDN-----VDNNKNNVNDNNVNDDDVFNHKNFN---1083
Db      2251 KNNKKKKKDDLEHNNKEKLOQCHNEBYLDSNDYNS--DNNT--KKNVPIYNNIKTTCNI 2307
Qy      1084 --NNEVLSYFOKRVDTIINNCLNSLDISMYDTEILNNILSKYKAEK--NVIKXYIN 1140
Db      2308 NQNNDIIS--KNVD--NSSKNDISNEKN-----INMKLKKMLEITNKLIG 2351
Qy      1141 EDIKMNSLEIDKTAOSIYERKVLTKLLLPKKNVDTQINNETSDLKDLVMCHICNN 1200
Db      2352 KKYRGIQYDPTNGMSTFYKGVRYKFFSSFK-----YGNLLA--KKKCIWFLKYL 2403
Qy      1201 NPDDQHFAYASRLKDIINLIMLROIWCESENLRLLYOFLVEXOKANSVGLNVSNN 1260
Db      2404 NNESS--HAYSFLKAKEEENEVL-----NDN-----YDVGILVDNKKDSNNNNNIKKN 2450
Qy      1261 -----NGDIILNKKL-----VODNIKSMDHNNHKK 1288
Db      2451 GNQDDGGRDILLYNVAFLNINVDENVKCFPTDDNDNVKDNKGTETIKIKKK 2504

```

```

Ox      NCBI_TaxID=44689;
Rn      [1]
Rp      SEQUENCE FROM N.A.
Rc      STRAIN=AA4;
Ra      Gloeochner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
Ra      Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
Ra      Tunngal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
Rt      "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
Rl      Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
Dr      EMBL, AC115593, AA922295.1; -.
Kw      Hypothetical protein.
Sq      SEQUENCE 2472 AA; 278497 MW; 30CCF7157D4008A7 CEC64;

Query Match      11.8%; Score 810.5; DB 5; Length 2472;
Best Local Similarity 22.3%; Pred. No. 6e-25;
Matches 302; Conservative 191; Mismatches 400; Indels 459; Gaps 41;

Qy      214 RSHAIIIDDKINKTSLGKIAFIDLAGSEGDVYSQKQOTDGANINRSLALKEC 273
Db      291 QSLSLNFDSDGDNNF-----NNNSNNNNNNNNNNNNNNNNNNNNRRDDNLR-V 338
Qy      274 IRANDSKNHPFRDS--ELTKVLRFIVGSKSIMTANISPTISCCQTLNTRYSRVK 332
Db      339 IEELDEDDDYLSDSYSSRPSSVDLNTKMTFTADIISSI-----PLSSSFS-- 390
Qy      333 NFKKSTCINBEDDTERISILDSKSEMMASIEENVYIKSHLISNNNNKINRGKIN 392
Db      391 -----TTTESNINSSNSKIKLPTI--NLSQNNINQNNNNNNNNNSN 436
Qy      393 DKIERNNILKOKSPDKPRGFTSG--KYSGLNDIDIKKKKKGLINYKSTLYNDNTIN 451
Db      437 SNTNGNNTOPKFE-----TFSPLMLNNNNNVNNGN-----NSNNNNNNNIS 482
Qy      452 KGHNNNNNNNDNNNDNNNNNNNNNDSSSMVNMIMHMTNNNNNNNNNNNNNNNNNN 511
Db      483 GNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 542
Qy      512 NNSHNNHLPQPNVAFDTSPFSLDQWCHLNNDKSIPLHKKRLRNITKLRSSCDNI 571
Db      543 NNNNNNN-----NNNNNNNNNN-----GTSSSSSA 567
Qy      572 NNKKKNNLHLARHSVSKLTMFSYDPOKKNDF-----FKSNIKMEDN--TPKDI 622
Db      568 TAASAGILSPRLMSPRLTVIQAPASTASNPFTVASPRQSWANINSLAPGWSKSLE 627
Qy      623 Y-----ESRNVSNNGVLLGLNKNTHHDSIDTDEHNDKINNGVINIINNNGVN 673
Db      628 FLHSDMKSKSKSDSOQERDVTQLGSIIEFDVNNNNNNNNNNNNNNNNNNNNNN 687
Qy      674 SINNSNNNSINNSNNSIYKSNVNSNOSISDVQIRYVEMDTSNKNDNIFPDALSCD 733
Db      688 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNSSN-----NNINNNI-----728
Qy      734 NNMV-----PNIYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 779
Db      729 NNNYNSNYNKSINNNSINNNNNNNNNNNNNSINNNGINGNSVNSNNNNNNNNNN 788
Qy      780 SHNLFQ-----PDNNKQTSNIONIN--TNK 802
Db      789 QOOQFQOOQIQQOVYQOQDESITPRELSRRNSSGGLNLSPSRNNNNNNNNNNNGSTK 848
Qy      803 NNQD-----GNVYSNMFCHYNLNDKNVLDLNKKEQKDKNIGCDNNIIONEN-----851
Db      849 GTTKLPTLQIKNINSYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 908
Qy      852 -----DEKKKKT-----859
Db      909 NTVANNIPVAPPPYVPEVDQYKTIKHLTRVSSEPSIRFNGWPIQOLQLOLOQPOIQ 968
Qy      860 -----859
Db      969 QOOQOQPOIQOOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQOQ 1028

```

OC Eukaryota; Mycetozoa; Dictyostelidia; Dictyostelium.
 * OC

[illegible]

Query Match 11.8%, Score 810, DB 5, Length 1200;
Best Local Similarity 25.1%, Pred. No. 3-25;
Matches 309; Conservative 201; Mismatches 370; Indels 352; Gaps 50;

KM ATP-binding; Coiled coil; Microtubules; Motor protein.
SQ SEQUENCE 1200 AA; 138263 KM; 7673746EEFB604614 CRC64;

3 SKIKVVRKRLPSELEKKKKDSDIITVKNNCTLYIDEPR---YKDMTKYIERHEFIYD 58
256 SNVKAIVAKIRIGESESE-----NIVSIFKNKYVILIEKENEKECYLLAQKK--KQSTVVPD 308
59 KVPFDYDNFTVYVENTIKPLIIDLYENGCVSCRAYQQTSGSKTYTLMGSPYQSPG 118
309 SVFVNATQEEVEFPQTAKPLIPHYFK-GINCTVPAAYATGASGKYTYMLDCK-----NQNG 362
119 IFQYAGDIFPEFLIYDKNTKGFIISFEYIEYCKGLVDLLQKR-AWALENGKEVYVK 177
363 IVQLSLLEFLIIEKKCKRIK-VLMSEFLEYNETINDLLGKEKNTLEYQEDVAYAEKVS 421
178 DKLIRLVYKEELLKIMIDGVLARKIGVNSQNDSSRSHAILNI---DLKDINKNT--S 231
422 NLCEIEVNVYQWALLINEGVKVRKMSPTBANKVSSSHAILQIYVYNEILDMMNTISY 481
232 LGLIAFIDLAGSEKGLTVSQNKOTQTDGANINRSLALKECTRADSDK---HIPFR 287
482 KAKLCFVDLAGSEFASATSKNGERFK-EGSYINQSLALANCNISLASNENISKVRYKR 540
288 DSELTKVLRIDFVFKSISIMANISPTISQCEQTLNTRASSVYHVKRKNKSTCINEBDT 347
541 DSKLTHLKSLSENCIVMTIANINPRTSPQESNNLTAKYAFRRNKK--LCATVQTN 597
348 NTERISILDSKGSSEMASSIEVVYIKSNHLLSNNNKKINRGKINDIKIERNNILKNKSPD 407
598 NKE-----SDIEKLTKNENI-----QKEYD 618
408 KPRGFLSTGKTSYSLND---IDKIKKKKGLINYK-----STLYN 446
619 -----TLGKYTNLKEPFFIINVLINQLYKQIISCYKLTENISDNMSAMELKODITMY- 670
447 DNTIKGKNN 506
671 DQIVRMK-----SDERYKVDLSKOLYQEEKQFNLNLFDFPLEKLNLYVINSKVDND 722
507 NNNNNNNSHNNHLPQPYAFTDTSDFSSLDNMCHLNNDKSIIFLHKNLRDNIKLNRS 566
723 NKK-----SLEEM-----IFFKHNKYNENFLVNEK 750
567 SCDNINMKKKNLILAHRSVSKLTWESYDPQKNKONTPEKSNINMKMEDTTPKDIYESR 626
751 VVD-----KNNV-----LNGNVVVDEN-----VYDKN 772
627 NVSMNGVYLLGLKATKTHDITSTKDEKHNDKLNNGVYININNSNV---NSINNSMNS 682
773 NV--LNGNVVVDENVVVDENVVVDENVVVDENVVVDENVVVDENVVVDENVVVDENVVVD 823
683 INNSMNSNGSYKSYNSVNSQSI-----SDQIRYVEMDTNSKQNDNIFPDALSCNNMY 737
824 DENVMVENYVVDKNSVVENIIVSEKHYGLSAEGKSEHNKKNKD--DIEDNDKOTI 880
738 PNTINNNNNNNNNNN--NNNNIDVENYNNRDCGTTNSKLYAYNSHLFQPDNNKNTSNIO 796
881 KDIIHNNNSSDNDNDEYQANSPEVS-----DIYKEKKKKKKP-I 919
797 NINTNKANQOGANVYSNFCYHNLANDKNTLYIDLNKEQCKDKNIHGCDDNIIIONRDEKK 856
920 NMETKKKRTNGTQDPIHKTPTDYIN---IVGLINKEDVSNKSDNYATNKNIEKNYVEKK 975
857 KKTIV-FYNN-----NNNV--IYNNMGN--NSPRMYGGLCGSHTSIDMKKNEMKKNEMK 907
976 GEYVPEFNNILTMQNSILYNIINNVEVNSHSPRKK----- 1011
908 DNEKDKNHIKSNNNSSSSSSSSNNNTYNNINDDTFQNDYCHNDNTFTIRKKNNTINSN 967

[illegible]

```

QY 988 TLAFKERYTYPTLSTNEDIYNKMEGKHRLDDQDYDNDNNVNDNNKNNVNDNVN 1047
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 2469 MNITYLKSHINQSSFKK-KEKEKESNFNPENNKY-SNKNTSNTKFLSNKSHN 2526
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1048 NNVNDVNDNDKN-----VDNNVNDVDDDDVDFHNKFNNNNYS---YFQ 1092
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 2527 NNNNNNAFNEQKNTNVRKIGKFMKGIQNNKIPND-----FK-FNDEYNMRKKNYE 2577
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1093 KNVDTINNCLNSLDISSMYDDTKEILN-NILSKYAEKD 1132
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 2578 NKHEINSNNIIEQLD-----KTLMKSTIMNKKKKPD 2610
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 27
Q8SSW3 PRELIMINARY; PRT: 1918 AA.
ID Q8SSW3
AC Q8SSW3;
DT 01-JUN-2002 (Tremblrel, 21, Created)
DT 01-JUN-2002 (Tremblrel, 21, Last sequence update)
DT 01-OCT-2002 (Tremblrel, 22, Last annotation update)
DE Erythrocyte membrane protein PFEMP3.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RA "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AC115586; AAL92259.1; -; BFA078455C60D8E CRC64;
SQ SEQUENCE 1918 AA; 217043 MW; BFA078455C60D8E CRC64;

Query Match 11.8%; Score 807; DB 5; Length 1918;
Best Local Similarity 21.1%; Pred. No. 6.6e-25;
Matches 361; Conservative 204; Mismatches 468; Indels 674; Gaps 55;

QY 156 DLQKRMVALENGKEVYVVKDKLIR-----VLTEELLKMIIDGVLKIGVNSQND 210
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 29 EVIQTKEVQLRQKEKEGNIKMEKFKRRKNOISDED-----INDLDD 73
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 211 ESSSHAILNI-DKIDINKTSLGKIAFIDLAGSERGADTV---SONKQOTD----- 259
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 74 EDSNDDDDDNTNDDDDENQD-----KQKEETIKGFTSKDVLGDYFKKVL 120
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 260 ----GANINRSL-LALKECIR-AMSDKNHIFRDELTGVLDIFVGSKSIMANIS 312
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 121 GTPGPESTNSLNGISYQPFSTSSAHKHPFRSTLSYSTPTPKNQOKPFLSPLK 180
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 313 PTISCCQTLNTLRYSSRVKN-----FKNKSTCINEBDTTERIS--IIDSKGSE 361
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 181 STLTSSNTLPMSMTSNPEIKSIDPKDITHKRSTG-NIPNNSNNGSLNIIMKINISNE 239
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 362 MNASSIEN-----VYKSNHL-----SNNNNKINRGKINDIEENNL--KQKS 405
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 240 HNIISNNNNNTTFGPTVSKSLSFGKNNNDNSNNNNKNNNDNNNDLANNNSNNNSN 299
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 406 FDKREGFTSTFGKYSLANDIKIK-----KXKKGLINYKSLTYNDNTINKKHNN 456
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 300 INNSKNIINNNGNLITSSNNNSNINISAGSNSTKNTSTSNNNNNNNIINNNSNNINN 359
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 457 NNNNNNDNNNDNNNNNN-----NDS-----SNV----- 483
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 360 NNNNNNNNNNNNNNNNNNNFVGNLSGNNNSLPNRVNPSTSPIVNSPSTSPNQLSPR 419
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 484 -----NNMIMHINNINNINIVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 536
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 420 HNPQAQNNVNRN--NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 477
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 537 DMN-----CHLNNDKSLFLHKQLR--DNIKLKNRSSCDNIYNNKKK----- 577
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

Db 478 SNNNNNGNNNNNNNNINSIGNNNVNGTTNNNNNISNNISNNNNKSSQPIORVPNTON 537
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 578 -----NLH----- 580
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 538 IKQPLENHIQIQIQIPQSOVQQAPOQVPOQAPOQQAQQAQQAQQLLPQPOQNRISPO 597
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 581 -----LARSVSGSLTFMSYDPQKNDKNTF 605
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 598 PQQPQQRNRSIPQQTQAQAQQAQQAQQAQQAQQAQQAQQAQQAQQAQQAQQAQQAQ 655
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 606 FKSINIMEDNTPKDIYESRNVSNMG----- 633
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 656 ---RISPOQHOPTQINVGKRSIPOLDGINIDDKGLIPILQSVPEQIRQLQEQFVQM 712
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 634 -----NVL----- 637
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 713 QQQQLQQQQQQQQQLLQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 772
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 638 -----GLN---KNTH-----DISTKD----- 651
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 773 QSQQYPOQNNIQSQPOQKGLTPPLKQVHTNEQDQVVELITEDSKFSPISPNSSNNGRN 832
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 652 --ENHNDKIN-----GYINIINSNVNSINNSNNSINNSNNSIYKSNVNS 700
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 833 IEEVNGNFIVNGHNHNRGRKSGPIN--NNININ--NNINNNNNNNNNNSSSSSNSN 889
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 701 NQSIQDVQRYVEMTSTKQNDNIFPDALSCNNYEPN-----TNNNNNNNN 751
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 890 NIS-SNSNNNI-SNNNNNNNNNNNNNNVNSGFRSNNNGNINIGANGFNSSNNNSNN 948
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 752 NNNNNNIDV-----NYNNDGTNSWKLY 776
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 949 NNNNNNISMKNMAMTPLYKSPNNSGNNQNYINNGNNGNNAAYNNNNNNNNNN 1008
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 777 AYNSHLPOPDN-----KNTSNIQININTK-----NNQGNVYSNMFECHYNL-DKN-- 824
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1009 NNNNNNNNNNSNYNYHQNNQNIQNNNNKKNINNNOINNSNNSNIISQNIINTDKRI 1068
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 825 -----YLDANKKEQDKRIHCD-----NNIIONRDEKKKNTFY- 862
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1069 NISVNPQPSHQKILLIQAHQAQOIIRKEHTRQOOQPLQOOIENKNSQOOVYTKHQ 1128
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 863 -----NNNNIYVNNMGNNS----- 879
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1129 HLDQLIQAHQNPENQIQIQNPNSQIQNLQYQQQQQLLQOQHLLQOQQQQQQ 1188
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 880 -----PRMKYGLCGSHTSIDNKNEMKN 903
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1189 QPQOQQQQPQOQNPQOQKMQQLQPNQOPTVQLPLPSQNYQNSQNSQNPQNPQ 1248
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 904 -----NEKDNEMKDNHKK-----SNNNSSSSSSSNNNIYNNINDDT 942
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1249 PNQNPQNPQNPQNPQNPQSTHLOKQSPPTNNSNNVANNNNNNNNNNNNNNNN 1308
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 943 FONDYCHNDTFTIRKKNNTINSNIYONDIIYITNSLNDYNSNTLHFKEKYTYPTLS 1002
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1309 NNNNINHNNNFNNNNNNNNNNNNNNNNNNNNNNNNKANGYINISYQNN-----S 1355
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1003 TNEDIYNKMEGKHRLDDQDYDNDNNVNDNNNNKNNVNDNVN--DNNVNDVNDNDKN 1061
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1356 NNNNNNN-----NNNNNNNNNNNNNNNNNNNNNNNGFNNNNNFNNNNN 1402
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1062 V---DNNVNDVNDVDFHNIRKFNNNNELYSTQKVD-----TIIN 1100
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1403 IINNNNNNNRNSGDGYNSTVTNNNNIIRMEYKSNNEQNPVSSKPMVIGDTSFTLTLLN 1462
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1101 NCLNS-----LDISSYDDTKEILNLLSKYKAEKDNVIKTYINEDIKN 1146
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1463 DVPKPEEQVIALKETTFILKINVSGAANSVYNQOTLRLSK--AVYKGHEBITAT 1519
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1147 SLEIDTKAQSIYKERVLLTKLLLFKKVDTQINNETSDLRKDLVMC-----HICN 1199
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

Db 1520 SPNDSFKLHGVKSEQGVL-----QFDVKIRNGVNTPSHLVLI.FHLDHGSIVH 1569
Qy 1200 NNPDQHFYAYVSKLEKDIIIMLRQIWCSENLRLIYQFLVVEYQKXANSVLNASS 1259
Db 1570 SIESKRISFFTRSKAPYLPFIYIMQSKCFLPLSRSLYR-----NNTESNTVNTNASS 1623
Qy 1260 NNGDIIILNKLKLVODNIKNSMDHNNIH 1286
Db 1624 SN-----NNSNNNNNNNTY 1637

RESULT 28
Q81B94
ID 081B94 PRELIMINARY; PRT; 2206 AA.

AC 081B94; 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Hypothetical protein.
GN PF07.0061.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota, Alveolata, Apicomplexa, Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Seeger K., Murphy L., Harris D., Berriman M., Pain A., Hall N.,
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL844506; CAD50900.1; -
KW Hypothetical protein.
SQ SEQUENCE 2206 AA; 258401 MW; D4ED711AE470383C CRC64;

Query Match 11.8%; Score 804; DB 5; Length 2206;
Best Local Similarity 22.7%; Pred. No. 9,9e-25;
Matches 353; Conservative 226; Mismatches 381; Indels 598; Gaps 73;

Qy 168 ENGKKEVVVDLKL-ILRVLTKEEILKMGIDVLRKIGVNSQNDSSRSHALINIDKD 225
Db 467 ENVEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKED 516
Qy 226 INKNTSLKIAFIDIASERGADTVSONKQOTGDGANINRSLA--LKECTPAMDSD-KN 282
Db 517 -----DIKEDVKEEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKEDIDIKED 561
Qy 283 HIPRDSLTATVLRPIFYGKSKSIMIANISPTISCEQOTLNTLRSSVKNPKNKCSTCIN 342
Db 562 HIIED-----IKHIIIDK-----CVEDOI-----INRNISNINNSYILN 597
Qy 343 EEDD-----TNTER-ISIDSKSEMNASSIENV-----VIKSNHLLSNNNN 384
Db 598 ENIDKIKTSKESGHEERPRIVKQIPANISCCPINSIEQKYNNDLSKSTLSCSVNNN 657
Qy 385 --KINRGKINDKIERNNILKNKSPDKPREGFTSTFGYSSLANDIDIKKKN--KGLI 438
Db 658 MKKKTTLKLSPESEVNNMKK-----KENETEKIKGNKIECERK-- 697
Qy 439 NYKSTLYNDNTINKGNN 498
Db 698 -----NRRVSEQIDDDNN 735
Qy 499 INVVNN 525
Db 736 NNN 795
Qy 526 -----FTDT-----SDFSSLD----- 536
Db 796 YYDERKRTFFDDITKGNIIYVNDYEEYEEFESNRTKIGLQNFQKFLPNOFILSNE 855
Qy 537 -----DMNGLNNNDKSIPL-----HKNL----- 556
Db 856 TDINENKYNIDIKSNNTKNNDDQNKVNNKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 915
Qy 557 RDNILKIKRSS-----CD-----NINMKKNNL--HILARHSGVSKLTWFSYDPOKKN 603

Db 916 KDSWHISNKKIKHATVECEDENFESYKQKIKNDILOELVXKSPFNSINDIYNNKEKIE 975
Qy 604 TTFKSNINRKEDNTPKDI--LYESRNVSNNGVLLGLNKGTTHDIDSTKDEHNDKINN 661
Db 976 -LNDSHLKCEVINSNKRREYNQSRNHEV--VLYAHNN-----NDKDKNNERN 1025
Qy 662 GVINI--INNSVNSINN--SNMNSINNSMNSISYK-----SNYSNQSISDVQIRYVN 713
Db 1026 NVCTLKNISSFNVYTNMNMNN 1078
Qy 714 EMDTSKNNDNIFEDA-----ISCDDNMYPIITNNNNNNNNNNNNNNNNNNNNNNNNNN 757
Db 1079 -----DRNKGNIDPDNMLTNDISKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1134
Qy 758 -----IDVENYNNRGTNSM 773
Db 1135 MRAVSLSLQKLIIEHNKILREKXNHKITQIGNODNCIFKISSESASENENHNNNNNL 1194
Qy 774 KLY--AYNSHLFQPDNNKKT--SNIQININTKNODGVNVYSMPFCHYMLNDKLYIDL 829
Db 1195 NIHSINNTNINHFPNNKKTATFVSNKTNVMM-----NITNIMNNVINSI-L 1241
Qy 830 NNKEQKDN-----HGCDDNITIQ-----RDFEKKKKTFFYNNNNIYVNN-- 872
Db 1242 NNAANNMNNNAPTVVMNTSNSILMNNAPTVVINTSNSILMNNAPTVVINTSNSILMNNAP 1301
Qy 873 -NMGNNSPMMKYVLCSSHSIDMKNNENKNNEMKO-----NEKDKHIK 917
Db 1302 TNVAINNTSNML--MNNAPTVVINTSNSILMNNVAVSOLINNGTNNHMMNGTNNHMMN 1358
Qy 918 S--NNNNSSSS--SSNNNIYNNI--NDDTFQ-----NDYCHNDNTFT 955
Db 1359 SLINNNMNNMNIPIVDIDKSKYKFNENEPVQLNDSIQKLLHKGSPYEMNNLRIS 1418
Qy 956 --IRKNNNTINSIYON--DDIYITINSINDYMSVTLHFKEKTYPPPLSTMEDLYNK 1010
Db 1419 NNLNNDKSNVNSPFIKNNNVGENISTCOHNNNNYNN-----ITTSQPRYNC 1465
Qy 1011 EMEKHIRLDQDQKYDDNDNN--VDNNKNNVD-----NNVDN--NNVDNNVND 1058
Db 1466 -INRYNPKDYEENKDIKKSNNVYKVDNEKCYTIDERYGFPYNNCEVNDMKHRRGNSN 1524
Qy 1059 KNNVDNNVNDVDDDDVDFHNIKFN--NNNEYSFYQKNVDTIINNCLNSIDIS----- 1110
Db 1525 CSNT--NNKKNKQKGVYGVYDNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1583
Qy 1111 --MYDTKE-----IANNILSKYKAEKQNV 1135
Db 1584 TYILIDDDNDTDISTDKRNNPLNRNNKKNLKNLKNLKNLKNLKNLKNLKNLKNLKNLKN 1640
Qy 1136 KKYI-----NEDIKMSLEIDKTAQSI--YEKK-----VLTFLKLLPFKN 1176
Db 1641 TKYVCLGKENSRENHNNNEENEINLEMIINDYHONQVADIISTYIHSKIQETKKG 1700
Qy 1177 VDTQINN-----ETSDLR-----KDLVMCHIANN 1201
Db 1701 KDISNNYNNVOKIOTTHGVNPHKIGDINIOENRVNVQNNNNNNNSFAENIGRILTRS 1760
Qy 1202 PDQGFHYAYVSKLEKDIIIMLRQIY-----GSENLRLIYQFLVVEYQ 1246
Db 1761 SSQGDIIHA--LKEIGNVQNDKSIYNNNTVNMDEVVEICTNEN--EDK 1807
Qy 1247 NKSANSVLLANSNNGDIIILNKLVDN-----IKNSMDHNNHK 1288
Db 1808 NDSANS--LRREKNGTLLYAKEKEEENNETQVRSVRLHNNKVKNQETKOREIEKK 1863

RESULT 29
Q81B94
ID 081B94 PRELIMINARY; PRT; 8591 AA.
AC 081B94; 01-MAR-2003 (Tremblrel. 23, Created)


```

Db      823 PKTEVIDKGVVLRGPVYASSYKISTVNGVYRSHCLLYDGSDAEBRML----- 878
Qy      237 FIDLASRGADTVSONKOTODGANINRSLALKECIRAMSDKNIIPFDSSELTLYLR 296
Db      879 -----FDTSTLG-----TFLKIKPF-----SNPIPLIGSIFK--- 906
Qy      297 DIFVGSKIMIANISPTISCEQTLNTRYSRKNFKNSTCINEEDPTTERISILD 356
Db      907 ---AGQCKIEV-----CSHDSAQFIQYPERISLHTNTPNTNN----- 944
Qy      357 SKGSEMAASIEYVVKSNHLLSNNNKIRKINDKIERNNILKNSFKPKREGFTST 416
Db      945 -----NNNNNADRRNDNDNNNTNNNNNNNNNNNNNNNNNNNNNNNN 982
Qy      417 FGKYSILNDIKIKKKKKGLINYKSTLYNDNTIKKKNNNNNNNNDVNNNNNNNN 476
Db      983 SG-----STNN-----NGGNNSANHTNNNNNNNNNNNNNNNNNNNNNN 1026
Qy      477 NDSSMVNMNINH-MINNINNINIVNNNNNNNNNN--NNNSHNHLPO--PNYAF---TD 528
Db      1027 NNNNSNNNNNNNNSSNNAPVSSHANNHSDNNINNNYNNNHVHTCISNNYHRNSGN 1086
Qy      529 TSDESLDDNACHLNNNDKSIIFLHKKNLRDNIKLRSSCDNIMKKKKNLHLAHSYGS 588
Db      1087 TNNS--NNHSSYNNIINGIY---NYQNNSRNLNNSSPERTIILQDNH---HEMMS 1137
Qy      589 KLTNFSYDPOKKONTF-----FKSNINMK-EDNTPKDLIYERANVNNAGVLLGLN 640
Db      1138 NMA-----NONNFEALIVONLEFORVNTLGRNNPS--LFSSRNO-----LR 1178
Qy      641 KNTHHIDSTKENHNDKINNGVINIINNSVNSINNSMNSINNSNNNSIYKSYN-- 698
Db      1179 LNNNNINNNNNNTNNNNNNNN--NNNNNNNNNNNNNNNNNNNNNNNSHGDITYNYLR 1233
Qy      699 -----NSQOSISDVOIRYVENMDTSKNKNDIIFPAISCDNNMYPIITNNNN-- 747
Db      1234 YSVNNGRNNHNSGS--IDYLNDESDNNNNNN-----NNNNNSTSTERNNSS 1281
Qy      748 -----NNNNNNNNNNIIVENTYNNRD-----GTNSKLYAYNSHLFQPDN 788
Db      1282 VNDSCIVENHOHYHQNNNNNNNDNDHDDHNNNSSGHGNNNNN--SNSHNSQNN 1338
Qy      789 NKNTSNIQNTNNTKNKNOGVNYSW-----NFCYNLNDKUYLLDLNKKKQDKNINHC 842
Db      1339 NNNNS--NSNSNHHGHNHNYKSHSNHNYNLHVTPPYPRNVATRPREHAYNSL 1395
Qy      843 DNNIIONRDEPEKKKTNFYNNNNIIVYNN--NMGNNSPRMKYGLCSHTSIDMKNE 900
Db      1396 GSCFLKNKNSWQIPQNLCTLSNHNMMNPFVNCNDNYNFIPLYL-----D 1442
Qy      901 MKNMKNEMKMDNHIKSNNSSSSSSSNNNIYNNINDDTFOQDYNCHNDT----- 953
Db      1443 QSNSTYKNNISFINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1502
Qy      954 -FTIRKONTNINSIYQNDIITYGINSLDYMSNTLHFKEKYTYPTLSTEDYLYNEM 1012
Db      1503 KFTLERR-NINICANI--NSIFNNINRDSPLDRV-----NLASNETIONAPI 1548
Qy      1013 EKHRIELDDQKYDDNNDNNVNDN--NKNNVNDNNVNDNNVNDNNNDKNNV----- 1062
Db      1549 RNMH-SLAVNKKSEKPKNDYKINIKNNIIRKNSKNGLKJFLNNKLDILKKRRHS 1607
Qy      1063 -----DNNNVDDDDVDVFNHFKNFNNNEYLS-YFOQKVDTIINNCLSLDISMYDT 1115
Db      1608 EFTLYTNQWSTQDEEETGPNTINTNYAAGIYENKMSLKLINYINNINNNKNTV 1667
Qy      1116 KEILNNIILSKYKAEKNDVIKYINEDIKNMS-----LEIDTAOSIYEKRVLLTJKLL 1171
Db      1668 SP-TNNI1-----ECNSDLKLENNANTYKLSLSCGEFNIITERNHNNN----- 1712
Qy      1172 LFKKVVDTQINNSTDRLKDLVWCHICNNPPDQPHF-----YAYSRLKEDIINLIMLROI 1227

```

```

Db      1713 --NNNNMNMNNINSH-----NHINYNNQNNNNHENDLHHSYNNINDEP-----I 1755
Qy      1228 WCESENRLLYQFLVVEYONKSANSVLLANVSNN 1261
Db      1756 IGDIKTYKLLFS-----DHNNVNONSPFOSTIKANN 1785

RESULT 31
081148
ID 081148 PRELIMINARY; PRT; 2763 AA.
AC 081148;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, last sequence update)
DE 01-MAR-2003 (Tremblrel. 23, last annotation update)
PT Hypothetical protein.
GN pf11.0326.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxId=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7; PubMed=12368864;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.B., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Angiuoli S.,
RA Petrea M., Allen J., Selengut J., Haft D., Mather M.W., Vaidya A.B.,
RA Martin D.M.A., Falcitamb A.H., Fraumholz G.M., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrett B.;
RT "Genome sequence of the human malaria parasite Plasmodium
RL falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AE014840; AAN35910.1; -.
KW Hypothetical protein.
SQ SEQUENCE 2763 AA; 330300 MW; 23AF0D9286193774 CRC64;

Query Match 11.7%; Score 802; DB 5; Length 2763;
Best Local Similarity 24.8%; Pred. No. 1.56-24;
Matches 316; Conservative 166; Mismatches 358; Indels 434; Gaps 59;

Qy      248 DTVSQNKOTODG-ANINRSLALKECIRAMSDKNIIPFDSSELTLYLRDIFVGSKSI 306
Db      11 NTSNNKNNKNTNNKNNNTNTNTSYSGYKNLDS-----TNPQNNKLR----- 53
Qy      307 MIANISPTISCEQTLNTRYSRKNFKNSTCINEEDPTTERISILDSKSEMASS 366
Db      54 ---SVSNMMSCSRHTDLCNNY-----KFHNNN--NKEQTNIFGKVYTSNDQYNTDR 102
Qy      367 IENVYISNHLNNSNN--NKINRGINDKIERNNILKN--KSFDPREGFTST----- 416
Db      103 NNNRGDKKHNRKNNRDKNNHKKVGDGSNNNNNNNNNNNNNNNNNNNNNNNNNNNN 162
Qy      417 --FGKYSILNDIKK-----KMKKGLI-NYKSTLYNDNTINKKH 454
Db      163 DMFKRNEKLCMNNVVRQNGESFLCNKKGIMLQDKSYNKGIFPNQDKKIKNNPPNNNNN 222
Qy      455 NNNNNNNNDNNNNNNNN-----NNNNSSMYN----- 484
Db      223 NNNNNNNNNNNNNNNNNNNNNIYRNPVEENNIMAHKYNLSLDQQRKNNKNTTYINKNKF 282
Qy      485 -----NNI-----N 488
Db      283 EDHEKNSLQKKIYDETIYVGNFVQRKKNYKQGGDIKNMVGSPKFSYTEKYVKNDNN 342
Qy      489 HMINNNINNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 548
Db      343 H--NNNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 400
Qy      549 IFLL-----KKNLRDNK--LKNRSSCDNIMKKKNNLHLARHSVSGKLTMFSYDPOKN 600

```



```

Db 401 YFLNKKYKGGKQYKQSVSTLPYNNI CTNDEKKN-----ITKQTHEYTQDTN 452
Qy 601 KDWTFEKSINIKMEDNTPKDIYESRVN-SNMGNVLLGLNKTHTDITKDEHNDKI 659
Db 453 K-----SYVMDNMFINTYKKNKASATNNVPELENNRGD---486
Qy 660 NNGVNIINNSVNSINNSNNNSINNSNNNSIYKSNVNSOSIDVQIRYVENMDTSN 719
Db 487 ---ICNVNVIDIDKNDHNNNNNNNDNSKSHSDHNSNDHND-----DSDN 534
Qy 720 KNDNIFPDALISCDNNYFNTTNNNNNNNNNNNN--NNNIDVNNRGGTNNSMCLYA 777
Db 535 DSDSN-----DDNNNNYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 563
Qy 778 ---YNSHNFOPNNKNTSNIOINTKNNODGNV-NYSNMFCHYLN--DKN-----824
Db 584 SYEENKVIIDIMNKKKFNIN-EKSENETINHHYDYVDEIDIDHVKNNIF 642
Qy 825 ---YLIDLN-----KEQDKNI--HGDNNIIONR-----DEKK 856
Db 643 DHNSFEVDENFLHYVKNHEEYKNIKLYNPEMNNKTGKENVYIOEYEEYEDE 702
Qy 857 KKNFYNNNNIYVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 912
Db 703 DLSNNYVMD--YLYNDQIQNNDSQIHDINNYDIFSLIPNNNNNNNNNNNNNNNN 757
Qy 913 DNHKSNNNS-----SSSSSSNNNNIYNNINDDPQNDY--CHNDTFTIRKNNNTIN 965
Db 758 -NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 806
Qy 966 SNIVQN-DIIYITNSLNDY-----SNTLHFKEKYYTPTLSTN-----1004
Db 807 NNIEVNNPLLIYHNEVNHFLKQKEKKNKTNNI KKHENDKYNI KSHDNNFLOEIMKNF 866
Qy 1005 --BDI--YKMEGKHIR-----1018
Db 867 IYEDIKTNNKFEKYSIDNVVEKTHPLDYI INNDMNYVQEKEDTNNNPFHDKTDGTOK 926
Qy 1019 ---LDDQDKYDNDNNNNVNN--NKNVNDNNVNNNNVNDVND--NNDKKNVD 1063
Db 927 IYLLINHHDHNNKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 986
Qy 1064 NNNVNDVDDVDVPHN--IKNFNNNEYL--YFOKAVDTI-----INNCINSL 1106
Db 987 NNNKDDYVD-DNHKCI FQKKDNTNHLDIYKQNSISNTHIEHGEKHLNKGDIINTKN-L 1044
Qy 1107 DISSMD-----DTK-EILANNILSK-YKAEKDVYKYINEDIKNM 1146
Db 1045 HASKYDALHRECTIYIDNISYGGDWKIDYTNKKDSQMEKKKHHTTNIQLNHLVN- 1103
Qy 1147 SLEIDKTAOSIYEKRVLLTKLLLEKKAVDTQINNETSDLRKDLVMCHIGN-----1200
Db 1104 --EKAKTSSIIYKGNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1200
Qy 1201 ---NPDQFHFYAY 1211
Db 1147 KKNKDHQFNYK 1160

```

```

RX MEDLINE=22255708; PubMed=12368867;
RA Hall N., Pain A., Berriman M., Churcher C., Harris B., Harris D.,
RA Mungall K., Bowman S., Atkin R., Baker S., Barron A., Brooks K.,
RA Bucke C.O., Burrows C., Chevreach I., Chillingworth C.,
RA Chillingworth T., Christodoulou Z., Clark L., Clark R., Corton C.,
RA Cronin A., Davies R., Davis P., Dear P., Dearden F., Doggett J.,
RA Faltwell T., Goble A., Goodhead I., Gwilliam R., Hamlin N., Hance Z.,
RA Harper D., Hauser H., Hornsby T., Holroyd S., Horrocks P.,
RA Humphrey S., Jagels K., James K.D., Johnson D., Kethornou A.,
RA Knights A., Konfortov B., Kyes S., Larke N., Lawson D., Lennard N.,
RA Line A., Maddison M., Mclean J., Mooney P., Moute S., Murphy L.,
RA Oliver K., Ormond D., Price C., Quail M.A., Rabinowitch E.,
RA Rajadream M.A., Rutter S., Rutherford K.M., Sanders M., Simmonds M.,
RA Seeger K., Sharp S., Smith R., Squares R., Squares S., Stevens K.,
RA Taylor K., Tivey A., Unwin L., Whitehead S., Woodward J.,
RA Sulston J.E., Craig A., Newbold C., Barrell B.G.,
RT "Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13."
RL Nature 419:527-531 (2002).
DR EMBL, AL929355, CAD51731.1; -.
KM Hypothetical protein.
SQ SEQUENCE 1770 AA; 207567 MW; 83195F911DFC548F CRC64;

Query Match 11.7%; Score 801; DB 5; Length 1770;
Best Local Similarity 23.0%; Pred.No.1,1e-24;
Matches 363; Conservative 236; Mismatches 476; Indels 506; Gaps 78;

Qy 12 RPLSELEKKKKKSDITTVKNN-----CTLYIDEPYKVMQTKYI 50
Db 239 RPLNDNNNNISKDDIEKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 297
Qy 51 ERHEFIVKVPDVTNFTYENTIKPLIIDYENGCVCSCFAYGOTGSGKTYMLGSP 110
Db 298 KKK-----NIMVSNKKIINELVNN-----LIYD 322
Qy 111 YGOS--DTFGIFOYAAAGDIPTFLNYDKNTYKGFISF-YEYICGLYLLORRKAVAL 167
Db 323 YSENNILSKGVKXKHEIYEYEQNTHMKANESTNISIDIPCCQIYDNDVADTN-EQY 381
Qy 168 ENGKKEV-----VKDILRLVTKRELILMIDGVLRK-IGVNSQNDSSRSIAI-- 218
Db 382 DNSQDKTYNWKNTNNNLVHINENLFLRKIQDYFYQKYINIKFSVDTYDYIHL 441
Qy 219 --LNDLKDINKNTSGKIAFTDLGS-----BRGAD-----TVSQNKOTQDGANI 263
Db 442 EWFNKLKRIINNESN-----DPPGISNWELEYETHDEIKANNIYSSNVPFSDDKM 494
Qy 264 NRSLLAKECIRA-MDSKNH-----IPPROSE 290
Db 495 NNNIYLLKQCLKNLKEGRDYICTNKKWMRFLOFLYNGPCIKRISNNIYTFPISSND 554
Qy 291 L-----TKVLADIF-----YGKSKI-----MI 308
Db 555 INNNNNIYLLSRVYIKNLSFLNYIDHTKFIYNEKGEHLLYKNEVYNDNDKYTHDYTL 614
Qy 309 ANISPTISCC-----EQLNTLRY-----SSRVNFKQKST--- 339
Db 615 EETNEKVCANHYHELQYFNLYKEQEKNIILYIEYDDKHINKEIIDEIKIKIKKSNMNO 674
Qy 340 ---CINEE-----DNTTERISILDSK-----GSENNAS---SI 367
Db 675 NILISNDENFSSDSSNMVNI INAKHNDKILNTQKLFLENDKICANSHTSSNNQTEYISL 734
Qy 368 ENVVVIKSNHLLSN-----NNNNKINRGKI-----NDX 394
Db 735 DN--FDADYLLNPNHLSRGFPNSYKLDINTDNNVNDNGVDSNENVDNSNENVDNSN 792
Qy 395 IERN-NILKNSKSPDRBGFSTFGKYSGLNDIDIK-----KNKKGLINYSKTYLND 447
Db 793 VNNNEVDSNENVDN-NEMMDANDMNNEN-VDNSKQFINKNCQGRSRIKKSSTNSTR 850
Qy 448 NTINKKNNNNNNNNNDNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 507
Db 851 RNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 904

```

```

RESULT 32
Q813A3
ID Q813A3 PRELIMINARY; PRT; 1770 AA.
AC Q813A3;
DT 01-MAR-2003 (T-EMBLrel. 23, Created)
DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (T-EMBLrel. 23, Last annotation update)
DE Hypothetical protein.
GN PF10225W.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.

```

OY 508 NNNNNNNNNHLPDPNYAFTDTPSPSSLDMMCHLNNDKSLFLHKKLRLDNITLKRSS 567
 DB 905 NNNNNNNNNNNKDN-----TSD-----NNNN-----NINKEEDKKKKT 940
 OY 568 CDNIINNNKNNKHLARSHVSGKLTMSFYPOKKNKONFFKSNINMEEDNTPKDLIYSERN 627
 DB 941 ----NNKKEN-----EKDEBK-CKKNLNGSYE-----IYELKR 970
 OY 628 VSNNGVLLG---LNKATHTDSTKDNHND-NKINGVITINNSVNSINNSNNSTI 683
 DB 971 EFEENNNIIVYDSYNNRRINNVIDLKKNEDIKINDRNIYILSPNISANEMINNFESK 1030
 OY 684 NNS-----NMSNSTYKS--NNS-NGSISDVQIYVNMEDMSKNNNNIFPDA 729
 DB 1031 YNSSNNKKSIPCNSSNGNDIYKSCSEYNNDEKIS--SNGLYLTTSOSQKTTD---- 1083
 OY 730 ISCNMMYPTITNN 789
 DB 1084 ---GNTGSGIYEYENDNN 1131
 OY 790 KNTSNIQNTNNKNNQGNVNVSMFCHYNLNDK-NYLID--LNKEQKDKNTHGCDN 845
 DB 1132 KKKKHIKNA---QNNTTNNRVCSNCGEQVTEKININILDTHTLNNIQNNKNNLNKNNSS 1188
 OY 846 IIOBNDEKKKKKTFYNNNNNIVYNN--NMGNNSPPMKGLGCSHTSIDNNKNNMKK 903
 DB 1189 TIQNGCTI-KGEOVNVKNTNNINEBDNTITNENHK-----DQKKKNNHMK 1233
 OY 904 NEMKDNEMKDNHKSNNNNSSSSNNNNIYNNINDDTPONDY-----CHNDTFTLR 958
 DB 1234 KKLDDIDYKQGLKSNHH-----ENKQVDENMEDETNNNSMDPOQRCHLISYFNKQK 1287
 OY 959 KNNNTINSNIYQND-----IITYTNSLNDYWSNTLLHPKEXYTPYLTSTNEDIYKME 1013
 DB 1288 NKKNNISNNNNKKDDDDDOGVYSNITNTNSS--LH--NSCSSSSGCGNNSLYNE--- 1340
 OY 1014 GKHIRLDQDKY---DDNDNNN-----VDNNKNNVNDNNVNDNNVNDNNVNDNNVNDNN 1065
 DB 1341 ----NDISKYINNNNDNDLKKULLVPNNNSNN--NNNNNNIITINSNNNNNNNNNN 1392
 OY 1066 NVNDND-DVDFH-----NIKFNNEEYLSYFOKQVDTIINNCCLNSLIDISSMYD 1114
 DB 1393 NFKPNBESSLANTHSIMTKEOPAGIINSTCYIN-----VWQCL--SVFVK 1438
 OY 1115 TKELIINILSKYK-----AEKQVYIKKYINEDI-----KNMSLEETDK-- 1153
 DB 1439 LIYTLANTYVYKVKVNNSSDENENNNSFINKNEFTNISIPNIFGSNNNNKKDECL 1498
 OY 1154 -----TAOSIYKRRYL-LTKLLLFKKVNDQIN-NETSJLRLQV-----MC 1195
 DB 1499 LTFSEKLPOLSKNNHKKVLCVKKLNLNDKYSYLFPEYNEQDCHFLVDFPIHNV 1558
 OY 1196 HICNNNPDOQHFYVARSLEKDIILNLM-----ROIWC-ESENLRLYQFLVVEYQNSA 1250
 DB 1559 KYIDSVDKNOIDYLLKKEQSIIIGLFLGLEBKITSCQCEYVYIYQ-----PYNNISV 1614
 OY 1251 NSVLINVSNN-NGDIITLNNK 1270
 DB 1615 NVFKKKNPENNINDNLEFVK 1635
 RESULT 33
 O8IHP9 PRELIMINARY; PRT; 2940 AA.
 O8IHP9;
 AC 01-MAR-2003 (Tremblrel. 23, Created)
 DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
 DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
 DE Hypothetical protein.
 GN PF1 0480.
 OS Plasmodium falciparum (isolate 3D7).
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.

OX NCBI_TaxID=36329;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=3D7;
 RX MEDLINE=22355705; PubMed=12368864;
 RA Gardner M.J., Hall N., Fung E., White O., Bertram M., Hyman R.W.,
 RA Carlson J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
 RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
 RA Chan M.-S., Nene V., Shallow S.J., Sub B., Peterson J., Angiolini S.,
 RA Perce M., Allen J., Selengut U., Haft D., Mather M.W., Vaidya A.B.,
 RA Martin D.M.A., Fairhead A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
 RA Macaden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
 RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
 RA Fraser C.M., Barrell B.;
 RT "Genome sequence of the human malaria parasite Plasmodium
 RT falciparum.";
 RL Nature 419:498-511(2002).
 DR EMBL; AB014843; AAN36060.1; -
 KW Hypothetical protein.
 SQ SEQUENCE 2940 AA; 348040 MW; BF8748DA051BAD2 CRC64;

Query Match 11.78; Score 800; DB 5; Length 2940;
 Best Local Similarity 23.88; Pred. No. 1.9e-24;
 Matches 360; Conservative 233; Mismatches 444; Indels 478; Gaps 77;

OY 132 NIYDKNTKGIFISFYRIYCGKLYDLQK-----RKMYA--ALENGKEVAVKDL 179
 DB 1116 NNSNSNQVCLYNNHLLY-NSNYNTQHPSSNDVPKIQKIANINNMGHHEHIEK 1174
 OY 180 KILRLTKBELILKMDIGVLLRKIGVNSQNDSSRSHAILNIDLKDK-NTSLGKIATF 238
 DB 1175 K-----SKEE-----TKTNEQVYRS-----INQNNVTILKENEI 1204
 OY 239 DLASERGAOTVSNKQOTQDGNINRSLALKECFRANSDKQ-HIHPDSELTLYLRD 297
 DB 1205 D-----ENDITLNNLNINIKDMMND--NIINLKN-----LNNINITYPYQNNILKN--NE 1253
 OY 298 I-FVGSKSIIMIANISPTISCCQTLNTR-YSSRV---KNFKKSTCIINEED---DTNT 349
 DB 1254 IQPLNNKVEY-ITGHATHSNEININIVYKNIDQINIRKNNENNDDIINKEQKDISTN 1312
 OY 350 ER-----ISIDSKSEMNASSIENVVYKSHLLSNNNNNKINRGKINDKI 395
 DB 1313 EQNGTFYVYTSVNGEYSILDSPTDKYKKNLNLNISSY---NTNDHIN--NYHDDI 1366
 OY 396 ERNNILKNSKSPDKR-----EGFTSTGK-YSSLNDIDKIKKNNKGLINYKSTLYN 446
 DB 1367 DKTN--KDNKYEKKKDIINININNSNGKNNFNINSYFDLNEKKKKXIN--IFYH 1421
 OY 447 DNTINKKNNNNNNNN-----NDNNNDNNNNNN-----NN--NND-----SS 480
 DB 1422 DNKSLKINISBELNTNTPYKICINNTIDNNNDHKQGYELNENINNSINNNDEKITTAYLNN 1481
 OY 481 SMVNNMINHMT-----NNNININIVNNN--NNNNNNNNNNNNNNNNNNNNNNNNNNNN 521
 DB 1482 RVQNGSLSHDILNEDVSINTHSNKENKNDNNNNNSNSNSRNNNNNNNNNNNNNNNNNN 1538
 OY 522 PNVAFTDTSDDSSLDMMCHLNNDKSLFLHKKLRLDNITLKRSSCDNINNNKKNKNNH 581
 DB 1539 -----ANSYVAKNDL-QINNNNSYIKNEKVVHQF-----NENNNILYK-----HY 1578
 OY 582 ARSHVSGKLTMSFYPOKKN-KDNTF-----FKSNI-NKMEEDNTP-KDILYESRNVNM 631
 DB 1579 SNH-VHNYITKQTIQEQKNHSDKYEKCSLPEKKNIYEPNSQNSPNSQKLPNSQNLNS 1637
 OY 632 NG-----NYVLGLNKTHTHDIK-----KQENHNDKIN 660
 DB 1638 QNLPSVPLPNSQNLPSNPLPNCFTYVNNQTDILISLVLYVQEOKLNDOKEKMSNNNIN 1697
 OY 661 NGVINIINNSVNSINNSNNM-----SINNSMNSNSTYKSNVNSNGSISDVQI 709
 DB 1698 NTKMNNAYNNEVQVNNNIVAEIINILPYPSKNNENINLEHNSNIYHDKNNQH---DIRT 1753

OY		710	RVYNEMDTSNKK-----NNNDINFEADISCDN-----	734		
Dd		1754	YNDSTKITNKLIHIESGNKKLTNDIAHTTNVEYTINSRYPICONSATITAPEKNCPCOMMA	1813		
OY		735	-----NMYPNIITTNNNNNN--NNNNNNNNNNIDVEN-----YNNR--DGT	769		
Dd		1814	MNFENNIEEYVIQNHNVAVDGKNKKKDPIIDNNNNNNNDNIEIFNIIOOTKOIKYNNNTTDTN	1873		
OY		770	NNSMKLVIYNSHNLFPDPNNKNTS--NIQININTNK-----NNOGANVY--SMNECH	817		
Dd		1874	NNSL-----IHNV---ENNYVTGDLDISNISYNNYTYNNMMYNLANNIDINNMYMPQNYTH	1924		
OY		818	YNLN-----DKYYLLIDLANKKEGOKNIIHGCONNIIQQANDPEKCKKTTFYNNNNIVIYNN	872		
Dd		1925	IYNNNIATSENNQLQIINN-YNINFIN--DIINIITHANSYKENDKKOILYNNNI-----N	1977		
OY		873	NMGNN--NSPRKYGLCGSHTSIDMKNNMEMKNEMKO-----NEMKONHIKSNNNSS	925		
Dd		1978	MNANDINIHDKY-ICNSNSNNNNNNNNNNNNNNNNNNNNHHYYYTCRCREBYKINDNNYIN	2036		
OY		926	SSSSNNNIYNNIDDTEFONDYCHNDFTIRRKNTINSNY-----QNDDII	975		
Dd		2037	IQNKKNIVND-NSTNIILKSQG--NNTNQMIILEGINIMMEDNYQINSULCLKNDIST	2094		
OY		976	YTINSINDYMNSTLHAFEKXTTPFLSTNEDIY-----NKENEG	1014		
Dd		2095	TCCDNINNNNNNN--NNKYSNBEINSNEYLYKFDEQYDKONNVASAMCINIKKHOKYN	2156		
OY		1015	KHIRLDPODKYD-----NDNNVVDNN-----	1037		
Dd		2151	NYVAYNTNGSTEYMSNFSSNNVYNNKCPTNNNNNNNNNNNNNNNNNNCYNHGYGVANTKY	2210		
OY		1038	-----KXNVVDNNVNDNNVNDNN	1057		
Dd		2211	NKAGNKFSSVOIDTQMNPRIHYDKKAKNDILERNIKSIIINNDSNDNDNNDDNNNDNN	2270		
OY		1058	DCNVVDNNVNDDDDDVDV-HNIKFNPNNEYLSFYQ--KANVTIINNCLNSLDISMYDD	1114		
Dd		2271	NNDVASNNNN--NDTNNINYLMNIIKUTNNPFDSTNNPDS-----TNNPFDSTNNPDS	2323		
OY		1115	TK-----ELIINNLLSKYAEKONVAKKYINEDIKMMSLEIDKT	1154		
Dd		2324	TNNFNRRNPNRRNPNRRNPFHIIINNINKLIIHDNENNLCRE--DENNNHTILTNYKNT	2381		
OY		1155	AQSITYERKVVLLFKLLLFKKQVNDTOINNETSDLRKDLWMCHI CANNPDQGFHYAAYSRL	1214		
Dd		2382	TNKEY--INICTDHNLKATNLANNYILLKINKLANDYYNSIIKSGDGCNTFLQNSL	2439		
OY		1215	EKDIINLMLBQICESENRLLYQPLVVEYQNSANSVLLNVASNNGDIILLNKQLVOD	1274		
Dd		2440	NNQ-SNIIQNNNIYE NNRIQ-LVYVPSEFYNNNIIINTMQKNTNNSYNSIPLSNVC	2497		
OY		1275	NIKN---SMDRNINH	1286		
Dd		2498	NWKHHIFNVTONNAH	2512		
RESULT 34						
Q8IBV8						
ID	Q8IBV8	PRELIMINARY;	PRT,	3569 AA.		
AC	Q8IBV8;					
DT	01-MAR-2003	(TREMBLrel. 23, Created)				
DT	01-MAR-2003	(TREMBLrel. 23, Last sequence update)				
DT	01-MAR-2003	(TREMBLrel. 23, Last annotation update)				
DE	Hypothetical protein.					
DE	PF07_0053.					
OS	Plasmodium falciparum (isolate 3D7).					
OC	Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.					
OX	NCBI_Taxid=36329;					
BN	[1]					
RP	SEQUENCE FROM N.A.					
RA	Seeger K., Murphy L., Harris D., Berriman M., Pain A., Hall N., Quail M., Barrett B.;					

Rt	Submitted (SPP-2002) to the EMBL/GenBank/DBJ databases.
DR	EMBL; AL844506; CAD50890.1; ..
Kw	Hypothetical protein.
SQ	SEQUENCE 3569 AA; 415260 MW; 8C2BFF5BD2D93F28 CRC64;

Query Match	11.7%; Score 799.5; DB 5; Length 3569;
Best Local Similarity	23.5%; Pred. No. 2,3e-24;
Matches 338;	Conservative 228; Mismatches 441; Indels 429; Gaps 66

Qy	149	IYCGKLYDLQKRIMVALENGKEVYVKDKILRV-LTKEELIKMIDGVLRLRTIGVS	207
Dd	96	IMLKRRNRMEKYKLTYKKNNKKKKFKFNIKDRNMKEYLTLYDASHSDISDGVSL----	151
Qy	208	QNDSSSHAILNLDKDINKGTSLGIAPFLDLAGSERGADTVSQN-KQTOTGDANITRS	266
Dd	152	SNDR-----PFKNMDTSMDDKNDLI-----IDDVTKNVLLANNNDNNKN	193
Qy	267	LIALKECIIRAMD-----SDKHIIPRDESELTGVLDIFVGSK-----	304
Dd	194	SLPLSGCHEHEDIMEYTSSQGYDETNNI--NKAKNTIIINN-DNRKRYDNSSNNLDY	249
Qy	305	----SIWIANISPTISCCEQL--NTL-----RYSRFVNKF-NKXSTCINEEDDTN	348
Dd	250	CINXYDIILED--PDMCCEMETMIKEKONILTHTDEYVIDLNFKNRKIRDSEINNLIS	307
Qy	349	T----EKLSILDGSGSEMASISENVVIKSNIHLSSNNNNKINKGKIINDKERNNILKN-	403
Dd	308	TINFEVETLYIQSTSRSEKDNINNDTLVADNKKMLYIPKRN-----INVNNMINNY	357
Qy	404	-KSPDKPRGF-----TSFGKYSLANDIDIKIKKKKKGLINYKSTLYNDWTI--NKKH	454
Dd	358	HTYIDNPKNNYALNIENNTHSEHQLVDDOIYVEDRIEG-SYNTEISSTNLLDGGDQSN	415
Qy	455	NNNNNNNDNDNDNNNDNNNNNNN-----DSSWVANNMIINHINNINNINNVN----	503
Dd	416	NNNSKNNNDNNNNNNNNNNNNNNNNFYNNNNSECSILLNDKDOFTFHSHNYTINNITVEQ	475
Qy	504	-----NNNNNNNNNNNNNNHHLPQRNYAFPTDISPSSLDMMCHLN-----NDKSIFLKH	553
Dd	476	DKSIYNNSSNNMYEGLFRNNLSNDINTLYTTINS--SSNDENICDVNNKL YDSNYITLVANP	534
Qy	554	KNLRDNITKLNRSSCDN-----INMKKKNNLHLARHSVSKLTFMSYDPQK	599
Dd	535	LNVMEN-----NCODKKYEELTDYVNNSPFINKKNNKNNLHYHS-----SM	576
Qy	600	NKONTPEFSKINRMKEDNTPKOILYESKSVSNMGANGVLLGLNKATHHDISTYDENHNDKI	659
Dd	577	NVNNLNTTEDFKRGDYAGSTTIYNTIENNNNNN--NNNNNNNNNSVDDGNCH-L	632
Qy	660	NNGVINIINNSVNSINNSNNWSINNSNMNNSISYKSNYSN-----QSISDVOI--	709
Dd	633	GHNITHINNNYININNIHNNNNSINNNDRSNSIASDEPKTIVITNOKI GKNNIDKVKIIS	692
Qy	710	-----RYVEMDT--SNKNDN-----	724
Dd	693	NNNSCTNYVDVNTDCENNSSNHDKI.PPKNDVDYTEMEHQYKKEFKMMILANKSEFT	752
Qy	725	-----IFFD-----AISCDNNYPNITN	742
Dd	753	TINENDELTYKTIVAFEKKKKILLMRRSLRKRRKSPXNEHLENDYAMODNNINEGOKN	812
Qy	743	NNNNN-----NNNNNNNNNNIIDVEN-----	762
Dd	813	ENHSNDLILNQVYVNSNDIDKNNMILKVEQEPAADSNNNNNNNNNNNNLNVHAKTTDDNDN	872
Qy	763	-----YNNRDGTN-NSMKLYAYNSH-----LFQPDNNKNTSNIQNI--NTNKNQDGN	808
Dd	873	LLVLTILNQKONSNGSNMME-----NNRNIENNAMLII.PKKCANSTIVKGVKATKTRNQOSD	928
Qy	809	VNISMFACHNLADKAVLIDLANKEQK-----DKVIH-----GCNNIIOQRNDF	853
Dd	929	TN--DMC-----VANDELICGD-NGTTOGVNRRKVGPGRKKVVNFMEENADITNVAYEKINI	981


```

Qy 935 N-NINDDDTFONDYCHANDNTFTTRKKNNTINSNYQNDIITYTINSANDYMSNTLHFK 993
Db 1101 NPSIN---LKKNNY-----EDKNSN-----YHSHVSTTD--KNSIYAK 1136
Qy 994 EKYVYPTLSTNEDIYNKEMEGKHRLDDQDYDND-----NNVNDNNKNNVNDND 1046
Db 1137 NKVAEVYTKNNE---KREDLH-KKEQYTFNNNDNNNDHNNHNNHNNHNNHNNH 1191
Qy 1047 N---NNVNDVNDKNNVNDNNVNDNDVDFNHNKNNNEKXLYFQKNVDTIIN-- 1100
Db 1192 NNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNH 1251
Qy 1101 ---NCLNS--LDIS-----SMVDPKELL-----NNILSKY 1127
Db 1252 NEKNPNATEKCLDINNKKKKKKI KSVHYDMDLILSKCYVDELDTCKCINMLTKNKK 1311
Qy 1128 KAEKONVKKY---INEDIKMSLEE---IDKTAOSIYKERRVLLTKLL-LFKKN-VDT 1179
Db 1112 LYEQ---LKKYKHKLDKDTKTKLYDECTSEKTKG-SYTMKDSYSSLLCNHKLHILN 1367
Qy 1180 QINNETSDLRKDLVWCHI CANNPPDQFHFYVSRLEKDIINLMRQIWCESENLRLLYQ 1239
Db 1368 KSNKKVSDDK-----HILSYN-----HHNNKNNHNNHNNHNNHNNHNNHNNH 1415
Qy 1240 FLVVEYQKNSANVILVNSNNGDILL--LKKLVQDNINKS 1279
Db 1416 INIHNHNNKDPNSGVFLPSDNTESVYNNHNRKLCNNFNVS 1458

```

RESULT 37

```

Q94GM1 PRELIMINARY: PRT; 800 AA.
ID Q94GM1 AC Q94GM1;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Kinesin-like protein.
OS Oryza sativa (Rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Eubacteriobacteriota; Oryzaeae; Oryza.
CX NCBI_TaxID=530;
RN [1]
RP SEQUENCE FROM N.A.
RA Hsing Y.-I.C., Chow T.-Y., Wu H.-P., Chao Y.-T., Liu S.-M., Lee P.-F.,
RA Su C.-L., Chen C.-S., Shaw J.-F.;
RT "Oryza sativa PAC P0431G05 genomes sequence.";
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC068551; AAK70904.1; -.
DR Gramene; Q94GM1; -.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS0067; KINESIN MOTOR DOMAIN2; 1.
KW ATP-binding; Coiled coil; Microtubules; Motor protein.
SQ SEQUENCE 800 AA; 88189 MW; D9B330375AC6F256 CRC64;

```

```

Query Match 11.6%; Score 796; DB 10; Length 800;
Best Local Similarity 34.7%; Pred. No. 8.2e-25;
Matches 207; Conservative 96; Mismatches 201; Indels 92; Gaps 18;
Qy 3 SKIKVVRKRPSELEKKKDDIIVKNNCTLYIDEPRYKVDMTKYIRHSEFIVDKVD 62
Db 198 AIKIVVVRKRPSELEKKKDDIIVKNNCTLYIDEPRYKVDMTKYIRHSEFIVDKVD 257
Qy 63 DTVNDNTVYENTIKPLIIDLVEKVCSCFPAVQGTSGKTYTMLGSPYQGSQDPTGIFQY 122
Db 258 EGVNSDEVYRETEPIPIIFQFRTKATCFAYGQTSKTYTMLGSPYQGSQDPTGIFQY 305
Qy 123 AAGDITFPLN--LYDMDNTKGIPISEYIYCGKLYDLQKRNKVALENGKKEVVKDK 180

```

```

Db 306 AADDMVRLHQPVRYNQNF-LWLSYFELYGKLPILLSRRLMREDOCKQVCIVGLQ 364
Qy 181 ILRVLTKEELILKMD-GVLRKIGVNSQNDSSSRSHALINDLKINKTSLGKIAFD 239
Db 365 EFVEY-SVQVQVKEIYERGNAASTGSGANESSRSHALIQLAIK--KHIIAVGKISFD 421
Qy 240 LAGSEKADVDSQNKQOTDQGANINRSLALKECISAMDSQKHIPRDELTQVLRDIF 299
Db 422 LAGSEKADVDSQNKQOTDQGANINRSLALKECISAMDSQKHIPRDELTQVLRDIF 481
Qy 300 VGSKSIIMANISPTISCEQTLNTRYSSRVNFKNSTCINEEDTNTERTISILDSKG 359
Db 482 VGNSTRVWISICISPNAGSCGHTLNTLRVADRVSLS-SKGSNTRKEQPTGPTIPSSKDS 540
Qy 360 SEMNASSIENVVKSNNHLSNNNNKINRKNIDK--IEKNHNLKNSFKPKREGFTSTF 417
Db 541 APSYPMPIETEELIAN-----QIEKRPVETSR-----KAENFTSNS 577
Qy 418 GYSLSLNDIDIKIKKKKKGLINYKSTLYNDNTINKGNNNNNNNNNDNN--DNNNDNNNN 475
Db 578 SMEEDRPVPMITPSYNSRG-----KEENGSGLANDREVDLNSRISYN 621
Qy 476 NNDSS--SVYNNMIHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNHNNH 530
Db 622 SKPQSVGSANLQEEKVTVSPRRKAYKDDKPERQSVYAKKDSGPEYKQVQAK 681
Qy 531 DF-----SLDD--NCHLNNDKSIPLKKNLRDINKL 562
Db 682 QLOQQQRPTSASQNSRSSQSEKSSCDVEIDALIEEBEALIAAHRKEIENHWEI 737

```

RESULT 38

```

Q9LMB1 PRELIMINARY: PRT; 706 AA.
ID Q9LMB1 AC Q9LMB1;
DT 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Similarity to kinesin heavy chain.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.
CX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Sato S., Nakamura Y., Kaneko T., Kato T., Asamizu E., Tabata S.;
RC Sato S., Nakamura Y., Kaneko T., Kato T., Asamizu E., Tabata S.;
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB012247; BAB02671.1; -.
DR DNA Res. 7; 131-135 (2000).
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS0067; KINESIN MOTOR DOMAIN2; 1.
KW ATP-binding; Coiled coil; Microtubules; Motor protein.
SQ SEQUENCE 706 AA; 79246 MW; 059658E9F69282F2 CRC64;

```

```

Query Match 11.6%; Score 795.5; DB 10; Length 706;
Best Local Similarity 36.8%; Pred. No. 7.6e-25;
Matches 203; Conservative 91; Mismatches 186; Indels 71; Gaps 16;

```

```

Qy 3 SKIVVVRKRLSELEKKKSDIITVANNCTLYIDEPRYVDMTKYIERHEFIVDVPD 62
Db 168 AKIVVVRKRLSELEKKKSDIITVANNCTLYIDEPRYVDMTKYIERHEFIVDVPD 226
Qy 63 DTYNFVYENTITPLIIDIYENGVCSCFAYGOTSGKTYTMYGSPYQSGDTPGIFQY 122
Db 227 EEFVNDVYRETVPEVPLIFQR-IKATCFAYGOTSGKTYTMYGSPYQSGDTPGIFQY 274
Qy 123 AAGDIFFLNYDKNTKGIPISEFYCYGLYDLOKRWALLENKKEVVVVDLKITL 182
Db 275 ASRIILMHTTYNQGOLFVSEFYCYGLYDLOKRWALLENKKEVVVVDLKITL 334
Qy 183 RVLTKRELILKMD-GVLLKRGVNSQNDSSRSALINIDL-KDINKNTS-----LGKI 235
Db 335 RV-SDTAIMEILIRGSATRGTTGGANBESSRHAILQALIKKSVGNGSKPRVLGKL 393
Qy 236 AFIDLASERGAUTVSONKQOTQDGNANINSLAKECIRAMSDCKNHIIPROSELTQV 295
Db 394 SFIDLASERGAUTVSONKQOTQDGNANINSLAKECIRAMSDCKNHIIPROSELTQV 453
Qy 296 RDIIVGSKSIMINISPTISCCQTLTLRYSRVNFK-----NKST 339
Db 454 RDSFVMSKRTVMISCISSSGSCHTTLTLRYADRVKSLKGNASKKDVSSSTNMLREST 513
Qy 340 CI-----NEEDTNTERISILDSKSGEMNASSIE--NVYIKSNHLNNNNNNKIN 387
Db 514 KIPISALPTPSNFDVVN-----EMWTEBDEFPASDEYEDOKMKKNGKGLPEPVN---- 565
Qy 388 RGTINDKIERNNLIKNSFKPREGFTSTFGKYSLNDIDIKIKKKKKGLINYKSTLYND 447
Db 566 -GMAOERIIPKPTI-QMKSMDPFRDM-----KKSNSDNLNALLQEEEDLVNARKQVED 618
Qy 448 NTINKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 500
Db 619 TNNIVKEEMVLLEADQPGQOLGYSILNTLITLSOKAGILIQONRLHAFQKRLREHVL 678
Qy 501 VNNNNNNNNNNNN 511
Db 679 VSTTGERKSQS 689

```

```

Db 69 SLANNDDNNNNNNNNNN--NNS-DNSKLSFSRNF-----KNSFNKGNRRNSVT 113
Qy 445 YNDNTINKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 503
Db 114 GNTIKGINNKKYTNMNNNGEHTNNDNNDVNDQNNYSGIFNNNTNTLNKAFYKNNKNNK 173
Qy 504 -----NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 547
Db 174 FNKTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 233
Qy 548 -SIFLHKN-----LRDNLKLRSSCDINMK-----KN 577
Db 234 NSNTMHSRNSVEEHLRNNNSIDMNSINNYTQOTRFSSEMEENENENKNNYHTGMMN 293
Qy 578 NLHLARHSVSKLTWESYDPOKKNKDTFFKSNINKMEDNPKDILYESRVSN----- 630
Db 294 NIFPKNYDNNSSMKRTDNKKTDTSTNNKGTIN--NDNNNMVYL--RINININEKGS 348
Qy 631 -----MGNVLLGLNKTTHDISYDKNHNDKINNGVANIINNSVNSINNSM- 680
Db 349 AKKPFYTNVNNKNNLKTQNNNDNMNTJEDNNNNNNNNNNNNNNNNNNNNNNNNNN 408
Qy 681 -NSINNSNNNSNITYSNYSNOSISDVQIRYNEHDTSKN--NDNIFFDALSCDNNM 736
Db 409 RNLNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 442
Qy 737 YPNTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 796
Db 443 YQNRKNSNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 488
Qy 797 NINTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 836
Db 489 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 548
Qy 837 KNTHGCDNNTIQNRNDEKKTNPYR-----NNNVIYVNNNG--NNNSPMMKGLCG 888
Db 549 MNNYGYDPTVHNNN--TPSTDFPSRAVGNNNNYLNNNNNNNNSAVNNNS----- 536
Qy 889 SHTSIDNNKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 948
Db 597 --SNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 647
Qy 949 HNDTFTIRKNNNTNINSNIYQND-----DIYTTINSIDVMSNTLHFEKRYTPPLS 1002
Db 648 -----NNQNNNEDEDDDWGELGEXYIDINSIMK-KKVYILNQL-----A 688
Qy 1003 TNEIDYINKMEGCHIR-----LDDQKYDNDNNNNVNDNNNNKNNVNDN 1044
Db 689 DLNLDLSKKGNDGKNNKKKKKKKDDLFVLPHNTLTLVYKKKKKKKKKKKAKNNNTSNNNN 748
Qy 1045 VDNNNVNDVNDNNNDKNNVNDNNVNDNDVNDVNDVNDVNDVNDVNDVNDVNDVND 1095
Db 749 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 808
Qy 1096 -----DTIIN-----NCLNSLDISSVYDTEILNNILSKYAEK 1131
Db 809 TKSTVDEBVKTDVANNKKKDLIEDKNNANNVNDVTPKPGDDNNNNNNNNNN--NKGE 863
Qy 1132 DNVIKK-----YINEDIKNNS-LEEDIKTAOSIYERKV-----LTKYLL 1171
Db 864 DNKEKEDNTVAEKPAKALYVFKKKKNNSPLEYMERQVSLNKLTVENFPITTEKMCQ 923
Qy 1172 LFKKNDVT-QINNETSDLRKDLVNGHICNNPPDOGHFYA-----YSRLKDI 1218
Db 924 IMESRLNTBEITQVNVQIDKALEH-----DMSWYADLCQTLKMSPNEMKKKTS 976
Qy 1219 INLIMRQIWCESBENRLLYOFLVVEYONKSANSV-----LNVSSNNNDIIL 1266
Db 977 FEIALAKTIQOEYENLPSTFESTMEKLSDENEEELSFEQOKKRLIGIVLIGI 1034
Qy 1267 LNKCLVODNIKNSMDHN 1283
Db 1035 FQROIIVISIVISIAHD 1051

```

```

Query Match 11.6%; Score 795.5; DB 5; Length 1192;
Best Local Similarity 25.5%; Pred. No. 1.2e-24;
Matches 295; Conservative 163; Mismatches 367; Indels 332; Gaps 48;
Qy 327 YSSRVKFKKNSCTINEEDTNTERTISILDSKSGEMNASSIENVVYIKSNHLN--NNNN 384
Db 27 FRNSIKNNENLIFPANNKD-----NGMEQCRMSNKKFPDMMNNRN 68
Qy 385 KINRGKINDKIERNNLIKNSFKPREGFTSTFGKYSLNDIDIKIKKKKKGLINYKSTL 444

```

```

RESULT 40
Q81C24 PRELIMINARY; PRT: 1437 AA.
ID Q81C24;
AC Q81C24;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Hypothetical protein.
GN Mal6P1.23.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN (1)
RP SEQUENCE FROM N.A.
RA Cherevach I., Davis P., Goodhead I., Stevens K., Mungall K.,
RA Berriman M., Patil A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrell B.,
RL Submitted (SEP-2002) to the EMBL/Genbank/DBJ databases.
DR EMBL; AL844505; CAD50294.1; -.
KW Hypothetical protein.
SQ
SEQUENCE 1437 AA; 165399 MW; FOADA05528A741DA CRC64;
Query Match 11.6%; Score 795; DB 5; Length 1437;
Best Local Similarity 24.8%; Pred. No. 1,5e-24;
Matches 311; Conservative 195; Mismatches 405; Indels 342; Gaps 56;
QY 219 LNIIDLKIDINKTSLGKIAFIDLAGSERGADTVSONKQOTDQ-ANINSLAL----- 270
DB 308 MNFDILD--NNAVKVAFCEFTDYENK-----NKNCKMKDQENEFNNSMTSYFSNNGK 360
QY 271 -----KECIRAMDSKNIIPRDSLTLYARDIFPGKSKSIMIANISFTISCEQTATLT 325
DB 361 ILEEKSNIIYHSNNNNYNNNNNNQSTHFEALNTYKT-----CELPVILL 408
QY 326 RYSSRVKFKNKSTCINEEDPTNTERISILDSKSEMAASIEYVIKSNHLSNNNNK 385
DB 409 T-SEVNDNNKKCKKFTLPTISFKDIA-----GIMNNSNNSCMGLSKYVLNNSNTS 462
QY 386 I-----NRKIND--KIERNNILKNKSF-----KPREGF 413
DB 463 IFDVTNLSTLFDMNDSKNNLTFNSCNTLEHLSFDELKSNNNNDPFISNEKSDGK 522
QY 414 TSTFKYSGSLNDIDIK--KAKKGLINYKSTLYNDNTINK-----HNNNNNNNDN 464
DB 523 NLKFSQFLSSNSSNGVRGANNNDLSIVMCGLDITNDN--NKEEDNPMDDNNNNNNND 580
QY 465 NDNNNDNNNNNN-----NDSSMWNMMIMINNNINNNINNNINNNNNNNNN 510
DB 581 NNNNNNNNNNNFLAKESKKEAKTEGTNSNNIOSNEENTPKPMNKSCKKAKKQALANNI 640
QY 511 NNNSHNNHLPQNYAFPTSDPSL--DMMCHLNNDKSIPLAKKGLRDNIKLR---N 564
DB 641 RNNSINRNLKGVNF-----SEVSLNNNEKSEVOEKKKNNKKNCKEKOQEBN 695
QY 565 RSSCCNINAKKAN-----LHLARHSVSKLTMFSYDPOKNDPTFFSKN 609
DB 696 KISNEKHLNKKKKKAGDEDEVTITDINVLKEKSKNOKIKNNENQHNKNNIGQNN 755
QY 610 INKMDNTPKDILYESRN--VSNMGNVL-----LGLNKTHHDISTFKDENHNDKIN 660
DB 756 INNNNNNN-----NSKNGRNSKKGQDINNQQTYAGNNKSEIKNGEKAKSNHNN 809
QY 661 NGVINIINN-----SNVNSINNSMNSINNSMNSISYKSNYSNQSISDVQIR 710
DB 810 DVLFNKKNNCSYQWKKKFTDVNVLNNHISDVNHAK--SSISVQSKNNENNN----- 861
QY 711 YVNEHDTSKKNDNIFFDALISCDNNYFVITNNNNNNNNNNNNNNNNNNNNNNNNRDGTN 770
DB 862 --KEKDNKKKNNNN-----NN-----NNNNNNNNNNNNNNNNNNNNNNNN 900
QY 771 NSMKLYAVNSHLFQPDNNKNTSNIQNI-----NTNKGNDGNNVYSMNFCHVNLNDK 823

```

```

DB 901 NILNNISNKENKYL--TNQKNNGLVGMSTGIISTHNSNNRNGKKY--MANNYVNSH-- 955
QY 824 NYLIDLNNKQKQK-----NIHGDNNIIONRDPFEKKKKTNNYNNNNIYIVANNMGN 878
DB 956 -----YANKENKNNINRIVNISNNN--NINNIEEDSK-----NNSNDILTNLNDTNIH 1003
QY 879 SPRAKYLCSHTSIDNNKNNEMKNNEMKNNKNNHISKNN----- 921
DB 1004 QILMHQQLDK--DMMKNNKDDNNIARNVLTNKKNNKNNNNNIGRAITTAVGTSF 1060
QY 922 -NSSSSSSNNNIYNNINDDTFQNDYCHNDFTTIRKNNNTINSNIYONDDIITYINS 980
DB 1061 INNSNIGTEMKNFVNDIIGD-----IHEKGRDN--NSIFLETDN-----YNN 1100
QY 981 LNDVMSNTLHFKEKTYPTLSTNEDIYNKEMSK-----HRLDQDKYDQNDNNNV 1034
DB 1101 LNKLI-----MOENENFNKINRSVKNILDYITMENKNNNNNNNNNNNN 1145
QY 1035 NNNKNVYDNNVNDNNVNDNNKNNVNDNNVNDDDVDYFHHIKNFNNNEYLSYFOKN 1094
DB 1146 NNNNNNSISPDNALFNNNNYMMGHEVLYTNNTMNGKIVDFDMRMNNS--YNNK- 1200
QY 1095 VDTIINNCL-----NSLDISSMYD--DTKEILNNILSKYKAEKDVYIKYINEDIKNM 1146
DB 1201 -----NDCMFLFKONTLSIGLVNLCNEKMMINESLNNIFKGDNNI-----NNM 1245
QY 1147 SL-----EEDKTA--QSIYERKVLTKLLLFKKNV--DTQINNE--TSDLRKD 1191
DB 1246 SLGINSBQLTKEDFPNCAGNNNVENKSK-----EYVISPNGINDSCDYTNMLNT 1296
QY 1192 LVMCHICNNPDDQFHF-----YAYSRLKDIINLIMLROIWCESENLRLL-- 1237
DB 1297 FLSCNSINENFDANETNNKINGFGENHNSYNNVGNISITDI--NSYNNSEHFPULFG 1354
QY 1238 -YQFL-----VVEYOKNSANSVLLNVSNNNGDIIILNKKLVQDNITKSMDHN 1283
DB 1355 NYNFFGNNCIHCCKSKYEIKR--LTQIKLMKEEILKYQULMSGINEKEFEKN 1406

```

Search completed: October 2, 2003, 16:20:40
Job time: 184 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:28:21 ; Search time 131 Seconds
(without alignments)
2537.189 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 1288

Sequence: 1 MNSKIKVVRKRPLSELEKK.....KRLVQDNKSMDDNNHHKK 1288

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 830525 seqs, 258052604 residues

Word size : 0

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 1000 summaries

Database :

SPTREMBL_23:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_protist:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvlnus:*
16: sp_bacteriophage:*
17: sp_archaeal:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1288	100.0	1351	5	0814Y0
2	19	1.5	1723	5	081224
3	18	1.4	348	5	08MN71
4	18	1.4	439	5	08T832
5	18	1.4	699	5	08MN10
6	18	1.4	815	5	08T686
7	18	1.4	1518	5	08T106
8	18	1.4	1887	5	08SS58
9	18	1.4	2994	5	0952G5
10	18	1.4	3177	5	09NA13
11	18	1.4	3619	5	09U573
12	17	1.3	104	5	08MN05
13	17	1.3	172	5	08MP24
14	17	1.3	204	5	08ST26
15	17	1.3	279	5	08T1B5
16	17	1.3	284	5	08ST23

17	17	1.3	288	5	09XY02	09xy02 dugesia_jap
18	17	1.3	293	5	08MX75	08mx75 cryptospori
19	17	1.3	300	5	08MN2	08mn2 dictyostei
20	17	1.3	371	5	08ICP1	08icp1 plasmodium
21	17	1.3	384	5	08IHR1	08ihr1 plasmodium
22	17	1.3	391	5	025768	025768 plasmodium
23	17	1.3	419	5	025774	025774 plasmodium
24	17	1.3	426	5	08MNF6	08mnf6 dictyostei
25	17	1.3	440	5	08T834	08t834 dictyostei
26	17	1.3	445	5	08T4W5	08t4w5 plasmodium
27	17	1.3	455	5	08MXW8	08mxw8 dugesia_jap
28	17	1.3	465	5	08T1U6	08t1u6 plasmodium
29	17	1.3	496	5	08SSX7	08ssx7 dictyostei
30	17	1.3	498	5	08MP37	08mp37 dictyostei
31	17	1.3	511	5	08SS25	08ss25 dictyostei
32	17	1.3	537	5	08T1K7	08t1k7 dictyostei
33	17	1.3	560	5	061085	061085 dictyostei
34	17	1.3	587	5	08MNG3	08mng3 dictyostei
35	17	1.3	597	5	08MYG9	08myg9 dictyostei
36	17	1.3	608	5	094474	094474 dictyostei
37	17	1.3	614	5	08T1X4	08t1x4 dictyostei
38	17	1.3	616	5	08MNJ9	08mnj9 dictyostei
39	17	1.3	628	5	08S5Y0	08s5y0 dictyostei
40	17	1.3	634	5	08MNI9	08mni9 dictyostei
41	17	1.3	635	5	08MYH5	08myh5 dictyostei
42	17	1.3	638	5	08T2T4	08t2t4 dictyostei
43	17	1.3	647	5	08MMY6	08mmv6 dictyostei
44	17	1.3	657	5	08MMU1	08mmu1 dictyostei
45	17	1.3	662	5	08T1P5	08t1p5 dictyostei
46	17	1.3	663	5	08MN61	08mn61 dictyostei
47	17	1.3	682	5	09GPR8	09gpr8 dictyostei
48	17	1.3	683	5	08MXN1	08mxn1 dictyostei
49	17	1.3	723	5	08T158	08t158 dictyostei
50	17	1.3	726	5	08MXL5	08mxl5 dictyostei
51	17	1.3	728	5	09G1C7	09g1c7 leishmania
52	17	1.3	734	5	08T807	08t807 dictyostei
53	17	1.3	740	5	08T138	08t138 dictyostei
54	17	1.3	749	5	002602	002602 plasmodium
55	17	1.3	754	5	08MMT9	08mmt9 dictyostei
56	17	1.3	756	5	08MYD6	08myd6 dictyostei
57	17	1.3	759	5	09U478	09u478 dictyostei
58	17	1.3	762	5	08MNN8	08mnn8 dictyostei
59	17	1.3	791	5	08T2U7	08t2u7 dictyostei
60	17	1.3	792	5	08I535	08i535 plasmodium
61	17	1.3	806	5	08T2A3	08t2a3 dictyostei
62	17	1.3	821	5	08MNC3	08mnc3 dictyostei
63	17	1.3	823	5	08MYH7	08myh7 dictyostei
64	17	1.3	827	5	08MP44	08mp44 dictyostei
65	17	1.3	828	5	08MN35	08mn35 dictyostei
66	17	1.3	833	5	08SSX5	08ssx5 dictyostei
67	17	1.3	863	5	08T1K7	08t1k7 plasmodium
68	17	1.3	868	5	08MNP7	08mnp7 dictyostei
69	17	1.3	887	5	08T1U0	08t1u0 dictyostei
70	17	1.3	887	5	08I8F4	08i8f4 dictyostei
71	17	1.3	917	5	08MMV3	08mmv3 dictyostei
72	17	1.3	929	5	09BLX2	09blx2 dictyostei
73	17	1.3	930	5	08T2J1	08t2j1 dictyostei
74	17	1.3	931	5	08T2K1	08t2k1 dictyostei
75	17	1.3	942	5	096611	096611 dictyostei
76	17	1.3	946	5	08IC68	08ic68 plasmodium
77	17	1.3	959	5	08T1P2	08t1p2 dictyostei
78	17	1.3	980	5	08MYI3	08myi3 dictyostei
79	17	1.3	1041	5	08MMT7	08mmt7 dictyostei
80	17	1.3	1057	5	08T133	08t133 plasmodium
81	17	1.3	1060	5	08SSQ6	08ssq6 dictyostei
82	17	1.3	1125	5	08MNO5	08mno5 dictyostei
83	17	1.3	1130	5	08I0Z4	08i0z4 plasmodium
84	17	1.3	1139	5	023865	023865 dictyostei
85	17	1.3	1197	5	08MP87	08mp87 dictyostei
86	17	1.3	1224	5	08TAX9	08tax9 plasmodium
87	17	1.3	1231	5	09T140	09t140 dictyostei
88	17	1.3	1297	5	08T1C8	08t1c8 plasmodium
89	17	1.3	1309	5	08T2H9	08t2h9 dictyostei

90	17	1.3	1321	5	081AR1	081ar1 plasmodium	163	17	1.3	4550	5	077336	077336 plasmodium
91	17	1.3	1338	5	023927	023927 dictyosteli	164	17	1.3	4760	5	081E54	081E54 plasmodium
92	17	1.3	1363	5	081CN3	081cn3 plasmodium	165	17	1.3	5561	5	081B46	081B46 plasmodium
93	17	1.3	1376	5	08T235	08T235 dictyosteli	166	17	1.3	8591	5	081B94	081B94 plasmodium
94	17	1.3	1407	5	08T175	08T175 dictyosteli	167	17	1.3	10061	5	081321	081321 plasmodium
95	17	1.3	1422	5	08MMY3	08MMY3 dictyosteli	168	17	1.2	65	5	08MXQ3	08MXQ3 dictyosteli
96	17	1.3	1437	5	081CZ4	081CZ4 plasmodium	169	16	1.2	68	5	08MN60	08MN60 dictyosteli
97	17	1.3	1457	5	044011	044011 dictyosteli	170	16	1.2	79	5	08MNB2	08MNB2 dictyosteli
98	17	1.3	1469	5	081KP6	081kp6 plasmodium	171	16	1.2	86	5	08MNB9	08MNB9 dictyosteli
99	17	1.3	1477	5	081LJ1	081lj1 plasmodium	172	16	1.2	88	5	08MN24	08MN24 dictyosteli
100	17	1.3	1483	5	08T273	08T273 dictyosteli	173	16	1.2	104	5	08T225	08T225 dictyosteli
101	17	1.3	1485	5	08MNB3	08MNB3 dictyosteli	174	16	1.2	130	10	08S2B4	08S2B4 oryza sativ
102	17	1.3	1502	5	08IS10	08IS10 dictyosteli	175	16	1.2	135	17	08P574	08P574 methanosarc
103	17	1.3	1523	5	0813B1	0813b1 plasmodium	176	16	1.2	150	10	09FH22	09FH22 arabidopsis
104	17	1.3	1543	5	09GV71	09GV71 dictyosteli	177	16	1.2	158	5	08MNP2	08MNP2 dictyosteli
105	17	1.3	1546	5	09SP11	09SP11 dictyosteli	178	16	1.2	160	11	035058	035058 mus musculu
106	17	1.3	1548	5	09SP10	09SP10 dictyosteli	179	16	1.2	166	5	08MND0	08MND0 dictyosteli
107	17	1.3	1565	5	08T1M2	08T1M2 dictyosteli	180	16	1.2	185	5	08MNS7	08MNS7 dictyosteli
108	17	1.3	1570	5	09U0H8	09U0H8 dictyosteli	181	16	1.2	187	5	08T279	08T279 dictyosteli
109	17	1.3	1631	5	0813H3	0813h3 plasmodium	182	16	1.2	188	10	064868	064868 arabidopsis
110	17	1.3	1670	5	023901	023901 dictyosteli	183	16	1.2	198	5	08MN88	08MN88 dictyosteli
111	17	1.3	1672	5	08T2M6	08T2M6 dictyosteli	184	16	1.2	212	5	08T1D8	08T1D8 dictyosteli
112	17	1.3	1709	5	09SPH5	09SPH5 dictyosteli	185	16	1.2	229	5	08MP31	08MP31 dictyosteli
113	17	1.3	1721	5	08SSQ0	08SSQ0 dictyosteli	186	16	1.2	238	5	08T2C1	08T2C1 dictyosteli
114	17	1.3	1722	5	0811I8	0811I8 plasmodium	187	16	1.2	252	5	08T227	08T227 dictyosteli
115	17	1.3	1728	5	08SSU4	08SSU4 dictyosteli	188	16	1.2	259	5	096550	096550 dictyosteli
116	17	1.3	1734	5	08MNM2	08MNM2 dictyosteli	189	16	1.2	261	5	08T668	08T668 dictyosteli
117	17	1.3	1736	5	09SPH7	09SPH7 dictyosteli	190	16	1.2	266	5	08T662	08T662 dictyosteli
118	17	1.3	1758	5	081CB2	081cb2 plasmodium	191	16	1.2	275	5	08SSQ4	08SSQ4 dictyosteli
119	17	1.3	1785	5	0815Z0	0815z0 plasmodium	192	16	1.2	282	5	08MXL8	08MXL8 dictyosteli
120	17	1.3	1789	5	08T2E3	08T2E3 dictyosteli	193	16	1.2	301	5	08T1N1	08T1N1 dictyosteli
121	17	1.3	1800	5	0817P5	0817P5 dictyosteli	194	16	1.2	302	5	081LP7	081LP7 plasmodium
122	17	1.3	1812	5	081E31	081e31 plasmodium	195	16	1.2	305	5	08MN18	08MN18 dictyosteli
123	17	1.3	1844	5	081E31	081e31 plasmodium	196	16	1.2	308	5	025778	025778 plasmodium
124	17	1.3	1880	5	08MP27	08MP27 dictyosteli	197	16	1.2	312	5	08MN18	08MN18 dictyosteli
125	17	1.3	1894	5	081S18	081s18 plasmodium	198	16	1.2	312	5	08MNA4	08MNA4 dictyosteli
126	17	1.3	1894	5	0813S3	0813s3 plasmodium	199	16	1.2	316	5	08MNF2	08MNF2 dictyosteli
127	17	1.3	1918	5	08SSW1	08SSW1 dictyosteli	200	16	1.2	317	5	097336	097336 plasmodium
128	17	1.3	1942	5	08MYF9	08MYF9 dictyosteli	201	16	1.2	322	5	08T1V7	08T1V7 dictyosteli
129	17	1.3	1969	5	015763	015763 dictyosteli	202	16	1.2	323	5	081CG7	081CG7 plasmodium
130	17	1.3	2015	5	09U5Y1	09U5Y1 dictyosteli	203	16	1.2	328	10	024463	024463 zea mays (m
131	17	1.3	2016	5	081LY1	081ly1 plasmodium	204	16	1.2	340	5	08T212	08T212 dictyosteli
132	17	1.3	2084	5	081LO6	081lo6 plasmodium	205	16	1.2	341	5	08T1C1	08T1C1 dictyosteli
133	17	1.3	2184	5	081LO6	081lo6 plasmodium	206	16	1.2	349	5	08MNB5	08MNB5 dictyosteli
134	17	1.3	2230	5	08MNM0	08MNM0 dictyosteli	207	16	1.2	351	5	096548	096548 dictyosteli
135	17	1.3	2235	5	081B09	081b09 plasmodium	208	16	1.2	357	5	081281	081281 plasmodium
136	17	1.3	2273	5	08MNB3	08MNB3 dictyosteli	209	16	1.2	369	5	08T1D9	08T1D9 dictyosteli
137	17	1.3	2344	5	08SSV9	08SSV9 dictyosteli	210	16	1.2	372	5	081UV8	081UV8 plasmodium
138	17	1.3	2359	5	081297	081297 plasmodium	211	16	1.2	373	8	035905	035905 saccharomyc
139	17	1.3	2388	5	08MYG5	08MYG5 dictyosteli	212	16	1.2	374	10	09SMX7	09SMX7 arabidopsis
140	17	1.3	2569	5	081BGC	081bgc plasmodium	213	16	1.2	375	5	08T1K2	08T1K2 dictyosteli
141	17	1.3	2577	5	081RAM1	081ram1 plasmodium	214	16	1.2	398	3	09Y764	09Y764 candida alb
142	17	1.3	2625	5	08MMZ9	08MMZ9 dictyosteli	215	16	1.2	398	3	09Y764	09Y764 candida alb
143	17	1.3	2722	5	08MP57	08MP57 dictyosteli	216	16	1.2	399	5	08MNB4	08MNB4 dictyosteli
144	17	1.3	2752	5	081CT8	081ct8 plasmodium	217	16	1.2	401	5	08T229	08T229 dictyosteli
145	17	1.3	2763	5	081I48	081i48 plasmodium	218	16	1.2	405	5	08MNA0	08MNA0 dictyosteli
146	17	1.3	2763	5	0813X5	0813x5 plasmodium	219	16	1.2	406	5	08MND0	08MND0 dictyosteli
147	17	1.3	2792	5	0815S2	0815S2 plasmodium	220	16	1.2	407	5	08T831	08T831 dictyosteli
148	17	1.3	2874	5	081CX0	081cx0 plasmodium	221	16	1.2	414	5	08T235	08T235 dictyosteli
149	17	1.3	2964	5	0817W7	0817W7 dictyosteli	222	16	1.2	417	17	08P5G9	08P5G9 methanosarc
150	17	1.3	3178	5	0812P8	0812P8 plasmodium	223	16	1.2	421	5	08MTX3	08MTX3 thermozon
151	17	1.3	3193	5	081590	081590 plasmodium	224	16	1.2	423	5	08MNP6	08MNP6 dictyosteli
152	17	1.3	3207	5	081H00	081h00 plasmodium	225	16	1.2	423	5	0967M5	0967M5 dictyosteli
153	17	1.3	3265	5	081D63	081d63 plasmodium	226	16	1.2	425	5	015755	015755 dictyosteli
154	17	1.3	3268	5	081C30	081c30 plasmodium	227	16	1.2	425	5	08T1K4	08T1K4 dictyosteli
155	17	1.3	3334	5	081ICS9	081ics9 plasmodium	228	16	1.2	425	5	08T828	08T828 neocallimast
156	17	1.3	3371	5	081I1W4	081i1w4 plasmodium	229	16	1.2	426	3	012646	012646 neocallimast
157	17	1.3	3417	5	08T1I6	08T1I6 dictyosteli	230	16	1.2	428	5	08T2C5	08T2C5 dictyosteli
158	17	1.3	3432	5	095BPH9	095bph9 dictyosteli	231	16	1.2	428	5	08T2C5	08T2C5 dictyosteli
159	17	1.3	3933	5	097239	097239 plasmodium	232	16	1.2	432	5	081R58	081R58 dictyosteli
160	17	1.3	4138	5	081IY3	081iy3 plasmodium	233	16	1.2	437	5	08SSX8	08SSX8 dictyosteli
161	17	1.3	4202	5	0812S8	0812s8 plasmodium	234	16	1.2	437	5	08T199	08T199 dictyosteli
162	17	1.3	4466	5	081LS4	081ls4 plasmodium	235	16	1.2	442	5	08SSQ9	08SSQ9 dictyosteli

236	16	1.2	450	5	Q8MP78	Q8mp78 dictyostell	309	16	1.2	700	5	Q8T616	Q8t616 dictyostell
237	16	1.2	457	5	Q8T283	Q8t283 dictyostell	310	16	1.2	705	5	Q8T182	Q8t182 dictyostell
238	16	1.2	459	5	Q8T562	Q8t562 plasmodium	311	16	1.2	714	5	Q8MN30	Q8mn30 dictyostell
239	16	1.2	463	5	Q8MMR7	Q8mmr7 dictyostell	312	16	1.2	714	5	Q8T1U9	Q8t1u9 plasmodium
240	16	1.2	463	5	Q8T1R4	Q8t1r4 plasmodium	313	16	1.2	715	5	Q8TKY0	Q8tky0 plasmodium
241	16	1.2	474	5	Q8SR35	Q8sr35 encaphalito	314	16	1.2	718	5	Q8XYP6	Q8xyp6 dictyostell
242	16	1.2	476	5	Q8T1Y3	Q8t1y3 dictyostell	315	16	1.2	720	3	Q8P3M3	Q8p3m3 neurospora
243	16	1.2	490	5	Q8T2J2	Q8t2j2 dictyostell	316	16	1.2	721	5	Q8T218	Q8t218 dictyostell
244	16	1.2	490	5	Q8T2R4	Q8t2r4 dictyostell	317	16	1.2	722	5	Q8T232	Q8t232 dictyostell
245	16	1.2	498	5	Q8T3H4	Q8t3h4 dictyostell	318	16	1.2	726	2	Q8AJB3	Q8ajb3 ruminococcu
246	16	1.2	508	5	Q8IDS4	Q8ids4 plasmodium	319	16	1.2	733	5	Q8T2R6	Q8t2r6 dictyostell
247	16	1.2	513	5	Q8T6C4	Q8t6c4 dictyostell	319	16	1.2	743	5	Q8NGX0	Q8ngx0 dictyostell
248	16	1.2	520	5	Q8T1J4	Q8t1j4 dictyostell	320	16	1.2	747	5	Q8MMQ3	Q8mmq3 dictyostell
249	16	1.2	520	5	Q8ISN1	Q8isn1 plasmodium	321	16	1.2	757	5	Q8GSG6	Q8gsg6 dictyostell
250	16	1.2	522	5	Q8I6Y6	Q8i6y6 dictyostell	322	16	1.2	768	5	Q8NAX6	Q8nax6 dictyostell
251	16	1.2	527	5	Q8T1V9	Q8t1v9 dictyostell	323	16	1.2	772	5	Q8MN14	Q8mn14 dictyostell
252	16	1.2	530	5	Q8T2A0	Q8t2a0 dictyostell	324	16	1.2	779	5	Q8BN14	Q8bn14 dictyostell
253	16	1.2	534	5	Q4J9B9	Q4j9b9 dictyostell	325	16	1.2	782	5	Q8IBN6	Q8ibn6 plasmodium
254	16	1.2	535	5	Q8T2U6	Q8t2u6 dictyostell	326	16	1.2	782	5	Q8MMV7	Q8mmv7 dictyostell
255	16	1.2	538	5	Q8SSY9	Q8ssy9 dictyostell	327	16	1.2	786	5	Q8IDS3	Q8ids3 plasmodium
256	16	1.2	540	5	Q76771	Q76771 dictyostell	328	16	1.2	791	5	Q00841	Q00841 dictyostell
257	16	1.2	540	5	Q8T1Y8	Q8t1y8 dictyostell	329	16	1.2	798	5	Q8T200	Q8t200 dictyostell
258	16	1.2	542	5	Q8T1R3	Q8t1r3 dictyostell	330	16	1.2	800	5	Q4J9B8	Q4j9b8 dictyostell
259	16	1.2	547	5	Q8T1D9	Q8t1d9 dictyostell	331	16	1.2	802	5	Q8T1R5	Q8t1r5 plasmodium
260	16	1.2	548	5	Q8T1H3	Q8t1h3 plasmodium	332	16	1.2	803	5	Q8T2J0	Q8t2j0 dictyostell
261	16	1.2	548	5	Q8T1S2	Q8t1s2 dictyostell	334	16	1.2	807	5	Q8IB74	Q8ib74 plasmodium
262	16	1.2	559	5	Q9GPT1	Q9gpt1 dictyostell	335	16	1.2	812	5	Q8MN39	Q8mn39 dictyostell
263	16	1.2	559	5	Q8T1R1	Q8t1r1 dictyostell	335	16	1.2	812	5	Q8ISD6	Q8isd6 plasmodium
264	16	1.2	565	5	Q15754	Q15754 dictyostell	337	16	1.2	818	5	Q8T5D6	Q8t5d6 dictyostell
265	16	1.2	566	5	Q2J310	Q2j310 dictyostell	338	16	1.2	822	5	Q8T5B3	Q8t5b3 plasmodium
266	16	1.2	566	5	Q8T285	Q8t285 dictyostell	339	16	1.2	823	5	Q8MNG7	Q8mng7 dictyostell
267	16	1.2	566	5	Q8MND0	Q8mnd0 dictyostell	340	16	1.2	824	5	Q00911	Q00911 dictyostell
268	16	1.2	569	2	Q9AJB2	Q9ajb2 ruminococcu	341	16	1.2	827	5	Q8T1E2	Q8t1e2 plasmodium
269	16	1.2	571	5	Q8T2A7	Q8t2a7 dictyostell	342	16	1.2	831	5	Q15756	Q15756 dictyostell
270	16	1.2	572	5	Q8MNX9	Q8mnx9 dictyostell	343	16	1.2	832	5	Q8T2K2	Q8t2k2 dictyostell
271	16	1.2	575	5	Q7J334	Q7j334 plasmodium	343	16	1.2	837	5	Q8MTE9	Q8mte9 dictyostell
272	16	1.2	577	5	Q8MNX8	Q8mnx8 dictyostell	344	16	1.2	851	5	Q94488	Q94488 dictyostell
273	16	1.2	578	5	Q8ICM3	Q8icm3 plasmodium	345	16	1.2	852	5	Q8SSS7	Q8sss7 dictyostell
274	16	1.2	579	5	Q6O950	Q6o950 dictyostell	346	16	1.2	853	5	Q8T4X1	Q8t4x1 dictyostell
275	16	1.2	585	5	Q8T1O8	Q8t1o8 plasmodium	347	16	1.2	855	5	Q8SSV6	Q8ssv6 dictyostell
276	16	1.2	586	5	Q8T2J6	Q8t2j6 dictyostell	348	16	1.2	860	5	Q8TK95	Q8tk95 plasmodium
277	16	1.2	595	5	Q8T2Q4	Q8t2q4 dictyostell	349	16	1.2	865	5	Q8TKP3	Q8tkp3 plasmodium
278	16	1.2	605	5	Q8SSZ9	Q8ssz9 dictyostell	350	16	1.2	872	5	P90523	P90523 dictyostell
279	16	1.2	609	5	Q9NGM8	Q9ngm8 dictyostell	351	16	1.2	876	5	Q8SSS4	Q8sss4 dictyostell
280	16	1.2	616	5	Q8T1D3	Q8t1d3 dictyostell	352	16	1.2	877	5	Q2J383	Q2j383 dictyostell
281	16	1.2	619	5	Q8MNB6	Q8mb6 dictyostell	353	16	1.2	882	5	Q8T1I5	Q8t1i5 plasmodium
282	16	1.2	620	5	Q8T2C0	Q8t2c0 dictyostell	354	16	1.2	885	5	Q8SSZ7	Q8ssz7 dictyostell
283	16	1.2	628	5	Q9VSB3	Q9vbs3 drosophila	355	16	1.2	893	5	Q8T7Y3	Q8t7y3 dictyostell
284	16	1.2	628	5	Q8ILB8	Q8ilb8 plasmodium	356	16	1.2	895	5	Q8T1B2	Q8t1b2 dictyostell
285	16	1.2	629	5	Q8T2A9	Q8t2a9 dictyostell	357	16	1.2	898	5	Q8T1G7	Q8t1g7 dictyostell
286	16	1.2	630	5	Q8T1B8	Q8t1b8 plasmodium	358	16	1.2	901	5	Q8T806	Q8t806 dictyostell
287	16	1.2	637	5	Q8MND3	Q8mnd3 dictyostell	359	16	1.2	911	5	Q8MXP0	Q8mxp0 dictyostell
288	16	1.2	637	5	Q8T1B2	Q8t1b2 plasmodium	360	16	1.2	919	5	Q8T1J2	Q8t1j2 plasmodium
289	16	1.2	637	5	Q8T1I24	Q8t1i24 plasmodium	361	16	1.2	934	5	Q8SSV2	Q8ssv2 dictyostell
290	16	1.2	649	5	Q9VW88	Q9vw88 drosophila	362	16	1.2	937	5	Q8MND6	Q8mnd6 dictyostell
291	16	1.2	655	5	Q8I4R6	Q8i4r6 plasmodium	363	16	1.2	947	5	Q15739	Q15739 dictyostell
292	16	1.2	665	5	Q8ICP6	Q8icp6 plasmodium	364	16	1.2	952	5	Q8MMW4	Q8mmw4 dictyostell
293	16	1.2	666	5	Q8T1R0	Q8t1r0 dictyostell	365	16	1.2	955	5	Q8T1D3	Q8t1d3 dictyostell
294	16	1.2	660	5	Q94485	Q94485 dictyostell	366	16	1.2	964	5	Q8T856	Q8t856 dictyostell
295	16	1.2	660	5	Q00885	Q00885 dictyostell	367	16	1.2	969	5	Q9XZ11	Q9xz11 drosophila
296	16	1.2	665	5	Q8T208	Q8t208 dictyostell	368	16	1.2	970	5	Q8T1A3	Q8t1a3 dictyostell
297	16	1.2	665	5	Q8I3I8	Q8i3i8 plasmodium	369	16	1.2	986	5	Q8MMQ8	Q8mmq8 dictyostell
298	16	1.2	666	5	Q8IM66	Q8im66 plasmodium	370	16	1.2	990	5	Q8I437	Q8i437 plasmodium
299	16	1.2	667	5	Q9UOK7	Q9uok7 plasmodium	371	16	1.2	992	5	Q8T1O4	Q8t1o4 plasmodium
300	16	1.2	680	5	Q8T1I8	Q8t1i8 plasmodium	372	16	1.2	995	5	Q8T1J91	Q8t1j91 plasmodium
301	16	1.2	684	5	Q8I3M7	Q8i3m7 plasmodium	373	16	1.2	1004	5	Q8MP26	Q8mp26 dictyostell
302	16	1.2	685	5	Q8ID39	Q8id39 plasmodium	374	16	1.2	1017	5	Q8MMN2	Q8mmn2 dictyostell
303	16	1.2	686	5	Q8MNU2	Q8mnu2 dictyostell	375	16	1.2	1022	5	Q8MMY9	Q8mmy9 dictyostell
304	16	1.2	686	5	Q96Z45	Q96z45 plasmodium	376	16	1.2	1022	5	Q8T1E1	Q8t1e1 plasmodium
305	16	1.2	687	5	Q8T527	Q8t527 plasmodium	377	16	1.2	1024	5	Q8MMW3	Q8mmw3 dictyostell
306	16	1.2	687	5	Q8MN01	Q8mn01 dictyostell	378	16	1.2	1032	5	Q8I524	Q8i524 plasmodium
307	16	1.2	692	5	Q8MNX4	Q8mnx4 dictyostell	379	16	1.2	1033	5	Q8MND0	Q8mnd0 dictyostell
308	16	1.2	694	5	Q8T2F2	Q8t2f2 dictyostell	380	16	1.2	1036	5	Q8I355	Q8i355 plasmodium
							381	16	1.2	1037	5	Q8IS18	Q8is18 dictyostell

382	16	1.2	1043	5	OBMB7	OBmb7 dictyosteli	455	16	1.2	1364	5	OBMN00	OBmn00 dictyosteli
383	16	1.2	1050	5	OB106	OB106 plasmodium	456	16	1.2	1368	5	O9V6J0	O9v6j0 drosophila
384	16	1.2	1064	5	Q25773	Q25773 plasmodium	457	16	1.2	1373	5	OB13A8	OB13a8 plasmodium
385	16	1.2	1075	3	Q12221	Q12221 saccharomyc	458	16	1.2	1374	5	OB1KR9	OB1kr9 plasmodium
386	16	1.2	1080	5	OB1T2	OB1t2 dictyosteli	459	16	1.2	1377	5	OB1S56	OB1s56 plasmodium
387	16	1.2	1090	5	OBMMY2	OBmmy2 dictyosteli	460	16	1.2	1380	5	OBMN90	OBmn90 dictyosteli
388	16	1.2	1099	5	O9U9K8	O9u9k8 dictyosteli	461	16	1.2	1390	5	OB1G65	OB1g65 dictyosteli
389	16	1.2	1104	5	OBMMM1	OBmm1 dictyosteli	462	16	1.2	1390	5	O770J3	O770j3 dictyosteli
390	16	1.2	1104	5	OB1JG4	OB1jg4 plasmodium	463	16	1.2	1393	5	OB1G60	OB1g60 dictyosteli
391	16	1.2	1108	5	OB1J25	OB1j25 dictyosteli	464	16	1.2	1394	5	OB1IG6	OB1ig6 plasmodium
392	16	1.2	1112	5	OBMM57	OBmm57 dictyosteli	465	16	1.2	1394	5	OB1DL6	OB1dl6 plasmodium
393	16	1.2	1118	5	OB1I14	OB1i14 dictyosteli	466	16	1.2	1402	5	O966F8	O966f8 dictyosteli
394	16	1.2	1123	5	OB1811	OB1811 dictyosteli	467	16	1.2	1404	5	OBMP67	OBmp67 dictyosteli
395	16	1.2	1126	5	OB1278	OB1278 dictyosteli	468	16	1.2	1405	5	OBMMN0	OBmmn0 dictyosteli
396	16	1.2	1140	5	OB1T0	OB1t0 dictyosteli	469	16	1.2	1419	5	OB1323	OB1323 plasmodium
397	16	1.2	1145	5	OB1IS6	OB1is6 plasmodium	470	16	1.2	1431	5	OBMM11	OBmm11 dictyosteli
398	16	1.2	1147	5	O95PH8	O95ph8 dictyosteli	471	16	1.2	1432	5	OB19W4	OB19w4 dictyosteli
399	16	1.2	1149	5	OB1LP5	OB1lp5 plasmodium	472	16	1.2	1434	5	OB1J13	OB1j13 plasmodium
400	16	1.2	1152	5	OB1216	OB1216 dictyosteli	473	16	1.2	1434	5	OB1J77	OB1j77 plasmodium
401	16	1.2	1156	5	OB1474	OB1474 plasmodium	474	16	1.2	1447	5	OB1S20	OB1s20 dictyosteli
402	16	1.2	1157	5	O00895	O00895 plasmodium	475	16	1.2	1461	5	OBST04	OBst04 dictyosteli
403	16	1.2	1165	5	OB1B76	OB1b76 plasmodium	476	16	1.2	1464	5	OB1TF6	OB1tf6 plasmodium
404	16	1.2	1166	5	OB1LR0	OB1lr0 plasmodium	477	16	1.2	1464	5	OB1HS3	OB1hs3 plasmodium
405	16	1.2	1172	5	OB1B93	OB1b93 plasmodium	478	16	1.2	1472	5	OB1TD7	OB1td7 dictyosteli
406	16	1.2	1176	5	OBS5V4	OBS5v4 dictyosteli	479	16	1.2	1476	5	OB1G76	OB1g76 dictyosteli
407	16	1.2	1185	5	OB1CL1	OB1cl1 plasmodium	480	16	1.2	1476	5	OBS766	OBS766 dictyosteli
408	16	1.2	1190	5	OB1JZ6	OB1jz6 plasmodium	481	16	1.2	1476	5	O965D3	O965d3 dictyosteli
409	16	1.2	1191	5	O9XYJ3	O9xyj3 dictyosteli	482	16	1.2	1478	5	OB1K03	OB1k03 plasmodium
410	16	1.2	1192	5	OB1E15	OB1e15 plasmodium	483	16	1.2	1484	5	OB1B67	OB1b67 plasmodium
411	16	1.2	1196	5	Q23866	Q23866 dictyosteli	484	16	1.2	1486	5	O9XZS0	O9xzS0 dictyosteli
412	16	1.2	1197	5	OB1391	OB1391 plasmodium	485	16	1.2	1488	5	OB1DP7	OB1dp7 plasmodium
413	16	1.2	1200	5	O97277	O97277 plasmodium	486	16	1.2	1492	5	OBS8U1	OBS8u1 dictyosteli
414	16	1.2	1203	5	OB1863	OB1863 dictyosteli	487	16	1.2	1509	5	OB1G68	OB1g68 dictyosteli
415	16	1.2	1204	5	OB1T34	OB1t34 dictyosteli	488	16	1.2	1520	5	OB1G87	OB1g87 dictyosteli
416	16	1.2	1212	5	O9U0L0	O9u0l0 plasmodium	489	16	1.2	1529	5	O9GQC2	O9gqc2 dictyosteli
417	16	1.2	1213	5	O95PH2	O95ph2 dictyosteli	490	16	1.2	1529	5	OB1S21	OB1s21 dictyosteli
418	16	1.2	1221	5	OB1BNO	OB1bno plasmodium	491	16	1.2	1551	5	OB1S13	OB1s13 dictyosteli
419	16	1.2	1223	5	OBST14	OBst14 dictyosteli	492	16	1.2	1552	5	OB13N4	OB13n4 plasmodium
420	16	1.2	1225	5	O15784	O15784 dictyosteli	493	16	1.2	1556	5	OBS725	OBS725 dictyosteli
421	16	1.2	1225	5	O95P12	O95p12 dictyosteli	494	16	1.2	1558	5	OB1LL5	OB1ll5 plasmodium
422	16	1.2	1236	5	OB1CJ8	OB1cj8 plasmodium	495	16	1.2	1559	5	OB1DC3	OB1dc3 plasmodium
423	16	1.2	1245	5	OB12R3	OB12r3 plasmodium	496	16	1.2	1560	5	O9GRX5	O9grx5 dictyosteli
424	16	1.2	1250	5	OB1611	OB1611 plasmodium	497	16	1.2	1561	5	O9U987	O9u987 dictyosteli
425	16	1.2	1252	5	OB1IG0	OB1ig0 plasmodium	498	16	1.2	1587	5	OB1C25	OB1c25 plasmodium
426	16	1.2	1256	5	O25770	O25770 plasmodium	499	16	1.2	1593	5	OB1T17	OB1t17 dictyosteli
427	16	1.2	1262	5	OBMM40	OBmm40 dictyosteli	500	16	1.2	1597	5	OB1JW6	OB1jw6 plasmodium
428	16	1.2	1271	5	O15749	O15749 dictyosteli	501	16	1.2	1604	5	OBMMW7	OBmmw7 dictyosteli
429	16	1.2	1287	5	O9NGS5	O9ngs5 dictyosteli	502	16	1.2	1606	5	OB1DH6	OB1dh6 plasmodium
430	16	1.2	1289	5	OB1BA2	OB1ba2 plasmodium	503	16	1.2	1612	5	OB1FNO	OB1fno plasmodium
431	16	1.2	1290	5	O9U6L1	O9u6l1 plasmodium	504	16	1.2	1618	5	OB1S13	OB1s13 plasmodium
432	16	1.2	1297	5	OB12U8	OB12u8 dictyosteli	505	16	1.2	1619	5	O77382	O77382 plasmodium
433	16	1.2	1298	5	O9U0T0	O9u0t0 plasmodium	506	16	1.2	1632	5	OB1KM7	OB1km7 plasmodium
434	16	1.2	1301	5	OBWSK5	OBwsks plasmodium	507	16	1.2	1641	5	OB1KZ0	OB1kz0 plasmodium
435	16	1.2	1301	5	OB1HO2	OB1hq2 plasmodium	508	16	1.2	1661	5	OB1E71	OB1e71 plasmodium
436	16	1.2	1310	5	OB1I26	OB1i26 dictyosteli	509	16	1.2	1662	5	OB1S69	OB1s69 plasmodium
437	16	1.2	1304	5	OB1KM2	OB1km2 plasmodium	510	16	1.2	1681	5	OB1J39	OB1j39 plasmodium
438	16	1.2	1312	5	OBMMV0	OBmmv0 dictyosteli	511	16	1.2	1697	5	OB1JAB	OB1jab plasmodium
439	16	1.2	1313	5	OB1TM7	OB1tm7 dictyosteli	512	16	1.2	1699	5	O95PH3	O95ph3 dictyosteli
440	16	1.2	1318	5	O95PH4	O95ph4 dictyosteli	513	16	1.2	1702	5	O9GTV7	O9gtv7 dictyosteli
441	16	1.2	1320	5	OBMMX3	OBmmx3 dictyosteli	514	16	1.2	1702	5	OB1IM14	OB1im14 plasmodium
442	16	1.2	1320	5	OB1LJ3	OB1lj3 plasmodium	515	16	1.2	1728	5	OB1S07	OB1s07 plasmodium
443	16	1.2	1324	5	OB12M1	OB12m1 dictyosteli	516	16	1.2	1754	5	OB1201	OB1201 plasmodium
444	16	1.2	1324	5	OB1F08	OB1f08 plasmodium	517	16	1.2	1770	5	OB13A3	OB13a3 plasmodium
445	16	1.2	1326	5	OB1B98	OB1b98 plasmodium	518	16	1.2	1774	5	OB1AN8	OB1an8 plasmodium
446	16	1.2	1331	5	OB1BF6	OB1bf6 plasmodium	519	16	1.2	1792	5	OB1D94	OB1d94 plasmodium
447	16	1.2	1336	5	OB1IFC8	OB1ifc8 plasmodium	520	16	1.2	1811	5	OB1UD3	OB1ud3 plasmodium
448	16	1.2	1337	5	OB1C23	OB1c23 plasmodium	521	16	1.2	1817	5	O96253	O96253 plasmodium
449	16	1.2	1338	5	OBMMZ3	OBmmz3 dictyosteli	522	16	1.2	1826	5	OB12V3	OB12v3 plasmodium
450	16	1.2	1340	5	OB1CF1	OB1cf1 plasmodium	523	16	1.2	1828	5	OB1IS4	OB1is4 plasmodium
451	16	1.2	1342	5	OB12I8	OB12i8 plasmodium	524	16	1.2	1831	5	OB1SFR	OB1sfr plasmodium
452	16	1.2	1348	5	OB1234	OB1234 dictyosteli	525	16	1.2	1833	5	OB1AZ5	OB1az5 plasmodium
453	16	1.2	1359	5	OBT6G6	OBT6g6 dictyosteli	526	16	1.2	1838	5	OB1TNS	OB1tns dictyosteli
454	16	1.2	1364	5	OB1223	OB1223 dictyosteli	527	16	1.2	1844	5	O96201	O96201 plasmodium

528	16	1.2	1855	5	Q9TX75	Q9c75 plasmodium	601	16	1.2	3569	5	Q8IBV8	Q8iv8 plasmodium
529	16	1.2	1855	5	Q9BHN0	Q9bhn0 plasmodium	602	16	1.2	3597	5	Q8ILR5	Q8ilr5 plasmodium
530	16	1.2	1868	5	Q8IAL9	Q8ial9 plasmodium	603	16	1.2	3620	5	Q968T6	Q968t6 plasmodium
531	16	1.2	1898	5	Q8ILA3	Q8ila3 plasmodium	604	16	1.2	3633	5	Q8IHL0	Q8ihl0 dictyostel
532	16	1.2	1912	5	Q9U0H1	Q9u0h1 plasmodium	605	16	1.2	3763	5	Q8RTA1	Q8rt2a1 dictyostel
533	16	1.2	1916	5	Q8IBCI	Q8ibci plasmodium	606	16	1.2	3787	5	Q8IIZ6	Q8iiz6 dictyostel
534	16	1.2	1922	5	Q8I2P4	Q8i2p4 plasmodium	607	16	1.2	3844	5	Q94648	Q94648 plasmodium
535	16	1.2	1923	5	Q8IBH8	Q8ibh8 plasmodium	608	16	1.2	3848	5	Q76737	Q76737 dictyostel
536	16	1.2	1929	5	Q8IHU2	Q8ihu2 dictyostel	609	16	1.2	3848	5	Q8IDR0	Q8idn0 plasmodium
537	16	1.2	1936	5	Q8ISA6	Q8isa6 plasmodium	610	16	1.2	4095	5	Q8ICN0	Q8icn0 plasmodium
538	16	1.2	1951	5	Q8ILY5	Q8ily5 plasmodium	611	16	1.2	4226	5	Q9N9H5	Q9n9h5 plasmodium
539	16	1.2	1988	5	Q8ITR8	Q8itr8 plasmodium	612	16	1.2	4226	5	Q8IHY1	Q8ihy1 plasmodium
540	16	1.2	1989	5	Q8IAU7	Q8iau7 plasmodium	613	16	1.2	4405	5	Q8ILZ2	Q8ilz2 plasmodium
541	16	1.2	1997	5	Q8ISL6	Q8isl6 plasmodium	614	16	1.2	4431	5	Q8IJ16	Q8ij16 plasmodium
542	16	1.2	2010	5	Q8ICX5	Q8icx5 plasmodium	615	16	1.2	4493	5	Q8MPA9	Q8mpa9 dictyostel
543	16	1.2	2062	5	Q9SPH6	Q9sph6 dictyostel	616	16	1.2	4494	5	Q8IS12	Q8is12 plasmodium
544	16	1.2	2062	5	Q8IBP4	Q8ibp4 plasmodium	617	16	1.2	4530	5	Q8I2K6	Q8i2k6 plasmodium
545	16	1.2	2133	5	Q9U9S7	Q9u9s7 dictyostel	618	16	1.2	4638	5	Q8IK96	Q8ik96 plasmodium
546	16	1.2	2130	5	Q8IBC6	Q8ibc6 plasmodium	619	16	1.2	4662	5	Q8ILR9	Q8ilr9 plasmodium
547	16	1.2	2147	5	Q8I1H3	Q8i1h3 plasmodium	620	16	1.2	4894	5	Q8IBJ2	Q8ibj2 plasmodium
548	16	1.2	2148	5	Q8I1N6	Q8i1n6 plasmodium	621	16	1.2	4891	5	Q77372	Q77372 plasmodium
549	16	1.2	2150	5	Q23863	Q23863 dictyostel	622	16	1.2	5251	5	Q8I1D4	Q8i1d4 plasmodium
550	16	1.2	2159	5	Q8ST00	Q8st00 dictyostel	623	16	1.2	5439	5	Q8IS86	Q8is86 plasmodium
551	16	1.2	2190	5	Q8IBL5	Q8ibl5 plasmodium	624	16	1.2	5561	5	Q8ILC9	Q8ilc9 plasmodium
552	16	1.2	2206	5	Q8IBU8	Q8ibu8 plasmodium	625	16	1.2	5910	5	Q8IAP1	Q8iap1 plasmodium
553	16	1.2	2221	5	Q8I2S9	Q8i2s9 plasmodium	626	16	1.2	6077	5	Q8IC86	Q8ic86 plasmodium
554	16	1.2	2224	5	Q8TIY5	Q8tiy5 dictyostel	627	16	1.2	6761	5	Q8IC77	Q8ic77 plasmodium
555	16	1.2	2275	5	Q8IHV8	Q8ihv8 plasmodium	628	16	1.2	9341	5	Q8I3N9	Q8i3n9 plasmodium
556	16	1.2	2283	5	Q8IC35	Q8ic35 plasmodium	629	16	1.2	125	12	Q9PMY7	Q9py7 shope fibro
557	16	1.2	2284	5	Q8ISY7	Q8isy7 plasmodium	630	16	1.2	389	5	Q8IC70	Q8ic70 plasmodium
558	16	1.2	2333	5	Q8ILH9	Q8ilh9 plasmodium	631	16	1.2	481	6	Q9SK23	Q9sk23 macaca fasc
559	16	1.2	2339	5	Q8I1W3	Q8i1w3 plasmodium	632	16	1.2	481	5	Q8SSR3	Q8ssr3 dictyostel
560	16	1.2	2380	5	Q96266	Q96266 plasmodium	633	16	1.2	481	5	Q8I3L2	Q8i3l2 plasmodium
561	16	1.2	2399	5	Q8IBB0	Q8ibb0 plasmodium	634	16	1.2	482	5	Q8ICP2	Q8icp2 plasmodium
562	16	1.2	2404	5	Q8ICD5	Q8icd5 plasmodium	635	16	1.2	515	5	Q15912	Q15912 dictyostel
563	16	1.2	2405	5	Q8I0L2	Q8iol2 plasmodium	636	16	1.2	563	5	Q8I2B2	Q8i2b2 plasmodium
564	16	1.2	2415	5	Q8I1X1	Q8i1x1 plasmodium	637	16	1.2	593	5	Q8I2U6	Q8i2u6 plasmodium
565	16	1.2	2432	5	Q8I5I9	Q8i5i9 plasmodium	638	16	1.2	608	5	Q8MMM3	Q8mm3 dictyostel
566	16	1.2	2454	5	Q8T2G3	Q8t2g3 dictyostel	639	16	1.2	612	5	Q8IDT5	Q8idt5 plasmodium
567	16	1.2	2467	5	Q8I1D3	Q8i1d3 plasmodium	640	16	1.2	626	5	Q9W1U4	Q9w1u4 drosophila
568	16	1.2	2472	5	Q8T2M5	Q8t2m5 dictyostel	641	16	1.2	631	5	Q8I1U1	Q8i1u1 plasmodium
569	16	1.2	2472	5	Q8I1P3	Q8i1p3 plasmodium	642	16	1.2	655	5	Q8I5P8	Q8i5p8 plasmodium
570	16	1.2	2515	5	Q77365	Q77365 plasmodium	643	16	1.2	670	6	Q95LT1	Q95lt1 macaca fasc
571	16	1.2	2518	5	Q8IEH2	Q8ieh2 plasmodium	644	16	1.2	670	6	Q8WNT8	Q8wnt8 macaca fasc
572	16	1.2	2535	5	Q8I4O3	Q8i4o3 plasmodium	645	16	1.2	673	4	Q96MA2	Q96ma2 homo sapien
573	16	1.2	2578	5	Q8I3P9	Q8i3p9 plasmodium	646	16	1.2	673	4	Q8N4N8	Q8n4n8 homo sapien
574	16	1.2	2612	5	Q8I5X5	Q8i5x5 plasmodium	647	16	1.2	684	10	Q940X8	Q940x8 arabidopsis
575	16	1.2	2668	5	Q8IEE4	Q8iee4 plasmodium	648	16	1.2	706	10	Q9AVP4	Q9avp4 nicotiana t
576	16	1.2	2672	5	Q8IEE4	Q8iee4 plasmodium	649	16	1.2	703	10	Q9LW81	Q9lw81 arabidopsis
577	16	1.2	2700	5	Q8ILC5	Q8ilc5 plasmodium	650	16	1.2	707	10	Q9PPA5	Q9ppa5 oryza sativ
578	16	1.2	2756	10	Q9LJ60	Q9lj60 arabidopsis	651	16	1.2	725	5	Q8I124	Q8i124 dictyostel
579	16	1.2	2770	5	Q8ILV0	Q8ilv0 plasmodium	652	16	1.2	763	5	Q8I3P2	Q8i3p2 plasmodium
580	16	1.2	2773	5	Q8IBP4	Q8ibp4 plasmodium	653	16	1.2	793	5	Q8SSR7	Q8ssr7 dictyostel
581	16	1.2	2792	5	Q8I4R2	Q8i4r2 plasmodium	654	16	1.2	800	10	Q94GW1	Q94gw1 oryza sativ
582	16	1.2	2814	5	Q8IC15	Q8ic15 plasmodium	655	16	1.2	816	5	Q8T2N6	Q8t2n6 dictyostel
583	16	1.2	2843	5	Q96315	Q96315 dictyostel	656	16	1.2	817	5	Q964V6	Q964v6 dictyostel
584	16	1.2	2849	5	Q8IHV4	Q8ihv4 plasmodium	657	16	1.2	825	5	Q8I2K4	Q8i2k4 plasmodium
585	16	1.2	2867	5	Q8IC71	Q8ic71 plasmodium	658	16	1.2	941	5	Q8TAN1	Q8tan1 plasmodium
586	16	1.2	2910	5	Q8IBY8	Q8iby8 plasmodium	659	16	1.2	961	5	Q8IC12	Q8ic12 plasmodium
587	16	1.2	2932	5	Q8I4T6	Q8i4t6 plasmodium	660	16	1.2	964	5	Q8I1G7	Q8i1g7 plasmodium
588	16	1.2	2940	5	Q8IHP9	Q8ihp9 plasmodium	661	16	1.2	1025	5	Q8IC13	Q8ic13 plasmodium
589	16	1.2	2943	5	Q8IK94	Q8ik94 plasmodium	662	16	1.2	1055	5	Q8NMN5	Q8nmn5 dictyostel
590	16	1.2	3099	5	Q8MYH0	Q8myh0 dictyostel	663	16	1.2	1104	5	Q8ISE2	Q8ise2 plasmodium
591	16	1.2	3134	5	Q8I4I4	Q8i4i4 plasmodium	664	16	1.2	1139	5	Q8IJS7	Q8ijs7 plasmodium
592	16	1.2	3135	5	Q8I3B5	Q8i3b5 plasmodium	665	16	1.2	1181	5	Q97260	Q97260 plasmodium
593	16	1.2	3209	5	Q8I5D0	Q8i5d0 plasmodium	666	16	1.2	1195	5	Q8I3S1	Q8i3s1 plasmodium
594	16	1.2	3218	5	Q8ILX0	Q8ilx0 plasmodium	667	16	1.2	1313	5	Q8IIT7	Q8iit7 plasmodium
595	16	1.2	3223	5	Q8IKJ2	Q8ikj2 plasmodium	668	16	1.2	1328	5	Q8IDY9	Q8idy9 plasmodium
596	16	1.2	3248	5	Q8ICP9	Q8icp9 plasmodium	669	16	1.2	1337	5	Q9Y008	Q9y008 plasmodium
597	16	1.2	3303	5	Q8I339	Q8i339 plasmodium	670	16	1.2	1379	5	Q8IY22	Q8iy22 plasmodium
598	16	1.2	3364	5	Q8IM60	Q8im60 plasmodium	671	16	1.2	1438	5	Q8IUR8	Q8iur8 plasmodium
599	16	1.2	3468	5	Q8I104	Q8i104 plasmodium	672	16	1.2	1461	5	Q8I5H0	Q8i5h0 plasmodium
600	16	1.2	3482	5	Q8ID46	Q8id46 plasmodium	673	16	1.2	1490	5	Q8I4I6	Q8i4i6 plasmodium

674	15	1.2	1559	5	081406	081406 plasmodium	747	14	1.1	853	5	081CM6	081cm6 plasmodium
675	15	1.2	1605	5	081BU3	081b13 plasmodium	748	14	1.1	867	5	081W5	081w5 plasmodium
676	15	1.2	1655	5	024754	024754 drosophila	749	14	1.1	897	10	09SS42	09ss42 arabidopsis
677	15	1.2	1731	5	081BQ8	081bq8 plasmodium	750	14	1.1	949	5	077386	077386 plasmodium
678	15	1.2	1813	5	081D65	081d65 plasmodium	751	14	1.1	967	10	09FHD2	09fhd2 arabidopsis
679	15	1.2	2041	5	081BK6	081bk6 plasmodium	752	14	1.1	974	5	081ED7	081ed7 plasmodium
680	15	1.2	2075	5	081HRS	081hrs plasmodium	753	14	1.1	982	5	081DQ6	081dq6 plasmodium
681	15	1.2	2249	5	081IY8	081iy8 plasmodium	754	14	1.1	987	10	09C9A8	09c9a8 arabidopsis
682	15	1.2	2539	5	096157	096157 plasmodium	755	14	1.1	992	5	081LE1	081le1 plasmodium
683	15	1.2	2577	5	081531	081531 plasmodium	756	14	1.1	1011	5	081AL6	081a6 plasmodium
684	15	1.2	2577	5	081531	081531 plasmodium	757	14	1.1	1031	5	081S64	081s64 plasmodium
685	15	1.2	2706	5	097292	097292 plasmodium	758	14	1.1	1056	10	09C9S6	09c9s6 arabidopsis
686	15	1.2	2723	5	0815X3	0815x3 plasmodium	759	14	1.1	1060	10	09C9C9	09cac9 arabidopsis
687	15	1.2	2820	5	081M32	081m32 plasmodium	760	14	1.1	1078	5	081ZV5	081zv5 plasmodium
688	15	1.2	3183	5	081BU1	081bu1 plasmodium	761	14	1.1	1087	10	08W1Y3	08w1y3 arabidopsis
689	15	1.2	3322	5	081KU0	081ku0 plasmodium	762	14	1.1	1093	5	081SR6	081sr6 plasmodium
690	15	1.2	3394	5	077384	077384 plasmodium	763	14	1.1	1109	10	09SH47	09sh47 arabidopsis
691	15	1.2	4044	5	081ID4	081id4 plasmodium	764	14	1.1	1162	10	09LPQ7	09lpq7 arabidopsis
692	15	1.2	4230	5	081C31	081c31 plasmodium	765	14	1.1	1173	5	081EM5	081em5 plasmodium
693	15	1.2	4261	5	081FP4	081fp4 plasmodium	766	14	1.1	1232	5	087821	087821 dictyosteli
694	15	1.2	5415	5	081E74	081e74 plasmodium	767	14	1.1	1245	5	08MNT0	08mnt0 dictyosteli
695	15	1.2	5704	5	081AT1	081at1 plasmodium	768	14	1.1	1245	5	096195	096195 plasmodium
696	15	1.2	6088	5	081EN1	081en1 plasmodium	769	14	1.1	1267	5	081BD1	081bd1 plasmodium
697	15	1.1	105	5	081FM7	081fm7 plasmodium	770	14	1.1	1268	10	09LUG0	09lug0 arabidopsis
698	14	1.1	140	13	09PSH8	09ps8 xenopus lae	771	14	1.1	1288	5	081DE5	081de5 plasmodium
699	14	1.1	150	13	09PSH8	09ps8 xenopus lae	772	14	1.1	1292	10	09LDN0	09ldn0 arabidopsis
700	14	1.1	157	10	09AVD1	09avd1 nicotiana t	773	14	1.1	1313	10	08L7Y8	08l7y8 arabidopsis
701	14	1.1	158	10	09AVD2	09avd2 nicotiana t	774	14	1.1	1315	5	09BLV2	09blv2 leishmania
702	14	1.1	168	11	035068	035068 mus muscicu	775	14	1.1	1352	5	081T55	081t55 plasmodium
703	14	1.1	205	5	019307	019307 caenorhabdi	776	14	1.1	1361	5	081BV5	081bv5 plasmodium
704	14	1.1	312	10	08S9D7	08s9d7 equisetum a	777	14	1.1	1444	5	081CB9	081cb9 plasmodium
705	14	1.1	347	10	093XPF	093xf8 zea mays (m	778	14	1.1	1449	5	081LP9	081lp9 plasmodium
706	14	1.1	354	5	093XPF	093xf5 zea mays (m	779	14	1.1	1465	5	08ST07	08st07 dictyosteli
707	14	1.1	354	5	093XPF	093xf5 zea mays (m	780	14	1.1	1467	5	081AN5	081an5 plasmodium
708	14	1.1	375	10	048527	048527 arabidopsis	781	14	1.1	1483	5	081T07	081t07 plasmodium
709	14	1.1	385	5	081FP5	081fp5 plasmodium	782	14	1.1	1499	13	09DDA6	09dda6 xenopus lae
710	14	1.1	393	5	081TPO	081tp0 dictyosteli	783	14	1.1	1585	5	081LE0	081le0 plasmodium
711	14	1.1	407	10	093XPF	093xf9 zea mays (m	784	14	1.1	1662	10	023274	023274 arabidopsis
712	14	1.1	416	5	081752	081752 plasmodium	785	14	1.1	1740	5	081JK9	081jk9 plasmodium
713	14	1.1	421	5	0814V3	0814v3 plasmodium	786	14	1.1	1753	5	0815W3	0815w3 plasmodium
714	14	1.1	433	5	081LH7	081lh7 plasmodium	787	14	1.1	1816	5	097275	097275 plasmodium
715	14	1.1	476	5	081FN3	081fn3 plasmodium	788	14	1.1	1838	5	081D26	081d26 plasmodium
716	14	1.1	477	5	08MN77	08mn77 dictyosteli	789	14	1.1	1840	5	081ED3	081ed3 plasmodium
717	14	1.1	495	5	08SUN1	08sun1 encephalito	790	14	1.1	1891	5	077275	077275 drosophila
718	14	1.1	521	5	081D10	081d10 plasmodium	791	14	1.1	1946	5	097291	097291 plasmodium
719	14	1.1	548	5	081L96	081l96 plasmodium	792	14	1.1	1960	5	09UOK8	09uok8 plasmodium
720	14	1.1	551	5	076494	076494 dictyosteli	793	14	1.1	1967	10	08GVH3	08gvh3 oryza sativ
721	14	1.1	555	5	081J43	081j43 plasmodium	794	14	1.1	1991	5	081515	081515 plasmodium
722	14	1.1	558	5	0815T1	0815t1 plasmodium	795	14	1.1	1997	5	081AP3	081ap3 plasmodium
723	14	1.1	560	5	081715	081715 plasmodium	796	14	1.1	2010	5	096171	096171 plasmodium
724	14	1.1	560	5	081516	081516 plasmodium	797	14	1.1	2031	5	081IR4	081ir4 plasmodium
725	14	1.1	576	5	081D42	081d42 plasmodium	798	14	1.1	2108	5	0815C7	0815c7 plasmodium
726	14	1.1	587	5	08RT29	08rt29 dictyosteli	799	14	1.1	2158	10	09LUT5	09lut5 arabidopsis
727	14	1.1	601	3	09C113	09c113 candida alb	800	14	1.1	2273	5	081UJ4	081uj4 plasmodium
728	14	1.1	625	5	081CK3	081ck3 plasmodium	801	14	1.1	2290	5	081UJ4	081uj4 plasmodium
729	14	1.1	627	5	081LX9	081lx9 plasmodium	802	14	1.1	2371	5	081RP2	081rp2 plasmodium
730	14	1.1	642	10	09S6G6	09s6g6 oryza sativ	803	14	1.1	2548	5	081E95	081e95 plasmodium
731	14	1.1	652	5	077168	077168 apis mellif	804	14	1.1	2558	5	0815L1	0815l1 plasmodium
732	14	1.1	668	5	060964	060964 leishmania	805	14	1.1	2698	5	0813F7	0813f7 plasmodium
733	14	1.1	677	5	081C73	081c73 plasmodium	806	14	1.1	3069	5	0813S0	0813s0 plasmodium
734	14	1.1	678	13	08UUN1	08uul1 oryzias lat	807	14	1.1	3270	5	081DB2	081db2 plasmodium
735	14	1.1	682	5	081I98	081i98 plasmodium	808	14	1.1	3347	5	081KVO	081kv0 plasmodium
736	14	1.1	687	5	081KE2	081ke2 plasmodium	809	14	1.1	5922	5	081IR2	081ir2 plasmodium
737	14	1.1	693	5	096680	096680 drosophila	810	14	1.1	7149	5	081W09	081w09 plasmodium
738	14	1.1	699	5	015816	015816 dictyosteli	811	14	1.1	7149	5	08MPB1	08mpb1 dictyosteli
739	14	1.1	730	5	08T674	08t674 dictyosteli	812	14	1.0	138	5	08MPB1	08mpb1 dictyosteli
740	14	1.1	733	10	081491	081491 oryza sativ	813	13	1.0	169	11	035061	035061 mus muscicu
741	14	1.1	767	10	092240	092240 arabidopsis	814	13	1.0	183	3	096UG3	096ug3 kluyveromyc
742	14	1.1	773	13	P79805	p79805 morone saxa	815	13	1.0	217	5	081FV2	081fv2 plasmodium
743	14	1.1	777	10	Q9M0X6	q9m0x6 arabidopsis	816	13	1.0	277	5	09NKA9	09nka9 drosophila
744	14	1.1	794	5	081I27	081i27 plasmodium	817	13	1.0	291	5	08T843	08t843 dictyosteli
745	14	1.1	801	10	091G54	091g54 oryza sativ	818	13	1.0	358	5	08MPB0	08mpb0 dictyosteli
746	14	1.1	810	10	0814J3	0814j3 oryza sativ	819	13	1.0	367	10	09M2P9	09m2p9 arabidopsis

820	13	1.0	374	10	Q94AJ2	Q94AJ2 arabidopsis	893	13	1.0	1081	5	Q24030	Q24030 drosophila
821	13	1.0	332	10	Q92RB9	Q92RB9 lycopersico	894	13	1.0	1081	5	Q8IP19	Q8IP19 drosophila
822	13	1.0	407	5	Q8IE15	Q8IE15 plasmodium	895	13	1.0	1083	5	Q45935	Q45935 caenorhabdit
823	13	1.0	411	5	Q8IDX4	Q8IDX4 plasmodium	896	13	1.0	1111	5	Q8IJA2	Q8IJA2 plasmodium
824	13	1.0	420	5	Q8SRB7	Q8SRB7 encephalito	897	13	1.0	1139	5	Q97237	Q97237 plasmodium
825	13	1.0	423	5	Q8IRK3	Q8IRK3 plasmodium	898	13	1.0	1148	5	Q8WYD8	Q8WYD8 dictyosteli
826	13	1.0	430	10	Q93XPF6	Q93XPF6 zea mays (m	899	13	1.0	1158	5	Q8IU40	Q8IU40 dictyosteli
827	13	1.0	439	5	Q969B0	Q969B0 giardia lam	900	13	1.0	1163	5	Q8MP92	Q8MP92 dictyosteli
828	13	1.0	442	5	Q8ILE4	Q8ILE4 plasmodium	901	13	1.0	1172	5	Q8ISE4	Q8ISE4 plasmodium
829	13	1.0	445	5	Q8T2E4	Q8T2E4 dictyosteli	902	13	1.0	1191	10	Q8GZU1	Q8GZU1 lycopersico
830	13	1.0	449	5	Q8NMG7	Q8NMG7 plasmodium	903	13	1.0	1212	5	Q9XZ29	Q9XZ29 drosophila
831	13	1.0	457	5	Q8NMX5	Q8NMX5 dictyosteli	904	13	1.0	1215	5	Q8IIQ6	Q8IIQ6 plasmodium
832	13	1.0	511	5	Q8MXL4	Q8MXL4 dictyosteli	905	13	1.0	1225	5	Q8ILF3	Q8ILF3 plasmodium
833	13	1.0	517	5	Q8IUP2	Q8IUP2 plasmodium	906	13	1.0	1235	5	Q8IB22	Q8IB22 plasmodium
834	13	1.0	575	5	Q8IM39	Q8IM39 plasmodium	907	13	1.0	1280	5	Q8ICQ7	Q8ICQ7 plasmodium
835	13	1.0	592	5	Q8IDT9	Q8IDT9 plasmodium	908	13	1.0	1281	5	Q15802	Q15802 plasmodium
836	13	1.0	597	5	Q8I476	Q8I476 plasmodium	909	13	1.0	1281	5	Q8IBZ5	Q8IBZ5 plasmodium
837	13	1.0	601	5	Q8IUJ8	Q8IUJ8 plasmodium	910	13	1.0	1299	5	Q8IUQ0	Q8IUQ0 plasmodium
838	13	1.0	604	5	Q8IS16	Q8IS16 dictyosteli	911	13	1.0	1316	5	Q8IAS8	Q8IAS8 plasmodium
839	13	1.0	608	5	Q77331	Q77331 plasmodium	912	13	1.0	1318	5	Q8IDI3	Q8IDI3 plasmodium
840	13	1.0	647	5	Q9NH62	Q9NH62 schistosoma	913	13	1.0	1335	5	Q00886	Q00886 dictyosteli
841	13	1.0	649	5	Q8TI09	Q8TI09 dictyosteli	914	13	1.0	1335	10	Q9FME7	Q9FME7 arabidopsis
842	13	1.0	674	5	Q8IB50	Q8IB50 plasmodium	915	13	1.0	1341	5	Q8IM28	Q8IM28 plasmodium
843	13	1.0	679	5	Q9W3E3	Q9W3E3 drosophila	916	13	1.0	1342	5	Q97364	Q97364 plasmodium
844	13	1.0	684	5	Q9W3E3	Q9W3E3 plasmodium	917	13	1.0	1384	5	Q8I3B3	Q8I3B3 plasmodium
845	13	1.0	707	5	Q00910	Q00910 dictyosteli	918	13	1.0	1401	5	Q8ISD4	Q8ISD4 plasmodium
846	13	1.0	717	5	Q9VM27	Q9VM27 drosophila	919	13	1.0	1404	5	Q8IKT7	Q8IKT7 plasmodium
847	13	1.0	734	5	Q8II21	Q8II21 plasmodium	920	13	1.0	1411	5	Q8I277	Q8I277 plasmodium
848	13	1.0	742	5	Q8ISE7	Q8ISE7 plasmodium	921	13	1.0	1495	5	Q8WML8	Q8WML8 dictyosteli
849	13	1.0	743	5	Q8ILV4	Q8ILV4 plasmodium	922	13	1.0	1542	5	Q8I2T2	Q8I2T2 plasmodium
850	13	1.0	771	5	Q9XZJ3	Q9XZJ3 dictyosteli	923	13	1.0	1550	5	Q8IDI7	Q8IDI7 plasmodium
851	13	1.0	786	5	Q8TIB7	Q8TIB7 dictyosteli	924	13	1.0	1554	5	Q8IUY4	Q8IUY4 plasmodium
852	13	1.0	794	10	Q940B8	Q940B8 arabidopsis	925	13	1.0	1575	5	Q8SNN3	Q8SNN3 dictyosteli
853	13	1.0	796	5	Q8IENS	Q8IENS plasmodium	926	13	1.0	1594	5	Q8I2N7	Q8I2N7 plasmodium
854	13	1.0	799	10	Q9IUS1	Q9IUS1 arabidopsis	927	13	1.0	1701	5	Q8II50	Q8II50 plasmodium
855	13	1.0	818	5	Q8S510	Q8S510 encephalito	928	13	1.0	1706	5	Q8I2W9	Q8I2W9 plasmodium
856	13	1.0	838	5	Q8ILS1	Q8ILS1 plasmodium	929	13	1.0	1737	5	Q8IEH8	Q8IEH8 plasmodium
857	13	1.0	838	5	Q8IUB9	Q8IUB9 plasmodium	930	13	1.0	1754	5	Q8TIC5	Q8TIC5 plasmodium
858	13	1.0	842	5	Q8ISJ8	Q8ISJ8 plasmodium	931	13	1.0	1790	5	Q9BK49	Q9BK49 drosophila
859	13	1.0	857	5	Q8IBF8	Q8IBF8 plasmodium	932	13	1.0	1816	5	Q8IUL6	Q8IUL6 plasmodium
860	13	1.0	863	5	Q8ICT6	Q8ICT6 plasmodium	933	13	1.0	1830	5	Q8IIR3	Q8IIR3 plasmodium
861	13	1.0	865	6	Q95UL1	Q95UL1 macaca fasc	934	13	1.0	1893	5	Q9W4J1	Q9W4J1 drosophila
862	13	1.0	899	5	Q8NMR2	Q8NMR2 dictyosteli	935	13	1.0	1903	5	Q9UON7	Q9UON7 plasmodium
863	13	1.0	904	3	Q04195	Q04195 saccharomyc	936	13	1.0	1920	5	Q46205	Q46205 drosophila
864	13	1.0	935	5	Q8ID72	Q8ID72 plasmodium	937	13	1.0	2084	5	Q8TIC29	Q8TIC29 dictyosteli
865	13	1.0	936	5	Q8I2A7	Q8I2A7 plasmodium	938	13	1.0	2121	5	Q9GYC1	Q9GYC1 leishmania
866	13	1.0	937	5	Q8MP59	Q8MP59 dictyosteli	939	13	1.0	2269	5	Q77360	Q77360 plasmodium
867	13	1.0	938	5	Q8IHY0	Q8IHY0 plasmodium	940	13	1.0	2310	5	Q8IBZ1	Q8IBZ1 plasmodium
868	13	1.0	954	5	Q9XYL1	Q9XYL1 dictyosteli	941	13	1.0	2558	5	Q8IKF6	Q8IKF6 plasmodium
869	13	1.0	960	5	Q8IEC6	Q8IEC6 plasmodium	942	13	1.0	2573	5	Q96185	Q96185 plasmodium
870	13	1.0	975	5	Q8IAY8	Q8IAY8 plasmodium	943	13	1.0	2653	5	Q8IHX2	Q8IHX2 plasmodium
871	13	1.0	1011	5	Q8IEP4	Q8IEP4 plasmodium	944	13	1.0	2657	5	Q8ILG1	Q8ILG1 plasmodium
872	13	1.0	1016	5	Q8IS83	Q8IS83 plasmodium	945	13	1.0	2691	5	Q8ILS2	Q8ILS2 plasmodium
873	13	1.0	1029	5	Q8IKV7	Q8IKV7 plasmodium	946	13	1.0	2705	5	Q8ISL0	Q8ISL0 plasmodium
874	13	1.0	1032	10	Q9FIJ9	Q9FIJ9 arabidopsis	947	13	1.0	3001	5	Q8IL08	Q8IL08 plasmodium
875	13	1.0	1033	5	Q8IBB8	Q8IBB8 plasmodium	948	13	1.0	3063	5	Q8I284	Q8I284 plasmodium
876	13	1.0	1035	10	Q8G571	Q8G571 arabidopsis	949	13	1.0	3377	5	Q8IEH5	Q8IEH5 plasmodium
877	13	1.0	1044	5	Q9GT38	Q9GT38 plasmodium	950	13	1.0	3429	5	Q8IBP1	Q8IBP1 plasmodium
878	13	1.0	1044	5	Q8IS70	Q8IS70 plasmodium	951	13	1.0	3535	5	Q8IC29	Q8IC29 plasmodium
879	13	1.0	1048	5	Q9VWK4	Q9VWK4 drosophila	952	13	1.0	3574	5	Q8IDA8	Q8IDA8 plasmodium
880	13	1.0	1048	5	Q9NMG7	Q9NMG7 drosophila	953	13	1.0	3610	5	Q968T7	Q968T7 plasmodium
881	13	1.0	1051	10	Q94LM7	Q94LM7 arabidopsis	954	13	1.0	3628	5	Q968Y0	Q968Y0 plasmodium
882	13	1.0	1063	5	Q8ICV5	Q8ICV5 plasmodium	955	13	1.0	3704	5	Q8IKY8	Q8IKY8 plasmodium
883	13	1.0	1065	5	Q24029	Q24029 drosophila	956	13	1.0	5767	5	Q8IS25	Q8IS25 plasmodium
884	13	1.0	1065	5	Q8IP21	Q8IP21 drosophila	957	13	1.0	5890	5	Q8IK84	Q8IK84 plasmodium
885	13	1.0	1072	5	Q9VWK6	Q9VWK6 drosophila	958	13	1.0	5987	5	Q8IDN3	Q8IDN3 plasmodium
886	13	1.0	1072	5	Q24031	Q24031 drosophila	959	13	1.0	6118	5	Q8I396	Q8I396 plasmodium
887	13	1.0	1072	5	Q24027	Q24027 drosophila	960	13	1.0	6473	5	Q8IKH9	Q8IKH9 plasmodium
888	13	1.0	1073	5	Q8IUM5	Q8IUM5 plasmodium	961	13	0.9	74	5	Q9GVB2	Q9GVB2 plasmodium
889	13	1.0	1074	5	Q24028	Q24028 drosophila	962	12	0.9	106	10	Q8ITL1	Q8ITL1 lycopersico
890	13	1.0	1074	5	Q8IP20	Q8IP20 drosophila	963	12	0.9	108	5	Q8T211	Q8T211 dictyosteli
891	13	1.0	1075	10	Q9SNE3	Q9SNE3 arabidopsis	964	12	0.9	125	5	Q8T2H7	Q8T2H7 dictyosteli
892	13	1.0	1076	5	Q8IL74	Q8IL74 plasmodium	965	12	0.9	155	11	Q99PR6	Q99PR6 mus musculus

966	12	0.9	196	11	08C2X4	08C2X4 mus musculus
967	12	0.9	239	5	025772	025772 plasmodium
968	12	0.9	246	5	09U4U4	09U4U4 cryptospori
969	12	0.9	263	5	09W2T4	09W2T4 drosophila
970	12	0.9	278	15	09U0P8	09U0P8 equine infe
971	12	0.9	301	5	08IE30	08IE30 plasmodium
972	12	0.9	306	5	09VM35	09VM35 drosophila
973	12	0.9	319	5	094499	094499 dictyosteli
974	12	0.9	325	5	094492	094492 dictyosteli
975	12	0.9	327	5	08MP29	08MP29 dictyosteli
976	12	0.9	334	5	08T2M7	08T2M7 dictyosteli
977	12	0.9	334	5	08I2B5	08I2B5 plasmodium
978	12	0.9	373	10	08L841	08L841 arabidopsis
979	12	0.9	387	5	08X0Z8	08X0Z8 candida alb
980	12	0.9	388	5	08T1M8	08T1M8 plasmodium
981	12	0.9	389	13	09PTK9	09PTK9 brachydanio
982	12	0.9	399	8	09B6E2	09B6E2 yarrowia li
983	12	0.9	403	5	08IBV2	08IBV2 plasmodium
984	12	0.9	404	8	095946	095946 saccharomyc
985	12	0.9	405	10	093XF2	093XF2 zea mays (m
986	12	0.9	420	5	076853	076853 dictyosteli
987	12	0.9	427	5	09V1U6	09V1U6 drosophila
988	12	0.9	431	3	012124	012124 saccharomyc
989	12	0.9	451	5	095ZC1	095ZC1 leishmania
990	12	0.9	468	4	08NSM1	08NSM1 homo sapien
991	12	0.9	522	5	08MN27	08MN27 dictyosteli
992	12	0.9	551	5	08T1Y2	08T1Y2 plasmodium
993	12	0.9	563	5	08T6E1	08T6E1 dictyosteli
994	12	0.9	578	5	08I3B7	08I3B7 plasmodium
995	12	0.9	579	5	076734	076734 dictyosteli
996	12	0.9	588	5	08MMH8	08MMH8 dictyosteli
997	12	0.9	603	10	09C6K3	09C6K3 arabidopsis
998	12	0.9	611	5	08I449	08I449 plasmodium
999	12	0.9	616	5	08I5Q2	08I5Q2 plasmodium
1000	12	0.9	640	5	08I6Z8	08I6Z8 plasmodium

ALIGNMENTS

RESULT 1

Q814Y0 PRELIMINARY; PRT; 1351 AA.

```
AC Q814Y0
ID Q814Y0
CD Q814Y0
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DE 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Kinesin-like protein, putative.
GN PF02165W.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Hemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=22255705; PubMed=12368864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Patin A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Anguilo J.S.,
RA Petrea M., Allen V., Selengut J., Haft D., Mather M.W., Vaidya A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrell B.;
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AF014851; AAN36517.1; -.
SQ SEQUENCE 1351 AA; 156007 MW; 8B69594BFD73C788 CRC64;
```

Query Match 100.0%; Score 1288; DB 5; Length 1351;
Best Local Similarity 100.0%; Pred. No. 0;

Matches 1288; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY	1	MSKIKVVRKRP	PLSELEKKKKSDIITVKNCTIYIDERRYVDMKTYIERHFFYDKV	60					
DB	64	MSKIKVVRKRP	PLSELEKKKKSDIITVKNCTIYIDERRYVDMKTYIERHFFYDKV	123					
QY	61	FDDTVNDFVYENTIKPLIDLYENGVCSCFAYVGTGSGKTYTMLGSGQDPGPIF	120						
DB	124	FDDTVNDFVYENTIKPLIDLYENGVCSCFAYVGTGSGKTYTMLGSGQDPGPIF	183						
QY	121	QYAAGDIFTFLNYDKDNTGFIPISEYIYCGKLYDLQRRKVAALENGKGVVVDLK	180						
DB	184	QYAAGDIFTFLNYDKDNTGFIPISEYIYCGKLYDLQRRKVAALENGKGVVVDLK	243						
QY	181	ILRLTKSELILKMGVGLRKIGVNSQNESSRSHALIIDDKINHTSLGKIATIDL	240						
DB	244	ILRLTKSELILKMGVGLRKIGVNSQNESSRSHALIIDDKINHTSLGKIATIDL	303						
QY	241	AGSERGADTVSONKQOTDGANINRSLALKECIRAMDSQKNIIPFDSBLTKVLRDIFV	300						
DB	304	AGSERGADTVSONKQOTDGANINRSLALKECIRAMDSQKNIIPFDSBLTKVLRDIFV	363						
QY	301	GKSKSIMIANISPTISCEQTLNTRYSSRVKQFKKSTCINBEDTNTERTSLDSKGS	360						
DB	364	GKSKSIMIANISPTISCEQTLNTRYSSRVKQFKKSTCINBEDTNTERTSLDSKGS	423						
QY	361	EMASSIENVYIKSNHLSSNNNNKINRGKINIKIEBNNTLKKSFPKREGFTSTGKY	420						
DB	424	EMASSIENVYIKSNHLSSNNNNKINRGKINIKIEBNNTLKKSFPKREGFTSTGKY	483						
QY	421	SSLINDIKIKKKKKGLINYKSTLYNDNTJNKGHNNNNNNNDNDNDNNNNNNNDSS	480						
DB	484	SSLINDIKIKKKKKGLINYKSTLYNDNTJNKGHNNNNNNNDNDNDNNNNNNNDSS	543						
QY	481	SMVNNMIMNMINNNINNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	540						
DB	544	SMVNNMIMNMINNNINNNINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	603						
QY	541	HLNNNDKSTFLHKKKRLBDNTKLKRRSSCDNIMKKKKNNLHLARRSVGSKLTMPFYDPOKN	600						
DB	604	HLNNNDKSTFLHKKKRLBDNTKLKRRSSCDNIMKKKKNNLHLARRSVGSKLTMPFYDPOKN	663						
QY	601	KDNFFPKSNINKMEDNTPKDIYESRNVSNNGVLLGLNKNTHDISTDENNDNKKIN	660						
DB	664	KDNFFPKSNINKMEDNTPKDIYESRNVSNNGVLLGLNKNTHDISTDENNDNKKIN	723						
QY	661	NGVNIITINNSVNSINNSNNNSINNSNNNSIYKSYNSNOSISDVQIRYVEMDTSNK	720						
DB	724	NGVNIITINNSVNSINNSNNNSINNSNNNSIYKSYNSNOSISDVQIRYVEMDTSNK	783						
QY	721	NNNDIIPFDAISCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	780						
DB	784	NNNDIIPFDAISCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	843						
QY	781	HNLFQPDNNKNTSNIQNIINTKNNQDGNVYVSNFCHYNLNDKNYLIDLNNKEQDKNIIH	840						
DB	844	HNLFQPDNNKNTSNIQNIINTKNNQDGNVYVSNFCHYNLNDKNYLIDLNNKEQDKNIIH	903						
QY	841	GCDNNIITQNDPEKKKKTTFYNNNNIYIYNNMGNNNSPRMKGLCGSHTSINMKONE	900						
DB	904	GCDNNIITQNDPEKKKKTTFYNNNNIYIYNNMGNNNSPRMKGLCGSHTSINMKONE	963						
QY	901	MKNMEMDKEMKONHISNNNSSSSSSSNNNIYNNINDDTFONDYCHNDNFTTIRKN	960						
DB	964	MKNMEMDKEMKONHISNNNSSSSSSSNNNIYNNINDDTFONDYCHNDNFTTIRKN	1023						
QY	961	NTNINSNIYQNDIITYINSINDYMSNTLLHFKEKTYPTLSTNEDIYNNKMEKHAIRLD	1020						
DB	1024	NTNINSNIYQNDIITYINSINDYMSNTLLHFKEKTYPTLSTNEDIYNNKMEKHAIRLD	1083						
QY	1021	DQDKYDDNNNNVNNNNKAVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNV	1080						
DB	1084	DQDKYDDNNNNVNNNNKAVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNV	1143						


```
QY 1081 NFNNNNYSYFQKNVDTIINNCLNSDISMYDTKEIINNILLSKYKAEKQNVIRKYN 1140
    |||||
DB 1144 NFNNNNYSYFQKNVDTIINNCLNSDISMYDTKEIINNILLSKYKAEKQNVIRKYN 1203
QY 1141 EDIKMNSLEIDIKTAOSIYEKKRVLLTKLLLFKKNVDTQINNETSGLKQDVMCHI CNN 1200
    |||||
DB 1204 EDIKMNSLEIDIKTAOSIYEKKRVLLTKLLLFKKNVDTQINNETSGLKQDVMCHI CNN 1263
QY 1201 NPDDQHFYASRLKEDIINLIMLROIWCESENLRLLYQFLVVEYQKNSANSVLLNVSSN 1260
    |||||
DB 1264 NPDDQHFYASRLKEDIINLIMLROIWCESENLRLLYQFLVVEYQKNSANSVLLNVSSN 1323
QY 1261 NGDIILINKKLYQDNIKNSMDHNNHKK 1288
    |||||
DB 1324 NGDIILINKKLYQDNIKNSMDHNNHKK 1351

RESULT 2
Q8T8224 PRELIMINARY; PRT; 1723 AA.
ID 08T8224;
AC 08T8224;
DT 01-JUN-2002 (TREMBlrel. 21, Created)
DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical 188.9 kDa protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC116030; AAL92981.1; -.
DR InterPro; IPR002048; EF-hand.
DR InterPro; IPR001356; Homeobox.
DR Pfam; PF00036; ehfand; 1.
DR Pfam; PF00046; homeobox; 1.
DR SMART; SM00389; HOX; 1.
DR PROSITE; PS50071; HOMEBOX_2; 1.
DR DR
KW Hypothetical protein.
SQ SEQUENCE 1723 AA; 188915 MM; F68A3B702B3EB95 CRC64;

Query Match 1.5%; Score 19; DB 5; Length 1723;
Best Local Similarity 100.0%; Pred. No. 6.1e-09;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 739 NITNNNNNNNNNNNNNNNNNN 757
    |||||
DB 544 NITNNNNNNNNNNNNNNNNNN 562

RESULT 3
Q8MN71 PRELIMINARY; PRT; 348 AA.
ID 08MN71;
AC 08MN71;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC117177; AAM43662.1; -.
DR EMBL; AC117177; AAM43662.1; -.
KW Hypothetical protein.
SQ SEQUENCE 699 AA; 79820 MM; 5A1D395C439A4D CRC64;

Query Match 1.4%; Score 18; DB 5; Length 699;
Best Local Similarity 100.0%; Pred. No. 2.7e-08;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC117079; AAM43722.1; -.
KW Hypothetical protein.
SQ SEQUENCE 348 AA; 39051 MM; 9A3DDDC4941FF548 CRC64;

Query Match 1.4%; Score 18; DB 5; Length 348;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNID 759
    |||||
DB 164 NNNNNNNNNNNNNNNNNNID 181

RESULT 4
Q8T832 PRELIMINARY; PRT; 439 AA.
ID 08T832;
AC 08T832;
DT 01-JUN-2002 (TREMBlrel. 21, Created)
DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE Hypothetical 51.5 kDa protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC115581; AAL92229.1; -.
KW Hypothetical protein.
SQ SEQUENCE 439 AA; 51503 MM; DBEC69EA046B0C2E CRC64;

Query Match 1.4%; Score 18; DB 5; Length 439;
Best Local Similarity 100.0%; Pred. No. 1.8e-08;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 740 ITNNNNNNNNNNNNNNNNNN 757
    |||||
DB 358 ITNNNNNNNNNNNNNNNNNN 375

RESULT 5
Q8MN10 PRELIMINARY; PRT; 699 AA.
ID 08MN10;
AC 08MN10;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC117177; AAM43662.1; -.
DR EMBL; AC117177; AAM43662.1; -.
KW Hypothetical protein.
SQ SEQUENCE 699 AA; 79820 MM; 5A1D395C439A4D CRC64;

Query Match 1.4%; Score 18; DB 5; Length 699;
Best Local Similarity 100.0%; Pred. No. 2.7e-08;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```



```

RT "RNAi in Dictyostelium: developmental regulation and the role of RdRPs
RT and dsRNase."
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AJ314911; CAC41976.1; -.
DR InterPro: IPR001410; DEAD.
DR InterPro: IPR001650; Helicase_C.
DR InterPro: IPR000999; RNase_3.
DR InterPro: IPR000330; SNF2_N.
DR Pfam: PF04243; DUF425; 1.
DR Pfam: PF00271; helicase_C; 1.
DR Pfam: PF00636; Ribonuclease_3; 2.
DR Pfam: PF00176; SNF2_N; 1.
DR SMART: SM00487; DEXDC; 1.
DR SMART: SM00490; HELICC; 1.
DR SMART: SM00535; RIBOC; 2.
DR PROSITE: PS00517; RNase_3_1; 2.
DR PROSITE: PS50142; RNase_3_2; 2.
DR ATP-binding; Helicase; Hydrolase.
KW SEQUENCE 2994 AA; 348080 MW; E88B2E33AFBACCD4 CRC64;

Query Match
Best Local Similarity 1.4%; Score 18; DB 5; Length 2994;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 740 ITNNNNNNNNNNNNNNNNNN 757
DB 1386 ITNNNNNNNNNNNNNNNNNN 1403

RESULT 10
ID Q9NA13 PRELIMINARY; PRT; 3177 AA.
AC Q9NA13;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Inositol 1,4,5-trisphosphate receptor-like protein.
GN IPLA.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX2;
RX MEDLINE=20428450; PubMed=10970875;
RA Traynor D., Milne J.L.S., Insall R.H., Kay R.R.;
RT "Ca2 signalling is not required for chemotaxis in Dictyostelium.";
RL EMBL: AJ277590; CAB97127.1; -.
DR EMBL: AJ277590; CAB97127.1; -.
DR InterPro: IPR000699; Ca-rel_channel.
DR InterPro: IPR001682; Ca/Na_Pore.
DR InterPro: IPR000493; Insp3_receptor.
DR Pfam: PF01365; RYDR_TPR; 2.
DR PRINTS: PR00779; INSP3RCEPTR.
KW Receptor.
SQ SEQUENCE 3177 AA; 360526 MW; 381BCEA20A7C84A2 CRC64;

Query Match
Best Local Similarity 1.4%; Score 18; DB 5; Length 3177;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNN 759
DB 593 NNNNNNNNNNNNNNNNNN 610

RESULT 11
Q9U573
AC Q9U573; PRELIMINARY; PRT; 3619 AA.
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

```

```

DE Beige protein homolog.
GN LVSA.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DH1;
RX MEDLINE=20056115; PubMed=10588668;
RA Kwak E., Gerald N., Laroche D.A., Vitaliani K.K., Niswonger M.L.,
RA Maready M., De Lozanne A.;
RT "Lvsa, a protein related to the mouse beige protein, is required for
RT cytokinesis in Dictyostelium."
RL Mol. Biol. Cell 10:4429-4439 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=DH1;
RA De Lozanne A.;
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF088979; AAD52096.2; -.
DR InterPro: IPR000409; Beige_BEACH.
DR InterPro: IPR001680; WD40.
DR Pfam: PF02138; Beach; 1.
DR Pfam: PF00400; WD40; 5.
DR ProDom: PD007848; Beige_BEACH; 1.
DR SMART: SM00320; WD40; 4.
DR PROSITE: PS50197; BEACH; 1.
DR PROSITE: PS00678; WD_REPEATS_1; 1.
DR PROSITE: PS50082; WD_REPEATS_2; 1.
DR PROSITE: PS50294; WD_REPEATS_REGION; 1.
KW Repeat; WD repeat.
SQ SEQUENCE 3619 AA; 408069 MW; 24B74A953B2885F9 CRC64;

Query Match
Best Local Similarity 1.4%; Score 18; DB 5; Length 3619;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 740 ITNNNNNNNNNNNNNNNNNN 757
DB 2600 ITNNNNNNNNNNNNNNNNNN 2617

RESULT 12
Q8MN05
AC Q8MN05; PRELIMINARY; PRT; 104 AA.
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tungal B., Cox B., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AC116961; AAM33740.1; -.
KW Hypothetical protein.
SQ SEQUENCE 104 AA; 12132 MW; 7694A678A730A5F4 CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 104;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNN 758
DB 75 NNNNNNNNNNNNNNNNNN 91

```

```
RESULT 13
Q8MP24 ID Q8MP24 PRELIMINARY; PRT; 172 AA.
AC Q8MP24;
DT 01-OCT-2002 (TRENBLrel. 22, Created)
DT 01-OCT-2002 (TRENBLrel. 22, Last sequence update)
DE 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC123513; AAM44372.1; -.
KW Hypothetical protein.
SQ SEQUENCE 172 AA; 20800 MW; CE6A456B2B3CFDCE CRC64;

Query Match 1.3%; Score 17; DB 5; Length 172;
Best Local Similarity 100.0%; Pred. No. 7.9e-08;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
DB 111 TNNNNNNNNNNNNNNNNNN 127

RESULT 14
Q8ST26 ID Q8ST26 PRELIMINARY; PRT; 204 AA.
AC Q8ST26;
DT 01-JUN-2002 (TRENBLrel. 21, Created)
DT 01-JUN-2002 (TRENBLrel. 21, Last sequence update)
DE 01-OCT-2002 (TRENBLrel. 22, Last annotation update)
DE HSPC305 10/100.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC115575; AAL92188.1; -.
SQ SEQUENCE 204 AA; 23921 MW; EFCD3733CTBA9C81 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 204;
Best Local Similarity 100.0%; Pred. No. 9.1e-08;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
DB 156 NNNNNNNNNNNNNNNNNI 172

RESULT 15
Q8T1B5 ID Q8T1B5 PRELIMINARY; PRT; 279 AA.
AC Q8T1B5;
DT 01-JUN-2002 (TRENBLrel. 21, Created)
DT 01-JUN-2002 (TRENBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TRENBLrel. 22, Last annotation update)
DE Hypothetical 31.4 kDa protein.
```

```
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC116960; AAM08485.1; -.
KW Hypothetical protein.
SQ SEQUENCE 279 AA; 31413 MW; 182A4849594CBD04 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 279;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
DB 100 TNNNNNNNNNNNNNNNNNN 116

RESULT 16
Q8ST23 ID Q8ST23 PRELIMINARY; PRT; 284 AA.
AC Q8ST23;
DT 01-JUN-2002 (TRENBLrel. 21, Created)
DT 01-JUN-2002 (TRENBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TRENBLrel. 22, Last annotation update)
DE HDCKB03P 10/100.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC115681; AAL92673.1; -.
SQ SEQUENCE 284 AA; 32029 MW; B52D22929F7D526A CRC64;

Query Match 1.3%; Score 17; DB 5; Length 284;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
DB 197 NNNNNNNNNNNNNNNNNI 213

RESULT 17
Q9XY02 ID Q9XY02 PRELIMINARY; PRT; 288 AA.
AC Q9XY02;
DT 01-NOV-1999 (TRENBLrel. 12, Created)
DT 01-NOV-1999 (TRENBLrel. 12, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE PLOX5-DJ (Fragment).
GN PLOX5-DJ.
OS Dugesia japonica (Planarian).
OC Eukaryota; Metazoa; Platyhelminthes; Turbellaria; Sericata; Tricladida;
OC Paludicola; Dugesidae; Dugesia.
OX NCBI_TaxID=6161;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=GI;
RX MEDLINE=99287788; PubMed=10357903;
RA Orit H., Kato K., Umesono Y., Sakurai T., Agata K., Watanabe K.;
```

RT "The planarian HOM/HOX homeobox genes (Plox) expressed along the
 antero-posterior axis.";
 RL Dev. Biol. 210:456-468(1999).
 CC -1- SUBCELLULAR LOCATION: NUCLEAR (BY SIMILARITY).
 DR EMBL: AB024409; BAA7405.1; -.
 DR HSSP: P02833; 9ANT.
 DR InterPro: IPR001827; Antennapedia.
 DR InterPro: IPR001356; Homeobox.
 DR Pfam: PF00046; homeobox; 1.
 DR PRINTS: PR00025; ANTENNAPEDIA.
 DR PRINTS: PR00024; HOMEBOX.
 DR ProDom: PD000010; Homeobox; 1.
 DR SMART: SM00389; HOX; 1.
 DR PROSITE: PS00027; HOMEBOX_1; 1.
 DR PROSITE: PS50071; HOMEBOX_2; 1.
 KM DNA-binding; Homeobox; Nuclear protein.
 FT NON TER 1
 SQ SEQUENCE 288 AA; 33191 MW; 693C649656B290A CRC64;

Query Match 1.3%; Score 17; DB 5; Length 288;
 Best Local Similarity 100.0%; Pred. No. 1.2e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
 DB 146 TNNNNNNNNNNNNNNNNNN 162

RESULT 18

Q8MX75 PRELIMINARY; PRT; 293 AA.
 ID Q8MX75;
 AC Q8MX75;
 DT 01-OCT-2002 (TReMBLrel. 22, Created)
 DT 01-OCT-2002 (TReMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE CP47 (Fragment).
 GN CP47.
 OS Cryosporidium parvum.
 OC Eukaryota; Alveolata; Apicomplexa; Coccidia; Eimeriida;
 OC Cryosporididae; Cryosporidium.
 OC NCBI_TaxID=5807;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Jenkins M.C., Trout J.M., Fayer R.;
 RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF384127; AAM46174.1; -.
 FT NON TER 1
 SQ SEQUENCE 293 AA; 32688 MW; 7C81729D50B46E0D CRC64;

Query Match 1.3%; Score 17; DB 5; Length 293;
 Best Local Similarity 100.0%; Pred. No. 1.2e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
 DB 97 TNNNNNNNNNNNNNNNNNN 113

RESULT 19

Q8MNN2 PRELIMINARY; PRT; 300 AA.
 ID Q8MNN2;
 AC Q8MNN2;
 DT 01-OCT-2002 (TReMBLrel. 22, Created)
 DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE Hypothetical protein.
 OS Dictyostelium discoideum (slime mold).
 OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
 OC NCBI_TaxID=44689;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA STRAIN=KX4;
 RC Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,

RA Lehmann R., Baumgart C., Parra G., April J.F., Guiso R., Kumpf K.,
 RA Tungal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
 RT "Sequence and Analysis of Chromosome 2 of Dictyostelium";
 RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AC116965; AAM33218.1; -.
 DR InterPro: IPR001159; DS_RBD.
 DR Pfam: PF00035; dsrm; 1.
 DR SMART: SM00358; DSRM; 1.
 DR PROSITE: PS50137; DS_RBD; 1.
 KM Hypothetical protein.
 SQ SEQUENCE 300 AA; 35188 MW; C4EC727AF8C6DE2D CRC64;

Query Match 1.3%; Score 17; DB 5; Length 300;
 Best Local Similarity 100.0%; Pred. No. 1.3e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 DB 185 NNNNNNNNNNNNNNNNNNNI 201

RESULT 20

Q8ICP1 PRELIMINARY; PRT; 371 AA.
 ID Q8ICP1;
 AC Q8ICP1;
 DT 01-MAR-2003 (TReMBLrel. 23, Created)
 DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE Hypothetical protein.
 GN MAL6P1.298.
 OS Plasmodium falciparum (isolate 3D7).
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 OC NCBI_TaxID=36329;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Chervach I., Davis P., Goodhead I., Stevens K., Mungall K.,
 RA Berriman M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
 RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrett B.;
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AL844505; CND50400.1; -.
 KM Hypothetical protein.
 SQ SEQUENCE 371 AA; 43460 MW; 8A81197CA8F81BC2 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 371;
 Best Local Similarity 100.0%; Pred. No. 1.5e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 DB 227 NNNNNNNNNNNNNNNNNNNI 243

RESULT 21

Q8IHR1 PRELIMINARY; PRT; 384 AA.
 ID Q8IHR1;
 AC Q8IHR1;
 DT 01-MAR-2003 (TReMBLrel. 23, Created)
 DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE Hypothetical protein.
 GN PF11.0468.
 OS Plasmodium falciparum (isolate 3D7).
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 OC NCBI_TaxID=36329;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=3D7;
 RX MEDLINE=22255705; PubMed=12368864;
 RA Gardner M.J., Hall N., Pung E., White O., Berriman M., Hyman R.W.,
 RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
 RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
 RA Chan M.-S., Nene V., Shallow S.J., Suh B., Peterson J., Angiuoli S.,
 RA Perera M., Allen J., Selengut J., Haft D., Mather M.W., Vaidya A.B.,

```

RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McPadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venier J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrett B.,
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL: AE014643; AAM36048.1; -
KM Hypothetical protein.
SQ SEQUENCE 384 AA; 46253 MW; F20DP4F1EF5089CB CRC64;

Query Match 1.3%; Score 17; DB 5; Length 384;
Best Local Similarity 100.0%; Pred. No. 1.5e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
Db 211 TNNNNNNNNNNNNNNNNNN 227

RESULT 22
QY 025768 PRELIMINARY; PRT; 391 AA.
ID 025768
AC Q25768;
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Asparagine-rich antigen (Clone 14C1) (Fragment).
OS Plasmodium falciparum.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_TaxID=5833;
RN [1]
RP SEQUENCE FROM N.A.
RA Schreiber W.G., Deutsche U., Storck T., Mueller-Hill B.;
RL Submitted (DEC-1989) to the EMBL/GenBank/DBJ databases.
DR EMBL: X17483; CAA35519.1; -.
FT NON TER 1
FT NON TER 391
SQ SEQUENCE 391 AA; 45309 MW; 336596F24F071A8 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 391;
Best Local Similarity 100.0%; Pred. No. 1.6e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
Db 162 TNNNNNNNNNNNNNNNNNN 178

RESULT 23
QY 025774 PRELIMINARY; PRT; 419 AA.
ID 025774
AC Q25774;
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Asparagine-rich antigen (Clone 52C11) (Fragment).
OS Plasmodium falciparum.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_TaxID=5833;
RN [1]
RP SEQUENCE FROM N.A.
RA Schreiber M.G., Deutsche U., Storck T., Mueller-Hill B.;
RL Submitted (DEC-1989) to the EMBL/GenBank/DBJ databases.
DR EMBL: X17489; CAA35525.1; -.
FT NON TER 1
FT NON TER 419
SQ SEQUENCE 419 AA; 47365 MW; 08DFBD456298DE31 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 419;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757

```

```

Db 25 TNNNNNNNNNNNNNNNNNN 41

RESULT 24
QY 08MNF6 PRELIMINARY; PRT; 426 AA.
ID 08MNF6
AC 08MNF6;
DT 01-OCT-2002 (TREMBLrel. 22, Created)
DT 01-OCT-2002 (TREMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidae; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafarski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium."
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AC117072; AAM33165.1; -.
KM Hypothetical protein.
SQ SEQUENCE 426 AA; 48800 MW; 10D36C7BA3AC69A CRC64;

Query Match 1.3%; Score 17; DB 5; Length 426;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
Db 401 NNNNNNNNNNNNNNNNNNNI 417

RESULT 25
QY 08T834 PRELIMINARY; PRT; 434 AA.
ID 08T834
AC 08T834;
DT 01-JUN-2002 (TREMBLrel. 21, Created)
DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Hypothetical 49.6 kDa protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelidae; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafarski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium."
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AC115581; AAL92226.1; -.
DR InterPro: IPR001594; Znf-DHHC.
DR Pfam: PF01528; Znf-DHHC.
DR ProDom: PD003041; Znf-DHHC.1.
DR ProSITE: PS50216; ZF_DHHC.1.
KM Hypothetical protein.
SQ SEQUENCE 434 AA; 49641 MW; 256228913AA55E9A CRC64;

Query Match 1.3%; Score 17; DB 5; Length 434;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
Db 288 NNNNNNNNNNNNNNNNNNNI 304

RESULT 26

```

```

0814W5 ID 0814W5 PRELIMINARY; PRT; 440 AA.
AC 0814W5;
DT 01-MAR-2003 (TREMBlrel. 23, Created)
DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
GN Hypothetical protein.
PFL2240W.
OC Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=2255705; PubMed=1236864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Sub B., Peterson J., Angiuoli S.,
RA Perte M., Allen J., Selengut J., Haft D., Mather M.W., Valdivia A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrall B.;
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AB014851; AAN36532.1; -.
KW Hypothetical protein.
SQ SEQUENCE 440 AA; 51713 MW; E2FBF15E1039566 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 440;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNNNN 757
Db 253 TNNNNNNNNNNNNNNNNNNNN 269

RESULT 27
Q8MXW8 ID 08MXW8 PRELIMINARY; PRT; 455 AA.
AC 08MXW8;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
GN Winged helix/forkhead transcription factor (Fragment).
PFL2240W.
OC Dugesia japonica (Planarian).
OC Eukaryota; Metazoa; Platyhelminthes; Turbellaria; Seriata; Tricladida;
OC Paludicola; Dugesidae; Dugesia.
OX NCBI_TaxID=6161;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=GI;
RA Kojima S., Umesono Y., Matanabe K., Agata K.;
RT "The expression of planarian brain factor homologues, DjFoxg and
RT DjFoxD."
RL Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB091062; BAC10918.1; -.
DR InterPro; IPR001766; TF_Fork_head.
DR Pfam; PF00250; Fork head; 1.
DR PRINTS; PR00053; FORKHEAD.
DR PRODOM; PD000425; TF_Fork_head; 1.
DR SMART; SM00339; FH; 1.
DR PROSITE; PS00657; FORK_HEAD_1; 1.
DR PROSITE; PS00658; FORK_HEAD_2; 1.
DR PROSITE; PS50039; FORK_HEAD_3; 1.
FT NON TER 1
SQ SEQUENCE 455 AA; 53245 MW; 1F35B9F5BEEF2140 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 455;

```

```

Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNNNN 757
Db 357 TNNNNNNNNNNNNNNNNNNNN 373

RESULT 28
0811J6 ID 0811J6 PRELIMINARY; PRT; 465 AA.
AC 0811J6;
DT 01-MAR-2003 (TREMBlrel. 23, Created)
DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
GN Ubiquitin C-terminal hydrolase, family 1, putative.
PFL1_0177.
OC Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=3D7;
RX MEDLINE=2255705; PubMed=1236864;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.,
RA Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S.,
RA Chan M.-S., Nene V., Shallow S.J., Sub B., Peterson J., Angiuoli S.,
RA Perte M., Allen J., Selengut J., Haft D., Mather M.W., Valdivia A.B.,
RA Martin D.M.A., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A.,
RA McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C.,
RA Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W.,
RA Fraser C.M., Barrall B.;
RT "Genome sequence of the human malaria parasite Plasmodium
RT falciparum."
RL Nature 419:498-511(2002).
DR EMBL; AB014838; AAN35761.1; -.
KW Hydrolase.
SQ SEQUENCE 465 AA; 54460 MW; 138A55EB774F99DD CRC64;

Query Match 1.3%; Score 17; DB 5; Length 465;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 TNNNNNNNNNNNNNNNNNNNN 758
Db 277 TNNNNNNNNNNNNNNNNNNNN 293

RESULT 29
08SSX7 ID 08SSX7 PRELIMINARY; PRT; 496 AA.
AC 08SSX7;
DT 01-JUN-2002 (TREMBlrel. 21, Created)
DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
GN Hypothetical protein E01A2.2_9/101.
PFL2240W.
OC Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachbat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunngal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium."
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC115685; AML92706.1; -.
DR InterPro; IPR00504; RNA_rec_mot.
DR PROSITE; PS50102; RNA; 1.
SQ SEQUENCE 496 AA; 56227 MW; 614DC0EDED769126 CRC64;

```



```

OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RT Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
DL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
EMBL: AC117072; AM33146.1; -.
KW Hypothetical protein.
SQ
SEQUENCE 587 AA; 66683 MW; 4B960B35F9379E06 CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 587;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
DB 59 NNNNNNNNNNNNNNNNNNNI 75

RESULT 35
Q8MYG9 PRELIMINARY; PRT; 597 AA.
AC Q8MYG9;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Uracl1-DNA glycosylase.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
NCBI_TaxID=44689;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
DL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
EMBL: AC117073; AM43634.1; -.
DE InterPro: IPR002043; UDNA_glycylase.
DR InterPro: IPR005122; UDNA_glycylaseSF.
DR Pfam: PF03167; UDG; 1.
DR ProDom: PD001589; U_glycylase_notp; 1.
DR TIGRfam: TIGR00628; ung; 1.
SQ
SEQUENCE 597 AA; 68757 MW; 4FA01507B04D04CF CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 597;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
DB 475 NNNNNNNNNNNNNNNNNNNI 491

RESULT 36
Q94474 PRELIMINARY; PRT; 608 AA.
ID Q94474;
AC Q94474;
DT 01-FEB-1997 (TrEMBLrel. 02, Created)
DT 01-FEB-1997 (TrEMBLrel. 02, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE ORPveg132 (Fragment).
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
NCBI_TaxID=44689;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
```

```

RA Loomis W.F.;
RL Submitted (AUG-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL: U66369; AAB06761.1; -.
FT NON_TER
FT NON_TER
SQ
SEQUENCE 608 AA; 68205 MW; 22CF2B5A8402E2BC CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 608;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
DB 345 NNNNNNNNNNNNNNNNNNNI 361

RESULT 37
Q8TIX4 PRELIMINARY; PRT; 614 AA.
ID Q8TIX4;
AC Q8TIX4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Hypothetical 71.7 Kda protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
NCBI_TaxID=44689;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
DL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
EMBL: AC116032; AAL93044.1; -.
KW Hypothetical protein.
SQ
SEQUENCE 614 AA; 71715 MW; 2034BD48222F622 CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 614;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
DB 106 NNNNNNNNNNNNNNNNNNNI 122

RESULT 38
Q8MNJ9 PRELIMINARY; PRT; 616 AA.
ID Q8MNJ9;
AC Q8MNJ9;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
NCBI_TaxID=44689;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
RT "Sequence and Analysis of Chromosome 2 of Dictyostelium.";
DL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
EMBL: AC116984; AM33199.1; -.
KW Hypothetical protein.
SQ
SEQUENCE 616 AA; 71182 MW; 9940E42E65B85F0D CRC64;

Query Match
Best Local Similarity 1.3%; Score 17; DB 5; Length 616;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 742 NNNNNNNNNNNNNNNNNNNI 758
 |||||
 Db 270 NNNNNNNNNNNNNNNNNNNI 286

RESULT 39

Q8SSY0
 ID Q8SSY0 PRELIMINARY; PRT; 628 AA.
 AC Q8SSY0;
 DT 01-JUN-2002 (TReMBLrel. 21, Created)
 DT 01-JUN-2002 (TReMBLrel. 21, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE FMTA-like protein. 10/100.
 OS Dictyostelium discoideum (Slime mold).
 OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
 CX NCBI_TaxID=44689;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=AX4;
 RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
 RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
 RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
 RT "Sequence and Analysis of Chromosome 2 of Dictyostelium";
 RI Submitted (MAR-2002) to the EMBL/Genbank/DBJ databases.
 DR EMBL; AC115581; AAL92233.1.-.
 DR InterPro; IPR001466; Beta_lactamase.
 DR Pfam; PF00144; beta_lactamase; 1.
 SQ SEQUENCE 628 AA; 72065 MW; 335F256D12173915 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 628;
 Best Local Similarity 100.0%; Pred. No. 2.3e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNNN 757
 |||||
 Db 243 TNNNNNNNNNNNNNNNNNN 259

RESULT 40

Q8MNI9
 ID Q8MNI9 PRELIMINARY; PRT; 634 AA.
 AC Q8MNI9;
 DT 01-OCT-2002 (TReMBLrel. 22, Created)
 DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE Hypothetical protein.
 OS Dictyostelium discoideum (Slime mold).
 OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
 CX NCBI_TaxID=44689;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=AX4;
 RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,
 RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,
 RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;
 RT "Sequence and Analysis of Chromosome 2 of Dictyostelium";
 RI Submitted (MAY-2002) to the EMBL/Genbank/DBJ databases.
 CC -1- SIMILARITY: CONTAINS 1 PH DOMAIN.
 DR EMBL; AC117082; AAM34384.1.-.
 DR InterPro; IPR001849; PH.
 DR InterPro; IPR000306; Znf_FYVE.
 DR Pfam; PF01363; FYVE; 1.
 DR Pfam; PF00169; PH; 1.
 DR SMART; SM00064; FYVE; 1.
 DR SMART; SM00233; PH; 1.
 DR PROSITE; PS50003; PH DOMAIN; 1.
 DR PROSITE; PS50178; ZF_FYVE; 1.
 KW Hypothetical protein.
 SQ SEQUENCE 634 AA; 71127 MW; 0C35565610AC89C7 CRC64;

Query Match 1.3%; Score 17; DB 5; Length 634;

Best Local Similarity 100.0%; Pred. No. 2.3e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 |||||
 Db 132 NNNNNNNNNNNNNNNNNNNI 148

Search completed: October 2, 2003, 16:35:27
 Job time : 170 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:35:32 ; Search time 85 Seconds
(without alignments)
2397.392 Million cell updates/sec

Title: US-10-006-780-2
Perfect score: 1288
Sequence: 1 NMSKIKVVRKRPRLSELEKK.....KTLVODINKSMDDNNHHKK 1288

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 587654 seqs, 158212981 residues

Word size : 0

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 1000 summaries

Database :

Published Applications_AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*

3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*

4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*

5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*

6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*

8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*

9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*

10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*

13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*

14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*

15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*

16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*

17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1288	100.0	1288	US-10-006-780-2	Sequence 2, Appli
2	354	27.5	355	US-10-006-780-6	Sequence 4, Appli
3	332	25.8	332	US-10-006-780-4	Sequence 6, Appli
4	332	25.8	332	US-10-006-780-10	Sequence 10, Appli
5	330	25.6	361	US-10-006-780-8	Sequence 8, Appli
6	17	1.3	666	US-09-801-368-36	Sequence 36, Appli
7	16	1.2	213	US-10-032-585-7714	Sequence 7714, Ap
8	16	1.2	732	US-09-994-485-8	Sequence 8, Appli
9	16	1.2	732	US-09-832-292-12	Sequence 12, Appli
10	16	1.2	758	US-09-801-368-224	Sequence 224, App
11	16	1.2	798	US-10-032-585-7565	Sequence 7565, Ap
12	16	1.2	961	US-09-801-368-132	Sequence 132, App
13	16	1.2	1331	US-10-087-464-50	Sequence 50, Appli
14	16	1.2	2150	US-10-135-322-17	Sequence 17, Appli
15	16	1.2	2184	US-10-304-095-6	Sequence 6, Appli

16	1.2	2690	15	US-10-184-644-35	Sequence 35, Appli
17	1.2	2690	15	US-10-184-644-35	Sequence 35, Appli
18	1.2	73	9	US-09-864-761-47535	Sequence 47535, A
19	1.2	303	12	US-10-422-866-4	Sequence 4, Appli
20	1.2	492	12	US-10-422-866-2	Sequence 2, Appli
21	1.2	794	12	US-10-304-095-8	Sequence 8, Appli
22	1.2	888	9	US-09-826-752-6	Sequence 6, Appli
23	1.1	375	9	US-09-839-185-2	Sequence 2, Appli
24	1.1	458	12	US-10-032-585-7575	Sequence 7575, Ap
25	1.1	1662	15	US-10-195-144-37	Sequence 37, Appli
26	1.1	1770	10	US-09-801-368-288	Sequence 298, App
27	1.0	947	12	US-10-032-585-7237	Sequence 7237, Ap
28	1.0	941	12	US-10-032-585-7930	Sequence 7930, Ap
29	1.0	1151	10	US-09-801-368-134	Sequence 134, App
30	1.0	1151	15	US-10-060-019-31	Sequence 31, Appli
31	0.9	387	12	US-10-032-585-7034	Sequence 7034, Ap
32	0.9	410	10	US-09-925-300-1074	Sequence 1074, Ap
33	0.9	511	12	US-10-032-585-7788	Sequence 7788, Ap
34	0.9	725	12	US-09-849-602-20	Sequence 20, Appli
35	0.9	1501	10	US-09-924-154-17	Sequence 4938, Ap
36	0.9	160	15	US-10-106-698-4938	Sequence 462, App
37	0.9	250	11	US-09-934-455-462	Sequence 36, Appli
38	0.9	298	15	US-10-286-264-36	Sequence 188, App
39	0.9	298	16	US-10-278-536-188	Sequence 134, App
40	0.9	309	10	US-09-991-496-134	Sequence 30, Appli
41	0.9	314	11	US-09-893-519A-30	Sequence 2, Appli
42	0.9	319	10	US-09-723-276-2	Sequence 4, Appli
43	0.9	338	10	US-09-883-096-4	Sequence 8, Appli
44	0.9	343	15	US-10-159-151-8	Sequence 10, Appli
45	0.9	363	13	US-10-159-151-10	Sequence 4, Appli
46	0.9	373	15	US-10-159-151-4	Sequence 6, Appli
47	0.9	381	15	US-10-159-151-6	Sequence 5, Appli
48	0.9	383	10	US-09-883-096-5	Sequence 7054, Ap
49	0.9	409	12	US-10-032-585-7054	Sequence 302, App
50	0.9	676	10	US-09-801-368-302	Sequence 6, Appli
51	0.9	864	10	US-09-883-096-2	Sequence 2, Appli
52	0.9	1230	12	US-10-093-524-6	Sequence 62, Appli
53	0.9	1369	12	US-10-342-224-62	Sequence 2, Appli
54	0.9	1368	15	US-10-159-151-2	Sequence 82, Appli
55	0.9	1388	15	US-10-146-473-82	Sequence 40, Appli
56	0.8	16	11	US-09-539-382-40	Sequence 40, Appli
57	0.8	16	15	US-10-067-790-40	Sequence 40, Appli
58	0.8	16	15	US-10-067-892-40	Sequence 40, Appli
59	0.8	16	15	US-10-067-893-40	Sequence 226, App
60	0.8	40	12	US-10-083-768-226	Sequence 7166, Ap
61	0.8	265	12	US-10-032-585-7166	Sequence 12, Appli
62	0.8	412	10	US-09-788-345-12	Sequence 7710, Ap
63	0.8	412	12	US-10-337-312-12	Sequence 29, Appli
64	0.8	488	12	US-10-032-585-7710	Sequence 34, Appli
65	0.8	500	12	US-10-320-646-39	Sequence 27, Appli
66	0.8	500	12	US-10-320-646-34	Sequence 28, Appli
67	0.8	501	12	US-10-320-646-27	Sequence 7, Appli
68	0.8	501	12	US-10-320-646-28	Sequence 1982, Ap
69	0.8	511	9	US-09-949-780-2	Sequence 7849, Ap
70	0.8	522	9	US-09-965-313-7	Sequence 2, Appli
71	0.8	523	12	US-10-017-161-1982	Sequence 125, App
72	0.8	546	12	US-10-032-585-7849	Sequence 120, App
73	0.8	546	12	US-10-167-831-2	Sequence 47, Appli
74	0.8	623	14	US-10-108-605-125	Sequence 33, Appli
75	0.8	623	14	US-10-108-605-129	Sequence 35, Appli
76	0.8	659	10	US-09-833-555-20	Sequence 312, App
77	0.8	690	9	US-09-334-477-47	Sequence 109, App
78	0.8	694	9	US-09-334-477-49	Sequence 249, App
79	0.8	708	9	US-09-334-477-33	Sequence 116, App
80	0.8	711	9	US-09-334-477-35	Sequence 7766, Ap
81	0.8	824	10	US-09-801-368-132	Sequence 38, Appli
82	0.8	861	11	US-09-820-843A-109	Sequence 48088, A
83	0.8	1068	10	US-09-801-368-242	
84	0.8	1420	12	US-10-241-556-116	
85	0.8	1598	12	US-10-032-585-7766	
86	0.8	1648	15	US-10-157-031-38	
87	0.7	34	9	US-09-864-761-48088	
88	0.7	57	9	US-09-864-761-43371	

89	9	0.7	177	12	US-09-903-190-164	Sequence 164, App	162	8	0.6	1015	12	US-10-032-585-7162	Sequence 7162, App
90	9	0.7	354	12	US-10-032-585-7079	Sequence 7079, App	163	8	0.6	1115	12	US-10-335-711-2	Sequence 2, Appl1
91	9	0.7	440	15	US-10-083-357-1256	Sequence 1266, App	164	8	0.6	1207	14	US-10-108-605-71	Sequence 71, Appl1
92	9	0.7	454	12	US-10-032-585-7816	Sequence 7816, App	165	8	0.6	1242	10	US-09-903-248-5	Sequence 5, Appl1
93	9	0.7	498	12	US-10-032-585-7230	Sequence 7230, App	166	8	0.6	1242	10	US-09-903-064-5	Sequence 5, Appl1
94	9	0.7	564	10	US-09-801-368-190	Sequence 190, App	167	8	0.6	1242	10	US-09-903-063-5	Sequence 5, Appl1
95	9	0.7	670	12	US-10-032-585-7568	Sequence 7568, App	168	8	0.6	1242	10	US-09-903-216-5	Sequence 5, Appl1
96	9	0.7	715	12	US-10-171-404-44	Sequence 44, App	169	8	0.6	1242	10	US-09-903-023-5	Sequence 5, Appl1
97	9	0.7	740	12	US-10-032-585-7673	Sequence 7673, App	170	8	0.6	1242	10	US-09-903-023-5	Sequence 5, Appl1
98	9	0.7	769	12	US-10-032-585-7597	Sequence 7597, App	171	8	0.6	1242	11	US-09-436-184-5	Sequence 5, Appl1
99	9	0.7	769	12	US-10-032-585-7117	Sequence 7117, App	172	8	0.6	1242	14	US-10-085-027-1	Sequence 11, Appl1
100	9	0.7	807	11	US-09-820-843A-108	Sequence 108, App	173	8	0.6	1284	9	US-09-119-855-11	Sequence 9, Appl1
101	9	0.7	856	12	US-09-949-029-66	Sequence 66, App	174	8	0.6	1284	15	US-10-160-224-9	Sequence 11, Appl1
102	9	0.7	887	12	US-09-949-029-130	Sequence 130, App	175	8	0.6	1403	14	US-10-185-867-11	Sequence 93, Appl1
103	9	0.7	928	10	US-09-801-368-282	Sequence 282, App	176	8	0.6	1403	15	US-10-108-605-93	Sequence 5, Appl1
104	9	0.7	1143	12	US-10-032-585-7789	Sequence 7789, App	177	8	0.6	1860	12	US-10-146-657-5	Sequence 5, Appl1
105	9	0.7	1165	14	US-10-016-768-10	Sequence 10, App	178	7	0.5	10	12	US-09-572-270A-530	Sequence 530, App
106	9	0.7	1207	12	US-09-949-029-144	Sequence 144, App	179	7	0.5	10	12	US-09-572-270A-532	Sequence 532, App
107	9	0.7	1221	14	US-10-016-768-11	Sequence 11, App	180	7	0.5	10	12	US-09-572-270A-534	Sequence 534, App
108	9	0.7	1245	12	US-10-032-585-7657	Sequence 7657, App	181	7	0.5	10	12	US-09-572-270A-536	Sequence 536, App
109	9	0.7	3092	10	US-09-801-368-172	Sequence 172, App	182	7	0.5	10	12	US-09-572-270A-538	Sequence 538, App
110	8	0.6	10	12	US-09-572-270A-565	Sequence 565, App	183	7	0.5	10	12	US-09-572-270A-544	Sequence 544, App
111	8	0.6	39	9	US-09-864-761-41774	Sequence 41774, A	184	7	0.5	10	12	US-09-572-270A-546	Sequence 546, App
112	8	0.6	41	9	US-09-864-761-4443	Sequence 4443, A	185	7	0.5	10	12	US-09-572-270A-548	Sequence 548, App
113	8	0.6	52	9	US-09-864-761-33973	Sequence 33973, A	186	7	0.5	10	12	US-09-572-270A-550	Sequence 550, App
114	8	0.6	75	9	US-09-864-761-44431	Sequence 44431, A	187	7	0.5	10	12	US-09-572-270A-552	Sequence 552, App
115	8	0.6	90	15	US-10-253-007-59	Sequence 59, App	188	7	0.5	10	12	US-09-572-270A-554	Sequence 554, App
116	8	0.6	146	15	US-10-180-375-138	Sequence 138, App	189	7	0.5	10	12	US-09-572-270A-563	Sequence 563, App
117	8	0.6	164	9	US-09-745-763-104	Sequence 104, App	190	7	0.5	10	12	US-09-572-270A-567	Sequence 567, App
118	8	0.6	175	14	US-10-108-605-97	Sequence 97, App	191	7	0.5	10	12	US-09-572-270A-834	Sequence 834, App
119	8	0.6	195	12	US-10-314-372-4	Sequence 4, App	192	7	0.5	10	12	US-09-572-270A-836	Sequence 836, App
120	8	0.6	221	15	US-10-021-811-14	Sequence 14, App	193	7	0.5	10	12	US-09-572-270A-1008	Sequence 1008, App
121	8	0.6	222	12	US-10-032-585-7349	Sequence 7349, App	194	7	0.5	10	12	US-09-572-270A-1010	Sequence 1010, App
122	8	0.6	223	9	US-09-925-301-1283	Sequence 1283, App	195	7	0.5	16	9	US-09-935-682-11	Sequence 11, Appl1
123	8	0.6	234	8	US-08-808-031A-35	Sequence 35, App	196	7	0.5	17	9	US-09-864-761-42401	Sequence 42401, A
124	8	0.6	250	11	US-09-934-455-256	Sequence 256, App	197	7	0.5	17	11	US-09-876-904A-233	Sequence 233, App
125	8	0.6	250	15	US-10-180-375-194	Sequence 194, App	198	7	0.5	19	9	US-09-864-761-37256	Sequence 7256, A
126	8	0.6	251	12	US-10-032-585-7420	Sequence 7420, App	199	7	0.5	22	9	US-09-864-761-40447	Sequence 40447, A
127	8	0.6	251	15	US-10-295-403-142	Sequence 142, App	200	7	0.5	23	11	US-09-967-869A-1	Sequence 1, Appl1
128	8	0.6	256	9	US-09-925-301-1083	Sequence 1083, App	201	7	0.5	24	14	US-10-123-427-7	Sequence 7, Appl1
129	8	0.6	259	8	US-08-808-031A-5	Sequence 5, Appl1	202	7	0.5	25	9	US-09-864-761-45219	Sequence 45219, A
130	8	0.6	300	9	US-09-861-451A-42	Sequence 42, App	203	7	0.5	26	9	US-09-864-761-44765	Sequence 44765, A
131	8	0.6	302	9	US-09-443-704-12	Sequence 12, App	204	7	0.5	30	9	US-09-864-761-41595	Sequence 41595, A
132	8	0.6	302	14	US-10-008-118A-12	Sequence 12, App	205	7	0.5	30	9	US-09-864-761-42325	Sequence 42325, A
133	8	0.6	312	11	US-09-934-455-160	Sequence 160, App	206	7	0.5	31	10	US-09-764-846-248	Sequence 248, App
134	8	0.6	324	9	US-09-874-923-53	Sequence 53, App	207	7	0.5	31	15	US-10-091-483-248	Sequence 248, App
135	8	0.6	324	10	US-09-991-496-53	Sequence 53, App	208	7	0.5	32	9	US-09-864-761-36029	Sequence 36029, A
136	8	0.6	333	15	US-10-278-173-146	Sequence 146, App	209	7	0.5	33	9	US-09-864-761-3613	Sequence 3613, A
137	8	0.6	341	12	US-10-017-161-2038	Sequence 2038, App	210	7	0.5	33	9	US-09-864-761-47462	Sequence 47462, A
138	8	0.6	342	15	US-10-132-652-3	Sequence 3, App	211	7	0.5	43	14	US-10-124-557-12	Sequence 12, App
139	8	0.6	354	10	US-09-801-368-414	Sequence 414, App	212	7	0.5	44	9	US-09-864-761-43901	Sequence 43901, A
140	8	0.6	372	15	US-10-132-652-2	Sequence 2, App	213	7	0.5	46	9	US-09-864-761-45070	Sequence 45070, A
141	8	0.6	378	15	US-10-278-173-142	Sequence 142, App	214	7	0.5	51	12	US-10-008-524A-100	Sequence 100, App
142	8	0.6	406	9	US-09-802-213-9	Sequence 9, App	215	7	0.5	52	9	US-09-864-761-33647	Sequence 43647, A
143	8	0.6	419	11	US-09-934-455-422	Sequence 422, App	216	7	0.5	54	9	US-09-864-761-34566	Sequence 34566, A
144	8	0.6	420	12	US-10-032-585-7653	Sequence 7653, App	217	7	0.5	58	9	US-09-726-643-59	Sequence 59, App
145	8	0.6	430	12	US-09-769-736-6	Sequence 6, App	218	7	0.5	58	14	US-10-042-141-59	Sequence 59, App
146	8	0.6	464	12	US-10-161-051-119	Sequence 119, App	219	7	0.5	63	9	US-09-877-358-2	Sequence 2, Appl1
147	8	0.6	528	12	US-10-032-585-7571	Sequence 7571, App	220	7	0.5	63	9	US-09-864-761-42311	Sequence 42311, A
148	8	0.6	554	10	US-09-801-368-142	Sequence 142, App	221	7	0.5	63	10	US-09-764-846-260	Sequence 260, App
149	8	0.6	555	8	US-08-808-031A-11	Sequence 31, App	222	7	0.5	63	15	US-10-091-483-260	Sequence 260, App
150	8	0.6	586	8	US-08-808-031A-28	Sequence 28, App	223	7	0.5	66	10	US-09-764-846-11302	Sequence 1302, App
151	8	0.6	605	10	US-09-758-269-16	Sequence 16, App	224	7	0.5	71	10	US-09-738-627-6442	Sequence 6442, App
152	8	0.6	652	9	US-09-351-794A-2	Sequence 2, App	225	7	0.5	72	9	US-09-764-869-683	Sequence 683, App
153	8	0.6	653	9	US-09-746-801A-13	Sequence 13, App	226	7	0.5	72	15	US-10-091-504-683	Sequence 683, App
154	8	0.6	710	12	US-10-032-585-7813	Sequence 7813, App	227	7	0.5	74	15	US-10-178-213-368	Sequence 368, App
155	8	0.6	721	15	US-10-286-264-70	Sequence 70, App	228	7	0.5	94	10	US-09-764-864-1273	Sequence 1273, App
156	8	0.6	725	11	US-09-934-455-442	Sequence 442, App	229	7	0.5	100	9	US-09-922-138-70	Sequence 20, App
157	8	0.6	770	9	US-09-303-232-2	Sequence 2, App	230	7	0.5	101	9	US-09-858-664A-10	Sequence 10, App
158	8	0.6	809	12	US-10-032-585-7691	Sequence 7691, App	231	7	0.5	104	9	US-09-864-761-41552	Sequence 41552, A
159	8	0.6	834	12	US-09-826-752-4	Sequence 4, App	232	7	0.5	104	10	US-09-764-864-1276	Sequence 1276, App
160	8	0.6	854	12	US-10-335-711-9	Sequence 9, App	233	7	0.5	105	14	US-10-135-322-6	Sequence 6, App
161	8	0.6	945	12	US-10-032-585-7114	Sequence 7114, App	234	7	0.5	108	10	US-09-764-864-817	Sequence 817, App

235	7	0.5	109	9	US-09-764-853-625	Sequence 625, App	308	7	0.5	229	15	US-10-325-878-9	Sequence 9, Appl
236	7	0.5	109	11	US-09-989-442-114	Sequence 114, App	309	7	0.5	231	14	US-10-124-557-30	Sequence 30, Appl
237	7	0.5	109	15	US-10-073-865-101	Sequence 101, App	310	7	0.5	238	15	US-10-195-117-3	Sequence 3, Appl
238	7	0.5	110	9	US-09-765-272-102	Sequence 102, App	311	7	0.5	238	15	US-10-195-117-4	Sequence 4, Appl
239	7	0.5	111	9	US-09-858-664-8	Sequence 8, Appl	312	7	0.5	242	12	US-10-296-658-17	Sequence 17, Appl
240	7	0.5	112	10	US-09-764-864-812	Sequence 812, App	313	7	0.5	243	11	US-09-533-029-14	Sequence 34, Appl
241	7	0.5	118	14	US-10-027-559-8	Sequence 8, Appl	314	7	0.5	243	11	US-09-934-455-416	Sequence 416, App
242	7	0.5	112	15	US-10-106-698-4760	Sequence 4760, App	315	7	0.5	246	9	US-09-864-761-36100	Sequence 36100, A
243	7	0.5	119	9	US-09-740-288A-10	Sequence 10, Appl	316	7	0.5	248	15	US-10-103-313-442	Sequence 442, App
244	7	0.5	120	15	US-10-101-464A-641	Sequence 641, App	317	7	0.5	256	15	US-10-156-761-11972	Sequence 11972, A
245	7	0.5	130	14	US-10-071-751-39	Sequence 39, Appl	318	7	0.5	259	11	US-09-934-455-298	Sequence 298, App
246	7	0.5	132	14	US-10-078-923-36	Sequence 36, Appl	319	7	0.5	260	11	US-09-936-333A-18	Sequence 18, Appl
247	7	0.5	134	10	US-09-738-626-5042	Sequence 5042, App	320	7	0.5	261	12	US-10-032-201B-162	Sequence 162, App
248	7	0.5	139	11	US-09-934-455-6	Sequence 6, Appl	321	7	0.5	261	14	US-10-062-254-142	Sequence 140, App
249	7	0.5	148	15	US-10-012-542-453	Sequence 453, App	322	7	0.5	261	14	US-10-062-254-142	Sequence 142, App
250	7	0.5	150	11	US-09-934-455-86	Sequence 86, Appl	323	7	0.5	262	11	US-09-906-393A-14	Sequence 14, Appl
251	7	0.5	152	11	US-09-305-736-542	Sequence 542, App	324	7	0.5	262	11	US-09-906-393A-16	Sequence 16, Appl
252	7	0.5	152	11	US-09-305-736-544	Sequence 544, App	325	7	0.5	270	14	US-10-078-929-38	Sequence 38, Appl
253	7	0.5	156	9	US-09-925-301-1154	Sequence 1154, App	326	7	0.5	270	15	US-10-286-264-56	Sequence 96, Appl
254	7	0.5	165	10	US-09-764-864-1267	Sequence 1267, App	327	7	0.5	273	9	US-09-815-242-5550	Sequence 5550, App
255	7	0.5	166	12	US-10-076-747-83	Sequence 83, Appl	328	7	0.5	282	15	US-10-295-403-54	Sequence 54, Appl
256	7	0.5	169	9	US-09-864-761-42972	Sequence 42972, A	329	7	0.5	284	11	US-09-056-019-3	Sequence 3, Appl
257	7	0.5	172	14	US-10-124-557-88	Sequence 88, Appl	330	7	0.5	284	11	US-09-934-455-104	Sequence 104, App
258	7	0.5	173	10	US-09-738-626-6015	Sequence 6015, App	331	7	0.5	285	15	US-10-157-031-132	Sequence 130, App
259	7	0.5	176	15	US-10-106-698-5506	Sequence 5906, App	332	7	0.5	286	9	US-09-815-242-12234	Sequence 12234, App
260	7	0.5	180	9	US-09-910-150-29	Sequence 29, Appl	333	7	0.5	288	12	US-09-896-168B-24	Sequence 24, Appl
261	7	0.5	181	14	US-10-062-254-369	Sequence 369, App	334	7	0.5	290	15	US-10-106-698-5388	Sequence 5388, App
262	7	0.5	181	15	US-10-149-819-14	Sequence 14, Appl	335	7	0.5	295	16	US-10-278-556-184	Sequence 184, App
263	7	0.5	185	12	US-10-342-224-80	Sequence 80, Appl	336	7	0.5	296	16	US-10-124-557-70	Sequence 70, Appl
264	7	0.5	187	12	US-09-903-190-102	Sequence 102, App	337	7	0.5	297	16	US-10-278-556-74	Sequence 74, Appl
265	7	0.5	191	11	US-09-934-455-54	Sequence 54, Appl	338	7	0.5	302	11	US-09-725-311-2	Sequence 2, Appl
266	7	0.5	192	11	US-09-764-868-1192	Sequence 1192, App	339	7	0.5	306	12	US-10-166-225A-101	Sequence 101, App
267	7	0.5	194	14	US-10-124-557-90	Sequence 90, Appl	340	7	0.5	307	12	US-10-238-075-453	Sequence 453, App
268	7	0.5	194	9	US-09-910-150-28	Sequence 28, Appl	341	7	0.5	307	15	US-10-278-173-148	Sequence 148, App
269	7	0.5	195	10	US-09-764-864-854	Sequence 854, App	342	7	0.5	307	16	US-10-278-556-52	Sequence 92, Appl
270	7	0.5	199	10	US-09-764-864-1291	Sequence 1291, App	343	7	0.5	310	15	US-10-007-521-21	Sequence 22, Appl
271	7	0.5	200	9	US-09-867-550-1934	Sequence 1934, App	344	7	0.5	311	12	US-10-259-165-318	Sequence 318, App
272	7	0.5	201	10	US-09-764-864-836	Sequence 836, App	345	7	0.5	312	10	US-09-738-626-5731	Sequence 5731, App
273	7	0.5	204	11	US-09-934-455-84	Sequence 84, Appl	346	7	0.5	313	12	US-09-896-186B-2	Sequence 2, Appl
274	7	0.5	204	14	US-10-124-557-92	Sequence 92, Appl	347	7	0.5	314	9	US-09-768-82-43	Sequence 43, Appl
275	7	0.5	207	10	US-09-965-602-34	Sequence 34, Appl	348	7	0.5	315	15	US-10-232-563-11	Sequence 11, Appl
276	7	0.5	207	11	US-09-975-719-211	Sequence 211, App	349	7	0.5	319	12	US-10-168-080-2	Sequence 2, Appl
277	7	0.5	208	14	US-10-062-254-174	Sequence 174, App	350	7	0.5	321	11	US-09-934-455-118	Sequence 418, App
278	7	0.5	207	9	US-09-733-507-13	Sequence 13, Appl	351	7	0.5	323	12	US-10-017-161-1620	Sequence 1620, App
279	7	0.5	209	14	US-10-124-557-132	Sequence 132, App	352	7	0.5	324	9	US-09-734-411-2	Sequence 2, Appl
280	7	0.5	211	10	US-10-124-557-94	Sequence 94, Appl	353	7	0.5	325	11	US-09-934-455-138	Sequence 138, App
281	7	0.5	211	10	US-09-908-805B-10	Sequence 10, Appl	354	7	0.5	328	10	US-09-900-557-2	Sequence 2, Appl
282	7	0.5	211	12	US-10-331-695-2	Sequence 2, Appl	355	7	0.5	328	15	US-10-157-031-12	Sequence 12, Appl
283	7	0.5	212	9	US-09-350-874-63	Sequence 63, Appl	356	7	0.5	330	11	US-09-725-311-4	Sequence 4, Appl
284	7	0.5	212	10	US-09-908-805B-4	Sequence 4, Appl	357	7	0.5	339	11	US-09-967-869A-14	Sequence 14, Appl
285	7	0.5	212	10	US-09-908-805B-12	Sequence 12, Appl	358	7	0.5	343	16	US-10-212-677-247	Sequence 247, App
286	7	0.5	212	12	US-10-331-695-4	Sequence 4, Appl	359	7	0.5	343	16	US-10-212-677-248	Sequence 248, App
287	7	0.5	212	15	US-10-038-010-60	Sequence 60, Appl	360	7	0.5	347	16	US-10-212-677-249	Sequence 249, App
288	7	0.5	212	15	US-10-278-173-122	Sequence 122, App	361	7	0.5	349	10	US-09-816-127-3	Sequence 3, Appl
289	7	0.5	212	15	US-10-295-403-16	Sequence 16, Appl	362	7	0.5	349	9	US-09-802-213-7	Sequence 7, Appl
290	7	0.5	212	15	US-10-106-698-63	Sequence 63, Appl	363	7	0.5	349	11	US-09-820-598-3	Sequence 3, Appl
291	7	0.5	214	9	US-09-925-302-649	Sequence 649, App	364	7	0.5	351	14	US-10-095-992-3	Sequence 3, Appl
292	7	0.5	214	12	US-10-293-971-16	Sequence 16, Appl	365	7	0.5	351	9	US-09-350-874-61	Sequence 61, Appl
293	7	0.5	216	12	US-10-267-430-2	Sequence 2, Appl	366	7	0.5	351	15	US-10-106-969-61	Sequence 61, Appl
294	7	0.5	217	14	US-10-124-557-76	Sequence 76, Appl	367	7	0.5	352	12	US-10-259-165-216	Sequence 216, App
295	7	0.5	217	15	US-10-021-811-63	Sequence 63, Appl	368	7	0.5	360	9	US-09-817-647-7	Sequence 7, Appl
296	7	0.5	217	15	US-10-106-698-5191	Sequence 5191, App	369	7	0.5	360	10	US-09-877-665-7	Sequence 7, Appl
297	7	0.5	217	15	US-10-106-698-5795	Sequence 5795, App	370	7	0.5	360	10	US-10-136-573A-7	Sequence 7, Appl
298	7	0.5	218	11	US-09-934-455-192	Sequence 192, App	371	7	0.5	360	15	US-10-215-862-7	Sequence 7, Appl
299	7	0.5	218	13	US-10-010-901-31	Sequence 31, Appl	372	7	0.5	368	9	US-09-805-550-4	Sequence 4, Appl
300	7	0.5	220	14	US-10-124-557-96	Sequence 96, Appl	373	7	0.5	368	10	US-09-801-368-308	Sequence 308, App
301	7	0.5	220	15	US-10-101-464A-628	Sequence 628, App	374	7	0.5	369	15	US-10-036-542-84	Sequence 84, Appl
302	7	0.5	221	12	US-10-032-585-7567	Sequence 7567, App	375	7	0.5	372	14	US-10-124-557-44	Sequence 64, Appl
303	7	0.5	222	15	US-10-156-761-7686	Sequence 7686, App	376	7	0.5	373	11	US-09-819-142-2	Sequence 2, Appl
304	7	0.5	222	15	US-10-156-761-12311	Sequence 12311, A	377	7	0.5	373	11	US-09-934-455-108	Sequence 108, App
305	7	0.5	226	11	US-09-967-869A-15	Sequence 15, Appl	378	7	0.5	379	9	US-09-740-288A-26	Sequence 26, Appl
306	7	0.5	229	12	US-10-411-224-150	Sequence 130, App	379	7	0.5	383	12	US-10-032-201B-196	Sequence 196, App
307	7	0.5	229	15	US-10-091-333-9	Sequence 9, Appl	380	7	0.5	383	15	US-10-141-531-72	Sequence 72, Appl

381	7	0.5	383	15	US-10-141-531-87	Sequence 87, Appl	454	7	0.5	490	15	US-10-121-746-6	Sequence 6, Appl1
382	7	0.5	383	15	US-10-141-531-96	Sequence 96, Appl	455	7	0.5	491	11	US-09-999-220B-3	Sequence 3, Appl1
383	7	0.5	383	15	US-10-141-531-105	Sequence 105, Appl	456	7	0.5	491	11	US-09-999-220B-4	Sequence 4, Appl1
384	7	0.5	383	15	US-10-141-531-114	Sequence 114, Appl	457	7	0.5	491	12	US-10-032-588-7161	Sequence 7161, Ap
385	7	0.5	383	15	US-10-141-531-123	Sequence 123, Appl	458	7	0.5	491	12	US-10-032-588-7161	Sequence 73, Appl
386	7	0.5	383	15	US-10-141-531-132	Sequence 132, Appl	459	7	0.5	500	15	US-10-006-852-16	Sequence 16, Appl
387	7	0.5	383	15	US-10-141-531-141	Sequence 141, Appl	460	7	0.5	500	15	US-10-219-220-149	Sequence 149, Appl
388	7	0.5	383	15	US-10-141-531-150	Sequence 150, Appl	461	7	0.5	500	15	US-10-228-897-13	Sequence 13, Appl
389	7	0.5	383	15	US-10-141-531-159	Sequence 159, Appl	462	7	0.5	503	10	US-09-801-368-424	Sequence 424, Appl
390	7	0.5	383	15	US-10-141-531-168	Sequence 168, Appl	463	7	0.5	506	10	US-09-976-165-19	Sequence 19, Appl
391	7	0.5	383	15	US-10-141-531-177	Sequence 177, Appl	464	7	0.5	506	12	US-10-342-276-19	Sequence 19, Appl
392	7	0.5	383	15	US-10-141-531-186	Sequence 186, Appl	465	7	0.5	511	11	US-09-928-523B-13	Sequence 13, Appl
393	7	0.5	383	15	US-10-141-531-195	Sequence 195, Appl	466	7	0.5	511	15	US-10-128-714-8150	Sequence 8150, Ap
394	7	0.5	383	15	US-10-141-531-204	Sequence 204, Appl	467	7	0.5	511	15	US-10-128-714-8150	Sequence 8150, Ap
395	7	0.5	384	10	US-09-945-249-8	Sequence 8, Appl1	468	7	0.5	511	15	US-10-156-761-9625	Sequence 9625, Ap
396	7	0.5	385	12	US-10-183-708-96	Sequence 96, Appl1	469	7	0.5	513	11	US-09-298-522B-12	Sequence 12, Appl
397	7	0.5	387	12	US-10-082-272-3	Sequence 3, Appl1	470	7	0.5	518	9	US-09-925-299-862	Sequence 862, Appl
398	7	0.5	391	15	US-10-156-275-6	Sequence 6, Appl1	471	7	0.5	518	11	US-09-925-299-862	Sequence 4, Appl1
399	7	0.5	392	10	US-09-168-474-9	Sequence 9, Appl1	472	7	0.5	518	11	US-09-815-379-4	Sequence 2, Appl1
400	7	0.5	392	12	US-10-054-399A-9	Sequence 9, Appl1	473	7	0.5	518	15	US-10-283-023-2	Sequence 182, Appl
401	7	0.5	392	15	US-10-060-036-67	Sequence 67, Appl1	474	7	0.5	519	16	US-10-278-536-182	Sequence 107, Appl
402	7	0.5	395	14	US-09-949-427-2	Sequence 2, Appl1	475	7	0.5	522	15	US-10-081-051-107	Sequence 56, Appl1
403	7	0.5	395	14	US-10-029-180-40	Sequence 40, Appl1	476	7	0.5	524	15	US-10-253-007-56	Sequence 56, Appl1
404	7	0.5	398	10	US-09-961-527A-9	Sequence 9, Appl1	477	7	0.5	530	12	US-10-032-588-7659	Sequence 7659, Ap
405	7	0.5	399	11	US-09-934-455-278	Sequence 278, Appl	478	7	0.5	532	9	US-09-925-301-1004	Sequence 1004, Ap
406	7	0.5	401	12	US-09-949-029-146	Sequence 146, Appl	479	7	0.5	543	10	US-09-736-457-337	Sequence 337, Appl
407	7	0.5	403	9	US-09-802-213-5	Sequence 5, Appl1	480	7	0.5	543	10	US-09-902-941-337	Sequence 337, Appl
408	7	0.5	406	11	US-09-056-019-1	Sequence 1, Appl1	481	7	0.5	543	10	US-09-849-626-337	Sequence 337, Appl
409	7	0.5	411	15	US-10-156-761-11579	Sequence 11579, A	482	7	0.5	543	11	US-09-476-300-337	Sequence 337, Appl
410	7	0.5	414	9	US-09-802-213-3	Sequence 3, Appl1	483	7	0.5	543	11	US-10-251-661-6	Sequence 6, Appl1
411	7	0.5	414	9	US-09-931-457A-64	Sequence 64, Appl1	484	7	0.5	543	12	US-10-113-872-337	Sequence 337, Appl
412	7	0.5	415	10	US-10-124-557-68	Sequence 68, Appl1	485	7	0.5	543	12	US-10-032-588-7577	Sequence 7577, Ap
413	7	0.5	422	14	US-10-124-557-68	Sequence 68, Appl1	486	7	0.5	543	15	US-10-017-754-337	Sequence 337, Appl
414	7	0.5	423	14	US-10-124-557-66	Sequence 66, Appl1	487	7	0.5	543	15	US-10-017-754-337	Sequence 337, Appl
415	7	0.5	428	11	US-09-056-019-24	Sequence 24, Appl1	488	7	0.5	544	12	US-10-032-588-7924	Sequence 7924, Ap
416	7	0.5	431	9	US-09-815-242-5406	Sequence 5406, Ap	489	7	0.5	553	12	US-10-347-272-13	Sequence 13, Appl1
417	7	0.5	431	9	US-09-815-242-12488	Sequence 12488, A	490	7	0.5	553	12	US-10-347-272-13	Sequence 13, Appl1
418	7	0.5	433	10	US-09-801-368-38	Sequence 38, Appl1	491	7	0.5	555	15	US-10-106-698-5847	Sequence 5847, Ap
419	7	0.5	435	10	US-09-866-626-33	Sequence 33, Appl1	492	7	0.5	555	15	US-10-032-588-7914	Sequence 7914, Ap
420	7	0.5	438	10	US-09-738-626-6703	Sequence 6703, Ap	493	7	0.5	562	15	US-10-083-357-1329	Sequence 1329, Ap
421	7	0.5	446	12	US-10-254-995-6	Sequence 6, Appl1	494	7	0.5	562	15	US-10-083-357-1329	Sequence 7793, Ap
422	7	0.5	446	12	US-10-254-995-9	Sequence 9, Appl1	495	7	0.5	578	12	US-10-032-588-7793	Sequence 4, Appl1
423	7	0.5	447	12	US-10-082-272-2	Sequence 2, Appl1	496	7	0.5	579	14	US-10-384-743-4	Sequence 4, Appl1
424	7	0.5	448	11	US-09-934-455-126	Sequence 126, Appl	497	7	0.5	582	15	US-10-158-895-3	Sequence 3, Appl1
425	7	0.5	450	9	US-09-826-752-2	Sequence 2, Appl1	498	7	0.5	590	12	US-10-122-805-3	Sequence 15, Appl1
426	7	0.5	450	15	US-10-153-668-268	Sequence 268, Appl	499	7	0.5	590	14	US-10-158-895-15	Sequence 15, Appl1
427	7	0.5	450	15	US-10-153-668-380	Sequence 380, Appl	500	7	0.5	594	12	US-10-137-870-10	Sequence 10, Appl1
428	7	0.5	450	15	US-10-153-668-382	Sequence 382, Appl	501	7	0.5	594	12	US-10-140-018-10	Sequence 10, Appl1
429	7	0.5	452	9	US-09-815-242-10493	Sequence 10493, A	502	7	0.5	594	12	US-10-140-021-10	Sequence 10, Appl1
430	7	0.5	455	12	US-09-848-841-12	Sequence 12, Appl1	503	7	0.5	594	12	US-10-140-274-10	Sequence 10, Appl1
431	7	0.5	459	11	US-09-056-019-39	Sequence 39, Appl1	504	7	0.5	594	12	US-10-140-471-10	Sequence 10, Appl1
432	7	0.5	460	10	US-09-925-300-1228	Sequence 1228, Ap	505	7	0.5	594	12	US-10-140-807-10	Sequence 10, Appl1
433	7	0.5	460	11	US-09-056-019-38	Sequence 38, Appl1	506	7	0.5	594	12	US-10-140-922-10	Sequence 10, Appl1
434	7	0.5	463	14	US-10-124-557-54	Sequence 54, Appl1	507	7	0.5	594	12	US-10-140-924-10	Sequence 10, Appl1
435	7	0.5	464	11	US-09-770-509-22	Sequence 22, Appl1	508	7	0.5	594	12	US-10-140-926-10	Sequence 10, Appl1
436	7	0.5	465	9	US-09-884-260A-52	Sequence 52, Appl1	509	7	0.5	594	12	US-10-141-698-10	Sequence 10, Appl1
437	7	0.5	466	12	US-10-032-585-7466	Sequence 7466, Ap	510	7	0.5	594	12	US-10-141-702-10	Sequence 10, Appl1
438	7	0.5	471	8	US-08-954-771-34	Sequence 34, Appl1	511	7	0.5	594	12	US-10-141-702-10	Sequence 10, Appl1
439	7	0.5	471	9	US-09-741-669-428	Sequence 428, Appl	512	7	0.5	594	12	US-10-142-421-10	Sequence 10, Appl1
440	7	0.5	474	10	US-09-736-457-1812	Sequence 1812, Ap	513	7	0.5	594	12	US-10-142-432-10	Sequence 10, Appl1
441	7	0.5	474	10	US-09-902-941-1812	Sequence 1812, Ap	514	7	0.5	594	12	US-10-142-432-10	Sequence 10, Appl1
442	7	0.5	474	10	US-09-849-626-1812	Sequence 1812, Ap	515	7	0.5	594	12	US-10-142-432-10	Sequence 10, Appl1
443	7	0.5	474	12	US-10-113-872-1812	Sequence 1812, Ap	516	7	0.5	594	12	US-10-143-033-10	Sequence 10, Appl1
444	7	0.5	474	12	US-10-113-872-1812	Sequence 1812, Ap	517	7	0.5	594	12	US-10-144-994-10	Sequence 10, Appl1
445	7	0.5	474	12	US-10-017-754-1812	Sequence 1812, Ap	518	7	0.5	594	12	US-10-144-994-10	Sequence 10, Appl1
446	7	0.5	475	9	US-10-205-823-381	Sequence 381, Appl	519	7	0.5	594	12	US-10-145-633-10	Sequence 10, Appl1
447	7	0.5	475	15	US-10-318-780-4	Sequence 14, Appl1	520	7	0.5	594	12	US-10-145-633-10	Sequence 10, Appl1
448	7	0.5	476	10	US-09-774-414-3	Sequence 3, Appl1	521	7	0.5	594	12	US-10-145-746-10	Sequence 10, Appl1
449	7	0.5	477	12	US-10-161-051-43	Sequence 43, Appl1	522	7	0.5	594	12	US-10-145-823-10	Sequence 10, Appl1
450	7	0.5	484	12	US-10-347-278-17	Sequence 17, Appl1	523	7	0.5	594	12	US-10-145-826-10	Sequence 10, Appl1
451	7	0.5	484	12	US-10-347-252-17	Sequence 17, Appl1	524	7	0.5	594	12	US-10-145-826-10	Sequence 10, Appl1
452	7	0.5	489	9	US-09-956-425-6	Sequence 6, Appl1	525	7	0.5	594	12	US-10-145-876-10	Sequence 10, Appl1
453	7	0.5	489	11	US-09-533-029-60	Sequence 60, Appl1	526	7	0.5	594	12	US-10-145-959-10	Sequence 10, Appl1

673	7	0.5	594	15	US-10-121-045-10	Sequence 10, Appl	746	7	0.5	594	15	US-10-123-235-10	Sequence 10, Appl
674	7	0.5	594	15	US-10-123-292-10	Sequence 10, Appl	747	7	0.5	594	15	US-10-124-818-10	Sequence 10, Appl
675	7	0.5	594	15	US-10-123-903-10	Sequence 10, Appl	748	7	0.5	594	15	US-10-137-868-10	Sequence 10, Appl
676	7	0.5	594	15	US-10-124-819-10	Sequence 10, Appl	749	7	0.5	594	15	US-10-147-497-10	Sequence 10, Appl
677	7	0.5	594	15	US-10-124-822-10	Sequence 10, Appl	750	7	0.5	594	15	US-10-158-782-10	Sequence 10, Appl
678	7	0.5	594	15	US-10-140-925-10	Sequence 10, Appl	751	7	0.5	594	15	US-10-123-905-10	Sequence 10, Appl
679	7	0.5	594	15	US-10-160-498-10	Sequence 10, Appl	752	7	0.5	594	15	US-10-123-907-10	Sequence 10, Appl
680	7	0.5	594	15	US-10-124-824-10	Sequence 10, Appl	753	7	0.5	594	15	US-10-124-815-10	Sequence 10, Appl
681	7	0.5	594	15	US-10-127-825A-10	Sequence 10, Appl	754	7	0.5	594	15	US-10-125-921A-10	Sequence 10, Appl
682	7	0.5	594	15	US-10-127-829A-10	Sequence 10, Appl	755	7	0.5	594	15	US-10-125-928A-10	Sequence 10, Appl
683	7	0.5	594	15	US-10-127-835A-10	Sequence 10, Appl	756	7	0.5	594	15	US-10-127-821A-10	Sequence 10, Appl
684	7	0.5	594	15	US-10-127-839A-10	Sequence 10, Appl	757	7	0.5	594	15	US-10-127-822A-10	Sequence 10, Appl
685	7	0.5	594	15	US-10-127-901A-10	Sequence 10, Appl	758	7	0.5	594	15	US-10-127-832A-10	Sequence 10, Appl
686	7	0.5	594	15	US-10-128-693A-10	Sequence 10, Appl	759	7	0.5	594	15	US-10-127-826A-10	Sequence 10, Appl
687	7	0.5	594	15	US-10-131-818A-10	Sequence 10, Appl	760	7	0.5	594	15	US-10-127-827A-10	Sequence 10, Appl
688	7	0.5	594	15	US-10-131-818A-10	Sequence 10, Appl	761	7	0.5	594	15	US-10-127-828A-10	Sequence 10, Appl
689	7	0.5	594	15	US-10-131-823A-10	Sequence 10, Appl	762	7	0.5	594	15	US-10-127-830A-10	Sequence 10, Appl
690	7	0.5	594	15	US-10-131-824A-10	Sequence 10, Appl	763	7	0.5	594	15	US-10-127-832A-10	Sequence 10, Appl
691	7	0.5	594	15	US-10-131-830A-10	Sequence 10, Appl	764	7	0.5	594	15	US-10-127-833A-10	Sequence 10, Appl
692	7	0.5	594	15	US-10-131-837A-10	Sequence 10, Appl	765	7	0.5	594	15	US-10-127-833A-10	Sequence 10, Appl
693	7	0.5	594	15	US-10-137-872A-10	Sequence 10, Appl	766	7	0.5	594	15	US-10-127-836A-10	Sequence 10, Appl
694	7	0.5	594	15	US-10-147-500-10	Sequence 10, Appl	767	7	0.5	594	15	US-10-127-841A-10	Sequence 10, Appl
695	7	0.5	594	15	US-10-147-502-10	Sequence 10, Appl	768	7	0.5	594	15	US-10-127-844A-10	Sequence 10, Appl
696	7	0.5	594	15	US-10-147-515-10	Sequence 10, Appl	769	7	0.5	594	15	US-10-128-687A-10	Sequence 10, Appl
697	7	0.5	594	15	US-10-147-517-10	Sequence 10, Appl	770	7	0.5	594	15	US-10-128-688A-10	Sequence 10, Appl
698	7	0.5	594	15	US-10-147-526-10	Sequence 10, Appl	771	7	0.5	594	15	US-10-128-689A-10	Sequence 10, Appl
699	7	0.5	594	15	US-10-147-527-10	Sequence 10, Appl	772	7	0.5	594	15	US-10-128-694A-10	Sequence 10, Appl
700	7	0.5	594	15	US-10-121-041-10	Sequence 10, Appl	773	7	0.5	594	15	US-10-131-825A-10	Sequence 10, Appl
701	7	0.5	594	15	US-10-121-043-10	Sequence 10, Appl	774	7	0.5	594	15	US-10-131-818A-10	Sequence 10, Appl
702	7	0.5	594	15	US-10-121-047-10	Sequence 10, Appl	775	7	0.5	594	15	US-10-131-818A-10	Sequence 10, Appl
703	7	0.5	594	15	US-10-123-215-10	Sequence 10, Appl	776	7	0.5	594	15	US-10-131-821A-10	Sequence 10, Appl
704	7	0.5	594	15	US-10-123-902-10	Sequence 10, Appl	777	7	0.5	594	15	US-10-131-822A-10	Sequence 10, Appl
705	7	0.5	594	15	US-10-123-908-10	Sequence 10, Appl	778	7	0.5	594	15	US-10-131-828A-10	Sequence 10, Appl
706	7	0.5	594	15	US-10-123-909-10	Sequence 10, Appl	779	7	0.5	594	15	US-10-131-835A-10	Sequence 10, Appl
707	7	0.5	594	15	US-10-123-910-10	Sequence 10, Appl	780	7	0.5	594	15	US-10-137-864A-10	Sequence 10, Appl
708	7	0.5	594	15	US-10-124-813-10	Sequence 10, Appl	781	7	0.5	594	15	US-10-137-869A-10	Sequence 10, Appl
709	7	0.5	594	15	US-10-124-817-10	Sequence 10, Appl	782	7	0.5	594	15	US-10-137-869A-10	Sequence 10, Appl
710	7	0.5	594	15	US-10-125-922-10	Sequence 10, Appl	783	7	0.5	594	15	US-10-147-523-10	Sequence 10, Appl
711	7	0.5	594	15	US-10-125-924-10	Sequence 10, Appl	784	7	0.5	594	15	US-10-158-785-10	Sequence 10, Appl
712	7	0.5	594	15	US-10-140-860-10	Sequence 10, Appl	785	7	0.5	594	15	US-10-121-051-10	Sequence 10, Appl
713	7	0.5	594	15	US-10-142-417-10	Sequence 10, Appl	786	7	0.5	594	15	US-10-123-912-10	Sequence 10, Appl
714	7	0.5	594	15	US-10-147-519-10	Sequence 10, Appl	787	7	0.5	594	15	US-10-192-007-10	Sequence 10, Appl
715	7	0.5	594	15	US-10-157-782-10	Sequence 10, Appl	788	7	0.5	594	15	US-10-194-359-10	Sequence 10, Appl
716	7	0.5	594	15	US-10-152-395-10	Sequence 10, Appl	789	7	0.5	594	15	US-10-146-788-10	Sequence 10, Appl
717	7	0.5	594	15	US-10-125-926A-10	Sequence 10, Appl	790	7	0.5	594	15	US-10-127-847A-10	Sequence 10, Appl
718	7	0.5	594	15	US-10-125-930A-10	Sequence 10, Appl	791	7	0.5	594	15	US-10-175-590-10	Sequence 10, Appl
719	7	0.5	594	15	US-10-127-831A-10	Sequence 10, Appl	792	7	0.5	594	15	US-10-137-866-10	Sequence 10, Appl
720	7	0.5	594	15	US-10-127-837A-10	Sequence 10, Appl	793	7	0.5	594	15	US-10-146-726-10	Sequence 10, Appl
721	7	0.5	594	15	US-10-127-838B-10	Sequence 10, Appl	794	7	0.5	594	15	US-10-146-727-10	Sequence 10, Appl
722	7	0.5	594	15	US-10-127-842A-10	Sequence 10, Appl	795	7	0.5	594	15	US-10-146-788-10	Sequence 10, Appl
723	7	0.5	594	15	US-10-127-843A-10	Sequence 10, Appl	796	7	0.5	594	15	US-10-152-380-10	Sequence 10, Appl
724	7	0.5	594	15	US-10-127-845A-10	Sequence 10, Appl	797	7	0.5	594	15	US-10-153-934-10	Sequence 10, Appl
725	7	0.5	594	15	US-10-127-846A-10	Sequence 10, Appl	798	7	0.5	594	15	US-09-815-242-10990	Sequence 10990, A
726	7	0.5	594	15	US-10-127-848A-10	Sequence 10, Appl	799	7	0.5	635	12	US-09-848-841-16	Sequence 16, Appl
727	7	0.5	594	15	US-10-127-849A-10	Sequence 10, Appl	800	7	0.5	646	9	US-09-815-242-10311	Sequence 10311, A
728	7	0.5	594	15	US-10-127-850A-10	Sequence 10, Appl	801	7	0.5	646	9	US-09-815-242-13769	Sequence 13769, A
729	7	0.5	594	15	US-10-127-851A-10	Sequence 10, Appl	802	7	0.5	653	12	US-10-199-672-402	Sequence 402, App
730	7	0.5	594	15	US-10-128-684A-10	Sequence 10, Appl	803	7	0.5	653	12	US-10-187-749-402	Sequence 402, App
731	7	0.5	594	15	US-10-128-686A-10	Sequence 10, Appl	804	7	0.5	653	12	US-10-194-457-402	Sequence 402, App
732	7	0.5	594	15	US-10-128-690A-10	Sequence 10, Appl	805	7	0.5	653	12	US-10-184-642-402	Sequence 402, App
733	7	0.5	594	15	US-10-128-691A-10	Sequence 10, Appl	806	7	0.5	653	12	US-10-196-747-402	Sequence 402, App
734	7	0.5	594	15	US-10-131-819A-10	Sequence 10, Appl	807	7	0.5	653	12	US-10-173-689-402	Sequence 402, App
735	7	0.5	594	15	US-10-131-829A-10	Sequence 10, Appl	808	7	0.5	653	12	US-10-173-690-402	Sequence 402, App
736	7	0.5	594	15	US-10-131-836A-10	Sequence 10, Appl	809	7	0.5	653	12	US-10-173-691-402	Sequence 402, App
737	7	0.5	594	15	US-10-146-729-10	Sequence 10, Appl	810	7	0.5	653	12	US-10-173-692-402	Sequence 402, App
738	7	0.5	594	15	US-10-146-791-10	Sequence 10, Appl	811	7	0.5	653	12	US-10-173-694-402	Sequence 402, App
739	7	0.5	594	15	US-10-147-484-10	Sequence 10, Appl	812	7	0.5	653	12	US-10-173-698-402	Sequence 402, App
740	7	0.5	594	15	US-10-147-508-10	Sequence 10, Appl	813	7	0.5	653	12	US-10-173-707-402	Sequence 402, App
741	7	0.5	594	15	US-10-147-512-10	Sequence 10, Appl	814	7	0.5	653	12	US-10-174-569-402	Sequence 402, App
742	7	0.5	594	15	US-10-175-735-10	Sequence 10, Appl	815	7	0.5	653	12	US-10-174-583-402	Sequence 402, App
743	7	0.5	594	15	US-10-121-040-10	Sequence 10, Appl	816	7	0.5	653	12	US-10-174-587-402	Sequence 402, App
744	7	0.5	594	15	US-10-121-056-10	Sequence 10, Appl	817	7	0.5	653	12	US-10-174-587-402	Sequence 402, App
745	7	0.5	594	15	US-10-121-061-10	Sequence 10, Appl	818	7	0.5	653	12	US-10-174-589-402	Sequence 402, App


```
965 7 0.5 653 15 US-10-188-773-402 Sequence 402, App
966 7 0.5 653 15 US-10-188-781-402 Sequence 402, App
967 7 0.5 653 15 US-10-194-361-402 Sequence 402, App
968 7 0.5 653 15 US-10-194-423-402 Sequence 402, App
969 7 0.5 653 15 US-10-195-897-402 Sequence 402, App
970 7 0.5 653 15 US-10-195-901-402 Sequence 402, App
971 7 0.5 653 15 US-10-195-902-402 Sequence 402, App
972 7 0.5 653 15 US-10-196-743-402 Sequence 402, App
973 7 0.5 653 15 US-10-196-760-402 Sequence 402, App
974 7 0.5 653 15 US-10-173-708-402 Sequence 402, App
975 7 0.5 653 15 US-10-176-479-402 Sequence 402, App
976 7 0.5 653 15 US-10-176-748-402 Sequence 402, App
977 7 0.5 653 15 US-10-176-916-402 Sequence 402, App
978 7 0.5 653 15 US-10-179-507-402 Sequence 402, App
979 7 0.5 653 15 US-10-179-519-402 Sequence 402, App
980 7 0.5 653 15 US-10-179-519-402 Sequence 402, App
981 7 0.5 653 15 US-10-179-525-402 Sequence 402, App
982 7 0.5 653 15 US-10-180-540-402 Sequence 402, App
983 7 0.5 653 15 US-10-180-545-402 Sequence 402, App
984 7 0.5 653 15 US-10-183-006-402 Sequence 402, App
985 7 0.5 653 15 US-10-183-008-402 Sequence 402, App
986 7 0.5 653 15 US-10-183-017-402 Sequence 402, App
987 7 0.5 653 15 US-10-183-019-402 Sequence 402, App
988 7 0.5 653 15 US-10-184-618-402 Sequence 402, App
989 7 0.5 653 15 US-10-184-625-402 Sequence 402, App
990 7 0.5 653 15 US-10-184-626-402 Sequence 402, App
991 7 0.5 653 15 US-10-184-645-402 Sequence 402, App
992 7 0.5 653 15 US-10-184-645-402 Sequence 402, App
993 7 0.5 653 15 US-10-184-654-402 Sequence 402, App
994 7 0.5 653 15 US-10-184-655-402 Sequence 402, App
995 7 0.5 653 15 US-10-188-774-402 Sequence 402, App
996 7 0.5 653 15 US-10-188-775-402 Sequence 402, App
997 7 0.5 653 15 US-10-194-462-402 Sequence 402, App
998 7 0.5 653 15 US-10-196-745-402 Sequence 402, App
999 7 0.5 653 15 US-10-196-762-402 Sequence 402, App
1000 7 0.5 653 15 US-10-197-695-402 Sequence 402, App
```

ALIGNMENTS

```
RESULT 1
US-10-006-780-2
: Sequence 2, Application US/10006780
: Publication No. US20030104496A1
:
: GENERAL INFORMATION:
: APPLICANT: Sakowicz, Roman
: APPLICANT: Beraud, Christophe
: APPLICANT: Guo, Jun
: APPLICANT: Freedman, Richard
: TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
: TITLE OF INVENTION: METHODS FOR ITS USE
: FILE REFERENCE: CYTOPO83
: CURRENT APPLICATION NUMBER: US/10/006,780
: CURRENT FILING DATE: 2001-11-30
: NUMBER OF SEQ ID NOS: 10
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 2
: LENGTH: 1288
: TYPE: PRT
: ORGANISM: Plasmodium falciparum
US-10-006-780-2
```

```
Query Match 100.0%; Score 1288; DB 15; Length 1288;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1288; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 MNSKIKVYVRRKPSLEKKKKSDIITVKNKCTLYIDPRYKVMYKIRHETIVKV 60
DB 1 MNSKIKVYVRRKPSLEKKKKSDIITVKNKCTLYIDPRYKVMYKIRHETIVKV 60
QY 61 FDDTVNFTVYENTIKPLIIDLYENGCVSCFAYGQTSGKTYTMLGSGQYDTPGIF 120
```

```
DB 61 FDDTVNFTVYENTIKPLIIDLYENGCVSCFAYGQTSGKTYTMLGSGQYDTPGIF 120
QY 121 QYAGDIFFELNYDKONTGIFISPELEYCGALYDLOKRVAAALENKEKEVYVDLK 180
DB 121 QYAGDIFFELNYDKONTGIFISPELEYCGALYDLOKRVAAALENKEKEVYVDLK 180
QY 181 ILVLVTEBELILKMDGVLLRKIGVSONDESSRSHAILNIDKIDKNTSLGKIAEIDL 240
DB 181 ILVLVTEBELILKMDGVLLRKIGVSONDESSRSHAILNIDKIDKNTSLGKIAEIDL 240
QY 241 AGSERGADITYSONKQOTGDANINRSILAKCEIRAMDSPKNTIPRDSLTLYVLRIFV 300
DB 241 AGSERGADITYSONKQOTGDANINRSILAKCEIRAMDSPKNTIPRDSLTLYVLRIFV 300
QY 301 GKSKSIIMANISPTISCCCEOTLNTLRYSRVKQFKKSTCINEEDPTNTERISILDSKGS 360
DB 301 GKSKSIIMANISPTISCCCEOTLNTLRYSRVKQFKKSTCINEEDPTNTERISILDSKGS 360
QY 361 EMNASSIENVVIKSNHLSNNNNKINRGKINDKIERNNILKXKSPDKPREGFTSTFGKY 420
DB 361 EMNASSIENVVIKSNHLSNNNNKINRGKINDKIERNNILKXKSPDKPREGFTSTFGKY 420
QY 421 GSLNDIDKIKKXKKGGLINYKSTLYNDNTINKGHNNNNNNNDNNNDNNNNNNNDSS 480
DB 421 GSLNDIDKIKKXKKGGLINYKSTLYNDNTINKGHNNNNNNNDNNNDNNNNNNNDSS 480
QY 481 SMVNMNMNHNINNNINNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNDSS 540
DB 481 SMVNMNMNHNINNNINNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNDSS 540
QY 541 HLNNNDKSIPLHKKKLNLDNITKLXNRSSCDNIMKKKKNNILHARHVSXKLTWFSYDPOKN 600
DB 541 HLNNNDKSIPLHKKKLNLDNITKLXNRSSCDNIMKKKKNNILHARHVSXKLTWFSYDPOKN 600
QY 601 KDNTPFSSNINXKMDNTPKDIYIESRVSVMNGVLLGLKNTKTHDSTDEHNDKIN 660
DB 601 KDNTPFSSNINXKMDNTPKDIYIESRVSVMNGVLLGLKNTKTHDSTDEHNDKIN 660
QY 661 NGVNIITNNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNS 720
DB 661 NGVNIITNNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNSINNSNNS 720
QY 721 NNDNIFFDAISCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNDSS 780
DB 721 NNDNIFFDAISCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNDSS 780
QY 781 HNLFPDNNKQTSNIQININNNKNOGQNVVYSNMFCYINLNDKYYLLDLNNKEQKQNIH 840
DB 781 HNLFPDNNKQTSNIQININNNKNOGQNVVYSNMFCYINLNDKYYLLDLNNKEQKQNIH 840
QY 841 GCDNNIITQNRNDEPKKKTTFYNNNNIYVNNNNGNNSPRMKYGLGSHTSIDNMKNE 900
DB 841 GCDNNIITQNRNDEPKKKTTFYNNNNIYVNNNNGNNSPRMKYGLGSHTSIDNMKNE 900
QY 901 MKNNEMKDNEMKONHISKNNSSSSSSSSNNNIYNNINDDTFONDYCHANDFTIRKN 960
DB 901 MKNNEMKDNEMKONHISKNNSSSSSSSSNNNIYNNINDDTFONDYCHANDFTIRKN 960
QY 961 NTNINSNIYONDDIITYINSLANDYMSNTLLHFKEKYPTLSTNEDYNNKEMEKHRLD 1020
DB 961 NTNINSNIYONDDIITYINSLANDYMSNTLLHFKEKYPTLSTNEDYNNKEMEKHRLD 1020
QY 1021 DDDKYDDNNNNVNNNNKNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNN 1080
DB 1021 DDDKYDDNNNNVNNNNKNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNN 1080
QY 1081 NFNANNEYLSYFOKQAVDTIINNCLNSLDISSGYDTEKILNNIILSKYAEKQVYIKYYIN 1140
DB 1081 NFNANNEYLSYFOKQAVDTIINNCLNSLDISSGYDTEKILNNIILSKYAEKQVYIKYYIN 1140
QY 1141 EDIKNMSLEBIDKTAOSIYERKRVLLTKLILLFKQAVDTQINNETSPLRDLVWCHICNN 1200
DB 1141 EDIKNMSLEBIDKTAOSIYERKRVLLTKLILLFKQAVDTQINNETSPLRDLVWCHICNN 1200
```

QY 1201 NPDDQHFYAYSRLEKDIINLMROIWCESENLRLYQPLVVEYONKSNANSVLNVSSN 1260
| | | | |
Db 1201 NPDDQHFYAYSRLEKDIINLMROIWCESENLRLYQPLVVEYONKSNANSVLNVSSN 1260
| | | | |
QY 1261 NGDIILINKKLVDNDIKNSMDHNNHKK 1288
| | | | |
Db 1261 NGDIILINKKLVDNDIKNSMDHNNHKK 1288
| | | | |

RESULT 2

US-10-006-780-6
; Sequence 6, Application US/10006780
; Publication No. US20030104496A1
; GENERAL INFORMATION:
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
; FILE REFERENCE: CYTOPO83
; CURRENT APPLICATION NUMBER: US/10/006,780
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 355
; TYPE: PRT
; ORGANISM: P. Falciparum
US-10-006-780-6

Query Match 27.5%; Score 354; DB 15; Length 355;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 354; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 KIKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 63
| | | | |
Db 2 KIKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 61
| | | | |
QY 64 TVDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 123
| | | | |
Db 62 TVDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 121
| | | | |
QY 124 AGDIFFLNIYDKDNTKGFISFYELCYGKLYDLQKRKVAALENGKEVVKDKILIR 183
| | | | |
Db 122 AGDIFFLNIYDKDNTKGFISFYELCYGKLYDLQKRKVAALENGKEVVKDKILIR 181
| | | | |
QY 184 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAIINIDLKQINKTSLGKIAFIDLAGS 243
| | | | |
Db 182 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAIINIDLKQINKTSLGKIAFIDLAGS 241
| | | | |
QY 244 ERGADTVSONKQOTQTDGANINNSLALKECIRAMSDKNHIIPRDELTQVLRDIFVGKS 303
| | | | |
Db 242 ERGADTVSONKQOTQTDGANINNSLALKECIRAMSDKNHIIPRDELTQVLRDIFVGKS 301
| | | | |
QY 304 KSIIMANISPTISCEQOTINTLRYSRVKNFKKSTCINEEDTNTERTISILDS 357
| | | | |
Db 302 KSIIMANISPTISCEQOTINTLRYSRVKNFKKSTCINEEDTNTERTISILDS 355
| | | | |

RESULT 3

US-10-006-780-4
; Sequence 4, Application US/10006780
; Publication No. US20030104496A1
; GENERAL INFORMATION:
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
; FILE REFERENCE: CYTOPO83

; CURRENT APPLICATION NUMBER: US/10/006,780
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-10-006-780-4

Query Match 25.8%; Score 332; DB 15; Length 332;
Best Local Similarity 100.0%; Pred. No. 2e-300;
Matches 332; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 KIKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 63
| | | | |
Db 1 KIKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 60
| | | | |
QY 64 TVDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 123
| | | | |
Db 61 TVDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 120
| | | | |
QY 124 AGDIFFLNIYDKDNTKGFISFYELCYGKLYDLQKRKVAALENGKEVVKDKILIR 183
| | | | |
Db 121 AGDIFFLNIYDKDNTKGFISFYELCYGKLYDLQKRKVAALENGKEVVKDKILIR 180
| | | | |
QY 184 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAIINIDLKQINKTSLGKIAFIDLAGS 243
| | | | |
Db 181 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAIINIDLKQINKTSLGKIAFIDLAGS 240
| | | | |
QY 244 ERGADTVSONKQOTQTDGANINNSLALKECIRAMSDKNHIIPRDELTQVLRDIFVGKS 303
| | | | |
Db 241 ERGADTVSONKQOTQTDGANINNSLALKECIRAMSDKNHIIPRDELTQVLRDIFVGKS 300
| | | | |
QY 304 KSIIMANISPTISCEQOTINTLRYSRVKNFK 335
| | | | |
Db 301 KSIIMANISPTISCEQOTINTLRYSRVKNFK 332
| | | | |

RESULT 4

US-10-006-780-10
; Sequence 10, Application US/10006780
; Publication No. US20030104496A1
; GENERAL INFORMATION:
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
; FILE REFERENCE: CYTOPO83
; CURRENT APPLICATION NUMBER: US/10/006,780
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 332
; TYPE: PRT
; ORGANISM: P. Falciparum
US-10-006-780-10

Query Match 25.8%; Score 332; DB 15; Length 332;
Best Local Similarity 100.0%; Pred. No. 2e-300;
Matches 332; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 IKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 64
| | | | |
Db 1 IKVVRKRPPLSELEKKKDSIIIVKNNCTLYIDPRYKVDMTKYIERHEFIVDKVPDD 60
| | | | |
QY 65 VDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 124
| | | | |
Db 61 VDNFVYENTIKPLIIDLYENGCVSCFAYGOTGSGKTYTLMGSPYGSDFPGIFQYA 120
| | | | |

Query Match	25.6%	Score 330;	DB 15;	Length 361;
Best Local Similarity	100.0%	Pred. No. 1,6e-298;		
Matches 330;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
QY	4	KIKVVRKRLPLSELEKKKKDSDIITVKNNTCTLYIDEPRYKVDMTKYIERHEFIVDKYVDD	63	
Db	2	KIKVVRKRLPLSELEKKKKDSDIITVKNNTCTLYIDEPRYKVDMTKYIERHEFIVDKYVDD	61	
QY	64	TYDNPVYVENTIRPLIIDIYENGCVCSCPAYGQGSCKYITMLGSQYRGSDTFGIGIROYA	122	
Db	62	TYDNPVYVENTIRPLIIDIYENGCVCSCPAYGQGSCKYITMLGSQYRGSDTFGIGIROYA	122	
QY	124	AGDIPFTLNIYDKONTKGFISFPEIYCGALYDLQRRKVAALENGKEKVEVVDLKLIR	183	
Db	122	AGDIPFTLNIYDKONTKGFISFPEIYCGALYDLQRRKVAALENGKEKVEVVDLKLIR	183	
QY	184	VLTKEELLKMDIGVLRLKIGVNSQNDSSRSHALINIDIKDINKNTSLGKIAFIDLAGS	244	
Db	182	VLTKEELLKMDIGVLRLKIGVNSQNDSSRSHALINIDIKDINKNTSLGKIAFIDLAGS	244	
QY	244	ERGADTVSONKQOTDGGANINRSLALKECIRAMDSKXNHI PFRDSELTIVKLARDI FVGKS	303	
Db	242	ERGADTVSONKQOTDGGANINRSLALKECIRAMDSKXNHI PFRDSELTIVKLARDI FVGKS	303	
QY	304	KSIMINISPTISCCBOTLNTLTKYSSRVKN	333	
Db	302	KSIMINISPTISCCBOTLNTLTKYSSRVKN	331	

RESULT 8
US-09-994-485-8
; Sequence 8, Application US/09994485
; Patent No. US20020142429A1
; GENERAL INFORMATION:


```
; ORGANISM: Candida albicans
US-10-032-585-7565

Query Match
Best Local Similarity 1.2%; Score 16; DB 12; Length 798;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
Db 390 NNNNNNNNNNNNNNNNN 405

RESULT 12
US-09-801-368-132
; Sequence 132, Application US/09801368
; Patent No. US20020128250A1
; GENERAL INFORMATION:
; APPLICANT: Busby, Robert
; APPLICANT: Cali, Brian
; APPLICANT: Hecht, Peter
; APPLICANT: Holtzman, Doug
; APPLICANT: Madden, Kevin
; APPLICANT: Maxon, Mary
; APPLICANT: Milne, Todd
; APPLICANT: No. US20020128250A1man, Thea
; APPLICANT: Royer, John
; APPLICANT: Salama, Sofie
; APPLICANT: Sherman, Amit
; APPLICANT: Silva, Jeff
; APPLICANT: Summers, Eric
; TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
; FILE REFERENCE: 109272.147
; CURRENT APPLICATION NUMBER: US/09/801,368
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 09/487,558
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 60/160,587
; PRIOR FILING DATE: 1999-10-20
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 132
; LENGTH: 961
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-801-368-132

Query Match
Best Local Similarity 1.2%; Score 16; DB 10; Length 961;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
Db 515 NNNNNNNNNNNNNNNNN 530

RESULT 13
US-10-087-464-50
; Sequence 50, Application US/10087464
; Publication No. US20030059436A1
; GENERAL INFORMATION:
; APPLICANT: Chishti, Athar
; APPLICANT: Oh, Steven
; APPLICANT: Liu, David
; APPLICANT: Goel, Vikas
; APPLICANT: Li, Xuerong
; TITLE OF INVENTION: Band 3 Antigenic Peptides, Malaria Polypeptides and Uses Thereof
; FILE REFERENCE: S1237/7019
; CURRENT APPLICATION NUMBER: US/10/087,464
; CURRENT FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 06/272,930
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 50
; LENGTH: 1331
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-10-087-464-50

Query Match
Best Local Similarity 1.2%; Score 16; DB 15; Length 1331;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
Db 1178 NNNNNNNNNNNNNNNNN 1193

RESULT 14
US-10-135-322-17
; Sequence 17, Application US/10135322
; Publication No. US20020173017A1
; GENERAL INFORMATION:
; APPLICANT: BENNEY, PN
; APPLICANT: HELARUTTA, Y
; APPLICANT: MAHONEN, AP
; APPLICANT: BONKE, AMW
; APPLICANT: KAPPINEN, L
; APPLICANT: RIKONEN, M
; TITLE OF INVENTION: WOODEN LEG GENE, PROMOTER AND USES THEREOF
; FILE REFERENCE: 5914-086-999
; CURRENT APPLICATION NUMBER: US/10/135,322
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: 60/253,739
; PRIOR FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 2150
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-10-135-322-17

Query Match
Best Local Similarity 1.2%; Score 16; DB 14; Length 2150;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
Db 105 NNNNNNNNNNNNNNNNN 120

RESULT 15
US-10-304-095-6
; Sequence 6, Application US/10304095
; Publication No. US20030134275A1
; GENERAL INFORMATION:
; APPLICANT: Long, David M.
; APPLICANT: Metz, Anneke M.
; APPLICANT: Love, Ruschelle A.
; TITLE OF INVENTION: Telomerase Reverse Transcriptase (TERT) Genes
; FILE REFERENCE: 47714-5009-US
; CURRENT APPLICATION NUMBER: US/10/304,095
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: US/09/417,485
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 2184
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
FEATURE:
NAME/KEY: unsure
LOCATION: (330)..(335)
OTHER INFORMATION: Xaa at position 330 = Leu or Ile;
```

```
; OTHER INFORMATION: Xaa at position 335 = Asp or Gly.
US-10-304-095-6
Query Match      1.2%; Score 16; DB 12; Length 2184;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNNNNNN 757
DB      239 NNNNNNNNNNNNNNNNNN 254

RESULT 16
US-10-184-644-35
; Sequence 35, Application US/10184644
; Publication No. US20030044930A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C227
; CURRENT APPLICATION NUMBER: US/10/184,644
; CURRENT FILING DATE: 2002-06-28
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 35
; LENGTH: 2690
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 2039-2065
; OTHER INFORMATION: unknown base
US-10-184-644-35

Query Match      1.2%; Score 16; DB 15; Length 2690;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNNNNNN 757
DB      2039 NNNNNNNNNNNNNNNNNN 2054

RESULT 17
US-10-184-634-35
; Sequence 35, Application US/10184634
; Publication No. US20030068684A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C217
```

```
; CURRENT APPLICATION NUMBER: US/10/184,634
; CURRENT FILING DATE: 2002-06-28
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 35
; LENGTH: 2690
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 2039-2065
; OTHER INFORMATION: unknown base
US-10-184-634-35

Query Match      1.2%; Score 16; DB 15; Length 2690;
Best Local Similarity 100.0%; Pred. No. 1.7e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNNNNNN 757
DB      2039 NNNNNNNNNNNNNNNNNN 2054

RESULT 18
US-09-864-761-47535
; Sequence 47535, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
```

```

; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 47535
; LENGTH: 73
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC010436.4
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 46
; OTHER INFORMATION: EST_HUMAN HIT: BF327361.1, EVALU 2.20e+00
US-09-864-761-47535

Query Match          1.2%; Score 15; DB 9; Length 73;
Best Local Similarity 100.0%; Pred. No. 5.8e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNNNN 756
Db      11 NNNNNNNNNNNNNNNN 25

RESULT 19
US-10-422-866-4
; Sequence 4, Application US/10422866
; Publication No. US20030170857A1
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. US20030170857A1e1 motor proteins and methods for
; FILE REFERENCE: 1054
; CURRENT APPLICATION NUMBER: US/10/422,866
; PRIOR FILING DATE: 2003-04-23
; PRIOR APPLICATION NUMBER: US/09/722,129
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 303
; TYPE: PRT
; ORGANISM: Human
US-10-422-866-4

Query Match          1.2%; Score 15; DB 12; Length 303;
Best Local Similarity 100.0%; Pred. No. 2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      91 CFAYGQTSGKTYTM 105
Db      90 CFAYGQTSGKTYTM 104

RESULT 20
US-10-422-866-2
; Sequence 2, Application US/10422866
; Publication No. US20030170857A1
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. US20030170857A1e1 motor proteins and methods for
; FILE REFERENCE: 1054
; CURRENT APPLICATION NUMBER: US/10/422,866
; PRIOR FILING DATE: 2003-04-23
; PRIOR APPLICATION NUMBER: US/09/722,129
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 492
; TYPE: PRT
; ORGANISM: Human
US-10-422-866-2
```

```

Query Match          1.2%; Score 15; DB 12; Length 492;
Best Local Similarity 100.0%; Pred. No. 3.1e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      91 CFAYGQTSGKTYTM 105
Db      279 CFAYGQTSGKTYTM 293

RESULT 21
US-10-304-095-8
; Sequence 8, Application US/10304095
; Publication No. US20030134275A1
; GENERAL INFORMATION:
; APPLICANT: Long, David M.
; APPLICANT: Metz, Anneke M.
; APPLICANT: Love, Ruschelle A.
; TITLE OF INVENTION: Telomerase Reverse Transcriptase (TERT) Genes
; FILE REFERENCE: 47714-5009-US
; CURRENT APPLICATION NUMBER: US/10/304,095
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: US/09/417,485
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 794
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-10-304-095-8

Query Match          1.2%; Score 15; DB 12; Length 794;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      744 NNNNNNNNNNNNNNNI 758
Db      130 NNNNNNNNNNNNNNNI 144

RESULT 22
US-09-826-752-6
; Sequence 6, Application US/09826752
; Patent No. US20010026930A1
; GENERAL INFORMATION:
; APPLICANT: Guarente, Leonard P.
; APPLICANT: Austriaco Jr., Nicanor
; APPLICANT: Claus, James J.
; APPLICANT: Cole, Francesca
; APPLICANT: Kennedy, Brian
; TITLE OF INVENTION: GENES DETERMINING CELLULAR SENESENCE IN
; FILE REFERENCE: YEAST
; FILE REFERENCE: 0050.1491-005
; CURRENT APPLICATION NUMBER: US/09/826,752
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: US 08/396,001
; PRIOR FILING DATE: 1995-02-28
; PRIOR APPLICATION NUMBER: PCT/US94/09351
; PRIOR FILING DATE: 1994-08-15
; PRIOR APPLICATION NUMBER: US 08/107,408
; PRIOR FILING DATE: 1993-08-16
; PRIOR APPLICATION NUMBER: US 09/323,433
; PRIOR FILING DATE: 1999-06-01
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 888
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-826-752-6

Query Match          1.2%; Score 15; DB 9; Length 888;
```


Best Local Similarity 100.0%; Pred. No. 5.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNN 756
Db 521 NNNNNNNNNNNNNN 535

RESULT 23

US-09-839-185-2
; Sequence 2, Application US/09839185
; Patent No. US20020069433A1
; GENERAL INFORMATION:
; APPLICANT: Schmidt, Eduard Daniel Leendert
; De Vries, Sape Cornelis
; Hecht, Valerie France Gabrielle
; TITLE OF INVENTION: Apomixis Conferred by Expression of SRK
; Interacting Proteins
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Syngenta Patent Dept.
; STREET: 3054 Cornwallis Road
; CITY: RTP
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/839,185
; FILING DATE: 19-Apr-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Weigls, J. Timothy
; REGISTRATION NUMBER: 38,241
; REFERENCE/DOCKET NUMBER: S-30683A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8587
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 375 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Arabidopsis thaliana
; IMMEDIATE SOURCE:
; CLONE: 3A35
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-839-185-2

Query Match 1.1%; Score 14; DB 9; Length 375;
Best Local Similarity 100.0%; Pred. No. 0.00021;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 755
Db 262 NNNNNNNNNNNNNN 275

RESULT 24
US-10-032-585-7575
; Sequence 7575, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Koemer D.
; APPLICANT: Bo, Jiaang

; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7575
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Candida albicans
US-10-032-585-7575

Query Match 1.1%; Score 14; DB 12; Length 458;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 755
Db 187 NNNNNNNNNNNNNN 200

RESULT 25
US-10-195-144-37
; Sequence 37, Application US/10195144
; Publication No. US20030126646A1
; GENERAL INFORMATION:
; APPLICANT: BROWN, GREGORY G.
; APPLICANT: FORMANOVA, NATASA
; APPLICANT: DENDY, CHARLES
; APPLICANT: LANDRY, BENOIT S.
; APPLICANT: CHEUNG, WING
; APPLICANT: JIN, HUA
; TITLE OF INVENTION: NUCLEAR FERTILITY RESTORER GENES AND METHODS OF USE IN
; TITLE OF INVENTION: PLANTS
; FILE REFERENCE: 16313-0136
; CURRENT APPLICATION NUMBER: US/10/195,144
; PRIOR FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/305,026
; PRIOR FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 60/305,363
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 60/308,736
; PRIOR FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 37
; LENGTH: 1062
; TYPE: PRT
; ORGANISM: Raphanus sativum
US-10-195-144-37

Query Match 1.1%; Score 14; DB 15; Length 1062;
Best Local Similarity 100.0%; Pred. No. 0.00053;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 PAYGOTGSGKTYTM 105
Db 523 PAYGOTGSGKTYTM 536

RESULT 26
US-09-801-368-298
; Sequence 298, Application US/09801368
; Patent No. US20020128250A1
; GENERAL INFORMATION:
; APPLICANT: Busby, Robert
; APPLICANT: Cali, Brian
; APPLICANT: Hecht, Peter
; APPLICANT: Holtzman, Doug
; APPLICANT: Madden, Kevin
; APPLICANT: Maxon, Mary

```

; APPLICANT: Milne, Todd
; APPLICANT: No. US20020128250A1man, Thea
; APPLICANT: Royer, John
; APPLICANT: Salama, Sofie
; APPLICANT: Sherman, Amir
; APPLICANT: Silva, Jeff
; APPLICANT: Summers, Eric
; TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
; FILE REFERENCE: 109272.147
; CURRENT APPLICATION NUMBER: US/09/801,368
; PRIOR FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 09/487,558
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 60/160,587
; PRIOR FILING DATE: 1999-10-20
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 298
; LENGTH: 1770
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
; US-09-801-368-298

Query Match      1.1%; Score 14; DB 10; Length 1770;
Best Local Similarity 100.0%; Pred. No. 0.00084;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNN 755
      |||
Db      345 NNNNNNNNNNNNNN 358

RESULT 27
US-10-032-585-7237
; Sequence 7237, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jjiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7237
; LENGTH: 397
; TYPE: PRT
; ORGANISM: Candida albicans
; US-10-032-585-7237

Query Match      1.0%; Score 13; DB 12; Length 397;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 NNNNNNNNNNNNNN 754
      |||
Db      177 NNNNNNNNNNNNNN 189

RESULT 28
US-10-032-585-7930
; Sequence 7930, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jjiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
```

```

; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7930
; LENGTH: 941
; TYPE: PRT
; ORGANISM: Candida albicans
; US-10-032-585-7930

Query Match      1.0%; Score 13; DB 12; Length 941;
Best Local Similarity 100.0%; Pred. No. 0.0041;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      741 TNNNNNNNNNNNNN 753
      |||
Db      654 TNNNNNNNNNNNNN 666

RESULT 29
US-09-801-368-134
; Sequence 134, Application US/09801368
; Patent No. US20020128250A1
; GENERAL INFORMATION:
; APPLICANT: Busby, Robert
; APPLICANT: Cali, Brian
; APPLICANT: Hecht, Peter
; APPLICANT: Holtzman, Doug
; APPLICANT: Madden, Kevin
; APPLICANT: Maxon, Mary
; APPLICANT: Milne, Todd
; APPLICANT: No. US20020128250A1man, Thea
; APPLICANT: Royer, John
; APPLICANT: Salama, Sofie
; APPLICANT: Sherman, Amir
; APPLICANT: Silva, Jeff
; APPLICANT: Summers, Eric
; TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
; FILE REFERENCE: 109272.147
; CURRENT APPLICATION NUMBER: US/09/801,368
; CURRENT FILING DATE: 2001-03-07
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 09/487,558
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 60/160,587
; PRIOR FILING DATE: 1999-10-20
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 134
; LENGTH: 1151
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
; US-09-801-368-134

Query Match      1.0%; Score 13; DB 10; Length 1151;
Best Local Similarity 100.0%; Pred. No. 0.0049;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      502 NNNNNNNNNNNNS 514
      |||
Db      38 NNNNNNNNNNNNS 50

RESULT 30
US-10-060-019-31
; Sequence 31, Application US/10060019
; Publication No. US20030003564A1
; GENERAL INFORMATION:
; APPLICANT: Tyers, Mike
; APPLICANT: Williams, Andrew
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING UBIQUITIN
; TITLE OF INVENTION: DEPENDENT PROTEOLYSIS
; FILE REFERENCE: 11757.10USU1
; CURRENT APPLICATION NUMBER: US/10/060,019
```

```

; CURRENT FILING DATE: 2002-01-29
; PRIOR APPLICATION NUMBER: US/09/177,165
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/092,443
; PRIOR FILING DATE: 1998-07-10
; PRIOR APPLICATION NUMBER: 60/063,254
; PRIOR FILING DATE: 1997-10-24
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 31
; LENGTH: 1151
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
; US-10-060-019-31

Query Match
Best Local Similarity 1.0%; Score 13; DB 15; Length 1151;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 502 NNNNNNNNNNNNS 514
Db 38 NNNNNNNNNNNNS 50

RESULT 31
US-10-032-585-7034
; Sequence 7034, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Ho, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7034
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Candida albicans
; US-10-032-585-7034

Query Match
Best Local Similarity 0.9%; Score 12; DB 12; Length 387;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 INVNNNNNNNNN 510
Db 238 INVNNNNNNNNN 249

RESULT 32
US-09-925-300-1074
; Sequence 1074, Application US/09925300
; Patent No. US20020151681A1
; GENERAL INFORMATION:
; APPLICANT: Craig Rosen,
; APPLICANT: Steve Ruben
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA101
; CURRENT APPLICATION NUMBER: US/09/925,300
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05988
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 1890
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1074
; LENGTH: 410
```

```

; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (14)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (21)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (177)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (248)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (300)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (372)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; US-09-925-300-1074

Query Match
Best Local Similarity 0.9%; Score 12; DB 10; Length 410;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 91 CFAYGQTSGKT 102
Db 143 CFAYGQTSGKT 154

RESULT 33
US-10-032-585-7788
; Sequence 7788, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Ho, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7788
; LENGTH: 511
; TYPE: PRT
; ORGANISM: Candida albicans
; US-10-032-585-7788

Query Match
Best Local Similarity 0.9%; Score 12; DB 12; Length 511;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 457 NNNNNNNNNNN 468
Db 50 NNNNNNNNNNN 61

RESULT 34
US-09-849-602-20
; Sequence 20, Application US/09849602
; Publication No. US20030165834A1
; GENERAL INFORMATION:
; APPLICANT: Scanlan, Matthew J.
; APPLICANT: Old, Lloyd J.
; APPLICANT: Stockert, Elisabeth
; APPLICANT: Chen, Yao-Tseng
; TITLE OF INVENTION: Colon Cancer Antigen Panel
; FILE REFERENCE: L0461/7105(JRV)
```

```
; CURRENT APPLICATION NUMBER: US/09/849,602
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; CURRENT FILING DATE: 2001-05-04
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 725
; TYPE: PRT
; ORGANISM: Homo sapiens
;
US-09-849-602-20

Query Match
Best Local Similarity 100.0%; Score 12; DB 12; Length 725;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 91 CFAAGGTGSGKT 102
DB 344 CFAAGGTGSGKT 355

RESULT 35
US-09-924-154-17
; Sequence 17, Application US/09924154
; Patent No. US20020127241A1
; GENERAL INFORMATION:
; APPLICANT: Narum, David L.
; TITLE OF INVENTION: Anti-Plasmodium Compositions and Methods of Use
; FILE REFERENCE: 05213-0465 43170-262105
; CURRENT APPLICATION NUMBER: US/09/924,154
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/223,525
; PRIOR FILING DATE: 2000-08-07
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 1501
; TYPE: PRT
; ORGANISM: Mammalian
;
US-09-924-154-17

Query Match
Best Local Similarity 100.0%; Score 12; DB 10; Length 1501;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 503 NNNNNNNNNNS 514
DB 46 NNNNNNNNNNS 57

RESULT 36
US-10-106-698-4938
; Sequence 4938, Application US/10106698
; Publication No. US20030109690A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Colon and Colon Cancer Associated Polynucleotides and Polypeptide
; FILE REFERENCE: PA005P1
; CURRENT APPLICATION NUMBER: US/10/106,698
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: PCT/US00/26524
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/157,137
; PRIOR FILING DATE: 1999-09-29
; PRIOR APPLICATION NUMBER: US 60/163,280
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 8564
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 4938
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC_FEATURE
```

```
; LOCATION: (3)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; US-10-106-698-4938

Query Match
Best Local Similarity 100.0%; Score 11; DB 15; Length 160;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 AYGQTGSGKTY 103
DB 89 AYGQTGSGKTY 99

RESULT 37
US-09-934-455-462
; Sequence 462, Application US/09934455
; Publication No. US20030121070A1
; GENERAL INFORMATION:
; APPLICANT: Adam, Luc
; APPLICANT: Creelman, Robert
; APPLICANT: Dubell, Arnold
; APPLICANT: Heard, Jacqueline
; APPLICANT: Jiang, Cai-Zhong
; APPLICANT: Keddie, James
; APPLICANT: Pilgrim, Marsha
; APPLICANT: Ratcliffe, Oliver
; APPLICANT: Reuber, Lynne
; APPLICANT: Riechmann, Jose Luis
; APPLICANT: Yu, Guo-Liang
; APPLICANT: Pineda, Omaira
; TITLE OF INVENTION: Genes for Modifying Plant Traits IV
; FILE REFERENCE: MBI-0025
; CURRENT APPLICATION NUMBER: US/09/934,455
; CURRENT FILING DATE: 2001-08-22
; PRIOR APPLICATION NUMBER: 60/227439
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: MBI-0022
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: MBI-0023
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 516
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 462
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
;
US-09-934-455-462

Query Match
Best Local Similarity 100.0%; Score 11; DB 11; Length 250;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 502 NNNNNNNNNNN 512
DB 4 NNNNNNNNNNN 14

RESULT 38
US-10-286-264-36
; Sequence 36, Application US/10286264
; Publication No. US20030093837A1
; GENERAL INFORMATION:
; APPLICANT: Keddie, James
; APPLICANT: Riechmann, Jose-Luis
; APPLICANT: Ratcliffe, Oliver
; APPLICANT: Zhang, James
; APPLICANT: Jiang, Cai-Zhong
; APPLICANT: Pineda, Omaira
; APPLICANT: Heard, Jacqueline
; APPLICANT: Yu, Guo-Liang
; APPLICANT: Adam, Luc
; APPLICANT: Broun, Pierre
; APPLICANT: Reuber, Lynne
```

```
; APPLICANT: Pilgrim, Marsha
; APPLICANT: Samaha, Raymond
; TITLE OF INVENTION: POLYNUCLEOTIDES FOR SEED TRAIT ALTERATION
; FILE REFERENCE: MBI-008
; CURRENT APPLICATION NUMBER: US/10/286,264
; CURRENT FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: 60/125,814
; PRIOR FILING DATE: 1999-03-23
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 298
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
; FEATURE:
; OTHER INFORMATION: G1362
US-10-286-264-36
```

```
Query Match          0.9%; Score 11; DB 15; Length 298;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 504 NNNNNNNNS 514
Db 204 NNNNNNNNS 214
```

```
RESULT 39
US-10-278-536-188
; Sequence 188, Application US/10278536
; Publication No. US20030131386A1
; GENERAL INFORMATION:
; APPLICANT: Samaha, Raymond
; APPLICANT: Heard, Jacqueline
; APPLICANT: Jiang, Cai-Zhong
; APPLICANT: Pineda, Omaira
; APPLICANT: Reuber, Lynne
; APPLICANT: Riechmann, Jose-Luis
; APPLICANT: Yu, Guo-Liang
; APPLICANT: Keddle, James
; APPLICANT: Ratcliffe, Oliver
; APPLICANT: Pilgrim, Marsha
; APPLICANT: Adam, Luc
; APPLICANT: Broun, Pierre
; FILE REFERENCE: MBI-011
; TITLE OF INVENTION: STRESS-INDUCED POLYNUCLEOTIDES
; CURRENT APPLICATION NUMBER: US/10/278,536
; CURRENT FILING DATE: 2002-10-22
; PRIOR APPLICATION NUMBER: 60/125,814
; PRIOR FILING DATE: 1999-03-23
; NUMBER OF SEQ ID NOS: 238
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 188
; LENGTH: 298
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
; FEATURE:
; OTHER INFORMATION: G1362
US-10-278-536-188
```

```
Query Match          0.9%; Score 11; DB 16; Length 298;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 504 NNNNNNNNS 514
Db 204 NNNNNNNNS 214
```

```
RESULT 40
US-09-991-496-134
; Sequence 134, Application US/09991496
; Patent No. US20020169285A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skelley, Yasir A.W.
; APPLICANT: Bhatia, Ajay
; APPLICANT: Coler, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE REFERENCE: 210121.420C9
; CURRENT APPLICATION NUMBER: US/09/991,496
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 137
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 309
; TYPE: PRT
; ORGANISM: Leishmania major and chagasi
US-09-991-496-134
```

```
Query Match          0.9%; Score 11; DB 10; Length 309;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 92 PAYGOTSGGT 102
Db 256 PAYGOTSGGT 266
```

```
Search completed: October 2, 2003, 16:45:20
Job time : 102 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:07:05 / Search time 29 Seconds

(without alignments)
2088.634 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 6842
Sequence: 1 MNSKIKVVKRPLSELEK.....KLIQDNINKSMDDNNHHK 1288

Scoring table: BIOSUM62
Gapop 10.0, Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	761.5	11.1	730	1 KCM1_XENLA	Q91636 xenopus lae
2	752.5	11.0	725	1 KF2C_HUMAN	Q99661 homo sapien
3	747.5	10.9	671	1 KF2C_MACFA	Q05151 macaca fasc
4	735.5	10.7	679	1 KIF2_HUMAN	O00139 homo sapien
5	735	10.7	718	1 KF2C_CRIGR	P70096 cricetulus
6	732	10.7	721	1 KF2C_MOUSE	Q92268 mus musculu
7	728	10.6	716	1 KIF2_MOUSE	P28740 mus musculu
8	722	10.6	671	1 KF2C_RAT	Q62909 rattus norv
9	719.5	10.5	682	1 KIF2_XENLA	Q91637 xenopus lae
10	597	8.4	537	1 ARP_PLAFA	P04931 plasmodium
11	576	8.4	624	1 DSK1_CYLFU	Q39493 cylindrothe
12	561.5	8.2	1111	1 KIF2_YEAST	P28742 sacccharomyc
13	560.5	8.2	2339	1 RPP1_PLAFA	P27625 plasmodium
14	543	7.9	1956	1 ATX1_PLAFA	Q04936 plasmodium
15	538.5	7.6	1085	1 CMT7_SCHPO	P24339 schizosacch
16	520.5	7.6	1056	1 K125_ARATH	P82266 arabidopsis
17	513	7.5	1006	1 K125_TORAC	Q03826 nicotiana t
18	500.5	7.3	967	1 KINH_LOJPE	P21613 loligo peal
19	500	7.3	1184	1 B1MC_EMINI	P17110 emericella
20	482.5	7.1	2663	1 CENE_HUMAN	Q02224 homo sapien
21	477	7.0	784	1 KL68_DROME	P46867 drosophila
22	472.5	6.9	747	1 KF3B_HUMAN	O15066 homo sapien
23	472.5	6.9	747	1 KF3B_MOUSE	O61771 mus musculu
24	465.5	6.8	554	1 KLUP3_SCHPO	Q9560 schizosacch
25	465.5	6.8	1585	1 P3K3_DICDI	P54675 dictyosteli
26	463	6.8	1038	1 C1N8_YEAST	P27895 sacccharomyc
27	460	6.7	702	1 KF3A_HUMAN	Q94476 homo sapien
28	459	6.7	1066	1 KL61_DROME	P46863 drosophila
29	453	6.6	963	1 K1N3_HUMAN	P33174 mus musculu
30	452.5	6.6	805	1 K1P3_YEAST	P33066 sacccharomyc
31	449	6.6	883	1 KLUP5_SCHPO	O14343 schizosacch
32	447.5	6.5	1057	1 K1I1_HUMAN	P52732 homo sapien
33	447	6.5	963	1 KINH_MOUSE	Q61768 mus musculu

34	446	6.5	1648	1 KFI4_HUMAN	Q15058 homo sapien
35	445.5	6.5	701	1 KF3A_MOUSE	P28741 mus musculu
36	443.5	6.5	956	1 KF5C_MOUSE	P28738 mus musculu
37	442.5	6.5	1226	1 KF4A_XENLA	Q91784 xenopus lae
38	439.5	6.4	1067	1 EG52_XENLA	Q91783 xenopus lae
39	439	6.4	957	1 KF5C_HUMAN	O60282 homo sapien
40	439	6.4	975	1 KINH_DROME	P17210 drosophila
41	437.5	6.4	1231	1 KF4I_MOUSE	P33174 mus musculu
42	435	6.4	786	1 FL10_CHIRE	P46869 chlamydomon
43	435	6.4	989	1 PTP3_DICDI	P54637 dictyosteli
44	434	6.3	2452	1 RPP1_PLAFA	P14248 plasmodium
45	433.5	6.3	742	1 K121_STRPU	P46871 strongyloce

ALIGNMENTS

```

RESULT 1
ID KCM1_XENLA          STANDARD;          PRT;          730 AA.
AC Q91636;
DT 01-NOV-1997 (Rel. 35, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Kinesin central motor 1 (XKCM1).
GN KCM1.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Ovary;
RX MEDLINE=96140638; PubMed=8548824;
RA Walczak C.E., Mitchison T.J., Desai A.;
RT "XKCM1: a Xenopus kinesin-related protein that regulates microtubule
RT dynamics during mitotic spindle assembly.";
RL Cell 84:37-47(1996).

RN [2]
RP REVISION TO 516.
RC TISSUE=Ovary;
RA Walczak C.E.;
RT Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: REGULATES MICROTUBULE DYNAMICS DURING MITOTIC SPINDLE
CC ASSEMBLY. REQUIRED FOR BOTH ESTABLISHMENT AND MAINTENANCE OF
CC MITOTIC SPINDLES. MAY ACT DIRECTLY ON MICROTUBULES, CAUSING A
CC DESTABILIZATION AND EVENTUAL DEPOLYMERIZATION OF THE MICROTUBULE.
CC -!- SUBUNIT: Homodimer (potential).
CC -!- SUBCELLULAR LOCATION: Nuclear and cytoplasmic.
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.

-----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
-----
DR EMBL; U36485; AAC59743.2; -.
DR HSSP; P17119; 3KAR
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil.
FT DOMAIN 1 256 GLOBULAR (POTENTIAL).
FT DOMAIN 257 598 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 599 730 COILED COIL (POTENTIAL).

```

FT	NP	BIN	352	359	APP (POTENTIAL)	915123	CRC64;
SEQ	SEQUENCE	730	AA,	82585	MM;	25C31C187E491523	
	Query Match			11.1%;	Score	761.5;	DB 1; Length 730;
	Best Local Similarity			42.1%;	Pred. No.	1,3e-26;	
	Matches	175;	Conservative	85;	Mismatches	129;	Indels 27; Gaps 12
QY	4	KIKVYVRKRPPLSELEKKKDDSDIITYKNNCTLYIDEPKYVDMTKTIERHEFLVDKFFDD	63				
DB	262	RICVCVRKRPLPKQELSKKEIDISVPSKNIIVLHPPKLVDTLTKYLENAQFFBDSFDE	321				
QY	64	TYDNFTVYNTIKPLIIDLYENGCVCSCPAYGQGTSGSKTYTMLS-QPYGQSPTPGIFQY	1222				
DB	322	TATNEVYVFTARPLVQSIFFBG-KATCPAYGQGTSGSKHTHMGDSBGSKQNVSKGYAF	380				
QY	123	GAAGDIFFTFLNIYDKDNTK---GIFISFEYIYCGKLYDLLQKRWAAALENGKEVVVKD	178				
DB	381	ASRDVFLTL---DQPRYKHLIDLDFVLTPEIYNGKVFDDLNTKTKVLVEDAKQEVQVVG	437				
QY	179	LKILKVLTKLEELIKMID-GVLLRKIGVNSQNDSSRSALINIMDLKDINKATSL-GKIA	236				
DB	438	ILKEKYIASDD-VFKMKIEIGSACRTSGQTFPANTSSRSNACLOIILR---RGSKLHKFS	493				
QY	237	FIDLAGSEKGAFTVSOKOTOTGAININSILAKCIRAMDSDKNHIPRDESELTFLVR	286				
DB	494	LYDLGNENGVDTASADRLTRREGALINSLLKECIRALGQNKSTTPRRESKLTIOILR	553				
QY	297	DIFVK-SKSIIMANISPTISCCQOTLNTLYSSRYVNFNKSCTCINEEDTITERISIL	355				
DB	554	DSFIGNSRSTCMIAMLSPGFSNCEYTLNTFLRYADVRELSQNA-----ETMDNDLQME	607				
QY	356	DSKSGEMNASLLENVYIKSNHLLSNNNKKNKNGKINDKIERNNILKNKSFDPRE	411				
DB	608	DSGGSH---ASJIEGLQDODFLKDELSSTHN--SFQDANLRVGELEDAKVDIRE	658				

RESULT 2	PF2C_HUMAN	STANDARD;	PFT;	725 AA.
ID	PF2C_HUMAN			
AC	Q96G61; Q96C18; Q96HB8; Q9BWV8;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	28-FEB-2003 (Rel. 41, Last sequence update)			
DT	15-SEP-2003 (Rel. 42, Last annotation update)			
DE	Kinesin-like protein KIF2C (Mitotic centromere-associated kinesin)			
DE	(MCAN) (Kinesin-like protein 6).			
-GN	KIF2C OR KNSL6.			
OS	Homo sapiens (Human).			
OC	Eumetazoa; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RC	TISSUE=T-cell;			
PX	MEDLINE=98094213; Pubmed=9434124;			
RA	Kim I.-G., Jun D.Y., Sohn U., Kim Y.H.;			
RT	"Cloning and expression of human mitotic centromere-associated kinesin			
RT	gene.";			
RL	Biochim. Biophys. Acta 1359:181-186(1997).			
RN	[2]			
RP	SEQUENCE FROM N.A. (ISOFORM 2).			
RC	TISSUE=Testis;			
RA	Cheng L.U.;			
RT	"Cloning of human testis specific mitotic centromere-associated			
RT	kinesin.";			
RL	Submitted (MAR-2001) to the EMBL/GenBank/DBD databases.			
RN	[3]			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RC	TISSUE=Kidney, and Uterus;			
RX	MEDLINE=22388257; Pubmed=12477932;			
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,			
RA	Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			

RA	Dischenko L., Marsina B., Palmer A.A., Rabbin G.M., Hong L.,
RA	Stapleton M., Soares M.K., Donald M.F., Casavant T.L., Schetz T.B.,
RA	Brownelein M.-J., Usdin T.B., Toshiyuki S., Carinini P., Prange C.,
RA	Rana S.S., Loquellano N.A., Peters G.J., Adamson R.D., Mullany S.J.,
RA	Bosak S.A., McQueen P.J., McKernan K.J., Malek J.A., Gundratne P.H.,
RA	Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulky S.W.,
RA	Villalon D.K., Wozley D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA	Faney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA	Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalloe D.E.,
RA	Schmerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT	"Generation and initial analysis of more than 15,000 full-length
RT	human and mouse cDNA sequences."
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC	-1- FUNCTION: Present throughout the cell cycle, associates with
CC	centromeres at early prophase, and remains associated with the
CC	centromeres until after telophase (By similarity).
CC	-1- SUBCELLULAR LOCATION: Cytoplasmic and nuclear (By similarity).
CC	-1- ALTERNATIVE PRODUCTS:
CC	Event=Alternative splicing; Named isoforms=2;
CC	Name=1;
CC	Isoid=099661-1; Sequence=Displayed;
CC	Name=2; Synonyms=TS-MCAK;
CC	Isoid=099661-2; Sequence=VSP_002866;
CC	-1- TISSUE SPECIFICITY: EXPRESSED AT HIGH LEVELS IN THYMUS AND TESTIS,
CC	AT LOW LEVELS IN SMALL INTESTINE, THE MUCOSAL LINING OF COLON, AND
CC	PLACENTA. AND AT VERY LOW LEVELS IN SPLEEN AND PANCREAS. EXPRESSION
CC	IS NOT DETECTED IN PROSTATE, PERIPHERAL BLOOD LEUKOCYTES, HEART,
CC	BRAIN, LUNG, LIVER, SKELETAL MUSCLE, KIDNEY, OR PANCREAS.
CC	-1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC	SUBFAMILY.
CC	-----
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation
CC	the European Bioinformatics Institute. There are no restrictions on its
CC	use by non-profit institutions as long as its content is in no way
CC	modified and this statement is not removed. Usage by and for commercial
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC	or send an email to license@isb-sib.ch).
CC	-----
DR	EMBL; U63743; AAC27660.1; -;
DR	EMBL; AY026505; AAK20168.1; -;
DR	EMBL; BC014924; AAH14924.1; -;
DR	EMBL; BC008764; AAH08764.1; -;
DR	HSSP; P17119; 3KAR.
DR	GeneW: HGNC:6393; KIF2C.
DR	MIM; 604538; -;
DR	GO; GO:0005871; C:kinesin complex; TAS.
DR	GO; GO:0003777; F:microtubule motor activity; TAS.
DR	GO; GO:0008283; P:cell proliferation; TAS.
DR	GO; GO:0007002; P:centromere binding; TAS.
DR	GO; GO:0007067; P:mitosis; TAS.
DR	InterPro; IPR001752; Kinesin_motor.
DR	Pfam; Pf00225; Kinesin; 1.
DR	PRINTS; PR00380; KINESINHEAVY.
DR	SMART; SM00129; KISC; 1.
DR	PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR	PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KM	Motor protein; Microtubules; ATP-binding; coiled coil;
KM	Nuclear protein; Alternative splicing.
FT	DOMAIN 1 254 GLOBULAR (POTENTIAL).
FT	DOMAIN 255 518 KINESIN MOTOR (BY SIMILARITY).
FT	DOMAIN 618 658 COILED COIL (POTENTIAL).
FT	NP_BIND 348 355 ATP (POTENTIAL).
FT	DOMAIN 415 418 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
FT	VARSPLIC 1 55 MAMUSLOARLPGLATIGQNSNGIHSAANRYVLEKSC
FT	SVFAEGGATKGKE -> M (in isoform 2).
FT	/FTId=VSP_002866.
FT	CONFLICT 449 449 I -> I (IN REF. 3; AAH08764).
FT	CONFLICT 698 698 R -> P (IN REF. 3; AAH08764).
SO	SEQUENCE 725 AA; 81312 MW; 5BDECC133AB4B55C CnC64;

```

CC the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by, and for commercial entities requires a license agreement (See http://www.ebi.ac.uk/announce/ or send an email to license@ebi.ac.uk).
```

```

CC EMBL; U63743; AAC27660.1; -.
DR EMBL; AY026505; AAK20168.1; -.
DR EMBL; BC014924; AAH14924.1; -.
DR EMBL; BC008764; AAH08764.1; -.
DR HSSP; P17119; 3KAR.
DR Genew; HGNC:6393; KIF2C.
DR MIM; 604538; -.
DR GO; GO:0005871; C:kinesin complex; TAS.
DR GO; GO:0003777; F:microtubule motor activity; TAS.
DR GO; GO:0008283; P:cell proliferation; TAS.
DR GO; GO:0007002; P:centromere binding; TAS.
DR GO; GO:0007067; P:mitosis; TAS.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00417; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00667; KINESIN MOTOR DOMAIN2; 1.
KM Motor protein; Microtubule; ATP-binding; Coiled coil;
KW Nuclear protein; Alternative splicing.
FT DOMAIN 1 254 GLOBULAR (POTENTIAL).
FT DOMAIN 255 518 KINESIN MOTOR (BY SIMILARITY).
FT DOMAIN 618 658 COILED COIL (POTENTIAL).
FT NP_BIND 348 355 ATP (POTENTIAL).
FT DOMAIN 415 418 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
FT VARSPLIC 1 55 MAMSDLSARLPFGALITQKSNGLHSANRYVLEKSCV
SVEMAEAGATKGKE -> M (in isoform 2).
/FTid=VSP 002866.
FT CONFLICT 449 449 I -> L (IN REF. 1 AND 2).
FT CONFLICT 698 698 R -> P (IN REF. 3, AAH07644).
SQ SEQUENCE 725 AA; 81312 MW; 5BDECC13JAB4B55C CRC64;
```



```

Query Match      11.0%; Score 752.5; DB 1; Length 725;
Best Local Similarity 42.1%; Pred. No. 3,1e-26;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

QY      4 KIVVVRKRPISELEKKKKDSDITVKNKNTLYIDEPKYVDMTYIRBHEFIVDKVYDD 63
DB      258 RIVCVRRKRPINKOLAKKEIDIVISIPSKCLLVHPEPLKTLFYELNQAFCDFPAPDE 317

QY      64 TVDNFTYVENTIKPILIDYENGCCSCFPAVGQSSGKTYMLGS-QEYGSDFRGIQY 122
DB      318 TASNENVVRFARPLVQITTFBSG-KATFPAVGQSSGKTHTMGSLSKAONASKGIYAM 376

QY      123 AAGDIETFLN--IYDKONTKGIETSEYIEYCGKYDYLQKTKMVAALENGKKEVAVVXDLK 180
DB      377 ASRDVFLFKNQCPCRYKGLG-YYVTFEITNGKLPDLINKKAKURVLEDGQQQYVYGLQ 435

QY      181 ILRVITLKEELLKIMD-GVLLRKIGVNSQNDSSRSAAIINLIDKDKINKTSLGKIAFID 239
DB      436 EHLVNSAD-VIKIMDWSACRTSGQTFPANSNSSSHACFOIILR--AKGHMGKFSILVD 492

QY      240 LAGSERGADTVSONKQOTQDGINIRSLALAKECIRADSDSKNHIPRDSILTKYLRDIF 299
DB      493 LAGNERGADTSSARQRTMEGAELINKSLALAKECIRALGQNKAHTPPFEESTLTQYLRDSF 552

QY      300 VGR-SKSIIMANISPTTISCCEQTINTLTYSRSRVKNFKNKSTCINEEDTNTERTISILDSK 358
DB      553 IGENSRITOMITATISFGISSCEYTLNTLTLYARVKEILSPHSGPGEQ-----LTOME 603

QY      359 GSENVASISRENVVILKSNLLNNNNNNKINRKINDKIERNNILNKNSPDKRE 411
DB      604 TEEHEACG--NGALIPGNLSKEEELSSQMSFNEAMTQIRELEKAAEELEKE 654

```

```

RESULT 3
KF2C_MACFA
ID_KF2C_MACFA STANDARD: PRT; 671 AA.
AC_Q95LEP1;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE kinesin-1like protein KIF2C (Mitotic centromere-associated kinesin)
DE (MCAK).
GN KIF2C.
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
OC Cercopithecinae; Macaca.
OX NCBI_TaxID=9541;
RX [1]
RN SEQUENCE FROM N.A.
RP TISSUE=Testis;
RC Hashimoto K., Oseida N., Hida M., Kusuda J., Tanuma R., Hirai M.,
RA Terao K., Sugano S.;
RT "Isolation of novel full-length cDNA clones from macaque testis cDNA
RT libraries.";
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Present throughout the cell cycle, associates with the
CC centromeres at early prophase, and remains associated with the
CC centromere until after telophase (By similarity).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic and nuclear (By similarity).
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements/
CC or send an email to license@ebi.ac.uk).
CC -----
DR EMBL; AB072747; BAB69716.1; -.

```

DR	InterPro: IPR001752; kinesin_motor.
DR	Pfam: PF00225; kinesin_1.
DR	PRINTS: PR00380; KINESINHEAVY.
DR	SMART: SM00129; KISG; 1.
DR	PROSITE: PS00411; KINESIN MOTOR DOMAIN; 1.
DR	PROSITE: PS50067; KINESIN MOTOR DOMAIN; 1.
KW	Motor protein; Microtubules; ATP-binding; Coiled coil;
KW	Nuclear protein.
FT	DOMAIN 1 200 GLOBULAR (POTENTIAL) .
FT	DOMAIN 201 464 KINESIN-MOTOR.
FT	DOMAIN 564 604 COILED COIL (POTENTIAL) .
FT	NP BIND 294 301 ATP (POTENTIAL).
SQ	SEQUENCE 671 AA; 75639 MW; 4EA83958B5BBA6 CRC64;

```

Query Match      10.9%; Score 747.5; DB 1; Length 671;
Best Local Similarity 41.9%; Pred. No. 4,7e-26;
Matches 173; Conservative 76; Mismatches 143; Indels 21; Gaps 10;

OY      4 KIKVVRKRPRLSELLEKKKKSDIITVKNCKTLYIDEPRVYDMTKYTERHEFIYDKYVDD 63
DB      204 RICVCVRKRPRLNKOELAKKSIDIVSIPSKCLLVHEPKLVLDITKYLENOAFCDFAFDE 263
OY      64 TVDFVTVYEMTKIKPLIDLYENGVCSCPAVGGGSGKYTMGS-QPYGSDTPGIFQY 122
DB      264 TASNEVYRTTARPLVOTIREGC-KATCFAYGGTSGSKITMGSDLSGKAOMASKGIYAM 322
OY      123 AAGDIFTELN-IYDKNTKGFIISFEIYICGKLYLDLQRRKAAALENGKEVAVVDLK 180
DB      323 ASRDVFLKQPCYRKGLG-VYTFPEIYINGKLPDLNKKAKKLRLVEDQKQYQVVGLO 381
OY      181 ILRLVTEELLKKID-GVLRLKIGVNSQNDDESSRHALLINTDCKINKTSLGKIAFID 239
DB      382 EHLVNSADD-VIKNIDWGSACFTSGQTFSANSSRSIACFOILLR-AKRMHGKFTSLVD 438
OY      240 LAGSERADVTSQNKQOTQDGNANINRSLALKECIRAMDSDKNHIFPRDSELTFKVLIDIF 299
DB      439 LAGNERADVTSNADROIRMEGAEINSLALKECIRALGONKXATPRRESKLTQVLRDSF 498
OY      300 VGR-SKSIIMTANISPTISCEQTLNTRYSRYVKNFKNKTCTINEEDDTNTERISIIDSK 358
DB      499 IGENSRICMTATISPGISCEYTLNTRVADRYKEIISPHGSPGEQ-----LIQME 549
OY      359 GSENNASISENVYIKSNHLLNNNNNNKINKGINKDKIERNNILKNKSPDKPRE 411
DB      550 TEEMEACS--NGALIPGNLSKEBEELSSQMSFNEAWTQILREBERAVEBELKE 600

RESULT 4
KIF2_HUMAN
ID_KIF2_HUMAN STANDARD; PRT; 679 AA.
AC 000139;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Kinesin-like protein KIF2 (Kinesin-2) (HK2).
GN KIF2 OR KNS2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97321046; PubMed=917777;
RA Debernardi S., Fontanelia E., de Gregorio L., Pierotti M.A.,
RA Della D.;
RT "Identification of a novel human kinesin-related gene (HK2) by the
RT cDNA differential display technique.";
RL Genomics 42:67-73 (1997).
CC -!- FUNCTION: THE KINESIN FAMILY MAY RECOGNIZE, TRANSPORT AND POSITION
CC -!- THEIR SPECIFIC CARGOS IN A SINGLE TYPE OF NEURONAL CELL.
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.

```

	CC	This SWISS-PROT entry is copyrighted. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - CC the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb.ch/announce/ or send an email to license@isb-sib.ch).
	CC	-----
	DR	EMBL; Y08319; CAA69621.1; -.
	DR	HSSP; P17119; 3KAR.
	DR	GeneW; HGNC:6318; KIF2.
	DR	MIM; 602591; -.
	DR	GO:G0:0004002; F:adenosinetriphosphatase activity; TAS.
	DR	GO:G0:0003774; F:motor activity; TAS.
	DR	InterPro; IPR001752; kinesin_motor.
	DR	Pfam; PF00225; kinesin_1.
	DR	PRINTS; PR00380; KINESINHEAVY.
	DR	SMART; SM00129; Kisc; 1.
	DR	PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
	DR	PROSITE; PS50067; KINESIN_MOTOR_DOMAIN2; 1.
	KM	Motor Protein; Microtubules; ATP-binding; Coiled coil; Neurone.
	FT	DOMAIN 1 190 GLOBULAR (POTENTIAL).
	FT	DOMAIN 191 525 KINESIN-MOTOR (BY SIMILARITY).
	FT	DOMAIN 525 679 COILED COIL (POTENTIAL).
	FT	NP BIND 286 293 ATP (BY SIMILARITY).
	SQ	SEQUENCE 679 AA; 76927 MW; F96A88BA871BCECD CRC64;
	Query Match	10.7%; Score 735.5; DB 1; Length 679;
	Best Local Similarity	45.8%; Pred. No. 1.6e-25;
	Matches 167; Conservative	62; Mismatches 111; Indels 25; Gaps 9;
Oy	4	KIKVVRKRRLSELEKKKKDSITIVKNNCTIYIDEPKYDMMTYIERHERIVDKVDD 63
Dd	196	RICVCVRRRPLNKKKTOMKDLDVITIPSKDVVMVHPPKOKVDLTLYLENQTFRFDYAFDD 255
Oy	64	TVDNFVTYENTIKTPIILIDYENGCVCSCPAYGTSGSKTYTMLGS-QPYGOSDPFGIFYOY 122
Dd	256	SAPNENMYRTFAKPFLVETIFFENG-MATCFAYIQQTSGKTHTMGPSPGKNQDCSGIYAL 314
Oy	123	AAGDIPTFPLNIYDKNTK---GIFISFEYIYCGLYDLLQRRKVAALENGKEVVVKD 178
Dd	315	AARDVFMLMK---KENYKKLELVQVATPEIYSKGVPDLNRKTKLRVLDEDKQQOVVG 371
Oy	179	LKILRVLTKSELILKMD-GVLLRKIGVNSQNDSSRSAILINTDLKINKTSLSGIKIAF 237
Dd	372	LOEREVKVED-VLKLIIDIGNSCRFSGGTSAHAHSRSIAVPOILL-RKKKLHGKPSL 428
Oy	238	IDLAGSERGADIVSONKOTQTOGANINRSLLAKECIRAMDSDKHIIIPRDELTKVIRD 297
Dd	429	IDLAGERADIVSSADROTRLBGAEIANKSLMLKECIRALGNKKKHTTPFRASKLQVLRD 488
Oy	298	IFVAG-SKSIMIANISPTISCCBOTLNLTVSRVKNFKNKSTCI-----NEED 345
Dd	489	SIIGENSRCMTATISPGMAASCENTLNTLRANRYKELVLPDTAAGDVAPRIHHHPNQID 548
Oy	346	DTNTE 350
Dd	549	DIETQ 553
	RESULT 5	
	KF2C CRIGR	
ID	KF2C CRIGR	STANDARD; PRT; 718 AA.
AC	P70056;	
DT	01-NOV-1997 (Rel. 35, Created)	
DT	30-MAY-2000 (Rel. 39, Last sequence update)	
DT	28-FEB-2003 (Rel. 41, Last annotation update)	
DE	Kinesin-like protein KIF2C (Mitotic centromere-associated kinesin) (MCAK) (Kinesin-like protein 6).	
DE	KIF2C OR KNSL6.	
OS	Cricetulus griseus (Chinese hamster).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;	

```

OC Cricetus.
OX NCBI_TaxId=10029;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95122643; PubMed=7822426;
RA Wordeman L., Mitchson T.J.
RT "Identification and partial characterization of mitotic centromere-
RT associated kinesin, a kinesin-related protein that associates with
RT centromeres during mitosis."
RL J. Cell Biol. 128:95-105(1995).
RN [2]
RP REVISIONS.
RA Wordeman L.
CC Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
CC -! FUNCTION: Present throughout the cell cycle, associates with the
CC centromeres at early prophase, and remains associated with the
CC centromere until after telophase.
CC -! SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
CC -! SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
CC -----
DR EMBL, U11790; AAB17358.2; -.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; Kisc; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil;
KM Nuclear protein.
FT DOMAIN 1 248 GLOBULAR (POTENTIAL).
FT DOMAIN 249 512 KINESIN-MOTOR.
FT DOMAIN 613 651 COILED COIL (POTENTIAL).
FT DOMAIN 689 716 COILED COIL (POTENTIAL).
FT NP_BIND 342 349 ATP (POTENTIAL).
FT DOMAIN 409 412 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
SQ SEQUENCE 718 AA; 80918 MW; 16ABDBCC6AD1B2 CQC64;

Query Match 10.7%; Score 735; DB 1; Length 718;
Best Local Similarity 40.9%; Pred. No. 1,8e-25;
Matches 172; Conservative 75; Mismatches 136; Indels 38; Gaps 9;

OY 4 KIKVVRKRPRLSELEKKKSDITVKNKCTLYIDEPKRYKVDMTKIIRHFEYDKVDD 63
DB 252 RLCVCVRKRPINKQLAKKEIDIVISVPKCLLFVHEPKLKYDLTTYLENQAFCEDFADE 311
OY 64 TYDNTVYENTIKPLIIDLYENGCCSCFEAYGQSGSGKTYMTGS-QYGGSDPPIGY 122
DB 312 TASNVEVRYFTARPLVQTIFEGG-KATCFAYGQTSGKTYHMGDLGSKSQNTSGITYAM 370
OY 123 AAGDIETFT-----LNIYDKMTKGIFISFYEYCCKLYDLLQKRMTVALENGKEV 174
DB 371 ASRDVFLKSPRYNNL-----EYVVFPELYNGKVDPLNKKAKVLVBESKQYV 423
OY 175 VKDKILRLVLTKEELLKMTIDGVLRKIGVNSQNDSSSHALINIDLKINKNTSLGK 234
DB 424 QVVGQEVLYNVACDDVIVKMLNMGSACTSGQCFANSSSRSHACFOILLR-AKGRLHGK 481
OY 235 IAFIDLASGEGADTVSONKQQTIDGANINNSLALKECTIAMDSDKNHPRDSELTKV 294
DB 482 FSLVLDAGNERADTVSSADROTREMGAINSLLALKECTIRALGQNKAKHTPPRESKLTQV 541
OY 295 LADIVGK-SKSIIMANISPTISCEQTLNLTARYSRVKNFKNKCTCINEEDDTWTERIS 353

```

```

OC Cricetus.
OX NCBI_TaxId=10029;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95122643; PubMed=7822426;
RA Wordeman L., Mitchson T.J.
RT "Identification and partial characterization of mitotic centromere-
RT associated kinesin, a kinesin-related protein that associates with
RT centromeres during mitosis."
RL J. Cell Biol. 128:95-105(1995).
RN [2]
RP REVISIONS.
RA Wordeman L.
CC Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
CC -! FUNCTION: Present throughout the cell cycle, associates with the
CC centromeres at early prophase, and remains associated with the
CC centromere until after telophase.
CC -! SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
CC -! SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
CC -----
DR EMBL, U11790; AAB17358.2; -.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; Kisc; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil;
KM Nuclear protein.
FT DOMAIN 1 248 GLOBULAR (POTENTIAL).
FT DOMAIN 249 512 KINESIN-MOTOR.
FT DOMAIN 613 651 COILED COIL (POTENTIAL).
FT DOMAIN 689 716 COILED COIL (POTENTIAL).
FT NP_BIND 342 349 ATP (POTENTIAL).
FT DOMAIN 409 412 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
SQ SEQUENCE 718 AA; 80918 MW; 16ABDBCC6AD1B2 CQC64;

Query Match 10.7%; Score 735; DB 1; Length 718;
Best Local Similarity 40.9%; Pred. No. 1,8e-25;
Matches 172; Conservative 75; Mismatches 136; Indels 38; Gaps 9;

OY 4 KIKVVRKRPRLSELEKKKSDITVKNKCTLYIDEPKRYKVDMTKIIRHFEYDKVDD 63
DB 252 RLCVCVRKRPINKQLAKKEIDIVISVPKCLLFVHEPKLKYDLTTYLENQAFCEDFADE 311
OY 64 TYDNTVYENTIKPLIIDLYENGCCSCFEAYGQSSGKTYMTLS-QYGGSDPPIGY 122
DB 312 TASNVEVRYFTARPLVQTFEGG-KATCFAYGQTSCKTHTMGDLGSKSQNTSGITYAM 370
OY 123 AAGDIEFTF-----LNIYDKMTKGIFISFEYIECKLYDLLQKRMTVALENGKEV 174
DB 371 ASRDVFLKSPRYNNLV-----EYVVFPELYNGKVDPLNKKAKVLVBESKQYV 423
OY 175 VKDKILRLVLTKEELLKMTIDGVLLRKIGVNSQNDSSSHALINIDLKINKNTSLGK 234
DB 424 QVVGQEVLYNVACDDVIVKMLNMGSACTSGQCFANSSSRSHACFOILLR-AKGRLHGK 481
OY 235 IAFIDLASGEGADTVSONKQQTIDGANINNSLALKECTIAMDSDKNHPRDSELTKV 294
DB 482 FSLVLDAGNERADTVSSADROTREMGAIIINSLALKECTIRALGQNKAKHTPPRESKLTQV 541
OY 295 LADIVGK-SKSIIMANISPTISCEQTLNLTARYSRVKNFKNKCTCINEEDDTWTERIS 353

```

```

OC Cricetus.
OX NCBI_TaxId=10029;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95122643; PubMed=7822426;
RA Wordeman L., Mitchson T.J.
RT "Identification and partial characterization of mitotic centromere-
RT associated kinesin, a kinesin-related protein that associates with
RT centromeres during mitosis."
RL J. Cell Biol. 128:95-105(1995).
RN [2]
RP REVISIONS.
RA Wordeman L.
CC Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
CC -! FUNCTION: Present throughout the cell cycle, associates with the
CC centromeres at early prophase, and remains associated with the
CC centromere until after telophase.
CC -! SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
CC -! SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
CC -----
DR EMBL, U11790; AAB17358.2; -.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; Kisc; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil;
KM Nuclear protein.
FT DOMAIN 1 248 GLOBULAR (POTENTIAL).
FT DOMAIN 249 512 KINESIN-MOTOR.
FT DOMAIN 613 651 COILED COIL (POTENTIAL).
FT DOMAIN 689 716 COILED COIL (POTENTIAL).
FT NP_BIND 342 349 ATP (POTENTIAL).
FT DOMAIN 409 412 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
SQ SEQUENCE 718 AA; 80918 MW; 16ABDBCC6AD1B2 CQC64;

Query Match 10.7%; Score 735; DB 1; Length 718;
Best Local Similarity 40.9%; Pred. No. 1,8e-25;
Matches 172; Conservative 75; Mismatches 136; Indels 38; Gaps 9;

OY 4 KIKVVRKRPVSELEKKKSDITVKNKCTLYIDEPKXVDMTKIIRHFIYDKVDD 63
DB 252 RLCVCVRKRPINKQLAKKEIDIVSPKCLFVHEPKLKYDLTYLENQAFCEDFADE 311
OY 64 TYDNTVYENTIKPLIIDLYENGCCSCFEAYGQSGSGTYMTLS-QYGGSDPPIGY 122
DB 312 TASNIVVRYFTARPLVQTFEGG-KATCFAYGQSGSGTYMTLSGDSKQSTSGIYAM 370
OY 123 AAGDIEFTF-----LNIYDKMTKGIFISFYEYCCKLYDLLQKRMVALENGKEV 174
DB 371 ASRDVFLKSGPRYNNLV-----EYVVFPELYNGKVDLNLKKAKVLVBSKQYV 423
OY 175 VKDKILRVLTKEELLKMTIDGVLLRKIGVNSQNDSSSHALINIDLKINKNTSLGK 234
DB 424 QVVGQEVLYNVACDDVIVKMLNMGSACTSGQCFANSSSRSHACFOILLR-AKGRLHGK 481
OY 235 IAFIDLASGEGADIVSONKQTQTDGANINNSLALKECTIAMDSDKNHPRDSELTKV 294
DB 482 FSLVLDAGNERADVSSADROTREMGAIIINSLALKECTIRALGQNKAKHTPPRESKLTQV 541
OY 295 LADIVGK-SKSIIMANISPTISCEQTLNTRYSRYKNFKNKSTCINEEDDTWTERIS 353

```

```

Db 542 LRDSFGNSRTNCMIAMISPGISCEYTLNLTARYADRKELSPHSIGSGEOP----- 593
Qy 354 ILDSKSGENNAASSTEN---VVIKSNHLISNNNNKINRGKINDKIERNNILKNKSPDKPR 410
Db 594 -IOMETEMEMASSNGTSLAVNFKEEELSSOMSS-----FNEAMSOIRLEERAMEELR 646
Qy 411 E 411
Db 647 E 647

RESULT 6
KF2C MOUSE STANDARD; PRT; 721 AA.
ID KF2C MOUSE
AC 092258;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Kinesin-like protein KIF2C (Mitotic centromere-associated kinesin)
DE (MCAK).
GN KIF2C.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=2238257; PubMed=12477932;
RA Strauberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heish F.,
RA Diatchenko L., Marusina K., Farmer A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uscin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Boulford G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallue D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Matra M.A.;
RT "generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -I- FUNCTION: Present throughout the cell cycle, associates with the
CC centromeres at early prophase, and remains associated with the
CC centromere until after telophase (By similarity).
CC SUBCELLULAR LOCATION: Cytoplasmic and nuclear (By similarity).
CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: BC006841, AA006841.1; -
DR MGD: MGI:1921054; KIF2C.
DR InterPro: IPR001752; Kinesin_motor.
DR Pfam: PF00225; kinesin_1.
DR PRINTS: PRO0380; KINESINHEAVY.
DR SMART: SM00129; KISC; 1.
DR PROSITE: PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE: PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil;
KW Nuclear protein.

```

```

FT DOMAIN 1 250 GLOBULAR (POTENTIAL).
FT DOMAIN 251 514 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 614 652 COILED COIL (POTENTIAL).
FT NP BIND 348 355 ATP (POTENTIAL).
SQ SEQUENCE 721 AA; 81085 MW; 92FFBFFA05B7E35 CRC64;

Query Match 10.7%; Score 732; DB 1; Length 721;
Best Local Similarity 41.2%; Pred. No. 2.4e-25;
Matches 170; Conservative 78; Mismatches 141; Indels 24; Gaps 10;

Qy 4 KIVVVRKRLSLSELEKKDDSDIITVKNNTLYIDPRYVDMTKTYIERHFIYDKVEDD 63
Db 254 RICVCVRKRLPNKQELAKKEIDIVSPSKCLLVHBPVKLVLTLYLENQAFDFPAFDE 313
Qy 64 TVDNFTYENTPIPLIIDYENGCVCSFPAVGOTSGSKTYTMGS-QPVGSDTPGIFGY 122
Db 314 TASNEVYRFTARPLVQTTFEGG-KATCPAYGOTSGSKTHMGDLSGSKNSKGIYAM 372
Qy 123 AAGDIFFTLN--IYDKDNTKGFISFYEIYCGLYDLQKRWVAALENGKEVWVDLK 180
Db 373 ASRDVFLKNQPRYRNLANLE-VYTFEITNGKVPFLDNKAKATLVLEDSRQGVVGLQ 431
Qy 181 ILRVLTKEELILMID-GVLLRKIGVNSQNDSSRHAILNIDKDNKNTSLGKIAFID 239
Db 432 EYLVTCADD-VIKIMNGSACRTSGOTFANSSNSRHACFQILLR--TKGRLLHKESTLYD 488
Qy 240 LAGSERGADTVSONKQOTDGDANINRSLALKECIRAMSDKNHIFPDSLETIKVLRIDF 299
Db 489 LAENRGADTVSSADROTREGAINGSLALKECIRALGONKATPRESKLTQVLNDSF 548
Qy 300 VGR-SKSIMANISPTISCEOTLNTLRYSRKNFNKSTCINEEDDTTERISILDSK 358
Db 549 IGENSTCMJAMISPGISCEYTLNLTARYADRKELSPHSIGSGEOPVQMETEVMASNN 608
Qy 359 GSEMAASSSTENVVIKSNHLISNNNNKINRGKINDKIERNNILKNKSPDKPR 411
Db 609 GTSLTGNHEEL---SSOMSS-----FNEAMTOIRLEERALEELRE 647

RESULT 7
KF2C MOUSE STANDARD; PRT; 716 AA.
ID KF2C MOUSE
AC P28740;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Kinesin-like protein KIF2.
GN KIF2 OR KIF2A OR KNS2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93077686; PubMed=1447303;
RA Mizawa H., Sekine Y., Takemura R., Zhang Z., Nangaku M.,
RA Hirokawa N.;
RT "Kinesin family in murine central nervous system."
RL J. Cell Biol. 119:1287-1296(1992).
CC -I- FUNCTION: THE KINESIN FAMILY MAY RECOGNIZE, TRANSPORT AND POSITION
CC THEIR SPECIFIC CARGOS IN A SINGLE TYPE OF NEURONAL CELL.
CC -I- TISSUE SPECIFICITY: EXPRESSED AMONG VARIOUS TISSUES UNOUTOUSLY;
CC ITS EXPRESSION LEVEL IN BRAIN DECREASES WITH DEVELOPMENT.
CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/

```



```

DT 01-NOV-1997 (Rel. 35, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Kinesin-like protein KIF2 (Kinesin-related protein XKIF2).
GN KIF2.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
OC Xenopodidae; Xenopus.
OC NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A., AND REVISIONS.
RC TISSUE=Ovary;
RA Walczak C.E.;
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE OF 124-682 FROM N.A.
RC TISSUE=Ovary;
RA MEDLINE=96140638; PubMed=8548824;
RA Walczak C.E., Mitchison T.J., Desai A.;
RT "XKIM1: a Xenopus kinesin-related protein that regulates microtubule
RT dynamics during mitotic spindle assembly.";
RL Cell 84:37-47(1996).
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U36486; AAC59744.2; ALT_INIT.
DR HSPF; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PRO0380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN_MOTOR_DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil.
KW DOMAIN 1 192 GLOBULAR (POTENTIAL).
FT DOMAIN 193 542 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 543 682 COILED COIL (POTENTIAL).
FT NP_BIND 288 295 ATP (BY SIMILARITY).
SQ SEQUENCE 682 AA; 77414 MW; 3DA295BB319063F8 CRC64;

Query Match 10.5%; Score 719.5; DB 1; Length 682;
Best Local Similarity 47.1%; Pred. No. 7.9e-25;
Matches 162; Conservative 62; Mismatches 105; Indels 15; Gaps 9;

QY 4 KIVAVRKRPLSLSEKKKKDDITIVKNNCTLYIDPRYVDMTKYIERHEFTVDKVEDD 63
DB 198 RIVCVCKRKLPELKKETTKIDLDVITIPKDVVWVHEKQKVDLRFLENQTFRFDYAFDE 257
QY 64 TVDNFTYVENTIRELLIIDLYENGCVCSFAYGOTGSKTYTMIGS-QPIYGSDTPGIFQY 122
DB 258 TAPNETVYRFTAPRLVETLIFERG-MATCFAYGQTGSKTYTMIGSDSGKNQDCKSYAL 316
QY 123 AAGDITFTPLNIYDKDWTK-----GIFSFYIYCGKLYDLQKRMVAALENGKEVAVKD 178
DB 317 AARDVQOMLK---KPKYKKELEQVATFFEYISGKVPDLNRKTKRLVLEDEGQVQVYG 373
QY 179 LKILRVLTKEELILKMD-GVLLRKIGVNSONDESSSHAIIINDLKINKNTSLGKIAP 237
DB 374 LQREYKCVVD-VLKIIIEIENS CRTSGQTSANAHSSSHAVFOIILR--KKGMMHGFSL 430
QY 238 IDLAGERGADTVSONKQOTGDGANINRSLALKECRAMDSDKNHPPRDSLTATVLRD 297
DB 431 IDLAGNRGADTVSSADQTRLEGAELINKSLALKECRALGRNKPHTPFASKLTOVLRD 490

```

```

QY 298 IPVGR-SKSIIMANISPTISCEQITNTLYSRGVNFKKSTC 340
DB 491 SFIGNSRSTCMITATISPMASCENTLNTLRANRVKEL-DPSRC 533

RESULT 10
ARP PLAF
ID ARP PLAF STANDARD; PRT; 537 AA.
AC P04931;
DT 13-AUG-1987 (Rel. 05, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-NOV-1995 (Rel. 32, Last annotation update)
DE Asparagine-rich protein (AG319) (ARP) (Fragment).
OS Plasmodium falciparum.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OC NCBI_TaxID=5833;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=86176787; PubMed=2421257;
RA Stahl H.-D., Bianco A.E., Crewther P.E., Burkot T., Coppel R.L.,
RA Brown G.V., Anders R.F., Kemp D.J.;
RT "An asparagine-rich protein from blood stages of Plasmodium
RT falciparum shares determinants with sporozoites.";
RL Nucleic Acids Res. 14:3089-3102(1986).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M24328; AAA29491.1;
DR PIR; A23770; A23770.
KW Malaria.
FT NON_TER 1 1
FT NON_TER 537 537
SQ SEQUENCE 537 AA; 63000 MW; A6D76B15318CC239 CRC64;

Query Match 8.7%; Score 597; DB 1; Length 537;
Best Local Similarity 28.5%; Pred. No. 1.3e-19;
Matches 212; Conservative 92; Mismatches 193; Indels 246; Gaps 39;

QY 424 NQIDTKKKKKKGLIYKSTLVNDNTINKKNNNNNNNNNDNNNDNNNNNDSSSW 483
DB 2 NNNNNNNNNNDGENTINYQNT--NEFKDKK--NNNFKQYNNNYKFDENNNSNTWHSRN 57
QY 484 NNNINMINNNIN-NNINNVN-----NNNNNNNNNNSHNNHLPPRYAFETDS 530
DB 58 SIVEEHLRNNSIDMNNNSINNTYNOQTRPSSFWENENENENKCYHTG----- 104
QY 531 DRESSLDMMCHLANNDSIFLHKQLRDNIKLNRSSCDNINMKKNNILHARHVSGL 590
DB 105 -----GNMNN-----IHKNKYDN-----NNSSMKQTDNNK----- 130
QY 591 TMSYDPOKKNKNTPFKSNINMKMEDTPKDIYESNVNMGNGV-----LGLNKQTH 645
DB 131 TDTSTV-----MKGTIN--NDNNNDYLRINNINNEYKSAKKEKTYTNKNNLK 179
QY 646 DISTDENHNKINNGVINIINNSVNSINNSNNNSINNSNN--SNS-YKSNVNSOS 703
DB 180 FTQNNNDNNINIEDNN-----NNNNNNNNNNGVFENYQNNNNNRNNSINIKRLNNNN 233
QY 704 ISDVQIRYVENDTSKKNNDNIFPDALSCDNNMYPNITNNNNNNNNNNNNNNNNNN 763
DB 234 INN-----NNNKVGSQPKONS-----NNNFYNNYVYQNKNSKNNNNNNNN 274
QY 764 NNRDGTNNMGLYAVNSHLPOPDDNNKQTSNITNTNKNQDGVNYSMFCHYVLDK 823
DB 275 -----MNNNN-----NNNN-----NNNNNNNNNNNNNNNNNNNNNN 311
QY 824 NYLIIDLNKQKDKNKHGCDNNIIONRNDPEKKKKTTFYNNNNNIYLVNNMGNNSPRMK 883

```

```

Db 312 N-----NINSLSDMGSPNTHAAYKMSM--YNNN-----ESNTANPR--QMN 350
QY 884 YGLCGSHTSIDNMKNMKNEMKNEMKDNKHIXSNNSSSSSSNNNINNNINDDTF 943
Db 351 F-----EQNNNDNMKR--ENNMMNNYGYDDNTVHVNNNTPTSDPFSRAVGYN----- 395
QY 944 QNDYCHANDNTFTIRKKNNTNINSNIYQNDIITITNSLNDYMSNTLHFKEKTYPTLST 1003
Db 396 -NNYLNANN--NNNSAANNNS-----SN 415
QY 1004 NEDLYNKEMGKHILRDDQDYDDVD--NNNVNDDNNKNVDDNNVDDNNVDDNNKGN 1061
Db 416 GNNKKNKESEKAVN-----DNDDSLANNKNNNNNNINNMESINNNTLNN--NNEVNN 466
QY 1062 VDDNNVDDDDDD-----VDFHNIKFNNNEYSYQKNVDITINNCSL-DISSM 1111
Db 467 -QNNNEDEDDDDWGLGEDKYTDINSIMK-----KKNV--ILNQLEADLNDLSKK 513
QY 1112 YDDTKELIANILSLKYKAKGNV 1134
Db 514 GNDGKN-----KKKNKKMKDDL 530

RESULT 11
DSKI CYLFU
ID _DSKI CYLFU STANDARD: PRT; 624 AA.
AC Q39493;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE Diatom spindle kinesin 1.
GN DSKI.
OS Cylinthotheca fusiformis (Marine diatom).
OC Eukaryota; stramenopiles; Bacillariophyta; Bacillariophyceae;
OC Bacillariophycidae; Bacillariales; Bacillariaceae; Cylinthotheca.
OX NCBI_TaxID=2853;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96222363; PubMed=8636234;
RX Wein H., Foss M., Brady B., Candé W.Z.;
RT "DSKI, a novel kinesin-related protein from the diatom Cylinthotheca
RT fusiformis that is involved in anaphase spindle elongation.";
RL J. Cell Biol. 133:595-604(1996).
CC -!- FUNCTION: INVOLVED IN ANAPHASE SPINDLE ELONGATION.
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U51680; AAB05681.1; -.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF002255; kinesin.1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC.1.
DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN_MOTOR_DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil.
KW DOMAIN 1 85
KW DOMAIN 2 85
FT DOMAIN 86 425 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 426 624 COILED COIL (POTENTIAL).
FT NP BIND 186 193 ATP (POTENTIAL).
SQ SEQUENCE 624 AA; 70308 MW; DC996FBECC22BB155 CRC64;

Query Match: 8.4%; Score 576; DB 1; Length 624;
Best Local Similarity 37.5%; Pred No. 1,3e-18;

```

```

Matches 138; Conservative 60; Mismatches 138; Indels 32; Gaps 6
OY 2 NSKRVKVRKRPSELEKKKDSIIYVKNKNTIYIDPRKKD-MTKYIERHPIYKV 60
Db 93 NSNCICVRKKPIDDKERQKLDHDSVGFQK-KWHSIAKLKVGITKYLTHNSQDLHT 151
OY 61 FDDIVDNFTVENIKPFLIIDYENGCVCSCFAYAGQTGSGKTYTMLGSQPYGSDPTPGIF 120
Db 152 FGEISTTEQIYLAITTLPLVDHVSTQGRATYFCYGGIOSGKTYTMNGQ----- 200
OY 121 QYAAGDIFFTFLNIYDKONTKGFISFYEYIYCGKLYDLLQRRKMAALENGKEVVYDKL 180
Db 201 QILAYDIYQGLAEHTDD--LEITVAFFELIYSGNVILDLHGCRCKLLEDGNGEAVITGLR 258
OY 181 ILRLVLTKEELIKKIDGVLLRKIGVNSQNDSSSRSHALNIDLKINKTSLGKAFIDL 240
Db 259 EVAPTPPAFLQVIEEGHSILRTQKTEANDASSSHALQVFLRDYGNLR-GKIGLVDL 317
OY 241 AGSRGADTVSONKOTQDTGAINRSLALKECTIRAMDSDKNHIIFPDSELTQVLRIYV 300
Db 318 AGSERGSTTKRHSNQKRRESADINTSLALKECTIRALGQKSAHPYRSKLTLLIKDQFS 377
OY 301 GKSKSIMIANISPTISCEQTLNTLTRYSSRYVKNFKNSTCINEDDNTTERISIIIDSKGS 360
Db 378 PDSKTTWATVYPSFGMSADHSLNLTLRVADRIKE-----QVSSNGQGRGK 421
OY 361 EMASSTIE 368
Db 422 AAKASNRE 429

RESULT 12
KIP1_YEAST STANDARD; PRT; 111 AA.
ID KIP1_YEAST
AC P28742;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE kinesin-like protein KIP1.
GN KIP1 OR CIN9 OR YBL063W OR YBL0504 OR YBL0521.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C;
RX MEDLINE=92317166; PubMed=1618910;
RA Roof D.M., Meluh P.B., Rose M.D.;
RT "Kinesin-related proteins required for assembly of the mitotic spindle."
RL J. Cell Biol. 118:95-108(1992).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C;
RX MEDLINE=94205266; PubMed=8154187;
RA Scherens B., el Bakoury M., Vierendeels F., Dubois E., Messenguy F.;
RT "Sequencing and functional analysis of a 32,560 bp segment on the left arm of yeast chromosome II. Identification of 26 open reading frames, including the KIP1 and SEC17 genes."
RL Yeast 9:1355-1371(1993).
RN [3]
RP CHARACTERIZATION.
RC STRAIN=S288C;
RX MEDLINE=92354062; PubMed=1643659;
RA Saunders W.S., Hoyt M.A.;
RT "Kinesin-related proteins required for structural integrity of the mitotic spindle."
RC -I- FUNCTION: REQUIRED FOR ASSEMBLY OF THE MITOTIC SPINDLE. INTERACT WITH SPINDLE MICROTUBULES TO PRODUCE AN OUTWARDLY DIRECTED FORCE ACTING UPON THE POLES. FOLLOWING SPINDLE ASSEMBLY, CIN8 AND KIP1 APPARENTLY ACT TO OPPOSE A FORCE THAT DRAWS SEPARATED POLES

```

```

CC BACK TOGETHER. THIS FORCE SEEMS TO BE MEDIATE BY KAR3.
CC -1- SUBUNIT: MIGHT BE DIMERIC.
CC -1- SUBCELLULAR LOCATION: SPINDLE MICROTUBULES THAT LIE BETWEEN THE
CC POLES.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BINC
CC SUBFAMILY.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; Z11962; CAAB8019.1; -
DR EMBL; Z23261; CAAB80785.1; -
DR EMBL; Z35824; CAAB84883.1; -
DR PIR; A42640; A42640.
DR HSSP; P17119; 3KAR.
DR SGD; S0000159; KIP1.
DR GO; GO:0005816; C:spindle pole body; IDA.
DR GO; GO:0005200; F:structural constituent of cytoskeleton; IPI.
DR GO; GO:0007020; P:mitotic anaphase B; IMP.
DR GO; GO:0000092; P:mitotic anaphase B; IMP.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin_1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Cell division; Microtubules; ATP-binding; Coiled coil;
KM Mitosis; Cell cycle.
FT DOMAIN 50 423 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 424 510 COILED COIL (POTENTIAL).
FT DOMAIN 648 770 COILED COIL (POTENTIAL).
FT DOMAIN 710 780 COILED COIL (POTENTIAL).
FT NP BIND 808 828 COILED COIL (POTENTIAL).
FT NP BIND 141 148 ATP (BY SIMILARITY).
SQ SEQUENCE 1111 AA; 125794 MW; 212F8279766137FC CRC64;

Query Match 8.2%; Score 561.5; DB 1; Length 1111;
Best Local Similarity 22.9%; Pred. No. 1e-17;
Matches 255; Conservative 204; Mismatches 393; Indels 263; Gaps 48;

QY 2 NSKIKVYVRKRPSELEKKKSDITV---KNNCTIYIDPRKYDMTYIERHETVD 58
DB 50 DSNIHVYRCRSNRKREIEKSSVISTLGPQKEIILNSGSHQSYSSK--KTYQF--D 105
QY 59 KVFDDTVDFNFTYENTIKPLIIDLYENGCVSCFAYGQTSGKTYTMG-----S 108
DB 106 QVFGEBSDDQETVNAATKNIKEML-HGVNCTIFAYGQTGTGKTYTMSGINILGVDQST 164
QY 109 QPFGQSTPGIFQYAGDITFLNITDKNTKGIFFISFYICGKLYDLIQ----- 159
DB 165 DNLILGHAGIIPRVLDFELKESLNKEYS--VKISFELVYENMLKDLIDSEDDPAV 222
QY 160 ---KRRK-VAALNGKEVVVKDKILRVLTKEELIKMIDVGLRKIGVNSQNDSSRS 215
DB 223 NDRPRQRIFFDNNNNNSIWKNGQELFINSAGHGLMLQSGSLKRRVATKCNDSLSSRS 282
QY 216 HALINI-----DLKD--INKN-TSLGKIAFIDLASRGAPTVSONKOTQTDGANIN 265
DB 283 HTVFTITTNVEDSDKHQGNKRFVKIGLNLVDLAGSEINNSGAEKRAQAGL-INK 341
QY 266 SLALKECTIRAMDSKKNHPRPDSLTQVLDIFVGSKSKIMTANISPTISCEQTLNLT 335
DB 342 SLTLTGAVINALVDHSHNIPYRESKLTIRLQDSLGWTKCIATISPAKISMEETASTL 401
QY 326 RYSSRVNPKN-----KSCVINE-----EDDNTERTISLDSKSEMA 364
DB 402 EYATRAKSIKNTQVNNOSLSKDTLKVYIOEIKLRNLDKNSKNGKGIPTQ---DQLDL 458

```

```

QY 365 SSIEYVVKSNHLLSNNNNNKINRGKIN--DKIERNNILKN-----KSPDKREGF 413
DB 459 YESNIDLBQNKIKINLAEQIKKFKENTANQDNLNLLQSEKELIATIQNPNVPSNF 518
QY 414 TSTFGK--YSSLNDIDIKKKKKGLINKSTLYNDN-----TINKKNNNN 458
DB 519 YSEIQIKHHTNLEIMNEVITQORDPSLENSQKQ-YNTNQMWQKISQOVLQTLNTLOGSLN 577
QY 459 NNNNDND-----NNNDNNNNNNNS--SMVNNMIMHNNNNNNNI--VNNNNNNN 507
DB 578 NYSKSEVYKVTBELTRVNTKHKADSTLSKLINLTTLMMQNNELVRSISTSL 637
QY 508 NNNNNNSH--NHLPOPNVAF-----TDTSPSSLDWM--NCHLNNDK 547
DB 638 FQSDSTSHRKDLNLEYQHQFLKVLQNDIKSCLSISSILTSINELSQNTTLNLSM 697
QY 548 STFLKKKLDNITKLNKSSCDNINAKKKNL-----HLAR- 583
DB 698 NVLIENQSGSSSLDIKEQ--DLKIKLKNLDINERRISNQFNQQLAEMKRYFQDHVSRT 754
QY 584 ---HSVGSKLTMFSYDPQKNKNTFFKSN-----INKGENDTPKDIYESRN-- 627
DB 755 RSEFHDELKCIDNLKOKOSKLDQDIWQKTASTFNETDIYVVKIHSDDIASLAHMENTL 814
QY 628 --VSNNN---GNVLGLANKVTHHDISTK---DENHNDKINNGVINIINNSVNSINNS 678
DB 815 KTVSQNNSEFTNLDLSLSRGAMNDISSKLRSLPINFELKISGTICETGDDDTIA-SNP 873
QY 679 NNSGINSN-SMNSNSIYKSNYSNOSISDVQIRYVNEMDT-SKKNNDNIFDAISCDNNM 736
DB 874 VLTSIKKFPONIIICSDIALNTEKIMSLIDEIQ---SQIETISENNINL----- 918
QY 737 YPNTNNNNNNNNNN-----NNNNNIDVENYNNNRDGTNNSMKLYA-----YNSHNL 784
DB 919 ---IATNEPNSICNFLTIDYBENTIQISKTDDEVLSSECEKQSLIKGMDIFTHASIE 975
QY 785 QP---DNKNKTSNIQNTNKNKNQDGNVYVSMNFCYHNLNDKRYLLIDLNNKEQKQ-KNH 840
DB 976 KPLHEHTREASVYKALPL-----LDYPQGFQYR-----DAKNSKDDTSNR 1019
QY 841 GCDNNITIQNRN---DFEKK-----KKTNFPNNNNIYIVNNMG----- 875
DB 1020 TCIPLNSTENPPLSQFSPKTPVPVDPQPLPKVLLPKFSINSKSNKSLTPYTEGTGRS 1079
QY 876 NNSPRMKYGLGSHTSIDMKNNEMKNNEMDNE 910
DB 1080 QNNLKR-----RFTTEPLKGEETENNDDIQNK 1107

RESULT 13
RPCL_PLAFA
ID_RPCL_PLAFA STANDARD; PRT; 2339 AA.
AC P27625;
DT 01-AUG-1992 (Rel. 23, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last annotation update)
DE DNA-directed RNA polymerase III largest subunit (EC 2.7.7.6).
OS Plasmodium falciparum.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
NCBI_TaxId=5833;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92018020; PubMed=1656254;
RA Li W.B., Baik D.J., Tanaka M., Gu H., Fox B.A., Imelburg J.;
RT "Characterization of the gene encoding the largest subunit of
RT Plasmodium falciparum RNA polymerase III."
RL Mol. Biochem. Parasitol. 46:229-240 (1991).
CC -1- FUNCTION: DNA-DEPENDENT RNA POLYMERASE CATALYZES THE TRANSCRIPTION
CC OF DNA INTO RNA USING THE FOUR RIBONUCLEOSIDE TRIPHOSPHATES AS
CC SUBSTRATES.
CC -1- CATALYTIC ACTIVITY: N nucleoside triphosphate = N diphosphate +
CC {RNA} (N).
CC -1- SUBUNIT: RNA POLYMERASE III CONSISTS OF ABOUT 15 DIFFERENT

```



```

Db      1227 HRTNDI-QFDLCILINKDPRNVNIVLTGKAFIFLKKKPYSPHLPYEECKNIYHYIMK 1285
      : : : : | : : : | : : : |
Qy      803 -----NNQGNVNYSNMFCYINLNDKRYLIDLNNKCK-DKIHGCDNNITON- 849
      : : : : | : : : | : : : |
Db      1286 KGHKKIKININNNHNSLYY-----HYNIIDT-FVKRNKMYCMCNKLLYKIQOGLVNL 1338
      : : : : | : : : | : : : |
Qy      850 -RNDPEKK-KTNFNNNNIYIVNNNNNNNSPRKYGKCSHSTSIDMKNNKNNKNNEMK 907
      : : : : | : : : | : : : |
Db      1339 IHNLYKKKKYNNNYIYDIDVHLIGNNNNNN-----KNNSEKKPL 1380
      : : : : | : : : | : : : |
Qy      908 DNEKNDHIKSN-NNNSSSSSSSSNNNI-----YNNINDDTFONDYCHNDYFTIRKKN 961
      : : : : | : : : | : : : |
Db      1381 KKKCK-HIRKQESNDITFTMTYSNNIHLKYKXVHHKNYYPDSCIN-----LRKKCN 1433
      : : : : | : : : | : : : |
Qy      962 T--NINSNIYQNDIITYTNSLNDYMSNTLHFEKTYTFTLSNEDI-YNKEMEGKI 1017
      : : : : | : : : | : : : |
Db      1434 SLFVNLKKYIYER-----KKYLQHCILK-HDNKYKVELPRIKDINYSYQMESIKT 1483
      : : : : | : : : | : : : |
Qy      1018 R-----LDDQDKYD-----NDNNVDNN-----NKNVNDNNVNDNNVNDNDX 1059
      : : : : | : : : | : : : |
Db      1484 RNFHLSLSEQFASNLISFTYIKDDNNVYKNTYTKNYIYN---KNSICNKYICNK 1540
      : : : : | : : : | : : : |
Qy      1060 NNVNNDNNVNDNDVDFNHNKFNNNNEYLSEYOKNVDTIINNCLNSLDISMYDTKEIL 1119
      : : : : | : : : | : : : |
Db      1541 NYIYNKN-----NIVYKN-----INKNKILTHAKSVL-----LSGSSKKELKFF 1581
      : : : : | : : : | : : : |
Qy      1120 NNILSKYKAEKDNVYKTYINEDIKMSLEBIDKTAQSIYERKYLTKLILFKKNDVT 1179
      : : : : | : : : | : : : |
Db      1582 SNIRRHKLKEKKN-----KKNIKRYKNNHYNNNTS-----KGHILMCTGHEFKDYSS 1630
      : : : : | : : : | : : : |
Qy      1180 Q-----INNEFSDLRKDLVWCHICNNNPDQFHYAVSRLEKODINLIMLRQIWCESN 1233
      : : : : | : : : | : : : |
Db      1631 LKAKRYIYNNKRYMLKNDV-----YDRHMYNITDWTYRGTOIGCSK- 1672
      : : : : | : : : | : : : |
Qy      1234 LRLLYQFLVEYQNKANSVLLNVSSNNGDIILNK-----KLVQDNIKNSMDH 1282
      : : : : | : : : | : : : |
Db      1673 -----KKN-----NIYNNNNNNILKKNIRPLEHLLVDCCKKNICH 1708
      : : : : | : : : | : : : |

RESULT 15
CUT7_SCHPO STANDARD; PRT; 1085 AA.
ID_CUT7_SCHPO
AC P24339;
DT 01-MAR-1992 (Rel. 21, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Kinesin-like protein cut7.
GN CUT7 OR SPAC25G10.07C.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RX MEDLINE=21848401; Pubmed=11859360;
RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouros J., Peat N., Haylee J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Fellwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris P., Hidalgo J., Hodgson G.,
RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagsels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,

```

```

RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabbintowlsch E.,
RA Skeltonford K., Rutter S., Squares D., Seeger K., Sharp S.,
RA Taylor J., Simmonds M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Voicakeert G., Aert R., Robben J., Grymowicz B.,
RA Weidens I., Vansteels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs C., Fritzc C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Leirach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Medler H., Mamut R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaire V., Mortier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Galliard C., Tallada V.A., Garzon A., Thode G.,
RA Daea R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA Cerutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA Shpakovski G.V., Usery D., Barrett B.G., Nure P.,
RT "The genome sequence of Schizosaccharomyces pombe."
RL Nature 415:871-880(2002).
CC -1- FUNCTION: COULD BE A SPINDLE POLE BODY MOTOR. ON TRANSITION FROM
CC G2 TO M PHASE OF THE CELL CYCLE, THE SPINDLE POLE BODY DUPLICATES;
CC THE DAUGHTER POLE BODIES SEED MICROTUBULES WHICH INTERDIGITATE TO
CC FORM A SHORT SPINDLE THAT ELONGATES TOWARD THE NUCLEUS AT
CC METAPHASE. MUTATIONS AT CUT7 BLOCK SPINDLE FORMATION.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BINC
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
CC -----
DR EMBL; X57513; CA40738.1; -
DR EMBL; Z70691; CA94636.1; -
DR PIR; T38378; T38378.
DR HSSP; P17119; 3KAR.
DR GeneDB; Spombe; SPAC25G10.07C; -.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin_1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Cell division; Microtubules; ATP-binding; Coiled coil;
KW Mitosis; Cell cycle; Phosphorylation; Repeat.
FT DOMAIN 70 435 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 436 604 COILED COIL (POTENTIAL).
FT DOMAIN 715 740 COILED COIL (POTENTIAL).
FT DOMAIN 897 955 COILED COIL (POTENTIAL).
FT NP_BIND 159 166 ATP (BY SIMILARITY).
FT REPEAT 987 998
FT REPEAT 999 1010
FT MOD_RES 1011 1011
FT FT
FT COMPACT 34 61 PHOSPHORYLATION (BY CDC2) (BY
FT SIMILARITY).
FT SASNRRKREPTDITGCPYPRSDNSPT ->
FT LRLTNDVSLILLTL (IN REP. 1).
SQ SEQUENCE 1085 AA; 122133 MM; 5669277875559D58 CRC64;
Query Match 7.9%; Score 538.5; DB 1; Length 1085;
Best Local Similarity 20.7%; Pred. No. 1e-16;
Matches 235; Conservative 223; Mismatches 410; Indels 265; Gaps 43;
Qy 3 SKIVYVRKPLSLSEKKKDSIITYKNNCTLYID-----EPKRVDMTKIERHEF 55
      : : : : | : : : | : : : |
Db 71 TNNVAVVRKRTIOE-----VRDSSSLAVSTSGAMGALAAQSPSSMLVTKTY 120
      : : : : | : : : | : : : |
Qy 56 IVDVFPDVTNFTVYNTIKPLIIDYENGCVSCFAYGQTSKGYTM/GSQPYGQSD 115
      : : : : | : : : | : : : |
Db 121 AFDVYFGEADQLMFLFNSVAPMLQV-LNRYNCTIRAYIGDTGKGYTMSGD---LSD 175
      : : : : | : : : | : : : |
Qy 116 TPGIFYAAG---DIFFLNIYDKNTK-GIFISFYEYIGKLYDL--QKRNVAAAL 167
      : : : : | : : : | : : : |

```

```

Db      176 SDILSEAGLIPRALYQLFSSLDNSQOEYAVKCYVELYNEBIRDLVSEELRKPARYP 235
      168 EN-----GKEVAVKD-----LKILVFLFMEELIMMGIOFLRKIVNSONDESS 213
      236 EDISRGAVVITIGIEBYIKNAGDGLHLR-----BSHRROVAATKCNLDLSS 283
      214 RSHAILNIDLK-----DINKNTS-----LGKIAFDLAGSERGADTVSONKO 255
      284 RSHSIFITILHRAVSSGMTDETSLTINNNSDDLRLASKLHMDVLGSEMGIGSGAENKR 343
      256 TQTDGANINSLALKECIPAMSDKNHIFPDSSELTQVLRDIFVGSKSIIMANTISPT 315
      344 ARETGM-INOSLLTIGVINALVEKAHPIYRESKILRLQDSDIGGKTKSMITVIVSTN 402
      316 SCEQOTLNTLRSSRVNPFKNGSTCINEEDTTERISI-----LDSKSENNASSIEN 369
      403 TNEETITISLEIYARAKSIRNKP-----QNNQVFRKVLKOLVLDIIRLKNLDNATRKKN 458
      370 VV-----IKSNHLGNNNNNKINRGINDKIERNNI--LKNKSPDKPREGPT 414
      459 GYLAESTYKELMDRVQONKDLCOEQARKLEVLDLWVKSRELOQYVSKSNGHKEVEA 518
      415 STGKTSILNDIKIKKKKKGLINTYSTLYNDNTINKKNNNNNN-----462
      519 LQOLVNSSTELSESXSENEK-----LKNELVLEIEKKKETEAKITTVATDLSQYRE 574
      463 -----DNNDNNNNNNNNNNSSVMNNMINH--INNINNINN-----VNNNN 506
      575 SKEIYALSVEKLDRTERRNNKENNNFNWNLTLMRSPHSGFTBETNGYFTLLDPNA 634
      507 NNNNNNNHNNHLPORNYAFTD--TSDPSSLDH-----NCHLANNNDKSIFLHKKMLRDN 559
      635 SWEELINTSNOL--LISWTKITEHQSLDEALQASRSCAIPNS--SIDLVSELKD--688
      560 IKAKNRSSCDNINMKKKNNLHLARSHVGSGLTMSYDPOKNDTPFKSNINMEEDNTPK 619
      689 ---SKNSLIDALEHSLIODISMSQKLGNGISSELELOKDMESY-----R 731
      620 DILYESRVNMMNGVNLGLNKRTHHDISTKEDNHNDKINNVININNSNVNSINNSN 679
      732 QVQELRSLNLYN-----QHTHEE-----SOKELMYGVNR-----DIDALVKTC 769
      680 MNSINNSNM--NSNSIYKSNVNSNO-----SISDQAIRVNMEDTSNKNNDIIPDALS 731
      770 TSLNADIIISLYISDQSKFSKQODLIANGIKVSNLOE-----QNESLYTKA--821
      732 CDNNMYPNITNNNNNNNNNNNNNNIIVENYNNRDGTNNSMELVAYNSHNLFOPDNNKN 791
      822 -----DILSHLNDTNSNIRKANEI-----MNNRSEFLRNA-----853
      792 TSNIGNINNNKNNQDGNVYNSMFCYNNLNDKYYLLDLNKEQKDKIHGCC-----NN 845
      854 ASQAEIYVGNKERIQTENVESQL-----LDSKSKALHSNSRSRYDHCLALAESQKQGVNL 909
      846 IIGNRNDFEKKKTNFYNNNN-----IYVNNMNGANNNSPRMYGLCSGSHTSIDMKNN 899
      910 EYQUTLRLIQYVEHEDNTEKGGQQLDLLESLVGNND-----LIDISIKTP 957
      900 EMKNEMKONEMKONHIKSNNNNS--SSSSSSNNNINNNINDDTFONDYCHANDNFTTIR 957
      958 HTELQKITHTVLKGTISLANHTHELGLDEGESCINLETTIEDTSLVK-----LETTGDP 1012
      958 RKNNTNINSNIYONDDIITYINSIDYNSNTLHFXEKTYTPLSTINEDIYK 1010
      1013 SKRELPAFSPWTRDSSLIKETTLN--LSDKKFVREYITSSNQINEPDVYDK 1063

```

RESULT 16
K125 ARATH
ID K125 ARATH STANDARD; PRT; 1056 AA.
AC P82266;
DT 16-OCT-2001 (Rel. 40, Created)

```

DT      16-OCT-2001 (Rel. 40, Last sequence update)
DT      16-OCT-2001 (Rel. 40, Last annotation update)
DB      Probable 125 kDa kinesin-related protein.
GN      ATG36200 OR P2H17.19.
OS      Arabidopsis thaliana (Mouse-ear cress).
OC      Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC      Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC      euroside II; Brassicales; Brassicaceae; Arabidopsis.
OX      NCBI_Taxid=3702;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=cv. Columbia; PubMed=10617197;
RX      MEDLINE=20083487; Pubmed=10617197;
RA      Lin X., Kaul S., Rounsley S.D., Shea T.P., Benito M.-I., Town C.D.,
RA      Fujii C.Y., Mason T.M., Bowman C.L., Barnstead M.E., Feldblum T.V.,
RA      Buell C.R., Ketchum K.A., Lee J.J., Ronning C.M., Koo H.L.,
RA      Moffit K.S., Cronin L.A., Shen M., Pal G., Van Aken S., Unayen L.,
RA      Tallon L.J., Gill J.E., Adams M.D., Carrera A.V., Creasy T.H.,
RA      Goodman H.M., Somerville C.R., Copenhaver G.P., Preuss D.,
RA      Nierman W.C., White O., Eisen J.A., Salzberg S.L., Fraser C.M.,
RA      Venter J.C.;
RT      "Sequence and analysis of chromosome 2 of the plant Arabidopsis
RT      thaliana."
RL      Nature 402:761-768 (1999).
CC      -1- FUNCTION: RESPONSIBLE FOR MICROTUBULE TRANSLLOCATION. MAY BE
CC      IMPORTANT FOR THE ORGANIZATION OF PHRAGMOPLAST-SPECIFIC ARRAYS OF
CC      MICROTUBULES (BY SIMILARITY).
CC      -1- SUBCELLULAR LOCATION: MICROTUBULE-ASSOCIATED (BY SIMILARITY).
CC      -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BIRC
CC      SUBFAMILY.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
DR      EMBL; AC006921; AAP21445.1; -.
DR      PIR; H84777; H84777.
DR      HSSP; P17119; 3KAR.
DR      InterPro; IPR001752; kinesin_motor.
DR      Pfam; PF00225; kinesin; 1.
DR      PRINTS; PR00380; KINESINHEAVY.
DR      SMART; SM00129; KISC; 1.
DR      PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR      PROSITE; PS0067; KINESIN MOTOR DOMAIN2; 1.
KW      Motor protein; Microtubule; ATP-binding; Coiled coil.
FT      DOMAIN 1 406 526 KINESIN-MOTOR (BY SIMILARITY).
FT      NP_BIND 98 105 COILED COIL (POTENTIAL).
SQ      SEQUENCE 1056 AA; 119267 MW; 7AD18A39A9AB9211 CRC64;

```

Query Match 7.6%; Score 520.5; DB 1; Length 1056;
Best Local Similarity 21.6%; Pred. No. 66-16;
Matches 240; Conservative 207; Mismatches 424; Indels 241; Gaps 42;

```

      5 IYVVRKAPLSELEKKKDSIITYKNNCTLYDEPRYKVDWT-KYIERHEFTVDKVEDD 63
      13 VQVLLRCRPFPSDELRSNAPQVLT-----CNDLQREVAVASONAGKHIDR-VTFPKVGP 67
      64 TYDNFTYVENTIKPLIIDLYENGCCSCGFAGGCGSSGTYTMLG-----SQPYQSDPT- 116
      68 SAQQKDLDDQAVAPLVNEVL-GENCTTFAVGQGTGTGKTYTMEGCRSRKSPACGLPAE 126
      117 PGIFQYAGDIFTPLNIYDKNTKGIFFSYEYIGKLYDL-----OKRKYV 164
      127 AGVIRAVAKQIFDLE--GQAQAEYSVKYTFLELVNEEITDLADPEDLSRVAAEKQKPL 184
      165 AALENGKEVVVKDKILIRVLTKHEELILKMTDGLVRKIGVNSONDESSRSHAILNIDLK 224
      185 PLMEDGKGVLVRGIEEIVTSANEIPTLIERGSSKRRTAETFLNKQSSRSHLSFSITL- 243

```



```
Db 170 ERFVSPSEVMEVDEGKNNHVAVTNNNEHSRSHVFLINVKQENVETQKLSGLYL 229
Qy 238 IDLAGSEGAFTVQONKOTQDGNINRSLALKECTIAM--DSQKNIHPFDSSELTCLR 296
Db 230 VDLAGESEVSKTGAEG--AVLDEAKINRSLALGNVSLADGNSHVYRDSKLTLLQ 288
Qy 297 DIFGKSKSIAMIANISPTISCECCEQTLNTRYSRVRKFNKSTCINEB-----DDT 347
Db 289 ESLGNNARTMVICSPASVNESEKSTLLFGQAKTIK--VSVNEBELTDEMRREREK 347
Qy 348 NTERISILDSKGESEMASSIEENVIKSNHLLSNNNNNKINQKINDKI--ERNNILNK 404
Db 348 EKEVETKLKATMAKLEA-----ELQWRKSGQAASVEQVYDLKEDV 387
Qy 405 SFDPREBGFPS--TFGKYSLLNDIKIKKKKKGLINYSTLYNNTIKK-----453
Db 388 PAESPATSTISLAGLASMNEGDTQLEER--LKYQOLDKDEINNOQLIEKLEQ 446
Qy 454 -----HNNNNNNNDNNNDNNNDNNNDSSVNNMINNNNNNNNNNNNNNN 504
Db 447 MMEQEDLIAQRDYENIQODMSRQADNESAKDEVEVLOALEELANNYDQKGEVEDK 506
Qy 505 NNNNNNNNNNNHNPQPNVYAFDTSDFSLLDMNCHLNNDKSTFLHKKLNDI--KL 562
Db 507 NKEENILSEELNOKL-----STINSIQNEILDQKDSMHRKKEVTDMMINIL 553
Qy 563 KNRSSCDINMKKKNNLHLARHSVSKLTMTFSYDPQKKNDTFPSKNTNKMEDNPKOIL 622
Db 554 KDLGDIPTVG--GNALETPTAGS-----GKIEEFVAVLYISKMS-----596
Qy 623 YESRNVSNMGNVLLGLNKNTHTDSTKDENNHNDKINNGVNIINNSVNSINNSNNS 682
Db 597 -EVATIVSRNNQL-----ENTQODNFKIETHEKOLSKCKILQCHEAKMASLOAIDS 650
Qy 683 INNSNNSNSTYKSNYSNOSISDVQIRYV---NEMDTSKNNDNIFDAISCDNNYF 738
Db 651 ENKRMLEDNDVDSLNEEYAKLKAQOMHIALSEREKETSQASETR--EVLEKQMEMHR 707
Qy 739 NITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 795
Db 708 E-QHQKQLOSLRDEISEKQATVDNLDK--DNORLSIALBKLO--DYDKLKEVEVKAAL 763
Qy 796 QNITNKNQNO-----DGNVYSNMFCHYNIDKNVLLDLNKK-----EOKDK 837
Db 764 ADLSGIDRRQAKODLKGLETVAKELQTLH-NLR-KLFPVODLONKVKKSCSKTEEBDE 821
Qy 838 NIHGCDNNIIONRDEFEKKKTTFYNNN--NIVIVNNNNNNNNNNNNNNNNNNNNNN 889
Db 822 DTGG-----NAAQOKISFLENNLEQLTKVHKLVDNADLRCELPLEKRL---868
Qy 890 HTSIDNNKNNEMKNNEMKDNEMKD 913
Db 869 RATERVRKLSALKAKEGAVRD 892

RESULT 19
BIMC_EMENT STANDARD; PRT; 1184 AA.
AC P17120;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1990 (Rel. 15, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE kinesin-like protein BIMC.
GN BIMC.
OS Emericella nidulans (Aspergillus nidulans).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; Emericella.
OX NCBI_Taxid=162425;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=9019985; PubMed=2138511;
RA Enos A.P., Morris N.R.;
RT "Mutation of a gene that encodes a kinesin-like protein blocks
```

```
RT nuclear division in A. nidulans.";
RL Cell 60:1019-1027(1990).
CC -!- FUNCTION: IMPORTANT ROLE IN MITOTIC DIVIDING CELLS. MICROTUBULE
CC MOTOR REQUIRED FOR SPINDLE BODY SEPARATION.
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BIMC
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M32075; AAA33298.1; -.
DR PIR; A34795; A34795.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin_1;
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; Kisc; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN; 1.
KW Motor protein; Cell division; Microtubules; ATP-binding; Coiled coil;
KW Mitosis; Cell cycle; Phosphorylation.
FT DOMAIN 79 485 KINESIN-MOTOR (BY SIMILARITY).
FT 489 900 COILED COIL (POTENTIAL).
FT DONAIN 901 1184 GLOBULAR (POTENTIAL).
FT NP_BIND 167 174 ATP (BY SIMILARITY).
FT MOD_RSS 1006 1006 PHOSPHORYLATION (BY CDC2) (BY
FT FT SIMILARITY).
SQ SEQUENCE 1184 AA; 131630 MW; CEA01SEC8F980E4F CRC64;

Query Match 7.3%; Score 500; DB 1; Length 1184;
Best Local Similarity 21.1%; Pred. No. 5.3e-15;
Matches 253; Conservative 194; Mismatches 415; Indels 338; Gaps 48;

Qy 2 NSKTKVVRKRPSELEKKKSDIITVKNKNTLYDEPRYKVM--TKYIERHEFIYDKV 60
Db 79 DTSIHVVVRCKRNEREYKENVGLVDTGEG-----VAGKYVELSMGNAVSNKTYTDPKV 133
Qy 61 FDDTVDFVTEVNTIKPLIIDLYENGCVCFAVGOTSGKTYTMLGSOYPGOSDTPGIF 120
Db 134 FSAADQITVYEDVVLIVEMLA--GYNCTIFAVGOTGTGKTYMSGD---MMDTLGIL 188
Qy 121 QYAGDI-----FTFLAIYDKONTKGIPISTYEYICKGLVDL-----OKR 161
Db 189 SDNAGIIPRYLVSFAKLADTEST--VKCSFTELYNEBELRDLSEAENPKIYDNEQKK 246
Qy 162 KVAVALENGKKEVVVKD-----LKLIRVLTKEELIKMIDGVLLRKIGVNSQNDSESRSHA 217
Db 247 GHWSTLVQMEETIYIDNATGIKLQ-----QSHKQVAAATKNDSSSHT 294
Qy 218 ILNIDLDINKNTSL-----GKIAPIDLASERGADTVSONKOTQDGNINRSLAL 270
Db 295 VFTITV-NIKRTTSGEEVYCPGLNLVDLAGSENGRGAENKRA--TEAGLKNKSLTL 352
Qy 271 KECIRAMDSDKNHIPPDSSELTQVLRDIPFGKSKSIAMIANISPTISCECQTLNTRYSR 330
Db 353 GRVINALVDSQHIPPRESKLTLLQDSLGRTTCIATMSPRSNILEFTISTLDYAFR 412
Qy 331 VKNFKNSTCIN-----EEDPTNERISILDSKGESEMASSIEENVI--KS 374
Db 413 AKNIRNKRQ--INSTMPKQTLIREPTAEIKLAKELIATRRHNGVYMAVESYEEKMKNES 471
Qy 375 NHLISNNNNKIN--RGKINDKIERNNILKKNSEFKREGFTSTFGKYSSINDI--DK 428
Db 472 RRIISSEGRAKIESMESSLRHKVQELLTVSK--FNDLKONDPTLAALCSTNDVLOQTDI 530
Qy 429 IKKKK-----KGLIN--YKSTLYNDNTINKKNNNNNNNNND 463
Db 531 VLQNTRAQLREEMRLCAHERTEHQLQDVGGLISTGQVEDINSLSQK-----LD 582
```



```

Db 221 NCEGSKVSHNLNVLADGSEBAQGAAGVRLK--EGCINRSLFLLQGVIKKLSDGQVGG 279
Qy 283 HIRPDESLTVADLDFVGSKSMIMANISPTISCEBTANTLKXSVNFRKSTCIN 342
Db 280 FINRDSLTUTLQNSLOGNEPKTRICITTPV--SFDETLTALPASTAKTKM--TPVNV 336
Qy 343 E--DDNTTERI--SILDSK-----GSENNASSIEN-----VIKSNHLNNNNNNKINR 388
Db 337 EVSTDEALIKRYKEIMDLKKQLEVSLETPAQAMEKQALQLEBKLLQKQNEKEN 396
Qy 389 -----GKINDKIERN-----N-399
Db 397 LTRMLVTSSSLTLOOELKAKRRRVTCIGKINKKNSNVADQENIPNITTKTKHLKSLN 456
Qy 400 ILK--NNSFDPREGFTSPFGYSSLNDIKIKKKKGLINYSLTLYNDTINKKHN-- 456
Db 457 LLREIDESVCSDFNSNT-----LDTLSEIEMNPATKLNQENISELSLRADYDL 510
Qy 457 -----NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 490
Db 511 VLDTYQULTEKEEMELKKEKQDLDREFALERTKQDEMOILHISMLKLVGRVYN 570
Qy 491 --INNNTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 537
Db 571 ODLENELESSKYELLREKEDQIKLQEYIDSGLENIKMDLSYLSIESIEDPKMQKQLEDA 630
Qy 538 MNCMLNNNDKSIPLHKKRLRDNIKAKNSSCDNIMKKNNLHLARHSVSKLTMFSYDP 597
Db 631 ETVALDARESAPFARSENLELEKEKKELAT--TYKQEMENDIQLYQOLEKAKKK--QVLD 686
Qy 598 QKNKDNTEPKSNINIKM--EDNTPKDIYE-----SRNVSMMNGNV 635
Db 687 EKELOASAF--NEITGLTJLIDQKVPKDLCLNLELGKTDQKELKEVEENALRESVI 744
Qy 636 LLGLNKNTHDI-----STKOE-----NENDKKNNGVINIINNSNV 672
Db 745 LLSEKSLPSFEVRLKEIOPKSEELHITSEKDLFSEVVKESRGQLLEIGKTKD 804
Qy 673 NSINNSNNNSINNSNNNSIYKSNYNNQGISDVQIY--VNMDSISKNKNDIIFPDA 729
Db 805 LATTQSNKYSTDOEFQNKFTLH-----MDEQKYKAVLENERMNOEIVNLSKEA 854
Qy 730 ISCDNNM-----YPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 768
Db 855 QKFPSSSLGALKTELSTYKTOLOEKREVOERLNEHQLEQENRDSPLQTYEREKTLIT 914
Qy 769 -----TNSMKLYAVNSHL-----FQPDNNKNTSNIQ--NINTKNDQGNVNSYN 814
Db 915 EKLQOTLEEVKTLTQEKDQLKQLQESLQIERDQLSDIDHTVNMNIDTQOQLRNALSLK 974
Qy 815 FCHYNLKNKVLIDLANKQCKDNHGGDNNIIONRNPFEKKKTNFNNNNIYVNNNM 874
Db 975 QHOETINTLKSKI-----SEVSRLNH--MEENGETKDEQCKM-----1012
Qy 875 GNNNSPRMKYGLCGSHSIDMKNEMKNEKMDKEMDNHKSNNNNSSSSSSNNNIY 934
Db 1013 -----VGIDKKQDLAANTQTLTADVADNEIIEQOKRIFSLIQEKELQ 1056
Qy 935 NNI-----NDDTFQN-----DYCHNDTFTIRKNTNTINSNIYQ 970
Db 1057 QMLESVIAKEQKTLDKENIEMTLENQBELRLDDELKQOEIVAOEKNHA-----TKK 1111
Qy 971 NDDIITYTINSLNDY-----MSNTLHKEKTYTTLSTNE-----DIYKE 1011
Db 1112 EGEISRTCDRLAEVEKLEKESQOLOEQOQQLNVQOESEMOKINIENLKNLKKKE 1171
Qy 1012 MEGKHI-----RLDDQOKYDNDNNNDNNNNKNNVNDNNNDNNNDNNNDKNNVND-- 1064
Db 1172 LTLHEMETERLELAKL-----NENVEVKSITERKVLKELQKLSFETERHLAGY 1222
Qy 1065 -NNVD-----NDDVDVFNINKNNNNYSLYFQKAVDTIINNCLNSLDSISMY----- 1112
Db 1223 IREIBATGLQTEEBELKIAHILHKEHOETIDELRBSVSEKTAQIINTQDEKSHTLQBEI 1282

```

```

Qy 1113 -----DOTEILNINI--ILSKYAEKDNVIKKYI-----NE 1141
Db 1283 PVLHEBQELPKNKVSSETQETMNELELLLEQSTTOSTTLARIEMERLNEKFSQOE 1342
Qy 1142 DIKMS-----LEEDKTAQSIYEKRVKLLTLLLFKNKVDTOI 1181
Db 1343 EIKSLTERDNLTKEALEVKHQDLKEHIRETLAKIQESQSKOQESLNNKKNERTYKI 1402
Qy 1182 NNETSD-----LRDVMCHICNNPPDQHFHFAVSLEKDIINLIMROIWCESEN 1233
Db 1403 VSEMEQFKPSQALRLRIEIMLGLSKRLQSHDEMSVAEKDQLQRYELO--SSDQ 1460
Qy 1234 LRLTQFLAVEY-----QKNSANSVLINSSNNNDIILLNKL--VQDN 1275
Db 1461 LKENIKETIVAKHLETERELKVAHCCLEKQEBETINELRVNLSKETELSTIQOLEALNDK 1520
Qy 1276 IKNSMDHNNIHKK 1288
Db 1521 LQNKI--QEIYEK 1531

RESULT 21
ID K168 DROME STANDARD; PRT; 784 AA.
AC P46867; O9VTN8;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Kinesin-like protein KLP68D.
OS KLP68D OR KLP5 OR CG7293.
GN Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
NCBI_TaxID=7227;
RN NX
RP NCB1
RP SEQUENCE FROM N.A.
RX MEDLINE=95050960; PubMed=7525600;
RA Peravento P.A., Stewart R.J., Goldstein L.S.B.;
RT "Characterization of the KLP68D kinesin-like protein in Drosophila:
RT possible roles in axonal transport."
RL J. Cell Biol. 127:1041-1048 (1994).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=Berkley;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazer J.G., Champe M., Pfeiffer B.D.,
RA Abail J.F., Agbayani A., An H.-J., Andrews-Planonoch C., Baldwin D.,
RA Ballew R.M., Baau R.A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Boltsakov S.,
RA Bokova D., Botchan M.R., Bouck J., Brocksieper P., Brottier P.,
RA Butts K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.R., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Dublin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodex A., Gong F., Gorrell J.H., Gu Z., Guan P., Harrie M.,
RA Harris N.L., Harvey D., Helman I.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jajalji M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Laoko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Nodary C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.W., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusekern D.R., Paclob J.M.,

```


RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Rainer K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Slier E., Stradling A.C., Stapleton M., Strong R., Sun E.,
RA Stykhaas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasserman D.A., Weinstein G.M., Weissendach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "the genome sequence of *Drosophila melanogaster*.";
RL Science 287:2185-2195(2000).
RN [3]
RP SEQUENCE OF 220-342 FROM N.A.
RX MEDLINE=92020874; PubMed=1924306;
RA Stewart R.J., Pesavento P.A., Moerpel D.N., Goldstein L.S.B.;
RT "Identification and partial characterization of six members of the
RT kinesin superfamily in *Drosophila*.";
RL Proc. Natl. Acad. Sci. U.S.A. 88:8470-8474(1991).
CC -1- FUNCTION: PLUS-END DIRECTED MICROTUBULE MOTOR THAT MAY BE USED FOR
CC ANTROGRADE AXONAL TRANSPORT AND COULD CONCEIVABLY MOVE CARGOES IN
CC FLY NEURONS DIFFERENT THAN THOSE MOVED BY KINESIN HEAVY CHAIN OR
CC OTHER PLUS-END DIRECTED MOTORS.
CC -1- TISSUE SPECIFICITY: EXPRESSED PRIMARILY IN THE CENTRAL NERVOUS
CC SYSTEM AND IN A SUBSET OF THE PERIPHERAL NERVOUS SYSTEM DURING
CC EMBRYOGENESIS.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC IS A SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U15974; AAA69929.1; -
DR EMBL; M74431; AAA28658.1; -
DR EMBL; AE003543; AAF50008.1; -
DR PIR; A55236; A55236.
DR HSSP; P17119; 3KAR.
DR FLYBase; FBgn0004381; Klp68D.
DR GO; GO:0003774; F: motor activity; IDA.
DR GO; GO:0008089; P: anterograde axon cargo transport; IEP.
DR InterPro; IPRO01752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00667; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil.
FT DOMAIN 16 275 KINESIN-MOTOR.
FT DOMAIN 351 385 COILED COIL (POTENTIAL).
FT DOMAIN 426 582 COILED COIL (POTENTIAL).
FT NP BIND 106 113 ATP (POTENTIAL).
FT CONFLICT 220 221 SS -> TC (IN REF. 3).
FT CONFLICT 338 342 GSRK -> VRGV (IN REF. 3).
FT CONFLICT 338 338 G -> A (IN REF. 2).
SQ SEQUENCE 784 AA; 88193 MW; 94BB9BAF072DFC0 CRC64;
Query Match 7.0%; Score 477; DB 1; Length 784;
Best Local Similarity 22.4%; Pred. No. 3,4e-14;
Matches 185; Conservative 130; Mismatches 291; Indels 220; Gaps 27;
QY 2 NSKIVVVRKRPSELKKKSDITVKNKNTLYIDEPYKVDMTKYI-----ERHEPT 56
DB 17 NECVVVVVRCRPMNSERSERSPEVVVYVN-----RGVELQNVVDGNKQKRVFT 68
QY 57 VDKVFPDVTDFNVYVENTIKELIIDLYE--NGCVSCFAVGCGSGKTYTMYLGSQPYGGS 114
DB 69 YDAAYDASATQTTLTHHEVFPVLSVLEGNGL---FAYGOTGTGKTFMEGVR--GND 123

QY 115 DPEGIFQYAGDIFTELNIYDKDNTKG---IFISFYEYICGLYDLQKRRKVAALENG 170
DB 124 ELMGILIPRFEQWILHIN-----RTENPQFLVDVSYLIEYMEIRDLKPNKSHLEVRER 178
QY 171 KKEVYVKDKILRVLTKELILKMDIGVLIRKIGVNSQNDSSRSNAT--LNDLKDINK 228
DB 179 GSCVVPVNIJHAINCKSEVEMIKMQGNKRRVGVGFNNMHSRSHAIMIKILEMCDJET 238
QY 229 NT-SLGIKFIADLAGEGADVTQKOTQDGNINRSILALKECIRAMDSKNIIPR 287
DB 239 NTKVGRKMLIDLAGESROSKTGASAEKIK-EASKINLALSLGNVISLAEBSPPHYPR 297
QY 288 DSELTQVLADIFVGSKSIIMANISPTISCCEQTTLTYSSRVKPNKSTCINEDPT 347
DB 298 DSLTRTLQDSLGNSKTIIMINIGPSNVNMTLTLAYGSAKIQNP--IKNEDEPQ 355
QY 348 NT-----ERI-----SILDSKSEMANASTEN 369
DB 356 DAKLKEQYEIRLKLIGPQOQSEKQVAKKQVKKPKKELVTKEMSDSLQVSTIRQ 415
QY 370 VTKSNH-----LLSNNNKIRKINDKIERNNILKNKSPDKPRE-----GFTSTG 418
DB 416 PVEDSDPFGASESDKNEAEVAKSNELEERVENSKLAALAELEGOLYFGCKNLID 475
QY 419 KYSSLN-DIDK---IKNKKKGL-INYKSTLYNDNTINKKNNNNNNNNNDN----- 464
DB 476 TYSERQIELEKTLVLAERKKREIEIQQLLEIQTLEIRRNVSLEQVELKRRKLR 535
QY 465 -----NDNNNNNNNNND--SSMYNN-----MINMINNNNNNNNN 503
DB 536 CYAKYLALQOEINDCKSDHODLRELEMAQNELVYELKRLIIDFVIEVQRLYTOA 595
QY 504 NNNNNNNNNNNHNLPOENVAFPTDSDPSLDDNNCHLNNNDKSLFLKKNLRLDKIK 563
DB 596 KIDEEDEEKKFSMSLPT----- 614
QY 564 NRSSCDINMKKNNMLHARHSVSKLTWFSYDPQKNKNTPEKSNINKMENDTPDILY 623
DB 615 --PGDGKRSKRPVSH-----PQRRRTSYA--LQSAKNSPSSLAF 654
QY 624 ESRNVSNNN-----GNVLLGKNTHTDITKDNHNDKINQV 663
DB 655 KSENIYVLELMPCTRTOERTPKVASLQAVLAQMQTGSDIDIVDS--HTNSLRSL 712
QY 664 INITNNS-----NVNSINNSNNNSNNNSNN 691
DB 713 ENINANNANGAGPGAGVAGSSIPVNRKIKSRGLPSAASNLDNSN 758
RESULT 22
KF3B_HUMAN STANDARD; PRT; 747 AA.
ID KF3B_HUMAN
AC 015066;
DT 15-DEC-1998 (rel. 37, Created)
DT 15-DEC-1998 (rel. 37, Last sequence update)
DT 15-SEP-2003 (rel. 42, Last annotation update)
DE kinesin-like protein KIF3B (Microtubule plus end-directed kinesin
DE motor 3B) (H00048).
GN KIF3B OR KIAA0359.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.
OC NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=97349384; PubMed=9205841;
RA Nagase T., Ishikawa K.-I., Nakajima D., Ohira M., Seki N.,
RA Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. VII.
RT The complete sequences of 100 new cDNA clones from brain which can
RT code for large proteins in vitro.";
RL DNA Res. 4:141-150(1997).

[2]
 RN SEQUENCE FROM N.A.
 RA MEDLINE=2636749; PubMed=11780052;
 RA Deloukas P., Matthews L.H., Ashurst J., Burton J., Gilbert J.G.R.,
 RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Baggaley C.L.,
 RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
 RA Beasley O.P., Bird C.P., Blakey S.E., Bridgman A.M., Brown A.J.,
 RA Buck D., Burrill W.D., Butler A.P., Gardner C., Carter N.P.,
 RA Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
 RA Cligson S., Colley V.E., Collier R.E., Connor R.E., Corby N.R.,
 RA Coulson A., Coville G.J., Deacon R., Dhami P.D., Dunn M.,
 RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
 RA Giffiths D.V., Giffiths C., Giffiths M.N.D., Gwilliam R., Hall R.E.,
 RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
 RA Humble E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
 RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
 RA Lehar V.L., Martin S.L., Leverste M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
 RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
 RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
 RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsey H.,
 RA Rice C.M., Ross M.T., Scott C.E., Senra H.K., Showkeen R., Sims S.,
 RA Skuse C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
 RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
 RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
 RA Whitehead S.L., Whitaker P., Willey D.L., Williams L., Williams S.A.,
 RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
 RA Rogers J.;
 RT "The DNA sequence and comparative analysis of human chromosome 20.";
 RL Nature 414:865-871(2001).
 RN [3]
 RP IDENTIFICATION IN A COMPLEX WITH SMC3 AND KIFAP3B.
 RX MEDLINE=98175913; PubMed=9506951;
 RA Shimizu K., Shirataki H., Honda T., Minami S., Takai Y.;
 RT "Complex formation of SWAP/RAIP, a KIF3A/B ATPase motor-associated
 RL protein, with a human chromosome-associated polypeptide.";
 RJ J. Biol. Chem. 273:6591-6594(1998).
 CC -I- FUNCTION: Involved in tethering the chromosomes to the spindle
 CC pole and in chromosome movement. Microtubule-based anterograde
 CC translocator for membranous organelles. Plus end-directed
 CC microtubule sliding activity in vitro (By similarity).
 CC -I- SUBUNIT: Heterodimer of KIF3A and KIF3B (By similarity). Interacts
 CC with the SMC3 subunit of the cohesin complex.
 CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
 CC II SUBFAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL; AB002357; BAA20815.1; -;
 DR EMBL; AL121897; CAC16425.1; -;
 DR HSSP; P17119; 3KAR.
 DR Genew; HGNC:6320; KIF3B.
 DR MIM; 603754; -;
 DR GO; GO:0005873; C:plus-end kinesin complex; TAS.
 DR GO; GO:0003777; F:microtubule motor activity; TAS.
 DR GO; GO:0008574; F:plus-end-directed kinesin ATPase activity; TAS.
 DR GO; GO:0008089; P:anterograde axon cargo transport; TAS.
 DR GO; GO:0007366; P:determination of left/right asymmetry; TAS.
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin; 1.
 DR PRINTS; PR00380; KINESINHEAVY.
 DR SMART; SM00129; KITS; 1.
 DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
 DR PROSITE; PS00417; KINESIN MOTOR DOMAIN2; 1.
 DR Motor protein; Microtubules; ATP-binding; Coiled coil; Neurone.
 KW DOMAIN 1 345 KINESIN-MOTOR (BY SIMILARITY).
 FT DOMAIN 346 579 COILED COIL (BY SIMILARITY).

FT DOMAIN 580 747 GLOBULAR.
 FT NP_BIND 96 103 ATP (POTENTIAL).
 FT DOMAIN 386 393 POLY-GLY.
 FT DOMAIN 394 406 POLY-GLU.
 FT DOMAIN 723 730 POLY-SER.
 SQ SEQUENCE 747 AA; 85125 MW; 97FA573AFA87023 CRC64;
 Query Match 6.9%; Score 472.5; DB 1; Length 747;
 Best Local Similarity 32.0%; Pred. No. 5,1e-14;
 Matches 136; Conservative 74; Mismatches 148; Indels 71; Gaps 14;
 QY 2 NSKIKVVRKRPSELEK-----KKDSDI-----ITYKNNCTLYIDPRKVDMTKIER 52
 DB 7 SESVAVVVRCPNMGKEKASYDKVDVAVLGVSVYKNGKTAHEMPK----- 55
 QY 53 HEFIVDVFPDPTDNFVVENTIKPLIDLYE--NGCVSCPAVYGNGSKTYTMLGSOP 110
 DB 56 -TFFDVAVYMNNAKQFELYDETRPLVDSVLQNGNTI--FAVGQGTGKTYMGIR- 110
 QY 111 YGQSDTGFIOYAAAGDIFTEFLNIYDKNTGIFISFEYICGLYDLQK--RKMVALE 168
 DB 111 -GPEKRGVAPNSGDHIFTHIS--RSQNGQVIVASVYEIVQEI RDLSDQTKRLKE 168
 QY 169 NGKKEVVVVDLKITLVLTKEELIKMDGVLRKIGVNSQNDSSSHALNTDK---- 224
 DB 169 RPDGVVYVVDLSFVTSKVEIEHVMNVGNQNSVGTANNMHSRSHAFVITIECEV 228
 QY 225 --DINKRTSGKIAFIDLAGSERGADPVSONKQOTQDGMNINSLAKCEIRAM--DSDK 281
 DB 229 GLDSENIHVRGKLVLDLASSERAKTGAQGERLK--BATKINISLSLGNVISLVDGKS 287
 QY 282 NHIFRDESEKTVLRDIFVSKSKSIMIANISPTISCCQTLNTRYSSRYKFNKSTCI 341
 DB 288 THIVRSKTLRLQDLSGNNAKTVMVANGPASYVEETLTTLRYANRAKNIKNGR-V 346
 QY 342 NEEDDTERISLIDSGSENNASSINNVVVKSNHLSNNNNKINRGKINDKIERNITL 401
 DB 347 NE-----DPRDALRFEQEIARLKA-----OLEKRSIG 375
 QY 402 KNSKFDKREG 412
 DB 376 RKRKRERREG 386
 RESULT 23
 KIF3B_MOUSE
 ID KIF3B_MOUSE STANDARD; PRT; 747 AA.
 AC Q61771;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE kinesin-like protein KIF3B (Microtubule plus end-directed kinesin
 DE motor 3B).
 DE KIF3B.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ICR; TISSUE=Brain;
 RX MEDLINE=96032268; PubMed=7559760;
 RA Yamazaki H., Nakata T., Okada N., Hirokawa N.;
 RT "KIF3A/B: a heterodimeric kinesin superfamily protein that works as a
 RT microtubule plus end-directed motor for membrane organelle
 RT transport.";
 RL J. Cell Biol. 130:1387-1399(1995).
 CC -I- FUNCTION: Involved in tethering the chromosomes to the spindle
 CC pole and in chromosome movement. Microtubule-based anterograde
 CC translocator for membranous organelles. Plus end-directed
 CC microtubule sliding activity in vitro (By similarity).
 CC -I- SUBUNIT: Interacts with the SMC3 subunit of the cohesin
 CC complex (By similarity). Heterodimer of KIF3A and KIF3B.

CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
 CC IF SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; D26077; BAA05070.1; --
 DR PIR; A57107; A57107.
 DR HSSP; P17119; 3KAR.
 DR MGI; 107688; Klf3b.
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin_1.
 DR PRINTS; PR00380; KINESINHEAVT.
 DR SMART; SM00129; KISC; 1.
 DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
 DR PROSITE; PS0067; KINESIN MOTOR DOMAIN2; 1.
 KW Motor protein; Microtubules; ATP-binding; Coiled coil; Neutone.
 FT DOMAIN 1 345 KINESIN-MOTOR (BY SIMILARITY).
 FT DOMAIN 346 579 COILED COIL (BY SIMILARITY).
 FT DOMAIN 580 747 GLOBULAR.
 FT NP BIND 96 103 ATP (POTENTIAL).
 FT DOMAIN 386 393 POLY-GLY.
 FT DOMAIN 394 405 POLY-GLU.
 FT DOMAIN 723 730 POLY-SER.
 SQ SEQUENCE 747 AA; 85288 MW; FA369AA190ECB847 CRC64;
 Query Match 6.9%; Score 472.5; DB 1; Length 747;
 Best Local Similarity 32.0%; Pred. No. 5,1e-14;
 Matches 139; Conservative 74; Mismatches 148; Indels 71; Gaps 14;
 QY 2 NSKIKVVRKRPPLSELEK-----KKKDSI-----ITVKNCTIYIDPRYKVDTKYIER 52
 DB 7 SESVRVVRRCRPMNGEKAKASYDKVDVAVLQGVSVKPKGTSHEMPK----- 55
 QY 53 HEPIVDKVPDDYDNTFVYENTIKPLIDLYE--NGVCSCFAYGQSGSKTYTMLGSP 110
 DB 56 -TTFPAVVYDWMNAKQFELYDETRPLVDVSLQGFNGT---FAYGQGTGKTYTMEGRV- 110
 QY 111 YGQSDTPGIFQVYAGDIFETPLNYDKDNTGIFISFEIYCGKLYDLQK--RKMVALE 168
 DB 111 -GPEKRGVTPNSFDHIFTHIS-RSQNQVYLVASYSIEIYQERIDLSQDQTKRLKE 168
 QY 169 NGKEVVVVDKILRLVTKKELILKMDGVLLKRGIVNSQNDSSRSRSHALINDLK--- 224
 DB 169 RPDGVVYVDLSSFVTKSVKEIEHVNVVGNQNSVGTANNHSHSRSHALFVITIESEV 228
 QY 225 --DINKNTSLGKIAFLDILASRGADTVSQNKOTQTDGAININSLAKECITAM-DSDK 281
 DB 225 GIDGENHIRVGKILNVDLASESGAQAGGERLK-EATKINISLSMAGVIALVDGKS 287
 QY 282 NHIPRDSSELTXYLRIDFVKGKSIMTANISPTISCEQTLNTRYSRVKFNKSTCI 341
 DB 282 THIPYDSKTRILLQDSLGNATVYANVGPASVYVEELITLIRANRKAIKMFR-V 346
 QY 342 NEEDDINTERISILDSKSEMANASSIENVVVKSNHLLSNNNKKNNGKINDKIERNMIL 401
 DB 347 NE-----DPKDLALREFQERIALKA-----OLEKRSIG 375
 QY 402 KNSKFDKPRRG 412
 DB 376 RRRRRRKRREG 386

RESULT 24
 KLP3_SCHPO
 ID KLP3_SCHPO STANDARD; PRT; 554 AA.
 AC Q9US60; Q9US61;
 DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Kinesin-like protein 3 (Kinesin-related protein 1).
 GN KLP3 OR KRPI OR SPAC1834.07
 OS Schizosaccharomyces pombe (fission yeast).
 OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
 OC Schizosaccharomycetales; Schizosaccharomycetaceae;
 OC Schizosaccharomyces.
 OX NCBI_TaxID=4896;
 RN [1]
 RP SEQUENCE FROM N.A., FUNCTION, AND SUBCELLULAR LOCATION.
 RC STRAIN=972;
 RC MEDLINE=22127603; PubMed=10641037;
 RA Brazer S.-C.W., Williams H.P., Chappell T.G., Cande W.Z.;
 RT "A fission yeast kinesin affects Golgi membrane recycling.";
 RL Yeast 16:143-166(2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=972;
 RC MEDLINE=22127603; PubMed=12132578;
 RA Jeong J.W., Rhoe D.K., Cho S.Y., Hae K.L., Kim D.U., Won M., Kim H.B.;
 RT "Cloning and characterization of the kinesin-related protein, Krip1,
 in Schizosaccharomyces pombe.";
 RL Mol. Cells 13:389-398(2002).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=972;
 RC MEDLINE=21648401; PubMed=11859360;
 RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
 RA Sgouros J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
 RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
 RA Collins M., Connor R., Cronin A., Davis P., Fellwell T., Fraser A.,
 RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
 RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
 RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
 RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
 RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
 RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
 RA Skelton J., Simmonds M., Squares R., Squares S., Stevens K.,
 RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
 RA Woodward J., Volckaert G., Aert R., Robben J., Grynolprez B.,
 RA Wellcens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
 RA Gabell K., Fuchs M., Fritze C., Holzer E., Moestl D., Hilbert H.,
 RA Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M.,
 RA Eger P., Zimmermann W., Medler H., Wambutt R., Purnelle B.,
 RA Goffeau A., Cadieu E., Driano S., Gloux S., Lelaure V., Mottier S.,
 RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
 RA Lucas M., Rochet M., Galliardin C., Tallada V.A., Garzon A., Thode G.,
 RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
 RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forburg S.L.,
 RA Cernetti L., Lowe T., McCombie W.R., Paulsen O., Potashkin J.,
 RA Shipatovskii G.V., Ussery D., Barrett B.G., Nurse P.;
 RT "The genome sequence of Schizosaccharomyces pombe.";
 RL Nature 415:871-880(2002).
 CC -1- FUNCTION: CYTOPLASMIC MOTOR THAT COULD PLAY A ROLE IN GOLGI
 CC MEMBRANE RECYCLING.
 CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF154055; AAF14525.1; --
 DR EMBL; AF156965; AAF22609.1; --
 DR EMBL; AF247188; AAF81205.1; --
 DR EMBL; AL157734; CAB75775.1; --
 DR PIR; T50118; T50118.
 DR HSSP; P33176; 1BG2.


```

Db 75 ITVAVRGRGRNEREISKSSVYVAVPDITSKEISINTT-----GDGTITAGMANKRY 127
Qy 56 IVDVDDVDYDNFTVENTIKPLIIDYENGCVCSFAYGOTSGGKTYMGSOPY--GQ 113
Db 128 TVDKVFPFGASQDIDFVAGPLFQD--FIKYNCTVAVYGMTSTGKYTYMGDEKLYNGE 186
Qy 114 -SDTFPGIYQYAGGIFTFELNYDKDNKGFISFYEIYCGLYD-----156
Db 187 LSDAAGIIPVVLKFTLELQNDYV--VKCSFELYNEELKOLLDSNSGSGNTGPDG 244
Qy 157 -----LQKRKRAVALENGX 171
Db 245 QFMKKLIPDSSTANTNTSSASSRSRSRSPSLNDLTPKAAALRKRLRTSLPNTI 304
Qy 172 KE-----VVKDKLIRV 184
Db 305 KOQYQOQOAVNSRNNSSSGSTNNASSTNTNGGSSMAVNDQNGIYQIMQIEPHI 364
Qy 185 LTKBELIKMIDGVLRLKIGVNSQNDSSRSHATLIDL--KDINKTSLGKIAPIDLAG 242
Db 365 TNAMGLNLQKGLKRVASTKMDPSSRSHITFTLYKKHODELFRISKMLVLDLAG 424
Qy 243 SERGADVSKQKOTODGANINRSLALKECIRAMDSQKHI PRDSELTLYRLDIFVEX 302
Db 425 SENINRSGALNQRAKEG-SINGSLITLGRVIMLVDSGHIIPRESKLTFLDLSLGN 483
Qy 303 SKSIMIANISPTISCCQTLNTRYSSVFNKFKKSTCINEBDTNTERTISILDSKSEM 362
Db 484 TKTALITATISPAKVTESETCSTLEVASAKNIKNK-----POL 521
Qy 363 NASSIENVIKSNHLSSNNNNKINRGKINKIEBNLIKVKSPDKREGFTSPGKXSS 422
Db 522 GSPFMKDLV-----NITMELAKI--KSDLSLTKS--KEGYMSQDHYK 563
Qy 423 LN-DIDKIX-----KNNKGLINYKSTLYNDNTINKKNNNNNNNDNNNDNNNN 475
Db 564 LNSDLESYKNEVQEKREIESLTSKNALLVMDKLSKETISQONQIIS-----612
Qy 476 NNDSSVNNNNINEM--INNINNINIVNNNNNNNNNNNNNNNNNNNNNNNNNNNN 532
Db 613 -----LKTIDHLRAQIDKQKTEIISDPNNKLQK-----LVEWQM 650
Qy 533 SSLDMNCHLNNNDK--SIFLHKKNLNDNLKLN--NRSSCONIMKK--KNNLHARBSV 586
Db 651 ALHDKYKRELDNQFVWHITTEIKKLSYTLFQNTMQOESILQETNIQPLDMITKEV 710
Qy 587 GSKLTMSYDPOKKNKNTFFKSNINKMEDNTPKDIYVESRVNSNNGVNLGLANKTTHD 646
Db 711 ---LTLNR--TMQEKALMYKOCVKKILNESPK-----738
Qy 647 ISTDENHNKINKNGVINIINNSVNSINNSNNNSINNSNNNSIYKSNVNSQISD 706
Db 739 -----FVVV-----IEKIDIRVDFOKFYK--NIAMENLSD 767
Qy 707 VOIRVNMEDTNSKND-----NIFDALSCDNMMYPIITNNNNNNNNNNNNNNNDV 760
Db 768 I-----SENNNNKKOYIKNHP-----KNNHDELLRHVDSTYENTEKTEFEV 811
Qy 761 ENYNRRDGTNNSMKLYAVYSHNLFOPDNNKNTSNIQNTINKNDGAVNYGMEFCHYL 820
Db 812 ENFKK-----VANDH-----LDEKKLI--MQLTLTAS--AVIDQMDL-----847
Qy 821 NDKNYLIDLNKEQDKN-----IHGDNNTIONRNDPEKKKKTFFYNNNNIYIVANNNGN 876
Db 848 -----FEPKRVKWNESFDLINDCS-----MNEEFYSMATLISQIKSTYDTSNSMN 895
Qy 877 NNSPRMKYGLGSHHSIDMKNNKMMKNNKMMKNDKNNKNNNNSSSSSSN-----NN 932
Db 896 BSISVWKGOVESENNALIKNNKYFNDFEQLINKHNLKONIKNSITSTSHITVND 955
Qy 933 IYNNINDDOTFONDYCHNDNTFTIRKNNNTINSNIYQDDDIYITNSINDYMSNTLHF 992
Db 956 IYNTIE-----NIMKN--YGNKE-----NAKMDMINIIL--983

```

```

Qy 993 KEKTYPTLTSTNEDIYNKMEGKIRLDDQDXDNDNNNNVNNNNKNNV-----DN 1043
Db 984 KE---IPNLS-----KKMP-----LKL-----SNINSNVQSVSPKKAIED 1019
Qy 1044 NVDNNNVND 1052
Db 1020 NKSENVND 1028

RESULT 27
KF3A HUMAN STANDARD; PRT; 702 AA.
ID KF3A HUMAN
AC 09496;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Kinesin-like protein KIF3A (Microtubule plus end-directed kinesin motor 3A).
DE motor 3A).
GN KIF3A.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Retina;
RX MEDLINE=20018159; PubMed=10548469;
RA Whitehead J.L., Wang S.Y., Best-Usinger L., Hoang E., Frazer K.A.,
RA Burnside B.;
RT Photoreceptor localization of the KIF3A and KIF3B subunits of the
RT heterotrimeric microtubule motor kinesin II in vertebrate retina."
RL Exp. Eye Res. 69:491-503(1999).
CC -!- FUNCTION: MICROTUBULE-BASED ANTEROGRADE TRANSLOCATOR FOR
CC MEMBRANOUS ORGANELLES. PLUS END-DIRECTED MICROTUBULE SLIDING
CC ACTIVITY IN VITRO.
CC -!- SUBUNIT: HETERODIMER OF KIF3A AND KIF3B.
CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC II SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF041853; AAC72294.1; -.
DR HSSP; P17119; 3KAR.
DR Genew; HGNC:6319; KIF3A.
DR MIM; 604683; -.
DR GO; GO:0006996; P:organelle organization and biogenesis; TMS.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil; Neutone.
FT DOMAIN 1 350 KINESIN-MOTOR (BY SIMILARITY).
FT 351 587 COILED COIL (BY SIMILARITY).
FT 588 702 GLOBULAR
FT NP BIND 100 107 ATP (BY SIMILARITY).
FT DOMAIN 443 446 POLY-GLU.
SQ SEQUENCE 702 AA; 80337 MM; 24507DIEC6D540DB CRC64;

Query Match 6.7%; Score 460; DB 1; Length 702;
Beet local Similarity 29.8%; Pred. No. 1.7e-11;
Matches 147; Conservative 84; Mismatches 192; Indels 70; Gaps 15;
5 IKVVRKRLSELEKKKKSDIITVKNKNTLYIDEPKYKMTYIERHE---FYDKV 60

```

Db 15 VKVVRRCRPLNERKSKMCKYQAVS-----DEMGGITVHKHTDSSNEPKTFETDV 66
 Qy 61 FDDTVDFNFTYENTIKPLILDYE--NGCVSCFAYGQGTSGKTYTMGSPYQSPDPG 118
 Db 67 FGPESSKQDLYNNLTARPIIDSVLEGNGTI---FAYGQTGKGTFTMEGVRAT--PELRG 121
 Qy 119 IFQYAADIFTEFLNIYDKNTKGIFFISFYEIYCGKLYDLQK--RKNVAALENGKEVVV 176
 Db 122 IIPNSFAHIFGHIAKEGDTFRFLVRVSYLFIYNEEVDDLQDQORLAVERPQVYI 181
 Qy 177 KDLKILAVLTKEELIKMIDGVLRKIGVNSQNDSSRSHLIMIDK-----DINKT 230
 Db 182 KDLAAVYNNADNDRIITLTGHKNRSVGATNMNNSHAFITLTTECEKSIDGMHV 241
 Qy 231 SLGKIATFDLAGSRGADTVSONKOTGDGANINRSLATKECIRAM--DSPKNIIPRDS 289
 Db 242 RMGLTHLVDLAGSRQAKTATGQRK--EARKILSLSTLGNVSLAVDGSTHVPFRNS 300
 Qy 290 ELTKVLRFVGVSKSIMIANISPTISCEQTLNTLRYSRKNFKKSTCINEED--- 345
 Db 301 KLTFLDLSLGNKSKTMWCANIGPADYNYDETISTLRANRAKNIKAKAR--INEDPRDL 359
 Qy 346 ----DITTERSLIDSQSEMMASISENVYKSNHLSNNNNKINRKNKIND----KIE 396
 Db 360 LRQFQKEIEELKKLEEGEISGSDI-----SGSEEDDEGEVEDEGEKRRK 408
 Qy 397 RNNILKKK-----SFDKPREGFTSTFG-----KYSLNDIDIKIKKKKKGLNY 440
 Db 409 RIQIGKKKVPBDMKIEIMQAKIDERRKALETKIDMEBERKAKAELEKREDLLKAOEH 468
 Qy 441 KSTLYNDNTINKK 453
 Db 469 QSLLEKLSALEKK 481
 RESULT 28
 KL61_DROME STANDARD; PRT; 1066 AA.
 ID KL61_DROME
 AC P46863; OST0A6; Q9W018;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 26-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Bipolar kinesin KRP-130 (Kinesin-like protein Klp61F).
 GN KLP61F OR KLP2 OR CG9131.
 OS Drosophila melanogaster (Fruit fly).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
 OC Ephydroidea; Drosophilidae; Drosophila.
 OC NCBI_TaxID=7227;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Embryo;
 RX MEDLINE=94043448; PubMed=8227131;
 RA Heck M.W.S., Pereira A., Pesavento P.A., Yannoni Y., Spradling A.C.,
 RA Goldstein L.S.B.;
 RT "The kinesin-like protein Klp61F is essential for mitosis in
 RT Drosophila";
 RL J. Cell Biol. 123:665-679(1993).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Berkely;
 RX MEDLINE=20196006; PubMed=10731132;
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
 RA Brandon R.C., Rogers Y.-H.C., Blazer R.G., Champe M., Pfeiffer B.D.,
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
 RA April J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
 RA Balow R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
 RA Beeson K.Y., Beres P.V., Berman B.P., Bhandari D., Bolintinas D.,
 RA Borokova D., Botchan M.R., Bouck J., Brokstein P., Brotlier P.,
 RA Burris K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,

RA Cherry J.M., Cawley S., Dahike C., Davenport L.B., Davies P.,
 RA de Pablo B., Delcher A., Deng Z., Maye A.D., Dew I., Dietz S.M.,
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
 RA Durbin K.U., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
 RA Foster C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
 RA Goeler A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
 RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
 RA Houten D., Houston K.A., Howland T.J., Wei M.-H., Idegwan C.,
 RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kenison J.A., Ketchum K.A.,
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kuip D., Lai Z.,
 RA Laske P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
 RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
 RA Merkulov G., Mishina N.V., Mobarry C., Morris J., Moshrefi A.,
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
 RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Paclob J.M.,
 RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
 RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
 RA Slier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
 RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
 RA Wang Z.-Y., Wasmann D.A., Weinstein G.M., Weissenbach J.,
 RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
 RA Ye J., Yen R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
 RT "The genome sequence of Drosophila melanogaster";
 RL Science 287:2165-2195(2000).
 RN [3]
 RP REVISIONS.
 RC STRAIN=Berkely;
 RX MEDLINE=22426069; PubMed=12537572;
 RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
 RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,
 RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
 RA Betencourt B.R., Celniker S.E., de Grey A.D.N.U., Drysdale R.A.,
 RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
 RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
 RA Lewis S.E.;
 RT "Annotation of the Drosophila melanogaster euchromatic genome: a
 RT systematic review";
 RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
 RN [4]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Berkely; TISSUE=Embryo;
 RX MEDLINE=22426066; PubMed=12537569;
 RA Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
 RA George R.A., Guarin H., Krommiller B., Paclob J.M., Park S., Wan K.H.,
 RA Rubin G.M., Celniker S.E.;
 RT "A Drosophila full-length cDNA resource";
 RL Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
 RN [5]
 RP SEQUENCE OF 228-357 FROM N.A.
 RC STRAIN=DP CN BW;
 RX MEDLINE=92020874; PubMed=1924306;
 RA Stewart R.J., Pesavento P.A., Woerpel D.N., Goldstein L.S.B.;
 RT "Identification and partial characterization of six members of the
 RT kinesin superfamily in Drosophila";
 RL Proc. Natl. Acad. Sci. U.S.A. 88:8470-8474(1991).
 RN [6]
 RP PARTIAL SEQUENCE, AND IDENTIFICATION AS KRP-130.
 RX MEDLINE=97078747; PubMed=8918872;
 RA Keshna A.S., Scholey J.M., Leszyk J.D., Saxton W.M.;
 RT "An essential bipolar mitotic motor";
 RL Nature 384:225-225(1996).
 CC -1- FUNCTION: IMPORTANT ROLE IN MITOTIC DIVIDING CELLS. MICROTUBULE
 CC MOTOR REQUIRED FOR SPINDLE BODY SEPARATION. SLOW PLUS-END DIRECTED
 CC MICROTUBULE MOTOR CAPABLE OF CROSS-LINKING AND SLIDING APART
 CC ANTIPARALLEL MICROTUBULES, THEREBY PUSHING APART THE ASSOCIATED
 CC SPINDLE POLES DURING SPINDLE ASSEMBLY AND FUNCTION.
 CC -1- SUBUNIT: Homodimer.
 CC -1- DEVELOPMENTAL STAGE: SPECIFICALLY EXPRESSED IN PROLIFERATING
 CC TISSUES DURING EMBRYONIC AND LARVAL DEVELOPMENT.
 CC -1- PTM: PHOSPHORYLATION DURING MITOSIS AT THR-933 CONTROLS THE

```

CC      ASSOCIATION OF KLPI6F WITH THE SPINDLE APPARATUS (BY SIMILARITY).
CC      -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BINC
CC      SUBFAMILY.
CC      -----
CC      THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation-
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
DR      EMBL: U01842; AAA03718.1; -.
DR      EMBL: AE003471; AAF47458.2; -.
DR      EMBL: AY069442; AAL39587.1; -.
DR      EMBL: M74428; AAA28655.1; -.
DR      PIR: A48669; A48669.
DR      HSP: P17119; 3KAR.
DR      FLYBase: FBgn0004378; KLP61F.
DR      GO: GO:0005737; C:cytoplasm; IDA.
DR      GO: GO:0005871; C:kinesin complex; IDA.
DR      GO: GO:0003774; F:motor activity; IDA.
DR      GO: GO:0007100; P:centrosome separation; IGI.
DR      InterPro: IPR001752; kinesin_motor.
DR      Pfam: PF00225; kinesin_1.
DR      PRINTS: PR00380; KINESINHEAVY.
DR      SMART: SM00129; KISC.1.
DR      PROSITE: PS00411; KINESIN_MOTOR_DOMAIN1; 1.
DR      PROSITE: PS0067; KINESIN_MOTOR_DOMAIN2; 1.
DR      Motor protein; Cell division; Microtubules; ATP-binding; Coiled coil;
DR      Mitosis; Cell cycle; Phosphorylation.
FT      DOMAIN 17 361 KINESIN-MOTOR (BY SIMILARITY).
FT      DOMAIN 362 462 COILED COIL (POTENTIAL).
FT      DOMAIN 463 569 COILED COIL (POTENTIAL).
FT      DOMAIN 570 678 COILED COIL (POTENTIAL).
FT      DOMAIN 679 787 COILED COIL (POTENTIAL).
FT      DOMAIN 788 896 COILED COIL (POTENTIAL).
FT      NP_BIND 103 110 ATP (POTENTIAL).
FT      MOT_RES 933 933 PHOSPHORYLATION (BY CDC2) (BY
FT      VARIANT 595 595 M -> V.
FT      VARIANT 869 869 R -> K.
FT      VARIANT 904 904 H -> Q.
FT      VARIANT 962 962 L -> Q (IN REF. 1).
FT      CONFLICT 983 983 V -> D (IN REF. 1).
SQ      SEQUENCE 1066 AA, 121163 MW, 36364736EBE0721F CRC64;

Query Match 6.7%; Score 459; DB 1; Length 1066;
Best Local Similarity 21.0%; Pred. No. 2.9e-13;
Matches 180; Conservative 175; Mismatches 327; Indels 176; Gaps 28;

QY      2 NSKIVVVRKRPRLSELEKKKSDIITYKNNCTLYIDBRVYVMTKTIERH----- 53
DB      17 NQNTQVYVVRVPLNSRERCIRSAEAVDV-----VGPREVYVTRTLTDSKLTK 62
QY      54 EPIYVAVDDVDYNTFYENTIKPLIDLYENGCVCSFAYGQSGKYTMGSGO----- 109
DB      63 KFTFPRSPGSKQCDVSVVSPLEEVYLNQNCYFAGVGTGKHTMVGEMTEL 121
QY      110 --PYQSDTPGIFQYAGDIFFTFLNYDKNTKGFISFYEYICKLYDL--OKRNV 164
DB      122 KSSWDDDDIGIIPRALSHLPDELMMVEYLT--KRISLELYNELCDLSTDDTTKIR 179
QY      165 AALENGKK-EVNVKDKILRVLTKELLIKMIDGLVLRKIGVNSQNDSSSRSHALNTDL 223
DB      180 IFDDSTKGSVITIQGLEIPVHASKDVYVLTLEKGERKRTATTLMAQSSRSHTVFSI-V 238
QY      224 KDINKN-----TSLGKAFIDLAGSEKADTVSQNNQOTQDGNINRSILALKECIRA 276
DB      239 VHIRENGIEGDMKIKGKNTLVLAGSENVSRKNGEKIRVRETVYINQSLTLTLGRVITA 298
QY      277 MDSDKNHLPRFDSKLTVLRLDIFVSKSKIMIANISPTISCEQTLNLTFRSSRVNFKN 336

```

```

DB      299 LVDRAPVPRYSKLTLLLOESIGRTKTSIIATISPGKDIIBETLLEYAHRKNIQ 358
QY      337 -----KSTCNER-----DQNTTERISIIILSKSENMASSENVIKSNHLSNN- 382
DB      359 KPEVNOQLTKTKVLTKEETEEIDKIKRDMARDNGVLYLAEFTGEITLK-----LESQNR 415
QY      383 -NNKI-----NRGKINDIKERNILKNKSPDKPREGFTSPFGY-----SLNDI 426
DB      416 LNEKMLLLKALKDELOKKEKIFSEVSMVLVEKQELKTEENLNTGTLTLTKVLT 475
QY      427 DKIKNNKKGLINYKST-----LYNDNT-----INKKA 454
DB      476 KRYKEKKEKELVASHMKTEQVLTQAOEILAAADLATDPTQLHGTIERREDEKIRSC 535
QY      455 NNNNNNNNDNNNDNNNNNNNNNNSSSMVNMIMNINN-INNNINNNNN----- 506
DB      536 DQFKRQDNLKEMIGGSLNIYQDQALKEQLSOEWNSSVYSORLLNSKSIEMIKEM 595
QY      507 ---NNNNNNSHNNHLPQPNVAFDTSDFSLDMMCHLNNDKSIPLAKKNLRDNIKL- 562
DB      596 CAOSLOQDTLHNLKLE-----VVKISDQHSQAFVAKLMQMOQQLMSKEIQTNLOVI 651
QY      563 ---KRRSSCDNIMNK-----KKNHLIARHSVSKLTMTSPQKXKN 603
DB      652 EENNQRHKAMLDSSQEFATIIISLSQSVESHAQKHKKLEQAGMSLPABEIQNLQEE 711
QY      604 TFEKSNINKMEDNTPKDIIVESRNVSMNG-----NVLTGLNKTHHDISTDEHNDKI 659
DB      712 LANRALAQDQDALLBSMMQMEQIKULRSKNSISVHLAK--MEESRLTRNHRIDDI 768
QY      660 NNGV-----INIINSNVNS-----INNSNNSINNSNNSIYKSNY 698
DB      769 KSGIQDYQKGIEMSGAQAELISQMEAGMLCIDQGVANQSMQVHKKNLNQ-----KYEK 824
QY      699 NSNGISDVQIRYVNEWD 716
DB      825 ETNENVSVRVH-NQVE 841

RESULT 29
KIN_HUMAN STANDARD; PRT; 963 AA.
ID KIN_HUMAN
AC P33176;
DT 01-OCT-1993 (Rel. 27, Created)
DT 01-OCT-1993 (Rel. 27, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE kinesin heavy chain (Ubiquitous kinesin heavy chain) (UHKC).
GN KIF5B OR KNS1 OR KNS.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RX MEDLINE=92299683; PubMed=160738;
RA Navone F., Niclas J., Hom-Booher N., Sparks L., Bernstein H.D.,
RA Mc Caffrey G., Vale R.D.;
RA "Cloning and expression of a human kinesin heavy chain gene:
RA interaction of the COOH-terminal domain with cytoplasmic microtubules
RA in transfected Cyt-1 cells."
RL J. Cell Biol. 117:1263-1275 (1992).
RN [2]
RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-349.
RX MEDLINE=96195066; PubMed=8606779;
RA Kull F.J., Sablin E.P., Lau R., Fletcher R.D., Vale R.D.;
RA "Crystal structure of the kinesin motor domain reveals a structural
RA similarity to myosin."
RL Nature 380:550-555 (1996).
RN [3]
RP TISSUE SPECIFICITY.
RX MEDLINE=94242426; PubMed=7514426;
RA Niclas J., Navone F., Hom-Booher N., Vale R.D.;

```


RT "Cloning and localization of a conventional kinesin motor expressed
exclusively in neurons.";
RL Neuron 12:1059-1072(1994).
CC -1- FUNCTION: KINESIN IS A MICROTUBULE-ASSOCIATED FORCE-PRODUCING
CC PROTEIN THAT MAY PLAY A ROLE IN ORGANELLE TRANSPORT.
CC -1- SUBUNIT: OLIGOMER COMPOSED OF TWO HEAVY CHAINS AND TWO LIGHT
CC CHAINS.
CC -1- SUBCELLULAR LOCATION: UNIFORMLY DISTRIBUTED BETWEEN THE CELL BODY
CC AND THE PROCESSES IN THE NEURONS.
CC -1- TISSUE SPECIFICITY: FOUND IN NEURON AND ADULT BRAIN, LIVER,
CC KIDNEY, SPLEEN, HEART, LUNG AND SCIATIC NERVE.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS: A LARGE GLOBULAR N-
CC TERMINAL DOMAIN WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY OF
CC KINESIN (IT HYDROLYZES ATP AND BINDS MICROTUBULE), A CENTRAL
CC ALPHA-HELICAL COILED COIL DOMAIN THAT MEDIATES THE HEAVY CHAIN
CC DIMERIZATION; AND A SMALL GLOBULAR C-TERMINAL DOMAIN WHICH
CC INTERACTS WITH OTHER PROTEINS (SUCH AS THE KINESIN LIGHT CHAINS),
CC VESICLES AND MEMBRANOUS ORGANELLES.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X65873; CAA46703.1; -.
DR PIR; A41919; A41919.
DR PDB; 1BG2; 14-OCT-98.
DR Genew; HGNC:6324; KIF5B.
DR MIM; 602809; -.
DR GO; GO:0005871; C:kinesin complex; TAS.
DR GO; GO:0004002; F:adenosinetriphosphatase activity; TAS.
DR GO; GO:0003777; F:microtubule motor activity; TAS.
DR GO; GO:0007018; P:microtubule-based movement; TAS.
DR InterPro; IPR001752; Kinesin_motor.
DR Pfam; PF00225; kinesin_1.
DR PRINTS; PRO0380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN; 1.
KM Motor protein; Microtubules; ATP-binding; Coiled coil; 3D-structure.
FT DOMAIN 1 256 KINESIN-MOTOR.
FT NP_BIND 915 963 COILED COIL.
FT STRAND 8 15 GLOBULAR.
FT HELIX 20 25 ATP (BY SIMILARITY).
FT STRAND 26 26
FT STRAND 29 29
FT STRAND 32 34
FT STRAND 35 37
FT STRAND 38 41
FT TURN 42 43
FT STRAND 44 47
FT STRAND 50 52
FT TURN 54 55
FT HELIX 58 65
FT HELIX 66 66
FT TURN 74 74
FT TURN 75 76
FT STRAND 84 84
FT TURN 87 88
FT HELIX 91 95
FT TURN 96 96
FT STRAND 97 97
FT TURN 99 100
FT TURN 102 104
FT STRAND 105 105
FT HELIX 107 122

FT STRAND 126 138
FT TURN 139 140
FT STRAND 141 144
FT TURN 148 149
FT STRAND 153 153
FT STRAND 155 157
FT TURN 159 160
FT STRAND 166 167
FT TURN 171 173
FT HELIX 176 189
FT TURN 190 193
FT HELIX 197 203
FT STRAND 205 216
FT TURN 217 219
FT STRAND 222 231
FT TURN 246 247
FT HELIX 256 269
FT TURN 270 271
FT HELIX 277 279
FT STRAND 281 285
FT HELIX 286 288
FT TURN 289 289
FT STRAND 295 302
FT STRAND 305 305
FT HELIX 306 308
FT HELIX 309 320
FT TURN 321 321
SQ SEQUENCE 963 AA; 109685 MW; A1PE5760C3250C8B CRC64;
Query Match 6.6%; Score 453; DB 1; Length 963;
Best Local Similarity 21.8%; Pred. No. 4,7e-13;
Matches 215; Conservative 171; Mismatches 421; Indels 178; Gaps 34;
QY 5 IKVVRKRPISLEKKKKSDIITVKNCTLYIDPRKYKDMTKYIERHFEIVDKVPDDT 64
9 IKMCHFRPPIINESEVNRGDK-----YI-AKQGEDIVVIASKPYAFDRVQSS 55
QY 65 VDNFTYENTIKLIIDLYE--NGCVSCSPVAGTSGKTYMTLGS--QPYGSDPDPGIF 120
56 TSOEIVYNDCAKKTIVDVLGNYGTI--FAYQTSKGKTHTEGKLHDEGNGIIPRIIV 112
QY 121 QVAAQDIFPEFLNYDKDNTKGIPISEFEIYCGIYDLQKRKVAALENGKKEV-IVKDL 179
113 Q-----DIFNYIYMDENLEPHIKVSYFEIYLDKIRDLDSKTNLSVHEKKNVPPYKGC 168
QY 180 KILRVLTKEELIKMIDGVLLRKIGVNSQNDSSSRSHAILNIDKIDINKTS---LGKIA 236
169 TERFVCSPEVMDTIDEGKSNRHVAVTNNMHESSRSHSIFLINVKQENTQTEQKSGKLY 228
QY 237 FIDLASSEKADPVSONKOTQDGNINNSLALKECIRAMSDKXHIIPRDELTKVLR 296
229 LVDLASSEKSVSKGAGG-AVLDEAKNINSLALGVNIALAGSTYVPYRDKMRILQ 287
QY 297 DIFVGSKSIIMIANIPTISCCBOTLTLRYSRVNPNFKSTCINEEDDTNTERISILD 356
288 DSLGNCRTTIIVCCPSSSYNESETSTILFGRATIKK-TYCAVVE----- 334
QY 357 SKGSENNASSIENNVIKSHLLSNNNNNKINRGKINDKIERNNI--LKQKSFDPREGFT 414
335 -----LTAEQWKKKYKEKEKGIKILRNITQMLENE-LNRMRNGET 373
QY 415 STFGKYSIINDIDIKKKNKKGLINYSKSTLYNDNTINKGNNNNNNNNNNNDND----- 466
374 VPIDE-----QDFKEVANELEAFTVDKDTLTLNDKPATYAIQVIGNFTDARRKCEEETAKL 428
QY 467 -NNNDNNNNNNNDSSGVANNIMINHMNNNNNNNNNNNNNNNNNNNNNNHNLPOPNYA 525
429 YKQLDQKDEINQSGVLEKTKQMLDQF-----ELLASTRDQDMQALNRLQLENDA 483
QY 526 FTD--TSDFSSLDQNMCHLNNDKSTFLHKKNLRDNIKLNKSSCDNINAKKKKNINILHAR 583
484 SKEEVEKVIQALEEL--AVNYDQKS-----QEVED--KTYEVELLSDELINQKSATL----- 530
Db

DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Kinesin-like protein 5.
 GN KLP5 OR SPBC2F12.13.
 OS Schizosaccharomyces pombe (fission yeast).
 CC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
 CC Schizosaccharomycetales; Schizosaccharomycetaceae;
 CC Schizosaccharomycetes.
 CX NCBI_TaxID=4896;
 RN [1]
 RP SEQUENCE FROM N.A., FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
 RX MEDLINE=21963728; PubMed=11967147;
 RA Garcia M.A., Koonrunga N., Toda T.;
 RT "Two kinesin-like kin I family proteins in fission yeast regulate the
 RT establishment of metaphase and the onset of anaphase A.";
 RL Curr. Biol. 12:610-621(2002).
 RL [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=972;
 RX MEDLINE=21848401; PubMed=11859360;
 RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
 RA Scouras J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
 RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
 RA Collins M., Connor R., Cronin A., Davis P., Feltham T., Fraser A.,
 RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
 RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagsels K.,
 RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
 RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
 RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinovich E.,
 RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
 RA Seaton J., Simmonds M., Squares R., Squares S., Stevens K.,
 RA Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
 RA Woodward J., Voicakeert G., Aert R., Robben J., Gymnopoulos B.,
 RA Weltsch J., Vansteels E., Rieger M., Schaefer M., Mueller-Auer S.,
 RA Gabel C., Fuchs M., Fritz C., Holzer E., Moestl D., Hilbert H.,
 RA Borzym K., Janger I., Beck A., Lehnach H., Reinhardt R., Pohl T.M.,
 RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
 RA Goifeu A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
 RA Gaillet F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
 RA Lucas R., Rocher M., Galliard C., Tallada V.A., Garzon A., Thode G.,
 RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito G.,
 RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
 RA Cerutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
 RA Sipakovski G.V., Ussery D., Barrett B.G., Nuree P.;
 RT "The genome sequence of Schizosaccharomyces pombe.";
 RL Nature 415:871-880(2002).
 CC -!- FUNCTION: Has a role in establishing metaphase during mitosis.
 CC Required for chromosome segregation where it generates tension
 CC during kinetochore capturing.
 CC -!- SUBUNIT: Heterodimer with klp6.
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic microtubules in interphase,
 CC mitotic kinetochores in metaphase and spindle midzone in anaphase
 CC and telophase.
 CC -!- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
 CC II SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements>
 CC or send an email to license@ebi.ac.uk).
 CC -----
 DR EMBL, AB072924, BAB69885.1; -.
 DR EMBL, Z97211, CAB1060.1; -.
 DR PIR, T40128; T40128.
 DR HSP, P17119; 3KAR.
 DR GeneDB Spombe; SPBC2F12.13; -.
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin_1.
 DR SMART; SMO0380; KINESINHEAVY.
 DR SMART; SMO0129; KISC; 1.

DR PROSITE, PS00411; KINESIN MOTOR DOMAIN1; 1.
 DR PROSITE, PS0067; KINESIN MOTOR DOMAIN2; 1.
 KM Mitosis; Chromosome partition; Motor protein; Microtubules;
 KW ATP-binding; Coiled coil.
 FT DOMAIN 1 388 KINESIN-MOTOR (BY SIMILARITY).
 FT DOMAIN 396 435 COILED COIL (POTENTIAL).
 FT DOMAIN 563 588 COILED COIL (POTENTIAL).
 FT NP BIND 144 151 ATP (POTENTIAL).
 SQ SEQUENCE 883 AA; 99058 MW; BB8A60E22DA397E8 CRC64;
 Query Match 6.5%; Score 449; DB 1; Length 883;
 Best Local Similarity 21.3%; Pred. No. 6, 4e-13;
 Matches .218; Conservative 159; Mismatches 354; Indels 294; Gaps 37;
 3 SKIKVVRKRPSELEKKK-KDSD-----IITVKNCTYIDE 39
 5 SSTVTYVRVRFPTASANLIASDRLSGTSSSLNPGSGRIKRVVYLDKRVLYFDP 64
 40 PRYKVDMTKYEERH-----EFIVKVFDDTVNFTYEENT 74
 65 PDRTATVLSATNRLSTSGQSLRLSRKSNNSAGFGRDLRYARDFDEATQOQYVERT 124
 75 IKRLIIDLYENGVCSCFAYGQTSQKTYTMLASQYGGSDTTCIROYAAGDIFTEINTY 134
 125 ARPLDNIID-GFNATIFVAGATGCGKTHISGTM-----ODPGLYLTKELFERMDHL 178
 135 DKONTGIFISFEIYCGKLYDYL-----QKRKVALENGKKEVVVKDLIRVLTKEE 189
 179 RDKRTIDRLRSYEIETNETRDLVSPTRQAKPLVREDADRRITVPGLTISPSLEEE 238
 190 LILKMTIDGVLRKIGVNSONDESSRAIINIDL-----KDKNTSLGKIAFIDLAGS 243
 239 IIDIIKGNANRMTSPTEANASRSRAVLQVTLQKPRFAGINEDHTLATISIIDLAGS 298
 244 ERADPVSQKQQTGTGANINSLALKECIRAM--DSDKNIPFDESLTKVLRDIPFG 301
 299 ERATATKLGSRL-FEGANINKSLALGNCINALCPHRAHVPYDSKTRLLKESLOG 357
 302 KSKSIVIANISPTSCCEOTLNTLRSSRVKPKNKSTGINEEDDINTERISIDSGKSE 361
 358 NCRTWIVCVSPSVAYEETHNTLKYANPAKINKT-----EYLRNNTSV-----D 402
 362 MNASILENVVIVKSNHLLSNNNNNKIRKINDKIEBNNILKNSKPDKREGFTSTFGKYS 421
 403 RHVSQYVKAIVELREGISELENRLA-----QID-----LSQSGNSDDQAVTQSAHNS 451
 422 SLNDIDKIKKKKKGLINTKSTL-YNDNTINK--KHNNNNNNNNDNNNNNNNNNN 476
 452 KLAERANLRL-----MFEETLPLQNDTINKVEKYKH-----F 484
 477 NQSSSVVNNMNNMNN 536
 485 DDSIRVLTQVL-----SCYERILP----- 503
 537 DMNCHLNNDKSIFLKKKRL-----DNIKLNKSSCDNIMNKKNNLHL 581
 504 -----NSADERFLVRSKLSLESLTRARLADIADIDELVYQKFRQSVSHIINTYKQ----- 553
 582 ARHVSQKLTWESYDQKKNNTFPKSNL-----NKMEDNTP--KQILYESRVNSNM 631
 554 -----EGATVYADVLDQDVED--LKSIILENVQLDAQNVYDEPTPLVESILSRSPFASSL 605
 632 -NGNV-----LGLNKTHTHDISTQENHNNDKINGVINIINNSVNSINNSN 679
 606 LKEGGQBELPSILEKKLLGLIGLGEKPNISVLSESY--KLNK-----TSDSRTINRDR 656
 680 MNS-----INNSNNSNITSYS-----NYSNOSISDV-QIRYVNEMDT 717
 657 VHSFPQPLNNLNNLPRMFFVKSPPKRVFVSXKSPKRVAFDDSMGSDSGAAYSPIQT 716
 718 SKKNDNITFFDAISCDNNMYPNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 774
 717 SKLKNMNF-----NTMHPSTPAKRPEKNQIDIVE--INTLSPVSPMLIEDXP 763

QY 775 ---LYAVNSHLFOPDNKNTSNIONINTKNOGQVNY-----SNMFC 816
DB 764 EPGLLISPLEKKQVNSSTQDLDLEDSTDSVSPHLDITDLDGSPVPRKPDLDNFS 823
QY 817 HYNLDKNVYLIDLNKQKDKNHCDDNIIIONRNDPEKKKTKFNNTNNTIVIVNNNGN 876
DB 824 RANMDSPTFL--LNNEA-----IHFDFSKEPTKQSLSLTLTLHNSPANIIRKSLSWAE 876
QY 877 NNSPR 881
DB 877 NEEK 881

RESULT 32
KF11_HUMAN STANDARD; PRT; 1057 AA.
ID P52732; Q15716;
AC 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DE 15-SEP-2003 (Rel. 42, Last annotation update)
DE Kinesin-like protein KIF11 (Kinesin-related motor protein Eg5)
DE (Kinesin-like spindle protein HSP) (thyroid receptor interacting
DE protein 5) (TRIP5) (Kinesin-like protein 1).
GN KIF11 OR KNSL1 OR EG5.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., PHOSPHORYLATION SITE THR-927, AND MUTAGENESIS.
RX MEDLINE=96128120; PubMed=8548803;
RA Blangy A., Lane H.A., D'Herin P., Harper M., Kress M., Nigg E.A.;
RT "Phosphorylation by p34cdc2 regulates spindle association of human
RT Eg5, a kinesin-related motor essential for bipolar spindle formation
RT in vivo.";
RL Cell 83:1159-1169 (1995).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=98369052; PubMed=9701554;
RA Whitehead C.M., Ratner J.B.;
RT "Expanding the role of HsEg5 within the mitotic and post-mitotic
RT phases of the cell cycle.";
RL J. Cell Sci. 111:2551-2561 (1998).
RN [3]
RP SEQUENCE OF 819-868 FROM N.A.
RX MEDLINE=95295737; PubMed=7776974;
RA Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D.;
RT "Two classes of proteins dependent on either the presence or absence
RT of thyroid hormone for interaction with the thyroid hormone
RT receptor.";
RL Mol. Endocrinol. 9:243-254 (1995).
CC -I- FUNCTION: MOTOR PROTEIN REQUIRED FOR ESTABLISHING A BIPOLAR
CC SPINDLE. BLOCKING OF EG5 PREVENTS CENTROSOME MIGRATION AND ARREST
CC CELLS IN MITOSIS WITH MONOCLONAL MICROTUBULE ARRAYS.
CC -I- SUBUNIT: INTERACTS WITH THE THYROID HORMONE RECEPTOR IN THE
CC PRESENCE OF THYROID HORMONE.
CC -I- PTM: PHOSPHORYLATED EXCLUSIVELY ON SERINE DURING S PHASE, BUT ON
CC BOTH SERINE AND THR-927 DURING MITOSIS, SO CONTROLLING THE
CC ASSOCIATION OF EG5 WITH THE SPINDLE APPARATUS (PROBABLY DURING
CC EARLY PROPHASE).
CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BINC
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DB EMBL; X85137; CAA59449.1; -.

DR EMBL; U37426; AAA86132.1; -
DR EMBL; L40372; AAC41739.1; -
DR PIR; G02157; G02157.
DR PDB; 1IIF; 18-UTL-01.
DR Genew; HGNC:6388; KIF11.
DR GK; P52732; -
DR MIM; 148760; -
DR GO; GO:0005871; C:kinesin complex; TAS.
DR GO; GO:0005819; C:spindle; TAS.
DR GO; GO:0004002; F:adenosinetriphosphatase activity; TAS.
DR GO; GO:0003777; F:microtubule motor activity; TAS.
DR GO; GO:0007052; P:mitotic spindle assembly; TAS.
DR InterPro; IPR001752; Kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SMO0129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil; Mitosis;
KW Phosphorylation; 3D-structure.
FT DOMAIN 16 363 KINESIN-MOTOR (BY SIMILARITY).
FT 364 480 COILED COIL (POTENTIAL).
FT DOMAIN 737 764 COILED COIL (POTENTIAL).
FT NP BIND 105 112 ATP (POTENTIAL).
FT MOD BIND 927 927 PHOSPHORYLATION (BY CDC2).
FT MUTAGEN 927 927 T->A: NO MITOTIC PHOSPHORYLATION. NO
FT BINDING TO SPINDLE APPARATUS.
FT CONFLICT 674 676 RNS -> EL (IN REF. 2).
SQ SEQUENCE 1057 AA; 119273 MW; E322F214BEF1601 CRC64;
Query Match 6.5%; Score 447.5; DB 1; Length 1057;
Best Local Similarity 20.9%; Pred. No. 9.1e-13;
Matches 209; Conservative 164; Mismatches 387; Indels 241; Gaps 34;
QY 5 IKVVRKRPSELEKKKKSDITVKNQCTLYIDEPYKVD-----MTKTEHEEFTYDK 59
DB 19 IQVVVRCPPEFLERKASAHIV-----DPVKEVSVRTGLADKSSRKYTFDM 70
QY 60 VEDTVNFTVYENTIFPLIIDLYENCVCSPAYGOTGSGKYTMG-----SQPYQSD 115
DB 71 VEGASTQIDIDYRVCVP-ILDEVIMGYNCTIFAYGOTGKFTFMGERSPNEYTWEE 129
QY 116 TP--GIFQYAGDIFFTFLNIYDKNTGIFISFEIYCGKLYDL-----QKRWVAAL 167
DB 130 DPLAGIIPRTLHQFEKLT--DNGTERSVAVSLIETINELFDLINSQVSESLQMFDD 187
QY 168 ENKKEVAVVDKILRVLTKEELILKMDGVLLKIGVNSONDESSSHALINIDK--- 224
DB 188 PRNRGVYIKGLEIETVHNKDEVYQILEKGAKRRTAATLMNAVSSSHSVFTIMKE 247
QY 225 ---DINKTSLGKIAFTIDLAGSESGADTVSONKQOTDGNINNSLLALKECIRAMSDK 281
DB 248 TTIGBELVKIKGLNLDVLAGSENIGSGADKARENG--NINOSLTITGRVITAVERT 306
QY 282 NHIFPDSSELTKVLRDIFVGSKSIMTANISPTISCEOTLNTLYSRVNFNKGSTCI 341
DB 307 PHVYRESKLRILQDLSGGRTRSLATISPAINLEETSTLEYHRAKNIILNK----- 362
QY 342 NEEDDTERTISLDSKSENNASSIENVVVK-----SNHLSNNN 383
DB 363 -----PEVYQKLTAKKALKEETEEIERLKRDLAAREKNGYVISEN 404
QY 384 NKIRGKINDKIER--NNILKNSFDPDRPREGFTSPCKYSSLNDIDK---KXKKGLI 438
DB 405 FRVWSGKLTVOEBOIVELIEXIGAVEELNRVTLF--MDKKNLDDCKSLQKKTGLE 462
QY 439 NYKSTLYV-----DNTINKGNNNNNNNNNDNNNDNNNNNNNNSSSMV 483
DB 463 TTQGHLETKQLVKEEYTSALSTEEKLHDAASKLNTLYVEETTKOVSGLSKLDKKA 522
QY 484 NNMNINMNNINNNIN--VANNNNNNNNNNNNNNNNHNPQPNVAFD--TSDESLDMN 539
DB 523 VDHNAEADIFGKLNLSLFPNNMEELIKDGSKOKAMLEVHKTFLGNLLSSVSALDIT 582

```

QY 540 C-----HIANNDKSIFLHKKNL-----RDNIKLRSSCONINKKKNL-----579
D 583 TVALGSLTSPENSTHVSOIFNNMLKEQSLAEASKVLOGLIVLTLDTLSLEMTLSP 642
QY 580 -----HIAHSVSKLTMF-SYDPQKKNDTPFKS-----NINMEDTPTDILYES 625
D 643 TVASILKINSQLKHIPTSLTVAADRIDQKKRNSDGLSLCNMHLQEWNTLSVESQ 702
QY 626 RANSNMNGNVLGLKNTHTD-----ISTDENNN-----DNKINGVI 664
D 703 KQCGNLIED--LKTIKQTHSQELCKMLNLTWTERFCALEKCKENIQKPLSVQENIQKSK 760
QY 665 NIINNSVNS-----INNSNM-----NSINNSNNSNIYSKNSVNSQSI 704
D 761 DIYAKMTFHSKFCADSDGFSQELRNQOESTKLIVESVAKSDGLNGLKTSOETQRC 820
QY 705 SDVQIRYV-----NEMD-----TSKNNDNT 725
D 821 ESINTRFVYFSEQWVSSLINEEQELHNLLEVVSQCEASSSDITEKSDGRKAHEKQHNI 880
QY 726 FPDASCDNNMYPRITNNNNNN-----NNNNNNNDIVENNNDGTNSMKLY 776
D 881 FLDDMTIDEXL--IAQNLBNLETKIGLTKLNCFLBODLKDIP-----GTPQKRSY 933
QY 777 AYNS-----HNLFPDNNKNTSNINININQNDQAV 809
D 934 LYPTLVTRTEPREHLLOLKRKQPELMLNCSNNNEETI 974

RESULT 33
KINH MOUSE STANDARD; PRT; 963 AA.
ID 061768; 008711; 061580.
AC 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE kinesin heavy chain. (ubiquitous kinesin heavy chain) (UKHC).
GN KIF5B OR KNS1 OR KHCS.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
ON NCBI_TaxId=10090;
RX 1 [1]
RC TISSUE=PANCREAS;
RX MEDLINE=9726654; PubMed=9112396;
RA Meng Y.X., Wilson G.W., Avery M.C., Varden C.H., Balczon R.;
RT "Suppression of the expression of a pancreatic beta-cell form of the
RT kinesin heavy chain by antisense oligonucleotides inhibits insulin
RT secretion from primary cultures of mouse beta-cells.";
RL Endocrinology 138:1979-1987(1997).
RN [2]
RP SEQUENCE OF 1-881 FROM N.A.
RC STRAIN=BALB/c;
RX MEDLINE=94224818; PubMed=8170981;
RA Gudkov A.V., Kazarov A.R., Thimmapaya R., Axenovich S.A., Mazo I.A.,
RA Robinson I.B.;
RT "Cloning mammalian genes by expression selection of genetic
RT suppressor elements: association of kinesin with drug resistance and
RT cell immortalization.";
RL Proc. Natl. Acad. Sci. U.S.A. 91:3744-3748(1994).
CC -1- FUNCTION: KINESIN IS A MICROTUBULE-ASSOCIATED FORCE-PRODUCING
CC PROTEIN THAT MAY PLAY A ROLE IN ORGANELLE TRANSPORT. MAY BE
CC INVOLVED IN THE MECHANISMS OF GROWTH ARREST INDUCED BY EXPOSURE TO
CC DNA-DAMAGING DRUGS OR BY CELLULAR SENSICENCE.
CC -1- SUBUNIT: OLIGOMER COMPOSED OF TWO HEAVY CHAINS AND TWO LIGHT
CC CHAINS.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS: A LARGE GLOBULAR N-
CC TERMINAL DOMAIN WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY OF
CC KINESIN (IT HYDROLYZES ATP AND BINDS MICROTUBULE), A CENTRAL
CC ALPHA-HELICAL COILED COIL DOMAIN THAT MEDIATES THE HEAVY CHAIN
CC DIMERIZATION, AND A SMALL GLOBULAR C-TERMINAL DOMAIN WHICH

```

```

CC INTERACTS WITH OTHER PROTEINS (SUCH AS THE KINESIN LIGHT CHAINS),
CC VESICLES AND MEMBRANOUS ORGANELLES.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U86090; AAB53940.1; -
DR EMBL; L27153; AAA20133.1; -
DR EMBL; L28223; AAA20132.2; -
DR HSSP; P31176; 1BG2.
DR MCD; MGI:1098268; KIF5B.
DR GO; GO:0005515; F:protein binding activity; IPI.
DR GO; GO:0007028; P:cytoplasm organization and biogenesis; IMP.
DR InterPro; IPR001752; Kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil.
DR Kinesin_motor; Kinesin_motor (BY SIMILARITY).
FT DOMAIN 1 328
FT 329 914
FT DOMAIN 915 963
FT NP BIND 85 92
FT CONFLICT 20 21
FT CONFLICT 40 40
FT CONFLICT 75 75
FT CONFLICT 191 191
FT CONFLICT 255 255
FT CONFLICT 396 396
FT CONFLICT 403 403
FT CONFLICT 451 451
FT CONFLICT 520 520
FT CONFLICT 523 523
FT CONFLICT 653 653
FT CONFLICT 664 664
FT CONFLICT 744 744
FT CONFLICT 814 814
FT CONFLICT 865 865
FT CONFLICT 881 881
SQ SEQUENCE 963 AA; 109549 MW; 718CDBD102E0475E CRC64;

Query Match 6.5%; Score 447; DB 1; Length 963;
Best Local Similarity 21.3%; Pred. No. 8 6e-13;
Matches 211; Conservative 177; Mismatches 414; Indels 188; Gaps 37;

QY 5 IKVVRKRPLESELEKKKSDIITVKNONCTLYIDREPRYKVDMTKYIERHEFIVDKYFDDT 64
D 9 IKVRCFRPLNBESEVNRGDK-----YV-AKFOEDTVVIAKRYAFDRVQSS 55
QY 65 VDNFTYENTIKRLIIDLYE--NGCVSCFAYQQTSSGKTYTLAGS--QPYGSDTPGIF 120
D 56 TSOEOVYNCAKKIVADVLEGVNGTI---FAYQTSKGKHTWEGKLHPDEGMIIPRIY 112
QY 121 QVAAAGIIFPLINLYDNDKRGIFISFYETIYCGVLYLLOKRVKVALENGKKEV-VVKOL 179
D 113 Q-----DIFVITYMDENLEPHIVSFEIYLKIRLDLVSKTNLSVHEKXNRPVYVKG 168
QY 180 KILRVLTKEELIKMIDGVLLRKIGVNSQNDSSRSALINTLDKINNTS---LQKIA 236
D 169 TERFVCSPEVDVMTIDEGKSNRHAATVNNHNSRSHSIFLIVNQENQTEBCKLGSKY 228
QY 237 FIDLASSEKADPVDSKQOTQDGNANINSLAKKCIAMSDKXNHIIPRSELEKVL 296
D 229 LVDLASSEKVSKTGAGG-AVLDEAKNINSLGALGNVISALEAGSTYVPRDSKMTRILO 287

```



```

Db 823 -----GTTGKPKYKPNSSHDQISGLIADHCTIKV--FGGTVSIIPVEAKTYVN 872
QY 544 -----NNDKSI-----FLHKKNLRNITLKRSSCDNIMNK-----KKN 577
Db 873 GKILLETTVLRHGDVRLVGGDHFRRFHPVAVQ---KGKPSGHDPTISGPPDPEPAKN 929
QY 578 NLHLARHSVSKLTMPESYDPO-KNKONTPEKSNINK---MEDNTPKDIILYESRNVSMNG 633
Db 930 ELLMAQR---SQLEAEIKEAQULAKEMMGQIQAKEMAQOELSSQCAAESEK----- 979
QY 634 NVLLGKNTKTHDIDSTODENHNKINNGVNIINNSNVNSINNSNMNSINNSNMNSI 693
Db 980 -----IKALEAEIRESQKQKQEIINQKA---NHKILELEKAKOHLBOEITYVNRKL 1029
QY 694 YKSNVNSNOSISDPOIRYVNMEDTSPKNNKNNIIFPDALSCNNMYPTNTNNNNNNNNNN 753
Db 1030 EMETLATKQLEHDSIRHARILELETEKOKIAKV----- 1065
QY 754 NNNNIDVENYNNEDGTN-----NSMKL-----YVNSHNLFOPDNMK 790
Db 1066 ---QILQONNNNRDKPTVQTTWSSMKLSMWIOEANAISSKLTQYVFGHSDISDKSSSD 1122
QY 791 NTSNIQNI-----NTNKNQOGVNVYSNMFCNYLNDKNYL 826
Db 1123 TSIRVRNLKLGISTFWSLEKESKLAAMELYESNGSNGEDPA---FCDPEDEWEPI 1177
QY 827 IDL-----NNKEQDKNKHGCONNIIONNDEPKKKKTTPYNNNNI.VIYNNMNGN 877
Db 1178 TDAPVSSLRSRRSRSLMKNRIRISGCLHDI---QVHPIKHLSSHSGSLMDXSSTIYSN 1232
QY 878 NSPRMKYGLC---GS-----HTSIDNMKNEM-----KNEMKDNEM 911
Db 1233 SASEPLPGLIKELIGSLDFPGQSYDEERTIADSLINSFLKINGLFAISKAHEDEBS 1292
QY 912 KDNHISNNNNSSSSSSNNNNIYNNINDDTFONDYCHANDNTTIRKKNNTNI--NSNIT 969
Db 1293 QDNLFSSDRAIOFL-----TIQTF-ACAPQLVLMKHMWLSLDLPCNTNIA 1335
QY 970 Q-NDIIYNTSLNDY-----MSNTL 989
Db 1336 RLEDELROEVKKLGIVLQFLQGCCDLISSMIKEAQKNAIQIQAQVYVQGLAVLKGSK 1395
QY 990 LHEKEKYTPYLTSTNEDIYNKEME---GKHRLDD-QDKYDNDNNNNVNNKNNVNN 1044
Db 1396 LHFLEGNKNAKAVQGEFMDAVCDGVLGKMKILLDSLEKAKELQHLPRQCTKREVTKE 1455
QY 1045 VDNNDVND---NNVDNNDKNNVNDNNDVDFPHNIKFNENN--EYLSYFQKKNVDT 1097
Db 1456 MKNAMGLIRSLNIFAESKIKSFRRQV--QENFQYQDFKRVNNAPEFLK----- 1505
QY 1098 IINNCCNSLDISSMYDTEKILNNILSKYK-AEKONVIAKKYINEDIKNMSLE-----EL 1151
Db 1506 -LKHCL-----EKALEIITISALKGCHSDINLQTCVSEIRNLASDFYSDFSV 1551
QY 1152 DKTAOSIYERKAVLTKLLLLFKKNVDTQINNETSLDKDLVWCHICNNPD 1203
Db 1552 PSTSVSYSESR-----VTHIVHQLSESLAKSLFLCFSESESPD 1589

```

```

RESULT 35
KF3A MOUSE STANDARD; PRT; 701 AA.
AC P28741;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Kinesin-like protein KIF3A (Microtubule plus end-directed kinesin motor 3A).
GN KIF3A OR KIF3.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

```

```

OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=93077686; PubMed=1447303;
RA Mizawa H., Sekine Y., Takemura R., Zhang Z., Nangaku M., Hirokawa N.;
RT "Kinesin family in murine central nervous system."
RL J. Cell Biol. 119:1287-1296(1992).
CC -1- FUNCTION: MICROTUBULE-BASED ANTEROGRADE TRANSLOCATOR FOR MEMBRANOUS ORGANELLES. PLUS END-DIRECTED MICROTUBULE SLIDING ACTIVITY IN VITRO.
CC -1- SUBUNIT: HETERODIMER OF KIF3A AND KIF3B.
CC -1- TISSUE SPECIFICITY: EXPRESSED ALMOST EXCLUSIVELY IN ADULT BRAIN TISSUE (MAINLY IN THE CEREBELLAR GRANULAR LAYER) WITHIN A SINGLE TYPE OF NEURONAL CELL.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN II SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC -----
DR EMBL: D12645; BAA02166.1;
DR PIR: B44259; B44259.
DR HSSP: P17119; 3KAR.
DR MGD: MGI:107689; Kif3a.
DR InterPro: IPR001752; kinesin_motor.
DR Pfam: PF00225; kinesin; 1.
DR PRINTS: PR00380; KINESINHEAVY.
DR SMART: SM00129; KISC. 1.
DR PROSITE: PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE: PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil; Neurone.
FT DOMAIN 1 350 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 351 586 COILED COIL (BY SIMILARITY).
FT NP_BIND 587 701 GLOBULAR.
FT NP_BIND 100 701 ATP (BY SIMILARITY).
FT DOMAIN 442 445 POLY-GLU.
FT DOMAIN 509 512 POLY-ARG.
SQ SEQUENCE 701 AA; 80167 MW; 2405872DP2D85A29 CRC64;

```

```

Query Match 6.5%; Score 445.5; DB 1; Length 701;
Best Local Similarity 29.6%; Pred. No. 7.1e-13;
Matches 145; Conservative 84; Mismatches 196; Indels 65; Gaps 16;

```

```

QY 5 IKVVRKRPLELEKKKSDIITVKNNTCTLYIDEPYVDWTKYIERHE---FIVDKV 60
Db 15 VAVVVRKRLNREKSMCKRQAVSV-----DEMKGITTHAKTDSNEPKTFPFDV 66
QY 61 PDDTVNFTVYENTIKPLIIDYE--NGCVSCFAYGQTSKTYMTLGSQPYGSDPFG 118
Db 67 FGPESKQDLYVNLTPRIIDSVLEGNGTI--FAYGQGTGKTFMTBGR--AVGGLRG 121
QY 119 IFQYAAGDIFTPLNIYDNDNTKGIIFISPEYICGLYDLQK--RKMAALENGKEVYV 176
Db 122 VIPNSFAHIFGHIAAEGDTRFLVSVSLIYNEVRLDGLDQTORLEVKERPVGVI 181
QY 177 KDLKILRVLTKEELIKMIDGVLTKRIGVNSONDESSRSALNTIDLK-----DINKVT 230
Db 182 KQLSAVYVNNADMDRIMTLGHKRSVGTATNNENSSSHALFTTIBESKGVGNMNV 241
QY 231 SLGKIAFIDLAGSEKADVTSONKQOTGDGANINSLALKECIRAM--DSDKNHLPFRDS 289
Db 242 RMGKLHVLVDLAGESEKQATGARGRLK-EATKINISLTLGNVISALVDGSKTHVYRNS 300
QY 290 ELTKVLRIPIVCKSKSIAMNISPTISCEQTLNTRYSRKYRKNKSTCINED----- 345
Db 301 KTLRILOSLGNSKTMCMCANIGPADYVDETISTRLYRANRKNKIKNKR--INEDPKDL 359

```

```

QY 346 ----DTNTERISILDSKSEMNASSIENVVIKSNHLLSNNNKINKINDKIERNNIL 401
DB 360 LROFOKEIEELKLEBEEVSGSDISGEDEDEGEIGEDGCK-RRKRDQAGKKV 417
QY 402 KNR-----SPDKREGFTSTFGKYSSINDIKIKNK-----KKGLI---NYKST 443
DB 418 PDKVEMQAKIDEERKALLETYL-----DWESEERNVRAELRRERKLLKAOQHQS 470
QY 444 LYNDNTINKK 453
DB 471 LEKLIALEKK 480

RESULT 36
KFSC_MOUSE STANDARD: PRT: 956 AA.
ID KFSC_MOUSE
AC P28738; Q922F8;
DT 01-DEC-1992 (Rel. 24, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE kinesin heavy chain isoform 5C (kinesin heavy chain neuron-specific
  2).
GN KIF5C OR NKHC2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Scleroglossi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PRELIMINARY SEQUENCE FROM N.A.
RC STRAIN=BALB/c; TISSUE=Brain;
RA Kato K.;
RT "A collection of cDNA clones with specific expression patterns in
  mouse brain."
RL Eur. J. Neurosci. 2:704-711(1991).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=99000842; PubMed=9782088;
RA Xia C., Rahman A., Yang Z., Goldstein L.S.B.;
RT "Chromosomal localization reveals three kinesin heavy chain genes in
  mouse."
RL Genomics 52:209-213(1998).
CC - FUNCTION: KINESIN IS A MICROTUBULE-ASSOCIATED FORCE-PRODUCING
  PROTEIN THAT MAY PLAY A ROLE IN ORGANELLE TRANSPORT.
CC - SUBUNIT: OLIGOMER COMPOSED OF TWO HEAVY CHAINS AND TWO LIGHT
  CHAINS.
CC - DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS: A LARGE GLOBULAR N-
  TERMINAL DOMAIN WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY OF
  KINESIN (IT HYDROLYSES ATP AND BINDS MICROTUBULE), A CENTRAL
  ALPHA-HELICAL COILED COIL DOMAIN THAT MEDIATES THE HEAVY CHAIN
  DIMERIZATION, AND A SMALL GLOBULAR C-TERMINAL DOMAIN WHICH
  INTERACTS WITH OTHER PROTEINS (SUCH AS THE KINESIN LIGHT CHAINS),
  VESICLES AND MEMBRANOUS ORGANELLES.
CC - SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
  SUBFAMILY.
CC - CAUTION: REF.1 SEQUENCE SEEMS TO HAVE BEEN A HYBRID OF A KIF5A
  AND A KIF5C SEQUENCE.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
  between the Swiss Institute of Bioinformatics and the EMBL outstation
  at the European Bioinformatics Institute. There are no restrictions on its
  use by non-profit institutions as long as its content is in no way
  modified and this statement is not removed. Usage by and for commercial
  entities requires a license agreement (See http://www.isb-sib.ch/announce/
  or send an email to license@isb-sib.ch).
CC EMBL: X61435; CAA43677.1;
DR EMBL: AF067180; AAC79804.1;
DR HSPF: P56536; 2XIN.
DR MGI: 1098269; Kif5c.
DR GO: 0005515; F:protein binding activity; IPI.
DR GO: 0008045; P:motor axon guidance; IMP.
DR InterPro: IPR001752; kinesin_motor.

```

```

DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINEAVY.
DR SMART; SM00129; KISC. 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil.
FT DOMAIN 1 386
FT DOMAIN 406 923
FT DOMAIN 859 956
FT DOMAIN 174 315
FT NP BIND 86 93
FT BIND 956 AA; 109240 MW; D5A8C701A2911AB2 CRC64;
SQ SEQUENCE

Query Match 6.5%; Score 443.5; DB 1; Length 956;
Best Local Similarity 21.8%; Pred. No. 1,2e-12;
Matches 216; Conservative 162; Mismatches 426; Indels 185; Gaps 38;

QY 5 IKVVRKRPISLEKKKSDIITVKNCTLYDEPRYKVMTKYI-ERHEFLVDKVPDD 63
DB 9 IKVRCRPPLNEAELIRGDKFI-----EKFGEETVVIQGGKPYVFDVLP 55
QY 64 TVDNFTYENTIPLIIDYE--NGCVSCFAVGOTSGSKTYMTLSQPYGSDTGIFQ 121
DB 56 NTTQEOVYNACAIQVADVLEGYNGT--FAVGQTSKGTHMEGK--LHPQLMGILP 110
QY 122 YAAGDITPTINIDKONTKGIFFSYEYICGLYDLQKKRVAALENGKKEV-VVXDLK 180
DB 111 RIADIDPHYSMDENIEPHIKSYPEIYDKIRDLIDVSKTMLVAHEDKGRVPYVGC 170
QY 181 ILRVLYTEELLKMDGVLLRKIGVNSQDESSRSHAILNIDLKDNKNTS---LGIAP 237
DB 171 ERFVSPSEVWDVDEGKARHVAVTNMNHSRSHSIFLINIKOEVEVEKKLSGLYL 230
QY 238 IDLAGSRGADVTYQNKQOTDGNINRSLALKECIRAM-DDDKNRIPRDSELTQVR 296
DB 231 VDLAGESEKVKRTAGEG-AVLEAKNINKSLSALGNVTSALAEGTKTHVPRDSKTRILQ 289
QY 297 DIFVGSKSIIMANISPTISCCBOTLNTLYSSRVKFNKSKTCIN-----E 343
DB 290 DSLQGNKRTTIVICSSVSNEAETKSTLMFGQAKITIK-TYVNLIELAEWKKKYK 348
QY 344 EDDNTERISILDSKSEMN-----ASSIENVVIKSNHLLSNNNK1--NEGKIND 394
DB 349 EKEGNKALKSVLQHLMEINRWENGEAVPEDEQISAKDHSLFECDDTPIIDNTPVVDG 408
QY 395 IERNNLIKNSFKDPRREGFTSTF---QYSSINDIDIKIKKKKKGLINKSTLYNDTI 450
DB 409 ISAEK-----EKYDEITSLYRQLDKQDEINQOSQLAEKLAQQLDDELASTRRD 461
QY 451 NKKNNNNNNNNNDNNNNNNNNNN-----NNDSSSMVNN--MINNNNNNNNN 498
DB 462 YEKIQEELTRQIENEAKEVEKVALABELAVNYQKQOEVDKTRAEQLDELAAQ 521
QY 499 INVNNNNNNNNNNNNNNNNHLLPDP-----NYAFPD-----TSPSSLDPMNCILN 544
DB 522 TTTLTTRQELSQOELSNHOKKRATEILMLLLDLLEIGIIGTNTVKTADVNGVIE 581
QY 545 NDKSIFLHKRLRNK-LKRS-----SCNINMKKKNLHLARSGSKLTMPSPDOK 599
DB 582 EFTMARLYISPKKEVSLVRSKQLBSAQMDSRRKN--ASRELLACOLLISQHEAK 638
QY 600 NKDNTPFKSN1-----NKMEENTPDIILYESHNVSNNNGVYLLGLNKTHHDISTKDEHN 655
DB 639 IKSITDYNQMEQKRQLEES--QDSL--SEELAKLA-----QKRMHVSFD----- 683
QY 656 DNKINGVINIINNSVNSINNSNNSINNSNNSINNSINNSINNSINNSINNSINNSIN 713
DB 684 --KEKEHLTRQDAEVEYKALEQOMESHREAHQQLSRLREIEKQRIID-ETRDINQK 740
QY 714 -EMDTSKNDNITFPDAISCDNNMYPIITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 772
DB 741 LQLEBERLSD-----YKLTIEDEREVVKLEK 769

```



```

RX MEDLINE=94299012; PubMed=8026619;
RA Holliston E., le Guellec R., Kress M., Philippe M., le Guellec K.;
RT "The kinesin-related protein Eg5 associates with both interphase and
RL spindle microtubules during Xenopus early development.";
RL Dev. Biol. 164:147-159 (1994).
CC -I- FUNCTION: PLUS END-DIRECTED MOTOR PROTEIN REQUIRED FOR
CC ESTABLISHING A BIPOLAR SPINDLE. ASSOCIATES WITH BOTH INTERPHASE
CC AND SPINDLE MICROTUBULES. MAY BE INVOLVED IN NUCLEAR DIVISIONS
CC TAKING PLACE DURING THE DEVELOPMENT OF UNFERTILIZED EGGS.
CC -I- SUBUNIT: HETEROTETRAMER OF TWO HEAVY AND TWO LIGHT CHAINS (BY
CC SIMILARITY).
CC -I- SUBCELLULAR LOCATION: CONCENTRATED AROUND THE POLAR ENDS OF
CC BOTH MEIOTIC AND MITOTIC SPINDLES.
CC -I- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN UNFERTILIZED EGGS,
CC ESPECIALLY IN THE GERMINAL VESICLE AND IN THE RADIAL YOLK-POOR
CC CHANNELS. ALSO PRESENT IN TESTIS.
CC -I- DEVELOPMENTAL STAGE: ACCUMULATES DURING THE LATTER STAGES OF
CC OOOGENESIS AND LEVELS INCREASE THREE-FOLD DURING OOCYTE MATURATION.
CC LEVELS DECREASE AFTER FERTILIZATION.
CC -I- PPM: PHOSPHORYLATION DURING MITOSIS AT THR-937 CONTROLS THE
CC ASSOCIATION OF EG5 WITH THE SPINDLE APPARATUS (BY SIMILARITY).
CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. BIOC
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL collaboration -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement and this agreement (See http://www.isb-sb.ch/announce/
CC or send an email to license@isb-sb.ch).
CC -----
DR EMBL, X71864; CAAS0695.1; -.
DR PIR, I51616; S3417.
DR HSSP, P17119; 3KAR.
DR InterPro: IPR001752; kinesin_motor.
DR Pfam: PF00225; kinesin; 1.
DR PRINTS: PR00380; KINESINHEAVY.
DR SMART, SM00129; KISC; 1.
DR PROSITE: PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE: PS00067; KINESIN MOTOR DOMAIN2; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil; Mitosis;
KW Phosphorylation.
FT DOMAIN 16 363 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 364 487 COILED COIL (POTENTIAL).
FT DOMAIN 692 736 COILED COIL (POTENTIAL).
FT DOMAIN 884 920 COILED COIL (POTENTIAL).
FT DOMAIN 1040 1067 COILED COIL (POTENTIAL).
FT NP_BIND 105 112 ATP (BY SIMILARITY).
FT MOD_RES 937 937 PHOSPHORYLATION (BY CDC2) (BY
FT SIMILARITY).
SQ SEQUENCE 1067 AA; 119885 MW; 48AA47DBE2559115 CRC64;
Query Match 6.4%; Score 439.5; DB 1; Length 1067;
Best Local Similarity 22.1%; Pred. No. 2e-12;
Matches 198; Conservative 156; Mismatches 327; Indels 213; Gaps 31;
OY 1 MNSK-----IKVVRKRPSELEKKKSDIITVRKNCTLYIDPRYK-----DMTK 48
DB 8 MSSKKDDKGNIOVVVRCPFNQLEK-----ASSHSVLECSQKREKVCRTGEVND 59
OY 49 YIERHEFIVDKYEDDTVNFYTYENTIKPLIIDIVENGVCSCAPYGGTSGKTYMTGS 108
DB 60 KLGKTYTFDWFGPAPAKQIDYRSVCP-IIDVIMGNCTITFAIGGTGKTFTMBGE 118
OY 109 Q-----PYGSGDTFGIFQYAGDIFTFNIIVDKNTKGIIFSFEIYCGKLYDLQ-- 159
DB 119 RSSDDEFTWEDPPLAGIIPRIHQIFKTS--EIGREPVKSKLSEIYVEHLEFDLSSP 176
OY 160 ---KRMVALENGKEVVVVDKILRVLTKEELIKIMIDGVLKRLIGVNSQNDSSRSH 216
DB 177 DVGERLQWFDPRDKRNGKGVILKGLSEISVANKDEVQQLIERGAAKRTASTLMNAVSSRSH 236

```

```

OY 217 AININDK-----DINKNTSLGKIAFIIDAGSERGADTVSONKQOTQTDGAINIRSLAL 270
DB 237 SVFSVTHMETTIDGELVYKIGKLNIVDLASENIGRSGAVDKRAREAG-NINGSLTL 295
OY 271 KECIRAMDSPKNHIFPDSSELTKVARDIFVGSKSIIMIANISPTISCEBOTLNTLYSSR 330
DB 296 GRVITLALVERAPHIPYRESKLTIRLOPSLGRTSTIIATVSPASINLEETMSTLDVSR 355
OY 331 VKRPNKSTGICNEEDPTNTERISILD-SKSENMASSIENVVAKSNHLLNNNNKINRG 389
DB 356 AKNIMNP-----EVNQKLTAKALKETYEIERLRELATAREKNGVYLSNENEOL-QG 410
OY 390 KI-----NDKIER-----NNILK 402
DB 411 KVLSDGEMITEYSKIAMBEIIRIGELPADNKKELBECTTLIQCKEKELEATQNNLQE 470
OY 403 NKSFDKREGFTSTFGYSSLLNDID-KIKKQKKGLINYSTLYNDNTINK----- 453
DB 471 SKK-QLAQEAFV-----VSAMEETKEKLGHTANGLSTVETTRDVSGLHEKLDKRAVE 524
OY 454 -HNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNND 478
DB 525 QHNSOVHENPBAQINRRPSVIOQTVDVSVKQGMDFYNSIDDLGASSALSATATA 584
OY 479 ---SSSVNMMNMINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 510
DB 585 VAKFPASVOETVSGVSHSVBEILKQETLSQAKDDQLKMTAHTGLEQALRTDLLPV 644
OY 511 ---NNNSHNNHLPQVYAFDTSDPSLDDNCHLNNDKSLFLKKNLRDNLKORS 566
DB 645 TAVLDLNSHLSHCQSQSLGVADKID-SHKEDMNSFTEHSRS-LHKLRLDSSSL--S 698
OY 567 SCDNINMKKKNNLHLAR--HSVSKLTMFSYDPOKN-----KDNFEPKINIKMEDNT 617
DB 699 SIQSEYSLKEEITAFQSTHSEGVNNLISSIQNLNLAMETROQFGFLSKGKLOESV 758
OY 618 PKDLIYSRNVSNNNGVLLGLNKTHTHDISTXDENHNDKINNGVINIINNSVNSINN 677
DB 759 --GGLQDDLDVSSDAIECI-----SSHHSKRTGEGQAVTVEIRQ-----LAGSNWSTLEE 807
OY 678 SN-----MNSINNSNNNSIYKSNVNSNOSIDVOIRYVN-----EMDSNKN 721
DB 808 SSKQCEKLTNSINITICQESQCMCESAGOKMDSLBEQVCYLHSSKKOIQTLAKD 861
RESULT 39
KF5C_HUMAN STANDARD; PRT; 957 AA.
AC 060282; 095079;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Kinesin heavy chain isoform 5C (Kinesin heavy chain neuron-specific
DE 2).
GN KF5C OR NKHC2 OR KIA0531.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OC NCBI_TaxID=9606;
OX NCBI_TaxID=9606;
RN (1)
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=98290545; PubMed=9628581;
RA Nagase T., Ishikawa K.-I., Miyajima N., Tanaka A., Kotani H.,
RA Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. IX.
RT The complete sequences of 100 new cDNA clones from brain which can
RT code for large proteins in vitro.";
RL DNA Res. 5:31-39(1998).
RN (2)
RP SEQUENCE OF 355-585 FROM N.A.
RA Engelder S., Sharp A.H., Colomer V., Tokito M.K., Lanahan A.,
RA Worley P., Holzbaur E.L.F., Ross C.A.;

```

```

RT "Huntingtin associated protein 1 (HAP1) interacts with the p150glued
RL subunit of dyactin.";
CC Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: KINESIN IS A MICROTUBULE-ASSOCIATED FORCE-PRODUCING
CC PROTEIN THAT MAY PLAY A ROLE IN ORGANELLE TRANSPORT.
CC -1- SUBUNIT: OLIGOMER COMPOSED OF TWO HEAVY CHAINS AND TWO LIGHT
CC CHAINS.
CC -1- TISSUE SPECIFICITY: HIGHEST EXPRESSION IN BRAIN, PROSTATE, AND
CC TESTIS, AND MODERATE EXPRESSION IN KIDNEY, SMALL INTESTINE, AND
CC OVARY.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS: A LARGE GLOBULAR N-
CC TERMINAL DOMAIN WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY OF
CC KINESIN (IT HYDROLYZES ATP AND BINDS MICROTUBULE), A CENTRAL
CC ALPHA-HELICAL COILED COIL DOMAIN THAT MEDIATES THE HEAVY CHAIN
CC DIMERIZATION, AND A SMALL GLOBULAR C-TERMINAL DOMAIN WHICH
CC INTERACTS WITH OTHER PROTEINS (SUCH AS THE KINESIN LIGHT CHAINS),
CC VESICLES AND MEMBRANOUS ORGANELLES.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AB011103; BAA25457.1; -
DR EMBL; AF010146; AAD01456.1; -
DR HSSP; P56536; 2KIN.
DR Genew; HGNC:6325; KIF5C.
DR MIM; 604593; -
DR GO; GO:0005871; C:kinesin complex; TAS.
DR GO; GO:0003777; F:microtubule motor activity; TAS.
DR GO; GO:0006996; P:organelle organization and biogenesis; TAS.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin_1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS50067; KINESIN MOTOR DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil.
FT DOMAIN 1 386 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 406 923 COILED COIL.
FT DOMAIN 859 956 GLOBULAR.
FT NP_BIND 174 315 MICROTUBULE-BINDING.
FT NP_BIND 86 93 ATP (BY SIMILARITY).
FT CONFLICT 355 360 TLKNVI -> STHSAV (IN REF. 2).
FT CONFLICT 583 585 EFT -> DRV (IN REF. 2).
SQ SEQUENCE 957 AA; 109494 MW; A9F25B81C994322A CRC64;

```

```

Query Match 6.4%; Score 439; DB 1; Length 957;
Best Local Similarity 21.4%; Pred. No. 1.9e-12;
Matches 216; Conservative 173; Mismatches 395; Indels 226; Gaps 41;

```

```

QY 5 IKVYVRRPISLEKKKKSDIIVKNNCTLYIDEPKYDMTKYT-ERHEFIYDKYFD 63
DB 9 IKVWCRRPLNEAFILGDKFI-----PFKGGETVIVIQGKRYVFDRLPP 55
QY 64 TVDNFTYENTIKELIDYE-NGCVSCFAYGQTSQKTYTLAGSPYQSDPTGIFQ 121
DB 56 NTTQEQVYNNCAQIVADVLEGVNGLT---FAYGQTSQKTHMEGR--LHDPQLMGIIP 110
QY 122 YAAADITFTPLNIYDKNTKGIPISEFYIYQKLYDLQKRMVAALENGKEV-VYKDLK 180
DB 111 RIHADIDPHIYSMDENLEFHIKVSFEIYDLKIRDLIDVSKTNLAVEDKRRVYVVGCT 170
QY 181 ILRLVTEELLKMDGVLLRKIGVNSQNDSSSHALINLIDKIDKNKTS---LGKIAP 237
DB 171 ERFVSSFEEDVADYDEGKANRHVAVTMMNHSSSHIFILNIOQEVETEKLSKLYL 230
QY 238 IDLAGSERGADTVSOKQOTDGANINRSLALKECIRAM-DSDKNHIFRDESELTQVLR 296

```

```

DB 231 VDLAGESEKVTAGEAG-AVLDEAKINIKSSALGAVNISALABEGTHVPRDSMTRLQ 289
QY 297 DIPFGKSKIMINISPTISCCQOTLNTLAFSSRVKFR-----KSTINE 343
DB 290 DSLGCKRTTIVICSSVSNEAEATSTLMFGRAKTKVAVNLETAEEWKYKE 349
QY 344 EDDTNT-----ERISILDSKSEM--NASTIENVY----- 371
DB 350 KKKKTKLVNIQHLMEELNRWRGEAVPEBQISADQKLEPCDPTIIDNAPVAGI 409
QY 372 -----IKSNHLSNNNNKIN-RGKINDK-----IERNNILKN--KSPDKREG 412
DB 410 STEEKEYDEISLVRQLDDKDEINQSQLAEKLQKQLDQDELLASTRDYEKIQEE 469
QY 413 FTS-TRKYSLSLDDIKKIKKKKKGLINY--KSTLYNDNTINKKNNNNNNNDNDNN 469
DB 470 LTRQLIENEAKQVEVEVLQALEELAVNQKQVEDEKT-----RANQLTDELAQKT 523
QY 470 DNNNNNNNDSSMNNNNINM-----INNINNINIVNNNNNNNNNNNNNNNNHLPQPN 523
DB 524 TLTITTORELSQI-QELSNHQKRAATEILMLDKLGEIG----- 562
QY 524 YAFETDSFSSLDNMCHLNNDKSIPLHKQLRDNK-LKNS-----SCDNIMKKKN 578
DB 563 -GIIGTNDVKTLDVGVIEEFTMARLYISKKSEKSVLSVNSKQLESAQMSNRKM- 620
QY 579 LHLARISVSKLTMFSYDPQKNDTFPKSNT---NKMEDNTPKDIYSRVSNMNGN 634
DB 621 --ASERELACQLLISQHEAKIKSLTDYMNQMKRQLEES--QDSL--SEELAKLRA- 673
QY 635 VLLGLNKNTHTDSTQDENNDKINNGVINIINNNSVNSINNNSNNSINNNSISYI 694
DB 674 -----QEKHAEVSFD-----KEKHLTRIDAEEMKALQEQHSEHFAQKQSL 721
QY 695 KSNYNSNOSISDVQIRYVN---EMDTSNKNNDNIFPDALSCDNNYPTITNNNNNNNN 751
DB 722 RDEIEEKQKIID-EIRDNLQKIQLEQKLSDD----- 752
QY 752 NNNNNNIDVENVNRRGCTNNSMCLYAVNSHNLFPQDNNKTSINQINTKANNQDGVNY 811
DB 753 ---YNKLKIEDQREMKLEKLL-----NDKR-----EQAREDLKGLIEFTVS 793
QY 812 SNAFCYNNLDDKYLLDNLNKEQDKNIGCDNNIIONRDEFEKKKTNYNNN--NIVI 869
DB 794 ELDTLH-NLR-KLFVDDLTTRVKKSVLENDDEG-----GSAQOKQISTLENNLEOLT 846
QY 870 VNNNMGNNS-----PRMKYGLCGSHTSIDNKKNNEMKNEMKDNEMKD 913
DB 847 VHQQLVRDANADLCELPKLEKRL---RATYERVKALESLKEXENAMRD 993

```

```

RESULT 40
KININ DROME
ID KININ DROME STANDARD; PRT; 975 AA.
AC P17210; O9V719;
DT 01-AUG-1990 (Rel. 15, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Kinesin heavy chain.
GN KHC OR KIN OR CG7765.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OC NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=89168428; PubMed=2522352;
RA Yang J.T., Laymon R.A., Goldstein L.S.B.;
RT "A three-domain structure of kinesin heavy chain revealed by DNA
RT sequence and microtubule binding analyses.";
RL Cell 56:879-889 (1989).

```

[2]
RN SEQUENCE FROM N.A.
RP STRAIN=Berkeley;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blake J.R.G., Champé M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Bertram B.P., Bhandari D., Bolshakov S.,
RA Borokova D., Botchan M.R., Bouck J., Brokstein P., Brotler P.,
RA Butris K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cusley S., Dahlke C., Daventport L.B., Davies P.,
RA de Pablo B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodex A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Nixon K., Nusskern D.R., Pacle J.,
RA Jajali M., Kalush F., Karpen G.H., Ke Z., Kemsinn J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kalp D., Lai Z.,
RA Lako P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Mekulov G., Mishina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacle J.,
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kimios I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svrtkars R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
[3]
RN MUTAGENESIS.
RP MEDLINE=93030741; PubMed=1384131;
RX Gho M., McDonald K., Ganetzky B., Saxton W.M.;
RT "Effects of kinesin mutations on neuronal functions.";
RL Science 258:313-316(1992).
CC -1- FUNCTION: KINESIN IS A MICROTUBULE-ASSOCIATED FORCE-PRODUCING
CC PROTEIN THAT MAY PLAY A ROLE IN ORGANELLE TRANSPORT.
CC -1- SUBUNIT: OLIGOMER COMPOSED OF TWO HEAVY CHAINS AND TWO LIGHT
CC CHAINS.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS: A LARGE GLOBULAR N-
CC TERMINAL DOMAIN WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY OF
CC KINESIN (IT HYDROLYZES ATP AND BINDS MICROTUBULE), A CENTRAL
CC ALPHA-HELICAL COILED COIL DOMAIN THAT MEDIATES THE HEAVY CHAIN
CC DIMERIZATION, AND A SMALL GLOBULAR C-TERMINAL DOMAIN WHICH
CC INTERACTS WITH OTHER PROTEINS (SUCH AS THE KINESIN LIGHT CHAINS),
CC VESICLES AND MEMBRANOUS ORGANELLES.
CC -1- MISCELLANEOUS: MUTANT FLIES DISPLAY IMPAIRED ACTION POTENTIAL
CC PROPAGATION AND NEUROTRANSMITTER RELEASE AT NEUROMUSCULAR
CC JUNCTIONS, BUT ARE STILL CAPABLE OF TRANSPORTING CERTAIN
CC MEMBRANES, INCLUDING SYNAPTIC VESICLES, TO THE NERVE TERMINAL.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. KINESIN
CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sdb.ch/announce/>
CC or send an email to license@isb-sdb.ch).

CC EMBL: M24441; AAA28652.1; -
DR EMBL: AF003807; AAF58029.1; -
DR PIR: A31497; A31497.
DR HSSP: P33176; 18G2.
DR FLYBae; FBgn0001308; Khc.
DR GO: GO:0005871; C:kinesin complex; IDA.
DR GO: GO:0008017; F:microtubule binding activity; IDA.
DR GO: GO:0003774; F:motor activity; NAS.
DR GO: GO:0007317; P:regulation of pole plasm oskar mRNA localiz. . . ; IMP.
DR InterPro; IPR001752; Kinesin motor.
DR PRINTS; PR00380; KINESINHEAVY.
DR PRINTS; PS00411; KINESIN MOTOR DOMAIN1; 1.
DR PROSITE; PS00667; KINESIN MOTOR DOMAIN1; 1.
DR Motor protein; Microtubules; ATP-binding; Coiled coil.
KM DOMAIN 1 334 KINESIN-MOTOR (BY SIMILARITY).
FT DOMAIN 1 335 COILED COIL.
FT DOMAIN 932 975 GLOBULAR.
FT DOMAIN 180 321 MICROTUBULE-BINDING.
FT NP BIND 92 99 ATP (BY SIMILARITY).
FT CONFLICT 515 515 A -> T (IN REF. 1).
SQ SEQUENCE 975 AA; 110399 MW; 24840EF414790888 CRC64;

Query Match 6.4%; Score 439; DB 1; Length 975;
Best Local Similarity 21.9%; Pred. No. 1.9e-12;
Matches 219; Conservative 164; Mismatches 429; Indels 186; Gaps 37;

5 IKVVRKRPSELEKKKKDDITVKNKNTLYDEPRKYDMTYIRHEIYDKVDDT 64
13 IKVCRFRPLNDSEKKSGKRVVFPNN--VEENCISLAGKY-----LFQKVRPN 62
65 VDNFTVENTIKPLIDLYE--NGCVSCFPAYGGTSGKTYTMGSGPDPIFGY 122
63 ASQKRVNKAASVTVTLACVNTI--RAYGTSKTHTMG--VIGSVAGIIR 117
123 AAGDIFPLNTYDKNTKGIFISFYRYCGLYDLQKRKVAALENGKKEV-VKDKI 181
118 IVNDIFPHIYMEVNLPHIYVEIYEMDKIRDLDSVKNLISVHEDKKNVPYKATE 177
182 LRVLTKEELIKMIDGVLRKIGVNSQNDSSRHALLINDKIN---KNTSLGIAF 237
178 RFVSSPEDEVFEVIEGKSNRIHIAVTNNHSSRSVFLINVQENLENQKLS-GKLYL 236
238 IDLAGSERGADTVSONNOTDGA-NINRSILAKCECIRAM-DSGKHIPRDELTQVL 295
237 VDLGSEKSVSKTGAEG--TVDEKKNIKLSALGNVISALADGKTHIPRDSKLRIL 294
296 RDIFFVGSKSIIMANISPTISCCBOTNTLRYSSRVKNFKXKSTCINEEDPTNTERISIL 355
295 QESLGKNAARTIVICSPASFNESETSTLDFGRRAKTVKN-VVCNVE--LTAEWKRR 351
356 DSKSGEMNA--SSIEENVIKSNHLSNNNNKINRGKINDIKERN----- 398
352 YEKEKEKNAARLKGVYEKLEIELARAGETVKAEOINMEDLMAESPNIIEVAAQTAA 411
399 -----NLIKKSPEKPREGFTSTGKYSINDIDIKIKKKKKGLINYKSTLYN 446
412 EALAAQRTALNALSASAAVVEQARLATCEGRLYQOUDKDE-EINQOS--QYAEQAKE 467
447 DNTINKKANN 506
468 QVMOEELIAAREVEYELQSEMARIQEENSAEEVEYVLALEELAVND-QKQSD 526
507 NNNNNNNSHNHLPOPNVAFDTDS-DRSSLDPNACHLANNDKSFLFKKLRD----- 558
527 NKNKDIDALNELLOOKQSVFNAASTELQOLDKMSHOKRIETELTYNL--LRDGEVGA 584
559 -----NLIKKNRSSCNINMKKKNNLHLASHVSGSKLTWMSYDPOKKNDFPFSNIN 612
585 IAPGESSIDLKMSLAGTDAKVEEDFTMALFISKKTAKNAIQRSNVETQOADSNC 644
613 MEDNTPKDIILYESRNVSNNGNVLLGLNKNTHTDISTKD-----ENHNDKINNGVINI 666

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:14:11; Search time 52 Seconds

(without alignments)
2382.024 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 6842

Sequence: 1 MNSKIKVVRKRPISLEKK.....KLIVDNIKSMNDNNIHKK 1288

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	789.5	11.5	4550	T18440	hypothetical prote
2	778	11.4	1844	D71612	hypothetical prote
3	765	11.2	1619	T18499	hypothetical prote
4	755	11.0	668	T02791	mitotic centromere
5	752	11.0	3394	T18501	hypothetical prote
6	748.5	10.9	1817	D71606	hypothetical prote
7	732	10.7	1254	T18277	kinasin heavy chai
8	728	10.6	716	A44259	kinasin-related pr
9	722	10.6	671	T10755	kinasin-related pr
10	698	10.2	1436	D71618	hypothetical prote
11	696	10.2	807	B71605	hypothetical prote
12	676	9.9	2150	S71629	senesory transducti
13	656.5	9.6	747	T23607	hypothetical prote
14	646	9.4	1256	S14556	asparagine-rich pr
15	611	8.9	1711	T18429	hypothetical prote
16	603.5	8.8	2523	T18477	hypothetical prote
17	601.5	8.8	4981	T18489	hypothetical prote
18	597	8.7	537	A23770	asparagine-rich pr
19	591	8.6	3724	T18427	hypothetical prote
20	587	8.6	2485	H71621	serine/chreonine-s
21	584	8.5	1650	T18444	hypothetical prote
22	581	8.5	2708	T09079	probable chloroqui
23	579	8.5	3844	T18402	asparagine/asparta
24	579	8.5	2380	E71604	hypothetical prote
25	577.5	8.4	2500	G71609	hypothetical prote
26	569.5	8.3	2010	B71616	phosphatase (acid
27	567	8.3	2819	T09080	probable chloroqui
28	563.5	8.2	3973	B71612	hypothetical prote
29	561.5	8.2	1111	A42640	kinasin-related pr

30	560.5	8.2	2339	2	A45597	DNA-directed RNA p
31	552	8.1	2539	2	B71619	hypothetical prote
32	549	8.0	2510	2	T28160	hypothetical prote
33	544	8.0	2269	2	T18472	hypothetical prote
34	543	7.9	1984	2	A44396	P-type cation tran
35	542.5	7.9	1553	2	T18502	hypothetical prote
36	541.5	7.9	1073	2	S14032	kinasin-related pr
37	538.5	7.9	1085	2	T38378	kinasin-like prote
38	537.5	7.9	1714	2	E71609	Ser/Thr protein ki
39	534.5	7.8	1516	2	E71619	RAD2 endonuclease
40	534	7.8	1058	2	T47525	kinasin-related pr
41	533.5	7.8	2391	2	T18410	cardamoyl-phosphat
42	533	7.8	1390	2	T14004	trifA protein - sal
43	532	7.8	813	2	T46242	kinasin-like prote
44	529.5	7.7	669	2	S14535	asparagine-rich pr
45	528	7.7	1166	2	H71609	hypothetical prote

ALIGNMENTS

RESULT 1

T18440
hypothetical protein C0425w - malaria parasite (Plasmodium falciparum)
C/Species: Plasmodium falciparum
C/Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #ext_change 09-Jun-2000
C/Accession: T18440
R/Lawson, D.; Bowman, S.; Barrell, B.
Submitted to the EMBL Data Library, August 1997
A/Reference number: Z18935
A/Accession: T18440
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-4550 <LAW>
A/Cross-references: EMBL:Z98547; NID:e1325376; PID:e1325396; PIDN:CAB1121.1
C/Genetics:
A/Map position: 3
A/Note: C0425w

Query Match	11.5%	Score 789.5;	DB 2;	Length 4550;
Best Local Similarity	21.0%	Pred. No. 2.7e-25;		
Matches 380;	Conservative 247;	Mismatches 498;	Indels 683;	Gaps 70;
QY	11	KRPISLEKKKKSDIIVKNNCTLYID-EPYKVDMTYIRHFIYDVKVPDDPTVD-NF	68	
DB	795	KQDDNKDDKDDDD---KQDDKYDDGDDKTYDDDDNKYDDDD---DQYDDDDDFNF	845	
QY	69	TYENTIKPL-----IIDLYENGCV-----CSCFAYGQ--TSGKTYTW-----L	106	
DB	846	DHDSKSKSLSYVDLKKKKGKILKKEDTLKSKIMNVQKSKKMYCMTNNCVV	905	
QY	107	GSQPYGQSD-----TPGIFYAAGDIFFLNIYDKNTKGIFISFY	147	
DB	906	KEKNYFVNDYMHINNLSDHEMNIMMSPG--YNNLFDVDFIHKRD-----FI	954	
QY	148	EIVCGKLYDLQKRKVAALENGKEVVVKDILKIRVLTKEEL-----ILKMI	195	
DB	955	NANILKLT---KEKIQVLQNNYKQVCYFCCKTGITGKCMFPCSCSTFYHYCYNNKM	1010	
QY	196	DGVLLRKIGVNSQNDSSSRSHAILNIDLKINKNTSLGKIAFTIDLAGSERGADVSONQ	255	
DB	1011	QVRRKKNDLQASQKSR-----KNQRAASV-----KRGAE-----GK	1045	
QY	256	TQTDGANINRSLALKECIRAMDSKNIHPPDSLTLYLIDIPVQKSKSIMIANISPTI	315	
DB	1046	DKKDS-----RSIDRRKKDKVTRRSNYYESSANDSDKKNG-----	1082	
QY	316	SCCEQTLNTRYSRVKPKKNSCTCINEDDTNTRIRIILDSKSGEMVAASITENVIKSN	375	
DB	1083	-----DDKKKGQNI GKNNNNNNNNDDDSNNNDDBDNNNGDGNNTINGDGN	1135	
QY	376	HLLSNNNNKIN-----RGKINDKIERNNIINKSFDKP	409	

1136	NNINGDGNNNINBDGNNNNNDCELEKNOGDQKRRKRRKRRGNNDPTSLSVLANK--DDS	1193
QY	410 REGTSTFGKXSSJLNDID-----KIKKXKKKGLINTYSTLYNDNTINKKXNN	457
Db	1194 ROKKXKXKXGDHSDQOEKXDPESKINNRSKRNKXVKKXDEKVGNI-----NDDKINNNTDD	1246
QY	458 NNNNNDNNNDNNND--NNNNNDSSWVNNMNI--HNINNIN-----	496
Db	1247 NKNNNINGDNNKNNINGDNNKNNINGDKNINNINGDKINNINDKISKNTSHSNINNEE	1306
QY	497 -----NNINNVNN-----NNNNNNNNNNHNLPOPNVAFDTDSFSSGLD	537
Db	1307 ITHGQKNFKNKNTKXRYKRSINDKEMDILNNKNGDTDKLKNYCNFLMEYOKLISS-DK	1365
QY	538 MNCMLNNNDKSIFLHKKQLRD-----NIK-----LKRRSCDNINMKKK	576
Db	1366 ITSGISNNMKDI-----KXIKDIKDIKIKIKIKDIKDIKDIKDIKIVKNIKDIKS	1421
QY	577 N-----NLHLABHSVSKLTMFSYDB--QKNKDNTPFKSINNMENPTFKDI	621
Db	1422 NEDIKIDKDVNDVSSVHLNK--CVNNKSDTODFCPSDDKVLINIIKKNKINIKTDQVYNPL	1480
QY	622 LYESRNVSNMNGVNLGLKNKTHHDISTKDEHNHNDKINNGVINIINNSVNSIINNSMN	681
Db	1481 VDSSSSTDCXKXNY-----KKKEXAVKKIGMIKNIKLHNNNNNNNNNN	1526
QY	682 SINNSNNNSNIYKSNYNSNOSISDVQIRYNEKDTNKNNDNIFFD-----A	729
Db	1527 NNNNNNISNNVQEDYEMKGGSKHK--NEKHSYVNODDIYDNDFSSICSLSSS	1582
QY	730 ISCONNM-----	736
Db	1583 LSTNNDDISSYVSNSLTYNSSSMFSNDCEFLCYSSVSSSYEYDINNVLKNIHNPFS	1642
QY	737 -YPNITNN	792
Db	1643 FYKHELNNN	1702
QY	793 SNIONINTNKNODGNVNYSMNFCHYNLNDKNYLI-----D	828
Db	1703 SEIS--NNLSPSDKSENYCISISDEH-EKDVITRYNTYHRIINRMKDGKNTGSKKRD	1759
QY	829 LNNHEQ-----KDKNIGHGDN--NIIQNR-----NDEKXKKKTNPYN	863
Db	1760 MSNKKGDKSCNKKNI--CDNKKNIYDNKKLIYDNKDSSTDPARVENIDHLEKEIETDILN	1817
QY	864 NNNIYIVNNNNNNNSPRM--KYGLCSGHS-----	892
Db	1818 NLGLYTYLKNNNNNNNVYMKIILKTLCTSHENHTKAVMMIKANTLNNKKYNNINCFY	1877
QY	893 -----IDNNKNNEMKNNEMK	907
Db	1878 HYYNSFLHSLFYSDEYIELIRKEERKEDIKXIKYKXCHQEDRDMVNNND--NNDNN	1935
QY	908 DNEKMDNHIKNNNNSSSSSSNNNTYNNINDDTFFOND-----YCHN--DN	952
Db	1936 NNNNDNNNNNDNNNNNDNNNNNDNNNDNNNDNNNDNNNDNNNDNNNDNNNDNNNDNNND	1995
QY	953 TFLIRKKN-----TINSNIYONDIIYTTINSLDY	984
Db	1996 NKEPKKKKKXKNEITDINDTNYKKEFHKEIDHKEQKDTNCDNGIEKKD--QVSKSNNT	2052
QY	985 MSNTLHFEKXYPTLSTNEDIYNKEMEGKILRLD-----QDKYDNDNNNNYDNNKN	1039
Db	2053 ISKVHFERKKN-----NIKDEHKKEXNERNDKXSECDMLLQNRKRDNDHNN--NNNN	2106
QY	1040 NYDNNVNDNNVDNNVDNNDKNNVDNNNNVDNDDVDVFNHKNFNNN-----EYLSY--	1090
Db	2107 DDDNNNNNNDDDDNNNNNNNDNDHNNNNNNNDNNNNNNNDNNNDNNNDNNNDNNNDNNK	2166
QY	1091 -----FOKNVDTIINN--CL-----NSLDISMDVDTKEILN	1121
Db	2167 EINQKEINIFSYKIXIKLIENETKMKNNVCDGIYLLIRQENGINTI-----QKXNN	2220

```

Oy 1122 ILISKYAEK-----DNVKKYINEDIKNNLSLEIDKTAQSIYKRAKVLTKL 1169
Db 2221 IIKKKKKOEKPYKKKKKKONNNHKKKKKKKKYIVDITINNVVPD-----IOKKYINTINI 2274
Oy 1170 LLLFFKKVVDQINNET-----SDLRKDLVMGHCICNNNPDDQFHFAYSARLE--- 1215
Db 2275 IINNNNNNNNSNSHSHNNNNNNHINISDLKKKI-----NINK-----YTLFVRLPLEFL 2324
Oy 1216 -----KDIINLIMLRQIWCESENL-----RLYQFLVVEYQNSANSVLLN----- 1256
Db 2325 FGDKYINDIDDVKSIYMKFFNQYNDVNTSNILVYIDLKKYNTNHNILKKNNMIQS 2384
Oy 1257 -----VSSNNGDI-----ILLNKKLVODINKNS 1279
Db 2385 PKNYICEKEQSDNPAKNTVHPFNNALDTSHPVDTITNTLSDVNIETMEIQEHINN 2444
Oy 1280 M--DHNNI 1285
Db 2445 IRNDHNNV 2452

RESULT 2
D71612
hypochemical protein PF80540w - malaria parasite (Plasmodium falciparum)
CISpecies: Plasmodium falciparum
CISdate: 13-Nov-1998 #sequence_revision 13-Nov-1998 #text_change 21-Jul-2000
CISaccession: D71612
RIGardner, M.J.; Jetelelin, H.; Carucci, D.J.; Cummings, L.M.; Aravind, L.; Koonin, E.V.;
Pierrea, M.; Salzberg, S.; Zhou, L.; Sutton, G.G.; Clayton, R.; White, O.; Smith, H.O.
Science 282, 1126-1132, 1998
A:Title: Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
A:Reference number: A71600; MUID:99021743; PMID:9804551
A:Accession: D71612
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-1844 <GAR>
A:Cross-references: GB:AE001401; GB:AE001362; NID:G3845209; PIDN:AACT1897.1; PID:G384522
A:Experimental source: clone 3D7
C:Genetics:
A:Gene: PF80540w

Query Match 11.4%, Score 778, DB 2, Length 1844;
Best Local Similarity 24.5%, Pred. No. 3.2e-25;
Matches 340; Conservative 202; Mismatches 439; Indels 406; Gaps 66;

Oy 205 VNSQNDSESRHALINT-DLKDINKNTSLGIAPFDLAGSBRGADTVSQNKOTOT----- 258
Db 37 VNRRIIDNMEYMSINSNGHMSINNNNTNNLDDAYINKELHYMNSDKITIAKHQVHMHTA 96
Oy 259 -----DGANIRSLALAEKCIKRAMSDSKHIFPRDSELTLYLRDIFVGSKSIMIANISP 313
Db 97 TYNNMDKNNANNNIHILNNHIN-MTDDQNY--FYNSTNNKK-----NNTLKENNENFN 146
Oy 314 TISCEQTLNLTLYSSRYKFNKSTCINEED-DTNRISILDSKGSBMAASLEN--- 369
Db 147 MNM-----TVNNSFYHNTDNNFLNFRNQNEQDTYVNNNIINNPNQNVDKNNNNNNFN 202
Oy 370 -----VTKSHLLSNNNN-----KINRGKIDKEKNNILKKKSPDKREGSTFGKYS 421
Db 203 KNVESINKFNHIYNNQNNHFI PNISNGK-NGULENNASLSH-----NVNSVS 249
Oy 422 SLANDIDKIKKKKKGLINYKSTLYNDTINKKNNNNNNNNNDNDNNNDNNNN-----NNND 478
Db 250 TISELHNNTYNNMMDLNVDMNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNND 309
Oy 479 SSSM-----VNNM-IHMLNNNTN-NNIVANNNNNNNNNN-----NNNSSHN-N 517
Db 310 VNSNNNNNNMMNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 369
Oy 518 HLPQNN-----YAFDTSDFSLLDNMCHLNNNDKSIPLAKKN----- 555
Db 370 SIQPNSSSRFNNTIFHNNGISHVANNVNSGN-----NAHLDSNNMRRLNVNPFGLD 425

```


QY 556 -----LRDNIKLKNRSSCDNINMKKNLHLARHSVGSKLTMTFSDPO----- 598
Db 426 SFHDLPLNMQVLKKNVVMQMEHNF-IVNDEMKNVNVK-----RINSISHIYMANLKN 479
QY 599 -----KXKNDTFPKSNINKEDETPKDI---LYESRVSNMNGVTLG-LNKOTHH 646
Db 480 YNEHTSMVKGKGTNRKKSNNLKIINPGSVNARAISENNQSTAHGNI PMGSVDKYL KHD 539
QY 647 ISFKD-----ENNDKKN-----NGVININNSVNSIN-----SMMNSINN-SNM 688
Db 540 RMDNDLKNINNNNNNSMNNNSMNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 599
QY 689 NSNSIYKSNYSNQSII-----SDVQIRYVNMDSNR-----NND 723
Db 600 NNTSILN-----NNKKITRGRACKNSTINININKNKSTNKSMTNNSVNNMNSVNNM 656
QY 724 NTFEDALSCDN-NMPTNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 780
Db 657 NSYKNNNSVNNNNNSVNN 716
QY 781 HNLF-----QPDNNKNTSNINONIN-----TNKNQOGVNVYSNPFCHYNL 820
Db 717 NNNFNVNPNQNLINGIMKDIINNNNIYVSNKKKLMNNYINDNNIMMGSINETYNF-DGTL 775
QY 821 NDKVYLIDLNNKEQKDNHIGCDN-----NIIQRNDFEKKKKTNFY 862
Db 776 NNNK-VSNNNNNDIHKGVANTLNRSKSSYIKPHRLTLPIMYNNNTYNNYSKAYNY 834
QY 863 NNNNVIV-----NNNNKNNNSPRMKYGLGSHTSIDNMKNEMKNEMKNEMKNEMKN 917
Db 835 ENQNNMAQODCDNKGSLNEGPRYN-----DNNNNNNNNNNNNNNNNNNNNNNNN 883
QY 918 SNNNNSSSSSSNNNNIYNNINDDTPONDY-----CHNDFTFRKKNNTIN-----S 966
Db 884 NNNNNNNNNHIIINNNTIÖGHGSMINNOHFDELSTYNGIFLEKTTITVNNEMLSGYN 943
QY 967 NIY-----QNDIIYITINSIDYMSN-----TLL 990
Db 944 NMVDKAAVKNMMLIGHSNYDLMKNGMNGIKLMOBYOKGMEVYKGRAPRRAKTI 1003
QY 991 HPEKTYPTLSTNEDIYNKMEGKHIRLDDQKYDNDN-----NNVD 1034
Db 1004 NLKSINRFVTVSLG-----LKGNH-NMENNNMMDDMMNNMIVSVNNVNNNNNNVVA 1055
QY 1035 N-NKKNVD--NNVDN--NNVDN--NNVDN--NDKKNVDN-----NNVDNDDVDVPHNIKPN 1083
Db 1056 NVNN 1115
QY 1084 NNEVLSYFOKN-----VDTIINNCLNSLIDISMYDDTEILNNILLSKYAKKONVTK 1136
Db 1116 NNRNRMHIDNNMTYNTLNMKNKINNAGNNLN-----GEFSKILYN----- 1156
QY 1137 KYINEDIKNNSLEIDKTAQSIYERKAVLLTKLLLFKKNVDPQINNETSD-----LRKD 1191
Db 1157 -----RSKSTENIKEMQPHNEANNI-----SGNNTSDSNITLKNK 1193
QY 1192 LVNCHICNNP--DDQPH--FYAISRLEKDIINLMLRQICE-----SENRLXY 1238
Db 1194 LVEMIRNNKPSIDKIHESVNSYTSFLMNISSSYLKKKTAIEIKTEGNTENNNGIYVA 1253
QY 1239 QPLVEYONKSANSVLLNV-----SSNNGDIILNKKLVQDNIKN-----SMD 1281
Db 1254 VNSQVEBKSGSEKSIIEIKGGOIKAVIYNNNNNNNEKQADQYODQKXHKHQDQROD 1313
QY 1282 HNNIHK 1288
Db 1314 QNKSHKQ 1320

RESULT 3
T18499
hypoetical protein C0770c - malaria parasite (Plasmodium falciparum)

C/Species: Plasmodium falciparum
C/Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000
C/Accession: T18499
R/Lawson, D.; Bowman, S.; Barrell, B.
Submitted to the EMBL Data Library, August 1997
A/Reference number: Z18935
A/Accession: T18499
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-1619 <Law>
A/Cross-references: EMBL:298551; NID:e1331903; PID:e1331920; PIDN:CAB1138.1
A/Map position: 3
A/Intons: 87/3
A/Note: C0770c

Query Match 11.2%; Score 765; DB 2; Length 1619;
Best Local Similarity 22.0%; Pred. No. 9, 6e-25;
Matches 369; Conservative 246; Mismatches 568; Indels 496; Gaps 66;

QY 5 IKVVRKRLPSELEKK-KDSIIITVKNCTIYIDPRKVDMTYIERHEFVDCVFPD 63
Db 16 IKVVRKRLPSELEKK-KDSIIITVKNCTIYIDPRKVDMTYIERHEFVDCVFPD 69
QY 64 TVDNFTVYENTIKPLIIDYENGCVSCFAYGQSGKTYTMLGS-----QPYG----- 112
Db 70 DVDQKTLFNNYIYQ-IVDEVLOGFNCTLFYCGQTGTGKTYTMBGKLEHLKQDNNKKVD 128
QY 113 -----QSDTPGIFQYAGDITFL-----NIYD-KDN-- 138
Db 129 LNESINSIDSYCELCENEDTGLIFRVTKRIPDIINLKRKEEKIRHFKKKNIFDEKDNH 188
QY 139 -----TKG----- 141
Db 189 INVINKETGNNNNNIINNYYNNLNCNKINIDKNDIYNNLKNKEPNLLVNEKSDITCD 248
QY 142 -----IFISFEIYCGKLYDL-----QKKNVVAAL 167
Db 249 VVQKSVDRKNNNDVQTFDDKNMYDFNIKISYLEIYNELCDLSTNENKRLRYEDS 308
QY 168 ENGKKEVVVKDKILRLVTKBELILKMDGVILRKIGVNSQNDSSRSNIIITDL--KO 225
Db 309 NKSXGLNVDKLEKKSINSFEIYIYICAIKRRRTAETAAVKKSSRSISITITLIIYD 368
QY 226 IN-----KNTSLKIAFIDLAGEERG-ADTVSQNKQOTQDGAIVNSILAKCIRAMDSD 280
Db 369 INNVGESITIKGLMLVDLAGEENALKSSYGLKTRQDSQINOSLTLGIVNSLLEN 428
QY 281 KXHIPRDELTFRVADIFVGRKSIIMTANISPTISCEQTLNTRYSGRVKNFRNKSVC 340
Db 429 SSIIYPRDSKLRLLQDSLGKTKTFIYATISPSLSLIDETLSTLDYVFRANKINRP-- 486
QY 341 INEEDTNTERTISLDSKSENNASSIENVVIXSNHLLSNNNNNKINRGKINDKIERNI 400
Db 487 -EINKTKTKQKIKD-----LNNEIKELNAL--NLSEKRGVLYDTEEYNNI 531
QY 401 -----LKNS-----FDRPREGTSTFGYSSLNDI-----DKIKKKK-- 434
Db 532 QNSLKKKEIILEKEKILFEKSK--IKQLLNKQVTDLDLQNKIFFLKDTTÖKYNTIOAF 590
QY 435 -----KGLINYKSTLYNDNTINKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 484
Db 591 HQILIKKITEER--YITQFLANKYSLEENFINQKKSFOQITMNSNIMHDLNLIKNI 648
QY 485 NMINEMINNN 536
Db 649 HOENHLNDICTIILFIIDTQVLYVQKKSYNDYINHFELINSINIKFYNTDLNF-IID 707
QY 537 DMNCHLNNDKSIPLAKKLR-----DNITKL----- 563
Db 708 HMDI-LQKYDHDYFSLSENIEKKEISQCKINIPHISDEAKQKPAIIGVYNTNGLKEKOS 766
QY 564 -----NRSKCDINMKKKNNLH-LARHSVGSKLTMTFSD----- 596

[illegible]

```

RESULT 4
T02791
mitotic centromere-associated kinesin MCAK [imported] - Leishmania major (strain Friedlin
C/Species: Leishmania major
C/Date: 24-Mar-1999 #sequence_revision 24-Mar-1999 #text_change 19-May-2000
C/Accession: C81455; T02791
R/Miyler, P. J.; Audlemann, L.; deVos, T.; Hixson, G.; Kiser, P.; Lemley, C.; Magness, C.;
Proc. Natl. Acad. Sci. U.S.A. 96, 2902-2906, 1999
A/Title: Leishmania major Friedlin chromosome 1 has an unusual distribution of protein-c
A/Reference number: A81455; PMID:99178987; PMID:10077609
A/Accession: C81455
A/Status: preliminary
A/Molecule type: DNA

```

A:Residues: 1..668 <PI>
A:Cross-references: GB:EM001274; NID:93264850; PIDN:AA024615.1; PID:92978452; GSPDB:GN0
A:Experimental source: strain MHOM/IL/81/Friedlin
C:Genetics:
A:Gene: MCAK
A:Map position: 1
A:Note: MCAK
C:Superfamily: kinesin-related protein KIF2; kinesin motor domain homology
F:135-459/Domain: kinesin motor domain homology <KMO>

Query Match	11.0%;	Score 755;	DB 2;	Length 668;
Best Local Similarity	-42.9%;	Pred. No. 9.8e-25;		
Matches 172;	Conservative 67;	Mismatches 134;	Indels 28;	Gaps 8;

```

Qy      3 SKIVAVVRKRPPLSELEKKKDDSDIITVKNNTDITIDSPRYVDMTKYIERHEEFTVDKFD
Db      133 SRILVAIRKRPPLSGEOTNGFTDMDADNNGEIVLKEPKKAVYDLKTKTHHRRFFPEFVED
Qy      63 DTVNFTVYENTTAPLIIIDYENGCVCSFPAVGGTSGKTYTLMGSDPYGSDTPGIFQY
Db      193 EACONVDVYVRAARALIDTVPDGC-ATCFAYGQTSGKTHTMLGK-EPGLAYAL
Qy      123 AAGDIFPFLNYDKDNTKGFIFISYEIYCGKLYLLOKKRVAVALLENGKEVYVKDLKIL
Db      247 AAKMFPRLT----SDTR-IYVSFEYEIYSGCLPDLNGRRLALIEDKGRVNRGLTEH
Qy      183 RVLKKEELILKIDGVLRLKIGVNSONDESSRAIINTIDJLKNKNTSLKIAFIADAG
Db      302 CSTVEDMTITIDGSGVSCGSGTGANDTSSRAHLEIKLAKAKTSKQSGKFTPIDAG
Qy      243 SERGADTVYSONKQOTDGCANINRSLALKECIRAMDSBKNI PRDSELYTVLADIYVGK
Db      362 SERGADTVDCARQRLRBOAEINKSLALKECIRFLDQGRKHVPRGSKLTLEVLDSFIGN
Qy      303 SKSIIMIANISTTICCEOTLNTLYKSSRVKFKRKS-----CINEED-----DTNTER-
Db      422 CRTVMIGAVSPNNNAHTLNTLYARVAKELKNATERRTVCMPPDDDEAFPTTESRP
Qy      352 -----ISILDSKGSNNNAASIEENVIVYINSHLNNNNKIN 387
Db      482 PSRRRTTRLSTAAPLFGSSSTAAPALNST-LLSSRSVNTLS 521

```

RESULT 5
T18501
hypochemical protein C0760c - malaria parasite (Plasmodium falciparum)
C|Species: Plasmodium falciparum
C|Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000
C|Accession: T18501
R|Lawson, D.; Bowman, S.; Barrel, B.
submitted to the EMBL Data Library, August 1997
A|Reference number: Z18935
A|Accession: T18501
A|Status: preliminary; translated from GB/EMBL/DBD1
A|Molecule type: DNA
A|Residues: 1-3394 <LAW>
A|Cross-references: EMBL:Z98551; NID:e1331903; PID:e1331922; PIDN:CAB1140.1
C|Genetics:
A|Map position: 3
A|Note: C0760c

```

Query Match 11.0%; Score 752; DB 2; Length 3394;
      Best Local Similarity 21.9%; Pred. No. 7,46-24;
Matches 308; Conservative 249; Mismatches 432; Indels 416; Gaps 58;

OY 15 SELEKK-----KKSDPIITKNNCTLYIDB-----PRKYVMTKTIE 51
      ||||| :|||:|||||
Db 2187 SELEKSDMDLENYKELKEKNEELTYKLNDDIMLSNNCKKLKESIMMEKKKIIMNNNIO 2246
      ||||| :|||:|||||

OY 52 RHEFIIVDKV-----PDDIVDNFTYENTKIPILIDLYENGCVCSCFPAFYQGTSGKTYT 104
      ||||| :|||:|||||
Db 2247 EKDIIEIKKKYKNNKLDLIDNNNSVYDKSI-----VSCC----- 2281
      ||||| :|||:|||||

```

```

Qy 105 MLAGSOPYGSDTFCIGFYAAGDIFFTLNTYDKONTGKIFISFEYIYSGKULYDLQKRW 164
Db 2282 -----EDSNIMSPSCNDIILNFPNNLSKSNK-----VCTMMDICENMDSISSIN 2328
Qy 165 AALENGKEVAVVKKLRLVLTKEELKMLIDGLAKIGVNSOND-----211
Db 2329 NNINNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 2387
Qy 212 -SSRSHAILNIDLKDNKNTSLGKIAFLAGSERGADTV-----SONKOTQTDGANINR 265
Db 2388 LGSGLYLTIRNKLKEI-----QMLKNQILSLSESLKSLNEFINLAKNEKNEKELLKINFE 2443
Qy 266 SLALKECIRAMD--DKNHIIPRDELTKV-LRDI FVGKSKSIMIANISPTISCC-- 318
Db 2444 EILTKKNNLQDNESCIONLNNYLTKEEELNKNINKNIF--KYGYIHLIQSVVFCIF 2501
Qy 319 -----EQLTLTRYSRVKNF-----KAKSTCINER--D-----TN 348
Db 2502 KHFENKIIDQSLINKLYLKSPDFYWDYSVQIEIRENNKIIINOFLTDEYFKHIQTF 2561
Qy 349 TERISILDSKG-----SENNASIEVNVIKSNHLSSNNNNKINRGKINDIERNNILK 402
Db 2562 TKTCNVLIQGYLSILKDTNNDPFIQ--KQSNQOGNQGHNIMNCNITPDEIYVAD 2618
Qy 403 NKSPDKREGFTSTFGKYSLLNDIDKIKKKKKGLINYSKTYNDTIN--KKNNNNNN 460
Db 2619 QQIFD-----GTENVQOSIQNEBEDYVNEEM--YTQKMDLNNMNGDDDDDDDD 2667
Qy 461 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 520
Db 2668 DDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 2726
Qy 521 QPVAFTDTSFSLDDMCHLNNNDKSIPLAKKKLNDIKLKN-BSSCCNIMKKKKNNL 579
Db 2727 -QNIYINDVNDNNV-----IENIKILIKKODIINDDELKKEHNLIRLINESIEA 2779
Qy 580 HLAHSHVSKLTWESYDPOKXKNTPEKSNINRA-EDNTPKD--ILY--ESRNVSMNGN 634
Db 2780 H-----NLENVYQVANDANLINDINIKKEFTLVFVDEKDVSN--2816
Qy 635 VILGLKNTKHTDSTKDEHNDKINNGVNIINNSVNSINNSMNSINNSMNSISY 694
Db 2817 -----ESNSKCD-----DDKKEMDIIOAKKENPVSTHYDNDNDIKDIN--2858
Qy 695 KSNVNSQSIQVQIRVNEMDTSNKKNDNIFPDALSCDNNVPTITNNNNNNNNNNNN 754
Db 2859 --NDNNNDNIND-----DNNNDNI-----NNNNNDNINDN 2888
Qy 755 NNNIDVENYNNRGTJNNSMKLYAVNSHLEFQPDNNKTSNIQNI-NTKKNODGAVVYSM 813
Db 2889 INNDNINNDNNNDNNND-----NSNNGFVCELSINIDFNNILAVNKNQFQ-INKSN 2940
Qy 814 NFCHYLNLDKQY-----LID-----LANKKQDKNIGCCDNNIIONRDEFEKKKKTNFYNN 864
Db 2941 NF-STNLSFNYDAVYKIVAGSALENKKOD-----KRRKYFSD 2979
Qy 865 NNIVYVNNNGNNNSPMMKYGLGSHTSIDNKKNNKNNKNNKNNKNNKNNKNNNS 924
Db 2980 SETTKENGVLGESNSIKIRKYSVGG-----DNDNNDDNDNDNDNDNDNDNDNDNDND 3035
Qy 925 SSSSS-----NNNINNNINDDTPONDYCHNDFTTIRKKNNTINSNIYOND 973
Db 3036 DNDSDYDEKEQENSDVNTLNNHVTEFEDISVHNN-----IQENKKYVFSNVHENP 3090
Qy 974 IITINSINDYMGNTLHFEKXTYPTLSTNED-----YINKMEGHKIRLDDQ 1022
Db 3091 NLAHVEDVHEDLQ-----YEDYVNNNNNNNDNDNEESNNSCYIISSDEGKRVKYSK 3145
Qy 1023 DKYDDNDNNVNNNNKNNVNDNNVNDNNVNDNNVNDNNVNDNNVNDNNVNDNNVNDNNVND 1082
Db 3146 NDDDEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 3202
Qy 1083 NNNEVLSYFOKNVDTIINNCLNSLDISMYDTEKIELNILLSKRYAEKDNVIAKYYINED 1142

```

```

Db 3203 ENEDDDNVANEDDDNNYEN-----DDDDYENDDD-----DNYENDDN-----YEND 3245
Qy 1143 IKKMSLEEDIKTAQSIYERKRVLTLLLFKKNVDTQIINNETSIDRKVLVCHICNNNP 1202
Db 3246 DDN-----YE-----NGDDNDNDNDND-----DNDND 3266
Qy 1203 DDQHFVAYSRLKDIINLIMLRQIWCESENLRLLQPLVVEYONKSANSVLLNYSNNG 1262
Db 3267 EEKYS-----CHDD-----KQEHNTNDDLNDIDHDN- 3291
Qy 1263 DIILNKKLVQDNIRK-----SMDHN 1283
Db 3292 -----NKNNTIDELSTYVNSVSHN 3311

RESULT 6
D71606
hypoetical protein PFB0800C - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C:Date: 13-Nov-1998 #sequence_revision 13-Nov-1998 #text_change 21-Jul-2000
C:Accession: D71606
R:Gardner, M.J.; Tectelin, H.; Carnucci, D.J.; Cummings, L.M.; Aravind, L.; Koonin, E.V.;
  .; Pereira, M.; Salzberg, S.; Zhou, L.; Sutton, G.G.; Clayton, R.; White, O.; Smith, H.O.
  Science 282, 1126-1132, 1998
A:Title: Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
A:Reference number: A71600; MUID:99021743; PMID:9804551
A:Accession: D71606
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-1817 <GAR>
A:Cross-references: GB:AE001418; GB:AE001362; NID:g3845275; PIDN:AA071949.1; PID:g38452
A:Experimental source: clone 3D7
A:Genetics:
A:Gene: PFB0800C

Query Match 10.9%; Score 748.5; DB 2; Length 1817;
Best Local Similarity 23.6%; Pred. No. 5.3e-24;
Matches 356; Conservative 197; Mismatches 410; Indels 543; Gaps 69;

Qy 79 IIDLYENGVCSCFAYGQTGSGKTYTMLGSPYGGSDTFCIF-----QYAGDIFFTLNI 133
Db 391 IFELFEGCYLFLPLNEKIKSNINY-----TPNIFLKULKNYITSNDFV--I 435
Qy 134 YXKNTKGIKIFISFEIYCGK-----LYDLQKRWAALENGKEVAVVKL-- 180
Db 436 HINDRLNRYIKFLSYHSCNNIYVHILENDLYTHKIKFT-----NNYDMLIKHYKSTA 490
Qy 181 --ILRVLTKEELILKMLIDVLK--IGVNSQDNDESSRSHAILNIDLK-----DI 226
Db 491 DHILVITNKG--NLWYLVNTLILNNYSLYNNKKNKQSLNLAVKI FPSHLNYKQHTT 549
Qy 227 NKQTSIGKIAFLDLAGSERGADTVSQNKOTQTDGANINBSLLAKCECIRAMDSDKNHIF 286
Db 550 NKQVNV-----DPNQOHKHXDQ-----SYDNTYEQMKNNKKKIYP 584
Qy 287 RSESLTKVLRLDIFVGKSKSIMIANISPTISCCBOTLNTLRYSRVKNFKNKSTCINEED 346
Db 585 NRYITTHILQ-----NYEONLSYFOK-----DD 609
Qy 347 TWTERTSLDSKSENNASIEVNVIKSNHLSSNNNNKINRGKINDIERNNILK-----402
Db 610 TWINNIFDL-HKREGDIYEEKEN-----ESGDI PRDSYKKRIKEK-----KKKNITKYEDH 660
Qy 403 --NKSPDKREGFTSTFGKYSLLNDIDKIKKKKKGLINYSKTYN--DNTINKKHN 457
Db 661 PLNKKKKKKKKFFIYNEKGDNDKNDL-----YANNIYSKQLENIQNKQYVNN 709
Qy 458 NNNNNNDNNNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 517
Db 710 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 756
Qy 518 HLPQNYAFTDTSFSSL-----DMNCHLNNNDKSI F-LAKKULRDNIK-----LKN 564

```

[illegible]

t18277
 kinesin heavy chain - slime mold (Dictyostelium discoideum)
 CSpecies: Dictyostelium discoideum
 CDate: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
 CAccession: T18277
 RDehostos, E.L.; McCaffrey, G.; Vale, R.D.
 submitted to the EMBL Data Library, November 1995
 A.Reference number: T18853
 A.Accession: T18277
 A.Status: preliminary; translated from GB/EMBL/DBJ
 A.Molecule type: mRNA
 A.Residues: 1-1254 <DE>
 A.Cross-references: EMBL:U41289; NID:g1526990; PID:g1526991; PIDN:AA07748.1

Query Match 10.7%; Score 732; DB 2; Length 1254;
 Best Local Similarity 22.3%; Pred. No. 1.7e-23;
 Matches 321; Conservative 217; Mismatches 399; Indels 504; Gaps 59

1 MNSKIRVRRRRLPSELEKKKKSDIITVKNKNTLYI--DEPRYKVMTKYIERHEFIVD 58
 25 VSSNIRVCRVRLPLETEKGRNHESHVAFPSKISISIRANGP-----QFTFD 71
 59 KYFEDTVNFTVYENTTLPILIIDLYENCOCVSCFPGYGGTSGKYTMLGSPYGGSPRG 118
 72 RIFGYQETQSQIFEDVAEPYVND-FLDGYHGIIIAVGGTASAKITPMV-----GPDHSG 125
 119 IFQVYAGDIFTFLN-IYDKONTKGIFF--ISFYEYIGKLYDL-----LQRRKV 164
 126 IIPRIYESIFGISMREKQTSLSAFCLKISALETYNEKLYDLYIAGSKNLIINREHKON 185
 165 MALENGKEVYVYKDK---ILRVITKEELIKMIDGYLKRITGVNSQNDSESRHAIIN 220
 186 GIYVGEISEIYITSIEEAYNFNTISNN-----PAIATSKVSAASSRSHSVLM 233
 221 IDLKQIN---KNTSGIKAFIDLAGSEKADVTSQNKOTQTDGANINSLALKECIRAM 277
 234 IELSQNLMSBESKSKFLVYDLAAGSDLSHKTAGGDMQ--EAKNINLSLALGVINVL 292
 278 DSDKNHIFPRLSELTKVLADIFVFGSKSIMANISPTISCEQIINTLYRYSRVKFKVK 337
 293 TCGVAVYVPRLDKLTRLVLODSLGSGSKTSLIINCSPNNNEHETITTLTLOFGRATIKQ 352
 338 STCINEEDTNERISILD-SKGSNMNASITENVV---IKSHHLSNNNNKIRKGIN 392
 353 PK-INKKITTYHLELFIILAKOLEKSKRECEITRSKULEINNLLIQLENNQKVAEEN 411
 393 DKIE--RNNILNKKSPDKREGFTSTFGKYSLANDIKIKKKKKGLINYSKTLVNDTI 450
 412 QKLELLNSQISNHSFD-----NPFKEIENTCENSK-----IIFDD--L 448
 451 MKKHHNNNNNNNDNNNDNNNNNNNNNNSSSVNMIMHMINNNNNNNNNNNNNNNNN 510
 449 NHHNNNNNVDDNNNTNNNNNDN-----NNNDNNNNNN 478
 511 NNNSHNNHLPQENYVAFPTSDPSLSLDNMCHLNNDKSIIFLHKONLRDNIKUKNRSSCDN 570
 479 QYQEBENQYQEN-----NQKQDG-----QNNSSFDS 505
 571 IMKKKKNNLHLARSHVSGKLTFPSYDPQKONKONTFFKSNINMKEDNTPKQDILYESAVSN 630
 506 I-----KVEDLRDL-----DEPDIED 522
 631 MNGVNLGLKNTKTHHDISTKENHNDKINNGVINIINNSVNSINNSMNSINNSMNS 690
 523 IILNSTLGG-----NISDDDDDDDDHSHNN-----NNVDDNNNGELIND----- 560
 691 NSIYKSNVNSNOSISDVQIRYVNEMDTSSKNNDNIFFDALSCDNNMYPNITNNNNNNNN 750
 561 -----SDGVLNRLSKDIKIPRISDLNDHNIN-----NNNNNNNNIN 596
 751 NNNNNN-----NIDVENYNNROGNTNSMGLXAVNSHNLFPQDNNKKT----- 792
 597 NDNNSNGGLRSTVSTYITSSPMLISTEYQCH--NHSPLPSTFYTKYDPPSSDENDKPF 653

```

QY 793 -----SNIQNTNKNODGN-----VNSMNFCH-----817
Db 654 NDIAKENGQOQOQOQHNDDEDEIKSTSNATTTTITIDMASHSGIDPIEFTLIK 713
QY 818 -----YNLDKNYLIDLNKQ-----KDK 837
Db 714 SDKTTTIERETIQPSSLSTSLDIEFVESSTLPAPPVTTTTLTITVTTKLTKT 773
QY 838 NIHCDDNIIQNRNDFEKKKTNNYNNNVIYVNNMGNNSPMPKGLGSGHSIDMK 897
Db 774 NIPS-NTNDINSIDDFPSK-----IEEGSSSNKP-----NDTALLSFG 813
QY 898 NNEKKNEMKDNEMKDNHKSNNNSSSSSNNNININDDTFONDYCHND-----NT 953
Db 814 DDDDEENE--DNEDEDVIVDDED--THSGKNLLN-----TFNDHHRGDFGAPT 861
QY 954 FTIRKN-----NTNINSNY-----969
Db 862 KSIFNKNGITIKFEFTPOOQOQOQOQOQOQOQOQOPLIQTSTSTNFTIISKSKE 921
QY 970 -----QNDLIYTLNSLNDVMSNTL-----HREKXT-----997
Db 922 PPSSTSTTSIKKKKNFKRSWITFTLTITVSSSLCLCYPEYERLVRGRLYLNKL 981
QY 998 --YPTLTSTNEDI--YN-----KEMEGKHIR--LDQODKYDDNNDNNNNNNNDNN 1044
Db 982 GIYSDYFTNEKISLAQNOQSLAKELYGKSKOYDEMSFNTAYNHLIEMHLETAISK 1041
QY 1045 VDNNDVNDVNDNDK-NNVD-----NNVDND-DDVDNFHNKFNNEEYLSYFQ 1092
Db 1042 IFGSAIDLRFGSDVINSICKRAIHKLKTNNYVGNLDQOQOQHNY--ITKIDQLSEQS 1099
QY 1093 KANDTIINCLNSDJSMTDDTFEILNINILSKYAKKNVKKYIN--EDIKMSLEB 1150
Db 1100 KEQQLIENF--KLDLK--NKTSEIEK--LEKEIKQKNKKEKEKIELIESRYLNE 1151
QY 1151 IDTKAQSIYE-----KRVLLTKLL-----LTFKKVND-TOINNETSDLRK 1190
Db 1152 -EKGEKVLVDQIISLNDKNTLSTQILNEGDKSGVLVYKLSKTEIQNEVEKLK 1210

RESULT 8
A44259
kinesin-related protein Kif2 - mouse
C/Species: Mus musculus (house mouse)
C/Date: 03-Mar-1994 #sequence_revision 03-Mar-1994 #text_change 19-Jan-2001
C/Accession: A44259; S27871
R/Alzawa, H.; Sekine, Y.; Takemura, R.; Zhang, Z.; Nangaku, M.; Hirokawa, N.
J. Cell Biol. 119, 1287-1296, 1992
A/Title: Kinesin family in murine central nervous system.
A/Reference number: A44259; MUID:93077686; PMID:1447303
A/Accession: A44259
A/Molecule type: mRNA
A/Residues: 1-716 <AIZ>
A/Cross-references: EMBL:DJ2644; NID:g220467; PIDN:BA02165.1; PID:g220468
A/Experimental source: brain
A/Note: sequence extracted from NCBI backbone (NCBI:P:118908)
C/Superfamily: kinesin-related protein Kif2; kinesin motor domain homology
C/Keywords: ATP; microtubule binding; nucleotide binding; P-loop
F/196-531/Domain: kinesin motor domain homology <KMOT>
F/285-292/Region: nucleotide-binding motif A (P-loop)
F/291/Binding site: ATP (Lys) #status predicted

```

```

Query Match 10.6%; Score 728; DB 1; Length 716;
Best Local Similarity 47.6%; Pred. No. 1.4e-23;
Matches 161; Conservative 61; Mismatches 102; Indels 14; Gaps 8;
QY 4 KIKVVRKRPLESELEKKKSDITVKNCTLYIDERYVDMKYERHEHFLVDKFD 63
Db 195 RICVCVRKRPUNKKETOIMKDLDTITPSKVVMVHEKQKVDLTRYENGTFRPDVAFD 254
QY 64 TVDNFTVYENTIKPLILIDLYENGCVSCFAYGQTSGKTYTMLS-QPYGSDTPGIFQY 122

```

```

Db 255 SAPNEMVYRFTAPLVEITFERG-MATCFAYGQTSGKTHMGDGSKQDCKGIAL 313
QY 123 AAGDITFTNINVDKMTK-----GIFISFYEITGKLYDLQKRMVAALENGKEVVKD 178
Db 314 AARDVPLMKK--KPNYKLEIQVATPFEITSYSGKDFDLNRTKRLVLEDGQOQVVG 370
QY 179 LKILRLYTEKEILLKMD-GVLLRKIGVNSQNDSSRSHALINDLKINKNTSLGKIAF 237
Db 371 LQREKVCYED-VLKLIDIGNSCRTSGQSANAHSSRHAVPQIILR--RKGLHKEFSL 427
QY 238 IDLAGERGADTVSONKQOTGDGANINRSLALKECIRAMDSDKNHIFRDSLETKVLRD 297
Db 428 IDLAGNERGADTSSADROTRLEGAEINKSLRLKECIRALGRNKPPTPFRAKLTQVLRD 487
QY 298 IFVGK-SKSIIMANISPTISCCQTLNTRYSSRVKNF 334
Db 488 SFIGNSRTCMATISPGMASENTINTLRYANRVEF 525

RESULT 9
T10755
kinesin-related protein 2 - rat
C/Species: Rattus norvegicus (Norway rat)
C/Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 29-Sep-1999
C/Accession: T10755
R/Sperdy, A.O. -
submitted to the EMBL Data Library, January 1998
A/Reference number: Z17121
A/Accession: T10755
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-671 <SPR>
A/Cross-references: EMBL:U44979; NID:g2772515; PID:g2772516
A/Experimental source: strain Sprague-Dawley, testes
A/Genetic: KRP2
C/Superfamily: kinesin-related protein Kif2; kinesin motor domain homology
F/205-542/Domain: kinesin motor domain homology <KMOT>

```

```

Query Match 10.6%; Score 722; DB 2; Length 671;
Best Local Similarity 41.2%; Pred. No. 2.3e-23;
Matches 171; Conservative 78; Mismatches 138; Indels 28; Gaps 11;
QY 4 KIKVVRKRPLESELEKKKSDITVKNCTLYIDPRKRVDMTKYIERHEHFLVDKFD 63
Db 204 RICVCVRKRPUNKQELAKKEIDIVSPSKCLLVHPPKLVDTLYLHQAFQDFAPDE 263
QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCFAYGQTSGKTYTMLS-QPYGSDTPGIFQY 122
Db 264 TASNEVYVFTARPLVOTIFBEG-KATCFAYGQTSGKTHMGDLSGSKQANASKIYAM 322
QY 123 AAGDITFTNIN--LYDKNTKGIIFISFYEITGKLYDLQKRMVAALENGKEVVKDK 180
Db 323 ASRDVPLLNKQPRYSRLNE-VVYTFEITNGVFELLNKKAFLVLEDSKQOVVVGQ 381
QY 181 ILRVLTKEELLKMD-GVLLRKIGVNSQNDSSRSHALINDLKINKNTSLGKIAFD 239
Db 382 EYLVTGAD-VIKIMMGACARISGQTFANSSSRSHAFQIILR--AAGRLLHKEFSLV 438
QY 240 LAGSERGADTVSONKQOTGDGANINRSLALKECIRAMSDKNHIFRDSLETKVLRDIF 299
Db 439 LAGNERGADTSSADROTRLEGAEINKSLRLKECIRALGRNKPPTPFRAKLTQVLRD 498
QY 300 VEG-SKSIIMANISPTISCCQTLNTRYSSRVKNKSTCINEEDDTNTERISILDSK 358
Db 499 IGENSRTCIMAMISPGISCEYTLNTRYADYVKELSPHSGSGEQ-----AVQME 549
QY 359 GSEPMASLENVIVKSNHLSNNNNKIN--RGKINDKIERNNILKNKSPDKRE 411
Db 550 TEEMDSS-----HGASLTGNEEELSQMSFNEAMTQIREBERAMEELRE 597

```



```

Db      837 QMTNQ-MANQMK-NQVNSHINSQVAGHMANMNFNGNNSGTNNLGNMMLNNVNSMND 894
Qy      808 NV--NYSMNF---CHYNLDKNLYLIDLNKEOKDKNIHGCDDNIIONRDNFEKK---KKT 859
      895 NVNNNYSNNYPGSGNNGNNTSCVANNNGAEIDM---DNVIEH-NQHEHNNMLEKE 949
Qy      860 NFYNNNNIV---IVNNMGNNSPRMKYGLCSHTSIDMKKNEMKNEMKDN 915
      950 DSINNDSIITTTTATNINSNNNS-----NNANSLNLTVMNSGNGN-TKLTNI 997
Qy      916 IKSNNNNSSSSSSNNNNIYNNINDDTFQNDYCHNDVTFTRKNNNNI---NSNTYON 971
      998 INNNNNNNNNNSSGGGVMMVNN---VANNNNMNTYNNNNNNIINDGNSVYGN 1049
Qy      972 DDIITYNSLNDYNSNTLHFKEKYTYPLTSTNEDIYNKEMEGHRLDQDQKDDNDN 1031
      1050 ESMHKKNVNV-----CINNDE-----DDLGNMNNHNN 1079
Qy      1032 NVDDNNKNVNDVNNNDVNDVNDNDKN-NVDNNVNDVDDVDFH-NIKNPNNNEYLS 1089
      1080 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1139
Qy      1090 YFOKNVDTIINNCLNSLSDISMYDTKEILNILLSKYAKKONVYIKYINEDIKMSLE 1149
      1140 EGRIN---FHTAGKHVDKNNMOSGTTVNVV-----NNDENYIKSNINYTNMD 1186
Qy      1150 EIDTAOSIYEKKFVLTLLKLLFKKAVDTQINNETSDLRKDLVMCHICNNNDP 1203
      1187 NMKNNDPIDDDNNNIYENMLRYEKNI---LNNNDE-----HIINNTED 1229

```

```

RESULT 15
T18429
hypothetical protein C0345w - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000
C:Accession: T18429
R:Lawson, D.; Bowman, S.; Barrett, B.
submitted to the EMBL Data Library, August 1997
A:Reference number: Z18935
A:Accession: T18429
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-1711 <LAW>
A:Cross-references: EMBL:Z98547; NID:e1325376; PID:e1325381; PIDN:CAB1106.1
C:Genetics:
A:Note: PFC0345w

```

```

Query Match      8.9%; Score 611; DB 2; Length 1711;
Best Local Similarity 23.8%; Pred. No. 2.8e-18;
Matches 284; Conservative 202; Mismatches 406; Indels 300; Gaps 57;

Qy      127 IFFPLNIYDKDKGIFISFEIYCGLYDLQKRVNVALENGKEVYVVKDKILRYLT 186
      665 ILPFTDY-----MNEIIS-YQIKC-----KRNKLSHKEKRVASRI-YLICHT 709
Db      187 KEELIMGIDVGLRKIGVNSONDESSSHAILNIDKIDNKTSLGKIFIDLASERG 246
      710 HSKYI-----KSKNYQND-----FDENVSHKNDVAGSIY-EMEQNE-- 747
Qy      247 ADVTSQNKQOTGDGANINRSLALKEC-IRAMDKNHIFPRDELTKVARDIFVGSKS 305
      748 -----INEGERRDQ-----EMLGVDENENKNIENYHIDNASSEISN-KENCLIQNMS 796
Qy      306 IMTANISPTISCEQITLNTLRYSRVNFKKSKCINEEDDTTERSIID---SKGSE 361
      797 NNSINDIESITICSNV-----EIKMF-----NDPNTITITILEKSNYSYIE 838
Db      362 MNASSIENVYIKSNHLLNNNNN-----KIRGKINDK 394
      839 LTEVNDKDLV-GWLLSQNNKDMKELIHLCAIKKGNKAKARIPFYKINNNNSMFN 897
Qy      395 IERNN---ILKNKSFDPREGF---TSTF-----GRY---SSINDIDIKKKKKGLINY 440

```

```

Db      898 YHENNISTTYKNFSANLIEPSYFINTSEHEKDERDCKYLEASINDYMSDKKKR---Y 953
Qy      441 KS-----LYNDNTIRKKNNN-----NNNNNDNNNNNDNNNNNNNDSSSMVNNMI 487
      954 DSIESLRGSDKIKNDQIYQGGHSSLLYYYDNNNDNNNNNNMYDSSSSHNNYIILTNDKR 1013
Qy      488 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 547
      1014 LNN-DNFINNNLEINNSQNKVIEKOLEYIN-----NVKLTKSNSYQSNNTN---SKDH 1064
Qy      548 STPLAKKNIJDNIKLKNRSSCD-----NIMKKKNLHLARHVSGLTTFPSYDQKN 600
      1065 NISDSKKKEDTLNLSKSSYEYNNKILOSTSNKSLNGAY-----ENNLFSGKKKK 1116
Qy      601 KDTFFK---SNTKMEDNPKDILYSRVSMNGVLLGLKN-----THHDSIKDEN 653
      1117 K-GTVLKDIHINDIQDKPEDL-----NINCNAKVIEEKEHLPLEEYVNVSSDER 1170
Qy      654 HNDKINNGVINIINNSVNSINNSMNSINNSMNSIYKSNV---SNQISLSDVOI 709
      1171 FGLNKIK-----NDNNIYKQHQYHNLXDQNGKHILFPTNKVQSIQRNNNINSYIK 1223
Qy      710 RYVNEQTSNK---NNDN-----IFPDALSCDNNMYPN---ITNNNNNNNNNNNN 755
      1224 TNHYEVEKNNKQQRNYDFTCDKKKIYYNIINSDKDIYHNNIITYKNEKEGIGHLR 1283
Qy      756 NNIDVENYN--NRDGNNSMKIYA---YNSHLLFQDNNKTSNIONITNKQNDQGVN 810
      1284 NDKDITNELLKIDGKEFLDFFKDSYIDCHN-----KKNILNM-TNNKKEHQI- 1333
Qy      811 YSNMFCYMLNDKNLYLIDLNKEOKDKNIHGCDDNIIONRDNFEKKKKTFYNNNNIVIV 870
      1334 --IDVADKIFNETNMTMNNKIYDDKVN-----EKKCTNDVYIHHMDLI 1378
Qy      871 NNNMGNNSPRMKYGLCSHTSIDN-MKNNEK-----KNEMKDNEMKNIKSNNNNS 923
      1379 STSIRKNE-----ENLFIDTYQKNRIGDIYMRINILQEDDDDNHNNNNNN 1428
Qy      924 SSS-----SSNNIYNNINDDTFQ--NDCYCHNDVFTTRKKNNTNINSIYQNDI 974
      1429 NNNKILFEYTKNDQMLHNNKNKLEGEFEFSDFIEKKNIKIKKNNS-----YHKIDE 1482
Qy      975 IYTLNSLNDYMSNTLHFKEKYTYPLTSTNEDIYNKEMEGHRIRLDQDQKDDNDNNND 1034
      1483 SLLSNEKNNKVSLLIN-----ANKDSSVDMKNNKNNKNNKNNNNKNNNE 1526
Qy      1035 NNNKNVNDVNNVNDVNNVNDVNNNDKNVNDVNNVNDVDDVDFHNIKFNENN-----E 1086
      1527 NNNKNNKNNNNDSFSKDNLLINNDDNNNNNNNDSSKDNLLINNDDNNNNNNNNKVIKKE 1586
Qy      1087 YLSYQKN-----VDIINNCLNSLSDISMYD-TTEILNILLSKYKAEK 1131
      1587 IIDDEKNDIHKRDNIYRKDVSPILNNHPN---LNSRKORTIEPL-KIINGKKNLIK 1642
Db      1132 D-NVICKYINEDIKNNLSLEIDTAOSIYEKKFVLTLLKLLF--KQAVDTQ 1180
      1643 DLKTIQOYERKIRKTKTIQMDQENKPPSPKKNKMSINLIDIDDQNVDSQ 1694

```

```

RESULT 16
T18477
hypothetical protein C0495w - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 11-Jan-2002
C:Accession: T18477
R:Lawson, D.; Bowman, S.; Barrett, B.
submitted to the EMBL Data Library, November 1998
A:Reference number: Z18937
A:Accession: T18477
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-2523 <LAW>

```

A:Cross-references: EMBL:AL008970; NID:e1407852; PIDN:CA15620.1

C:Genetics:

A:Map position: 3

A:Introns: 148/3

A>Note: C0485w

Query Match 8.8%; Score 603.5; DB 2; Length 2523;
Best Local Similarity 21.8%; Pred. No. 8.6e-18;
Matches 360; Conservative 231; Mismatches 548; Indels 513; Gaps 78;

```

Oy 1 MNSKIKVVRKRPSELEKKKKSDITFVNKCTLYIDEPYKYVDMTYIERHFIYDK- 59
Db 772 LNSYQKGIYKLIETLNTEKIKINLIDITSDVNTKDTSLNVLTKEVNKKKGGPFPPNKG 831
Oy 60 -----VFDYVDFVNTIKPL- IIDLYE-----NGCVCSCFA 93
Db 832 EMCLENHEDVDIFG--EGKKKGIKRVVDYDKHNNNNNNSSSSNKKCCNCCSSSYD 889
Oy 94 YGOTSGKTI-----YTMLSQPYGSDTFCIGFYAAGDIFTPLNIYDKNTKGIPTSF 146
Db 890 KQKQKKQTTTEINILINSMCDINNTYHTNTSVIIKEDYDKIQQKISSKNDTFRNYSF 949
Oy 147 Y-----EIVCGKLYDLLQKKM-----VAALENGKKEVVKDKILRLTKELLILMI 195
Db 950 VFSLNMNTQILKKNLEMKKKNDLDMGCNEILKGENEIGMDPLMKIDQTNK--IVSKV 1006
Oy 196 DGVLLRKI--GVNSQNDSSRSHT--LNIIDKD--INKTSLCKLAFIDLASRGADTVS 251
Db 1007 DGSNFKKVDGINFNKTDGSNFKKIDGINFNKTDGINFNKT-----DGIN 1050
Oy 252 QNKQOTQDGANINR-----SLALK--ECIRAMDSQNHIPFRDELTKYLRIIFYGSKSI 306
Db 1051 FNK--TDGINFNKVDNINFKIKDEVEKYVDPLEPSHI--RDDMKKKKSKELLSSKOSI 1105
Oy 307 MIANISPT-----ISCCEQTLNTRLYSRV-----KNFKKSTCINEEDDTN 348
Db 1106 IISNIDTSHFEINLSRSEIQNEMCKENSFVQCLNKLILLEKEIKDEEKNLQNEILERS 1165
Oy 349 TERISILD--SKGSNNASSIENVVIXSNHLSNNNNKI-----NR-GKINDKERMIL 401
Db 1166 NWSIDIEDLDKDLINKESRD---IKYKHWIDINKDNVMYIYODKCRKRMKSQNKLL 1222
Oy 402 -----KNKSPDKPREGFTSTFGKSSLNDI--DKIKKKKKGLINVKSTLYNDNTINKK 454
Db 1223 IKKKRIKRNKHEKKK--IRFPFKLYKNDTHKCLRPFRVGHVVDKLDNDKTYMLKN 1280
Oy 455 NNNNNNNNDNDN-----NNDNN--NNNNNDSSSVNNMIMHMTNN-----NINNNTIV 501
Db 1281 EIRDVKGEDKGEDYFDFLNKDNNGNMENKKNVKNVKNVKN--VNNVVDVKNVNNVKNV 1338
Oy 502 NNNNNNNN-----NNN-----NSHNNHLQPPNY----- 524
Db 1339 NNVNNNVNVKDKVNNNEHIDKYNKKEVMIKKKGSNNVPHKGNKKKNVCNVDLGMHSIQ 1398
Oy 525 -AFTDTSDFS--LDDMNCHLNNDKSIPLHKKN-----LRDNIKLNNSSCDN 570
Db 1399 NHHITTSVSKFLCKMKNVYFDKSNNSIIEHKISNSIPRTMTCVASNITKENKNGN 1458
Oy 571 INNKKK-----NNILHARHSVSKLTWESYDPQKNKDTFPEKSNINKED--NTPEDILY 623
Db 1459 INVKGPATKALVNLKPLISKESKRAIT-----SSKKRD-----DNINVKKINTFSQKVS 1509
Oy 624 ESRNVSNNGNVLLGLNKRTNHD--ISTKD-----ENHNDKINNVINININS 670
Db 1510 EKRNNNNNNNNVLDGNKKNKNDDELFTKIKSTISKQKGNKNGTAKHKONINILND 1569
Oy 671 -----NVSIN--SNMNSINSNMSISIKSYNVSNO--ISDVOIRYVEMD 716
Db 1570 VHFKOPSLRELVTKKNKKNKKNKKNKKNKKNKKNKKNKKNKKNKKNKKNKKNKKNKKN 1627
Oy 717 TSNKNNNDIFDAISCDNNMYPN--ITN-----NNNNNNNNNNNNNNNNNNNNNNNNNN 770
Db 1628 IYRESBSDLY--VSCDEGCYKNGDIYNNEIINNVDNIHKIDKKNDID--YKDKSLN 1681

```

```

Oy 771 N-----SMKLYAVNSHNLFPDPN 788
Db 1682 NKKQKKQKGLIKLIPSSYTEKEKEKEKERRKKKKNYIPLTASRTVAVPINDTRKDV 1741
Oy 789 NK-----NT-----SNIQNINTKKNQDGNVSNMFCNYL----- 820
Db 1742 NKLHTLKRNCTVYCNVDNIQNKKKKGDDKNIKRD--QHVGLEKFLDEMSAMEKKKIK 1800
Oy 821 -NDKNYIIDLNNKQDKNHSGDNNIQNRNDFEK-----KKTNPYNNNNIYI 869
Db 1801 KDIINKKEDINKDKNDINKNDINKDKNDINKDKNDINKDKNDINKDKNDINKDKNN-- 1857
Oy 870 VNNMGNNSPRMKYGLCSHTSIDMKKN--EMKNNEMKDNEMKN-----HIKNNNN 922
Db 1858 YNNNSNNNNVVK--FSKHQNEKIKGNITYIRKHLQKGGKENIGLKKKIKERRNT 1914
Oy 923 SSSSSSSNNNI-----YNNINDDTFQNDYCHNDNTFTIRKNNNTIN----- 965
Db 1915 TIATKGDNIIDIKKQKKNKMIKNSKFG--CLNKQGTQIENKQMIISGKKTQNLV 1971
Oy 966 --SNYQNDIITYINSINDYMSNTLLH-----FREKTYPT 1000
Db 1972 RMKSKHQNKVEYNLNNISKELEKKKIKYKFKGKIKDIENMGNLKVSFDMKKKKSD 2031
Oy 1001 LSTNE-----DYNKEM--EGKH--IRLDQDXYDDNNNNVNNNNKNNVNNNNVND 1051
Db 2032 IKRKGGLLYEWNTKYTYNDGKELKMDSKRYKD--NIDCKNNNNCDJSKNNMCD 2087
Oy 1052 NNVNDNDKNNVNDNNVNDDDVDVFNHINKFNNNEVLSYQKQVDTIINNCLNSLDISM 1111
Db 2088 KN-----KNMCCDNKNNMCD-----KSKNN-----M 2109
Oy 1112 YDTRK--EILNILLSKYAEKONVYIKY--INEDIKNMSLEIDKTAQSIYERKVL 1166
Db 2110 CDDMKKEIEIVNIHTS-----NARQNKTKNEKIKNSREVMESYGDISTP----- 2157
Oy 1167 TKLLLFKRVVDQIINE-----TSDLRKDLVWCHICNNPDDQFHFAYASRL 1214
Db 2158 -----LKVNVNVNDIHIINDKHERICTKNNNPLHLIQPTNDDGDK----- 2202
Oy 1215 EKDIINILMLRQ-----IWCSEENLRLLYQFLVEYQKNSANSVLLNVSNNGDITLL 1267
Db 2203 KKNIVKFSVENRPPHYLLFKNDENKAYLEVMSVNVNKK----- 2243
Oy 1268 NKLIVQDNIKSMD-----HNNHKK 1288
Db 2244 -KKAQHNTIKIDVENSSPVHVPFHNIYK 2274

```

RESULT 17

T18489

hypothetical protein C0820w - malaria parasite (Plasmodium falciparum)

C:Species: Plasmodium falciparum

C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000

C:Accession: T18489

A:Reference number: Z18935

R:Lawson, D.; Bowman, S.; Bartell, B. submitted to the EMBL Data Library, August 1997

A:Accession: T18489

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-4981 <LAW>

A:Cross-references: EMBL:Z98551; NID:e1331903; PID:e1331910; PIDN:CA11128.1

C:Genetics:

A:Map position: 3

A>Note: C0820w

Query Match 8.8%; Score 601.5; DB 2; Length 4981;
Best Local Similarity 20.3%; Pred. No. 2.1e-17;
Matches 313; Conservative 256; Mismatches 457; Indels 519; Gaps 75;

Oy 17 LEKKKOSDI-----ITVKNKCTLYIDEPYK--VDMTYIERHFIYDK--VFDD 63

Db 1270 IINDVLSKDDKFKEMINSKE--INIKDFCKVDKNNDICLN--LNELNKQSY-----NSNT 1320
Qy 1203 DDQ---PFFAYSRLEKDIILIML-RQIMCESENRL-----YOFLAVEYQWKA 1250
Db 1321 TEKIDIDHDPDYVE-NKDVHDKIHEDKREYCDSEKATKYLPAADDIKKRSRSTIKKSKRE 1379
Qy 1251 NSVLLNVSNNNGDIILNKKLIVQDNINSMDN-NIH 1286
Db 1380 N--FLIISYMNIEIYFLIKKLKVEIPEPSIILNKGMH 1414

RESULT 20
H71621
serine/threonine-specific protein kinase (EC 2.7.1.-) PF80150C - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 10-Sep-1999
C:Accession: H71621
R:Gardner, M.J.; Tetteh, H.; Carucci, D.J.; Cummings, L.M.; Aravind, L.; Koonin, E.V.; Pertea, M.; Salzberg, S.; Zhou, L.; Sutton, G.G.; Clayton, R.; White, O.; Smith, H.O.
Science 282, 1126-1132, 1998
A:Title: Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
A:Reference number: A71600; MIMD:99021743; PMID:9804551
A:Accession: H71621
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-2485 <GAR>
A:Cross-references: GB:AE001376; GB:AE001362; NID:g3845108; PID:AACT1820.1; PID:g384510
A:Experimental source: clone 307
C:Genetic8
A:Gene: PF80150C
C:Superfamily: malaria parasite serine/threonine-specific protein kinase PF80150C; protease F;2087-2352/Domain: protein kinase homology <KIN>

Query Match 8.6%; Score 587; DB 1; Length 2485;
Best Local Similarity 20.5%; Pred. No. 4.1e-17; Indels 616; Gaps 85;
Matches 356; Conservative 249; Mismatches 517;

Qy 21 KKSDIITVKNCTLYIDEPYKVDKTYERHEFIVDKVFDPTVDNFTYENTIKPLII 80
Db 359 KENINISNKEC--HDEK---EBEKIMYNSLVEE---KKOKKIMNSLNLVPI 407
Qy 81 D-LYENG-----CVSCFAYGQTSGKTYTLGSPGOSDTPGIFQYAGDIPTFL 131
Db 408 DILLKNGHDEINKEICKKKKSPFSQNDIKSKMLYNNKSYSKSEKV----- 453
Qy 132 NIYDKONTKGIFFSFEITYCGKLYDLQKRKVAALENGKEVYVVDKLTLYLVEEL- 190
Db 454 -LYTNKNKSNFTPIPIF--FLNKVGDKFKNSENIYDMYNNKNVYIHDKKIYTMYSNKLK 510
Qy 191 -----ILKMIQGLV-----LRKIG 204
Db 511 QKHYTSTSNINLNNYNGKVLNGLHLSNNMYCRLSNPPYKISILINNVPFYKRRKS 570
Qy 205 VNSQND-----ESSRSHAILNIDLKINKNTSLGKIAFIDLASERGADTVSQNK 254
Db 571 SNNNNNNNNISSSSSSSKNHYIN-----KISSYNIHYER-KDSFKN- 616
Qy 255 QOTDGNINRSLALKECIRAMDSDKNHIPPDSLETYKLRDIPYKSKSIIITA--N 310
Db 617 -----FLFFKE--KILPSKQDTCVFNERQ-----KDLFEKSNHICVSSFPN 657
Qy 311 ISPTISCEQGT-----LNTLRYSRVKNF---KNSCTINEDDPTNTERISILDS 357
Db 658 TSDDISHSVKNKEPFALKNNISIRHIPPENNIITYSGKS--FNHVQD--KERTVLKK 713
Qy 358 KGEEMNASSIENVVYKSN--HLSSNNNNKINRGKINDKI-----ERNILKKNKSPDKR 410
Db 714 KKEINDKNTFSSGCLINNITTYTLQNGVKNLMLGIRDSITYKIDENNNMLKS----- 766
Qy 411 EGTSTFTGKSSSLNDIDKIKKAKKGLINYSKTLVNDN-----TINKGANNN----- 458
Db 767 -----CYNGNDSNNKKKKKKCL-SFSCDIINDNITPYESDKKNSNNIKSMIDIF 817

Qy 459 -----NNNDNDNNNDNNNNNNNDSSMV--NNMINHMINNNIN----- 497
Db 818 NYKRSNLYNNLSSNRDSTVDMENKYNSEYINIOETKIYELSKRIANRYKLYSMDEI 877
Qy 498 -NINVNN-----NNNNNNNNNNNNHNLPPNYAFTDTSDFSLDDNCHLNNDKSIFLH 552
Db 878 FKVSLKEKKYIDNISNNMERVYKNEH--INEKISMDIDILYPCDKKSLNMSCPVY--- 932
Qy 553 KKKLRKNI-KLNRSSCDNINKKK-----NHLAHSVSKLTMSYDPQRK 601
Db 933 ---IENNISRERENKSSVILNKKKNEMFNCGVRLCHMGK-----MNNQ 975
Qy 602 DNTFFKSNINKMEDNTPKDIYESRVSN-ANGVNLGLNKQTHHDI--STKDEHHNN 657
Db 976 DNIYDGNIKKBEETTKDEYISREKQKYSKICRNDDYKQVLSYHTLDEBKKN 1035
Qy 658 KIN-----NGVINII-----NNSN----- 671
Db 1036 DMNNLIDMNNNEAIETVNGVINIILDRKDNSSRKOMEKEMEKEKEMEKEMEKE 1095
Qy 672 -----VNSNNNSNNNSNNNSNNSTYKSN--YNSQISDVQIRVYNE-- 714
Db 1096 MEKMEKEVEKELKQEMNNRNNNNNNEMKBNINIKNNEIYVDN---DKELIYNEBK 1151
Qy 715 -----MDTS-NKNN-----DNIFPAI--SC-----DNNYPIUTNNNNNN 747
Db 1152 KLIYFPNYSDVHAKNNNSININCKCDYNNILKEVDNSCLAQKEENIFRPLNLKKD 1211
Qy 748 N-----NNNN-----NNNNIDVENYNNRD----- 767
Db 1212 KWKRPNIKNNIKTIHHEEMKRIYQINIKAVFPIYFNRYENPLINHLTYFPKNDLFX 1271
Qy 768 -----GTNNSMGLYVNSH--NLFOPDN--NKN-----TSNQN----- 797
Db 1272 LSKYKSMNIRNLVLANKHINNYYDMKLYNQNTYTLKYQVANDNDHILCKKGGLDY 1331
Qy 798 INTN-----KNNQDGNVYNSMFCYH-----LNDK-----NYLIDLNNEQKDN- 838
Db 1332 IMMNISKECRNKD--KTYLNLFIYKKKKDARFINDETSGNDMYDIKKKYSNDENNY 1389
Qy 839 -----IHG-----CDNNIIQNR-----NDPEKK 857
Db 1390 KLNEMKNISMSDEMIPTLNGEHNFPSCQPNLEKKSITYIDLNDVDSNMDP-TEE 1448
Qy 858 KTFNYYNNNIVYVNNNNKNSPRMKYGLCSHTSIDMKKNEMKONEKD----- 908
Db 1449 KTFNVNENDLF-----NTKRWKF--NFSKGKULFNKFPNVSNEDEVSPFFKYM 1496
Qy 909 NEMKDNHISKNNNNSSSSSSNNNLYNNINDDGTFQNDYCHNDNFTIRKKNNTINSNI 968
Db 1497 NLFRELANSNNLSLKESVYKSNNSCSN--KGDNDIGNENNNNTVTTIASDEHISTKGI 1555
Qy 969 Y-----QNDDIYITINSNDYMSNTLHPEKXT-----YPTLSTNEDIY--- 1008
Db 1556 HDESPRDNDCTILKIGRSKYSIDITLYNEDKSNLENDFTINEYVCSNIDNEME 1615
Qy 1009 -----NKEGKHILDDODKYDDNDNNVNNNNKNNVNNVNNVNNVNNVNN 1057
Db 1616 DRYNGTCSVSGKETEKKNNEKNEKNEKNEKNEKNEKNEKNEKNEKNEKNEKNEKNEK 1674
Qy 1058 DKNNVNNNDND--DVPFHNIKNPNNNEVLYSQKAVDTIINNCLSLDSSMYDPTK 1116
Db 1675 EENNEENNEENNEENNDIEKNDIKONNSQO--VKENI--IVNNNTNMDVDN--DDN 1726
Qy 1117 ELINNI-----LISKYAE-----KDNVYKYYINDIKMSD-----E 1149
Db 1727 NNNYVVSDEGIDIDIKIKSEKNDYIYNDNIMIKNNKSIDLMNINKQKNPFLNTNEK 1786
Qy 1150 EIDKTAQSY-----EKRVLLTKLLLFKNV-----DTQINNET 1185
Db 1787 DIHMSNSSYVNDKQNLFNNEKTEKNTSLNDLYRKEBELDEKISEYKDTVLTNT 1846


```

Db      1308  IKGRVYKINNLVIRKRELFIYH-KCLVIMKLEKKKKKKYDNGKN---DIDINTICM 1363
Qy      185  LTKBELIKMIDVLLRKIGVNSQNDSSSHAL--NIDLKDKINTKTSIGKIAFIDLAG 242
Db      1364  IDOKKL-----DNEKIKMELIDITVANKKDCSN-----MVD 1397
Qy      243  SERGADVSONKOTOTDGANINRSLALKECIRAMSDKNHIFPRSELTQVLRFVGR 302
Db      1398  DEKNEDOTSNNTITSNG-KINNVVLKMYIILND-----ECKL----- 1437
Qy      303  SKSIMANISPTISCEQTLNLRYSRVKPKKSTCIN-----E 343
Db      1438  ----NIDIFSCIIKSCYTFDPFSNELYYLEKILCSNFVVRNSHISIDIVYSSNY 1490
Qy      344  EDDNTERISILDSKSEMASSISENVIKSNHLS-----NNNNKINGKINDKIER- 397
Db      1491  KDITCSISLNFLENDNNNNNNNIKNELPKSNEMIQKEILNNNHTEPKKENDMTTPF 1550
Qy      398  ---NNILKNK---SFDKPREGFTSTFGKYSSLINDIKIKKKKKGLINYKSTLYNDT 449
Db      1551  STGNDILKILLFDISGNNPDIICINIFIK-----EKNLYILEKKSITNLK 1600
Qy      450  I---NKKHNNNNNNNDNNNDNNNNNDSSVMNMIMHMIN-NNINNNIVANN 504
Db      1601  LICLTFEHHNFYILIKTEHRLKTHFLIMDPSMLFDIQENLFTINLICDOLYINN 1660
Qy      505  NNNNNNNNNHNNHLPQPNYAFDITDPSLDMNCHLNNDKSIPLHKLNADNIKLN 564
Db      1661  NNNNNNNNNCLCILHPEY---YSQIIIPYLTCKNNKNVNDVSFKK---NFFKK 1713
Qy      565  RSSCDNIMKKKN---LHILAR-HSVG---SKLT---MFSYDPOK---NKONTF 606
Db      1714  FKDDHILRNKQYNGSFLNIQDHSKGLVERGDKITRDLLSFSQYTSILANQVF- 1772
Qy      607  KSNINKEADTTPKDI-LYESRNVSN-NGVVLGLKNKTHDISTKDEHNDRKINNGVI 664
Db      1773  ---IDNDE---BDLFIYFLANCLINPNI-----TNNVNS---QYND-KISD-L 1813
Qy      665  NIINNS------VNSINN-----SNNGI---NNSNMS 690
Db      1814  NKTKNKKEERSFWSSSLKLLTKFDEEIFSTNDLRVEEYEMFISNLYILKKNKTISS 1873
Qy      691  NSIYKSN-----YNSNOSIDVQI-----RYNEMDTSNKND---NIF-----F 727
Db      1874  EVFFPSEYFLPYLYNLFEFLRTGLWLTGLRKADYDTINLRANDRNICNVQYITAK 1933
Qy      728  DAISCDNNMYPNITNNNNNNNN-----NNNNNNNIDV-----ENYV 764
Db      1934  NSKSWDQNPPEVYNNMTDENNTTTTKKKDDNDQNDIYIHLIMNIYVRTLTYERLN 1993
Qy      765  NRGCTNSMKLYA---YNSHNLFOPNNAKQTSNIQUNINTKANODGVNYSNPFCHYLN 821
Db      1994  NDRKINNARKKYEFTFTNMDIDFPDDN--NCINIMINVEDKKE-----NIK 2037
Qy      822  DKAVYLDIANKKEDKDY--IHGCDNNTIQNRNDEPKKKKTFYNNNNIVIVNNMGNNNS 879
Db      2038  DLTKKLTKEGKGVNDEFIQVTDNHI-----EINPKKTSSTQNEO---PNTINTING 2090
Qy      880  PRMKYGLCGSHTSIDNNKNEMK-----NNEMKDNEMKDHKISNNSSSSSSNN 931
Db      2091  NMATYSILNSTLTILNNIHLKRWKYLINTYCFNNYIMFFQTQNKVLLNRILKKAFLRS 2150
Qy      932  NIANNINDDTF-----QNDYCHNDFTTRKKNNTINSNIY-----QNDIITYIN 979
Db      2151  LKDDDFDIKSYKRYKVEINYC--DSNY---KNNKADTAQOYIHLKEDQKEKELINF 2204
Qy      980  SLNDYSNLT-----LHFEKRYTPTLSTNEDIYKKEGKIRLDODKY----- 1025
Db      2205  HIINYSNNIWSQIHL-----LTHGISLY---FENVGEVDEEDAMFYCLQKKKI 2253
Qy      1026  --DD---NDNNVYDNNNNKNVND--NVNND--NVNNDVNDKNNVNDNNVNDDDVDFH 1077

```

```

Db      2254  NEDDNKNGDNKNGDNKNGDNKNGDNKNGDNKNGDNKNGDNKNGDNKNGDNKNGD 2313
Qy      1078  -NIKFNENNEYLSPQKAVDTIINNCLNSLDSISMYDTR-----EILANNILSKY 1127
Db      2314  GANNKGGD-----KNCDD-NKNC---DNNKCDNKNISDGEVCEBSRKLLIY 2361
Qy      1128  KAEKDNVIR-----KYINEDIKNMSLEIDK---TAOSIYKRV-----L 1165
Db      2362  ---KDNILKENCEINCSLNIYKYIRIWLRLKLOVDVFCILNEVINDKKKICEFSSL 2418
Qy      1166  LTKLLILFKKAVDTQINETSU-----RKDLVWCHICNNPDDQFHYVANS 1212
Db      2419  VNSVLSYEHSHDFWLKNTDVLCSPIETOPTLEBEKQVINDNNNEKSDLFLKYKN 2478
Qy      1213  R-----LEKDIINILMRQIWCESENLRLVQPLVEYONKSANSVLLNVSNNGDI- 1265
Db      2479  KKKETKYNDKKFEIIL-IFPIIKEGEEKNLMDNLIKI-NKNDIKIDYNDMANSMDIIT 2536
Qy      1266  -----LINKLVODNIKNSMDHNI 1285
Db      2537  NEDDKYLSNYINNNT--KNIKNIKNNNDV 2564

```

RESULT 23

```

T18402
asparagine/aspartate rich protein - malaria parasite (Plasmodium falciparum) (fragments)
C:Species: Plasmodium falciparum
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #ext_change 09-Jun-2000
C:Accession: T18402
C:Barale, J.C.; Candelle, D.; Atsal-Bonnefoy, G.; Dehoux, P.; Bonnefoy, S.; Ridley, R.;
Infect. Immun. 65, 3003-3010, 1997
A:Title: Plasmodium falciparum AARP, a giant protein containing repeated motifs rich in
A:Reference number: T18929; MUID:97378065; PMID:9234746
A:Accession: T18402
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-3844 <BAR>
A:Cross-references: EMBL:Y08926; NID:e1154302; PID:e111435; PIDN:CAA70130.1
C:Genetic8:
A:Gene: aarpi

```

```

Query Match      8.5%; Score 581; DB 2; Length 3844;
Best Local Similarity 20.7%; Pred. No. 1.2e-16;
Matches 315; Conservative 224; Mismatches 474; Indels 502; Gaps 63;

Qy      45  DMTKTYERIEF-IYDKVPDPTVDNFTVYENTIKPLIIDYENGVCSCRAYGOTSGKTY 103
Db      898  DMVVELEIHHIKMAKIFSDIYTKSTVDS----- 928
Qy      104  TMLGQPVGQSDPTGIFQYAAADIFPLNIYDKONTKGFISFEYIYCGKLYDLQKRYM 163
Db      929  -----KIHIIYFOFFYI-----IIRLFNELYILEYNSIRKTSY 964
Qy      164  VALENGKKEVVKDLIRLVLTKEELIKMIDGV-----LARRIGVNSQND 210
Db      965  EKYLEGKVAH--VKKI-LIQLLASQDFQGEJENVPKQFRHHPSEYELVNNKYGYKTHMP 1021
Qy      211  ESRSHAILINTDLKDKNTKTSIGKIAFIDLASSEKADVSONKOTOTDGANINSLAL 270
Db      1022  RS-----NVALIKLNKMSWLYDAFWPL-----SAFKQFOT-----AN 1054
Qy      271  KECIRAMSDKNHIFPRSELTQVLRFVGRSKSIMANISPTISCEQTLNLRYSR 330
Db      1055  EKCIKEENS-----YIGSR-----BEDKEYLNFSTR 1082
Qy      331  -YKN---FNKSTC-----INEEDNTERISILDSKSEMASSISENVIKSNH 376
Db      1083  KYQNLLEFYFKNSCLVSIILLIYIINDEFQRIEKKKKELEKEEKKKHMKADVTGEDDS 1142
Qy      377  LLS-----NNNNKINRG-KINDKIERNNILKKNKSDKPREGFTSTFGKYS--LNDIDK 428
Db      1143  LNKQKGTNNNTCDGVAVINEANRSS-----GMSQNVVYTESGINNNNDV 1190

```


Db 1226 KONTLFIKOKKCAL-----DLOYINKRK-----NANYEYENYINNYI 1267
 Qy 80 IDLYENGVCSCFAYGOTSGKTYTLMGSOYGOGSDTPG-----IFQYAGDIF----- 128
 Db 1268 LHLV-----TSFKKYYAMKQEDDMKDDKNNELMTYLIIKHSSGLFKPIR 1314
 Qy 129 ---TFNLVYDKONTKGIFFISFYEYICGLYDLLQKRWAALENGKEVAVVDKILRY 184
 Db 1315 IKGRVYKINLVDYKRELFYH-KCLVIMKLEKKEKKKKYDNGKK--DDINICM 1370
 Qy 185 LTKELLIKMIDGVLLKIKIGVNSQNDSSRSHAL--NIDKOLINKTSLGKIAFIDL 242
 Db 1371 IDOKRL-----DNEKIKKMEIIDTVNMKDCSN-----MVD 1404
 Qy 243 SERADTVSONKOTQOTOGANINRSLALKECIRAMDSDKHIIPRSEDLTKVLDFV 302
 Db 1405 DEKQEDTSNTTISNEG-KINMWVLIKMYILLND-----ECLKL----- 1444
 Qy 303 SKSIMANISPTISCCEQTLNTLRYSRVKNFKKSTCIN-----E 343
 Db 1445 ---NILDIFSCIISKCYTFPDSNELLYLENKILCSNVVANSIHSDIYYSN 1497
 Qy 344 EDDNTERISILDSKGBMAASJENYVYKSNHLS-----ANNKINKGKINDKIER- 397
 Db 1498 KDITCSISLWFLANNEYNNNNNNNNIKNELPKSNEMIQKEEILNNHNTEFKQNRDMTPF 1557
 Qy 398 ---NNILKKN-----SFDKPREGFTSTGKYSSLNDIDKIKNKKKGLINYKSTLYND 449
 Db 1558 STCDILKLLFLDISFNPIDCINNIFIK-----EKNMLYILEKKSISTYLK 1607
 Qy 450 I---NKKHNNNNNNNDNDNNNDNNNNNNNDSSSVNMNINMIN-ANNINNNIVANN 504
 Db 1608 LICLYEFHNFYILIKTNEHLAKTFPLIMDPSMLFDIYENLFTINILICDOLYINN 1667
 Qy 505 NNNNNNN-----NSHNHL-----519
 Db 1668 NNNNNNNMLCCLILHPEYSSQIIIPYLTCYNNKNVENDVSFKKQYFFKQFKDIDL 1727
 Qy 520 POPY--AFTD-----TSD-----FSSLDMMCHLNNDKS-- 548
 Db 1728 KQYNGSFLNIQDHSKGLERDKITRDLLSFEVQYTSINNQNVEFIDNDEEDLF 1787
 Qy 549 --IFLHKKRLDNIKLKRSSCDNI-----MNKKNNLHLARHSVSKLTMSYDPOK 600
 Db 1788 IYFLANVCNL-INFINNNNVSOYNDKISDLNTKA-----KN 1825
 Qy 601 KDNTEFSKINKEEDNTPKOL-----YES-----RNVSNNGNV----- 635
 Db 1826 EERSFWSSSLKKLTKFEDEEFTNDLRVEEYEMFISNIKYLKMKKIISSVEFFSP 1885
 Qy 636 -----LGLKNTHHDSIDDEHNN-----DN 657
 Db 1886 YFLPTVYVNFELRTGLVTLGLKNDYTDINLKNDRICNVFOYITAKKNSKWDN 1945
 Qy 658 KINNVGININNSVNSINNNSNNNSNNNSN-----SIYKSYNSQSI 704
 Db 1946 QPNEVQNM--NDENNTTTTKKKKDDNDQNDIYIHLIMYVNTLYTEELANDRK 2003
 Qy 705 SDVOIRYVEMDTSNKNNNIFPDALSCN-----N 735
 Db 2004 SNARKY-----EFHTMDDIFDNDNCININIVEDNKEENIKOLKYKKLKTNBEVEKVD 2059
 Qy 736 MYPLITNN-----NNNNNNNNNNNNIDVENYNNRDG-----NNSMK----- 774
 Db 2060 EFOVTDNNNIEINPKKKTSTONEBOHININENGMWYISLINSTLTNNHMKRWY 2119
 Qy 775 ---LAYNSHL--FQPDNNKNTSN-----IONINTKN 803
 Db 2120 LINTYCFNNYIMFQOTQNKYILNRRLIKKAFRLSKLPDDNDIKSYKKVKEINCDN 2179
 Qy 804 NQDN-VNYSNMFCHYLANDK-----NYLID-----828
 Db 2180 NHRKKNKDTAQOYIHYLKEDEKELINPDHIIYMMSDNIWVSQIHYLTHGISLYEEN 2239

Qy 829 --LNKE-----QDKNIGHGCDNNIIQNRNDPEKKKKTNYNNNNIYVNNMGNNSP 880
 Db 2240 EBYDEEDAFYCLQKKKKTNGDNNK-----NGDNKNGKNGKNGKNGKNGKNGDNN 2295
 Qy 881 RMKYGLCSHTSIDNNKNNEMKNNEMKNNEMKNNISNNSSSSSSNNNNIYNNIND 940
 Db 2296 NGDNKNG-----DNKNGDNNKNN--GDNNKNGDNNKNGDNNKNGDNNKNGD--NKNGD 2346
 Qy 941 DTQNDYCNH-DNFTIRKKN--TNINSNIYQNDIITYINSLN-DYNSNTLHREK 996
 Db 2347 NKNNGKNGKNGKNGKNGKNGKNGKNGKNGKNGD-----NKNGDNNKNN 2392
 Qy 997 TYPTLSTNEDINYNKEMGKHRLDDODKYDDNDNNNNNNNNNNNNNNNNNNNN 1056
 Db 2393 -----GDNNKNGKNGKNGKNGKNGKNGKNGKNGDNN--KNCD--DNKNGDNNK 2442
 Qy 1057 NDKNNVNNNNVNDND-----1072
 Db 2443 DNKNGDNNKNGKNGKNGKNGKNGKNGKNGKNGKNGKNGKNGKNGKNGKNGK 2502
 Qy 1073 --DVD-FHNK-----FNN--NEVLSYQ-----KNVDI----- 1097
 Db 2503 LQDVDFCILEVINDKKEICEFSSLVENSYSYEHLDVWLSKTTDVLCSPIETOPT 2562
 Qy 1098 -----IINNCLNSLDISSM-----YDDTK--EILNNILSKYAEK-----D 1132
 Db 2563 LREKQVINDNNNNKSLFLKYKKNKKEIKYNDKTEIILIPITIEKEBEKYLND 2622
 Qy 1133 NVIKKYINEDIK-----NMSLE--EIDKTAOSIYERKAYLTGLLFFKQVDTQIN 1182
 Db 2623 NTL-KYKNQDKIDVDYNNNSMDIINKEDDEKYLNSYNNNI--KNIKIKNNDVQNS 2678
 Qy 1183 NETSDLR-DLVN-----CHICNNPDDQFHYAASRLKEDILNLMRQICESENL 1236
 Db 2679 NMSNYKNIDIMTLNALSVCVN-----YNNIK--INVKRYMPC----- 2717
 Qy 1237 LYQFLVEXQ-----NKSANSVLLN--VSS-----NNGDILLLKXVLQDNKMSMDN 1283
 Db 2718 --PFKIISYNNKDLIKKNDSDIISFOISSLPVKNLKQVYINNEPFIPLVTHIDL 2775
 Qy 1284 NIHK 1288
 Db 2776 VAHER 2780
 RESULT 28
 B71612
 hypothetical protein PFB0555c - malaria parasite (Plasmodium falciparum)
 C:Species: Plasmodium falciparum
 C:Date: 13-Nov-1998 #sequence_revision 13-Nov-1998 #ext_change 21-Jul-2000
 C:Accession: B71612
 R:Gardner, M.J.; Tettelin, H.; Carnucci, D.J.; Cummings, L.M.; Aravind, L.; Koonin, E.V.;
 ; Pertea, M.; Salzberg, S.; Zhou, L.; Sutton, G.G.; Clayton, R.; White, O.; Smith, H.O.
 Science 282, 1126-1132, 1998
 A:Title: Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
 A:Reference number: A71600; PMID:99021743; PMID:9804551
 A:Accession: B71612
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-3973 <GAR>
 A:Cross-references: GB:AE001402; GB:AE001362; NID:g3845213; PIDN:AACT1900.1; PID:g38452;
 A:Experimental source: clone 3D7
 C:Genetics:
 A:Gene: PFB0555c
 C:Superfamily: Plasmodium falciparum hypothetical protein PFB0555c
 Query Match
 Best Local Similarity: 20.6%; Pred No. 6.5e-16;
 Matches 352; Conservative 246; Mismatches 541; Indels 573; Gaps 82;
 17 LEKKKKSDIITVKNCTLYI-----DEPRYKV-----DMTK-----YIERHFIYD- 58

C:Genetics:
A:Gene: SGD:KIP1; MIPS:YBL063w
A:Cross-references: SGD:S0000159; MIPS:YBL063w
C:Superfamily: kinesin-related protein KIP1; kinesin motor domain homology
C:Keywords: ATP; coiled coil; microtubule binding; mitosis; nucleotide binding; P-loop
F:53-416/Domain: kinesin motor domain homology <KMT>
F:141-148/Region: nucleotide-binding motif A (P-loop)
F:147/Binding site: ATP (lys) #statue predicted

Query Match 8.2%; Score 561.5; DB 1; Length 1111;
Best Local Similarity 22.9%; Pred. No. 2e-16;
Matches 255; Conservative 204; Mismatches 393; Indels 263; Gaps 48;

QY 2 NSKIVYVVRKRLPSELEKKKSDITV--KNNCTLYIDEPRYKVDMTKYEIRHEFLVD 58
Db 50 DSNIHVVYVCRSRNKRKEIEKSSVISTLTPQGEKILLNSGSHSYSSSK--KTYQF--D 105
QY 59 KYEDDTVNFYTYENTIKPLIDLYENGCCSCGPAVGQTSSGKTYTMLG-----S 108
Db 106 QYFGASDDETVFNATKAYIKEML-HGVNCTIFAAGQDTGKTYTWSGINILGDVOST 164
QY 109 QPYGSDPFGIFQYAAAGDIFFTFLNIDKNTKGIFFISFYEYIGKYLDDQ----- 159
Db 165 DNLLEGHNGIIPRYVLDLFKELSLANKES--VKISFLELYENELKDLSDSDDDPAV 222
QY 160 ---KRM--VALENGKEVVVDKILRVLTKEELIKMIDGVLLRKIGVNSQNDSSRS 215
Db 223 NDPKQIRIFDNNNNNSIMVKGMQEIFINSAHEGINTLMQGLSKRVAAATKNDLSRS 282
QY 216 HALNL-----DKD--INR--TSLGKAFIDLAGSEGADTVSQNKQTQTDGANINR 265
Db 283 HTVFPTITNIVEDSDKHQGNKPFVKGKLNVLADLASEINNSGANKQAQEAGL--INK 341
QY 286 SLATLKECIRAMDSDKNHLPFRDELTKYLRDIFVGSKSIMANISPTSCCQOTNTL 325
Db 342 SULTIGRYNALVDHNSHLPYRESKTLRLDQSLGCKTTCIATISPAKISMETASTL 401
QY 326 RYSSRVKFKN-----KSTCINE-----EDDTERISILDSKSEMA 364
Db 402 EYATRAKSIKNTPOVQNSKDTCLKDYIQEIKLRNDLNSRNKQGIPTQ--DQLD 458
QY 365 SSIENVVTKSNHLLSNNNNKKINRGIN--DKIERNNILKN-----KSPKPEGEF 413
Db 459 YESNSILDEQMLKHNLEQIKKPKENYLNQDINLLQSEKELAIQNFVDFPSNF 518
QY 414 TSTPCK--YSSLNDIDKIKKKKKGLINKSTLYNN-----TINKHANN 458
Db 519 YSEIQKIHTHTJELMNEVLIQORPSELENSQKQ--YNTQNNQOLKISQVLOTLLNTLQSLN 577
QY 459 NNNNDND-----NNNDNNNNNNNDSS--SMVNNMIMHNNNNNNNN--NVNNNNNN 507
Db 578 NYNSKCSSEVIKGVTEBELTRNVVTHKAKHSTLSKLSLNTITNLNQNQLVRSISTLEI 637
QY 508 NNNNNNSN---NHLPOPNYAF-----TSTSPSSLDDM--NCHLNNDK 547
Db 638 FQSDSTSHRKDLNIEYQHQOFLKNLQNDIKSLDLSIGSSITLSINEISQNTTNLSM 697
QY 548 SIFLKKNLNDIKLKNRSSCNIMKKKNL-----HAR-- 583
Db 698 NVLINQOQSGSKLIEQ--DLEIKLKNLIDINERRISQNFQOQLAEMKRYPODHVRT 754
QY 584 ---HSVSKLTMPFSYDPOKNDKNTFFKS-----INKMEDTTPDILYESRN-- 627
Db 755 RSEFDELANKCIDNLKDKQSKLDQDIWQKTASIFNETDIYVNNKIHSSIASLHNAENTL 814
QY 628 ---VSNN---GNVLGLNKTTHDIDSTK---DENHNDKINNGVINIINNSVNSINNS 678
Db 815 KTVSQNNSEFTNDLISIRGMNDISSKLSRLPINEFLNKISQICETCGDDNTIA--SNP 873
QY 679 NNNNSLNN--SNMNSNGIYKSNYNSNOSISDVQIRYVNMCP--SKNNDNIIFPDALSCNM 736
Db 874 VLTSTKCFQNIICSDALTNEKIMSLIDEIQ---SQIETISNNNTNL----- 918

[illegible]

[illegible][illegible]

```

Db      1236 ENIIFKIKNHONIKESTRIYHVFLKLFPHNLFICTNNSTYTTKMLHPLQNIQFY 1295
Qy      551 LHKKNLR-DNIIKLNRSSCDINMKKKNLHLARHVSGLTWESYDPOKKNCTPFKSN 609
Db      1296 RYKKNIFETNNQKIYNTYIHNKYEKIQNFNNKSYVINDMOSLYLYDTQDNRIIMST 1355
Qy      610 INKME-----DNTPKDI-----LYESSNVSNNM----- 632
Db      1356 ILSLIFKNIIIPKCDNHKSFPLFFHYAKYLIHYONGSNQFINTYVPODVNNINILHC 1415
Qy      633 -----GNVLG-----LNK-----THHISTK 650
Db      1416 TKKKRPGRGSTPDEKYGGELKGGDIIKESDIKCDNIKESDVVYVKNELIVERNIIIEK 1475
Qy      651 DE-----NENDKINGVINIINNVSINNNSINNNSNNS--TYK 695
Db      1476 DEIKTDKTEPIKIDNTSDAKSISTSTSVLSSESNLSPOCANKLTKEMENANVITK 1535
Qy      696 SNYSNOSISDVOIRYVEMDTSKNNNDNI.FDAISCDNNMYPITNNNNNNNNNNNN 755
Db      1536 NNNNDNN-----NENNENNENNND-----NENNENNNDNNNNNNNN 1570
Qy      756 NNIDV-----NENNENNENNND-----ENY 764
Db      1571 NNEVEYKPYKINGLQNIINSCLNFCSKKNIKKIKKIKKIKKIKKIKKIKKKN 1630
Qy      765 NR-----DGTNNSMKLYVYNSHNLFPDNNKNTSNIQNIINTKNNQDGV--NYSNMF 816
Db      1631 TRHRGNQIINKVLVNIITPYILRYPNNNSSKSLCTKIKKIKKIPRICESDIDKND 1690
Qy      817 HYNLDKNY-LID-IN-NKQKDKNHGCDNNIIONRN-----DPEKKKTKFY----- 862
Db      1691 IHVNNKGYKKIDDTLVHKEIDTSKQHTDEKICKIKQKYLVDYVRKAYISLYMYNKK 1750
Qy      863 ---NNNNIYVNNMGNNSPRKMYGLCSGHTSIDMKNNEMKKNEMKKNEMKNDHKSN 919
Db      1751 KGGDTNNKNIQKKKKKEKKKSYNISKHNSI--LNNRMKKNIIIDMYKKNNFYK 1807
Qy      920 NNNSSSSSSNNNIYNNI-NDDDTPOND-----YCHNDN--TFITIR 958
Db      1808 DN-----YKIIYYDELNDINISYLIKQINILNTIIGMKNVGTFLSK 1855
Qy      959 -KONTNINSNIY-QNDIITYINSND-----YMSNTLHFEKTYTPTLST 1003
Db      1856 IENNIIIDIDEYLKDEIKFDKLSIDFRYEEVYTFISLYLAFYILTFPRNLSAPRDT 1915
Qy      1004 NEDITYKMEGKAIRLDDQKTDNDNNNNVNDNNKANNVDN-NVDNNVNDNNVNDNNKN- 1060
Db      1916 GATIKHVIDEIKINSKQKQTEYDNDINDNNNNYNSDNHNLHNNKDNQHTSTYKQIQ 1975
Qy      1061 -----NVDNNNVNDDDVDPHNIKFNPNNEEYLSYPOKNDVTIINNCLNSI--- 1106
Db      1976 KKVSPSVCETIYVDGPFEN-----KNDNDNIFYTYNKGI-TFYNNKINDPFCK 2024
Qy      1107 -----DISM-----YDTKEIL-----NNILSKYAEKDNVYK 1138
Db      2025 IAKKCIQEKQNGEHQNTVITVIGGIIIEFDKSEVYKLLKNTILI---KRDIDEIYDC 2081
Qy      1139 INEDIKMSLEEDIKTAQSIYEKVALTLKLLLPKKNV--DTQINN--ETSPLRDLVW 1194
Db      2082 INNINIK---PKNGNFKDIIHRRITLYDKLSNAFHIIPSENNINKYIHSSEYNYXI- 2135
Qy      1195 CHICNNNP--DDQPHFYAYSRLKDI--NLIMLRQWSESNLRLLYQFLVVEYONKSA 1250
Db      2136 ---NNNELIVHGFLEFNFYPFKKPLIGDITNYKIDKNEKN-----DEKDEK 2181
Qy      1251 NSVLNVSSN--NGDIILNKLKLVODNIKSNMDHNNIHK 1288
Db      2182 NDEKNEKDEKNGD-----NNDNDND--NNEDENNKKK 2215

```

RESULT 32
T28160

hypothetical protein - malaria parasite (Plasmodium falciparum)
C/Species: Plasmodium falciparum
C/Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #ext_change 01-Dec-2000
C/Accession: T28160; S23688
R/Kun, J.F.; Hibbs, A.R.; Saul, A.; McColl, D.J.; Coppel, R.L.; Anders, R.F.
Mol. Biochem. Parasitol. 85, 41-51, 1997
A/Title: A putative Plasmodium falciparum exported serine/threonine protein kinase.
A/Reference number: Z20482; MUID:91376328; PMID:1896607
A/Accession: T28160
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-2510 <KUN>
A/Cross-references: EMBL:U40232; NID:g1658332; PID:g1658333; PIDN:AAB54058.1
A/Experimental source: strain FCQ27/PNG
R/Kun, J.; Hesselbach, J.; Schreiber, M.; Scherf, A.; Gysin, J.; Mattei, D.; Pereira da
Res. Immunol. 142, 199-210, 1991
A/Title: Cloning and expression of genomic DNA sequences coding for putative erythrocyte
A/Reference number: S23684; MUID:91376328; PMID:1896607
A/Molecule type: DNA
A/Residues: 241, 'S', 243-244, 673-959, 'R', 961-977, 'S', 1493-1494 <KUN>
A/Cross-references: EMBL:X53019
C/Genetics:
A/Gene: FEET
A/Intons: 645/2
C/Keywords: surface antigen

Query Match 8.0%; Score 549; DB 2; Length 2510;
Best Local Similarity 20.3%; Pred. No. 1,6e-15;
Matches 355; Conservative 242; Mismatches 516; Indels 638; Gaps 81;

```

Qy      2 NSKIKVAVKRPLELEKKKSDIITVGNCTL-----YIDEPYK-----V 44
Db      32 SSNVEIENDNKNREILNKRKEHPCSNLSNNTLNPSSVHGNPNKSHVNVYSSNNIM 91
Qy      45 DMTKTYIERHEFIVDKVDDTVNFTVEN-----TKPLIIDYENGCVSCFAYGOT 97
Db      92 DFRKYIK-----DDSSNDITKQSNLSIESHTNM--LSNIYFNFNICN----- 132
Qy      98 GSGKTYTLMGSPYQGSDFPGIFQYAAAGDIFFLNIYDKNKGIFFISYEIYCGKL-YD 156
Db      133 -----EINSYGRKSP-----LDNTR--VQNNSSSYCQMKYS 163
Qy      157 LQKRMAVVAALENGKEVYVVDKILRYLTKEELIKMIDGLR-----KIGVNSQND 211
Db      164 DYQHKPCLCHRG-----ILNTSNGSENOINSDDVSLKNDYTKISMPFNAS 213
Qy      212 SSRSHAILNIDKDKNKTSLGKI--AFIDLAGSERGADIVSQKQOTDGANINRSL 268
Db      214 SS-----VVDSDNVVNSNTIAPCVNMSSPMNVNKGMSGDIINMQTTMNNLKINDLYL 268
Qy      269 ALKECIRAMDSQKNIIPRDSSELTKVLRDIFVGRKSKIMIANISPTISGCEQTANTLYKS 328
Db      269 -----NEINNINIFQSDSL-----SICSHGTS----- 289
Qy      329 SRVKNPKNSCTINBEDPTNTERISLDSKSENNASSIENVYIKSHLNSN--NNNKI 386
Db      290 ---KSKKHS-----DYSTVPYILSN--MKPNFTSNVSNNIL 326
Qy      387 NRGKINDKIERN-----ILKKN--SPDKPRGFTST--FGKYSLANDIDKIKKKKGL 437
Db      327 SNMNPNNIALNMSSSSISINNMASCNIPLNNMISTWEYQYILSNLLKTYQQHTSY 386
Qy      438 INYKSTLYVDNTIYNKKH-----NNNNNNNDNDNDNNNNNNNNSSNV----- 483
Db      387 VSYDMLIYEHMLINNNSMNSMNSMNSMNSMNSMNSMNSMNSMNSMNSMNSMNSMNS 446
Qy      484 -----NNMI--NHMINNN--INNINIVNNNNNNNNNNNNNNNNNNNNNNNNNN 520
Db      447 ISNMMSNLFLKSLSNFIPDHLIPNNSNSGNIISNVVNLNFPVSNFTSHMEYNNRK 506
Qy      521 QPNVAFPTDTSDFSSLDNN-----CHLANNDSIF--LH--KKNLRDNIK 563

```


Db 544 INITPEPRRIACIALSKILSELTEKLGOKIGYRIGESGLYDSEKTVITYITIGYFKL 603
QY 889 -----SHSINMKNNEM-----KNEMKNNEM----- 911
Db 604 FLHHKNNYKFKTHVILDEIHDSRILDLIVLPIKLYLHNGKOKDQMLIIMSATWQSNL 663
QY 912 -----KDNHKSNNNNSSSSSSNN 931
Db 664 FYSYFEPHNIKMSIFIGTKIFSIDTFYIEDIINVTYSGSNHIDEKINDEKINDEKIND 723
QY 932 NIYNN--INDDTFQND-----YCHNDNFT-----IRKONTNINSNIYOND 972
Db 724 EKINDEKINDNNKSCDDKSCDDKSCDDNNNFVESVIDFILRRKNCVKI--NLKSN 781
QY 973 D-IITYNSLNDVYNSNLLHFKEX-----TYPTLST--NEDIYKEM 1012
Db 782 EMLLYKIKSEYDKNIHFNNNNNKRYCNDKNDLVDIEIPANVFSNISNLCELYVNLCL 841
QY 1013 EGKHIPL-----DDODKYDND--NNNVNNNNKNNVNDNNVNDNNVNDNNKNNVD 1063
Db 842 KGSVILFLSGMDITLMTYHQLSMIINNNDNPSNSNI-----NINNGDANDANDVN 894
QY 1064 N-NNVDDDDVDVFNHFKFNNEEYLSYFQKNVDT--IINCLNSLIDISSMYDTKEIL 1119
Db 895 NMHNMH-----MHNHNIANQ--LTYHRTDIKIHIMLHSCU-----YDNTIHL 938
QY 1120 N-----NILSKYAKKQNVK--KYINEDIKMSLEBIDKTAQSTYERKVLITLTL 1171
Db 939 KANDTDINIFLSSNIASSITTPNVLIVDFICQKNIENYDK-----KHAHLVVK-- 989
QY 1172 LFKKNVDTQJNNETSDLRKDLV--MCH-ICNNPDDQFHFAVSRLEKDIINIL--MLR 1225
Db 990 -----WINKSMERKRCRCRTCHGIC-----IRMIKSNLNLRLDKHIS 1029
QY 1226 QIWCESENLRLLYQFLVVEYQNSANSVLLNVSSNNDII-----LNLKLYQDN-- 1275
Db 1030 ELYTHS--LHLLYLYL-----KSMVSLNGLINKRBEVYHCDNTVYVKEVYDQNGI 1081
QY 1276 IKNSMDNNNIHKK 1288
Db 1082 KNEISHSHAENK 1094

RESULT 34
A44396
P-type cation translocating ATPase - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C:Date: 10-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jun-2000
C:Accession: A44396
R:Kishna, S.; Cowan, G.; Meade, J.C.; Wells, R.A.; Stringer, J.R.; Robson, K.J.
J. Cell Biol. 120, 385-398, 1993
A:Title: A family of cation ATPase-like molecules from Plasmodium falciparum.
A:Reference number: A44396; MUID:93132070; PMID:8421054
A:Accession: A44396
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: nucleic acid
A:Residues: 1-1984 <KRI>
A>Note: sequence extracted from NCBI backbone (NCBIP:122678)

Query Match 7.9%; Score 543; DB 2; Length 1984;
Best Local Similarity 21.5%; Pred. No. 2,2e-15;
Matches 321; Conservative 202; Mismatches 412; Indels 560; Gaps 73;

QY 22 KDSDIIVKNN--CTLYIDE-----PRKYDNTKITEHEPIVDKVPDIDVNDFTVYE 72
Db 568 KDNMIMHKNKSIISSEYIKDMKMLATSSKKKSITK--ERSNPLV-----QITKSCILKD 620
QY 73 NTLKPLILDYENGCV-----SCFAYGQSSGKTYMLGQPYGSDGTGIGIQA 124
Db 621 HYIEKKKEYYTNNVYCNLDHNDSTCSSY-----LNNSE----- 655
QY 125 GDIFPLNIYKNTKGIFISFYEYIGKLYDLLQKRKVALENGKKEVVVDLKLIV 184

Db 656 -----TDAYCEYNI--DHLCDINKKQMDI--NSKNEIMGK----- 688
QY 185 LTKPELILMIDGVLARKIGVNSQNDSSRSALINLIDKINDKNTSLCKIAFDLAG-- 242
Db 689 YSKNEIMGKTIKNEIMGKYSKNEIMGKSKNEI--NGKYSKNEIMGKYSKNEIMGK 743
QY 243 --SERGADTVSQKQOTQGDANINRSLALKECIRAMDSKNIHPRDSLETYVLIDIFV 300
Db 744 SKNEIMGKTIKQNGVDTNIYHNN-----CDNDVYN----- 774
QY 301 GSKSITMANISFTISC--CEOTLNTLRYSSRYKFNKSTCINEEDTNTERTISLDSK 358
Db 775 -----DYPCDYCNKNCNDTYHRLYEYH-----INKNSFN-----IPPEK 809
QY 359 GSEMASSTENVTIKN-----HLSNNNNKINRGIN-----DKIER 398
Db 810 NKSNNIIEH--IKINYPLEBALCCPTLS--KVNNKIMGVDLEILMFNFTNCMLINN 865
QY 399 N--ILKNGSFDRREGFTSTFGKYSLANDIDKIKNKKKG--LINY----- 440
Db 866 NSFTIIEK-----KNGSYDPQKIDGDKNIGANDERCHLNNLVSYIILK 911
QY 441 --KSTLYNDNTINKKNNNNNNNDNNNDNNNNNNNDSSSVYNNMINHMINNNIN 497
Db 912 FEFQSLQRMASYIVKSTYGNNNDNNDDNNDDNNDDNNDDNN--NN 953
QY 498 NINNN 557
Db 954 DDNNNDNNDDNN 980
QY 558 DNK--LKNR--SSCDNTNNKNNNLHARSVSKLTMPFSYDQKND--NTE 605
Db 981 EKIKECLSKSIKNVDEILNKTKO-----GMRILISYKRYKSKNINLVKGRF 1032
QY 606 FKSNI-----NKEDNTPKDIILYESR-----NVSNN 632
Db 1033 VESNLHFLGFLFTNNMKGNAP--DIHNLQSGQCQIMSTGDNVLTSIHVAKKGIINN 1091
QY 633 -----GNVLGLNKRT-----HDSIKDENHNNKINNIVININNSVNSINN 677
Db 1092 VESIIIGDVIPIVVGKNNKOKKLWYNHKNIDYLLKCHDTCIDNEFTSIOQWNSDNIQ 1151
QY 678 SNM--NSINNSMNSISYKSNYSNQSISDVQIRVNMDSNKNNDIIFPAISCDN-- 734
Db 1152 DNICGDNIGDNICGDNIGDNIGD-----NINGDNIGDNIGDNI 1194
QY 735 -----NMYPNITNNNN-----NNNNNNNNNNNIDVENYNNRD--GTNNSMKLYA 777
Db 1195 NGDNINTYDNIGDYNLIDYCEPTEYHKTYYNSILYRNNFLYKKEKKOKNKNISTLYE 1254
QY 778 YNSHNLFPQDN-----NKQTSIONINTK----- 802
Db 1255 HRTNDI--QPDKCDLILNDPBNVNLVILGKAFILPKKKFYSFHLPYEECKNIYHYIMK 1313
QY 803 -----NNQDGNNVSNMFCYNNLMDKAYLLDLANKKQK--DKNHGCDNNIION-- 849
Db 1314 KKHKKIKNIINNNNSLYY-----HYNIIDT--FYKNNKKEYMCKKLYKIQQKLLYVL 1366
QY 850 -RNDPEKKK--KTNFYNNNNIIVINNMGNNNSPRKYGCGSHTSIDNNKNNEMKNNEMK 907
Db 1367 IHHLYKKKKYNNMYDIDEVHILGNNNNNN-----KNNSEKKKPL 1408
QY 908 DNEKDNHITSN--NNSSSSSSSSNNNT--YNNINDDTQNDYCHANDNFTTIRKKN 961
Db 1409 KKKMK--HKKNSNDNITFNNTYSNNHLSKYKVVHNNKYYPDSCTN-----LRKKK 1461
QY 962 T--NINSNIYONDIIYITINSIDYMSNTLLHFKEXYTPLTSTNEDI--YKMEGKHII 1017
Db 1462 SLFYNLKKTIYIEK-----KYLQHCCLK--HDNYKAVLPRIKDINYSYQMSIST 1511
QY 1018 R-----LDDQKYDD-----NDNNVNDN--NKNVNDNNVNDNNVNDNNNDK 1059

Db 1512 RNFHLSLEQFAFNSLILSPYLIKDDNNVYKNIYKNIYIN---KNSICNKKVYICNK 1568
 Qy 1060 NNVNNDNDNDVDDVDVFNINIKFNNNELSLFQKQVDTITNCNLSLDSMYDDTKIL 1119
 Db 1569 NYIYKKN---NIIYKKN---IYKKNILTHAKSVL---LSGSKKFLKFF 1609
 Qy 1120 NNILSKYKAEKDNVYKIKYIMEDIKMSLEEDTQAGSIEYERKVLTKLLLFKQVDT 1179
 Db 1610 SNIRPHLAKKKK---KKNIKYGMHVNNTS---KGHILMCTHGFQKQYSS 1658
 Qy 1180 Q-----INNETSDLRKQVLMCHICNNPDDQFHFAYASRLKEDIIIMLRQIWCESEN 1233
 Db 1659 LKNKRYIVNNKRYMKNKDNV-----YDRHMYNLTDMYRGTYQYGCSSK- 1700
 Qy 1224 LRLYQFLVVEYQNSANSVLLNVSNNGDITLTK-----KIVQDIIKMSMDH 1282
 Db 1701 -----KKN-----NIYNNNNNLIKKNINRFLKHLVDCRKNICH 1736

RESULT 35

T18502
 hypothetical protein C0755c - malaria parasite (Plasmodium falciparum)
 C:Species: Plasmodium falciparum
 C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000
 C:Accession: T18502
 R:Lawson, D.; Bowman, S.; Barrett, B.
 Submitted to the EMBL Data Library, August 1997
 A:Reference number: Z18935
 A:Accession: T18502
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-1553 <LAW>
 A:Cross-references: EMBL:Z98551; NID:e1331903; PID:e1331923; PID:CA61141.1
 C:Genetics:
 A:Map position: 3
 A>Note: C0755c

Query Match 7.9%; Score 542.5; DB 2; Length 1553;
 Best Local Similarity 24.4%; Pred. No. 1.8e-15;
 Matches 243; Conservative 162; Mismatches 307; Indels 283; Gaps 54;
 Qy 341 INEEDDTTERISILDSKGEKMASSIEENVV---KSNHLNNNNNNKINRGI---ND 393
 Db 1 MNIDQNNNIK-KIANKKGNKK--KNILLNQKNEVIMKKMKKVKYKKEKICKNGD 57
 Qy 394 KIE-----RNNILK--KSPDKPREGFTSTG--KYSGLNDIDIKKKKKKG 436
 Db 58 NIEETSTHINRRKDNHKEAIYKDELEKKEKFASTGTSTIKSSGLDLNKK-EHVEKG 116
 Qy 437 LINYSTLYNDNTIKKNNNNNNNDNNNDNNNNNNNDSSMANNMIMHMINNI- 495
 Db 117 MVDNKSIVITRTSS-NYSILNFKNSKDTKSGMTNNNNNNNN---INNIN--NNNIV 168
 Qy 496 -----NNNINNNNNNNNNNNNNSHN-----NHLPOPNVAFD----- 528
 Db 169 KTSSSGNTTRNINNNRNHNKNGVNLKDNIKITNWKOSDRHEKKNVEHLDJRGYK 228
 Qy 529 TSDPSSLDPMCHL---NNNKSIFLAKKLNFDNITLKRSSCDNINAKKNNLHLAHS 585
 Db 229 DDNYKKTFTNNHNYLSEMKNNIENNLMNKKCKLDRJHAENSSIDISFOSKDDKQVIE-- 285
 Qy 586 VGSKLTFWSYDPQKKNDTFPKSNINKNMEDNTPKQIIVESRVS--NMGQNVLLGLKNQTH 644
 Db 286 -----NKDTYKKEKTYINKOVN-----LEHKDSDYDMCN-RLGTSCNVL 326
 Qy 645 HDISTDENHNDKINNGVININNSNVNSINNSMNSINNSMNSIYKSN--YNSNQ 702
 Db 327 NTSISQK-NDN-IN--LNAQNSLVIKGEERKSRCTGQARASVGLKKNSTYKKE 381
 Qy 703 SISDVOIRVNEMD---TSKQNDNIFDAISCONNMPNITNNNNNNNN----- 751
 Db 382 NLRDGLNNCVMEMNDTTKNINN---MKNDLQVSNI--NYNNVINNNVNNKGLINSS 435

RESULT 36

S14032
 kinesin-related protein cut7 - fission yeast (Schizosaccharomyces pombe)
 C:Species: Schizosaccharomyces pombe
 C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 02-Feb-2001
 C:Accession: S14032
 R:Hagan, I.; Yanagida, M.
 Nature 347, 563-566, 1990
 A:Title: Novel potential mitotic motor protein encoded by the fission yeast cut7(+) gen
 A:Reference number: S14032; MUID:91015362; PMID:2145514
 A:Accession: S14032
 A:Molecule type: DNA
 A:Residues: 1-1073 <HAG>
 A:Cross-references: EMBL:X57513
 A>Note: the authors translated the codon GCC for residue 2 as Gly and AGT for residue 1.
 C:Genetics:
 A:Gene: cut7
 A:Introns: 50/1
 C:Function:
 A:Description: probably involved in mitotic spindle body duplication
 C:Superfamily: unassigned kinesin-related proteins; kinesin motor domain homology
 C:Keywords: ATP; microtubule binding; mitosis; nucleotide binding; P-loop
 F:61-415/Domain: kinesin motor domain homology <KWO>
 F:147-154/Region: nucleotide-binding motif A (P-loop)
 F:153/Binding site: ATP (Lys) #status predicted

Query Match 7.9%; Score 541.5; DB 2; Length 1073;
 Best Local Similarity 20.8%; Pred. No. 1.3e-15;
 Matches 236; Conservative 222; Mismatches 410; Indels 265; Gaps 43;
 Qy 3 SKIVVVRKRLSELEKKKQSDIITVKNNTCTYID-----EPRYVMTKTYERHEF 55
 Db 59 TNIVVYAVKRTQF-----VRNSSLAVSTSGMAGALALQSDPSMLVYKTY 108
 Qy 56 IVDKVPDVTVDNFTVYENTIKPLIIDYENGCVSCFAYGQTGSGKTYTLMGSPYQSD 115

```

Db 109 AFDKVFGEADQMLFENSAVAPMLEOVL-NGVNCITFAVGQGTGKTYTMSGD-----LSD 163
Qy 116 TPGIFYAAG----DIFPLNIYDKDNTK-GIFISFEIYCGKLYDL---QKRKVAAL 167
Db 164 SDGLISGAGLIPALVQLPSSLDNSNOEYAVKCSYELVNEIRDLVSELRKPARVF 223
Qy 168 EN-----GKKEVVVD---LKILRVLTKEEILKMIIDVLRKIGVNSQNDSS 213
Db 224 EDTSRGNGVVTIGIEESYIKNAGGLRLR-----EGSHRQVAATKCDLSS 271
Qy 214 RSHAILIIDLK-----DINKTS---LGKIAFDLAGSEGADTVSQNKQ 255
Db 272 RSHSIFITLHRYKVSQMTDETNSLTINNNSDILLRASKLIMVLDLASENIGRGAENKR 331
Qy 256 TOTGAMINRSLALKECIRAMDSQKHIPRDESELTKVLRDIFVGSKSIIMANISPTI 315
Db 332 ARETGM-INOSLTLTGKRVINLAVKAAHPIYRSKLTRLDQSLGKTKTSMITVASTN 390
Qy 316 SCCEQTLNLTLYSSRYKFNKSTCINEEDPTNERISI-----LDSKSEMNASSIEN 369
Db 391 TNEETISTLEVAARAKSIRNKP-----QNNQVFRKVLIKDLVDIRLKNIDLNATRKKN 446
Qy 370 VV-----IKSNHLSNNNNKINRGIKINDKIERNNI--LKNSFPKPREGFT 414
Db 447 GVTYLAESTYKELMDRVONKDLCOEQARKLEVLDLVNYSREOLQYVSKSNOEHKKEVEA 506
Qy 415 STEFGYSLNDIDIKIKKKKKGLINYKSTLYNDNTINKKNNNNNNNN-----462
Db 507 LQLOLVNSSTELSEVSKSENEK---LKNEVLLEIEKKRYKETNAKTTVAATLSQYRE 562
Qy 463 -----DNDNDNNNNNNNNNNSSSVNMMINEM--INNINNINNIN-----VNNNNN 506
Db 563 SKEVIASLYEKLDRTERRNNKENENNFMNLKFNLLTMRSPHSGFTDENGFLLNDPNA 622
Qy 507 NNNNNNSHNHLPQRYAFTD-TSDPSSLD-----NCHLANNDKSIFLKKKLRDN 559
Db 623 SMEELLNTHSNQ---LISMTKITEHFQSIDELAQARSSCAVPNS--SIDLIVSELKD- 676
Qy 560 IKLNRSSCDNIMKKKNNLHLARHVSGLTWFSDYPOKKKONTFPKSNINRKNEDTPK 619
Db 677 ---SKNSLIDALHSLQDISMSQKLGNGISSELEIQDKMKEY-----R 719
Qy 620 DILYESHNSNMNGNVLLGLANKTTHDITKDEBNHNNKINNGVINIINNSVNSINNSN 679
Db 720 QLVQELASLYNL-----QHTHEE-----SQKELMYGVRN-----DIDALVKT 757
Qy 680 MNSIINNSNM---NSNSIYKSNYNSNQ---SISDVOIRYVNEMDTSKNNNDNIFPAIS 731
Db 758 TTSINDADILSDYISDQSKFESKQODLIANIGKIVSNFLOE-----QNESLYTRA-- 809
Qy 732 CDNNMYFNITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 791
Db 810 -----DILHSLNDTNSNIRKANEI-----MNNKSEFELRNA-----841
Qy 792 TSNIQNTNNTKNNODGNVNSMNEFCHYNLNDKNYLLIDLNNEQDKNIGHCD-----NN 845
Db 842 ASQAEIYGANKERIQKTVENGSQL-----LDSKKAHINSNSMSWDHICALALAESQKQVNL 897
Qy 846 IIQNRNDEPKKKKTNFNNNN-----IVYVNNNGNNSNFRMYGLCGSHTSIDNNKN 899
Db 898 EVQTLDRLLQKVEKSHSEDTKEKHQQLDLLESLVGNNDN-----LIDSIXTP 945
Qy 900 EMKNNENKDNEMKCNHISKNNNS--SSSSSSNNNINNNINDDDTPONDYCHNDNTTIR 957
Db 946 HTEIQKTTDHVKTSTSLANTNELLGLGDESLCNLETTIEDISLVK-----LETTGDT 1000
Qy 958 RKNNTNINSNIYQDDIYITINSIDYMSNTLHFKKRYTPTLSTEDYINK 1010
Db 1001 SKRELPAETPSWTRSSSLIKETTNN--LSDSKKFRVRETYTSSNSQNSNPDYDK 1051

```

RESULT 37
T38378

```

kinesin-like protein - fission yeast (Schizosaccharomyces pombe)
C/Species: Schizosaccharomyces pombe
C/Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 31-Jan-2000
C/Accession: T38378
R/McLean, U.; Harris, D.; Barrell, B.G.; Rajadream, M.A.; Walsh, S.V.; Wood, V.
submitted to the EMBL Data Library, September 1997
A/Reference number: Z21790
A/Accession: T38378
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-1085 <MCL>
A/Cross-references: EMBL:Z70691; PIDN:CAA94636.1; GSPDB:GN00066; SPDB:SPAC25G10.07c
A/Experimental source: clone c25G10
A/Map position: 1
C/Superfamily: unassigned kinesin-related proteins; kinesin motor domain homology

Query Match 7.9%; Score 538.5; DB 2; Length 1085;
Best Local Similarity 20.7%; Pred. No. 1.8e-15;
Matches 235; Conservative 223; Mismatches 410; Indels 265; Gaps 43;

Qy 3 SKTKVYVRKPLSELEKKKDSITIVKNNCTIYID-----EPKYVDMTKIENHEF 55
Db 71 TNNVYVRVGRFDQ-----VRDSSLAIVSTSGAMGALAIQSDPSSMLVTKY 120
Qy 56 IVDKVPDVTVDNFTVVENTIKPLIIDLYENGCVCSGPAVGQTSQGTMYLGSQPYGQSD 115
Db 121 AFDKVFGEADQMLFENSAVAPMLEOVL-NGVNCITFAVGQGTGKTYTMSGD-----LSD 175
Qy 116 TPGIFYAAG----DIFPLNIYDKDNTK-GIFISFEIYCGKLYDL---QKRKVAAL 167
Db 176 SDGLISGAGLIPALVQLPSSLDNSNOEYAVKCSYELVNEIRDLVSELRKPARVF 235
Qy 168 EN-----GKKEVVVD---LKILRVLTKEEILKMIIDVLRKIGVNSQNDSS 213
Db 236 EDTSRGNGVVTIGIEESYIKNAGGLRLR-----EGSHRQVAATKCDLSS 283
Qy 214 RSHAILIIDLK-----DINKTS---LGKIAFDLAGSEGADTVSQNKQ 255
Db 284 RSHSIFITLHRYKVSQMTDETNSLTINNNSDILLRASKLIMVLDLASENIGRGAENKR 343
Qy 256 TOTGAMINRSLALKECIRAMDSQKHIPRDESELTKVLRDIFVGSKSIIMANISPTI 315
Db 344 ARETGM-INOSLTLTGKRVINLAVKAAHPIYRSKLTRLDQSLGKTKTSMITVASTN 402
Qy 316 SCCEQTLNLTLYSSRYKFNKSTCINEEDPTNERISI-----LDSKSEMNASSIEN 369
Db 403 TNEETISTLEVAARAKSIRNKP-----QNNQVFRKVLIKDLVDIRLKNIDLNATRKKN 458
Qy 370 VV-----IKSNHLSNNNNKINRGIKINDKIERNNI--LKNSFPKPREGFT 414
Db 459 GVTYLAESTYKELMDRVONKDLCOEQARKLEVLDLVNYSREOLQYVSKSNOEHKKEVEA 518
Qy 415 STEFGYSLNDIDIKIKKKKKGLINYKSTLYNDNTINKKNNNNNNNN-----462
Db 519 LQLOLVNSSTELSEVSKSENEK---LKNEVLLEIEKKRYKETNAKTTVAATLSQYRE 574
Qy 463 -----DNDNDNNNNNNNNSSSVNMMINEM--INNINNINNIN-----VNNNNN 506
Db 575 SKEVIASLYEKLDRTERRNNKENENNFMNLKFNLLTMRSPHSGFTDENGFLLNDPNA 634
Qy 507 NNNNNNSHNHLPQRYAFTD-TSDPSSLD-----NCHLANNDKSIFLKKKLRDN 559
Db 635 SMEELLNTHSNQ---LISMTKITEHFQSIDELAQARSSCAVPNS--SIDLIVSELKD- 688
Qy 560 IKLNRSSCDNIMKKKNNLHLARHVSGLTWFSDYPOKKKONTFPKSNINRKNEDTPK 619
Db 689 ---SKNSLIDALHSLQDISMSQKLGNGISSELEIQDKMKEY-----R 731
Qy 620 DILYESHNSNMNGNVLLGLANKTTHDITKDEBNHNNKINNGVINIINNSVNSINNSN 679
Db 732 QLVQELASLYNL-----QHTHEE-----SQKELMYGVRN-----DIDALVKT 769

```


C:Genetics:

A:Map position: 3

A:introns: 56/2; 99/3; 151/3; 310/3; 343/2; 395/3; 419/1; 444/3; 462/3; 489/3; 527/1; 55

A:Note: F1612, 60

C:Superfamily: kinesin-related protein KIP1; kinesin motor domain homology

Query Match

7.8%; Score 534; DB 2; Length 1058;

Best Local Similarity 22.4%; Pred. No. 2,7e-15;

Matches 227; Conservative 192; Mismatches 412; Indels 184; Gaps 36;

```

QY      5 IKVVRKRPISLEKKKKSDIITVKNKCTLYIDPRYKDMT-----KTERHEFTYDK 59
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      49 VQVILRCRPLSEDEARHTPTVISCEN-----RREVAQTQSIACKHIDRH-FAPDK 99
QY      60 VEDTVNDFYTYENTIKPLIIDLYNGCVSCFAYGCGSKTYMTMGSPYQSDPT-- 117
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      100 VFGPASQCKDLYDQAIQIPEVELE-GYNCITFAYGQTGTGTYMEGARKKNGEPPSD 158
QY      118 -GIFQYAGDIPTFLINIDKNTKGIPTSFYEIYCGKLYDLL-----QKRMVA 165
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      159 AGVTPRAVKQIFDILEAGAEYS--MKYTFLELYNEISDLLAPETIKFYDEKSKSIA 216
QY      166 ALENGKEVVVKDLKILRVLTKEELLKMDIGVLKIGVNSQNDSSSHALINIDIKD 225
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      217 LMEDKGSVFRGLEEEIYSTANEIYKILEKGSARRTAEFTLNKSSRSHSIFSITI-H 275
QY      226 INKNT-----SLGKIAPIDLAGSERGADTVSONKQOTOGANINRSLALKECIRAMD 278
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      276 IKENTPEGEEMIKCKGLMLVDLAGSENI SRSGAREGRAREAG-ETNKSLLTIGRYINALV 334
QY      279 SDKNHIIPRDESLTYRLDIFVQKSKSIMIANISPTISCCEQTLNLTLYSSRVKNFKNS 338
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      335 EHSGHIPYRDSLTFLRESLOGKTKTCVIATISPSHCLBETLSTLDYAHRAKNIKNP 394
QY      339 TCINE--EDQNTERRISILDSKSGSEMASSIEEN-VTIKSHLLSNNNNKINRGKINDK 394
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      395 E-INQKMKSAVMKQLYSEIDRLKQEVYAAREKNGIYIPKQRYIQEAEKK---AMA EK 449
QY      395 IERNNILKNSKFDKREGFTSPFGKYSLND--IDIKKKKKGLINYKSTLYNDNTINK 452
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      450 IERLE-LOSESKDKKVVLDQLQELYNQOITIAELSEKLEKTEKK-LEETHSLPD--LEE 504
QY      453 KANNNNNNNDNNNDNNNNNNNDSSGMVNNNMIMNNINNNINNNNNNNNNNNNN 512
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      505 KYRQANATIKK-----EFVISNLKSEKSLVER----- 533
QY      513 NSHNNHLPOPNYAFTDTSDFSLDPMNCHLNNDKSIPLAKNLRDNTIKLNRSSCDIM 572
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      534 -----AFQIRTELESA-----SSDVSNLFSKIERKDKIEDGNRFLIOKFQ 573
QY      573 NKKKNMLHARHSVSKLT-----MFSYDPOKNKNTFFKSNINMGEDNTPKD 620
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      574 SOLTQQLLHKTIVASVTQOEVLKHEMEDMESFVSTKSEATEELRDLRLSKLR----- 628
QY      621 ILYESRNVSNMNGVLLGLNKVTHHDISTDENHNDKINNGVINIINN--SNVNSINNS 678
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      629 -VYGS-GIFALD-NAVAKLDGNSQSTFSSL--NSEVSKSHLELVFKGFASEADMLLD 683
QY      679 NNSNSINNSN-----MNSNSIYKSNYSNOSISDVQIRYVNMEDTSNKANDNIFPDALS 731
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      684 LQSSLNKQEEKLITFAQQQORAKASRAVDARSVSKTVEFFKTLDTHTATKLTGIVEAQ 743
QY      732 CDNNNYPTNTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 791
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      744 VNHKLISEFENKFEBCAABERQLLEKVAELLANSNARKKNLVQMAV--HDLRESASTRT 801
QY      792 TSNIQNTNKNKNOG--NVNYSNMFCHYNLDKNYLLIDLNKEQDKDNIH---GCDNNI 846
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      802 TTLQHEMSTMDQSTSIKAEWGI--HMEKTESHHEDTSAYBSGKKAQEVILNCKEKT 858
QY      847 IQRNDFEKKKKTFTYNNNNIYIVANNMGNNSPRMKYGLCSGHTSIDNMKNEMKNEM 906
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      859 EMSAHQWRKAOE-----SLVSLERNNV-----ASVDSIVRGMDANE- 895

```

```

QY      907 KDNEMKDNHIXSNNNNNSSSS-----SNNNIYNNINDDDTFQNDYCHNDNTFTI 956
DB      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB      896 -----NLRSGFSTRVSSSLVFPDAANSLLTSLDHSIQLDNDACTKNSMI 942

```

Search completed: October 2, 2003, 16:21:28
 Job time : 94 secs

Db 245 ERADARSDRQRTMEGAENQSLALKECIRALDQEHHTTFRQSKLTQVLKDSFGNA 304
QY 304 KSIIMANISPTISCEQTLNLTFRYSRYKPKNSTCINEEDDTN 348
Db 305 KTCMIANISPSHVATEHTLTLRYADRYKELKGKICCTSVTSRN 349

RESULT 2

US-09-967-908A-6
; Sequence 6, Application US/09967908A
; Patent No. 6514738
; GENERAL INFORMATION:
; APPLICANT: Cytokines, Inc.
; APPLICANT: Berard, Christopher
; APPLICANT: Freedman, Richard
; APPLICANT: Guo, Jun
; APPLICANT: Patel, Umesh A.
; APPLICANT: Davies, Katherine A.
; TITLE OF INVENTION: KINI-3 MOTOR PROTEIN AND METHODS FOR ITS USE
; FILE REFERENCE: 020552-002400US
; CURRENT FILING DATE: 2001-09-28
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 381
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide
; OTHER INFORMATION: fragment V195-5566 with flanking vector sequence.
US-09-967-908A-6

Query Match 11.2%; Score 768.5; DB 4; Length 381;
Best Local Similarity 47.5%; Pred. No. 6.8e-49;
Matches 164; Conservative 58; Mismatches 116; Indels 7; Gaps 3;

QY 4 KIKVVRKRPSELEKKKSDIITVKNCTLYIDEPRYVDMTKYIERHEFYDKVDD 63
Db 30 KIRVCVRKRPGLGMRERVRGEINIIIVEDKETLLVHEKKEAVDLTOYILQHVFYDEVEFGE 89
QY 64 TVDNFTYENTIKPLIIDLYENGCVCSGFAYGOTSGSKTYMTMGSPYGGSDPTGIRQYA 123
Db 90 ACTNODVMKTTHTPLIQHIF-NGGNATCFAYGOTGAGKTYMTIGTH-----ENPGLYALA 143
QY 124 AGDIFFTPLNIYDKONTGIFISFEIYCGKLYDLQKRKVAALENGKEVVDLKLIR 183
Db 144 AKDIFRQLEVSQPRKHLFWISFEIYCGQLYDLNRRKRLFARSDSKHWQIVGLQELQ 203
QY 184 VLTRBELILKMDGVLLRKIGVNSQNDSSRSHAILNIDLKDNKNTSLGKIAFIDLGS 243
Db 204 VDSVELLEVLILKSKERSGTATGVNADSSRSHAVIQIQIDSART-FGRISFIDLGS 262
QY 244 ERGADTVSONKQOTODGANINRSILALKECIRAMDSQKNHLPDSELTKVLRDIFVGS 303
Db 263 ERADARSDRQRTMEGAENQSLALKECIRALDQEHHTTFRQSKLTQVLKDSFGNA 322
QY 304 KSIIMANISPTISCEQTLNLTFRYSRYKPKNSTCINEEDDTN 348
Db 323 KTCMIANISPSHVATEHTLTLRYADRYKELKGKICCTSVTSRN 367

RESULT 3

US-09-967-908A-2
; Sequence 2, Application US/09967908A
; Patent No. 6514738
; GENERAL INFORMATION:
; APPLICANT: Cytokines, Inc.
; APPLICANT: Berard, Christopher
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard

; APPLICANT: Patel, Umesh A.
; APPLICANT: Davies, Katherine A.
; TITLE OF INVENTION: KINI-3 MOTOR PROTEIN AND METHODS FOR ITS USE
; FILE REFERENCE: 020552-002400US
; CURRENT FILING DATE: 2001-09-28
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1368
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: KINI-3 motor
; OTHER INFORMATION: domain fragment
US-09-967-908A-2

Query Match 11.2%; Score 768.5; DB 4; Length 1368;
Best Local Similarity 47.5%; Pred. No. 4.1e-48;
Matches 164; Conservative 58; Mismatches 116; Indels 7; Gaps 3;

QY 4 KIKVVRKRPSELEKKKSDIITVKNCTLYIDEPRYVDMTKYIERHEFYDKVDD 63
Db 223 KIRVCVRKRPGLGMRERVRGEINIIIVEDKETLLVHEKKEAVDLTOYILQHVFYDEVEFGE 282
QY 64 TVDNFTYENTIKPLIIDLYENGCVCSGFAYGOTSGSKTYMTMGSPYGGSDPTGIRQYA 123
Db 283 ACTNODVMKTTHTPLIQHIF-NGGNATCFAYGOTGAGKTYMTIGTH-----ENPGLYALA 336
QY 124 AGDIFFTPLNIYDKONTGIFISFEIYCGKLYDLQKRKVAALENGKEVVDLKLIR 183
Db 337 AKDIFRQLEVSQPRKHLFWISFEIYCGQLYDLNRRKRLFARSDSKHWQIVGLQELQ 396
QY 184 VLTRBELILKMDGVLLRKIGVNSQNDSSRSHAILNIDLKDNKNTSLGKIAFIDLGS 243
Db 397 VDSVELLEVLILKSKERSGTATGVNADSSRSHAVIQIQIDSART-FGRISFIDLGS 455
QY 244 ERGADTVSONKQOTODGANINRSILALKECIRAMDSQKNHLPDSELTKVLRDIFVGS 303
Db 456 ERADARSDRQRTMEGAENQSLALKECIRALDQEHHTTFRQSKLTQVLKDSFGNA 515
QY 304 KSIIMANISPTISCEQTLNLTFRYSRYKPKNSTCINEEDDTN 348
Db 516 KTCMIANISPSHVATEHTLTLRYADRYKELKGKICCTSVTSRN 560

RESULT 4

US-09-967-908A-8
; Sequence 8, Application US/09967908A
; Patent No. 6514738
; GENERAL INFORMATION:
; APPLICANT: Cytokines, Inc.
; APPLICANT: Berard, Christopher
; APPLICANT: Freedman, Richard
; APPLICANT: Guo, Jun
; APPLICANT: Patel, Umesh A.
; APPLICANT: Davies, Katherine A.
; TITLE OF INVENTION: KINI-3 MOTOR PROTEIN AND METHODS FOR ITS USE
; FILE REFERENCE: 020552-002400US
; CURRENT FILING DATE: 2001-09-28
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 343
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide


```
RESULT 7
US-09-724-884-3
; Sequence 3, Application US/09724884
; Patent No. 6429304
; GENERAL INFORMATION:
; APPLICANT: Vale, Ronald D.
; APPLICANT: Hartman, James J.
; TITLE OF INVENTION: The Regents of the University of California
; TITLE OF INVENTION: Assays for the Detection of Microtubule
; FILE REFERENCE: 18557B-000510US
; CURRENT APPLICATION NUMBER: US/09/724,884
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/291,170
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 730
; TYPE: PRF
; ORGANISM: Xenopus laevis
; FEATURe:
; OTHER INFORMATION: Xenopus kinesin central motor 1 (XKCM1)
US-09-724-884-3

Query Match      11.1%; Score 758.5; DB 4; Length 730;
Best Local Similarity 42.1%; Pred. No. 9.3e-48;
Matches 175; Conservative 84; Mismatches 130; Indels 27; Gaps 12;

Qy      4 KIKVVRKRPPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTYIERHFIYDKVFD 63
Db      262 RICVCKRRPLNKQELSKKEIDIVSPEKNTVYVHEPKYDLTKYLENQAFCDFAFDE 321

Qy      64 TVDNFTYENTIKPLIIDLYENGCVSCFAYGQSGKTYTMLS-QPYGSDTPGIFQY 122
Db      322 TATNEVYRFTARPLVQITIEGG-KATCFAYGQSGKTHMGDSGKSNVSGYVAF 380

Qy      123 AAGDIFFTFLN-IYDKONTGIFISPEYICGLYLLQKRVNVALENGKKEVYVDLX 178
Db      381 ASRDVFLKNQPCYRKLGLE-VYVTFEYINGKLFIDLKAKLRVLEDKQOVVGLQ 437

Qy      179 LKIRLVTEKEELIKMID-GVLLRKIGVNSQNDSSRSRAIINIDLKQINKNTSL-GKIA 236
Db      438 LLEKQVISAD-VERKMEITGACRTSGOTFANTSSRSRAICQIILR-RGSKLHGKFS 493

Qy      237 FIDLAGSERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFPDSBELTVLR 296
Db      494 LVDLAGNERGVDTASADRITMKGAENRSLLALKECIRALGQNSHTPPRESKLTQILR 553

Qy      297 DIFWQK-SKSMINANISPTISCCBOTLNTLRYSRYKFNKSTCINEEDTTERISIL 355
Db      554 DSFGNSRCTMIAWLSGFGNSCETTLNTLRYADKVKLSPOA-----ETNDNLQME 607

Qy      356 DSKSEWMASSIEENVVIKSNHLLSNNNKINRGKINDKIERNNILKNKSPDKPRE 411
Db      608 DSGSH--ASIEGLQLODPLFKDELESTHN--SFQALNRVGELEKAVDELARE 658

RESULT 8
US-09-594-669-12
; Sequence 12, Application US/09594669
; Patent No. 6331424
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: US 09/295,612
```

```
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; PRIOR FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 405
; TYPE: PRF
; ORGANISM: Human
US-09-594-669-12

Query Match      11.0%; Score 752.5; DB 4; Length 405;
Best Local Similarity 42.1%; Pred. No. 1.1e-47;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

Qy      4 KIKVVRKRPPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTYIERHFIYDKVFD 63
Db      3 RICVCKRRPLNKQELSKKEIDIVSPEKNTVYVHEPKYDLTKYLENQAFCDFAFDE 62

Qy      64 TVDNFTYENTIKPLIIDLYENGCVSCFAYGQSGKTYTMLS-QPYGSDTPGIFQY 122
Db      63 TATNEVYRFTARPLVQITIEGG-KATCFAYGQSGKTHMGDSGKSNVSGYVAF 121

Qy      123 AAGDIFFTFLN-IYDKONTGIFISPEYICGLYLLQKRVNVALENGKKEVYVDLX 180
Db      122 ASRDVFLKNQPCYRKLGLE-VYVTFEYINGKLFIDLKAKLRVLEDKQOVVGLQ 180

Qy      181 ILRLVTEKEELIKMID-GVLLRKIGVNSQNDSSRSRAIINIDLKQINKNTSLGKIAFID 239
Db      181 EHLVNSAD-VIRKIDGSACTSGOTFANSNSRSRAICQIILR-AKGRMHKESLVD 237

Qy      240 LAGSERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFPDSBELTVLRDIF 299
Db      238 LAGNERGADTVSADROTMEGAEINKSLALKECIRALGQNSHTPPRESKLTQVLRDSF 297

Qy      300 VGR-SKSMINANISPTISCCBOTLNTLRYSRYKFNKSTCINEEDTTERISILDSK 358
Db      298 IGENSRCTMIAWLSGFGNSCETTLNTLRYADKVKLSPOA-----ETNDNLQME 348

Qy      359 GSEWMASSIEENVVIKSNHLLSNNNKINRGKINDKIERNNILKNKSPDKPRE 411
Db      349 TEEMKAS--NGALIPNLSEKEBELSSQNSFNEATQIRELEKAMEELKE 399

RESULT 9
US-09-594-669-10
; Sequence 10, Application US/09594669
; Patent No. 6331424
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: US 09/295,612
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; PRIOR FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 434
; TYPE: PRF
; ORGANISM: Human
US-09-594-669-10

Query Match      11.0%; Score 752.5; DB 4; Length 434;
Best Local Similarity 42.1%; Pred. No. 1.2e-47;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

Qy      4 KIKVVRKRPPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTYIERHFIYDKVFD 63
```

```
Db      32 RLCVCRKRPPLNKKOELAKKEIDIVISIPSKCLLVHPEKLVLDLTKYLENQAFCDFPAFDE 91
Qy      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLGS-QPGSGDTPGIFQY 122
Db      92 TASNEVYRFTARPLVQTIFEGG-KATCFAYGOTSGKTHTWGDLGSGKAQNSKGIYAM 150
Qy      123 AAGDIFTFLN--IYDKONTGIFISFEYIYCGKLYDLQKRWVALENGKKEVVVDLK 180
Db      151 ASRDVFLKNQPCYRKGLG-YYVTFEYINGKLPDLNKKAKRLVLEDGKQOVVVGLO 209
Qy      181 ILRVLTKEELIKMID-GVLLRKIGVNSQNDSSRSRSHALINDLKDKINKNTSLGKIAFID 239
Db      210 EHLVNSADD-VIKMIDMGSACTSGOTFANSNSRSHACFOIILR--AKRWHGKFSLVD 266
Qy      240 LAGSERGADTVSONKQOTODGANINRSLALKECIRAMSDKNHIFPRSELTKVLARDIF 299
Db      267 LAGNERGADTVSSADROTMEGAELNKSLLALKECIRALGONKATTPRESKLTQVLRDSF 326
Qy      300 VGR-SKSMIMANISPTISCEQOTLNTLRYSRVKNFKNSTCINEEDDTNTERTISLDSK 358
Db      327 IGENSRCTMIATISPGISSCEYTLNTRVADRVKELSPHSGPGEQ-----LIQME 377
Qy      359 GSEMASSIEVNVIKSNHLSNNNNKINRGKINDKIERNNILKNKSPDKPRE 411
Db      378 TEEMERACS--NGALIPGNLSKEEBELSSQMSFNEAMTQIRELEBKAMELKE 428
```

RESULT 10

```
US-09-594-669-8
; Sequence 8, Application US/09594669
; Patent No. 6331424
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: US 09/295,612
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; PRIOR FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 473
; TYPE: PRT
; ORGANISM: Human
US-09-594-669-8
```

Query Match 11.0%; Score 752.5; DB 4; Length 473;
Best Local Similarity 42.1%; Pred. No. 1.4e-47;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

```
Qy      4 KIKVVVRKRPPLSELEKKKDSOILTYKNNCTLYIDPRKYVDMTKYIERHEFIVDKVFPD 63
Db      71 RLCVCRKRPPLNKKOELAKKEIDIVISIPSKCLLVHPEKLVLDLTKYLENQAFCDFPAFDE 130
Qy      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLGS-QPGSGDTPGIFQY 122
Db      131 TASNEVYRFTARPLVQTIFEGG-KATCFAYGOTSGKTHTWGDLGSGKAQNSKGIYAM 189
Qy      123 AAGDIFTFLN--IYDKONTGIFISFEYIYCGKLYDLQKRWVALENGKKEVVVDLK 180
Db      190 ASRDVFLKNQPCYRKGLG-YYVTFEYINGKLPDLNKKAKRLVLEDGKQOVVVGLO 248
Qy      181 ILRVLTKEELIKMID-GVLLRKIGVNSQNDSSRSRSHALINDLKDKINKNTSLGKIAFID 239
Db      249 EHLVNSADD-VIKMIDMGSACTSGOTFANSNSRSHACFOIILR--AKRWHGKFSLVD 305
Qy      240 LAGSERGADTVSONKQOTODGANINRSLALKECIRAMSDKNHIFPRSELTKVLARDIF 299
```

```
Db      306 LAGNERGADTVSSADROTMEGAELNKSLLALKECIRALGONKATTPRESKLTQVLRDSF 365
Qy      300 VGR-SKSMIMANISPTISCEQOTLNTLRYSRVKNFKNSTCINEEDDTNTERTISLDSK 358
Db      366 IGENSRCTMIATISPGISSCEYTLNTRVADRVKELSPHSGPGEQ-----LIQME 416
Qy      359 GSEMASSIEVNVIKSNHLSNNNNKINRGKINDKIERNNILKNKSPDKPRE 411
Db      417 TEEMERACS--NGALIPGNLSKEEBELSSQMSFNEAMTQIRELEBKAMELKE 467
```

RESULT 11

```
US-09-594-669-14
; Sequence 14, Application US/09594669
; Patent No. 6331424
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: US 09/295,612
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; PRIOR FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 723
; TYPE: PRT
; ORGANISM: Human
US-09-594-669-14
```

Query Match 11.0%; Score 752.5; DB 4; Length 723;
Best Local Similarity 42.1%; Pred. No. 2.6e-47;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

```
Qy      4 KIKVVVRKRPPLSELEKKKDSOILTYKNNCTLYIDPRKYVDMTKYIERHEFIVDKVFPD 63
Db      256 RLCVCRKRPPLNKKOELAKKEIDIVISIPSKCLLVHPEKLVLDLTKYLENQAFCDFPAFDE 315
Qy      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLGS-QPGSGDTPGIFQY 122
Db      316 TASNEVYRFTARPLVQTIFEGG-KATCFAYGOTSGKTHTWGDLGSGKAQNSKGIYAM 374
Qy      123 AAGDIFTFLN--IYDKONTGIFISFEYIYCGKLYDLQKRWVALENGKKEVVVDLK 180
Db      375 ASRDVFLKNQPCYRKGLG-YYVTFEYINGKLPDLNKKAKRLVLEDGKQOVVVGLO 433
Qy      181 ILRVLTKEELIKMID-GVLLRKIGVNSQNDSSRSRSHALINDLKDKINKNTSLGKIAFID 239
Db      434 EHLVNSADD-VIKMIDMGSACTSGOTFANSNSRSHACFOIILR--AKRWHGKFSLVD 490
Qy      240 LAGSERGADTVSONKQOTODGANINRSLALKECIRAMSDKNHIFPRSELTKVLARDIF 299
Db      491 LAGNERGADTVSSADROTMEGAELNKSLLALKECIRALGONKATTPRESKLTQVLRDSF 550
Qy      300 VGR-SKSMIMANISPTISCEQOTLNTLRYSRVKNFKNSTCINEEDDTNTERTISLDSK 358
Db      551 IGENSRCTMIATISPGISSCEYTLNTRVADRVKELSPHSGPGEQ-----LIQME 601
Qy      359 GSEMASSIEVNVIKSNHLSNNNNKINRGKINDKIERNNILKNKSPDKPRE 411
Db      602 TEEMERACS--NGALIPGNLSKEEBELSSQMSFNEAMTQIRELEBKAMELKE 652
```

RESULT 12

```
US-09-594-669-16
; Sequence 16, Application US/09594669
; Patent No. 6331424
```

```

; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/295,612
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 725
; TYPE: PRT
; ORGANISM: Human
US-09-594-669-16

Query Match      11.0%; Score 750.5; DB 4; Length 725;
Best Local Similarity 41.9%; Pred. No. 3.6e-47;
Matches 173; Conservative 76; Mismatches 143; Indels 21; Gaps 10;

Qy      4 KIKVVRKRPISLEKKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHFIYDKVPDD 63
Db      258 RICCVKRPPLNKQELAKKIDIVISPSKCLLVHBPVKLVDTKYLENQAFCDPADE 317
Qy      64 TVNFTYVENTIKPLIIDLYENGVCVSCFAYGQTSGKTYMLGS-QPYGSDTPGIFQY 122
Db      318 TASNEVVYRFTAPLVQITIEGG-KATCFAYGQTSGKTHMGDLSGKQNSKGIYAM 376
Qy      123 AAGDIETFLN--IYDKNTKGFISFYIYCGKLYDLQKKNVAALENGKEVYVVDLK 180
Db      377 ASRDVFLKQPCYKRLGLE-VYVTFEINYKLPDLNKKAKRLVLEDGQOVVGLQ 435
Qy      181 ILRVLYKEILKMKID-GVLLRKIGVNSQNDSSRSRSHAILNIDLKDKINKTSLGKIAFID 239
Db      436 EHLVNSADD-VIKMLDMSACRTSGQTFANSSRSRSHACFOIILR--AKGRMHGKESLVD 492
Qy      240 LAGSERGADTVSONKQOTGDGANINRSLALKEICIRAMSDKNHIFPRDSELTLYLARDIF 299
Db      493 LAGNERGADTSSADROTMEGAELIKSLALKEICIRALGQNKATPPRESKLTQVLRDSF 552
Qy      300 VGR-SKSIIMANISPTISCCQOTLNTLYSRVKNFKNKTCTINEEDTNTERISIIDSK 358
Db      553 IGENSRTMTATISPGISSCEYTLNLTLYADRVKELSPHSGPSGEQ-----LIQME 603
Qy      359 GSEMWASSIENVVIKSNHLSNNNNKINRGINDKIERNNILKKKSFDPKPRE 411
Db      604 TEEMEACS--NGALIPGLSKREBELSSQMSFNEAMTOIRELEKAMEBLKE 654

RESULT 13
US-09-595-684B-33
; Sequence 33, Application US/09595684B
; Patent No. 6544766
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Ohashi, Cara
; APPLICANT: Sakowicz, Roman
; APPLICANT: Vaisberg, Eugeni
; APPLICANT: Wood, Kenneth
; APPLICANT: Yu, Ming
; TITLE OF INVENTION: Human kinesins and methods of producing
; TITLE OF INVENTION: and purifying human kinesins
; FILE REFERENCE: cytop036
; CURRENT APPLICATION NUMBER: US/09/595,684B
; PRIOR FILING DATE: 2002-06-24
; PRIOR APPLICATION NUMBER: 09/295,612
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
```

```

; SEQ ID NO 33
; LENGTH: 725
; TYPE: PRT
; ORGANISM: Human
US-09-595-684B-33

Query Match      11.0%; Score 750.5; DB 4; Length 725;
Best Local Similarity 41.9%; Pred. No. 3.6e-47;
Matches 173; Conservative 76; Mismatches 143; Indels 21; Gaps 10;

Qy      4 KIKVVRKRPISLEKKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHFIYDKVPDD 63
Db      258 RICCVKRPPLNKQELAKKIDIVISPSKCLLVHBPVKLVDTKYLENQAFCDPADE 317
Qy      64 TVNFTYVENTIKPLIIDLYENGVCVSCFAYGQTSGKTYMLGS-QPYGSDTPGIFQY 122
Db      318 TASNEVVYRFTAPLVQITIEGG-KATCFAYGQTSGKTHMGDLSGKQNSKGIYAM 376
Qy      123 AAGDIETFLN--IYDKNTKGFISFYIYCGKLYDLQKKNVAALENGKEVYVVDLK 180
Db      377 ASRDVFLKQPCYKRLGLE-VYVTFEINYKLPDLNKKAKRLVLEDGQOVVGLQ 435
Qy      181 ILRVLYKEILKMKID-GVLLRKIGVNSQNDSSRSRSHAILNIDLKDKINKTSLGKIAFID 239
Db      436 EHLVNSADD-VIKMLDMSACRTSGQTFANSSRSRSHACFOIILR--AKGRMHGKESLVD 492
Qy      240 LAGSERGADTVSONKQOTGDGANINRSLALKEICIRAMSDKNHIFPRDSELTLYLARDIF 299
Db      493 LAGNERGADTSSADROTMEGAELIKSLALKEICIRALGQNKATPPRESKLTQVLRDSF 552
Qy      300 VGR-SKSIIMANISPTISCCQOTLNTLYSRVKNFKNKTCTINEEDTNTERISIIDSK 358
Db      553 IGENSRTMTATISPGISSCEYTLNLTLYADRVKELSPHSGPSGEQ-----LIQME 603
Qy      359 GSEMWASSIENVVIKSNHLSNNNNKINRGINDKIERNNILKKKSFDPKPRE 411
Db      604 TEEMEACS--NGALIPGLSKREBELSSQMSFNEAMTOIRELEKAMEBLKE 654

RESULT 14
US-09-594-669-6
; Sequence 6, Application US/09594669
; Patent No. 6331424
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Sakowicz, Roman
; TITLE OF INVENTION: No. 6331424e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1042
; CURRENT APPLICATION NUMBER: US/09/594,669
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/295,612
; PRIOR FILING DATE: 1999-04-20
; PRIOR APPLICATION NUMBER: US 09/314,464
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 362
; TYPE: PRT
; ORGANISM: Human
US-09-594-669-6

Query Match      10.9%; Score 745.5; DB 4; Length 362;
Best Local Similarity 45.7%; Pred. No. 3.2e-47;
Matches 168; Conservative 65; Mismatches 116; Indels 19; Gaps 9;

Qy      4 KIKVVRKRPISLEKKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHFIYDKVPDD 63
Db      3 RICCVKRPPLNKQELAKKIDIVISPSKCLLVHBPVKLVDTKYLENQAFCDPADE 62
Qy      64 TVNFTYVENTIKPLIIDLYENGVCVSCFAYGQTSGKTYMLGS-QPYGSDTPGIFQY 122
```



```

; APPLICANT: Wood, Kenneth
; APPLICANT: Yu, Ming
; TITLE OF INVENTION: Human kinesins and methods of producing
; TITLE OF INVENTION: and purifying human kinesins
; FILE REFERENCE: cytop036
; CURRENT APPLICATION NUMBER: US/09/595,684B
; CURRENT FILING DATE: 2002-06-24
; PRIOR APPLICATION NUMBER: 09/295,612
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 678
; TYPE: PRT
; ORGANISM: Human
US-09-595-684B-25

Query Match      10.8%; Score 736; DB 4; Length 678;
Best Local Similarity 45.6%; Pred. No. 3,9e-46;
Matches 166; Conservative 62; Mismatches 112; Indels 24; Gaps 8;

Qy      4 KIKVVRKRPPLSELEKKKKSDITTVKNNCTLYIDEPYKVDMTKYIERHEFIYDKVFD 63
      196 RLCVCKRRPLNKKETQMKDLVITIPSKDVVWVHEPKQVDLTRYLENQTFRFDYAFDD 255
Qy      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLS-QPYGSDTPGIFQYA 122
      256 SAPNEMVYRFPKFLVETIFERG-MATCFAYGOTSGKTYTHTMGDFSGKNDSCSGIYAL 314
Qy      123 AAGDIFFTPLNYDKDNTK---GIFISFEYIYCGKLYDLLQKRVVAALENKKEVVKD 178
      315 AARVFLMLK--KPNYKKELOVYATPFETIYSGVFPFLNRTKRLARLEDGKQGVYV 371
Db      179 LKIRVLTKEELILKMDGVLLRKIGVNSONDESSRSHAIINIDKJNKTSIGKIAFI 238
      372 LQEREVKVED-VLKLDIDINSCRTSGQTSANAHSSRSHAVFOILIR--RKSKLHGKFSLI 428
Qy      239 DLASERGADTVSONKQOTGDGANINRSLLALKECIRAMDSKNIHPRDSELTIVLADI 298
      429 DLASERGADTVSSADROTRLSGAETNKSLLALKECIRALGKRKPTPRASKLTOVLNDS 488
Qy      299 FVGK-SKSMIANISPTISCEOTLNTLRYSSRVNFKNKSTCI-----NEEDD 346
      489 FIGNSRCTMATISPGWASCENTLNTLRANRVKELVDDPLAAGDVARPIHHHPNQIDD 548
Db      Qy      347 TMT 350
      549 LETQ 552

RESULT 18
US-09-724-510-2
; Sequence 2, Application US/09724510
; Patent No. 6432659
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6432659e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1032
; CURRENT APPLICATION NUMBER: US/09/724,510
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/675,227
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 319
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (154)...(183)
; OTHER INFORMATION: (154)...(183)
```

```

; OTHER INFORMATION: Xaa = any amino acid
US-09-724-510-2

Query Match      10.2%; Score 696.5; DB 4; Length 319;
Best Local Similarity 45.8%; Pred. No. 1.1e-43;
Matches 149; Conservative 51; Mismatches 118; Indels 7; Gaps 3;

Qy      4 KIKVVRKRPPLSELEKKKKSDITTVKNNCTLYIDEPYKVDMTKYIERHEFIYDKVFD 63
      1 KIRVCVRKRPKRGREVRGRGINIITVEDKETLVHEKKEAVDLQYTLQHVTFDEVFGE 60
Db      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLSQPYGSDTPGIFQYA 123
      61 ACTNODVYMKTTPLHGIHF-NGGNATCFAYGOTGAKTYMTIGTH-----ENPGYALA 114
Qy      124 AAGDIFFTPLNYDKDNTKGIIFISFEYIYCGKLYDLLQKRVVAALENKKEVVKDLILR 183
      115 AKDIFRQLEVSQPKRLFWWISFEYIYCGQLYDLNRRKXXXXXXXKXXXXXXXXXXXX 174
Db      184 VLTGKEELILKMDGVLLRKIGVNSONDESSRSHAIINIDKJNKTSIGKIAFIDLAGS 243
      175 XXXXXXXXXVILGSKERSGTGATGVNADSSRSHAVIOIQKDSAKRT-FGRISFIDLAGS 233
Qy      244 ERGADTVSONKQOTGDGANINRSLLALKECIRAMDSKNIHPRDSELTIVLADIYVGS 303
      234 ERAADADSDROTMEGABINOSILALKECIRALDQHTHTPPROSKLTQVLKDSFTGNA 293
Qy      304 KSMIANISPTISCEOTLNTLRYSS 328
      294 KTCMIANISPSHVATEHTLNTLRYA 318

RESULT 19
US-09-723-216-2
; Sequence 2, Application US/09723216
; Patent No. 6436686
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6436686e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1032
; CURRENT APPLICATION NUMBER: US/09/723,216
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/675,227
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 319
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (154)...(183)
; OTHER INFORMATION: Xaa = any amino acid
US-09-723-216-2

Query Match      10.2%; Score 696.5; DB 4; Length 319;
Best Local Similarity 45.8%; Pred. No. 1.1e-43;
Matches 149; Conservative 51; Mismatches 118; Indels 7; Gaps 3;

Qy      4 KIKVVRKRPPLSELEKKKKSDITTVKNNCTLYIDEPYKVDMTKYIERHEFIYDKVFD 63
      1 KIRVCVRKRPKRGREVRGRGINIITVEDKETLVHEKKEAVDLQYTLQHVTFDEVFGE 60
Db      64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGOTSGKTYTMLSQPYGSDTPGIFQYA 123
      61 ACTNODVYMKTTPLHGIHF-NGGNATCFAYGOTGAKTYMTIGTH-----ENPGYALA 114
Qy      124 AAGDIFFTPLNYDKDNTKGIIFISFEYIYCGKLYDLLQKRVVAALENKKEVVKDLILR 183
      115 AKDIFRQLEVSQPKRLFWWISFEYIYCGQLYDLNRRKXXXXXXXXXXXXXXX 174
```

QY 184 VLTKEELIKMIDGVLRLKIGVNSONDESSRSHAIINIDKIDINKTSIGKIAFIIDLAGS 243
175 XXXXXXXXXXXXVILGSKERSGTGAGVADSSRSHAVIQIQKDSAKRT-FGRISFIDLAGS 233
QY 244 ERGADTVSONKQOTQDGININSLALKECIRAMSDSKNHIIPRDELTIVLADIVGKS 303
234 ERADADARSDRQRTMGAEINOSILALKECIRALDQEHHTPPROSKLTQVLKDSFGNA 293
QY 304 KSIMINISPTISCCBOTLNTLARS 328
294 KTCMINISPSHVATEHTLNTLRYA 318
Db

RESULT 20
US-09-675-227-2
Sequence 2, Application US/09675227
Patent No. 6461855
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6461855el motor proteins and methods for
TITLE OF INVENTION: their use
FILE REFERENCE: 1032
CURRENT APPLICATION NUMBER: US/09/675,227
CURRENT FILING DATE: 2000-09-29
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 319
TYPE: PRT
ORGANISM: Human
FEATURE:
NAME/KEY: VARIANT
LOCATION: (154)...(183)
OTHER INFORMATION: Xaa = any amino acid
US-09-675-227-2

Query Match 10.2%; Score 696.5; DB 4; Length 319;
Best Local Similarity 45.8%; Pred. No. 1.1e-43;
Matches 149; Conservative 51; Mismatches 118; Indels 7; Gaps 3;
QY 4 KIKVVRKRPPLSELEKKKDSIIITVKNCTLYIDPRYKVMTRYIERHEFIVDKVFPD 63
1 KIKVCVRKRPPLQREVRGRGRIITVEDKETLLVHEKKEAVDLYQYLQVFFDEVFGE 60
QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCFAYGQSGKTYTMGSOPIGSDTPGIFQYA 123
61 ACTNOGVYMKTTPLIQHIF-NGGNATCFAYGQSGKTYTMGTH----ENPGIYALA 114
QY 124 AGDIFFTLNYDKDNKGFISFYEYICGLYDLOKRMVVALENGKKEVVVVKDKILR 183
115 AKDIFPOLEVSQPKLFWISYEYICGLYDILNRKXXXXXXXKXXXXXXXXXXXX 174
QY 184 VLTKEELIKMIDGVLRLKIGVNSONDESSRSHAIINIDKIDINKTSIGKIAFIIDLAGS 243
175 XXXXXXXXXXXXVILGSKERSGTGAGVADSSRSHAVIQIQKDSAKRT-FGRISFIDLAGS 233
QY 244 ERGADTVSONKQOTQDGININSLALKECIRAMSDSKNHIIPRDELTIVLADIVGKS 303
234 ERADADARSDRQRTMGAEINOSILALKECIRALDQEHHTPPROSKLTQVLKDSFGNA 293
QY 304 KSIMINISPTISCCBOTLNTLARS 328
294 KTCMINISPSHVATEHTLNTLRYA 318
Db

RESULT 21
US-09-722-129-4
Sequence 4, Application US/09722129
Patent No. 6582958
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe

APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6582958el motor proteins and methods for
TITLE OF INVENTION: their use
FILE REFERENCE: 1054
CURRENT APPLICATION NUMBER: US/09/722,129
CURRENT FILING DATE: 2000-11-24
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 4
LENGTH: 303
TYPE: PRT
ORGANISM: Human
US-09-722-129-4

Query Match 8.6%; Score 589.5; DB 4; Length 303;
Best Local Similarity 43.6%; Pred. No. 8.4e-36;
Matches 132; Conservative 56; Mismatches 108; Indels 7; Gaps 5;
QY 4 KIKVVRKRPPLSELEKKKDSIIITVKNCTLYIDPRYKVMTRYIERHEFIVDKVFPD 63
4 KICVCVRKRPPLQREVTLLDILITVPSDNVVMVHESKQVLDLTRYLQNTFCFHAFFD 63
QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCFAYGQSGKTYTMGSOPIGSDTPGIFQYA 122
64 KASNELVYQFTAPQPVESIFRKG-MATCFAYGQSGKTYTMGSDTPGIFQYA 122
QY 123 AGDIFFTL-NIYDKDNKGFISFYEYICGLYDLOKRMVVALENGKKEVVVVKDKILR 180
123 VADVFLRLNRYEGLDK-VYGFPEYIGKVDLWKKKLOVLEGNQOIOVVGLO 181
QY 181 ILRLVLTKEELIKMIDGVLRLKIGVNSONDESSRSHAIINIDKIDINKTSIGKIAFIID 240
182 EKREVCVEEVLNLVLEIGNSCRSTRQTPVVAHSRSHAVQIILK--SGRIMGKFSVLVD 239
QY 241 AGSERGADTVSONKQOTQDGININSLALKECIRAMSDSKNHIIPRDELTIVLADIV 300
240 AGNERGADTVKASRRKQLEGAEINKSILALKECIRALDQEHHTPPRAKTLVLADSF 299
QY 301 GKS 303
300 GQN 302
Db

RESULT 22
US-09-722-129-2
Sequence 2, Application US/09722129
Patent No. 6582958
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6582958el motor proteins and methods for
TITLE OF INVENTION: their use
FILE REFERENCE: 1054
CURRENT APPLICATION NUMBER: US/09/722,129
CURRENT FILING DATE: 2000-11-24
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 492
TYPE: PRT
ORGANISM: Human
US-09-722-129-2

Query Match 8.6%; Score 589.5; DB 4; Length 492;
Best Local Similarity 43.6%; Pred. No. 1.7e-35;
Matches 132; Conservative 56; Mismatches 108; Indels 7; Gaps 5;
QY 4 KIKVVRKRPPLSELEKKKDSIIITVKNCTLYIDPRYKVMTRYIERHEFIVDKVFPD 63
133 KICVCVRKRPPLQREVTLLDILITVPSDNVVMVHESKQVLDLTRYLQNTFCFHAFFD 252
QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCFAYGQSGKTYTMGSOPIGSDTPGIFQYA 122

Db 253 KASNELVYQTAQPLVESIFRKG-MATCFAYGQTGSGKTYMGDFSGTAQDSCSGIYAL 311

Qy 123 AAGGIFFL--NIDKONTKGFISFYIYCGKLYDLOKRMMAALENGKEVAVYD 180

Db 312 VAQGVFLLRNSTEKLDK-VGTFEPIYGGKYVDLLNWRKKQVLEDGQOIQVGLQ 370

Qy 181 ILRLYTEELIKMIDVILRKIGVNSQNDSSRHALLNIDLOKNTSLGKIAFDL 240

Db 371 EKEVCCEEVANLVEIGNSCSTSPYNAHSSRHAFQIILK--SGRIHGKFSVL 428

Qy 241 AGSERGADTVSONKQOTGDGANINRSLALKECTIRAMDSKXNHPERDSELTXYLDIV 300

Db 429 AGNERGADTVKASRKRQLEGAEINKSLALKECILAQONKPHIPEFRASKLTLYLRDSFI 488

Qy 301 GKS 303

Db 489 GON 491

RESULT 23

US-09-914-259-28

; Sequence 28, Application US/09914259

; Patent No. 6495336

; GENERAL INFORMATION:

; APPLICANT: Makowski, Lee

; APPLICANT: Hyman, Paul

; TITLE OF INVENTION: STAGED ASSEMBLY OF NANOSTRUCTURES

; FILE REFERENCE: 8471-010-999

; CURRENT APPLICATION NUMBER: US/09/914.259

; CURRENT FILING DATE: 2000-11-21

; NUMBER OF SEQ ID NOS: 180

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO: 28

; LENGTH: 1111

; TYPE: PRT

; ORGANISM: Saccharomyces cerevisiae

US-09-914-259-28

Query Match 8.2%; Score 561.5; DB 4; Length 1111;

Best Local Similarity 22.9%; Pred. No. 6.1e-33;

Matches 255; Conservative 204; Mismatches 393; Indels 263; Gaps 48;

Qy 2 NSKIRVVVRKPLSELEKKKDDSIITV---KNNCTLYIDEPKYVDMTKYIERHEFI 58

Db 50 DSNHIVYRCRSMRKRREIEKSSVISTLGPOGKIIISNGSHQSYSSK--KTYQF--D 105

Qy 59 KVFDDTVNFTYENTIKPLIIDLYENGCVSCFAYGQTGSGKTYMLG-----S 108

Db 106 QVFGAESDQEFVFNATANKYIKEML-HGYNCTIFAYGQTGSGKTYMGDINILGDVGT 164

Qy 109 QPYGSDTPGIFQYVAGGIFITFLNLYDKNTKGFISFYIYCGKLYDLO----- 159

Db 165 DNLLGHEAGIIPRVLVDLFEKELSLNKEYS--VKISPLEVENMLKDLLDSEDDDPAY 222

Qy 160 ---KRM-VAALENGKEVAVYDILRLVLTKEELIKMIDVILRKIGVNSQNDSSRS 215

Db 223 NDPKQIHPDNNNNSSIMVKGQEIFPNSAHEGLNLMQSLKRYAAATCNDLSRS 282

Qy 216 HAILNI-----DLKD--INKN-TSLGIAPIDLAGSERGADTVSONKQOTGDGANIN 265

Db 283 HTVFITTNIVQDSKDHQONKNFVIGKLNLDLAGSENINRSGAENKRAQEAEL-INK 341

Qy 266 SILALKECTIRAMDSKXNHPERDSELTXYLDIVFGKSKSIMIANISPIISCEOTLNTL 325

Db 342 SLLTIGRAYINMLVDHSHNHPYRESKLTIRLDPSLGMTKCTIAITISPAKISMEETASTL 401

Qy 326 RYSSRVKPKN-----KSTCINE-----EDDTERISILDSKSEWNA 364

Db 402 EYATRAKSKNTPOVQSLSKDTCLKDYIQTIEKLRNDLKSRNKGQIFITD--DQDL 458

Qy 365 SSIENVVAKSNHLNANNNNKINRGKIN--DKIERNNILKN-----KSFDPKRGF 413

Db 459 YESNSILIDQONKIHNLREOIKFKKENYLNQDLINNLQSEKELIATIONENVSNE 518

Qy 414 TSTFGK--VSSLNDIDIKKXKKKGLINYSTLYND-----TINKKHANN 458

Db 519 YSEIQKHHTNLELMEVIOQRPSELSQKQ--YNTQNNQKLSQOVLQTLTLOGSLN 577

Qy 459 NNNNDND-----NNNDNNNNNDSS-SMVNNMIMMNNNNNNNN--NVNNNNN 507

Db 578 NYSKCEVAKGTBELTRVNVTHKAKHDSTLSKLNITTNLMMQNNBELVRSISTLEI 637

Qy 508 NNNNNNSH--NHLFQPYAF-----TDTSDSSLDMM--NCHLNNDK 547

Db 638 FQSDSTSHYKRDINEIYQSHQOFLKQNDIKSCDLSIGSILTSINEISQNTTNLSM 697

Qy 548 SIFLHKRLKNDIKLKVRSSCDNIMNKKNNL-----HLAR- 583

Db 698 NVLIENQSSGSKLIKQ---DLFIKLDKDLINERISQFNOQLAMERYQDHSRT 754

Qy 584 ---HVGSKLTWESYDPQKKNKNTPEKSN-----INKMEDTPKDIYESRN-- 627

Db 755 RSEFHDLELNKIDNLKQKQSKLDQDIQXTASIFNETDIVVKNLHSDIASLAHAENTL 814

Qy 628 --VSNN--GNVLGLNKTHHDISTK---DENNDKINNGVINIINNSVNSINNS 678

Db 815 KTVSONNESFTNDLISLRGMNDISKLSLPINEFLNKISQITCETCGDNTIA-SNP 873

Qy 679 NNNNSINN-SMVNSNSIYKSNVNSQISDVQIRYVNMOT-SNKNNDIFPDALSCDNN 736

Db 874 VLTSIKKFOINICSDILNTEKIMSLDEIQ---SQEITSNENNINL----- 918

Qy 737 YPNITNNNNNNNNNN-----NNNNNIDVENYNNRDNNSMKLYA-----YNSHLF 784

Db 919 ---IATNENFSLCNFLTIDYDERIMQISKTQEVASEHCEKQLQSLKILGMDIFTASIE 975

Qy 785 QP--DNKKTSNQNINTKKNQDGVNYSANFCHNLNDKRYLDLNKQKQD-KNII 840

Db 976 KPLHEHTRPEASVYKALPL-----LDYPKQFOIYR-----DAENKSKDQTSNSR 1019

Qy 841 GCDNNIIONRN---DPEKK-----KTNFYNNNNIIVNNNG----- 875

Db 1020 TCINLSTNENFPLSOPSPTVPVPPQPLKYLIPKSTISAKSNRSKTLPTNBTGTRS 1079

Qy 876 NNNSPRMKYGICGSHTSIDNNKNEMKNEMKONE 910

Db 1080 QNNLKR-----RFTTEPILKGETENNDILOQK 1107

RESULT 24

US-09-541-782-6

; Sequence 6, Application US/09541782

; Patent No. 6284480

; GENERAL INFORMATION:

; APPLICANT: Nislow, Corey

; APPLICANT: Sakowicz, Roman

; APPLICANT: Beraud, Christophe

; TITLE OF INVENTION: Antifungal Assay

; FILE REFERENCE: 1015

; CURRENT APPLICATION NUMBER: US/09/541.782

; CURRENT FILING DATE: 2000-04-03

; NUMBER OF SEQ ID NOS: 10

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO: 6

; LENGTH: 1073

; TYPE: PRT

; ORGANISM: S.pombe

US-09-541-782-6

Query Match 7.9%; Score 538.5; DB 3; Length 1073;

Best Local Similarity 20.7%; Pred. No. 2.9e-31;

Matches 235; Conservative 223; Mismatches 410; Indels 265; Gaps 43;

Qy 3 SKIRVVVRKPLSELEKKKDDSIITVKNCTLYID-----EPKYVDMTKYIERHEF 55

Db 59 TNNVVRVGRDDE-----VRNSSLAVSTSGAMGAEALAIQSPSSMLVTKY 108

QY 56 IYDKVEDDIDVDFVNTYENTIKPLIIDLYENGCVSCFAVGTGSGKTYMLGSPYQSD 115

Db 109 AFDKVGEPADQMLPENSVAEMLEQVL-NGNCTIFAVGTGTGKTYMSGD-----LSD 163

QY 116 TPGIPOYAG-----DIFPLNIYDKNTK-GIFISFEYICGKYDYL--QKRVVAAL 167

Db 164 SDGILSEAGLIPRALYQFLSSLDNSQGEYAVKCSYELVNEIRDLVSEELKPARVF 223

QY 168 EN-----GKEEVVVD-----LKIIRVLTKEBILIMIDGVLKRGVNSQNDSS 213

Db 224 EDTSRKGNVITIGIESYIKNAGDGLRLR-----EGSHRQVAATKCDLSS 271

QY 214 RSHAILNIDLK-----DINKNTS-----LGKIAFDLAGSEKADTVSQNKQ 255

Db 272 RSHSIFITLHRRVSSGMDTETNSLTNNSSDDLRSKLAHMDVLAGSENGSGAENR 331

QY 256 TOTDGANINSLALKECIRAMSDKNHIFPRDSELTQVLDIFVGSKSIMIANISPTI 315

Db 332 ARETGM-INOSLLTLGRVINALVEKAHIIPRESKTLRLQDSLGKTKTSMITVSSIN 390

QY 316 SCCEOTLNTLRYSRVKFNKSTCINEEDTNTERTSI-----LDSKSEMASSIEN 369

Db 391 TNLSEITSTLEVAARAKSIRNKP-----QNNQVFRKVLIKDVLDIERLKNDLNATRKKN 446

QY 370 VV-----IKSNHLSSNNNNKINRGKINDKIERNNI--LKNKSPKPREGFT 414

Db 447 GYVLAESTYKELMDRVQNDLCOEOARKLEVLDIANVKSREQLQVYSKNOHKEVEA 506

QY 415 STFGKYSLLNDIDIKKKNKGLINYKSTLYNDNTINKKNNNNNNNN-----462

Db 507 LQQLVNSSTELSVKSENEK-----LKNELVLEIEKKKYTEAKITVATDLSQYRE 562

QY 463 -----DNDNNDNNNNNNNDSSSVANNMINHM--INNINNIN--VNNNN 506

Db 563 SKEVYASLYEKLDRTERRNKENENNFMNLFNLLTMRSPHGSFTDETYGFTLLNDFVA 622

QY 507 NNNNNNNSHNNHLPOPVYAFD--TSPFSLD-----MNCNLNNDKSIPLHKKULRDV 559

Db 623 SHELANTHSNOL--LISMTKITEHFQSLDEALQASRSCAVPNS--SLDLIVSELKD- 676

QY 560 IKLKNSSCDNIMKKKNLHLARHSVGSKLTMFSYDPOKKNKNTFFKSNINMEDNTPK 619

Db 677 -----SKKSLDLALHSLQDISMSQKLNGISELLELOKDMKESY-----R 719

QY 620 DIYERBNVSNNGANVLGLANKTTHDICTKENHNDKINNGVINIINNNSVNSINNSN 679

Db 720 QLVQELRSLYNL-----OHTHER-----SQKELMYGVRN--DIDALVKT 757

QY 680 MNSINNSNM--NSNSIYKSNYNSQ-----SISDVQIRVNMEDNSKKNNDIIFDAYS 731

Db 758 TTSNLADITLSYIDQSKFESKQOOLIANIGKIVSNFLOE-----QNESLYTKA-- 809

QY 732 CDNNMYPNTTNN 791

Db 810 -----DLHSHLNTNSNIRKANEI-----MNNRSEEPFLRNA-----841

QY 792 TSNIQNINTKANNQDGNVSNVFCMYNLNDKNYLLDANKEQKDYKNIHCCD-----NN 845

Db 842 ASQAEIVGANKERILOKTVENGSQL-----LDSKSKALHSNSRSMYDCLALAEQKOGVNL 897

QY 846 IIONRNDFEKKKKKTNFPNNNN-----IIVNNNMGNNSNPMKHYGLCSGHTSIDMMKN 899

Db 898 EYVTLDRLOKQVKEHEDNTKEKQOOLLIDLESVLGNND-----LIDSIKTP 945

QY 900 EMKNNEMKONEMKDNHISNNNS--SSSSSNNNNIYNNINDDTFQNDYCHNDNFTIR 957

Db 946 HTLEQKITDHLVKGTTSLAHNTNELGLGBESLCNLETTIEDTSVAK-----LETTGDRP 1000

QY 958 RKNNTNINSIYONDIIYITINSIANDYMSGTLHFEKTYPTLSTNEDIYAK 1010

Db 1001 SKRELPAATPSWTRDSSLIKETTNLN--LDSKKFVREYTSNQNTNEPPDYDK 1051

RESULT 25
US-09-723-820-6
; Sequence 6, Application US/09723820
; Patent No. 6468760
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/723,820
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/541,782
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 1073
; TYPE: PR1
; ORGANISM: S. pombe
US-09-723-820-6

Query Match 7.9%; Score 538.5; DB 4; Length 1073;
Best Local Similarity 20.7%; Pred. No. 2.9e-31;
Matches 225; Conservative 223; Mismatches 410; Indels 265; Gaps 43;

QY 3 SKIKYVVRKRLPSELEKKKKSDIITVKNCTLYID-----EPRIYKDMTKYIERHEF 55

Db 59 TNNVVRVGRDDE-----VRNSSLAVSTSGAMGAEALAIQSPSSMLVTKY 108

QY 56 IYDKVEDDIDVDFVNTYENTIKPLIIDLYENGCVSCFAVGTGSGKTYMLGSPYQSD 115

Db 109 AFDKVGEPADQMLPENSVAEMLEQVL-NGNCTIFAVGTGTGKTYMSGD-----LSD 163

QY 116 TPGIPOYAG-----DIFPLNIYDKNTK-GIFISFEYICGKYDYL--QKRVVAAL 167

Db 164 SDGILSEAGLIPRALYQFLSSLDNSQGEYAVKCSYELVNEIRDLVSEELKPARVF 223

QY 168 EN-----GKEEVVVD-----LKIIRVLTKEBILIMIDGVLKRGVNSQNDSS 213

Db 224 EDTSRKGNVITIGIESYIKNAGDGLRLR-----EGSHRQVAATKCDLSS 271

QY 214 RSHAILNIDLK-----DINKNTS-----LGKIAFDLAGSEKADTVSQNKQ 255

Db 272 RSHSIFITLHRRVSSGMDTETNSLTNNSSDDLRSKLAHMDVLAGSENGSGAENR 331

QY 256 TOTDGANINSLALKECIRAMSDKNHIFPRDSELTQVLDIFVGSKSIMIANISPTI 315

Db 332 ARETGM-INOSLLTLGRVINALVEKAHIIPRESKTLRLQDSLGKTKTSMITVSSIN 390

QY 316 SCCEOTLNTLRYSRVKFNKSTCINEEDTNTERTSI-----LDSKSEMASSIEN 369

Db 391 TNLSEITSTLEVAARAKSIRNKP-----QNNQVFRKVLIKDVLDIERLKNDLNATRKKN 446

QY 370 VV-----IKSNHLSSNNNNKINRGKINDKIERNNI--LKNKSPKPREGFT 414

Db 447 GYVLAESTYKELMDRVQNDLCOEOARKLEVLDIANVKSREQLQVYSKNOHKEVEA 506

QY 415 STFGKYSLLNDIDIKKKNKGLINYKSTLYNDNTINKKNNNNNNNN-----462

Db 507 LQQLVNSSTELSVKSENEK-----LKNELVLEIEKKKYTEAKITVATDLSQYRE 562

QY 463 -----DNDNNDNNNNNNNDSSSVANNMINHM--INNINNIN--VNNNN 506

Db 563 SKEVYASLYEKLDRTERRNKENENNFMNLFNLLTMRSPHGSFTDETYGFTLLNDFVA 622

QY 507 NNNNNNNSHNNHLPOPVYAFD--TSPFSLD-----MNCNLNNDKSIPLHKKULRDV 559

Db 623 SHELANTHSNOL--LISMTKITEHFQSLDEALQASRSCAVPNS--SLDLIVSELKD- 676

QY 560 IKLKNSSCDNIMKKKNLHLARHSVGSKLTMFSYDPOKKNKNTFFKSNINMEDNTPK 619

Db 677 -----SKSLDALAEHSIADIDISMSQKXGNGISSSELIELQXDMKSY-----R 719
Qy 620 DILYESRNVSMNGNVLGLKNTKTHDIDTYDENHNDKINNGVYININNSNVNSINN 679
Db 720 QLVQELRSLVYL-----QHTHEE-----SQKELMYGVN-----DIDALVTC 757
Qy 680 MNSINNSNM--NSNSTYKSYNSNO-----SIDVOIRYVEMDTSKNNNDNIFPAIS 731
Db 758 TTSINDADILISDYISDQKSFESKQODLANIGKISNFIQF-----QNESLITTKA-- 809
Qy 732 CDNNMYPNITNNNNNNNNNNNNNNNNIDVENYNNRDGTNSMKLYAVNSHNLFOPDNNKN 791
Db 810 -----DILHSLDNTNSNIRKANEL-----MNNSEELRNA----- 841
Qy 792 TSNIGNNTKKNODGAVNYSMAFCHYNLDKATYILDLANKQXDKIHGCD-----NN 845
Db 842 ASQAEIVGANKERIQKTVENGSQL-----LDSKSKAISHNSRSMYDHCIALAESOKQGVNL 897
Qy 846 IIONRNDPEKKKTNFVNNNN-----IVYNNMGNNSPRMKYGLGSHTSIDNMKN 899
Db 898 EVQTLDRLLQVKHSEBNTYKHOQLDLLESILVGNNDN-----LIDSIKTP 945
Qy 900 EMKNNEMKDNEMKDNHIKSNNNNS--SSSSSSNNNINNNINDDDTFQNDYCHNDNPTIR 957
Db 946 HTELOKITDHYLKGTSILANTHTELGLGDESICNLETTIEDISLVK-----LETTGDT 1000
Qy 958 RKNNTNINSNIYQDDIYITNSLNDYMSNTLLHFKEKTYPTLSTNEDIYNK 1010
Db 1001 SKRELPAFPWTRDSLSLIKETTINL--LDSDKKFVRETYTSSNQTNEPDYDK 1051

RESULT 26
US-09-417-485D-6
; Sequence 6, Application US/09417485D
; Patent No. 6541202
; GENERAL INFORMATION:
; APPLICANT: Metz, David M.
; APPLICANT: Metz, Anneke M.
; TITLE OF INVENTION: Telomerase Reverse Transcriptase (TERT) Genes
; FILE REFERENCE: 47714-5009-US
; CURRENT APPLICATION NUMBER: US/09/417, 485D
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 2184
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (330)..(335)
; OTHER INFORMATION: Xaa at position 330 = Leu or Ile;
; OTHER INFORMATION: Xaa at position 335 = Asp or Gly.
US-09-417-485D-6

Query Match 7.9%; Score 538.5; DB 4; Length 2184;
Best local similarity 21.4%; Pred. No. 8e-31;
Matches 330; Conservative 234; Mismatches 489; Indels 487; Gaps 73;

Qy 4 KIKVYVRRLPSELEKKKSDIITVKNKNTLY-----IDERYKQDMKTYIERH--EPI- 56
Db 429 QIKSTKNDISHIITSRKENHLFHVQKLENNYKAPNINKQLRKTKILKYVNYNFKREFIN 488
Qy 57 -----VDKVF-----DDTVNFTVYENTIKPLIIDLYE 84
Db 469 NVINTKFGKIYKFFPRKHILANKIHKIFKILQIILKYYRIINIMNRKFIQKYVDFPF 548
Qy 85 NCCVCSFAYVGGTSGKTYTLMGSOPIYGGSDTPGIFQVAAADIFPLNLYDKONTKGIPTI 144
Db 549 KNYDFLSFSF-----KTYKINFVYITKCKIPKILGSKNPF--KIFLKNVKKVFLLF 599

Qy 145 SFYEIYC-----GKLYDLLQKRNVAALENGKEVVVVDL-----KIILVLTKEEL 190
Db 600 NYKESISLNGVMKNIKVIKNIPOKK-----ISKYNIKNILKNIIPDNVYENKILH--RNNKEI 655
Qy 191 ILKMDIGVLKRTIGVNSQNDSSRSIAIILIDKINKTSLQKIAFIDLAGEBGADT- 249
Db 656 ITVININDIKI-----YKKKNDLNNNSFKIKTTLFNNKLRK--YFNKIKKINIAIQRLHMNR 710
Qy 250 -----VSQNKOTQTOGANNRSLALLKECIRAMDSDK-----HIPF 286
Db 711 LIYFLENYIMPLIRREFFLTKSEOT-----LHKTIFFPRKIWNHFTKISNFCVHOIF 764
Qy 287 RDESLTK-----VLRIDFVGRKSIMANISPTISCCBOTLNTLRYSRVNFKNKST 339
Db 765 RNNKLLKRNPEPDYQNMENVKKG-----EKIKTNKYIF--IKMKKKST 809
Qy 340 --CINEEDDNTERTISLDSKSEMAASSIENVYKSNHLSNNNNKIKRG----- 389
Db 810 NKCINNK--FSKKCIPKKKKKNUYITRANNIFIKDMKKSKTNNLINSIDNLYK 866
Qy 390 KINDKI-----ERNNIIKNSF-----DK 408
Db 867 EINKSVRYPIYKFFYKIKKKYFALKKMYIHMMAKEKSNIKLEAFKAPFIFAQEKH 926
Qy 409 PREGFTSTFGKYSLND-----IDKIK-----KNKK--GLINTKSTLYND 447
Db 927 ILKFSHFQONKINVGKRFNLIRIKIILIKONGSIVKNDKFTLHIIKNSKNKN 986
Qy 448 NTINKKNNNNNNNDNDNDNDNDNDNDNDSSSVANNMIMHMINNNINNNINNNNN 507
Db 987 NKKKKNNN 1036
Qy 508 NNNNNNNHNLHPQVNAFTDTSDFSLDMNCHLNNDKSIPLHKKNLADNIKLRSS 567
Db 1037 KKAQNEKN-----IDSN--LEKKKKKIY-----KIKIIE 1069
Qy 568 CDNIMNKKNNLHLARHVSGLTMFSPDQKNKNDTFPSNINKMEDNTPK-----D 620
Db 1070 KRNFMKL-----LNSINFIKSLRI--NWIPKKG-----LRLPLNLTSLNPEIYQRIFE 1120
Qy 621 ILYESRNVSMNGNVLGLKNTKTHDIDTYDENHNDKINNGVYININNSNVNSINN 680
Db 1121 ILKSKSESEFYFNHILNNLER-----EKDKINIKKKRYNK--KNPNVSLNNICNPSL 1172
Qy 681 NSINNSMNSSTIKSYNSNQSISDVOI-----RYVNEMDTSKND 723
Db 1173 KCLGNMHRNNNSLFK--NTLTGTGETELKLLKMLYKLMWFKKKMKKIKIKKLLKONK 1229
Qy 724 NIF-FDAISCDNNMYPNITNNNNNN-----NNNNNNNNIDVENYNNRDGTNSMKLY 776
Db 1230 KIVAYICIGPSCNCEHI-----NHNYLFKILKVFONINNFEIYLFKR-----SPFLY 1279
Qy 777 AYNSHNLF--QPNNTK--TSNIGN--TNKNQOGVNYSMN--FCHYNLDKRYLI 827
Db 1280 NKNLNNFLSYPVNVKSGFLGYIRNRELIIKSHLDNHHFLLNOMFKTKSKSDLYIFA 1339
Qy 828 DLNKEQDKK-----IHGCDNIIORNDPEKKKKNFY-----NNNNIYIVN- 871
Db 1340 DSYSLQVDSKDIEMTITIVIRYYLNIYSIKFELKRNKQIFFOJFOENQMGVSLV 1399
Qy 872 -----NNMGNNSPRMKYGLGSHTSIDNMKNEMKDNEMKDNHKK 917
Db 1400 RDKRVENIKKMYLNSMKIINHDEILSLKSSININN-----KNFMICTNHEQTEEK 1453
Qy 918 SNNNSSSSSSNNNINNNINDDDTFQNDYCHNDNTFTIRKNTNINSNIYQDDIYIT 977
Db 1454 GNTQNKKEGDIYIGPIYNSPSTY-----TTHSSNNY--KGNIIHVSQD--YKNDGLHK 1505
Qy 978 INSLNDYMSNTLLHFKEKTYPTLSTNEDIYNKMEGHIRLDDQKYDDNDNNNVNNDNN 1037
Db 1506 GNN-----SNMB--CYVKKI-----CANNNNNNNNNN 1531
Qy 1038 KNNVNDNVNNDNVNNDNVNNDNNVNDNNVNDNDVDFHNIKNFNNNEKLYSFOKNDVT 1097

Db 1532 NNNNNSSY---NKLNCTVNNSSKNDI-----IKYHKTIIDTDSKNHTEYFK----- 1572
Qy 1098 IINNCLNSLD---ISSWYDDTKET-IANNILSKYAEKONVYIKYINEDIKNMSLEBIDK 1153
Db 1573 --NKFNLFLDKKITSINIGLPQSGSLNIIICSLYYAYLDK-----NEEQNL----- 1617
Qy 1154 TAOSIYERKRVLLTKLLELFKQVNDTOINNE---TSDLRKDLVWCHICNNNP----- 1202
Db 1618 ---LYSEK-----QINNKYFLANGT-----CNYFNLSILIRF 1647
Qy 1203 DDQHFPAVSRLEKDI-I-NILMLRQIWCESN-----LRLLYQ--FLVVEYQKNSAN 1251
Db 1648 IDDFLFTTLNKKIKIKIFKNLLKCKIKWGSINSSKTIKFIPLIYKNDLIIYNQNKYQK 1707
Qy 1252 SVLLNVSNNGDIIILNKKLVDONIKNSMDHN--NIHKK 1288
Db 1708 K-----KYKIKKKKKIO-SVRKURJHNOVLVANKK 1736

RESULT 27

US-08-446-855A-2
Sequence 2, Application US/08446855A
Patent No. 5849573
GENERAL INFORMATION:
APPLICANT: Stewart, Thomas S
APPLICANT: Flores, Maria V
APPLICANT: O'Sullivan, William J
TITLE OF INVENTION: Nucleotide sequence encoding carbamoyl
phosphate synthetase II
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nixon & Vanderhye PC
STREET: 1100 No. 5849573th Glebe Road, 8th Floor
City: Arlington
STATE: Virginia
COUNTRY: USA
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/446,855A
FILING DATE: 06-Jul-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mitchard, Leonard C
REGISTRATION NUMBER: 29,009
REFERENCE/DOCKET NUMBER: 47-80
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4000
TELEFAX: 703-816-4100
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 2391 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-446-855A-2

Query Match 7.8%; Score 533.5; DB 2; Length 2391;
Best Local Similarity 20.4%; Pred. No. 2.1e-30;
Matches 272; Conservative 225; Mismatches 404; Indels 431; Gaps 57;

Qy 189 ELILKIMID---GVILRKIGVNSQ-----NDSSSRSHAILN----- 220
Db 948 ELALKVITHTNIIIGECNIQFGINPQGEYCIIEVNAIRLSRSSALASAGATVPAYISAKI 1007
Qy 221 -----IDLKD-INKNTS-----LCKIAPIDLAGSERGADIVYSONKQOTQDGANI 263

Db 1008 ALGYDILSLKNSITTKTTACFEPSPLDYITTKIPRMWLINKEFASNTNWSMKSGVEYMSI 1067
Qy 264 NRSL-LALKECIRAMPDSKNIHIFR-----DSELTJVLARDIFVGSKSIAMIANISP-TIS 316
Db 1068 GRTEFESSIQSLACID--NYLGFSMTYCIIDWBEKIIIE-----LKNPSPKRIID 1115
Qy 317 CCEQTLNT-----LRYSRVYNFKKSTCINEEDTNTERTISILDSKG 359
Db 1116 AIHQAFHLMMPMDKIHETLHIDYWFPLHKFYNIYLNQKLT-----KLEQSPNDLKY 1169
Qy 360 SEMNASSIENVVKSNNHLS-----NNNNKTNRKINDKIRNNILKKSFKDKREGF 413
Db 1170 FKHGFSDDQIA---HLSFNTSDNNNNNNNISCRTVE---NDVMK-----Y 1211
Qy 414 TSFEGKYSINDIDKI-----KKNKKKG 436
Db 1212 REKLGLPHRIKVIYDITSAEPALTYLYLTQOGEHDVLPIMKRRKICTLANKRANANK 1271
Qy 437 LINYKSTLYN-----DNTINKKNNNNNNNNNDNDN-----NNNNNNNNDS 479
Db 1272 KVHVKHLYNEVVDKOTQOLHKENNNNNNNNSGVENKCKLANKESYGNNSSCMTNTNI 1331
Qy 480 SSMVNNMIMMIMNN 539
Db 1332 N--IENNICHDISINIKIKVITNNSSNISNNNEVBETN-----LN 1369
Qy 540 CHLNNDKSIPLHKKULRDIKLNKSSCONKKNLHLARHSVSKLTWFSYDPOK 599
Db 1370 C-----VSEKAGSHIIYKGEK-----SIGSDT--NILSAQ 1399
Qy 600 NKDTEFKSINIKMEDNTPDILYESRNVSNNGNVLLGINKTTHDITKDEHNHDKI 659
Db 1400 NSNNFSCNN-----EMNKANVDVNL-----ENDTKREEDINTTTF 1438
Qy 660 NNGVITINNSVNSINNSMANSINNSMANSIYSYNSNSGSDVQIRYVENDTSN 719
Db 1439 MEGQNSVINNKKE--NSSILKGEDEDIWVNLKKNENYNS-----VINVDCKR 1486
Qy 720 KNNND--NIFPDALSCNNMYPNITNNN-----NNNNNNNNNNNIDVENYNNND--GTN 770
Db 1487 KMDGKNIINDECTYKKNYKKGGLNNNIVDELSTGTSHTDHLVLDNFNTSDEETGNN 1546
Qy 771 NSMKLYAYNSHNLPQDNNKNTSN-----IONITNKN--NODGNVNS 812
Db 1547 KKNNDVLSKESKJ-----SKNKPENSYVVDVYNNNEKIKKMKELIDNEIENLDEYNNNV 1602
Qy 813 MNFCNYLNDKQVYLDLNNKEQKDKNIHGC--DNNTIQNRNDEPKKKTNFYNNNNIYVN 871
Db 1603 MNCSTNYN---NASAFVNGKDRDNLENDCIEKMDHTYKYHYNLRNRSTERNMLMVN 1658
Qy 872 NNNGNNSPRMKYGLCGSHTSIDNMKNEMKNNEMKNNEMKNNNNSSSSSSNN 931
Db 1659 NEKESNHEKGRNGLNKKKKEKMKKGNKD--KKNHYYVHKKNNEYSNNISKFN 1717
Qy 932 NIYNINDDTEFONDYCHND--NTFTIRKQNTINSINYONDIIYTINSIANDYMSNTLL 990
Db 1718 NYVDIDINKKEYEDE--NDIYFTHSQGN-----NDNL-----SNQNYLSSEEL 160
Qy 991 HFEKETYPTLTNEDITYNKEMEGKHRLDDQDKYD--NDNNNVNNNNKQNVN--NV 1045
Db 1761 NTDE-----YDDDYDYDE-----DEEDYDDDDDDDDDDDEDEEDNDYND 1804
Qy 1046 DNNNVNDNVNDNDKNNVD-----NNNVNDND--DDVDPHNIKKNPNNNE----- 1086
Db 1805 DGYDSYNSLSSSKISDVSSVYISGNENITNEKYNIDGFKIIDRNKEKEKKKCFVLGC 1864
Qy 1087 -----YLSYQKQVNDTIINNCLNSLDISSYVDT-----KEILNLI 1123
Db 1865 GCYRIGSVPEPMSAHCYKTRIKLNHKAILLNC--NPEIVSTVDYDSRLYFDEITTEYI 1923
Qy 1124 LSKYRAEKON-VYKKTINEDIKMSLEBIDKTAQSIYEKRVLLTKLLELFKQVNDTOIN 1182
Db 1924 KPIYNPENSNGVIAFGQTSNNL-----VPSLYKNV----- 1956


```

; APPLICANT: Williams, Mark
; TITLE OF INVENTION: STAGED ASSEMBLY OF NANOSTRUCTURES
; FILE REFERENCE: 8471-010-999
; CURRENT APPLICATION NUMBER: US/09/914,259
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 967
; TYPE: PRF
; ORGANISM: Loligo pealeii
US-09-914-259-21

```

```

Query Match      7.3%; Score 500.5; DB 4; Length 967;
Best Local Similarity 22.1%; Pred. No. 1,6e-28;
Matches 217; Conservative 189; Mismatches 403; Indels 175; Gaps 35;

```

```

QY 5 IKVVRKRPLSELEKKKSDITVKNCTLYIDPRYKVDKTYIERHEFIVDKYFDDT 64
DB 9 IKVCHVRPLNEAEERAGSKFIL-----KFPDSDISLAGVFVFDKYLKPN 55
QY 65 VDNFTYENTIKLLIIDYENGVCSCFAYGOTSGKTYTMLGSQPYGSDTP---GIFQ 121
DB 56 VSGEYVYVNAKPIVADVL--SGCNGTIFAYGQTSSGKTHM---EGVLDKESMHGILP 109
QY 122 YAAGDIFPLNYDKONTKGIFFSFEIYCGKLYDLLQKKMVALENGKEVAVVDLKI 181
DB 110 RIVQDIFNYIYGMDEWLEPHIKSYEIIYDKIRDLIDVTKMLVAHEDKNRPPFKGAT 169
QY 182 LRVLYKEELIKMID--GVLLRKIGVNSQNDSSRSHAIINIDIKINKNTS---LQKIAF 237
DB 170 ERFVSSPEEVEVIEDGKKNRHVAVTNMHSHSRSHSVFLINQOEVEVETOKLSGLYL 229
QY 238 IDLAGSERADYVSKQKOTDGANINRSLAKKECIKRAM--DDKRNHPRDELTIKVL 296
DB 230 VDLAGEKYSKTAEG--AVLDEKKNINKSLGALGNVIALADKNKHVPYRDSKLTIRIQ 288
QY 297 DIVEGSKSMIMANISPTISCEOTINTLAYSRVKFKKSTCINBE-----DDT 347
DB 289 ESIQGNARTMTVCCSPASINSESTSLIFGQRAKTIK--VSVVBEELADMEKRYEK 347
QY 348 NTERISILDSKSEMNASSIENVIKSNHLLSNNNKINRGKINDKI---ERNMILKKN 404
DB 348 EKERVTKLKATWAKLBA-----ELQRMRTGQAVSVEQVDLKEVY 387
QY 405 SPFKREBGTFS--TFGKYSLANDIKKAKKGLINYKSLTYNDNTINK----- 453
DB 388 PASEPATSTTSLAGLIASNMEDRTQLEBER--LKLQQDLDDKDEINQSLIEKLKQ 446
QY 454 -----HNNNNNNNNNDNNNNNNNNNNNNNNSSMVNNMIMNINNNINNVN 504
DB 447 MNEQEBLIAOSRDYENLQODMSRIQADNESAKOBEYKVLQALELANAYDQKSOYEDEK 506
QY 505 NNNNNNNNNSHNNHLPOPNYAFTDTSDFSSLDDMNGHLNNNDKSIPLHKKNLNDI--KL 562
DB 507 NKENENLSEELNQL-----STLNSLQWBLDQLKDSMHHKRVAVDMINIL 553
QY 563 KRRSSCDNIMKKKNNLHLARHSVSKLTMFSYDPOKKNONTFFKSNINKMEONTPKOL 622
DB 554 KDLGIDIGTIVG--GNAAEKPTAGS-----GEKIEEFYARLYISKMS----- 596
QY 623 YESRNVSNMNGVLLGLKNTTHHDISTKDNHNDNKINNGVINIINNSVNSINNSMNS 682
DB 597 -EYKTVSRNNQI-----EVTQODNFKLITHEKDLSNCKLLIQHEAKMASIQEAKIDS 650
QY 683 INNSNNNSIYKSNYNSQISDVQIRYV---NEMDTSKNKNDNIFPDALSNDNNMP 738
DB 651 ENKCKMLIEDVDSLNEBYAKLKAQEBQHLLALESEKREKTSQASETR---EVLKQWEMH 707
QY 739 NITNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 795
DB 708 E-OHQROLSDRDEISEKATVNLKD-DNQRSLALEKLQD--DYDKLQOEVEVERAKL 763

```

```

QY 796 QNINIRKNNQ-----DGNVNSKNFCHYNLNDKNYIDLNNK-----EQDK 837
DB 764 ADLSIQIDRREQAKODLKGLIEFVAKEQLTLH-NLR-KLFLVODLQKKVCSKTEBEDE 821
QY 838 NIHGCNNIIONRNDPEKKKTTFYNN--NIYVNNMGNNS-----PRKXGLGCS 889
DB 822 DTGG-----NAAQOKISFLENNLEQLTKYKQIVRNADLRCELPLEKRL--- 868
QY 890 HTSIDNKNMKNEMKNEMKD 913
DB 869 RATMERVKSLESALKAKGAMRD 892

```

```

RESULT 30
US-09-541-782-2

```

```

; Sequence 2, Application US/09541782
; Patent No. 6284480
; GENERAL INFORMATION:
; APPLICANT: Naslow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Berand, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/541,782
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 1184
; TYPE: PRF
; ORGANISM: A. nidulans
US-09-541-782-2

```

```

Query Match      7.3%; Score 500; DB 3; Length 1184;
Best Local Similarity 21.1%; Pred. No. 2.4e-28;
Matches 253; Conservative 194; Mismatches 415; Indels 338; Gaps 48;
QY 2 NSKIKVVRKRPLSELEKKKSDITVKNCTLYIDPRYKVDK--TKYIERHEFIVDKY 60
DB 79 DTSIHVVACRGKRENEVEKNSGVVLTQEG-----VKGKVELSMGPNVNSKTYTFDKY 133
QY 61 FDDTVDNFTYENTIKPLIIDYENGVCSCFAYGOTSGKTYTMLGSQPYGSDTPGIF 120
DB 134 FSAADQIIVYEDVPLVITEMLA--GYNCTIFAYGQTGKTYTMGSD---MTDILGIL 188
QY 121 QVAAGI-----FTPLNIDKONTKGIFFSFEIYCGKLYDL-----QKR 161
DB 189 SDNAGIIPVLYSLFAKLADTEST--VKCSFIELVNEELRDLISAENPKLIYDNEQKK 246
QY 162 KVAALENGKKEVVVD-----LKILRVLTKEBLIKMIDGVLLRKIGVNSQNDSSRSHA 217
DB 247 GHVSTLVQWMEETIYISATAGIKLQD-----QSHKRVAAATKCDLSRSRST 294
QY 218 ILNIDKIDINKTSL-----GKIAFIDLAGSERGADTVSKQKOTDGANINRSLAL 270
DB 295 VFTITV-NIKRTSESGEYVCGKLNVLVDLASENIGRGAERKRA--TEAGLINSKLTLL 352
QY 271 KECIRAMSDKNIHPRDELTKVLDIVGSKSMIMANISPTISCEOTLNTLKYSSR 330
DB 353 GRVYNALVKSQHIPIYRESKLTIRLQDSLGGRTKTOIIATMSPARSNLEETISTLYAFR 412
QY 331 VKNFKKSTCIN-----EEDDTNERISILDSKSEMNASSIENVVI--KS 374
DB 413 AKNIIRKPO-INSTMEKMTLLEFTEIEKLAELIATHRNQVNVSVSEYEEMKNENES 471
QY 375 NHLSSNNNNKIN--RGKINDKIERNNILKNKSPDKREBGTSTFGKYSLANDI---DK 428
DB 472 BRITSEQAKIESMESSLRHKVQELTLTSK--FNDLKKDNDPTLALCSTNDVLQOTDI 530
QY 429 IKKKK-----KGLN--YKSTLYNDNTINKKNNNNNNNNND 463
DB 531 VLNTRQAOLEEBEEMRLCAHEETEHOLODVKGGLISTLQGTVEDINLSQK-----LD 582

```

```

QY 464 NNDNNNNNNNNSSSMVNMNMHNNNNI-----NNNNNN-----NN 504
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 583 RKAEIDATNMLWMASSSTEVS-D-VTKRIDQVEAFQTRHAKLLETTSVKVFIATEISN 641
QY 505 NNNNNNNNNHNNHLPQ-NTAFPTSDSFSLDDMCHLNNDKSIPLHKKNLBDNITLK 563
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 642 IERTSDISEYRSLDAACNNAKAETS--SAHEDMN-----NVLEIIDLBEVYSK 691
QY 564 NRSSCDNIMNKKNNHLLARHSVSKLTMSFYDQKNDKTFPKSNINKMEDNTPKOLY 623
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 692 -----VGEGLNGLSAAARISEEVI-----GEFTQHSQULTSFFNKGDL- 732
QY 624 ESRNVSMNGVNLGLNKTHHDISTKDEHNDKNNKINGVINIINNSVNSINNSNMNSI 683
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 733 -----KSIFETMAT-HLSQKNEIN-----LRALQSSNQNIEFT 768
QY 684 NNSMNSNISIYKSNVNSNOSTSDVOIRYVEMDTSNKNDNIFPDA-----ISCNN 735
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 769 HKASAHILAQALIEEBHVAEAEREILMSQIKALVESROKOPARAKIDGVTETISASGD 828
QY 736 MYPIITNNNNNNNNNNNNNNNNNNNNNNNDGTNSMKLYAYNSHNLFOPDNNKNTSNI 795
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 829 MLEQAT-----TQHDROIDEWVF-----KSEQFA 852
QY 796 QNINTNNKNDGNVYSMNFCHYNLNDKNYLIDLNKEQKDKNTHGCDNNIIONRNDPEK 855
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 853 KDVAASKD-----EIRTKLQNDWEAFDQNSIT 880
QY 856 KKKTNFYNNNNIIVN--NNMGNNSPRMKYGLCGSHTSIDNMKNEMKNEMKDNEMK 912
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 881 RKATESYHKEIVRIYDVOVDMGROME-----ALDDFAKARSON--GRYR 924
QY 913 DNHIKSNNNNS-----SSSSNNNIYNNINDPTFONDYCHNDNFTIR-----RKN 960
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 925 DAHIAITDITATGVRDYSSTIEGRVENLTGRMNOFOQATHHHATLESIAPLSNDVKP 984
QY 961 NTNINSNIYQNDIITYTINSNDYMSNTLHFKEKYT---PTLSTNEDIYN-----KE 1011
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 985 LTDLSSS-FQV-----RSLBEYVATGVTPKKRYDYISVLPSTESHEVLKSRRTTKE 1036
QY 1012 MEKGIRLLDQDK-----YDND-----NNVYDNNKNNVNNV 1045
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1037 MEVLFPNSDDQLSGPSSSPGSPSKGFYNDVEDEVGTHAPVTYVNVNSNGLREVDAV 1096

RESULT 31
US-09-723-820-2
; Sequence 2, Application US/09723820
; Patent No. 6468760
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Betaud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/723, 820
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/541,782
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 1184
; TYPE: PRT
; ORGANISM: A. nidulans
US-09-723-820-2

Query Match 7.3%; Score 500; DB 4; Length 1184;
Best Local Similarity 21.1%; Pred. No. 2.4e-28;
Matches 253; Conservative 194; Mismatches 415; Indels 338; Gaps 48;
2 NSKIRVVVRKRPLELEKKKDDIITYKNNCTLYIDPRYKVDV-TKYIERHREIVDKV 60
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

Db 79 DTSIHVVVRGRGRNEREVKNSGVLTQEG-----VKGKTVELSMGNVANSKTYTEDKV 133
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 61 FDDTVDFNFTYVENTIKELIIDLYENGCVCSCFAYAGTSGKTYTMLGSGPYGOSDTPGIF 120
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 134 FSAADQITTYEDVVLPIVTEMLA-GYNCITFAVGOTGTCTKTYMSD-----MTDITGIL 188
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 121 QYAAGDI-----FTFLNIYDKDNTKGIPIFPEYIYCGKLYDL-----OKR 161
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 189 SDNAGILPRVLYSFAKADTEST--VKCSFIELYNBELDLSAEENPKIKIYDNOQK 246
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 162 KMAVALENGKEVYVKD-----KLIRLVLTBEELLKIMIDVLLRKIGVNSGNDSSRSRA 217
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 247 GHWSTLVQGMEEYTIIDATGATGILQ-----QSHKQVATYKNDLSSSHT 294
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 218 ILINDLDINKNTSL-----GKIAFIDLASERGADTVSONKOTODGANIRSLAL 270
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 295 VFTITV-NIKRTTSGSEYCYCPGLNVLDAAGSNIGRSGAENRA-TEAGILKSLITL 352
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 271 KECIRAMDSDKNHIFPDSELTGYLIDIFVGSKSIIMANISPTISCCBOTLNTLYSSR 330
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 353 GRVINALVDKSQIHPIYRESKLTRLQDSLGRTXCIIATMSPARSMLERTISTLDYAFR 412
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 331 VKAFKAKSTCIN-----BEDTNTFRIILDSKSGENMASSIENTVI--KS 374
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 413 AKNIRNKPQ-INSTMPKTLREFTAEIEKLABELIATRRHNGVYMSVESEEMKENES 471
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 375 NHLSSNNNNKIN--RGKINDIERNNILKNKSPDKREGFTSPFGYSSINDI-----DK 428
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 472 RRIISEORAKIESMESSLRKHVQELLTLISK-FNDLKNDNDTLAALCSNDVLOQTDI 530
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 429 IKRKKK-----KGLIN-YKSTLYNDNTINKGNNNNNNND 463
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 531 VLQNTBQLEBEEMLRCAHEETEHQLODVGKGLISTLGQVEDINSLSK-----LD 582
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 464 NNDNNNNNNNNNNSSSMVNMNMHNNNNI-----NNNNNN-----NN 504
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 583 RKAEIDATNMLWMASSSTEVS-D-VTKRIDQVEAFQTRHAKLLETTSVKVFIATEISN 641
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 505 NNNNNNNNNHNNHLPQ-NTAFPTSDSFSLDDMCHLNNDKSIPLHKKNLBDNITLK 563
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 642 IERTSDISEYRSLDAACNNAKAETS--SAHEDMN-----NVLEIIDLBEVYSK 691
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 564 NRSSCDNIMNKKNNHLLARHSVSKLTMSFYDQKNDKTFPKSNINKMEDNTPKOLY 623
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 692 -----VGEGLNGLSAAARISEEVI-----GEFTQHSQULTSFFNKGDL- 732
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 624 ESRNVSMNGVNLGLNKTHHDISTKDEHNDKNNKINGVINIINNSVNSINNSNMNSI 683
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 733 -----KSIFETMAT-HLSQKNEIN-----LRALQSSNQNIEFT 768
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 684 NNSMNSNISIYKSNVNSNOSTSDVOIRYVEMDTSNKNDNIFPDA-----ISCNN 735
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 769 HKASAHILAQALIEEBHVAEAEREILMSQIKALVESROKOPARAKIDGVTETISASGD 828
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 736 MYPIITNNNNNNNNNNNNNNNNNNNNNNNDGTNSMKLYAYNSHNLFOPDNNKNTSNI 795
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 829 MLEQAT-----TQHDROIDEWVF-----KSEQFA 852
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 796 QNINTNNKNDGNVYSMNFCHYNLNDKNYLIDLNKEQKDKNTHGCDNNIIONRNDPEK 855
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 853 KDVAASKD-----EIRTKLQNDWEAFDQNSIT 880
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 856 KKKTNFYNNNNIIVN--NNMGNNSPRMKYGLCGSHTSIDNMKNEMKNEMKDNEMK 912
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 881 RKATESYHKEIVRIYDVOVDMGROME-----ALDDFAKARSON--GRYR 924
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 913 DNHIKSNNNNS-----SSSSNNNIYNNINDPTFONDYCHNDNFTIR-----RKN 960
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 925 DAHIAITDITATGVRDYSSTIEGRVENLTGRMNOFOQATHHHATLESIAPLSNDVKP 984
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 961 NTNINSNIYQNDIITYTINSNDYMSNTLHFKEKYT---PTLSTNEDIYN-----KE 1011
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 985 LTDLSSS-FQV-----RSLBEYVATGVTPKKRYDYISVLPSTESHEVLKSRRTTKE 1036
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```



```
Db 246 NQWVRIAKSLIDLAGER-ASTSGAKGTRFVGTINRSLALGVYNALADSKISFLC 304
Qy 282 -----NHIPRDESEFLVLDIFVCGSKSIMIANISPTISCCQTLNTLAFSRVKNFKN 336
Db 305 FQKRNQHIPIRNSKLTIRLKKOSLGNCQTTIMAAVSPSSVFYDITNTLYKANRADIKS 364

RESULT 36
US-09-541-782-4
; Sequence 4, Application US/09541782
; Patent No. 6284480
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/541,782
; CURRENT FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 1038
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-541-782-4

Query Match 6.8%; Score 465; DB 3; Length 1038;
Best Local Similarity 20.2%; Pred. No. 7.5e-26;
Matches 246; Conservative 172; Mismatches 366; Indels 434; Gaps 46;

Qy 5 IKVVRKRLPSELEKKKDDSIITVKN-----NCTLYIDPRYKVMYKTYIRHEF 55
Db 75 IYVAACRGNRNEISMSSVVVAVPDITGSKISINTT-----GDTGITAQMKAKRY 127
Qy 56 IYDVFDDTVNDFVYENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLAGSQPY--GQ 113
Db 128 IYDVFDPGASQDLIFDEVAGPLFQD-FIKGYNCYLVVGMSTGKTYTMTGDEKLYNGB 186
Qy 114 -SDTPGIFQYAGDITFLNIYDKNTKGIFFIYEGCKLYD----- 156
Db 187 LSDAAGIIPRLVLFDTLELQNDYV--VKCSFIEIYNEELKDLDSNNGSSNTGFDG 244
Qy 157 -----LQKRWAAALENGK 171
Db 245 QPMKRLIRIASSANTNTNSASSSSRNSRNSPRLNDITPQALLRKLTKYSLPNTI 304
Qy 172 KE-----VVVQDLKILRY 184
Db 305 KQOYQOQAVNSRNNSSSGSTTNASSTNTNNGQSRSMAPNDQTNIGYIQNLQDFHI 364
Qy 185 LYKEEILKMDIGVLLRKIGVNSQNDSSRSHAILNDL--KQINKNTSLGKIAFDLAG 242
Db 365 TNAMEGIANILOKGLKRRQVASTMNDPSSRSHTIFITLYKKQDELFRISKNNLVDLAG 424
Qy 243 SERGATVSONKOTQDGNINRSLALKECIAMSDKNIIFERSELTLYVDFVYK 302
Db 425 SENINRSGALNCGAKAG--SINQSLTLGLRVINALVDKSGHLPFRSKLTIRLQDLSGN 483
Qy 303 SKSIMIANISPTISCCQTLNTLRYSSRVNPFNKSTCIINEEDTTERISIDSKGSEM 362
Db 484 TKTALATISPAKVSTSEETCTLEFVASKAKINIKK-----PQI 521
Qy 363 NASSINNVVYKSNHLSNNNNKINRGTNDKTERNNLIKNSFDKPRGFTSTPEKYS 422
Db 522 GSEIMDILYK-----NITMELAKI-----KSDLSTKS-----KEGIYMSQDHYNK 563
Qy 423 LN-DIDKIR-----KMKKGLINYKSTLYNDNTINKHNNNNNNNNNDNNNNNNNN 475
Db 564 LMSDLESYKNEVEQCKREIESTLSKVALVKDLAKSETIQQSONCIES----- 612
Qy 476 NNDSSSMVNMIMNM--INNINNNINNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 532
```

```
Db 613 -----LKTIDHLRAQDLQKHTEIEISDFNNKLQK-----LTFVQM 650
Qy 533 SSIDNNCHLNNDK---SIFLKKLRLDNKIK--NRSSODNIMNK--KNLHLARSHV 586
Db 651 ALHDYKRELDLQCKEEMHYTEIKLKSTLFQILNTMOQESILQSTNIQPNIDMIKNEV 710
Qy 587 GSKLTMSYDPOKRNKNTFFKSNINRMEEDTNPDIIESRNVSNMGNVLLGLKNTTHD 646
Db 711 ---LTLMR--TMOEKALMYKQCVKKILNBSERK----- 738
Qy 647 ISTKDEHNDKINNGVINIINNSVNSINNSMANSINNSMANSIYKSNVNSQISD 706
Db 739 -----FFNVV-----IEKIDIRVDFQFYK---NIAELSD 767
Qy 707 VOIRYVEMDTSKND-----NIFPDALSCNNMYEPNITNNNNNNNNNNNNNNNN 760
Db 768 I-----SENNMKQYLNKHPF-----KNHOBELNRHVSTYENIEKRTNEFV 811
Qy 761 ENYNN--RDGTNNSMKLYAVN-----SHNLFQDPNNKNTSNIQININTKANNQD 807
Db 812 ENFKYVLDHLDENKGLIHNLITATSAYIDQEMDLFEPRK----- 851
Qy 808 NVNYSNMFCHYNLDRKYLIDLNKKEQDKNIHGCNNITIQNRNDEKKKKTNFYNNNI 867
Db 852 RVKWNSEF-----DL-----INDCDS---MNEFYNSMAATLSQIKST 886
Qy 868 VYVNNMKNNSPRMYKGLCGSHITSIDNKNMKNMKNMKNMKNMKNMKNMKNMKNMKN 927
Db 887 VDTSSNMSIESIVMGQVEESENALSLKNTKTFNDQFQOLINKNMKDNINKSITST 946
Qy 928 SSN---NNIYNNINDDTFQNDYCHNDNTFTIRKQNTNINSNIYQNDIITYNSLND 983
Db 947 HSHITVDDIYNTIF-----NIMKN-YGNKE-----NATKD 976
Qy 984 YMSNTLLHFKKXYPTLSTNEDIYNKEMEGRIPLDDQKYDDNDNNVNNNNKNV-- 1041
Db 977 EMENTIL--KE--IPNLS-----KKMP--LRL-----SNINSVQSIVS 1010
Qy 1042 -----DNNVNNNNVDN 1052
Db 1011 PKKHALEDENKSENVND 1028

RESULT 37
US-09-723-820-4
; Sequence 4, Application US/09723820
; Patent No. 6468760
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/723,820
; PRIOR APPLICATION NUMBER: 2000-11-28
; PRIOR FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 1038
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-723-820-4

Query Match 6.8%; Score 465; DB 4; Length 1038;
Best Local Similarity 20.2%; Pred. No. 7.5e-26;
Matches 246; Conservative 172; Mismatches 366; Indels 434; Gaps 46;

Qy 5 IKVVRKRLPSELEKKKDDSIITVKN-----NCTLYIDPRYKVMYKTYIRHEF 55
Db 75 IYVAACRGNRNEISMSSVVVAVPDITGSKISINTT-----GDTGITAQMKAKRY 127
```

```

QY 56 IYDVFPDVTVDNFTVYENTIKELIIDLYENGVCSCFAYGOTGSKTYTLMGSOBY--GQ 113
D 128 TWDVYFPGASODILFEBVAGPLFOD-FIKGYNCTVLVYGMTSGKTYTLMGDEKLYNGE 186
QY 114 -SDTPGIFQYVAGDIFTELNYDKONTGFISEFYEYCGLYD----- 156
D 187 LSDAAGIIPRYLKLFTLLEQONDYV--VACSFIELNEELKOLLDSNSGSSNTGPDG 244
QY 157 -----LQKRCMVAALENGK 171
D 245 QPMKRLIFASSTANTTSNSASSRSNSRNSSPRLNDLTPKALLKRLRTSLPVTI 304
QY 172 KE-----VVVKDLKILRV 184
D 305 KOYQOQOQAVNSRNNSSSGSTTNMSSNTTNNGQSSMAPDQTMGIYIIONQEPHI 364
QY 185 LTKRELKIMIDVLLRKIGVNSQNDSSRSHAILNIDL-KDINKTSLGKIAFIDLAG 242
D 365 TNAMEGNTLQKGLKHQVASTKONDPSSRSHITFTILYKQODELFRISKMLVLDLGA 424
QY 243 SERADIVSQKQOTODGANINRSLALKECIRAMDSPKHIIPRDSFLTVALDIPYK 302
D 425 SENINRSGALNQRAKEAG-SINOSILTLGRVINALVDSGHIIPRESKLTRELDSDSGN 483
QY 303 SKSIMINISPTISCCBOTLNTLRYSSRVKPKKSTCINEDDPTNERISILDSKSEM 362
D 484 TKMLALITISPAKYTSEETCTLEYASAKAIKXK-----POL 521
QY 363 NASSIENVVIXNHLSSNNNNKINRGKINDIERNNILKXKSPDREGTSTFGYXS 422
D 522 GSFIMKDLVX-----NITMELAKI-----KSDILSTKS-----KEGIYMSODHYKN 563
QY 423 LN-DIDIK-----KXKGLINYKSTLYNDNTINKGHNNNNNNNNNDNNNDNNNN 475
D 564 LNSLSEYKXEVOCREIESLTSKNALLVDPKLSKETIOSONCOIIS----- 612
QY 476 NNDSSWVNNMINNH-----INNINNINIVNNNNNNNNNNNNNNNNHLLPQVYAFDTSD 532
D 613 -----LKTIDILHRAOLDKQHKTEIISDPNNKLOK-----LTVWQM 650
QY 533 SSLDMNCHLNNDK-----SIFLHKKNLRDNIK-LNRSSCDNINNK-----KONLHARSHV 586
D 651 ALHDYKRELDLNOQFEMHITKEIKKSTLFLQNTQOSILQETNIQPLDMIKNEV 710
QY 587 GSKLTMSYDPOKAKONTPEKSNINXKMDNTPKOLLYESRNVSNMNGVLLGLAKNTHD 646
D 711 ---LTLNR--TMOEKALMYKDCVKKILNESPK----- 738
QY 647 ISTDENNDKKNNGVNIINNSVNSINNSNNNSIYKSNYNSQISID 706
D 739 -----FNNV-----IKIITIRYDPOKFK-----NLAENISD 767
QY 707 VOIRVYEMDTSNKND-----NIFDALSCDNNMYNITNNNNNNNNNNNNNNNDIV 760
D 768 I-----SEENNNKQYLYKNHF-----KNNHQLNBRHVSITYENIEKKTNEFV 811
QY 761 ENYNN--RDGTNNSKLYAYN-----SHLFPQDNKAKTSNIQNTNKNQD 807
D 812 ENFKKVLNDHLDENKGLTMRHLYTATSAVIODEMDLFEPR----- 851
QY 808 NVANSNMFCHYNLDKNTLIDLNKEQDKNIHGGDNIIQNRNDFEKKKKTNFNNNI 867
D 852 RYKMNST-----DL-----INDCS-----MNEFYMSAALTLSQIST 886
QY 868 VIANNMGNNSPRKYGCGSHTSIDNMKNEMKONEMKDNHKSNNNSSSS 927
D 887 VDTSSNMSIESVKGQVESENAISLKNNTKFNQDEQJINKHMLKONIKSIST 946
QY 928 SSN-----NIIYNNINDDTFQNDYCHNDNTFTIRKKNNTINSNIYONDIIYTNLSND 983
D 947 HSHITNVDDIYNTI-----NIMKN-YGNKE-----NATKD 976

```

```

QY 984 YMSNTLLHFKEKYPTLSTNEDIYNKMEGKHIRLDDQKDYDNDNNNNNNNNV-- 1041
D 977 EMENIL--KE---IPULS-----KKMP---LRL-----SNINSVQSVIS 1010
QY 1042 -----DNNVNNNDVN 1052
D 1011 PKKHAIEDENKSENVDN 1028

RESULT 38
US-09-724-511-4
; Sequence 4, Application US/09724511
; Patent No. 6391601
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6391601el motor proteins and methods for
; FILE REFERENCE: 1046
; CURRENT APPLICATION NUMBER: US/09/724,511
; PRIOR FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/632,344
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 355
; TYPE: PR
; ORGANISM: Human
US-09-724-511-4

Query Match 6.8%; Score 464.5; DB 4; Length 355;
Best Local Similarity 34.0%; Pred. No. 1.8e-26;
Matches 122; Conservative 65; Mismatches 137; Indels 35; Gaps 6;

QY 5 IKVVRKRPUSLEKKKKSDIITVKNKCTLYIDEPYKVD-----MTKTYER 52
D 4 MKVVRVRPEVTEKKAAGFHKVYHVVDKHLVFPDKQEVVSFFHGKTYNQNVYKONKD 63
QY 53 HEFTVDKVPDVTVDNFTVYENTIKELIIDLYENGVCSCFAYGOTGSKTYTLMGSOBY 112
D 64 LKFPDVPFBETSTQSEVFPHHTKP-ILRSFPLNGYNTVLAYGATGAGKTHMGS--- 118
QY 113 QSDTPGIFQYVAGDIFTELNYDKONTGFISEFYEYCGLYDLOKRCMVAALENGK 172
D 119 -ADPEGMVYLMHLYKCMOBEIKEKICSTAVSYLEYVYNNQIRLVLVNSGLAVREDTOK 177
QY 173 EVVVKDLILVLTKEELILKMDIGVLLRKIGVNSQNDSSRSHAILNIDIK-----DI 226
D 178 GVVHGTLHQPKSSEILHLLDNGKNKRCQHPDPMNATSSRSHAVFOIYLRQODKTASI 237
QY 227 NKQTSLGKIAFIDLAGEGRADIVTSQNKQOTODGANINRSLALKECIRAMDSDK----- 281
D 238 NQNVRIAKMSLIDLAGSER-ASTIGAGTRFVBETNINRSLALGANVINALADSKISFLC 296
QY 282 -----NHIPRDSFLTVALDIPYKSKSIMIANISPTISCCBOTLNTLRYSSRVKXK 335
D 297 FORKNQHIPIYNSKLTLLKDSLOGNCOTIMIAVSVSSVYDDTYNTLTKANAKDIX 355

RESULT 39
US-09-723-097-4
; Sequence 4, Application US/09723097
; Patent No. 6492151
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6492151el motor proteins and methods for
; FILE REFERENCE: 1046
; CURRENT APPLICATION NUMBER: US/09/723,097
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/632,344

```

```
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 355
; TYPE: PRT
; ORGANISM: Human
US-09-723-097-4
```

Query Match 6.8%; Score 464.5; DB 4; Length 355;

Best Local Similarity 34.0%; Pred. No. 1.8e-26;

Matches 122; Conservative 65; Mismatches 137; Indels 35; Gaps 6;

```
QY 5 IKVVVRKRPSELEKKKSDIITVKNKNTLYIDEPKYD-----MTKYIER 52
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 4 MKVVRVRPENTTEKAGFHVHVVDKHLVDPKKEVSFPHGKTTNQNVIKKQND 63
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 53 HEPIVDKVPDVTYDNFTVYENTIKPLIIDLYENGCVSCFAYGQTSCKTYTLMGSQPYG 112
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 64 LKRFVDAVFDETSQSEVFETHTKP-ILRSFLNGYNTCTVLAAGATGAKTHMLGS---- 118
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 113 QSDTPGIFQYAGDIFTEFLNIYDKNTKGIIFISFEIYCGKLYDLQKRMVAALENGKK 172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 119 -ADEPGVMYITMLHLKYKMDIKEKICSTAVSYLEVYNEQIRDLVNSGFLAVREDTQK 177
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 EVVVKDLKILRVLTKEELIKMIDGVLRLKIGVNSQNDSSRSHALINIDLK-----DI 226
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 178 GVVVHGLTLHQPSSEIHLHLNDGNKNTQHPIDMNAISSRSHAVFOIYLRQODKTASI 237
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 227 NKNTSLGKIAFIDLASRGADTVSONKQOTDGANINRSLALKECIRAMDSK----- 281
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 238 NQVVRIAKMSLIDLASER-ASTSGAKGTRFVEGTNINRSLALGNVINALADSKISFLC 296
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 282 -----NHIPRDELTQVLADIFVGSKSIIMIANISPTISCCQTLNTLAYSRRVKNFK 335
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 297 FQRKNQHIPIYRNSKLTRLLDLSGNCQTMIAVSPSVFYDDTYNTLYKANRAKDIX 355
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

RESULT 40

```
US-09-632-344-4
; Sequence 4, Application US/09632344
; Patent No. 6534309
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6534309el motor proteins and methods for
; FILE REFERENCE: 1046
; CURRENT APPLICATION NUMBER: US/09/632,344
; CURRENT FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 355
; TYPE: PRT
; ORGANISM: Human
US-09-632-344-4
```

Query Match 6.8%; Score 464.5; DB 4; Length 355;

Best Local Similarity 34.0%; Pred. No. 1.8e-26;

Matches 122; Conservative 65; Mismatches 137; Indels 35; Gaps 6;

```
QY 5 IKVVVRKRPSELEKKKSDIITVKNKNTLYIDEPKYD-----MTKYIER 52
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 4 MKVVRVRPENTTEKAGFHVHVVDKHLVDPKKEVSFPHGKTTNQNVIKKQND 63
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 53 HEPIVDKVPDVTYDNFTVYENTIKPLIIDLYENGCVSCFAYGQTSCKTYTLMGSQPYG 112
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 64 LKRFVDAVFDETSQSEVFETHTKP-ILRSFLNGYNTCTVLAAGATGAKTHMLGS---- 118
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 113 QSDTPGIFQYAGDIFTEFLNIYDKNTKGIIFISFEIYCGKLYDLQKRMVAALENGKK 172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 119 -ADEPGVMYITMLHLKYKMDIKEKICSTAVSYLEVYNEQIRDLVNSGFLAVREDTQK 177
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

```
QY 173 EVVVKDLKILRVLTKEELIKMIDGVLRLKIGVNSQNDSSRSHALINIDLK-----DI 226
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 178 GVVVHGLTLHQPSSEIHLHLNDGNKNTQHPIDMNAISSRSHAVFOIYLRQODKTASI 237
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 227 NKNTSLGKIAFIDLASRGADTVSONKQOTDGANINRSLALKECIRAMDSK----- 281
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 238 NQVVRIAKMSLIDLASER-ASTSGAKGTRFVEGTNINRSLALGNVINALADSKISFLC 296
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 282 -----NHIPRDELTQVLADIFVGSKSIIMIANISPTISCCQTLNTLAYSRRVKNFK 335
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 297 FQRKNQHIPIYRNSKLTRLLDLSGNCQTMIAVSPSVFYDDTYNTLYKANRAKDIX 355
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

Search completed: October 2, 2003, 16:28:17

Job time : 44 secs

THIS PAGE BLANK (10/10)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:20:46 ; Search time 85 Seconds
(without alignments)
2397.392 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 6842
Sequence: 1 MNSKIKVVRKRPLESLERK.....KXIVQDINKSMDDNNHKK 1288

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 587654 seqs, 158212981 residues

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-Processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications_AA:*

- 1: /cgn2_6/ptodata/2/pubppa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/2/pubppa/PCT_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/2/pubppa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/2/pubppa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/2/pubppa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/2/pubppa/PCTUS_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/2/pubppa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/2/pubppa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/2/pubppa/US09_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/2/pubppa/US09_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/2/pubppa/US09_PUBCOMB.pep:*
- 12: /cgn2_6/ptodata/2/pubppa/US09_NEW_PUB.pep:*
- 13: /cgn2_6/ptodata/2/pubppa/US10_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/2/pubppa/US10_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/2/pubppa/US10_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/2/pubppa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/2/pubppa/US60_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/2/pubppa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	length	ID	Description
1	6842	100.0	1288	US-10-006-780-2	Sequence 2, Appli
2	1815	26.5	355	US-10-006-780-6	Sequence 6, Appli
3	1703	24.9	332	US-10-006-780-10	Sequence 10, Appli
4	1702	24.9	332	US-10-006-780-4	Sequence 8, Appli
5	1692	24.7	361	US-10-006-780-8	Sequence 4, Appli
6	768.5	11.2	363	US-10-159-151-10	Sequence 10, Appli
7	768.5	11.2	381	US-10-159-151-6	Sequence 6, Appli
8	768.5	11.2	1368	US-10-159-151-2	Sequence 2, Appli
9	758.5	11.1	343	US-10-159-151-8	Sequence 4, Appli
10	758.5	11.1	373	US-10-159-151-4	Sequence 8, Appli
11	750.5	11.0	725	US-09-849-602-20	Sequence 20, Appli
12	696.5	10.2	319	US-09-723-276-2	Sequence 2, Appli
13	696	10.2	807	US-09-820-843A-108	Sequence 108, App
14	694.5	10.2	861	US-09-820-843A-109	Sequence 109, App
15	676	9.9	2150	US-10-135-322-17	Sequence 17, Appli

16	672	9.8	410	10	US-09-925-300-1074	Sequence 1074, Ap
17	596	8.7	1331	15	US-10-087-464-50	Sequence 50, Appli
18	589.5	8.6	303	12	US-10-422-866-4	Sequence 4, Appli
19	589.5	8.6	492	12	US-10-422-866-2	Sequence 2, Appli
20	538.5	7.9	2184	12	US-10-304-095-6	Sequence 6, Appli
21	518.5	7.6	1610	15	US-10-155-533-9	Sequence 9, Appli
22	491	7.2	464	12	US-10-161-051-119	Sequence 119, App
23	460.5	6.7	1388	15	US-10-146-473-82	Sequence 82, Appli
24	454.5	6.6	1269	12	US-10-342-224-62	Sequence 62, Appli
25	453	6.6	383	10	US-09-883-096-5	Sequence 5, Appli
26	451	6.6	864	10	US-09-883-096-2	Sequence 2, Appli
27	446	6.5	1648	15	US-10-157-031-38	Sequence 38, Appli
28	429	6.3	338	10	US-09-883-096-4	Sequence 4, Appli
29	395.5	5.8	1103	10	US-09-847-874A-1	Sequence 1, Appli
30	388.5	5.7	596	12	US-10-167-831-2	Sequence 2, Appli
31	376.5	5.5	1253	12	US-10-363-798-2	Sequence 2, Appli
32	374.5	5.5	794	12	US-10-304-095-8	Sequence 8, Appli
33	373	5.5	1191	15	US-10-087-464-47	Sequence 47, Appli
34	348.5	5.1	665	11	US-09-820-843A-107	Sequence 107, App
35	342.5	5.0	6281	9	US-09-815-242-12996	Sequence 12996, A
36	336.5	4.9	460	10	US-09-925-300-1228	Sequence 1228, Ap
37	333.5	4.9	890	15	US-10-171-311-196	Sequence 196, App
38	333	4.9	652	9	US-09-351-794A-2	Sequence 2, Appli
39	327	4.8	1093	10	US-09-801-368-392	Sequence 392, App
40	325.5	4.8	959	12	US-10-342-224-40	Sequence 40, Appli
41	323.5	4.7	2086	9	US-09-815-242-5639	Sequence 5639, Ap
42	323.5	4.7	5795	9	US-09-815-242-12610	Sequence 12610, A
43	316.5	4.6	887	12	US-09-948-029-130	Sequence 130, App
44	314.5	4.6	1349	9	US-09-815-242-5898	Sequence 5898, Ap
45	314.5	4.6	1349	9	US-09-815-242-13137	Sequence 13137, A

ALIGNMENTS

RESULT 1
US-10-006-780-2
; Sequence 2, Application US/10006780
; Publication No. US20030104496A1
; GENERAL INFORMATION:
; APPLICANT: Sakowitz, Roman
; APPLICANT: Beraud, Christophe
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
; TITLE OF INVENTION: METHODS FOR ITS USE
; FILE REFERENCE: CYTOP083
; CURRENT APPLICATION NUMBER: US/10/006,780
; CURRENT FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 1288
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-10-006-780-2

Query Match	100.0%	Score 6842;	DB 15;	Length 1288;
Best Local Similarity	100.0%	Pred. No. 0;		
Matches 1288;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;
QY	1	MNSKIKVVRKRPLESLERKDDSDIYVKNKCTIYIDPRYKVDMTKTYIERHEFIVDKV	60	
DB	1	MNSKIKVVRKRPLESLERKDDSDIYVKNKCTIYIDPRYKVDMTKTYIERHEFIVDKV	60	
QY	61	PDDYDNFTVYENTIKPLIIDYENGCVSCFAYGQTSGKTYTIMGSPYQSDTPGIF	120	
DB	61	PDDYDNFTVYENTIKPLIIDYENGCVSCFAYGQTSGKTYTIMGSPYQSDTPGIF	120	
QY	121	QYAAGDIFFLNIYKDNKKGIFISFYELCYGKLDLLOKRWVALENGKEVVVKDK	180	
DB	121	QYAAGDIFFLNIYKDNKKGIFISFYELCYGKLDLLOKRWVALENGKEVVVKDK	180	

QY	181	LRVLTEBELT,KMIDGLVLRKICVSONDESSSH,I,INLTD,KDINKMISLGIA,FTDL	240
Db	181	ILRLVTEBELT,KMIDGLVLRKICVSONDESSSH,AILNIDLKDKINKMISLGIA,FTDL	240
QY	241	AGSERGADTVS,QNKQOTQTDGANINRSLAL,ECECR,ADSDCKNH,PFPRDSELT,KVLARD,IFV	300
Db	241	AGSERGADTVS,QNKQOTQTDGANINRSLAL,ECECR,ADSDCKNH,PFPRDSELT,KVLARD,IFV	300
QY	301	GKSGSIM,IANISPTIS,SCCEQTLANTLR,VSRYAKENKSG,STC,INEDDTNTEI,STLDSKGS	360
Db	301	GKSGSIM,IANISPTIS,SCCEQTLANTLR,VSRYAKENKSG,STC,INEDDTNTEI,STLDSKGS	360
QY	361	EMANSS,IEENVY,KSNHLLSNNNK,INRKG,INDKIERNN,I,KKNS,PKDPRG,FGSTGKY	420
Db	361	EMANSS,IEENVY,KSNHLLSNNNK,INRKG,INDKIERNN,I,KKNS,PKDPRG,FGSTGKY	420
QY	421	SSLANDIDK,IKKKKKGLINYKSTLYNDPT,IKKKNNNNNNNNNDNNNDNNNNNNNDSS	480
Db	421	SSLANDIDK,IKKKKKGLINYKSTLYNDPT,IKKKNNNNNNNNNDNNNDNNNNNNNDSS	480
QY	481	SMVNNM,IMHT,INNN,INNN,IN,AVNNNNNNNNNNNS,SHNHL,POPNYA,FTDTSDFSS,LDPMNC	540
Db	481	SMVNNM,IMHT,INNN,INNN,IN,AVNNNNNNNNNNNS,SHNHL,POPNYA,FTDTSDFSS,LDPMNC	540
QY	541	HLNNNDKSI,FLHKKUL,RDNI,KL,KORSS,CDNI,IMNKKONN,HL,ARBSVSK,LMF,SYD,POKN	600
Db	541	HLNNNDKSI,FLHKKUL,RDNI,KL,KORSS,CDNI,IMNKKONN,HL,ARBSVSK,LMF,SYD,POKN	600
QY	601	KDNTEPFK,INIKMEEDT,PKD,IL,YES,RYNS,SNNG,AVL,GL,ANKT,HHDS,STKDEHNNDK,IN	660
Db	601	KDNTEPFK,INIKMEEDT,PKD,IL,YES,RYNS,SNNG,AVL,GL,ANKT,HHDS,STKDEHNNDK,IN	660
QY	661	NGVIN,IN,INNS,VNS,INNS,SNMS,INNS,SNNS,SI,YKSNYS,NQOS,ISDVO,IRYVNE,MDTSNK	720
Db	661	NGVIN,IN,INNS,VNS,INNS,SNMS,INNS,SNNS,SI,YKSNYS,NQOS,ISDVO,IRYVNE,MDTSNK	720
QY	721	NNDN,IF,FD,ALIS,CDNNM,PN,IT,NNNNNNNNNNNNNNNNNN,I,DVENYNNR,DCTNNS,SMK,YA,NS	780
Db	721	NNDN,IF,FD,ALIS,CDNNM,PN,IT,NNNNNNNNNNNNNNNNNN,I,DVENYNNR,DCTNNS,SMK,YA,NS	780
QY	781	HNLF,PODNNK,KT,SN,I,QN,INT,KKNQ,ODG,AVNT,SMNFC,YNLMD,KYVL,IDL,ANKEQ,OK,IA,II	840
Db	781	HNLF,PODNNK,KT,SN,I,QN,INT,KKNQ,ODG,AVNT,SMNFC,YNLMD,KYVL,IDL,ANKEQ,OK,IA,II	840
QY	841	GCDNNI,IONRND,FEKKKKT,PNFYNNNN,IV,IVNNNM,GNNS,PRMKYGL,CGSHTS,SDMK,NE	900
Db	841	GCDNNI,IONRND,FEKKKKT,PNFYNNNN,IV,IVNNNM,GNNS,PRMKYGL,CGSHTS,SDMK,NE	900
QY	901	MKNMEK,KNEM,KD,NH,IKSNNNNSSSSSSSSNN,I,YNN,INDDOT,FQNDY,CH,NDNT,PI,IR,KN	960
Db	901	MKNMEK,KNEM,KD,NH,IKSNNNNSSSSSSSSNN,I,YNN,INDDOT,FQNDY,CH,NDNT,PI,IR,KN	960
QY	961	NTNINSN,I,YONDD,I,YYT,INSL,NDY,SN,TL,HP,KE,KY,TP,PTL,STNED,I,YNKE,MEG,KH,ILD	1020
Db	961	NTNINSN,I,YONDD,I,YYT,INSL,NDY,SN,TL,HP,KE,KY,TP,PTL,STNED,I,YNKE,MEG,KH,ILD	1020
QY	1021	DQDKYD,DDNND,NNNN,KNN,VONN,VDN,NVND,NVND,NK,NVND,NVNN,VNDDDD,VDY,PH,NI,K	1080
Db	1021	DQDKYD,DDNND,NNNN,KNN,VONN,VDN,NVND,NVND,NK,NVND,NVNN,VNDDDD,VDY,PH,NI,K	1080
QY	1081	NFNNNN,YSY,FOK,AVDT,II,NN,CLNS,LD,ISSM,YD,TK,EL,IAN,NI,LS,KY,AE,KD,NV,TK,II	1140
Db	1081	NFNNNN,YSY,FOK,AVDT,II,NN,CLNS,LD,ISSM,YD,TK,EL,IAN,NI,LS,KY,AE,KD,NV,TK,II	1140
QY	1141	EDIKMSI,LE,ID,KT,AS,IYER,KYVL,IT,KULL,IF,KKNV,TO,Q,INNE,ST,DK,OL,VM,OH,IC,N	1200
Db	1141	EDIKMSI,LE,ID,KT,AS,IYER,KYVL,IT,KULL,IF,KKNV,TO,Q,INNE,ST,DK,OL,VM,OH,IC,N	1200
QY	1201	NPDDQ,FH,FA,YR,LE,KD,II,IN,IL,ML,ROI,WC,ES,EN,FL,YO,FL,VE,YQ,NS,AV,LL,AN,VS,N	1260
Db	1201	NPDDQ,FH,FA,YR,LE,KD,II,IN,IL,ML,ROI,WC,ES,EN,FL,YO,FL,VE,YQ,NS,AV,LL,AN,VS,N	1260
QY	1261	NGDII,LLNKK,IVOD,NI,KNS,MDH,NN,I,HKK	1288

[illegible]

TYPE: PRT
ORGANISM: P. falciparum
US-10-006-780-10

Query Match 24.9%; Score 1703; DB 15; Length 332;
Best Local Similarity 100.0%; Pred. No. 4e-112;
Matches 332; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 IKVAVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 64
DB 1 IKVAVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 60
QY 65 VDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 124
DB 61 VDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 120
QY 125 GDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 184
DB 121 GDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 180
QY 185 LTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 244
DB 181 LTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 240
QY 245 RGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGSK 304
DB 241 RGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGSK 300
QY 305 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 336
DB 301 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 332

RESULT 4
US-10-006-780-4
Sequence 4, Application US/10006780
Publication No. US20030104496A1
GENERAL INFORMATION:
APPLICANT: Sakowicz, Roman
APPLICANT: Beraud, Christophe
APPLICANT: Guo, Jun
APPLICANT: Freedman, Richard
TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
FILE REFERENCE: CYTOPO83
CURRENT APPLICATION NUMBER: US/10/006,780
CURRENT FILING DATE: 2001-11-30
NUMBER OF SEQ ID NOS: 10
SOFTWARE: FastSeq for windows Version 4.0
SEQ ID NO 4
LENGTH: 332
TYPE: PRT
ORGANISM: Plasmodium falciparum
US-10-006-780-4

Query Match 24.9%; Score 1702; DB 15; Length 332;
Best Local Similarity 100.0%; Pred. No. 4.7e-112;
Matches 332; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 KIKVVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 63
DB 1 KIKVVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 60
QY 64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 123
DB 61 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 120
QY 124 AGDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 183
DB 121 AGDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 180
QY 184 VLTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 243
DB 181 VLTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 240

DB 181 VLTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 240
QY 244 ERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGS 303
DB 241 ERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGS 300
QY 304 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 335
DB 301 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 332

RESULT 5
US-10-006-780-8
Sequence 8, Application US/10006780
Publication No. US20030104496A1
GENERAL INFORMATION:
APPLICANT: Sakowicz, Roman
APPLICANT: Beraud, Christophe
APPLICANT: Guo, Jun
APPLICANT: Freedman, Richard
TITLE OF INVENTION: NOVEL MOTOR PROTEIN OF P. FALCIPARUM AND
FILE REFERENCE: CYTOPO83
CURRENT APPLICATION NUMBER: US/10/006,780
CURRENT FILING DATE: 2001-11-30
NUMBER OF SEQ ID NOS: 10
SOFTWARE: FastSeq for windows Version 4.0
SEQ ID NO 8
LENGTH: 361
TYPE: PRT
ORGANISM: P. falciparum
US-10-006-780-8

Query Match 24.7%; Score 1692; DB 15; Length 361;
Best Local Similarity 99.4%; Pred. No. 2.7e-111;
Matches 331; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 KIKVVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 63
DB 2 KIKVVRKRPLSELEKKKSDIITVKNKCTLYIDEPYKVDMTKYIERHEFIYDKVEDDT 61
QY 64 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 123
DB 62 TVDNFTYVENTIKPLIIDLYENGCVSCFAYGQTSGKTYTLMGSPYQSDPTGFIQYAA 121
QY 124 AGDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 183
DB 122 AGDIFFELNLYDKNTKGFISFEYICGKLYDLQKRMVAALENGKEVVVVDKILIR 181
QY 184 VLTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 243
DB 182 VLTKEELILKMDGVLRLKIGVNSONDESSRSHAILNIDLKDKINNTSLGKIAFIDLAGE 241
QY 244 ERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGS 303
DB 242 ERGADTVSONKQOTQDGANINRSLLALKECIRAMSDKNHIFRDSSELTAVLRDIFVGS 301
QY 304 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 336
DB 302 KSIMIANISPTISCEQTLNLTIRYSSRVKNFKN 334

RESULT 6
US-10-159-151-10
Sequence 10, Application US/10159151
Publication No. US20030036075A1
GENERAL INFORMATION:
APPLICANT: CytoKinetics, Inc.
APPLICANT: Beraud, Christopher
APPLICANT: Guo, Jun
APPLICANT: Freedman, Richard
APPLICANT: Patel, Umesh A.
APPLICANT: Davies, Katherine A.


```

Db      283 ACTNODVVMKTTPLIOHIF-NGSNATCFAYGQTGAGKTYMTGTH-----ENPGLYALA 336
      124 AGDIFPEFLNIYDKDNKGFISFEYCYGQLYDLLOKRWVALLENKEKEVVKDKILIR 183
      337 AKDIFROLEVSQPRKHLFWMISFEYICGQLYDLNRRKRLPARBDSKHMVQIVGLQELQ 396
Qy      184 VLTKEELILKMDIGVLLRKIGVNSONDESSRSHAILNIDKDKINKTSLGKIAFIDLAGS 243
      397 VDSVELLEVLILGSKERSGTATGVNADSSRSHAVIQIKDSAKRT-FGRISFIDLAGS 455
Db      244 ERADTVVSQNKQOTDGNANINSLALKECIRAMSDKNHIPPDSSELTKVLDIVGKS 303
      456 ERAADARDSDRQTKMEGAEINOSLALKECIRALDQEHHTPFRQSKLTQVLDKDSFIGNA 515
Qy      304 KSIIMANISPTISCCQOTLNTLRYSSRVKFKKSTCINEDDTN 348
      516 KTCMIANISPSHVATEHTLNTLRYADRVKELKGIKCTISVTSRN 560
```

```

RESULT 9
US-10-159-151-8
; Sequence 8, Application US/10159151
; Publication No. US20030036075A1
; GENERAL INFORMATION:
; APPLICANT: CytoKinecs, Inc.
; APPLICANT: Beraud, Christopher
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; APPLICANT: Patel, Umesh A.
; APPLICANT: Davies, Katherine A.
; TITLE OF INVENTION: KINI-3 MOTOR PROTEIN AND METHODS FOR ITS USE
; FILE REFERENCE: 020552-002400US
; CURRENT APPLICATION NUMBER: US/10/159,151
; CURRENT FILING DATE: 2002-05-31
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 09/675,908
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 343
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide
; OTHER INFORMATION: Fragment E213-S546.
US-10-159-151-8
```

```

Query Match      11.1%; Score 758.5; DB 15; Length 343;
Best Local Similarity 48.9%; Pred. No. 1.5e-45;
Matches 161; Conservative 58; Mismatches 103; Indels 7; Gaps 3;
Qy      4 KIRVVRRKRPPLSELEKKKDSIIIVKNNCTLYIDEPKYVDMTKYIERHEFIVDKVFD 63
      12 KIRVCVRKRPGLRGREVRGRGINIITVEDKETLLVHEKKEAVDLYQYILGHVFDFEVPGE 71
Qy      64 TYDNFVYENTIKPLIIDLYENGCVSCFAYGQTGSGKTYTLMGSOPYGOSDTPGIFQYA 123
      72 ACTNODVVMKTTPLIOHIF-NGSNATCFAYGQTGAGKTYMTGTH-----ENPGLYALA 125
Qy      124 AGDIFPEFLNIYDKDNKGFISFEYCYGQLYDLLOKRWVALLENKEKEVVKDKILIR 183
      126 AKDIFROLEVSQPRKHLFWMISFEYICGQLYDLNRRKRLPARBDSKHMVQIVGLQELQ 185
Db      184 VLTKEELILKMDIGVLLRKIGVNSONDESSRSHAILNIDKDKINKTSLGKIAFIDLAGS 243
      186 VDSVELLEVLILGSKERSGTATGVNADSSRSHAVIQIKDSAKRT-FGRISFIDLAGS 244
Qy      244 ERADTVVSQNKQOTDGNANINSLALKECIRAMSDKNHIPPDSSELTKVLDIVGKS 303
      245 ERAADARDSDRQTKMEGAEINOSLALKECIRALDQEHHTPFRQSKLTQVLDKDSFIGNA 304
```

```

Qy      304 KSIIMANISPTISCCQOTLNTLRYSSRVK 332
      305 KTCMIANISPSHVATEHTLNTLRYADRVK 333
Db
```

```

RESULT 10.
US-10-159-151-4
; Sequence 4, Application US/10159151
; Publication No. US20030036075A1
; GENERAL INFORMATION:
; APPLICANT: CytoKinecs, Inc.
; APPLICANT: Beraud, Christopher
; APPLICANT: Guo, Jun
; APPLICANT: Freedman, Richard
; APPLICANT: Patel, Umesh A.
; APPLICANT: Davies, Katherine A.
; TITLE OF INVENTION: KINI-3 MOTOR PROTEIN AND METHODS FOR ITS USE
; FILE REFERENCE: 020552-002400US
; CURRENT APPLICATION NUMBER: US/10/159,151
; CURRENT FILING DATE: 2002-05-31
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 09/675,908
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 373
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Fragment
; OTHER INFORMATION: encoding residues D183-U546 with flanking vector
US-10-159-151-4
```

```

Query Match      11.1%; Score 758.5; DB 15; Length 373;
Best Local Similarity 48.9%; Pred. No. 1.7e-45;
Matches 161; Conservative 58; Mismatches 103; Indels 7; Gaps 3;
Qy      4 KIRVVRRKRPPLSELEKKKDSIIIVKNNCTLYIDEPKYVDMTKYIERHEFIVDKVFD 63
      42 KIRVCVRKRPGLRGREVRGRGINIITVEDKETLLVHEKKEAVDLYQYILGHVFDFEVPGE 101
Qy      64 TYDNFVYENTIKPLIIDLYENGCVSCFAYGQTGSGKTYTLMGSOPYGOSDTPGIFQYA 123
      102 ACTNODVVMKTTPLIOHIF-NGSNATCFAYGQTGAGKTYMTGTH-----ENPGLYALA 155
Qy      124 AGDIFPEFLNIYDKDNKGFISFEYCYGQLYDLLOKRWVALLENKEKEVVKDKILIR 183
      156 AKDIFROLEVSQPRKHLFWMISFEYICGQLYDLNRRKRLPARBDSKHMVQIVGLQELQ 215
Db      184 VLTKEELILKMDIGVLLRKIGVNSONDESSRSHAILNIDKDKINKTSLGKIAFIDLAGS 243
      216 VDSVELLEVLILGSKERSGTATGVNADSSRSHAVIQIKDSAKRT-FGRISFIDLAGS 274
Qy      244 ERADTVVSQNKQOTDGNANINSLALKECIRAMSDKNHIPPDSSELTKVLDIVGKS 303
      275 ERAADARDSDRQTKMEGAEINOSLALKECIRALDQEHHTPFRQSKLTQVLDKDSFIGNA 334
Qy      304 KSIIMANISPTISCCQOTLNTLRYSSRVK 332
      335 KTCMIANISPSHVATEHTLNTLRYADRVK 363
Db
```

```

RESULT 11
US-09-849-602-20
; Sequence 20, Application US/09849602
; Publication No. US20030165834A1
; GENERAL INFORMATION:
; APPLICANT: Scania, Matthew J.
; APPLICANT: Old, Lloyd J.
```

```

APPLICANT: Stockert, Elisabeth
APPLICANT: Chen, Yao-Tseung
TITLE OF INVENTION: Colon Cancer Antigen Panel
FILE REFERENCE: L0461/7105 (JRV)
CURRENT APPLICATION NUMBER: US/09/849,602
CURRENT FILING DATE: 2001-05-04
NUMBER OF SEQ ID NOS: 30
SOFTWARE: PatentIn version 3.0
SEQ ID NO 20
LENGTH: 725
TYPE: PRT
ORGANISM: Homo sapiens
US-09-849-602-20

```

```

Query Match      11.0%; Score 750.5; DB 12; Length 725;
Best Local Similarity 41.9%; Pred. No. 1.5e-44;
Matches 173; Conservative 76; Mismatches 143; Indels 21; Gaps 10;

```

```

QY 4 KIRVVRRKRLPSELEKKKDDIITVKNKCTLYIDEPRYVDMTKYIERHEFIVDKVFD 63
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 258 RICVCRKRLPKQELAKKEIDVISIPKCLLVHEPKLVLDLTKYLENCAFCDFADE 317
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 64 TVDNFTYENTIKPLIIDLYENGCVSCGFAYGQTSGKTYMTLGS-QPYGSDTPGIFQY 122
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 318 TASNEVYVYRFTARPLVQTFEGG-KATCFAYGQTSGKTHMGDLSGAQNAKGIYAM 376
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 123 AAGHIFPLN-IYDKNTKGIFFSYIYCGKLYDLLQKRMVAALENGKEVAVVDLX 180
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 377 ASRVVFLKQPCYKRGLE-VYVTFEYINGKLFLLNKAKAKRVLEDGKQOVVGLQ 435
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 181 ILRLVTEELIKMID-GVLRKIGVNSQNDSSSHA1LINDLKINDKNTSLGKIAPD 239
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 436 EHLVNSAD-VIKMLDKMSACRTSQTRANSSSHACFQIILR-AKGMHGKFSLYD 492
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 240 LAGSEGDVTSQNKQOTGDANINRSLLALKECIRAMSDKNH1PFRDSELTXYLRDIF 299
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 493 LAGNERGADTSSADROTMEGAELNKSLLALKECIRALGQNAH1PFRSKLTQVLRDSF 552
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 300 VGR-SKSMINISPTISCEQTLNTLYSSRVKFKKSCINCINEDDTNERISIDSK 358
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 553 IGENSRITMATTISGISSCETTLNTLYRADRVKELSPHSGPSGQ-----LIQME 603
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 359 GSEMASSIENVVYKSNHLSNNNNKINRGKINDIRNNILKKKSPDKPRE 411
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 604 TEEMACG-NGALIPGLNLSKEBELSSQMSFNAHQIPELEKAMELEKE 654
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

RESULT 12
US-09-723-276-2
Sequence 2, Application US/09723276
Patent No. US20020101952A1
GENERAL INFORMATION:
APPLICANT: Berard, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. US20020101952A1 motor proteins and methods for
TITLE OF INVENTION: their use
FILE REFERENCE: 1032
CURRENT APPLICATION NUMBER: US/09/723,276
CURRENT FILING DATE: 2000-11-27
PRIOR APPLICATION NUMBER: 09/675,227
PRIOR FILING DATE: 2000-09-29
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 319
TYPE: PRT
ORGANISM: Human
FEATURE:
NAME/KEY: VARIANT
LOCATION: (154)...(183)
OTHER INFORMATION: Xaa = any amino acid
US-09-723-276-2

```

```

Query Match      10.2%; Score 696.5; DB 10; Length 319;
Best Local Similarity 45.8%; Pred. No. 3.2e-41;
Matches 149; Conservative 51; Mismatches 118; Indels 7; Gaps 3;

```

```

QY 4 KIRVVRRKRLPSELEKKKDDIITVKNKCTLYIDEPRYVDMTKYIERHEFIVDKVFD 63
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 1 KIRVCRKRLPGRREVRGEINIIIVDEKKTLLVHEKKEAVDLYQLIQHVFDFEVEGE 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 64 TVDNFTYENTIKPLIIDLYENGCVSCGFAYGQTSGKTYMTLGSQPYGSDTPGIFQYA 123
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 61 ACTNODVYMKTTHEPLIHIF-NGGNATCFAYGQTSGAKTYMTGTH-----ENPGLYALA 114
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 124 AGHIFPLNIYDKNTKGIFFSYIYCGKLYDLLQKRMVAALENGKEVAVVDLX 183
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 115 AKDIFRQLEVSQPRKHLFWISFYIYCGQLYDLNRRKXXXXXXXKXXXXXXX 174
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 184 VLYTEELIKMIDGVLRKIGVNSQNDSSSHA1LINDLKINDKNTSLGKIAPDLAGS 243
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 175 XXXXXXXXXVILKSKSRSTGATGVNADSSRSHAVIQIQRDSAKRT-FGRISFDLAGS 233
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 244 ERGADTVSQNKQOTGDANINRSLLALKECIRAMSDKNH1PFRDSELTXYLRDIFYKGS 303
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 234 ERADADSDROTMEGAELNKSLLALKECIRALDQETHHTTTPROSKLTQVLRDSFIGNA 293
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 304 KSIIMANISPTISCEQTLNTLYRS 328
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 294 KTCMIANISPSHVATEHTLNTLYRA 318
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

RESULT 13
US-09-820-843A-108
Sequence 108, Application US/09820843A
Publication No. US2003003963A1
GENERAL INFORMATION:
APPLICANT: Council of Scientific and Industrial Research
TITLE OF INVENTION: A COMPUTATIONAL METHOD FOR THE IDENTIFICATION OF CANDIDATE PROTE
FILE REFERENCE: 063915
CURRENT APPLICATION NUMBER: US/09/820,843A
CURRENT FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 118
SOFTWARE: PatentIn version 3.0
SEQ ID NO 108
LENGTH: 807
TYPE: PRT
ORGANISM: Plasmodium falciparum
FEATURE:
NAME/KEY: misc_feature
OTHER INFORMATION: hypothetical protein
NAME/KEY: misc_feature
OTHER INFORMATION: g1|3845292
US-09-820-843A-108

```

```

Query Match      10.2%; Score 696; DB 11; Length 807;
Best Local Similarity 26.6%; Pred. No. 1.2e-40;
Matches 253; Conservative 151; Mismatches 300; Indels 246; Gaps 43;

```

```

QY 328 SSRKKNFKNKSTCINEDDTNERISIDSKGSEMASSIENVVYKSNHLSNNNNKIN 387
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 10 SSRKKNEN--DITNKCDN-----KINGKE-NIFAYAKVGINSGHMSNDINK-N 58
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 388 RGKINDKIERNNIILKNSFDKPREGFTSPGKYSLSLNDIDKIKKKKKGLINYKSTLYN 446
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 59 QEKKKKKKKKKKTHKYNINHTNHTNDKNGG-QDINKPEYIERNNIINIKNDTNI 117
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 447 -DNTINKGNNNNNDNDNDNDNNNNNDSSSVYNN-----MINEMINNNI----- 495
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 118 LDSSYNEBGENENRNDINNNNNNNNNININNNNNINNSCANNYGLKKKITTILRRNDIKDEGY 177
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 496 -NNNTINNNNNNNNNNNNNNNNNHLPQPNVAFDTSDSSSLDDNNCHLNNDKSGIFLHKX 554
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 178 NNEIITTLNKNKLNKNNNNYNDNR-----NNNN----- 205
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

[illegible]

```

Query Match      10.2%; Score 694.5; DB 11; Length 861;
Best Local Similarity 26.4%; Pred. No. 1.6e-40;
Matches 254; Conservative 145; Mismatches 325; Indels 237; Gaps 41;

Qy      393 DKIERNNILKKSDEPKREGEFTSTFGKYSLSLNDIDKIKKKKKGLINYKSTLYNDNTINK 452
Db      21 DILNKYCFIPERKRYKPGG-----NKY-----IPDRSSNNNNNIGNVNKGNNFVLLNN 69

Qy      453 KHNNNNNNNNNNNNNNNNNNNNNNNNNNNNNSSMWNNMLNHMLNNNNNNI- NVNNNNNNNNNN 511
Db      70 NNNNNNRJLNTYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 123

Qy      512 NNSHNHNLPOPNYAFTDTSDFSSLDMMCHLNNNDKISFLHKKYLRLDIKLLKRRSSC--- 568
Db      124 NNNHFNHINIDYDSDSYVKGHRGNLYSSLSLNNINGKYF---KLLDDN-----CYNL 172

Qy      569 --DNIMKKKKNNLHLA-----RHVSQSKLTWFSYDPOKKKDNTPFKSNINMKED 615
Db      173 PTNNLYIDKEGKMLTGKEHYNAASBNYNNNNKXTN- NYNNNSYNNNNF CNNNYNDNNY 231

Qy      616 NTPRD-----LYESNVSNM-----GVLGLMKNTHDI 647
Db      232 NNSNNKMGKNTYESSLYLLKKEHDMVDLEYNNKGIRKDS EKYWDNPLFLYSKKNDI 291

Qy      648 ST-----KDEHNNDKILNNGVINI-----INNSVNSINNSNMSINNSNMSNSIYKSNY 698
Db      292 FTLDIDIKYAKNNKEKGKNNKYMMNHNNNSNSN- NVLNNNNMS- NSN- NYNNIFKND 347

Qy      699 NSNOSISDVQIRRYNEMDTSKKNDNIFPDAISCDNNY---YPIITNNNNNNNN- NN 752
Db      348 EENLTJKN---FAKWFKNNNNNNNVNNENTDILIKYLNKNSQSGSDGKKNNNNNNNNNNINN 403

Qy      753 NNNNNIDVENYNNNDGNNNSMKLYAAYNSHNLFOGDNNKNTGNIQNIITNNKNOGQNVYS 812
Db      404 NSNNKNNIFQNSGNSYENRYMYNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 461

Qy      813 MNFCHYNLNDKQYLLIDLNKEQKDKNLHGCDNNIIIONRND---FEKKKKTNYNNNNNV 868
Db      462 -----NTVAELMKQ-----ISMIKERNKGLDVLEKKNTFGFLDNN--- 497

Qy      869 IYNNNMGNNSPRAKYGLCGSHITSIDMKNNNMKNEMKDNEMKDNHISKNNNSSSSS 928
Db      498 --YQYSGNN-----SLEKNNKENDIYSKASKRIW-DIFRTLSNGLVGOES 545

Qy      929 -----SNNNIYNNINDDTFQNDCHNDNTFTIRKNTNTINSNIYONDDIYITNS 980
Db      546 LLYVQSVLNNNNNNYNNYNSNNNRKQNNNNNN-----NNNNNNNNNNNNNNNN- NNN 595

Qy      981 LNDYMSSTLHFKEKTYTPTLSTVEDIYKMEBSGKHLRLDDQKYDDNDNNNNVNNNNKN 1040
Db      596 NNYVKNKHKYSMDNVTYKKIFIN-----NYSNNDGNN- NSNNSN 634

Qy      1041 VDNVND-----NN- NVNNNVND-----NDKNNVNNNVDDDDVDVDFPHIKNFNNNEYSL 1089
Db      635 SNNNVHYNNMKKQNFQKILNNYINLPEDKKMMNNNNNTYNNINKNGLSNMENNFPSP- LS 692

Qy      1090 YFOQKRVDTIINNCLNSLDISSMYDTEKILNNLILSKYKAEKDNVYIKKYINEDIKMSLE 1149
Db      693 F--NNSDINKKNAAGNINIT-----PIINSIL- RLDEVDNVHNNISISENIQNAKVS 741

Qy      1150 EIDTASIIYEKRVLLTKLLLFKKRVDPQINNETSBDLKDLYVMCHI CNNNPDDQHFHY 1209
Db      742 NVLDLSLSLKLASQSGNN-----NYNIPKPNK-----NNNNNNNSKFI 781

Qy      1210 AYSLRLEKDIINLIMLRQIWCESENLRLLYFLVVEYONKSANSVILNVSSNNGDIILNK 1269
Db      782 NYSN-----QQYVPSHQQQQQQOHQ-----QQQQQQQQQQLIQTQINSHTLNDPNK 826

Qy      1270 K 1270
Db      827 K 827

```


Qy	145	SFEYIYC-----GKLYDLQKRCMAVAALENGKEVYVYL-----KILRVLITKEEL	190
Db	600	NYKSFSLNQWKNIKVNIPOK---ISKYINIKRILLKIPDNVYENKILH--RNNEI	655
Qy	191	ILKMDGLVLRKIGVNSDSSREHALINTDLKQINNTSGLKIAFLDLGSERGADT-	249
Db	656	ITNINDNIKI-----YNGQDNLNNSFKITTLFNLGRK--YENKIKKINIYIQRHLMNR	710
Qy	250	-----VSQNKQOTDGANINRSLALKECIRAMDSDGN---HIPF	286
Db	711	LIYFLFNYFIMPLIRRFPEFLTKSEGT-----LHKTIPEDRKIMWHFKISNPGLYHQIF	764
Qy	287	RDSELTK-----VLBDIFVQKXSIMIANISPTISCEBOTLNTLRYSRVQFKONKST	339
Db	765	RNKLIKKEBPEMDYVQWFMFVKKKG-----EKIKTKYIF-IKQWKKKST	809
Qy	340	--CINEEDTMTERTISLDKSGSENNASSIENVYKSNHLLSNNNNNKING-----	389
Db	810	NKCLINNK---FSKCKIPKKKKKKNLYNITRHNNIFIKQMEKKSXTNNLINSIDNLYLK	866
Qy	390	KINDKI-----ERNILKXKSF-----DK	408
Db	867	EINKKSVAPYIKKFPYKIKKKYFALKKYIIMHRAKAKESKNIKLEAPAKHFPFAQEKH	926
Qy	409	PREGFTSTFGYKSSLND-----IDKIK-----KXKKK--GLINYKSTLYND	447
Db	927	ILKYFSSHFPQNRKINYGKRFENKLIHRKINIIKONGSIVKQKDTFLHLIKKSKNNKN	986
Qy	448	NTIKKHNNNNNNNNNDNNNDNNNNNNNNSSSVNMMIMHMINNNINNNNNNNNN	507
Db	987	NKKGNKNNYNNNNINNNNNNNNNNNNNNNNNNNKCLSN-----SKRYNIRNNNN	1036
Qy	508	NNNNNNSHNNPLPOPNYFATDSTDFSJLDDMACHLNNNDKIFLHKVLRONIKLKXRSS	567
Db	1037	KKAKNNNEQN-----IDDSN--LEKKKKIIYI-----KIKKIIIE	1069
Qy	568	CDNIMNKKKNNLILARSHVSGSKLTWFSYDPOKQKDNTPFKSINKMEBTEPK-----D	620
Db	1070	KRNFLK---LNSINHFISKKLR-IWIPKKKG---LRPLINSLTNVPEIVKORIFE	1120
Qy	621	ILYSRVNSNNGVNLGLNQTQTHDITKQBNHNDKINNGVNIINNSVANSINSM	680
Db	1121	ILKSKSSEFYFHHILNNLER-----EKQDKIKKRRKYNK--KNFVPVSIANNICVPSL	1172
Qy	681	NSINNSNNNSIYKSVNSNSQSTSDVOI-----RYVNMDSNSKND	723
Db	1173	KCLGNMRHNNNSLRF--NLTLTGEIEHLKLLKQVLYKQWFPYKKRRKKYIKKKLKNNK	1229
Qy	724	NIF-FDAISCONNMYPNITNNNNNNNN-----NNNNNNNNNIIDVENYNRDGTNNSMKLY	776
Db	1230	KIYAYICIGDPSNCEHI-----NHNLYFKLQKPFEDINNFELIYLFKR-----SRPLY	1279
Qy	777	AYNSHNLF--QPDNNKC--TSNIOIN--TNKNNQGVNYSMN--FCHYNLDKNVLI	827
Db	1280	NKNLNNSFLSYYPVNVVSFGHLIYRNLRELIIFKSHLNDHNFLLNQWFKTSKSDLYIFA	1339
Qy	828	DLNKKQKDKK-----IHGDDNNIQRANDPEKKKKTKNFY-----NNNNIYVN-	871
Db	1340	DSYKSLQYDKRDIPTMTIITVIRYYLYNLVYFISKEFKLARKNIFFYQIIFQEQMKGYLYSV	1399
Qy	872	-----NNMGNNNSPMRYKGLCSHSHSIDMKRQNEKNNEMKNNKQDNHKK	917
Db	1400	RDKKRVENIKKMYLNSMKKINHDELBELKXSSININ--KNFMICINHEQDIBEK	1453
Qy	918	SNNNNSSSSSSNNNINNDODTFOVDYCHANDTFTIRKKNNTINNSIYONDIIYT	977
Db	1454	GNTONKEKHDIYIGIYINNSFDSTT---TTHSSNNY--KGNNIHVSGD--YKQDGLLHK	1505
Qy	978	INSLNDVNSNLTLLHFKEKYTYPTLSTNEDIYNKMEGCHIRLDDQDKDNDNDVNNNN	1037
Db	1506	GNN---SME-CYVQIK-----CANNNNNNNNNN	1531

[illegible]

Db 175 PDKGVVQGLSFHQPASABQLELITRGNRNRQHPDANATSSRSHAIPIFYKQDRV 234
QY 226 --INKNTSLGKIATIDLAGSERGADTVSONKOTODGANINRSLALKECTIRAM---DSD 280
Db 235 PGLTQAVQVAKMSLIDLAGSERASTAKGERLR-EGANINRSLALINVALADAKGR 293
QY 281 KNHHPRDSLETKVLRDIFVSGSKSIMANISPTISCECEOTLNTU 325
Db 294 KTHVPYRDSKLTRLKOSLGGNCRTVMIAISPSLSLTEDYNTLU 338

RESULT 29

US-09-847-874A-1
; Sequence 1, Application US/09847874A
; Patent No. US20020127668A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Y. Tom
; APPLICANT: Corley, Neil C.
; APPLICANT: Guegler, Karl J.
; APPLICANT: Patterson, Chandra
; TITLE OF INVENTION: KINESIN-LIKE MOTOR PROTEIN
; FILE REFERENCE: PR-0593 US
; CURRENT APPLICATION NUMBER: US/09/847.874A
; CURRENT FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 09/467,946
; PRIOR FILING DATE: 1999-12-21
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 1103
; TYPE: PR
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: 1281811
US-09-847-874A-1

Query Match 5.8%; Score 395.5; DB 10; Length 1103;
Best Local Similarity 31.3%; Pred. No. 2,7e-19;

Matches 126; Conservative 71; Mismatches 156; Indels 49; Gaps 16;

QY 3 SKIKVAVKRPRLSELEKKKSDITVKNKCTLYIDEPRYKVDMTKYLE-----RHEFI 56
Db 4 ASVKAVAVRPFNAETSDQDAKCVSMQNTTSIIN-EKQSKDAKSFDPDYSVSHST 62
QY 57 VDKVFDVTVDNFTYENTIKPLIIDLYENGCVCSFANGQSGCTTVMLSQPGQSDT 116
Db 63 EDPGF---ASQOQVVRDIDGEEMLTHAFEGYNVC-IFAVGQTCAGKSYTMGROEPGQO-- 116
QY 117 PGIPQYAGDIPTFLINIDKONTK---GIFISFYEIYQCKLYDL--OKRKVVALENGK 171
Db 117 -GIYPOLCEDLFS--RVSENOQAQLSYSEVSYMEIYCEYVADLNPGRSLRVREHPI 173
QY 172 KEVVVKDLKILRVLTKEELILKMLIDGVLLRKIGVNSQNDSSSRSHAIINI-----DL 223
Db 174 LGPYVQDSLKAVTSYADIDLMDCGNKARTVAATNMNMTSRSRAVFTIVTQCHDOL 233
QY 224 KDINKNTSLGKIATIDLAGSERGADTVSONKOTODGANINRSLALKECTIRAM---DSD 280
Db 224 TGLD--SEKYSKISLVDLAGSER-ADSSGARGMGLGEGANINKSLTTLGKVISALADMSK 291
QY 281 K---NHIPRDELTKVLRDIFVSGSKSIMANISPTISCEOTLNTLRYSRVKNPKK 337
Db 292 KRKSDPTFRDSVLTWMLKENIGNSRTMIALSPADINVEETLSTLRVADRTKQIR-C 350
QY 338 STCINEEDTNTERTISILDSK-----GSENNASSIENY 370
Db 351 NALINE--DPNARLREIQEVEVARRELLMAGGLASALMGL 390

RESULT 30
US-10-167-831-2
; Sequence 2, Application US/10167831
; Publication No. US20030166209A1

; GENERAL INFORMATION:
; APPLICANT: Shuman, Stewart
; APPLICANT: Ho, C. Kiong
; TITLE OF INVENTION: Pharmacological Targeting of mRNA Cap Formation
; FILE REFERENCE: D6388D
; CURRENT APPLICATION NUMBER: US/10/167,831
; CURRENT FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: US 09/752,165
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 104
; SEQ ID NO 2
; LENGTH: 596
; TYPE: PR
; ORGANISM: Plasmodium falciparum
; FEATURE:
; NAME/KEY: PEPTIDE
; OTHER INFORMATION: Plasmodium falciparum RNA triphosphatase Pct1
US-10-167-831-2

Query Match 5.7%; Score 388.5; DB 12; Length 596;
Best Local Similarity 21.5%; Pred. No. 3,7e-19;

Matches 171; Conservative 107; Mismatches 245; Indels 271; Gaps 33;

QY 372 IKSNNHLSNNNNNNKINRNGKINDKIERN---NIIKNSFDC-PREGFTSTFGKXSLNDID 427
Db 24 LSGNIIILAFDHNHINNKDQIEIEGRVGLVIDKKNRILKIPINTDAIENNSYDPQ--A 81
QY 428 KIKKKKKGLINYKSLYNDNTINKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNSSSVNMI 487
Db 82 GIDRESEFELDYFHNNTLKKRLSIRNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 130
QY 488 NHHNN 544
Db 131 ---NN 164
QY 545 NDKSIFLHKCN--LRDNIKLNSSCCDINMKKKNNLHLARHSGSLTWFSDYDPOKND 602
Db 165 -----DKGNACIYDPLELKTTSIDKYVIKNN-----SRIRTTY----- 201
QY 603 NTFPKSNINKMEDTPKDIYESRNVSNMGNVLLGLNKTHTHDISTDENHNDKINNG 662
Db 202 ----- 201
QY 663 VINIINNSNVNINSNNNSNNNSNNNSIYSKSNVNSQISDVQIRYVENMOTSKN 722
Db 202 ---LNDNKGTESSMIOQLQKDNLTIMVYTG-----NN 233
QY 723 DNIFPDASCDNNMYPNITNN 782
Db 234 YDYFDDEEDDDDY-----NNNNNNNNNGDGTCTKNINAT--NTHGLTTSKSGHYN--N 284
QY 783 LFQPDNNKNTSNICNINTKKNQDGNVNSMNF-CHYNLNDK---NYL---IDLNKE 833
Db 285 LV--DKDISIDYRISINIEYTKPIKSLYSKNTPVHERLKERFTFINTYVLOLQVDMKIK 342
QY 834 QKDNHNGCD-----NNIQNRNDFEKKKKTFFNNNNNIVYVNNMGNNSPRKAYGLCG 888
Db 343 TKNNELVELEIPSKTIFKAMSLNRKKKSNVYH-----FTGSLVNNR-----GIC- 391
QY 889 SHTSIDMKNEMKNEMKNEMKNEMKNHKSNNNNSSSSSSNNNIVNNINDDTFON--- 945
Db 392 -----GQNAVFKSKMLKNTM---ITLANN--SNQNNLSLRLPHRPDDTITSKEK 439
QY 946 ---DYCN-----DNTFTIRRNNTNINSNIYONDIIYTTNSLNDYNSNTLHFEK 995
Db 440 EKFKYIHSVLPVIGDYVYRVVTKNKKHKKI--KQDLITNKKKINIFKNVNDIRRNK 497
QY 996 YTPPLSLNE-DIYNKMEGK-----IRDDQKXDDND-----NNNVNNNNKNVND 1043
Db 498 KSLQTI--NEVHVNKKMAFRGRTKIEVLLCSDEEYQNDVODINNEYDYQKNEEDT 555
QY 1044 NVDNNNV--DNNVNNNDKNNVNDNNVNDDDVDVFNHINKFNNEEYLSYFQKNVDITINN 1101

Db 590 TSTKDALNGAKLAEAKAARONIGTLNHTNAQRTDLEGOINQATTVGVNTVKTANT 649
Qy IYKSNVNSNOSIS--DVQIRYVNMEDTSNKNNDNIFFPAISCDNNMYNINNNNNNN 749
Db 650 LDGAMNSIQSGINDKDATLRNQNYLD--ADESKRAVYTOAVPAEGILNKKQGTSGKADV 708
Qy 750 -----NNNNNNNNIDENYNNRDTGTSNKKLYAYN--SHNLFOPDN----- 788
Db 709 DNALNAVTRAKALNGADNLNNAKTSANTIDGLPNLTQLOKDNILKHOVEQAQVAVGVNG 768
Qy 789 ---NKTSN-----TONINTKNNO-----DGVNYSNMFCHYN--LNDKNVLIID 828
Db 769 VKDKCNTLTAMGALRTSIQNDNTKTSQNYLDASDSNKN-----NYNTAVNNANGVIN 822
Qy 829 LNKKEQKXKN-----IHGCDN-----NIGORNDFFKKKKNF----- 861
Db 823 ATNPNMAMNAINGMANOVTTKALANGAONIAQAKTNATNTINAHDLNQQKQKALKTQ 882
Qy 862 YNNNNIVLVNNMGNMNSPRMKYGLGSGHTSIDNNKNNEMKNEMKDNHKSNNN 921
Db 883 VNNAQVSDANNV--QHTATELNSAMTALKAIADEKERTKASGNVYVNAQEKQAVDSKYT 941
Qy 922 NSSSSSSNNNIYNNINDDTFFQNDY-----CHNDTFTTRKNNNTINSNIYQNDII 975
Db 942 NAENIISGTPNATLTIVNDVNSAASQVNAKTAALNDGNNMLRVAKHEHANNITIDGLAQ----- 996
Qy 976 YTINSINDYMENTLHFEKXT-----YPLSTNEDIYKMEKGIIRLDDQKXNDNN- 1030
Db 997 -----LNNAQAKLKEQVQASATLTDGVQTVKNSQTLNTAMKGLDSTIANEATTIKAGONY 1051
Qy 1031 NNVDNNNNKQNV-----NNVDNNNNVDNN-----VDN 1056
Db 1052 TDASPNNNEVDSAVTAKAIIINOINSNTMEBNTITQVTSQVTTKEQALNGARNLAQAKT 1111
Qy 1057 NDKNNVDN-----NNVDND--DDVD-----FINIKX--FNNNERYL 1088
Db 1112 TAKNNMLNTSINNAXKDALTRSIDGATTVAGVNOETAKATELNNAMSLQNGINDETQ 1171
Qy 1089 SYFOKNVDTIINNCNSLSDISMYDTEILNINILSYKAEKQNVIKKIYINEDIKNNSL 1148
Db 1172 KQTKYTLDAEPSK-----KSAYQAVNAKAIILT--KASGVNDVRAVQEQALQNVN- 1220
Qy 1149 EIIDTKAQSIYEKRYLTKLLLFKQVNDTQINNETSRLKDL--VMCHICN 1199
Db 1221 -----STKTAL-----NGDAKLNKAKAQKQTLGTLRHNN 1251

RESULT 36
US-09-925-300-1228
; Sequence 1228, Application US/09925300
; Patent No. US20020151681A1
; GENERAL INFORMATION:
; APPLICANT: Craig Rosen,
; APPLICANT: Steve Ruben,
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA101
; CURRENT APPLICATION NUMBER: US/09/925,300
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05988
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 1890
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1228
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (75)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE

; LOCATION: (147)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (435)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-925-300-1228

Query Match
Best Local Similarity 28.7%; Pred. No. 1,2e-15;
Matches 100; Conservative 71; Mismatches 145; Indels 33; Gaps 10;

4.9%; Score 336.5; DB 10; Length 460;
Query 3 SKIRVVRRKPLSELEKKKDSIIIVKNNCTLYIDEPKYKDMTKYTERHEPVDKVPD 62
Db 20 ARVAVLRRLPFDVGTAGASDPFCVRGMDSCSLIEMWRHNOETLKY-----QF--DAFYG 73
Qy 63 DTVNFVYENTIKPLLIIDYENGCVSCFAYGOTSGKTYTMGSGPYGSDPRTGIFQY 122
Db 74 EXSTQDPIVAGSVQPIRLHLE--QONASVLAYGTTGAKGKHTMLGS-----PEQGVIPR 127
Qy 123 AAGDIFFLNIYDKNTKG-----IFISFYEYICGLYLDLQKX--MVALENGKKEV 175
Db 128 ALMDL---LQTRREGAGRRPKLSTVMSYIEIQEKVLDLDPASGDVIREDCRNIL 184
Qy 176 VKDKILRVLTKEELIKMIDGVLLRKIGVNSQNDSSRSHAIINIDKQINKTSL--- 232
Db 185 IPLGSKPISGFADFERHFLPASRRTVGTATRLQSRSSHAVAL--LVKVDQRELAPE 241
Qy 233 ---GKIAFLDLASERGADPVSONKQOTQDGNINISLLALKECIRAMDSKNHIPPED 288
Db 242 RQREKYLIDLASSENRRKNGRLKSGA--INSLFVGLGVVALNGLPFVRYD 300
Qy 289 SELTKVLRDIFVGSKSIMIANISPTISCEQTLNTRYSRVKNFRKX 337
Db 301 SKLTRLQDSUGSAHSILIANIPERRFYLDYTSALNPARSKEVINR 349

RESULT 37
US-10-171-311-196
; Sequence 196, Application US/10171311
; Publication No. US20030087270A1
; GENERAL INFORMATION:
; APPLICANT: Schlegel, Robert
; APPLICANT: Chen, Yan
; APPLICANT: Zhao, Xumei
; APPLICANT: Monahan, John
; APPLICANT: Kametkar, Shubhangi
; APPLICANT: Glatic, Karen
; APPLICANT: Gannavara, Manjula
; APPLICANT: Hoerish, Sebastian
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY
; TITLE OF INVENTION: OF CERVICAL CANCER
; FILE REFERENCE: MRI-035
; CURRENT APPLICATION NUMBER: US/10/171,311
; CURRENT FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: US 60/298,159
; PRIOR FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US 60/298,155
; PRIOR FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US 60/335,936
; PRIOR FILING DATE: 2001-11-14
; NUMBER OF SEQ ID NOS: 238
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 196
; LENGTH: 890
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-171-311-196

Query Match
Best Local Similarity 25.7%; Pred. No. 4.7e-15;
Matches 117; Conservative 64; Mismatches 128; Indels 147; Gaps 15;


```

Oy 4 KIVVAKRPL--SELEKKKSDITVGNQCTVLDIBPRXVDMTKYIEE-----HEF 55
Db 64 KVVVYLRVRLPSELE RQEDQGCVRILENVTVLQAPKPSFL- KSNENGIGQATHRF 121
Oy 56 IYDKVDDVYDNFTVYENTIKPLIIDYENGVCSCFAYGOTGSGKTYTMIGSORVQSD 115
Db 122 TFSQIGPPEHQGQSFNNLTIVKEMVXDVLK- GQNMVLITYGVATNSGKTHITIGTKDG-- 177
Oy 116 TPGIIFYAGDIPTFL----- 131
Db 178 --GILPRLALINLSIQGLHPTPLDKPLNSNEVIMLDSKQIRQEMKGLSLNGLOEE 235
Oy 132 -----NIY-----DKDNTK----- 140
Db 236 ELSTLKRVSUYIESRIGTSTFDSGIAGLSSISQCTSSSQIDERTSHRQWQDTARLVPA 295
Oy 141 ----GIFISYELYCGKLYDLDQ-----KRMVAALENGKEVVYKDLKLRVLTUEL 190
Db 296 NIRFSIWISPFELYNELVLDLLEPPSQQRKTELYCEDONGNPVYKDLNMNIHQDAEE 354
Oy 191 ILKMGIVGLLRKIGVNSQ-----NDESSRHAILNIDLDKINQK-----TSLGKIAFID 239
Db 355 -----AMKLLIKVGRNQSFASHTLQNQNSRSHSIFSRILHLQGEGBIVKISIELSD 408
Oy 240 LAGSERGADTVSONKOTQTDGANINRSLALKECTRIM-----DSDKNHLPFRDSELYK 293
Db 409 LAGSERCKD--QKSGERLKEAGNINTSLHTLRCIALALRQONQNRSKONLVPFRDSELYK 466
Oy 294 VLRDIFVYKSKSIMIANISPTISCEBQNTLIRVAS 329
Db 467 VFQGFPTGKRGRSCMIVNVPCASTYDETLHVAKFSA 502

```

```

RESULT 38
US-09-351-794A-2
; Sequence 2, Application US/09351794A
; Patent No. US20020042382A1
; GENERAL INFORMATION:
; APPLICANT: DUFFY, PATRICK E.
; APPLICANT: OCKENHOUSE, CHRISTIAN F.
; TITLE OF INVENTION: SEQUESTERIN
; FILE REFERENCE: 38644-17519
; CURRENT FILING DATE: 1999-07-13
; PRIOR APPLICATION NUMBER: 08/559,896
; PRIOR FILING DATE: 1995-11-17
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 652
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-09-351-794A-2

Query Match          4.9% Score 333; DB 9; Length 652;
Beet Local Similarity 21.5%; Pred. No.3,4e-15;
Matches 176; Conservative 132; Mismatches 283; Indels 226; Gaps 38;

Qy      335  KKSTCIIEEDDTTERISILDSKSEWNNASSIENVVKNHNLSSNNNNKINRCKINDK 394
Db      6      KKEENTNTNTNTSTNTSA-----NTNTSTNTSANTNTSTKESHILDSKLETFPYRDEL-DK 59

Qy      395  IERNNI-----LKNKSFDPKPRREGFTSPGKYSLANDIDIKIKKKKKGLINYKSTLYND 447
Db      60      MGEKEIETFPKGNIDKSKLDE-----FKHI-LLEELNKMDKDELVEW--YREEL--- 105

Qy      448  NTIKKHHNNNNNNNDNDNDNNNDNNNNNNNDSSSVNVMINMILNINNINNNINNVNNNNN 507
Db      106  NRIEQKIRNNKKQOIKNTYDEDEINNNMSDQVCKIHRELEKIEKEKI-----NKMD 157

Qy      508  NNNNNNNNNNLPGQNYAFTDTSDESSLDDNNCHLNNNDKSLFLKKULRDNIKLRSS 567
Db      158  KQELDKYREELDKVD--RDATYSMTYEDIS--NKIKIDIL--KVEKETNDKNNKK 208

```

Qy	568	CDNIANKKXKXLIHARSVSKLTMFYSYDPOXKNDT--	PFKSINIKME----	DNTPCDI	621
Db	209	DIDINKKKKKDIDID-----	VDIDKIDHDHVEELXGEVKNLSDSEELMRBDA		258
Qy	622	LYE--SRVSNMNGNVL--	LGALNTXTHHSDTKDENHD--	NKINGVINIINNSVNSI	675
Db	259	LYRYVEELRMRNDELRYRYVEELERKIDKEKEKIHREKLAHKE	IKINMXDKQIDKI		318
Qy	676	NNSMNSIINNSMNS-----	NSLYKSYNNSQISDYQIRYVEMD-----		716
Db	319	YEELINKRSDSEIOWVERAILLEDIÖKEREI--	ONLELEELDRLYKEELRMDREARAYELPMR		377
Qy	717	-TSKKNNDNI.FPDASICDNMMYPIVITNN-----	NNNNNNNNNNNNIDVENVYNNRDOTN		770
Db	378	NLSNEKNDNIHRIHRIKIESÖKÖKKEKENVYFI	IHDNDSSNNNNNNNNRDVNNLNKKHTNN		437
Qy	771	NSMKLYAVNSHNLEFÖPNNKNTSNIÖNI	INTKNNQÖDQNVYSMNFCHYNLNDKNYLIDLN		830
Db	438	N-----YN-----	ENVEVELVVRILDXDKGAK-----	IED-----IDYF	467
Qy	831	NKE-ÖKÖKNIHGCDDNIIOÖNRNDEKKKKKTFRFYNNNIIV--	LVNNMGNNSPRMKYGLCG		888
Db	468	NKEIKKÖKÖNV-----	NVSIIVFLNSKYÖKNDTP-----		496
Qy	889	SHTSIDMKKNEM-----	KNNEMKONKÖKHIXKNNSSSSSSNNINYNINDDTPÖ		944
Db	497	----IÖHKKENÖQVVRKNIÖI-----	IÖEDNIKKÖKÖKNDTEMLDNN-----		535
Qy	945	NDYCHNDNFTIRKKNNTINSNIYÖNDI--	IYTINGSLNDYMSNTLLHFKEKYTPPLS		1002
Db	536	-----KELTNI--	DIKNVDDIKNVGDISVGD-----	IK	562
Qy	1003	TNEDITYN-----	KEMEGGHIRLDDÖKYDDNDNNVNDNNKKNVDNNDVNNVDNNVDND		1058
Db	563	SVYDINNVDGIKNVGD--	IKNVGDIKNVGDGINNVGDIINNAGDTINNAGDTINNV-----	GDI	615
Qy	1059	KNNVNDNNVNDDDDDVDVFHNIKNFNNNEYLSPÖKNY			1095
Db	616	NNSVDIYNVEHIDEAKKPNLNDPKKFDKÖVFEKDKY			652

```

RESULT 39
US-09-801-368-1992
Sequence 392, Application US/09801368
Patent No. US20020128250A1
GENERAL INFORMATION:
APPLICANT: Busby, Robert
APPLICANT: Cali, Brian
APPLICANT: Hecht, Peter
APPLICANT: Holtzman, Doug
APPLICANT: Madden, Kevin
APPLICANT: Maxon, Mary
APPLICANT: Milne, Todd
APPLICANT: No. US20020128250A1man, Thea
APPLICANT: Royer, John
APPLICANT: Salama, Sofie
APPLICANT: Sherman, Amir
APPLICANT: Silva, Jeff
APPLICANT: Summers, Eric
TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
FILE REFERENCE: 109272.147
CURRENT APPLICATION NUMBER: US/09/801,368
CURRENT FILING DATE: 2001-03-07
PRIORITY APPLICATION NUMBER: US 09/487,558
PRIORITY FILING DATE: 2000-01-19
PRIORITY APPLICATION NUMBER: US 60/160,587
PRIORITY FILING DATE: 1999-10-20
NUMBER OF SEQ ID NOS: 440
SOFTWARE: PatentIn version 3.0
SEQ ID NO 392
LENGTH: 1093
TYPE: prt

```


THIS PAGE BLANK (RSP10)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:06:35 ; Search time 92 Seconds

(without alignments)
2222.172 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 6842
Sequence: 1 MMSKIKVVRKRPLESEKK.....KLVQDNKMSDNNHKK 1288

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

A_Geneseq_19Jun03.*
1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	940	13.7	590	AA11019	Apo-lipoprotein E
2	786	11.5	790	AA11019	Arabidopsis thaliana
3	786	11.5	794	AA11019	Arabidopsis thaliana
4	786	11.5	814	AA11019	Arabidopsis thaliana
5	783	11.4	803	AA11019	Arabidopsis thaliana
6	778	11.4	1844	AA11019	Plasmodium falciparum
7	768.5	11.2	363	AA11019	Human Kint-3 DNA
8	768.5	11.2	381	AA11019	Human Kint-3 DNA
9	768.5	11.2	1368	AA11019	Human kinesin

10	758.5	11.1	343	AA11019	Human Kint-3 DNA
11	758.5	11.1	373	AA11019	Human Kint-3 DNA
12	758.5	11.1	730	AA11019	Xenopus laevis kin
13	752.5	11.0	405	AA11019	Human mitotic cent
14	752.5	11.0	434	AA11019	Human mitotic cent
15	752.5	11.0	473	AA11019	Human mitotic cent
16	752.5	11.0	723	AA11019	Human mitotic cent
17	750.5	11.0	725	AA11019	Human mitotic cent
18	748.5	10.9	1317	AA11019	Plasmodium falciparum
19	745.5	10.9	362	AA11019	Human mitotic cent
20	745.5	10.9	391	AA11019	Human mitotic cent
21	745.5	10.9	430	AA11019	Human mitotic cent
22	745.5	10.9	729	AA11019	Drosophila melanog
23	733	10.7	728	AA11019	Human polyprotein
24	732.5	10.7	679	AA11019	Human polyprotein
25	732.5	10.7	690	AA11019	Human polyprotein
26	732.5	10.7	694	AA11019	Human polyprotein
27	732.5	10.7	694	AA11019	Human polyprotein
28	698	10.2	1436	AA11019	Plasmodium falciparum
29	696	10.2	807	AA11019	Drosophila melanog
30	686.5	10.0	626	AA11019	Wooden leg (MOL) g
31	676	9.9	2150	AA11019	Human prostate can
32	672	9.8	410	AA11019	Mitotic centromere
33	663	9.7	604	AA11019	Sequence of the As
34	604.5	8.8	537	AA11019	Plasmodium falciparum
35	596	8.7	1331	AA11019	Plasmodium falciparum
36	587	8.6	2485	AA11019	Plasmodium falciparum
37	579	8.5	2380	AA11019	Plasmodium falciparum
38	577.5	8.4	2500	AA11019	Plasmodium falciparum
39	576.5	8.4	342	AA11019	Human lutropin-cho
40	569.5	8.3	2010	AA11019	Plasmodium falciparum
41	563.5	8.2	3373	AA11019	Plasmodium falciparum
42	552	8.1	2339	AA11019	Plasmodium falciparum
43	540.5	7.9	4134	AA11019	Plasmodium falciparum
44	538.5	7.9	1073	AA11019	Amino acid sequenc
45	538.5	7.9	1073	AA11019	Yeast cut', a homo

ALIGNMENTS

RESULT 1	AA11019	standard; Protein; 590 AA.
ID	AA11019	
XX	AA11019	
AC	AA11019	
DT	25-MAR-2003	(updated)
DT	17-MAY-1991	(first entry)
DE	Apo-lipoprotein E induced cell differentiation copying polypeptide (1).	
XX	Apo-lipoprotein E; cell differentiation; hypercholesterolaemia;	
KW	androgen; diagnosis.	
XX		
OS	Synthetic.	
XX		
PH	Key	Location/Qualifiers
FT	Protein	1..20
FT		/label= leader segment
FT		/note= "may be replaced by NH2"
FT	Region	21..40
FT		/label= first spacing segment
FT		/note= "may be omitted"
FT	Region	41..55
FT		/label= p(141-155)
FT	Region	56..76
FT		/label= second spacing segment
FT	Region	21..130
FT		/label= repeated segment
FT		/note= "present at least twice"
XX		
PN	WO9102751-A.	

PD 07-MAR-1991.
XX
XX
XX 17-AUG-1990; 90WO-US04651.
XX
XX 18-AUG-1989; 89US-0395732.
PR 26-FEB-1990; 90US-0485158.
PR 18-JUN-1990; 90US-0540363.
XX
PA (SCRI) SCRIPPS CLINIC & RES FOUND.
XX
XX Dyer CA, Curtiss LK, Smith R,
XX WPI; 1991-087246/12.
DR
XX
XX Polypeptide(s) copying apo-1lipoprotein E induced cell
PT differentiation - useful for treating hypercholesterolemia,
PT inhibiting ovarian androgen secretion and for prodn. of diagnostic
PT systems.
XX
XX
PS Claim 2; Page 98; 123pp; English.
CC
CC A polypeptide capable of inhibiting lymphocyte proliferation and/or
CC ovarian androgen secretion comprises a plurality of segments, as
CC indicated in the features. The segment may be repeated 2-10 times.
CC In this example the segment is repeated 10 times. The N-terminal
CC may comprise NH2 or a leader segment of 1-20 amino acids, the
CC C-terminal comprises COOH or a tail segment of 1-20 amino acids.
CC Between each segment is a first and second spacing segment of
CC 1-20 amino acids. P(141-155) is a peptide obtained from apo E.
CC See also AAR1107 and AAR1109.
CC (Updated on 25-MAR-2003 to correct PA field.)

Query Match	13.7%	Score 940;	DB 12;	Length 590;
Best Local Similarity	32.4%;	Pred. No. 4.4e-45;		
Matches 235; Conservative	99;	Mismatches 215;	Indels 176;	Gaps 18

[illegible][illegible]

PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139219.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142820.
PR 12-JUL-1999; 99US-0142877.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145218.
PR 26-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145813.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.

PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161922.

PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144684.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147392.
PR 06-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155133.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.

PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 11.5%; Score 786; DB 21; Length 794;
Best Local Similarity 34.8%; Pred. No. 3e-36;
Matches 210; Conservative 103; Mismatches 183; Indels 108; Gaps 21;

QY 3 SKIVVVRKRPVSELEKKKKSDIITVKNKCTLYIDEPPYKDMYKIERHEFIYDKVPD 62
DB 192 AKIKVVRKRPINKKETAKKEEDVVTVDN-SITVHEPRVKDITAYVEKHECFDAVLD 250
QY 63 DTYDNFTYENTKPIIDLYENGCVCSCEFAVGQSGSKTYMTLSQPYGQSTPPIFY 122
DB 251 EDVSNDEVYRATIEPIPIIFOR-TKATCFAYGQTSKTFPM--KP-----LPIR 298
QY 123 AAGDIPTFLN--IYDKNTKGIFISFEIYCGKLYDLQKRKVAALENGKKEVVKDK 180
DB 299 AVEDMLRLRQPVYSNQRF-LWLSYFEIYGKLPDLSEKTKCMREDRQVCIVGLD 357
QY 181 ILRLTKBELILKMD-GVLRKIGVNSONDESSRSHAIL-----NIDIKDNKTS-- 211
DB 358 EYEV-SDVOIVKDFLEKGNARSTGSGTGANESSRSHAILQVKKGHVVKOTRRRNNDS 416
QY 232 -----LGIKFIPIDLAGSERGADTVSONKOTOTDANINRSLALKECIRAMDSPKNH 284
DB 417 NELPGKVVGKISFIDLAGSERGADTVTDNRQTRISGAELNKSILALKECIRALDNOHLH 476
QY 285 PRDSELTAVLRDIFVKGKSGSIMIANISPTISCCEQTLNLTLYSSRVK-----NFKNS 338
DB 477 PRGSKLTFLVLDSPFGNSRTVMISGISPNASCHETLNTLRYADRVKLSLGSNGSKXQ 536
QY 339 TC-----INEBDYTERISIIIDSKGSENNASIEENVYKSHLSNNNNKINRCKIND 393
DB 537 TANSMPVAKDLDLGNDEVEDVEFEPQEVNVEPTRRVRVEKD---SNSSTSGIDFRQPTN 593
QY 394 KIERNNILKNGSPDKREGFTSTF--GKYSLNDI-----DKIK--NKKKGLI 438
DB 594 YREESGI-PSFMDKGRSEPNSSFAGSTISQRNNISSYPOETDRREKVKVSPPRKGL- 651
QY 439 NYKSTLYNDNTINKKANNNNNNNDNNNDNNNNNNNNSSSMVNMNMIMNNNNNN 498

DB 652 -----REKPRPQWMSKRVSS-----SD 671
QY 499 INVNNNNNNNNNNNNHNPQPNVAFPTDTSDFSSLDNMCHLNNDKSTFLHKRLRD 558
DB 672 IPTLTNRQWASEFASRQYETASRQYE-TDPSLDENIDAL---LEEEFALIAHREKIED 727
QY 559 NIKL 562
DB 728 TWEI 731
RESULT 4
ID AAG41921 standard; Protein: 814 AA.
AC AAG41921;
DT 18-OCT-2000 (first entry)
XX Arabidopsis thaliana protein fragment SEQ ID NO: 52217.
XX Protein identification; signal transduction pathway; metabolic pathway;
KM hybridisation assay; genetic mapping; gene expression control; promoter;
XX Arabidopsis thaliana.
XX EPI033405-A2.
XX PD 06-SEP-2000.
XX PF 25-FEB-2000; 2000EP-0301439.
XX 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 28-APR-1999; 99US-0130891.
PR 30-APR-1999; 99US-0132048.
PR 04-MAY-1999; 99US-0132407.
PR 05-MAY-1999; 99US-0132484.
PR 06-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 07-MAY-1999; 99US-0132487.
PR 11-MAY-1999; 99US-0132863.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.

PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 14-JUN-1999; 99US-0138847.
PR 16-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 17-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145112.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.

```

PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152263.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161820.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

```

Query Match 11.5%; Score 786; DB 21; Length 814;
 Best Local Similarity 34.8%; Pred. No. 3e-36;
 Matches 210; Conservative 103; Mismatches 183; Indels 108; Gaps 21;

```

QY 3 SKIKVVRKRPPISELEKKKKSDIITVKNCTLYIDEPRYKVMTYIERHEFIVDKFVD 62
Dp 212 AKIKVVRKRPPISELEKKKKSDIITVKNCTLYIDEPRYKVMTYIERHEFIVDKFVD 270
QY 63 DTVDNFTYENTIKKPIIDLYENGCVSCGCAVQOTSSGKTYMTLGSOPYQOSTPGIFQY 122
Dp 271 EDVSNDEVYRATIEPIIPILIFOR-TRATCPAVQOTSSGKTYMTLGSOPYQOSTPGIFQY 318
QY 123 AAGDIFLPLN--LYDKONTGKIFISFEYIYCGLYLLOKRAVVAALENGKEVVVDLK 180
Dp 319 AVEDLMKRLRQPYVYSNQRK-LMLSTFEIYIGLTPILLSRKTKCKREDRQOVCIYGLQ 377
QY 181 IRLVLTKEELLIMID-GVLLRKIGVNSQNDSSSRSHAIL-----NIDLKDKINTS-- 221
Dp 378 EYEV-SDVQIVKDPFIKGNARETGSTGANBESSRHAILQLVKKGHVEVKDTRRRNDS 436
QY 232 -----LGIAPIDLAGSERGADTVSOKQOTODGANINRSLIAKECIRANDSDKNI 284
Dp 437 NELPGKRVGKISFIDLAGSERGADTVSOKQOTODGANINRSLIAKECIRANDSDKNI 496
QY 285 PFRDSELTQVLRDIFVYKSKSIMIANISPTISCCQOTLNTLRYSRVK-----NFKNKS 338
Dp 497 PFRGSKLTVLRDIFVYKSKSIMIANISPTISCCQOTLNTLRYSRVK-----NFKNKS 556
QY 339 TC-----INEBDTNTERTISLDSKSEMNASIENVVJKNHLSNNNNKINRQKIND 393
Dp 557 TANSMPVKKDPLLGNDVEDVEPEPQEVNPEPTRRVEKD---SNSSTSGIDFROPV 613
QY 394 KIERNNILKQKSDKREGFTSF-GKYSGLNDI-----DKIKK--NKKKGLI 438
Dp 614 YRESGI-PSFGMDKRSSEPNSSFAGSTQQRNNISYPOETSDBREKVKVSPRKGGL- 671
QY 439 NYKSTLYNDNTINKKNNNNNNNDNNNDNNNNNDSSSMVNMNINHMINNNNN 498
Dp 672 -----REKPDPPQWKSQDVSS-----SD 691
QY 499 INVNNNNNNNNNNNNNNHNLPOPNYAFTDTSDFSLDDMNCHLNNNDKSIPLAKKRLD 558
Dp 692 IPTLTNFRQNASBTASROYETASROYE-TDPSIDENLDAL---LEBEALIAHREKIED 747
QY 559 NIKL 562
Dp 748 TWEI 751

```

RESULT 5
 ABB58104
 ID ABB58104 standard; Protein; 803 AA.
 AC ABB58104;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Drosophila melanogaster polypeptide sEQ ID NO 1104.
 XX
 KW Drosophila; developmental biology; cell signalling; insecticide;
 pharmaceutical.
 XX
 OS Drosophila melanogaster.
 OS
 PN WO200171042-A2.
 XX
 PD 27-SEP-2001.
 XX
 PF 23-MAR-2001; 2001WO-US09231.
 XX
 PR 23-MAR-2000; 2000US-191637P.
 PR 11-JUL-2000; 2000US-0614150.
 XX
 PA (PEKE) PE CORP NY.
 XX
 PI Venter JC, Adams M, Li PWD, Myers EW;
 XX

DR WPI: 2001-6556860/75.
 DR N-PSDB; ABL02207.
 PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX
 PS Disclosure; SEQ ID NO 1104; 21pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (AB16176-AB16511), expressed DNA
 CC sequences (AB101840-AB16175) and the encoded proteins
 CC (AB161737-AB162072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX
 XX Sequence 803 AA;
 Query Match 11.4%; Score 783; DB 22; Length 803;
 Best Local Similarity 38.8%; Pred. No. 4,4e-36;
 Matches 193; Conservative 78; Mismatches 153; Indels 74; Gaps 13;

QY 4 KIKVVRKRRLSELLEKKKSDITTVKNNCTLYIDEPYKIDMTYIRHEFIYDKFPDD 63
 DB 276 QITVCVRKRRLSELLEKKKSDITTVKNNCTLYIDEPYKIDMTYIRHEFIYDKFPDD 335
 QY 64 TVNDFVTYENTIKELIIDLYENGCCGCFAYGOTSGYTMLSQPGV--QSPDPGIFQ 121
 DB 336 TCDNANVYKTKAKPLVKTIFEGG--MATFAVGOTSGKTHM--GGEFGKQVDDCKNGIYA 393
 QY 122 YAAADIFTEFLNI--YDKNTKGIFISFYEYICGLYDLQKRWAALENGKEVAVVDL 179
 DB 394 MAADVFTLMPRYRANLV--VSAFPEISGKVFDLSPQKRLVLEDKQVQVAVGL 452
 QY 180 KILNLTKEELILKMD--GVLLRKIGVNSQNDSSRSHAIITDKINKTSLGKIAFI 238
 DB 453 -TERKVGVEHEVLKLIQGNARITSGQTSANSNSRSHAVQIVLRPGSGTKIHGKFSFI 511
 QY 239 DIASSEGADIVSONKOROTGAMNBSLALKECTRAMDDQKHIIPRDELTGVADI 298
 DB 512 DLAGNERVDTSSADROTIRMGAEITNSLALKECTRAMDQKHIIPRDELTGVADI 571
 QY 299 FVG--KSKSIMIANISPTISCEQTLNLTLYSSRVNFKNKSTCINEEDTNTERTSILDS 357
 DB 572 FIGRKSCTKCMIAISPGLSCEHTLNTLRADRVKELVVD--IVEVCPGSDTEPIEITDD 630
 QY 358 KSEMNASSIENVVYKSHLSSNNNNKINKNGKINDKIERNNILKNKSFDPREBGFSTF 417
 DB 631 EEEBE-----LNMVPHSHQHPNSHAPASQ----- 656
 QY 418 GKYSSLNDIKTKKKKKGLINYKSTLYNDNTINKNNNNNNNNNDNNNNNNNNNN 477
 DB 657 -----SNQORAPASHHSGAVT-----HNNNNNNKNGAHGMD----- 689

QY 478 DSSSVNNMNMNNNNI 495
 DB 690 --LAWLSLSLSEHMSDEL 705

RESULT 6
 AAB18250
 ID AAB18250 standard; Protein; 1844 AA.
 AC AAB18250;
 XX
 XX 07-NOV-2000 (first entry)
 DT
 XX Plasmodium falciparum chromosome 2 related protein SEQ ID NO:107.

XX
 KW Plasmodium falciparum; chromosome 2; human malaria parasite; vaccine;
 KW antimalarial; malaria; protozoacide; infection; insecticide.
 XX
 OS Plasmodium falciparum.
 XX
 PN WO200025728-A2.
 XX
 PD 11-MAY-2000.
 XX
 XX 05-NOV-1999; 99WO-US26796.
 PF
 XX 05-NOV-1998; 98US-0107311.
 PR
 XX (HOFF/) HOFFMAN S.
 PA (CARU/) CARUCCI D.
 PA (GARD/) GARDNER M.
 PA (VENT/) VENTER J C.
 XX
 PI Hoffman S, Carucci D, Gardner M, Venter JC;
 XX
 DR WPI: 2000-365347/31.
 XX
 PT Proteins encoded by chromosome 2 of the human malarial parasite,
 PT Plasmodium falciparum, useful as antimalarial vaccines and in the
 PT diagnosis of P.falciparum infection -
 XX
 PS Disclosure; Page 246-250; 577pp; English.

QY The present invention describes proteins and their fragments (I) encoded
 CC by chromosome 2 of the human malarial parasite, Plasmodium falciparum.
 CC Also described are: (I) nucleotide sequences (II) encoding (I); and (2)
 CC vaccines against P. falciparum infection comprising (I) or (II).
 CC (I) and (II) are useful for the development of vaccines against
 CC P. falciparum infection. (I) and polyclonal antisera or a monoclonal
 CC antibody raised to immunogens comprising the sequences of (I), are
 CC useful in the detection of infection with P. falciparum. Furthermore,
 CC (I) (especially when they are rifins or secreted or membrane proteins)
 CC can aid the identification of drugs to treat or prevent P. falciparum
 CC infection, or they can be used to identify drug resistance in
 CC P. falciparum. Sequencing of the Plasmodium chromosome 2 and the
 CC subsequent identification of proteins encoded by it will help to expand
 CC our understanding of parasite biology, a process hampered by the
 CC complexity of the parasite lifecycle, and provide new targets for
 CC vaccine and drug development. Parasite resistance to drugs and mosquito
 CC resistance to insecticides have led to a resurgence of malaria in many
 CC parts of the world, and there is a pressing need for vaccines and new
 CC drugs. AA170078 to AA170287 and AAB18144 to AAB18352 represent nucleotide
 CC and protein sequences given in the present invention, but which are not
 CC specifically mentioned within the specification.

QY Sequence 1844 AA;
 Query Match 11.4%; Score 778; DB 21; Length 1844;
 Best Local Similarity 24.5%; Pred. No. 2,2e-35;
 Matches 340; Conservative 202; Mismatches 439; Indels 406; Gaps 66;

QY 205 VNSQNDSSRSHALINI--DLKDINKTSLGKIAFIIDLAGSRGADTVSONKQOT----- 258
 DB 37 VNRNDNMYEMWYNSINGSHMSNINNNTNLODAIYNELHMYNSDKINIAONHONVHTA 96
 QY 259 -----DGANIRSLALKECIRAMSDKNHIFPRDSELTGVARDIFVQKSKSIMIANISP 313
 DB 97 TYNNMDKNANNNIHILNHNIN--WTDQNT--FVNSTTNNM-----NNTLKNNPN 146
 QY 314 TISCEQTLNLTLYSSRVNFKNKSTCINEED--TNTERTSILDSKSEMNASSIEN-- 369
 DB 147 NNN-----TVNNSFYHNTDNNFLNFTRNQEDTYVNNNIINNENNQVDDKINNINNPN 202
 QY 370 -----VVKSHNLLSNNNN-----KINGKINDKIERNNILKNKSFDPREBGFSTFGKYS 421
 DB 203 KNVESINKFNHTYNNQNFNHFIPNISNGK--NGNLNNASLASH-----NVASVS 249

Db 72 ACTNODVYMKTTHTPLQIHIF-NGGNATCFAYGQTGAGKTYMTIGTH-----ENPGLYALA 125

Qy 124 AGDIFFTLNIYDKNTKGIFISFEIYCGKLYDLQKRWAALENGKEVVDKILR 183

Db 126 AKDIFRQLEVSQPRKHLFWMISFEIYCGQLYDLNRRKRLFAEDSKHAWQIVGLQELQ 185

Qy 184 VLTEBELILKMDVLLRKIGVNSQNDSSRSHAILNDLKDKINKNTSLGKIAFIDLAGS 243

Db 186 VDSVELLEVLILKSGSKERSTGATGVNADSSRSHAVIQIQKDSAKRT-FGRISFIDLAGS 244

Qy 244 ERGADTVSQRKQOTDGNINRSLALKECIRAMDSDKNHIPPDSSETLVLDIFVGS 303

Db 245 ERADADSDRQRTMEGAELNOSLALKECIRALDQETHTPRQSKLTQVLKDSFIGNA 304

Qy 304 KSIIMANISPTISCCQOTLNTLRYSRKNFKNKTCTINEEDPTN 348

Db 305 KTCMIANISPSHVATEHTLNTLRADRVKELKGIKCTSVTSRN 349

RESULT 8

AAU77184 standard; Protein, 381 AA.

AAU77184;

02-JUL-2002 (first entry)

Human Kint-3 DNA fragment with flanking vector sequences #2.

Human Kint-3 motor protein; Kint-3; microtubule; hyperplasia; depolymerisation; cellular proliferation disorder; cancer; restenosis; vascular malfunction; abnormal wound healing; cardiac hypertrophy; gout; inflammatory disorder; immune disorder; rheumatoid arthritis; psoriasis; diabetic retinopathy; neurological disorder; immunosuppressive; vasotropic; vesicular transport disorder; immunosuppressive; antiinflammatory; cyostatic.

Homo sapiens.

Synthetic.

WO200226929-A2.

04-APR-2002.

28-SEP-2001; 2001WO-US30750.

29-SEP-2000; 2000US-0675227.

(CYTO-) CYTOKINETICS INC.

Beraud C, Guo J, Freedman R, Patel UA, Davies KA;

WPI; 2002-352124/38.

N-PSDB; ABK47999.

An novel isolated microtubule motor protein, Kint-3 used for preparing compositions for the diagnosis, prevention or treatment of diseases such as cancers, hyperplasias or restenosis -

Disclosure; Fig 4; 68pp; English.

The invention relates to a human kinesin motor protein (Kint-3), with microtubule depolymerisation activity, and the polynucleotide encoding it. The novel Kint-3 motor protein can be used to prepare compositions for the diagnosis, prevention or treatment of cellular proliferation disorders, cancers, hyperplasias, restenosis, vascular malfunctions, abnormal wound healing, cardiac hypertrophy, inflammatory and immune disorders (such as rheumatoid arthritis, gout, psoriasis and diabetic retinopathy) neurological disorders and disorders of vesicular transport. This sequence represents a human Kint-3 polypeptide fragment with flanking vector sequences.

Sequence 381 AA;

Query Match 11.2%; Score 768.5; DB 23; Length 381;

Best Local Similarity 47.5%; Pred. No. 1,3e-35;

Matches 164; Conservative 58; Mismatches 116; Indels 7; Gaps 3;

Qy 4 KIRVAVKRPRLSELEKKKQSDIITVKNCTLYIDEPRYVDMTKYIERHEFVYDKYFD 63

Db 30 KIRVAVKRPRLGMRVVRGGINIITVEDKETLLVHEKKEAVDILTQYLQHFYFDEVEGE 89

Qy 64 TVDNFTYENTITKPLIIDLVENGVCSCFAYGQTGAGKTYMTIGTH-----ENPGLYALA 123

Db 90 ACTNODVYMKTTHTPLQIHIF-NGGNATCFAYGQTGAGKTYMTIGTH-----ENPGLYALA 143

Qy 124 AGDIFFTLNIYDKNTKGIFISFEIYCGKLYDLQKRWAALENGKEVVDKILR 183

Db 144 AKDIFRQLEVSQPRKHLFWMISFEIYCGQLYDLNRRKRLFAEDSKHAWQIVGLQELQ 203

Qy 184 VLTEBELILKMDVLLRKIGVNSQNDSSRSHAILNDLKDKINKNTSLGKIAFIDLAGS 243

Db 204 VDSVELLEVLILKSGSKERSTGATGVNADSSRSHAVIQIQKDSAKRT-FGRISFIDLAGS 262

Qy 244 ERGADTVSQRKQOTDGNINRSLALKECIRAMDSDKNHIPPDSSETLVLDIFVGS 303

Db 263 ERADADSDRQRTMEGAELNOSLALKECIRALDQETHTPRQSKLTQVLKDSFIGNA 322

Qy 304 KSIIMANISPTISCCQOTLNTLRYSRKNFKNKTCTINEEDPTN 348

Db 323 KTCMIANISPSHVATEHTLNTLRADRVKELKGIKCTSVTSRN 367

RESULT 9

AAU77182 standard; Protein, 1368 AA.

AAU77182;

02-JUL-2002 (first entry)

Human kinesin motor protein Kint-3.

Human; kinesin motor protein; Kint-3; microtubule; hyperplasia; depolymerisation; cellular proliferation disorder; cancer; restenosis; vascular malfunction; abnormal wound healing; cardiac hypertrophy; gout; inflammatory disorder; immune disorder; rheumatoid arthritis; psoriasis; diabetic retinopathy; neurological disorder; immunosuppressive; vasotropic; vesicular transport disorder; immunosuppressive; antiinflammatory; cyostatic.

Homo sapiens.

Homo sapiens.

Key Location/Qualifiers

Domain 224..545

/label=Motor_domain

WO200226929-A2.

04-APR-2002.

28-SEP-2001; 2001WO-US30750.

29-SEP-2000; 2000US-0675227.

(CYTO-) CYTOKINETICS INC.

Beraud C, Guo J, Freedman R, Patel UA, Davies KA;

WPI; 2002-352124/38.

N-PSDB; ABK47999.

An novel isolated microtubule motor protein, Kint-3 used for preparing compositions for the diagnosis, prevention or treatment of diseases such as cancers, hyperplasias or restenosis -

PS Claim 11; Fig 2; 68pp; English.

XX The invention relates to a human kinesin motor protein (Kini-3), with
XX microtubule depolymerisation activity, and the polynucleotide encoding
CC it. The novel Kini-3 motor protein can be used to prepare compositions
CC for the diagnosis, prevention or treatment of cellular proliferation
CC disorders, cancers, hyperplasias, restenosis, vascular malfunctions,
CC abnormal wound healing, cardiac hypertrophy, inflammatory and immune
CC disorders (such as rheumatoid arthritis, gout, psoriasis and diabetic
CC retinopathy) neurological disorders and disorders of vesicular transport.
CC This sequence represents the human Kini-3 polypeptide.

XX Sequence 1368 AA;

Query Match 11.2%; Score 768.5; DB 23; Length 1368;
Best Local Similarity 47.5%; Pred. No. 5,3e-35;
Matches 164; Conservative 58; Mismatches 116; Indels 7; Gaps 3;

QY 4 KIRVVRRKRPSELEKKKKSDIITVKNCTLYIDPRYKVDMTKYIERHEFIIVDKVPDD 63
DB 223 KIRVCVRKRPPLGMRVREVRGEINIIIVEDKETTLLVHEKKEAVDLTYIIQHVFFDEVFGE 282
QY 64 TVDNFTVYENTIKPLIIDYENGCVSCFAYGQTSKTYTLMGSPYQGSOTPGIFQYA 123
DB 283 ACTNODVYMKTHPILOHIF-NGGNATCFAYGQTGAKTYTMIQTH-----ENPGLYALA 336
QY 124 AGDIFELNIYDKDNTKGIFISFYEIYCGKLYDLQKRMVALENGKKEVVKDKILR 183
DB 337 AADIFQLEVSOPRKHLPFWISFYEIYCGQLYDLNRRRLPAREDSKIMVOIVGLQELQ 396
QY 184 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAILNIDLKDNKNTSLGKIAFIDLACS 243
DB 397 VDSVELLEVLIIKSKERSTGATGVNADSRSHAVIQIKDSAKRT-FGRISFDLACS 455
QY 244 ERGADTVSONKQOTQDGNANINSLALKECIRAMSDSKNHIIPRSELTKVLRDIFVGS 303
DB 456 ERADARDSDROTCKMEGAINOSLALKECIRALDOEHHTPFRSKLTQVLKDSPIGNA 515
QY 304 KSIMTANISPTSCCEOTLNTLRYSRVRNFKKSTCINEBDPTN 348
DB 516 KTCMTANISPSHVATEHTLNTLRVADRVKELKGIKCTSVTSRN 560

RESULT 10
AAU77185

ID AAU77185 standard; Protein; 343 AA.

AC AAU77185;

DT 02-JUL-2002 (first entry)

DE Human Kini-3 DNA fragment with flanking vector sequences #3.

XX Human; kinesin motor protein; Kini-3; microtubule; hyperplasia;
KW depolymerisation; cellular proliferation disorder; cancer; restenosis;
KW vascular malfunction; abnormal wound healing; cardiac hypertrophy; gout;
KW inflammatory disorder; immune disorder; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; neurological disorder; immunosuppressant; vasotrophic;
KW vesicular transport disorder; immunosuppressive; antiinflammatory;
KW cytoskeletal.

OS Homo sapiens.
OS Synthetic.

XX WO200226929-A2.

XX 04-APR-2002.

XX 28-SEP-2001; 2001WO-US30750.

XX 29-SEP-2000; 2000US-067527.

XX (CYTO-) CYTOKINETICS INC.

XX Beraud C, Guo J, Freedman R, Patel UA, Davies KA;
XX WPI: 2002-352124/38.
DR N-PSDB; ABK48000.

XX An novel isolated microtubule motor protein, Kini-3 used for preparing
PT compositions for the diagnosis, prevention or treatment of diseases
XX such as cancers, hyperplasias or restenosis -
PS Disclosure; Fig 5; 68pp; English.

XX Sequence 343 AA;

Query Match 11.1%; Score 758.5; DB 23; Length 343;
Best Local Similarity 48.9%; Pred. No. 4,1e-35;
Matches 161; Conservative 58; Mismatches 103; Indels 7; Gaps 3;

QY 4 KIRVVRRKRPSELEKKKKSDIITVKNCTLYIDPRYKVDMTKYIERHEFIIVDKVPDD 63
DB 12 KIRVCVRKRPPLGMRVREVRGEINIIIVEDKETTLLVHEKKEAVDLTYIIQHVFFDEVFGE 71
QY 64 TVDNFTVYENTIKPLIIDYENGCVSCFAYGQTSKTYTLMGSPYQGSOTPGIFQYA 123
DB 72 ACTNODVYMKTHPILOHIF-NGGNATCFAYGQTGAKTYTMIQTH-----ENPGLYALA 125
QY 124 AGDIFELNIYDKDNTKGIFISFYEIYCGKLYDLQKRMVALENGKKEVVKDKILR 183
DB 126 AADIFQLEVSOPRKHLPFWISFYEIYCGQLYDLNRRRLPAREDSKIMVOIVGLQELQ 185
QY 184 VLTKEELIKMIDGVLRLKIGVNSQNDSSRSHAILNIDLKDNKNTSLGKIAFIDLACS 243
DB 186 VDSVELLEVLIIKSKERSTGATGVNADSRSHAVIQIKDSAKRT-FGRISFDLACS 244
QY 244 ERGADTVSONKQOTQDGNANINSLALKECIRAMSDSKNHIIPRSELTKVLRDIFVGS 303
DB 245 ERADARDSDROTCKMEGAINOSLALKECIRALDOEHHTPFRSKLTQVLKDSPIGNA 304
QY 304 KSIMTANISPTSCCEOTLNTLRYSRVRK 332
DB 305 KTCMTANISPSHVATEHTLNTLRVADRVK 333

RESULT 11
AAU77183

ID AAU77183 standard; Protein; 373 AA.

AC AAU77183;

DT 02-JUL-2002 (first entry)

DE Human Kini-3 DNA fragment with flanking vector sequences #1.

XX Human; kinesin motor protein; Kini-3; microtubule; hyperplasia;
KW depolymerisation; cellular proliferation disorder; cancer; restenosis;
KW vascular malfunction; abnormal wound healing; cardiac hypertrophy; gout;
KW inflammatory disorder; immune disorder; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; neurological disorder; immunosuppressant; vasotrophic;
KW vesicular transport disorder; immunosuppressive; antiinflammatory;
KW cytoskeletal.

OS Homo sapiens.

OS Synthetic.
XX
XX WO200226929-A2.
XX
XX 04-APR-2002.
XX
XX 28-SEP-2001; 2001WO-US30750.
XX
XX 29-SEP-2000; 2000US-0675227.
XX
XX (CYTO-) CYTOKINETICS INC.
XX
XX Beraud C, Guo J, Freedman R, Patel UA, Davies KA;
XX
XX WPI; 2002-352124/38.
XX
XX N-PSDB; ABR47998.
XX
XX An novel isolated microtubule motor protein, Kint-3 used for preparing
PT compositions for the diagnosis, prevention or treatment of diseases
PT such as cancers, hyperplasias or restenosis -
XX
XX Disclosure; Fig 3; 68pp; English.
XX
XX The invention relates to a human kinesin motor protein (Kint-3), with
CC microtubule depolymerisation activity, and the polynucleotide encoding
CC it. The novel Kint-3 motor protein can be used to prepare compositions
CC for the diagnosis, prevention or treatment of cellular proliferation
CC disorders, cancers, hyperplasias, restenosis, vascular malfunctions,
CC abnormal wound healing, cardiac hypertrophy, inflammatory and immune
CC disorders (such as rheumatoid arthritis, gout, psoriasis and diabetic
CC retinopathy) neurological disorders and disorders of vesicular transport.
CC This sequence represents a human Kint-3 polypeptide fragment with
CC flanking vector sequences.
XX
XX
SQ Sequence 373 AA;
Query Match 11.1%; Score 758.5; DB 23; Length 373;
Best Local Similarity 48.9%; Pred. No. 4.5e-35;
Matches 161; Conservative 58; Mismatches 103; Indels 7; Gaps 3;
QY 4 KIKVVRKRPRLSELEKKKSDIITVKNCTLYIDEPYKVDWTKYIERHEFTVDKVPDD 63
DB 42 KIRCVRRKRPPLGMEVRERGEINIITVEDKETLIVHEKKEAVDLQYIIQHVFEDEVEGE 101
QY 64 TVDNFTYVENTIKRPIIDLYENGCVCSGFAVGOTSGSKTYTMLGSPYQSGDTPGIFQY 123
DB 102 ACTQDVYMKTHPLIQHIF-NGGNATCFAYGQTGAGKTYTWIGTH-----ENPELVALA 155
QY 124 AGDIFFTFLNIYDKNTKGIFFISFYEYCGKLYDLLQKRKMAVALENGKEVAVVVDLKITLR 183
DB 156 AKDIFRQLEVOGPRKHLFWWISFYIYCGQLYDLNRRKRLPARBDSKHMQIVGLQLOLQ 215
QY 184 VLTKEELLKMIIDGVLLRKIGVNSONDESSSRSHALINIDLKINKNTSLGKIAFTDLGAS 243
DB 216 VDSVELLEVLILKSGKERSTGATGVNADSSSHAVIQIOLKDSAKRT-FGRISFDLAGS 274
QY 244 ERGADTVSONKQOTQDGANINRSILALKECIRAMSDKNHIFPERSLTKVLROIIVFKS 303
DB 275 ERRAARDSDRQTKMEGAEINQSLALKECIRALDOETHHPFRQSKLTQVLKDSFIGNA 334
QY 304 KSIMIANISPTISCEOTLNTLRYSSRYK 332
DB 335 KTCMIANISPSHVATEHTLNTLRKYADRYK 363
Db
RESULT 12
ID AAY49949
AAAY49949 standard; Protein; 730 AA.
XX
XX AAY49949;
XX
XX 02-FEB-2000 (first entry)
XX

DE Xenopus laevis kinesin central motor 1.
XX
XX Strongylocentrotus purpuratus; katanin; p60 subunit; p80 subunit;
XX microtubule severing protein; ATPase; detection; identification;
XX microtubule depolymerisation inhibitor; screening; cell cycle;
XX kinesin central motor 1; XKCM1; regulation; antimitotic.
XX
XX Xenopus laevis.
XX
XX WO9953295-A1.
XX
XX 21-OCT-1999.
XX
XX 13-APR-1999; 99WO-US08086.
XX
XX 14-APR-1998; 98US-0081734.
XX
XX (REGC) UNIV CALIFORNIA.
XX
XX Vale RD, Hartman JJ;
XX
XX WPI; 2000-013108/01.
XX
XX N-PSDB; AAZ35759.
XX
XX Identifying agents that modulate microtubule depolymerisation -
PT
PT Disclosure; Page 66; 69pp; English.
XX
XX The present invention describes a method for identifying a modulator of
CC microtubule (MT) depolymerisation by contacting a polymerised MT with
CC an MT severing or depolymerising protein and a candidate agent in the
CC presence of ATP or GTP, and detecting formation of tubulin monomers,
CC dimers or oligomers. The method is useful to detect agents that
CC regulate the cytoskeleton and the cell cycle. Such agents have potential
CC for use as anti-mitotic agents. The present sequence represents the
CC Xenopus laevis kinesin central motor 1 (XKCM1), which regulates
CC microtubule dynamics during mitotic spindle assembly. XKCM1 localises
CC to centrosomes and appears to regulate the polymerisation dynamics of
CC microtubules, and so is suitable for use in the method of the invention.
XX
XX
SQ Sequence 730 AA;
Query Match 11.1%; Score 758.5; DB 21; Length 730;
Best Local Similarity 42.1%; Pred. No. 9.6e-35;
Matches 175; Conservative 84; Mismatches 130; Indels 27; Gaps 12;
QY 4 KIKVVRKRPRLSELEKKKSDIITVKNCTLYIDEPYKVDWTKYIERHEFTVDKVPDD 63
DB 262 RICEVVRKRPPLNKOELSKEDIISVPSKNIIVLHEKRLVDLTKYLENOAFRDFSPDE 321
QY 64 TVDNFTYVENTIKRPIIDLYENGCVCSGFAVGOTSGSKTYTMLGSPYQSGDTPGIFQY 122
DB 322 TATNEVVYRTFARPLVOSIFEKG-KATCFAYGOTSGSKTYTMLGDPFGSKQNVSKGYAF 380
QY 123 AAGDIFFTFLNIYDKNTK---GIFISFYEYCGKLYDLLQKRKMAVALENGKEVAVVVD 178
DB 381 ASRVVFLLL--DQPRKHLDLDFVTFEFLYNGKVPDLNKKTKTLVLEDAKQEOVYVG 437
QY 179 LKILRVLTKEELLKMIID-GVLLRKIGVNSONDESSSRSHALINIDLKINKNTSL-GKIA 236
DB 438 LLEKQVLSADQ-VEKMIETISGACTSGQTFANSSSRSHACLQILR--RGSLLHGFSS 493
QY 237 FIDLAGSERGADTVSONKQOTQDGANINRSILALKECIRAMSDKNHIFPERSLTKVLRI 296
DB 494 LVLDLAGNERGVDTASADRIITMKGAELNRSILALKECIRALGQKSHTPPESRLTQILR 553
QY 297 DIFVKG-SKSIIMIANISPTISCEOTLNTLRYSSRVNFKNKSCTCINEEDDTNTERISIL 355
DB 554 DSFIGENSRCTMIMLSGFGNSCYTTLNLRKYADRVLELSPQNA-----ETNDNLQME 607
QY 356 DSKGSENNAGSIEENVVYKSNHLLSNNNNNKINRGKINDKIERNNIILNKKSPDKRE 411
DB 608 DSGGSH--ASIEGLQLODDPLDKDEBLSTHN--SFODALNRVGELEBDKAVDELRE 658


```

RESULT 13
AAE14504 standard; Protein: 405 AA.
ID AAE14504
XX
AC AAE14504;
XX
DT 09-APR-2002 (first entry)
XX
DE Human mitotic centromere-associated kinesin protein fragment #6.
XX
KW Human; MCAK; mitotic centromere-associated kinesin; motor domain;
KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
KW arthritis; graft rejection; inflammatory bowel disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 2 /note="Encoded by AC"
FT
XX
PN US631424-B1.
XX
PD 18-DEC-2001.
XX
PF 15-JUN-2000; 2000US-0594669.
XX
PR 20-APR-1999; 99US-0295612.
PR 18-MAY-1999; 99US-0314464.
XX
PA (CYTO-) CYTOKINETICS INC.
XX
PI Berand C, Sakowicz R;
XX
DR WPI; 2002-089075/12.
DR N-PSDB; AAD24085.
XX
PT New human MCAK (mitotic centromere-associated kinesin) protein useful
PT in identifying agents for use in the treatment of cellular
PT proliferation disorders -
XX
PS Claim 1; Fig 12; 44pp; English.
XX
CC The invention relates to human MCAK (mitotic centromere-associated
CC kinesin) protein, and its fragments that comprise a motor domain and
CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
CC its fragments are used in methods to identify compounds that modulate
CC their activity. Modulators of MCAK are useful as therapeutic agents
CC for treating cellular proliferation disorders such as cancer,
CC hyperplasias, restenosis, cardiac hypertrophy, immune disorders,
CC inflammation, autoimmune disease, arthritis, graft rejection,
CC inflammatory bowel disease. The present sequence is a human MCAK
CC fragment.
XX
SQ Sequence 405 AA;
XX
Query Match 11.0%; Score 752.5; DB 23; Length 405;
Best Local Similarity 42.1%; Pred. No. 1, de-34;
Matches 1/4; Conservative 75; Mismatches 143; Indels 21; Gaps 10;
XX
QY 4 KIKVVRKRPPLSELEKKKSDIITVKNNTLYIDBPRYKDMTKYIERHFIIVDKVFPD 63
DB 3 RICVCVRKRPKLNQELAKKEIDIVISPSKCLLVHHPKLVKDLTKYLENOAFCPDPAFDB 62
QY 64 TVDNFTVYENTIKPLIIDYENGCVSCFAYGQTGSGKTYTMGS-QPYGQSDTPGIFQY 122
DB 63 TASNENVVYFTAPLVIQTFIEGQ-KATCFAYGQTGSGKTHWGDSGKAQNNSKGIYAM 121
QY 123 AAGDITFTFLN--TYDQNTKGIISFYELYCGTLVLLQKRVVALLENGKKEVYVVKDK 180
DB 122 ASRDVFLKNQPCYRKLGLE-VVTFPEIYNGKLFDLNNKAKLRLVLEDKQGVVQVGLQ 180

```

```

QY 181 ILRLTKBELILMID-GVLLRKIGVNSQNDSSRSHAILNDLKDINNTSLGKIAFID 239
DB 181 EHLVNSADP-VIKMIDMSACRISGOTFANSSSRHAFQIILR--AGRNHGKRSYVD 237
QY 240 LAGSERGADTVSONKOTQTDGANINSLALKECTIPAMSDKNHIFPDSLETKVLRDIF 299
DB 238 LAGNERGADTVSSADPQTRMEGAIEINKSLALKECIRALGQNKATPFRSKLTQVLRDSF 297
QY 300 VCK-SKSIIMIANISPTISCCBOTLNTLRYSRVKPKNKSTCINEEDDINTERTISLDSK 358
DB 298 IGENSRKTMATISPSGISCEYTLNTRVADRVKELSPHSGSGEQ-----LQWE 348
QY 359 GSEMNASTIENVIKSNHLLSNNNNKIRGKINDKIEENNILKNKSPDKPRE 411
DB 349 TERMEACG--NGALLIPGNLSKEBEELSSQMSSTFENMTQIRLEEKAMELKE 399

```

```

RESULT 14
AAE14503
ID AAE14503 standard; Protein: 434 AA.
XX
AC AAE14503;
XX
DT 09-APR-2002 (first entry)
XX
DE Human mitotic centromere-associated kinesin protein fragment #5.
XX
KW Human; MCAK; mitotic centromere-associated kinesin; motor domain;
KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
KW arthritis; graft rejection; inflammatory bowel disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 2 /note="Encoded by CA"
FT
XX
PN US631424-B1.
XX
PD 18-DEC-2001.
XX
PF 15-JUN-2000; 2000US-0594669.
XX
PR 20-APR-1999; 99US-0295612.
PR 18-MAY-1999; 99US-0314464.
XX
PA (CYTO-) CYTOKINETICS INC.
XX
PI Berand C, Sakowicz R;
XX
DR WPI; 2002-089075/12.
DR N-PSDB; AAD24084.
XX
PT New human MCAK (mitotic centromere-associated kinesin) protein useful
PT in identifying agents for use in the treatment of cellular
PT proliferation disorders -
XX
PS Claim 1; Fig 10; 44pp; English.
XX
CC The invention relates to human MCAK (mitotic centromere-associated
CC kinesin) protein, and its fragments that comprise a motor domain and
CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
CC its fragments are used in methods to identify compounds that modulate
CC their activity. Modulators of MCAK are useful as therapeutic agents
CC for treating cellular proliferation disorders such as cancer,
CC hyperplasias, restenosis, cardiac hypertrophy, immune disorders,
CC inflammation, autoimmune disease, arthritis, graft rejection,
CC inflammatory bowel disease. The present sequence is a human MCAK
CC fragment.
XX
SQ Sequence 434 AA;
XX

```

Query Match 11.0%; Score 752.5; DB 23; Length 434;
Best Local Similarity 42.1%; Pred. No. 1.2e-34;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

QY 4 KIKVVRKRPPLSELEKKKKSDIITVKNKNTLYIDEPYKVMKYIERHEFIVDKYEDD 63
DB 32 RICCVKRRPLNKQELAKKEIDVISPCKLLVHEPKLVDLTKYLENQAFCDFPAFDE 91
QY 64 TVDNFTYENTIKPLIIDLYENGCVCSFANGOTSGKTYTMLS-QPYGSDTPGIFQY 122
DB 92 TASNEVYRRTARPLVQITFEFG-KATCFAYGOTSGKTHMGDLSGKAQNSKGIYAM 150
QY 123 AAGDIFFTFLN--IYDKONTGIFISFYIYCGKLYDLLQKRVVALENGKEVYVVDLK 180
DB 151 ASRVEFLKNQPCRYKLGLE-VYVTFPEIYNGKLFDLNKKAKALVLEDEQOQVVGLO 209
QY 181 ILRLVLTKEELLKIID-GVLLRKIGVNSQNDSSRSHAILNIDKDKNTSLGKIAFID 239
DB 210 EHLVNSADD-VIKMIDMSACRTSGQTPFANSNSRSHACFOILR--AKGRMHGKESLVD 266
QY 240 LAGSERGADTVSONKQOTQDGNINRSLALKECIRAMDSKXHIPRDESLTKVLDIF 299
DB 267 LAGNERGADTSSADROTRMEGAELNKSLLALKECIRALGQNKATPFRESKLTQVLRDSF 326
QY 300 VGR-SKSIIMIANISPTISCCBOTNTLRYSSRVKNFKNKSTCINEEDDTNTERISILDSK 358
DB 327 IGENSRCMTATISPGISSCEYTLNTRLYADRVKELSPHSGPSGEO-----LIQME 377
QY 359 GSENNASSIENVVIKSNHLLSNNNNNKINRGKINDKIERNNILKNKSPDKPRE 411
DB 378 TEEMWACS--NGALIPGNLSKEBELSSQMSFNEAMQIRELEKAMEBLKE 428

RESULT 15
AAE14502
ID AAE14502 standard; Protein: 473 AA.
XX
AC AAE14502;
XX
DT 09-APR-2002 (first entry)
XX
DE Human mitotic centromere-associated kinesin protein fragment #4.
XX
KW Human; MCAK; mitotic centromere-associated kinesin; motor domain;
KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
KW arthritis; graft rejection; inflammatory bowel disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 2 /note= "Encoded by GG"
FT
XX
PN US6331424-B1.
XX
PD 18-DEC-2001.
XX
PF 15-JUN-2000; 2000US-0594669.
XX
PR 20-APR-1999; 99US-0295612.
PR 18-MAY-1999; 99US-0314464.
XX
PA (CYTO-) CYTOKINETICS INC.
XX
PI Beraud C, Sakowicz R;
XX
DR WPI; 2002-089075/12.
DR N-PSDB; AAD24083.
XX
PT New human MCAK (mitotic centromere-associated kinesin) protein useful
PT in identifying agents for use in the treatment of cellular

PT proliferation disorders -
XX
PS Claim 1; Fig 8; 44pp; English.
XX
XX The invention relates to human MCAK (mitotic centromere-associated
CC kinesin) protein, and its fragments that comprise a motor domain and
CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
CC its fragments are used in methods to identify compounds that modulate
CC their activity. Modulators of MCAK are useful as therapeutic agents
CC for treating cellular proliferation disorders such as cancer,
CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
CC inflammation, autoimmune disease, arthritis, graft rejection,
CC inflammatory bowel disease. The present sequence is a human MCAK
CC fragment.
XX
SQ Sequence 473 AA;
XX
Query Match 11.0%; Score 752.5; DB 23; Length 473;
Best Local Similarity 42.1%; Pred. No. 1.3e-34;
Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;

QY 4 KIKVVRKRPPLSELEKKKKSDIITVKNKNTLYIDEPYKVMKYIERHEFIVDKYEDD 63
DB 71 RICCVKRRPLNKQELAKKEIDVISPCKLLVHEPKLVDLTKYLENQAFCDFPAFDE 130
QY 64 TVDNFTYENTIKPLIIDLYENGCVCSFANGOTSGKTYTMLS-QPYGSDTPGIFQY 122
DB 131 TASNEVYRRTARPLVQITFEFG-KATCFAYGOTSGKTHMGDLSGKAQNSKGIYAM 189
QY 123 AAGDIFFTFLN--IYDKONTGIFISFYIYCGKLYDLLQKRVVALENGKEVYVVDLK 180
DB 190 ASRVEFLKNQPCRYKLGLE-VYVTFPEIYNGKLFDLNKKAKALVLEDEQOQVVGLO 248
QY 181 ILRLVLTKEELLKIID-GVLLRKIGVNSQNDSSRSHAILNIDKDKNTSLGKIAFID 239
DB 249 EHLVNSADD-VIKMIDMSACRTSGQTPFANSNSRSHACFOILR--AKGRMHGKESLVD 305
QY 240 LAGSERGADTVSONKQOTQDGNINRSLALKECIRAMDSKXHIPRDESLTKVLDIF 299
DB 306 LAGNERGADTSSADROTRMEGAELNKSLLALKECIRALGQNKATPFRESKLTQVLRDSF 365
QY 300 VGR-SKSIIMIANISPTISCCBOTNTLRYSSRVKNFKNKSTCINEEDDTNTERISILDSK 358
DB 366 IGENSRCMTATISPGISSCEYTLNTRLYADRVKELSPHSGPSGEO-----LIQME 416
QY 359 GSENNASSIENVVIKSNHLLSNNNNNKINRGKINDKIERNNILKNKSPDKPRE 411
DB 417 TEEMWACS--NGALIPGNLSKEBELSSQMSFNEAMQIRELEKAMEBLKE 467

RESULT 16
AAE14505
ID AAE14505 standard; Protein: 723 AA.
XX
AC AAE14505;
XX
DT 09-APR-2002 (first entry)
XX
DE Human mitotic centromere-associated kinesin protein fragment #7.
XX
KW Human; MCAK; mitotic centromere-associated kinesin; motor domain;
KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
KW arthritis; graft rejection; inflammatory bowel disease.
XX
OS Homo sapiens.
XX
PI Beraud C, Sakowicz R;
XX
DR US6331424-B1.
XX
PD 18-DEC-2001.
XX
PF 15-JUN-2000; 2000US-0594669.
XX

PR 20-APR-1999; 99US-0295612.
 PR 18-MAY-1999; 99US-0314464.
 XX
 PA (CYTO-) CYTOKINETICS INC.
 XX
 XX Berard C, Sakowicz R;
 PI
 DR MPI; 2002-089075/12.
 DR N-PSDB; AAD24086.
 XX
 PT New human MCAK (mitotic centromere-associated kinesin) protein useful
 PT in identifying agents for use in the treatment of cellular
 PT proliferation disorders -
 XX
 PS Claim 1; Fig 14; 44pp; English.
 XX
 CC The invention relates to human MCAK (mitotic centromere-associated
 CC kinesin) protein, and its fragments that comprise a motor domain and
 CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
 CC its fragments are used in methods to identify compounds that modulate
 CC their activity. Modulators of MCAK are useful as therapeutic agents
 CC for treating cellular proliferation disorders such as cancer,
 CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
 CC inflammation, autoimmune disease, arthritis, graft rejection,
 CC inflammatory bowel disease. The present sequence is a human MCAK
 CC fragment.
 CC
 XX
 SO Sequence 723 AA;
 Query Match 11.0%; Score 752.5; DB 23; Length 723;
 Best Local Similarity 42.1%; Pred. No. 2.1e-34;
 Matches 174; Conservative 75; Mismatches 143; Indels 21; Gaps 10;
 QY 4 KIRVVVRKRPRLSELEKKKSDIITVKNCTLYIDPRYKVMTKYIERHEFTVDKVPD 63
 DB 256 RLCVCVRKRPRLNQLAKKEIDVISPSKCLLVHPEKLVDTKYLENQAFCFDPAFDE 315
 QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCPAYGQTSKTYTMLGS-QPYGSDTPGIFQY 122
 DB 316 TASNEVYVFTARPLVQITFEFG-KATCFAYGQTSKTHMGDLSGRQANSKGIYAM 374
 QY 123 AAGDIFTFLN-IYDKONTKGIFFISFYEYICGLYDLQKRVAALENGKEVVKDK 180
 DB 375 ASRDVFLKNQPCYRKLGLE-VYVTFEYINGKLPDLNKKAKLRYLEDGKQOVVGLQ 433
 QY 181 IIRVLTKEELIKMD-GYLARKIGVNSQNDSSRSHALINIDKINKTSLGKIAFID 239
 DB 434 EHLVNSADD-VIKIMDGSACRTSGQTFANSSSRSHACFOILR-AKGRMHGKESLVD 490
 QY 240 LAGSERGADTVSONKOTOTGDANINNSIALKECIRAMSDKNHIFPDSLETKVLRDIF 299
 DB 491 LAGNERGADTVSSADRTREGAEINKSLALKECIRALQONKAHTFRESKLTQVLRDSF 550
 QY 300 VGR-SKSIIMIANISPTISCCQOTLNTLRYSSRVKNFKNSTCINEEDDTNTERISILDSK 358
 DB 551 IGENSRICMIATISPISSCEYTLNTRLYADRVKELSPHSGPSGEQ-----LIQME 601
 QY 359 GSEMASSIEVNVIKSNHLSNNNNKINRGKINDIERNNILKNSPDKPRE 411
 DB 602 TEEMEXCS--NGALIPGNLSKEEELSSQMSFNEAMTQIRELEKAMELKE 652
 Db
 RESULT 17
 ID AAE14506 standard; Protein; 725 AA.
 XX
 AC AAE14506;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human mitotic centromere-associated kinesin protein.
 XX
 KW Human; MCAK; mitotic centromere-associated kinesin; motor domain;

KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
 KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
 KW arthritis; graft rejection; inflammatory bowel disease.
 XX
 OS Homo sapiens.
 XX
 PN US6331424-B1.
 XX
 PD 18-DEC-2001.
 XX
 PF 15-JUN-2000; 2000US-0594669.
 XX
 XX 20-APR-1999; 99US-0295612.
 PR 18-MAY-1999; 99US-0314464.
 XX
 PA (CYTO-) CYTOKINETICS INC.
 XX
 XX Berard C, Sakowicz R;
 PI
 DR MPI; 2002-089075/12.
 DR N-PSDB; AAD24087.
 XX
 PT New human MCAK (mitotic centromere-associated kinesin) protein useful
 PT in identifying agents for use in the treatment of cellular
 PT proliferation disorders -
 XX
 PS Disclosure; Fig 16; 44pp; English.
 XX
 CC The invention relates to human MCAK (mitotic centromere-associated
 CC kinesin) protein, and its fragments that comprise a motor domain and
 CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
 CC its fragments are used in methods to identify compounds that modulate
 CC their activity. Modulators of MCAK are useful as therapeutic agents
 CC for treating cellular proliferation disorders such as cancer,
 CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
 CC inflammation, autoimmune disease, arthritis, graft rejection,
 CC inflammatory bowel disease. The present sequence is human MCAK protein.
 CC
 XX
 SO Sequence 725 AA;
 Query Match 11.0%; Score 750.5; DB 23; Length 725;
 Best Local Similarity 41.9%; Pred. No. 2.7e-34;
 Matches 173; Conservative 76; Mismatches 143; Indels 21; Gaps 10;
 QY 4 KIRVVVRKRPRLSELEKKKSDIITVKNCTLYIDPRYKVMTKYIERHEFTVDKVPD 63
 DB 258 RLCVCVRKRPRLNQLAKKEIDVISPSKCLLVHPEKLVDTKYLENQAFCFDPAFDE 317
 QY 64 TVDNFTVYENTIKPLIIDLYENGCVSCPAYGQTSKTYTMLGS-QPYGSDTPGIFQY 122
 DB 318 TASNEVYVFTARPLVQITFEFG-KATCFAYGQTSKTHMGDLSGRQANSKGIYAM 376
 QY 123 AAGDIFTFLN-IYDKONTKGIFFISFYEYICGLYDLQKRVAALENGKEVVKDK 180
 DB 377 ASRDVFLKNQPCYRKLGLE-VYVTFEYINGKLPDLNKKAKLRYLEDGKQOVVGLQ 435
 QY 181 IIRVLTKEELIKMD-GYLARKIGVNSQNDSSRSHALINIDKINKTSLGKIAFID 239
 DB 436 EHLVNSADD-VIKIMDGSACRTSGQTFANSSSRSHACFOILR-AKGRMHGKESLVD 492
 QY 240 LAGSERGADTVSONKOTOTGDANINNSIALKECIRAMSDKNHIFPDSLETKVLRDIF 299
 DB 493 LAGNERGADTVSSADRTREGAEINKSLALKECIRALQONKAHTFRESKLTQVLRDSF 552
 QY 300 VGR-SKSIIMIANISPTISCCQOTLNTLRYSSRVKNFKNSTCINEEDDTNTERISILDSK 358
 DB 553 IGENSRICMIATISPISSCEYTLNTRLYADRVKELSPHSGPSGEQ-----LIQME 603
 QY 359 GSEMASSIEVNVIKSNHLSNNNNKINRGKINDIERNNILKNSPDKPRE 411
 DB 604 TEEMEXCS--NGALIPGNLSKEEELSSQMSFNEAMTQIRELEKAMELKE 654

RESULT 18
AAB18301
ID AAB18301 standard; Protein, 1817 AA.
XX
AC AAB18301;
XX
DT 07-NOV-2000 (first entry)
XX
DE Plasmodium falciparum chromosome 2 related protein SEQ ID NO:159.
XX
KW Plasmodium falciparum; chromosome 2; human malaria parasite; vaccine;
KM antimalarial; malaria; protozoacide; infection; insecticide.
XX
OS Plasmodium falciparum.
XX
PN W0200025728-A2.
XX
PD 11-MAY-2000.
XX
PF 05-NOV-1999; 99WO-US26796.
XX
PR 05-NOV-1998; 98US-0107131.
XX
PA (HOFF/) HOFFMAN S.
PA (CARU/) CARUCCI D.
PA (GARD/) GARDNER M.
PA (VENT/) VENTER J C.
XX
PI Hoffman S, Carucci D, Gardner M, Venter JC,
XX
DR WPI: 2000-365347/31.
XX
PT Proteins encoded by chromosome 2 of the human malarial parasite.
PT Plasmodium falciparum, useful as antimalarial vaccines and in the
PT diagnosis of P.falciparum infection -
XX
PS Disclosure: Page 374-379; 577pp; English.
XX
CC The present invention describes proteins and their fragments (i) encoded
CC by chromosome 2 of the human malarial parasite, Plasmodium falciparum.
CC Also described are: (i) nucleotide sequences (ii) encoding (i); and (2)
CC vaccines against P. falciparum infection comprising (i) or (ii).
CC (i) and (ii) are useful for the development of vaccines against
CC P. falciparum infection. (i) and polyclonal antisera or a monoclonal
CC antibody raised to immunogens comprising the sequences of (i), are
CC useful in the detection of infection with P. falciparum. Furthermore,
CC (i) (especially when they are ritins or secreted or membrane proteins)
CC can aid the identification of drugs to treat or prevent P. falciparum
CC infection, or they can be used to identify drug resistance in
CC P. falciparum. Sequencing of the Plasmodium chromosome 2 and the
CC subsequent identification of proteins encoded by it will help to expand
CC our understanding of parasite biology, a process hampered by the
CC complexity of the parasite lifecycle, and provide new targets for
CC vaccine and drug development. Parasite resistance to drugs and mosquito
CC resistance to insecticides have led to a resurgence of malaria in many
CC parts of the world, and there is a pressing need for vaccines and new
CC drugs. AAT70078 to AAT70287 and AAB18144 to AAB18352 represent nucleotide
CC and protein sequences given in the present invention, but which are not
CC specifically mentioned within the specification.
XX
SQ Sequence 1817 AA;
Query Match 10.9%; Score 748.5; DB 21; Length 1817;
Best local similarity 23.6%; Pred. No. 9,8e-34;
Matches 356; Conservative 197; Mismatches 410; Indels 543; Gaps 69;
QY 79 IIDLYENCVCSCFAVQGTGSGKTYTMLSQPYGSDTPGIF-----OYAAGDITFTFNI 133
D 391 IFELETCGYLFLNENKIKSNNIY-----IPNIFLKLKLYITISNDV---I 435
QY 134 YDKNTKGIFTSFYIYCGK-----LYDLQKRMVAALNGKKEVVQDLK--- 180
D 436 HINDRTLRKYLIFLSYHCSNNIYVAILFNDLYITLHKXIFI-----NNVDMLIKHYKSTA 490

QY 181 --ILRVLTKEELLKMGIDVLRK-IGVANSQNDSSRSHAILNIDLK-----DI 226
D 491 DHILYLTNKE-NLNIYANTILLNNYSLYKKNENKRGSLBNLKVXIPSHLYKQHTT 549
QY 227 NKQTSIAKIAFIDLAGSERGADVSONKQOTGACANINRSLALKECIRAMDSDKHIIF 286
D 550 NKNVN-----DPQGHKDKD-----SYDNTVEQMKNNKNTY 584
QY 287 RDSLETLYADIFVGSKSLIMANISPTISCCGTTLNTLAYSRYKFKKSTCTINEDD 346
D 585 NEYTTTHLON-----NYEONLVSFOKK-----DD 609
QY 347 TTERISILDSKSGEMNASSIENVVIKSNHLNNNNNKINRGKINDKIRNNILK---- 402
D 610 TNNINIFDL-HKRGQIYEYKEN---ESSDIFPDSYRKIKKEK-----KKNIYXEDH 660
QY 403 --NKSFDKPREGFTSTFGKYSLLNDIDKIKKKKGLINYKSLTYN---DWTINKKINN 457
D 661 PLNKEKKKKKKFFYINYEKDDDKNDL-----YNNIYSKLENIQKKNYNN 709
QY 458 NNNNNNDNNNDNNNNNNNDSSSMVNNMIMNINNNINNNNNNNNNNNNNNNNNNDXY 517
D 710 NNN 756
QY 518 HLPQNYAFTDTSDFSSL-----DDMCHLNNDKSIPL-LHKQLRDNK-----LKN 564
D 757 NIPCTNINSLIYKEXELPLETYAYDKIQYTYEELSKYKISITKIDRNIKMLFKFLKN 816
QY 565 RSS-----CDNINKKKONLHLARHVSGLTFMSYPOKQKNT-----FFS----- 608
D 817 YNNNENTYVDNIIS-KKNIFFHLA-SMKNKVT-----NKTTHKDIQYFIHSHWYHK 866
QY 609 --NINK-----MEDTPDIIYESRNVSNMGNVLLGKNTKTHDISTRDEN-----HND 656
D 867 LADQNKHSFODDKYLLINLVEKHKVQ-----NMTHTIHKEDKGDHLMENN 917
QY 657 NKINNVINIINNSVNS-----INNS-----NNNSINNS-MNNS 690
D 918 NMLNNMSLNNSNLSNLSIPLNNSIPLNNSIPLNNSIPLNNSIPLNNSIPLNNSIPLN 977
QY 691 -----NSIYSNYSNOSISDVQIR-YVEMQDS----- 718
D 978 CISLYNSISYSNKQTSFNLNYYNITDTCFIONNYSNOQYONKNEKNTMEHYNEK 1037
QY 719 -----NKNNDNIF----- 727
D 1038 FIYPIYLEDKNYFLAVNNNIFPKKNYNTFTYCOINILSKLYIFINITYTLISSNYK 1097
QY 728 -DAISCDNNWYPNITNN 786
D 1098 ABEIKTDNKC-NINNN 1149
QY 787 DNNKNTS-----NIONINTNK-----NNQGVNYSNMFCH--- 817
D 1150 INHFTTTFEYEVATLKNIYAIHISKFEYFVALSKFEPLNYSYQOSTNKRKNSIHENV 1209
QY 818 -----YLANDKNTLIDLNNKQDKNTHGCDNNIION-----RND 853
D 1210 LYLLIIRKQYEHVKSILYDKSNENYFRNENKDIKMENTNMLYNIILNFFEDHDF 1269
QY 854 EKKKKTFFYNNNNIIVIVNNNMGNNSPRMKYGLGSHTSIDNMKNEMKEMKDNEMKD 913
D 1270 MTLQKNEDNNKMIIDININVDNIN-----DLISHCDNNKED----- 1309
QY 914 NHIKSNSSSSSSSSNNNINNDTTPONDYCHANDNFTTIRKANTNINSINUYOND 973
D 1310 -----TSLHNKLYNGLHFLIMFLANNLADYTKFKFI-----NHFLSSFYTNK- 1352
QY 974 IITYTNSLNDYNSMTLLH-----FKERYTYTTLSTNEDIYV-----KEMEGKHRLDQD 1023
D 1353 -IIPNKMGMWHTLETYLHKHKIKYKKNKFY-----IYNGDLKKKSYLVHVK----- 1398

```

QY 1024 KYDDNNNNVNDNNKNNVNDNNVNDNNVNDNN--DKNNVNDNNVNDNDDVDVFNHKN 1081
DB 1399 KLYNYSYKSYNNKKK-----NNVNGDVNNFMFKYNI-----YDNIDYFIKK 1443
QY 1082 -----FNNNEYSYFQKNDVTIINNCLNSDISMYDDTTEILNLLSKYKAE----KD 1132
DB 1444 KMFCTYNNHSLYF-----TYIYS-LNKFYCTLYN-----ISKCFYKINENIHFNK 1493
QY 1133 NVIKKYINEDIKNMSLEIDKTAQSIY---EKRRV-----LTKLLLFKKVNDTQINN 1183
DB 1494 KILFPIFOCKYIYKFFFLVQSIFFSSSEFQKVGKLSYILSNILLVKSRRKMTNI 1553
QY 1184 ETSDLKDLVMCHI CANNPDQFHYAVYSRLEKDIINLMKQIWE---SENRLLYQ 1239
DB 1554 KKKKIYKN-ISKIYSNN-----EFINNKKIKKHITNNNSMKVLFCKN 1597
QY 1240 FLVVEYQ-----NKSANSVLLNVSNNNGDIILANKLVQDNIN 1278
DB 1598 LNLTIQNNYIFPMDLFISSNLSHETELINLKEQNIILNNNNNNN-----NNNNN 1647
QY 1279 SMDHNN 1284
DB 1648 NKKHNN 1653

RESULT 19
AAE14501
ID AAE14501 standard; Protein; 362 AA.
AC AAE14501;
XX
XX 09-APR-2002 (first entry)
DE Human mitotic centromere-associated kinesin protein fragment #3.
XX
XX Human; MCAK; mitotic centromere-associated kinesin; motor domain;
XX cellular proliferation disorder; cancer; hyperplasia; restenosis;
XX cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
XX arthritis; graft rejection; inflammatory bowel disease.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
XX FT Misc-difference 2 /note= "Encoded by AC"
XX FT
XX
XX PN US6331424-B1.
XX
XX PD 18-DEC-2001.
XX
XX PF 15-JUN-2000; 2000US-0594669.
XX
XX PR 20-APR-1999; 99US-0295612.
XX PR 18-MAY-1999; 99US-0314464.
XX
XX PA (CYTO-) CYTOKINETICS INC.
XX
XX PI Beraud C, Sakowicz R;
XX
XX DR WPI; 2002-089075/12.
XX DR N-PSDB; AAD24082.
XX
XX PT New human MCAK (mitotic centromere-associated kinesin) protein useful
XX in identifying agents for use in the treatment of cellular
XX proliferation disorders -
XX
XX PS Claim 1; Fig 6; 44p; English.
XX
XX CC The invention relates to human MCAK (mitotic centromere-associated
XX kinesin) protein, and its fragments that comprise a motor domain and
XX directly or indirectly produce ADP or phosphate. The MCAK enzyme and
XX its fragments are used in methods to identify compounds that modulate
XX their activity. Modulators of MCAK are useful as therapeutic agents

```

```

CC for treating cellular proliferation disorders such as cancer,
CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
CC inflammation, autoimmune disease, arthritis, graft rejection,
CC inflammatory bowel disease. The present sequence is a human MCAK
CC fragment.
XX
XX SQ Sequence 362 AA;
QY
Query Match 10.9%; Score 745.5; DB 23; Length 362;
Best Local Similarity 45.7%; Pred. No. 2,3e-34;
Matches 168; Conservative 65; Mismatches 116; Indels 19; Gaps 9;
QY 4 KIKVVRKRPKPLSELEKKKSDIIVKNNCTIYIDPRYKVDTKYIERHFIYDKVFPD 63
DB 3 RICVCYRKRPKNQBLAKKEIDVISIPSKCLLVHBPXKLVDTKYLENQAFCFDPAFDE 62
QY 64 TYDNFTYENTIKPLIIDYENGCVSCFAYGQTSGSKTYTMLS-QPYGQSTPBIQY 122
DB 63 TSNSEVYVYFTARPLVQITFEFG-KATCFAYGQTSGSKTHYMGDLSGKAQNASKGIYAM 121
QY 123 AAGDIFTPLN--IYDKNTKGIFISFYEYICGLYDLGRKRVVAALENGKKEVVVKDK 180
DB 122 ASHDFVFLKNQPCYRKGLGE-VYVTFEYNGKLPDLNKKAKRLVLEBGKQVQVVGQ 180
QY 181 ILRLTKBELILKMD-GVILRKITGVNSQNDSSRSHALINIDLKINKNTSLGTAFTD 239
DB 181 EHLVNSADD-VIKMIDMSACRTSGOTFANSSSRHACFQIILR--AAGRMHGRKSLVD 237
QY 240 LAGSEFGADTVSONKOTQTDGANINRSLALKECTIRAMSDKNHIFPDSLTQVLRDIF 299
DB 238 LAGNERGADTSSADROTRMEGABINKSLALKECIRALQONVAHTPFRESKLTQVLRDSF 297
QY 300 VCK-SKSIIMANISPTISCCQETLNTLRYSRVKFNKNTCINEEDDTNTERISILDSK 358
DB 298 IGENSKTMATITISPEISCEYTLNTRYADRVKELSPHSGSGQ-----LITQME 348
QY 359 GSEMNASS 366
DB 349 TEMEMACS 356

RESULT 20
AAE14500
ID AAE14500 standard; Protein; 391 AA.
AC AAE14500;
XX
XX 09-APR-2002 (first entry)
DE Human mitotic centromere-associated kinesin protein fragment #2.
XX
XX Human; MCAK; mitotic centromere-associated kinesin; motor domain;
XX cellular proliferation disorder; cancer; hyperplasia; restenosis;
XX cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
XX arthritis; graft rejection; inflammatory bowel disease.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
XX FT Misc-difference 2 /note= "Encoded by CA"
XX FT
XX
XX PN US6331424-B1.
XX
XX PD 18-DEC-2001.
XX
XX PF 15-JUN-2000; 2000US-0594669.
XX
XX PR 20-APR-1999; 99US-0295612.
XX PR 18-MAY-1999; 99US-0314464.
XX
XX PA (CYTO-) CYTOKINETICS INC.
XX

```

PI Berand C, Sakowicz R;
 XX
 DR WPI; 2002-089075/12.
 DR N-PSDB; AAD24081.
 XX
 PT New human MCAK (mitotic centromere-associated kinesin) protein useful
 PT in identifying agents for use in the treatment of cellular
 PT proliferation disorders -
 XX
 PS Claim 1; Fig 4; 44pp; English.
 XX
 CC The invention relates to human MCAK (mitotic centromere-associated
 CC kinesin) protein, and its fragments that comprise a motor domain and
 CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
 CC its fragments are used in methods to identify compounds that modulate
 CC their activity. Modulators of MCAK are useful as therapeutic agents
 CC for treating cellular proliferation disorders such as cancer,
 CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
 CC inflammation, autoimmune disease, arthritis, graft rejection,
 CC inflammatory bowel disease. The present sequence is a human MCAK
 CC fragment.
 CC
 XX
 SQ Sequence 391 AA;
 Query Match 10.9%; Score 745.5; DB 23; Length 391;
 Best Local Similarity 45.7%; Pred. No. 2.6e-34;
 Matches 168; Conservative 65; Mismatches 116; Indels 19; Gaps 9;

QY 4 KIKVVRKRPSELEKKKSDIITVKNKCTLYIDPRYKVMTRYERHEFIYDKVFD 63
 DB 32 RIVCVRRKRPUNKQELAKKEIDIVISPSKULLVHEPKLVDTLYENQAFCEDFAFDE 91
 QY 64 TVDNFTYVENTIKRLIIDLYENGCVCSFAYGQSGKTYTMLS-QPYQSDTPGIFQY 122
 DB 92 TASNEVYRFTARPLVQTFIEGG-KATCFAYGQSGKTYTMDGLSGKAQNASKGIYAM 150
 QY 123 AAGDIFTFIN--IYDKNTKGIFISFYCYGKLYDLQKRRVVALENGKEVVDLX 180
 DB 151 ASRVFLFKQPCRYKGLG-VYVTFEINYNGKLFDLINKAKAKRVLDEGQVQVGLQ 209
 QY 181 ILRLVTKBELILKMD-GVLLRKIGVNSQNDSSRSHAILNIDLKINKTSLGKIAFID 239
 DB 210 EHLVNSADD-VIKMIDMSACRTSGQTFANSSRSRSHACFOIILR--AKGMRHGKESLVD 266
 QY 240 LAGSERGADTVSONKQOTDGNANIRSLALKECIRAMSDKNHPRPDSLTLYLDIF 299
 DB 267 LAGNERGADTVSSAQRQRMGAELNKSLLALKECIRALGQNKAKHPRPESKLTQVLRDSF 326
 QY 300 VGG-SKSMIMANISPTISCEQTLNTRYSRVKNFKKSTCINEEDTNTERTSIIDSK 358
 DB 327 IGENSRCTMIATISGISCEYTLNTRLYADRVKELSPHSGPSGQ-----LIQME 377
 QY 359 GSEMNASS 366
 DB 378 TEEMDACS 385

RESULT 21
 ID AAE14499 standard; Protein; 430 AA.
 AC AAE14499;
 DT 09-APR-2002 (first entry)
 XX Human mitotic centromere-associated kinesin protein fragment #1.
 DB
 XX Human; MCAK; mitotic centromere-associated kinesin; motor domain;
 KW cellular proliferation disorder; cancer; hyperplasia; restenosis;
 KW cardiac hypertrophy; immune disorder; inflammation; autoimmune disease;
 KW arthritis; graft rejection; inflammatory bowel disease.
 XX
 XX Homo sapiens.

XX
 FH Key Location/Qualifiers
 FT Misc-difference 2
 FT /note= "Encoded by CG"
 XX
 PN US6331424-B1.
 XX
 PD 18-DEC-2001.
 XX
 PF 15-JUN-2000; 2000US-0594669.
 XX
 PR 20-APR-1999; 99US-0295612.
 PR 18-MAY-1999; 99US-0314464.
 XX
 PA (CYTO-) CYTOKINETICS INC.
 XX
 PI Berand C, Sakowicz R;
 XX
 DR WPI; 2002-089075/12.
 DR N-PSDB; AAD24080.
 XX
 PT New human MCAK (mitotic centromere-associated kinesin) protein useful
 PT in identifying agents for use in the treatment of cellular
 PT proliferation disorders -
 XX
 PS Claim 1; Fig 2; 44pp; English.
 XX
 CC The invention relates to human MCAK (mitotic centromere-associated
 CC kinesin) protein, and its fragments that comprise a motor domain and
 CC directly or indirectly produce ADP or phosphate. The MCAK enzyme and
 CC its fragments are used in methods to identify compounds that modulate
 CC their activity. Modulators of MCAK are useful as therapeutic agents
 CC for treating cellular proliferation disorders such as cancer,
 CC hyperplasia, restenosis, cardiac hypertrophy, immune disorders,
 CC inflammation, autoimmune disease, arthritis, graft rejection,
 CC inflammatory bowel disease. The present sequence is a human MCAK
 CC fragment.
 CC
 XX
 SQ Sequence 430 AA;
 Query Match 10.9%; Score 745.5; DB 23; Length 430;
 Best Local Similarity 45.7%; Pred. No. 2.6e-34;
 Matches 168; Conservative 65; Mismatches 116; Indels 19; Gaps 9;

QY 4 KIKVVRKRPSELEKKKSDIITVKNKCTLYIDPRYKVMTRYERHEFIYDKVFD 63
 DB 71 RIVCVRRKRPUNKQELAKKEIDIVISPSKULLVHEPKLVDTLYENQAFCEDFAFDE 130
 QY 64 TVDNFTYVENTIKRLIIDLYENGCVCSFAYGQSGKTYTMLS-QPYQSDTPGIFQY 122
 DB 131 TASNEVYRFTARPLVQTFIEGG-KATCFAYGQSGKTYTMDGLSGKAQNASKGIYAM 189
 QY 123 AAGDIFTFIN--IYDKNTKGIFISFYCYGKLYDLQKRRVVALENGKEVVDLX 180
 DB 190 ASRVFLFKQPCRYKGLG-VYVTFEINYNGKLFDLINKAKAKRVLDEGQVQVGLQ 248
 QY 181 ILRLVTKBELILKMD-GVLLRKIGVNSQNDSSRSHAILNIDLKINKTSLGKIAFID 239
 DB 249 EHLVNSADD-VIKMIDMSACRTSGQTFANSSRSRSHACFOIILR--AKGMRHGKESLVD 305
 QY 240 LAGSERGADTVSONKQOTDGNANIRSLALKECIRAMSDKNHPRPDSLTLYLDIF 299
 DB 306 LAGNERGADTVSSAQRQRMGAELNKSLLALKECIRALGQNKAKHPRPESKLTQVLRDSF 365
 QY 300 VGG-SKSMIMANISPTISCEQTLNTRYSRVKNFKKSTCINEEDTNTERTSIIDSK 358
 DB 366 IGENSRCTMIATISGISCEYTLNTRLYADRVKELSPHSGPSGQ-----LIQME 416
 QY 359 GSEMNASS 366
 DB 417 TEEMDACS 424

FT /note= "potential protein kinase C phosphorylation site"
 FT Modified-site 516..518
 FT /note= "potential protein kinase C phosphorylation site"
 FT Modified-site 608..610
 FT /note= "potential protein kinase C phosphorylation site"
 FT Modified-site 656..658
 FT /note= "potential protein kinase C phosphorylation site"
 PN W09858064-A1.
 PD 23-DEC-1998.
 XX
 PF 19-JUN-1998; 98MO-US12856.
 XX
 PR 19-JUN-1997; 97US-0878865.
 XX
 PA (INCY-) INCYTE PHARM INC.
 XX
 PI Au-Young J, Lal P, Shah P;
 DR WPI; 1999-080955/07.
 DR N-PSDB; AAX06945.
 XX
 PT New kinesin-related protein - useful for treating cancer and inflammation
 PS
 XX Claim 1; Page 49-50; 72pp; English.
 XX
 CC This is the amino acid sequence of human kinesin-related protein (KINRELp), as deduced from a consensus cDNA sequence (see AAX06945).
 CC KINRELp shares 97% identity with murine kinesin-related protein K1F2. The invention provides expression vectors, host cells, agonists, antibodies and antagonists, as well as methods for treating disorders associated with expression of KINRELp. KINRELp and its agonists are used to stimulate cell proliferation, and to treat a disorder associated with increased apoptosis. Antagonists are used to treat cancer and inflammation (claimed). Particularly, KINRELp or its fragment may be used to prevent or treat AIDS and other infectious or genetic immunodeficiencies, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa and cerebellar degeneration; myelodysplastic syndromes such as aplastic anaemia; ischemic diseases such as myocardial infarction, stroke and reperfusion injury; toxin-induced diseases such as alcohol-induced liver damage, cirrhosis and lathyrism; wasting diseases such as cachexia and osteoporosis; viral infections such as those caused by hepatitis B and C; and diseases associated with inflammation including adult respiratory distress syndrome, allergy, asthma, arteriosclerosis, bronchitis, emphysema, hypersplenophilia, myocardial or pericardial inflammation, rheumatoid arthritis, Addison's disease, AIDS, anaemia, CC atherosclerosis, diseases of the digestive system, atopic dermatitis, dermatomyositis, diabetes mellitus, glomerulonephritis, gout, Grave's disease, lupus erythematosus, multiple sclerosis, myasthenia gravis, osteoarthritis, osteoporosis, pancreatitis, polycystic kidney disease, polymyositis, scleroderma, Sjogren's syndrome, autoimmune thyroiditis, complications of cancer, extracorporeal circulation, viral, bacterial, fungal, parasitic, CC protozoal and helminthic infections and trauma.

Query Match 10.7%; Score 732.5; DB 20; Length 679;
 Best Local Similarity 45.5%; Pred. No. 2.6e-33;
 Matches 166; Conservative 63; Mismatches 111; Indels 25; Gaps 9;
 QY 4 KIVVAVKRLPSELEKKKSDITVKNCTLYIDPRYVDWTKTYERHEPFDVKYFDD 63
 DB 196 RICVCVAKRLPKKKTOMKDLVITTPSKDVVWVHEPKQKVDLTRYLENQTFRFDYAFDD 255

QY 64 TVDNFTYVENTIKPLIIDLYENGVCVCFAYGQTSGKTYTMLS-QPYGSDTPGIFQY 122
 Db 256 SAPNENWYRTARPLVETIFERG-MATCFAYGQTSGKTHTMGDDSGKNQDCKGYAL 314
 QY 123 AAGDITFTFLNYKDKNTK---GIFISFYETIYGKLYDLIQRKRWAALENGKEVVKD 178
 Db 315 AARDVFIMLK---KPYVKYLELQVYATFFETIYSGKVFDDLNRKTLRVLEDGKQVQVVG 371
 QY 179 LKILRVLTKEELLKMD-CVLLRKIGVNSQNDSSRSHAILINDLKDKNTSLGRTAF 237
 Db 372 LQREVKCYED-VLKLIIDIGNSCSTSGQTSANHSSRSHAVFQIILR--RKGLHGFSL 428
 QY 238 IDLAGSERGADTVSONKQOTDGANINRSLALKECIRAMDSDKNIIPRDSLETKYLRD 297
 Db 429 IDLAGNERGADTVSARQTRLEGAELNKSLALKECIRALGRKPHTPFPAASKLTQVLRD 488
 QY 298 IFVGK-SKSIIMANISPTISCCBOTLNTLRYSRVKNFKKSTCI-----NEED 345
 Db 489 SFIGENSRTCMATISPGMAASCENTLTLRYANRVKELTVDPYAGDVPRIMHPPNQID 548
 QY 346 DTNTE 350
 Db 549 DLETQ 553
 RESULT 25
 AAM39257
 ID AAM39257 standard; Protein; 690 AA.
 XX
 AC AAM39257;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polypeptide SEQ ID NO 2402.
 XX
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer; peripheral nervous system; neuropathy; central nervous system; CNS; Alzheimer's; Parkinson's disease; Huntington's disease; hemostatic; amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemocarcin; chemokine; thrombolytic; drug screening; arthritis; inflammation; leukemia.
 XX
 OS Homo sapiens.
 XX
 PN W0200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000MO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSB-) HYSBQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Weinman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 DR WPI; 2001-442253/47.
 DR N-PSDB; AA158413.
 PT Novel nucleic acids and polypeptides, useful for treating disorders such as central nervous system injuries -
 XX
 PS Example 4; SEQ ID NO 2402; 10078bp; English.

XX The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA36642-AA442213) with neurotropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localized neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.

SQ Sequence 690 AA;

Query Match	10.7%;	Score 732.5;	DB 22;	Length 690;
Best Local Similarity	45.5%;	Pred. No. 2.6e-33;		
Matches 166;	Conservative 63;	Mismatches 111;	Indels 25;	Gaps 9

[illegible]

RESULT 26
AAM41043
ID AAM41043 standard; Protein; 694 AA

AC	AAM41043;
XX	
DT	22-OCT-2001 (first entry)
XX	
DE	Human polypeptide SEQ ID NO 5974

KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Sly-Draeger Syndrome; chemocarcin;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.

OS	Homo sapiens.
XX	
PN	WO200153312-A1.

XX	26-JUL-2001.
PD	
XX	
PF	26-DEC-2000; 2000WO-US34263
...	

PR 21 JAN-2000; 2000US-0488725.
PR 25 APR-2000; 2000US-0552317.
PR 09 JUL-2000; 2000US-0598042.
PR 19 JUL-2000; 2000US-0620312.
PR 03 AUG-2000; 2000US-0653450.
PR 14 SEP-2000; 2000US-0662191.
PR 19 OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
PR

PA. (HYSE-) HYSEQ INC. .

PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D,
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

DR WPI; 2001-442253/47
DR N-PSDB; AAI60199.

PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -

PS Example 2; SEQ ID NO 5974; 10078bp; English.

CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA338642-AA442213) with neurotropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilization of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.

SQ Sequence 694 AA;

Query Match	10.7%	Score 732.5; DB 22;	Length 694;
Best Local Similarity	45.5%	Pred. No. 2.6e-33;	
Matches 166; Conservative	63;	Mismatches 111;	Indels 25; Gaps 9

```

QY KIKVAVKRPLSELEKKKSDSIIYKNNCTIYIEPXYKDMTEYERHEFIYDKVEDD 63
Db 211 R1CVCARRKPLANKETOMDLVYIT1PSKDVMVNHMPKOKDLTRYLENQCFRRDVAFDD 270
QY 64 TWDNFYVENTIKPLIIDLYENGCVCSGAYQOTSGKTYTMLS-QPYGSDPTGPIFY 122
Db 271 SAPNEMVYRFTAPPLVETIFERG-MATCPAYQOTSGKTHMGDFSGKNDCKSGIYAL 320
QY 123 AAGDIFTEFLNIYDKNTK----GIFSPFEIYCGLYXLLDKRKVVALENGKEVYVKD 178
Db 330 AARDFVFLMLK--KPNYKKELEQVAVATPFEIYSGVFPDLNRKTYLRYLEGGKOOVOVG 388
QY 179 LKIDRYLTKEELIKMID-GVLLRKIGVNSONDESSHA1N1D1KNNTS1GKIAP 231
Db 387 LOEHEVAVCVD-VKLIID1GNSCRTSGOISAAHSHSRSHAVQIILR--RKGXKHGRFSL 443
QY 238 IDLAGSERGADTVSONKQOTODGANINRSLALKECIRAMDSOKNHPFRDSELTXYLRD 297
Db 444 IDLAGNERGADTVSARQUTREGAELINKSLALKECIRALGANKPKHPTRFPAASKULTOYLRD 503
QY 298 IFVCK-SKSLMININISPT1SCCEQTLNTRYASRKNFKNSSTCI-----MBED 345

```


XX 05-NOV-1999; 99MO-US26796.
 PF
 PR 05-NOV-1998; 98US-0107131.
 PA (HOFF/) HOFFMAN S.
 PA (CARDU/) CARDUCCI D.
 PA (GARD/) GARDNER M.
 PA (VENT/) VENTER J C.
 PI Hoffman S, Carucci D, Gardner M, Venter JC;
 DR WPI; 2000-365347/31.
 XX
 PT Proteins encoded by chromosome 2 of the human malarial parasite,
 PT Plasmodium falciparum, useful as antimalarial vaccines and in the
 PT diagnosis of P.falciparum infection -
 XX
 PS Disclosure; Page 389-391; 577pp; English.
 XX
 CC The present invention describes proteins and their fragments (I) encoded
 CC by chromosome 2 of the human malarial parasite, Plasmodium falciparum.
 CC Also described are: (I) nucleotide sequences (II) encoding (I); and (2)
 CC vaccines against P. falciparum infection comprising (I) or (II).
 CC (I) and (II) are useful for the development of vaccines against
 CC P. falciparum infection. (I) and polyclonal antisera or a monoclonal
 CC antibody raised to immunogens comprising the sequences of (I), are
 CC useful in the detection of infection with P. falciparum. Furthermore,
 CC (I) (especially when they are rifine or secreted or membrane proteins)
 CC can aid the identification of drugs to treat or prevent P. falciparum
 CC infection, or they can be used to identify drug resistance in
 CC P. falciparum. Sequencing of the Plasmodium chromosome 2 and the
 CC subsequent identification of proteins encoded by it will help to expand
 CC our understanding of parasite biology, a process hampered by the
 CC complexity of the parasite life cycle, and provide new targets for
 CC vaccine and drug development. Parasite resistance to drugs and mosquito
 CC resistance to insecticides have led to a resurgence of malaria in many
 CC parts of the world, and there is a pressing need for vaccines and new
 CC drugs. AAA70078 to AAA70287 and AAB18144 to AAB18352 represent nucleotide
 CC and protein sequences given in the present invention, but which are not
 CC specifically mentioned within the specification.
 CC
 XX
 SQ Sequence 807 AA;
 Query Match 10.2%; Score 696; DB 21; Length 807;
 Best Local Similarity 26.6%; Pred. No. 3.6e-31;
 Matches 253; Conservative 151; Mismatches 300; Indels 246; Gaps 43;
 QY 328 SSRVKNFKKSTCINEDDTNTERISILDSKSEMNASSIENVVIKSNHLLSNNNNKIN 387
 DB 10 SSRKKEEN--DINCKDSN-----KINGKE-NIFAWEKGINESGMSNDINK-N 58
 QY 388 RGIINDKIERNNILKNSKSPKREGFTSTFGKYSLLNDIDIKKNNKKGLINYKSTLYN- 446
 DB 59 QEKKKKKKKKKTHKKYININHTHTDKNNG--QDIKKPEVIEDNINIKNDTNNI 117
 QY 447 -DNTIKKHNNNNNNNDNNNDNNNNNNNDSSVVNN-----MINHINNI----- 495
 DB 118 LDSSTVEEGENRRNDLNNN 177
 QY 496 -NNNINNN 554
 DB 178 NNNENITTLNNKNNLKNNNNNVNDNR-----NNNN----- 205
 QY 555 NLRDNTIKLKNRSSCDNIMKKNLHARHSVSKLTMSYSYDQKNKNTFFKSNINKE 614
 DB 206 NNNKNN 247
 QY 615 DNTPKDILVESRRVSN--NNGNVLLGLNKYTHHDISTKDNHNDK---INNGVINIINN 669
 DB 248 KNYQKKT---EQNNLNNHTYLLNNNNIINN-----NNGDNOAYATNN-FYHLYHN 290
 QY 670 SNVNSINNSNNNSINNSNNNSNSIYKSN---YNSNQSISDVQIRYVNEW-DTSNKNNDN 724

DB 291 NSYNHIYRONNIPICINNNHAPRIEKLNNPYHYHDN-----HIAATYTWYSTQNK- 341
 QY 725 IFFDAISCONM-----YNTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 775
 DB 342 -----NNMKTKOIGHYGINNEDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 389
 QY 776 YAYNSHLPDPDNKNTSNLQNTNTKNNODGVNYSNMFCHYLNLDKXYLD-LNNKE- 833
 DB 390 POLDNNTKKNFNOGTNNFNQCTNNFNCTNNFNNAKHIKHNINNTKNIETHLNNH1 449
 QY 834 ----OKXNIHGCNNNIIQNRNDEFEKKKKTNFYNNNNVIYNNNGNNNSPKYGLCG 888
 DB 450 YNFVEYENKNIYDANGLINNINSYTQLKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 504
 QY 889 SHSISIMKNNKNNKNNEMKDNKNNKNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 946
 DB 505 NDTNFPNEPTNKVK--KKEKKNIHNNNNNN-----NNKCLYKDIN-----QND 549
 QY 947 YCHNDNTFTIRKNTNINSNIYONDIIYTTISLNDYNSNTLLHFEKXYTPTLSTNED 1006
 DB 550 H-----NNSIITN--QNFHDINN-----KTFEONLQKHNNKMSQVSKOS 588
 QY 1007 IYNKEMEGHIRLDQKYDDNNNVNNDNNKNNVNDNV--DNNVNDNVND----- 1056
 DB 589 NNNKNNNSHLK-----KQININTNNNMDDKNNNSHISKVIVDDNKLKSHADNSNEIVTK 644
 QY 1057 -----NDKNNVDN-----NNVNDDDDDVDFHNKNNNEY-----LSVF 1091
 DB 645 GKKKKNTKKKINNINSVNNVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 704
 QY 1092 OKRVDTIINNCLNSDISM--YDDTKEILNNIILSKYKAEDNVYIKKYINEDIQNMSL 1148
 DB 705 DSIATALLYNNKR-IDFNFPQNLHNNHNLQNNIMNNVNL-NNULTTSNPNYLNINYSY 762
 QY 1149 E-----EIDKTAQ-SIYEKRYLLTKLLLFKKVNDTQINNETSDL 1188
 DB 763 EPEYENLNNDDPYCRDISLEYER-----YDRGNLQNNHRYDI 802
 RESULT 30
 ABB59733
 XX ABB59733 standard; Protein; 626 AA.
 ID
 AC ABB59733;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Drosophila melanogaster polyptide seq ID NO 5991.
 XX
 KW Drosophila; developmental biology; cell signalling; insecticide;
 KW pharmaceutical.
 OS
 OS Drosophila melanogaster.
 PN
 PN MO200171042-A2.
 XX
 PD 27-SEP-2001.
 XX
 PF 23-MAR-2001; 2001WO-US09231.
 XX
 PR 23-MAR-2000; 2000US-191637P.
 PR 11-JUL-2000; 2000US-0614150.
 XX
 XX (PEKE) PE CORP NY.
 PA
 PI Venter JC, Adams M, Li PWD, Myers EW;
 XX
 DR WPI; 2001-656860/75.
 DR N-PSDB; ABL03836.
 XX
 PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell

PT interactions -
XX
PS Disclosure; SEQ ID NO 5991; 21bp + Sequence listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from *Drosophila*. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIRO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 626 AA;
Query Match 10.0%; Score 686.5; DB 22; Length 626;
Best Local Similarity 42.1%; Pred. No. 9.2e-31;
Matches 159; Conservative 67; Mismatches 131; Indels 21; Gaps 7;
QY 4 KIKVVRKRPISLEKKKKDDITVKNCTLYIDEPKYVDMTKYIERHEPIVDKVPDD 63
DB 187 QIMVCVRKRPKRRELADREODVVSIPSKHTLVVHEPKHVNVLVFLNHSFRFYPVDE 246
QY 64 TVDNPFTYENTIKPLIDLYENGCVCSGFAVGQSGSKTYMTLSQP-YGSDPTGIFQY 122
DB 247 ECSNATYVEFTAPRLIKIIFDGG-MATFAVGQTSKGTYMGQFPERHOSMDGIYAM 305
QY 123 AAGDIFETLNI--VDKNTKGFISFYCYGKLYDLQKRR-MWALENGKKEVAVVDL 179
DB 306 AAKVFTSLTKVPYKNAKLVYCSFFRITGRVVDLMPKQPLRVLEDDNQVQVGL 364
QY 180 KILRVLTKEELIKMDIVLRLKIGVNSQNDSSSHALINIDKINKNTSLGKIAFID 239
DB 365 TQNPQNTAEVLDLELNGSVTSQHTSANSKSSSHAVFQVLVLSAAGEKLGKFSLID 424
QY 240 LAGSRGADTVSQNKQOTDQANINRSLALKECTRAMSDKNHPRDSELTLYLPIF 299
DB 425 LAGNERGADNSADQTRLESGEINKSLVLECEIRALGROSSHLFFGSKLTQVLRPSF 484
QY 300 VG--KSKSIMIANISPTISCEQTLNTRYSRVNFKNKSTCINEEDTTERISIDS 357
DB 485 IGGKKVKTCMIAMISPCILSHVEHTLNTLRADRVLELSESLPSRMMDAN----- 535
QY 358 KGSNNASSIENVYIKSN 375
DB 536 ---LGTSMDSIDVCGSS 549
RESULT 31
AAO22566
ID AAO22566 standard; Protein; 2150 AA.
XX
AC AAO22566;
XX
DT 28-OCT-2002 (first entry)
XX
DE Wooden leg (WOL) gene related protein SEQ ID No 17.
XX
KW Wooden leg; WOL; vasculature; transgenic plant; agronomic; longer root;
XX wood production; plant; promoter; tree; crop plant.
XX
OS Arabidopsis thaliana.
XX
XX WO200244337-A2.
XX
XX 06-JUN-2002.
XX
XX 29-NOV-2001; 2001WO-US45053.
XX
XX 29-NOV-2000; 2000US-253739P.
XX
PR

XX
PA (UNIV) UNIV NEW YORK STATE.
PA (HELA) HELARIUTTA Y.
PA (MAHO) MAHONEN A P.
PA (BONK) BONKE A W M.
PA (KAUP) KAUPPINEN L.
PA (RIK) RIKKONEN M.
XX
PI Helariutta Y, Mahonen AP, Bonke AWM, Kauppinen L, Rikonen M;
PI Benfey PJ;
DR WPI: 2002-599423/64.
XX
XX Novel isolated polypeptide (WOODEN LEG) with ability to regulate a set
PT of asymmetric cell divisions that establish vascular tissue in root and
PT hypocotyl development, useful for improving agronomically valuable
PT plants -
XX
XX Example 1; Page 151-157; 187pp; English.
PS
PS The invention relates to an isolated WOODEN LEG (WOL) polypeptide,
XX comprising 15 contiguous amino acids of a fully defined Arabidopsis;
CC WOODEN LEG protein sequence of 1057 amino acids as given in the
CC specification, and to its encoding nucleic acid. The invention also
CC relates to an amino acid sequence of domains of protein, e.g., N-terminal
CC region, C-terminal domain, etc; or is a naturally occurring allelic
CC variant of the above mentioned polypeptide sequence. Expression levels of
CC the nucleic acid can be modified to improve the vasculature in transgenic
CC plants and enhance the agronomic properties of such plants. Also the WOL
CC promoter is used to drive expression of a heterologous coding sequence of
CC trees to improve wood production. The WOL nucleic acid may be used as a
CC molecular marker for a qualitative trait loci, e.g., longer roots or
CC enhanced wood production, in molecular breeding of crop plants. The
CC nucleic acid is also useful in DNA amplification assays to identify the
CC endogenous WOL genes, WOL mutant alleles and/or WOL expression products
CC in cultivars as compared to wild-type plants. They can also be used as
CC markers for linkage analysis of qualitative trait loci. The WOL protein
CC and/or antibodies can be used as diagnostic reagents in immunoassays to
CC detect expression of the WOL gene in cultivars and wild-type plants. The
CC WOL protein, its encoding nucleic acid, and its corresponding antibody
CC are useful for improving agronomically valuable plants e.g., trees. This
CC sequence represents a protein relating to the wooden leg (WOL) protein of
CC the invention.
XX
SQ Sequence 2150 AA;
Query Match 9.9%; Score 676; DB 23; Length 2150;
Best Local Similarity 24.5%; Pred. No. 1.5e-25;
Matches 242; Conservative 146; Mismatches 255; Indels 344; Gaps 41;
QY 416 TFGKYSLLNDIDKIKKKKKGLINYKSTLVNDNTINKKNNNNNNNDNDNDNNNN 475
DB 85 SYGNHSFTHNVSPSP-----SYDINNNNNNNNNNNNNNNNNNNNNNNNNNNN 137
QY 476 N-----NDSSSM-VNNMINH 489
DB 138 NKNYNNNNYVSPLENSNISKSLESVLNGPFPNFNLNSNNYLNSSSLAHNIQSVNS 197
QY 490 MINNNNNNN-----INVNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 545
DB 198 LSNNNNNQTNQOPIINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 237
QY 546 DKSIFLAKKLNDRN-ILKRNSSCDJNKKNNKLNHLARHSVSGKL--TWFSYDPOK 601
DB 238 GN-----NNNNITDSPTKSKRSHSTYETIGS-----HQRKSIQSLANSALHSKLNK 288
QY 602 DNTEFKSINIMEDNTEPKDILYESRNVSNMNGVLLGINKNTHTDISTKQENHNDKINN 661
DB 289 -----PLSSSTSTV-----HTCGAVNNNSNN-----NNNNNNNST 319
QY 662 GVINIIN-----NSNVNSI-----NNS-----NNNSINNS-NM 688
DB 320 GSLGAIPIMDRSPDGNINNTITEESTGCGNNSPRSCNGSCNGSGIPLSPRNLSINSNGVN 379

```

QY 689 NSNSIYKSNYNSNQ-1SDVQIRYVN-EMDTSKNNDNIFPDAISCDNNMYPIITNNNN 746
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 380 SPENHILNMLNNSNSMLPLSPRHINHIIVSNLNNNN-----NNINPNNNPNNSN 431
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 747 NNNNN--NNNNNIDVENYNNEDGTNNSKLYAYNSHNLFOPDNNKNTSINQINTNKN 803
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 432 NSNNNVPNNNNINISPRGSNISPRSN-----GGSSTTISPRNISNNNNIIN----- 478
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 804 NQGGNNVYSNPFCHYMLNDKNYLIDLNNKQKDNHGCC-----NNIIONNDFE 854
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 479 -----NNNNNLTTPRNSPRLE-NVNPINSPLATSLTSLPIVSSLT 522
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 855 KKKKTFFYNNNNIVIVNNNNNNNSPRMKYGLGSHTSIDNMKNEMKNEMKNEDKN 914
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 523 SSNNNNQSNNTNTPSINNNGR-----GHCIQTISEILNKNKPVYVNNNGNN----- 570
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 915 HIKSNNNSSSSSSNNNIYNNINDDTFQNDYCHNDFTTIRKKNNTNINSNIYQ--- 970
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 571 -----NNNNNTNSTTNNNITNNNNNN-----NNNNINNNVLTSPRK 607
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 971 ---NDIITINSNDYMSNTLHFKEXKTYPTLSTNEDIYKMEGKHIRLDDQKPD 1026
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 608 RYKGNHS---KTSLODFETS-----SMNGGDSISGAGSGSLRRRRKNDND 652
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1027 DND-----NNNVNKNKNVNDNNVNDNNVNDNNVNDNNVNDNNVNDND 1073
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 653 ENDGNSNNTNNSNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 712
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1074 VDFHNKFNNNNEYSYFQKNVDITINNCLNSLDISMYDTKEILNNILSKYKAEKN 1133
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 713 NNNNNNNNNNNNN-----NNYNHNGATMMWSH-----NHQSIGMSSSPKKN 752
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1134 VIKKYINEDIKNNSLERIDKTAOSIYEKRVLLTKLLLFKRVNDVQINNETSDLRDLY 1193
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 753 NFEPF---SRNCSLGMGRAMAWI-----ILGLF-----YVSSSISILATLV 791
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1194 MCHICNNPDDQHFYAVSRLEKDIINLMLRQIWCESENRLLYOFLVEYQNK---S 1249
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 792 LRSEENSIAADF-----ARVARD--RFTYLR-----IEPNRLYITQ 827
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 1250 ANSVLLNV-SSNNGDIILNKKLVODN 1275
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 828 TSLSLTSEFSTSEDQFVPFSKLSMDN 854
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

RESULT 32

AAB56496 standard; Protein; 410 AA.

XX AAB56496;

DT 13-MAR-2001 (first entry)

DE Human prostate cancer antigen protein sequence SEQ ID NO:1074.

XX Human; prostate cancer; prostate cancer antigen; detection; diagnosis;
 KW neuroprotective; cytoskeletal; cardioactive; immunomodulatory; muscular;
 KW vulnary; gastrointestinal; nephrotoxic; antiinfective; gynaecological;
 KW antibacterial; gene therapy; neural; immune; reproductive; renal;
 KW gastrointestinal; pulmonary; cardiovascular; proliferative disorder;
 KW wound; infectious disease.

XX Homo sapiens.

XX WO200055174-A1.

XX 21-SEP-2000.

XX 08-MAR-2000; 2000MO-US05988.

XX 12-MAR-1999; 99US-0124270.

XX

```

PA (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE/) ROSEN C A.
XX Rosen CA, Ruben SM;
PI WPI; 2000-587513/55.
DR N-PSDB; AAF15699.
XX
PT Prostate cancer associated gene sequences, referred to as prostate
PT cancer antigens, useful for treatment, prevention, and diagnosis of
PT disorders such as prostate cancer -
XX
PS Claim 11; Page 1498-1499; 2338p; English.
XX
CC AAF1566 to AAF16505 encode the human prostate cancer associated
CC proteins, called prostate cancer antigens, given in AAB56363 to AAB57302.
CC The prostate cancer antigens can have neuroprotective, cytoskeletal,
CC cardioactive, immunomodulatory, muscular, vulnary, gastrointestinal,
CC nephrotoxic, antiinfective, gynaecological and antibacterial activities,
CC and can be used in gene therapy. The prostate cancer antigen
CC polynucleotides may be used for detection of prostate cancer, chromosome
CC identification, as chromosome markers, and for numerous other diagnostic
CC or research purposes. The prostate cancer antigens may be used to treat
CC disorders such as neural, immune, muscular, reproductive,
CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
CC disorders, wounds, and infectious diseases. AAF16506 to AAF16514 to
CC AAB57303 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 410 AA;
XX
QY Query Match 9.8%; Score 672; DB 21; Length 410;
QY Best Local Similarity 46.6%; Pred. No. 3.7e-30;
QY Matches 149; Conservative 59; Mismatches 102; Indels 10; Gaps 8;
QY
QY 4 KIRVVVRKPPLESELEKKKSDIITVKNCTLYIDEPKYVDNTXYIERHEFTVDKVPDD 63
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 57 RICVCVRKPPLNQELAKKEIDVISPSKCLLVHEPKLVDTXYLENQAFCEPDAFDE 116
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 64 TYDNFTYENTIKPLIIDLYENGCVSCFAYQGTGSKTYTLMGS-QPFGSSTPFGIFQY 122
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 117 TASNEVYRFTARPLVQITFEGG-KATCFAYGGTGGKTHYTMGGDLSGKAQNSKGIYAM 175
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 123 AAGDIFTPLN--LYDQNTKGFISFEYICGLYLLKRRKVAALENGKKEVVVVKDK 180
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 176 AKRDVFLKNQPCYRKLGE-VVYTFEYINGKLFPLNKKAKLVLESGKQGVQVGLQ 234
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 181 ILRLTKBELILKMD-GVILRKIGVNSQNDSSRSASHAILINDLKDINKNTSLGKIAFID 239
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 235 EHLVNSADD-VIKMKMGSACRTSGOTFANSSNSRSHACFQIILR--AGRMHMKRSLVD 291
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 240 LAGSERGADTVSONKOTDGANINSLALKECIKRAMSDKNHIFPDSLETXYLRDIF 299
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 292 LAGNERGAYTSSADROTRMEGAIEINKSLALXECIPALQNKAMTFPFRSKLTQVLRDSE 351
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 300 VCK-SKSIIMANISPTISCC 318
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 352 IGENSRCTMIAITISPEISCC 371
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

RESULT 33

AAB05593 standard; Protein; 604 AA.

XX AAB05593;

XX 22-APR-2002 (first entry)

XX Mitotic centromere-associated kinesin MYD-KIF2 protein.

XX Human; mitotic centromere-associated kinesin; MYD-KIF2;

XX human genome technology.

QY 844 -----NNIIONRND-EKKKTYFYNNNNIYVNNNGNNNSPRMKYGLGSHTSID 894
D 328 DNTAVGYNNNNYLNNNNNNNENSEKIVADNDSSINNNTLTNNNN--EYNL-GEDEKID 383
QY 895 -----NMKNEMKKNEMKDNEMKDHISNNNNSSSSNNNNIYNNIN--DDTFON 945
D 384 INSIMKSKKGGNGKKK--KKNKKNMNH-----NMNNNNMNNNSLSDSPN 429
QY 946 DYCH-NDNFTIRKNNNTINSNIYONDIIYITINSINDYMSNTLHFKEKYTPPTLSTN 1004
D 430 YHAAHVKNQNNFQOTNNNDNKKVHNNN-----TPST- 460
QY 1005 EDIYNKEMEGKHRLDDQKYDDNNNNNNKNNVNNNNVNNNNVNNNNVNNNDKNNVND 1064
D 461 -DFESR-----NSAVNNSSNG--NMKLNKNNNNNNNNNNNNNN 498
QY 1065 NNVNDNDDVDVFNHKNKNNNNNYLSTFQKAVDTIINCLNSL--DISMTDTEKIL 1119
D 499 NNEDEDDDD-----WGEKVV-----ILNQLADLIDLKDKDLFVL 533

RESULT 35

AAE29358 ID AAE29358 standard; Protein; 1331 AA.

AAE29358; AC

27-JAN-2003 (first entry)

Plasmodium falciparum BFP-5 protein.

Band 3 polypeptide; malarial infection; drug resistance; vaccine; protozoasid; gene therapy; BFP-5.

Plasmodium falciparum.

MO200270542-A2.

12-SEP-2002.

01-MAR-2002; 2002WO-US06415.

02-MAR-2001; 2001US-272930P.

(SELF-) ST ELIZABETH'S MEDICAL CENT INC.

Chiehchi AH, Oh SS, Liu D, Goel V,

WPI; 2002-759814/82.

DR N-PSDB; AAD47004.

New isolated Band 3 polypeptide which selectively binds to merozoite surface protein-1, useful for the prevention and treatment of malarial infection -

Claim 27; Page 148-153; 163pp; English.

The invention relates to an isolated Band 3 polypeptide that comprises any of 4 20 residue amino acid sequences, or their fragments that bind to an MSP-1 polypeptide or a polypeptide with any of 8 291-1331 base pair sequences. The methods and compositions of the present invention are useful for the prevention and treatment of malarial infection. The present invention develops new and more improved methods based upon inhibiting the particular interactions between the malarial parasite and a cognate molecule present in the host and subsequently minimizing harmful side effects and drug resistance that may be due to non-specific therapeutic approaches. The invention is useful in gene therapy. The present invention also provides a vaccine for malaria. The present sequence is Plasmodium falciparum BFP-5 protein.

Sequence 1331 AA;

Query Match 8.7%; Score 596; DB 23; Length 1331;
Best Local Similarity 22.3%; Pred. No. 2,7e-25;
Matches 317; Conservative 180; Mismatches 412; Indels 512; Gaps 68;

QY 122 YAAGDIPTFLNTYDKNKT-----GIFISFY---EYGGKLYDLLQKKMVA----- 166
D 52 YSSDILNPLKCSNINILANKPYDLYVSFLDGLGLG--YDISVFLILVAHEPEYC 109
QY 167 ----LENGKEVVVKDKILRLVLTKEELIKMIDGLVLRKIGVNSQNDSSRSALINID 222
D 110 RRIIDNENSDKKEFR-----TKNKSITK-----SQIDEDNIOGLLIKE 150
QY 223 LKD----INKTSLGKIAFDLAGSERGADT--VSQKOTQDTGANIRSLALKECIR 275
D 151 KEDYLSFLNENNE--ALKQVYESKRGNPVLHDESKYMDKDYDEEDSSPFIKPTFN 206
QY 276 AM-----DSDKNHLPFSDSELTLYLRD-----IVGSKSMTMINISPTISCCQTLN 323
D 207 YLGKNNNNNNNNNNNNNAFNFVWGNLSSDNISGCFVEKLNLYLFAMLN--KCSNKTYI 263
QY 324 TL-----RYSRKYKFKKSTCTINEEDTTERISLDSKSENNASSIENVVYKSNH 376
D 264 SVFPYEKFGKHESR-----NLAIQSFQEDYHRRITIEDLYANTONNLSVHNNKMSN- 317
QY 377 LLSN--NNNNK----INRGKINDKIERN-----NILKNSFPDKREGFTSTFGKYSLNDID 427
D 318 -MNNINNNKDIILINSGISNGSGQVPCFENIL--DYDKLK-----FVEI--INFS 365
QY 428 KIKKAKKKGLINYSKTLVNDNTIINK-----HNNNNNNNDN-----DNNNDN 472
D 366 DVKSSSPDIIGSSKNVIEGEGENLKVCYHNNNPFESGFEYNIENKQPLELEHNFIDIM 425
QY 473 NN-----NNNDSMVNNMIMHMTINNIN--NNIVNNNNNNNNNNNNNNNNNNHLPQPNYA 525
D 426 ENIKMYDNTNOEENNFVNSGILREDNSMWEIYTRONHNNNTHENENIYSINIKY- 484
QY 526 FDTSDPSSLDDMNCNLNNNDKSIPLAKNLRDNIKLKNSSCDNIMKKNKNLHLARHS 585
D 485 -----INHHFNKKDMI--WKCKMKGSIEMDNSS-----NNSNNNTHTEK-- 524
QY 586 VSGKLTMSFYDPQKDKNTFFKSNINKMEDNTPKDIILYSKRVSNMNGVLLGLNKQTHH 645
D 525 -----TLBSINPD--DHNIFNSEMDSMK--NERND--EEBQTATSIYILGITGDTY- 571
QY 646 DISTQDENH--DNKINGVINIINNSVNSINSNNNSINSNNNSIYKSYNSQSI 704
D 572 -IKRGSSNNTYDN--NNG--YSNBSSDYNNNGYNDSTNNNGYSN--SSYNSN-- 619
QY 705 SPVQIRYVNEMDTSNKNNDNIFEDAISSCDNNNYPNITNNNNNNNNNNNNNNNNNNIIVENYA 764
D 620 -----NEDNNNNNNND-----ENCNNNNNNNNNNNNNNNNNNNNNNNNNNNN--N 660
QY 765 NRDGTNNSMKLYAYNSH-----LFPDNNKATSNIOINTNNKNOGN-----VNYS 812
D 661 NKDNNNDGNGSSNNNNNDDEDEEDDDNNNNNDNNNDMSDNEBEMDEDEDEYNS 720
QY 813 KMFCHYNLNDKXYLIDLN-----NKEQDKNI--HCCDNNIIONRDEFKKTNTY 862
D 721 NDSYKTEEKDSHEKDKDIIEGDMINSVKDKIGHHTTKSEISTYFENSQMSVA 780
QY 863 NNNN-----IVVNNNNNNNSPRMKYGLC-----GSHTSIDNMKN 898
D 781 NSNNNEAYDNCNNGNFNHEGLTLNNGVSNK-----CDIIPEDGS--VMYEMMIN 831
QY 899 NEMKNEMKDNEMKDNHISNNNNSSSSSSNNNNIYNNINDDTFONDY----- 947
D 832 ---RGGLTSLNINNNNNV--SNNSNISCNADNVYNNIN--YINTMETTNNKNHIE 882
QY 948 --CHDNTFTIRK--NNTNINSNIYONDIIYITINSINDYMSNTLHFKE----- 994
D 883 NRCNDSYSTNEEPLSNHSINDPGKIKDGIWGDNDL--NNGIOEHSKEBGNDVFEENF 940
QY 995 -----KYTYPTLSTNEDIYNKEMEGKHIR-----LDDQDK----- 1024


```

QY 446 NDTNTKHHNNNNNNNDNNNNNNNNSSSVNMMINMIN-NNNNNNNN 504
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 201 IKOTLKN-----NNDGLMKNKSS-----LKDIKIKIYKIKITSK 239
QY 505 NNNNNNNNNHNLPOPNYAFTDTSFSLDNNCHLNNNDKSF----- 550
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 240 YISNDMDTCIRNLT-----YHIDKNYPIIKTKCFPLSTKYLKNRGVASCPLTVK 294
QY 551 ---LHKQLRDNITLK---NRSSCDINMKKKNNLHARSHV-----GSKLTMSYDP 597
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 295 GKIKHKNISSKIKLKERDSDNMFNMIRKDNMMNVCQDQIHNDTVNNMMTNDGCS 354
QY 598 OKNKDNF-----FKSNINKEEDNTPKDILYESRVNMMN-----GN 634
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 355 EPTDNTFLNIEEDEFKMLKNYLKDVKKKKYKGYISNFSHVGRLGTTSRIRGK 414
QY 635 VLLGLANTH-----HDISTDEN--HNDKINNGVINIINNS--NVNSINNSNNSINNS 686
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 415 CLL-KNKKHMYDNEELNKKKKKKKKDRIEGIMEDVADKKRKLDDNKIKFNDIEKE 473
QY 687 MNNSNLSYKSNYNSNOSISDVQIRYVNBMDTSNKNNDNIFFDALSCDNNMPTITNNNN 746
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 474 DLN-----ICDTE--NVNNSNNNNNN-----NNNNNN 499
QY 747 NNNNNNNNNIDVENYNNNRDGTNSM--KLAYN-----SHNLFOQDNN----- 789
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 500 NNNNNNNNNNGYKKKIKKKKKKKKKKKKKNLNNYNDNFVSNGSYDNYIDNNYINDEIR 559
QY 790 ---KNTSNIQNTNKN--QDGNVYVSNMFCYNNLD-----KNYLIDLNNKQKD 836
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 560 EKKKNNEVK--IWDKNDDEKDKKKYDTSY--SPNIKNTLSKYFKYKKNYVKKMIOQH 617
QY 837 KNHGCNNNIIQFNDEPEKKKKTNFYNNNNIYVNN-----NMGNNNSPR----- 881
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 618 NNHNTHN--IHNTNHNH--NTHNHNKVVLLDTEKADPNWLGISFSPAGLLIPYH 672
QY 882 ---MKYGLGSHTS-----IDMKNNEMK----- 902
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 673 LGVSSLIEKNILMHTSISAGSAGSICACCLSVGLSVNKCYLENIIISVYHGCYOK 732
QY 903 ---NNEKDNEMKDNHIKSN-----NN-----SSSSSS 928
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 733 LENTLNLKMYLVEDSYILNNRIGNFVGITQILPYKKLNNNFPDNDLISALIAS 792
QY 929 SNNNIYNNINDDTFONDYCHN-----DNFT-----IRKKNN 961
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 793 CNIPMYLSSNIFVNRKKCIDGFFSTKKDGGCENFETERIIKVSFSDSYVGIKNKN 852
QY 962 TNIN-----SNYONDIIYTNISLNDVMSNTLHF---K 993
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 853 SVISPHILIKYHILFLFCVKNIFHKYIINNMIKDYFLIENLKDIERKIPDYTFVK 912
QY 994 EKYTYPTLSTNEDIYNK-----EMEGHILDDQDKYD-----NDNNVNNNNKNV 1041
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 913 RYFPF--LRKNETIDKYEEDDEGEYEDDEDEDEBEYGHNNNDQDDDEGKKKT 970
QY 1042 DNNVD-----NNVNNVNDND--KANVNNVNDN-----DDDD-----VDHNT-- 1079
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 971 TNEKKKKKKKNNNNNNNNIENNINNNNNNNNNNNNSCVGSEKDFISTSVASFANIKRQ 1030
QY 1080 -----KNFNNNEYS----- 1089
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 1031 MNEKIKRKNKEKKEKELQKRNKNKCSKNRNNRYINKDSNIIHMLNIRIKFNKNLYNN 1090
QY 1090 -----YFOKNVDTIINNCLNSLDSMYDTEKILNILLSKYKAEK-----DNVI 1135
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 1091 MNSFEIEIYKINDIFLOPKHANNVNOFNFSITLIN--IMSKYSENNYAVNLEKIV 1148
QY 1136 KKYINEDIKNNLSLEIDKTAOSIYKRVLLTKLILFKKAVDQIINNETSDLRKDLVNC 1195
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 1149 YKFL--LNNKNFEYIEKQ--YSSKEDM-----NEIDLIVN--TYDMKYDKIIE 1190

```

```

QY 1196 HICNNN--PDQFHFAYASRLKEDIINLIMLQIWCESENILRYOLOL----- 1241
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 1191 ELKNGVYLKIDRY--IFYPLTKDIL--LFFPKIFLNDNLKIDRFLKKNITIMIEVLK 1248
QY 1242 ---VEYONKANSVLT--LVNSNNGDIIILNKKLVODNINKSM-----DHNN 1284
    : : : : : : : : : : : : : : : : : : : : : : : :
Db 1249 EIFFEYVKRCIKTVIFFPVHMKRHDV--MKKNYNNQVYNNSMNENTRGDHN 1301

```

RESULT 38

AAB18272

ID AAB18272 standard; Protein; 2500 AA.

XX

AC AAB18272;

XX

DT 07-NOV-2000 (first entry)

XX

DE Plasmodium falciparum chromosome 2 related protein SEQ ID NO:129.

XX

KM Plasmodium falciparum; chromosome 2; human malaria parasite; vaccine;

XX

KW antimalarial; malaria; protozoacide; infection; insecticide.

XX

OS Plasmodium falciparum.

XX

PN WO200025728-A2.

XX

PD 11-MAY-2000.

XX

PF 05-NOV-1999; 99WO-US26796.

XX

PR 05-NOV-1998; 98US-010731.

XX

PA (HOFF/) HOFFMAN S.

PA (CARU/) CARUCCI D.

PA (GARD/) GARDNER M.

PA (VENT/) VENTER J C.

XX

PI Hoffman S, Carucci D, Gardner M, Venter JC;

XX

DR WPI; 2000-365347/31.

XX

PT Proteins encoded by chromosome 2 of the human malaria parasite,

PT Plasmodium falciparum, useful as antimalarial vaccines and in the

PT diagnosis of P. falciparum infection -

XX

PS Disclosure; Page 302-309; 577pp; English.

XX

CC The present invention describes proteins and their fragments (I) encoded

CC by chromosome 2 of the human malaria parasite, Plasmodium falciparum.

CC Also described are: (I) nucleotide sequences (II) encoding (I); and (2)

CC vaccines against P. falciparum infection comprising (I) or (II).

CC (I) and (II) are useful for the development of vaccines against

CC P. falciparum infection. (I) and polyclonal antisera or a monoclonal

CC antibody raised to immunogens comprising the sequences of (I), are

CC useful in the detection of infection with P. falciparum. Furthermore,

CC (I) (especially when they are rifins or secreted or membrane proteins)

CC can aid the identification of drugs to treat or prevent P. falciparum

CC infection, or they can be used to identify drug resistance in

CC P. falciparum. Sequencing of the Plasmodium chromosome 2 and the

CC subsequent identification of proteins encoded by it will help to expand

CC our understanding of parasite biology, a process hampered by the

CC complexity of the parasitic lifecycle, and provide new targets for

CC vaccine and drug development. Parasite resistance to drugs and mosquito

CC resistance to insecticides have led to a resurgence of malaria in many

CC parts of the world, and there is a pressing need for vaccines and new

CC drugs. AAB70078 to AAB70287 and AAB18144 to AAB18352 represent nucleotide

CC and protein sequences given in the present invention, but which are not

CC specifically mentioned within the specification.

XX

Sequence 2500 AA;

Query Match 8.4%; Score 577.5; DB 21; Length 2500;

Best local Similarity 24.1%; Pred. No. 6.1e-24;

Matches 248; Conservative 164; Mismatches 389; Indels 229; Gaps 52;

```

QY 355 LDKSGSEPMASISIEENVYIKSNHLSNNNNKINRGKI-----NDKIERNNILKKKSPDKPR 410
Db 33 IDERGVLSNNNSVSNISTSTNNIGTNTMPPNNKGFILNPNENYKKNIC--TYLDHES 90
QY 411 EGFSTFGKYSLSLIDIKIRKKKKGLINYKSTLYNDNTINK-----KHNNNNNNNND 463
Db 91 TNINGGVNYD--NHDQNMQMOTNMQMNMQMNMQMNMQMNMQMNMQMOTNMQMOTNQ 148
QY 464 NNDNNNDNNNNNNSSSVNNNNIINNNNN-----NINNNNNNNNNNNNNNNNN-- 512
Db 149 MNQTMQNMOTNMQMNMQMNMQMNMQMNMQMNMQMNMQMNMQMNMQMNMQMNM 208
QY 513 --NSHNHLLPQRYAFDTSDFSLDMMCHLNNNDISFLHKKNLRDNTKLNRSSCDN 570
Db 209 VQSDNAHNP-----YDISEL--YNREKNEQKTFP-----RD--EYSNRITIKA 251
QY 571 INNKKNLHLARHSVSKLTMSYDPQK-----KDTFFKSNINKOE----- 614
Db 252 LINKITVPMIINNSVKNIEDTSSYNTDENVYVCSMDEYTKKYSKYNENDQVI VQG 311
QY 615 DNT---PKDILYESRVS---NANGVLLGLNKQTHDITKDEHNDNKINNGYINI 666
Db 312 NNTVPENDNNEIYKKEKLSIFODSLKONI--VEYNAVH-----SRHKPIDEQVAHY 362
QY 667 INNSNVNISNS--NMNSINN-----SMNSNSTYKSYNSNOSISDQIYV--NEMDTN 719
Db 363 INNYTNNNDPYTRNSTNNNGIAENNINVSAP--NOYKKNQYDILNFTGNIMERKN 421
QY 720 KKNNDIFEDAIISCDNNMYPNITNNNNNNNNNNNNNNNNNNID-----VENYNNRD-- 767
Db 422 IMMNVNDYNERINGNSI--NIQSNNOQMNDQVLDNNVNMCLMQGYINNNHMKPRYMG 479
QY 768 ---GTNNSMGLYAVNSHLFQPD-----NNKATSNI--QNTINK--NNODGVNRY- 811
Db 480 SNYGNNNNVHINIGTNNMHHNNMHHNNMGTNNMGTNNMGTNNMGTNNMGTNNMGTNN 539
QY 812 SMNFCHVNLMDKQVYLDLNNKEQDKKIHGCDNNIIONRDFFKKKTTFNYYNN--NIV 868
Db 540 TNNVTHNNMGNNN--IGTNNMHHNNMGTNNMGTNNMGTNNMGTNNMGTNNMGTNNMGT 587
QY 869 IANNMGNNNNSPRMKGYSIDMKKNNEMKNNEMKNNEMKNNHIIKSN--NNSSS 925
Db 588 MYNNNSTNN-----MGNMNGNDMMRRNNNNGTNNMGTNNMGTNNMGTNNMGTNNMGT 640
QY 926 SSSSSNNNIYNNINDDTFONDYCHNDTFTIRKKNNTNINSNIYONDII--YTINSINDY 984
Db 641 NNNMGTNNMGN--NMGNNYIGNDY--MRNNHII-----DYIINMVMNNVNN 683
QY 985 MSNTLLH--FKKYTYPTLSINDIYKMEKGKHIRDDQKDDNNNNVDDNNK--NNV 1041
Db 684 MVTVMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNM 725
QY 1042 DNN--VDNNNVNNDVNDND--KNNVNDNNNVNDDDVDVFNHINKFNNNEYSLFQKXVDTI 1098
Db 726 GNRIGNYNNMGNLNSNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNMNNM 780
QY 1099 INNCLNSL-----DISSMYDTKEILNLLSKYAEKQNVIKKYINEDIKXMSL 1148
Db 781 NNNNNMNTPOYIIPDNKIKISAVHPFKETNTGIIIN--NASODYTLRSLSGLVNL--NFSM 837
QY 1149 ----EEDTKAQSIEYERKVLTKLLLFKKNVDTQIINNETSLR--KDLVMCHICNN-- 1200
Db 838 IQSENDENSTPSNIEPVNQPLAVEPAIFB-----AVNLELFAESLNDQYCDENSNTD 892
QY 1201 -----NPDQFHFYAYSRLKODIINLIMLROIWCESENRLLYQFIVVEYQNKSAN 1251
Db 893 VIKSKPLVNDPLDDEHIYS--EHLNRRILNDETLPASQANVETL-----YEHHEYNBQRNM 946
QY 1252 SVLLNVSSNN 1261
Db 947 EORINEQRNM 956

```

RESULT 39
AAW03625
ID AAW03625 standard; peptide, 342 AA.
XX
AC AAW03625;
XX
DT 25-MAR-2003 (updated)
DT 17-DEC-1996 (first entry)
DE Human lutropin-choriogonadotropin GPR N-terminal sequence.
XX
KM G-protein coupled receptor; ligand binding assay; transmembrane domain;
KM schizophtenia; dopamine; cAMP; adenosine; thrombin; rhodopsin; opsin;
KM muscarinic acetylcholine; endothelin; bombesin; endocrine; rhodopsin;
XX odorant; cytomagalovirus; serotonegic.
XX
OS Homo sapiens.
XX
PN US5508384-A.
XX
PD 16-APR-1996.
XX
PF 09-SEP-1993; 93US-0118270.
XX
PR 09-SEP-1993; 93US-0118270.
PR 10-SEP-1992; 92US-0943236.
XX
PA (UYNV) UNIV NEW YORK STATE.
XX
PI Murphy RB, Schuster DI;
XX
DR WPI; 1996-208785/21.
XX
PT New dopamine receptor peptide - useful as antipsychotic agent. e.g.
PT for treating schizophtenia
XX
PS Disclosure; Fig 8B(2); 184pp; English.
XX
CC Proteins AAW02657-W02720 represent a range of G-protein coupled receptor
CC (GPR) proteins selected from cAMP, adenosine, muscarinic acetylcholine,
CC adrenergic, thrombin, endothelin, bombesin, endocrine, rhodopsin, opsin,
CC odorant, cytomagalovirus and other GPR proteins. The peptides
CC AAW0578-W03651 represent the N-terminal fragments of the above
CC proteins. The receptor proteins were used to design polypeptides, pref.
CC based on the transmembrane domains, for use in G-protein coupled receptor
CC ligand binding assays. The polypeptide fragments retain biological
CC activity such as binding a GPR ligand or modulating GPR ligand binding to
CC a GPR (see AAW02747-W02999 for examples of polypeptide fragments).
CC The polypeptide fragments can be used in compositions for treating
CC subjects suffering from a pathology related to a GPR abnormality e.g. a
CC psychotic disorder such as schizophtenia.
CC (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 342 AA;

Query Match 8.4%; Score 576.5; DB 17; Length 342;
Best Local Similarity 24.9%; Pred. No. 7.4e-25;
Matches 159; Conservative 43; Mismatches 63; Indels 373; Gaps 14;

```

QY 446 NDNTIKKNNNNNNNNNNNNNNNNNNNNNNNNNNNNSSSVNNMNNMNNNNNNNNNNNNNNNN 505
Db 34 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 79
QY 506 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 565
Db 80 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 94
QY 566 SSCDNIIMKKKNNLHARHSVSKLTMSYDPQKKNKDTFFKSNINKMEDNTPKDILYES 625
Db 95 ----- 94

```

QY 626 RNVSNNNGNVLGLKNTHTHDISTKDEHNDKINNGVITINNSVNSINNSMNSINTN 685
 Db 95 -----NNNNNNNNNN-----NNNNNNNNNNNNNNNNNNNNNNNNNNNN 121
 QY 686 SNMNSNSIYKSNYSNOSISDVQIRYVEMDTSKKNNDIPEFDAISCDNNMYPIITNNNN 745
 Db 122 NNN 147
 QY 746 NNN 805
 Db 148 NNN 187
 QY 806 DGNVYSWFCCHYNLDKGYLIDLNKKEQDKNIHCNDNIIONRDEFEKKKTYFNANN 865
 Db 188 NNNNN-----NNN 195
 QY 866 NIVIVNNNNNGNNSPRMKYGLGSHSTIDNNKKNEMKKNEMKKNHAKSNSSSS 925
 Db 196 N-----NNNNNNNNNN-----NNNNNNNNNNNNNNNNNNNNNNNNNNNN 221
 QY 926 SSSNNNNIYNNINDDTFQNDYCHNDFTIRKKNITINSIYONDIIYITNSLNDYM 985
 Db 222 NNN 242
 QY 986 SNTLLHFEKXYTPTLSTNEDIYNNKEMEKHRLDDQKDDNNNNVNNNNKNNVNNV 1045
 Db 243 -----NN 260
 QY 1046 DNNVVDNNVNDKNNVNDNNVDDDDVDFFHNKFN 1083
 Db 261 NNN 298

RESULT 40
 AAB18218
 ID AAB18218 standard; Protein; 2010 AA.
 AC AAB18218;
 DT 07-NOV-2000 (first entry)
 DE Plasmodium falciparum chromosome 2 related protein SEQ ID NO:75.
 KW Plasmodium falciparum; chromosome 2; human malaria parasite; vaccine;
 KM antimalarial; malaria; protozoacide; infection; insecticide.
 OS Plasmodium falciparum.
 XX WO200025728-A2.
 XX 11-MAY-2000.
 XX 05-NOV-1999; 99WO-US26796.
 XX 05-NOV-1998; 98US-0107131.
 XX (HOEF/) HOFFMAN S.
 XX (CARU/) CARUCCI D.
 XX (GARD/) GARDNER M.
 XX (VENT/) VENTER J C.
 PI Hoffman S, Carucci D, Gardner M, Venter JC;
 DR WPI; 2000-365347/31.
 PT Proteins encoded by chromosome 2 of the human malarial parasite,
 PT Plasmodium falciparum, useful as antimalarial vaccines and in the
 PT diagnosis of P.falciparum infection -
 XX Disclosure; Page 177-182; 577pp; English.
 CC The present invention describes proteins and their fragments (I) encoded
 CC by chromosome 2 of the human malarial parasite, Plasmodium falciparum.

CC Also described are: (I) nucleotide sequences (II) encoding (I); and (2)
 CC vaccines against P. falciparum infection comprising (I) or (II).
 CC (I) and (II) are useful for the development of vaccines against
 CC P. falciparum infection. (I) and polyclonal antisera or a monoclonal
 CC antibody raised to immunogens comprising the sequences of (I), are
 CC useful in the detection of infection with P. falciparum. Furthermore,
 CC (I) (especially when they are rifins or secreted or membrane proteins)
 CC can aid the identification of drugs to treat or prevent P. falciparum
 CC infection, or they can be used to identify drug resistance in
 CC P. falciparum. Sequencing of the plasmodium chromosome 2 and the
 CC subsequent identification of proteins encoded by it will help to expand
 CC our understanding of parasite biology, a process hampered by the
 CC complexity of the parasite life cycle, and provide new targets for
 CC vaccine and drug development. Parasite resistance to drugs and mosquito
 CC resistance to insecticides have led to a resurgence of malaria in many
 CC parts of the world, and there is a pressing need for vaccines and new
 CC drugs. AAB70078 to AAB70287 and AAB18144 to AAB18352 represent nucleotide
 CC and protein sequences given in the present invention, but which are not
 CC specifically mentioned within the specification.

XX Sequence 2010 AA;
 SO Query Match 8.3%; Score 569.5; DB 21; Length 2010;
 Best local Similarity 21.3%; Pred. No. 1.4e-23;
 Matches 287; Conservative 192; Mismatches 404; Indels 467; Gaps 59;

QY 224 KDINKNTSLKINAFIDLAGSERGADTVSONKOTQ---TDGANINRSLLALKECIRADSD 280
 Db 8 KEVKKKEKEK-----KGAKDKGDLFLSKKKERKKESQKIDRYL-----INSCDSN 56
 QY 281 KNHIF-----FRDSELTLYLRDIFVQKSKSIAMISP----- 313
 Db 57 KSNVSCYLNNECFVKNISICCKCMFSEFKKVTYKIVYRHGARTPKKKIKNIWPFKEG 116
 QY 314 ---TISCCEQTLTLFYSRVKNFKAKSTICNEEDTNTN---RISLIDSKGSEMANSSI 367
 Db 117 KGDLTFPLGFOOSIKVGEYLRKRYTTPNK---LNKKYKRRRGRLINKEKGYIKKNCVDV 173
 QY 368 ENVVYKSNHLLSNNNNNKIRGKINDKI---ERNNLKNSKSPDKREGFTSGKYSLLN 424
 Db 174 KCKCTLYKKNYNN 231
 QY 425 D----- 425
 Db 232 ELENRKRKLHFPYLRFIYEKYEFLKINRSNGHGVFKIKRRRRNNILKIMIHQHL 291
 QY 426 IDKIKKKKKGLINYKSTLYNDNTINK-----HNNNNNNNNNNNNNNNNNNNNNN 473
 Db 292 INKMKKIKKNMNN 351
 QY 474 NNNNDSSMVMNNMIMHMINNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 522
 Db 352 NNNNDNN-----NNNDNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 400
 QY 523 NYAFDTSDPSSL-----DMMNCHLNNDKSLF-----LAKKRLDNILKKNRSS 567
 Db 401 SFNVAADLKYTKYYKNNILKDKKVIYNNKKKELFFPLMEHLVYKKKLLIN-FKKKK- 457
 QY 568 CDNIMNKKK-----NHLAHSVGS---KIT-----MEGYDPQKN 600
 Db 458 --NIKKKKKKKYDKILKINKYLCTKTNSERCKLTAVGIIIGLIGISEYIYFFP----- 510
 QY 601 KDNTPKSNINKMEDNTPKDIYLSRVVSNMNGVLLGLKNTHTHDISTDQENNDNKN 660
 Db 511 --ILFKNVYDKTNDNNIDITYTKKKEKKCKLKNKSKCFQWILNRDITSGQYNCID-KNT 567
 QY 661 NGVINIINNSVNSINNSNNN-----SINNSMNSNSIYKSN-YNSNOSISD 706
 Db 568 APVKNYIIIGENLGCENCGKNGCGDILRGDILGDIIRGDNNSILPRSNRNICFKQS--- 624
 QY 707 VOIRYVEMDTSKKNNDIPEFDAI-----SCDNNMYPIITNNNNNNNNNNNNNNNN 761
 Db 625 -KITFCDEL-----YIFNKKIKRLQSLD-DMY-----KINHEVK 657

Qy 762 NY-NNRDGTNNS-MKLVAYNASHNLFOPDNNKNTSNIONINTNKNODGNVNYGWNFCBYN 819
Db 658 MFGNDKDVLANNSYKCYDKNDYGSY-PSYKYSNDYDS-----HYV 697
Qy 820 LNDKNTLIDLANKKQKDKNTHG--CDNN--IIONRNDPEKKKK-----TNFYNNNTIV 868
Db 698 I-----KKNKQVKSVOCSNESIILKERQENKKEKKKKKKMENTEPINNNNLM 744
Qy 869 -----IYNNNNGNNSPRMKYGLCGSHTSIDNNKNNEMKNNEMKDNHMKSN 920
Db 745 YNINVPFDLIINERGN-----FOFYNNIKKKQKNEK-----777
Qy 921 NNSSSSSSSNNNTYNNINDDPQ-----NDYCHNDNTFTIRKKNNTNINSNIYOND 973
Db 778 -----GLEEMNYN-----IFQLYMKYILNESKFEKLFKFLKNVENIDN-----818
Qy 974 IITYTINSL-----NDYNSNTLHFEKETYFTPLSTNEDIYK-EMEGKHRLDDQDKYDN 1028
Db 819 ---TFNSITNIYKYYINMVFVHRKDCFEKQIHSKEHMKKIHRLDKFIEYEKENEIIDN 875
Qy 1029 DNN-NVDNNNRK---NNVDNNVDNNVDNNVDNNND-----K 1059
Db 876 CNNINNDNKKKEIINNNTNNNNIDNNNIEIDSSNNFIETYIIFYLNNMTYIOFLFYLYK 935
Qy 1060 NN-----VDNNVDNDDDDVDVFNINIKNFNN-----EYLSYFOKNVDTII---1099
Db 936 NTYILFSVAVAEBSNLSMLTKTKNHYIKKLRNHIHNSDVYKILNNYKDELFIVYDI 995
Qy 1100 ---NNCNSLDISSMYDTK---EILNNIILSKYKAEDNVIKKYINEDIKNMSLEE 1150
Db 996 TKWTENCMTTDI--LYNDVKNTKIDLENIIDIPITNDKEEY-----HYNNSIISV 1046
Qy 1151 IDTAOSIYEKRVKVLTKLLLFKQAVDIOINNETSDLRDLYMCHICNNPPDDQFHEVA 1210
Db 1047 LKQNSSVYVLKKKLKNSTIL-----KDLKK--LNCNFINKNYIHNNTYDK 1090
Qy 1211 YSRLEKDIINLIMRQIWCESENRLIYQFLVVEYQKNSANSVLANVSSNN-----1261
Db 1091 HNKIYODKIKQWYTHPFFNKKQVKKIIFK-ISAIDAYIYHGVNLNFPRAVEKLSQHP 1149
Qy 1262 -GDIILINKLVODN-----IKNSMDHNN 1284
Db 1150 PSSIDLIKKEYGQNNYIINGEIKKYEEONN 1179

Search completed: October 2, 2003, 16:17:06
Job time : 105 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:28:56 ; Search time 52 Seconds
(without alignments)
2382.024 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 1288
Sequence: 1 NMSKIKVVRKRPISLEKK.....KLLVDPNIKSMDDNNHKK 1288

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 283308 seqs, 96168682 residues

Word size : 0

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 1000 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	1.3	391	2	SI4577
2	17	1.3	419	2	SI4508
3	17	1.3	666	2	S50452
4	17	1.3	749	2	S23467
5	17	1.3	758	2	S45825
6	17	1.3	943	2	S68824
7	17	1.3	1093	2	T18275
8	17	1.3	1139	2	S71092
9	17	1.3	1178	2	S57698
10	17	1.3	1338	2	T18287
11	17	1.3	1457	2	T14577
12	17	1.3	1671	2	S71628
13	17	1.3	1969	2	T08875
14	17	1.3	4550	2	T18440
15	16	1.2	188	2	T02389
16	16	1.2	317	2	S05356
17	16	1.2	328	2	T02046
18	16	1.2	373	2	T52593
19	16	1.2	401	2	T18285
20	16	1.2	490	2	A46391
21	16	1.2	490	2	S52830
22	16	1.2	495	1	S52641
23	16	1.2	566	2	S53813
24	16	1.2	580	2	T18439
25	16	1.2	600	2	T18446
26	16	1.2	686	2	A71607
27	16	1.2	720	2	T51007
28	16	1.2	758	2	S54522
29	16	1.2	831	2	T08611

30	16	1.2	947	2	T08605	hypothetical prote
31	16	1.2	961	2	S67568	probable membrane
32	16	1.2	962	2	JC5808	G protein-coupled
33	16	1.2	964	2	S48404	probable membrane
34	16	1.2	1075	2	S54067	probable membrane
35	16	1.2	1225	2	T09057	probable membrane
36	16	1.2	1256	2	SI4556	asparagine-rich pr
37	16	1.2	1271	2	T08607	hypothetical prote
38	16	1.2	1336	2	T18288	ABC transport prot
39	16	1.2	1365	2	SI4871	suppressor two of
40	16	1.2	1390	2	T14004	trfA protein - sli
41	16	1.2	1402	2	T17456	cell surface prote
42	16	1.2	1584	2	T18276	protein-tyrosine k
43	16	1.2	1585	2	T18274	1-phosphatidylinos
44	16	1.2	1619	2	T18499	hypothetical prote
45	16	1.2	1743	2	T18279	multidrug resistan
46	16	1.2	1817	2	D71606	hypothetical prote
47	16	1.2	1844	2	D71612	hypothetical prote
48	16	1.2	1855	2	S41649	DNA polymerase - m
49	16	1.2	1858	2	T18273	1-phosphatidylinos
50	16	1.2	1905	2	T18267	multidrug resistan
51	16	1.2	2150	2	S71629	sensory transducti
52	16	1.2	2280	2	E71604	hypothetical prote
53	16	1.2	2523	2	T18477	hypothetical prote
54	16	1.2	3544	2	T18402	asparagine/asparta
55	16	1.2	3848	2	T17414	Tipc protein - sli
56	16	1.2	4981	2	T18489	hypothetical prote
57	15	1.2	125	2	E43692	T3C protein - rabb
58	15	1.2	451	2	A23535	clustered asparagi
59	15	1.2	612	2	S65196	probable membrane
60	15	1.2	837	2	S36713	CCR4 protein - yea
61	15	1.2	888	2	S64016	probable regulator
62	15	1.2	1655	2	T13998	gene mastermind pr
63	15	1.2	2278	1	S55274	FAB1 protein - yea
64	15	1.2	2539	2	B71619	hypothetical prote
65	15	1.2	3594	2	T18501	hypothetical prote
66	14	1.1	150	2	D48835	kinasin-like prote
67	14	1.1	247	2	T34214	hypothetical prote
68	14	1.1	264	2	A44969	circumsporozoite p
69	14	1.1	375	2	T00929	squamosa-promoter
70	14	1.1	668	2	T02791	mitotic centromere
71	14	1.1	700	1	S09748	kinasin-related pr
72	14	1.1	744	2	T06048	kinasin-related pr
73	14	1.1	754	2	S48020	kinasin-related pr
74	14	1.1	777	2	C85065	kinasin-like prote
75	14	1.1	793	2	S34830	kinasin-related pr
76	14	1.1	832	2	T36749	kinasin-like prote
77	14	1.1	858	1	A42239	adenylate cyclase
78	14	1.1	913	2	T18503	hypothetical prote
79	14	1.1	955	2	A47334	Lckin kinasin-rela
80	14	1.1	987	2	B66766	protein kinasin F2
81	14	1.1	1056	2	C96661	kinasin-like prote
82	14	1.1	1245	2	D71613	GAF domain protein
83	14	1.1	1662	1	H71402	probable kinasin -
84	14	1.1	1770	2	S56221	hypothetical prote
85	14	1.1	1891	2	T13594	hypothetical prote
86	14	1.1	2010	2	B71616	phosphatase (acid
87	13	1.0	201	2	S54475	hypothetical prote
88	13	1.0	367	2	T46021	hypothetical prote
89	13	1.0	426	2	T04318	homeobox protein L
90	13	1.0	554	2	T50118	kinasin-related pr
91	13	1.0	608	2	T18437	hypothetical prote
92	13	1.0	669	2	S64795	suppressor protein
93	13	1.0	697	2	T16306	hypothetical prote
94	13	1.0	708	2	A51185	G-box-binding fact
95	13	1.0	728	2	S21913	BRCre-TNT1-Q1-Z1
96	13	1.0	851	2	S67285	NUP1 protein - yea
97	13	1.0	904	2	S69691	hypothetical prote
98	13	1.0	1065	2	T13230	dachshund isoform
99	13	1.0	1072	2	T13232	dachshund protein
100	13	1.0	1074	2	T13229	dachshund protein
101	13	1.0	1075	2	T45570	kinasin-like prote
102	13	1.0	1081	2	T13231	dachshund protein

103	1.0	1083	2	T26844	hypothetical prote	176	11	0.9	1388	2	T30335	KLP2 protein - Afr
104	1.0	1151	2	A41529	GRI1 protein - Yea	177	11	0.9	1459	2	T30196	kinesin motor prot
105	1.0	1335	2	T18289	racGp protein - S	178	11	0.9	1979	2	C71622	hypothetical prote
106	1.0	1920	2	T13893	gene hindsight pro	179	11	0.9	1997	2	F71607	DNA helicase II BR
107	1.0	2269	2	T18472	hypothetical prote	180	11	0.9	2061	2	T13751	DNA-directed RNA p
108	1.0	2573	2	D71614	hypothetical prote	181	11	0.9	2339	2	A45597	hypothetical prote
109	0.9	78	2	S23689	erythrocyte membra	182	11	0.9	2457	2	T18492	probable chloroqui
110	0.9	212	2	S49807	hypothetical prote	183	11	0.9	2708	2	T09079	hypothetical prote
111	0.9	239	2	S14470	asparagine-rich pr	184	11	0.9	3973	2	B71612	p511.5 (imported)
112	0.9	431	2	S50977	hypothetical prote	185	10	0.8	97	2	B96580	erythrocyte membra
113	0.9	537	2	A23770	asparagine-rich pr	186	10	0.8	100	2	S23586	metal cations ABC
114	0.9	590	2	A26638	homeocic protein D	187	10	0.8	240	2	A11305	erythrocyte membra
115	0.9	603	2	F96797	probable GT-like t	188	10	0.8	240	2	A11677	metal cations ABC
116	0.9	647	2	S06450	steroid hormone re	189	10	0.8	272	2	S23684	hypothetical prote
117	0.9	671	2	T10755	kinesin-related pr	190	10	0.8	368	1	S46601	ecdysone-inducibl
118	0.9	716	1	A44259	kinesin-related pr	191	10	0.8	390	1	B49070	ribosomal protein
119	0.9	747	2	T23607	hypothetical prote	192	10	0.8	398	1	R3BYM1	hypothetical prote
120	0.9	764	2	H71607	hypothetical prote	193	10	0.8	419	2	T18420	interleukin-9 rece
121	0.9	813	2	T46242	kinesin-like prote	194	10	0.8	522	2	B45268	glutamate decarbox
122	0.9	914	2	S46593	finger protein AZF	195	10	0.8	575	1	JH0827	hypothetical prote
123	0.9	1341	2	S50366	probable membrane	196	10	0.8	587	2	T19893	hypothetical prote
124	0.9	1516	2	E71619	RAD2 endonuclease	197	10	0.8	587	2	T29324	hypothetical prote
125	0.9	1570	2	T18272	1-phosphatidylinos	198	10	0.8	613	2	T15489	hypothetical prote
126	0.9	1864	2	T18485	hypothetical prote	199	10	0.8	623	1	S33167	gene pointed prote
127	0.9	2452	1	RNZQL	DNA-directed RNA p	200	10	0.8	633	2	T04179	hypothetical prote
128	0.9	2910	2	T28156	DNA-directed RNA p	201	10	0.8	648	1	JQ1150	protein kinase (EC
129	0.9	3724	2	T18437	hypothetical prote	202	10	0.8	695	2	T24950	hypothetical prote
130	0.9	95	2	F41298	kinesin-like prote	203	10	0.8	716	2	T26998	hypothetical prote
131	0.9	234	2	S14469	asparagine-rich pr	204	10	0.8	718	1	S33168	gene pointed prote
132	0.9	280	2	C66317	protein T10022.23	205	10	0.8	720	2	UQ1676	hypothetical prote
133	0.9	330	2	B48835	kinesin-like prote	206	10	0.8	726	2	S67044	hypothetical prote
134	0.9	331	2	G96785	protein F10A5.24 (207	10	0.8	766	2	T18469	probable protein k
135	0.9	443	2	A54813	cAMP receptor CAR4	208	10	0.8	821	2	S48986	ecdysone-inducibl
136	0.9	448	2	S05355	hypothetical prote	209	10	0.8	864	2	A49070	hypothetical prote
137	0.9	461	2	T10265	arabinogalactan-pr	210	10	0.8	928	2	T16759	hypothetical prote
138	0.9	472	2	A26357	homeocic protein C	211	10	0.8	974	1	A40213	optic lobe develop
139	0.9	519	2	I54523	kinesin-related pr	212	10	0.8	1068	2	S64015	pietotropic drug r
140	0.9	522	2	T18504	hypothetical prote	213	10	0.8	1121	2	T13750	kinesin-like prote
141	0.9	549	2	T20720	hypothetical prote	214	10	0.8	1121	2	T13796	kinesin-related pr
142	0.9	601	2	T00119	probable transcrip	215	10	0.8	1190	2	S47536	oxysterol-binding
143	0.9	622	2	A57281	kinesin-like motor	216	10	0.8	1195	2	S38174	probable purine nu
144	0.9	670	2	T29898	kinesin protein OS	217	10	0.8	1195	2	S37621	Ca2+-transporting
145	0.9	672	2	S54351	kinesin oem-3 - Ca	218	10	0.8	1254	2	T18277	kinesin heavy chai
146	0.9	676	2	S61977	transcription fact	219	10	0.8	1294	2	T18473	hypothetical prote
147	0.9	690	2	T34149	hypothetical prote	220	10	0.8	1308	2	E71622	probable membrane
148	0.9	703	2	A86319	P25116.11 protein	221	10	0.8	1365	2	T18419	hypothetical prote
149	0.9	722	2	D71607	VP845-like protein	222	10	0.8	1419	1	DVZOF	multidrug resistan
150	0.9	729	1	A34796	kinesin-related pr	223	10	0.8	1438	2	E71610	WD40 WEB-1 homolog
151	0.9	784	2	T40594	probable kinesin-1	224	10	0.8	1553	2	S67483	adenosinetriphosph
152	0.9	805	2	S64238	kinesin-related pr	225	10	0.8	1576	2	T29237	hypothetical prote
153	0.9	817	2	T50240	kinesin-like prote	226	10	0.8	1584	1	JN0114	kinesin-related pr
154	0.9	836	2	T18460	hypothetical prote	227	10	0.8	1584	2	T15832	kinesin-like prote
155	0.9	861	2	T00434	probable kinesin h	228	10	0.8	1711	2	T18429	hypothetical prote
156	0.9	920	2	T08853	protein phosphatas	229	10	0.8	1737	2	A59235	unconventional myo
157	0.9	921	2	T01775	hypothetical prote	230	10	0.8	1817	2	H71611	probable secreted
158	0.9	932	2	T30099	hypothetical prote	231	10	0.8	1893	2	T22661	hypothetical prote
159	0.9	935	2	T51930	kinesin (imported)	232	10	0.8	1921	2	T13827	kinesin-73 - fruit
160	0.9	968	2	T51933	kinesin motor prot	233	10	0.8	1921	2	T03094	A-kinase anchor pr
161	0.9	975	2	T08606	protein phosphatas	234	10	0.8	2529	2	A56923	transcription fact
162	0.9	987	2	T51360	kinesin-like heavy	235	10	0.8	2578	2	A56922	transcription fact
163	0.9	1025	2	T18376	multidrug resistan	236	10	0.7	32	2	S08482	regulatory protein
164	0.9	1032	2	B86224	hypothetical prote	237	9	0.7	114	2	T17927	hypothetical prote
165	0.9	1122	2	F71606	probable multiple	238	9	0.7	131	2	S33375	homeocic protein A
166	0.9	1225	2	A65514	chromokinesin - ch	239	9	0.7	160	2	S47661	topoisomerase II -
167	0.9	1226	2	I51617	kinesin-like prote	240	9	0.7	172	2	T20210	hypothetical prote
168	0.9	1229	2	T48959	kinesin-like prote	241	9	0.7	173	2	A47303	FTZ-F1 steroid rec
169	0.9	1230	2	T18256	probable serine/th	242	9	0.7	184	2	T28333	ORF MSV172 hypoch
170	0.9	1230	2	T18259	serine/threonine p	243	9	0.7	257	2	T00406	hypothetical prote
171	0.9	1231	2	A54803	microtubule-associ	244	9	0.7	266	2	E71601	probable integral
172	0.9	1265	2	T03792	kinesin-related pr	245	9	0.7	266	2	S61522	LMO protein - frui
173	0.9	1265	2	T07397	kinesin heavy chai	246	9	0.7	300	2	H96636	hypothetical prote
174	0.9	1269	2	T14476	psia protein - sli	247	9	0.7	305	2	T27151	hypothetical prote
175	0.9	1351	2	C71607	hypothetical prote	248	9	0.7	321	2	G84750	probable homeodoma

249	9	0.7	323	2	T15311	hypothetical prote	322	9	0.7	1557	2	T13160	protein CNK - fru
250	9	0.7	344	2	T48827	hypothetical prote	323	9	0.7	1677	2	T43021	vitellogenin precu
251	9	0.7	372	2	T50014	trehalose-6-phosph	324	9	0.7	1714	2	E71609	Ser/Thr protein ki
252	9	0.7	372	2	T29359	hypothetical prote	325	9	0.7	2206	2	G71611	hypothetical prote
253	9	0.7	375	2	A46390	CAMP receptor subu	326	9	0.7	2485	1	H71621	serine/threonine-s
254	9	0.7	377	1	A48711	protein-tyrosine-p	327	9	0.7	2510	2	T28160	hypothetical prote
255	9	0.7	387	2	T25452	hypothetical prote	328	9	0.7	2657	2	T18497	hypothetical prote
256	9	0.7	388	2	D85080	KNA1 homeobox-lik	329	9	0.7	2819	2	T09080	probable chloroqui
257	9	0.7	410	2	C86835	hypothetical prote	330	9	0.7	3092	2	S46009	GTPase-activating
258	9	0.7	452	2	T33049	hypothetical prote	331	9	0.7	3119	2	T18414	protein g377 - mal
259	9	0.7	472	2	S28026	nuclear pore compl	332	8	0.6	58	2	S78672	hypothetical prote
260	9	0.7	508	2	E71620	hypothetical prote	333	8	0.6	65	2	T17665	hypothetical prote
261	9	0.7	508	2	A32225	nerve growth facto	334	8	0.6	115	2	D61615	sericin Mg-1 - gre
262	9	0.7	518	2	S23692	erythrocyte membra	335	8	0.6	117	2	A45509	desiccation-relate
263	9	0.7	528	2	S32593	[RNA-polymerase]-s	336	8	0.6	118	2	C41298	kinesin-like prote
264	9	0.7	554	2	S16304	benomyl/methotrex	337	8	0.6	121	2	G71711	ribosomal protein
265	9	0.7	564	2	A71619	membrane transport	338	8	0.6	121	2	S67700	probable membrane
266	9	0.7	577	2	B44307	phosphoprotein pho	339	8	0.6	134	2	E84903	30S ribosomal prot
267	9	0.7	578	2	S55102	PSP2 protein - yea	340	8	0.6	145	2	H97707	high mobility grou
268	9	0.7	581	2	F84599	probable kinesin h	341	8	0.6	147	2	J01320	regulatory protein
269	9	0.7	589	2	C85360	hypothetical prote	342	8	0.6	150	2	G64077	hypothetical prote
270	9	0.7	594	2	JC5146	arylphorin gene-sp	343	8	0.6	151	2	T00286	hypothetical prote
271	9	0.7	598	2	T24717	hypothetical prote	344	8	0.6	163	2	T04467	hypothetical prote
272	9	0.7	602	2	B81420	GTP-binding protei	345	8	0.6	182	2	T20185	hypothetical prote
273	9	0.7	640	2	A41726	homeotic protein B	346	8	0.6	186	2	T30918	hypothetical prote
274	9	0.7	640	2	T03754	homeotic protein B	347	8	0.6	188	2	G96652	protein F23N19.15
275	9	0.7	642	2	S27806	homeotic protein B	348	8	0.6	205	2	T15450	hypothetical prote
276	9	0.7	643	2	S17997	hypothetical gene	349	8	0.6	215	2	F84508	probable CCAAT-box
277	9	0.7	658	2	C71856	excinuclease ABC c	350	8	0.6	236	2	B84718	hypothetical prote
278	9	0.7	658	2	B64659	excinuclease ABC c	351	8	0.6	237	2	T30920	homeobox protein -
279	9	0.7	669	2	S14535	asparagine-rich pr	352	8	0.6	242	2	T22915	hypothetical prote
280	9	0.7	675	2	B56232	excinuclease ABC c	353	8	0.6	256	2	S23691	erythrocyte membra
281	9	0.7	675	2	D81846	excinuclease ABC s	354	8	0.6	257	2	E89124	protein K07C11.1
282	9	0.7	675	2	F81095	cell-surface molec	355	8	0.6	259	2	G84685	probable DOF zinc
283	9	0.7	682	2	A49121	connectin precurs	356	8	0.6	260	2	S60480	low temperature-in
284	9	0.7	682	2	A43318	BRcore-NS-23 prote	357	8	0.6	265	2	B86338	protein F5M15.22
285	9	0.7	704	2	S21911	vacu protein - sll	358	8	0.6	273	2	T03254	probable carbonate
286	9	0.7	708	2	T03835	hypothetical prote	359	8	0.6	274	1	JQ0957	myb-related protei
287	9	0.7	713	1	S46838	ARPI protein - yea	360	8	0.6	275	2	D96826	hypothetical prote
288	9	0.7	719	2	S61046	MAD1 protein - yea	361	8	0.6	282	2	T08445	hypothetical prote
289	9	0.7	749	2	A57276	kinesin protein - yea	362	8	0.6	284	2	S58650	homeotic protein s
290	9	0.7	770	1	A44337	kinesin-related pr	363	8	0.6	285	2	S27843	unknown protein, 1
291	9	0.7	772	2	T43034	kinesin-like prote	364	8	0.6	286	2	C86423	sericin Mg-2 - gre
292	9	0.7	775	2	T43033	box A-binding fact	365	8	0.6	294	2	S19226	cold-regulated pro
293	9	0.7	779	1	S40382	SPR-1 protein - nu	366	8	0.6	298	2	A32872	myogenic factor CM
294	9	0.7	780	2	A48143	condensin complex	367	8	0.6	307	2	A45600	asparagine-rich bl
295	9	0.7	784	2	S26638	hypothetical prote	368	8	0.6	328	1	T00747	RINC-H2 finger pro
296	9	0.7	807	2	B71605	condensin complex	369	8	0.6	329	1	S61884	carbonate dehydrat
297	9	0.7	832	2	T49494	Erbb kinase activa	370	8	0.6	330	1	S61883	carbonate dehydrat
298	9	0.7	834	2	T06055	Erbb kinase activa	371	8	0.6	330	1	S61882	carbonate dehydrat
299	9	0.7	860	2	JC5702	hypothetical prote	372	8	0.6	331	1	S46675	probable transcript
300	9	0.7	868	2	JC5701	hypothetical prote	373	8	0.6	333	2	T51650	protein C05D11.6
301	9	0.7	883	2	T18484	F22M8.8 protein -	374	8	0.6	334	2	B88482	protein F3M18.16
302	9	0.7	885	2	D86151	SAP155 protein - y	375	8	0.6	335	2	D86410	ribosomal protein
303	9	0.7	905	2	S56295	hypothetical prote	376	8	0.6	336	2	S04682	Viril homolog - B
304	9	0.7	928	2	S50578	discs-large tumor	377	8	0.6	339	2	F47301	hypothetical prote
305	9	0.7	960	1	A39651	ker protein - fru1	378	8	0.6	341	2	T22551	single-stranded DN
306	9	0.7	968	2	T45746	USN1 protein - yea	379	8	0.6	354	2	A39609	probable DOF zinc
307	9	0.7	1003	2	T13856	probable regulator	380	8	0.6	356	2	G84904	probable membrane
308	9	0.7	1070	2	S57112	hypothetical prote	381	8	0.6	360	2	T33835	probable cyclin D
309	9	0.7	1091	2	T57112	stripe a/b protein	382	8	0.6	361	2	C84613	citremporozole p
310	9	0.7	1094	2	S46021	hypothetical prote	383	8	0.6	369	2	S76435	hypothetical prote
311	9	0.7	1104	2	T19673	probable transcript	384	8	0.6	372	2	I38042	single-stranded DN
312	9	0.7	1110	2	T19673	quandine nucleoti	385	8	0.6	373	2	S72368	myb-related transc
313	9	0.7	1180	2	S69205	adenylate cyclase	386	8	0.6	376	2	T51673	hypothetical prote
314	9	0.7	1193	2	G71605	hypothetical prote	387	8	0.6	377	2	F84473	cyclin delta-2 - A
315	9	0.7	1221	2	T13283	hypothetical prote	388	8	0.6	383	2	S51651	hfk protein (limp
316	9	0.7	1237	2	T18425	CAT8 protein - yea	389	8	0.6	384	2	AD3328	gene M5SP-2 protei
317	9	0.7	1397	2	T10466	hypothetical prote	390	8	0.6	389	2	S53612	
318	9	0.7	1407	2	B42239	hypothetical prote	391	8	0.6				
319	9	0.7	1436	2	D71618	hypothetical prote	392	8	0.6				
320	9	0.7	1445	2	T14913	hypothetical prote	393	8	0.6				
321	9	0.7	1553	2	T18502	hypothetical prote	394	8	0.6				

395	8	0.6	390	2	B81408	probable periplasm
396	8	0.6	397	2	T06531	pyruvate dehydroge
397	8	0.6	397	2	S54018	DBF2 protein-inter
398	8	0.6	403	2	T45580	hypothetical prote
399	8	0.6	403	2	T49480	hypothetical prote
400	8	0.6	403	2	S47659	CDC2/CDC13 suppres
401	8	0.6	411	2	E96665	protein F22C12.16
402	8	0.6	413	2	A55238	transcription fact
403	8	0.6	416	2	A55237	transcription fact
404	8	0.6	429	2	S24705	probable segment i
405	8	0.6	431	2	S50633	hypothetical prote
406	8	0.6	435	2	S51042	cat-binding protei
407	8	0.6	443	2	B84449	hypothetical prote
408	8	0.6	446	2	T14542	choline monooxygen
409	8	0.6	453	2	T47466	zinc finger protei
410	8	0.6	455	2	S46033	probable membrane
411	8	0.6	461	2	JN0097	secreted 45k prote
412	8	0.6	464	2	T45612	N-hydroxycinnamoyl
413	8	0.6	471	2	T32788	hypothetical prote
414	8	0.6	476	2	T17932	major capsid prote
415	8	0.6	479	2	T02623	hypothetical prote
416	8	0.6	485	2	S36184	translacton elonga
417	8	0.6	486	2	F69762	transporter homolo
418	8	0.6	488	2	B90355	allantoin permease
419	8	0.6	488	2	B69825	cell wall-binding
420	8	0.6	492	2	E80371	allantoin permease
421	8	0.6	497	2	T06727	hypothetical prote
422	8	0.6	507	2	S05542	hypothetical prote
423	8	0.6	520	2	F86401	protein T22C5.11 [
424	8	0.6	532	2	T18432	hypothetical prote
425	8	0.6	535	2	T47629	phosphate transpor
426	8	0.6	536	2	H89130	protein F52E1.13b
427	8	0.6	538	2	T16034	hypothetical prote
428	8	0.6	554	2	S37936	regulatory protein
429	8	0.6	559	2	G82326	MSHA biogenesis pr
430	8	0.6	566	2	S54629	hypothetical prote
431	8	0.6	566	2	T49988	ovule development
432	8	0.6	567	2	S58750	NADH2 dehydrogenas
433	8	0.6	576	2	G96763	probable MAP kinas
434	8	0.6	581	2	H95214	ABC transporter; A
435	8	0.6	583	1	S20495	ferredoxin-nitrite
436	8	0.6	594	2	G98078	hypothetical prote
437	8	0.6	604	2	S58643	probable transcrip
438	8	0.6	605	2	T07123	nine-cis-epoxycaro
439	8	0.6	610	2	T18441	asparagine synthas
440	8	0.6	612	2	T19946	hypothetical prote
441	8	0.6	612	2	T08602	protein tlpD - sli
442	8	0.6	628	2	T39494	kinesin-like prote
443	8	0.6	646	1	S16654	RNA-directed DNA p
444	8	0.6	653	2	B81277	hypothetical prote
445	8	0.6	655	2	A29945	neurogenesis regul
446	8	0.6	658	2	T41309	hypothetical threo
447	8	0.6	669	2	D82739	exonuclease ABC s
448	8	0.6	678	1	A30350	dorsal protein - f
449	8	0.6	688	2	T09941	transcription fact
450	8	0.6	695	2	T39954	probable gtpase ac
451	8	0.6	721	2	D84732	probable homeodoma
452	8	0.6	750	2	T04980	hypothetical prote
453	8	0.6	759	2	E84538	hypothetical prote
454	8	0.6	763	2	S17998	gene COX1 intron 4
455	8	0.6	769	2	T08431	gene bobby sox pro
456	8	0.6	779	2	T49717	related to BCS1 pr
457	8	0.6	784	1	A55236	kinesin-related pr
458	8	0.6	786	1	A47547	serine proteinase
459	8	0.6	840	2	S77615	hypothetical prote
460	8	0.6	841	2	S69563	suppressor protein
461	8	0.6	847	2	T12979	hypothetical prote
462	8	0.6	855	2	S47533	glucose-6-phosphat
463	8	0.6	865	2	S64195	HTP1 protein - yea
464	8	0.6	865	2	A25762	regulatory protein
465	8	0.6	870	2	B81689	ATP-dependent Clp
466	8	0.6	874	2	T00491	capsid protein pre
467	8	0.6	880	2	T38083	potassium transpor
468	8	0.6	883	2	T40128	kinesin-like prote
469	8	0.6	910	2	S40259	glucose-6-phosphat
470	8	0.6	911	2	T18451	hypothetical prote
471	8	0.6	941	2	T51135	ligand-gated chann
472	8	0.6	947	2	T03795	ornithine decarbox
473	8	0.6	962	2	D86186	hypothetical prote
474	8	0.6	962	2	S03818	carboxymethylcellu
475	8	0.6	970	2	F64230	spore germination
476	8	0.6	970	2	S48485	transcription acti
477	8	0.6	976	2	T51137	ionotropic glutama
478	8	0.6	1010	2	T13167	lola-like protein
479	8	0.6	1017	2	T18488	hypothetical prote
480	8	0.6	1028	2	A56038	DNA-binding protei
481	8	0.6	1038	2	S38801	pullulanase (EC 3.
482	8	0.6	1043	2	T13733	FTZ-F1 protein - f
483	8	0.6	1060	2	T30347	vitellogenin conve
484	8	0.6	1067	2	S35423	protein kinase sgg
485	8	0.6	1099	2	T18257	phospholipase C -
486	8	0.6	1119	2	T18491	hypothetical prote
487	8	0.6	1123	2	T28139	PK4 protein kinase
488	8	0.6	1152	2	F86363	hypothetical prote
489	8	0.6	1163	2	D64315	type I restriction
490	8	0.6	1166	2	C96945	cation efflux syst
491	8	0.6	1169	2	AD1069	type I site-specif
492	8	0.6	1213	2	S16356	ovo protein - fru1
493	8	0.6	1240	2	JC5209	insulin receptor s
494	8	0.6	1242	2	J50670	hypothetical prote
495	8	0.6	1247	2	E71616	probable secreted
496	8	0.6	1278	2	A71609	probable potassium
497	8	0.6	1284	2	T13168	transcription regu
498	8	0.6	1314	1	TNBYR6	conserved hypochet
499	8	0.6	1367	2	H82874	hypothetical prote
500	8	0.6	1367	2	T18466	DNA-directed RNA p
501	8	0.6	1384	2	S78132	hypothetical prote
502	8	0.6	1398	2	H71606	hemectic protein
503	8	0.6	1403	2	S24548	chromatin remodeli
504	8	0.6	1422	2	T18404	forked protein 5.4
505	8	0.6	1436	2	S57238	hypothetical prote
506	8	0.6	1441	2	T18422	forked protein 5.6
507	8	0.6	1449	2	S57237	nucleoporin - rat
508	8	0.6	1468	2	A44345	nuclear pore compl
509	8	0.6	1475	2	S42718	hypothetical prote
510	8	0.6	1529	2	S69688	sol protein, large
511	8	0.6	1597	1	BVFE8L	gene small optic l
512	8	0.6	1597	2	T08428	vitellogenin I - m
513	8	0.6	1704	2	T43141	cnjB protein - Tet
514	8	0.6	1748	2	S42136	vitellogenin precu
515	8	0.6	1788	2	T31095	vitellogenin II pr
516	8	0.6	1852	1	VUCH2	hypothetical prote
517	8	0.6	1965	2	T33216	polycomb protein e
518	8	0.6	2023	2	T13154	protein CTRP - mal
519	8	0.6	2098	2	T18397	homeotic protein c
520	8	0.6	2175	1	S03170	cardamoyl-phosphat
521	8	0.6	2391	2	T18410	hypothetical prote
522	8	0.6	2437	2	T18482	hypothetical prote
523	8	0.6	2500	2	G71609	hypothetical prote
524	8	0.6	2562	2	T14266	xin protein - chic
525	8	0.6	3005	2	S33642	homeotic protein z
526	8	0.6	3190	2	T13828	CREB-binding prote
527	8	0.6	3359	2	A35085	trithorax protein
528	8	0.6	43	2	AG2078	hypothetical prote
529	8	0.5	46	2	B29184	vitellogenin - duc
530	8	0.5	47	2	H81576	hypothetical prote
531	8	0.5	54	2	T10786	conserved hypochet
532	8	0.5	54	2	T06514	hypothetical prote
533	8	0.5	68	2	F69799	hypothetical prote
534	8	0.5	70	2	C90886	hypothetical prote
535	8	0.5	70	2	D85732	hypothetical prote
536	8	0.5	70	2	B64898	hypothetical prote
537	8	0.5	75	2	S37191	hypothetical prote
538	8	0.5	77	2	T41800	AcMNPV orf55 - Bom
539	8	0.5	80	2	T27603	hypothetical prote
540	8	0.5	85	2	A86282	protein F10B6.20 [

541	7	0.5	89	2	E96930	transposon related	614	7	0.5	166	2	T07089	dehydrin - soybean
542	7	0.5	97	2	S06983	hypothetical prote	615	7	0.5	166	2	F81707	hypothetical prote
543	7	0.5	98	2	S13623	ht-en protein - le	616	7	0.5	166	2	S30833	hypothetical prote
544	7	0.5	99	2	T06083	probable auxin-ind	617	7	0.5	167	2	S05545	dehydrin 3 - maize
545	7	0.5	99	2	S69516	hypothetical prote	618	7	0.5	167	2	T49638	hypothetical prote
546	7	0.5	99	2	T49636	related to cell di	619	7	0.5	167	2	AE2630	hypothetical prote
547	7	0.5	100	2	A26989	nonhistone chromos	620	7	0.5	167	2	T47385	hypothetical prote
548	7	0.5	101	2	S67034	auxin-induced prot	621	7	0.5	168	2	A39316	hypothetical prote
549	7	0.5	102	2	T05499	hypothetical prote	622	7	0.5	168	2	S08633	RAB-17 protein - m
550	7	0.5	102	2	S72682	hypothetical prote	623	7	0.5	168	2	C75425	hypothetical prote
551	7	0.5	102	2	G96775	hypothetical prote	624	7	0.5	169	2	F84571	hypothetical prote
552	7	0.5	102	2	S26409	protein i08 precu	625	7	0.5	169	2	T34520	hypothetical prote
553	7	0.5	104	2	S55169	hypothetical prote	626	7	0.5	170	2	AF2621	polypeptide deform
554	7	0.5	105	2	C89924	conserved hypochet	627	7	0.5	171	2	F97403	polypeptide deform
555	7	0.5	105	2	C86242	protein T16B5.1 (i	628	7	0.5	171	2	T29161	hypothetical prote
556	7	0.5	106	2	T14819	dehydrin DHN2 - so	629	7	0.5	172	2	G86463	hypothetical prote
557	7	0.5	107	2	B85356	glycine-rich prot	630	7	0.5	172	2	T36107	probable serine/ar
558	7	0.5	109	2	T12208	probable cytochrom	631	7	0.5	173	2	F70112	hypothetical prote
559	7	0.5	112	2	G72502	hypothetical prote	632	7	0.5	174	2	F85028	hypothetical prote
560	7	0.5	113	2	T48112	hypothetical prote	633	7	0.5	177	2	A84856	hypothetical prote
561	7	0.5	115	2	T07576	hypothetical prote	634	7	0.5	177	2	F96739	hypothetical prote
562	7	0.5	117	2	S48324	hypothetical prote	635	7	0.5	177	2	T37212	hypothetical prote
563	7	0.5	120	2	S65067	dehydrin DHN1 - po	636	7	0.5	178	2	T27193	hypothetical prote
564	7	0.5	121	2	B81872	hypothetical prote	637	7	0.5	178	2	T20599	hypothetical prote
565	7	0.5	123	2	S69460	hypothetical prote	638	7	0.5	179	2	B84587	probable glutaredo
566	7	0.5	124	2	S45788	probable membrane	639	7	0.5	180	2	A70170	hypothetical prote
567	7	0.5	125	2	S69871	hypothetical prote	640	7	0.5	180	2	C72676	hypothetical prote
568	7	0.5	127	1	KNMUHY	dehydrin-like prot	641	7	0.5	181	2	G96715	transcription fact
569	7	0.5	127	1	T45729	dehydrin-like prote	642	7	0.5	181	2	T46017	hypothetical prote
570	7	0.5	129	2	D41298	kinesin-like prote	643	7	0.5	182	2	G86410	protein F3M18.10 (
571	7	0.5	129	2	T00282	hypothetical prote	644	7	0.5	183	2	A56579	pre-intermoult gen
572	7	0.5	132	2	T49536	hypothetical prote	645	7	0.5	183	2	T06643	hypothetical prote
573	7	0.5	133	2	A41298	kinesin-like prote	646	7	0.5	184	2	S12095	embryonic abundant
574	7	0.5	134	2	S51087	dhnl protein - pot	647	7	0.5	185	2	H84601	probable dehydrin
575	7	0.5	135	2	T09876	dehydrin - upland	648	7	0.5	185	2	P96789	protein T23E18.12
576	7	0.5	135	2	A42098	transcription fact	649	7	0.5	185	2	T05008	hypothetical prote
577	7	0.5	139	2	S05544	dehydrin 8 - barley	650	7	0.5	187	2	S69466	hypothetical prote
578	7	0.5	139	2	T05715	dehydrin - barley	651	7	0.5	187	2	T49491	hypothetical prote
579	7	0.5	140	2	T27059	hypothetical prote	652	7	0.5	188	1	SORTAD	hypothetical prote
580	7	0.5	142	2	T34136	hypothetical prote	653	7	0.5	189	2	T02570	hypothetical prote
581	7	0.5	143	2	S05543	dehydrin 9 - barley	654	7	0.5	191	2	S29008	ADP-ribosylation f
582	7	0.5	145	2	S04042	embryonic abundant	655	7	0.5	192	2	S59537	heat shock transcr
583	7	0.5	149	2	S19130	rab15 protein - wh	656	7	0.5	192	2	H71605	probable integral
584	7	0.5	149	2	T23179	hypothetical prote	657	7	0.5	193	2	T19388	hypothetical prote
585	7	0.5	150	2	H96756	hypothetical prote	658	7	0.5	193	2	T00585	hypothetical prote
586	7	0.5	150	2	S55882	CCH finger protei	659	7	0.5	195	2	H95532	hypothetical prote
587	7	0.5	151	2	JQ2282	negatively phytoch	660	7	0.5	196	2	H82910	hypothetical prote
588	7	0.5	151	2	S11848	rab1d protein - r	661	7	0.5	196	2	G46326	hypothetical prote
589	7	0.5	153	2	S67294	hypothetical prote	662	7	0.5	196	2	T46326	hypothetical prote
590	7	0.5	154	2	T14727	dehydrin DHN1 - so	663	7	0.5	197	2	S55621	hypothetical prote
591	7	0.5	154	2	A05187	hypothetical prote	664	7	0.5	197	2	T256829	hypothetical prote
592	7	0.5	154	2	S55017	hypothetical prote	665	7	0.5	197	2	C88809	protein Y43C58.1 (
593	7	0.5	155	2	S43775	desiccation-relate	666	7	0.5	197	2	A90365	hypothetical prote
594	7	0.5	156	2	F85061	dehydrin 1 - Comme	667	7	0.5	197	2	A97060	N-terminal truncat
595	7	0.5	157	2	T10489	hypothetical prote	668	7	0.5	197	2	H85065	hypothetical prote
596	7	0.5	158	2	A75556	hypothetical prote	669	7	0.5	198	2	S07130	casein B precursor
597	7	0.5	159	2	T05279	transcription fact	670	7	0.5	198	2	A49243	GLOF-C4 protein -
598	7	0.5	159	2	T48956	hypothetical prote	671	7	0.5	199	2	H84015	hypothetical prote
599	7	0.5	160	2	B86614	CT832 hypothetical	672	7	0.5	199	2	T14468	pollen coat protei
600	7	0.5	160	2	T00836	probable dnuv prot	673	7	0.5	200	2	JC4357	HMGI protein - sea
601	7	0.5	160	2	F72010	CT832 hypothetical	674	7	0.5	200	2	S64905	hypothetical prote
602	7	0.5	161	2	S05547	dehydrin 17 - barl	675	7	0.5	200	2	T44143	DR3 protein (impor
603	7	0.5	161	2	T45055	hypothetical prote	676	7	0.5	200	2	T43953	hypothetical prote
604	7	0.5	162	2	D86418	unknown protein, 6	677	7	0.5	200	2	T09783	dehydration-induct
605	7	0.5	162	2	C85356	glycine-rich prote	678	7	0.5	202	2	D85058	hypothetical prote
606	7	0.5	163	2	S01152	RAB21 protein - ri	679	7	0.5	202	2	T11744	dehydrin - kidney
607	7	0.5	163	2	B81530	N utilization subs	680	7	0.5	203	2	T39117	hypothetical prote
608	7	0.5	164	2	T15525	hypothetical prote	681	7	0.5	203	2	S60449	probable membrane
609	7	0.5	164	2	S11846	rab16B protein - r	682	7	0.5	204	2	B71433	hypothetical prote
610	7	0.5	164	2	S11847	rab16C protein - r	683	7	0.5	205	2	T05713	hypothetical prote
611	7	0.5	164	2	T14187	hypothetical prote	684	7	0.5	206	2	G85065	dehydrin - barley
612	7	0.5	164	2	T16168	hypothetical prote	685	7	0.5	206	2	T23852	hypothetical prote
613	7	0.5	165	2	T03392	probable dehydrin	686	7	0.5	206	2	T34347	hypothetical prote

687	7	0.5	207	2	S58744	NADH2 dehydrogenas	760	7	0.5	250	2	S36769	ubiquitin-protein
688	7	0.5	207	2	S55200	hypothetical prote	761	7	0.5	251	1	B64456	bioc protein homol
689	7	0.5	207	2	B80140	hypothetical prote	762	7	0.5	252	2	G84450	hypothetical prote
690	7	0.5	209	2	E96517	hypothetical prote	763	7	0.5	252	2	H84423	hypothetical prote
691	7	0.5	209	2	T07779	dehydrin homolog C	764	7	0.5	252	2	A83276	hypothetical cytos
692	7	0.5	210	2	B96694	hypothetical prote	765	7	0.5	254	2	S50834	emerin - human
693	7	0.5	210	2	T49785	hypothetical prote	766	7	0.5	255	1	WJHUY4	homeotic protein H
694	7	0.5	211	2	D96507	hypothetical prote	767	7	0.5	255	2	AB1942	hypothetical prote
695	7	0.5	211	2	T18799	hypothetical prote	768	7	0.5	255	2	T05958	cold acclimation p
696	7	0.5	211	2	E85091	hypothetical prote	769	7	0.5	257	2	G84712	hypothetical prote
697	7	0.5	212	2	T48580	hypothetical prote	770	7	0.5	258	1	WMV235	3K major secreted
698	7	0.5	213	2	S35522	heterochromatin pr	771	7	0.5	258	2	S71561	drought-induced pr
699	7	0.5	214	2	F84853	hypothetical prote	772	7	0.5	258	2	T05194	hypothetical prote
700	7	0.5	216	2	T29039	hypothetical prote	773	7	0.5	259	2	A84476	hypothetical prote
701	7	0.5	216	2	B96794	unknown protein Fl	774	7	0.5	259	2	S55884	CCNH finger protei
702	7	0.5	216	2	S50766	dehydrin-related p	775	7	0.5	259	2	T47627	hypothetical prote
703	7	0.5	216	2	S05575	sporozite antigen	776	7	0.5	259	2	AB1080	conserved hypotet
704	7	0.5	217	2	T06455	Myb26 protein - ga	777	7	0.5	259	2	S64423	probable membrane
705	7	0.5	218	2	B86750	hypothetical prote	778	7	0.5	260	2	B64563	hypothetical prote
706	7	0.5	218	2	JC7220	nuclear protein SR	779	7	0.5	260	2	D86266	hypothetical prote
707	7	0.5	220	2	S12849	coat protein TP4 -	780	7	0.5	260	2	B96686	myb-related protei
708	7	0.5	221	2	T04271	probable chlorodox	781	7	0.5	261	2	T06650	thiol-disulfide in
709	7	0.5	222	2	G86168	hypothetical prote	782	7	0.5	261	2	E85439	hypothetical prote
710	7	0.5	224	2	S78129	ribosomal protein	783	7	0.5	261	2	T09075	hypothetical prote
711	7	0.5	224	2	H72346	basal-body rod mod	784	7	0.5	262	2	T40941	hypothetical serin
712	7	0.5	225	2	S05546	dehydrin 18 - harl	785	7	0.5	262	2	T02203	finger protein Dof
713	7	0.5	225	2	B84653	TINY-like AP2 doma	786	7	0.5	262	2	T14807	hypothetical prote
714	7	0.5	225	2	S59852	DNA-binding protei	787	7	0.5	262	2	S43953	cold acclimation p
715	7	0.5	228	2	S19132	rab25 protein - ri	788	7	0.5	263	2	H84918	glutathione S-tran
716	7	0.5	229	2	JC0928	coat protein - tom	789	7	0.5	263	2	S05433	corticosterone / 11
717	7	0.5	229	2	F84685	hypothetical prote	790	7	0.5	263	2	JC5271	oxygen-evolving co
718	7	0.5	229	2	T04764	hypothetical prote	791	7	0.5	263	2	H84547	hypothetical prote
719	7	0.5	229	2	T52364	hypothetical prote	792	7	0.5	264	2	T09377	hypothetical prote
720	7	0.5	229	2	UC7219	nuclear protein SR	793	7	0.5	264	2	T10637	hypothetical prote
721	7	0.5	230	2	D86352	protein T26F17.14	794	7	0.5	265	2	S48360	hypothetical prote
722	7	0.5	230	2	S71747	DAG protein precir	795	7	0.5	265	2	D96667	hypothetical prote
723	7	0.5	230	2	T39598	hypothetical serin	796	7	0.5	265	2	F85014	hypothetical prote
724	7	0.5	230	2	T26896	hypothetical prote	797	7	0.5	265	2	T29973	hypothetical prote
725	7	0.5	231	2	S17367	hypothetical prote	798	7	0.5	266	2	T05123	hypothetical prote
726	7	0.5	231	2	A10091	rab15B protein - w	799	7	0.5	268	2	T06802	cold acclimation p
727	7	0.5	233	2	T00966	probable RNA polym	800	7	0.5	269	2	C84707	hypothetical prote
728	7	0.5	233	2	H83753	hypothetical prote	801	7	0.5	270	2	F86177	protein F19P19.1 (
729	7	0.5	233	2	H97094	hypothetical prote	802	7	0.5	270	2	T22151	hypothetical prote
730	7	0.5	234	2	T49448	hypothetical prote	803	7	0.5	271	2	T13013	hypothetical prote
731	7	0.5	235	2	S48924	hypothetical prote	804	7	0.5	273	2	B64446	formylmethanofuran
732	7	0.5	235	2	D84602	hypothetical prote	805	7	0.5	273	2	F71645	hypothetical prote
733	7	0.5	235	2	T30656	hypothetical prote	806	7	0.5	274	2	S26953	photoystem II 22K
734	7	0.5	238	2	S77699	inner cell wall ma	807	7	0.5	274	2	T07393	myb-related transc
735	7	0.5	238	2	S66358	DNA-binding protei	808	7	0.5	275	2	T05595	hypothetical prote
736	7	0.5	238	2	T52505	hypothetical prote	809	7	0.5	276	2	A31864	vitellogenin III -
737	7	0.5	238	2	T32889	hypothetical prote	810	7	0.5	276	2	H97861	hypothetical prote
738	7	0.5	238	2	A97336	Na+ ABC transporte	811	7	0.5	276	2	F95259	conserved hypotet
739	7	0.5	240	2	D84645	hypothetical prote	812	7	0.5	276	2	A99525	conserved hypotet
740	7	0.5	242	2	D86343	hypothetical prote	813	7	0.5	277	2	T52513	hypothetical prote
741	7	0.5	243	2	T51989	protein T22I1.13	814	7	0.5	277	2	T19378	hypothetical prote
742	7	0.5	243	2	D84792	ethylene responsiv	815	7	0.5	278	2	T51641	myb-related transc
743	7	0.5	243	2	D84629	probable protein t	816	7	0.5	279	2	T01924	hypothetical prote
744	7	0.5	244	2	A44259	hypothetical prote	817	7	0.5	279	2	A86312	FilA6.5 protein -
745	7	0.5	244	2	A96806	B2XR protein - vac	818	7	0.5	279	2	H89827	mevalonate kinase
746	7	0.5	244	2	T51481	hypothetical prote	819	7	0.5	280	1	EDBE37	30K immediate-earl
747	7	0.5	244	2	B86197	hypothetical prote	820	7	0.5	281	2	F86450	hypothetical prote
748	7	0.5	244	2	E84885	hypothetical prote	821	7	0.5	281	2	T01612	hypothetical prote
749	7	0.5	244	2	S70176	year protein - Yar	822	7	0.5	282	2	C96687	hypothetical prote
750	7	0.5	244	2	T04700	hypothetical prote	823	7	0.5	282	2	S61663	probable membrane
751	7	0.5	244	2	D96937	SAM-dependent meth	824	7	0.5	282	2	T21222	hypothetical prote
752	7	0.5	245	2	AB0300	quorum-sensing tra	825	7	0.5	283	2	F86450	hypothetical prote
753	7	0.5	245	2	B86407	hypothetical prote	826	7	0.5	284	1	KART	alpha-casein precu
754	7	0.5	246	2	S58497	early auxin-induci	827	7	0.5	284	2	A35419	neutrophil protein
755	7	0.5	247	2	JB0307	membrane protein -	828	7	0.5	285	2	T06637	hypothetical prote
756	7	0.5	247	2	T47883	secretory protein -	829	7	0.5	285	2	G70100	hypothetical prote
757	7	0.5	249	2	E82917	metionine amnlope	830	7	0.5	285	2	T18689	hypothetical prote
758	7	0.5	250	2	C71611	probable secreted	831	7	0.5	286	2	H90018	hypothetical prote
759	7	0.5	250	2	T10663	hypothetical prote	832	7	0.5	286	2	C84857	hypothetical prote

833	7	0.5	286	2	T48572	hypotheical prote	906	7	0.5	335	2	B84024	phosphate ABC tran
834	7	0.5	286	2	T52373	homeobox protein T	907	7	0.5	336	1	S28412	carbonate dehydrat
835	7	0.5	288	2	B40722	homeotic protein 1	908	7	0.5	338	2	D72327	heat shock operon
836	7	0.5	289	2	T03395	probable lipase -	909	7	0.5	339	2	T04900	hypotheical prote
837	7	0.5	289	2	T52354	hypotheical prote	910	7	0.5	339	2	D90106	hypotheical prote
838	7	0.5	290	2	T21868	hypotheical prote	911	7	0.5	339	2	H86210	hypotheical prote
839	7	0.5	291	2	T08189	transcription fact	912	7	0.5	342	2	T28178	hypotheical prote
840	7	0.5	292	2	T51171	transcription fact	913	7	0.5	339	2	AF3357	anthranilate phosph
841	7	0.5	292	2	T48327	hypotheical prote	914	7	0.5	343	2	G63654	cell wall lytic ac
842	7	0.5	292	2	S41012	hypotheical prote	915	7	0.5	343	2	T01374	hypotheical prote
843	7	0.5	294	2	T05381	hypotheical prote	916	7	0.5	343	2	T13995	gag protein - fru1
844	7	0.5	294	2	S38983	kinesin-related pr	917	7	0.5	344	2	T05064	hypotheical prote
845	7	0.5	294	2	A96707	transcription fact	918	7	0.5	344	2	T40167	hypotheical prote
846	7	0.5	295	2	T08408	hypotheical prote	919	7	0.5	345	2	T06098	hypotheical prote
847	7	0.5	295	2	B86371	hypotheical prote	920	7	0.5	345	2	T07777	probable homebox
848	7	0.5	295	2	T00399	probable AP2 domai	921	7	0.5	347	2	T07108	glucan endo-1,3-be
849	7	0.5	295	2	T23989	hypotheical prote	922	7	0.5	347	2	H96504	hypotheical prote
850	7	0.5	297	2	B84731	hypotheical prote	923	7	0.5	347	2	H84608	probable RNA-bind
851	7	0.5	298	2	A86840	hypotheical prote	924	7	0.5	348	2	T28310	hypotheical prote
852	7	0.5	299	2	F84810	hypotheical prote	925	7	0.5	349	2	T41394	hypotheical serin
853	7	0.5	300	2	C84853	hypotheical prote	926	7	0.5	349	2	T29931	hypotheical prote
854	7	0.5	302	2	T01942	hypotheical prote	927	7	0.5	350	2	T07061	L-lactate dehydrog
855	7	0.5	302	2	T01540	hypotheical prote	928	7	0.5	350	2	T06689	heat shock protein
856	7	0.5	302	2	C86480	33.2K hypotheical	929	7	0.5	352	2	S22464	stricotosidine synt
857	7	0.5	302	2	H86391	hypotheical prote	930	7	0.5	353	2	AB2396	hypotheical prote
858	7	0.5	303	2	T15694	hypotheical prote	931	7	0.5	354	2	G71403	hypotheical prote
859	7	0.5	303	2	B84744	hypotheical prote	932	7	0.5	354	2	T49806	hypotheical prote
860	7	0.5	304	2	T04681	hypotheical prote	933	7	0.5	355	2	T04317	homeobox protein L
861	7	0.5	304	2	T09357	hypotheical prote	934	7	0.5	355	2	T34883	hypotheical prote
862	7	0.5	304	2	T16535	hypotheical prote	935	7	0.5	355	2	T24010	hypotheical prote
863	7	0.5	305	2	T47844	hypotheical prote	936	7	0.5	357	2	A54512	serine-repeat anti
864	7	0.5	305	2	JC4525	nucleic acid-bind	937	7	0.5	358	2	C86291	hypotheical prote
865	7	0.5	306	2	S33538	embryogenic cell p	938	7	0.5	360	2	T45649	hypotheical prote
866	7	0.5	306	2	T47832	hypotheical prote	939	7	0.5	362	2	T51464	gene NK6.1 protei
867	7	0.5	308	2	C84768	hypotheical prote	940	7	0.5	363	2	T49209	leucanthocyandidin
868	7	0.5	310	2	JC4343	uridine phosphoryl	941	7	0.5	363	2	S60684	adenylate cyclase
869	7	0.5	310	2	D86423	hypotheical prote	942	7	0.5	363	2	A96573	protein Fl2M16.15
870	7	0.5	311	2	T23846	transcription prote	943	7	0.5	364	2	A84890	probable flavonol
871	7	0.5	313	2	S55899	transcription elon	944	7	0.5	364	2	T48188	gene NK6.1 protei
872	7	0.5	313	2	S59448	hypotheical prote	945	7	0.5	364	2	A95730	hypotheical prote
873	7	0.5	313	2	S01303	homeotic protein a	946	7	0.5	364	2	H86384	40.1K hypotheical
874	7	0.5	313	2	T05256	hypotheical prote	947	7	0.5	365	2	C72308	conserved hypothe
875	7	0.5	314	2	T08933	hypotheical prote	948	7	0.5	365	2	F85018	hypotheical prote
876	7	0.5	314	2	A41544	developmental prot	949	7	0.5	366	2	T10452	farneyltransferas
877	7	0.5	314	2	A36195	developmental prot	950	7	0.5	366	2	T00439	hypotheical prote
878	7	0.5	314	2	T48514	developmental prote	951	7	0.5	366	2	A86392	hypotheical prote
879	7	0.5	315	2	JC7572	somite Mat1 protei	952	7	0.5	367	2	E64399	hypotheical prote
880	7	0.5	316	2	E96770	hypotheical prote	953	7	0.5	367	2	S28604	ATP-dependent RNA
881	7	0.5	317	2	T39869	probable lysophosp	954	7	0.5	368	2	F69531	Sl2p protein - Ar
882	7	0.5	318	2	T32340	hypotheical prote	955	7	0.5	368	2	A54430	hypoxic function t
883	7	0.5	318	2	T20063	hypotheical prote	956	7	0.5	368	2	T51200	melanoma antigen M
884	7	0.5	319	2	T43040	hypotheical prote	957	7	0.5	369	2	T38659	heat shock transcr
885	7	0.5	319	2	T23666	hypotheical prote	958	7	0.5	370	2	S59539	knoc protein 1 - g
886	7	0.5	319	2	B86433	hypotheical prote	959	7	0.5	371	2	T06382	hypotheical prote
887	7	0.5	320	2	D86259	protein T12C24.6 l	960	7	0.5	372	2	E85170	para-hydroxybenzo
888	7	0.5	321	2	A84792	hypotheical prote	961	7	0.5	372	2	S20056	probable ornithine
889	7	0.5	321	2	S55640	hypotheical prote	962	7	0.5	375	2	T06436	hypotheical prote
890	7	0.5	323	2	T51751	homeotic protein o	963	7	0.5	375	2	E96567	hypotheical prote
891	7	0.5	323	2	G96544	hypotheical prote	964	7	0.5	376	2	C85155	RING-H2 finger pro
892	7	0.5	324	2	F86192	hypotheical prote	965	7	0.5	376	2	S45763	hypotheical prote
893	7	0.5	324	2	B69521	hypotheical prote	966	7	0.5	377	1	W2WL13	E2 protein - huma
894	7	0.5	324	2	C86426	hypotheical prote	967	7	0.5	377	1	MFNZP2	matrix protein - p
895	7	0.5	325	2	G96718	unknown protein, 5	968	7	0.5	377	2	C64404	hypotheical prote
896	7	0.5	325	2	S46760	hypotheical prote	969	7	0.5	379	2	S42543	hypotheical prote
897	7	0.5	326	2	C96735	unknown protein, 5	970	7	0.5	380	2	F89811	cystathionine gamm
898	7	0.5	327	2	B84781	unknown protein, 5	971	7	0.5	381	2	T48623	hypotheical prote
899	7	0.5	328	1	S10200	carbonate dehydrat	972	7	0.5	381	2	H86856	hypotheical prote
900	7	0.5	328	2	G02469	homeotic protein D	973	7	0.5	381	2	C96657	hypotheical prote
901	7	0.5	329	2	D64245	peripheral membran	974	7	0.5	381	2	T09640	protein phosphatas
902	7	0.5	329	2	T13016	hypotheical prote	975	7	0.5	382	2	F75179	DNA topoisomerase
903	7	0.5	332	2	C48835	kinesin-like prote	976	7	0.5	382	2	D84766	hypotheical prote
904	7	0.5	332	2	T48083	hypotheical prote	977	7	0.5	383	2	T38443	hypotheical prote
905	7	0.5	333	1	JW0097	bicoid-related hom	978	7	0.5	383	2	T38442	hypotheical prote

```
979 7 0.5 383 2 T06753 zinc finger protei
980 7 0.5 383 2 T46707 proteophosphoglyca
981 7 0.5 383 2 S67462 hypothetical prote
982 7 0.5 383 2 S61195 hypothetical prote
983 7 0.5 383 2 A84552 probable thioredox
984 7 0.5 383 2 A82295 hypothetical prote
985 7 0.5 384 2 G96947 cystathionine gamm
986 7 0.5 386 2 S58755 ribosomal protein
987 7 0.5 386 2 F90112 DEAD box protein (
988 7 0.5 386 2 T48158 hypothetical prote
989 7 0.5 386 2 A82284 conserved hypotet
990 7 0.5 387 2 C96720 hypothetical prote
991 7 0.5 389 2 T04816 myb-related protei
992 7 0.5 391 2 S18666 KIN17 protein - mo
993 7 0.5 392 2 S11998 finger protein odd
994 7 0.5 392 2 T43490 hypothetical prote
995 7 0.5 393 2 A45017 transcription fact
996 7 0.5 393 2 T00647 glycosyl transfera
997 7 0.5 393 2 B84425 probable protein t
998 7 0.5 393 2 T48907 Stt2p protein [imp
999 7 0.5 394 2 C84905 probable extensin
1000 7 0.5 395 2 T00516 hypothetical prote
```

ALIGNMENTS

RESULT 1

S14577 asparagine-rich protein (clone 14C1) - malaria parasite (Plasmodium falciparum)

C:Species: Plasmodium falciparum

C>Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 09-Jun-2000

C:Accession: S14577 #sequence_revision 20-Feb-1995 #text_change 09-Jun-2000

R:Schreiber, L.; Deutsche, U.; Storck, T.; Mueller-Hill, D.

A:Submitted to the EMBL Data Library, December 1989

A:Reference number: S14469

A:Accession: S14577

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-391 <SCH>

A:Cross-references: EMBL:X17483; NID:G9842; PID:G9843

C:Superfamily: Saccharomyces cerevisiae ribosomal protein var1

Query Match 1.3% Score 17; DB 2; Length 391;
Best Local Similarity 100.0%; Pred. No. 8.2e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 741 TNNNNNNNNNNNNNNNNNN 757
DB 162 TNNNNNNNNNNNNNNNN 178

RESULT 2

S14508 asparagine-rich protein (clone 52C11) - Plasmodium falciparum (fragment)

C:Species: Plasmodium falciparum

C>Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 09-Sep-1997

C:Accession: S14508

R:Schreiber, L.; Deutsche, U.; Storck, T.; Mueller-Hill, D.

A:Submitted to the EMBL Data Library, December 1989

A:Reference number: S14469

A:Accession: S14508

A:Molecule type: mRNA

A:Residues: 1-419 <SCH>

A:Cross-references: EMBL:X17489; NID:G9854; PID:G9855

Query Match 1.3% Score 17; DB 2; Length 419;
Best Local Similarity 100.0%; Pred. No. 8.7e-08;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 741 TNNNNNNNNNNNNNNNNNN 757
DB 25 TNNNNNNNNNNNNNNNNNN 41

RESULT 3

S50452 hypothetical protein YEL007w - yeast (Saccharomyces cerevisiae)

C:Species: Saccharomyces cerevisiae

C>Date: 28-May-1993 #sequence_revision 24-Feb-1995 #text_change 19-Apr-2002

C:Accession: S50452

R:Dieterich, F.S. EMBL Data Library, December 1994

A:Submitted to the EMBL Data Library, December 1994

A:Description: Saccharomyces cerevisiae chromosome V cosmid 9871, 8199, 9867, 9495 and

A:Reference number: S50428

A:Accession: S50452

A:Molecule type: DNA

A:Residues: 1-666 <DIE>

A:Cross-references: EMBL:U18530; NID:G602367; PID:G602374; GSPDB:GN00005; MIPS:YEL007w

C:Genetics:

A:Gene: SCD:TOS9; MIPS:YEL007w

A:Cross-references: SGD:S0000733

A:Map position: 5L

Query Match 1.3% Score 17; DB 2; Length 666;
Best Local Similarity 100.0%; Pred. No. 1.3e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 742 NNNNNNNNNNNNNNNNNI 758
DB 351 NNNNNNNNNNNNNNNNNI 367

RESULT 4

S23467 probable long-chain-fatty-acid-CoA ligase (BC 6.2.1.3) - malaria parasite (Plasmodium f

C:Species: Plasmodium falciparum

C>Date: 22-Nov-1993 #sequence_revision 01-Dec-1995 #text_change 03-Jun-2002

C:Accession: S23467

R:Zhao, Y.; Kappe, B.; Yang, J.; Franklin, R.M.

Bur. J. Biochem. 207, 305-313, 1992

A:Title: Molecular cloning, stage-specific expression and cellular distribution of a pu

A:Reference number: S23466; MUID:92331669; PMID:1378403

A:Accession: S23467

A:Status: preliminary; translation not shown

A:Molecule type: mRNA

A:Residues: 1-749 <ZHA>

A:Cross-references: EMBL:X63648; NID:G9937; PID:G9939

C:Superfamily: human long-chain-fatty-acid-CoA ligase; acetate-CoA ligase homology

C:Keywords: acid-thiol ligase; coenzyme A

F:103-732/Domain: acetate-CoA ligase homology <ACL>

Query Match 1.3% Score 17; DB 2; Length 749;
Best Local Similarity 100.0%; Pred. No. 1.4e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 742 NNNNNNNNNNNNNNNNNI 758
DB 271 NNNNNNNNNNNNNNNNNI 287

RESULT 5

S45825 cell division control protein CDC27 - yeast (Saccharomyces cerevisiae)

N:Alternate names: protein YBL0718; protein YBL084C

C:Species: Saccharomyces cerevisiae

C>Date: 26-Aug-1994 #sequence_revision 09-Sep-1994 #text_change 11-Jan-2000

C:Accession: S45825; S45422; S28742; S59219

R:Domdey, H.; Gassenhuber, H.; Obermaier, B.; Piravandi, E.

A:Submitted to the Protein Sequence Database, August 1994

A:Reference number: S45816

A:Accession: S45825

A:Molecule type: DNA

A:Residues: 1-758 <DOM>

A:Cross-references: EMBL:Z35845; NID:G536135; PIDN:CAA84905.1; PID:G536136; MIPS:YBL084

A:Experimental source: strain S288C

R;Obermaier, B.; Gassenhuber, J.; Piravandi, E.; Domdey, H.
submitted to the EMBL Data Library, May 1994
A;Description: Sequence analysis of a 78,6 kb segment of the left end of Saccaromyces ce
A;Reference number: S45387
A;Accession: S45422
A;Molecule type: DNA
A;Residues: 141-758 <OEB>
A;Cross-references: EMBL:X79489; NID:9496661; PIDN:CAA56022.1; PID:9496695
A;Experimental source: strain S288C
R;Sikorski, R.S.; Michaud, W.A.; Mooton, J.C.; Boguski, M.S.; Connolly, C.; Hieter, P.
Cold Spring Harb. Symp. Quant. Biol. 56, 663-673, 1991
A;Title: TPR proteins as essential components of the yeast cell cycle.
A;Reference number: S28742; MUID:92306611; PMID:1819514
A;Accession: S28742
A;Status: not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 607-619 <SIK>
R;Obermaier, B.; Gassenhuber, J.; Piravandi, E.; Domdey, H.
Yeast 11, 1103-1112, 1995
A;Title: Sequence analysis of a 78.6 kb segment of the left end of Saccharomyces cerevis
A;Reference number: S59184; MUID:96076635; PMID:7502586
A;Accession: S59219
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 442-691 <OBW>
A;Cross-references: EMBL:X79489
C;Genetics:
A;Gene: SGD:CDC27; SNB1
A;Cross-references: SGD:S0000180; MIPS:YBL084C
A;Map position: 2L
C;Superfamily: unassigned tetratricopeptide repeat proteins; tetratricopeptide repeat hc
C;Keywords: nucleus
F;472-505/Domain: tetratricopeptide repeat homology <TT1>
F;506-539/Domain: tetratricopeptide repeat homology <TT2>
F;540-573/Domain: tetratricopeptide repeat homology <TT3>
F;574-607/Domain: tetratricopeptide repeat homology <TT4>
F;608-641/Domain: tetratricopeptide repeat homology <TT5>
F;642-675/Domain: tetratricopeptide repeat homology <TT6>
F;676-709/Domain: tetratricopeptide repeat homology <TT7>
F;710-743/Domain: tetratricopeptide repeat homology <TT8>

Query Match 1.3%; Score 17; DB 2; Length 758;
Best Local Similarity 100.0%; Pred. No. 1.5e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
Db 373 NNNNNNNNNNNNNNNNNI 389

RESULT 6
rnpB protein, cytosolic - slime mold (Dictyostelium discoideum)
N;Alternate names: RING finger protein
C;Species: Dictyostelium discoideum
C;Date: 04-Dec-1997 #sequence_revision 12-Dec-1997 #text_change 24-Apr-1998
C;Accession: S68824
R;Kawata, T.; Steel, J.B.; Williams, J.G.
FEBS Lett. 386, 103-109, 1996
A;Title: RINGB: a Dictyostelium RING finger protein that is specifically located in matur
A;Reference number: S68824; MUID:96228044; PMID:8647262
A;Accession: S68824
A;Molecule type: mRNA
A;Residues: 1943 <KAW>
A;Experimental source: maturing cells
C;Genetics:
A;Gene: rnpB
C;Superfamily: RING finger homology
C;Keywords: zinc
F;893-937/Domain: RING finger homology <RNG>

Query Match 1.3%; Score 17; DB 2; Length 943;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNNN 757
Db 433 TNNNNNNNNNNNNNNNNN 449

RESULT 7
T18275
1-phosphatidylinositol 3-kinase (BC 2.7.1.137) 4 - slime mold (Dictyostelium discoideum
C;Species: Dictyostelium discoideum
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T18275
R;Zhou, K.; Takegawa, K.; Emr, S.D.; Firtel, R.A.
Mol. Cell. Biol. 15, 5645-5656, 1995
A;Title: A phosphatidylinositol (PI) kinase gene family in Dictyostelium discoideum. Bi
A;Reference number: Z06411
A;Accession: T18275
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-1093 <ZHO>
A;Cross-references: EMBL:U23479; NID:g733527; PID:g733528; PIDN:AAA85725.1.
C;Genetics:
A;Note: PIK4
C;Keywords: phosphotransferase

Query Match 1.3%; Score 17; DB 2; Length 1093;
Best Local Similarity 100.0%; Pred. No. 2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
Db 282 NNNNNNNNNNNNNNNNNI 298

RESULT 8
UV-damaged DNA binding protein repp - slime mold (Dictyostelium discoideum)
C;Species: Dictyostelium discoideum
C;Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 01-Dec-2000
C;Accession: S71092; S21443
R;Alexander, H.; Lee, S.K.; Yu, S.L.; Alexander, S.
Nucleic Acids Res. 24, 2295-2301, 1996
A;Title: repp-The Dictyostelium homolog of the human xeroderma pigmentosum group E gene
A;Reference number: S71092; MUID:96279729; PMID:8710499
A;Accession: S71092
A;Status: preliminary; nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-1139 <ALE>
A;Cross-references: EMBL:U50042; NID:g1399511; PIDN:AA47162.1; PID:g1399512
R;Sydow, L.; Alexander, H.; Alexander, S.
submitted to the EMBL Data Library, April 1992
A;Reference number: S21443
A;Accession: S21443
A;Molecule type: mRNA
A;Residues: 860-1139 <SYD>
A;Cross-references: EMBL:X65937
C;Genetics:
A;Gene: repp
A;Introns: 654/2
C;Superfamily: UV-damaged DNA-binding protein

Query Match 1.3%; Score 17; DB 2; Length 1139;
Best Local Similarity 100.0%; Pred. No. 2.1e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
Db 115 NNNNNNNNNNNNNNNNNI 131

RESULT 9
S57698

regulatory protein PHO81 - yeast (*Saccharomyces cerevisiae*)
 N:Alternate names: protein 1178; protein G8567; protein YGR233C
 C:Species: *Saccharomyces cerevisiae*
 C>Date: 19-Oct-1995 #sequence_revision 03-Nov-1995 #text_change 23-Mar-2001
 C:Accession: S57698; S20136; S41074; J01032; S64557; S63914
 R:van der Aart, O.J.M.; Kleine, K.; Steensma, H.Y.
 A:Submitted to the EMBL Data Library, June 1995
 A:Description: Sequence analysis of the 43 KB CML-YLM9-PET54-SMT1-PHO81-YHB4-PFK1 region
 A:Reference number: S57680
 A:Accession: S57658
 A:Molecule type: DNA
 A:Residues: 1-1178 <VAN>
 A:Cross-references: EMBL:X87941; NID:G886908; PID:G886927
 A:Experimental source: strain S288C
 R:Coche, T.; Prozzi, D.; Legrain, M.; Hilger, F.; Vandenhaute, J.
 Nucleic Acids Res. 18, 2176, 1990
 A:Title: Nucleotide sequence of the PHO81 gene involved in the regulation of the repress
 A:Reference number: S20136; MUID:90245670; PMID:2186378
 A:Accession: S20136
 A:Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-918,920-1178 <COC>
 A:Cross-references: EMBL:X52482; NID:G4139; PID:CAA36726.1; PID:G4140
 A:Experimental source: strain GRF 88
 R:Creasy, C.L.; Madden, S.L.; Bergman, L.W.
 Nucleic Acids Res. 21, 1975-1982, 1993
 A:Title: Molecular analysis of the PHO81 gene of *Saccharomyces cerevisiae*.
 A:Reference number: S41074; MUID:93261834; PMID:8493108
 A:Accession: S41074
 A:Status: not compared with conceptual translation
 A:Molecule type: DNA
 A:Residues: 1-10 <CRE>
 A:Cross-references: GB:S61041; NID:G385415; PID:NAD13922.1; PID:G4261622
 R:Wu, J.S.; Ao, S.Z.
 Acta Biochim. Biophys. Sin. 26, 283-287, 1994
 A:Title: Conformation prediction and function analysis of yeast PHO81 protein.
 A:Reference number: J01032
 A:Accession: J01032
 A:Molecule type: DNA
 A:Residues: 1-39,41-78,80-119,121-159,161-199,201-230,232-279,281-282, 'U',284-319,321-35
 79,881-892, 'M',894-919,922-960,962-1000,1002-1040,1042-1080,1082-1103, 'U',1105-1120,1122
 R:van der Aart, O.J.M.; Kleine, K.; Steensma, H.Y.
 Yeast 12, 385-390, 1996
 A:Title: Sequence analysis of the 43 kb CML-YLM9-PET54-DIE2-SMT1-PHO81-YHB4-PFK1 region
 A:Reference number: S63914; MUID:96267763; PMID:8701610
 A:Accession: S63914
 A:Status: nucleic acid sequence not shown; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-1178 <VAF>
 A:Cross-references: EMBL:X87941; NID:G886908; PID:CAA61183.1; PID:G886927
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1995
 C:Genetics:
 A:Gene: SGD:PHO81
 A:Cross-references: SGD:S0003465; MIPS:YGR233C
 A:Map position: 7R
 C:Superfamily: ankryrin, ankryrin repeat homology
 C:Keywords: transmembrane protein
 F:330-346/Domain: transmembrane #status predicted <TM1>
 F:904-920/Domain: transmembrane #status predicted <TM2>

Query Match 1.3%; Score 17; DB 2; Length 1178;
 Best local Similarity 100.0%; Pred. No. 2.1e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNNI 758

Db 233 NNNNNNNNNNNNNNNNNI 249

RESULT 10
 T18287
 protein-tyrosine kinase (EC 2.7.1.112) - slime mold (*Dictyostelium discoideum*)
 C:Species: *Dictyostelium discoideum*
 C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 04-Feb-2000
 C:Accession: T18287
 R:Adler, K.
 Submitted to the EMBL Data Library, July 1996
 A:Reference number: Z18856
 A:Accession: T18287
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-1338 <ADL>
 A:Cross-references: EMBL:U64830; NID:G1468982; PID:G1468983; PIDN:AAB04999.1
 C:Genetics:
 A:Introns: 1181/3
 C:Keywords: ATP; phosphotransferase; tyrosine-specific protein kinase

Query Match 1.3%; Score 17; DB 2; Length 1338;
 Best local Similarity 100.0%; Pred. No. 2.4e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNNI 758

Db 5 NNNNNNNNNNNNNNNNNI 21

RESULT 11
 T14577
 protein kinase YAKA (EC 2.7.1.-) - slime mold (*Dictyostelium discoideum*)
 C:Species: *Dictyostelium discoideum*
 C>Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
 C:Accession: T14577
 R:Kuspa, A.; Lu, S.; Souza, G.M.
 Submitted to the EMBL Data Library, January 1998
 A:Description: YAKA, a protein kinase required for the growth to development transition
 A:Reference number: Z18146
 A:Accession: T14577
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-1457 <KUS>
 A:Cross-references: EMBL:AF045453; NID:G2854116; PID:G2854117; PIDN:AAC02554.1
 C:Genetics:
 A:Gene: YAKA
 C:Keywords: ATP; phosphoprotein; phosphotransferase; serine/threonine-specific protein

Query Match 1.3%; Score 17; DB 2; Length 1457;
 Best local Similarity 100.0%; Pred. No. 2.5e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 741 TNNNNNNNNNNNNNNNNN 757

Db 44 TNNNNNNNNNNNNNNNNN 60

RESULT 12
 S71628
 sensory transduction histidine kinase dokA - slime mold (*Dictyostelium discoideum*)
 C:Species: *Dictyostelium discoideum*
 C>Date: 27-Nov-1997 #sequence_revision 12-Dec-1997 #text_change 11-Jan-2002
 C:Accession: S71628; S78068
 R:Schuster, S.C.; Noegel, A.A.; Oehme, F.; Gerisch, G.; Simon, M.I.
 EMBO J. 15, 3880-3889, 1996
 A:Title: The hybrid histidine kinase DOKA is part of the osmotic response system of *Dictyostelium*.
 A:Reference number: S71628; MUID:96324396; PMID:8670893
 A:Accession: S71628
 A:Status: nucleic acid sequence not shown
 A:Molecule type: DNA
 A:Residues: 1-1670 <SCH>

A/Cross-references: EMBL:X96869
A/Experimental source: strain AX2; substrain 214
A/Schuster, S.C.; Noegel, A.A.; Oehme, F.; Gerisch, G.; Simon, M.I.
submitted to the EMBL Data Library, March 1996
A/Description: The hybrid histidine kinase Doka is part of the osmotic response system C
A/Reference number: S78068
A/Accession: S78068
A/Molecule type: DNA
A/Residues: 1-149, 'E', 151-219, 'TRVLKLIQSTNNMIYWY', 238-1671 <SCW>
A/Cross-references: EMBL:X96869; NID:g1237201; PIDN:CAA65612.1; PID:g1237202
C/Genetics:
A/Gene: doka
C/Function:
A/Description: modulates cell response to changes in osmolarity; involved in spore forma
C/Superfamily: response regulator homology
C/Keywords: phosphoprotein; signal transduction
F/1520-1629/Domain: response regulator homology #status predicted
F/1568/Binding site: phosphate (Asp) (covalent) #status predicted

Query Match 1.3%; Score 17; DB 2; Length 1671;
Best Local Similarity 100.0%; Pred. No. 2.9e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNN 757
DB 374 TNNNNNNNNNNNNNNNN 390

RESULT 13
T08875
histidine kinase homolog DHKB - slime mold (Dictyostelium discoideum)
N/Alternate names: hybrid histidine kinase DHKB
C/Species: Dictyostelium discoideum
C/Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 11-May-2000
C/Accession: T08875
R/Zinda, M.J.; Singleton, C.K.
Dev. Biol. 196, 171-183, 1998
A/Title: The hybrid histidine kinase dhkb regulates spore germination in Dictyostelium d
A/Reference number: Z16506; MUID:98248997; PMID:9576830
A/Accession: T08875
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-1969 <SIN>
A/Cross-references: EMBL:AF024654; NID:g2460282; PID:g2460283
A/Experimental source: strain KAX3
C/Genetics:
A/Gene: dhkb
A/Intons: 790/3
C/Superfamily: response regulator homology
C/Keywords: protein kinase; transmembrane protein
F/1841-1964/Domain: response regulator homology <RRH>

Query Match 1.3%; Score 17; DB 2; Length 1693;
Best Local Similarity 100.0%; Pred. No. 3.3e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 758
DB 37 NNNNNNNNNNNNNNNNN 53

RESULT 14
T18440
hypothetical protein C0425w - malaria parasite (Plasmodium falciparum)
C/Species: Plasmodium falciparum
C/Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000
C/Accession: T18440
R/Lawson, D.; Bowman, S.; Barrell, B.
submitted to the EMBL Data Library, August 1997
A/Reference number: Z18935
A/Accession: T18440
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA

A/Residues: 1-4550 <LAN>
A/Cross-references: EMBL:Z98547; NID:e1325376; PID:e1325396; PIDN:CA811121.1
C/Genetics:
A/Map position: 3
A/Note: C0425w

Query Match 1.3%; Score 17; DB 2; Length 4550;
Best Local Similarity 100.0%; Pred. No. 6.8e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 758
DB 1517 NNNNNNNNNNNNNNNNN 1533

RESULT 15
T02389
hypothetical protein At2g44340 [imported] - Arabidopsis thaliana
N/Alternate names: hypothetical protein F411.15
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 05-Mar-1999 #sequence_revision 05-Mar-1999 #text_change 16-Feb-2001
C/Accession: T02389; C84877
R/Rounsley, S.D.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.; Sykes, S.M.; Kau
submitted to the EMBL Data Library, May 1998
A/Description: Arabidopsis thaliana chromosome II BAC F411 genomic sequence.
A/Reference number: Z14667
A/Accession: T02389
A/Status: translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-188 <ROU>
A/Cross-references: EMBL:AC004521; NID:g3128166; PID:g3128179
A/Experimental source: cultivar Columbia
R/Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;
M.; Ko, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L
euss, D.; Nierman, W.C.; White, O.; Eisen, O.A.; Salzberg, S.L.; Fraser, C.M.; Venter,
Nature 402, 761-768, 1999
A/Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.
A/Reference number: A84420; MUID:20083487; PMID:10617197
A/Accession: C84877
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-188 <STO>
A/Cross-references: GB:AE002093; NID:g3128179; PIDN:AAC16083.1; GSPDB:GN00139
C/Genetics:
A/Gene: F411.15; At2g44340
A/Map position: 2
C/Superfamily: Arabidopsis thaliana hypothetical protein T10K17.210

Query Match 1.2%; Score 16; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 4e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
DB 161 NNNNNNNNNNNNNNNNN 176

RESULT 16
S05356
hypothetical protein (clone pUK330) - slime mold (Dictyostelium discoideum) (fragment)
C/Species: Dictyostelium discoideum
C/Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 29-Oct-1999
C/Accession: S05356
R/Shaw, D.R.; Richter, H.; Giorda, R.; Ohmachi, T.; Ennis, H.L.
Mol. Gen. Genet. 218, 453-459, 1989
A/Title: Nucleotide sequences of Dictyostelium discoideum developmentally regulated cdn.
A/Reference number: S05355; MUID:90066348; PMID:2511421
A/Accession: S05356
A/Molecule type: mRNA
A/Residues: 1-317 <SHA>
A/Cross-references: EMBL:X16523; NID:g7321; PIDN:CAA34530.1; PID:g7322

Query Match 1.2%; Score 16; DB 2; Length 317;

Best Local Similarity 100.0%; Pred. No. 6.3e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 54 NNNNNNNNNNNNNNNNN 69

RESULT 17

T02046
prolamin box binding factor - maize
C/Species: Zea mays (maize)
C/Date: 26-Feb-1999 #sequence_revision 26-Feb-1999 #text_change 29-Oct-1999
C/Accession: T02046
R/Vicente-Carbajosa, J.; Moose, S.P.; Parsons, R.L.; Schmidt, R.J.
Proc. Natl. Acad. Sci. U.S.A. 94, 7685-7690, 1997
A/Title: A maize zinc-finger protein binds the prolamin box in zein gene promoters and
A/Reference number: 214511; MUID:97352860; PMID:9207153
A/Accession: T02046
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-328 <VIC>
A/Cross-references: EMBL:U02230; NID:G2393774; PIDN:AA870119.1; PID:G2393775
A/Genetics:
A/Genome: PBF

Query Match 1.2%; Score 16; DB 2; Length 328;
Best Local Similarity 100.0%; Pred. No. 6.5e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 310 NNNNNNNNNNNNNNNNN 325

RESULT 18

T52593
squamosa promoter binding protein homolog 9 [imported] - Arabidopsis thaliana
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 24-Oct-2000 #sequence_revision 24-Oct-2000 #text_change 24-Oct-2000
C/Accession: T52593
R/Cardon, G.H.; Hohmann, S.; Nettesheim, K.; Saedler, H.; Huijser, P.
Plant J. 12, 367-377, 1997
A/Title: Functional analysis of the Arabidopsis thaliana SHP-box gene SPL3: a novel gene
A/Reference number: 224029; MUID:9301089; PMID:9301089
A/Accession: T52593
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-373 <CAR>
A/Cross-references: EMBL:AJ011639; PIDN:CAB56591.1
A/Experimental source: cultivar Landsberg erecta; Inflorescence
C/Genetics:
A/Genome: SPL9
A/Map position: 2
C/Keywords: DNA binding; transcription factor

Query Match 1.2%; Score 16; DB 2; Length 373;
Best Local Similarity 100.0%; Pred. No. 7.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 262 NNNNNNNNNNNNNNNNN 277

RESULT 19

T18285
hypochemical protein G2 - slime mold (Dictyostelium discoideum) plasmid
C/Species: Dictyostelium discoideum
C/Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 01-Dec-2000
C/Accession: T18285; S28720
R/Rieben Jr., W.K.; Gonzales, C.M.; Gonzales, S.T.; Pilkington, K.J.; Kiyosawa, H.; Hugh
Genetics 148, 1117-1125, 1998

A/Title: Dictyostelium discoideum nuclear plasmid Ddp5 is a chimera related to the Ddp1
A/Reference number: 214684; MUID:98198836; PMID:9539429

A/Accession: T18285
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-401 <RIE>

A/Cross-references: EMBL:U00796; NID:G2702254; PID:G932876; PIDN:AA18630.1
A/Experimental source: Plasmid Ddp5
R/Gurniak, C.B.; Bang, A.G.; Noegel, A.A.
Curr. Genet. 17, 321-325, 1990

A/Title: Transcript and sequence analysis of a 5.1 kb contiguous fragment of Dictyostel
A/Reference number: S28718; MUID:90234839; PMID:2340592
A/Accession: S28720
A/Molecule type: DNA
A/Residues: 155-401 <GUR>

A/Cross-references: EMBL:X53237; NID:G7280; PIDN:CAA37329.1; PID:G7283
A/Experimental source: Plasmid Ddp1
A/Note: the authors translated the codon TTT for residue 284 as Glu and GGT for residue

C/Genetics:
A/Genome: d-4
A/Genome: plasmid

Query Match 1.2%; Score 16; DB 2; Length 401;
Best Local Similarity 100.0%; Pred. No. 7.7e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 743 NNNNNNNNNNNNNNNNN 758
|||||
Db 358 NNNNNNNNNNNNNNNNN 373

RESULT 20

A46391
cAMP receptor subtype 3 - slime mold (Dictyostelium sp.)
C/Species: Dictyostelium sp.
C/Date: 18-Oct-1993 #sequence_revision 18-Nov-1994 #text_change 29-Oct-1999
C/Accession: A46391
R/Johnson, R.L.; Saxe III, C.L.; Gollup, R.; Kimmel, A.R.; Devreotes, P.N.
Genes Dev. 7, 273-282, 1993
A/Title: Identification and targeted gene disruption of cAR3, a cAMP receptor subtype e
A/Reference number: A46391; MUID:93170666; PMID:8382181
A/Accession: A46391
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-490 <JOH>
A/Cross-references: GB:S55235; NID:G265733; PIDN:AA825437.1; PID:G265734
A/Note: sequence extracted from NCBI backbone (NCBIN:125367, NCBI:P:125369)
C/Keywords: cAMP binding; G protein-coupled receptor; phosphoprotein; transmembrane pro

Query Match 1.2%; Score 16; DB 2; Length 490;
Best Local Similarity 100.0%; Pred. No. 9.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 399 NNNNNNNNNNNNNNNNN 414

RESULT 21

S52830
HMS1 protein - yeast (Saccharomyces cerevisiae)
N/Alternate names: protein YM9916.09; protein YMR070w
C/Species: Saccharomyces cerevisiae
C/Date: 19-May-1995 #sequence_revision 01-Sep-1995 #text_change 29-Oct-1999
C/Accession: S52830; S59820
R/Pearson, D.; Bowman, S.
submitted to the EMBL Data Library, April 1995
A/Reference number: S52814
A/Accession: S52830
A/Molecule type: DNA
A/Residues: 1-490 <PEA>
A/Cross-references: EMBL:Z48952; NID:G763008; PIDN:CAA88795.1; PID:G763017; MIPS:YMR070
A/Experimental source: strain AB972

R;Madison, J.; Winston, F.
submitted to the EMBL Data Library, April 1995
A;Reference number: S59820
A;Accession: S59820
A;Molecule type: DNA
A;Residues: 1-490 <MAD>
A;Cross-references: EMBL:U25279; NID:g805129; PIDN:AAC49982.1; PID:g805130
C;Genetics:
A;Gene: SGD:MOT3; HMS1
A;Cross-references: MIPS:YMR070w; SGD:S0004674
A;Map position: 13R

Query Match 1.2%; Score 16; DB 2; Length 490;
Best Local Similarity 100.0%; Pred. No. 9.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 743 NNNNNNNNNNNNNNNNNI 758
DB 143 NNNNNNNNNNNNNNNNNI 158

RESULT 22

S52641
heat shock transcription factor HSF1 - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
A;Variety: Columbia
C;Date: 01-Aug-1995 #sequence_revision 24-Mar-1999 #text_change 16-Jun-2000
C;Accession: F71447; S52641; S62227; S38873
R;Bevan, M.; Bancroft, I.; Bent, E.; Love, K.; Goodman, H.; Dean, C.; Bergkamp, R.; Dink
P.; Medler, H.; Wedler, E.; Wambutt, R.; Weitzenegger, T.; Pohl, T.M.; Terry, N.; Giel
avanagh, T.; Hempel, S.; Kotter, P.; Emtian, K.D.; Rieger, M.; Schaeffer, M.; Funk, B.
Nature 391, 485-488, 1998

A;Authors: Mueller-Auer, S.; Silvey, M.; James, R.; Montfort, A.; Pons, A.; Puigdomenech
erhoff, A.; Moores, T.; Jones, J.D.G.; Eneva, T.; Palme, K.; Benes, V.; Reckman, S.; Ans
C.; Chalwatzis, N.
A;Title: Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thal
A;Reference number: A71400; MUID:9812113; PMID:9461215
A;Accession: F71447

A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-495 <BEV>

A;Cross-references: GB:297344; NID:g2245126; PIDN:CAB10555.1; PID:g2245134
R;Huebel, A.; Schoeffl, F.
Plant Mol. Biol. 26, 353-362, 1994

A;Title: Arabidopsis heat shock factor: isolation and characterization of the gene and t
A;Reference number: S52641; MUID:95036006; PMID:7948881
A;Accession: S52641

A;Molecule type: DNA
A;Residues: 1-215, 'M', 217-284, 'D', 286-335, 'T', 337-389, 'Y', 391-469, 474-495 <HUE>
A;Cross-references: EMBL:X76167
A;Accession: S62227

A;Molecule type: mRNA
A;Residues: 31-215, 'M', 217-284, 'D', 286-335, 'T', 337-389, 'Y', 391-469, 474-495 <HUE>
R;Huebel, A.; Schoeffl, F.
submitted to the EMBL Data Library, November 1993

A;Description: Arabidopsis heat shock factor: isolation and characterization of the gene
A;Reference number: S38873
A;Accession: S38873

A;Molecule type: DNA
A;Residues: 1-215, 'M', 217-284, 'D', 286-335, 'T', 337-389, 'Y', 391-461, 474-495 <HUF>
A;Cross-references: EMBL:X76167; NID:g429154; PIDN:CAA53761.1; PID:g429155
C;Genetics:

A;Gene: HSF1
A;Map position: 4COP9-4G3845
A;Intons: 111/3
C;Function: <TFC>

A;Description: transcription factor that binds to heat shock promoter elements
C;Superfamily: tomato heat shock transcription factor HSF8; HSF DNA-binding domain homol
C;Keywords: DNA binding; heat shock; leucine zipper; nucleus; stress-induced protein; tr
F;53-148/Domain: HSF DNA-binding domain homology <HSF>
F;181-202/Region: leucine zipper

Query Match 1.2%; Score 16; DB 1; Length 495;

Best Local Similarity 100.0%; Pred. No. 9.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNN 757
DB 454 NNNNNNNNNNNNNNNN 469

RESULT 23

S53813
RNA helicase - slime mold (Dictyostelium discoideum) (fragment)
C;Species: Dictyostelium discoideum
C;Date: 15-Jul-1995 #sequence_revision 23-Aug-1997 #text_change 02-Feb-2001
C;Accession: S53813; S49262

R;Mahal, B.; Nellen, W.
Biol. Chem. Hoppe-Seyler 375, 759-763, 1994
A;Title: Developmental regulation of DEAD box proteins and cloning of putative RNA heli
A;Reference number: S53813; MUID:95209781; PMID:7695838
A;Accession: S53813
A;Status: preliminary; nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-566 <MAH>

A;Cross-references: EMBL:X81824; NID:g550330; PIDN:CAA57418.1; PID:g550331
C;Keywords: ATP; nucleotide binding; P-loop
F;189-196/Region: nucleotide-binding motif A (P-loop)
F;298-303/Region: nucleotide-binding motif B
F;302-305/Region: DEAD motif

Query Match 1.2%; Score 16; DB 2; Length 566;
Best Local Similarity 100.0%; Pred. No. 1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 743 NNNNNNNNNNNNNNNNNI 758
DB 74 NNNNNNNNNNNNNNNNNI 89

RESULT 24

T18439
hypothetical protein CO380w - malaria parasite (Plasmodium falciparum)

C;Species: Plasmodium falciparum
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 11-Jan-2002
C;Accession: T18439
R;Lawson, D.; Bowman, S.; Barrell, B.
submitted to the EMBL Data Library, August 1997

A;Reference number: Z18935
A;Accession: T18439
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-580 <LAW>

A;Cross-references: EMBL:298547; NID:e1325376; PIDN:CAB11119.1
C;Genetics:
A;Map position: 3
A;Intons: 437/3; 457/2; 482/3; 512/3
A;Note: CO380w

Query Match 1.2%; Score 16; DB 2; Length 580;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 187 NNNNNNNNNNNNNNNN 202

RESULT 25

T18446
hypothetical protein MAL3p.11 - malaria parasite (Plasmodium falciparum)

C;Species: Plasmodium falciparum
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 11-Jan-2002
C;Accession: T18446
R;Lawson, D.; Bowman, S.; Barrell, B.
submitted to the EMBL Data Library, August 1997

A:Reference number: 218935
A:Accession: T18446
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-600 <LAW>
A:Cross-references: EMBL:Z98547; NID:e1325376; PIDN:CAB51588.1
C:Genetics:
A:Map position: 3
A:Introns: 437/3; 477/2; 502/3; 532/3
A:Note: MAL3P3.11

Query Match 1.2%; Score 16; DB 2; Length 600;
Best Local Similarity 100.0%; Pred. No. 1.1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 187 NNNNNNNNNNNNNNNN 202

RESULT 26

A71607
Mtn3/RAC1P-like protein PFB0760w - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C>Date: 13-Nov-1998 #sequence_revision 13-Nov-1998 #text_change 21-Jul-2000
C:Accession: A71607
R:Gardner, M.J.; Tetteelin, H.; Carucci, D.J.; Cummings, L.M.; Aravind, L.; Koonin, E.V.;
; Pertea, M.; Salzberg, S.; Zhou, L.; Sutton, G.G.; Clayton, R.; White, O.; Smith, H.O.
Science 282, 1126-1132, 1998
A:Title: Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
A:Reference number: A71600; MUID:99021743; PMID:9804551
A:Accession: A71607
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-686 <GAR>
A:Cross-references: GB:AE001416; GB:AE001362; NID:g3845268; PIDN:AACT1941.1; PID:g384527
A:Experimental source: clone 3D7
C:Genetics:
A:Gene: PFB0760w

Query Match 1.2%; Score 16; DB 2; Length 686;
Best Local Similarity 100.0%; Pred. No. 1.2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 50 NNNNNNNNNNNNNNNN 65

RESULT 27

T51007
hypothetical protein B7J19.60 [imported] - Neurospora crassa
C:Species: Neurospora crassa
C>Date: 21-Jul-2000 #sequence_revision 21-Jul-2000 #text_change 21-Jul-2000
C:Accession: T51007
R:Schulte, U.; Aign, V.; Hohelsel, J.; Brandt, P.; Fartmann, B.; Holland, R.; Nyakatura,
submitted to the Protein Sequence Database, July 2000
A:Reference number: Z25286
A:Accession: T51007
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-720 <SCH>
A:Cross-references: EMBL:AL389899; GSPDB:GN00116; NCSP:B7J19.60
A:Experimental source: BAC clone B7J19; strain OR74A
C:Genetics:
A:Gene: NCSP:B7J19.60
A:Map position: 6
A:Introns: 534/2; 692/2

Query Match 1.2%; Score 16; DB 2; Length 720;
Best Local Similarity 100.0%; Pred. No. 1.3e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 545 NNNNNNNNNNNNNNNN 560

RESULT 28

S54522
hypothetical protein YMR164c - yeast (Saccharomyces cerevisiae)
N:Alternate names: hypothetical protein YMR520.13c
C:Species: Saccharomyces cerevisiae
C>Date: 08-Jul-1995 #sequence_revision 01-Sep-1995 #text_change 29-Oct-1999
R:Hunt, S.; Bowman, S.
submitted to the EMBL Data Library, May 1995
A:Reference number: S54510
A:Accession: S54522
A:Molecule type: DNA
A:Residues: 1-758 <HUN>
A:Cross-references: GB:Z49705; EMBL:Z49700; NID:g825556; PIDN:CAA89800.1; PID:g825569;
A:Experimental source: strain AB972
C:Genetics:
A:Gene: SGD:MS811
A:Cross-references: SGD:S0004774; MIPS:YMR164c
A:Map position: 13R

Query Match 1.2%; Score 16; DB 2; Length 758;
Best Local Similarity 100.0%; Pred. No. 1.3e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 605 NNNNNNNNNNNNNNNN 620

RESULT 29

T08611
hypothetical protein DocA - slime mold (Dictyostelium discoideum)
C:Species: Dictyostelium discoideum
C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 11-Jun-1999
C:Accession: T08611
R:Aubry, L.; Firtel, R.A.; Iranfar, N.
submitted to the EMBL Data Library, August 1997
A:Reference number: Z16456
A:Accession: T08611
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-831 <AUB>
A:Cross-references: EMBL:AF020409; NID:g2425146; PID:g2425147
A:Experimental source: strain AX4
C:Genetics:
A:Gene: docA

Query Match 1.2%; Score 16; DB 2; Length 831;
Best Local Similarity 100.0%; Pred. No. 1.4e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 740 ITNNNNNNNNNNNNNNN 755
DB 164 ITNNNNNNNNNNNNNNN 179

RESULT 30

T08605
hypothetical protein HefE - slime mold (Dictyostelium discoideum) (fragment)
C:Species: Dictyostelium discoideum
C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 11-Jun-1999
C:Accession: T08605
R:Loomis, W.F.; Iranfar, N.
submitted to the EMBL Data Library, August 1997
A:Reference number: Z16451
A:Accession: T08605
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA

A;Residues: 1-947 <LOO>
A;Cross-references: EMBL:AF019981; NID:g2425112; PID:g2425113
A;Experimental source: strain AX4
C;Genetics:
A;Gene: helle

Query Match 1.2%; Score 16; DB 2; Length 947;
Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 234 NNNNNNNNNNNNNNNN 249

RESULT 31

S67568
probable membrane protein YD035C - yeast (Saccharomyces cerevisiae)

N;Alternate names: hypothetical protein D2749
C;Species: Saccharomyces cerevisiae

C;Date: 12-Jul-1996 #sequence_revision 12-Jul-1996 #text_change 19-Apr-2002
C;Accession: S67568

R;Paulin, L.; Saren, A.M.; Laamanen, P.
Submitted to the Protein Sequence Database, July 1996

A;Reference number: S67560

A;Accession: S67568

A;Molecule type: DNA

A;Residues: 1-961 <PAU>

A;Cross-references: EMBL:Z74083; NID:g1431014; PID:e252968; PID:g1431015; GSPDB:GN00004;

A;Experimental source: strain S288C

C;Genetics:

A;Gene: SGD:GPRL1; MIPS:YD035C

A;Cross-references: SGD:S0002193

A;Map position: 4L

C;Keywords: transmembrane protein

F;7-73/Domain: transmembrane #status predicted <TM1>

F;72-108/Domain: transmembrane #status predicted <TM2>

F;140-156/Domain: transmembrane #status predicted <TM3>

F;181-197/Domain: transmembrane #status predicted <TM4>

F;256-272/Domain: transmembrane #status predicted <TM5>

F;623-639/Domain: transmembrane #status predicted <TM6>

F;662-678/Domain: transmembrane #status predicted <TM7>

Query Match 1.2%; Score 16; DB 2; Length 961;

Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 515 NNNNNNNNNNNNNNNN 530

RESULT 32

JCS808
G protein-coupled receptor 1 - yeast (Saccharomyces cerevisiae)

C;Species: Saccharomyces cerevisiae

C;Date: 04-Feb-1998 #sequence_revision 13-Mar-1998 #text_change 19-Apr-2002
C;Accession: JCS808

R;Fun, C.W.; Tanaka, H.; Nakayama, R.; Yamamoto, K.; Kumagai, H.

Biochem. Biophys. Res. Commun. 240, 287-292, 1997

A;Title: G-protein coupled receptor from yeast Saccharomyces cerevisiae.

A;Reference number: JCS808; MID:98049822; PMID:9388468

A;Accession: JCS808

A;Status: nucleic acid sequence not shown

A;Molecule type: DNA

A;Residues: 1-962 <YUN>

C;Comment: This protein monitors the extracellular signal such as nutrition and transduc

C;Genetics:

A;Gene: SGD:GPRL1; MIPS:YD035C

A;Cross-references: SGD:S0002193

F;56-74/Domain: transmembrane #status predicted <TM1>

F;91-109/Domain: transmembrane #status predicted <TM2>

F;139-157/Domain: transmembrane #status predicted <TM3>

F;180-198/Domain: transmembrane #status predicted <TM4>
F;255-273/Domain: transmembrane #status predicted <TM5>
F;622-640/Domain: transmembrane #status predicted <TM6>
F;661-679/Domain: transmembrane #status predicted <TM7>

Query Match 1.2%; Score 16; DB 2; Length 962;
Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 516 NNNNNNNNNNNNNNNN 531

RESULT 33

S48404
probable membrane protein YIL130W - yeast (Saccharomyces cerevisiae)

C;Species: Saccharomyces cerevisiae

C;Date: 02-Dec-1994 #sequence_revision 02-Dec-1994 #text_change 19-Apr-2002
C;Accession: S48404

R;Churcher, C.

Submitted to the EMBL Data Library, September 1994

A;Reference number: S48310

A;Accession: S48404

A;Molecule type: DNA

A;Residues: 1-964 <CHU>

A;Cross-references: GB:Z47047; EMBL:Z38059; NID:g603997; PID:g763216; MIPS:YIL130W

C;Genetics:

A;Cross-reference: SGD:S0001392

A;Map position: 9L

C;Superfamily: unassigned GAL4-type zinc cluster proteins; GAL4 zinc binuclear cluster

C;Keywords: DNA binding; nucleas; transcription regulation; transmembrane protein

F;16-52/Domain: GAL4 zinc binuclear cluster homology <GAL4>

F;289-305/Domain: transmembrane #status predicted <TM1>

F;346-362/Domain: transmembrane #status predicted <TM2>

Query Match 1.2%; Score 16; DB 2; Length 964;

Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 853 NNNNNNNNNNNNNNNN 868

RESULT 34

S54067
probable membrane protein YPR042C - yeast (Saccharomyces cerevisiae)

N;Alternate names: hypothetical protein YP3085.06c; hypothetical protein YP9499.01c
C;Species: Saccharomyces cerevisiae

C;Date: 08-Jul-1995 #sequence_revision 26-Jul-1996 #text_change 19-Apr-2002
C;Accession: S54067; S61063

R;Padcock, K.; Churcher, C.M.

submitted to the EMBL Data Library, May 1995

A;Reference number: S54059

A;Accession: S54067

A;Molecule type: DNA

A;Residues: 1-508 <BAD>

A;Cross-references: EMBL:Z49219; NID:g805025; PID:g805026; MIPS:YPR042C

A;Experimental source: strain AB972

R;Padcock, K.; Churcher, C.M.

submitted to the EMBL Data Library, November 1995

A;Reference number: S61058

A;Accession: S61063

A;Molecule type: DNA

A;Residues: 465-1075 <BAW>

A;Cross-references: EMBL:Z68111; MIPS:YPR042C

C;Genetics:

A;Gene: SGD:PUF2

A;Cross-references: SGD:S0006246

A;Map position: 16R

C;Keywords: transmembrane protein

F;711-727/Domain: transmembrane #status predicted <TM1>

Query Match 1.2%; Score 16; DB 2; Length 1075;
Best Local Similarity 100.0%; Pred. No. 1.8e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 1033 NNNNNNNNNNNNNNNNN 1048

RESULT 35
T09057
probable protein-histidine kinase (EC 2.7.3.-) Dhkc - slime mold (Dictyostelium discoideum)
N;Alternate names: histidine kinase C
C;Species: Dictyostelium discoideum
C;Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 11-Jun-1999
C;Accession: T09057
R;Singleton, C.K.; Mykyta, B.; Zinda, M.
submitted to the EMBL Data Library, October 1997
A;Reference number: Z16542
A;Accession: T09057
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-1225 <SIN>
A;Cross-references: EMBL:AF029726; NID:g2605923; PID:g2605924
C;Genetics:
A;Gene: dhkc
A;Map position: 4
C;Keywords: phosphotransferase; protein kinase

Query Match 1.2%; Score 16; DB 2; Length 1225;
Best Local Similarity 100.0%; Pred. No. 2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 101 NNNNNNNNNNNNNNNNN 116

RESULT 36
S14556
asparagine-rich protein (clone 18C1) - malaria parasite (Plasmodium falciparum)
C;Species: Plasmodium falciparum
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 01-Dec-2000
C;Accession: S14556; S14548
R;Schreiber, L.; Deutsche, U.; Storch, T.; Mueller-Hill, D.
submitted to the EMBL Data Library, December 1989
A;Reference number: S14469
A;Accession: S14556
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-1256 <SCH>
A;Cross-references: EMBL:X17485; NID:g9846; PID:g1335715
A;Accession: S14548
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 'Q', 210-1251, 'NESENDAIDTITQPIKKK' <SC2>
A;Cross-references: EMBL:X17488; NID:g9852; PID:g9853

Query Match 1.2%; Score 16; DB 2; Length 1256;
Best Local Similarity 100.0%; Pred. No. 2.1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 1078 NNNNNNNNNNNNNNNNN 1093

RESULT 37
T08607
hypothetical protein DG2033 - slime mold (Dictyostelium discoideum) (fragment)
C;Species: Dictyostelium discoideum
C;Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 11-Jun-1999

C;Accession: T08607
R;Loomis, W.F.; Tranfar, N.
submitted to the EMBL Data Library, August 1997
A;Reference number: Z16451
A;Accession: T08607
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-1271 <LOO>
A;Cross-references: EMBL:AF020282; NID:g2425132; PID:g2425133
A;Experimental source: strain AX3
C;Genetics:
A;Gene: DG2033

Query Match 1.2%; Score 16; DB 2; Length 1271;
Best Local Similarity 100.0%; Pred. No. 2.1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 1047 NNNNNNNNNNNNNNNNN 1062

RESULT 38
T18288
ABC transport protein - slime mold (Dictyostelium discoideum) (fragment)
C;Species: Dictyostelium discoideum
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T18288
R;Loomis, W.F.
submitted to the EMBL Data Library, August 1996
A;Reference number: Z18857
A;Accession: T18288
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-1336 <LOO>
A;Cross-references: EMBL:U66526; NID:g1513297; PID:g1513298; PIDN:AA06789.1
C;Genetics:
A;Gene: abca

Query Match 1.2%; Score 16; DB 2; Length 1336;
Best Local Similarity 100.0%; Pred. No. 2.2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 742 NNNNNNNNNNNNNNNNN 757
|||||
Db 789 NNNNNNNNNNNNNNNNN 804

RESULT 39
S14871
suppressor two of zeste protein - fruit fly (Drosophila melanogaster)
C;Species: Drosophila melanogaster
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jul-2000
C;Accession: S14871; S16845
R;Brunk, B.P.; Adler, P.N.
submitted to the EMBL Data Library, November 1990
A;Description: The Drosophila regulatory gene suppressor two of zeste encodes a large z
A;Reference number: S14871
A;Accession: S14871
A;Molecule type: mRNA
A;Residues: 1-1365 <BRU>
A;Cross-references: EMBL:X56799; NID:g8528; PID:g8529
R;Brunk, B.P.; Adler, P.N.
Nucleic Acids Res. 19, 3149, 1991
A;Title: The sequence of the Drosophila regulatory gene Suppressor two of zeste.
A;Reference number: S16845; MUID:91279476; PMID:2057369
A;Accession: S16845
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-612, 614-784, 'N', 786-830, 'R', 832-965, 967-1064, 'E', 1066-1096, 'N', 1097-1286,
A;Cross-references: EMBL:X56798; NID:g8526; PIDN:CAA40134.1; PID:g8527
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, November 1990
C;Genetics:

A;Gene: FlyBase:Su(z)2
A;Cross-references: FlyBase:FBgn0008654
A;Intons: 55/1; 139/2; 219/3
C;Superfamily: Drosophila suppressor protein of zeste; RING finger homology
C;Keywords: DNA binding; nucleus; zinc finger
F;31-79/Domain: RING finger homology <RING>

Query Match 1.2%; Score 16; DB 2; Length 1365;
Best Local Similarity 100.0%; Pred. No. 2.2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
|||
Db 1077 NNNNNNNNNNNNNNNN 1092

RESULT 40

T14004
trfA protein - slime mold (Dictyostelium discoideum)
C;Species: Dictyostelium discoideum
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 11-May-2000
C;Accession: T14004
R;Saigo, U.; Adachi, H.; Sutoh, K.
J. Biol. Chem. 273, 24654-24659, 1998
A;Title: Dictyostelium TRF homologous to yeast Sen6 is required for normal growth and e
A;Reference number: Z17852; MID:98406112; PMID:9733762
A;Accession: T14004
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-1390 <SAI>
A;Cross-references: EMBL:AB009080; NID:d1228566; PID:d1034109; PIDN:BAA33143.1
C;Genetics:
A;Gene: trfA
A;Intons: 333/3; 364/3; 637/1

Query Match 1.2%; Score 16; DB 2; Length 1390;
Best Local Similarity 100.0%; Pred. No. 2.2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
|||
Db 830 NNNNNNNNNNNNNNNN 845

Search completed: October 2, 2003, 16:36:14
Job time : 78 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:27:41 ; Search time 29 Seconds
(without alignments)
2088.634 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 1288
Sequence: 1 MNSKRVVVRKPLSELEKK.....KKLVQDNKSMDDNNHKK 1288

Scoring table: OLIGO
Gapop 60.0, Gapext 60.0

Searched: 127863 segs, 47026705 residues

Word size : 0

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 1000 summaries

Database : SwissProt_41.1*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	1.3	666	1	YEAF_YEAST
2	17	1.3	758	1	CC27_YEAST
3	17	1.3	1093	1	PI4K_DICDI
4	17	1.3	1178	1	PH81_YEAST
5	16	1.2	317	1	AAC4_DICDI
6	16	1.2	451	1	MYBH_DICDI
7	16	1.2	480	1	CAR3_DICDI
8	16	1.2	490	1	MOT3_YEAST
9	16	1.2	495	1	HSF1_ARATH
10	16	1.2	640	1	RABP_CANAL
11	16	1.2	732	1	KMHB_DICDI
12	16	1.2	735	1	CIGB_DICDI
13	16	1.2	758	1	YM38_YEAST
14	16	1.2	961	1	GPRI_YEAST
15	16	1.2	964	1	YINO_YEAST
16	16	1.2	989	1	PTP3_DICDI
17	16	1.2	1365	1	SUZ2_DROME
18	16	1.2	1584	1	KYK1_DICDI
19	16	1.2	1585	1	P3K3_DICDI
20	16	1.2	1743	1	TAGC_DICDI
21	16	1.2	1858	1	P3K2_DICDI
22	16	1.2	1905	1	TAGB_DICDI
23	15	1.2	451	1	ARP2_PLAFA
24	15	1.2	612	1	YP68_YEAST
25	15	1.2	837	1	CCR4_YEAST
26	15	1.2	888	1	YGB4_YEAST
27	15	1.2	2278	1	FABI_YEAST
28	14	1.1	700	1	NCD_DROME
29	14	1.1	730	1	KCMT_XENLA
30	14	1.1	745	1	ATK2_ARATH
31	14	1.1	754	1	ATK3_ARATH
32	14	1.1	793	1	ATK1_ARATH
33	14	1.1	793	1	ATK1_ARATH

34	14	1.1	832	1	KLPI_SCHPO
35	14	1.1	858	1	CYAG_DICDI
36	14	1.1	955	1	KINL_LEICH
37	14	1.1	1770	1	R115_YEAST
38	13	1.0	201	1	YMBD_YEAST
39	13	1.0	426	1	HKUB_LYCES
40	13	1.0	554	1	KLPI_SCHPO
41	13	1.0	669	1	FPSP_YEAST
42	13	1.0	708	1	GBF1_DICDI
43	13	1.0	851	1	NUDI_YEAST
44	13	1.0	1151	1	GRI1_YEAST
45	12	0.9	212	1	YMF3_YEAST
46	12	0.9	537	1	ARP_PLAFA
47	12	0.9	590	1	HMF2_DROME
48	12	0.9	624	1	DSK1_CYLFU
49	12	0.9	647	1	KNRL_DROME
50	12	0.9	671	1	KP2C_MACFA
51	12	0.9	671	1	KP2C_RAT
52	12	0.9	679	1	KIF2_HUMAN
53	12	0.9	682	1	KIF2_XENLA
54	12	0.9	716	1	KIF2_MOUSE
55	12	0.9	718	1	KP2C_CRIGR
56	12	0.9	721	1	KP2C_MOUSE
57	12	0.9	725	1	KP2C_HUMAN
58	12	0.9	727	1	BRC1_DROME
59	12	0.9	914	1	AZP1_YEAST
60	12	0.9	1177	1	SP97_DICDI
61	12	0.9	1341	1	YL78_YEAST
62	12	0.9	1570	1	P3K1_DICDI
63	12	0.9	2452	1	RPB1_PLAFA
64	11	0.9	172	1	PKIA_DICDI
65	11	0.9	331	1	COL6_ARATH
66	11	0.9	443	1	CAR4_DICDI
67	11	0.9	448	1	AAC2_DICDI
68	11	0.9	472	1	HMCA_DROME
69	11	0.9	672	1	OSM3_CAEEL
70	11	0.9	673	1	KFC1_HUMAN
71	11	0.9	726	1	RLM1_YEAST
72	11	0.9	739	1	KAR3_YEAST
73	11	0.9	784	1	KLPI_SCHPO
74	11	0.9	793	1	RECA_DICDI
75	11	0.9	805	1	KIP3_YEAST
76	11	0.9	935	1	KINH_SYNRA
77	11	0.9	987	1	ATK4_ARATH
78	11	0.9	1225	1	KP4A_CHICK
79	11	0.9	1226	1	KP4A_XENLA
80	11	0.9	1230	1	ST20_CANAL
81	11	0.9	1231	1	KP4A_MOUSE
82	11	0.9	1232	1	KP4A_HUMAN
83	11	0.9	2339	1	RPCL_PLAFA
84	10	0.8	240	1	MTNB_LISIN
85	10	0.8	240	1	MTNB_LISMO
86	10	0.8	368	1	YB11_YEAST
87	10	0.8	372	1	COUB_ARATH
88	10	0.8	522	1	IL9R_HUMAN
89	10	0.8	525	1	ESR1_MICUN
90	10	0.8	623	1	PMT1_DROME
91	10	0.8	648	1	KAPC_DICDI
92	10	0.8	718	1	PNT2_DROME
93	10	0.8	720	1	AB13_ARATH
94	10	0.8	726	1	NF11_YEAST
95	10	0.8	823	1	SCH9_YEAST
96	10	0.8	865	1	E78A_DROME
97	10	0.8	972	1	OMF_DROME
98	10	0.8	1038	1	KP17_MOUSE
99	10	0.8	1080	1	HDC_DROME
100	10	0.8	1195	1	YK76_YEAST
101	10	0.8	1228	1	ATC_PLAFA
102	10	0.8	1419	1	MDR_PLAFA
103	10	0.8	1584	1	U104_CAEEL
104	10	0.8	1648	1	KP14_HUMAN
105	10	0.8	1749	1	K13A_MOUSE
106	10	0.8	1805	1	K13A_HUMAN

Q92376	schizosacch
Q03101	dictyostell
P46865	leishmania
P43565	saccharomyc
P38429	saccharomyc
Q22300	lycoperisic
Q94600	schizosacch
P23300	saccharomyc
P36417	dictyostell
P32336	saccharomyc
P24814	saccharomyc
Q04978	saccharomyc
P04931	plasmodium
P07548	drosophilla
Q39493	cylindrothe
P13054	drosophilla
Q951P1	macaca fasc
Q62309	rattus norv
Q00139	homo sapien
Q91637	xenopus lae
P28740	mus musculu
P70096	cricetulus
Q92288	mus musculu
Q99661	homo sapien
Q01295	drosophilla
P41696	saccharomyc
Q95393	dictyostell
Q05854	saccharomyc
P54673	dictyostell
P14248	plasmodium
Q23921	dictyostell
Q91427	arabidopsis
Q94743	dictyostell
P14196	dictyostell
P09085	drosophilla
P46873	caenorhabd
Q96W19	homo sapien
Q12224	saccharomyc
P17119	saccharomyc
O59751	schizosacch
Q23117	dictyostell
P53086	saccharomyc
O43093	syncephalas
O81335	arabidopsis
Q90640	gallus gall
Q91784	xenopus lae
Q92212	candida alb
P33174	mus musculu
Q95339	homo sapien
P27425	plasmodium
Q92459	listeria in
O8Y651	listeria mo
P38180	saccharomyc
Q98855	arabidopsis
Q01113	homo sapien
P57753	microspor
P51022	drosophilla
P34099	dictyostell
P51023	drosophilla
Q01593	arabidopsis
Q12116	saccharomyc
P11992	saccharomyc
P45447	drosophilla
Q24432	drosophilla
Q99PW8	mus musculu
Q9N2M8	drosophilla
P36168	saccharomyc
Q08853	plasmodium
P13568	plasmodium
P23678	caenorhabd
Q15058	homo sapien
Q9EGW7	mus musculu
Q9N1H9	homo sapien

107	10	0.8	1826	1	K13B_HUMAN	Q9nqt8	homo sapien	180	8	0.6	397	1	YMP7_YEAST	Q04359	saccharomyc
108	9	0.7	375	1	CAR2_DICDI	P34907	dictyosteli	181	8	0.6	413	1	E2F4_HUMAN	Q16254	homo sapien
109	9	0.7	377	1	PRP2_DICDI	P34138	dictyosteli	182	8	0.6	429	1	HML2_HELPO	O01622	helobdella
110	9	0.7	384	1	KFZ5_HUMAN	Q9nlla	homo sapien	183	8	0.6	437	1	TISI_DROME	P47980	drosophila
111	9	0.7	398	1	HKLI_ARATH	P46349	arabidopsis	184	8	0.6	443	1	YERO_YEAST	P39929	saccharomyc
112	9	0.7	403	1	GBA8_DICDI	P34046	dictyosteli	185	8	0.6	446	1	CHMO_BETVU	O22533	beta vulgar
113	9	0.7	416	1	PKD1_DICDI	P34100	dictyosteli	186	8	0.6	455	1	YB12_YEAST	P38288	saccharomyc
114	9	0.7	472	1	NTU9_YEAST	Q00193	saccharomyc	187	8	0.6	461	1	YB45_LACLC	P22865	lactococcus
115	9	0.7	473	1	DCOR_CANAL	P78599	candida alb	188	8	0.6	516	1	P54_ENTFC	P13692	enterococcu
116	9	0.7	508	1	ECR1_RAT	P08154	rattus norv	189	8	0.6	535	1	C4C3_DROME	Q9vaf7	drosophila
117	9	0.7	528	1	CTK1_YEAST	Q03957	saccharomyc	190	8	0.6	554	1	HAP4_YEAST	P14064	saccharomyc
118	9	0.7	564	1	EMRP_CANAL	P28873	candida alb	191	8	0.6	567	1	NUZM_HANWI	P48906	hansenula w
119	9	0.7	577	1	P2B1_DROME	P48456	drosophila	192	8	0.6	569	1	MANC_PIRSP	P55287	plumyces s
120	9	0.7	578	1	PSP2_YEAST	P50109	saccharomyc	193	8	0.6	571	1	MANB_PIRSP	P55287	plumyces s
121	9	0.7	598	1	KLP3_CAEEL	P45962	caenorhabdi	194	8	0.6	583	1	NIR_BETVE	P38500	betula verr
122	9	0.7	658	1	UVRB_HELPJ	Q9akao	helicobacte	195	8	0.6	586	1	RT67_ECOLI	P21375	escherichia
123	9	0.7	658	1	UVRB_HELPY	P94846	helicobacte	196	8	0.6	604	1	SP20_YEAST	P50875	saccharomyc
124	9	0.7	675	1	UVRB_NEIGO	Q50939	neisseria g	197	8	0.6	612	1	TIPD_DICDI	O15736	dictyosteli
125	9	0.7	675	1	UVRB_NEIMA	P56996	neisseria m	198	8	0.6	653	1	DUS8_MOUSE	P39531	saccharomyc
126	9	0.7	675	1	UVRB_NEIMB	O33395	neisseria m	199	8	0.6	669	1	UVRB_XYLFA	Q09pe1	xyloella fas
127	9	0.7	682	1	CONN_DROME	O01819	drosophila	200	8	0.6	670	1	UVRB_METAC	O8tk53	methanosarc
128	9	0.7	696	1	UVRB_RALSO	Q8Y0M2	raistronia s	201	8	0.6	670	1	UVRB_METWA	O8tr29	methanosarc
129	9	0.7	713	1	YHC4_YEAST	P38741	saccharomyc	202	8	0.6	673	1	UVRB_XANAC	O8p7x1	xanthomonas
130	9	0.7	719	1	NRP1_YEAST	P32770	saccharomyc	203	8	0.6	673	1	UVRB_XANCP	O8p7x1	xanthomonas
131	9	0.7	740	1	KRE6_CANAL	P87023	candida alb	204	8	0.6	675	1	ECR_AEDAE	P05709	aedes aegypt
132	9	0.7	749	1	MAD1_YEAST	P40957	saccharomyc	205	8	0.6	697	1	SIM_DROME	O24248	drosophila
133	9	0.7	770	1	KUPA_EMENT	P28739	emeritella	206	8	0.6	717	1	ARA_DROME	P46867	drosophila
134	9	0.7	779	1	SRP_DROME	P52172	drosophila	207	8	0.6	784	1	KL68_DROME	O05319	drosophila
135	9	0.7	782	1	SP4_MOUSE	Q62445	mus musculu	208	8	0.6	786	1	STUB_DROME	P39016	saccharomyc
136	9	0.7	784	1	SP4_MOUSE	Q62446	homo sapien	209	8	0.6	834	1	MP75_YEAST	P54201	dictyosteli
137	9	0.7	868	1	NRG2_RAT	O35569	rattus norv	210	8	0.6	837	1	UBPA_DICDI	P50866	saccharomyc
138	9	0.7	904	1	ABRU_DROME	Q24174	drosophila	211	8	0.6	841	1	PSP1_YEAST	Q9st65	arabidopsis
139	9	0.7	926	1	PRP3_YEAST	P40048	saccharomyc	212	8	0.6	847	1	R132_ARATH	P08657	kluyveromyc
140	9	0.7	960	1	DIG1_DROME	P31007	drosophila	213	8	0.6	865	1	LAC9_KUTLA	Q9pkx8	chlamydia m
141	9	0.7	1000	1	S155_YEAST	P43612	saccharomyc	214	8	0.6	870	1	CLPC_CHLMU	O10065	schizosacch
142	9	0.7	1091	1	JSN1_YEAST	P47135	saccharomyc	215	8	0.6	880	1	TRK2_SCHPO	O14343	schizosacch
143	9	0.7	1094	1	YB00_YEAST	P38114	saccharomyc	216	8	0.6	883	1	KLP5_SCHPO	Q9uh19	h general t
144	9	0.7	1188	1	OSH1_YEAST	P35845	saccharomyc	217	8	0.6	959	1	G2D1_HUMAN	P10476	pseudomonas
145	9	0.7	1227	1	JTP3_DROME	Q9gcf5	drosophila	218	8	0.6	962	1	GUNA_PSEFL	P21657	saccharomyc
146	9	0.7	1398	1	TOP2_PLAFK	P41001	plasmodium	219	8	0.6	970	1	DA81_YEAST	Q49409	mycoplasma
147	9	0.7	1407	1	CYAA_DICDI	Q03100	dictyosteli	220	8	0.6	970	1	Y277_MYCGB	O8mxc8	drosophila
148	9	0.7	1566	1	PROS_DROI	Q9u6a1	drosophila	221	8	0.6	975	1	CRM_DROSE	P91655	drosophila
149	9	0.7	1677	1	VIT_ACTR	Q90243	acipenser t	222	8	0.6	975	1	MGR_DROME	P31521	drosophila
150	9	0.7	3092	1	IRAI_YEAST	P18963	saccharomyc	223	8	0.6	1028	1	OVO_DROME	P33244	drosophila
151	8	0.6	115	1	SER1_GALME	Q96614	galleria me	224	8	0.6	1043	1	FTF1_DROME	P18431	drosophila
152	8	0.6	117	1	DHA_TCAPL	P22238	craterosig	225	8	0.6	1067	1	SGG_DROME	Q7358	methanococc
153	8	0.6	121	1	RS6_RICCN	Q92JX3	ricicetstia	226	8	0.6	1075	1	Y124_METVA	O13453	candida alb
154	8	0.6	121	1	RS6_RICCN	Q92JX3	ricicetstia	227	8	0.6	1075	1	PLC1_CANAL	Q9j157	mus musculu
155	8	0.6	150	1	ASNC_HAEIN	P44337	haemophilus	228	8	0.6	1099	1	G2D1_MOUSE	P35568	homo sapien
156	8	0.6	193	1	UBC6_HUMAN	P51965	homo sapien	229	8	0.6	1104	1	IRS1_HUMAN	P09547	saccharomyc
157	8	0.6	193	1	UBC6_MOUSE	P52482	mus musculu	230	8	0.6	1242	1	SMI1_YEAST	P81122	mus musculu
158	8	0.6	215	1	FGFA_RAT	P70492	rattus norv	231	8	0.6	1321	1	IRS2_MOUSE	Q9Y412	homo sapien
159	8	0.6	220	1	SER2_GALME	Q96615	galleria me	232	8	0.6	1324	1	IRS2_HUMAN	P29671	drosophila
160	8	0.6	260	1	DH10_ARATH	P42759	arabidopsis	233	8	0.6	1403	1	PROS_DROME	P49791	rattus norv
161	8	0.6	265	1	DH47_ARATH	P31168	arabidopsis	234	8	0.6	1468	1	N153_RAT	Q04182	saccharomyc
162	8	0.6	265	1	JOIN_LYCPS	Q9fuf6	lycopersico	235	8	0.6	1475	1	N153_HUMAN	P49790	homo sapien
163	8	0.6	284	1	SMX5_SCHWA	Q26604	schistosoma	236	8	0.6	1529	1	PDRF_YEAST	O04182	saccharomyc
164	8	0.6	288	1	KADC_SCHLU	Q8hsnw1	solanum tub	237	8	0.6	1597	1	SOL_DROME	P27392	drosophila
165	8	0.6	298	1	MYOD_CHICK	P16075	gallus galli	238	8	0.6	1679	1	FUR2_DROME	P30458	drosophila
166	8	0.6	329	1	CAHX_FIAPR	P46281	flaveria pr	239	8	0.6	1704	1	VIT1_FUNHE	Q90508	funulus he
167	8	0.6	330	1	CAH1_FIALI	P46512	flaveria ii	240	8	0.6	1850	1	VIT2_CHICK	P02845	gallus galli
168	8	0.6	330	1	CAHX_FIAPR	P46510	flaveria br	241	8	0.6	2175	1	HMCU_DROME	P10180	drosophila
169	8	0.6	331	1	CAHX_FIAPR	P46510	flaveria bi	242	8	0.6	3005	1	ZEH2_DROME	P28167	drosophila
170	8	0.6	334	1	YPD6_CAEEL	P55112	caenorhabdi	243	8	0.6	3726	1	TRX_DROME	P20659	drosophila
171	8	0.6	339	1	RMAR_CANGA	P21358	candida gla	244	8	0.6	46	1	VIT_DROME	P56530	anas platytr
172	8	0.6	354	1	URE2_YEAST	P23202	saccharomyc	245	8	0.5	70	1	VNCH_ECOLI	P61118	escherichia
173	8	0.6	361	1	CGD2_ARATH	P42752	arabidopsis	246	8	0.5	91	1	MINE_WIGER	O6d211	wiggleswort
174	8	0.6	367	1	CSP_PLAYO	P06914	plasmodium	247	8	0.5	92	1	YNI3_MERTL	P40627	tetrahymena
175	8	0.6	369	1	DAG2_ARATH	Q9pny0	arabidopsis	248	8	0.5	97	1	HMEN_HELTR	P25769	methanococc
176	8	0.6	372	1	BAG2_HUMAN	O60909	h beta-1,4-	249	8	0.5	98	1	Y010_BPHPI	P23397	helobdella
177	8	0.6	372	1	MSSP_HUMAN	P23558	homo sapien	250	8	0.5	99	1	Y010_BPHPI	P51712	bacterioph
178	8	0.6	396	1	RMAR_YEAST	P02381	saccharomyc	251	8	0.5	100	1	LGI_TETTH	P11873	tetrahymena
179	8	0.6	397	1	ODPA_PEA	P52902	pleum sativ	252	8	0.5	100	1	LGI_TETTH	P11873	tetrahymena

253	7	0.5	102	1	108_LYCES	Q43495 lycopersico	326	7	0.5	247	1	DB83_HUMAN	P57088 homo sapien
254	7	0.5	102	1	M1H_PENVA	P55322 penaeus van	327	7	0.5	247	1	DB83_MOUSE	Q9c167 mus musculus
255	7	0.5	104	1	YJ04_YEAST	P47009 saccharomyc	328	7	0.5	247	1	DB83_RAT	Q92142 rattus norv
256	7	0.5	112	1	VE4_HPV29	P51897 human papil	329	7	0.5	250	1	UBC6_YEAST	P3396 saccharomyc
257	7	0.5	115	1	CTF5_MOUSE	Q9c137 mus musculu	330	7	0.5	251	1	YCS2_METUA	O5848 metanococ
258	7	0.5	117	1	YFB9_YEAST	P43576 saccharomyc	331	7	0.5	253	1	LI39_CAEEL	P34684 caenorhabd
259	7	0.5	122	1	M126_CHICK	P28318 gallus gall	332	7	0.5	254	1	EMD_HUMAN	P50402 homo sapien
260	7	0.5	122	1	PA25_TRIST	P82896 timemresuru	333	7	0.5	254	1	S5A2_MOUSE	Q99199 mus musculu
261	7	0.5	123	1	RL7_WIGBR	O8d234 wigglewort	334	7	0.5	255	1	BDNF_CAVPO	O70183 cavia porce
262	7	0.5	124	1	YBF3_YEAST	P38190 saccharomyc	335	7	0.5	255	1	HXD4_HUMAN	P09016 homo sapien
263	7	0.5	128	1	DHX1_ARATH	P25863 arabidopsis	336	7	0.5	258	1	VC23_VACCL	P19663 vaccinia vl
264	7	0.5	130	1	Y816_ARATH	O81868 arabidopsis	337	7	0.5	259	1	YG31_YEAST	P35369 saccharomyc
265	7	0.5	139	1	DH1_HORVU	P12951 hordeum vul	338	7	0.5	260	1	OLG1_MOUSE	Q91hm5 mus musculu
266	7	0.5	143	1	DH2_HORVU	P12952 hordeum vul	339	7	0.5	260	1	ZFP4_ARATH	Q93263 arabidopsis
267	7	0.5	145	1	DH11_GOSHI	P09442 gossypium h	340	7	0.5	262	1	COR4_WHEAT	P46524 triticum ae
268	7	0.5	148	1	PF02_ARATH	O91398 arabidopsis	341	7	0.5	263	1	COL1_PANCA	P11885 rana catesb
269	7	0.5	149	1	DH15_WHEAT	Q00742 triticum ae	342	7	0.5	263	1	PSF1_ARATH	Q42029 arabidopsis
270	7	0.5	150	1	ZFP2_ARATH	Q39261 arabidopsis	343	7	0.5	265	1	PSF2_ARATH	O49344 arabidopsis
271	7	0.5	151	1	DH1D_ORYSA	P22239 oryza sativ	344	7	0.5	265	1	Y1F6_YEAST	P40572 saccharomyc
272	7	0.5	155	1	DHB_CRAVL	P22239 creatorectig	345	7	0.5	266	1	SUB1_PYRAE	O8zu79 pyrobaculum
273	7	0.5	160	1	KFIC_MOUSE	O35071 mus musculu	346	7	0.5	268	1	LB13_ARATH	O9a61 arabidopsis
274	7	0.5	160	1	NUSB_CHLPP	Q92660 chlamydia p	347	7	0.5	268	1	UPK_BUCBP	P59523 buchnera ap
275	7	0.5	161	1	DH3_HORVU	P12948 hordeum vul	348	7	0.5	273	1	FMDC_METUA	O58471 metanococ
276	7	0.5	163	1	DH21_ORYSA	P12253 oryza sativ	349	7	0.5	274	1	PSBS_SEPOL	Q02060 spinaecta ol
277	7	0.5	164	1	DH1B_ORYSA	P22911 oryza sativ	350	7	0.5	275	1	HXA5_HETFR	O91a23 heterodontu
278	7	0.5	164	1	DH1C_ORYSA	P22912 oryza sativ	351	7	0.5	280	1	V1B3_HCMVT	P06434 human cytom
279	7	0.5	166	1	YEF4_YEAST	P32617 saccharomyc	352	7	0.5	284	1	CAS1_RAT	P02661 rattus norv
280	7	0.5	168	1	DH1_MAIZE	P12950 zea mays (m	353	7	0.5	285	1	Y007_BORBU	O51040 borrelia bu
281	7	0.5	168	1	PIG1_DROME	P26023 drosophila	354	7	0.5	285	1	YK62_CAEEL	P46582 caenorhabd
282	7	0.5	169	1	Y358_BUCAL	P57439 buchnera ap	355	7	0.5	292	1	Y042_CAEEL	P34680 caenorhabd
283	7	0.5	170	1	COP1_ARATH	Q39065 arabidopsis	356	7	0.5	297	1	TX20_MOUSE	Q9e003 mus musculu
284	7	0.5	170	1	DEF_AGR75	O8u1d1 agrobacteri	357	7	0.5	304	1	WR13_ARATH	Q9aeb7 arabidopsis
285	7	0.5	170	1	HSB7_HUMAN	O9ub9y homo sapien	358	7	0.5	306	1	EC40_DAUCA	O07322 danus caro
286	7	0.5	174	1	DEF_RHIME	Q92sh6 rhizobium m	359	7	0.5	308	1	ZDH7_HUMAN	O9uxf28
287	7	0.5	184	1	DHLE_RAPSA	P21298 raphanus sa	360	7	0.5	310	1	UDP_HUMAN	O16631 homo sapien
288	7	0.5	185	1	DH14_ARATH	P42763 arabidopsis	361	7	0.5	313	1	TF62_DROME	P02032 drosophila
289	7	0.5	188	1	ERBP_RAT	P06911 rattus norv	362	7	0.5	313	1	YMS8_YEAST	Q03695 saccharomyc
290	7	0.5	190	1	ARF_GIALA	P26991 giardia lam	363	7	0.5	314	1	SINA_DROME	P21661 drosophila
291	7	0.5	193	1	LB12_ARATH	O81bw3 arabidopsis	364	7	0.5	314	1	SINA_DROVI	P29904 drosophila
292	7	0.5	194	1	YK42_PYRPU	O8tze3 pyrococcus	365	7	0.5	323	1	OTX1_BRARE	O91994 brachydanio
293	7	0.5	198	1	AMOS_DROME	Q9y0a7 drosophila	366	7	0.5	324	1	Y170_ARCFU	O28112 archaeoglob
294	7	0.5	198	1	C4_GIALA	Q01832 giardia lam	367	7	0.5	325	1	YH03_YEAST	P38844 saccharomyc
295	7	0.5	198	1	CAS1_CAVPO	P40656 cavia porce	368	7	0.5	328	1	CAHC_PEA	P17067 pisum sativ
296	7	0.5	200	1	HMGH_STRPU	P40644 strongyloce	369	7	0.5	328	1	DLX2_HUMAN	Q07687 homo sapien
297	7	0.5	203	1	YGR3_YEAST	P53288 saccharomyc	370	7	0.5	329	1	PS7B_MYCGE	P47550 mycoplasma
298	7	0.5	207	1	NUGM_HANMT	P48927 hansenula w	371	7	0.5	333	1	PIX2_CHICK	O93385 gallus gall
299	7	0.5	207	1	YUT2_YEAST	P47087 saccharomyc	372	7	0.5	334	1	LYTE_BACSU	P54421 bacillus su
300	7	0.5	211	1	SOCI_HUMAN	O15524 homo sapien	373	7	0.5	335	1	HXDD_HUMAN	P35453 homo sapien
301	7	0.5	212	1	SOCI_MOUSE	O35716 mus musculu	374	7	0.5	336	1	CAHC_ARATH	P27140 arabidopsis
302	7	0.5	212	1	SOCI_RAT	O9qx78 rattus norv	375	7	0.5	338	1	FEN_METAC	O8t1y5 methanosarc
303	7	0.5	213	1	HPI_DROVI	P29227 drosophila	376	7	0.5	338	1	FEN_METMA	O8y1f6 methanosarc
304	7	0.5	216	1	ANSE_EIMTE	P15744 eimeria ten	377	7	0.5	338	1	HRC4_THENA	O9wzvs thermotoga
305	7	0.5	218	1	ESM2_DROME	O97177 drosophila	378	7	0.5	338	1	OTX3_BRARE	Q90617 brachydanio
306	7	0.5	218	1	WR12_ARATH	Q93wy4 arabidopsis	379	7	0.5	339	1	HXDD_MOUSE	P70217 mus musculu
307	7	0.5	219	1	CO4_TTVI	P19273 thermoprote	380	7	0.5	344	1	TRPD_BRUME	O8y1f7 bruceella me
308	7	0.5	222	1	COL1_THUOB	O9yGK2 t corticocor	381	7	0.5	344	1	YB1E_SCHPO	P81917 schizosacch
309	7	0.5	223	1	DEOC_STRP3	O8nu59 streptococc	382	7	0.5	347	1	E13A_SOYBN	O03173 glycine max
310	7	0.5	223	1	DEOC_STRPY	O99y51 streptococc	383	7	0.5	347	1	UTR2_YEAST	P36223 saccharomyc
311	7	0.5	224	1	RM01_RECAM	O21235 reglinomona	384	7	0.5	347	1	V1T3_CHICK	Q91025 gallus gall
312	7	0.5	225	1	DH4_HORVU	P12949 hordeum vul	385	7	0.5	352	1	STSY_CATRO	P18417 catharanthu
313	7	0.5	228	1	DH25_ORYSA	P30287 oryza sativ	386	7	0.5	355	1	HKL6_LYCES	O22299 lycopersico
314	7	0.5	229	1	COAT_TAV	P23627 tomato aspe	387	7	0.5	355	1	YDP6_SCHPO	O14009 schizosacch
315	7	0.5	229	1	LB11_ARATH	O9sk08 arabidopsis	388	7	0.5	357	1	V136_DICDI	O94480 dictyostell
316	7	0.5	230	1	DAG_ANTMA	O38732 antirrhinum	389	7	0.5	363	1	CVA2_RHIME	O52015 rhizobium m
317	7	0.5	235	1	YHE4_YEAST	P38727 saccharomyc	390	7	0.5	364	1	NK61_RHESAU	O60554 mesocricetu
318	7	0.5	238	1	CW14_YEAST	O13547 saccharomyc	391	7	0.5	365	1	NK61_MOUSE	Q99na9 mus musculu
319	7	0.5	238	1	MNBA_MAIZE	P38564 zea mays (m	392	7	0.5	365	1	GGP2_SINNA	O43313 sinapis alb
320	7	0.5	242	1	NAGB_MYCPE	O8emw7 mycoplasma	393	7	0.5	367	1	Y797_METUA	P78426 homo sapien
321	7	0.5	243	1	ERP2_ARATH	O80338 arabidopsis	394	7	0.5	367	1	NK61_HUMAN	O58407 metanococ
322	7	0.5	243	1	IM17_ARATH	O9sp35 arabidopsis	395	7	0.5	368	1	ROX1_YEAST	P25042 saccharomyc
323	7	0.5	244	1	VC23_VACCC	P21090 vaccinia vi	396	7	0.5	369	1	MAGA_HUMAN	P43363 homo sapien
324	7	0.5	244	1	YENR_YEREN	P54295 yerlinala en	397	7	0.5	372	1	COO2_YEAST	P33278 saccharomyc
325	7	0.5	246	1	AX1B_ARATH	Q38829 arabidopsis	398	7	0.5	372	1		

399	7	0.5	375	1	OTC_PEA	043814	pisum sativ	472	7	0.5	472	1	K1CP_HUMAN	P08779	homo sapien
400	7	0.5	376	1	YBC3_YEAST	P38201	saccharomyc	472	7	0.5	473	1	PLSB_SPIOL	Q3869	spiniacia ol
401	7	0.5	377	1	VE2_HPV13	Q02263	human papil	474	7	0.5	473	1	ATH1_ARATH	P48731	arabidopsis
402	7	0.5	377	1	VMAT_P12HT	P24266	human papil	475	7	0.5	474	1	LAM3_MOUSE	P48600	mus musculus
403	7	0.5	377	1	Y835_METUA	Q58245	methanococc	476	7	0.5	474	1	SOX4_HUMAN	Q06945	homo sapien
404	7	0.5	378	1	KLP2_BOMMO	P48245	bombyx mori	477	7	0.5	475	1	SIM1_YEAST	P40472	saccharomyc
405	7	0.5	379	1	HMB1_SOYBN	P46608	glycine max	478	7	0.5	476	1	CBP2_HORVU	P08818	hordeum vul
406	7	0.5	382	1	TP6A_PYRAF	Q94133	pyrococcus	479	7	0.5	476	1	REF3_SACBA	P05512	saccharomyc
407	7	0.5	382	1	TP6A_PYRFU	Q80043	pyrococcus	480	7	0.5	479	1	DPB1_BACSU	P42305	bacillus su
408	7	0.5	383	1	TP6A_PYRHO	Q59209	pyrococcus	481	7	0.5	479	1	YP66_YEAST	Q12194	saccharomyc
409	7	0.5	383	1	G1C2_YEAST	Q06648	saccharomyc	482	7	0.5	481	1	HH_DROH1	P56674	drosophila
410	7	0.5	383	1	TRB2_ARATH	Q39242	arabidopsis	483	7	0.5	482	1	YSR2_CAEEL	Q00950	caenorhabdi
411	7	0.5	386	1	RMAR_HAWMI	P48849	hansenuia w	484	7	0.5	484	1	YOD0_YEAST	Q08193	saccharomyc
412	7	0.5	387	1	WR36_ARATH	Q99474	arabidopsis	485	7	0.5	485	1	Y136_TREPA	Q83112	treponema p
413	7	0.5	389	1	SERI_BOMMO	P07856	bombyx mori	486	7	0.5	487	1	OAF_DROME	Q09166	drosophila
414	7	0.5	392	1	ODD_DROME	P23803	drosophila	487	7	0.5	489	1	MDM2_MOUSE	P23804	mus musculus
415	7	0.5	393	1	IRTF_HUMAN	Q00978	homo sapien	488	7	0.5	489	1	SFR4_MOUSE	Q28577	mus musculus
416	7	0.5	394	1	VATC_SCHPO	Q09466	schizosacch	489	7	0.5	489	1	WR47_ARATH	Q95817	arabidopsis
417	7	0.5	397	1	HKL2_MALDO	Q04135	malus domes	490	7	0.5	491	1	KCS3_HUMAN	Q94317	homo sapien
418	7	0.5	397	1	YK08_CAEEL	P34303	caenorhabdi	491	7	0.5	491	1	KCS3_RABIT	Q9CT17	oryctolagus
419	7	0.5	398	1	CAR4_RHINI	Q03700	rhizopus ni	492	7	0.5	491	1	KCS3_RAT	Q88759	rattus norv
420	7	0.5	399	1	HM39_CAEEL	Q22812	caenorhabdi	493	7	0.5	493	1	HMBB_DROME	P09087	drosophila
421	7	0.5	400	1	OMPA_THEMEA	P25724	thermotoga	494	7	0.5	500	1	DCE_PETRY	Q07346	petunia hyb
422	7	0.5	401	1	NNOS_DROME	P32583	saccharomyc	495	7	0.5	501	1	ANKH_BRARE	P58368	brachydanio
423	7	0.5	406	1	SR40_YEAST	Q16186	homo sapien	496	7	0.5	503	1	WSC2_YEAST	P26536	saccharomyc
424	7	0.5	407	1	ADRM_HUMAN	Q16186	homo sapien	497	7	0.5	504	1	VLI1_HPV51	P26536	human papil
425	7	0.5	407	1	ADRM_MOUSE	Q91KVI	mus musculus	498	7	0.5	505	1	GPW1_MYCPU	Q98947	mycoplasma
426	7	0.5	407	1	ADRM_RAT	Q91KVI	mus musculus	499	7	0.5	506	1	NPL3_HUMAN	Q99477	homo sapien
427	7	0.5	407	1	RP11_YEAST	P21075	rattus norv	500	7	0.5	508	1	CROC_DROME	P32027	drosophila
428	7	0.5	410	1	PGK_METFE	P20971	methanother	501	7	0.5	510	1	KPKC_PLAFK	Q02555	plasmodium
429	7	0.5	410	1	PO42_HUMAN	Q12837	homo sapien	502	7	0.5	510	1	MS2P_CRIGR	Q54862	cricetulus
430	7	0.5	410	1	VIE2_HCWMT	P06433	human cytom	503	7	0.5	511	1	GUNB_PSEFL	P18116	pseudomonas
431	7	0.5	411	1	PO42_MOUSE	Q63934	mus musculus	504	7	0.5	512	1	GLGT_VICFA	Q04931	arabidopsis
432	7	0.5	411	1	VIE2_HCWMA	P19893	human cytom	505	7	0.5	512	1	WR33_ARATH	Q08585	arabidopsis
433	7	0.5	411	1	VA12_SCHPO	Q09685	schizosacch	506	7	0.5	512	1	COX1_PAPHA	Q92472	papio hamad
434	7	0.5	414	1	NSR1_YEAST	P27476	saccharomyc	507	7	0.5	513	1	CBX2_MOUSE	P30658	mus musculus
435	7	0.5	416	1	OS3A_DROME	Q9V372	drosophila	508	7	0.5	519	1	MS2P_HUMAN	Q34362	homo sapien
436	7	0.5	416	1	SO_DROME	Q27350	drosophila	509	7	0.5	519	1	PTP1_DICDI	P34137	dictyosteli
437	7	0.5	421	1	SYT1_MOUSE	P46096	mus musculus	510	7	0.5	521	1	HME2_SCHMA	Q26601	schistosoma
438	7	0.5	421	1	SYT1_RAT	P21707	rattus norv	511	7	0.5	524	1	HUNB_TRICA	Q01774	tribolium c
439	7	0.5	422	1	SYT1_BOVIN	P46018	bos taurus	512	7	0.5	524	1	YACB_YEAST	Q19791	saccharomyc
440	7	0.5	422	1	SYT1_HUMAN	P21579	homo sapien	513	7	0.5	528	1	ICPO_HAVER	P28990	equine heip
441	7	0.5	423	1	VDR_RAT	P13053	rattus norv	514	7	0.5	532	1	YEN1_SCHPO	O13695	schizosacch
442	7	0.5	424	1	SYT1_CHICK	P47191	gallus gall	515	7	0.5	536	1	SP70_DICDI	P32659	dictyosteli
443	7	0.5	427	1	MYCN_SERCA	P26504	serinus can	516	7	0.5	537	1	IFC3_EUGER	P36177	euglena gra
444	7	0.5	427	1	STG1_DISOM	P24505	saccharomyc	517	7	0.5	538	1	EGRI_HUMAN	P18116	homo sapien
445	7	0.5	429	1	DR48_YEAST	P18899	saccharomyc	518	7	0.5	543	1	HMA1_ARATH	P28712	saccharomyc
446	7	0.5	431	1	AFER_EMENI	P31362	mus musculus	519	7	0.5	543	1	RRP3_YEAST	P48425	thermoplasm
447	7	0.5	433	1	RTG1_DICDI	P52957	emeritella	520	7	0.5	543	1	THSB_THEAC	O13318	candida alb
448	7	0.5	433	1	VO23_ROMPV	Q15746	dictyosteli	521	7	0.5	546	1	PHR2_CANAL	Q13628	homo sapien
449	7	0.5	434	1	SOX4_MOUSE	Q06831	mus musculus	522	7	0.5	548	1	ERF_HUMAN	Q12568	homo sapien
450	7	0.5	440	1	VRN2_ARATH	Q845b1	arabidopsis	523	7	0.5	548	1	WR72_ARATH	Q13058	arabidopsis
451	7	0.5	440	1	TIG_DREPA	Q12947	homo sapien	524	7	0.5	549	1	EPD2_CANMA	O74137	candida mal
452	7	0.5	449	1	THI2_YEAST	Q9P064	ureaplasma	525	7	0.5	551	1	ERF_MOUSE	P70459	mus musculus
453	7	0.5	450	1	LTH1_YEAST	P31141	saccharomyc	526	7	0.5	551	1	YG1F_YEAST	P53124	saccharomyc
454	7	0.5	450	1	K1CO_MOUSE	P36135	saccharomyc	527	7	0.5	552	1	HMEN_DROME	P02836	drosophila
455	7	0.5	452	1	PUB1_YEAST	Q61414	mus musculus	528	7	0.5	552	1	ENS2_YEAST	P12294	saccharomyc
456	7	0.5	452	1	MDHP_FLABI	P46489	flaveria b	529	7	0.5	559	1	GAT2_YEAST	P22146	saccharomyc
457	7	0.5	453	1	PLSB_PHAVU	Q43822	phaseolus v	530	7	0.5	560	1	P2B2_DROME	Q47029	saccharomyc
458	7	0.5	461	1	SELA_CLOPE	Q841k2	clostridium	531	7	0.5	560	1	CH13_CANAL	Q40954	candida alb
459	7	0.5	462	1	CAR_DICDI	P54654	dictyosteli	532	7	0.5	567	1	AP9_HUMAN	P42568	homo sapien
460	7	0.5	464	1	IFB_BRALA	Q04948	branchiosteo	533	7	0.5	569	1	ESR1_BRARE	P57717	brachydanio
461	7	0.5	464	1	HNF6_HUMAN	Q094dc0	homo sapien	534	7	0.5	571	1	YXNC_PSEFL	P23031	pseudomonas
462	7	0.5	465	1	CYP6_RAT	P07051	rattus norv	535	7	0.5	573	1	MTG8_MOUSE	Q61909	mus musculus
463	7	0.5	465	1	CYP6_MOUSE	P50116	caenorhabdi	536	7	0.5	577	1	MDLB_BUCAP	Q62073	mus musculus
464	7	0.5	466	1	KG3H_DICDI	P51136	dictyosteli	537	7	0.5	578	1	MDLB_BUCAP	Q62073	mus musculus
465	7	0.5	468	1	Y134_CAEEL	P34425	caenorhabdi	538	7	0.5	580	1	MDLB_BUCAP	Q62073	mus musculus
466	7	0.5	469	1	PLSB_CUCSA	Q39639	cucumis sat	539	7	0.5	581	1	AXU1_MOUSE	Q22777	homo sapien
467	7	0.5	470	1	HH_DROME	Q02936	drosophila	540	7	0.5	582	1	AXU1_MOUSE	P59054	mus musculus
468	7	0.5	471	1				541	7	0.5	583	1	CH12_CANAL	P40953	candida alb
469	7	0.5	471	1				542	7	0.5					
470	7	0.5	471	1				543	7	0.5					
471	7	0.5	471	1				544	7	0.5					

545	7	0.5	586	1	HM26_CABEL	P34522	caenorhabdi	618	7	0.5	689	1	KF1B_RAT	O88658	rattus norv
546	7	0.5	586	1	SYN2_RAT	O63537	rattus norv	619	7	0.5	690	1	GSN1_CANAL	O94788	candida alb
547	7	0.5	589	1	AXU1_HUMAN	O96855	homo sapien	620	7	0.5	693	1	CAUP_DROME	O54269	drosophila
548	7	0.5	590	1	HMAA_DROME	P29555	drosophila	621	7	0.5	697	1	AN3_XENLA	P24346	xenopus lae
549	7	0.5	590	1	NPAL_HUMAN	O99742	homo sapien	622	7	0.5	699	1	KI22_STRPU	P46872	strongyloce
550	7	0.5	592	1	ODP2_DICDI	P36413	dictyosteli	623	7	0.5	699	1	NP14_HUMAN	O14978	homo sapien
551	7	0.5	593	1	CC23_SCHPO	P23030	pseudomonas	624	7	0.5	699	1	SRCH_HUMAN	P23337	homo sapien
552	7	0.5	593	1	XYNB_PSEFL	O42709	schistosach	625	7	0.5	701	1	KF3A_MOUSE	P28177	mus musc
553	7	0.5	594	1	NPAL_MOUSE	P74759	mus musc	626	7	0.5	701	1	UBP2_XENLA	P25960	xenopus lae
554	7	0.5	594	1	RBUX_DROME	P81559	drosophila	627	7	0.5	702	1	DDX4_MOUSE	O61446	mus musc
555	7	0.5	598	1	RACA_DICDI	P34147	dictyosteli	628	7	0.5	702	1	KF3A_HUMAN	O94466	homo sapien
556	7	0.5	600	1	LAM2_CHICK	P14732	gallus gall	629	7	0.5	704	1	CT67_HUMAN	O94423	homo sapien
557	7	0.5	600	1	AKS1_YEAST	P42826	saccharomyc	630	7	0.5	704	1	NP1A_RAT	P11777	rattus norv
558	7	0.5	601	1	DEAD_BUCAL	P57453	buchnera ap	631	7	0.5	706	1	C1AA_PAEPP	O45338	paenibacilli
559	7	0.5	601	1	DEAD_BUCAL	O8K916	buchnera ap	632	7	0.5	706	1	CT67_MOUSE	P59114	mus musc
560	7	0.5	602	1	DEAD_BUCBP	O89419	buchnera ap	633	7	0.5	706	1	DREB_MOUSE	O94966	mus musc
561	7	0.5	603	1	BUD8_YEAST	P41658	saccharomyc	634	7	0.5	706	1	FTSH_MEDSA	O94966	mus musc
562	7	0.5	604	1	DED1_YEAST	P06634	saccharomyc	635	7	0.5	706	1	KIF2_YEAST	P28743	saccharomyc
563	7	0.5	604	1	MTG8_HUMAN	O06455	homo sapien	636	7	0.5	707	1	DREB_RAT	O07266	rattus norv
564	7	0.5	605	1	WIS1_SCHPO	P33886	schistosach	637	7	0.5	709	1	PP22_YEAST	P33329	saccharomyc
565	7	0.5	606	1	SAK7_HUMAN	O43318	homo sapien	638	7	0.5	710	1	GSOD_ERWCH	O01565	erwinia chr
566	7	0.5	610	1	SANI_YEAST	P22470	saccharomyc	639	7	0.5	712	1	GSPD_ERWCH	P31700	erwinia chr
567	7	0.5	611	1	XYNA_PSEFL	P14738	pseudomonas	640	7	0.5	713	1	DDX4_RAT	O64060	rattus norv
568	7	0.5	613	1	DEAD_HAFLN	P44566	haemophilus	641	7	0.5	715	1	ADSV_BOVIN	O28046	bos taurus
569	7	0.5	614	1	DDX5_MOUSE	P17844	homo sapien	642	7	0.5	720	1	NRG3_HUMAN	O01836	caenorhabdi
570	7	0.5	614	1	NRD1_HUMAN	O61656	mus musc	643	7	0.5	720	1	PKP1_BOVIN	P56975	homo sapien
571	7	0.5	614	1	DBP1_YEAST	P24784	saccharomyc	644	7	0.5	723	1	MASZ_RHILV	O92737	rhizobium l
572	7	0.5	617	1	ORC2_DROME	O24168	drosophila	645	7	0.5	723	1	MASZ_RHIME	O92734	rhizobium m
573	7	0.5	618	1	ZEST_DROVI	O24762	drosophila	646	7	0.5	724	1	DDX4_HUMAN	O94910	homo sapien
574	7	0.5	618	1	ZEST_DROVI	P26883	clostridium	647	7	0.5	727	1	MEPI_ARATH	O91765	arabidopsis
575	7	0.5	619	1	PPID_BUCAP	O8K987	buchnera ap	648	7	0.5	727	1	VIV_ORYSA	O28161	bos taurus
576	7	0.5	621	1	YRT1_CABEL	O10044	caenorhabdi	649	7	0.5	728	1	CDK9_HUMAN	O60505	homo sapien
577	7	0.5	622	1	RBPD_BACSU	P40750	baacillus su	650	7	0.5	730	1	GLN3_YEAST	P46551	caenorhabdi
578	7	0.5	624	1	KN12_HUMAN	O94942	homo sapien	651	7	0.5	730	1	BAF1_YEAST	P18494	saccharomyc
579	7	0.5	624	1	DEAD_ECOLI	P23304	escherichia	652	7	0.5	731	1	RRP6_YEAST	O14164	saccharomyc
580	7	0.5	628	1	CNEB_HUMAN	O9416	homo sapien	653	7	0.5	733	1	NEFL_MOUSE	O61965	mus musc
581	7	0.5	632	1	DNK2_SYNP7	P46593	candida alb	654	7	0.5	741	1	DBP1_YEAST	P46871	strongyloce
582	7	0.5	633	1	HMPI_CANAL	O15209	homo sapien	655	7	0.5	742	1	KM65_YEAST	O03656	saccharomyc
583	7	0.5	634	1	DED1_SCHPO	O13370	schistosach	656	7	0.5	742	1	GYP7_YEAST	P48363	saccharomyc
584	7	0.5	634	1	Y551_SYNY3	O01546	homo sapien	657	7	0.5	747	1	ASP4_BOVIN	O15066	homo sapien
585	7	0.5	636	1	Y551_SYNY3	P54123	synecocyst	658	7	0.5	747	1	2ASD_YEAST	O61717	mus musc
586	7	0.5	641	1	DEAD_KLEPN	P33573	petromyzon	659	7	0.5	747	1	PARC_HAEIN	P43702	haemophilus
587	7	0.5	644	1	BDT_DROME	P23396	klebsiella	660	7	0.5	748	1	GUNC_PSEFL	P27033	pseudomonas
588	7	0.5	644	1	LONH_METJA	O24266	drosophila	661	7	0.5	748	1	KHL1_HUMAN	O94910	homo sapien
589	7	0.5	649	1	DD17_HUMAN	O98812	methanococc	662	7	0.5	751	1	KHL1_MOUSE	O94910	homo sapien
590	7	0.5	650	1	Y411_HUMAN	O43295	homo sapien	663	7	0.5	753	1	TKR_DROME	P14083	drosophila
591	7	0.5	650	1	DRBB_CHICK	P18302	gallus gall	664	7	0.5	754	1	ASPH_BOVIN	O28056	bos taurus
592	7	0.5	652	1	HS77_YEAST	P12398	saccharomyc	665	7	0.5	757	1	AMY_GLOAB	P38993	saccharomyc
593	7	0.5	654	1	ACSA_RHOCA	O68040	rhododactyl	666	7	0.5	760	1	GLH1_CABEL	P23671	clostridium
594	7	0.5	656	1	YNE7_YEAST	P53955	saccharomyc	667	7	0.5	763	1	CSW_DROVI	P34689	caenorhabdi
595	7	0.5	657	1	GLGX_ECOLI	P15067	escherichia	668	7	0.5	764	1	UBP1_HUMAN	O24708	drosophila
596	7	0.5	657	1	DDXY_HUMAN	O15523	homo sapien	669	7	0.5	764	1	UBP1_RAT	P17480	homo sapien
597	7	0.5	660	1	PL10_MOUSE	P16381	mus musc	670	7	0.5	765	1	NEFL_MOUSE	P25977	rattus norv
598	7	0.5	661	1	DDX3_HUMAN	O00571	mus musc	671	7	0.5	772	1	KLPI_CHLRE	P25976	mus musc
599	7	0.5	661	1	VASA_DROME	O62167	mus musc	672	7	0.5	776	1	NIMI_NEUCR	O44840	h nuclear f
600	7	0.5	661	1	MBB1_CHIRE	P09052	drosophila	673	7	0.5	779	1	KMHI_NEUCR	P46870	chlamydomon
601	7	0.5	662	1	YEL8_YEAST	O9fns4	chlamydomon	674	7	0.5	783	1	KMHI_DICDI	P48479	neurospora
602	7	0.5	663	1	PIT_DROME	P43620	saccharomyc	675	7	0.5	785	1	SOK2_YEAST	P34125	dictyosteli
603	7	0.5	663	1	KUOS_YEAST	O9vds1	drosophila	676	7	0.5	786	1	FL10_CHLRE	P54669	chlamydomon
604	7	0.5	663	1	KF22_HUMAN	P47005	saccharomyc	677	7	0.5	789	1	ADOT_RAT	P46380	rattus norv
605	7	0.5	666	1	NOD_DROME	P14807	homo sapien	678	7	0.5	790	1	KIF9_MOUSE	O94904	mus musc
606	7	0.5	666	1	CHS5_YEAST	P18105	drosophila	679	7	0.5	790	1	KIF17_HUMAN	O94902	homo sapien
607	7	0.5	671	1	HSF_KLULA	P21214	kluyveromyc	680	7	0.5	793	1	KEF3_HUMAN	O14782	homo sapien
608	7	0.5	677	1	UBF1_XENLA	P25979	xenopus lae	681	7	0.5	795	1	TBC5_HUMAN	O92609	homo sapien
609	7	0.5	679	1	PAN3_YEAST	P26102	saccharomyc	682	7	0.5	796	1	KF3C_MOUSE	O35066	mus musc
610	7	0.5	684	1	EP84_HCVVA	P17151	human cytom	683	7	0.5	796	1	KF3C_RAT	O55165	rattus norv
611	7	0.5	684	1	RPFL_HUMAN	P78424	homo sapien	684	7	0.5	801	1	BRD2_HUMAN	P25440	homo sapien
612	7	0.5	686	1	PLB3_YEAST	O08108	saccharomyc	685	7	0.5	805	1	DF19_CABEL	O09585	caenorhabdi

691	7	0.5	805	1	E2F_DROME	Q27368 drosophila	764	7	0.5	1070	1	AGLU_CANTS	P29064 candida tsu
692	7	0.5	805	1	PIF1_SCHPO	Q9uua2 schizosacch	765	7	0.5	1075	1	FLOS_YEAST	P28894 saccharomyc
693	7	0.5	807	1	YAK1_YEAST	P14680 saccharomyc	766	7	0.5	1077	1	HUES_DROME	Q02308 drosophila
694	7	0.5	808	1	FREB_DROME	O05192 drosophila	767	7	0.5	1081	1	GALY_YEAST	P19655 saccharomyc
695	7	0.5	810	1	RBB1_YEAST	P21538 saccharomyc	768	7	0.5	1082	1	SP23_YEAST	P35203 saccharomyc
696	7	0.5	816	1	HUNB_DROVI	P13361 drosophila	769	7	0.5	1085	1	AMP1_PLAFO	Q36935 plasmodium
697	7	0.5	816	1	YG3A_YEAST	P53278 saccharomyc	770	7	0.5	1085	1	CUT7_SCHPO	P24349 schizosacch
698	7	0.5	817	1	VRP1_YEAST	P37370 saccharomyc	771	7	0.5	1090	1	NIT4_NEUCR	P28349 neurospora
699	7	0.5	829	1	E74A_DROME	P20105 drosophila	772	7	0.5	1093	1	AP17_HUMAN	P51828 homo sapien
700	7	0.5	838	1	L100_ADEP3	O9rt77 porcine ade	773	7	0.5	1097	1	CCT_DROME	O96433 drosophila
701	7	0.5	843	1	CO7_FIG	O9rtug3 sus scrofa	774	7	0.5	1097	1	KPID_RAT	O35787 retus norv
702	7	0.5	843	1	CPPI_BRUMA	Q27450 brugia mala	775	7	0.5	1103	1	KPIC_HUMAN	O43886 homo sapien
703	7	0.5	845	1	CLPC_CHLEPN	Q948a6 chlamydia p	776	7	0.5	1111	1	KIP1_YEAST	P28742 saccharomyc
704	7	0.5	845	1	ITBX_DROME	P11584 drosophila	777	7	0.5	1115	1	TBC2_CHIRE	Q8vxp3 chlamydomon
705	7	0.5	850	1	D7_DICDI	P54682 dictyosteli	778	7	0.5	1141	1	SRE2_HUMAN	Q12772 homo sapien
706	7	0.5	850	1	NRG2_HUMAN	O14511 homo sapien	779	7	0.5	1142	1	MGCI_HUMAN	O60703 homo sapien
707	7	0.5	854	1	CC24_YEAST	P14433 saccharomyc	780	7	0.5	1142	1	PAK1_YEAST	P38990 saccharomyc
708	7	0.5	856	1	KF23_HUMAN	Q02241 homo sapien	781	7	0.5	1146	1	YHC3_YEAST	P38742 saccharomyc
709	7	0.5	859	1	ALR1_YEAST	Q08269 saccharomyc	782	7	0.5	1147	1	KIN2_YEAST	P33166 saccharomyc
710	7	0.5	864	1	YCI8_HUMAN	Q9u1k2 homo sapien	783	7	0.5	1156	1	PHYB_SOYBN	P24499 glycine max
711	7	0.5	866	1	MYSP_SCHMA	O66198 schistosoma	784	7	0.5	1169	1	YK82_YEAST	P36170 saccharomyc
712	7	0.5	868	1	WV2_MOUSE	O60992 mus musculu	785	7	0.5	1184	1	BIMC_EMENT	P17120 emericella
713	7	0.5	878	1	KPCO_HUMAN	Q96216 homo sapien	786	7	0.5	1185	1	DRPL_HUMAN	P54259 homo sapien
714	7	0.5	878	1	VAV2_HUMAN	P52735 homo sapien	787	7	0.5	1189	1	YU6_YEAST	P47033 saccharomyc
715	7	0.5	880	1	BRC4_DROME	Q24206 drosophila	788	7	0.5	1202	1	RFM2_YEAST	Q02773 saccharomyc
716	7	0.5	881	1	PRY3_YEAST	P47033 saccharomyc	789	7	0.5	1210	1	AF4_HUMAN	P51825 homo sapien
717	7	0.5	883	1	E74B_DROME	P11536 drosophila	790	7	0.5	1211	1	BUN2_DROME	Q4523 drosophila
718	7	0.5	885	1	YD03_YEAST	O06639 saccharomyc	791	7	0.5	1214	1	BRF1_HUMAN	P55201 homo sapien
719	7	0.5	887	1	K20A_MOUSE	P97329 mus musculu	792	7	0.5	1224	1	ABL1_CAREL	P03949 caenorhabdi
720	7	0.5	890	1	K20A_HUMAN	O95235 homo sapien	793	7	0.5	1227	1	LAF4_HUMAN	P51826 homo sapien
721	7	0.5	892	1	ATX7_HUMAN	O15265 homo sapien	794	7	0.5	1235	1	TRK1_YEAST	P12685 saccharomyc
722	7	0.5	894	1	WPR4_BACSU	P54423 bacillus su	795	7	0.5	1237	1	E75A_DROME	P17671 drosophila
723	7	0.5	902	1	RNB_BUCAL	P57429 buchnera ap	796	7	0.5	1238	1	YNI3_YEAST	P33840 saccharomyc
724	7	0.5	903	1	DPOL_BPR69	O38087 bacterioph	797	7	0.5	1244	1	SLA1_YEAST	P32790 saccharomyc
725	7	0.5	909	1	WTC2_YEAST	P53185 saccharomyc	798	7	0.5	1271	1	Y338_MYCCE	P47580 mycoplasma
726	7	0.5	918	1	PMAI_YEAST	P05030 saccharomyc	799	7	0.5	1298	1	ICP4_HSV11	P08392 herpes slimp
727	7	0.5	925	1	PDCC_YEAST	P38966 saccharomyc	800	7	0.5	1310	1	ICP4_VZVD	P09310 varicella-z
728	7	0.5	928	1	KINH_NEUCR	P48467 neurospora	801	7	0.5	1324	1	SALI_HUMAN	Q09832 homo sapien
729	7	0.5	928	1	KKRI_YEAST	P36003 saccharomyc	802	7	0.5	1328	1	HUS2_SCHPO	O09811 schizosacch
730	7	0.5	936	1	PHL1_YEAST	P38521 saccharomyc	803	7	0.5	1337	1	YDM5_SCHPO	O8u1k3 schizosacch
731	7	0.5	939	1	STI20_YEAST	O03497 saccharomyc	804	7	0.5	1341	1	ACTN_HUMAN	O8u1k3 homo sapien
732	7	0.5	939	1	XPC_HUMAN	Q01831 homo sapien	805	7	0.5	1394	1	E75B_DROME	P17672 drosophila
733	7	0.5	946	1	YB16_YEAST	P38250 saccharomyc	806	7	0.5	1396	1	ITTA_DROME	P31280 drosophila
734	7	0.5	947	1	PM42_YEAST	P19657 saccharomyc	807	7	0.5	1402	1	SALM_DROVI	P39806 drosophila
735	7	0.5	950	1	URB1_USTMA	P40349 usrligo ma	808	7	0.5	1402	1	Y232_HUMAN	Q02628 homo sapien
736	7	0.5	958	1	MSH4_MOUSE	O99mt2 mus musculu	809	7	0.5	1415	1	ICP4_HSVWG	O02362 marek's dis
737	7	0.5	966	1	FIEB1_PETMA	P02674 petromyzon	810	7	0.5	1443	1	BT5C_DROME	P13055 drosophila
738	7	0.5	971	1	CLA4_CANAL	O14427 candida alb	811	7	0.5	1444	1	ADPI_MYCCE	P20796 mycoplasma
739	7	0.5	972	1	TOB1_DROME	P30189 drosophila	812	7	0.5	1446	1	IE18_PRYVA	P33479 pseudotabie
740	7	0.5	980	1	KFMS_FELCA	P13369 felis silve	813	7	0.5	1461	1	IE18_PRYVF	P16175 pseudotabie
741	7	0.5	982	1	CRM_DROME	O76906 drosophila	814	7	0.5	1487	1	ICP4_HSVB	P38925 equine hepr
742	7	0.5	989	1	SER4_PLARG	P13823 plasmodium	815	7	0.5	1487	1	ICP4_HSVBK	P17473 equine hepr
743	7	0.5	993	1	RROT_ARATH	O24600 arabidopsis	816	7	0.5	1489	1	VGPO_YEAST	P53115 saccharomyc
744	7	0.5	1004	1	SAU2_MOUSE	Q94x96 mus musculu	817	7	0.5	1509	1	GSRI_HUMAN	O9nrt4 homo sapien
745	7	0.5	1006	1	EPB6_HUMAN	O15197 homo sapien	818	7	0.5	1531	1	YQ38_CABEL	Q09459 caenorhabdi
746	7	0.5	1006	1	K125_TOBAC	O23826 nicotiana t	819	7	0.5	1537	1	DNM1_CHICK	Q02072 gallus galli
747	7	0.5	1007	1	SAL2_HUMAN	O9y467 homo sapien	820	7	0.5	1579	1	SSK2_YEAST	P35499 saccharomyc
748	7	0.5	1010	1	WNT5_DROME	P23466 drosophila	821	7	0.5	1581	1	PRPB_HUMAN	O15648 h peroxisom
749	7	0.5	1025	1	KG09_HUMAN	Q910a0 homo sapien	822	7	0.5	1603	1	PSC_DROME	P35880 drosophila
750	7	0.5	1029	1	RIP3_RAT	Q9ere6 rattus norv	823	7	0.5	1609	1	ADPI_MYCPN	P35653 saccharomyc
751	7	0.5	1029	1	KSPI_YEAST	P38691 saccharomyc	824	7	0.5	1627	1	VIT2_ONCMY	P11311 mycoplasma
752	7	0.5	1037	1	NIT2_NEUCR	P19212 neurospora	825	7	0.5	1659	1	VIT2_FUNHE	Q98893 fundulus he
753	7	0.5	1047	1	HTRA_DROME	O17468 drosophila	826	7	0.5	1687	1	WIT2_FUNHE	O98091 oncofrynchu
754	7	0.5	1050	1	UKL1_HUMAN	O75385 homo sapien	827	7	0.5	1690	1	KFLA_HUMAN	O12756 homo sapien
755	7	0.5	1051	1	UKL1_MOUSE	O70405 mus musculu	828	7	0.5	1695	1	KFLA_MOUSE	P33173 mus musculu
756	7	0.5	1052	1	MGPC_MYCCE	P22747 mycoplasma	829	7	0.5	1719	1	PRD2_HUMAN	Q13029 homo sapien
757	7	0.5	1056	1	K125_ARATH	P82266 arabidopsis	830	7	0.5	1723	1	PM20_CHLEPN	Q92812 chlamydia p
758	7	0.5	1057	1	GCSP_PEA	P26969 pium sativ	831	7	0.5	1772	1	MSPI_PLAHO	P32828 plasmodium
759	7	0.5	1057	1	KFL1_HUMAN	P22732 homo sapien	832	7	0.5	1782	1	VIT2_BOMMO	Q27309 bombyx mori
760	7	0.5	1060	1	EG51_XENLA	P28025 xenopus lae	833	7	0.5	1807	1	VTAA2_XENLA	P18709 xenopus lae
761	7	0.5	1065	1	SED4_YEAST	P23365 saccharomyc	834	7	0.5	1816	1	KPIB_HUMAN	O60333 homo sapien
762	7	0.5	1066	1	KL61_DROME	P46863 drosophila	835	7	0.5	1816	1	KPIB_MOUSE	O60575 mus musculu
763	7	0.5	1067	1	EG52_XENLA	Q91783 xenopus lae	836	7	0.5	1822	1	ZAP3_HUMAN	P49750 homo sapien

837	7	0.5	1823	1	VIT_ICHUN	Q91062	ichthyomyzo	910	6	0.5	122	1	MP22_PHLPR	P43214	phleum grat
838	7	0.5	1912	1	Y468_MYCPN	P75109	mycoplasma	911	6	0.5	122	1	PA2_VIRPB	P31854	viperia беру
839	7	0.5	1822	1	VIT1_CHICK	P87409	gallus gall	912	6	0.5	122	1	RL7_STRAM	Q9966	staphylococ
840	7	0.5	1956	1	ATX1_PLAFA	Q04956	plasmodium	913	6	0.5	122	1	YL15_ADE41	P32692	human adeno
841	7	0.5	1960	1	TF20_HUMAN	Q99800	homo sapien	914	6	0.5	124	1	CC26_YEAST	P14724	saccharomyc
842	7	0.5	1983	1	TF20_MOUSE	Q9988	mus musculus	915	6	0.5	124	1	RNP_CANDR	P00670	camelus dro
843	7	0.5	2004	1	CHDB_HUMAN	Q9388	homo sapien	916	6	0.5	125	1	Y394_RICPR	Q92407	ricicetia
844	7	0.5	2148	1	VIT1_AEDAE	P13709	drosophila	917	6	0.5	126	1	YE75_METUA	Q58807	methanococc
845	7	0.5	2167	1	BEM2_YEAST	Q16927	aedes aegypt	918	6	0.5	126	1	YBGS_ECOLI	P75578	escherichia
846	7	0.5	2148	1	BEM2_YEAST	P3960	saccharomyc	919	6	0.5	128	1	Y050_BPT4	P13103	bacterioph
847	7	0.5	2174	1	TF240_HUMAN	Q9887	homo sapien	920	6	0.5	130	1	OA2_DROVI	O44555	drosophila
848	7	0.5	2182	1	CAB1_RAT	Q8840	rattus norv	921	6	0.5	130	1	RS8_BUCAP	P59030	buchnera ap
849	7	0.5	2220	1	CAB1_HUMAN	Q95670	homo sapien	922	6	0.5	131	1	V092_FOWPV	Q91508	fowipox vir
850	7	0.5	2505	1	CCAA_HUMAN	Q00555	homo sapien	923	6	0.5	131	1	YOHF_BACSU	P45414	bacillus vir
851	7	0.5	2653	1	CENB_HUMAN	Q02224	homo sapien	924	6	0.5	132	1	RS19_PYRAB	Q91519	pyrococcus
852	7	0.5	3097	1	CADN_DROME	Q15943	drosophila	925	6	0.5	132	1	RS19_PYRPU	Q80002	pyrococcus
853	7	0.5	3174	1	CHAC_HUMAN	Q9617	homo sapien	926	6	0.5	132	1	RS19_PYRHO	O59422	pyrococcus
854	7	0.5	3255	1	POLG_LMYO	P31959	1 genome po	927	6	0.5	133	1	RBFA_CHLMU	Q9PKU1	chlamydia m
855	7	0.5	3255	1	POLG_LMYO	P89876	1 genome po	928	6	0.5	133	1	YIM5_BPPH1	P10429	bacterioph
856	7	0.5	3969	1	HRX_HUMAN	Q08164	homo sapien	929	6	0.5	134	1	RS24_YEAST	P26782	saccharomyc
857	7	0.5	4705	1	FAT2_DROME	Q9VW71	drosophila	930	6	0.5	135	1	YNP0_YEAST	P53902	saccharomyc
858	7	0.5	5147	1	FAT_DROME	P33450	drosophila	931	6	0.5	137	1	UCR7_SCHPO	O74533	schizosacch
859	6	0.5	37	1	PK35_EUGGR	P21592	euglena gra	932	6	0.5	137	1	YEBD_ECOLI	P31063	escherichia
860	6	0.5	40	1	VIT1_MERGA	P56531	meleagris g	933	6	0.5	138	1	ATPE_WIGBR	Q8D312	wig91eswort
861	6	0.5	50	1	R331_MYCPU	Q98477	mycoplasma	934	6	0.5	138	1	HEX9_ADE07	P03283	human adeno
862	6	0.5	65	1	V07K_CLV	P28898	carnation 1	935	6	0.5	138	1	IF1A_SCHPO	P55877	schizosacch
863	6	0.5	67	1	Y012_BACAN	Q9RND0	bacillus an	936	6	0.5	139	1	YN06_YEAST	P53842	saccharomyc
864	6	0.5	69	1	RL38_HUMAN	P23411	homo sapien	937	6	0.5	139	1	YVVF_BACSU	P39807	bacillus su
865	6	0.5	69	1	RL38_HUMAN	P46291	lycopericco	938	6	0.5	140	1	RL7D_ARATH	Q91217	arabidopsis
866	6	0.5	69	1	RL38_MOUSE	Q9J118	mus musculus	939	6	0.5	140	1	RR8_EUGGR	P21508	euglena gra
867	6	0.5	73	1	RL7_STRAU	P48860	staphylococ	940	6	0.5	140	1	YF62_ARCFU	Q28710	archaeoglob
868	6	0.5	74	1	CH11_STROI	P29115	streptomyces	941	6	0.5	141	1	PER_DROSR	Q04537	drosophila
869	6	0.5	77	1	S18M_HUMAN	Q9862	homo sapien	942	6	0.5	141	1	RNBR_GIRCA	Q29542	giraffa cam
870	6	0.5	78	1	KCRU_PIG	Q29577	sus scrofa	943	6	0.5	142	1	DIMI_HUMAN	O18544	homo sapien
871	6	0.5	79	1	RS18_UREPA	Q9PPE8	ureaplasma	944	6	0.5	142	1	DIMI_SCHPO	P87215	schizosacch
872	6	0.5	80	1	DBHL_RICCN	Q92H14	ricicetia	945	6	0.5	142	1	Y742_CHLPN	Q92793	chlamydia p
873	6	0.5	80	1	DBHL_RICPR	Q9ZD26	ricicetia	946	6	0.5	145	1	HA17_CLOBO	P46083	clostridium
874	6	0.5	80	1	IF1_DEIRA	Q95281	deinococcus	947	6	0.5	145	1	YE1A_METUA	P81238	methanococc
875	6	0.5	81	1	YSPF_SHIFL	O55298	shigella fl	948	6	0.5	145	1	YPH2_MYCCA	P45614	mycoplasma
876	6	0.5	88	1	YEAD_SCHPO	O13973	schizosacch	949	6	0.5	146	1	ADFE_ARATH	Q924K2	arabidopsis
877	6	0.5	89	1	SLTB_BPH30	P08027	bacterioph	950	6	0.5	146	1	VGA_SPVIR	P15695	spiroplasma
878	6	0.5	89	1	Y150_ARCFU	Q30087	archaeoglob	951	6	0.5	147	1	SPAM_SALTY	P40612	salmonella
879	6	0.5	89	1	YE96_CLOPE	Q8XK44	clostridium	952	6	0.5	147	1	Y211_MYCGE	P47453	mycoplasma
880	6	0.5	90	1	DBHL_RICRI	Q68451	ricicetia	953	6	0.5	147	1	YD05_METUA	O58701	methanococc
881	6	0.5	90	1	HSEB_RAT	Q9UK55	rattus norv	954	6	0.5	148	1	GM6_TRYBG	Q26755	trypanosoma
882	6	0.5	90	1	Y060_NPPOP	O10317	oryzias pseu	955	6	0.5	148	1	PTRI_METUA	O57615	methanococc
883	6	0.5	91	1	SMI3_CABEL	P55853	caenorhabdi	956	6	0.5	148	1	YG4E_YEAST	P42337	saccharomyc
884	6	0.5	97	1	IM8A_HUMAN	O60220	homo sapien	957	6	0.5	149	1	BTJ1_YEAST	P40314	saccharomyc
885	6	0.5	97	1	IM8A_RAT	Q9WVA1	rattus norv	958	6	0.5	149	1	YM66_CLOPE	O8X155	clostridium
886	6	0.5	103	1	KACS_RABIT	P01841	oryctolagus	959	6	0.5	150	1	YHY5_SCHPO	O60154	schizosacch
887	6	0.5	104	1	YJH8_YEAST	P47070	saccharomyc	960	6	0.5	152	1	FLJ1_BUCAP	Q8K411	buchnera ap
888	6	0.5	105	1	V248_FOWPV	P14363	fowipox vir	961	6	0.5	152	1	Y447_WIGBR	O8D2A7	wig91eswort
889	6	0.5	105	1	Y613_ARCFU	P29642	archaeoglob	962	6	0.5	153	1	VE6_HPV2A	P25484	human papil
890	6	0.5	106	1	RNT1_TRIHA	Q26875	trichoderma	963	6	0.5	154	1	PASC_ECOLI	P45599	escherichia
891	6	0.5	106	1	THIO_GEOCY	Q96952	geodia cydo	964	6	0.5	154	1	PFDS_SCHPO	O94037	schizosacch
892	6	0.5	107	1	FKB1_XENTIA	O42123	xenopus lae	965	6	0.5	155	1	ITRF_MAIZE	P01088	zea mays (m
893	6	0.5	107	1	YP94_YEAST	O06835	saccharomyc	966	6	0.5	155	1	PPU1_SCHPO	P87051	schizosacch
894	6	0.5	108	1	RL23_MYCGA	O52334	mycoplasma	967	6	0.5	156	1	RNP_MYOGL	Q9XU81	myoxus glis
895	6	0.5	108	1	SVS4_MOUSE	P18419	mus musculus	968	6	0.5	156	1	YB01_RHOA	O07461	myoxus glis
896	6	0.5	109	1	PRVA_AMPPE	P02626	amphiuma me	969	6	0.5	157	1	PA1F_HUMAN	P24666	homo sapien
897	6	0.5	111	1	RNPA_MYCPB	O8EU90	mycoplasma	970	6	0.5	157	1	PAIS_HUMAN	P24667	homo sapien
898	6	0.5	111	1	YPJD_BACSU	P42979	bacillus su	971	6	0.5	157	1	PPAC_BOVIN	P11064	bos taurus
899	6	0.5	113	1	RL30_SPOFR	P58375	spodoptera	972	6	0.5	157	1	PPAC_PIG	P81693	sus scrofa
900	6	0.5	114	1	PHS_SUIISO	Q97MM6	sulfolobus	973	6	0.5	157	1	YMM3_CABEL	O23679	caenorhabdi
901	6	0.5	114	1	Y0J5_CABEL	P34628	caenorhabdi	974	6	0.5	159	1	PPAC_RAT	P41498	rattus norv
902	6	0.5	115	1	A62P_DROME	O46202	drosophila	975	6	0.5	161	1	YP49_RALSO	Q8XK55	ratistonia s
903	6	0.5	115	1	KV02_RABIT	P01683	oryctolagus	976	6	0.5	161	1	YU12_CLOPE	Q93965	aeropyrum p
904	6	0.5	116	1	TCLA_MOUSE	P56280	mus musculus	977	6	0.5	162	1	RL30_AERPE	O9Y396	aeropyrum p
905	6	0.5	118	1	YE17_SYNY3	P72731	synchocyst	978	6	0.5	162	1	Y79A_METUA	P81133	methanococc
906	6	0.5	118	1	YE1J_SCHPO	Q92363	schizosacch	979	6	0.5	163	1	YAS3_METUA	O58453	methanococc
907	6	0.5	121	1	H2B1_TERTH	P08993	tetrahymena	980	6	0.5	164	1	HIT1_YEAST	P46573	saccharomyc
908	6	0.5	121	1	H2B2_TERTH	P08994	tetrahymena	981	6	0.5	167	1	HRS1_MOUSE	Q9GQU4	mus musculus
909	6	0.5	121	1	OMP7_STRAU	P21223	staphylococ	982	6	0.5	167	1	ISPF_BUCAP	Q8K507	buchnera ap

```

983 6 0.5 167 1 PSAG_SPIOL P12357 spincia o1
984 6 0.5 167 1 RNBR_BOVIN P39873 bos taurus
985 6 0.5 168 1 YNBP_YEAST P33897 saccharomyc
986 6 0.5 169 1 HSB7_MOUSE P35385 mus musculu
987 6 0.5 169 1 NUGC_MARPO P12199 marcantia
988 6 0.5 169 1 YGGD_ECOLI P11663 escherichia
989 6 0.5 170 1 RM06_DICDI O21037 dictyosteli
990 6 0.5 171 1 RS4_SULAC P34667 sulfobobus
991 6 0.5 171 1 TRPF_CLOAB O97663 clostridium
992 6 0.5 171 1 Y328_AQDME O66665 aquifex aeo
993 6 0.5 171 1 YTXU_AGRVI P70790 agrobacteri
994 6 0.5 172 1 INT2_BOVIN P56830 bos taurus
995 6 0.5 172 1 INT3_BOVIN P56830 bos taurus
996 6 0.5 173 1 SP12_YEAST P17123 saccharomyc
997 6 0.5 173 1 TMM3_TARAT O96977 arabidopsis
998 6 0.5 173 1 YNN3_YEAST P55913 saccharomyc
999 6 0.5 174 1 LEPP_STAMM P72364 staphylococ
1000 6 0.5 174 1 NU6M_ANOGA P34856 anopheles g

```

ALIGNMENTS

RESULT 1

YEAST_YEAST STANDARD; PRT; 666 AA.

AC P40002; 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Hypothetical 72.5 kDa protein in GCMA-WBPI intergenic region.
 GN YEL007W.

OS Saccharomyces cerevisiae (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 CC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 OX NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=S288C / AB972;

RA PubMed=9169868;
 RA Dietrich F.S., Mulligan J.T., Hennessey K.M., Yelton M.A., Allen E.,
 RA Arujo R., Ayiles E., Berio A., Brennan T., Carpenter J., Chen E.,
 RA Cherry J.M., Chung E., Duncan M., Guzman E., Hartzell G.,
 RA Hunnicke-Smith S., Hyman R.W., Kayser A., Komp C., Lashkari D., Lew H.,
 RA Lin D., Mosedale D., Nakahara K., Namath A., Norgren R., Oefner P.,
 RA Oh C., Petel F.X., Roberts D., Sehl P., Schramm S., Shogren T.,
 RA Smith V., Taylor P., Wei Y., Botstein D., Davis R.W.;
 RT "The nucleotide sequence of Saccharomyces cerevisiae chromosome V.";
 RL Nature 387:78-81(1997).
 CC -1 SIMILARITY: STRONG, TO YEAST YHR177W.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC EMBL; U18530; AAB64484.1; -
 DR PIR; S50452; S50452.
 DR SGD; S0000733; TOS9.
 KW Hypothetical protein
 FT DOMAIN 334 382 ASN-RICH
 SQ SEQUENCE 666 AA; 72533 MW; DC36F887BF2D17E0 CRC64;

Query Match 1.3%; Score 17; DB 1; Length 666;
 Best Local Similarity 100.0%; Pred. No. 4.3e-08;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNNI 758
 Db 351 NNNNNNNNNNNNNNNNNI 367

RESULT 2

CC27_YEAST STANDARD; PRT; 758 AA.

AC P38042; 01-OCT-1994 (Rel. 30, Created)
 DT 01-OCT-1994 (Rel. 30, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Cell division control protein 27.
 GN CDC27 OR SNB1 OR YBL084C OR YBL0718.

OS Saccharomyces cerevisiae (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 CC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 OX NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=S288C;
 RX MEDLINE=96076635; PubMed=7502586;

RA Obermaier B., Gassenhuber J., Piravandi E., Domdey H.;
 RT "Sequence analysis of a 78.6 kb segment of the left end of
 RT Saccharomyces cerevisiae chromosome II.";
 RL Yeast 11:1103-1112(1995).
 RN [2]
 RP PARTIAL SEQUENCE FROM N.A., AND MUTAGENESIS.

RX MEDLINE=92306611; PubMed=1819514;
 RA Sikorski R.S., Michaud W.A., Wootton J.C., Boguski M.S., Connelly C.,
 RT Hieter P.A.;
 RT "YPR proteins as essential components of the yeast cell cycle.";
 RL Cold Spring Harb. Symp. Quant. Biol. 56:663-673(1991).
 RN [3]
 RP SUBUNITS.

RA Lamb J.R., Michaud W.A., Sikorski R.S., Hieter P.A.;
 RT "Cdc15p, Cdc23p and Cdc27p form a complex essential for mitosis.";
 RL EMBO J. 13:4321-4328(1994).
 CC -1 FUNCTION: EXECUTES ESSENTIAL MITOTIC FUNCTIONS NEAR THE
 CC METAPHASE/ANAPHASE TRANSITION.
 CC -1 SUBUNIT: CDC15, CDC23 AND CDC27 FORMS A MACROMOLECULAR COMPLEX.
 CC -1 SIMILARITY: BELONGS TO THE CDC27/NUC2 FAMILY.
 CC -1 SIMILARITY: CONTAINS 8 TPR REPEATS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC EMBL; X79489; CAA56022.1; ALT_INIT.
 DR EMBL; Z35845; CAA84905.1; -
 DR PIR; S45825; S45825.
 DR SGD; S0000180; CDC27.
 DR InterPro; IPR001440; TPR.
 DR Pfam; PF00515; TPR; 8.
 DR SMART; SM00028; TPR; 5.
 KW Cell division; Cell cycle; Mitosis; Repeat; TPR repeat;

KW Nuclear protein.
 FT REPEAT 154 187 TPR 1.
 FT REPEAT 472 505 TPR 2.
 FT REPEAT 540 573 TPR 3.
 FT REPEAT 575 607 TPR 4.
 FT REPEAT 608 641 TPR 5.
 FT REPEAT 643 675 TPR 6.
 FT REPEAT 676 709 TPR 7.
 FT REPEAT 711 743 TPR 8.
 FT DOMAIN 358 391 ASN-RICH.
 FT MUTAGEN G->D: IN TEMPERATURE SENSITIVE MUTANT.
 SQ SEQUENCE 758 AA; 85436 MW; 8612EA4504327A02 CRC64;

Query Match 1.3%; Score 17; DB 1; Length 758;


```

CC -----
DR EMBL; X52482; CAA36726.1; -
DR EMBL; D13228; BAA02508.1; -
DR EMBL; X87941; CAA61183.1; -
DR EMBL; Z73018; CAA97261.1; -
DR EMBL; S61041; AAD13922.1; -
DR PIR; S57698; S57698.
DR SGD; S0003465; PHO81.
DR InterPro; IPR002110; ANK.
DR InterPro; IPR004331; SPX.
DR Pfam; PF00023; ank; 6.
DR Pfam; PF03105; SPX; 1.
DR SMART; SMO0248; ANK; 3.
DR PROSITE; PS50088; ANK_REPEAT; 2.
DR PROSITE; PS50297; ANK_REPEAT_REGION; 1.
DR ANK Repeat; Repeat.
KW ANK Repeat; Repeat.
FT DOMAIN 198 253 ASN/ASP-RICH.
FT DOMAIN 231 248 POLY-ASN.
FT REPEAT 423 452 ANK 1.
FT REPEAT 458 487 ANK 2.
FT REPEAT 506 535 ANK 3.
FT REPEAT 556 586 ANK 4.
FT REPEAT 591 620 ANK 5.
FT REPEAT 624 653 ANK 6.
FT CONFLICT 248 248 N -> NN (IN REF. 2).
FT CONFLICT 728 728 T -> I (IN REF. 2).
FT CONFLICT 762 762 S -> F (IN REF. 2).
FT CONFLICT 845 845 D -> H (IN REF. 2).
FT CONFLICT 873 873 N -> K (IN REF. 2).
FT CONFLICT 920 920 MISSING (IN REF. 1).
FT CONFLICT 984 984 A -> V (IN REF. 2).
SQ SEQUENCE 1178 AA; 134028 MW; 9314EDB94B3F667D CRC64;

```

```

Query Match 1.3%; Score 17; DB 1; Length 1178;
Best Local Similarity 100.0%; Pred. No. 7.3e-08;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 742 NNNNNNNNNNNNNNNNNI 758
Db 233 NNNNNNNNNNNNNNNNNI 249

```

```

RESULT 5
AAC4_DICDI
ID AAC4_DICDI STANDARD; PRT; 317 AA.
AC P14198;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JAN-1990 (Rel. 13, Last sequence update)
DT 01-FEB-1994 (Rel. 28, Last annotation update)
DE AAC-rich mRNA clone PIK330 protein (Fragment).
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=90066348; PubMed=2511421;
RA Shaw D.R., Richter H., Giorda R., Ohmachi T., Emis H.L.;
RT "Nucleotide sequences of Dictyostelium discoideum developmentally
regulated cDNAs rich in (AAC) imply proteins that contain clusters of
asparagine, glutamine, or threonine."
RL Mol. Gen. Genet. 218:453-459 (1989).
CC -I- DEVELOPMENTAL STAGE: THE CONCENTRATION OF AAC-RICH MRNAs IS LOW
CC -I- IN DORMANT SPORES AND GROWING CELLS, BUT INCREASES DURING
CC SPORE-GERMINATION AND MULTICELLULAR DEVELOPMENT.
CC -I- MICELLANEOUS: SEVERAL PROTEINS DERIVE FROM AAC-RICH MRNA, WHICH,
CC DUE TO A FRAMESHIFT ALSO HAVE ACA AND CAA CODONS AND THUS ARE
CC ASN-, THR- OR GLN-RICH.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial

```

```

CC -----
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X16523; CAA34530.1; -
DR PIR; S05356; S05356.
DR DictyDb; DD05008; -.
KW Repeat.
FT DOMAIN 54 73 ASN-RICH.
FT DOMAIN 314 317 ASN-RICH.
FT NON_TER 317 317
SQ SEQUENCE 317 AA; 35893 MW; 7FB8B5242D8D2CFC CRC64;

```

```

Query Match 1.2%; Score 16; DB 1; Length 317;
Best Local Similarity 100.0%; Pred. No. 2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 742 NNNNNNNNNNNNNNNNNI 757
Db 54 NNNNNNNNNNNNNNNNNI 69

```

```

RESULT 6
MYB_DICDI
ID MYB_DICDI STANDARD; PRT; 451 AA.
AC P34127;
DT 01-FEB-1994 (Rel. 28, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE MYB-like protein (Fragment).
GN MYB.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92195700; PubMed=1549373;
RA Stöber-Graesser U., Brydolf B., Bin X., Graesser F., Firtel R.A.,
RA Lipsick J.S.;
RT "The Myb DNA-binding domain is highly conserved in Dictyostelium
discoideum."
RL Oncogene 7:589-596 (1992).
CC -I- FUNCTION: MAY CONTROL CELLULAR DIFFERENTIATION.
CC -I- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -I- SIMILARITY: Contains 3 myb-like domains.
CC -I- CAUTION: IT IS UNCERTAIN WHETHER MET-1, MET-6, MET-110, MET-114
CC OR MET-123 IS THE INITIATOR.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; Z11534; CAB37862.1; -.
DR HSSP; P06876; IMBG.
DR DictyDb; DD05044; mybA.
DR InterPro; IPR001005; MYB_DNA_binding.
DR Pfam; PF00249; myb_DNA_binding; 3.
DR SMART; SMO0717; SANT; 3.
DR PROSITE; PS00037; MYB_1; 3.
DR PROSITE; PS00334; MYB_2; 3.
DR PROSITE; PS50090; MYB_3; 3.
KW Nuclear protein; DNA-binding; Repeat.
FT DNA_BIND 144 195 MYB 1.
FT DNA_BIND 196 247 MYB 2.
FT DNA_BIND 248 298 MYB 3.
FT DOMAIN 25 61 ASN-RICH.
FT DOMAIN 89 139 ASN-RICH.
FT DOMAIN 353 363 PRO-RICH.
FT DOMAIN 48 61 POLY-ASN.
FT DOMAIN 62 67 POLY-GLU.

```

FT	DOMAIN	68	74	POLY-ASP.	
FT	DOMAIN	108	132	POLY-ASN.	
FT	DOMAIN	338	349	POLY-THR.	
FT	DOMAIN	429	451	POLY-ASN.	
FT	NON_TER	451	451		
SO	SEQUENCE	451 AA;	51298 MW;	E199B3B471728F60 CRC64;	
Query Match					
Similarity		1.2%;	Score 16;	DB 1;	
Matches		16;	Conservative	0;	
		Mismatches	0;	Indels	
		Gaps	0;		
QY	742	NNNNNNNNNNNNNNNNNN	757		
Db	429	NNNNNNNNNNNNNNNNNN	444		
RESULT 7					
CAR3	DICD1	STANDARD;	PRT;	490 AA.	
ID	CAR3	DICD1	STANDARD;	PRT;	
AC	P35352;				
DT	01-JUN-1994	(Rel. 29,	Created)		
DT	01-JUN-1994	(Rel. 29,	Last sequence update)		
DT	28-FEB-2003	(Rel. 41,	Last annotation update)		
DE	Cyclic AMP receptor	3.			
OS	CARC OR CAR3.				
OC	Dicystostelium discoideum	(Slime mold).			
OX	Eukaryota; Mycetozoa;	Dicystostellida;	Dicystostelium.		
RN	NCBI_TaxID=44689;				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=AX3;				
RX	MEDLINE=93170666;	PubMed=8382181;			
RA	Johnson R.L., Saxe C.L. II,	Gollog R., Kimmel A.R.,	Devreotes P.N.;		
RT	"Identification and targeted	gene disruption of CAR3, a	CAMP receptor		
RT	subtype expressed during	multicellular stages of	Dicystostelium		
RL	development."				
RL	Genes Dev. 7:273-282	(1993).			
CC	-1- FUNCTION: RECEPTOR FOR	CAMP. COORDINATES THE	AGGREGATION		
CC	OF INDIVIDUAL CELLS INTO A	MULTICELLULAR ORGANISM	AND REGULATES		
CC	THE EXPRESSION OF A LARGE	NUMBER OF DEVELOPMENTALLY	REGULATED		
CC	GENES. THE ACTIVITY OF THIS	RECEPTOR IS MEDIATED BY	G PROTEINS.		
CC	-1- SUBCELLULAR LOCATION:	Integral membrane protein.			
CC	-1- DEVELOPMENTAL STAGE:	INDUCED AT EARLY	AGGREGATION (6 HRS) AND		
CC	MAXIMALLY EXPRESSED AT THE	WOUND STAGE (9-12HRS),	LEVEL OF		
CC	EXPRESSION PEAKS AGAIN	DURING THE SLUG STAGE	(18HRS) AND DECLINES		
CC	AT CUMINATION.				
CC	-1- PPM: CARBOXY-TERMINAL	SER OR THR RESIDUES MAY	BE PHOSPHORYLATED.		
CC	-1- SIMILARITY: BELONGS TO	FAMILY 5 OF G-PROTEIN	COUPLED RECEPTORS.		
CC	-1- CAUTION: IT IS	UNCERTAIN WHETHER	MET-1 OR MET-15 IS THE	INITIATOR.	
CC	-----				
CC	THIS SWISS-PROT entry is	copyright. It is produced	through a collaboration		
CC	between the Swiss Institute	of Bioinformatics and the	EMBL outstation -		
CC	the European Bioinformatics	Institute. There are no	restrictions on its		
CC	use by non-profit	institutions as long as	its content is in no way		
CC	modified and this	statement is not removed.	Usage by and for	commercial	
CC	entities requires a	license agreement (See	http://www.ibb-sib.ch/announce/		
CC	or send an email to	license@ibb-sib.ch).			
CC	-----				
DR	EMBL; S55235; AAB25437.1;	-.			
DR	Dic1ydb; DD02033; GARC.				
DR	InterPro; IPR000848; GPCR	CAMP.			
DR	InterPro; IPR000832; GPCR	secretin.			
DR	PRINTS; PR00247; GPCR	CAMP.			
DR	PROSITE; PS50261; G	PROTEIN RECEPTOR F2.4;	1.		
KW	G-protein coupled	receptor; Transmembrane;	Glycoprotein;		
KW	phosphorylation; Multi	gene family.			
FT	DOMAIN	1	23	EXTRACELLULAR (POTENTIAL).	
FT	TRANSSEM	24	43	1 (POTENTIAL).	
FT	DOMAIN	44	57	CYTOPLASMIC (POTENTIAL).	
FT	TRANSSEM	58	78	2 (POTENTIAL).	
FT	DOMAIN	79	94	EXTRACELLULAR (POTENTIAL).	
FT	TRANSSEM	95	120	3 (POTENTIAL).	
FT	DOMAIN	121	131	CYTOPLASMIC (POTENTIAL).	

FT	TRANSNM	132	150		4 (POTENTIAL).
FT	DOMAIN	151	173		EXTRACELLULAR (POTENTIAL).
FT	TRANSEM	174	192		5 (POTENTIAL).
FT	DOMAIN	193	216		CYTOPLASMIC (POTENTIAL).
FT	TRANSEM	217	235		6 (POTENTIAL).
FT	DOMAIN	236	246		EXTRACELLULAR (POTENTIAL).
FT	TRANSEM	247	271		7 (POTENTIAL).
FT	DOMAIN	272	490		CYTOPLASMIC (POTENTIAL).
FT	MOD RES	204	204		PHOSPHORYLATION (BY PKA) (POTENTIAL).
FT	DOMAIN	303	439		ASN-RICH.
FT	DOMAIN	399	427		POLY-ASN.
SQ	SEQUENCE	490 AA;	56161 MM;	A28BA83AD8626153 CRC64;	
Oy	742	NNNNNNNNNNNNNNNNN	757		
Dd	399	NNNNNNNNNNNNNNNNN	414		
<hr/>					
Query Match 1.2%; Score 16; DB 1; Length 490; Beet Local Similarity 100.0%; Pred. No. 3e-07; Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
<hr/>					
RESULT 8					
ID	MOT3_YEAST	STANDARD;	PRT;	490 AA.	
AC	P54785;				
DT	01-OCT-1996 (Rel. 34, Created)				
DT	01-OCT-1996 (Rel. 34, Last sequence update)				
DT	15-SEP-2003 (Rel. 42, Last annotation update)				
DE	Zinc finger protein MOT3/HMS1.				
GN	MOT3 OR HMS1 OR YMR070W OR YM9916.09.				
OS	Saccharomyces cerevisiae (Baker's yeast).				
OC	Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;				
OC	Saccharomycetales; Saccharomycetaceae; Saccharomycetes.				
OX	NCBI_TaxId=4932;				
[1]					
RN	SEQUENCE FROM N.A.				
RP	STRAIN=S288C / AB972;				
RC	STRAIN=S288c;				
RA	Madison J., Winston F.;				
RL	Submitted (APR-1995) to the EMBL/GenBank/DBJ databases.				
RT	[2]				
RT	SEQUENCE FROM N.A.				
RL	STRAIN=S288C / AB972;				
RX	PubMed=9169872;				
RA	Bowman S., Churcher C.M., Badcock K., Brown D., Chillingworth T.,				
RA	Connor R., Dedman K., Devlin K., Gentles S., Hamlin N., Hunt S.,				
RA	Jagels K., Lye G., Moule S., Odell C., Pearson D., Rajandream M.A.,				
RA	Rice P., Skelton J., Walsh S., Whitehead S., Barrett B.G.;				
RT	"The nucleotide sequence of Saccharomyces cerevisiae chromosome				
XIII."					
CC	Nature 387:90-93(1997).				
CC	-I- SUBCELLULAR LOCATION: Nuclear (Potential).				
CC	-I- SIMILARITY: Contains 2 C2H2-type zinc fingers.				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL Outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on ways				
CC	use by non-profit institutions as long as its content is in no way com-				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/				
CC	or send an email to license@isb-sib.ch).				
CC	-----				
DR	EMBL; U25279; AAC49982.1; -.				
DR	EMBL; Z48952; CAAB8795.1; -.				
DR	PIR; S52830; S52830.				
DR	TRANSFAC; T03446; -.				
DR	SGD; S0004674; MOT3.				
DR	GO; GO:0005634; C:nucleus; IDA.				
DR	GO; GO:0003677; F:DNA binding activity; IPT.				
DR	GO; GO:0016544; F:transcriptional repressor activity; IDA.				
DR	GO; GO:0006350; F:transcription; IGI.				
DR	InterPro; IPR007087; ZnF_C2H2.				

```

DR Pfam; PF00096; zf-C2H2; 2.
DR SMART; SM00355; Znf_C2H2; 2.
DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
DR PROSITE; PS00157; ZINC_FINGER_C2H2_2; 1.
KW Nuclear protein; Zinc-finger; Metal-binding; Repeat.
FT ZN_FING 346 368 C2H2-TYPE 1.
FT ZN_FING 374 397 C2H2-TYPE 2.
FT DOMAIN 8 35 POLY-GLN.
FT DOMAIN 98 104 POLY-ASN.
FT DOMAIN 143 157 POLY-ASN.
FT DOMAIN 173 177 POLY-ALA.
FT DOMAIN 240 245 POLY-HIS.
FT DOMAIN 417 420 POLY-SER.
FT DOMAIN 421 433 POLY-ASN.
FT DOMAIN 441 450 POLY-ALA.
SQ SEQUENCE 490 AA; 54382 MW; 4D0D8DE43F171ED CRC64;

Query Match 1.2%; Score 16; DB 1; Length 490;
Best Local Similarity 100.0%; Pred. No. 3e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 743 NNNNNNNNNNNNNNNNNI 758
Db 143 NNNNNNNNNNNNNNNNNI 158

RESULT 9
HSF1 ARATH STANDARD; PRT; 495 AA.
ID HSF1 ARATH STANDARD; PRT; 495 AA.
AC P4151; O23615;
DT 01-FEB-1995 (Rel. 31, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Heat shock factor protein 1 (HSF 1) (Heat shock transcription factor
DE 1) (HSF 1).
GN HSF1 OR AT4G1750 OR DL4910C.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophytes; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RX MEDLINE=95036006; PubMed=7948881;
RA Huebel A., Schoeffl F.;
RT "Arabidopsis heat shock factor: isolation and characterization of the
RT gene and the recombinant protein.";
RL Plant Mol. Biol. 26:353-362(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=9612113; PubMed=9461215;
RA Bevan M., Bancroft I., Bent E., Love K., Goodman H.M., Dean C.,
RA Bergkamp R., Dirkse W., van Staveren M., Stiekema W., Drost L.,
RA Ridley P., Hudson S.-A., Patel K., Murphy G., Piffeneill P.,
RA Weiler H., Weiler E., Wambutt R., Weitzenecker T., Pohl T., Terryn N.,
RA Gielen J., Villarroel R., De Clercq R., van Montagu M., Lecharny A.,
RA Aubourg S., Gylt, Kreis M., Lao N., Kavanagh T., Hempel S.,
RA Kotter P., Entian K.-D., Rieger M., Schaefer M., Funk B.,
RA Puigdomenech P., Douka A., Vouklatou E., Milioni D., Hatzopoulos P.,
RA Pirvadi E., Obermaier B., Hilbert H., Duesterhoeft A., Moores T.,
RA Jones J.D.G., Eneva T., Palme K., Benes V., Rechmann S., Anserge W.,
RA Cooke R., Berger C., Delseny M., Voet M., Volckaert G., Mewes H.-W.,
RA Klosterman S., Schueller C., Chalvatzis N.;
RT "Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of
RT Arabidopsis thaliana.";
RL Nature 391:485-488(1998).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=2008348; PubMed=10617198;
RA Mayer K.F.X., Schueller C., Wambutt R., Murphy G., Volckaert G.,

```

```

RA Pohl T., Duesterhoeft A., Stiekema W., Entian K.-D., Terryn N.,
RA Harris B., Anserge W., Brandt P., Grivell L.A., Rieger M.,
RA Weichselgartner M., de Simone V., Obermaier B., Maché R., Mueller M.,
RA Kreis M., Delseny M., Puigdomenech P., Watson M., Schmidthini T.,
RA Reichert B., Potteville D., Perez-Alonso M., Boutry M., Bancroft I.,
RA Vos P., Hohenseil U., Zimmermann W., Weiler H., Ridley P.,
RA Langham S.-A., McCullagh B., Bilham L., Robben J.,
RA Van der Schuren C., Grymoprez B., Chuang Y.-J., Vandebussche F.,
RA Braeken M., Weljens I., Voet M., Bastiaens I., Aert R., Defoor E.,
RA Weitzenecker T., Bothe G., Ramsperger U., Hilbert H., Braun M.,
RA Holzner E., Brandt A., Peters S., van Staveren M., Dirkse W.,
RA Moolman P., Klein Lankhorst R., Rose M., Haut J., Koetter P.,
RA Berneriser S., Hempel S., Feldpausch M., Lamberth S., Van den Daele H.,
RA de Keyser A., Buyschaert C., Gielen J., Villarroel R., De Clercq R.,
RA Van Montagu M., Rogers J., Cronin A., Quail M., Bray-Allen S.,
RA Clark L., Doggett J., Hall S., Kay M., Leonard N., McIay K., Mayes R.,
RA Petter A., Rajandream M.A., Lyne M., Benes V., Rechmann S.,
RA Borkova D., Bloeker H., Scharfe M., Grimm M., Loehner T.-H.,
RA Dose S., de Haan M., Maarse A.C., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fartmann B., Grandérath K., Dauner D., Herzl A.,
RA Maassen O., Argitrou A., Vitale D., Liguori R., Pirvadi E.,
RA Neumann S., Argitrou A., Vitale D., Liguori R., Pirvadi E.,
RA Schenkl S., Hiller R., Schmidt W., Lecharny A., Aubourg S.,
RA Chedof F., Cooke R., Berger C., Monfort A., Casacuberta E.,
RA Gibbons T., Weber N., Vandenbol M., Baryus M., Terol J., Torres A.,
RA Heijnen L., Schwarz S., Scholler P., Heber S., France P., Bietke C.,
RA Frishman D., Haase D., Lemcke K., Mewes H.-W., Stocker S.,
RA Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
RA Parnell L., Dedhia N., Gnoj L., Schutz K., Huang E., Spiegel L.,
RA Sehon M., Murray J., Shest P., Cordes M., Abu-Itreideh J.,
RA Stoneking T., Kalicki J., Graves T., Harmon G., Edwards J.,
RA Latreille P., Courney D., Cloud J., Abbott A., Scott K., Johnson D.,
RA Mix P., Bentley D., Fulton B., Miller N., Greco T., Kemp K.,
RA Kramer J., Fulton L., Mardis E., Dante M., Pepin K., Hillier L.,
RA Du H., Ali J., Berghoff A., Jones K., Drone K., Cotton M., Joshi C.,
RA Antoniou B., Zifan M., Strong C., Sun H., Lamar B., Yordan C.,
RA Ma P., Zhong Y., Preston R., Vil D., Shekher M., Maturo A., Shah R.,
RA Swaby I.K., O'Shaughnessy A., Rodriguez M., Hoffman J., Tili S.,
RA Grnati S., Shohy N., Haasegawa A., Hamed A., Lohdi M., Johnson A.,
RA Chen E., Marra M., Martensen R., McCombe W.R.;
RT "Sequence and analysis of chromosome 4 of the plant Arabidopsis
RT thaliana.";
RL Nature 402:769-777(1999).
CC -!- FUNCTION: DNA-BINDING PROTEIN THAT SPECIFICALLY BINDS HEAT SHOCK
CC PROMOTER ELEMENTS (HSE) AND ACTIVATES TRANSCRIPTION (BY
CC SIMILARITY).
CC -!- SUBUNIT: Homotrimer.
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- PTM: EXHIBITS TEMPERATURE-DEPENDENT PHOSPHORYLATION
CC (BY SIMILARITY).
CC -!- SIMILARITY: BELONGS TO THE HSF FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X76167; CA53761.1; -
DR EMBL; Z97344; CAB1055.1; -
DR EMBL; AL161547; CAB8778.1; -
DR PIR; F71447; S52641.
DR HSSP; P22121; 3HSF.
DR TRASNAPAC; T04394; -
DR InterPro; IPR002342; HSF_DNA_bind.
DR InterPro; IPR002341; HSF_ETS.
DR Pfam; PF00447; HSF_DNA_bind; 1.
DR PRINTS; PR00056; HSFDOMAIN.
DR Prodom; PD001788; HSF_DNA_bind; 1.

```

```

OY 742 NNNNNNNNNNNNNNNN 757
Db 419 NNNNNNNNNNNNNNNN 434

RESULT 11
KMBB D1CD1
ID KMBB D1CD1 STANDARD; PRT; 732 AA.
AC P90648;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Myosin heavy chain kinase B (EC 2.7.1.129) (MHCK B).
GN MHCKB OR MHCKB.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX3;
RX MEDLINE=97277316; PubMed=9115538;
RA Clancy C.E., Mendoza M.G., Natsumi T.V., Kolman M.F., Egelhoff T.T.;
RT "Identification of a protein kinase from Dictyostelium with homology
RL to the novel catalytic domain of myosin heavy chain kinase A.";
RL J. Biol. Chem. 272:11812-11815 (1997).
CC -1- FUNCTION: PHOSPHORYLATES THREONINE IN THE C-TERMINAL TAIL REGION
CC OF MYOSIN II HEAVY CHAIN. THIS PHOSPHORYLATION IS CRITICAL IN
CC REGULATING THE ASSEMBLY AND DISASSEMBLY OF MYOSIN II FILAMENT.
CC -1- CATALYTIC ACTIVITY: ATP + [myosin heavy-chain] = ADP + [myosin
CC heavy-chain] phosphate.
CC -1- DOMAIN: CONSISTS OF AN N-TERMINAL DOMAIN, A CENTRAL NONREPEATITIVE
CC CATALYTIC DOMAIN, AND A C-TERMINAL DOMAIN WITH SEVEN WD REPEATS.
CC -1- SIMILARITY: BELONGS TO THE MHCK / EF-2 PROTEIN KINASE FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U90946; AAB50136.1; -.
DR Dictydb; DD01087; mhkb.
DR InterPro; IPR004166; MHCK_EF2_kinase.
DR InterPro; IPR001680; WD40_
DR Pfam; PF02816; Alpha_kinase; 1.
DR Pfam; PF00400; WD40_7.
DR PRINTS; PR00320; GPROTEINRPT.
DR PRODOM; PD000018; WD40_2.
DR SMART; SM00320; WD40_7.
DR PROSITE; PS00678; WD_REPEATS_1; 5.
DR PROSITE; PS50082; WD_REPEATS_2; 6.
DR PROSITE; PS50294; WD_REPEATS_REGION; 1.
KW Transferrase; Serine/threonine-protein kinase; ATP-binding; Repeat;
KW WD repeat.
FT NP BIND 298 303 ATP (POTENTIAL).
FT DOMAIN 355 381 POLY-ASN.
FT REPEAT 458 486 WD 1.
FT REPEAT 500 528 WD 2.
FT REPEAT 540 568 WD 3.
FT REPEAT 580 608 WD 4.
FT REPEAT 620 648 WD 5.
FT REPEAT 660 688 WD 6.
FT REPEAT 700 730 WD 7.
SQ SEQUENCE 732 AA; 83167 MW; A723C4BD56f4088 CRC64;

Query Match 1.2%; Score 16; DB 1; Length 732;
Best Local Similarity 100.0%; Pred. No. 4,4e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Db 355 NNNNNNNNNNNNNNNNN 370

```

RESULT 12
CIGB DICI
ID_CIGB DICI STANDARD; PRT; 735 AA.
AC 094481;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Protein CIGB (Fragment).
CC
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX4;
RA Loomis W.F.;
RL Submitted (Aug-1996) to the EMBL/GenBank/DBJ databases.
CC
CC -1- SIMILARITY: TO D.DISCOTHEUM CIGB.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
DR EMBL; U66528; AAB06791.1; -.
DR DictyDb; DD01058; cigb.
DR InterPro; IPR00315; Znf_Box.
DR Pfam; PF00643; Zf-B_Box; 1.
KW Repeat.
FT NON_TER 1 1
FT DOMAIN 151 155 POLY-ASN.
FT DOMAIN 251 268 POLY-ASN.
FT DOMAIN 328 667 TANDDEM REPEATS.
SQ SEQUENCE 735 AA; 83443 MW; 9765013D88DA6C8C CRC64;

Query Match 1.2%; Score 16; DB 1; Length 735;
Best Local Similarity 100.0%; Pred. No. 4.4e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNN 757
Db 253 NNNNNNNNNNNNNNNNN 268

RESULT 13
YM38_YEAST STANDARD; PRT; 758 AA.
ID YM38_YEAST
AC Q03825;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Hypothetical 85.0 kDa protein in HLu1-SMP2 intergenic region.
GN YMR164C OR YM8520.13C.
OS Saccharomyces cerevisiae (Baker's Yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX PubMed=9169872;
RA Bowman S., Churcher C.M., Badcock K., Brown D., Chillingworth T.,
RA Connor K., Dedman K., Devlin K., Gentles S., Hamlin N., Hunt S.,
RA Jagsi R., Lyne G., Moule S., Odell C., Pearson D., Rajandream M.A.,
RA Rice P., Skelton J., Walsh S., Whitehead S., Barrett B.G.;
RT "The nucleotide sequence of Saccharomyces cerevisiae chromosome

```

```

RT XIII.";
RL Nature 387:90-93 (1997).
CC
CC -1- SIMILARITY: Contains 1 Lish domain.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
DR EMBL; Z49705; CAA89800.1; -.
DR PIR; S54522; S54522.
DR SGD; S0004774; MSS11.
DR GO; GO:0005634; C:nucleus; IC.
DR GO; GO:0003704; F:specific RNA polymerase II transcription fa...; IDA.
DR GO; GO:0045944; P:positive regulation of transcription from P...; IDA.
DR GO; GO:0007124; P:pseudophal growth; IGI.
DR GO; GO:0005983; P:starch catabolism; IMP.
DR InterPro; IPR006594; Lish.
DR SMART; SM00667; Lish; 1.
DR PROSITE; PS50896; LISH; 1.
KW Hypothetical protein.
FT DOMAIN 51 83 LISH.
FT DOMAIN 290 329 POLY-GLN.
FT DOMAIN 605 637 POLY-ASN.
FT DOMAIN 653 656 POLY-SER.
SQ SEQUENCE 758 AA; 85050 MW; BA05BFC754D9294B CRC64;

Query Match 1.2%; Score 16; DB 1; Length 758;
Best Local Similarity 100.0%; Pred. No. 4.6e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNN 757
Db 605 NNNNNNNNNNNNNNNNN 620

RESULT 14
GPR1_YEAST STANDARD; PRT; 961 AA.
ID GPR1_YEAST
AC Q12361;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE G protein-coupled receptor GPR1.
GN GPR1 OR YDL035C.
OS Saccharomyces cerevisiae (Baker's Yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C;
RX MEDLINE=97197972; PubMed=9046088;
RA Saren A.M., Laamanen P., Lejarcegui J.B., Paulin L.;
RT "The sequence of a 36.7 kb segment on the left arm of chromosome IV
RT from Saccharomyces cerevisiae reveals 20 non-overlapping open reading
RT frames (ORFs) including SIR4, FAD1, NAM1, RIM1, SIR2, NAT1, PRP9, ACT2
RT and MPT1 and 11 new ORFs."
RL Yeast 13:65-71 (1997).
CC
CC -1- FUNCTION: Seems to associate with GPA2 and act as G protein-
CC coupled receptor that senses glucose and controls filamentous
CC growth. It acts upstream of adenylate cyclase and is required for

```



```
DR InterPro: IPR000387; TYR_phosphatase.
DR InterPro: IPR000242; Tyr_PP.
DR Pfam; PF00102; Y_phosphatase.1.
DR PRINTS; PR00700; PRTPHPHATSE.
DR SMART; SM00194; PTPc; 1.
DR PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR PROSITE; PS00566; TYR_PHOSPHATASE_2; 1.
DR PROSITE; PS00555; TYR_PHOSPHATASE_PTP; 1.
DR Hydrolase.
KM ACT_SITE 649 649 BY SIMILARITY.
FT DOMAIN 460 716 PROTEIN-TYROSINE PHOSPHATASE.
FT DOMAIN 64 71 POLY-ASN.
FT DOMAIN 109 118 POLY-ASN.
FT DOMAIN 137 190 POLY-ASN.
FT DOMAIN 249 257 POLY-SER.
FT DOMAIN 258 265 POLY-THR.
FT DOMAIN 286 289 POLY-ASN.
FT DOMAIN 366 371 POLY-SER.
FT DOMAIN 787 790 POLY-GLN.
FT DOMAIN 834 839 POLY-GLN.
FT DOMAIN 883 892 POLY-GLN.
FT DOMAIN 906 914 POLY-ASN.
FT DOMAIN 943 963 POLY-ASN.
SQ SEQUENCE 989 AA; 103995 MW; 9371105AF80974AF CRC64;

Query Match 1.2%; Score 16; DB 1; Length 989;
Best Local Similarity 100.0%; Pred. No. 5.8e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNNNN 757
Db 137 NNNNNNNNNNNNNNNNNNN 152

RESULT 17
SUZ2 DROME STANDARD; PRT; 1365 AA.
AC P25172;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Suppressor 2 of zeste protein (Protein posterior sex combs).
GN SU(2)2.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Canton-S;
RX MEDLINE=91279476; PubMed=2057369;
RA Brunk B.P., Adler P.N.;
RT "The sequence of the Drosophila regulatory gene Suppressor two of
RT zeste.";
RL Nucleic Acids Res. 19:3149-3149(1991).
CC -!- FUNCTION: REGULATES EXPRESSION OF THE HOMEOTIC SELECTOR GENES BY
CC INTERFERING HIGHER-ORDER CHROMATIN STRUCTURE THROUGH INTERACTION
CC WITH OTHER PROTEINS.
CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X56798; CAA40134.1;
CC EMBL; X56799; CAA40135.1;
CC PIR; S14871; S14871.
```

```
DR FlyBase; FBgn0008654; Su(z)2.
DR InterPro: IPR001841; Znf_ring.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00589; ZF_RING_2; 1.
KM Zinc-finger; Developmental protein; DNA-binding; Nuclear protein.
FT ZN_FING 35 74 RING-TYPE.
FT DOMAIN 623 628 POLY-GLN.
FT DOMAIN 1077 1096 POLY-ASN.
FT DOMAIN 1241 1251 POLY-SER.
FT CONFLICT 603 603 MISSING (IN REF. 1; CAA40134).
FT CONFLICT 785 785 K -> N (IN REF. 1; CAA40134).
FT CONFLICT 831 831 A -> R (IN REF. 1; CAA40134).
FT CONFLICT 965 965 MISSING (IN REF. 1; CAA40134).
FT CONFLICT 1065 1065 D -> E (IN REF. 1; CAA40134).
FT CONFLICT 1076 1076 MISSING (IN REF. 1; CAA40134).
FT CONFLICT 1287 1287 A -> P (IN REF. 1; CAA40134).
SQ SEQUENCE 1365 AA; 146058 MW; 7B4BA0F35B0FA683 CRC64;

Query Match 1.2%; Score 16; DB 1; Length 1365;
Best Local Similarity 100.0%; Pred. No. 7.9e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNNNNN 757
Db 1077 NNNNNNNNNNNNNNNNNNN 1092

RESULT 18
KYK1 D1CD1 STANDARD; PRT; 1584 AA.
AC P18160;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Non-receptor tyrosine kinase spore lysis A (EC 2.7.1.112) (Tyrosine-
DE protein kinase 1).
GN PYKA OR SPLA OR DPYK1.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostellium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JH10;
RX MEDLINE=97053827; PubMed=8698241;
RA Nuckolls G.H., Osheroov N., Loomis W.F., Spudich J.A.;
RT "The Dictyostelium dual-specificity kinase spla is essential for
RT spore differentiation.";
RL Development 122:3295-3305(1996).
RN [2]
RP SEQUENCE OF 1248-1584 FROM N.A.
RX MEDLINE=90287147; PubMed=1972546;
RA Tan J.L., Spudich J.A.;
RT "Developmentally regulated protein-tyrosine kinase genes in
RT Dictyostelium discoideum.";
RL Mol. Cell. Biol. 10:3578-3583(1990).
CC -!- FUNCTION: ESSENTIAL FOR SPORE DIFFERENTIATION.
CC -!- CATALYTIC ACTIVITY: ATP + a protein tyrosine = ADP + protein
CC tyrosine phosphate.
CC -!- DEVELOPMENTAL STAGE: EXPRESSED THROUGHOUT DEVELOPMENT WITH A PEAK
CC DURING THE MOUND STAGE OF MORPHOGENESIS.
CC -!- SIMILARITY: BELONGS TO THE TYR FAMILY OF PROTEIN KINASES.
CC -!- SIMILARITY: Contains 1 sterile alpha motif (SAM) domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
```


R	P	SEQUENCE FROM N.A.
RC	RA	STRAIN-AX4;
RK	RM	MEDLINE=971140317; PubMed=8986798;
RA	RS	Shaulsky G., Escalante R., Loomis W.F.;
RT	RT	"Developmental signal transduction pathways uncovered by genetic suppressors";
RL	Proc. Natl. Acad. Sci. U.S.A.	93:15260-15265(1996).
CC	-I-	FUNCTION: INTERCELLULAR COMMUNICATION VIA TAGC MAY MEDIATE INTEGRATION OF CELLULAR DIFFERENTIATION WITH MORPHOGENESIS (BY SIMILARITY).
CC	-I-	SIMILARITY: IN THE N-TERMINAL SECTION; BELONGS TO PEPTIDASE FAMILY S8.
CC	-I-	SIMILARITY: IN THE C-TERMINAL SECTION; BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY (ABC TRANSPORTERS). MDR SUBFAMILY.
CC	-I-	SIMILARITY: STRONG, TO TAGB.
CC	-I-	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb.ch/announce/isb-stb.ch) or send an email to licenses@isb-stb.ch).
CC	EMBL; U60086; AAB03331.1; -	
DR	PIR; T18279; T18279.	
DR	Diclydb; DD02060; tagC.	
DR	InterPro; IPR003593; AAA_ATPase.	
DR	InterPro; IPR001140; ABC_TM_transpt.	
DR	InterPro; IPR003439; ABC_transporter.	
DR	InterPro; IPR000209; Peptide_S8.	
DR	Pfam; PF00664; ABC_membrane; 1.	
DR	Pfam; PF00005; ABC_tran; 1.	
DR	Pfam; PF00082; Peptidase_S8; 1.	
DR	PRINTS; PR00723; SUBTILISIN.	
DR	SMART; SM00382; AAA_1	
DR	PROSITE; PS00211; ABC_TRANSPORTER_1; 1.	
DR	PROSITE; PS50893; ABC_TRANSPORTER_2; 1.	
DR	PROSITE; PS00136; SUBTILASE_ASP; FALSE_NEG.	
DR	PROSITE; PS00137; SUBTILASE_HIS; 1.	
DR	PROSITE; PS00138; SUBTILASE_SER; FALSE_NEG.	
KW	Hydrolase; Serine protease; ATP-binding; Transport; Transmembrane; Signal.	
FT	KW	Signal.
FT	CHAIN	1..27
FT	DOMAIN	28..1743 PRESTALK-SPECIFIC PROTEIN TAGC.
FT	DOMAIN	316..642 PROPEASE.
FT	DOMAIN	1450..1687 ABC TRANSPORTER.
FT	TRANSMEM	962..982 POTENTIAL.
FT	TRANSMEM	1027..1047 POTENTIAL.
FT	TRANSMEM	1072..1092 POTENTIAL.
FT	TRANSMEM	1157..1177 POTENTIAL.
FT	TRANSMEM	1260..1280 POTENTIAL.
FT	TRANSMEM	1288..1308 POTENTIAL.
FT	ACT_SITE	325..325 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT	ACT_SITE	372..372 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT	ACT_SITE	637..637 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT	NP_BIND	1485..1492 AAP (POTENTIAL).
FT	DOMAIN	42..46 POLY-ASN.
FT	DOMAIN	94..103 POLY-ASN.
FT	DOMAIN	643..646 POLY-ALA.
FT	DOMAIN	733..741 POLY-ASN.
FT	DOMAIN	766..792 POLY-SER.
FT	DOMAIN	1337..1340 POLY-GLU.
FT	DOMAIN	1346..1352 POLY-GLY.
FT	DOMAIN	1353..1357 POLY-ASP.
FT	DOMAIN	1358..1364 POLY-ASP.
FT	DOMAIN	1381..1386 POLY-ASN.
FT	DOMAIN	1707..1729 POLY-ASN.
FT	CARBOHYD	330..330 N-LINKED (GLCNAC...)(POTENTIAL).
FT	CARBOHYD	536..536 N-LINKED (GLCNAC...)(POTENTIAL).
FT	CARBOHYD	547..547 N-LINKED (GLCNAC...)(POTENTIAL).
FT	CARBOHYD	614..614 N-LINKED (GLCNAC...)(POTENTIAL).
FT	CARBOHYD	689..689 N-LINKED (GLCNAC...)(POTENTIAL).

```

FT CARBOHYD 735 735 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 741 741 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 776 776 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 832 832 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 887 887 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 1251 1251 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 1385 1385 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 1386 1386 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 1454 1454 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
FT CARBOHYD 1704 1704 N-LINKED (GLCNAC. . .) (POTENTIAL. .)
SQ SEQUENCE 1743 AA; 194145 MW; 12DB363E2F729839 CRC64;

Query Match 1.2%; Score 16; DB 1; Length 1743;
Matches 16; Conservativity 100.0%; Pred. No. 9.9e-07; Gaps 0;
Mismatches 0; Indels 0;

Db 742 NNNNNNNNNNNNNNNNNNNN 757
1714 NNNNNNNNNNNNNNNNNNNN 1729

RESULT 21.
P3K2_DICDI STANDARD; PRT; 1858 AA.
AC P54674;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Phosphatidylinositol 3-kinase 2 (EC 2.7.1.137) (PI3-kinase)
DE (Pcdln-3-kinase) (PI3K).
CN PI3K OR PI3K2.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxId=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AX3;
RX MEDLINE=96009592; PubMed=7565716;
RX Zhou K., Takegawa K., Emr S.D., Firtel R.A.;
RT "A phosphatidylinositol (PI) kinase gene family in Dictyostelium
RT discoideum: biological roles of putative mammalian p110 and yeast
RT Vps34p Pl 3-kinase homologs during growth and development."
RL Mol. Cell. Biol. 15:5645-5656(1995).
CC M-1. CATALYTIC ACTIVITY: ATP + 1-phosphatidy1-ID-myo-inositol = ADP +
CC 1-phosphatidy1-ID-myo-inositol 3-phosphate.
CC -1 SIMILARITY: BELONGS TO THE PI3/PI4-KINASES FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U23477; AAA85722.1; -.
CC DR PIR; T18273; T18273.
CC DR DictyDB; DD01100; p1KB.
CC DR InterPro; IPR000403; PI3_P14_kinase.
CC DR InterPro; IPR002420; PI3K_C2.
CC DR InterPro; IPR000341; PI3K_fae_bind.
CC DR InterPro; IPR001263; PI3Ka.
CC DR Pfam; PF00454; PI3_P14_kinase; 1.
CC DR Pfam; PF00792; PI3K_C2; 1.
CC DR Pfam; PF00794; PI3K_rbd; 1.
CC DR Pfam; PF00613; PI3Ka; 1.
CC DR SMART; SM00144; PI3K_C2; 1.
CC DR SMART; SM00144; PI3Ka; 1.
CC DR SMART; SM00146; PI3K; 1.
CC DR PROSITE; PS00915; PI3_4_KINASE_1; 1.
CC DR PROSITE; PS00916; PI3_4_KINASE_2; 1.
CC DR PROSITE; PS00917; PI3_4_KINASE_3; 1.
CC DR PROSITE; PS50290; PI3_4_KINASE_3; 1.

```

```

KM  Transferase; Kinase; Multigene family.
FT  DOMAIN 34 40 POLY-GLY.
FT  DOMAIN 166 172 POLY-SER.
FT  DOMAIN 185 226 POLY-ASN.
FT  DOMAIN 227 235 POLY-THR.
FT  DOMAIN 246 253 POLY-SER.
FT  DOMAIN 259 268 POLY-ASN.
FT  DOMAIN 294 303 POLY-THR.
FT  DOMAIN 361 364 POLY-SER.
FT  DOMAIN 369 384 POLY-SER.
FT  DOMAIN 425 429 POLY-GLN.
FT  DOMAIN 439 444 POLY-THR.
FT  DOMAIN 445 454 POLY-SER.
FT  DOMAIN 562 570 POLY-GLY.
FT  DOMAIN 715 727 POLY-THR.
FT  DOMAIN 982 990 POLY-GLN.
FT  DOMAIN 1015 1049 POLY-ASN.
FT  DOMAIN 1598 1858 P13K/PT4K.
SQ  SEQUENCE 1858 AA; 203945 MW; A6C033D4CDEA03 CRC64;

Query Match 1.2%; Score 16; DB 1; Length 1858;
Best Local Similarity 100.0%; Pred. No. 1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  742 NNNNNNNNNNNNNNNNNN 757
    |||||
Db  185 NNNNNNNNNNNNNNNNNN 200

RESULT 22
TAGB_DICDI STANDARD; PRT; 1905 AA.
ID  TAGB_DICDI
AC  P54683;
DT  01-OCT-1996 (Rel. 34, Last sequence update)
DT  01-OCT-1996 (Rel. 34, Last sequence update)
DT  28-FEB-2003 (Rel. 41, Last annotation update)
DE  Prestalk-specific protein tagB precursor (EC 3.4.21.-).
GN  TAGB.
OS  Dictyostelium discoideum (Slime mold).
OC  Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
OX  NCBI_TaxID=44689;
RN  (1)
RP  SEQUENCE FROM N.A.
RC  STRAIN=AX4;
RX  MEDLINE=95262903; Pubmed=7744252;
RA  Shauly G., Kuspa A., Loomis W.F.;
RT  "A multidrug resistance transporter/serine protease gene is required
    for prestalk specialization in Dictyostelium."
RL  Gene Dev. 9:1111-1122(1995).
CC  -1- FUNCTION: INTERCELLULAR COMMUNICATION VIA TAGB MAY MEDIATE
    INTEGRATION OF CELLULAR DIFFERENTIATION WITH MORPHOGENESIS.
CC  -1- SIMILARITY: IN THE N-TERMINAL SECTION, BELONGS TO PEPTIDASE FAMILY
    S8.
CC  -1- SIMILARITY: IN THE C-TERMINAL SECTION, BELONGS TO THE ATP-BINDING
    TRANSPORT PROTEIN FAMILY (ABC TRANSPORTERS). MOR SUBFAMILY.
CC  -1- SIMILARITY: STRONG, TO TAGC.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
    between the Swiss Institute of Bioinformatics and the EMBL outstation-
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC  -----
CC  EMBL: U20432; AAA62212.1; -.
CC  PIR: T18267; T18267.
CC  MEROPS: S08.UFW; -.
CC  DicyDdb: DPO2059; tagB.
CC  InterPro: IPR003593; AAA_ATPase.
CC  InterPro: IPR001140; ABC_TM_transp.
CC  InterPro: IPR003439; ABC_transporter.
CC  InterPro: IPR000209; Peptidase_S8.

```

```

DR  Pfam; PF00664; ABC membrane; 1.
DR  Pfam; PF00005; ABC tran; 1.
DR  Pfam; PF00082; Peptidase S8; 1.
DR  PRINTS; PR00723; SUBTILISIN.
DR  ProDom; PD000006; ABC_transporter; 1.
DR  SMART; SM00382; AAA; 1.
DR  PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR  PROSITE; PS00893; ABC_TRANSPORTER_2; 1.
DR  PROSITE; PS00136; SUBTILASE ASP; FALSE_NEG.
DR  PROSITE; PS00137; SUBTILASE HIS; 1.
DR  PROSITE; PS00138; SUBTILASE_SER; 1.
KW  Hydrolyase; Serine protease; Atp-binding; Transport; Transmembrane;
KW  Signal.
FT  SIGNAL 1 31
FT  CHAIN 32 1905 POTENTIAL.
FT  DOMAIN 378 700 PRESTALK-SPECIFIC PROTEIN TAGB.
FT  DOMAIN 1518 1756 PROTEASE.
FT  DOMAIN 1011 1031 ABC_TRANSPORTER.
FT  TRANSMEM 1076 1096 POTENTIAL.
FT  TRANSMEM 1121 1141 POTENTIAL.
FT  TRANSMEM 1210 1230 POTENTIAL.
FT  TRANSMEM 1309 1329 POTENTIAL.
FT  TRANSMEM 1332 1352 POTENTIAL.
FT  ACT_SITE 387 387 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT  ACT_SITE 432 432 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT  ACT_SITE 695 695 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT  NP_BIND 1553 1560 ATP (POTENTIAL).
FT  DOMAIN 63 67 POLY-GLN.
FT  DOMAIN 95 104 POLY-ASN.
FT  DOMAIN 107 134 POLY-ASN.
FT  DOMAIN 311 321 POLY-SER.
FT  DOMAIN 833 837 POLY-SER.
FT  DOMAIN 838 844 POLY-GLY.
FT  DOMAIN 871 876 POLY-LEU.
FT  DOMAIN 1012 1015 POLY-ILE.
FT  DOMAIN 1386 1389 POLY-GLU.
FT  DOMAIN 1398 1404 POLY-GLY.
FT  DOMAIN 1445 1450 POLY-GLN.
FT  DOMAIN 1465 1479 POLY-ASN.
FT  DOMAIN 1765 1779 POLY-ASN.
FT  DOMAIN 1782 1785 POLY-SER.
FT  DOMAIN 1807 1812 POLY-SER.
FT  DOMAIN 1813 1860 POLY-PRO.
FT  DOMAIN 1872 1878 POLY-PRO.
FT  CARBOHYD 594 594 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 621 621 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 672 672 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 747 747 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 823 823 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 1172 1172 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 1522 1522 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 1658 1658 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ  SEQUENCE 1905 AA; 212518 MW; B8E223F8A8B9A13C CRC64;

Query Match 1.2%; Score 16; DB 1; Length 1905;
Best Local Similarity 100.0%; Pred. No. 1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  742 NNNNNNNNNNNNNNNNNN 757
    |||||
Db  107 NNNNNNNNNNNNNNNNNN 122

RESULT 23
ARP2_PLAFA STANDARD; PRT; 451 AA.
ID  ARP2_PLAFA
AC  P13824;
DT  01-JAN-1990 (Rel. 13, Created)
DT  01-JAN-1990 (Rel. 13, Last sequence update)
DT  28-FEB-2003 (Rel. 41, Last annotation update)
DE  Clustered-asparagine-rich protein (Fragment).
OS  Plasmodium falciparum.
OC  Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX  NCBI_TaxID=5833;

```

```

RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=86206015; PubMed=3517875;
RA Walgren M., Aastlund L., Franzen L., Sundvall M., Waahlin B.,
RA Bezziens K., McNicol L.A., Bjorkman A., Wigzell H., Perlmann P.,
RA Petersson U.;
RT "A plasmodium falci-parum antigen containing clusters of asparagine
RT residues";
RL Proc. Natl. Acad. Sci. U.S.A. 83:2677-2681(1986).
RL -1- SIMILARITY: Contains 2 RNA recognition motif (RRM) domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL, M13021; AAA29485.1; -.
DR PIR, A23535; A23535.
DR InterPro, IPR005054; RNA_rec_mot.
DR Pfam, PF00076; xrm; 2.
DR SMART, SMO0360; xrm; 2.
DR PROSITE, PS00102; RRM; 2.
DR PROSITE, PS00030; RRM_RNP_1; FALSE_NEG.
KW RNA-binding; Repeat; Malaria.
FT TER 1
FT DOMAIN 24 114 RNA-BINDING (RRM) 1.
FT DOMAIN 350 443 RNA-BINDING (RRM) 2.
FT DOMAIN 119 128 POLY-ASN.
FT DOMAIN 175 180 POLY-ASN.
FT DOMAIN 195 210 POLY-ASN.
FT DOMAIN 237 245 POLY-ASN.
FT DOMAIN 264 285 POLY-ASN.
SQ SEQUENCE 451 AA; 52204 MW; B686354D85F8C293 CRC64;

Query Match 1.2%; Score 15; DB 1; Length 451;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 756
DB 271 NNNNNNNNNNNNNN 285

RESULT 24
YP68 YEAST
ID YP68 YEAST STANDARD; PRT; 612 AA.
AC Q08925;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Hypothetical 68.7 kDa protein in PPQ1-MFAL1 intergenic region.
GN YP184C.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=97133211; PubMed=9169875;
RA Bussey H., Storms R.K., Ahmed A., Albermann K., Allen E., Ansoorge W.,
RA Botstein D., Bowman S., Bruckner M., Carpenter J., Cherry J.M.,
RA Chung E., Churche C.M., Coster F., Davis K., Davis R.W.,
RA Dietrich F.S., Delius H., DiPaolo T., Dubois E., Diesterhoef A.,
RA Duncan M., Floeth M., Fortin N., Friesen J.D., Fritz C., Goffeau A.,
RA Hall J., Heblung U., Heumann K., Hillbert H., Hillier L.,
RA Hunnicke-Smith S., Hyman R., Johnston M., Kalman S., Kleine K.,
RA Komp C., Kurdi O., Lashkari D., Lew H., Lin A., Lin D., Louis E.J.,
RA Marthe R., Messenguy F., Newes H.-W., Mitterpat S., Moestl D.,

```

```

RA Mueller-Auer S., Nemath A., Nentwich U., Oelner P., Pearson D.,
RA Petel F.X., Pohl T.M., Purnelle D., Schafer M., Scharfe M.,
RA Scherrens B., Schramm S., Schroeder M., Sdicu A.M., Tetteilin H.,
RA Turrestarran L.A., Ushinsky S., Vierendeels F., Vissers S., Voss H.,
RA Walsh S.V., Wambut R., Wang Y., Wedler E., Wedler H., Winnett E.,
RA Zhong W.W., Zollner A., Vo D.H., Hami J.,
RA "The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI.",
RL Nature 387:103-105(1997).
CC - SIMILARITY: Contains 4 RNA recognition motif (RRM) domains.
CC - SIMILARITY: TO S.POMBE SPCC37.01C AND NR01.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL: Z73540; CAA97894.1; -.
DR PIR: S65196; S65196.
DR SGD: S0006105; YPL184C.
DR InterPro: IPR000504; RNA_rec_mot.
DR Pfam: PF00076; rrm; 4.
DR SMART: SM00360; RRM; 4.
DR PROSITE: PS50102; RRM; 4.
DR PROSITE: PS00030; RRM_RNP_1; 1.
DR Hypothetical protein; RNA-binding Repeat.
FT DOMAIN 201 274 RNA-BINDING (RRM) 1.
FT DOMAIN 292 379 RNA-BINDING (RRM) 2.
FT DOMAIN 431 504 RNA-BINDING (RRM) 3.
FT DOMAIN 522 602 RNA-BINDING (RRM) 4.
FT DOMAIN 6 19 POLY-ASN.
FT DOMAIN 22 28 POLY-ASN.
FT DOMAIN 45 48 POLY-SER.
FT DOMAIN 413 419 POLY-ALA.
SQ SEQUENCE 612 AA; 68663 MW; A1B2EB381C0B8C6E CRC64;

Query Match 1.2%; Score 15; DB 1; Length 612;
Best Local Similarity 100.0%; Pred. No. 3,5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

QY 744 NNNNNNNNNNNNNNNI 758
Db 6 NNNNNNNNNNNNNNNI 20

RESULT 25
CCR4_YEAST STANDARD; PRT; 837 AA.
ID CCR4_YEAST
AC P31384;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Glucose-repressible alcohol dehydrogenase transcriptional effector
DE (Carbon catabolite repressor protein 4).
GN CCR4 OR YAL021C OR FUN27.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93093455; PubMed=1459446;
RA Malvar T., Biron R.W., Kaback D.B., Denis C.L.;
RT "The CCR4 protein from Saccharomyces cerevisiae contains a
RT leucine-rich repeat region which is required for its control of Adh2
RT gene expression.";
RL Genetics 132:951-962(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=s288c / AB972;
RX MEDLINE=93209532; PubMed=8458570;
```

RA Ouellette B.F., Clark M.W., Keng T., Storms R.K., Zhong W.W.,
 RA Zeng B., Fortin N., Delaney S., Barton A.B., Kaback D.B., Bussey H.,
 RA "Sequencing of chromosome I from *Saccharomyces cerevisiae*: analysis
 RT of a 32 kb region between the LTR1 and SP07 genes.",
 RL Genome 36:32-42(1993).
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=94193531; PubMed=8144453;
 RA Barton A.B., Kaback D.B.;
 RT "Molecular cloning of chromosome I DNA from *Saccharomyces cerevisiae*:
 analysis of the genes in the FUN38-MAK16-SP07 region.",
 RL J. Bacteriol. 176:1872-1880(1994).
 CC -1- FUNCTION: CONTROL OF ADH2 GENE EXPRESSION. IT IS REQUIRED FOR THE
 CC EXPRESSION OF GENES INVOLVED IN NONFERMENTATIVE GROWTH AND IT
 CC MEDIATES OR IS REQUIRED FOR THE ACTION OF THE SPT6 & SPT10 GENES.
 CC -1- MISCELLANEOUS: THE 169 CARBOXYL-TERMINAL RESIDUES ARE IMPORTANT
 CC FOR CCR4 FUNCTION.
 CC -1- SIMILARITY: BELONGS TO THE CCR4/NOCTURIN FAMILY.
 CC -1- SIMILARITY: CONTAINS 5 LEUCINE-RICH (LRR) REPEATS.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; S50459; AAB24455.1; -;
 DR EMBL; L05146; AAC04936.1; -;
 DR PIR; S36713; S36713.
 DR TRANSFAC; T03228; -;
 DR SGD; S0000019; CCR4.
 DR GO; GO:0030015; C:CCR4-NOT core complex; IPI.
 DR GO; GO:0005737; C:cytoplasm; IDA.
 DR GO; GO:0000175; F:3'-5' exoribonuclease activity; IDA.
 DR GO; GO:0000289; P:poly(A) tail shortening; IDA.
 DR GO; GO:0006557; P:regulation of transcription from Pol II pro. .; IPI.
 DR InterPro; IPR005135; Exo_endo_phos.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR003591; LRR_cyp.
 DR Pfam; PF03372; Exo_endo_phos; 1.
 DR Pfam; PF00560; LRR; 3.
 DR PRINTS; PRO0019; LEURICHPT.
 DR SMART; SM00369; LRR_TYP; 1.
 DR SMART; SM00369; LRR_TYP; 1.
 DR TRANSCRIPTION regulation; Repressor; Leucine-rich repeat; Repeat.
 DR DOMAIN 15 24
 FT POLY-GLN.
 FT 77 103 ASN-RICH.
 FT 89 103 POLY-ASN.
 FT 190 206 GLN-RICH.
 FT 356 379 LRR 1.
 FT 380 402 LRR 2.
 FT 403 418 LRR 3.
 FT 419 444 LRR 4.
 FT 445 467 LRR 5.
 FT REPEAT 544 544 L -> I (IN REF. 2).
 FT REPEAT 544 544 L -> V (IN REF. 2).
 FT CONFLICT 803 803 E -> V (IN REF. 2).
 FT CONFLICT 803 803 E -> V (IN REF. 2).
 SQ SEQUENCE 837 AA; 94699 MW; B8DCFF24F5A35A9 CRC64;

Query Match 1.2%; Score 15; DB 1; Length 837;
 Best Local Similarity 100.0%; Pred. No. 4.7e-06;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 756
 DB 89 NNNNNNNNNNNNNNNN 103

RESULT 26
 YGB4_YEAST STANDARD; PRT; 888 AA.
 ID YGB4_YEAST
 AC P25339;
 DT 01-MAY-1992 (Rel. 22, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Hypothetical regulatory protein in PDR6-PDR1 intergenic region.
 GN YGL014W OR YGL023.
 OS *Saccharomyces cerevisiae* (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
 OC NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=IL125-2B;
 RX MEDLINE=91353083; PubMed=1909073;
 RA Chen W., Balzi E., Capleau E., Goffeau A.;
 RT "The YGL023 gene encodes a putative regulatory protein.",
 RL Yeast 7:309-312(1991).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=IL125-2B;
 RX MEDLINE=91353083; PubMed=1882553;
 RA Chen W., Balzi E., Capleau E., Choder M., Goffeau A.;
 RT "The DNA sequencing of the 17 kb HindIII fragment spanning the LTR1
 RT and ATR1 loci on chromosome VII from *Saccharomyces cerevisiae* reveals
 RT pleiotropic drug resistance.",
 RL Yeast 7:287-299(1991).
 RN [3]
 RP SEQUENCE FROM N.A.
 RA Hedling U., Hofmann B., Delius H.;
 RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: Is not essential for haploid growth, but may affect
 CC diploid formation.
 CC -1- SIMILARITY: BELONGS TO THE PUMILIO/MPFS FAMILY.
 CC -1- SIMILARITY: SOME, TO YEAST YUR091C.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; S57889; AAB19616.1; -;
 DR EMBL; S58126; AAD13898.1; -;
 DR EMBL; Z72536; CA96714.1; -;
 DR PIR; S64016; S64016.
 DR SGD; S0002982; PUF4.
 DR GO; GO:0007569; P:cell aging; IGI.
 DR GO; GO:0000288; P:mRNA catabolism, deadenylation-dependent; IGI.
 DR GO; GO:0006005; P:protein targeting; IMP.
 DR InterPro; IPR001313; Pumilio/Puf.
 DR Pfam; PF00806; PUF; 8.
 DR SMART; SM00025; Pumilio; 8.
 DR Hypothetical protein; Transcription regulation; Zinc-finger;
 DR Metal-binding; Repeat.
 DR DOMAIN 8 38
 FT 471 542 ASP/GLU-RICH (ACIDIC).
 FT 521 535 POLY-ASN (POTENTIAL ACTIVATING DOMAIN).
 FT 724 742 CA-TYPE.
 FT REPEAT 571 583
 FT REPEAT 607 619
 FT REPEAT 643 655
 FT REPEAT 679 691
 FT REPEAT 716 728
 FT REPEAT 752 764
 FT REPEAT 831 843
 FT REPEAT 843 843
 FT CONFLICT 595 595
 FT CONFLICT 595 595
 SQ SEQUENCE 888 AA; 97797 MW; 659BA1062439F642 CRC64;

Query Match 1.2%; Score 15; DB 1; Length 888;
 Best Local Similarity 100.0%; Pred. No. 5e-06;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Oy 742 NNNNNNNNNNNNNNNN 756
Db 521 NNNNNNNNNNNNNNNN 535

RESULT 27
FABI_YEAST STANDARD; PRT; 2278 AA.
AC P34755;
DT 01-FEB-1994 (Rel. 28, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE 1-phosphatidylinositol-3-phosphate 5-kinase FABI (EC 2.7.1.150)
DE [phosphatidylinositol-3-phosphate 5-kinase] (Type III PIP kinase).
GN FABI OR YFR019W.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_Taxid=4932;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95352039; PubMed=7663021;
RA Yamamoto A., Dewald D.B., Boronkov I.V., Anderson R.A., Emr S.D.,
RA Koshland D.;
RT "Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal vacuole
RT function and morphology in yeast.";
RL Mol. Biol. Cell 6:525-539(1995).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=95400292; PubMed=7670463;
RA Murakami Y., Naitou M., Hagiwara H., Shibata T., Ozawa M.,
RA Sasaoka S.-I., Sasaoka M., Tsuchiya Y., Soeda E., Yokoyama K.,
RA Yamazaki M., Tashiro H., Eki T.;
RT "Analysis of the nucleotide sequence of chromosome VI from
RT Saccharomyces cerevisiae.";
RL Nat. Genet. 10:261-268(1995).
RN [3]
RP CHARACTERIZATION
RX MEDLINE=99035548; PubMed=9811604;
RA Cooke F.T., Dove S.R., McEwen R.K., Painter G., Holmes A.B.,
RA Hall M.N., Mitchell R.H., Parker P.J.;
RT "The stress-activated phosphatidylinositol 3-phosphate 5-kinase Fab1p
RT is essential for vacuole function in S. cerevisiae.";
RL Curr. Biol. 8:1219-1222(1998).
RN [4]
RP SIMILARITY TO TCP1/CCT FAMILY.
RP MEDLINE=95314774; PubMed=7794526;
RX Waldmann T., Lupas A., Kellermann J., Peters J., Baumeister W.;
RT "Primary structure of the thermosome from Thermoplasma acidophilum.";
RL Biol. Chem. Hoppe-Seyler 376:119-126(1995).
CC -1- FUNCTION: Catalyzes the phosphorylation of phosphatidylinositol-3-
CC phosphate on the fifth hydroxyl of the myo-inositol ring, to form
CC phosphatidylinositol-4,5-bisphosphate. Required for endocytic-
CC vacuolar pathway and nuclear migration. The product of the
CC reaction it catalyzes functions as an important regulator of
CC vacuole homeostasis perhaps by controlling membrane flux to and/or
CC from the vacuole.
CC -1- CATALYTIC ACTIVITY: ATP + 1-phosphatidy1-D-myo-inositol 4-
CC monophosphate = ADP + 1-phosphatidy1-D-myo-inositol 4,5-
CC bisphosphate.
CC -1- COFACTOR: Magnesium or Manganese.
CC -1- SUBCELLULAR LOCATION: VACUOLE-ASSOCIATED (POTENTIAL).
CC -1- SIMILARITY: BELONGS TO THE PTDSING(4)P-5-KINASE FAMILY.
CC -1- SIMILARITY: Contains 1 FYVE-type zinc finger.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).

```

```

CC -----
DR EMBL: U01017; AAA81360.1; -.
DR EMBL: D50617; BAA09258.1; -.
DR PIR: S56274; S56274.
DR SGD: S0001915; FABI.
DR GO: GO:0000285; F:1-phosphatidylinositol-3-phosphate 5-kinase. . .; IDA.
DR GO: GO:0006644; P:phospholipid metabolism; IGI.
DR GO: GO:0007033; P:vacuole organization and biogenesis; IMP.
DR InterPro: IPR002498; PIP5K.
DR InterPro: IPR003065; Znf_FYVE.
DR Pfam: PF01363; FYVE; 1.
DR Pfam: PF01504; PIP5K; 1.
DR SMART: SM00064; FYVE; 1.
DR SMART: SM00330; PIP5K; 1.
DR PROSITE: PS0178; ZF_FYVE; 1.
KM Transferase; Kinase; Zinc-finger; Zinc.
FT ZN_FING 240 299 FYVE-TYPE.
FT DOMAIN 393 397 POLY-PRO.
FT DOMAIN 571 590 POLY-ASN.
FT DOMAIN 1808 1811 POLY-THR.
FT DOMAIN 1891 1897 POLY-GLN.
FT CONFLICT 2275 2275 R -> W (IN REF. 2).
SQ SEQUENCE 2278 AA; 257417 MW; 1A0A30E13165DE41 CRC64;

Query Match 1.2%; Score 15; DB 1; Length 2278;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNNNN 756
Db 576 NNNNNNNNNNNNNNNN 590

RESULT 28
CTK2_XENLA STANDARD; PRT; 643 AA.
ID CTK2_XENLA
AC P79955;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Cardoxy-terminal kinesin 2 (XCTK2).
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
OC Xenopodidae; Xenopus.
OX NCBI_Taxid=8355;
RN [1]
RP SEQUENCE FROM N.A.
RP TISSUE=Ovary;
RX MEDLINE=97201465; PubMed=9049251;
RA Walczak C.E., Verma S., Mitchison T.J.;
RT "XCTK2: a kinesin-related protein that promotes mitotic spindle
RT assembly in Xenopus laevis egg extracts.";
RL J. Cell Biol. 136:859-870(1997).
CC -1- FUNCTION: PROMOTES MITOTIC SPINDLE ASSEMBLY.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS; A SMALL GLOBULAR
CC N-TERMINAL, A CENTRAL ALPHA-HELICAL COILED COIL AND A LARGE
CC GLOBULAR C-TERMINAL WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY
CC (IT HYDROLYZES ATP AND BINDS MICROTUBULES).
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
CC SUBFAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL: U82809; AAB40402.1; -.
CC HSSP: P17119; 3KAR.
DR InterPro: IPR001752; kinesin_motor.

```


DR Pfam; PF00225; kinesin; 1.
 DR PRINTS; PR00380; KINESINHEAVY.
 DR SMART; SM00129; KISC; 1.
 DR PROSITE; PS00411; KINESIN MOTOR DOMAIN; 1.
 DR PROSITE; PSS0067; KINESIN MOTOR DOMAIN; 1.
 KW Motor protein; Microtubules; ATP-binding; Coiled coil.
 FT DOMAIN 1 116 GLOBULAR.
 FT DOMAIN 117 296 COILED COIL (POTENTIAL).
 FT DOMAIN 291 564 KINESIN-MOTOR.
 FT NP BIND 386 393 ATP (POTENTIAL).
 SQ SEQUENCE 643 AA; 71948 MW; D3D92D08B8E5057 CRC64;

Query Match 1.3%; Score 14; DB 1; Length 643;
 Best Local Similarity 100.0%; Pred. No. 3.5e-05;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGQTSGKTYM 105
 DB 383 FAYGQTSGKTYM 396

RESULT 29
 NCD DROME
 ID NCD DROME STANDARD; PRT; 700 AA.
 AC P20480; Q9VAG8;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1991 (Rel. 17, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Claret segregational protein.
 GN NCD OR CA(ND) OR CG7831.
 OS Drosophila melanogaster (Fruit fly).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
 OC Ephydroidea; Drosophilidae; Drosophila.
 NC NCB1_TaxID=7227;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Oregon-R, and Canton-S; TISSUE=Ovary;
 RX MEDLINE=90231469; PubMed=1691829;
 RT "Endow S.A., Henkoff S., Soler-Niedziela L.;
 RT "Mediation of meiotic and early mitotic chromosome segregation in
 RT Drosophila by a protein related to kinesin.";
 RL Nature 345:81-83(1990).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Berkely;
 RX MEDLINE=20196006; PubMed=10731132;
 RA Adams M.D., Ceiniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
 RA Ananthakrishnan P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
 RA Sutton G.G., Mortman J.R., Vandeil M.D., Zhang Q., Chen L.X.,
 RA Brandon R.C., Rogers Y.-H.C., Blazer R.G., Champe M., Pfeiffer B.D.,
 RA Wan R.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
 RA Abril J.F., Agbayani A., An H.-D., Andrews-Pfannkoch C., Baldwin D.,
 RA Baillew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
 RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
 RA Borokva D., Borstein M.R., Bouck J., Brokstein P., Brotter P.,
 RA Burris K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
 RA Cherry J.M., Cusley S., Dahlke C., Davenport L.B., Davies P.,
 RA de Pablo B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
 RA Dodson R.K., Dou P.L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
 RA Fester C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
 RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
 RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
 RA Houston K.A., Howard T.J., Wei M.-H., Ibegwam C.,
 RA Jalali B.E., Kalish F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
 RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshnell A.,
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
 RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,

RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
 RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
 RA Styrkas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
 RA Wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissenbach J.,
 RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
 RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
 RT "The genome sequence of Drosophila melanogaster.";
 RL Science 287:2185-2195(2000).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Berkely; TISSUE=Embryo;
 RP Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
 RA Champe M., Chavez C., Dorsett V., Fattan D., Frise E., George R.,
 RA Gonzalez M., Guarin H., Li P., Liao G., Miranda A., Mungall C.J.,
 RA Nuno J., Pacleb J., Paragas V., Park S., Phuenanavong S., Wan K.,
 RA Yu C., Lewis S.E., Rubin G.M., Ceiniker S.;
 RT Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RP SEQUENCE OF 16-700 FROM N.A.
 RX MEDLINE=90275618; PubMed=2140958;
 RT McDonald H.B., Goldstein L.S.B.;
 RT "Identification and characterization of a gene encoding a
 RT kinesin-like protein in Drosophila.";
 RL Cell 61:991-1000(1990).
 RN [5]
 RP MOTOR DIRECTIONALITY.
 RX MEDLINE=91043032; PubMed=2146510;
 RA Walker R.A., Salmon E.D., Endow S.A.;
 RT "The Drosophila claret segregation protein is a minus-end directed
 RT motor molecule.";
 RL Nature 347:780-782(1990).
 RN [6]
 RP CHARACTERIZATION.
 RX MEDLINE=9415838; PubMed=8112290;
 RA Lockhart A., Cross R.A.;
 RT "Origins of reversed directionality in the ncd molecular motor.";
 RL EMBO J. 13:751-757(1994).
 RN [7]
 RP MUTANT ALLELE NCD(D).
 RX MEDLINE=91122049; PubMed=1825056;
 RA Komma D.J., Horne A.S., Endow S.A.;
 RT "Separation of meiotic and mitotic effects of claret
 RT non-disjunctional on chromosome segregation in Drosophila.";
 RL EMBO J. 10:419-424(1991).
 RN [8]
 RP CHARACTERIZATION OF MUTANT ALLELE NCD(D).
 RX MEDLINE=96283629; PubMed=8670831;
 RA Moore J.D., Song H., Endow S.A.;
 RT "A point mutation in the microtubule binding region of the Ncd motor
 RT protein reduces motor velocity.";
 RL EMBO J. 15:3306-3314(1996).
 RN [9]
 RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 335-700.
 RX MEDLINE=96195067; PubMed=8606780;
 RA Sablin E.P., Kull F.D., Cooke R., Vale R.D., Fletcher R.J.;
 RT "Crystal structure of the motor domain of the kinesin-related motor
 RT ncd.";
 RL Nature 380:555-559(1996).
 CC -1- FUNCTION: NCD IS REQUIRED FOR NORMAL CHROMOSOMAL SEGREGATION IN
 CC MEIOSIS. IN FEMALES, AND IN EARLY MITOTIC DIVISIONS OF THE EMBRYO.
 CC THE NCD MOTOR ACTIVITY IS DIRECTED TOWARD THE MICROTUBULE'S MINUS
 CC END.
 CC -1- MISCELLANEOUS: NCD(D) IS A MUTANT ALLELE THAT SHOWS ABNORMAL
 CC CHROMOSOMAL SEGREGATION.
 CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
 CC SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; X52814; CAA36998.1; -
 DR EMBL; M33932; AAA28716.1; -
 DR EMBL; AE003771; AAF56942.1; -
 DR EMBL; AY058596; AAL13825.1; -
 DR EMBL; X57475; CAA40713.1; -
 DR PIR; S09748; S09748.
 DR PDB; 1CZ7; 05-NOV-99.
 DR PDB; 2NCD; 09-JUN-99.
 DR FlyBase; FBgn0002924; ncd.
 DR GO; GO:0007100; P:centrosome separation; IGI.
 DR GO; GO:0000212; P:mitotic spindle assembly; NAS.
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin_1.
 DR PRINTS; PR00380; KINESINHEAVY.
 DR SMART; SM00129; KISC; 1.
 DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
 DR PROSITE; PS50067; KINESIN_MOTOR_DOMAIN2; 1.
 DR Motor protein; Cell division; Microtubules; ATP-binding; Coiled coil;
 KW Meiosis; Mitosis; 3D-structure.
 FT DOMAIN 196 346 COILED COIL (POTENTIAL).
 FT NP_BIND 347 700 KINESIN-MOTOR (BY SIMILARITY).
 FT NP_BIND 434 441 ATP (BY SIMILARITY).
 FT MUTAGEN 556 556 V->F; IN NCD(D); REDUCES MOTOR VELOCITY.
 FT CONFLICT 697 697 S->N (IN REF. 1).
 SQ SEQUENCE 700 AA; 77473 MW; ADE043CBCE7FD561 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 700;
 Best Local Similarity 100.0%; Pred. No. 3.7e-05;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 92 FAYGQTSGKTYTM 105
 DB 431 FAYGQTSGKTYTM 444

RESULT 30
 ID_KCML_XENLA STANDARD; PRT; 730 AA.
 AC 091636;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Kinesin central motor 1 (XKCM1).
 GN KCML.
 OS Xenopus laevis (African clawed frog).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
 CC Xenopodidae; Xenopus.
 OX NCBI_TaxID=8355;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Ovary;
 RX MEDLINE=96140638; PubMed=8548824;
 RA Walczak C.E., Mitchison T.J., Desai A.;
 RT "XKCM1: a Xenopus kinesin-related protein that regulates microtubule
 RT dynamics during mitotic spindle assembly.";
 RL Cell 84:37-47(1996).
 RN [2]
 RP REVISION TO 516.
 RC TISSUE=Ovary;
 RA Walczak C.E.;
 RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
 CC -I- FUNCTION: REGULATES MICROTUBULE DYNAMICS DURING MITOTIC SPINDLE
 CC ASSEMBLY. REQUIRED FOR BOTH ESTABLISHMENT AND MAINTENANCE OF
 CC MITOTIC SPINDLES. MAY ACT DIRECTLY ON MICROTUBULES, CAUSING A
 CC DESTABILIZATION AND EVENTUAL DEPOLYMERIZATION OF THE MICROTUBULE.
 CC -I- SUBUNIT: Homodimer (Potential).

CC -I- SUBCELLULAR LOCATION: Nuclear and cytoplasmic.
 CC -I- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. MCAK/KIF2
 CC SUBFAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; U36485; AAC59743.2; -
 DR HSSP; P17119; 3KAR.
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin_1.
 DR PRINTS; PR00380; KINESINHEAVY.
 DR SMART; SM00129; KISC; 1.
 DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
 DR PROSITE; PS50067; KINESIN_MOTOR_DOMAIN2; 1.
 DR Motor protein; Microtubules; ATP-binding; Coiled coil.
 KW Domain 1 256 GLOBULAR (POTENTIAL).
 FT DOMAIN 257 598 KINESIN-MOTOR (BY SIMILARITY).
 FT NP_BIND 599 730 COILED COIL (POTENTIAL).
 FT NP_BIND 352 359 ATP (POTENTIAL).
 SQ SEQUENCE 730 AA; 82585 MW; 25C31C187E491523 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 730;
 Best Local Similarity 100.0%; Pred. No. 3.9e-05;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 263 INRSLLAKECIRA 276
 DB 520 INRSLLAKECIRA 533

RESULT 31
 ID_ATRK2_ARATH STANDARD; PRT; 745 AA.
 AC P46864; O9T047;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Kinesin 2 (kinesin-like protein B).
 GN ATK2 OR KATB OR ATG27180 OR T24A18.130.
 GN Arabidopsis thaliana (Mouse-ear cress).
 OS Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 CC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
 CC eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 OX NCBI_TaxID=3702;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Columbia;
 RX MEDLINE=94355659; PubMed=8075402;
 RA Mitsui H., Nakatani K., Yamaguchi-Shinozaki K., Shinozaki K.,
 RA Nishikawa K., Takahashi H.;
 RT "Sequencing and characterization of the kinesin-related genes katb
 RT and katec of Arabidopsis thaliana.";
 RL Plant Mol. Biol. 25:865-876 (1994).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Columbia;
 RX MEDLINE=20083488; PubMed=10617198;
 RA Mayer K.F.X., Schueller C., Wambutt R., Murphy G., Volckaert G.,
 RA Pohl T., Duesterhoeft A., Stiekema W., Entian K.-D., Terryn N.,
 RA Harris B., Ansoyge W., Brandt P., Grivell U.A., Rieger M.,
 RA Weichselgartner M., de Simone V., Obermaier B., Maché R., Mueller M.,
 RA Kreis M., Delseny M., Puigdomenech P., Watson M., Schmitthel T.,
 RA Reichert B., Portetlelle D., Perez-Alonso M., Boutry M., Bancroft I.,
 RA Vos P., Hohenseil U., Zimmermann W., Wedler H., Ridley P.,
 RA Langham S.-A., McCullagh B., Bilham L., Roben J., Vandenbusche F.,
 RA Van der Schueren J., Gymnopoulos B., Chang Y.-J., Vandenbusche F.,
 RA Breken M., Weltjens I., Voet M., Bastiaens I., Aert R., Defoor E.,

RA Weitzenecker T., Bothe G., Ramsperger U., Hilbert H., Braun M.,
RA Holzer E., Brandt A., Peters S., van Staveren M., Dirks W.,
RA Moilman P., Klein Lankhorst R., Rose M., Haut J., Koetser P.,
RA Bernisier S., Hempel S., Feldpausch M., Lamberth S., Van den Daele H.,
RA De Keyser A., Buyschaert C., Gielen J., Villarroel R., De Clercq R.,
RA Van Montagu M., Rogers J., Cronin A., Quail M., Bray-Allen S.,
RA Clark L., Doggett J., Hall S., Kay M., Lennard N., McLeay K., Mayes R.,
RA Pettit A., Rajandream M.A., Lyne M., Benes V., Reckman S.,
RA Borkova D., Bloeker H., Scharfe M., Grimm M., Lochert T.-H.,
RA Dose S., de Haan M., Maarse A.C., Schaefer M., Wellner Auer S.,
RA Gabel C., Fuchs M., Fartmann B., Granderath K., Danner D., Herzi A.,
RA Neumann S., Argirou A., Vitale D., Liguori R., Piravandi E.,
RA Massenet O., Quigley F., Clabaud G., Muendlein A., Felber R.,
RA Schnabl S., Hiller R., Schmidt W., Lecharny A., Aubourg S.,
RA Chefor F., Cooke R., Berger C., Monfort A., Casacuberta E.,
RA Glibons T., Weber N., Vandenbol M., Barges M., Terol J., Torres A.,
RA Perez-Perez A., Purnelle B., Bent E., Johnson S., Tacon D., Torres A.,
RA Heijnen L., Schwarz S., Scholler P., Heber S., Francis P., Bielke C.,
RA Frisman D., Haase D., Lemcke K., Mewes H.-W., Stocker S.,
RA Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
RA Parnell L., Dedina N., Gnoj L., Schutz K., Huang E., Spiegel L.,
RA Sekhon M., Murray J., Sheet P., Cordes M., Abu-Threideh J.,
RA Stenking T., Kalicki J., Graves T., Harmon G., Edwards J.,
RA Lareille P., Courteney L., Cloud J., Abbott A., Scott K., Johnson D.,
RA Minx P., Bentley D., Fulton B., Miller N., Greco T., Kemp K.,
RA Kramer J., Fulton L., Mardis E., Dante M., Pepin K., Hillier L.,
RA Nelson J., Spieth J., Ryan E., Andrews S., Gelsel C., Layman D.,
RA Du H., Ali J., Berghoff A., Jones K., Drone K., Cotton M., Joshi C.,
RA Antoniou B., Zidan M., Strong C., Sun H., Lamar B., Yordan C.,
RA Ma P., Zhong J., Preston R., Vil D., Shekhar M., Matero A., Shah R.,
RA Swaby I.K., O'Shaughnessy A., Rodriguez M., Hoffman J., Tili S.,
RA Granat S., Shoddy N., Haesgawa A., Hameed A., Lohi M., Johnson A.,
RA Chen E., Marra M., Martienssen R., McCombie W.R.,
RT "Sequence and analysis of chromosome 4 of the plant *Arabidopsis thaliana*,"
RT Nature 402:769-777(1999).
CC -1- FUNCTION: POSSIBLE ROLE IN MITOSIS.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS; A SMALL GLOBULAR
CC N-TERMINAL, A CENTRAL ALPHA-HELICAL COILED COIL AND A LARGE
CC GLOBULAR C-TERMINAL WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY
CC (IT HYDROLYZES ATP AND BINDS MICROTUBULES).
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
CC SUBFAMILY.
CC -1- CAUTION: Ref.2 sequences differ from that shown due to erroneous
CC gene model prediction.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: D21137, BAA04673.1; -
CC EMBL: AL035680, CAB38848.1; ALT_SEQ.
CC EMBL: AL161566, CAB79573.1; ALT_SEQ.
CC PIR: T06048; T06048.
CC HSSP: P17119, 3KAR.
CC InterPro: IPR001752, kinesin_motor.
CC DR Pfam: PF00225, kinesin_1.
CC DR SMART: SM00129, KISC; 1.
CC DR PROSITE: PS00411, KINESIN MOTOR DOMAIN; 1.
CC DR PROSITE: PS50067, KINESIN MOTOR DOMAIN; 1.
CC KW Motor protein; Microtubules; ATP-binding; Coiled coil;
CC Multigene family.
CC FT DOMAIN 1 35 GLOBULAR.
CC FT DOMAIN 36 384 COILED COIL.
CC FT DOMAIN 385 718 KINESIN-MOTOR (BY SIMILARITY).
CC FT NP_BIND 472 479 ATP (POTENTIAL).
CC SQ SEQUENCE 745 AA; 84359 MW; 6DB352FDF4FD7BC1 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 745;
Best Local Similarity 100.0%; Pred. No. 4e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 469 FAYGQSGSKTYTM 482
92 FAYGQSGSKTYTM 105
|||||
ATK3 ARATH STANDARD; PRT; 754 AA.
ID ATK3 ARATH
AC P46875; Q9FH38;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE kinesin 3 (kinesin-like protein C).
GN ATK3 OR KATC OR AT5G54670 OR K5F14.1 OR MEB17.18.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosid II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=94355659; PubMed=8075402;
RA Mitsui H., Nakatani K., Yamaguchi-Shinozaki K., Shinozaki K.,
RT "Sequencing and characterization of the kinesin-related genes *katB*
RT and *katC* of *Arabidopsis thaliana*,"
RL Plant Mol. Biol. 25:865-876(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=20181125; PubMed=10718197;
RA Sato S., Nakamura Y., Kaneko T., Katoh T., Asamizu E., Kotani H.,
RT Tabata S.;
RT "Structural analysis of *Arabidopsis thaliana* chromosome 5. X. Sequence
RT features of the regions of 3,076,755 bp covered by sixty P1 and TAC
RT clones,"
RL DNA Res. 7:31-63(2000).
CC -1- FUNCTION: POSSIBLE ROLE IN MITOSIS.
CC -1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS; A SMALL GLOBULAR
CC N-TERMINAL, A CENTRAL ALPHA-HELICAL COILED COIL AND A LARGE
CC GLOBULAR C-TERMINAL WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY
CC (IT HYDROLYZES ATP AND BINDS MICROTUBULES).
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
CC SUBFAMILY.
CC -1- CAUTION: Ref.2 sequence differs from that shown due to erroneous
CC gene model prediction.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: D21138, BAA04674.1; -
CC EMBL: AB022214, BAB09933.1; ALT_SEQ.
CC PIR: S48020; S48020.
CC HSSP: P17119, 3KAR.
CC InterPro: IPR001752, kinesin_motor.
CC DR Pfam: PF00225, kinesin_1.
CC DR SMART: SM00129, KISC; 1.
CC DR PROSITE: PS00411, KINESIN MOTOR DOMAIN; 1.
CC DR PROSITE: PS50067, KINESIN MOTOR DOMAIN; 1.
CC KW Motor protein; Microtubules; ATP-binding; Coiled coil; Mitosis;
CC Multigene family.
CC FT DOMAIN 1 45 GLOBULAR.

```

FT DOMAIN 46 393 COILED COIL.
FT DOMAIN 398 727 KINESIN-MOTOR (BY SIMILARITY).
FT NP BIND 481 488 ATP (POTENTIAL).
SQ SEQUENCE 754 AA; 85030 MW; 76091CD5B5D9C531 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 754;
Best Local Similarity 100.0%; Pred. No. 4e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 92 PAYGOTSGKTYM 105
DB 478 PAYGOTSGKTYM 491

RESULT 33
ATK1_ARATH
ID ATK1_ARATH STANDARD; PRT; 793 AA.
AC Q07970;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 33, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Kinesin 1 (Kinesin-like protein A).
GN ATK1 OR KATA OR AT4G21270 OR F7J7.210.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eustoids II; Brassicales; Brassicaceae; Arabidopsis.
OC NCBI_TaxID=3702;
RX MEDLINE=93261419; PubMed=8492804;
RA Matsui H., Yamaguchi-Shinozaki K., Shinozaki K., Nishikawa K.,
RA Takahashi H.;
RT "Identification of a gene family (kat) encoding kinesin-like proteins
RT in Arabidopsis thaliana and the characterization of secondary
RT structure of KAT1."
RL Mol. Gen. Genet. 238:362-368 (1993).

SEQUENCE FROM N.A.
RP STRAIN=cv. Columbia;
RC MEDLINE=20083488; PubMed=10617198;
RA Mayer K.F.X., Schueller C., Schueller R., Entian K.-D., Terryn N.,
RA Pohl T., Duescherhoef A., Stiekema W., Ertter K.-D., Terryn N.,
RA Harris B., Ansoorge W., Brandt P., Grivell L.A., Rieger M., Mueller M.,
RA Weichselgatterer M., de Simone V., Obermayer B., Maehne R., Schmidt T.,
RA Kreis M., Delseny M., Puigdomenech P., Watson M., Schmidt T.,
RA Reichert B., Portetelle D., Perez-Alonso M., Boutry M., Bancroft I.,
RA Vos P., Hehseisel J., Zimmermann W., Wedler H., Ridley P.,
RA Langham S.-A., McCullagh B., Bilham L., Robben J.,
RA Van der Schueren J., Grymoprez B., Chuang Y.-J., Vandebussche F.,
RA Breken M., Welfjens I., Voet M., Baetlaens I., Aert R., Deltor E.,
RA Holzernegger T., Bothe G., Ransperger U., Hilbert H., Braun M.,
RA Holzernegger T., Bothe G., Ransperger U., Hilbert H., Braun M.,
RA Moelmann P., Klein lankhorst R., Rose M., Hauf J., Koeltter P.,
RA Berner S., Hempel S., Feldpausch M., Lamberth S., Van den Daele H.,
RA De Keyser A., Buysaert C., Gielen J., Villarroel R., De Clercq R.,
RA Van Montagu M., Rogers J., Cronin A., Quail M., Bray-Allen S.,
RA Clark L., Doggett J., Hall S., Kay M., Leonard N., Mcay K., Mayes R.,
RA Petrecci A., Rajandream M.A., Lyne M., Benes V., Reumann S.,
RA Borikova D., Bloeker H., Scharf M., Grimm M., Loehner T.-H.,
RA Dose S., de Haan M., Maarse A.C., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fartmann B., Granderth K., Danner D., Herzi A.,
RA Neumann S., Argitrou A., Vitale D., Liguori R., Pivrandi E.,
RA Maesenet O., Quigley F., Clabaud G., Muendlein A., Feilber R.,
RA Schnabl S., Hiller R., Schmidt W., Lecharny A., Aubourg S.,
RA Chedors T., Weber N., Vandenhof M., Bargues M., Terol J., Torres A.,
RA Perez-Perez A., Furnelle B., Bent B., Johnson S., Tacon D., Jesse T.,
RA Heijmen D., Haase D., Lemcke K., Heber S., Francis P., Bleike C.,
RA Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
RA Parnell L., Dedhia N., Gnoj L., Schutz K., Huang E., Spiegel L.,

```

```

RA Sekhon M., Murray J., Sheet P., Cordes M., Abu-Threideh J.,
RA Stoneking T., Kalicki J., Graves T., Harmon G., Edwards J.,
RA Lareille P., Courtney L., Cloud J., Abbott A., Scott K., Johnson D.,
RA Minx P., Bentley D., Fulton B., Miller N., Greco T., Kemp K.,
RA Kramer J., Fulton L., Marks E., Dante M., Pepin K., Hillier L.,
RA Nelson J., Spieth J., Ryan E., Andrews S., Gelsel C., Layman D.,
RA Du H., Ali J., Berghoff A., Jones K., Drome K., Cotton M., Joshi C.,
RA Antonov B., Zidanic M., Strong C., Sun H., Lamar B., Jordan C.,
RA Ma P., Zhong J., Preston R., Vil D., Shekhar M., Matero A., Shah R.,
RA Swaby I.K., O'Shaughnessy A., Rodriguez M., Hoffman J., Till S.,
RA Granat S., Shohdy N., Hasegawa A., Hamed A., Lochi M., Johnson A.,
RA Chen E., Marra M., Martienssen R., McCombe W.R.;
RT "Sequence and analysis of chromosome 4 of the plant Arabidopsis
RT thaliana."
RL Nature 402:769-777 (1999).

[3]
RX PubMed=12112142;
RA Marcus A.I., Ambrose J.C., Blackley L., Hancock W.O., Cyr R.J.;
RT "Arabidopsis thaliana protein, ATK1, is a minus-end directed kinesin
RT that exhibits non-processive movement."
RL Cell Motil. Cytoskeleton 52:144-150 (2002).

[4]
RX PubMed=11973272;
RA Chen C., Marcus A., Li W., Hu Y., Calzada J.-P., Grossniklaus U.,
RA Cyr R.J., Ma H.;
RT "The Arabidopsis ATK1 gene is required for spindle morphogenesis in
RT male meiosis."
RL Development 129:2401-2409 (2002).

-1- FUNCTION: Kinesin that supports microtubule movement in an ATP-
dependent manner and has a minus-end directed polarity. Plays a
crucial role in spindle morphogenesis in male Arabidopsis meiosis.
in ATK1 mutants, male meiosis is defective, producing an abnormal
number of microspores of variable sizes.

-1- DOMAIN: COMPOSED OF THREE STRUCTURAL DOMAINS; A SMALL GLOBULAR
N-TERMINAL, A CENTRAL ALPHA-HELICAL COILED COIL, AND A LARGE
GLOBULAR C-TERMINAL WHICH IS RESPONSIBLE FOR THE MOTOR ACTIVITY
(1T HYDROLYZES ATP AND BINDS MICROTUBULES).

-1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
SUBFAMILY.

-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC The European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; D11371; BAA01972.1; -
DR EMBL; AL021960; CAA17546.1; -
DR EMBL; AL161554; CAB79127.1; -
DR PIR; S34830; S34830.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin_1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1, 1.
DR PROSITE; PS0067; KINESIN MOTOR DOMAIN2, 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil; Meiosis;
KW Multigene family.
FT DOMAIN 1 69 GLOBULAR.
FT DOMAIN 70 428 COILED COIL.
FT DOMAIN 429 778 KINESIN-MOTOR (BY SIMILARITY).
FT NP BIND 516 523 ATP (POTENTIAL).
SQ SEQUENCE 793 AA; 89047 MW; 85A195206D825C4E CRC64;

Query Match 1.1%; Score 14; DB 1; Length 793;
Best Local Similarity 100.0%; Pred. No. 4.2e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 92 FAYGOTSGKTYTM 105
 DB 513 FAYGOTSGKTYTM 526

RESULT 34
 ID KLP1_SCHPO STANDARD; PRT; 832 AA.
 AC 092376; 042669;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 15-DEC-1998 (Rel. 37, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Kinesin-like protein 1.
 GN PCL1 OR SPAC3A11.14C.
 OS Schizosaccharomyces pombe (Fission Yeast).
 OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
 OC Schizosaccharomycetales; Schizosaccharomycetaceae;
 OC Schizosaccharomyces.
 NCBI_TaxID=4896;
 RX SEQUENCE FROM N.A.
 RC STRAIN=972;
 RA MEDLINE=97053988; PubMed=8898367;
 RA Pidoux A.L., Ledizet M., Candé W.Z.;
 RT "Fission yeast pkl1 is a kinesin-related protein involved in mitotic
 RT spindle function."
 RL Mol. Biol. Cell 7:1639-1655(1996).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=972;
 RA MEDLINE=21848401; PubMed=11859360;
 RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
 RA Sgourou J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
 RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
 RA Collins M., Connor R., Cronin A., Davis P., Felwell T., Fraser A.,
 RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
 RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
 RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
 RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
 RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
 RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
 RA Skelton J., Simmonds M., Squares R., Squares S., Stevens K.,
 RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
 RA Woodward J., Voicakeert G., Aert R., Robben J., Gymnopreze B.,
 RA Wellens I., Vansireels E., Rieger M., Schaefer M., Mueller-Auer S.,
 RA Gabel C., Ruchs M., Fritze C., Holzer E., Moestl D., Hilbert H.,
 RA Borzym K., Langer I., Beck A., Lehach H., Reinhardt R., Pohl T.M.,
 RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
 RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
 RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
 RA Lucas M., Rochet M., Gallardin C., Tallada V.A., Garzon A., Thode G.,
 RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
 RA Dominguez A., Revuelta J.L., Moreno S., Armstrong U., Forsburg S.L.,
 RA Cerutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
 RA Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.;
 RL "The genome sequence of Schizosaccharomyces pombe."
 RL Nature 415:871-880(2002)
 CC -1- FUNCTION: MICROTUBULE-DEPENDENT MOTOR THAT IS INVOLVED IN
 CC MICROTUBULE ORGANIZATION IN THE MITOTIC SPINDLE.
 CC -1- SUBCELLULAR LOCATION: Nuclear.
 CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY. NCD
 CC SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; U63916; AAB88235.1; -
 CC EMBL; Z99296; CAB16597.1; -

DR EMBL; Z99260; CAB16389.1; -
 DR PIR; T38749; T38749.
 DR HSSP; P17119; 3KAR.
 DR GeneDB SPombe; SPAC3A11.14C; -
 DR InterPro; IPR001752; kinesin_motor.
 DR Pfam; PF00225; kinesin; 1.
 DR SMART; SM00380; KINESINHEAVY.
 DR PRINTS; SM00129; KISC; 1.
 DR PROSITE; PS00411; KINESIN MOTOR DOMAIN1; 1.
 DR PROSITE; PS50667; KINESIN MOTOR DOMAIN2; 1.
 KM Motor protein; Microtubules; ATP-binding; Coiled coil;
 FT Nucleic protein.
 FT DOMAIN 193 266 COILED COIL (POTENTIAL).
 FT DOMAIN 284 305 COILED COIL (POTENTIAL).
 FT DOMAIN 344 481 COILED COIL (POTENTIAL).
 FT DOMAIN 482 832 KINESIN-MOTOR (BY SIMILARITY).
 FT FT BIND 575 582 ATP (POTENTIAL).
 FT CONFLICT 343 343 E -> D (IN REF. 1).
 SQ SEQUENCE 832 AA; 96336 MW; 870CF74224B9F3E4 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 832;
 Best Local Similarity 100.0%; Pred. No. 4.4e-05;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTM 105
 DB 572 FAYGOTSGKTYTM 585

RESULT 35
 ID CYAG_DICDI STANDARD; PRT; 858 AA.
 AC 003101;
 DT 01-JUL-1993 (Rel. 26, Created)
 DT 01-JUL-1993 (Rel. 26, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Adenylate cyclase, germination specific (EC 4.6.1.1) (ATP
 DE pyrophosphate-lyase) (Adenylate cyclase).
 GN ACQA OR ACG.
 OS Dictyostelium discoideum (Slime mold).
 OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
 NCBI_TaxID=44689;
 RX SEQUENCE FROM N.A.
 RC MEDLINE=92233467; PubMed=1348970;
 RA Pitt G.S., Milona N., Bortels J., Lin K.C., Reed R.R.,
 RA Devreotes P.N.;
 RT "Structurally distinct and stage-specific adenylate cyclase genes play
 RT different roles in Dictyostelium development."
 RL Cell 69:305-315(1992).
 RN [2]
 RP 3D-STRUCTURE MODELING OF 387-543.
 RA MEDLINE=98054247; PubMed=9391039;
 RA Liu Y., Ruoho A.E., Rao V.D., Hurley J.H.;
 RT "Catalytic mechanism of the adenylate and guanylate cyclases: modeling
 RT and mutational analysis."
 RL Proc. Natl. Acad. Sci. U.S.A. 94:13414-13419(1997).
 CC -1- FUNCTION: ACG HAS A LARGE EXTRACELLULAR DOMAIN WHICH MAY BE
 CC INVOLVED IN THE RECOGNITION OF AN EXTRACELLULAR SIGNAL PRESENT
 CC DURING GERMINATION, LEADING TO ACTIVATION OR INHIBITION OF CAMP
 CC SYNTHESIS BY THE CYTOPLASMIC DOMAIN.
 CC -1- ENZYME ACTIVITY: ATP = 3',5'-cyclic AMP + diphosphate.
 CC -1- CATALYTIC ACTIVITY: INSENSITIVE TO GUANINE NUCLEOTIDES.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- DEVELOPMENTAL STAGE: AFTER FRUITING BODIES HAVE BEEN FORMED AND
 CC DURING GERMINATION.
 CC -1- SIMILARITY: Belongs to the adenylate cyclase class-4/guanylate
 CC cyclase family.
 CC -1- SIMILARITY: Contains 1 CHASE domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL; M87278; AAA33164.1; --
DR PDB; 1AMW; 28-JAN-98.
DR DictyDb; DD04007; acga.
DR InterPro; IPR006189; CHASE.
DR InterPro; IPR01054; G_cyclase.
DR Pfam; PF03924; CHASE; 1.
DR SMART; SM00044; CYCC; 1.
DR PROSITE; PS00839; CHASE; 1.
DR PROSITE; PS00452; GUANYLATE_CYCLASES_1; 1.
DR PROSITE; PS00125; GUANYLATE_CYCLASES_2; 1.
DR Lyase; CAMP biosynthesis; Transmembrane; Germination; Signal-anchor; 3D-structure.
KW TRANSMEM 1 18 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 19 41 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
FT DOMAIN 42 858 (POTENTIAL).
FT DOMAIN 86 317 EXTRACELLULAR (POTENTIAL).
FT DOMAIN 396 526 CHASE.
FT DOMAIN 738 848 GUANYLATE CYCLASE.
FT DOMAIN 835 848 ASN-RICH.
FT STRAND 391 398 POLY-ASN.
FT STRAND 403 408
FT HELIX 415 432
FT TURN 433 434
FT STRAND 439 443
FT TURN 444 445
FT STRAND 446 451
FT HELIX 462 473
FT TURN 474 474
FT TURN 479 482
FT STRAND 492 492
FT STRAND 495 500
FT STRAND 504 504
FT STRAND 511 511
FT HELIX 517 527
FT STRAND 534 534
FT HELIX 538 542
SQ SEQUENCE 858 AA; 98413 MW; B483FB25528965D CRC64;

Query Match 1.1%; Score 14; DB 1; Length 858;
Best Local Similarity 100.0%; Pred. No. 4.5e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 742 NNNNNNNNNNNNNN 755
DB 835 NNNNNNNNNNNNNN 848

RESULT 36
KINL_LEICH STANDARD; PRT; 955 AA.
ID KINL_LEICH
AC P46865;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-OCT-1996 (Rel. 34, Last annotation update)
DE Kinesin-like protein K39 (Fragment).
GN KIN
OS Leishmania chagasi.
OC Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.
OX NCBI_TaxID=44271;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MHOM/BR/82 / Isolate BA-2;
RX MEDLINE=93133867; PubMed=8421715;
RA Burns J.M. Jr., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., Reed S.G.;
RT "Molecular characterization of a kinesin-related antigen of

Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis.";
Proc Natl Acad Sci U S A. 90:775-779(1993).
CC -1- DEVELOPMENTAL STAGE: PREDOMINANT IN ANASTOGONES.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL; L07879; AAA29254.1; --
DR PIR; A47334; A47334.
DR HSSP; P17119; 3KAR.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
DR PROSITE; PS00067; KINESIN_MOTOR_DOMAIN2; 1.
KW Motor protein; Microtubules; ATP-binding; Coiled coil; Repeat.
FT DOMAIN 1 399 KINESIN-MOTOR (BY SIMILARITY).
FT NP BIND 426 >955
FT DOMAIN 122 129 COILED COIL (POTENTIAL).
FT NP BIND 704 >955
FT REPEAT 704 742 7 X 39 AA APPROXIMATE TANDEM REPEATS.
FT REPEAT 743 781 1.
FT REPEAT 782 820 2.
FT REPEAT 821 859 3.
FT REPEAT 860 898 4.
FT REPEAT 899 937 5.
FT REPEAT 938 955 6.
FT NON TER 955
SQ SEQUENCE 955 AA; 106168 MW; 8CA76815B84C6E9 CRC64;

Query Match 1.1%; Score 14; DB 1; Length 955;
Best Local Similarity 100.0%; Pred. No. 5e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 92 FAYGQTSGKTYTM 105
DB 119 FAYGQTSGKTYTM 132

RESULT 37
R115_YEAST STANDARD; PRT; 1770 AA.
ID R115_YEAST
AC P43565;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Serine/threonine-protein kinase RIM15 (EC 2.7.1.1).
GN RIM15 OR TAK1 OR YFP033C.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=95400292; PubMed=7670463;
RA Murakami Y., Naitou M., Hagiwara H., Shibata T., Ozawa M., Sasanuma S.-I., Sasanuma M., Tsuchiya Y., Soeda E., Yokoyama K., Yamazaki M., Tashiro H., Eki T.;
RT "Analysis of the nucleotide sequence of chromosome VI from Saccharomyces cerevisiae";
RL Nat. Genet. 10:261-268(1995).
RN [2]
RP SEQUENCE FROM N.A., AND CHARACTERIZATION.
RX MEDLINE=97265402; PubMed=9111339;


```

RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. VENT Cherry;
RX MEDLINE=98145476; Pubmed=9484482;
RT Janssen B.J., Williams A., Chen J.J., Mathern J., Hake S., Sinha N.;
RT "Isolation and characterization of two knotted-like homeobox genes
RT from tomato.";
RL Plant Mol. Biol. 36:417-425 (1998).
CC -1- FUNCTION: MAY HAVE A ROLE TO PLAY IN FORMATIVE EVENTS IN OVULE AND
CC EMBRYO MORPHOGENESIS.
CC -1- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -1- TISSUE SPECIFICITY: UBIQUITOUSLY EXPRESSED IN THE MATURE PLANT.
CC -1- SIMILARITY: BELONGS TO THE TALE/KNOX HOMEBOX FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF000142; AAC49918.1; -.
DR PIR; T04318; T04318.
DR TRASNFAAC; T04055; -.
DR InterPro; IPR005539; ELK.
DR InterPro; IPR001356; Homeobox.
DR InterPro; IPR005540; KNOX1.
DR InterPro; IPR005541; KNOX2.
DR Pfam; PF03789; ELK; 1.
DR Pfam; PF03790; KNOX1; 1.
DR Pfam; PF03791; KNOX2; 1.
DR Prodom; PD000010; Homeobox; 1.
DR SMART; SM00389; HOX; 1.
DR PROSITE; PS00027; HOMEBOX_1; 1.
DR PROSITE; PS00071; HOMEBOX_2; 1.
DR KNA-binding; Homeobox; Nuclear protein.
FT DOMAIN 15 24 POLY-GLN.
FT DOMAIN 69 76 POLY-ALA.
FT DOMAIN 140 152 POLY-ASN.
FT DOMAIN 283 287 POLY-ASP.
FT DOMAIN 325 348 ELK DOMAIN.
FT DNA BIND 349 411 HOMEBOX (TALE-TYPE).
SQ SEQUENCE 426 AA; 47581 MW; 5B52B9E0A34A86BC CRC64;

Query Match 1.0%; Score 13; DB 1; Length 426;
Best Local Similarity 100.0%; Pred. No. 0.00022;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 742 NNNNNNNNNNNNNN 754
Db 140 NNNNNNNNNNNNNN 152

RESULT 40
KLP3 SCHPO STANDARD; PRT; 554 AA.
AC Q9US60; Q9US61;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Kinesin-like protein 3 (Kinesin-related protein 1).
GN KLP3 OR KRP1 OR SPAC1834.07.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OC NCB1_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A., FUNCTION, AND SUBCELLULAR LOCATION.
RC STRAIN=972;
RX MEDLINE=20109189; PubMed=10641037;
RA Brazier S.-C.W., Williams H.P., Chapell T.G., Cande W.Z.;

```

```

RT "A fission yeast kinesin affects Golgi membrane recycling.";
RL Yeast 16:149-166 (2000).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=972;
RX MEDLINE=22127603; Pubmed=12132578;
RT Jeong J.W., Rhee D.K., Cho S.Y., Hae K.L., Kim D.U., Won M., Kim H.B.;
RT "Cloning and characterization of the kinesin-related protein, Kripip,
RT in Schizosaccharomyces pombe.";
RL Mol. Cells 13:389-398 (2002).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=972;
RX MEDLINE=21848401; Pubmed=11859360;
RL Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgourou J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Fellwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Mounle S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skelton J., Simmonds M., Squares R., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Voicakeert G., Aert R., Robben J., Grymoprez B.,
RA Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fritz C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Leirach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaue V., Mottier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rocher M., Gallardin C., Tallada V.A., Garzon A., Rhode G.,
RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsberg S.L.,
RA Cerrutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA Shpakovski G.V., Useary D., Barrett B.G., Nure P.;
RT "The genome sequence of Schizosaccharomyces pombe.";
RL Nature 415:871-880 (2002).
CC -1- FUNCTION: CYTOPLASMIC MOTOR THAT COULD PLAY A ROLE IN GOLGI
CC MEMBRANE RECYCLING.
CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
CC -1- SIMILARITY: BELONGS TO THE KINESIN-LIKE PROTEIN FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF154055; AAF14525.1; -.
DR EMBL; AF156966; AAF22609.1; -.
DR EMBL; AF247188; AAF81205.1; -.
DR EMBL; AL157734; CAB75775.1; -.
DR PIR; T50118; T50118.
DR HSSP; P33176; I862.
DR GeneDB; SPombe; SPAC1834.07; -.
DR InterPro; IPR001752; kinesin_motor.
DR Pfam; PF00225; kinesin; 1.
DR PRINTS; PR00380; KINESINHEAVY.
DR SMART; SM00129; KISC; 1.
DR PROSITE; PS00411; KINESIN_MOTOR_DOMAIN1; 1.
DR PROSITE; PS00067; KINESIN_MOTOR_DOMAIN2; 1.
KW ATP-binding; Coiled coil; Motor protein.
FT DOMAIN 1 332 KINESIN-MOTOR (BY
FT SIMILARITY).
FT NP_BIND 446 473 COILED COIL (POTENTIAL).
FT NP_BIND 84 91 ATP (POTENTIAL).
FT NP_BIND 233 240 ATP (POTENTIAL).
FT CONFLICT 57 57 O -> L (IN REF. 1).

```


SEQ SEQUENCE 554 AA; 61938 MW; B4533BD095C49CBD CRC64;

Query Match 1.0%; Score 13; DB 1; Length 554;

Best Local Similarity 100.0%; Pred. No. 0.00028;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 AYGQTSGSGKTYTM 105

Db 82 AYGQTSGSGKTYTM 94

Search completed: October 2, 2003, 16:32:52
Job time : 51 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:21:36 ; Search time 94 Seconds

(without alignments)
2174.892 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 1288

Sequence: 1 MNSKIKVVRKRPLSELEKK.....KKLVODNINSMNDNNHKK 1288

Scoring table: OLIGO
Gapop 60.0, Gapext 60.0, ...

Searched: 1107863 seqs, 158726573 residues

Word size: 0

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 1000 summaries

Database: A.Geneseq.19Jun03.*

1: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/genesep-emb1/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/genesep-emb1/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/genesep-emb1/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/genesep-emb1/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/genesep-emb1/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	17	1.3	190	14	Staphylococcus ent
2	17	1.3	190	14	Staphylococcus ent
3	17	1.3	190	14	Staphylococcus ent
4	17	1.3	190	14	Staphylococcus ent
5	17	1.3	190	14	Staphylococcus ent
6	17	1.3	190	14	Staphylococcus ent
7	17	1.3	190	14	Staphylococcus ent
8	17	1.3	190	14	Staphylococcus ent
9	17	1.3	190	14	Staphylococcus ent

10	17	1.3	190	14	Staphylococcus ent
11	17	1.3	190	14	Staphylococcus ent
12	17	1.3	190	14	Staphylococcus ent
13	17	1.3	190	14	Staphylococcus ent
14	17	1.3	190	14	Staphylococcus ent
15	17	1.3	190	14	Staphylococcus ent
16	17	1.3	190	14	Staphylococcus ent
17	17	1.3	190	14	Staphylococcus ent
18	17	1.3	190	14	Staphylococcus ent
19	17	1.3	190	14	Staphylococcus ent
20	17	1.3	190	14	Staphylococcus ent
21	17	1.3	190	14	Staphylococcus ent
22	17	1.3	190	14	Staphylococcus ent
23	17	1.3	190	14	Staphylococcus ent
24	17	1.3	190	14	Staphylococcus ent
25	17	1.3	190	14	Staphylococcus ent
26	17	1.3	190	14	Staphylococcus ent
27	17	1.3	190	14	Staphylococcus ent
28	17	1.3	190	14	Staphylococcus ent
29	17	1.3	190	14	Staphylococcus ent
30	17	1.3	190	14	Staphylococcus ent
31	17	1.3	190	14	Staphylococcus ent
32	17	1.3	190	14	Staphylococcus ent
33	17	1.3	190	14	Staphylococcus ent
34	17	1.3	190	14	Staphylococcus ent
35	17	1.3	190	14	Staphylococcus ent
36	17	1.3	190	14	Staphylococcus ent
37	17	1.3	190	14	Staphylococcus ent
38	17	1.3	190	14	Staphylococcus ent
39	17	1.3	190	14	Staphylococcus ent
40	17	1.3	190	14	Staphylococcus ent
41	17	1.3	190	14	Staphylococcus ent
42	17	1.3	190	14	Staphylococcus ent
43	17	1.3	190	14	Staphylococcus ent
44	17	1.3	190	14	Staphylococcus ent
45	17	1.3	190	14	Staphylococcus ent
46	17	1.3	190	14	Staphylococcus ent
47	17	1.3	190	14	Staphylococcus ent
48	17	1.3	190	14	Staphylococcus ent
49	17	1.3	190	14	Staphylococcus ent
50	17	1.3	190	14	Staphylococcus ent
51	17	1.3	190	14	Staphylococcus ent
52	17	1.3	190	14	Staphylococcus ent
53	17	1.3	190	14	Staphylococcus ent
54	17	1.3	190	14	Staphylococcus ent
55	17	1.3	190	14	Staphylococcus ent
56	17	1.3	190	14	Staphylococcus ent
57	17	1.3	190	14	Staphylococcus ent
58	17	1.3	190	14	Staphylococcus ent
59	17	1.3	190	14	Staphylococcus ent
60	17	1.3	190	14	Staphylococcus ent
61	17	1.3	190	14	Staphylococcus ent
62	17	1.3	190	14	Staphylococcus ent
63	17	1.3	190	14	Staphylococcus ent
64	17	1.3	190	14	Staphylococcus ent
65	17	1.3	190	14	Staphylococcus ent
66	17	1.3	190	14	Staphylococcus ent
67	17	1.3	190	14	Staphylococcus ent
68	17	1.3	190	14	Staphylococcus ent
69	17	1.3	190	14	Staphylococcus ent
70	17	1.3	190	14	Staphylococcus ent
71	17	1.3	190	14	Staphylococcus ent
72	17	1.3	190	14	Staphylococcus ent
73	17	1.3	190	14	Staphylococcus ent
74	17	1.3	190	14	Staphylococcus ent
75	17	1.3	190	14	Staphylococcus ent
76	17	1.3	190	14	Staphylococcus ent
77	17	1.3	190	14	Staphylococcus ent
78	17	1.3	190	14	Staphylococcus ent
79	17	1.3	190	14	Staphylococcus ent
80	17	1.3	190	14	Staphylococcus ent
81	17	1.3	190	14	Staphylococcus ent
82	17	1.3	190	14	Staphylococcus ent

83	14	1.1	375	21	AAG31717	156	12	0.9	729	22	ABBS9500	Drosophila melanog
84	14	1.1	375	21	AAV70952	157	12	0.9	761	22	ABR1561	Drosophila melanog
85	14	1.1	458	23	ABP73738	158	12	0.9	764	21	ABR18282	Plasmodium falcipa
86	14	1.1	693	24	ABE30108	159	12	0.9	803	22	ABBS8104	Drosophila melanog
87	14	1.1	700	22	ABBS8943	160	12	0.9	842	17	AAW00137	Drosophila FRU 2 p
88	14	1.1	730	21	AAV9949	161	12	0.9	995	22	ABBS2510	Drosophila melanog
89	14	1.1	955	15	AAAS7365	162	12	0.9	1023	22	ABR11436	D. discoidem ster
90	14	1.1	955	17	AAW03691	163	12	0.9	1341	23	ABP25703	Fungal ZBC protein
91	14	1.1	1245	21	AAI18244	164	12	0.9	1493	22	ABBS69228	Drosophila melanog
92	14	1.1	1460	21	AAAG40077	165	12	0.9	1501	23	AAU76762	Plasmodium falcipa
93	14	1.1	1462	21	AAAG40076	166	12	0.9	1516	21	AAI18195	Plasmodium falcipa
94	14	1.1	1518	21	AAAG40075	167	12	0.9	1568	24	ABP70152	Amino acid sequenc
95	14	1.1	1604	21	AAAG31284	168	12	0.9	2061	22	ABBS6938	Drosophila melanog
96	14	1.1	1606	21	AAAG31283	169	12	0.9	3502	22	ABBS58382	Drosophila melanog
97	14	1.1	1662	21	AAAG31282	170	12	0.9	5533	22	ABBS5772	Drosophila melanog
98	14	1.1	2010	21	AAI18218	171	12	0.9	5560	22	ABR11160	Drosophila melanog
99	13	1.0	39	22	AAI12902	172	12	0.9	121	21	AAAG4445	Arabidopsis thalia
100	13	1.0	48	12	AAI12903	173	12	0.9	133	23	ABP01443	Human ORFX protein
101	13	1.0	108	22	AAO00353	174	12	0.9	137	22	AAO05799	Human polypeptide
102	13	1.0	138	21	AAAG11796	175	12	0.9	160	22	AAAG74164	Human colon cancer
103	13	1.0	147	21	AAAG11795	176	12	0.9	205	23	AAE14609	Human microtubule
104	13	1.0	282	21	AAAG35584	177	12	0.9	205	24	ABU08213	Human kinesin moto
105	13	1.0	341	23	ABBS80078	178	12	0.9	250	23	AAU93167	Arabidopsis transc
106	13	1.0	341	24	ABG72398	179	12	0.9	278	22	ABBS9939	Drosophila melanog
107	13	1.0	363	21	AAAG35583	180	12	0.9	306	22	ABR70631	Drosophila melanog
108	13	1.0	367	23	ABP73400	181	12	0.9	314	23	AAU82970	C. albicans MTW1 p
109	13	1.0	397	23	ABP73400	182	12	0.9	338	23	ABR07411	Human Hsk1p3A moto
110	13	1.0	507	22	ABG050000	183	12	0.9	343	23	AAU77185	Human kint-3 DNA f
111	13	1.0	507	22	ABBS8212	184	12	0.9	348	22	ABG27551	Novel human diagno
112	13	1.0	790	21	AAAG11923	185	12	0.9	361	23	ABBS08099	Human HSET motor p
113	13	1.0	793	22	ABR71688	186	12	0.9	363	23	AAU77186	Human kint-3 DNA f
114	13	1.0	794	21	AAAG11922	187	12	0.9	369	23	ABBS08101	Human HSET motor p
115	13	1.0	814	21	AAAG11921	188	12	0.9	370	23	ABBS08100	Human HSET motor p
116	13	1.0	941	23	ABP74093	189	12	0.9	373	23	AAU77183	Human kint-3 DNA f
117	13	1.0	1003	22	ABBS61405	190	12	0.9	375	23	AAU79591	Human Hsk1f5, kin
118	13	1.0	1074	22	ABBS61124	191	12	0.9	375	23	AAE14491	Human Hsk1f5, kin
119	13	1.0	1151	21	AAI63251	192	12	0.9	381	23	AAU77184	Human kint-3 DNA f
120	13	1.0	1151	23	AAE28254	193	12	0.9	383	23	ABBS07412	Amino acid sequenc
121	13	1.0	1212	22	ABR71114	194	12	0.9	383	24	ABG72053	Human Hsk1p3 fragm
122	13	1.0	1279	23	ABG70787	195	12	0.9	409	22	AAU15082	Protein encoded by
123	13	1.0	1279	23	ABBS80078	196	12	0.9	409	23	ABP73217	Candida albicans e
124	13	1.0	1279	24	ABG72397	197	12	0.9	409	23	AAU79592	Human Hsk1f5, kin
125	13	1.0	1893	21	ABBS9829	198	12	0.9	409	23	AAE14402	Human Hsk1f5 prot
126	13	1.0	2573	21	AAI18234	199	12	0.9	461	16	AAE75506	Nicotiana alata ar
127	12	0.9	212	23	ABG31169	200	12	0.9	473	23	ABG70992	Human target prote
128	12	0.9	212	23	ABG31169	201	12	0.9	522	23	ABG70991	Human Hsk1f4 const
129	12	0.9	246	22	AAAB47285	202	12	0.9	526	22	ABBS68634	Drosophila melanog
130	12	0.9	263	22	ABR70399	203	12	0.9	561	22	ABBS67878	Drosophila melanog
131	12	0.9	306	22	ABBS60719	204	12	0.9	589	22	ABBS58929	Drosophila melanog
132	12	0.9	306	22	ABBS60722	205	12	0.9	601	22	ABBS61643	Drosophila melanog
133	12	0.9	362	23	AAE14501	206	12	0.9	673	22	AAI18739	Human polypeptide
134	12	0.9	387	23	ABP73197	207	12	0.9	676	23	ABG93214	S. cerevisiae BAX-
135	12	0.9	391	23	AAE14500	208	12	0.9	722	21	AAI18291	Plasmodium falcipa
136	12	0.9	405	23	AAE14504	209	12	0.9	774	22	ABBS6418	Drosophila melanog
137	12	0.9	410	21	ABBS6496	210	12	0.9	776	22	AAW40525	Human polypeptide
138	12	0.9	427	21	ABBS8461	211	12	0.9	782	22	AAI11348	Human kinesin rela
139	12	0.9	430	22	ABBS5442	212	12	0.9	864	23	ABBS07410	Human kinesin moto
140	12	0.9	430	22	AAI14499	213	12	0.9	864	24	ABG72052	Human kinesin moto
141	12	0.9	434	23	AAE14503	214	12	0.9	1025	23	ABBS2133	Plasmodium falcipa
142	12	0.9	473	23	AAE14502	215	12	0.9	1029	22	ABBS0649	Novel human diagno
143	12	0.9	511	23	ABP73951	216	12	0.9	1122	21	AAI18295	Plasmodium falcipa
144	12	0.9	638	22	ABR71320	217	12	0.9	1174	22	AAAB61704	Drosophila melanog
145	12	0.9	647	11	AAAR06001	218	12	0.9	1230	19	AAAB48895	Candida albicans C
146	12	0.9	675	17	AAW00136	219	12	0.9	1232	23	ABG70993	Human Hsk1f4 prote
147	12	0.9	679	20	AAAB8456	220	12	0.9	1234	23	ABG70993	Human Hsk1f4b prot
148	12	0.9	690	22	AAI19257	221	12	0.9	1269	21	AAU77955	A. thaliana enviro
149	12	0.9	691	21	AAV32253	222	12	0.9	1351	21	AAI18290	Plasmodium falcipa
150	12	0.9	691	22	ABBS64167	223	12	0.9	1368	23	AAU77182	Human kinesin moto
151	12	0.9	694	22	AAI1043	224	12	0.9	1373	22	ABR71036	Drosophila melanog
152	12	0.9	694	22	AAI1044	225	12	0.9	1388	23	AAU79590	Human kinesin moto
153	12	0.9	723	23	AAE14505	226	12	0.9	1388	23	AAE14400	Human kinesin supe
154	12	0.9	725	23	AAE14506	227	12	0.9	1388	22	ABR48222	Human bladder can
155	12	0.9	728	22	AAI19258	228	12	0.9	1848	24	ABBS68996	Drosophila melanog

229	11	0.9	1945	22	ABB64947	Drosophila melanog	302	10	0.8	633	21	AAG31266	Arabidopsis thaliana
230	11	0.9	1979	21	AA181871	Plasmodium falcipa	303	10	0.8	633	22	AAE01905	Arabidopsis thaliana
231	11	0.9	1997	21	AA182887	Plasmodium falcipa	304	10	0.8	644	22	ABE59973	Arabidopsis thaliana
232	11	0.9	2088	22	ABB60656	Drosophila melanog	305	10	0.8	645	22	ABB63654	Drosophila melanog
233	11	0.9	3973	21	AA182853	Plasmodium falcipa	306	10	0.8	659	17	AAW09294	L-proline-4-hydrox
234	10	0.8	12	24	ABU14073	Transdominant elite	307	10	0.8	676	22	ABB63098	Drosophila melanog
235	10	0.8	13	23	ABP72103	Beta 1,2-N-acetylgl	308	10	0.8	679	22	AAAB45693	P. falciparum gppe
236	10	0.8	16	22	AAU29011	Vector pMAL-P2 mal	309	10	0.8	690	21	AAU96694	MBP-VT-1 subunit A
237	10	0.8	16	22	AAAB97228	Maltose binding pr	310	10	0.8	690	23	AAU77830	MBP-VT-1 fusion p
238	10	0.8	24	21	AA107777	B. subtilis lumazi	311	10	0.8	694	21	AAU96695	MBP-VT-2 subunit A
239	10	0.8	26	22	AAAB70814	MBP/BMP fusion con	312	10	0.8	694	23	AAU77831	MBP-VT-2-A fusion p
240	10	0.8	26	22	AAAB70815	MBP/BMP fusion con	313	10	0.8	708	23	AAAB92360	Herbicideally activ
241	10	0.8	30	22	AAAB70816	MBP/BMP fusion con	314	10	0.8	708	17	AAW06411	Maltose binding pr
242	10	0.8	40	18	AAW35993	Peptide SEQ ID NO:	315	10	0.8	708	21	AAU96690	MBP-VT-1 subunit A
243	10	0.8	40	22	AAU26046	Peptide sequence o	316	10	0.8	708	23	AAU77826	MBP-VT-1-A fusion p
244	10	0.8	62	22	AAO01380	Human polypeptide	317	10	0.8	711	17	AAW06412	Maltose binding pr
245	10	0.8	67	21	AAAG9908	Peptide MSI-1922.	318	10	0.8	711	21	AAU96691	MBP-VT-2 subunit A
246	10	0.8	91	10	AAAP90415	Plasmodium falcipa	319	10	0.8	711	21	AAU77827	MBP-VT-2-A fusion p
247	10	0.8	100	20	AAW73960	Human TPc2/MBP fus	320	10	0.8	718	22	ABBB6061	Drosophila melanog
248	10	0.8	100	23	AAE15169	Maltose binding pr	321	10	0.8	720	22	AAE01346	Arabidopsis thaliana
249	10	0.8	108	22	AAO02887	Human polypeptide	322	10	0.8	732	22	ABBB6450	Drosophila melanog
250	10	0.8	110	22	ABBB64832	Drosophila melanog	323	10	0.8	740	23	ABG71293	Human oestrogen re
251	10	0.8	121	22	AAAG64025	Human polypeptide	324	10	0.8	740	23	AAAB51591	Fused ER protein.
252	10	0.8	147	21	AAAG02949	Human secreted pro	325	10	0.8	750	22	AAAB30813	Amino acid sequenc
253	10	0.8	147	21	ABG10926	Novel human diagno	326	10	0.8	752	21	AAU19569	P. falciparum gppe
254	10	0.8	240	22	ABBB49146	Literia monocyclo	327	10	0.8	757	22	AAU19569	Human diagnostic a
255	10	0.8	248	22	ABG10925	Novel human diagno	328	10	0.8	757	23	ABP51294	Human MDOT SEQ ID
256	10	0.8	265	23	ABP73329	Candida albicans e	329	10	0.8	762	23	ABBB60124	Human DITRP polype
257	10	0.8	274	23	ABG70881	Human kinesin HsKi	330	10	0.8	763	21	AAAB82155	Pseudomonas putida
258	10	0.8	274	23	ABBB79895	Human kinesin moto	331	10	0.8	784	20	AAAY06618	Thermomyces lanugi
259	10	0.8	274	23	ABG32861	Human kinesin HsKi	332	10	0.8	801	22	ABBB62287	Drosophila melanog
260	10	0.8	281	22	ABG17932	Novel human diagno	333	10	0.8	809	23	AAAB48930	Maltose binding pr
261	10	0.8	314	22	ABG14144	Novel human diagno	334	10	0.8	839	23	ABG71292	Human androgen rec
262	10	0.8	323	22	ABBB60025	Drosophila melanog	335	10	0.8	839	23	AAAG68238	Fused androgen rec
263	10	0.8	329	23	AAE17787	Human kinesin supe	336	10	0.8	931	22	ABBB61093	Drosophila melanog
264	10	0.8	355	22	ABBB68677	Drosophila melanog	337	10	0.8	953	21	AAAY82106	Pseudomonas putida
265	10	0.8	359	23	ABBB84482	Human HsKiF16b mot	338	10	0.8	988	22	ABBB60007	Drosophila melanog
266	10	0.8	359	23	ABBB79530	Human kinesin moto	339	10	0.8	1029	23	AAE17786	Human kinesin supe
267	10	0.8	359	23	AAE2526	Human HsKiF16b mot	340	10	0.8	1038	23	AAAB48337	Human kinesin supe
268	10	0.8	368	23	ABG93036	S. cerevisiae BAX-	341	10	0.8	1059	22	ABBB58331	Drosophila melanog
269	10	0.8	378	22	ABBB68211	Drosophila melanog	342	10	0.8	1068	19	ABBP35714	Fungal ZRC protein
270	10	0.8	412	21	AAAY90266	Protein chimera Q.	343	10	0.8	1084	23	AAAB59033	B. pallidus DNA po
271	10	0.8	412	24	ABG73864	L. infantum antige	344	10	0.8	1121	22	ABBB72021	Drosophila melanog
272	10	0.8	437	22	ABBB62782	Drosophila melanog	345	10	0.8	1172	23	ABBB93308	C. albicans BAX-as
273	10	0.8	437	22	ABBB65444	Drosophila melanog	346	10	0.8	1198	22	ABBB60371	Drosophila melanog
274	10	0.8	456	22	ABBB97389	Rice photosensitivi	347	10	0.8	1276	19	AAAB58034	B. pallidus DNA po
275	10	0.8	468	22	ABBB97390	Rice photosensitivi	348	10	0.8	1308	21	AAAB18167	Plasmodium falcipa
276	10	0.8	488	23	ABP73873	Candida albicans e	349	10	0.8	1362	23	ABBB44481	Human HsKiF16b pr
277	10	0.8	500	19	AAW64057	Human IL-9 recepto	350	10	0.8	1375	23	AAU74840	Human HsKiF16b pr
278	10	0.8	501	19	AAW64056	Human IL-9 recepto	351	10	0.8	1375	23	ABBB79531	Human kinesin moto
279	10	0.8	501	19	AAW64055	Human IL-9 recepto	352	10	0.8	1375	23	AAE29525	Human HsKiF16b pr
280	10	0.8	503	21	AAAB63190	Human secreted pro	353	10	0.8	1392	24	AAE32129	Human cytoskeleton
281	10	0.8	504	21	AAAB63189	Gene 5 human secre	354	10	0.8	1419	23	ABBP52134	Plasmodium falcipa
282	10	0.8	504	22	ABBB63967	Drosophila melanog	355	10	0.8	1438	21	AAAB18270	Plasmodium falcipa
283	10	0.8	511	23	AAAB51137	Maltose binding pr	356	10	0.8	1598	23	ABBP73929	Candida albicans e
284	10	0.8	514	21	AAAG31268	Arabidopsis thaliana	357	10	0.8	1805	23	ABBB68930	Human polypeptide
285	10	0.8	515	21	AAAG31267	Arabidopsis thaliana	358	10	0.8	1817	21	AAAB18255	Human polypeptide
286	10	0.8	521	24	AAO19700	IL-13 modulation m	359	10	0.8	1838	22	ABBB4225	Plasmodium falcipa
287	10	0.8	522	24	ABBB81964	Human IL-9 recepto	360	10	0.8	1921	22	ABBB62962	Drosophila melanog
288	10	0.8	530	22	ABBB61485	Drosophila melanog	361	10	0.8	1926	22	AAAG4915	Drosophila melanog
289	10	0.8	535	16	AAAB78524	Maltose binding pr	362	10	0.8	1991	22	ABBB60651	Shrimp white spot
290	10	0.8	537	7	AAAB60452	Sequence of the As	363	10	0.8	2112	22	ABBB60403	Drosophila melanog
291	10	0.8	542	23	AAU74356	Human cytoskeleton	364	10	0.8	2183	22	ABBB29838	Novel human diagno
292	10	0.8	544	23	ABP74012	Candida albicans e	365	10	0.8	2435	22	ABBB60448	Drosophila melanog
293	10	0.8	549	22	ABBB68830	Drosophila melanog	366	10	0.8	2532	22	ABBB63465	Drosophila melanog
294	10	0.8	573	21	AAAY82154	Pseudomonas putida	367	10	0.8	2532	22	ABBB61166	Drosophila melanog
295	10	0.8	580	22	ABBB63518	Drosophila melanog	368	10	0.8	3614	20	ABBB62664	Drosophila melanog
296	10	0.8	585	21	AAAY82157	Pseudomonas putida	369	10	0.8	4134	20	AAAY31946	Plasmodium falcipa
297	10	0.8	580	22	ABBB62524	Drosophila melanog	370	10	0.8	4904	22	ABBB62549	Drosophila melanog
298	10	0.8	596	23	ABBB68928	Plasmodium falcipa	371	9	0.7	34	23	ABBB40545	Human peptide enco
299	10	0.8	609	22	ABBB61332	Drosophila melanog	372	9	0.7	39	18	AAAB33332	Sequence encoded b
300	10	0.8	610	22	ABBB73117	Drosophila melanog	373	9	0.7	52	23	ABBP31745	Human structural p
301	10	0.8	624	22	ABBB70398	Drosophila melanog	374	9	0.7	57	22	ABBB52907	Human liver peptid

375	9	0.7	57	22	ABR38053	448	9	0.7	856	22	ABR68808	Drosophila melanog
376	9	0.7	57	22	AAW5868	449	9	0.7	858	22	ABR60597	Drosophila melanog
377	9	0.7	57	22	AAW7195	450	9	0.7	860	19	AAW63700	Receptor type tyro
378	9	0.7	57	22	AAW1476	451	9	0.7	885	22	ABR60372	Drosophila melanog
379	9	0.7	57	22	ABG40992	452	9	0.7	887	22	ABR71107	Drosophila melanog
380	9	0.7	72	23	ABR69713	453	9	0.7	898	22	ABR53123	Intracellular traf
381	9	0.7	139	22	ABR69010	454	9	0.7	898	23	AAU76957	Novel human kinase
382	9	0.7	140	21	AAAG09377	455	9	0.7	905	23	AAU76967	Novel human kinase
383	9	0.7	145	22	ABR71063	456	9	0.7	943	22	ABR62085	Drosophila melanog
384	9	0.7	159	21	AAAB43261	457	9	0.7	950	22	ABR71271	Drosophila melanog
385	9	0.7	167	21	AAAG31470	458	9	0.7	960	22	ABR59434	Drosophila melanog
386	9	0.7	176	24	AAE30194	459	9	0.7	1003	18	AAW19917	Drosophila vitellin
387	9	0.7	177	20	AAAY59708	460	9	0.7	1018	22	ABR63718	Drosophila melanog
388	9	0.7	180	24	AAAG30195	461	9	0.7	1036	22	AAAG55011	Shrimp white spot
389	9	0.7	187	21	AAAG54505	462	9	0.7	1094	23	ABP35676	Fungal ZBC protein
390	9	0.7	208	22	ABG15503	463	9	0.7	1140	22	ABR71145	Drosophila melanog
391	9	0.7	213	22	AAU19360	464	9	0.7	1143	23	ABP73852	Candida albicans e
392	9	0.7	248	21	AAAG60582	465	9	0.7	1165	23	AAE24372	Fruit fly E93 prog
393	9	0.7	257	21	AAAB18340	466	9	0.7	1186	22	ABR63516	Drosophila melanog
394	9	0.7	272	21	AAAY7118	467	9	0.7	1193	21	AAAB18306	Plasmodium falcipa
395	9	0.7	280	22	ABR65783	468	9	0.7	1195	22	ABR63694	Drosophila melanog
396	9	0.7	284	22	ABR69768	469	9	0.7	1207	22	ABR62248	Drosophila melanog
397	9	0.7	285	22	ABR65204	470	9	0.7	1221	23	AAE24373	Fruit fly E93 prog
398	9	0.7	300	21	AAAG31469	471	9	0.7	1245	23	ABP73820	Candida albicans e
399	9	0.7	313	22	ABR62420	472	9	0.7	1418	23	ABG93257	C. albicans BAX-as
400	9	0.7	314	22	ABR67734	473	9	0.7	1419	22	ABR65521	Drosophila melanog
401	9	0.7	320	21	AAAG54504	474	9	0.7	1436	21	AAAB18199	Plasmodium falcipa
402	9	0.7	323	21	AAAG54503	475	9	0.7	1445	23	ABP35623	Fungal ZBC protein
403	9	0.7	324	24	ABJ19039	476	9	0.7	1460	22	ABR71977	Drosophila melanog
404	9	0.7	330	23	ABP9157	477	9	0.7	1476	22	ABR58706	Drosophila melanog
405	9	0.7	354	23	ABP73242	478	9	0.7	1518	22	ABR64829	Drosophila melanog
406	9	0.7	357	23	AAU76958	479	9	0.7	1537	22	ABR58058	Drosophila melanog
407	9	0.7	372	22	ABR93414	480	9	0.7	1557	22	ABR62485	Drosophila melanog
408	9	0.7	378	22	ABR60643	481	9	0.7	1557	23	ABG70015	Larval viability a
409	9	0.7	398	21	AAAG29336	482	9	0.7	1714	21	AAAB18275	Plasmodium falcipa
410	9	0.7	410	23	ABR55031	483	9	0.7	1905	22	ABR64925	Drosophila melanog
411	9	0.7	412	21	AAAY97189	484	9	0.7	2037	22	ABR69099	Drosophila melanog
412	9	0.7	437	22	AAAG64524	485	9	0.7	2206	21	AAAB18254	Plasmodium falcipa
413	9	0.7	437	22	AAAG62618	486	9	0.7	2485	21	AAAB18172	Plasmodium falcipa
414	9	0.7	454	22	ABR30816	487	9	0.7	2938	15	AAE59923	GAP protein Irai.
415	9	0.7	454	22	ABP73979	488	9	0.7	4498	22	ABR58595	Drosophila melanog
416	9	0.7	470	22	ABR59219	489	9	0.6	10	22	AAAG83925	Arabidopsis thalia
417	9	0.7	498	23	ABP73393	490	9	0.6	27	17	AAAR94328	Anti-thrombogenic
418	9	0.7	502	22	ABR65558	491	9	0.6	39	21	AAAG58570	Arabidopsis thalia
419	9	0.7	508	21	AAAB18187	492	9	0.6	39	22	ABG58895	Human liver peptid
420	9	0.7	525	22	ABR67142	493	9	0.6	39	22	ABR43516	Peptide #11022 enc
421	9	0.7	548	22	ABR59005	494	9	0.6	39	22	ABR26476	Human brain expre
422	9	0.7	567	21	AAAB18197	495	9	0.6	39	22	AAAB64453	Human brain expre
423	9	0.7	568	22	ABR58131	496	9	0.6	39	22	AAW77259	Human bone marrow
424	9	0.7	578	22	ABR59076	497	9	0.6	39	22	AAW21195	Peptide #7629 enc
425	9	0.7	604	23	ABR05593	498	9	0.6	39	22	AAW37410	Peptide #11447 enc
426	9	0.7	613	22	ABR65716	499	9	0.6	39	23	ABG46275	Human liver peptid
427	9	0.7	621	22	ABR58165	500	9	0.6	41	22	ABG55641	Human liver peptid
428	9	0.7	629	22	AAAG70887	501	9	0.6	41	22	ABR40366	Peptide #7872 enc
429	9	0.7	645	22	ABR61545	502	9	0.6	41	22	AAW61175	Human brain expre
430	9	0.7	648	22	ABR63109	503	9	0.6	41	22	AAW73890	Human bone marrow
431	9	0.7	660	22	ABR68167	504	9	0.6	41	22	AAW34072	Peptide #8109 enc
432	9	0.7	670	23	ABP73731	505	9	0.6	41	23	ABG43778	Human peptid enc
433	9	0.7	675	24	ABP78737	506	9	0.6	42	22	ABR68447	Drosophila melanog
434	9	0.7	691	22	ABR57876	507	9	0.6	52	22	ABG48060	Human liver peptid
435	9	0.7	719	22	AAAG70700	508	9	0.6	52	22	ABR28036	Human peptid #687
436	9	0.7	724	22	ABR65778	509	9	0.6	52	22	ABR33210	Peptide #716 enc
437	9	0.7	726	21	AAAG31118	510	9	0.6	52	22	ABR18675	Protein #674 enc
438	9	0.7	729	22	AAAG70847	511	9	0.6	52	22	AAW54003	Human brain expre
439	9	0.7	740	23	ABP73836	512	9	0.6	52	22	AAW66393	Human bone marrow
440	9	0.7	764	23	ABP73760	513	9	0.6	52	22	AAW14263	Peptide #697 enc
441	9	0.7	769	23	ABP73280	514	9	0.6	52	22	AAW26673	Peptide #710 enc
442	9	0.7	807	21	AAAB18311	515	9	0.6	52	22	AAW01993	Peptide #675 enc
443	9	0.7	816	24	AAAB30116	516	9	0.6	52	23	ABG36042	Human peptid enc
444	9	0.7	829	21	AAAG31117	517	9	0.6	63	21	AAAG54171	Arabidopsis thalia
445	9	0.7	834	21	AAAG31116	518	9	0.6	71	22	ABR70696	Drosophila melanog
446	9	0.7	844	22	ABR66588	519	9	0.6	75	22	ABG55613	Human liver peptid
447	9	0.7	856	22	ABR60983	520	9	0.6	75	22	AAW61148	Human brain expre

521	8	0.6	75	22	AAW73862	Human bone marrow	594	8	0.6	265	23	AAU74518
522	8	0.6	75	23	ABG43750	Human peptide enco	595	8	0.6	267	21	AAG57270
523	8	0.6	76	19	AAW72051	HSV-2 strain SB5 C	596	8	0.6	272	16	AAW74043
524	8	0.6	82	21	AAH11545	SEN virus protein	597	8	0.6	275	21	AAAG09455
525	8	0.6	89	23	ABP31402	Human ORP375 prote	598	8	0.6	278	21	AAAG18311
526	8	0.6	90	18	AAW38201	Rice SCARECROW SRP	599	8	0.6	278	21	AAAG34007
527	8	0.6	90	21	ABG28581	Rice SCU4. Oriza	600	8	0.6	280	21	AAAG24816
528	8	0.6	95	22	ABG26892	Novel human diagno	601	8	0.6	282	21	AAAG18316
529	8	0.6	102	22	ABG26896	Novel human diagno	602	8	0.6	282	21	AAAG34006
530	8	0.6	103	22	ABG282378	Novel human diagno	603	8	0.6	282	21	AAAG46430
531	8	0.6	107	22	AAO07842	Human polypeptide	604	8	0.6	284	22	AAAB488014
532	8	0.6	114	22	ABH11091	Human nuclear pore	605	8	0.6	284	22	ABBS9014
533	8	0.6	117	22	ABBB7854	Drosophila melanog	606	8	0.6	285	23	AAOI50448
534	8	0.6	117	22	ABG27133	Novel human diagno	607	8	0.6	285	23	AAOI50494
535	8	0.6	126	22	ABG03470	Novel human diagno	608	8	0.6	285	23	AAOI50515
536	8	0.6	134	21	AAAG29946	Human polypeptide	609	8	0.6	288	21	AAAG24815
537	8	0.6	134	22	AAO01002	Human polypeptide	610	8	0.6	288	21	AAAG34307
538	8	0.6	134	22	MAO12584	Human polypeptide	611	8	0.6	290	21	AAAG46422
539	8	0.6	134	24	ABP81236	Arabidopsis thalia	612	8	0.6	294	16	AAW75512
540	8	0.6	137	23	ABU11269	Yeast selected int	613	8	0.6	295	24	ABBB65055
541	8	0.6	137	23	ABG77367	Selected interacti	614	8	0.6	299	22	AAAS01377
542	8	0.6	141	21	AAAG41855	Arabidopsis thalia	615	8	0.6	299	23	AAO216568
543	8	0.6	143	22	ABH71001	Drosophila melanog	616	8	0.6	300	21	AABO59545
544	8	0.6	145	21	AAAG47273	Arabidopsis thalia	617	8	0.6	301	23	ABP38070
545	8	0.6	146	21	AAV96215	Argemone mexicana	618	8	0.6	302	23	ABU10412
546	8	0.6	146	24	ABR40724	Argemone mexicana	619	8	0.6	303	23	AAAG20322
547	8	0.6	147	21	AAAG47272	Arabidopsis thalia	620	8	0.6	304	23	ABP293223
548	8	0.6	147	23	ABBB3125	Human glutaryl-CoA	621	8	0.6	312	23	AAU930423
549	8	0.6	151	21	AAAG29844	Arabidopsis thalia	622	8	0.6	316	21	AAAG30322
550	8	0.6	154	22	ABH70370	Drosophila melanog	623	8	0.6	316	21	AAAG30322
551	8	0.6	157	21	AAAG23969	Arabidopsis thalia	624	8	0.6	317	18	AAW23279
552	8	0.6	164	19	AAW80406	A secreted protein	625	8	0.6	324	19	AAW702355
553	8	0.6	164	23	ABP61824	Human polypeptide	626	8	0.6	324	23	AAAB71285
554	8	0.6	167	22	ABBB2385	Drosophila melanog	627	8	0.6	324	23	AAE249438
555	8	0.6	173	21	AAAG08442	Arabidopsis thalia	628	8	0.6	324	23	AAU718313
556	8	0.6	173	21	AAAG45492	Arabidopsis thalia	629	8	0.6	325	21	AAAG20320
557	8	0.6	184	21	AAAG51370	Arabidopsis thalia	630	8	0.6	326	21	AAAG24814
558	8	0.6	185	23	ABU11066	Yeast selected int	631	8	0.6	326	23	AAU993636
559	8	0.6	185	23	ABG77195	Selected interacti	632	8	0.6	326	23	ABBO82484
560	8	0.6	186	22	ABBB69467	Drosophila melanog	633	8	0.6	327	22	ABH703822
561	8	0.6	193	24	ABP71417	Human UBR2 related	634	8	0.6	328	21	AAAG64282
562	8	0.6	195	19	AAWS9053	Hls FRFL0 protein	635	8	0.6	331	21	AAAG43812
563	8	0.6	215	18	AAW24049	Rat fibroblast giro	636	8	0.6	332	21	AAAG40822
564	8	0.6	216	23	ABU11078	Yeast selected int	637	8	0.6	337	21	AAAG34811
565	8	0.6	216	23	ABG77207	Selected interacti	638	8	0.6	339	22	AAAG54170
566	8	0.6	221	22	ABBB64291	Drosophila melanog	639	8	0.6	339	22	ABUS3124
567	8	0.6	221	23	ABBO6719	Human oestrogen re	640	8	0.6	343	21	AAAG40821
568	8	0.6	222	23	ABP73512	Candida albicans e	641	8	0.6	349	21	AAAG23402
569	8	0.6	227	21	AAAG51369	Arabidopsis thalia	642	8	0.6	351	22	ABG08730
570	8	0.6	228	21	AAAG15809	Arabidopsis thalia	643	8	0.6	352	22	ABGI02020
571	8	0.6	228	22	ABBB62497	Drosophila thalia	644	8	0.6	354	21	AAAG34810
572	8	0.6	229	21	AAAB43838	Drosophila melanog	645	8	0.6	354	22	AAAB30799
573	8	0.6	229	21	AAAG17420	Human cancer assoc	646	8	0.6	356	21	AAAG12889
574	8	0.6	232	21	AAAG57272	Arabidopsis thalia	647	8	0.6	360	21	AAAG12888
575	8	0.6	234	21	AAAG51125	Arabidopsis thalia	648	8	0.6	363	21	AAAG12887
576	8	0.6	234	23	ABU11168	Yeast selected int	649	8	0.6	363	21	AAAG40820
577	8	0.6	234	23	ABG77254	Selected interacti	650	8	0.6	367	21	AAAG54169
578	8	0.6	235	21	AAAG15808	Arabidopsis thalia	651	8	0.6	386	22	ABBT0650
579	8	0.6	239	21	AAAG57271	Arabidopsis thalia	652	8	0.6	402	22	ABBT06534
580	8	0.6	240	22	ABBT70127	Arabidopsis thalia	653	8	0.6	403	20	AAV28916
581	8	0.6	242	22	ABBB69486	Drosophila melanog	654	8	0.6	406	18	AAW265233
582	8	0.6	249	22	ABBB60887	Drosophila melanog	655	8	0.6	406	22	ABBS87474
583	8	0.6	250	23	AAU93090	Arabidopsis transc	656	8	0.6	408	22	ABBB61479
584	8	0.6	250	24	ABR40794	Arabidopsis thalia	657	8	0.6	408	22	AAAB10837
585	8	0.6	251	23	ABP73583	Candida albicans e	658	8	0.6	413	17	AAW95247
586	8	0.6	255	21	AAAG23968	Arabidopsis thalia	659	8	0.6	413	19	AAW48390
587	8	0.6	255	21	AAAG43309	Arabidopsis thalia	660	8	0.6	419	23	AAU93147
588	8	0.6	256	21	AAAB43638	Human cancer assoc	661	8	0.6	420	23	ABP73816
589	8	0.6	258	21	AAAG15807	Arabidopsis thalia	662	8	0.6	428	24	ABP57973
590	8	0.6	259	21	AAAG23967	Arabidopsis thalia	663	8	0.6	428	24	ABP57973
591	8	0.6	259	21	AAAG43308	Arabidopsis thalia	664	8	0.6	431	21	AAV91277
592	8	0.6	260	21	AAAG17419	Arabidopsis thalia	665	8	0.6	435	22	ABBB60210
593	8	0.6	265	22	ABG23353	Novel human diagno	666	8	0.6	443	14	AAAB34895

[illegible]

667	8	0.6	443	22	ABG26895	Novel human diagno	740	8	0.6	787	23	ABE08247	Human HskIfc2. Ho
668	8	0.6	444	19	AAW60579	Drosophila neuron-	741	8	0.6	797	20	AAV05850	Banana ripening fr
669	8	0.6	445	21	AAAB0060	VRN2 polypeptide.	742	8	0.6	798	22	ABE62356	Drosophila melanog
670	8	0.6	446	19	AAAG6953	Sugarbeet choline	743	8	0.6	809	23	ABP73854	Candida albicans e
671	8	0.6	448	22	ABE58601	Drosophila melanog	744	8	0.6	811	22	ABG23352	Novel human diagno
672	8	0.6	461	12	AAAI4150	MSP encoded by pUC	745	8	0.6	812	21	AAI95985	Arabidopsis GABA r
673	8	0.6	461	12	AAAI4530	Usp45 protein. La	746	8	0.6	814	22	ABE65317	Drosophila melanog
674	8	0.6	464	23	ABE93400	Herbically activ	747	8	0.6	825	22	ABE59301	Drosophila melanog
675	8	0.6	464	23	AAAM7592	Drosophila cell cy	748	8	0.6	850	22	ABE65764	Drosophila melanog
676	8	0.6	469	22	ABE61392	Drosophila melanog	749	8	0.6	854	22	AAE67391	Partial amino acid
677	8	0.6	478	21	AAAB0788	Human IL-2/ P. yoe	750	8	0.6	865	23	ABP35641	Fungal ZBC protein
678	8	0.6	489	22	ABAB70861	Arabidopsis melanog	751	8	0.6	865	23	ABP35642	Fungal ZBC protein
679	8	0.6	497	21	AAAG30660	Arabidopsis thalia	752	8	0.6	875	19	AAW34987	Banila goldi endo
680	8	0.6	498	21	AAAG54168	Arabidopsis thalia	753	8	0.6	880	22	AAAB70938	S. pombe potassium
681	8	0.6	510	21	AAAG39697	Arabidopsis thalia	754	8	0.6	893	22	ABE64865	Drosophila melanog
682	8	0.6	525	23	ABG91725	Purine/pyrimidine	755	8	0.6	900	22	ABE60688	Drosophila melanog
683	8	0.6	528	23	ABP73734	Candida albicans e	756	8	0.6	916	22	ABE63615	Drosophila melanog
684	8	0.6	529	23	ABG77458	Selected interacti	757	8	0.6	927	21	AAI95984	Arabidopsis GABA r
685	8	0.6	530	23	ABU11360	Yeast selected int	758	8	0.6	938	22	ABE60562	Drosophila melanog
686	8	0.6	531	22	ABE70528	Drosophila melanog	759	8	0.6	944	21	ABE43351	Human ORFX ORF3115
687	8	0.6	535	22	ABE58106	Drosophila melanog	760	8	0.6	945	23	ABE73277	Candida albicans e
688	8	0.6	535	22	ABE58915	Drosophila melanog	761	8	0.6	951	22	ABE67950	Drosophila melanog
689	8	0.6	535	22	ABE52665	Herbically activ	762	8	0.6	959	22	AAE64950	Human Cream1 prote
690	8	0.6	537	23	AAOI4997	Rhodotorula minuta	763	8	0.6	970	23	ABP35631	Fungal ZBC protein
691	8	0.6	540	22	AAAG84948	Shrimp white spot	764	8	0.6	976	22	ABE65498	Drosophila melanog
692	8	0.6	541	22	ABE68621	Drosophila melanog	765	8	0.6	984	9	AAE80550	Malaria-specific 1
693	8	0.6	541	22	ABE70472	Drosophila melanog	766	8	0.6	984	13	AAE22247	SERP antigen. Pia
694	8	0.6	554	19	AAAG9223	HAP4 protein. Sac	767	8	0.6	984	13	AAE27529	Plasmodium falcipa
695	8	0.6	559	24	ABU02325	S. pneumoniae type	768	8	0.6	984	15	AAE60164	SERP protein encod
696	8	0.6	566	24	ABR40876	Arabidopsis thalia	769	8	0.6	984	16	AAE68837	Plasmodium falcipa
697	8	0.6	576	21	AAAG38679	Arabidopsis thalia	770	8	0.6	984	20	AAI29589	Plasmodium falcipa
698	8	0.6	581	23	ABP25491	Streptococcus poly	771	8	0.6	998	22	ABE60423	Drosophila melanog
699	8	0.6	585	11	AAAR07274	Reverse transcript	772	8	0.6	1003	22	ABE68762	Drosophila melanog
700	8	0.6	586	12	AAAI1920	Reverse transcript	773	8	0.6	1008	22	ABE59260	Drosophila melanog
701	8	0.6	586	16	AAAR3395	mdNA-Ec67 reverse	774	8	0.6	1015	23	ABP73325	Candida albicans e
702	8	0.6	586	21	AAV76811	E. coli mdNA-Ec67	775	8	0.6	1028	22	ABE62708	Drosophila melanog
703	8	0.6	586	23	AAAM49402	Escherichia coli C	776	8	0.6	1032	21	AAE45673	Arabidopsis thalia
704	8	0.6	594	24	ABP81457	Streptococcus pneu	777	8	0.6	1037	22	ABE70288	Arabidopsis thalia
705	8	0.6	603	24	ABU11606	Human MDT polypep	778	8	0.6	1045	21	AAE45672	Arabidopsis thalia
706	8	0.6	605	22	AAE04789	Lycopodium escul	779	8	0.6	1058	22	AAE68341	A human dishevelle
707	8	0.6	605	22	AAE72308	Neoxanthin cleavag	780	8	0.6	1080	21	AAE45671	Arabidopsis thalia
708	8	0.6	627	20	AAV05853	Banana ripening fr	781	8	0.6	1108	22	ABE63413	Drosophila melanog
709	8	0.6	634	22	ABE71624	Drosophila melanog	782	8	0.6	1132	21	AAE32139	Arabidopsis thalia
710	8	0.6	650	22	AAAG3793	Human polypeptide,	783	8	0.6	1152	21	AAE32138	Arabidopsis thalia
711	8	0.6	650	23	AAE68957	Human polypeptide	784	8	0.6	1157	22	ABE62647	Drosophila melanog
712	8	0.6	652	18	AAAI8010	Plasmodium falcipa	785	8	0.6	1173	22	ABE62245	Drosophila melanog
713	8	0.6	657	22	ABE57783	Drosophila melanog	786	8	0.6	1182	22	ABE64438	Drosophila melanog
714	8	0.6	663	18	AAW29150	Dual-specific murt	787	8	0.6	1200	22	ABE63533	Drosophila melanog
715	8	0.6	667	22	ABE62659	Drosophila melanog	788	8	0.6	1205	20	AAI33683	P. falciparum 1-de
716	8	0.6	668	22	ABE66214	Drosophila melanog	789	8	0.6	1205	21	AAW90882	Isoprenoid related
717	8	0.6	673	22	ABE59674	Drosophila melanog	790	8	0.6	1205	23	AAO21863	Drosophila melanog
718	8	0.6	677	22	ABE62562	Drosophila melanog	791	8	0.6	1238	22	ABE61259	Drosophila melanog
719	8	0.6	677	22	ABE62568	Drosophila melanog	792	8	0.6	1242	20	AAI13461	Amino acid sequenc
720	8	0.6	677	22	ABE65183	Drosophila melanog	793	8	0.6	1242	20	AAW93972	Human IRS-1 and IR
721	8	0.6	678	14	AAAR42087	D. melanogaster do	794	8	0.6	1242	22	AAE83921	Amino acid sequenc
722	8	0.6	710	23	ABP73976	Candida albicans e	795	8	0.6	1242	24	ABE89797	Human Insulin-rece
723	8	0.6	713	12	AAAI3991	Plasmodium falcipa	796	8	0.6	1242	24	ABE72368	Human Insulin-rece
724	8	0.6	717	22	ABE71958	Drosophila melanog	797	8	0.6	1242	24	ABE72369	Human Insulin-rece
725	8	0.6	718	22	ABE66734	Drosophila melanog	798	8	0.6	1242	24	ABE72370	Human Insulin-rece
726	8	0.6	725	23	AAU93157	Arabidopsis tiranac	799	8	0.6	1242	24	ABE72371	Human Insulin-rece
727	8	0.6	728	22	ABE64748	Drosophila melanog	800	8	0.6	1242	24	ABE72372	Human Insulin-rece
728	8	0.6	743	22	ABE68417	Drosophila melanog	801	8	0.6	1243	16	AAE67708	Insulin receptor s
729	8	0.6	745	22	ABE71016	Drosophila melanog	802	8	0.6	1247	21	AAI18215	Plasmodium falcipa
730	8	0.6	751	14	AAAR3424	GEPD. Plasmodium	803	8	0.6	1278	21	AAI18277	Plasmodium falcipa
731	8	0.6	757	21	AAAG41423	Arabidopsis thalia	804	8	0.6	1311	22	ABE61224	Drosophila melanog
732	8	0.6	765	22	ABE70099	Drosophila melanog	805	8	0.6	1316	22	ABE69263	Drosophila melanog
733	8	0.6	769	22	ABE58091	D. melanogaster ac	806	8	0.6	1321	17	AAE69694	Mouze IRS-2. Mus
734	8	0.6	770	21	AAV50814	Arabidopsis thalia	807	8	0.6	1398	21	AAI18292	Bifidobacterium lo
735	8	0.6	772	21	AAAG41422	Human polypeptide	808	8	0.6	1402	23	ABE66040	Drosophila melanog
736	8	0.6	780	22	AAAM42085	Drosophila melanog	809	8	0.6	1406	22	ABE71963	Drosophila melanog
737	8	0.6	784	22	ABE71112	Drosophila melanog	810	8	0.6	1412	22	ABE60943	Shrimp white spot
738	8	0.6	787	22	ABE711302	Human kinesin moto	811	8	0.6	1430	22	AAE85029	Human polypeptide
739	8	0.6	787	23	AAU99335		812	8	0.6	1475	22	AAW40232	

813	8	0.6	1486	22	ABB59325	Drosophila melanog	886	7	0.5	14	22	AAE05023	Cryptosporidium pa
814	8	0.6	1499	22	AAAM42018	Human polypeptide	887	7	0.5	16	23	ABG96233	Cysteine-containing
815	8	0.6	1629	22	ABB63122	Drosophila melanog	888	7	0.5	14	21	AAE08561	Peptide identified
816	8	0.6	1679	22	ABB60498	Drosophila melanog	889	7	0.5	16	22	AAE05034	Cryptosporidium pa
817	8	0.6	1679	22	ABB60502	Drosophila melanog	890	7	0.5	17	22	ABG59600	Human liver peptid
818	8	0.6	1703	22	ABB66623	Drosophila melanog	891	7	0.5	17	22	ABB44227	Peptide #1173 enc
819	8	0.6	1850	22	AAE72210	Modified Chicken v	892	7	0.5	17	22	ABB27103	Protein #9102 enc
820	8	0.6	1980	22	ABB67589	Drosophila melanog	893	7	0.5	17	22	AAE65259	Human brain expres
821	8	0.6	2023	22	ABB63487	Drosophila melanog	894	7	0.5	17	22	AAE77964	Human bone marrow
822	8	0.6	2070	22	ABG03703	Novel human diagno	895	7	0.5	17	22	AAE21858	Peptide #8292 enc
823	8	0.6	2175	22	ABB65698	Drosophila melanog	896	7	0.5	17	22	AAE38182	Peptide #12219 enc
824	8	0.6	2274	22	ABB58657	Drosophila melanog	897	7	0.5	17	22	ABB74469	DNA repair protein
825	8	0.6	2314	22	AAE69136	M. catarrhalis les	898	7	0.5	19	23	ABG51474	Human liver peptid
826	8	0.6	2391	15	AAE55694	Carbamoyl-phosphat	899	7	0.5	19	22	ABB31409	Peptide #4060 enc
827	8	0.6	2441	22	ABB62231	Drosophila melanog	900	7	0.5	19	22	ABB36623	Peptide #4129 enc
828	8	0.6	2500	21	AAE18272	Plasmodium falcipa	901	7	0.5	19	22	ABB21958	Protein #13957 enc
829	8	0.6	2543	22	ABG21295	Novel human diagno	902	7	0.5	19	22	AAE57384	Human brain expres
830	8	0.6	3005	22	ABB58102	Drosophila melanog	903	7	0.5	19	22	AAE69777	Human bone marrow
831	8	0.6	3190	22	AAE84634	Amino acid sequenc	904	7	0.5	19	22	AAE17602	Peptide #4036 enc
832	8	0.6	3332	22	ABB69873	Drosophila melanog	905	7	0.5	19	22	AAE30122	Peptide #4159 enc
833	8	0.6	3336	22	ABB65480	Drosophila melanog	906	7	0.5	19	22	AAE05262	Peptide #3944 enc
834	8	0.6	3726	22	ABB63947	Drosophila melanog	907	7	0.5	19	22	ABG38409	Human peptid enc
835	8	0.6	4152	22	AAE84992	Shrimp white spot	908	7	0.5	20	24	ABJ38224	Human cycomegalovi
836	8	0.6	6025	22	AAE84939	Shrimp white spot	909	7	0.5	22	18	AAE45350	Peptide #7 bearing
837	8	0.6	6077	22	ABE95996	White spot syndrom	910	7	0.5	22	22	ABG56539	Human liver peptid
838	7	0.5	7	21	AAE15678	Single-chain anticb	911	7	0.5	22	22	ABE41096	Peptide #8602 enc
839	7	0.5	10	22	AAE43308	Mycoplasma genital	912	7	0.5	22	22	ABE25149	Protein #7148 enc
840	7	0.5	10	22	AAE43310	Mycoplasma genital	913	7	0.5	22	22	AAE61952	Human brain expres
841	7	0.5	10	22	AAE43312	Mycoplasma genital	914	7	0.5	22	22	AAE74756	Human bone marrow
842	7	0.5	10	22	AAE43214	Mycoplasma genital	915	7	0.5	22	22	AAE20402	Peptide #6836 enc
843	7	0.5	10	22	AAE43216	Mycoplasma genital	916	7	0.5	22	22	AAE34872	Peptide #8909 enc
844	7	0.5	10	22	AAE43218	Mycoplasma genital	917	7	0.5	22	23	AAE44553	Human peptid enc
845	7	0.5	10	22	AAE43220	Mycoplasma genital	918	7	0.5	23	23	AAE22579	Drosophila MBD-1ik
846	7	0.5	10	22	AAE43222	Mycoplasma genital	919	7	0.5	24	23	ABG69758	Polypeptide identi
847	7	0.5	10	22	AAE43224	Mycoplasma genital	920	7	0.5	25	22	ABG57335	Human liver peptid
848	7	0.5	10	22	AAE43226	Mycoplasma genital	921	7	0.5	25	22	ABE41900	Peptide #9406 enc
849	7	0.5	10	22	AAE43228	Mycoplasma genital	922	7	0.5	25	22	AAE62779	Human brain expres
850	7	0.5	10	22	AAE43230	Mycoplasma genital	923	7	0.5	25	22	AAE75595	Human bone marrow
851	7	0.5	10	22	AAE43232	Mycoplasma genital	924	7	0.5	25	22	AAE35702	Peptide #9739 enc
852	7	0.5	10	22	AAE43234	Mycoplasma genital	925	7	0.5	26	21	AAE09850	Endoglucanase frag
853	7	0.5	10	22	AAE43236	Mycoplasma genital	926	7	0.5	26	22	ABG56388	Human liver peptid
854	7	0.5	10	22	AAE43238	Mycoplasma genital	927	7	0.5	26	22	ABE40942	Peptide #8448 enc
855	7	0.5	10	22	AAE43240	Mycoplasma genital	928	7	0.5	26	22	AAE41804	Human brain expres
856	7	0.5	10	22	AAE43242	Mycoplasma genital	929	7	0.5	26	22	AAE74603	Human bone marrow
857	7	0.5	10	22	AAE43244	Mycoplasma genital	930	7	0.5	26	22	AAE34715	Peptide #8752 enc
858	7	0.5	10	22	AAE43246	Mycoplasma genital	931	7	0.5	30	22	ABG58601	Human liver peptid
859	7	0.5	10	22	AAE43248	Mycoplasma genital	932	7	0.5	30	22	ABG59523	Human liver peptid
860	7	0.5	10	22	AAE43250	Mycoplasma genital	933	7	0.5	30	22	ABE43208	Peptide #10714 enc
861	7	0.5	10	22	AAE43252	Mycoplasma genital	934	7	0.5	30	22	ABE44143	Peptide #11649 enc
862	7	0.5	10	22	AAE43256	Mycoplasma genital	935	7	0.5	30	22	ABE26297	Protein #8296 enc
863	7	0.5	10	22	AAE43258	Mycoplasma genital	936	7	0.5	30	22	ABE27027	Human brain expres
864	7	0.5	10	22	AAE83890	Arbidiopsis thailia	937	7	0.5	30	22	AAE64114	Human liver expres
865	7	0.5	10	22	AAE83892	Arbidiopsis thailia	938	7	0.5	30	22	AAE76940	Human bone marrow
866	7	0.5	10	22	AAE83894	Arbidiopsis thailia	939	7	0.5	30	22	AAE77875	Human bone marrow
867	7	0.5	10	22	AAE83896	Arbidiopsis thailia	940	7	0.5	30	22	AAE21033	Peptide #7467 enc
868	7	0.5	10	22	AAE83898	Arbidiopsis thailia	941	7	0.5	30	22	AAE21772	Peptide #8206 enc
869	7	0.5	10	22	AAE83904	Arbidiopsis thailia	942	7	0.5	30	22	AAE37048	Peptide #11085 enc
870	7	0.5	10	22	AAE83906	Arbidiopsis thailia	943	7	0.5	30	22	AAE38096	Peptide #12133 enc
871	7	0.5	10	22	AAE83908	Arbidiopsis thailia	944	7	0.5	30	22	ABE46049	Human peptid enc
872	7	0.5	10	22	AAE83910	Arbidiopsis thailia	945	7	0.5	30	22	ABE46899	Human peptid enc
873	7	0.5	10	22	AAE83912	Arbidiopsis thailia	946	7	0.5	31	22	AAU18263	Novel human DNA-bi
874	7	0.5	10	22	AAE83914	Arbidiopsis thailia	947	7	0.5	31	23	ABG92684	Human DNA-binding
875	7	0.5	10	22	AAE83923	Arbidiopsis thailia	948	7	0.5	32	22	ABG50161	Human liver peptid
876	7	0.5	10	22	AAE83927	Arbidiopsis thailia	949	7	0.5	32	22	ABE30116	Peptide #2767 enc
877	7	0.5	10	22	AAE84194	Arbidiopsis thailia	950	7	0.5	32	22	ABE35288	Peptide #2794 enc
878	7	0.5	10	22	AAE84198	Arbidiopsis thailia	951	7	0.5	32	22	ABE20731	Protein #2730 enc
879	7	0.5	10	22	AAE84368	Arbidiopsis thailia	952	7	0.5	32	22	AAE56117	Human brain expres
880	7	0.5	10	22	AAE84370	Arbidiopsis thailia	953	7	0.5	32	22	AAE64889	Human bone marrow
881	7	0.5	10	22	AAE87012	Saccharomyces cere	954	7	0.5	32	22	AAE16297	Peptide #2731 enc
882	7	0.5	10	22	AAE93544	Forkhead related c	955	7	0.5	32	22	AAE28787	Peptide #2834 enc
883	7	0.5	10	22	AAE93545	Forkhead related c	956	7	0.5	32	22	AAE04032	Peptide #2714 enc
884	7	0.5	10	22	AAE93546	Peptide #6 bearing	957	7	0.5	32	23	ABG38071	Human peptid enc
885	7	0.5	13	18	AAE45349		958	7	0.5	33	22	ABG50270	Human liver peptid

959	7	0.5	33	22	ABG58748	Human liver peptid
960	7	0.5	33	22	ABR30242	Peptide #2893 enco
961	7	0.5	33	22	ABR35408	Peptide #2914 enco
962	7	0.5	33	22	ABR20845	Protein #2844 enco
963	7	0.5	33	22	AAW56232	Human brain expres
964	7	0.5	33	22	AAW68610	Human bone marrow
965	7	0.5	33	22	AAW16417	Peptide #2851 enco
966	7	0.5	33	22	AAW28916	Peptide #2953 enco
967	7	0.5	33	22	AAW04151	Peptide #2833 enco
968	7	0.5	33	22	ABG38189	Human peptid enco
969	7	0.5	35	21	AAW11032	Arabidopsis thalia
970	7	0.5	36	21	AAW14995	Arabidopsis thalia
971	7	0.5	40	22	AAW04685	Human polypeptide
972	7	0.5	42	22	AAW04746	Human polypeptide
973	7	0.5	44	21	AAW47925	Arabidopsis thalia
974	7	0.5	44	22	ABG54345	Human liver peptid
975	7	0.5	44	22	ABG39366	Peptide #6872 enco
976	7	0.5	44	22	AAW60044	Human brain expres
977	7	0.5	44	22	AAW72647	Human bone marrow
978	7	0.5	44	22	AAW32881	Peptide #6918 enco
979	7	0.5	44	23	ABG42471	Human peptid enco
980	7	0.5	45	17	AAW08985	Lysine/Serine cont
981	7	0.5	46	21	AAW57114	Arabidopsis thalia
982	7	0.5	46	22	ABG57063	Human liver peptid
983	7	0.5	46	22	ABG69029	Drosophila melanog
984	7	0.5	46	22	ABW41622	Peptide #9128 enco
985	7	0.5	46	22	AAW62493	Human brain expres
986	7	0.5	46	22	AAW75302	Human bone marrow
987	7	0.5	46	22	AAW35415	Peptide #9452 enco
988	7	0.5	48	21	AAW08479	Arabidopsis thalia
989	7	0.5	48	21	AAW47962	Arabidopsis thalia
990	7	0.5	50	23	ABP10282	Human ORFX protein
991	7	0.5	51	22	AAW07319	Human polypeptide
992	7	0.5	52	22	ABG53747	Human liver peptid
993	7	0.5	52	22	ABW38853	Peptide #6359 enco
994	7	0.5	52	22	AAW59498	Human brain expres
995	7	0.5	52	22	AAW72063	Human bone marrow
996	7	0.5	52	22	AAW32328	Peptide #6365 enco
997	7	0.5	52	23	ABW41878	Human peptid enco
998	7	0.5	53	22	ABW11731	Novel human diagno
999	7	0.5	53	22	ABG20393	Novel human diagno
1000	7	0.5	53	22	AAW02332	Human polypeptide

ALIGNMENTS

RESULT 1

AAW41989
ID AAR41989 standard; protein; 190 AA.

XX AAR41989;
AC
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B.
XX
KW Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KW autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
XX Key Location/Qualifiers
FH 97..157
FT /note= "Region undisclosed in the specification"
FT 162..186
FT Region /note= "Region undisclosed in the specification"

XX W09314634-A1.
PN
XX 05-AUG-1993.
PD

XX 28-JAN-1993; 93WO-US00839.
PF
XX 28-JAN-1992; 92US-0827540.
PR
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
PA
XX Kappler JW, Marrack P;
PI
XX WPI; 1993-320314/40.
DR
XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX Disclosure; Fig 3; 5app; English.
XX
XX This sequence represents the Staphylococcus enterotoxin B (SEB)
CC super antigen (SAg). Mutant versions of this sequence generated
CC by random mutation by PCR, may be used to modify the T-cell response
CC elicited by an antigen, by interacting with specific Vbeta elements
CC of the T-cell receptors. This T-cell response modulation may be
CC useful in a wide variety of autoimmune diseases, where self-reactive
CC T-cells may be activated by SAg that bind to particular Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 2

AAW41990
ID AAR41990 standard; protein; 190 AA.

XX AAR41990;
AC
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BR-75.
XX
KW Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KW autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
XX Key Location/Qualifiers
FH 97..157
FT /note= "Region undisclosed in the specification"
FT 162..186
FT Region /note= "Region undisclosed in the specification"

XX W09314634-A1.
PN
XX 05-AUG-1993.
PD
XX 28-JAN-1993; 93WO-US00839.
PF
XX 28-JAN-1992; 92US-0827540.
PR
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
PA
XX Kappler JW, Marrack P;
PI
XX WPI; 1993-320314/40.
DR

XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PR not T-cell activation
XX
PS Disclosure; Fig 3; 54pp; English.
CC The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by Sag that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC
XX
SQ Sequence 190 AA;
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 3
AAR41991
ID AAR41991 standard; protein; 190 AA.
AC AAR41991;
XX
XX
DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BR-210.
DE Staphylococcus enterotoxin B; SEB; super antigen; Sag; receptor;
KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KW autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
FH Key Location/Qualifiers
FT Region 97..157
FT /note= "Region undisclosed in the specification"
FT Region 162..186
FT /note= "Region undisclosed in the specification"
XX
XX PN WO9314634-A1.
XX
XX PD 05-AUG-1993.
XX
XX PF 28-JAN-1993; 93WO-US00839.
XX
XX PR 28-JAN-1992; 92US-0827540.
XX
XX PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX PI Kappler JW, Marrack P;
XX
XX DR WPI; 1993-320314/40.
XX
XX PT Preventing or treating toxic effects of super antigens - by admin. of
XX new modified or mutated super antigen which induces antibodies but
XX not T-cell activation
XX
XX PS Disclosure; Fig 3; 54pp; English.
XX
XX CC The sequences given in AAR41990-2013 are mutant versions of the
XX Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants

CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by Sag that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC
XX
SQ Sequence 190 AA;
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 4
AAR41992
ID AAR41992 standard; protein; 190 AA.
AC AAR41992;
XX
XX
DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BR-257.
DE Staphylococcus enterotoxin B; SEB; super antigen; Sag; receptor;
KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KW autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
FH Key Location/Qualifiers
FT Region 97..157
FT /note= "Region undisclosed in the specification"
FT Region 162..186
FT /note= "Region undisclosed in the specification"
XX
XX PN WO9314634-A1.
XX
XX PD 05-AUG-1993.
XX
XX PF 28-JAN-1993; 93WO-US00839.
XX
XX PR 28-JAN-1992; 92US-0827540.
XX
XX PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX PI Kappler JW, Marrack P;
XX
XX DR WPI; 1993-320314/40.
XX
XX PT Preventing or treating toxic effects of super antigens - by admin. of
XX new modified or mutated super antigen which induces antibodies but
XX not T-cell activation
XX
XX PS Disclosure; Fig 3; 54pp; English.
XX
XX CC The sequences given in AAR41990-2013 are mutant versions of the
XX Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
XX generated by random mutation by PCR, may be used to modify the T-cell
XX response elicited by an antigen, by interacting with specific Vbeta
XX elements of the T-cell receptors. This T-cell response modulation
XX may be useful in a wide variety of autoimmune diseases, where self-
XX reactive T-cells may be activated by Sag that bind to particular
XX Vbeta types.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
 Best Local Similarity 100.0%; Pred. No. 1.2e-07;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 |||||
 DB 171 NNNNNNNNNNNNNNNNNNNI 187

RESULT 5

AAK41993 ID AAK41993 standard; protein; 190 AA.

AC AAK41993;

DT 25-MAR-2003 (updated)

DT 21-APR-1994 (first entry)

DE Staphylococcus enterotoxin B mutant BR-291.

KM Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
 KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
 KM autoimmune disease.

OS Staphylococcus aureus.

Key Location/Qualifiers

FT Region 97..157

FT /note= "Region undisclosed in the specification"

FT Region 162..186

FT /note= "Region undisclosed in the specification"

W09314634-A1.

XX 05-AUG-1993.

PF 28-JAN-1993; 93WO-US00839.

PR 28-JAN-1992; 92US-0827540.

PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.

PI Kappeler JM, Marrack P;

DR WPI; 1993-320314/40.

PT Preventing or treating toxic effects of super antigens - by admin. of

PT new modified or mutated super antigen which induces antibodies but

PT not T-cell activation

PS Disclosure; Fig 3; 54pp; English.

CC The sequences given in AAK41990-2013 are mutant versions of the

CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants

CC generated by random mutation by PCR, may be used to modify the T-cell

CC response elicited by an antigen, by interacting with specific Vbeta

CC elements of the T-cell receptors. This T-cell response modulation

CC may be useful in a wide variety of autoimmune diseases, where self-

CC reactive T-cells may be activated by SAg that bind to particular

CC Vbeta types.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;

Best Local Similarity 100.0%; Pred. No. 1.2e-07;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 |||||
 DB 171 NNNNNNNNNNNNNNNNNNNI 187

RESULT 6
 AAK41994 ID AAK41994 standard; protein; 190 AA.

AC AAK41994;

DT 25-MAR-2003 (updated)

DT 21-APR-1994 (first entry)

DE Staphylococcus enterotoxin B mutant BC-6.

KM Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
 KW random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
 KM autoimmune disease.

OS Staphylococcus aureus.

Key Location/Qualifiers

FT Region 97..157

FT /note= "Region undisclosed in the specification"

FT Region 162..186

FT /note= "Region undisclosed in the specification"

W09314634-A1.

XX 05-AUG-1993.

PF 28-JAN-1993; 93WO-US00839.

PR 28-JAN-1992; 92US-0827540.

PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.

PI Kappeler JM, Marrack P;

DR WPI; 1993-320314/40.

PT Preventing or treating toxic effects of super antigens - by admin. of

PT new modified or mutated super antigen which induces antibodies but

PT not T-cell activation

PS Disclosure; Fig 3; 54pp; English.

CC The sequences given in AAK41990-2013 are mutant versions of the

CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants

CC generated by random mutation by PCR, may be used to modify the T-cell

CC response elicited by an antigen, by interacting with specific Vbeta

CC elements of the T-cell receptors. This T-cell response modulation

CC may be useful in a wide variety of autoimmune diseases, where self-

CC reactive T-cells may be activated by SAg that bind to particular

CC Vbeta types.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;

Best Local Similarity 100.0%; Pred. No. 1.2e-07;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNNNI 758
 |||||
 DB 171 NNNNNNNNNNNNNNNNNNNI 187

RESULT 7

AAK41995 ID AAK41995 standard; protein; 190 AA.

AC AAK41995;

DT 25-MAR-2003 (updated)

DT 21-APR-1994 (first entry)

XX		Staphylococcus enterotoxin B mutant BC-66.
DE		
XX		Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KW		random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KM		autoimmune disease.
XX		
OS		Staphylococcus aureus.
XX		
FH	Key	Location/Qualifiers
FT	Region	97..157
FT	/note= "Region undisclosed in the specification"	
FT	Region	162..186
FT	/note= "Region undisclosed in the specification"	
XX		
PN	WO9314634-A1.	
XX		
PD	05-AUG-1993.	
XX		
PF	28-JAN-1993;	93WO-US00839.
XX		
PR	28-JAN-1992;	92US-0827540.
XX		
PA	(NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.	
XX		
PI	Kappler JW, Marrack P;	
XX		
DR	WPI; 1993-320314/40.	
XX		
PT	Preventing or treating toxic effects of super antigens - by admin. of	
PT	new modified or mutated super antigen which induces antibodies but	
PT	not T-cell activation	
XX		
PS	Disclosure; Fig 3; 54pp; English.	
XX		
CC	The sequences given in AAR41990-2013 are mutant versions of the	
CC	Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants	
CC	generated by random mutation by PCR, may be used to modify the T-cell	
CC	response elicited by an antigen, by interacting with specific Vbeta	
CC	elements of the T-cell receptors. This T-cell response modulation	
CC	may be useful in a wide variety of autoimmune diseases, where self-	
CC	reactive T-cells may be activated by SAg that bind to particular	
CC	Vbeta types.	
CC	(Updated on 25-MAR-2003 to correct PN field.)	
XX		
SQ	Sequence	190 AA;
	Query Match:	1.3%; Score 17; DB 14; Length 190;
	Best Local Similarity	100.0%; Pred. No. 1.2e-07;
	Matches 17; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
OY	742	NNNNNNNNNNNNNNNNNI 758
DB	171	NNNNNNNNNNNNNNNNNI 187
RESULT 8		
AAR41996		
ID	AAR41996 standard; protein; 190 AA.	
XX		
AC	AAR41996;	
XX		
DY	25-MAR-2003 (updated)	
DT	21-APR-1994 (first entry)	
XX		
DE	Staphylococcus enterotoxin B mutant BC-88.	
XX		
KW	Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;	
KM	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;	
XX	autoimmune disease.	
XX		
SS	Staphylococcus aureus.	
XX		

PH	Key	Location/Qualifiers
FT	Region	97..157
FT	Region	/note="Region undisclosed in the specification"
FT	Region	162..186
FT	Region	/note="Region undisclosed in the specification"
XX	PN	WO9314634-A1.
XX	PD	05-AUG-1993.
XX	PF	28-JAN-1993; 93WO-US00839.
XX	PR	28-JAN-1992; 92US-0627540.
XX	PA	(NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX	PI	Kappler JW, Marrack P;
XX	DR	WPI, 1993-320314/40.
XX	PT	Preventing or treating toxic effects of super antigens - by admin. of new modified or mutated super antigen which induces antibodies but not T-cell activation
XX	PS	Disclosure; Fig 3; 54pp; English.
CC	CC	The sequences given in AAR41990-2013 are mutant versions of the Staphylococcus enterotoxin B (SEB) super antigen (SAG). These mutants generated by random mutation by PCR, may be used to modify the T-cell response elicited by an antigen, by interacting with specific Vbeta elements of the T-cell receptors. This T-cell response modulation may be useful in a wide variety of autoimmune diseases, where self-reactive T-cells may be activated by SAg that bind to particular Vbeta types.
CC	CC	(Updated on 25-MAR-2003 to correct PN field.)
SO	Sequence	190 AA;
QY	Query Match	1.3%; Score 17; DB 14; Length 190;
DB	Best Local Similarity	100.0%; Pred. No. 1.2e-07;
	Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
	742 NNNNNNNNNNNNNNNNT 758	
	171 NNNNNNNNNNNNNNNNNI 187	
RESULT 9		
AAR41997		
ID	AAR41997 standard; protein; 190 AA.	
XX	AAR41997;	
AC	XX	
DT	25-MAR-2003 (updated)	
DT	21-APR-1994 (first entry)	
XX	XX	
DE	Staphylococcus enterotoxin B mutant BR-358.	
XX	XX	
KW	Staphylococcus; enterotoxin B; SEB; super antigen; SAG; receptor;	
KW	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;	
XX	autoimmune disease.	
OS	Staphylococcus aureus	
XX	XX	
PH	Key	Location/Qualifiers
FT	Region	97..157
FT	Region	/note="Region undisclosed in the specification"
FT	Region	162..186
FT	Region	/note="Region undisclosed in the specification"
XX	PN	WO9314634-A1.
XX	PD	05-AUG-1993.

XX 28-JAN-1993; 93WO-US000839.
PF
XX
XX PR 28-JAN-1992; 92US-0827540.
XX
XX
PA (NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kappler JW, Marrack P;
XX
DR WPI; 1993-320314/40.
XX
PT Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX
PS Disclosure; Fig 3; 54pp; English.
XX
XX The sequences given in ARA41990-2013 are mutant versions of the
XX *Staphylococcus enterotoxin B* (SEB) super antigen (SAg). These mutants
XX generated by random mutation by PCR, may be used to modify the T-cell
XX response elicited by an antigen, by interacting with specific Vbeta
XX elements of the T-cell receptors. This T-cell response modulation
XX may be useful in a wide variety of autoimmune diseases, where self-
XX reactive T-cells may be activated by SAg that bind to particular
XX Vbeta types.
XX (Updated on 25-MAR-2003 to correct PN field.)
XQ Sequence 190 AA;

		1.3%	Score 17;	DB 14;	Length 190;
	Query Match			Pred. No.	1.2e-07;
	Best Local Similarity	100.0%		Mismatches	0;
	Matches	17;	Conservative	0;	Indels
				Gaps	0;
Qy	742	NNNNNNNNNNNNNNNNNI	758		
Db	171	NNNNNNNNNNNNNNNNNI	187		

RESULT	10
AAR41998	
ID	AAR41998 standard; protein; 190 AA.
XX	
AC	AAR41998;
XX	
D7	25-MAR-2003 (updated)
DT	21-APR-1994 (first entry)
XX	
DE	Staphylococcus enterotoxin B mutant BR-374.
XX	
KW	Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KV	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX	autoimmune disease.
OS	Staphylococcus aureus.
XX	
FH	Key
FT	Region
FT	Location/Qualifiers
FT	97..157
FT	/note= "Region undisclosed in the specification"
FT	162..186
XX	/note= "Region undisclosed in the specification"
PN	WO9314634-A1.
XX	
PD	05-AUG-1993.
XX	
PF	28-JAN-1993;
XX	93WO-US00839.
PR	28-JAN-1992;
XX	92US-0827540.
PA	(NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX	
P1	Kappler JW, Mairack P;
XX	

XX	WPI; 1993-320314/40.
XX	Preventing or treating toxic effects of super antigens - by admin. of
PT	new modified or mutated super antigen which induces antibodies but
PT	not T-cell activation
XX	
PS	Disclosure; Fig 3; 5app; English.
XX	
CC	The sequences given in AAR41990-2013 are mutant versions of the
CC	Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC	generated by random mutation by PCR, may be used to modify the T-cell
CC	response elicited by an antigen, by interacting with specific Vbeta
CC	elements of the T-cell receptors. This T-cell response modulation
CC	may be useful in a wide variety of autoimmune diseases, where self-
CC	reactive T-cells may be activated by Sag that bind to particular
CC	Vbeta types.
CC	(Updated on 25-MAR-2003 to correct PN field.)
XX	
SQ	Sequence 190 AA;
OY	Query Match 1.3%; Score 17; DB 14; Length 190; Best Local Similarity 100.0%; Pzed. No. 1.2e-07; Matches 17; Conservative 0; Mismatches 0; Indels- 0; Gaps 0;
DB	742 NNNNNNNNNNNNNNNNNI 758 171 NNNNNNNNNNNNNNNNNI 187

RESULT 11
AAK41999
ID AAK41999 standard; protein; 190 AA

TM	25-MAR-2003	(updated)	
DT	21-APR-1994	(first entry)	
DT			
XX			
DE	Staphylococcus enterotoxin B mutant BA-3.		
XX			
KW	Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;		
KW	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element.		
KW	autoimmune disease.		
XX			
OS	Staphylococcus aureus.		
XX			
FH	Key	Location/Qualifiers	
FT	Region	97..157	
FT		/note= "Region undisclosed in the specification"	
FT	Region	162..186	
FT		/note= "Region undisclosed in the specification"	
XX			
PN	WO93314634-A1.		
XX			
PD	05-AUG-1993.		
XX			
PF	28-JAN-1993;	93WO-US00839.	
XX			
PR	28-JAN-1992;	92US-0827540.	
XX			
PA	(NABJ-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.		
XX			
PI	Kappler JM, Marrack P;		
XX			
DR	WPI; 1993-320314/40.		
XX			
XX			
PT	Preventing or treating toxic effects of super antigens - by admin. of		
PT	new modified or mutated super antigen which induces antibodies but		
PT	not T-cell activation		
XX			
PS	Disclosure; Fig 3; 54pp; English.		
XX			
CC	The sequences given in ARA41990-2013 are mutant versions of the		

```
CC Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by Sag that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC
SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187

RESULT 12
AAR42000
ID AAR42000 standard; protein; 190 AA.
AC AAR42000;
XX
XX
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BA-15.
DE
XX
XX Staphylococcus; enterotoxin B; SEB; super antigen; Sag; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KM autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
XX Key Location/Qualifiers
FH Region 97.157
FT /note= "Region undisclosed in the specification"
FT Region 162.186
FT /note= "Region undisclosed in the specification"
XX
XX WO9314634-A1.
XX
XX
XX 05-AUG-1993.
PD
XX
XX 28-JAN-1993; 93WO-US00839.
PF
XX 28-JAN-1992; 92US-0827540.
PR
XX
XX (NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
PA
XX Kappler JW, Marrack P;
PI
XX
XX WPI; 1993-320314/40.
DR
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by Sag that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC
XX
```

```
SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187

RESULT 13
AAR42001
ID AAR42001 standard; protein; 190 AA.
AC AAR42001;
XX
XX
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BA-24.
DE
XX
XX Staphylococcus; enterotoxin B; SEB; super antigen; Sag; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KM autoimmune disease.
XX
XX Staphylococcus aureus.
OS
XX
XX Key Location/Qualifiers
FH Region 97.157
FT /note= "Region undisclosed in the specification"
FT Region 162.186
FT /note= "Region undisclosed in the specification"
XX
XX WO9314634-A1.
XX
XX
XX 05-AUG-1993.
PD
XX
XX 28-JAN-1993; 93WO-US00839.
PF
XX 28-JAN-1992; 92US-0827540.
PR
XX
XX (NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
PA
XX Kappler JW, Marrack P;
PI
XX
XX WPI; 1993-320314/40.
DR
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by Sag that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC
SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
```

```

RESULT 14
AAR42002
ID AAR42002 standard; protein; 190 AA.
XX
XX
AC AAR42002;
XX
DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BA-31.
XX
KM Staphylococcus enterotoxin B; SEB; super antigen; SAg; receptor;
random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
autoimmune disease.
XX
OS Staphylococcus aureus.
XX
FH Key Location/Qualifiers
FT Region 97..157
FT /note= "Region undisclosed in the specification"
FT Region 162..186
FT /note= "Region undisclosed in the specification"
XX
XX WO9314634-A1.
XX
XX PD 05-AUG-1993.
XX
XX PF 28-JAN-1993; 93WO-US00839.
XX
XX PR 28-JAN-1992; 92US-0827540.
XX
XX PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX PI Kappler JW, Marrack P;
XX
XX DR WPI; 1993-320314/40.
XX
XX PT Preventing or treating toxic effects of super antigens - by admin. of
new modified or mutated super antigen which induces antibodies but
not T-cell activation
XX
XX PS Disclosure; Fig 3; 54pp; English.
XX
XX CC The sequences given in AAR41990-2013 are mutant versions of the
Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
generated by random mutation by PCR, may be used to modify the T-cell
response elicited by an antigen, by interacting with specific Vbeta
elements of the T-cell receptors. This T-cell response modulation
may be useful in a wide variety of autoimmune diseases, where self-
reactive T-cells may be activated by SAg that bind to particular
Vbeta types.
XX
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187

RESULT 15
AAR42003
ID AAR42003 standard; protein; 190 AA.
XX
XX AC AAR42003;
XX
XX DT 25-MAR-2003 (updated)

```

```

DT 21-APR-1994 (first entry)
XX
XX DE Staphylococcus enterotoxin B mutant BA-50.
XX
XX KM Staphylococcus enterotoxin B; SEB; super antigen; SAg; receptor;
random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
autoimmune disease.
XX
XX OS Staphylococcus aureus.
XX
XX FH Key Location/Qualifiers
XX FT Region 97..157
XX FT /note= "Region undisclosed in the specification"
XX FT Region 162..186
XX FT /note= "Region undisclosed in the specification"
XX
XX PN WO9314634-A1.
XX
XX PD 05-AUG-1993.
XX
XX PF 28-JAN-1993; 93WO-US00839.
XX
XX PR 28-JAN-1992; 92US-0827540.
XX
XX PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX PI Kappler JW, Marrack P;
XX
XX DR WPI; 1993-320314/40.
XX
XX PT Preventing or treating toxic effects of super antigens - by admin. of
new modified or mutated super antigen which induces antibodies but
not T-cell activation
XX
XX PS Disclosure; Fig 3; 54pp; English.
XX
XX CC The sequences given in AAR41990-2013 are mutant versions of the
Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
generated by random mutation by PCR, may be used to modify the T-cell
response elicited by an antigen, by interacting with specific Vbeta
elements of the T-cell receptors. This T-cell response modulation
may be useful in a wide variety of autoimmune diseases, where self-
reactive T-cells may be activated by SAg that bind to particular
Vbeta types.
XX
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX SQ Sequence 190 AA;

Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187

RESULT 16
AAR42004
ID AAR42004 standard; protein; 190 AA.
XX
XX AC AAR42004;
XX
XX DT 25-MAR-2003 (updated)
XX DT 21-APR-1994 (first entry)
XX
XX DE Staphylococcus enterotoxin B mutant BA-53.
XX
XX KM Staphylococcus enterotoxin B; SEB; super antigen; SAg; receptor;
random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
autoimmune disease.
XX
XX OS Staphylococcus aureus.

```



```
XX Key Location/Qualifiers
FH Region 97..157
FT /note="Region undisclosed in the specification"
FT 162..186
FT /note="Region undisclosed in the specification"
XX
XX MO9314634-A1.
XX
XX 05-AUG-1993.
XX
XX 28-JAN-1993; 93WO-US00839.
XX
XX 28-JAN-1992; 92US-0827540.
XX
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kaplier JW, Marrack P;
XX
XX WPI; 1993-320314/40.
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
XX new modified or mutated super antigen which induces antibodies but
XX not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
XX Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
XX generated by random mutation by PCR, may be used to modify the T-cell
XX response elicited by an antigen, by interacting with specific Vbeta
XX elements of the T-cell receptors. This T-cell response modulation
XX may be useful in a wide variety of autoimmune diseases, where self-
XX reactive T-cells may be activated by Sag that bind to particular
XX Vbeta types.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred.No.1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 17
AAR42005
ID AAR42005 standard; protein; 190 AA.
XX
XX AAR42005;
XX
XX 25-MAR-2003 (updated)
XX 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BA-62.
XX
XX Staphylococcus; enterotoxin B; SEB; super antigen; Sag; receptor;
XX random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX autoimmune disease.
XX
XX Staphylococcus aureus.
XX
XX Key Location/Qualifiers
FH Region 97..157
FT /note="Region undisclosed in the specification"
FT 162..186
FT /note="Region undisclosed in the specification"
XX
XX MO9314634-A1.
XX
XX
```

```
PD 05-AUG-1993.
XX
XX 28-JAN-1993; 93WO-US00839.
XX
XX 28-JAN-1992; 92US-0827540.
XX
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kaplier JW, Marrack P;
XX
XX WPI; 1993-320314/40.
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
XX new modified or mutated super antigen which induces antibodies but
XX not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
XX Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
XX generated by random mutation by PCR, may be used to modify the T-cell
XX response elicited by an antigen, by interacting with specific Vbeta
XX elements of the T-cell receptors. This T-cell response modulation
XX may be useful in a wide variety of autoimmune diseases, where self-
XX reactive T-cells may be activated by Sag that bind to particular
XX Vbeta types.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred.No.1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 18
AAR42006
ID AAR42006 standard; protein; 190 AA.
XX
XX AAR42006;
XX
XX 25-MAR-2003 (updated)
XX 21-APR-1994 (first entry)
XX
XX Staphylococcus enterotoxin B mutant BB-14.
XX
XX Staphylococcus; enterotoxin B; SEB; super antigen; Sag; receptor;
XX random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX autoimmune disease.
XX
XX Staphylococcus aureus.
XX
XX Key Location/Qualifiers
FH Region 97..157
FT /note="Region undisclosed in the specification"
FT 162..186
FT /note="Region undisclosed in the specification"
XX
XX MO9314634-A1.
XX
XX 05-AUG-1993.
XX
XX 28-JAN-1993; 93WO-US00839.
XX
XX 28-JAN-1992; 92US-0827540.
XX
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kaplier JW, Marrack P;
XX
XX
```

XX	WP1; 1993-320314/40.
DR	
XX	
PT	Preventing or treating toxic effects of super antigens - by admin. of
PT	new modified or mutated super antigen which induces antibodies but
PT	not T-cell activation
XX	
PS	Disclosure; Fig 3; 54pp; English.
XX	
CC	The sequences given in AAR41990-2013 are mutant versions of the
CC	Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
CC	generated by random mutation by PCR, may be used to modify the T-cell
CC	response elicited by an antigen, by interacting with specific Vbeta
CC	elements of the T-cell receptors. This T-cell response modulation
CC	may be useful in a wide variety of autoimmune diseases, where self-
CC	reactive T-cells may be activated by SAg that bind to particular
CC	Vbeta types.
CC	(Updated on 25-MAR-2003 to correct PN field.)
CC	
SQ	Sequence 190 AA;
QY	Query Match 1.3%; Score 17; DB 14; Length 190;
	Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Db	Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
	742 NNNNNNNNNNNNNNNNNNNI 758
	171 NNNNNNNNNNNNNNNNNNNI 187
RESULT 19	
AAR42007	
ID	AAR42007 standard; protein; 190 AA.
XX	
AC	AAR42007;
XX	
DT	25-MAR-2003 (updated)
DT	21-APR-1994 (first entry)
XX	
DE	Staphylococcus enterotoxin B mutant BB-21.
XX	
KM	Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KW	autoimmune disease.
XX	
OS	Staphylococcus aureus.
XX	
FH	Key Location/Qualifiers
FT	Region 97..157
FT	/note= "Region undisclosed in the specification"
FT	162..186
FT	/note= "Region undisclosed in the specification"
XX	
PN	WO9314634-A1.
XX	
PD	05-AUG-1993.
XX	
PF	28-JAN-1993; 93WO-US00839.
XX	
PR	28-JAN-1992; 92US-0827540.
XX	
PA	(NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX	
PI	Kappler JW, Marrack P;
XX	
DR	WPI; 1993-320314/40.
XX	
PT	Preventing or treating toxic effects of super antigens - by admin. of
PT	new modified or mutated super antigen which induces antibodies but
PT	not T-cell activation
XX	
PS	Disclosure; Fig 3; 54pp; English.
XX	

CC	The sequences given in AAR41990-2013 are mutant versions of the
CC	Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC	generated by random mutation by PCR, may be used to modify the T-cell
CC	response elicited by an antigen, by interacting with specific Vbeta
CC	elements of the T-cell receptors. This T-cell response modulation
CC	may be useful in a wide variety of autoimmune diseases, where self-
CC	reactive T-cells may be activated by Sag that bind to particular
CC	Vbeta types.
CC	(Updated on 25-MAR-2003 to correct PN field.)
SQ	Sequence 190 AA;
OY	742 NNNNNNNNNNNNNNNNNNI 758 171 NNNNNNNNNNNNNNNNNNI 187
Db	
RESULT 20	
AAR42008	
ID	AAR42008 standard; protein: 190 AA.
XX	
AC	AAR42008;
XX	
DT	25-MAR-2003 (updated)
DT	21-APR-1994 (first entry)
DE	Staphylococcus enterotoxin B mutant BB-47.
XX	
KM	Staphylococcus; enterotoxin B; SEB; super antigen; Sag; receptor;
KW	random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX	autoimmune disease.
OS	Staphylococcus aureus.
FH	
Key	Location/Qualifiers
FT	97..157
FT	/note="Region undisclosed in the specification"
FT	162..186
FT	/note="Region undisclosed in the specification"
PN	
WO	WO9314634-A1.
PD	
05	-AUG-1993.
PF	
28	-JAN-1993; 93WO-US00839.
XX	
PR	28-JAN-1992; 92US-0827540.
PA	(NAME-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
PI	
Kappler JW,	Marrack P;
DR	
WPI,	1993-320314/40.
PT	
Preventing or treating toxic effects of super antigens - by admin. of	
new modified or mutated super antigen which induces antibodies but	
not T-cell activation	
Disclosure:	Fig 3; 54pp; English.
XX	
PS	
XX	
CC	The sequences given in AAR41990-2013 are mutant versions of the
CC	Staphylococcus enterotoxin B (SEB) super antigen (Sag). These mutants
CC	generated by random mutation by PCR, may be used to modify the T-cell
CC	response elicited by an antigen, by interacting with specific Vbeta
CC	elements of the T-cell receptors. This T-cell response modulation
CC	may be useful in a wide variety of autoimmune diseases, where self-
CC	reactive T-cells may be activated by Sag that bind to particular
CC	Vbeta types.
CC	(Updated on 25-MAR-2003 to correct PN field.)

```
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
Db 171 NNNNNNNNNNNNNNNNNI 187

RESULT 21
AAR42009
ID AAR42009 standard; protein; 190 AA.
XX
AC AAR42009;
XX
DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BR-30.
XX
KM Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KM autoimmune disease.
XX
OS Staphylococcus aureus.
XX
PH Key Location/Qualifiers
FT Region 97..157
FT /note="Region undisclosed in the specification"
FT 162..186
FT /note="Region undisclosed in the specification"
XX
PN MO9314634-A1.
XX
PD 05-AUG-1993.
XX
PF 28-JAN-1993; 93MO-US00839.
XX
PR 28-JAN-1992; 92US-0827540.
XX
PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
PI Kaplier JW, Marrack P;
XX
DR WPI; 1993-320314/40.
XX
PT Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
PS Disclosure; Fig 3; 54pp; English.
XX
CC The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by SAg that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 190 AA;
QY
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
Db 171 NNNNNNNNNNNNNNNNNI 187
```

```
Db 171 NNNNNNNNNNNNNNNNNI 187

RESULT 22
AAR42010
ID AAR42010 standard; protein; 190 AA.
XX
AC AAR42010;
XX
DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BR-311.
XX
KM Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
KM autoimmune disease.
XX
OS Staphylococcus aureus.
XX
PH Key Location/Qualifiers
FT Region 97..157
FT /note="Region undisclosed in the specification"
FT 162..186
FT /note="Region undisclosed in the specification"
XX
PN MO9314634-A1.
XX
PD 05-AUG-1993.
XX
PF 28-JAN-1993; 93MO-US00839.
XX
PR 28-JAN-1992; 92US-0827540.
XX
PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
PI Kaplier JW, Marrack P;
XX
DR WPI; 1993-320314/40.
XX
PT Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
PS Disclosure; Fig 3; 54pp; English.
XX
CC The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by SAg that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 190 AA;
QY
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
Db 171 NNNNNNNNNNNNNNNNNI 187

RESULT 23
AAR42011
ID AAR42011 standard; protein; 190 AA.
XX
AC AAR42011;
XX
```

```

DT 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BR-474.
XX
KW Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX autoimmune disease.
XX
OS Staphylococcus aureus.
XX
FH Key
FH Region
FT 97..157
FT /note= "Region undisclosed in the specification"
FT 162..186
FT /note= "Region undisclosed in the specification"
FT
XX
XX WO9314634-A1.
XX
XX 05-AUG-1993.
XX
XX 28-JAN-1993; 93WO-US00839.
XX
XX 28-JAN-1992; 92US-0827540.
XX
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kappler JW, Marrack P;
XX
XX WPI; 1993-320314/40.
XX
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by SAg that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 24
AAR42012
ID AAR42012 standard; protein; 190 AA.
XX
XX AAR42012;
AC
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BA-72.
XX
KW Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX autoimmune disease.
XX

```

```

OS Staphylococcus aureus.
XX
XX Key
XX Region
FT 97..157
FT /note= "Region undisclosed in the specification"
FT 162..186
FT /note= "Region undisclosed in the specification"
FT
XX
XX WO9314634-A1.
XX
XX 05-AUG-1993.
XX
XX 28-JAN-1993; 93WO-US00839.
XX
XX 28-JAN-1992; 92US-0827540.
XX
XX (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
XX Kappler JW, Marrack P;
XX
XX WPI; 1993-320314/40.
XX
XX
XX Preventing or treating toxic effects of super antigens - by admin. of
PT new modified or mutated super antigen which induces antibodies but
PT not T-cell activation
XX
XX Disclosure; Fig 3; 54pp; English.
XX
XX
XX The sequences given in AAR41990-2013 are mutant versions of the
CC Staphylococcus enterotoxin B (SEB) super antigen (SAg). These mutants
CC generated by random mutation by PCR, may be used to modify the T-cell
CC response elicited by an antigen, by interacting with specific Vbeta
CC elements of the T-cell receptors. This T-cell response modulation
CC may be useful in a wide variety of autoimmune diseases, where self-
CC reactive T-cells may be activated by SAg that bind to particular
CC Vbeta types.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 190 AA;
SQ
Query Match 1.3%; Score 17; DB 14; Length 190;
Best Local Similarity 100.0%; Pred. No. 1.2e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNI 758
DB 171 NNNNNNNNNNNNNNNNNI 187
RESULT 25
AAR42013
ID AAR42013 standard; protein; 190 AA.
XX
XX AAR42013;
AC
XX 25-MAR-2003 (updated)
DT 21-APR-1994 (first entry)
XX
DE Staphylococcus enterotoxin B mutant BA-267.
XX
KW Staphylococcus; enterotoxin B; SEB; super antigen; SAg; receptor;
KM random mutation; PCR; modify; T-cell; response; antigen; Vbeta element;
XX autoimmune disease.
XX
XX Staphylococcus aureus.
XX
XX Key
XX Region
FT 97..157
FT /note= "Region undisclosed in the specification"
FT 162..186
FT /note= "Region undisclosed in the specification"
FT
XX
XX WO9314634-A1.
XX

```


PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-01452918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147309.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150882.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155138.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158332.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0158293.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.

PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160778.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 25-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 1.2%; Score 16; DB 21; Length 141;
Best Local Similarity 100.0%; Pred. No. 8, 6e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 741 TNNNNNNNNNNNNNNN 756
Db 2 TNNNNNNNNNNNNNNN 17

RESULT 27
AAG49726
ID AAG49726 standard; Protein; 150 AA.
XX
AC AAG49726;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 62936.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
hybridisation assay; genetic mapping; gene expression control; promoter;
termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EPI033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 09-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.

PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 07-MAY-1999; 99US-0132487.
PR 11-MAY-1999; 99US-0132863.
PR 14-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137502.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142290.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 21-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.

PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 23-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 03-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.

PR 21-OCT-1999; 99US-0160770.
 PR 21-OCT-1999; 99US-0160814.
 PR 21-OCT-1999; 99US-0160815.
 PR 22-OCT-1999; 99US-0160980.
 PR 22-OCT-1999; 99US-0160981.
 PR 22-OCT-1999; 99US-0160989.
 PR 25-OCT-1999; 99US-0161404.
 PR 25-OCT-1999; 99US-0161405.
 PR 25-OCT-1999; 99US-0161406.
 PR 26-OCT-1999; 99US-0161359.
 PR 26-OCT-1999; 99US-0161360.
 PR 26-OCT-1999; 99US-0161361.
 PR 28-OCT-1999; 99US-0161920.
 PR 28-OCT-1999; 99US-0161992.
 PR 28-OCT-1999; 99US-0161993.
 PR 29-OCT-1999; 99US-0162142.

Query Match 1.2%; Score 16; DB 21; Length 150;
 Best Local Similarity 100.0%; Pred. No. 9.1e-07;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNN 756
 DB 11 TNNNNNNNNNNNNNNNN 26

RESULT 28

ABP73877
 ID ABP73877 standard; Protein; 213 AA.

AC AAB73877;
 XX

DT 30-JAN-2003 (first entry)

DE Candida albicans essential protein SEQ ID NO 7714.

KW Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;

KW signal transduction; DNA replication; cell growth;

KW proliferation; Candida albicans; fungicide; antifungal.

OS Candida albicans.

PN WO200253728-A2.

PD 11-JUL-2002.

PF 26-DEC-2001; 2001WO-US49486.

PR 29-DEC-2000; 2000US-259128P.

PR 20-FEB-2001; 2001US-0792024.

PR 22-AUG-2001; 2001US-314050P.

XX (ELIT-) ELITRA PHARM INC.

XX Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;

XX WPI: 2002-566694/60.

DR N-PSDB; ABZ32427.

XX

XX

XX

XX

XX

CC The invention relates to constructing (M1) a strain of diploid fungal cells in which both alleles of a gene are modified, comprising modifying one allele by insertion or replacement by a cassette having an expressible selectable marker and modifying other allele by recombination, of a promoter replacement fragment with a heterologous promoter, so that expression of the second allele is regulated by the promoter. (M1) is useful for constructing a strain of diploid fungal

CC cells in which both alleles of a gene are modified. The diploid fungal cells having both alleles modified are useful for identifying a gene that is essential to the survival or growth of a fungus, a gene that contributes to the virulence and/or pathogenicity of a fungus, a gene that contributes to the resistance of a diploid fungus to an antifungal agent, an antifungal agent that inhibits the growth of a diploid fungus and for identifying a therapeutic agent for treatment of a mammalian disease. (M1) is useful for identifying a compound which modulates the activity of a gene product, preferably enzymatic activity, carbon compound catabolism, biosynthetic, transporter, transcriptional, CC translational, signal transduction, DNA replication and cell division activity. The method is useful for identifying a compound having the ability to inhibit growth or proliferation of C. albicans cells and for treating infection by C. albicans. The present sequence is that of an essential Candida albicans protein used in the method of the invention. Note: The sequence data for this patent is not represented in the printed specification but is based on sequence information supplied to Derwent by the European Patent Office.

CC SQ Sequence 213 AA;

Query Match 1.2%; Score 16; DB 23; Length 213;
 Best Local Similarity 100.0%; Pred. No. 1.2e-06;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 TNNNNNNNNNNNNNNNN 756
 DB 172 TNNNNNNNNNNNNNNNN 187

RESULT 29

AAR24796
 ID AAR24796 standard; Protein; 256 AA.

AC AAR24796;
 XX

DT 25-MAR-2003 (updated)

DT 02-JAN-1992 (first entry)

DE Sequence of fibronectin-derived peptide which binds GPIIb-IIIa.

KW Fibronectin; cell attachment; cell adhesion; adhesive glycoprotein.

OS Homo sapiens.

PN WO9209200-A1.

PD 11-JUN-1992.

PF 03-DEC-1991; 91WO-US09029.

PR 03-DEC-1990; 90US-0620668.

PR 03-JUL-1991; 91US-0725600.

PR 27-NOV-1991; 91US-0803623.

XX (SCRI) SCRIPPS RES INST.

XX Bowditch R, Ginsberg MH, Plow EF;

XX WPI: 1992-216714/26.

XX

XX

XX

XX

XX

CC New polypeptide(s) derived from human fibronectin - promote cell attachment to substrates, inhibit platelet aggregation and thrombus formation and modulate coagulation and inflammatory response
 Claim 5; Page 97; 112pp; English.
 AAQ25592 comprises bps 901-1506 of a human fibronectin (Fn) encoding DNA


```

PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147302.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147303.
PR 09-AUG-1999; 99US-0147303.
PR 09-AUG-1999; 99US-0147303.
PR 10-AUG-1999; 99US-0147303.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148341.
PR 16-AUG-1999; 99US-0148341.
PR 16-AUG-1999; 99US-0148341.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149175.
PR 20-AUG-1999; 99US-0149175.
PR 20-AUG-1999; 99US-0149175.
PR 20-AUG-1999; 99US-0149175.
PR 20-AUG-1999; 99US-0149175.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149902.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151303.
PR 01-SEP-1999; 99US-0151303.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153707.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157765.
PR 06-OCT-1999; 99US-0157765.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158322.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160881.
PR 22-OCT-1999; 99US-0160881.
PR 25-OCT-1999; 99US-0161089.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161920.

```

```

PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.
Query Match 1.2% Score 16; DB 21; Length 346;
Best Local Similarity 100.0%; Pred. No. 1.9e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNN 757
Db 230 NNNNNNNNNNNNNNNNNN 245
RESULT 33
AA82392
ID AA82392 standard; Protein; 349 AA.
AC AA82392;
XX 27-JUN-2000 (first entry)
DE C. trachomatis MOMP containing fusion protein SEQ ID NO:5.
XX Chlamydia trachomatis; fusion protein; major outer membrane protein;
XX MOMP; hydrophilic polypeptide; antibody; detection; diagnosis;
XX infection; infectious disease.
OS Chlamydia trachomatis.
XX Synthetic.
XX JP2000041678-A.
XX 15-FEB-2000.
XX 28-JUL-1998; 98JP-0213212.
XX 28-JUL-1998; 98JP-0213212.
XX (ELED) DENKI KAGAKU KOGYO KK.
XX WPI; 2000-295780/26.
XX N-PSDB; AAA08124.
XX A soluble fused protein useful for diagnosis of Chlamydia infection,
XX comprises at least part of major outer membrane protein (MOMP) of
XX Chlamydia trachomatis -
XX Claim 9; Page 24-25; 37pp; Japanese.
XX The present invention describes fusion proteins (I) comprising at least
XX part of a major outer membrane protein (MOMP) of Chlamydia trachomatis,
XX at least one hydrophilic polypeptide having no immunoreactivity to
XX human serum and their connected part. AAA08120 to AAA08125 encode
XX specifically claimed examples of the fusion proteins given in AA82388
XX to AA82393. Also described is a method (A) for the detection of
XX Chlamydia trachomatis antibody using (I) as the antigen. (I) is used for
XX the diagnosis of Chlamydia trachomatis infectious diseases. The method
XX can diagnose Chlamydia trachomatis infectious diseases specifically in a
XX high sensitivity.
XX
SQ Sequence 349 AA;
Query Match 1.2% Score 16; DB 21; Length 349;
Best Local Similarity 100.0%; Pred. No. 2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 742 NNNNNNNNNNNNNNNNNN 757
Db 168 NNNNNNNNNNNNNNNNNN 183
RESULT 34
AA019019
ID AA019019 standard; Protein; 357 AA.

```

XX AA019019;
 AC 16-DEC-2002 (first entry)
 DT
 XX Human kinesin motor protein HsKif16a motor domain.
 XX
 KW Human; kinesin motor protein; kinesin; HsKif16a; cancer; motor domain;
 KW vesicular transport disorder; neurological disorder; immune disorder;
 KW inflammation; cytostatic; neuroprotective; gene therapy.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 16 /note= "encoded by AGN"
 FT Misc-difference 17 /note= "encoded by NNN"
 FT Misc-difference 18 /note= "encoded by NNN"
 FT Misc-difference 19 /note= "encoded by NNN"
 FT Misc-difference 20 /note= "encoded by NNN"
 FT Misc-difference 21 /note= "encoded by NNN"
 FT Misc-difference 22 /note= "encoded by NNN"
 FT Misc-difference 23 /note= "encoded by NNN"
 FT Misc-difference 24 /note= "encoded by NNN"
 FT Misc-difference 25 /note= "encoded by NNN"
 FT Misc-difference 26 /note= "encoded by NNN"
 FT Misc-difference 27 /note= "encoded by NNN"
 FT Misc-difference 28 /note= "encoded by NNN"
 FT Misc-difference 29 /note= "encoded by NNN"
 FT Misc-difference 30 /note= "encoded by NNN"
 FT Misc-difference 31 /note= "encoded by NNN"
 FT Misc-difference 32 /note= "encoded by NNN"
 FT Misc-difference 33 /note= "encoded by NNN"
 FT Misc-difference 34 /note= "encoded by NNN"
 FT Misc-difference 35 /note= "encoded by NNN"
 FT Misc-difference 36 /note= "encoded by NNN"
 FT Misc-difference 37 /note= "encoded by NNN"
 FT Misc-difference 37 /note= "encoded by NNN"
 XX
 XX US6420162-B1.
 XX
 XX 16-JUL-2002.
 XX
 XX 22-NOV-2000; 2000US-0718810.
 XX
 XX 22-NOV-2000; 2000US-0718810.
 XX
 XX (CYTO-) CYTOKINETICS INC.
 XX
 XX Beraud C, Freedman R;
 XX
 XX WPI; 2002-664560/71.
 XX
 XX N-PSDB; AAL49367.
 DR

XX New nucleic acid encoding a motor protein which has microtubule
 PT stimulated ATPase activity, designated HsKif16a, for preventing and
 PT treating cancer, and neurological and vesicle transport disorders -
 XX
 XX Claim 1; Column 35-36; 27pp; English.
 XX
 CC The present invention provides the protein and coding sequences of a
 CC human motor protein which has microtubule stimulated ATPase activity and
 CC is designated HsKif16a. The nucleic acid is used to diagnose, treat and
 CC prevent cancer, immune disorders, inflammation, neurological disorders
 CC and disorders of vesicular transport. The present sequence is the motor
 CC domain of the protein of the invention.
 XX
 SQ Sequence 357 AA;
 XX
 QY 92 FAYGQTGSGKTYTMLG 107
 DB 98 FAYGQTGSGKTYTMLG 113
 XX
 RESULT 35
 AAU74558
 ID AAU74558 standard; Protein; 357 AA.
 XX
 AC AAU74558;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Human kinesin motor protein HsKif16a motor domain.
 XX
 KW Human; kinesin motor protein; HsKif16a; motor domain; inflammation;
 KW microtubule-stimulated ATPase activity; adenosine triphosphatase; cancer;
 KW neurological disorder; vesicular transport disorder; autoimmune disease;
 KW arthritis; graft rejection; proliferation; cytostatic; neurotropic;
 KW immunosuppressive; antarthritic; antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 16 /label= unknown
 FT Misc-difference 17 /note= "Encoded by AGN"
 FT Misc-difference 17..37 /label= unknown
 FT Misc-difference 21 /note= "Encoded by 21 (NNN)"
 FT Misc-difference 357 /note= "Encoded by AT"
 FT
 XX
 XX US6333184-B1.
 XX
 XX 25-DEC-2001.
 XX
 XX 22-NOV-2000; 2000US-0718841.
 XX
 XX 22-NOV-2000; 2000US-0718841.
 XX
 XX (CYTO-) CYTOKINETICS INC.
 XX
 XX Beraud C, Freedman R;
 XX
 XX WPI; 2002-163180/21.
 XX
 XX N-PSDB; ABK14094.
 XX
 PT New human kinesin motor protein, HsKif16a, having
 PT microtubule-stimulated ATPase activity, useful for identifying specific
 PT modulators for e.g. treating cancer
 XX
 PS Claim 3; Fig 4; 27pp; English.

XX The invention relates to a human kinesin motor protein, HsKif16a,
CC comprising a motor domain and having microtubule-stimulated ATPase
CC (adenosine triphosphatase) activity. The protein of the invention and its
CC associated nucleic acid are useful in diagnosis, treatment and prevention
CC of cancer, neurological disorders, disorders of vesicular transport,
CC autoimmune diseases, arthritis, graft rejection, inflammation and
CC proliferation induced after medical procedures. The protein is also used
CC to identify its specific modulators, potentially useful as therapeutic
CC agents. This sequence represents the motor domain of the HsKif16a
CC polypeptide of the invention.

XX Sequence 357 AA;

Query Match 1.2%; Score 16; DB 23; Length 357;

Best Local Similarity 100.0%; Pred. No. 2e-06; Mismatches 0; Indels 0; Gaps 0;

Qy 92 FAYGQTGSGKTYTMLG 107
|||
Db 98 FAYGQTGSGKTYTMLG 113

RESULT 36

AA616707 standard; Protein; 376 AA.

AA616707;

DT 17-OCT-2000 (first entry)

XX Arabidopsis thaliana protein fragment SEQ ID NO: 17456.

KW Protein identification; signal transduction pathway; metabolic pathway;
KM hybridisation assay; genetic mapping; gene expression control; promoter;
XX termination sequence.

OS Arabidopsis thaliana.

XX EPI033405-A2.

PD 06-SEP-2000.

PF 25-FEB-2000; 2000EP-0301439.

XX 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.

PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.

PR	28-JUN-1989;	99US-0145954;
PR	02-AUG-1989;	99US-0146386;
PR	02-AUG-1989;	99US-0146388;
PR	02-AUG-1989;	99US-0146389;
PR	03-AUG-1989;	99US-0147038;
PR	04-AUG-1989;	99US-0147204;
PR	04-AUG-1989;	99US-0147302;
PR	05-AUG-1989;	99US-0147192;
PR	05-AUG-1989;	99US-0147260;
PR	06-AUG-1989;	99US-0147303;
PR	06-AUG-1989;	99US-0147416;
PR	09-AUG-1989;	99US-0147493;
PR	10-AUG-1989;	99US-0147935;
PR	11-AUG-1989;	99US-0148177;
PR	12-AUG-1989;	99US-0148319;
PR	13-AUG-1989;	99US-0148341;
PR	13-AUG-1989;	99US-0148565;
PR	16-AUG-1989;	99US-0148684;
PR	16-AUG-1989;	99US-0149368;
PR	17-AUG-1989;	99US-0149175;
PR	18-AUG-1989;	99US-0149426;
PR	20-AUG-1989;	99US-0149722;
PR	20-AUG-1989;	99US-0150884;
PR	22-AUG-1989;	99US-0151065;
PR	27-AUG-1989;	99US-0149929;
PR	27-AUG-1989;	99US-0151066;
PR	27-AUG-1989;	99US-0151080;
PR	30-AUG-1989;	99US-0151303;
PR	31-AUG-1989;	99US-0151438;
PR	01-SEP-1989;	99US-0151930;
PR	07-SEP-1989;	99US-0153063;
PR	10-SEP-1989;	99US-0153070;
PR	13-SEP-1989;	99US-0153758;
PR	15-SEP-1989;	99US-0154018;
PR	16-SEP-1989;	99US-0154539;
PR	20-SEP-1989;	99US-0154779;
PR	22-SEP-1989;	99US-0155139;
PR	23-SEP-1989;	99US-0155486;
PR	24-SEP-1989;	99US-0155569;
PR	28-SEP-1989;	99US-0155458;
PR	29-SEP-1989;	99US-0155596;
PR	05-OCT-1989;	99US-0157117;
PR	05-OCT-1989;	99US-0157753;
PR	06-OCT-1989;	99US-0157865;
PR	07-OCT-1989;	99US-0158029;
PR	08-OCT-1989;	99US-0158332;
PR	12-OCT-1989;	99US-0158239;
PR	13-OCT-1989;	99US-0158293;
PR	13-OCT-1989;	99US-0158294;
PR	13-OCT-1989;	99US-0158295;
PR	14-OCT-1989;	99US-0158329;
PR	14-OCT-1989;	99US-0158330;
PR	14-OCT-1989;	99US-0158331;
PR	14-OCT-1989;	99US-0158337;
PR	14-OCT-1989;	99US-0158538;
PR	14-OCT-1989;	99US-0158568;
PR	14-OCT-1989;	99US-0158584;
PR	21-OCT-1989;	99US-0160741;
PR	21-OCT-1989;	99US-0160767;
PR	21-OCT-1989;	99US-0160768;
PR	21-OCT-1989;	99US-0160770;
PR	21-OCT-1989;	99US-0160814;
PR	21-OCT-1989;	99US-0160815;
PR	22-OCT-1989;	99US-0160980;
PR	22-OCT-1989;	99US-0160981;
PR	22-OCT-1989;	99US-0160989;
PR	25-OCT-1989;	99US-0161405;
PR	25-OCT-1989;	99US-0161406;
PR	25-OCT-1989;	99US-0161359;
PR	26-OCT-1989;	99US-0161359;

PR	26-OCT-1999;	99US-0161360.
PR	26-OCT-1999;	99US-0161361.
PR	28-OCT-1999;	99US-0161920.
PR	28-OCT-1999;	99US-0161922.
PR	28-OCT-1999;	99US-0161993.
PR	29-OCT-1999;	99US-0162142.
Query Match		
Best Local Similarity 1.2%; Score 16; DB 21; Length 376;		
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
OY	742 NNNNNNNNNNNNNNNN 757 	
Db	260 NNNNNNNNNNNNNNNN 275	
RESULT 37		
ID	AAG16706	
AC	AAG16706 standard; Protein; 378 AA.	
XX	AAG16706;	
DT	17-OCT-2000 (first entry)	
DE	Arabidopsis thaliana protein fragment SEQ ID NO: 17455.	
KW	protein identification; signal transduction pathway; metabolic pathway;	
KM	hybridisation assay; genetic mapping; gene expression control; promoter;	
OS	termination sequence.	
XX	Arabidopsis thaliana.	
XX		
PN	EP1033405-A2.	
XX		
PD	06-SEP-2000.	
XX		
Pf	25-FEB-2000; 2000EP-0301439.	
XX		
PR	25-FEB-1999;	99US-0121825.
PR	05-MAR-1999;	99US-0123180.
PR	09-MAR-1999;	99US-0123548.
PR	23-MAR-1999;	99US-0125788.
PR	25-MAR-1999;	99US-0126264.
PR	29-MAR-1999;	99US-0126785.
PR	01-APR-1999;	99US-0127462.
PR	06-APR-1999;	99US-0128234.
PR	08-APR-1999;	99US-0128714.
PR	16-APR-1999;	99US-0129845.
PR	19-APR-1999;	99US-0130077.
PR	21-APR-1999;	99US-0130449.
PR	23-APR-1999;	99US-0130510.
PR	23-APR-1999;	99US-0130891.
PR	28-APR-1999;	99US-0131449.
PR	30-APR-1999;	99US-0132048.
PR	30-APR-1999;	99US-0132407.
PR	04-MAY-1999;	99US-0132484.
PR	05-MAY-1999;	99US-0132485.
PR	06-MAY-1999;	99US-0132486.
PR	06-MAY-1999;	99US-0132487.
PR	07-MAY-1999;	99US-0132863.
PR	11-MAY-1999;	99US-0134256.
PR	14-MAY-1999;	99US-0134218.
PR	14-MAY-1999;	99US-0134219.
PR	14-MAY-1999;	99US-0134221.
PR	14-MAY-1999;	99US-0134370.
PR	18-MAY-1999;	99US-0134768.
PR	19-MAY-1999;	99US-0134941.
PR	20-MAY-1999;	99US-0135124.
PR	21-MAY-1999;	99US-0135353.
PR	24-MAY-1999;	99US-0135629.
PR	25-MAY-1999;	99US-0136021.
PR	27-MAY-1999;	99US-0136392.
PR	28-MAY-1999;	99US-0136782.

PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139819.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142290.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145813.
PR 27-JUL-1999; 99US-0145818.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 03-AUG-1999; 99US-0146389.
PR 04-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.

PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148345.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154039.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 1.2%; Score 16; DB 21; Length 378;
 Best Local Similarity 100.0%; Pred. No. 2.1e-06;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
 |||||
 DB 262 NNNNNNNNNNNNNNNNN 277

RESULT 38

AAB18414
 ID AAB18414 standard; Protein; 432 AA.

XX AAB18414;

DT 15-JAN-2001 (first entry)

XX Amino acid sequence of a Celf cellulase protein.

XX Celf; cellulase; endoglucanase; cellobiose; glucose; cellobiose;
 KM cellulose material; textile; paper; ethanol; fuel;

XX cellulose feed stock.

XX Orpinomyces sp.

XX Key Location/Qualifiers

FT Peptide 1..21 /note= "signal peptide"

FT Protein 22..432 /note= "mature protein"

FT Domain 22..57 /note= "fungal cellulose binding domain"

FT Peptide 67..105 /note= "Asn-rich linker sequence"

FT Domain 106..432 /note= "catalytic domain"

PN US6114158-A.

XX 05-SEP-2000.

XX 17-JUL-1998; 98US-0118319.

XX 17-JUL-1998; 98US-0118319.

XX (UYGE-) UNIV GEORGIA RES FOUND INC.

XX Li X, Ljungdahl LG, Chen H;

XX WPI; 2000-593548/56.

XX N-PSDB; AAA75403.

XX Recombinant DNA molecule encoding a mature Celf cellulase, useful for
 PT degrading cellulosic material in textile and paper industries, and for
 PT ethanol production -

XX Disclosure; Column 13-16; 26pp; English.

XX The present sequence represents a Celf protein of Orpinomyces sp. FC-2.

XX Celf is a cellulase, which has endoglucanase activity and produces
 CC cellobiose from cellobiose and glucose and
 CC cellobiose from cellobiose. The Celf polynucleotide is useful for
 CC recombinantly expressing Celf mature protein in Escherichia coli or
 CC other host cells. The cellulase protein is useful for degrading
 CC cellulosic material in textile and paper industries, and also for
 CC producing ethanol. Cellulase is also useful for producing fuels and
 CC chemicals from cellulosic feed stocks.

XX Sequence 432 AA;

SO

Query Match 1.2%; Score 16; DB 21; Length 432;
 Best Local Similarity 100.0%; Pred. No. 2.4e-06;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
 |||||
 DB 78 NNNNNNNNNNNNNNNNN 93

RESULT 39

AAB30815
 ID AAB30815 standard; Protein; 477 AA.

XX AAB30815;

DT 02-APR-2001 (first entry)

XX Amino acid sequence of a prion-like amyloidogenic protein.

XX SCHAG; self-coalesce; higher-order aggregate; amyloidogenic domain;
 KM aggregation; fibril; phenotypic alteration; gene therapy;

XX disease resistance; plant pigmentation; prion disease.

XX Saccharomyces cerevisiae.

XX WO200075324-A2.

XX 14-DEC-2000.

XX 09-JUN-2000; 2000WO-US15876.

XX 09-JUN-1999; 99US-0138833.

XX (ARCH-) ARCH DEV CORP.

XX Lindquist S, Li L, Ma J, Liu J, Sondheimer N, Scheibel T;

XX WPI; 2001-061723/07.

XX New nucleic acid encoding chimeric proteins with self-assembly
 PT properties, useful e.g. for diagnosis and treatment of prion diseases,
 PT also related aggregates, fibrils and polymers -

XX Claim 11; Page 162-163; 188pp; English.

XX AAB30803-17 represent prion-like amyloidogenic proteins which have
 CC been identified from a yeast protein database. The specification
 CC describes chimeric polypeptides, which comprise at least one SCHAG
 CC (self-coalesces into higher-order aggregates) amino acid sequence fused
 CC in frame with a polypeptide of interest (which is other than a marker
 CC protein). The specification also describes chimeric polypeptides that
 CC comprises an amyloidogenic domain that causes aggregation into fibrils.
 CC The chimeric polypeptides are used to prepare polymers with multiple
 CC reactivities, e.g. derivatised with enzymes, or specific binding
 CC partners, and useful e.g. for performing multi-step chemical reactions.
 CC They can be used create an inducible, or stable phenotypic alteration
 CC in a cell, e.g. for gene therapy, protein production, imparting disease
 CC resistance to plants, altering plant pigmentation and for diagnosis
 CC and treatment of prion diseases.

XX Sequence 477 AA;

XX Query Match 1.2%; Score 16; DB 22; Length 477;

XX Best Local Similarity 100.0%; Pred. No. 2.6e-06;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNNN 757
 |||||

DB 244 NNNNNNNNNNNNNNNNN 259

RESULT 40

AAB019018
 ID AAB019018 standard; Protein; 563 AA.

XX

AC AA019018;
 XX
 DT 16-DEC-2002 (first entry)
 XX
 DE Human kinesin motor protein HsKif16a.
 XX
 KW Human; kinesin motor protein; kinesin; HsKif16a; cancer;
 KW vesicular transport disorder; neurological disorder; immune disorder;
 KW inflammation; cytostatic; neuroprotective; gene therapy.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 16 /note= "encoded by AGN"
 FT Misc-difference 17 /note= "encoded by NNN"
 FT Misc-difference 18 /note= "encoded by NNN"
 FT Misc-difference 19 /note= "encoded by NNN"
 FT Misc-difference 20 /note= "encoded by NNN"
 FT Misc-difference 21 /note= "encoded by NNN"
 FT Misc-difference 22 /note= "encoded by NNN"
 FT Misc-difference 23 /note= "encoded by NNN"
 FT Misc-difference 24 /note= "encoded by NNN"
 FT Misc-difference 25 /note= "encoded by NNN"
 FT Misc-difference 26 /note= "encoded by NNN"
 FT Misc-difference 27 /note= "encoded by NNN"
 FT Misc-difference 28 /note= "encoded by NNN"
 FT Misc-difference 29 /note= "encoded by NNN"
 FT Misc-difference 30 /note= "encoded by NNN"
 FT Misc-difference 31 /note= "encoded by NNN"
 FT Misc-difference 32 /note= "encoded by NNN"
 FT Misc-difference 33 /note= "encoded by NNN"
 FT Misc-difference 34 /note= "encoded by NNN"
 FT Misc-difference 35 /note= "encoded by NNN"
 FT Misc-difference 36 /note= "encoded by NNN"
 FT Misc-difference 37 /note= "encoded by NNN"
 FT Misc-difference 391 /note= "encoded by NNN"
 FT Misc-difference 392 /note= "encoded by NNN"
 FT Misc-difference 393 /note= "encoded by NNN"
 FT Misc-difference 394 /note= "encoded by NNN"
 FT Misc-difference 395 /note= "encoded by NNN"
 FT Misc-difference 396 /note= "encoded by NNN"
 FT Misc-difference 397 /note= "encoded by NNN"
 FT Misc-difference 398 /note= "encoded by NNN"
 FT /note= "encoded by NNN"

FT Misc-difference 399 /note= "encoded by NNN"
 FT Misc-difference 400 /note= "encoded by NNN"
 FT Misc-difference 401 /note= "encoded by NNN"
 FT Misc-difference 402 /note= "encoded by NNN"
 FT Misc-difference 403 /note= "encoded by NNN"
 FT Misc-difference 404 /note= "encoded by NNN"
 FT Misc-difference 405 /note= "encoded by NNN"
 FT Misc-difference 406 /note= "encoded by NNN"
 FT Misc-difference 407 /note= "encoded by NNN"
 FT Misc-difference 408 /note= "encoded by NNN"
 FT Misc-difference 409 /note= "encoded by NNN"
 FT Misc-difference 410 /note= "encoded by NNN"
 FT Misc-difference 411 /note= "encoded by NNN"
 FT Misc-difference 412 /note= "encoded by NNN"
 FT /note= "encoded by NNN"

US6420162-B1.

16-JUL-2002.

22-NOV-2000; 2000US-0718810.

22-NOV-2000; 2000US-0718810.

(CYTO-) CYTOKINETICS INC.

Beraud C, Freedman R;

WPI, 2002-664560/71.

DR N-PSDB; AAL49366.

PT New nucleic acid encoding a motor protein which has microtubule
 stimulated ATPase activity, designated HSKIF16A, for preventing and
 treating cancer, and neurological and vesicle transport disorders -

XX Claim 1; Column 29-34; 27pp; English.

CC The present invention provides the protein and coding sequences of a
 CC human motor protein which has microtubule stimulated ATPase activity and
 CC is designated HSKIF16A. The nucleic acid is used to diagnose, treat and
 CC prevent cancer, immune disorders, inflammation, neurological disorders
 CC and disorders of vesicular transport. The present sequence is the protein
 CC of the invention.

XX Sequence 563 AA;

Query Match 1.2%; Score 16; DB 23; Length 563;
 Best Local Similarity 100.0%; Pred. No. 3e-06;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTGSGKTYTMG 107
 |||||
 DB 98 FAYGOTGSGKTYTMG 113

Search completed: October 2, 2003, 16:32:15
 Job time : 115 secs

THIS PAGE BLANK (25PT0)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 16:30:31 ; Search time 23 Seconds
(without alignments)
2369.408 Million cell updates/sec

Title: US-10-006-780-2

Perfect score: 1288

Sequence: 1 MNSKIKVVRKRLSELEKK.....KKLVODINISMDNNHKK 1288

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 328717 seqs, 42310858 residues

Word size: 0

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 1000 summaries

Database :

Issued_Patents_AA:*
1: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/prodata/1/1aa/6A_COMB.pep:*
4: /cgn2_6/prodata/1/1aa/6B_COMB.pep:*
5: /cgn2_6/prodata/1/1aa/PCTUS_COMB.pep:*
6: /cgn2_6/prodata/1/1aa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16	1.2	286	4	US-09-384-162-6
2	16	1.2	357	4	US-09-718-841-4
3	16	1.2	357	4	US-09-718-810-4
4	16	1.2	428	3	US-09-118-319-5
5	16	1.2	432	3	US-09-118-319-2
6	16	1.2	563	4	US-09-718-841-2
7	16	1.2	563	4	US-09-718-810-2
8	16	1.2	732	4	US-08-914-999-8
9	16	1.2	1311	1	US-08-340-011-5
10	16	1.2	1311	3	US-08-901-710-5
11	16	1.2	1584	4	US-09-457-040B-27
12	16	1.2	2184	4	US-09-417-485D-6
13	15	1.2	303	4	US-09-722-129-4
14	15	1.2	492	4	US-09-722-129-2
15	15	1.2	794	4	US-09-417-485D-8
16	15	1.2	888	2	US-08-861-464-6
17	15	1.2	888	2	US-08-396-001-6
18	15	1.2	888	3	US-09-323-433A-6
19	15	1.1	888	3	US-09-098-901-11
20	14	1.1	337	4	US-09-641-806-4
21	14	1.1	337	4	US-09-723-129-4
22	14	1.1	337	4	US-09-722-862-4
23	14	1.1	342	4	US-09-641-806-2
24	14	1.1	342	4	US-09-723-129-2
25	14	1.1	342	4	US-09-722-862-2
26	14	1.1	730	4	US-09-291-170A-3
27	14	1.1	730	4	US-09-724-884-3

28	14	1.1	955	1	US-08-006-676B-1	Sequence 1, Appl1
29	14	1.1	955	1	US-08-282-845-2	Sequence 2, Appl1
30	14	1.1	955	1	US-08-428-41A-3	Sequence 3, Appl1
31	14	1.1	955	5	PCT-US94-00324-1	Sequence 1, Appl1
32	13	1.0	341	4	US-09-724-517-4	Sequence 4, Appl1
33	13	1.0	341	4	US-09-641-807A-4	Sequence 4, Appl1
34	13	1.0	341	4	US-09-723-096-4	Sequence 4, Appl1
35	13	1.0	1151	4	US-09-177-165A-31	Sequence 31, Appl1
36	13	1.0	1279	4	US-09-724-517-2	Sequence 2, Appl1
37	13	1.0	1279	4	US-09-641-807A-2	Sequence 2, Appl1
38	13	1.0	1279	4	US-09-723-096-2	Sequence 2, Appl1
39	12	0.9	246	3	US-09-451-117-2	Sequence 2, Appl1
40	12	0.9	246	4	US-09-888-655-2	Sequence 2, Appl1
41	12	0.9	362	4	US-09-594-665-6	Sequence 6, Appl1
42	12	0.9	391	4	US-09-594-665-4	Sequence 4, Appl1
43	12	0.9	405	4	US-09-594-665-12	Sequence 12, Appl1
44	12	0.9	430	4	US-09-594-665-2	Sequence 2, Appl1
45	12	0.9	434	4	US-09-594-665-10	Sequence 10, Appl1
46	12	0.9	473	4	US-09-386-495-10	Sequence 10, Appl1
47	12	0.9	675	5	PCT-US96-02331-10	Sequence 10, Appl1
48	12	0.9	678	4	US-09-595-684B-25	Sequence 25, Appl1
49	12	0.9	723	4	US-09-594-668-14	Sequence 14, Appl1
50	12	0.9	725	4	US-09-594-668-16	Sequence 16, Appl1
51	12	0.9	725	4	US-09-595-684B-33	Sequence 33, Appl1
52	12	0.9	842	5	PCT-US96-02331-15	Sequence 15, Appl1
53	12	0.9	842	4	US-09-637-481-2	Sequence 2, Appl1
54	11	0.9	205	4	US-09-723-428-2	Sequence 2, Appl1
55	11	0.9	205	4	US-09-724-520-2	Sequence 2, Appl1
56	11	0.9	319	4	US-09-724-510-2	Sequence 2, Appl1
57	11	0.9	319	4	US-09-723-216-2	Sequence 2, Appl1
58	11	0.9	319	4	US-09-675-227-2	Sequence 2, Appl1
59	11	0.9	343	4	US-09-967-908A-8	Sequence 8, Appl1
60	11	0.9	361	4	US-09-596-541-2	Sequence 2, Appl1
61	11	0.9	361	4	US-09-723-595-2	Sequence 2, Appl1
62	11	0.9	363	4	US-09-967-908A-10	Sequence 10, Appl1
63	11	0.9	369	4	US-09-596-541-6	Sequence 6, Appl1
64	11	0.9	369	4	US-09-723-262-4	Sequence 4, Appl1
65	11	0.9	370	4	US-09-596-541-4	Sequence 4, Appl1
66	11	0.9	370	4	US-09-723-595-4	Sequence 4, Appl1
67	11	0.9	373	4	US-09-967-908A-4	Sequence 4, Appl1
68	11	0.9	375	4	US-09-572-191-4	Sequence 4, Appl1
69	11	0.9	375	4	US-09-723-262-4	Sequence 4, Appl1
70	11	0.9	375	4	US-09-723-262-4	Sequence 4, Appl1
71	11	0.9	381	4	US-09-967-908A-6	Sequence 6, Appl1
72	11	0.9	409	4	US-09-572-191-6	Sequence 6, Appl1
73	11	0.9	409	4	US-09-723-262-6	Sequence 6, Appl1
74	11	0.9	409	4	US-09-723-262-6	Sequence 6, Appl1
75	11	0.9	473	4	US-09-592-054-6	Sequence 6, Appl1
76	11	0.9	519	4	US-09-595-684B-17	Sequence 17, Appl1
77	11	0.9	522	4	US-09-592-054-4	Sequence 4, Appl1
78	11	0.9	935	4	US-09-914-259-25	Sequence 25, Appl1
79	11	0.9	1231	4	US-09-595-684B-23	Sequence 23, Appl1
80	11	0.9	1232	4	US-09-592-054-2	Sequence 2, Appl1
81	11	0.9	1234	4	US-09-592-054-8	Sequence 8, Appl1
82	11	0.9	1368	4	US-09-597-908A-2	Sequence 2, Appl1
83	11	0.9	1368	4	US-09-572-191-2	Sequence 2, Appl1
84	11	0.9	1388	4	US-09-723-262-2	Sequence 2, Appl1
85	11	0.9	1388	4	US-09-723-219-2	Sequence 2, Appl1
86	11	0.9	1388	4	US-08-764-640-238	Sequence 238, Appl1
87	10	0.8	24	3	US-08-973-225-226	Sequence 226, Appl1
88	10	0.8	40	1	US-08-478-312-54	Sequence 54, Appl1
89	10	0.8	40	1	US-08-485-302-54	Sequence 54, Appl1
90	10	0.8	40	1	US-08-476-169-59	Sequence 59, Appl1
91	10	0.8	40	1	US-08-484-083-59	Sequence 59, Appl1
92	10	0.8	40	2	US-08-764-640-238	Sequence 238, Appl1
93	10	0.8	40	3	US-09-723-225-226	Sequence 226, Appl1
94	10	0.8	40	3	US-09-244-296A-238	Sequence 238, Appl1
95	10	0.8	40	3	US-09-516-704-238	Sequence 238, Appl1
96	10	0.8	40	4	US-09-549-090-226	Sequence 226, Appl1
97	10	0.8	40	4	US-09-832-230A-238	Sequence 238, Appl1
98	10	0.8	100	2	US-08-710-249-16	Sequence 16, Appl1
99	10	0.8	100	4	US-09-220-157A-16	Sequence 16, Appl1
100	10	0.8	274	4	US-09-723-430-2	Sequence 2, Appl1

101	10	0.8	274	4	US-09-632-155-2	Sequence 2, Appli	174	8	0.6	444	1	US-07-881-075-3	Sequence 3, Appli
102	10	0.8	274	4	US-09-724-518-2	Sequence 2, Appli	175	8	0.6	444	1	US-08-120-827-3	Sequence 3, Appli
103	10	0.8	359	4	US-09-722-139-4	Sequence 4, Appli	176	8	0.6	444	1	US-08-478-675-3	Sequence 3, Appli
104	10	0.8	359	4	US-09-721-832-4	Sequence 4, Appli	177	8	0.6	446	1	US-09-004-3938-4	Sequence 4, Appli
105	10	0.8	359	4	US-09-721-889-4	Sequence 4, Appli	178	8	0.6	441	1	US-08-186-222-2	Sequence 2, Appli
106	10	0.8	412	4	US-09-471-396-1	Sequence 1, Appli	179	8	0.6	478	1	US-08-155-888-2	Sequence 2, Appli
107	10	0.8	412	4	US-09-788-345-12	Sequence 12, Appli	180	8	0.6	554	3	US-09-319-989-6	Sequence 6, Appli
108	10	0.8	522	1	US-08-164-614A-10	Sequence 10, Appli	181	8	0.6	586	6	US-08-419-810-12	Sequence 12, Appli
109	10	0.8	522	2	US-08-456-489B-10	Sequence 10, Appli	182	8	0.6	5405775-11	Patent No. 5405775		
110	10	0.8	536	1	US-08-164-614A-12	Sequence 12, Appli	183	8	0.6	652	4	US-08-559-986B-2	Sequence 2, Appli
111	10	0.8	536	2	US-08-456-489B-12	Sequence 12, Appli	184	8	0.6	653	4	US-09-513-057C-13	Sequence 13, Appli
112	10	0.8	596	4	US-09-752-165-2	Sequence 2, Appli	185	8	0.6	673	4	US-09-107-532A-5134	Sequence 14, Appli
113	10	0.8	659	2	US-08-709-874A-20	Sequence 20, Appli	186	8	0.6	674	4	US-08-653-648A-14	Sequence 14, Appli
114	10	0.8	659	3	US-09-104-382-70	Sequence 20, Appli	187	8	0.6	678	5	PCT-US93-03027-3	Sequence 3, Appli
115	10	0.8	675	2	US-08-971-036-2	Sequence 2, Appli	188	8	0.6	787	4	US-09-721-137-2	Sequence 2, Appli
116	10	0.8	675	3	US-09-096-570-2	Sequence 2, Appli	189	8	0.6	787	4	US-08-861-464-4	Sequence 4, Appli
117	10	0.8	675	4	US-09-265-617B-2	Sequence 2, Appli	190	8	0.6	834	2	US-08-396-001-1	Sequence 4, Appli
118	10	0.8	694	3	US-08-816-977-49	Sequence 49, Appli	191	8	0.6	834	2	US-08-396-001-1	Sequence 4, Appli
119	10	0.8	694	3	US-08-816-977-49	Sequence 49, Appli	192	8	0.6	834	3	US-09-323-333A-4	Sequence 4, Appli
120	10	0.8	708	3	US-08-816-977-35	Sequence 35, Appli	193	8	0.6	984	1	US-08-257-073-3	Sequence 3, Appli
121	10	0.8	711	3	US-08-816-977-35	Sequence 35, Appli	194	8	0.6	984	2	US-08-184-009-120	Sequence 120, Appli
122	10	0.8	809	4	US-09-660-552-5	Sequence 5, Appli	195	8	0.6	984	2	US-08-458-356-120	Sequence 120, Appli
123	10	0.8	1084	1	US-08-717-515-6	Sequence 6, Appli	196	8	0.6	984	3	US-08-460-736-120	Sequence 120, Appli
124	10	0.8	1276	1	US-08-717-515-8	Sequence 8, Appli	197	8	0.6	984	4	US-09-535-770-120	Sequence 120, Appli
125	10	0.8	1375	4	US-09-722-139-2	Sequence 2, Appli	198	8	0.6	1242	4	US-09-508-691-1	Sequence 2, Appli
126	10	0.8	1375	4	US-09-721-832-2	Sequence 2, Appli	199	8	0.6	1243	2	US-08-557-139-2	Sequence 2, Appli
127	10	0.8	1375	4	US-09-721-832-2	Sequence 2, Appli	200	8	0.6	1284	4	US-09-343-494-9	Sequence 9, Appli
128	9	0.7	11	1	US-08-040-548-43	Sequence 43, Appli	201	8	0.6	1284	4	US-09-358-830C-11	Sequence 11, Appli
129	9	0.7	11	1	US-08-466-344-43	Sequence 43, Appli	202	8	0.6	1341	2	US-08-317-310A-64	Sequence 64, Appli
130	9	0.7	11	6	5206152-12	Patent No. 5206152	203	8	0.6	1850	4	US-09-620-093A-5	Sequence 5, Appli
131	9	0.7	23	3	US-09-098-901-7	Sequence 7, Appli	204	8	0.6	2314	4	US-09-268-347-49	Sequence 49, Appli
132	9	0.7	177	4	US-09-247-155-164	Sequence 164, App	205	8	0.6	2391	2	US-08-446-855A-2	Sequence 2, Appli
133	9	0.7	330	4	US-09-134-001C-4002	Sequence 4002, Ap	206	8	0.6	2391	3	US-09-150-741-2	Sequence 3, Appli
134	9	0.7	355	4	US-09-724-511-4	Sequence 4, Appli	207	7	0.5	9	1	US-08-106-981-11	Sequence 11, Appli
135	9	0.7	355	4	US-09-723-057-4	Sequence 4, Appli	208	7	0.5	14	1	US-08-346-293-17	Sequence 17, Appli
136	9	0.7	355	4	US-09-632-344-4	Sequence 4, Appli	209	7	0.5	14	2	US-08-727-688-23	Sequence 23, Appli
137	9	0.7	367	4	US-09-724-511-2	Sequence 2, Appli	210	7	0.5	14	4	US-08-248-058-1	Sequence 1, Appli
138	9	0.7	367	4	US-09-723-097-2	Sequence 2, Appli	211	7	0.5	24	2	US-08-752-891-7	Sequence 7, Appli
139	9	0.7	367	4	US-09-632-344-2	Sequence 2, Appli	212	7	0.5	24	2	US-09-144-178-7	Sequence 7, Appli
140	9	0.7	416	4	US-09-457-040B-10	Sequence 10, Appli	213	7	0.5	24	3	US-09-406-654-7	Sequence 6, Appli
141	9	0.7	677	4	US-09-328-352-4365	Sequence 4365, Ap	214	7	0.5	43	4	US-09-098-901-6	Sequence 6, Appli
142	9	0.7	1003	1	US-08-571-758-4	Sequence 4, Appli	215	7	0.5	43	4	US-07-757-022B-12	Sequence 12, Appli
143	9	0.7	1003	1	US-08-909-984A-4	Sequence 4, Appli	216	7	0.5	51	4	US-09-314-268-100	Sequence 100, App
144	9	0.7	1003	1	US-08-909-983-4	Sequence 4, Appli	217	7	0.5	69	2	US-08-563-669-1	Sequence 1, Appli
145	9	0.7	2938	5	PCT-US94-00198-3	Sequence 3, Appli	218	7	0.5	73	4	US-09-328-352-4164	Sequence 4164, Ap
146	8	0.6	90	4	US-08-186-276B-59	Sequence 59, Appli	219	7	0.5	75	3	US-08-927-219-51	Sequence 51, Appli
147	8	0.6	90	4	US-08-842-445-59	Sequence 59, Appli	220	7	0.5	85	4	US-09-134-001C-3387	Sequence 3387, Ap
148	8	0.6	90	4	US-09-186-188B-59	Sequence 59, Appli	221	7	0.5	101	4	US-09-858-664A-10	Sequence 10, Appli
149	8	0.6	193	2	US-08-679-765-3	Sequence 3, Appli	222	7	0.5	110	2	US-08-569-166-34	Sequence 34, Appli
150	8	0.6	193	2	US-09-196-525-3	Sequence 3, Appli	223	7	0.5	110	3	US-08-961-083-102	Sequence 102, App
151	8	0.6	193	2	US-09-318-317-3	Sequence 3, Appli	224	7	0.5	110	4	US-09-536-784-102	Sequence 102, App
152	8	0.6	261	6	5320958-5	Patent No. 5320958	225	7	0.5	111	4	US-09-858-664A-8	Sequence 8, Appli
153	8	0.6	265	4	US-09-611-659A-4	Sequence 4, Appli	226	7	0.5	129	4	US-09-328-352-6408	Sequence 6408, Ap
154	8	0.6	272	2	US-08-492-027A-4	Sequence 4, Appli	227	7	0.5	130	2	US-08-630-822A-90	Sequence 90, Appli
155	8	0.6	299	3	US-09-621-233-2	Sequence 2, Appli	228	7	0.5	130	2	US-09-005-069-90	Sequence 90, Appli
156	8	0.6	299	4	US-09-724-508-2	Sequence 2, Appli	229	7	0.5	130	4	US-09-171-156A-39	Sequence 39, Appli
157	8	0.6	299	4	US-09-724-516-2	Sequence 2, Appli	230	7	0.5	130	4	US-09-004-730A-39	Sequence 39, Appli
158	8	0.6	301	4	US-09-134-001C-2915	Sequence 2915, Ap	231	7	0.5	130	4	US-08-981-799A-39	Sequence 39, Appli
159	8	0.6	317	1	US-08-221-750A-13	Sequence 13, Appli	232	7	0.5	148	4	US-09-134-001C-4679	Sequence 4679, Ap
160	8	0.6	324	4	US-09-183-861-53	Sequence 53, Appli	233	7	0.5	148	4	US-09-461-325-453	Sequence 453, App
161	8	0.6	324	4	US-09-022-765-53	Sequence 53, Appli	234	7	0.5	159	3	US-08-992-176-6	Sequence 6, Appli
162	8	0.6	326	4	US-09-551-974A-53	Sequence 53, Appli	235	7	0.5	159	4	US-09-107-532A-6434	Sequence 6434, Ap
163	8	0.6	326	4	US-09-721-383-4	Sequence 4, Appli	236	7	0.5	172	4	US-07-757-022B-88	Sequence 88, Appli
164	8	0.6	326	4	US-09-721-177-4	Sequence 4, Appli	237	7	0.5	179	4	US-09-252-991A-21165	Sequence 21165, A
165	8	0.6	342	1	US-09-118-464-3	Sequence 3, Appli	238	7	0.5	179	4	US-09-158-452A-1064	Sequence 1064, Ap
166	8	0.6	361	1	US-08-415-751-3	Sequence 3, Appli	239	7	0.5	180	4	US-09-134-001C-2966	Sequence 2966, Ap
167	8	0.6	372	4	US-09-404-296B-30	Sequence 30, Appli	240	7	0.5	187	4	US-09-247-155-102	Sequence 102, App
168	8	0.6	372	4	US-09-118-464-2	Sequence 2, Appli	241	7	0.5	188	3	US-09-130-663-30	Sequence 30, Appli
169	8	0.6	406	1	US-07-973-431B-1	Sequence 1, Appli	242	7	0.5	188	3	US-09-332-934-14	Sequence 14, Appli
170	8	0.6	413	3	US-08-481-814A-8	Sequence 8, Appli	243	7	0.5	188	3	US-09-432-335-10	Sequence 30, Appli
171	8	0.6	413	3	US-08-836-582-2	Sequence 2, Appli	244	7	0.5	188	3	US-09-614-022-30	Sequence 30, Appli
172	8	0.6	413	4	US-09-265-566-2	Sequence 2, Appli	245	7	0.5	192	4	US-07-757-022B-90	Sequence 90, Appli
173	8	0.6	413	4	US-09-242-737-4	Sequence 4, Appli	246	7	0.5	204	4	US-07-757-022B-92	Sequence 92, Appli

247	7	0.5	206	3	US-09-156-580-2	Sequence 2, Appl1	320	7	0.5	377	1	US-08-525-697-2	Sequence 2, Appl1
248	7	0.5	207	4	US-09-199-637A-211	Sequence 211, App	321	7	0.5	382	4	US-08-213-418B-19	Sequence 19, Appl1
249	7	0.5	208	4	US-07-757-022B-132	Sequence 132, App	322	7	0.5	382	4	US-09-724-519-4	Sequence 4, Appl1
250	7	0.5	209	4	US-07-757-022B-94	Sequence 94, Appl	323	7	0.5	382	4	US-09-592-037-4	Sequence 4, Appl1
251	7	0.5	211	2	US-08-708-958-2	Sequence 2, Appl1	324	7	0.5	391	1	US-08-602-010A-6	Sequence 6, Appl1
252	7	0.5	211	4	US-09-502-769-10	Sequence 10, Appl	325	7	0.5	391	1	US-08-680-726A-6	Sequence 6, Appl1
253	7	0.5	211	4	US-09-972-800A-12	Sequence 12, Appl	326	7	0.5	393	3	US-09-092-409-6	Sequence 6, Appl1
254	7	0.5	212	4	US-09-302-769-4	Sequence 4, Appl1	327	7	0.5	393	4	US-09-230-371A-29	Sequence 29, Appl1
255	7	0.5	212	4	US-09-302-769-12	Sequence 12, Appl	328	7	0.5	413	2	US-08-282-197C-49	Sequence 49, Appl1
256	7	0.5	212	4	US-09-399-913-63	Sequence 63, Appl	329	7	0.5	414	1	US-07-667-276A-4	Sequence 4, Appl1
257	7	0.5	212	4	US-09-341-349D-2	Sequence 2, Appl1	330	7	0.5	422	3	US-08-872-978-8	Sequence 8, Appl1
258	7	0.5	217	4	US-07-757-022B-76	Sequence 76, Appl	331	7	0.5	422	4	US-07-757-022B-68	Sequence 68, Appl
259	7	0.5	218	1	US-08-463-115-92	Sequence 92, Appl	332	7	0.5	423	4	US-07-757-022B-66	Sequence 66, Appl
260	7	0.5	218	3	US-08-465-388-92	Sequence 92, Appl	333	7	0.5	433	4	US-09-595-424-2	Sequence 2, Appl1
261	7	0.5	218	3	US-09-068-655-7	Sequence 7, Appl1	334	7	0.5	446	4	US-09-286-981B-6	Sequence 6, Appl1
262	7	0.5	219	1	US-08-463-115-91	Sequence 91, Appl	335	7	0.5	446	4	US-09-286-981B-9	Sequence 9, Appl1
263	7	0.5	219	1	US-08-465-388-91	Sequence 91, Appl	336	7	0.5	450	2	US-08-861-464-2	Sequence 2, Appl1
264	7	0.5	219	4	US-09-134-001C-4581	Sequence 4581, Ap	337	7	0.5	450	2	US-08-396-001-2	Sequence 2, Appl1
265	7	0.5	220	4	US-07-757-022B-96	Sequence 96, Appl	338	7	0.5	450	3	US-09-323-433A-2	Sequence 2, Appl1
266	7	0.5	223	4	US-09-206-676C-1	Sequence 1, Appl1	339	7	0.5	460	4	US-09-134-001C-5322	Sequence 5322, Ap
267	7	0.5	223	4	US-09-009-816-4	Sequence 4, Appl1	340	7	0.5	463	4	US-07-757-022B-54	Sequence 54, Appl
268	7	0.5	226	4	US-09-206-676C-2	Sequence 2, Appl1	341	7	0.5	463	4	US-09-345-236B-2	Sequence 2, Appl1
269	7	0.5	229	4	US-09-604-978-9	Sequence 9, Appl1	342	7	0.5	465	3	US-09-537-357-52	Sequence 52, Appl
270	7	0.5	229	4	US-09-604-978-9	Sequence 9, Appl1	343	7	0.5	465	4	US-09-252-991A-17635	Sequence 17635, A
271	7	0.5	230	3	US-09-248-335-44	Sequence 44, Appl	344	7	0.5	467	4	US-08-495-484-12	Sequence 12, Appl
272	7	0.5	230	3	US-07-757-022B-30	Sequence 30, Appl	345	7	0.5	471	1	US-08-176-427B-11	Sequence 11, Appl
273	7	0.5	233	2	US-08-458-568A-4	Sequence 4, Appl1	346	7	0.5	471	2	US-08-356-060A-34	Sequence 34, Appl
274	7	0.5	243	4	US-09-166-350-19	Sequence 19, Appl	347	7	0.5	471	3	US-08-460-900C-34	Sequence 34, Appl
275	7	0.5	246	3	US-09-185-160-7	Sequence 7, Appl1	348	7	0.5	471	3	US-08-757-230A-8	Sequence 8, Appl1
276	7	0.5	250	2	US-08-861-269-5	Sequence 5, Appl1	349	7	0.5	471	3	US-08-674-509B-34	Sequence 34, Appl
277	7	0.5	250	3	US-09-134-596-5	Sequence 5, Appl1	350	7	0.5	471	3	US-08-954-698-34	Sequence 34, Appl
278	7	0.5	252	3	US-09-293-273-5	Sequence 5, Appl1	351	7	0.5	471	4	US-08-957-874-34	Sequence 34, Appl
279	7	0.5	254	4	US-09-294-531B-3	Sequence 3, Appl1	352	7	0.5	471	4	US-08-700-393-8	Sequence 8, Appl
280	7	0.5	258	2	US-08-720-258-4	Sequence 4, Appl1	353	7	0.5	474	4	US-09-639-698-34	Sequence 34, Appl
281	7	0.5	262	1	US-08-106-981-6	Sequence 6, Appl1	354	7	0.5	474	4	US-09-702-705-1812	Sequence 1812, Ap
282	7	0.5	264	1	US-08-463-115-93	Sequence 93, Appl	355	7	0.5	474	4	US-09-736-457-1812	Sequence 1812, Ap
283	7	0.5	264	1	US-08-465-388-93	Sequence 93, Appl	356	7	0.5	475	2	US-08-861-464-14	Sequence 14, Appl
284	7	0.5	264	3	US-08-894-731-4	Sequence 4, Appl1	357	7	0.5	475	3	US-08-396-001-14	Sequence 14, Appl
285	7	0.5	266	4	US-09-252-991A-17646	Sequence 17646, A	358	7	0.5	475	3	US-09-323-433A-14	Sequence 14, Appl
286	7	0.5	285	3	US-08-482-085B-20	Sequence 20, Appl	359	7	0.5	475	4	US-09-569-804-4	Sequence 4, Appl1
287	7	0.5	288	4	US-09-134-001C-3292	Sequence 3292, Ap	360	7	0.5	476	3	US-09-316-083-3	Sequence 3, Appl1
288	7	0.5	296	4	US-07-757-022B-70	Sequence 70, Appl	361	7	0.5	476	4	US-09-933-700-3	Sequence 3, Appl1
289	7	0.5	302	4	US-09-725-311-2	Sequence 22, Appl	362	7	0.5	484	4	US-09-242-913B-17	Sequence 17, Appl
290	7	0.5	310	3	US-08-651-136C-22	Sequence 22, Appl	363	7	0.5	484	4	US-09-724-224-8	Sequence 8, Appl1
291	7	0.5	310	4	US-09-229-911A-22	Sequence 22, Appl	364	7	0.5	489	1	US-07-903-103-4	Sequence 4, Appl1
292	7	0.5	314	4	US-09-544-618-20	Sequence 20, Appl	365	7	0.5	489	1	US-08-044-619A-4	Sequence 4, Appl1
293	7	0.5	315	4	US-09-404-296B-8	Sequence 8, Appl1	366	7	0.5	489	1	US-08-283-911-4	Sequence 4, Appl1
294	7	0.5	320	4	US-09-134-001C-4439	Sequence 4439, Ap	367	7	0.5	489	1	US-08-245-500A-5	Sequence 5, Appl1
295	7	0.5	325	4	US-09-252-991A-27128	Sequence 27128, A	368	7	0.5	489	1	US-08-390-546-5	Sequence 5, Appl1
296	7	0.5	330	4	US-09-725-311-4	Sequence 4, Appl1	369	7	0.5	489	1	US-08-390-479A-5	Sequence 5, Appl1
297	7	0.5	338	4	US-09-634-957-4	Sequence 4, Appl1	370	7	0.5	489	1	US-08-557-393-5	Sequence 5, Appl1
298	7	0.5	338	4	US-09-723-153-4	Sequence 4, Appl1	371	7	0.5	489	1	US-08-390-516C-5	Sequence 5, Appl1
299	7	0.5	345	2	US-09-723-429-4	Sequence 4, Appl1	372	7	0.5	489	1	US-08-390-517A-5	Sequence 5, Appl1
300	7	0.5	348	4	US-08-282-197C-50	Sequence 50, Appl	373	7	0.5	489	2	US-08-801-718-5	Sequence 5, Appl1
301	7	0.5	346	4	US-09-724-224-6	Sequence 6, Appl1	374	7	0.5	489	2	US-09-170-159A-5	Sequence 5, Appl1
302	7	0.5	347	3	US-09-094-557-3	Sequence 3, Appl1	375	7	0.5	489	4	US-09-480-718-46	Sequence 46, Appl
303	7	0.5	349	4	US-09-162-524-3	Sequence 3, Appl1	376	7	0.5	489	4	US-09-480-718-46	Sequence 46, Appl
304	7	0.5	351	4	US-09-399-913-61	Sequence 61, Appl	377	7	0.5	490	4	US-09-336-643A-6	Sequence 6, Appl1
305	7	0.5	351	4	US-09-452-991A-11990	Sequence 17990, A	378	7	0.5	494	4	US-09-595-424-4	Sequence 4, Appl1
306	7	0.5	360	3	US-08-899-437-7	Sequence 7, Appl1	379	7	0.5	496	3	US-09-350-268-2	Sequence 2, Appl1
307	7	0.5	360	3	US-09-126-121-7	Sequence 7, Appl1	380	7	0.5	496	4	US-09-558-679-2	Sequence 2, Appl1
308	7	0.5	366	4	US-09-718-692-4	Sequence 4, Appl1	381	7	0.5	500	4	US-09-325-932A-149	Sequence 149, App
309	7	0.5	366	4	US-09-718-852-4	Sequence 4, Appl1	382	7	0.5	506	2	US-08-820-170A-19	Sequence 19, Appl
310	7	0.5	366	4	US-09-718-815-4	Sequence 4, Appl1	383	7	0.5	506	3	US-09-055-699-19	Sequence 19, Appl
311	7	0.5	367	1	US-07-737-736B-4	Sequence 4, Appl1	384	7	0.5	506	3	US-09-273-565-19	Sequence 19, Appl
312	7	0.5	367	4	US-08-213-419B-15	Sequence 15, Appl	385	7	0.5	506	4	US-09-565-536-19	Sequence 19, Appl
313	7	0.5	367	4	US-09-009-816-2	Sequence 2, Appl1	386	7	0.5	506	4	US-09-661-468-19	Sequence 19, Appl
314	7	0.5	368	3	US-09-413-574-4	Sequence 4, Appl1	387	7	0.5	506	4	US-09-976-165-19	Sequence 19, Appl
315	7	0.5	368	4	US-09-724-519-10	Sequence 10, Appl	388	7	0.5	512	4	US-09-724-519-10	Sequence 10, Appl
316	7	0.5	368	4	US-09-592-037-10	Sequence 10, Appl	389	7	0.5	513	4	US-09-724-519-6	Sequence 6, Appl1
317	7	0.5	369	2	US-08-773-870-4	Sequence 4, Appl1	390	7	0.5	513	4	US-09-592-037-6	Sequence 6, Appl1
318	7	0.5	370	4	US-09-724-224-2	Sequence 2, Appl1	391	7	0.5	516	1	US-08-097-829-4	Sequence 4, Appl1
319	7	0.5	372	4	US-07-757-022B-64	Sequence 64, Appl	392	7	0.5	516	1	US-08-577-403-4	Sequence 4, Appl1

393	7	0.5	524	4	US-09-186-276B-56	Sequence 56, Appl	466	7	0.5	823	4	US-09-650-855-19	Sequence 19, Appl
394	7	0.5	524	4	US-08-842-445-56	Sequence 56, Appl	467	7	0.5	845	4	US-09-198-4525-48	Sequence 48, Appl
395	7	0.5	524	4	US-09-186-188B-56	Sequence 56, Appl	468	7	0.5	846	2	US-07-728-215-33	Sequence 33, Appl
396	7	0.5	527	4	US-09-134-001C-3358	Sequence 3358, Ap	469	7	0.5	846	4	US-08-938-085B-33	Sequence 33, Appl
397	7	0.5	535	4	US-09-134-001C-3338	Sequence 3338, Ap	470	7	0.5	846	4	US-10-072-844-33	Sequence 33, Appl
398	7	0.5	536	4	US-09-463-712C-10	Sequence 10, Appl	471	7	0.5	866	2	US-08-483-101-4	Sequence 4, Appl
399	7	0.5	543	2	US-08-224-482-4	Sequence 4, Appl	472	7	0.5	878	4	US-09-735-334A-2	Sequence 2, Appl
400	7	0.5	543	2	US-08-469-412A-7	Sequence 7, Appl	473	7	0.5	898	4	US-09-585-858-37	Sequence 2, Appl
401	7	0.5	543	3	US-09-021-715-7	Sequence 7, Appl	474	7	0.5	928	4	US-09-914-259-23	Sequence 23, Appl
402	7	0.5	543	4	US-09-702-705-337	Sequence 337, App	475	7	0.5	947	4	US-09-418-780A-1	Sequence 1, Appl
403	7	0.5	543	4	US-09-736-457-337	Sequence 337, App	476	7	0.5	957	4	US-09-595-684B-27	Sequence 2, Appl
404	7	0.5	548	2	US-08-469-412A-2	Sequence 2, Appl	477	7	0.5	957	4	US-09-595-684B-27	Sequence 4021, Ap
405	7	0.5	548	2	US-09-021-715-2	Sequence 2, Appl	478	7	0.5	957	4	US-09-107-532A-4021	Sequence 8, Appl
406	7	0.5	551	4	US-09-252-913B-13	Sequence 27787, A	479	7	0.5	960	4	US-09-595-424-8	Sequence 2, Appl
407	7	0.5	551	4	US-09-242-913B-13	Sequence 13, Appl	480	7	0.5	989	4	US-08-213-419B-2	Sequence 8, Appl
408	7	0.5	568	1	US-08-330-559-30	Sequence 30, Appl	481	7	0.5	989	4	US-08-213-419B-2	Sequence 4, Appl
409	7	0.5	568	3	US-08-545-860D-30	Sequence 30, Appl	482	7	0.5	1003	4	US-09-521-511C-11	Sequence 11, Appl
410	7	0.5	568	5	PCT-US94-04496-30	Sequence 30, Appl	483	7	0.5	1049	4	US-07-757-022B-58	Sequence 58, Appl
411	7	0.5	575	4	US-09-724-519-8	Sequence 8, Appl	484	7	0.5	1050	4	US-09-428-711A-16	Sequence 16, Appl
412	7	0.5	575	4	US-09-592-037-8	Sequence 8, Appl	485	7	0.5	1051	4	US-09-428-711A-14	Sequence 14, Appl
413	7	0.5	579	4	US-09-529-279-4	Sequence 4, Appl	486	7	0.5	1053	4	US-09-724-519-2	Sequence 2, Appl
414	7	0.5	579	4	US-10-158-895-4	Sequence 4, Appl	487	7	0.5	1053	4	US-09-592-037-2	Sequence 2, Appl
415	7	0.5	582	3	US-08-906-865-3	Sequence 3, Appl	488	7	0.5	1056	4	US-09-595-684B-29	Sequence 29, Appl
416	7	0.5	582	4	US-09-428-711A-2	Sequence 2, Appl	489	7	0.5	1057	3	US-09-541-782-10	Sequence 10, Appl
417	7	0.5	582	4	US-09-129-668-3	Sequence 3, Appl	490	7	0.5	1057	4	US-09-723-820-10	Sequence 10, Appl
418	7	0.5	590	2	US-08-785-310A-5	Sequence 5, Appl	491	7	0.5	1066	3	US-09-541-782-8	Sequence 8, Appl
419	7	0.5	590	4	US-09-529-279-15	Sequence 15, Appl	492	7	0.5	1066	3	US-09-723-820-8	Sequence 8, Appl
420	7	0.5	590	4	US-10-158-895-15	Sequence 15, Appl	493	7	0.5	1073	3	US-09-541-782-6	Sequence 6, Appl
421	7	0.5	592	1	US-08-217-327-8	Sequence 8, Appl	494	7	0.5	1073	3	US-09-723-820-6	Sequence 6, Appl
422	7	0.5	594	2	US-08-785-310A-6	Sequence 6, Appl	495	7	0.5	1093	3	US-08-545-860D-55	Sequence 55, Appl
423	7	0.5	607	4	US-09-252-991A-32643	Sequence 32643, A	496	7	0.5	1103	3	PCT-US94-04496-55	Sequence 55, Appl
424	7	0.5	609	4	US-09-198-452A-579	Sequence 579, App	497	7	0.5	1103	3	US-09-162-573-1	Sequence 1, Appl
425	7	0.5	637	4	US-09-284-768A-20	Sequence 20, Appl	498	7	0.5	1103	3	US-09-467-946-1	Sequence 1, Appl
426	7	0.5	646	4	US-09-328-352-6017	Sequence 6017, Ap	499	7	0.5	1111	4	US-09-914-259-28	Sequence 28, Appl
427	7	0.5	658	4	US-09-585-424-6	Sequence 6, Appl	500	7	0.5	1140	4	US-07-757-022B-104	Sequence 104, App
428	7	0.5	660	3	US-09-058-469-18	Sequence 18, Appl	501	7	0.5	1141	1	US-08-131-365B-54	Sequence 54, Appl
429	7	0.5	660	3	US-09-058-469-91	Sequence 91, Appl	502	7	0.5	1141	2	US-08-668-123-54	Sequence 54, Appl
430	7	0.5	662	3	US-09-058-489-15	Sequence 15, Appl	503	7	0.5	1142	2	US-08-993-118-7	Sequence 7, Appl
431	7	0.5	662	3	US-09-058-489-16	Sequence 16, Appl	504	7	0.5	1142	3	US-08-845-528C-7	Sequence 7, Appl
432	7	0.5	665	4	US-09-595-684B-35	Sequence 35, Appl	505	7	0.5	1142	3	US-09-061-709-2	Sequence 2, Appl
433	7	0.5	674	4	US-09-284-768A-21	Sequence 21, Appl	506	7	0.5	1142	4	US-09-066-281B-7	Sequence 7, Appl
434	7	0.5	693	4	US-09-107-532A-5812	Sequence 5812, Ap	507	7	0.5	1182	4	US-09-899-651-2	Sequence 2, Appl
435	7	0.5	694	3	US-08-559-397A-31	Sequence 31, Appl	508	7	0.5	1184	3	US-09-541-782-2	Sequence 2, Appl
436	7	0.5	696	3	US-08-899-437-23	Sequence 23, Appl	509	7	0.5	1184	4	US-09-723-820-2	Sequence 2, Appl
437	7	0.5	703	3	US-09-126-121-23	Sequence 23, Appl	510	7	0.5	1185	3	US-09-266-825D-13	Sequence 13, Appl
438	7	0.5	706	3	US-08-910-925-4	Sequence 2, Appl	511	7	0.5	1185	3	US-09-041-885-21	Sequence 21, Appl
439	7	0.5	706	3	US-09-408-820-2	Sequence 2, Appl	512	7	0.5	1187	1	US-08-320-859-28	Sequence 28, Appl
440	7	0.5	706	4	US-09-914-259-29	Sequence 29, Appl	513	7	0.5	1187	3	US-08-545-860D-28	Sequence 28, Appl
441	7	0.5	715	3	US-08-669-286-5	Sequence 5, Appl	514	7	0.5	1187	5	PCT-US94-04496-28	Sequence 26, Appl
442	7	0.5	715	3	US-09-469-253-5	Sequence 5, Appl	515	7	0.5	1210	1	US-08-320-859-26	Sequence 26, Appl
443	7	0.5	715	3	US-09-642-146-5	Sequence 5, Appl	516	7	0.5	1210	3	US-08-545-860D-26	Sequence 26, Appl
444	7	0.5	716	4	US-09-107-532A-5208	Sequence 5208, Ap	517	7	0.5	1210	5	PCT-US94-04496-26	Sequence 26, Appl
445	7	0.5	717	3	US-08-910-925-1	Sequence 1, Appl	518	7	0.5	1235	1	US-08-118-101A-2	Sequence 2, Appl
446	7	0.5	720	3	US-08-899-437-6	Sequence 6, Appl	519	7	0.5	1235	2	US-08-650-873-2	Sequence 2, Appl
447	7	0.5	720	3	US-09-126-121-6	Sequence 6, Appl	520	7	0.5	1238	3	US-09-259-821A-2	Sequence 2, Appl
448	7	0.5	731	3	US-09-185-160-11	Sequence 11, Appl	521	7	0.5	1238	3	US-08-843-659-2	Sequence 2, Appl
449	7	0.5	734	3	US-09-185-160-13	Sequence 13, Appl	522	7	0.5	1313	4	US-07-757-022B-142	Sequence 142, App
450	7	0.5	739	4	US-09-1134-001C-3586	Sequence 3586, Ap	523	7	0.5	1314	4	US-07-757-022B-50	Sequence 50, Appl
451	7	0.5	743	3	US-08-910-925-3	Sequence 3, Appl	524	7	0.5	1328	3	US-08-781-891-76	Sequence 76, Appl
452	7	0.5	750	3	US-09-185-160-14	Sequence 14, Appl	525	7	0.5	1328	4	US-09-618-166-76	Sequence 76, Appl
453	7	0.5	752	1	US-08-244-189-2	Sequence 2, Appl	526	7	0.5	1354	4	US-07-757-022B-48	Sequence 48, Appl
454	7	0.5	764	4	US-09-370-838-67	Sequence 67, Appl	527	7	0.5	1363	4	US-07-757-022B-52	Sequence 52, Appl
455	7	0.5	769	3	US-08-727-308-1	Sequence 1, Appl	528	7	0.5	1404	4	US-07-757-022B-2	Sequence 2, Appl
456	7	0.5	789	4	US-09-390-234-16	Sequence 16, Appl	529	7	0.5	1404	4	US-07-757-022B-62	Sequence 62, Appl
457	7	0.5	790	4	US-09-634-957-2	Sequence 2, Appl	530	7	0.5	1451	4	US-09-060-299-25	Sequence 25, Appl
458	7	0.5	790	4	US-09-723-153-2	Sequence 2, Appl	531	7	0.5	1451	4	US-09-402-823A-25	Sequence 25, Appl
459	7	0.5	805	4	US-09-723-429-2	Sequence 2, Appl	532	7	0.5	1481	2	US-08-616-944-40	Sequence 40, Appl
460	7	0.5	805	4	US-09-425-335-6	Sequence 6, Appl	533	7	0.5	1481	2	US-08-599-654-40	Sequence 40, Appl
461	7	0.5	809	4	US-09-186-276B-58	Sequence 58, Appl	534	7	0.5	1481	3	US-08-944-688A-40	Sequence 40, Appl
462	7	0.5	809	4	US-08-847-445-58	Sequence 58, Appl	535	7	0.5	1481	3	US-08-944-423A-40	Sequence 40, Appl
463	7	0.5	809	4	US-09-186-188B-58	Sequence 58, Appl	536	7	0.5	1481	3	US-08-944-496-40	Sequence 40, Appl
464	7	0.5	821	1	US-09-377-465A-2	Sequence 2, Appl	537	7	0.5	1581	3	US-09-110-517-2	Sequence 2, Appl
465	7	0.5	823	4	US-09-651-656-19	Sequence 19, Appl	538	7	0.5	1584	4	US-09-060-299-39	Sequence 39, Appl

539	7	0.5	1584	4	US-09-402-923A-39	Sequence 39, Appl	612	6	0.5	22	3	US-08-940-095-173	Sequence 173, App
540	7	0.5	1586	4	US-09-060-299-44	Sequence 44, Appl	613	6	0.5	22	3	US-08-940-095-175	Sequence 175, App
541	7	0.5	1586	4	US-09-402-923A-44	Sequence 44, Appl	614	6	0.5	22	3	US-08-940-093-173	Sequence 173, App
542	7	0.5	1591	4	US-09-060-299-4	Sequence 4, Appl1	615	6	0.5 ⁴	22	3	US-08-940-093-175	Sequence 175, App
543	7	0.5	1591	4	US-09-060-299-43	Sequence 43, Appl	616	6	0.5	22	3	US-08-940-096-173	Sequence 173, App
544	7	0.5	1591	4	US-09-402-923A-4	Sequence 43, Appl1	617	6	0.5	22	3	US-08-940-096-175	Sequence 173, App
545	7	0.5	1591	4	US-09-402-923A-43	Sequence 43, Appl	618	6	0.5	22	3	US-09-465-719-173	Sequence 173, App
546	7	0.5	1614	4	US-09-060-299-42	Sequence 42, Appl	619	6	0.5	22	3	US-09-465-719-175	Sequence 175, App
547	7	0.5	1614	4	US-09-402-923A-42	Sequence 42, Appl	620	6	0.5	22	4	US-09-453-605-173	Sequence 173, App
548	7	0.5	1615	4	US-09-060-299-3	Sequence 3, Appl1	621	6	0.5	22	4	US-09-453-605-175	Sequence 175, App
549	7	0.5	1615	4	US-09-402-923A-3	Sequence 3, Appl1	622	6	0.5	22	4	US-09-453-838-173	Sequence 173, App
550	7	0.5	1622	4	US-09-231-899-72	Sequence 72, Appl	623	6	0.5	22	4	US-09-453-838-175	Sequence 175, App
551	7	0.5	1627	1	US-07-665-792B-9	Sequence 9, Appl1	624	6	0.5	22	4	US-08-940-136-173	Sequence 173, App
552	7	0.5	1637	4	US-09-718-692-2	Sequence 2, Appl1	625	6	0.5	22	4	US-08-940-136-175	Sequence 175, App
553	7	0.5	1637	4	US-09-718-852-2	Sequence 2, Appl1	626	6	0.5	22	4	US-09-453-841-173	Sequence 173, App
554	7	0.5	1637	4	US-09-718-815-2	Sequence 2, Appl1	627	6	0.5	22	4	US-09-453-841-175	Sequence 175, App
555	7	0.5	1639	4	US-09-060-299-29	Sequence 29, Appl	628	6	0.5	24	3	US-09-098-901-4	Sequence 4, Appl1
556	7	0.5	1639	4	US-09-402-923A-29	Sequence 29, Appl	629	6	0.5	24	3	US-09-098-901-5	Sequence 5, Appl1
557	7	0.5	1665	4	US-09-858-664A-2	Sequence 2, Appl1	630	6	0.5	24	6	5198345-26	Patent No. 5198345
558	7	0.5	1690	4	US-09-595-684B-39	Sequence 39, Appl	631	6	0.5	25	2	US-08-473-475A-6	Sequence 6, Appl1
559	7	0.5	1706	2	US-08-459-568-2	Sequence 2, Appl1	632	6	0.5	25	3	US-09-200-757-5	Sequence 5, Appl1
560	7	0.5	1706	2	US-08-399-411-2	Sequence 2, Appl1	633	6	0.5	25	6	5198345-12	Patent No. 5198345
561	7	0.5	1706	3	US-08-516-859A-2	Sequence 2, Appl1	634	6	0.5	26	1	US-08-254-493-7	Sequence 7, Appl1
562	7	0.5	1706	4	US-09-586-472-2	Sequence 2, Appl1	635	6	0.5	26	1	US-08-408-222B-7	Sequence 7, Appl1
563	7	0.5	1706	4	US-09-528-706-2	Sequence 2, Appl1	636	6	0.5	27	3	US-09-056-222B-8	Sequence 8, Appl1
564	7	0.5	1719	2	US-08-459-568-4	Sequence 4, Appl1	637	6	0.5	28	6	5198345-19	Patent No. 5198345
565	7	0.5	1719	2	US-08-399-411-4	Sequence 4, Appl1	638	6	0.5	30	1	US-08-446-692-39	Sequence 39, Appl
566	7	0.5	1719	3	US-08-516-859A-4	Sequence 4, Appl1	639	6	0.5	30	2	US-08-488-351A-39	Sequence 39, Appl
567	7	0.5	1719	4	US-09-586-472-4	Sequence 4, Appl1	640	6	0.5	30	3	US-09-100-414B-6	Sequence 66, Appl
568	7	0.5	1719	4	US-09-528-706-4	Sequence 4, Appl1	641	6	0.5	30	3	US-09-100-414B-70	Sequence 70, Appl
569	7	0.5	1783	4	US-09-362-336A-2	Sequence 4, Appl1	642	6	0.5	30	3	US-09-303-323-66	Sequence 66, Appl
570	7	0.5	1804	4	US-09-362-336A-4	Sequence 4, Appl1	643	6	0.5	30	3	US-09-303-323-70	Sequence 70, Appl
571	7	0.5	1805	4	US-09-004-838-92	Sequence 92, Appl	644	6	0.5	30	4	US-09-770-014-66	Sequence 66, Appl
572	7	0.5	1817	4	US-09-004-838-125	Sequence 125, App	645	6	0.5	30	4	US-09-770-014-70	Sequence 70, Appl
573	7	0.5	1854	4	US-09-004-838-108	Sequence 108, App	646	6	0.5	31	3	US-09-023-082A-25	Sequence 25, Appl
574	7	0.5	1874	4	US-09-331-403-2	Sequence 8, Appl1	647	6	0.5	34	4	US-09-301-978C-19	Sequence 19, Appl
575	7	0.5	1890	4	US-09-004-838-88	Sequence 88, Appl	648	6	0.5	35	4	US-09-082-279B-289	Sequence 289, App
576	7	0.5	2265	2	US-08-149-097D-36	Sequence 36, Appl	649	6	0.5	35	3	US-09-082-279B-290	Sequence 290, App
577	7	0.5	2509	2	US-08-149-097D-35	Sequence 35, Appl	650	6	0.5	35	3	US-09-082-279B-291	Sequence 291, App
578	7	0.5	2662	4	US-09-595-684B-31	Sequence 31, Appl	651	6	0.5	35	3	US-09-082-279B-292	Sequence 292, App
579	7	0.5	3788	4	US-09-336-447A-76	Sequence 76, Appl	652	6	0.5	35	3	US-09-082-279B-293	Sequence 293, App
580	7	0.5	3969	3	US-08-061-376-5	Sequence 5, Appl1	653	6	0.5	35	3	US-09-082-279B-294	Sequence 294, App
581	7	0.5	7	3	US-08-478-316-51	Sequence 51, Appl	654	6	0.5	35	3	US-09-082-279B-295	Sequence 295, App
582	6	0.5	7	4	US-09-019-793A-51	Sequence 51, Appl	655	6	0.5	35	3	US-09-082-279B-296	Sequence 296, App
583	6	0.5	9	4	US-09-144-280-13	Sequence 13, Appl	656	6	0.5	35	3	US-09-082-279B-297	Sequence 297, App
584	6	0.5	10	4	US-09-468-265-6	Sequence 6, Appl1	657	6	0.5	35	3	US-09-082-279B-298	Sequence 298, App
585	6	0.5	10	4	US-09-434-476A-6	Sequence 6, Appl1	658	6	0.5	35	3	US-09-082-279B-299	Sequence 299, App
586	6	0.5	10	4	US-09-434-476A-7	Sequence 7, Appl1	659	6	0.5	35	3	US-09-082-279B-300	Sequence 300, App
587	6	0.5	12	4	US-08-481-968A-27	Sequence 27, Appl	660	6	0.5	35	3	US-09-082-279B-301	Sequence 301, App
588	6	0.5	12	4	US-08-154-712B-27	Sequence 27, Appl	661	6	0.5	35	3	US-09-082-279B-302	Sequence 302, App
589	6	0.5	12	4	US-09-257-825B-26	Sequence 26, Appl	662	6	0.5	35	3	US-09-082-279B-303	Sequence 303, App
590	6	0.5	13	1	US-08-346-293-16	Sequence 16, Appl	663	6	0.5	35	3	US-09-082-279B-304	Sequence 304, App
591	6	0.5	13	1	US-08-057-167-16	Sequence 16, Appl	664	6	0.5	35	3	US-09-082-279B-305	Sequence 305, App
592	6	0.5	13	5	PCT-US93-05412-16	Sequence 16, Appl	665	6	0.5	35	3	US-09-082-279B-306	Sequence 306, App
593	6	0.5	14	6	5204097-4	Patent No. 5204097	666	6	0.5	35	4	US-09-315-304B-289	Sequence 289, App
594	6	0.5	15	4	US-08-481-968A-17	Sequence 17, Appl	667	6	0.5	35	4	US-09-315-304B-290	Sequence 290, App
595	6	0.5	15	4	US-08-154-712B-17	Sequence 17, Appl	668	6	0.5	35	4	US-09-315-304B-291	Sequence 291, App
596	6	0.5	16	3	US-08-851-843A-201	Sequence 201, App	669	6	0.5	35	4	US-09-315-304B-292	Sequence 292, App
597	6	0.5	16	3	US-08-974-549A-320	Sequence 320, App	670	6	0.5	35	4	US-09-315-304B-293	Sequence 293, App
598	6	0.5	16	3	US-08-931-858B-92	Sequence 92, Appl	671	6	0.5	35	4	US-09-315-304B-294	Sequence 294, App
599	6	0.5	16	3	US-08-981-739-92	Sequence 92, Appl	672	6	0.5	35	4	US-09-315-304B-295	Sequence 295, App
600	6	0.5	16	3	US-09-146-755-1	Sequence 1, Appl1	673	6	0.5	35	4	US-09-315-304B-296	Sequence 296, App
601	6	0.5	16	3	US-08-854-050-201	Sequence 201, App	674	6	0.5	35	4	US-09-315-304B-297	Sequence 297, App
602	6	0.5	16	4	US-09-430-323-201	Sequence 201, App	675	6	0.5	35	4	US-09-315-304B-298	Sequence 298, App
603	6	0.5	16	4	US-09-128-026-92	Sequence 92, Appl	676	6	0.5	35	4	US-09-315-304B-299	Sequence 299, App
604	6	0.5	18	3	US-09-100-414B-26	Sequence 26, Appl	677	6	0.5	35	4	US-09-315-304B-300	Sequence 300, App
605	6	0.5	18	3	US-09-100-414B-30	Sequence 30, Appl	678	6	0.5	35	4	US-09-315-304B-301	Sequence 301, App
606	6	0.5	18	3	US-09-303-323-26	Sequence 26, Appl	679	6	0.5	35	4	US-09-315-304B-302	Sequence 302, App
607	6	0.5	18	3	US-09-303-323-30	Sequence 30, Appl	680	6	0.5	35	4	US-09-315-304B-303	Sequence 303, App
608	6	0.5	18	4	US-09-770-014-26	Sequence 26, Appl	681	6	0.5	35	4	US-09-315-304B-304	Sequence 304, App
609	6	0.5	18	4	US-09-770-014-30	Sequence 30, Appl	682	6	0.5	35	4	US-09-315-304B-305	Sequence 305, App
610	6	0.5	19	3	US-08-817-926-12	Sequence 12, Appl	683	6	0.5	35	4	US-09-315-304B-306	Sequence 306, App
611	6	0.5	20	6	5204097-3	Patent No. 5204097	684	6	0.5	35	4	US-09-834-784-289	Sequence 289, App

685	6	0.5	35	4	US-09-834-784-290	Sequence 230, App	758	6	0.5	93	3	US-08-931-858E-176	Sequence 176, App
686	6	0.5	35	4	US-09-834-784-291	Sequence 231, App	759	6	0.5	93	3	US-09-220-528-16	Sequence 16, App
687	6	0.5	35	4	US-09-834-784-292	Sequence 232, App	760	6	0.5	93	3	US-08-469-660A-19	Sequence 19, App
688	6	0.5	35	4	US-09-834-784-293	Sequence 233, App	761	6	0.5	93	4	US-08-488-446-19	Sequence 19, App
689	6	0.5	35	4	US-09-834-784-294	Sequence 234, App	762	6	0.5	93	4	US-08-467-344A-19	Sequence 19, App
690	6	0.5	35	4	US-09-834-784-295	Sequence 235, App	763	6	0.5	94	3	US-08-931-858E-87	Sequence 87, App
691	6	0.5	35	4	US-09-834-784-296	Sequence 236, App	764	6	0.5	94	3	US-08-931-858E-172	Sequence 172, App
692	6	0.5	35	4	US-09-834-784-297	Sequence 237, App	765	6	0.5	94	3	US-08-981-739-87	Sequence 87, App
693	6	0.5	35	4	US-09-834-784-298	Sequence 238, App	766	6	0.5	94	3	US-08-981-739-172	Sequence 172, App
694	6	0.5	35	4	US-09-834-784-299	Sequence 239, App	767	6	0.5	94	3	US-09-128-026-87	Sequence 87, App
695	6	0.5	35	4	US-09-834-784-300	Sequence 240, App	768	6	0.5	94	4	US-09-128-026-172	Sequence 172, App
696	6	0.5	35	4	US-09-834-784-301	Sequence 301, App	769	6	0.5	97	3	US-08-816-977-23	Sequence 23, App
697	6	0.5	35	4	US-09-834-784-302	Sequence 302, App	770	6	0.5	98	4	US-09-134-001C-4659	Sequence 4659, App
698	6	0.5	35	4	US-09-834-784-303	Sequence 303, App	771	6	0.5	103	3	US-08-535-681-46	Sequence 46, App
699	6	0.5	35	4	US-09-834-784-304	Sequence 304, App	772	6	0.5	103	3	US-08-535-681-49	Sequence 49, App
700	6	0.5	35	4	US-09-834-784-305	Sequence 305, App	773	6	0.5	103	4	US-09-615-192A-398	Sequence 398, App
701	6	0.5	35	4	US-09-834-784-306	Sequence 306, App	774	6	0.5	104	3	US-08-535-681-44	Sequence 44, App
702	6	0.5	37	2	US-08-631-328-45	Sequence 45, App	775	6	0.5	104	3	US-08-535-681-48	Sequence 48, App
703	6	0.5	37	2	US-08-631-328-48	Sequence 48, App	776	6	0.5	105	4	US-08-311-731A-227	Sequence 227, App
704	6	0.5	37	2	US-08-631-328-52	Sequence 52, App	777	6	0.5	106	6	5204258-4	Sequence 4307, App
705	6	0.5	37	2	US-08-631-328-53	Sequence 53, App	778	6	0.5	108	4	US-09-107-532A-4307	Sequence 4307, App
706	6	0.5	37	2	US-09-732-210-510	Sequence 510, App	779	6	0.5	110	4	US-09-732-210-299	Sequence 299, App
707	6	0.5	38	1	US-07-977-630-59	Sequence 69, App	780	6	0.5	112	4	US-09-134-001C-3352	Sequence 3352, App
708	6	0.5	45	3	US-08-776-059-11	Sequence 11, App	781	6	0.5	113	4	US-09-378-088A-92	Sequence 92, App
709	6	0.5	45	3	US-09-205-258-554	Sequence 554, App	782	6	0.5	113	4	US-09-378-088A-94	Sequence 94, App
710	6	0.5	46	4	US-09-369-247-127	Sequence 127, App	783	6	0.5	113	4	US-09-107-532A-4336	Sequence 4336, App
711	6	0.5	48	1	US-08-446-692-41	Sequence 41, App	784	6	0.5	114	3	US-08-535-681-42	Sequence 42, App
712	6	0.5	48	2	US-08-488-351A-41	Sequence 41, App	785	6	0.5	115	4	US-08-535-681-50	Sequence 50, App
713	6	0.5	49	2	US-08-248-839C-81	Sequence 81, App	786	6	0.5	115	1	US-08-152-922A-7	Sequence 7, App
714	6	0.5	51	1	US-08-188-228-32	Sequence 32, App	787	6	0.5	115	1	US-09-219-983A-4	Sequence 4, App
715	6	0.5	51	1	US-08-332-643-32	Sequence 32, App	788	6	0.5	117	4	US-09-378-088A-96	Sequence 96, App
716	6	0.5	51	1	US-08-332-638-32	Sequence 32, App	789	6	0.5	117	4	US-09-378-088A-98	Sequence 98, App
717	6	0.5	51	2	US-08-760-075A-27	Sequence 27, App	790	6	0.5	117	4	US-09-378-088A-100	Sequence 100, App
718	6	0.5	51	3	US-09-338-546-37	Sequence 27, App	791	6	0.5	117	4	US-09-378-088A-102	Sequence 102, App
719	6	0.5	51	4	US-09-659-084-27	Sequence 27, App	792	6	0.5	117	4	US-09-378-088A-104	Sequence 104, App
720	6	0.5	52	3	5198345-14	Patent No. 5198345	793	6	0.5	117	4	US-09-378-088A-106	Sequence 106, App
721	6	0.5	64	3	US-09-188-930-122	Sequence 122, App	794	6	0.5	119	3	US-09-023-082A-80	Sequence 80, App
722	6	0.5	64	4	US-09-312-283C-122	Sequence 122, App	795	6	0.5	120	1	US-09-107-532A-5730	Sequence 3700, App
723	6	0.5	64	4	US-09-107-532A-4650	Sequence 4650, App	796	6	0.5	120	1	US-08-249-013-9	Sequence 9, App
724	6	0.5	65	4	US-09-230-041-28	Sequence 28, App	797	6	0.5	120	2	US-08-886-863-9	Sequence 9, App
725	6	0.5	67	4	US-09-230-041-26	Sequence 26, App	798	6	0.5	120	4	US-09-175-229-9	Sequence 9, App
726	6	0.5	69	2	US-08-292-968-21	Sequence 21, App	799	6	0.5	120	5	PCT-US95-06764-9	Sequence 9, App
727	6	0.5	69	2	US-08-467-974-21	Sequence 21, App	800	6	0.5	121	4	US-09-107-532A-7107	Sequence 7107, App
728	6	0.5	69	2	US-08-467-536-21	Sequence 21, App	801	6	0.5	122	4	US-09-107-532A-5730	Sequence 5730, App
729	6	0.5	69	3	US-08-467-976-21	Sequence 21, App	802	6	0.5	122	4	US-09-107-532A-6744	Sequence 6744, App
730	6	0.5	69	3	US-08-985-159-31	Sequence 21, App	803	6	0.5	123	1	US-08-131-625B-17	Sequence 17, App
731	6	0.5	69	3	US-09-082-514-21	Sequence 21, App	804	6	0.5	123	2	US-08-789-464A-13	Sequence 13, App
732	6	0.5	69	4	US-09-134-001C-3787	Sequence 3787, App	805	6	0.5	123	3	US-08-686-568C-11	Sequence 11, App
733	6	0.5	69	4	US-09-545-605-3	Sequence 3, App	806	6	0.5	123	3	US-09-113-750A-42	Sequence 42, App
734	6	0.5	69	4	US-09-732-210-1003	Sequence 1003, App	807	6	0.5	123	4	US-09-311-924-2	Sequence 2, App
735	6	0.5	69	4	US-09-732-210-1004	Sequence 1004, App	808	6	0.5	123	4	US-09-732-210-209	Sequence 209, App
736	6	0.5	70	4	US-09-134-001C-4143	Sequence 4143, App	809	6	0.5	123	5	PCT-US95-09927-13	Sequence 13, App
737	6	0.5	70	6	5204097-1	Patent No. 5204097	810	6	0.5	123	5	PCT-US95-10904-19	Sequence 19, App
738	6	0.5	71	4	US-09-134-001C-4271	Sequence 4271, App	811	6	0.5	123	5	PCT-US95-10904-53	Sequence 53, App
739	6	0.5	73	3	US-09-100-804-28	Sequence 28, App	812	6	0.5	123	5	PCT-US95-10904-55	Sequence 55, App
740	6	0.5	75	3	US-08-480-640A-191	Sequence 191, App	813	6	0.5	123	5	PCT-US95-10904-57	Sequence 57, App
741	6	0.5	75	3	US-08-686-968C-191	Sequence 191, App	814	6	0.5	123	5	PCT-US95-10904-59	Sequence 59, App
742	6	0.5	75	3	US-08-488-237A-191	Sequence 191, App	815	6	0.5	123	5	PCT-US95-10904-61	Sequence 61, App
743	6	0.5	75	3	US-08-375-992A-191	Sequence 191, App	816	6	0.5	126	4	US-08-328-352-7948	Sequence 7949, App
744	6	0.5	75	4	US-08-472-679H-191	Sequence 191, App	817	6	0.5	127	4	US-09-134-001C-5283	Sequence 5283, App
745	6	0.5	76	4	US-09-328-352-4506	Sequence 4506, App	818	6	0.5	129	3	US-08-942-886-3	Sequence 3, App
746	6	0.5	77	4	US-09-328-352-4362	Sequence 4362, App	819	6	0.5	129	3	US-08-942-886-4	Sequence 4, App
747	6	0.5	77	2	US-08-530-280-16	Sequence 16, App	820	6	0.5	130	4	US-09-134-001C-3231	Sequence 3331, App
748	6	0.5	79	4	US-08-858-207A-305	Sequence 305, App	821	6	0.5	132	4	US-09-563-269-4	Sequence 4, App
749	6	0.5	79	4	US-09-328-352-4679	Sequence 4679, App	822	6	0.5	132	4	US-09-732-210-123	Sequence 123, App
750	6	0.5	81	4	US-09-134-001C-5248	Sequence 5248, App	823	6	0.5	134	1	US-08-564-458-1	Sequence 1, App
751	6	0.5	81	4	US-09-198-452A-1186	Sequence 1186, App	824	6	0.5	134	1	US-08-564-633-1	Sequence 1, App
752	6	0.5	86	4	US-09-134-001C-3986	Sequence 3986, App	825	6	0.5	134	1	US-08-535-682-1	Sequence 1, App
753	6	0.5	88	4	US-09-134-001C-4055	Sequence 4055, App	826	6	0.5	134	1	US-08-446-383A-1	Sequence 1, App
754	6	0.5	89	3	US-08-816-977-4	Sequence 4, App	827	6	0.5	134	1	US-08-446-383A-2	Sequence 2, App
755	6	0.5	89	3	US-09-107-532A-6533	Sequence 6533, App	828	6	0.5	134	1	US-08-795-628-1	Sequence 1, App
756	6	0.5	93	3	US-08-931-858E-51	Sequence 51, App	829	6	0.5	134	1	US-08-519-777-76	Sequence 76, App
757	6	0.5	93	3	US-08-931-858E-134	Sequence 134, App	830	6	0.5	134	1	US-08-519-777-77	Sequence 77, App

831	6	0.5	134	1	US-08-519-777-78	Sequence 78, Appl	904	6	0.5	160	4	US-09-732-210-1604	Sequence 1604, Ap
832	6	0.5	134	1	US-08-618-543-1	Sequence 1, Appl1	905	6	0.5	161	4	US-09-252-991A-30294	Sequence 30294, A
833	6	0.5	134	1	US-08-742-035-76	Sequence 76, Appl	906	6	0.5	162	4	US-09-198-452A-948	Sequence 948, App
834	6	0.5	134	1	US-08-742-035-77	Sequence 77, Appl	907	6	0.5	164	4	US-09-134-001C-5325	Sequence 5325, Ap
835	6	0.5	134	1	US-08-742-035-78	Sequence 78, Appl	908	6	0.5	164	4	US-09-252-991A-30166	Sequence 30166, A
836	6	0.5	134	2	US-08-777-019-76	Sequence 76, Appl	909	6	0.5	164	4	US-09-252-991A-32517	Sequence 32517, A
837	6	0.5	134	2	US-08-777-019-77	Sequence 77, Appl	910	6	0.5	167	2	US-08-747-887-23	Sequence 23, Appl
838	6	0.5	134	2	US-08-777-019-78	Sequence 78, Appl	911	6	0.5	167	2	US-09-328-352-6684	Sequence 6684, Ap
839	6	0.5	134	2	US-08-606-176A-1	Sequence 1, Appl1	912	6	0.5	169	1	US-08-414-926A-12	Sequence 12, Appl
840	6	0.5	134	2	US-08-777-143-76	Sequence 76, Appl	913	6	0.5	169	2	US-08-926-922-12	Sequence 12, Appl
841	6	0.5	134	2	US-08-777-143-77	Sequence 77, Appl	914	6	0.5	169	3	US-09-253-682-12	Sequence 12, Appl
842	6	0.5	134	2	US-08-777-143-78	Sequence 78, Appl	915	6	0.5	169	3	US-09-527-657-12	Sequence 12, Appl
843	6	0.5	134	2	US-08-710-219A-1	Sequence 1, Appl1	916	6	0.5	169	4	US-09-134-001C-4590	Sequence 4590, Ap
844	6	0.5	134	2	US-08-452-242-4	Sequence 4, Appl1	917	6	0.5	169	4	US-09-544-716-17	Sequence 17, Appl
845	6	0.5	134	2	US-08-452-242-6	Sequence 6, Appl1	918	6	0.5	169	4	US-09-557-921-18	Sequence 18, Appl
846	6	0.5	134	3	US-08-453-176A-4	Sequence 4, Appl1	919	6	0.5	171	1	US-08-313-075A-32	Sequence 32, Appl
847	6	0.5	134	3	US-08-453-176A-6	Sequence 6, Appl1	920	6	0.5	171	3	US-09-023-082A-116	Sequence 116, App
848	6	0.5	134	3	US-08-775-414-76	Sequence 76, Appl	921	6	0.5	172	4	US-09-252-991A-28151	Sequence 28151, A
849	6	0.5	134	3	US-08-775-414-77	Sequence 77, Appl	922	6	0.5	174	3	US-09-023-082A-43	Sequence 43, Appl
850	6	0.5	134	3	US-08-775-414-78	Sequence 78, Appl	923	6	0.5	174	3	US-09-023-082A-55	Sequence 55, Appl
851	6	0.5	134	3	US-08-451-374-4	Sequence 4, Appl1	924	6	0.5	174	3	US-09-023-082A-66	Sequence 66, Appl
852	6	0.5	134	3	US-08-451-374-6	Sequence 6, Appl1	925	6	0.5	174	3	US-08-941-155-2	Sequence 2, Appl1
853	6	0.5	134	3	US-08-535-681-2	Sequence 2, Appl1	926	6	0.5	174	4	US-08-936-162A-451	Sequence 451, App
854	6	0.5	134	3	US-08-935-268A-4	Sequence 4, Appl1	927	6	0.5	174	4	US-09-872-047-2	Sequence 2, Appl1
855	6	0.5	134	3	US-08-935-268A-6	Sequence 6, Appl1	928	6	0.5	176	4	US-09-252-991A-21613	Sequence 21613, A
856	6	0.5	134	3	US-08-931-858B-76	Sequence 76, Appl	929	6	0.5	178	2	US-08-680-326-4	Sequence 4, Appl1
857	6	0.5	134	3	US-08-931-858B-77	Sequence 77, Appl	930	6	0.5	178	4	US-09-328-352-6697	Sequence 6697, Ap
858	6	0.5	134	3	US-08-931-858B-78	Sequence 78, Appl	931	6	0.5	179	4	US-09-328-352-7612	Sequence 7612, Ap
859	6	0.5	134	3	US-08-981-739-76	Sequence 76, Appl	932	6	0.5	181	4	US-08-185-433-6	Sequence 6, Appl1
860	6	0.5	134	3	US-08-981-739-77	Sequence 77, Appl	933	6	0.5	182	1	US-09-134-001C-5022	Sequence 5022, Ap
861	6	0.5	134	3	US-08-981-739-78	Sequence 78, Appl	934	6	0.5	184	4	US-09-328-352-6638	Sequence 6638, Ap
862	6	0.5	134	3	US-09-220-528-13	Sequence 13, Appl	935	6	0.5	184	3	US-09-023-082A-30	Sequence 30, Appl
863	6	0.5	134	4	US-08-452-229-4	Sequence 4, Appl1	936	6	0.5	184	3	US-08-741-411-1	Sequence 1, Appl1
864	6	0.5	134	4	US-08-452-229-6	Sequence 6, Appl1	937	6	0.5	185	1	US-07-741-940-6	Sequence 6, Appl1
865	6	0.5	134	4	US-09-128-026-76	Sequence 76, Appl	938	6	0.5	185	1	US-08-289-546A-6	Sequence 6, Appl1
866	6	0.5	134	4	US-09-128-026-77	Sequence 77, Appl	939	6	0.5	185	1	US-08-452-653A-6	Sequence 6, Appl1
867	6	0.5	134	4	US-09-128-026-78	Sequence 78, Appl	940	6	0.5	185	1	US-08-452-655B-6	Sequence 6, Appl1
868	6	0.5	134	4	US-09-732-210-1566	Sequence 1566, Ap	941	6	0.5	185	2	US-08-865-336-4	Sequence 4, Appl1
869	6	0.5	135	3	US-08-535-681-47	Sequence 47, Appl	942	6	0.5	185	3	US-08-450-582-6	Sequence 6, Appl1
870	6	0.5	136	3	US-09-107-532A-6435	Sequence 6435, App	943	6	0.5	185	4	US-08-449-731-6	Sequence 211, App
871	6	0.5	136	4	US-09-107-532A-6435	Sequence 6435, App	944	6	0.5	185	4	US-09-996-244-211	Sequence 211, App
872	6	0.5	137	4	US-09-252-991A-27555	Sequence 27555, A	945	6	0.5	186	4	US-09-252-991A-30615	Sequence 30615, A
873	6	0.5	138	4	US-09-180-422B-12	Sequence 12, Appl	946	6	0.5	186	4	US-09-107-532A-7101	Sequence 7101, Ap
874	6	0.5	138	4	US-09-107-532A-4755	Sequence 4755, Ap	947	6	0.5	189	4	US-09-107-532A-4526	Sequence 4526, Ap
875	6	0.5	138	6	5218098-1	Patent No. 5218098	948	6	0.5	191	4	US-09-252-991A-29829	Sequence 29829, A
876	6	0.5	139	3	US-09-367-953B-116	Sequence 116, App	949	6	0.5	193	4	US-08-671-546C-40	Sequence 40, Appl
877	6	0.5	139	4	US-09-252-991A-21299	Sequence 21299, A	950	6	0.5	194	4	US-09-134-001C-3563	Sequence 3563, App
878	6	0.5	139	4	US-09-328-352-7601	Sequence 7601, Ap	951	6	0.5	194	4	US-09-149-476-735	Sequence 735, App
879	6	0.5	140	4	US-09-732-210-1255	Sequence 1255, Ap	952	6	0.5	194	4	US-09-252-991A-21846	Sequence 21846, A
880	6	0.5	143	4	US-09-134-001C-4711	Sequence 4711, Ap	953	6	0.5	195	4	US-09-487-792-11	Sequence 11, Appl
881	6	0.5	144	4	US-09-134-001C-3102	Sequence 3102, Ap	954	6	0.5	195	4	US-09-908-594-11	Sequence 11, Appl
882	6	0.5	144	4	US-09-252-991A-26540	Sequence 26540, A	955	6	0.5	196	4	US-09-252-991A-24314	Sequence 24314, A
883	6	0.5	145	4	US-09-252-991A-22630	Sequence 22630, A	956	6	0.5	197	4	US-09-328-352-5000	Sequence 5000, Ap
884	6	0.5	147	4	US-09-134-001C-5392	Sequence 5392, Ap	957	6	0.5	200	3	US-09-113-750A-40	Sequence 40, Appl
885	6	0.5	149	4	US-09-198-452A-792	Sequence 792, App	958	6	0.5	200	3	US-09-562-737-101	Sequence 101, App
886	6	0.5	151	4	US-09-328-352-6429	Sequence 6429, Ap	959	6	0.5	200	4	US-09-562-737-102	Sequence 102, App
887	6	0.5	152	4	US-09-732-210-53	Sequence 53, Appl	960	6	0.5	200	4	US-09-562-737-109	Sequence 109, App
888	6	0.5	154	4	US-09-252-991A-17864	Sequence 17864, A	961	6	0.5	200	4	US-09-562-737-110	Sequence 110, App
889	6	0.5	154	4	US-09-198-452A-2239	Sequence 239, App	962	6	0.5	200	4	US-09-562-737-110	Sequence 110, App
890	6	0.5	155	2	US-08-844-057-4	Sequence 4, Appl1	963	6	0.5	200	4	US-09-252-991A-27855	Sequence 27855, A
891	6	0.5	155	2	US-09-006-730-4	Sequence 4, Appl1	964	6	0.5	204	2	US-08-760-075A-16	Sequence 16, Appl
892	6	0.5	155	4	US-09-107-532A-5729	Sequence 5729, Ap	965	6	0.5	204	3	US-09-338-546-16	Sequence 16, Appl
893	6	0.5	157	2	US-08-630-822A-60	Sequence 60, Appl	966	6	0.5	204	4	US-09-659-084-16	Sequence 16, Appl
894	6	0.5	157	2	US-09-005-069-60	Sequence 60, Appl	967	6	0.5	205	4	US-09-252-991A-18239	Sequence 18239, A
895	6	0.5	157	4	US-09-171-156A-18	Sequence 18, Appl	968	6	0.5	205	4	US-09-198-452A-829	Sequence 829, App
896	6	0.5	157	4	US-09-004-730A-18	Sequence 18, Appl	969	6	0.5	206	4	US-09-134-001C-5047	Sequence 5047, Ap
897	6	0.5	157	4	US-09-252-991A-22957	Sequence 22957, A	970	6	0.5	207	4	US-09-252-991A-39505	Sequence 29505, A
898	6	0.5	157	4	US-08-981-799A-18	Sequence 18, Appl	971	6	0.5	207	4	US-09-434-354-40	Sequence 40, Appl
899	6	0.5	158	4	US-09-433-248A-4	Sequence 4, Appl1	972	6	0.5	208	1	US-08-462-169B-20	Sequence 20, Appl
900	6	0.5	159	4	US-09-252-991A-16672	Sequence 16672, A	973	6	0.5	208	2	US-08-951-822-30	Sequence 30, Appl
901	6	0.5	159	4	US-09-252-991A-20158	Sequence 20158, A	974	6	0.5	208	3	US-09-103-079-20	Sequence 20, Appl
902	6	0.5	159	4	US-09-452-991A-21183	Sequence 21183, A	975	6	0.5	208	3	US-09-023-082A-2	Sequence 2, Appl1
903	6	0.5	160	4	US-09-328-352-6929	Sequence 6929, Ap	976	6	0.5	208	3	US-09-023-082A-30	Sequence 20, Appl

```
977 6 0.5 208 3 US-09-023-082A-24 Sequence 24, Appl
978 6 0.5 208 3 US-09-023-082A-39 Sequence 39, Appl
979 6 0.5 208 3 US-09-218-44A-2 Sequence 2, Appl
980 6 0.5 208 4 US-09-358-951-30 Sequence 30, Appl
981 6 0.5 208 4 US-09-425-021-20 Sequence 20, Appl
982 6 0.5 208 4 US-09-229-947-30 Sequence 30, Appl
983 6 0.5 208 4 US-09-252-991A-21959 Sequence 21959, A
984 6 0.5 209 4 US-09-134-099-14 Sequence 14, Appl
985 6 0.5 209 4 US-09-198-452A-286 Sequence 286, Appl
986 6 0.5 210 1 US-07-741-940-4 Sequence 4, Appl
987 6 0.5 210 1 US-08-289-548A-4 Sequence 4, Appl
988 6 0.5 210 1 US-08-452-654-4 Sequence 4, Appl
989 6 0.5 210 1 US-08-452-655B-4 Sequence 4, Appl
990 6 0.5 210 3 US-09-450-582-4 Sequence 4, Appl
991 6 0.5 210 4 US-09-134-001C-3671 Sequence 3671, Ap
992 6 0.5 210 4 US-08-449-731-4 Sequence 4, Appl
993 6 0.5 217 4 US-08-679-483A-196 Sequence 196, App
994 6 0.5 218 4 US-09-252-991A-22136 Sequence 22136, A
995 6 0.5 220 1 US-07-820-154A-4 Sequence 4, Appl
996 6 0.5 220 2 US-08-097-554A-4 Sequence 4, Appl
997 6 0.5 220 3 US-08-453-176A-26 Sequence 26, Appl
998 6 0.5 220 3 US-08-480-640A-4 Sequence 4, Appl
999 6 0.5 220 3 US-08-451-374-26 Sequence 26, Appl
1000 6 0.5 220 3 US-08-295-802-4 Sequence 4, Appl
```

ALIGNMENTS

```
RESULT 1
US-09-384-162-6
; Sequence 6, Application US/09384162
; Patent No. 6376747
```

```
; GENERAL INFORMATION:
; APPLICANT: King, Ti
; APPLICANT: Malik, Kamal
; APPLICANT: Martin-Heller, Teresa
; APPLICANT: Miki, L., Brian
; TITLE OF INVENTION: No. 6376747e1 Plant-Derived Map Kinase Kinase
; FILE REFERENCE: 08-884280US
; CURRENT APPLICATION NUMBER: US/09/384,162
; CURRENT FILING DATE: 1999-08-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 286
; TYPE: PRT
; ORGANISM: Dictyostelium discoideum
; US-09-384-162-6
```

```
Query Match 1.2%; Score 16; DB 4; Length 286;
Best Local Similarity 100.0%; Pred. No. 2.6e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 742 NNNNNNNNNNNNNNNNN 757
Db 206 NNNNNNNNNNNNNNNNN 221
```

```
RESULT 2
US-09-718-841-4
; Sequence 4, Application US/09718841
; Patent No. 6333184
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6333184e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1051
; CURRENT APPLICATION NUMBER: US/09/718,841
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 4
; LENGTH: 357
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (16)...(37)
; OTHER INFORMATION: Xaa = any amino acid
US-09-718-841-4
```

```
Query Match 1.2%; Score 16; DB 4; Length 357;
Best Local Similarity 100.0%; Pred. No. 3.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 92 FAYGQTSGKTYTMLG 107
Db 98 FAYGQTSGKTYTMLG 113
```

```
RESULT 3
US-09-718-810-4
; Sequence 4, Application US/09718810
; Patent No. 6420162
```

```
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6420162e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1051
; CURRENT APPLICATION NUMBER: US/09/718,810
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 357
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (16)...(37)
; OTHER INFORMATION: Xaa = any amino acid
US-09-718-810-4
```

```
Query Match 1.2%; Score 16; DB 4; Length 357;
Best Local Similarity 100.0%; Pred. No. 3.2e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 92 FAYGQTSGKTYTMLG 107
Db 98 FAYGQTSGKTYTMLG 113
```

```
RESULT 4
US-09-118-319-5
; Sequence 5, Application US/09118319
; Patent No. 6114158
```

```
; GENERAL INFORMATION:
; APPLICANT: Li, Xin-Liang
; APPLICANT: Chen, Huizhong
; APPLICANT: Ljungdahl, Lars G.
; TITLE OF INVENTION: Orythomyces Cellulase Celf Protein and Coding Sequences
; FILE REFERENCE: 33-98sequence listing
; CURRENT APPLICATION NUMBER: US/09/118,319
; CURRENT FILING DATE: 1998-07-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 428
; TYPE: PRT
; ORGANISM: Neocallimastix patriciarum
; US-09-118-319-5
```

```
Query Match 1.2%; Score 16; DB 3; Length 428;
```

Best Local Similarity 100.0%; Pred. No. 3.8e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 68 NNNNNNNNNNNNNNNN 83

RESULT 5

US-09-118-319-2
; Sequence 2, Application US/09118319
; Patent No. 6114158
; GENERAL INFORMATION:
; APPLICANT: Li, Xin-Liang
; APPLICANT: Chen, Huizhong
; APPLICANT: Lundahl, Lars G.
; TITLE OF INVENTION: Oryzomyces Cellulase Celf Protein and Coding Sequences
; FILE REFERENCE: 33-98sequence listing
; CURRENT APPLICATION NUMBER: US/09/118,319
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 2
; LENGTH: 432
; TYPE: PRT
; ORGANISM: Oryzomyces sp. PC-2
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-118-319-2

Query Match 1.2%; Score 16; DB 3; Length 432;
Best Local Similarity 100.0%; Pred. No. 3.8e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
DB 78 NNNNNNNNNNNNNNNN 93

RESULT 6

US-09-718-841-2
; Sequence 2, Application US/09718841
; Patent No. 6333184
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6333184el motor proteins and methods for
; FILE REFERENCE: 1051
; CURRENT APPLICATION NUMBER: US/09/718,841
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 563
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (16)...(37)
; OTHER INFORMATION: Xaa = any amino acid
; NAME/KEY: VARIANT
; LOCATION: (391)...(412)
; OTHER INFORMATION: Xaa = any amino acid
US-09-718-841-2

Query Match 1.2%; Score 16; DB 4; Length 563;
Best Local Similarity 100.0%; Pred. No. 4.8e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTMLG 107
DB 98 FAYGOTSGKTYTMLG 113

RESULT 7

US-09-718-810-2
; Sequence 2, Application US/09718810
; Patent No. 6420162
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6420162el motor proteins and methods for
; FILE REFERENCE: 1051
; CURRENT APPLICATION NUMBER: US/09/718,810
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 563
; TYPE: PRT
; ORGANISM: Human
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (16)...(37)
; OTHER INFORMATION: Xaa = any amino acid
; NAME/KEY: VARIANT
; LOCATION: (391)...(412)
; OTHER INFORMATION: Xaa = any amino acid
US-09-718-810-2

Query Match 1.2%; Score 16; DB 4; Length 563;
Best Local Similarity 100.0%; Pred. No. 4.8e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTMLG 107
DB 98 FAYGOTSGKTYTMLG 113

RESULT 8

US-08-914-999-8
; Sequence 8, Application US/08914999
; Patent No. 6346406
; GENERAL INFORMATION:
; APPLICANT: Ryzanov, Alexey G.
; APPLICANT: Hailt, William N.
; APPLICANT: Pavut, Karen S.
; TITLE OF INVENTION: ELONGATION FACTOR-2 KINASE (EF-2 KINASE)
; TITLE OF INVENTION: AND METHODS OF USE THEREFOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David A. Jackson, Esq.
; STREET: 411 Hackensack Ave, Continental Plaza, 4th
; STREET: Floor
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/914,999
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 601-1-078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800
; TELEFAX: 201-343-1684

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 732 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Dictyostelium discoideum
US-08-914-999-8

Query Match 1.2%; Score 16; DB 4; Length 732;
Best Local Similarity 100.0%; Pred. No. 6,1e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
Db 355 NNNNNNNNNNNNNNNN 370

RESULT 9
US-08-340-011-5
Sequence 5, Application US/08340011
Patent No. 5776755
GENERAL INFORMATION:
APPLICANT: Alltalo, et al.
TITLE OF INVENTION: FLT4, A NOVEL RECEPTOR TYROSIN KINASE
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
City: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/340,011
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/959,951
FILING DATE: 09-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Thomas C.
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 32267
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 1311 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-340-011-5

Query Match 1.2%; Score 16; DB 1; Length 1311;
Best Local Similarity 100.0%; Pred. No. 1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
Db 613 NNNNNNNNNNNNNNNN 628

RESULT 10
US-08-901-710-5
Sequence 5, Application US/08901770
Patent No. 6107046
GENERAL INFORMATION:
APPLICANT: Alltalo, Kari
APPLICANT: Appellkova, Olga
APPLICANT: Pajusola, Kari
APPLICANT: Armstrong, Eilina
APPLICANT: Korhonen, Jaana
APPLICANT: Kaipainen, Arja
APPLICANT: Matikainen, Marja-Terttu
TITLE OF INVENTION: FLT4, A RECEPTOR TYROSINE KINASE, AND USES
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
City: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/901,710
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/340,011
FILING DATE: 14-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,754
FILING DATE: 09-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/959,951
FILING DATE: 09-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaas, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 28113/33824
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 1311 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-901-710-5

Query Match 1.2%; Score 16; DB 3; Length 1311;
Best Local Similarity 100.0%; Pred. No. 1e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNNNN 757
Db 613 NNNNNNNNNNNNNNNN 628

RESULT 11
US-09-457-040B-27
Sequence 27, Application US/09457040B
Patent No. 6387641
GENERAL INFORMATION:
APPLICANT: Vertex Pharmaceuticals Incorporated

```

; APPLICANT: Bellon, Steve
; TITLE OF INVENTION: Crystallized P38 Complexes
; FILE REFERENCE: VPI/98-14
; CURRENT APPLICATION NUMBER: US/09/457,040B
; CURRENT FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 27
; LENGTH: 1584
; TYPE: PRT
; ORGANISM: DICTY - Dictyostelium Discoideum
US-09-457-040B-27

```

```

Query Match      1.2%; Score 16; DB 4; Length 1584;
Best Local Similarity 100.0%; Pred. No. 1.2e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      742 NNNNNNNNNNNNNNNNN 757
DB      449 NNNNNNNNNNNNNNNNN 464

```

```

RESULT 12
US-09-417-485D-6
; Sequence 6, Application US/09417485D
; Patent No. 6541202
; GENERAL INFORMATION:
; APPLICANT: Long, David M.
; APPLICANT: Metz, Anneke M.
; APPLICANT: Love, Ruschelle A.
; TITLE OF INVENTION: Telomerase Reverse Transcriptase (TERT) Genes
; FILE REFERENCE: 47714-5009-US
; CURRENT APPLICATION NUMBER: US/09/417,485D
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 2184
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (330)..(335)
; OTHER INFORMATION: Xaa at position 330 = Leu or Ile;
; OTHER INFORMATION: Xaa at position 335 = Asp or Gly.
US-09-417-485D-6

```

```

Query Match      1.2%; Score 16; DB 4; Length 2184;
Best Local Similarity 100.0%; Pred. No. 1.6e-06;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      742 NNNNNNNNNNNNNNNNN 757
DB      239 NNNNNNNNNNNNNNNNN 254

```

```

RESULT 13
US-09-722-129-4
; Sequence 4, Application US/09722129
; Patent No. 6582958
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6582958el motor proteins and methods for
; FILE REFERENCE: 1054
; CURRENT APPLICATION NUMBER: US/09/722,129
; CURRENT FILING DATE: 2000-11-24
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 303
; TYPE: PRT

```

```

; ORGANISM: Human
US-09-722-129-4

```

```

Query Match      1.2%; Score 15; DB 4; Length 303;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      91 CFAYGQTSGKTYTM 105
DB      90 CFAYGQTSGKTYTM 104

```

```

RESULT 14
US-09-722-129-2
; Sequence 2, Application US/09722129
; Patent No. 6582958
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6582958el motor proteins and methods for
; FILE REFERENCE: 1054
; CURRENT APPLICATION NUMBER: US/09/722,129
; CURRENT FILING DATE: 2000-11-24
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 492
; TYPE: PRT
; ORGANISM: Human
US-09-722-129-2

```

```

Query Match      1.2%; Score 15; DB 4; Length 492;
Best Local Similarity 100.0%; Pred. No. 4.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      91 CFAYGQTSGKTYTM 105
DB      279 CFAYGQTSGKTYTM 293

```

```

RESULT 15
US-09-417-485D-8
; Sequence 8, Application US/09417485D
; Patent No. 6541202
; GENERAL INFORMATION:
; APPLICANT: Long, David M.
; APPLICANT: Metz, Anneke M.
; APPLICANT: Love, Ruschelle A.
; TITLE OF INVENTION: Telomerase Reverse Transcriptase (TERT) Genes
; FILE REFERENCE: 47714-5009-US
; CURRENT APPLICATION NUMBER: US/09/417,485D
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 794
; TYPE: PRT
; ORGANISM: Plasmodium falciparum
US-09-417-485D-8

```

```

Query Match      1.2%; Score 15; DB 4; Length 794;
Best Local Similarity 100.0%; Pred. No. 6.3e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      744 NNNNNNNNNNNNNNNNN 758
DB      130 NNNNNNNNNNNNNNNNN 144

```

```

RESULT 16
US-08-861-464-6
; Sequence 6, Application US/08861464

```

```
/ Patent No. 5874210
/ GENERAL INFORMATION:
/ APPLICANT: Guarente, Leonard P.
/ APPLICANT: Austriaco Jr., Nicanor
/ TITLE OF INVENTION: Genes Determining Cellular Senescence
/ TITLE OF INVENTION: In Yeast
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
/ STREET: Two Militia Drive
/ CITY: Lexington
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02173
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/861,464
/ FILING DATE: 22-MAY-1997
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/396,001
/ FILING DATE: 28-FEB-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US94/09351
/ FILING DATE: 15-AUG-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/107,408
/ FILING DATE: 16-AUG-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Granahan, Patricia
/ REGISTRATION NUMBER: 32,227
/ REFERENCE/DOCKET NUMBER: MIT-6408A2Z
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 781-861-6240
/ TELEFAX: 781-861-9540
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 888 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-08-861-464-6

Query Match 1.2%; Score 15; DB 2; Length 888;
Best Local Similarity 100.0%; Pred. No. 6.9e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 756
Db 521 NNNNNNNNNNNNNN 535

RESULT 17
US-08-396-001-6
/ Sequence 6, Application US/08396001
/ Patent No. 5919618
/ GENERAL INFORMATION:
/ APPLICANT: Guarente, Leonard P.
/ APPLICANT: Austriaco Jr., Nicanor
/ APPLICANT: Cole, James
/ APPLICANT: Cole, Francesca
/ APPLICANT: Kennedy, Brian
/ TITLE OF INVENTION: Genes Determining Cellular Senescence in
/ TITLE OF INVENTION: Yeast
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
/ STREET: Two Militia Drive
```

```
CITY: Lexington
STATE: MA
COUNTRY: USA
ZIP: 02173
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/396,001
/ FILING DATE: 28-FEB-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Granahan, Patricia
/ REGISTRATION NUMBER: 32,227
/ REFERENCE/DOCKET NUMBER: MIT-6408A2
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617-861-6240
/ TELEFAX: 617-861-9540
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 888 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-08-396-001-6

Query Match 1.2%; Score 15; DB 2; Length 888;
Best Local Similarity 100.0%; Pred. No. 6.9e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 756
Db 521 NNNNNNNNNNNNNN 535

RESULT 18
US-09-323-433A-6
/ Sequence 6, Application US/09323433A
/ Patent No. 6218512
/ GENERAL INFORMATION:
/ APPLICANT: Guarente, Leonard P.
/ APPLICANT: Austriaco Jr., Nicanor
/ APPLICANT: Cole, James J.
/ APPLICANT: Cole, Francesca
/ APPLICANT: Kennedy, Brian
/ TITLE OF INVENTION: GENES DETERMINING CELLULAR SENESCENCE IN
/ TITLE OF INVENTION: YEAST
/ FILE REFERENCE: 0050,1491-003
/ CURRENT APPLICATION NUMBER: US/09/323,433A
/ CURRENT FILING DATE: 1999-06-01
/ PRIOR APPLICATION NUMBER: US 08/396,001
/ PRIOR FILING DATE: 1995-02-28
/ PRIOR APPLICATION NUMBER: PCT/US94/09351
/ PRIOR FILING DATE: 1994-08-15
/ PRIOR APPLICATION NUMBER: US 08/107,408
/ PRIOR FILING DATE: 1993-08-16
/ NUMBER OF SEQ ID NOS: 48
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 6
/ LENGTH: 888
/ TYPE: PRT
/ ORGANISM: Saccharomyces cerevisiae
/ US-09-323-433A-6

Query Match 1.2%; Score 15; DB 3; Length 888;
Best Local Similarity 100.0%; Pred. No. 6.9e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 NNNNNNNNNNNNNN 756
Db 521 NNNNNNNNNNNNNN 535
```

```

RESULT 19
US-09-098-901-11
; Sequence 11, Application US/09098901B
; Patent No. 6218144
; GENERAL INFORMATION:
; APPLICANT: Scott, Matthew
; APPLICANT: Sisson, John C.
; TITLE OF INVENTION: Costal2 Genes and their Uses
; FILE REFERENCE: SUN-65P
; CURRENT APPLICATION NUMBER: US/09/098,901B
; CURRENT FILING DATE: 1998-06-17
; EARLIER APPLICATION NUMBER: 60/051,347
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 11
; LENGTH: 23
; TYPE: PRT
; ORGANISM: CONSENSUS
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(23)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-098-901-11

```

```

Query Match
Best Local Similarity 1.1%; Score 14; DB 3; Length 23;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 92 FAYGOTSGKTYTM 105
Db 8 FAYGOTSGKTYTM 21

```

```

RESULT 20
US-09-641-806-4
; Sequence 4, Application US/09641806
; Patent No. 6395527
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6395527el motor proteins and methods for
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/641,806
; CURRENT FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 337
; TYPE: PRT
; ORGANISM: Human
US-09-641-806-4

```

```

Query Match
Best Local Similarity 1.1%; Score 14; DB 4; Length 337;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 92 FAYGOTSGKTYTM 105
Db 80 FAYGOTSGKTYTM 93

```

```

RESULT 21
US-09-723-129-4
; Sequence 4, Application US/09723129
; Patent No. 6551787
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6551787el motor proteins and methods for

```

```

; TITLE OF INVENTION: their use
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/723,129
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/641,806
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 337
; TYPE: PRT
; ORGANISM: Human
US-09-723-129-4

```

```

Query Match
Best Local Similarity 1.1%; Score 14; DB 4; Length 337;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 92 FAYGOTSGKTYTM 105
Db 80 FAYGOTSGKTYTM 93

```

```

RESULT 22
US-09-722-862-4
; Sequence 4, Application US/09722862
; Patent No. 6562610
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6562610el motor proteins and methods for
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/722,862
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/641,806
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 337
; TYPE: PRT
; ORGANISM: Human
US-09-722-862-4

```

```

Query Match
Best Local Similarity 1.1%; Score 14; DB 4; Length 337;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 92 FAYGOTSGKTYTM 105
Db 80 FAYGOTSGKTYTM 93

```

```

RESULT 23
US-09-641-806-2
; Sequence 2, Application US/09641806
; Patent No. 6395527
; GENERAL INFORMATION:
; APPLICANT: Beraud, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6395527el motor proteins and methods for
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/641,806
; CURRENT FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 342
; TYPE: PRT
; ORGANISM: Human
US-09-641-806-2

```

Query Match 1.1%; Score 14; DB 4; Length 342;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGQTSGKTYTM 105
|||||
Db 81 FAYGQTSGKTYTM 94

RESULT 24
US-09-723-129-2
; Sequence 2, Application US/09723129
; Patent No. 6551787
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6551787e1 motor proteins and methods for
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/723,129
; PRIOR APPLICATION NUMBER: 09/641,806
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 342
; TYPE: PRT
; ORGANISM: Human
US-09-723-129-2

Query Match 1.1%; Score 14; DB 4; Length 342;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGQTSGKTYTM 105
|||||
Db 81 FAYGQTSGKTYTM 94

RESULT 25
US-09-722-862-2
; Sequence 2, Application US/09722862
; Patent No. 6562610
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6562610e1 motor proteins and methods for
; FILE REFERENCE: 1034
; CURRENT APPLICATION NUMBER: US/09/722,862
; PRIOR APPLICATION NUMBER: 09/641,806
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 342
; TYPE: PRT
; ORGANISM: Human
US-09-722-862-2

Query Match 1.1%; Score 14; DB 4; Length 342;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGQTSGKTYTM 105
|||||
Db 81 FAYGQTSGKTYTM 94

RESULT 26

US-09-291-170A-3
; Sequence 3, Application US/09291170A
; Patent No. 6410687
; GENERAL INFORMATION:
; APPLICANT: Vale, Ronald D.
; APPLICANT: Hartman, James J.
; TITLE OF INVENTION: The Regents of the University of California
; TITLE OF INVENTION: Assays for the Detection of Microtubule
; FILE REFERENCE: 18557B-000510US
; CURRENT APPLICATION NUMBER: US/09/291,170A
; PRIOR FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: US 60/081,734
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 730
; TYPE: PRT
; ORGANISM: Xenopus laevis
; OTHER INFORMATION: Xenopus kinesin central motor 1 (XKCM1)
US-09-291-170A-3

Query Match 1.1%; Score 14; DB 4; Length 730;
Best Local Similarity 100.0%; Pred. No. 5.6e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 INRSLALKECIRA 276
|||||
Db 520 INRSLALKECIRA 533

RESULT 27
US-09-724-884-3
; Sequence 3, Application US/09724884
; Patent No. 6429304
; GENERAL INFORMATION:
; APPLICANT: Vale, Ronald D.
; APPLICANT: Hartman, James J.
; TITLE OF INVENTION: The Regents of the University of California
; TITLE OF INVENTION: Assays for the Detection of Microtubule
; FILE REFERENCE: 18557B-000510US
; CURRENT APPLICATION NUMBER: US/09/724,884
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/291,170
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 730
; TYPE: PRT
; ORGANISM: Xenopus laevis
; FEATURE:
; OTHER INFORMATION: Xenopus kinesin central motor 1 (XKCM1)
US-09-724-884-3

Query Match 1.1%; Score 14; DB 4; Length 730;
Best Local Similarity 100.0%; Pred. No. 5.6e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 INRSLALKECIRA 276
|||||
Db 520 INRSLALKECIRA 533

RESULT 28
US-08-006-676B-1
; Sequence 1, Application US/08006676B
; Patent No. 5411865
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven

TITLE OF INVENTION: Diagnosis of Leishmaniasis
NUMBER OF SEQUENCES: 3
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jeffrey B. Oster
STREET: 8339 SE 57th Street
CITY: Mercer Island
STATE: Washington
COUNTRY: USA
ZIP: 98040-4906
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORD for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/006,676B
FILING DATE: 15-JAN-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Oster, Jeffrey B.
REGISTRATION NUMBER: 32,585
REFERENCE/DOCKET NUMBER: REED-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 232 7845
TELEFAX: (206) 236 0205
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-006-676B-1

Query Match 1.1%; Score 14; DB 1; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.1e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTM 105
DB 119 FAYGOTSGKTYTM 132

RESULT 29
US-08-282-845-2
Sequence 2, Application US/08282845
Patent No. 5719263
GENERAL INFORMATION:
APPLICANT: Reed, Steven G.
TITLE OF INVENTION: A 230kd Antigen Present in Leishmania
TITLE OF INVENTION: Species
NUMBER OF SEQUENCES: 3
CORRESPONDENCE ADDRESS:
ADDRESSEE: Immunex Corporation
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Apple Macintosh Operating System 7.1
SOFTWARE: Microsoft Word for Macintosh 5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/282,845
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/006,676
FILING DATE: JANUARY 15, 1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne

REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 5004-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-282-845-2

Query Match 1.1%; Score 14; DB 1; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.1e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTM 105
DB 119 FAYGOTSGKTYTM 132

RESULT 30
US-08-428-414A-3
Sequence 3, Application US/08428414A
Patent No. 5912166
GENERAL INFORMATION:
APPLICANT: Reed, Steven G.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR DIAGNOSIS OF
TITLE OF INVENTION: LEISHMANIASIS
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/428,414A
FILING DATE: 21-APR-1995
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Kadlecik, Ann T.
REGISTRATION NUMBER: 39,244
REFERENCE/DOCKET NUMBER: 210121.407
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836 SEEDANDBERRY
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
US-08-428-414A-3

Query Match 1.1%; Score 14; DB 2; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.1e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 FAYGOTSGKTYTM 105
DB 119 FAYGOTSGKTYTM 132

RESULT 31

PCT-US94-00324-1
; Sequence 1, Application PC/TUS9400324
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven
; TITLE OF INVENTION: Diagnosis of Leishmaniasis
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Immunex Corporation
; STREET: 51 University Street
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Apple System 7.1
; SOFTWARE: Microsoft Word, version 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/00324
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/006,676
; FILING DATE: 15-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Perkins, Patricia Anne
; REGISTRATION NUMBER: 34,693
; REFERENCE/DOCKET NUMBER: 5004-WO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 587-0430
; TELEFAX: (206) 233-0644
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 955 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US94-00324-1

Query Match 1.1%; Score 14; DB 5; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.1e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 FAYGQTSGSKTYT 105
Db 119 FAYGQTSGSKTYT 132

RESULT 32
US-09-724-517-4
; Sequence 4, Application US/09724517
; Patent No. 6379941
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6379941e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1031
; CURRENT APPLICATION NUMBER: US/09/724,517
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: US/09/641,807
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 341
; TYPE: PRT
; ORGANISM: Human
; US-09-724-517-4

Query Match 1.0%; Score 13; DB 4; Length 341;
Best Local Similarity 100.0%; Pred. No. 0.00027;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 FAYGQTSGSKTYT 104
Db 80 FAYGQTSGSKTYT 92

RESULT 33
US-09-641-807A-4
; Sequence 4, Application US/09641807A
; Patent No. 6440731
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6440731e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1031
; CURRENT APPLICATION NUMBER: US/09/641,807A
; CURRENT FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 341
; TYPE: PRT
; ORGANISM: Human
; US-09-641-807A-4

Query Match 1.0%; Score 13; DB 4; Length 341;
Best Local Similarity 100.0%; Pred. No. 0.00027;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 FAYGQTSGSKTYT 104
Db 80 FAYGQTSGSKTYT 92

RESULT 34
US-09-723-096-4
; Sequence 4, Application US/09723096
; Patent No. 6448026
; GENERAL INFORMATION:
; APPLICANT: Berard, Christophe
; APPLICANT: Freedman, Richard
; TITLE OF INVENTION: No. 6448026e1 motor proteins and methods for
; TITLE OF INVENTION: their use
; FILE REFERENCE: 1031
; CURRENT APPLICATION NUMBER: US/09/723,096
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: US/09/641,807
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 341
; TYPE: PRT
; ORGANISM: Human
; US-09-723-096-4

Query Match 1.0%; Score 13; DB 4; Length 341;
Best Local Similarity 100.0%; Pred. No. 0.00027;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 FAYGQTSGSKTYT 104
Db 80 FAYGQTSGSKTYT 92

RESULT 35
US-09-177-165A-31
; Sequence 31, Application US/09177165A
; Patent No. 6426205
; GENERAL INFORMATION:
; APPLICANT: Tyers, Mike

```
APPLICANT: Willems, Andrew
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING UBIQUITIN
FILE OF INVENTION: DEPENDENT PROTEOLYSIS
FILE REFERENCE: 11757.10USU1
CURRENT APPLICATION NUMBER: US/09/117,165A
CURRENT FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/092,443
PRIOR FILING DATE: 1998-07-10
PRIOR APPLICATION NUMBER: 60/063,254
PRIOR FILING DATE: 1997-10-24
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patencin Ver. 2.1
SEQ ID NO 31
LENGTH: 1151
TYPE: PRT
ORGANISM: Saccharomyces cerevisiae
US-09-177-165A-31
```

```
Query Match      1.0%; Score 13; DB 4; Length 1151;
Best Local Similarity 100.0%; Pred. No. 0.0008;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      502 NNNNNNNNNNNNS 514
DB      38 NNNNNNNNNNNNS 50
```

```
RESULT 36
US-09-724-517-2
Sequence 2, Application US/09724517
Patent No. 6379941
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6379941e1 motor proteins and methods for
FILE OF INVENTION: their use
FILE REFERENCE: 1031
CURRENT APPLICATION NUMBER: US/09/724,517
CURRENT FILING DATE: 2000-11-27
PRIOR APPLICATION NUMBER: US/09/641,807
PRIOR FILING DATE: 2000-08-17
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 1279
TYPE: PRT
ORGANISM: Human
FEATURE:
NAME/KEY: VARIANT
LOCATION: (409)...(436)
OTHER INFORMATION: Xaa = any amino acid
US-09-724-517-2
```

```
Query Match      1.0%; Score 13; DB 4; Length 1279;
Best Local Similarity 100.0%; Pred. No. 0.0008;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      92 PAYGQTSGSKTYT 104
DB      82 PAYGQTSGSKTYT 94
```

```
RESULT 37
US-09-641-807A-2
Sequence 2, Application US/09641807A
Patent No. 6440731
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6440731e1 motor proteins and methods for
FILE OF INVENTION: their use
FILE REFERENCE: 1031
CURRENT APPLICATION NUMBER: US/09/641,807A
```

```
CURRENT FILING DATE: 2000-08-17
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 1279
TYPE: PRT
ORGANISM: Human
FEATURE:
NAME/KEY: VARIANT
LOCATION: (409)...(446)
OTHER INFORMATION: Xaa = any amino acid
US-09-641-807A-2
```

```
Query Match      1.0%; Score 13; DB 4; Length 1279;
Best Local Similarity 100.0%; Pred. No. 0.0008;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      92 PAYGQTSGSKTYT 104
DB      82 PAYGQTSGSKTYT 94
```

```
RESULT 38
US-09-723-096-2
Sequence 2, Application US/09723096
Patent No. 6448026
GENERAL INFORMATION:
APPLICANT: Beraud, Christophe
APPLICANT: Freedman, Richard
TITLE OF INVENTION: No. 6448026e1 motor proteins and methods for
FILE OF INVENTION: their use
FILE REFERENCE: 1031
CURRENT APPLICATION NUMBER: US/09/723,096
CURRENT FILING DATE: 2000-11-27
PRIOR APPLICATION NUMBER: US/09/641,807
PRIOR FILING DATE: 2000-08-17
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 1279
TYPE: PRT
ORGANISM: Human
FEATURE:
NAME/KEY: VARIANT
LOCATION: (409)...(436)
OTHER INFORMATION: Xaa = any amino acid
US-09-723-096-2
```

```
Query Match      1.0%; Score 13; DB 4; Length 1279;
Best Local Similarity 100.0%; Pred. No. 0.0008;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      92 PAYGQTSGSKTYT 104
DB      82 PAYGQTSGSKTYT 94
```

```
RESULT 39
US-09-451-117-2
Sequence 2, Application US/09451117
Patent No. 6277973
GENERAL INFORMATION:
APPLICANT: Jenkins, Mark C.
APPLICANT: Fayer, Ronald
TITLE OF INVENTION: Cloning and Expression of a DNA Sequence Encoding A 41
TITLE OF INVENTION: Kda Cryptosporidium parvum Oocyst Wall Protein
FILE REFERENCE: 0046.99
CURRENT APPLICATION NUMBER: US/09/451,117
CURRENT FILING DATE: 1999-11-30
NUMBER OF SEQ ID NOS: 4
SOFTWARE: Patencin Ver. 2.1
```

; SEQ ID NO 2
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Cryptosporidium parvum
US-09-451-117-2

Query Match 0.9%; Score 12; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 741 TNNNNNNNNNN 752
|||
Db 235 TNNNNNNNNNN 246

RESULT 40
US-09-888-655-2
; Sequence 2, Application US/09888655
; Patent No. 6521229
; GENERAL INFORMATION:
; APPLICANT: Jenkins, Mark C.
; APPLICANT: Fayer, Ronald
; APPLICANT: Trout, James
; TITLE OF INVENTION: Cloning and Expression of a DNA Sequence Encoding A 41
; Patent No. 6521229
; TITLE OF INVENTION: kDa Cryptosporidium parvum Oocyst Wall Protein
; FILE REFERENCE: 0046.99
; CURRENT APPLICATION NUMBER: US/09/888,655
; CURRENT FILING DATE: 2001-06-26
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Cryptosporidium parvum
US-09-888-655-2

Query Match 0.9%; Score 12; DB 4; Length 246;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 741 TNNNNNNNNNN 752
|||
Db 235 TNNNNNNNNNN 246

Search completed: October 2, 2003, 16:36:31
Job time : 36 secs